variant_id,doc_id,confidence_score,bao_format,description,tid,assay_test_type,assay_tissue,chembl_id,curated_by,assay_tax_id,assay_subcellular_fraction,relationship_type,assay_category,assay_type,assay_id,assay_strain,cell_id,assay_organism,src_id,src_assay_id,tissue_id,assay_cell_type
,11087,8,BAO_0000019,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,12052,,,CHEMBL615117,Autocuration,,,H,,B,1,,,,1,,,
,684,0,BAO_0000219,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,22226,,,CHEMBL615118,Autocuration,,,U,,F,2,,,,1,,,
,15453,0,BAO_0000019,,22226,,,CHEMBL615119,Autocuration,,,U,,B,3,,,,1,,,
,17841,4,BAO_0000249,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,104729,,,CHEMBL615120,Autocuration,9913.0,,H,,B,4,,,Bos taurus,1,,,
,17430,1,BAO_0000219,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),80001,,,CHEMBL615121,Intermediate,9606.0,,N,,F,5,,163.0,Homo sapiens,1,,,143B
,17430,1,BAO_0000219,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),80001,,,CHEMBL615122,Intermediate,9606.0,,N,,F,6,,163.0,Homo sapiens,1,,,143B
,13799,1,BAO_0000219,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,80001,,,CHEMBL615123,Intermediate,10090.0,,N,,F,7,,163.0,Mus musculus,1,,,143B
,17774,1,BAO_0000219,In vitro cell cytotoxicity was determined against 143B cell line,80001,,,CHEMBL615124,Expert,9606.0,,N,,F,8,,163.0,Homo sapiens,1,,,143B
,3801,1,BAO_0000219,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,80001,,,CHEMBL615125,Intermediate,9606.0,,N,,F,9,,163.0,Homo sapiens,1,,,143B
,17430,1,BAO_0000219,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,80001,,,CHEMBL615126,Intermediate,9606.0,,N,,F,10,,163.0,Homo sapiens,1,,,143B
,17430,1,BAO_0000219,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,80001,,,CHEMBL615127,Intermediate,9606.0,,N,,F,11,,163.0,Homo sapiens,1,,,143B
,17774,1,BAO_0000219,In vitro cell cytotoxicity was determined against 143B-LTK cell line,80001,,,CHEMBL615128,Expert,9606.0,,N,,F,12,,163.0,Homo sapiens,1,,,143B
,11324,1,BAO_0000218,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,,,CHEMBL857900,Intermediate,1280.0,,N,,F,13,,,Staphylococcus aureus,1,,,
,11324,1,BAO_0000218,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,,,CHEMBL615129,Intermediate,1280.0,,N,,F,14,,,Staphylococcus aureus,1,,,
,11324,1,BAO_0000218,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,,,CHEMBL615130,Intermediate,1280.0,,N,,F,15,,,Staphylococcus aureus,1,,,
,11324,1,BAO_0000218,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,,,CHEMBL615131,Intermediate,1280.0,,N,,F,16,,,Staphylococcus aureus,1,,,
,11347,9,BAO_0000357,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,100122,,,CHEMBL884521,Expert,10116.0,,D,,A,17,,,Rattus norvegicus,1,,,
,16474,8,BAO_0000357,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),12054,,,CHEMBL615132,Autocuration,,,H,,B,18,,,,1,,,
,10091,8,BAO_0000019,Inhibition of partially purified 15-lipoxygenase from human leukocytes,12054,,,CHEMBL615133,Autocuration,,,H,,B,19,,,,1,,,
,16474,8,BAO_0000357,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),12054,,,CHEMBL615134,Autocuration,,,H,,B,20,,,,1,,,
,16474,8,BAO_0000357,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),12054,,,CHEMBL615135,Autocuration,,,H,,B,21,,,,1,,,
,16474,8,BAO_0000357,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),12054,,,CHEMBL615136,Autocuration,,,H,,B,22,,,,1,,,
,16474,8,BAO_0000357,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,12054,,,CHEMBL615137,Autocuration,,,H,,B,23,,,,1,,,
,16474,8,BAO_0000357,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,12054,,,CHEMBL615138,Autocuration,,,H,,B,24,,,,1,,,
,14352,0,BAO_0000219,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",22226,,,CHEMBL836324,Autocuration,,,U,,B,25,,,,1,,,
,5646,8,BAO_0000357,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,12054,,,CHEMBL615139,Autocuration,9986.0,,H,,B,26,,,Oryctolagus cuniculus,1,,,
,5646,8,BAO_0000357,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),12054,,,CHEMBL615140,Autocuration,9986.0,,H,,B,27,,,Oryctolagus cuniculus,1,,,
,10997,8,BAO_0000219,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,12426,,,CHEMBL615141,Autocuration,,,H,,B,28,,,,1,,,
,6309,8,BAO_0000357,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,12054,,,CHEMBL615142,Autocuration,3847.0,,H,,B,29,,,soya bean,1,,,
,167,8,BAO_0000357,Inhibitory activity against soybean 15-lipoxygenase was evaluated,12054,,,CHEMBL615143,Autocuration,3847.0,,H,,B,30,,,Glycine max,1,,,
,167,8,BAO_0000357,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,12054,,,CHEMBL615144,Autocuration,3847.0,,H,,B,31,,,Glycine max,1,,,
,11087,8,BAO_0000357,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,12054,,,CHEMBL872867,Autocuration,3847.0,,H,,B,32,,,Glycine max,1,,,
,11087,8,BAO_0000357,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,12054,,,CHEMBL615145,Autocuration,3847.0,,H,,B,33,,,Glycine max,1,,,
,13622,8,BAO_0000357,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,12054,,,CHEMBL615146,Autocuration,3847.0,,H,,B,34,,,Glycine max,1,,,
,13622,8,BAO_0000357,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,12054,,,CHEMBL615147,Autocuration,3847.0,,H,,B,35,,,Glycine max,1,,,
,11347,0,BAO_0000019,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,22226,,,CHEMBL615148,Autocuration,10116.0,,U,,A,36,,,Rattus norvegicus,1,,,
,5926,0,BAO_0000019,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,22226,,,CHEMBL615149,Autocuration,562.0,,U,,B,37,,,Escherichia coli,1,,,
,4567,0,BAO_0000019,Dissociation constant with dimeric 16S rRNA RNA construct B,22226,,,CHEMBL615150,Autocuration,,,U,,B,38,,,,1,,,
,3782,3,BAO_0000225,Dissociation constant towards 16S rRNA construct A,22222,,,CHEMBL615151,Intermediate,,,M,,B,39,,,,1,,,
,3782,3,BAO_0000225,Dissociation constant towards 16S rRNA construct B,22222,,,CHEMBL615152,Intermediate,,,M,,B,40,,,,1,,,
,4466,3,BAO_0000225,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,100263,,,CHEMBL615153,Expert,562.0,,M,,B,41,,,Escherichia coli,1,,,
,6592,3,BAO_0000225,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,100263,,,CHEMBL615154,Expert,562.0,,M,,B,42,,,Escherichia coli,1,,,
,898,8,BAO_0000019,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),13053,,,CHEMBL615155,Autocuration,,,H,,B,43,,,,1,,,
,898,8,BAO_0000019,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),13053,,,CHEMBL615156,Autocuration,,,H,,B,44,,,,1,,,
,13163,8,BAO_0000019,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,20001,,,CHEMBL615157,Autocuration,9606.0,,H,,B,45,,,Homo sapiens,1,,,
,13163,8,BAO_0000019,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,20001,,,CHEMBL615158,Autocuration,9606.0,,H,,B,46,,,Homo sapiens,1,,,
,10691,9,BAO_0000019,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",12971,,,CHEMBL615159,Expert,10116.0,,D,,B,47,,,Rattus norvegicus,1,,,
,10691,9,BAO_0000019,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",12971,,,CHEMBL615172,Expert,10116.0,,D,,B,48,,,Rattus norvegicus,1,,,
,10691,9,BAO_0000019,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",12971,,,CHEMBL615173,Expert,10116.0,,D,,B,49,,,Rattus norvegicus,1,,,
,10691,9,BAO_0000019,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",12971,,,CHEMBL615174,Expert,10116.0,,D,,B,50,,,Rattus norvegicus,1,,,
,898,8,BAO_0000019,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),13053,,,CHEMBL884518,Autocuration,,,H,,B,51,,,,1,,,
,912,8,BAO_0000357,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),11512,,,CHEMBL615175,Autocuration,,,H,,B,52,,,,1,,,
,912,8,BAO_0000357,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,11512,,,CHEMBL615176,Autocuration,,,H,,B,53,,,,1,,,
,912,8,BAO_0000357,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,11512,,,CHEMBL615177,Autocuration,,,H,,B,54,,,,1,,,
,15103,5,BAO_0000249,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,104740,,,CHEMBL615178,Autocuration,10116.0,Membranes,D,,B,55,,,Rattus norvegicus,1,,,
,5116,1,BAO_0000219,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,80002,,,CHEMBL615179,Intermediate,9606.0,,N,,F,56,,506.0,Homo sapiens,1,,,1A9
,14578,7,BAO_0000219,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,104835,,,CHEMBL615180,Autocuration,10116.0,,D,,F,57,,,Rattus norvegicus,1,,,Oocytes
,14578,7,BAO_0000219,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,104821,,,CHEMBL615181,Autocuration,10116.0,,D,,F,58,,,Rattus norvegicus,1,,,Oocytes
,14578,7,BAO_0000219,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,104848,,,CHEMBL615182,Autocuration,10116.0,,D,,F,59,,,Rattus norvegicus,1,,,Oocytes
,4787,1,BAO_0000219,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,80002,,,CHEMBL615183,Expert,9606.0,,N,,F,60,,506.0,Homo sapiens,1,,,1A9
,4787,1,BAO_0000219,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,80002,,,CHEMBL615184,Intermediate,9606.0,,N,,F,61,,506.0,Homo sapiens,1,,,1A9
,3547,1,BAO_0000219,Cytotoxic activity against human ovarian cancer (1A9) cell line,80002,,,CHEMBL615185,Intermediate,9606.0,,N,,F,62,,506.0,Homo sapiens,1,,,1A9
,3547,1,BAO_0000219,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,80002,,,CHEMBL615186,Intermediate,9606.0,,N,,F,63,,506.0,Homo sapiens,1,,,1A9
,6726,1,BAO_0000219,Effective dose of compound against replication of 1A9 cell line was evaluated,80002,,,CHEMBL615187,Intermediate,9606.0,,N,,F,64,,506.0,Homo sapiens,1,,,1A9
,3455,1,BAO_0000219,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,80002,,,CHEMBL885343,Expert,9606.0,,N,,F,65,,506.0,Homo sapiens,1,,,1A9
,5726,1,BAO_0000219,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),80002,,,CHEMBL615188,Intermediate,9606.0,,N,,F,66,,506.0,Homo sapiens,1,,,1A9
,5726,1,BAO_0000219,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,80002,,,CHEMBL615189,Intermediate,9606.0,,N,,F,67,,506.0,Homo sapiens,1,,,1A9
,5726,1,BAO_0000219,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,80002,,,CHEMBL615190,Intermediate,9606.0,,N,,F,68,,506.0,Homo sapiens,1,,,1A9
,3395,1,BAO_0000219,Inhibitory activity against Taxol resistant 1A9 cell lines,80002,,,CHEMBL615191,Intermediate,9606.0,,N,,F,69,,506.0,Homo sapiens,1,,,1A9
,3415,1,BAO_0000219,Cytotoxicity against human ovarian cancer (1A9) cell lines.,80002,,,CHEMBL615192,Expert,9606.0,,N,,F,70,,506.0,Homo sapiens,1,,,1A9
,3415,1,BAO_0000219,Percentage inhibition of human ovarian cancer (1A9) cell lines.,80002,,,CHEMBL827083,Expert,9606.0,,N,,F,71,,506.0,Homo sapiens,1,,,1A9
,17099,1,BAO_0000219,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,80002,,,CHEMBL615193,Expert,9606.0,,N,,F,72,,506.0,Homo sapiens,1,,,1A9
,17099,1,BAO_0000219,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,80002,,,CHEMBL615194,Intermediate,9606.0,,N,,F,73,,506.0,Homo sapiens,1,,,1A9
,17099,1,BAO_0000219,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,80002,,,CHEMBL615195,Intermediate,9606.0,,N,,F,74,,506.0,Homo sapiens,1,,,1A9
,17099,1,BAO_0000219,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,80002,,,CHEMBL615196,Intermediate,9606.0,,N,,F,75,,506.0,Homo sapiens,1,,,1A9
,17721,1,BAO_0000219,Inhibitory concentration against Jurkat cells,81072,,,CHEMBL615197,Intermediate,9606.0,,N,,F,76,,503.0,Homo sapiens,1,,,Jurkat
,1229,0,BAO_0000019,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,22226,,,CHEMBL615198,Intermediate,,,U,,F,77,,,,1,,,
,11347,9,BAO_0000357,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,100121,,,CHEMBL615199,Expert,10116.0,,D,,A,78,,,Rattus norvegicus,1,,,
,17117,8,BAO_0000357,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",11231,,,CHEMBL615200,Expert,,,H,,B,79,,,,1,,,
,17117,8,BAO_0000357,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",11231,,,CHEMBL615201,Expert,,,H,,B,80,,,,1,,,
,17117,8,BAO_0000357,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",11231,,,CHEMBL615202,Expert,,,H,,B,81,,,,1,,,
,11375,8,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",11231,,,CHEMBL615203,Autocuration,5476.0,Microsomes,H,,B,82,,,Candida albicans,1,,,
,11375,8,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",11231,,,CHEMBL615204,Autocuration,5476.0,Microsomes,H,,B,83,,,Candida albicans,1,,,
,11375,8,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",11231,,,CHEMBL615205,Autocuration,4932.0,Microsomes,H,,B,84,,,Saccharomyces cerevisiae,1,,,
,11375,8,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",11231,,,CHEMBL615206,Autocuration,4932.0,Microsomes,H,,B,85,,,Saccharomyces cerevisiae,1,,,
,11375,8,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",12083,,Liver,CHEMBL615207,Autocuration,9823.0,Microsomes,H,,B,86,,,Sus scrofa,1,,2107.0,
,791,8,BAO_0000019,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",11231,,,CHEMBL827084,Autocuration,10116.0,,H,,B,87,,,Rattus norvegicus,1,,,
,791,8,BAO_0000019,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",11231,,,CHEMBL615208,Autocuration,10116.0,,H,,B,88,,,Rattus norvegicus,1,,,
,791,8,BAO_0000019,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",11231,,,CHEMBL615209,Autocuration,10116.0,,H,,B,89,,,Rattus norvegicus,1,,,
,11375,9,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",12083,,Liver,CHEMBL615210,Autocuration,10116.0,Microsomes,D,,B,90,,,Rattus norvegicus,1,,2107.0,
,11375,9,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",12083,,Liver,CHEMBL615211,Autocuration,10116.0,Microsomes,D,,B,91,,,Rattus norvegicus,1,,2107.0,
,153,9,BAO_0000251,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",12083,,Liver,CHEMBL615212,Autocuration,10116.0,Microsomes,D,,B,92,,,Rattus norvegicus,1,,2107.0,
,8269,8,BAO_0000357,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),11377,,,CHEMBL615213,Expert,,,H,,B,93,,,,1,,,
,8269,8,BAO_0000357,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,11377,,,CHEMBL615273,Expert,,,H,,B,94,,,,1,,,
,17653,1,BAO_0000219,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,81020,,,CHEMBL615274,Expert,9606.0,,N,,F,95,,726.0,Homo sapiens,1,,,HepG2
,14277,1,BAO_0000219,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,81020,,,CHEMBL615275,Intermediate,9606.0,,N,,F,96,,726.0,Homo sapiens,1,,,HepG2
,1717,1,BAO_0000219,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,81020,,,CHEMBL615276,Intermediate,9606.0,,N,,F,97,,726.0,Homo sapiens,1,,,HepG2
,14091,1,BAO_0000219,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,81020,,,CHEMBL615277,Intermediate,9606.0,,N,,F,98,,726.0,Homo sapiens,1,,,HepG2
,14091,1,BAO_0000219,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,81020,,,CHEMBL615326,Intermediate,9606.0,,N,,F,99,,726.0,Homo sapiens,1,,,HepG2
,17653,1,BAO_0000218,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,50606,,,CHEMBL883130,Expert,10407.0,,N,,F,100,,,Hepatitis B virus,1,,,
,13105,1,BAO_0000219,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,81020,,,CHEMBL884519,Intermediate,9606.0,,N,,F,101,,726.0,Homo sapiens,1,,,HepG2
,1717,1,BAO_0000219,Concentration required to inhibit 50% of 2.2.15 cell line,81020,,,CHEMBL615327,Intermediate,9606.0,,N,,F,102,,726.0,Homo sapiens,1,,,HepG2
,13105,1,BAO_0000219,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,81020,,,CHEMBL615328,Intermediate,9606.0,,N,,A,103,,726.0,Homo sapiens,1,,,HepG2
,13600,1,BAO_0000218,Cytotoxic activity of compound against uninfected 2.2.15 cells.,50587,,,CHEMBL615329,Intermediate,9606.0,,N,,F,104,,,Homo sapiens,1,,,2.2.15
,13467,1,BAO_0000218,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,50587,,,CHEMBL615330,Intermediate,9606.0,,N,,F,105,,,Homo sapiens,1,,,2.2.15
,17477,1,BAO_0000218,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",50606,,,CHEMBL615331,Expert,10407.0,,N,,F,106,,,Hepatitis B virus,1,,,2.2.15
,1593,1,BAO_0000218,In vitro anti-HBV activity in 2.2.15 cells,50587,,,CHEMBL615332,Intermediate,9606.0,,N,,F,107,,,Homo sapiens,1,,,2.2.15
,1593,1,BAO_0000218,In vitro anti-HBV activity in 2.2.15 cells; Not determined,50587,,,CHEMBL615333,Intermediate,9606.0,,N,,F,108,,,Homo sapiens,1,,,2.2.15
,15089,1,BAO_0000218,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,50587,,,CHEMBL615334,Intermediate,9606.0,,N,,F,109,,,Homo sapiens,1,,,2.2.15
,15089,1,BAO_0000218,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,50587,,,CHEMBL615335,Intermediate,9606.0,,N,,F,110,,,Homo sapiens,1,,,2.2.15
,1593,1,BAO_0000218,Cytotoxicity in 2.2.15 cells,50587,,,CHEMBL615336,Intermediate,9606.0,,N,,F,111,,,Homo sapiens,1,,,2.2.15
,1593,1,BAO_0000218,Cytotoxicity in 2.2.15 cells; Not determined,50587,,,CHEMBL615337,Intermediate,9606.0,,N,,F,112,,,Homo sapiens,1,,,2.2.15
,13600,1,BAO_0000218,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,50587,,,CHEMBL615338,Intermediate,9606.0,,N,,F,113,,,Homo sapiens,1,,,2.2.15
,13467,1,BAO_0000218,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,50587,,,CHEMBL615339,Intermediate,9606.0,,N,,F,114,,,Homo sapiens,1,,,2.2.15
,13467,1,BAO_0000218,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,50587,,,CHEMBL615340,Intermediate,9606.0,,N,,F,115,,,Homo sapiens,1,,,2.2.15
,14764,1,BAO_0000219,Antiviral activity against HBV was determined in 2.215 cell line,81020,,,CHEMBL615341,Intermediate,9606.0,,N,,F,116,,726.0,Homo sapiens,1,,,HepG2
,6531,0,BAO_0000251,Inhibition of 20-HETE synthesis in human renal microsomes,22226,,,CHEMBL615342,Autocuration,9606.0,Microsomes,U,,B,117,,,Homo sapiens,1,,,
,17322,0,BAO_0000019,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,22226,,,CHEMBL615343,Autocuration,,,U,,B,118,,,,1,,,
,17072,1,BAO_0000219,Inhibitory concentration against 2008 (ovarian) cells,80612,,,CHEMBL615344,Intermediate,9606.0,,N,,F,119,,388.0,Homo sapiens,1,,,2008
,16936,1,BAO_0000219,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,80612,,,CHEMBL615345,Intermediate,9606.0,,N,,F,120,,388.0,Homo sapiens,1,,,2008
,16936,1,BAO_0000219,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),80612,,,CHEMBL615346,Intermediate,9606.0,,N,,F,121,,388.0,Homo sapiens,1,,,2008
,17146,1,BAO_0000219,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,80612,,,CHEMBL615347,Intermediate,9606.0,,N,,F,122,,388.0,Homo sapiens,1,,,2008
,17146,1,BAO_0000219,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,80612,,,CHEMBL615348,Intermediate,9606.0,,N,,F,123,,388.0,Homo sapiens,1,,,2008
,10797,1,BAO_0000219,In vitro inhibition of 2008/R ovarian cancer cell line,80613,,,CHEMBL827085,Intermediate,9606.0,,N,,F,124,,561.0,Homo sapiens,1,,,2008/R
,10797,1,BAO_0000219,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,80613,,,CHEMBL615349,Intermediate,9606.0,,N,,F,125,,561.0,Homo sapiens,1,,,2008/R
,10797,1,BAO_0000219,In vitro inhibition of 2008/S ovarian cancer cell line,80614,,,CHEMBL615350,Intermediate,9606.0,,N,,F,126,,389.0,Homo sapiens,1,,,2008/S
,10797,1,BAO_0000219,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,80614,,,CHEMBL615351,Intermediate,9606.0,,N,,F,127,,389.0,Homo sapiens,1,,,2008/S
,4823,2,BAO_0000220,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,100256,,,CHEMBL615352,Expert,9606.0,,S,,B,128,,,Homo sapiens,1,,,
,12912,2,BAO_0000220,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,100256,,,CHEMBL615353,Intermediate,9606.0,,S,,B,129,,,Homo sapiens,1,,,
,2957,2,BAO_0000220,Inhibition of chymotrypsin-like activity of 20S proteasome,100256,,,CHEMBL615354,Expert,,,S,,B,130,,,,1,,,
,2957,2,BAO_0000220,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,100256,,,CHEMBL615355,Expert,,,S,,B,131,,,,1,,,
,3260,2,BAO_0000220,Inhibitory activity against 20S proteosome,100256,,,CHEMBL615356,Intermediate,,,S,,B,132,,,,1,,,
,3451,0,BAO_0000019,Compound was tested for inhibitory activity against tryptase,22226,,,CHEMBL615357,Autocuration,9606.0,,U,,B,133,,,Homo sapiens,1,,,
,13885,1,BAO_0000219,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,81020,,,CHEMBL615358,Intermediate,9606.0,,N,,F,134,,726.0,Homo sapiens,1,,,HepG2
,13885,1,BAO_0000219,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,81020,,,CHEMBL827086,Intermediate,9606.0,,N,,F,135,,726.0,Homo sapiens,1,,,HepG2
,3676,0,BAO_0000019,Compound was tested for the inhibition of Alpha-glucosidase,22226,,,CHEMBL615359,Autocuration,,,U,,B,136,,,,1,,,
,6043,8,BAO_0000357,Inhibitory concentration against human neutrophil elastase (HNE),235,,,CHEMBL615360,Autocuration,,,H,,B,137,,,,1,,,
,11140,0,BAO_0000218,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,22226,,Heart,CHEMBL615361,Autocuration,10116.0,,U,,F,138,,,Rattus norvegicus,1,,948.0,
,10543,8,BAO_0000019,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,19640,,,CHEMBL615362,Autocuration,,,H,,F,139,,,,1,,,
,10543,8,BAO_0000019,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,19640,,,CHEMBL615363,Expert,,,H,,F,140,,,,1,,,
,10543,8,BAO_0000357,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,19640,,,CHEMBL615364,Autocuration,,,H,,B,141,,,,1,,,
,10543,8,BAO_0000019,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,19640,,,CHEMBL615365,Expert,,,H,,F,142,,,,1,,,
,11365,1,BAO_0000219,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,80360,,,CHEMBL615366,Intermediate,10090.0,,N,,F,143,,524.0,Mus musculus,1,,,P338
,11365,1,BAO_0000219,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,80360,,,CHEMBL615367,Intermediate,10090.0,,N,,F,144,,524.0,Mus musculus,1,,,P338
,11803,1,BAO_0000219,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,80384,,,CHEMBL615368,Intermediate,9606.0,,N,,F,145,,554.0,Homo sapiens,1,,,PBL
,11803,0,BAO_0000019,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,22226,,,CHEMBL615369,Autocuration,9940.0,,U,,F,146,,,Ovis aries,1,,,
,11803,0,BAO_0000019,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,22226,,,CHEMBL615370,Autocuration,9940.0,,U,,F,147,,,Ovis aries,1,,,
,12278,8,BAO_0000357,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),191,,,CHEMBL615673,Autocuration,,,H,,B,148,,,,1,,,
,8249,0,BAO_0000019,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,22226,,,CHEMBL615674,Autocuration,9606.0,,U,,F,149,,,Homo sapiens,1,,,
,8249,0,BAO_0000019,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,22226,,,CHEMBL615675,Autocuration,9606.0,,U,,F,150,,,Homo sapiens,1,,,
,8249,0,BAO_0000219,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,22226,,,CHEMBL615676,Autocuration,9606.0,,U,,F,151,,635.0,Homo sapiens,1,,,CCRF-CEM
,8249,0,BAO_0000219,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,22226,,,CHEMBL615677,Autocuration,9606.0,,U,,F,152,,635.0,Homo sapiens,1,,,CCRF-CEM
,8249,0,BAO_0000219,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,22226,,,CHEMBL615678,Autocuration,9606.0,,U,,F,153,,635.0,Homo sapiens,1,,,CCRF-CEM
,8249,0,BAO_0000219,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,22226,,,CHEMBL615679,Autocuration,9606.0,,U,,F,154,,635.0,Homo sapiens,1,,,CCRF-CEM
,8249,0,BAO_0000019,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,22226,,,CHEMBL615680,Autocuration,9606.0,,U,,F,155,,,Homo sapiens,1,,,
,8249,0,BAO_0000019,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,22226,,,CHEMBL615681,Autocuration,9606.0,,U,,F,156,,,Homo sapiens,1,,,
,16992,6,BAO_0000249,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,104290,,,CHEMBL857972,Autocuration,,,H,,B,157,,,,1,,,
,10543,1,BAO_0000218,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,50264,,,CHEMBL857899,Intermediate,1314.0,,N,,F,158,,,Streptococcus pyogenes,1,,,
,17833,1,BAO_0000218,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),50527,,,CHEMBL615371,Intermediate,10335.0,,N,,F,159,,,Human herpesvirus 3,1,,,
,17290,1,BAO_0000218,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,50527,,,CHEMBL615372,Expert,10335.0,,N,,F,160,,468.0,vericilla zoster virus,1,,,HEL
,17290,1,BAO_0000218,Antiviral activity against 07/1 strain of VZV; ND: No data,50527,,,CHEMBL615373,Intermediate,10335.0,,N,,F,161,,,vericilla zoster virus,1,,,
,17290,1,BAO_0000218,Antiviral activity against 07/1 strain of VZV; ND=No data,50527,,,CHEMBL615374,Intermediate,10335.0,,N,,F,162,,,vericilla zoster virus,1,,,
,10932,1,BAO_0000218,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",50145,,,CHEMBL615375,Intermediate,561.0,,N,,F,163,,,escherichia cloac,1,,,
,9707,0,BAO_0000019,Ratio of Ki at A2 to Ki at A1 receptors,22226,,,CHEMBL615376,Autocuration,,,U,,B,164,,,,1,,,
,2346,8,BAO_0000249,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",11143,,,CHEMBL615377,Expert,5476.0,,H,,B,165,,,Candida albicans,1,,,
,2205,8,BAO_0000357,"Inhibition of 1,3-beta-glucan synthase",18077,,,CHEMBL615378,Expert,284593.0,,H,,B,166,,,Candida glabrata CBS 138,1,,,
,11900,1,BAO_0000219,Inhibition of growth of 1-87 human tumor cell line,80609,,,CHEMBL615379,Intermediate,9606.0,,N,,F,167,,832.0,Homo sapiens,1,,,1-87 tumor cell line
,14864,9,BAO_0000219,Inhibition of 1-lipoxygenase (LOX)in RBL cells,12166,,,CHEMBL615380,Expert,10116.0,,D,,B,168,,,Rattus norvegicus,1,,,
,16474,9,BAO_0000357,Inhibitory activity against soybean 1-lipoxygenase (SLO),100171,,,CHEMBL615381,Autocuration,3847.0,,D,,B,169,,,Glycine max,1,,,
,16474,9,BAO_0000357,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,100171,,,CHEMBL615382,Autocuration,3847.0,,D,,B,170,,,Glycine max,1,,,
,16474,9,BAO_0000357,% inhibition against soybean 1-lipoxygenase (SLO),100171,,,CHEMBL615383,Autocuration,3847.0,,D,,B,171,,,Glycine max,1,,,
,16474,9,BAO_0000357,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,100171,,,CHEMBL615384,Autocuration,3847.0,,D,,B,172,,,Glycine max,1,,,
,3094,9,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,100171,,,CHEMBL615385,Autocuration,3847.0,,D,,B,173,,,Glycine max,1,,,
,3094,9,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,100171,,,CHEMBL615386,Autocuration,3847.0,,D,,B,174,,,Glycine max,1,,,
,3094,9,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,100171,,,CHEMBL615387,Autocuration,3847.0,,D,,B,175,,,Glycine max,1,,,
,3094,9,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,100171,,,CHEMBL615388,Autocuration,3847.0,,D,,B,176,,,Glycine max,1,,,
,3094,9,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,100171,,,CHEMBL615214,Autocuration,3847.0,,D,,B,177,,,Glycine max,1,,,
,3094,9,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,100171,,,CHEMBL827087,Autocuration,3847.0,,D,,B,178,,,Glycine max,1,,,
,3094,9,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,100171,,,CHEMBL615215,Autocuration,3847.0,,D,,B,179,,,Glycine max,1,,,
,3094,9,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,100171,,,CHEMBL615216,Autocuration,3847.0,,D,,B,180,,,Glycine max,1,,,
,3094,9,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,100171,,,CHEMBL615217,Autocuration,3847.0,,D,,B,181,,,Glycine max,1,,,
,3094,9,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,100171,,,CHEMBL615218,Autocuration,3847.0,,D,,B,182,,,Glycine max,1,,,
,3094,9,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,100171,,,CHEMBL615219,Autocuration,3847.0,,D,,B,183,,,Glycine max,1,,,
,10413,0,BAO_0000019,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,22226,,,CHEMBL615220,Autocuration,10090.0,,U,,B,184,,,Mus musculus,1,,,
,16929,1,BAO_0000219,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),80049,,,CHEMBL615221,Intermediate,10090.0,,N,,F,185,,294.0,Mus musculus,1,,,C3H 10T1/2
,1229,0,BAO_0000019,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,22226,,,CHEMBL615222,Intermediate,,,U,,F,186,,,,1,,,
,16587,8,BAO_0000357,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),11489,,,CHEMBL615223,Autocuration,,,H,,B,187,,,,1,,,
,16587,8,BAO_0000357,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),11862,,,CHEMBL615224,Autocuration,,,H,,B,188,,,,1,,,
,16587,8,BAO_0000357,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,11862,,,CHEMBL615225,Autocuration,,,H,,B,189,,,,1,,,
,16587,8,BAO_0000357,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,11489,,,CHEMBL615226,Autocuration,,,H,,B,190,,,,1,,,
,16587,8,BAO_0000357,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,11862,,,CHEMBL615227,Autocuration,,,H,,B,191,,,,1,,,
,8058,9,BAO_0000019,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,12347,,,CHEMBL615228,Expert,9913.0,,D,,F,192,,,Bos taurus,1,,,
,9065,9,BAO_0000357,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,100120,,,CHEMBL615229,Expert,10116.0,,D,,B,193,,,Rattus norvegicus,1,,,
,8865,9,BAO_0000357,Inhibition of 11 beta-hydroxylase from rat adrenal gland,100120,,Adrenal gland,CHEMBL615230,Expert,10116.0,,D,,B,194,,,Rattus norvegicus,1,,2369.0,
,9066,9,BAO_0000357,Inhibition of rat adrenal 11-beta-hydroxylase,100120,,,CHEMBL615231,Expert,10116.0,,D,,B,195,,,Rattus norvegicus,1,,,
,8394,9,BAO_0000357,Inhibition of rat adrenal 11-beta-hydroxylase,100120,,,CHEMBL884520,Expert,10116.0,,D,,B,196,,,Rattus norvegicus,1,,,
,8394,9,BAO_0000357,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,100120,,,CHEMBL615232,Expert,10116.0,,D,,B,197,,,Rattus norvegicus,1,,,
,6431,8,BAO_0000019,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,10328,,,CHEMBL615233,Autocuration,,,H,,B,198,,,,1,,,
,6431,8,BAO_0000357,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,11490,,,CHEMBL827088,Autocuration,,,H,,B,199,,,,1,,,
,6431,8,BAO_0000357,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,11490,,,CHEMBL615234,Autocuration,,,H,,B,200,,,,1,,,
,9295,8,BAO_0000019,Compound was tested for the percent of inhibition against 12-LO at 10 uM,11134,,,CHEMBL615235,Autocuration,,,H,,F,201,,,,1,,,
,10193,8,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,12052,,,CHEMBL615236,Autocuration,,,H,,B,202,,,,1,,,
,13622,8,BAO_0000019,Compound was tested in vitro for inhibition of 12-LO human platelet,11134,,,CHEMBL615237,Autocuration,,,H,,B,203,,,,1,,,
,12079,8,BAO_0000019,Inhibitory concentration against human platelet 12-lipoxygenase,11134,,,CHEMBL615238,Autocuration,,,H,,F,204,,,,1,,,
,13622,8,BAO_0000019,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,11134,,,CHEMBL615239,Autocuration,,,H,,B,205,,,,1,,,
,12079,9,BAO_0000019,Inhibitory concentration against human platelet 12-lipoxygenase,11134,,,CHEMBL615240,Autocuration,9606.0,,D,,F,206,,,Homo sapiens,1,,,
,13500,8,BAO_0000019,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,11835,,,CHEMBL615241,Expert,,,H,,B,207,,,,1,,,
,13723,8,BAO_0000357,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,11601,,,CHEMBL615242,Expert,,,H,,B,208,,,,1,,,
,16474,8,BAO_0000019,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),11134,,,CHEMBL615243,Autocuration,,,H,,B,209,,,,1,,,
,1630,8,BAO_0000019,Inhibitory activity against human platelet 12-lipoxygenase,11134,,,CHEMBL615244,Autocuration,,,H,,B,210,,,,1,,,
,167,8,BAO_0000019,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,11134,,,CHEMBL615245,Autocuration,,,H,,B,211,,,,1,,,
,16474,8,BAO_0000019,% inhibition against human platelet 12-lipoxygenase (12-HLO),11134,,,CHEMBL615246,Autocuration,,,H,,B,212,,,,1,,,
,167,8,BAO_0000019,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,11134,,,CHEMBL615247,Autocuration,,,H,,B,213,,,,1,,,
,16474,8,BAO_0000019,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,11134,,,CHEMBL615248,Autocuration,,,H,,B,214,,,,1,,,
,10091,8,BAO_0000357,Inhibitory activity towards porcine 12-lipoxygenase,11601,,,CHEMBL615249,Autocuration,,,H,,B,215,,,,1,,,
,11966,8,BAO_0000357,Tested for inhibition against porcine 12-LO,11601,,,CHEMBL615250,Autocuration,,,H,,B,216,,,,1,,,
,951,8,BAO_0000019,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,12052,,,CHEMBL615251,Autocuration,,,H,,B,217,,,,1,,,
,10997,8,BAO_0000019,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,12052,,,CHEMBL615252,Autocuration,,,H,,B,218,,,,1,,,
,10193,8,BAO_0000019,In vitro inhibition of rat platelet 12-lipoxygenase,12052,,,CHEMBL828340,Expert,,,H,,B,219,,,,1,,,
,10193,8,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,12052,,,CHEMBL615253,Autocuration,,,H,,B,220,,,,1,,,
,10193,8,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,12052,,,CHEMBL615254,Autocuration,,,H,,B,221,,,,1,,,
,10193,8,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,12052,,,CHEMBL615255,Autocuration,,,H,,B,222,,,,1,,,
,10193,8,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,12052,,,CHEMBL615256,Autocuration,,,H,,B,223,,,,1,,,
,10193,8,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase,12052,,,CHEMBL615257,Autocuration,,,H,,B,224,,,,1,,,
,11087,8,BAO_0000019,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,12052,,,CHEMBL615258,Autocuration,,,H,,B,225,,,,1,,,
,15569,1,BAO_0000219,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,80007,,,CHEMBL615259,Intermediate,9606.0,,N,,F,226,,621.0,Homo sapiens,1,,,41M
,12989,1,BAO_0000219,In vitro antitumor activity against 41M cell line.,80007,,,CHEMBL615260,Expert,9606.0,,N,,F,227,,621.0,Homo sapiens,1,,,41M
,16745,1,BAO_0000219,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,80007,,,CHEMBL615261,Intermediate,9606.0,,N,,F,228,,621.0,Homo sapiens,1,,,41M
,15569,1,BAO_0000219,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,80007,,,CHEMBL615262,Intermediate,9606.0,,N,,F,229,,621.0,Homo sapiens,1,,,41M
,12989,1,BAO_0000219,In vitro antitumor activity against 41McisR cell line.,80007,,,CHEMBL615263,Expert,9606.0,,N,,F,230,,621.0,Homo sapiens,1,,,41M
,12989,1,BAO_0000219,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,80007,,,CHEMBL838393,Expert,9606.0,,N,,F,231,,621.0,Homo sapiens,1,,,41M
,16745,1,BAO_0000219,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,80007,,,CHEMBL615264,Intermediate,9606.0,,N,,F,232,,621.0,Homo sapiens,1,,,41M
,6210,9,BAO_0000357,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),84,,,CHEMBL615265,Expert,9606.0,,D,,B,233,,,Homo sapiens,1,,,
,6210,9,BAO_0000357,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),68,,,CHEMBL615266,Expert,9606.0,,D,,B,234,,,Homo sapiens,1,,,
,6226,8,BAO_0000357,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),68,,,CHEMBL615267,Expert,,,H,,B,235,,,,1,,,
,17855,8,BAO_0000357,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,10201,,,CHEMBL615268,Expert,,,H,,B,236,,,,1,,,
,17855,8,BAO_0000357,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,10201,,,CHEMBL615269,Expert,,,H,,B,237,,,,1,,,
,17855,8,BAO_0000357,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,10201,,,CHEMBL615270,Expert,,,H,,B,238,,,,1,,,
,10413,8,BAO_0000357,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",12220,,,CHEMBL615271,Autocuration,,,H,,B,239,,,,1,,,
,10413,8,BAO_0000357,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",11303,,,CHEMBL615272,Autocuration,562.0,,H,,B,240,,,Escherichia coli,1,,,
,10413,8,BAO_0000357,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",11303,,,CHEMBL615103,Autocuration,562.0,,H,,B,241,,,Escherichia coli,1,,,
,10413,8,BAO_0000357,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",11303,,,CHEMBL615104,Autocuration,562.0,,H,,B,242,,,Escherichia coli,1,,,
,10413,8,BAO_0000357,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",12220,,,CHEMBL615105,Autocuration,,,H,,B,243,,,,1,,,
,10413,8,BAO_0000357,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",12220,,,CHEMBL872866,Autocuration,,,H,,B,244,,,,1,,,
,7587,8,BAO_0000357,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",11303,,,CHEMBL615106,Autocuration,9823.0,,H,,B,245,,,Sus scrofa,1,,,
,7587,8,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",11303,,,CHEMBL615107,Autocuration,9823.0,,H,,B,246,,,Sus scrofa,1,,,
,7587,8,BAO_0000357,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",11303,,,CHEMBL615108,Autocuration,9823.0,,H,,B,247,,,Sus scrofa,1,,,
,7587,8,BAO_0000357,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",11303,,,CHEMBL615109,Autocuration,9823.0,,H,,B,248,,,Sus scrofa,1,,,
,7587,8,BAO_0000357,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",11303,,,CHEMBL615110,Autocuration,9823.0,,H,,B,249,,,Sus scrofa,1,,,
,7587,8,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",11303,,,CHEMBL840105,Autocuration,9823.0,,H,,B,250,,,Sus scrofa,1,,,
,7587,8,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",11303,,,CHEMBL615111,Autocuration,9823.0,,H,,B,251,,,Sus scrofa,1,,,
,7587,8,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",11303,,,CHEMBL615112,Autocuration,9823.0,,H,,B,252,,,Sus scrofa,1,,,
,7587,8,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",11303,,,CHEMBL615113,Autocuration,9823.0,,H,,B,253,,,Sus scrofa,1,,,
,7587,8,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",11303,,,CHEMBL615114,Autocuration,9823.0,,H,,B,254,,,Sus scrofa,1,,,
,7587,8,BAO_0000357,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",11303,,,CHEMBL615115,Autocuration,9823.0,,H,,B,255,,,Sus scrofa,1,,,
,7587,8,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",11303,,,CHEMBL615116,Autocuration,9823.0,,H,,B,256,,,Sus scrofa,1,,,
,7323,8,BAO_0000357,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",11303,,,CHEMBL615698,Autocuration,,,H,,B,257,,,,1,,,
,7587,0,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",22226,,,CHEMBL615699,Autocuration,9823.0,,U,,B,258,,,Sus scrofa,1,,,
,7587,0,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",22226,,,CHEMBL615700,Autocuration,9823.0,,U,,B,259,,,Sus scrofa,1,,,
,13750,8,BAO_0000357,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,100249,,,CHEMBL615701,Expert,4932.0,,H,,B,260,,,Saccharomyces cerevisiae,1,,,
,7662,0,BAO_0000019,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,22226,,,CHEMBL615702,Autocuration,10116.0,,U,,B,261,,,Rattus norvegicus,1,,,
,7662,0,BAO_0000019,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,22226,,,CHEMBL615703,Autocuration,10116.0,,U,,B,262,,,Rattus norvegicus,1,,,
,7662,0,BAO_0000019,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",22226,,,CHEMBL615704,Autocuration,10116.0,,U,,B,263,,,Rattus norvegicus,1,,,
,12211,6,BAO_0000019,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",104698,,,CHEMBL615705,Autocuration,,,H,,F,264,,,,1,,,
,12211,6,BAO_0000019,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",104698,,,CHEMBL615706,Autocuration,,,H,,F,265,,,,1,,,
,12211,9,BAO_0000221,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,20033,,Ileum,CHEMBL615707,Intermediate,10141.0,,D,,F,266,,,Cavia porcellus,1,,2116.0,
,12211,8,BAO_0000019,Stimulatory activity of intragastric pressure was tested in the rat,10623,,,CHEMBL615708,Expert,,,H,,F,267,,,,1,,,
,15453,8,BAO_0000357,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,121,,,CHEMBL615709,Autocuration,,,H,,B,268,,,,1,,,
,11884,0,BAO_0000218,Dose to reduce neuronal firing against 5-HT cells in rats (iv),22226,,,CHEMBL615710,Autocuration,10116.0,,U,,F,269,,,Rattus norvegicus,1,,,
,7185,8,BAO_0000019,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,12688,,,CHEMBL615711,Autocuration,,,H,,F,270,,,,1,,,
,6876,9,BAO_0000357,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,121,,,CHEMBL615712,Expert,9606.0,,D,,B,271,,,Homo sapiens,1,,,
,6876,9,BAO_0000357,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,121,,,CHEMBL836325,Expert,9606.0,,D,,B,272,,,Homo sapiens,1,,,
,11863,8,BAO_0000019,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,12198,,,CHEMBL615713,Autocuration,,,H,,F,273,,,,1,,,
,11863,8,BAO_0000357,Inhibition constant of high-affinity 5-HT uptake,12198,,,CHEMBL615714,Autocuration,,,H,,B,274,,,,1,,,
,11863,8,BAO_0000019,Michaelis-Menten constant was reported for high affinity transport of 5-HT,12198,,,CHEMBL615715,Autocuration,,,H,,F,275,,,,1,,,
,11863,8,BAO_0000019,Maximum rate was determined for high affinity transport of 5-HT,12198,,,CHEMBL615716,Autocuration,,,H,,F,276,,,,1,,,
,4639,4,BAO_0000019,Compound was tested for agonistic activity against 5-HT uptake,104714,,,CHEMBL615717,Autocuration,,,H,,F,277,,,,1,,,
,15796,8,BAO_0000019,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,10577,,,CHEMBL881818,Expert,,,H,,B,278,,,,1,,,
,15796,8,BAO_0000357,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,105,,,CHEMBL884540,Expert,9913.0,,H,,B,279,,,Bos taurus,1,,,
,12801,5,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,104744,,,CHEMBL615718,Autocuration,10116.0,,D,,B,280,,,Rattus norvegicus,1,,,
,12801,4,BAO_0000224,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,104744,,,CHEMBL615719,Autocuration,,,H,,B,281,,,,1,,,
,12120,4,BAO_0000249,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,104744,,,CHEMBL615720,Autocuration,,Membranes,H,,B,282,,,,1,,,
,12120,4,BAO_0000249,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,104744,,,CHEMBL615721,Autocuration,,Membranes,H,,B,283,,,,1,,,
,11963,4,BAO_0000019,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,,,CHEMBL615722,Autocuration,,,H,,B,284,,,,1,,,
,11701,8,BAO_0000019,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,51,,,CHEMBL615723,Autocuration,,,H,,F,285,,,,1,,,
,9995,8,BAO_0000221,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,Hippocampus,CHEMBL615724,Autocuration,,,H,,B,286,,,,1,,10000000.0,
,9995,8,BAO_0000221,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,Hippocampus,CHEMBL615725,Autocuration,,,H,,B,287,,,,1,,10000000.0,
,9995,8,BAO_0000221,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,Hippocampus,CHEMBL615726,Autocuration,,,H,,B,288,,,,1,,10000000.0,
,16394,8,BAO_0000218,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),10576,In vivo,,CHEMBL615727,Autocuration,,,H,,F,289,,,,1,,,
,11574,9,BAO_0000019,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,105570,,,CHEMBL615728,Intermediate,10141.0,,D,,F,290,,,Cavia porcellus,1,,,
,15779,8,BAO_0000219,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,279,,,CHEMBL857971,Autocuration,,,H,,B,291,,449.0,,1,,,CHO
,15363,8,BAO_0000357,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,107,,,CHEMBL615729,Autocuration,,,H,,B,292,,,,1,,,
,15363,9,BAO_0000019,Efficacy against 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL615730,Expert,10116.0,,D,,F,293,,,Rattus norvegicus,1,,,
,15329,8,BAO_0000019,Intrinsic activity towards 5-HT2A receptor of rat tail artery,12687,,,CHEMBL615731,Expert,,,H,,F,294,,,,1,,,
,15329,8,BAO_0000019,Relative potency towards 5-HT2A receptor of rat tail artery,12687,,,CHEMBL615732,Expert,,,H,,F,295,,,,1,,,
,15329,8,BAO_0000019,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,12687,,,CHEMBL615733,Expert,,,H,,F,296,,,,1,,,
,15329,8,BAO_0000019,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,12687,,,CHEMBL615734,Expert,,,H,,F,297,,,,1,,,
,15329,8,BAO_0000019,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,12687,,,CHEMBL615735,Autocuration,,,H,,F,298,,,,1,,,
,15329,8,BAO_0000019,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,12687,,,CHEMBL615736,Expert,,,H,,F,299,,,,1,,,
,273,9,BAO_0000221,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,20033,,Ileum,CHEMBL615737,Intermediate,10141.0,,D,,F,300,,,Cavia porcellus,1,,2116.0,
,273,9,BAO_0000221,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),20033,,Ileum,CHEMBL615738,Intermediate,10141.0,,D,,F,301,,,Cavia porcellus,1,,2116.0,
,273,9,BAO_0000221,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,20033,,Ileum,CHEMBL615739,Intermediate,10141.0,,D,,F,302,,,Cavia porcellus,1,,2116.0,
,12092,8,BAO_0000357,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,10623,,,CHEMBL615278,Autocuration,,,H,,B,303,,,,1,,,
,1317,9,BAO_0000019,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,10623,,,CHEMBL615279,Expert,10116.0,,D,,F,304,,,Rattus norvegicus,1,,,
,12409,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 4 receptor,168,,,CHEMBL615280,Expert,,,H,,B,305,,,,1,,,
,11126,0,BAO_0000019,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,22226,,,CHEMBL615281,Autocuration,9031.0,,U,,B,306,,,Gallus gallus,1,,,
,11126,0,BAO_0000019,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,22226,,,CHEMBL615282,Autocuration,9606.0,,U,,F,307,,,Homo sapiens,1,,,
,11126,0,BAO_0000019,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,22226,,,CHEMBL615283,Autocuration,9606.0,,U,,F,308,,,Homo sapiens,1,,,
,11126,1,BAO_0000219,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,80156,,,CHEMBL615284,Autocuration,9606.0,,N,,B,309,,649.0,Homo sapiens,1,,,HL-60
,11126,0,BAO_0000019,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,22226,,,CHEMBL615285,Autocuration,9606.0,,U,,B,310,,,Homo sapiens,1,,,
,11126,0,BAO_0000019,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,22226,,,CHEMBL615286,Autocuration,9606.0,,U,,B,311,,,Homo sapiens,1,,,
,17807,7,BAO_0000219,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,104703,,,CHEMBL615287,Autocuration,9606.0,,D,,B,312,,,Homo sapiens,1,,,Oocytes
,16575,2,BAO_0000220,Chymotryptic inhibitory activity against 26S proteasome,100256,,,CHEMBL615288,Intermediate,,,S,,F,313,,,,1,,,
,15407,2,BAO_0000220,Inhibitory activity against 26S proteasome degradation of IkB,100256,,,CHEMBL615289,Intermediate,,,S,,B,314,,,,1,,,
,10797,1,BAO_0000219,In vitro inhibition of 2780/DOX ovarian cancer cell line,81034,,,CHEMBL615290,Intermediate,9606.0,,N,,F,315,,478.0,Homo sapiens,1,,,A2780
,10797,1,BAO_0000219,In vitro inhibition of 2780/S ovarian cancer cell line,81034,,,CHEMBL884522,Intermediate,9606.0,,N,,F,316,,478.0,Homo sapiens,1,,,A2780
,3469,0,BAO_0000019,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,22226,,,CHEMBL615291,Autocuration,9606.0,,U,,F,317,,,Homo sapiens,1,,,
,16037,3,BAO_0000225,Association constant for binding to AATT 28-mer AATT hairpin,22222,,,CHEMBL615292,Intermediate,,,M,,B,318,,,,1,,,
,16037,3,BAO_0000225,Kinetically Defined Association Constant for 28-mer AATT hairpin.,22222,,,CHEMBL615293,Intermediate,,,M,,B,319,,,,1,,,
,16037,3,BAO_0000225,Reaction Rate Parameter for 28-mer AATT hairpin,22222,,,CHEMBL615294,Intermediate,,,M,,B,320,,,,1,,,
,16037,3,BAO_0000225,Reaction Rate Parameter for 28-mer AATT hairpin,22222,,,CHEMBL615295,Intermediate,,,M,,B,321,,,,1,,,
,16524,0,BAO_0000019,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),22226,,,CHEMBL825021,Autocuration,9606.0,,U,,F,322,,,Homo sapiens,1,,,
,16524,0,BAO_0000019,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),22226,,,CHEMBL615296,Autocuration,9606.0,,U,,F,323,,,Homo sapiens,1,,,
,16524,0,BAO_0000019,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,22226,,,CHEMBL615297,Autocuration,9606.0,,U,,F,324,,,Homo sapiens,1,,,
,16758,0,BAO_0000019,Cytotoxicity against cell line 2SC/20 determined by MTT test,22226,,,CHEMBL615298,Autocuration,10029.0,,U,,F,325,,,Cricetulus griseus,1,,,
,16758,0,BAO_0000019,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,22226,,,CHEMBL615299,Autocuration,10029.0,,U,,F,326,,,Cricetulus griseus,1,,,
,16758,0,BAO_0000019,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,22226,,,CHEMBL615300,Autocuration,10029.0,,U,,F,327,,,Cricetulus griseus,1,,,
,14360,8,BAO_0000357,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,241,,,CHEMBL615301,Autocuration,,,H,,B,328,,,,1,,,
,14360,9,BAO_0000357,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,241,,,CHEMBL615302,Expert,9606.0,,D,,B,329,,,Homo sapiens,1,,,
,9964,0,BAO_0000019,Selectivity ratio of ID50 in liver and heart,22226,,,CHEMBL615303,Autocuration,10116.0,,U,,B,330,,,Rattus norvegicus,1,,,
,9964,8,BAO_0000019,"Selectivity, ratio of relative ID50 in liver and heart",12132,,,CHEMBL615304,Autocuration,,,H,,B,331,,,,1,,,
,9964,8,BAO_0000019,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,12132,,,CHEMBL615305,Autocuration,,,H,,B,332,,,,1,,,
,9964,8,BAO_0000218,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,,,CHEMBL615306,Autocuration,,,H,,B,333,,,,1,,,
,9964,8,BAO_0000218,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,,,CHEMBL615307,Autocuration,,,H,,B,334,,,,1,,,
,9964,8,BAO_0000218,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,In vivo,,CHEMBL615308,Autocuration,,,H,,B,335,,,,1,,,
,9964,8,BAO_0000218,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,In vivo,,CHEMBL615309,Autocuration,,,H,,F,336,,,,1,,,
,9964,0,BAO_0000019,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",22226,,,CHEMBL615310,Autocuration,,,U,,B,337,,,,1,,,
,9964,8,BAO_0000019,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,12132,,,CHEMBL615311,Autocuration,,,H,,B,338,,,,1,,,
,9964,0,BAO_0000019,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",22226,,,CHEMBL615312,Autocuration,9606.0,,U,,B,339,,,Homo sapiens,1,,,
,9964,8,BAO_0000019,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,12132,,,CHEMBL615313,Autocuration,,,H,,B,340,,,,1,,,
,9964,8,BAO_0000019,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,12132,,,CHEMBL615314,Autocuration,,,H,,F,341,,,,1,,,
,9964,8,BAO_0000019,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",12132,,,CHEMBL615315,Autocuration,,,H,,B,342,,,,1,,,
,9964,0,BAO_0000218,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",22226,,,CHEMBL615316,Autocuration,10116.0,,U,,B,343,,,Rattus norvegicus,1,,,
,9964,8,BAO_0000218,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,12132,In vivo,,CHEMBL615317,Autocuration,,,H,,B,344,,,,1,,,
,9964,8,BAO_0000218,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,,,CHEMBL615318,Autocuration,,,H,,B,345,,,,1,,,
,9964,0,BAO_0000218,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",22226,,,CHEMBL615319,Autocuration,10116.0,,U,,B,346,,,Rattus norvegicus,1,,,
,9964,8,BAO_0000019,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",12132,,,CHEMBL615320,Autocuration,,,H,,B,347,,,,1,,,
,9964,8,BAO_0000019,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",12132,,,CHEMBL615321,Autocuration,,,H,,F,348,,,,1,,,
,3796,0,BAO_0000019,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",22226,,,CHEMBL615322,Autocuration,10116.0,,U,,B,349,,,Rattus norvegicus,1,,,
,4251,8,BAO_0000357,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,19690,,,CHEMBL615323,Autocuration,562.0,,H,,B,350,,,Escherichia coli,1,,,
,4251,8,BAO_0000357,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,19690,,,CHEMBL615407,Autocuration,562.0,,H,,B,351,,,Escherichia coli,1,,,
,4251,8,BAO_0000357,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,19690,,,CHEMBL857267,Autocuration,562.0,,H,,B,352,,,Escherichia coli,1,,,
,4251,8,BAO_0000357,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,19690,,,CHEMBL615408,Autocuration,562.0,,H,,B,353,,,Escherichia coli,1,,,
,166,8,BAO_0000357,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,19690,,,CHEMBL615409,Autocuration,,,H,,B,354,,,,1,,,
,17861,8,BAO_0000357,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,19690,,,CHEMBL615410,Autocuration,,,H,,B,355,,,,1,,,
,166,8,BAO_0000357,Inhibition constant against 3-dehydroquinate synthase,19690,,,CHEMBL615411,Autocuration,,,H,,B,356,,,,1,,,
,166,8,BAO_0000357,Association rate constant against 3-dehydroquinate synthase,19690,,,CHEMBL615412,Autocuration,,,H,,B,357,,,,1,,,
,166,8,BAO_0000357,Rate constant against 3-dehydroquinate synthase,19690,,,CHEMBL615413,Autocuration,,,H,,B,358,,,,1,,,
,3548,0,BAO_0000019,Inhibitory activity against fuc-TVII,22226,,,CHEMBL615414,Autocuration,,,U,,B,359,,,,1,,,
,9877,9,BAO_0000251,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,,Liver,CHEMBL615415,Autocuration,10116.0,Microsomes,D,,B,360,,,Rattus norvegicus,1,,2107.0,
,9877,9,BAO_0000251,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,,Liver,CHEMBL615416,Autocuration,10116.0,Microsomes,D,,B,361,,,Rattus norvegicus,1,,2107.0,
,9877,9,BAO_0000251,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,,Liver,CHEMBL615417,Autocuration,10116.0,Microsomes,D,,B,362,,,Rattus norvegicus,1,,2107.0,
,9877,9,BAO_0000251,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,,Liver,CHEMBL615418,Autocuration,10116.0,Microsomes,D,,B,363,,,Rattus norvegicus,1,,2107.0,
,9877,9,BAO_0000251,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,,Liver,CHEMBL615419,Autocuration,10116.0,Microsomes,D,,B,364,,,Rattus norvegicus,1,,2107.0,
,9877,9,BAO_0000251,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,12236,,Liver,CHEMBL615420,Autocuration,10116.0,Microsomes,D,,B,365,,,Rattus norvegicus,1,,2107.0,
,9877,9,BAO_0000251,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,12236,,Liver,CHEMBL615421,Autocuration,10116.0,Microsomes,D,,B,366,,,Rattus norvegicus,1,,2107.0,
,9877,9,BAO_0000251,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,12236,,Liver,CHEMBL615422,Autocuration,10116.0,Microsomes,D,,B,367,,,Rattus norvegicus,1,,2107.0,
,9877,9,BAO_0000251,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,12236,,Liver,CHEMBL615423,Autocuration,10116.0,Microsomes,D,,B,368,,,Rattus norvegicus,1,,2107.0,
,9877,9,BAO_0000251,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,12236,,Liver,CHEMBL872868,Autocuration,10116.0,Microsomes,D,,B,369,,,Rattus norvegicus,1,,2107.0,
,9877,9,BAO_0000251,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,12236,,Liver,CHEMBL615424,Autocuration,10116.0,Microsomes,D,,B,370,,,Rattus norvegicus,1,,2107.0,
,3003,4,BAO_0000224,Inhibitory activity against 3-phosphoglycerate kinase.,104832,,,CHEMBL825022,Autocuration,,,H,,B,371,,,,1,,,
,3003,4,BAO_0000224,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,104832,,,CHEMBL615425,Autocuration,,,H,,B,372,,,,1,,,
,3003,4,BAO_0000224,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",104832,,,CHEMBL615426,Autocuration,,,H,,B,373,,,,1,,,
,17185,9,BAO_0000357,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,10612,,,CHEMBL615427,Expert,9606.0,,D,,B,374,,,Homo sapiens,1,,,
,6072,1,BAO_0000219,Cytotoxicity on 3677 melanoma cells,80616,,,CHEMBL615428,Intermediate,9606.0,,N,,F,375,,844.0,Homo sapiens,1,,,3677 melanoma cell line
,6072,1,BAO_0000219,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,80616,,,CHEMBL615429,Intermediate,9606.0,,N,,F,376,,844.0,Homo sapiens,1,,,3677 melanoma cell line
,5018,1,BAO_0000219,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,80617,,,CHEMBL615430,Intermediate,10090.0,,N,,F,377,,700.0,Mus musculus,1,,,MC-38
,2852,0,BAO_0000019,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,22226,,,CHEMBL615431,Intermediate,9606.0,,U,,F,378,,,Homo sapiens,1,,,
,8663,0,BAO_0000218,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,22226,,,CHEMBL615432,Autocuration,,,U,,F,379,,798.0,,1,,,B16
,8663,0,BAO_0000218,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,22226,,,CHEMBL615433,Autocuration,,,U,,F,380,,798.0,,1,,,B16
,3245,9,BAO_0000019,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,12464,,,CHEMBL615434,Expert,12131.0,,D,,F,381,,,Human rhinovirus 14,1,,,
,3245,1,BAO_0000218,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,50085,,,CHEMBL615435,Intermediate,169066.0,,N,,F,382,,,Human rhinovirus sp.,1,,,
,3877,1,BAO_0000218,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,50679,,,CHEMBL615436,Intermediate,169066.0,,N,,F,383,,,human rhinovirus type 14,1,,,
,3877,1,BAO_0000218,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,50679,,,CHEMBL615437,Intermediate,169066.0,,N,,F,384,,,human rhinovirus type 14,1,,,
,5861,9,BAO_0000019,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,12464,,,CHEMBL615438,Expert,12131.0,,D,,F,385,,,Human rhinovirus 14,1,,,
,5861,9,BAO_0000019,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,12464,,,CHEMBL615439,Expert,12131.0,,D,,F,386,,,Human rhinovirus 14,1,,,
,5861,9,BAO_0000019,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,12464,,,CHEMBL615440,Expert,12131.0,,D,,F,387,,,Human rhinovirus 14,1,,,
,5861,9,BAO_0000019,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,12464,,,CHEMBL615441,Expert,12131.0,,D,,F,388,,,Human rhinovirus 14,1,,,
,13748,1,BAO_0000218,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,50665,,,CHEMBL615641,Intermediate,12059.0,,N,,F,389,,,Enterovirus,1,,,
,13748,1,BAO_0000218,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,50665,,,CHEMBL872065,Intermediate,12059.0,,N,,F,390,,,Enterovirus,1,,,
,13748,1,BAO_0000218,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,50665,,,CHEMBL825023,Intermediate,12059.0,,N,,F,391,,,Enterovirus,1,,,
,13748,1,BAO_0000218,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,50665,,,CHEMBL615642,Intermediate,12059.0,,N,,F,392,,,Enterovirus,1,,,
,13748,8,BAO_0000357,Inhibition of human rhinovirus 3C protease,12464,,,CHEMBL615643,Expert,147712.0,,H,,B,393,,,Human rhinovirus B,1,,,
,17699,0,BAO_0000019,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,22226,,,CHEMBL615644,Autocuration,9606.0,,U,,B,394,,,Homo sapiens,1,,,
,7145,1,BAO_0000218,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),80619,,,CHEMBL615645,Intermediate,10090.0,,N,,F,395,,833.0,Mus musculus,1,,,3EM 37
,7145,1,BAO_0000218,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),80619,,,CHEMBL615646,Intermediate,10090.0,,N,,F,396,,833.0,Mus musculus,1,,,3EM 37
,7145,1,BAO_0000218,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),80619,,,CHEMBL615647,Intermediate,10090.0,,N,,F,397,,833.0,Mus musculus,1,,,3EM 37
,7145,1,BAO_0000218,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),80619,,,CHEMBL615648,Intermediate,10090.0,,N,,F,398,,833.0,Mus musculus,1,,,3EM 37
,7145,1,BAO_0000218,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,80619,,,CHEMBL615649,Intermediate,10090.0,,N,,F,399,,833.0,Mus musculus,1,,,3EM 37
,7145,1,BAO_0000218,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,80619,,,CHEMBL615650,Intermediate,10090.0,,N,,F,400,,833.0,Mus musculus,1,,,3EM 37
,5325,1,BAO_0000218,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,80620,,,CHEMBL615651,Intermediate,10090.0,,N,,F,401,,847.0,Mus musculus,1,,,3LL cell line
,5325,1,BAO_0000218,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,80620,,,CHEMBL615652,Intermediate,10090.0,,N,,F,402,,847.0,Mus musculus,1,,,3LL cell line
,5325,1,BAO_0000218,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,80620,,,CHEMBL615653,Expert,10090.0,,N,,F,403,,847.0,Mus musculus,1,,,3LL cell line
,16169,1,BAO_0000219,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,80620,,,CHEMBL615654,Intermediate,10090.0,,N,,F,404,,847.0,Mus musculus,1,,,3LL cell line
,16169,1,BAO_0000219,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,80620,,,CHEMBL615655,Intermediate,10090.0,,N,,F,405,,847.0,Mus musculus,1,,,3LL cell line
,16169,1,BAO_0000219,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,80620,,,CHEMBL825024,Intermediate,10090.0,,N,,F,406,,847.0,Mus musculus,1,,,3LL cell line
,16169,1,BAO_0000219,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,80620,,,CHEMBL615656,Intermediate,10090.0,,N,,F,407,,847.0,Mus musculus,1,,,3LL cell line
,16169,1,BAO_0000219,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,80620,,,CHEMBL615657,Intermediate,10090.0,,N,,F,408,,847.0,Mus musculus,1,,,3LL cell line
,16169,1,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,80620,,,CHEMBL615658,Intermediate,10090.0,,N,,F,409,,847.0,Mus musculus,1,,,3LL cell line
,16169,1,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,80620,,,CHEMBL615659,Intermediate,10090.0,,N,,F,410,,847.0,Mus musculus,1,,,3LL cell line
,16169,1,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,80620,,,CHEMBL615660,Intermediate,10090.0,,N,,F,411,,847.0,Mus musculus,1,,,3LL cell line
,16169,1,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,80620,,,CHEMBL615661,Intermediate,10090.0,,N,,F,412,,847.0,Mus musculus,1,,,3LL cell line
,16169,1,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,80620,,,CHEMBL615662,Intermediate,10090.0,,N,,F,413,,847.0,Mus musculus,1,,,3LL cell line
,16169,1,BAO_0000219,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,80620,,,CHEMBL615663,Intermediate,10090.0,,N,,F,414,,847.0,Mus musculus,1,,,3LL cell line
,16169,1,BAO_0000219,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,80620,,,CHEMBL615664,Intermediate,10090.0,,N,,F,415,,847.0,Mus musculus,1,,,3LL cell line
,16169,1,BAO_0000219,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,80620,,,CHEMBL615665,Intermediate,10090.0,,N,,F,416,,847.0,Mus musculus,1,,,3LL cell line
,16169,1,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,80620,,,CHEMBL615666,Intermediate,10090.0,,N,,F,417,,847.0,Mus musculus,1,,,3LL cell line
,16169,1,BAO_0000219,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,80620,,,CHEMBL615667,Intermediate,10090.0,,N,,F,418,,847.0,Mus musculus,1,,,3LL cell line
,16169,1,BAO_0000219,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,80620,,,CHEMBL615668,Intermediate,10090.0,,N,,F,419,,847.0,Mus musculus,1,,,3LL cell line
,16169,1,BAO_0000219,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,80620,,,CHEMBL615669,Intermediate,10090.0,,N,,F,420,,847.0,Mus musculus,1,,,3LL cell line
,16169,1,BAO_0000219,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,80620,,,CHEMBL615670,Intermediate,10090.0,,N,,F,421,,847.0,Mus musculus,1,,,3LL cell line
,16169,1,BAO_0000219,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,80620,,,CHEMBL836739,Intermediate,10090.0,,N,,F,422,,847.0,Mus musculus,1,,,3LL cell line
,16169,1,BAO_0000219,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,80620,,,CHEMBL615671,Intermediate,10090.0,,N,,F,423,,847.0,Mus musculus,1,,,3LL cell line
,16169,1,BAO_0000219,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,80620,,,CHEMBL615672,Intermediate,10090.0,,N,,F,424,,847.0,Mus musculus,1,,,3LL cell line
,16169,1,BAO_0000219,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,80620,,,CHEMBL615791,Intermediate,10090.0,,N,,F,425,,847.0,Mus musculus,1,,,3LL cell line
,16169,1,BAO_0000219,spermine levels in 3LL cells after the treatment of 1 uM of Compound,80620,,,CHEMBL615792,Intermediate,10090.0,,N,,F,426,,847.0,Mus musculus,1,,,3LL cell line
,16169,1,BAO_0000219,spermine levels in 3LL cells after the treatment of 10 uM of Compound,80620,,,CHEMBL615793,Intermediate,10090.0,,N,,F,427,,847.0,Mus musculus,1,,,3LL cell line
,16169,1,BAO_0000219,spermine levels in 3LL cells after the treatment of 250 uM of Compound,80620,,,CHEMBL615794,Intermediate,10090.0,,N,,F,428,,847.0,Mus musculus,1,,,3LL cell line
,16169,1,BAO_0000219,spermine levels in 3LL cells after the treatment of 50 uM of Compound,80620,,,CHEMBL615795,Intermediate,10090.0,,N,,F,429,,847.0,Mus musculus,1,,,3LL cell line
,15547,1,BAO_0000219,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,80621,,,CHEMBL615590,Intermediate,9606.0,,N,,F,430,,971.0,Homo sapiens,1,,,3LLD122
,8663,0,BAO_0000218,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,22226,,,CHEMBL615591,Autocuration,,,U,,F,431,,,,1,,,
,8663,0,BAO_0000218,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,22226,,,CHEMBL615592,Autocuration,,,U,,F,432,,,,1,,,
,8663,0,BAO_0000218,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,22226,,,CHEMBL615593,Autocuration,,,U,,F,433,,,,1,,,
,8663,0,BAO_0000218,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,22226,,,CHEMBL615594,Autocuration,,,U,,F,434,,,,1,,,
,4504,1,BAO_0000219,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,80951,,,CHEMBL615595,Intermediate,10090.0,,N,,F,435,,723.0,Mus musculus,1,,,NIH3T3
,4504,1,BAO_0000219,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,80951,,,CHEMBL615596,Intermediate,10090.0,,N,,F,436,,723.0,Mus musculus,1,,,NIH3T3
,12695,8,BAO_0000219,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,11169,,,CHEMBL615597,Expert,,,H,,F,437,,723.0,,1,,,NIH3T3
,12695,1,BAO_0000219,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,80951,,,CHEMBL615598,Intermediate,10090.0,,N,,F,438,,723.0,Mus musculus,1,,,NIH3T3
,12695,1,BAO_0000219,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,80951,,,CHEMBL615599,Intermediate,10090.0,,N,,F,439,,723.0,Mus musculus,1,,,NIH3T3
,17642,1,BAO_0000219,Effective dose against murine 3T3 fibroblasts cells,80951,,,CHEMBL615600,Expert,10090.0,,N,,F,440,,723.0,Mus musculus,1,,,NIH3T3
,17642,1,BAO_0000219,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,80951,,,CHEMBL615601,Expert,10090.0,,N,,F,441,,723.0,Mus musculus,1,,,NIH3T3
,12340,1,BAO_0000219,Cytotoxic effect on 3T3 cells,80951,,,CHEMBL615602,Expert,10090.0,,N,,F,442,,723.0,Mus musculus,1,,,NIH3T3
,12340,1,BAO_0000219,Cytotoxic effect on 3T3 cells,80951,,,CHEMBL615603,Expert,10090.0,,N,,F,443,,723.0,Mus musculus,1,,,NIH3T3
,12716,1,BAO_0000219,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,80951,,,CHEMBL615604,Intermediate,10090.0,,N,,F,444,,723.0,Mus musculus,1,,,NIH3T3
,6277,1,BAO_0000219,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,80951,,,CHEMBL615605,Intermediate,10090.0,,N,,F,445,,723.0,Mus musculus,1,,,NIH3T3
,6277,1,BAO_0000219,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,80951,,,CHEMBL615606,Intermediate,10090.0,,N,,F,446,,723.0,Mus musculus,1,,,NIH3T3
,6277,1,BAO_0000219,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,80951,,,CHEMBL884526,Expert,10090.0,,N,,F,447,,723.0,Mus musculus,1,,,NIH3T3
,6277,1,BAO_0000219,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,80951,,,CHEMBL615607,Expert,10090.0,,N,,F,448,,723.0,Mus musculus,1,,,NIH3T3
,6277,1,BAO_0000219,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,80951,,,CHEMBL615608,Intermediate,10090.0,,N,,F,449,,723.0,Mus musculus,1,,,NIH3T3
,6277,1,BAO_0000219,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,80951,,,CHEMBL615609,Expert,10090.0,,N,,F,450,,723.0,Mus musculus,1,,,NIH3T3
,6277,1,BAO_0000219,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,80951,,,CHEMBL615682,Expert,10090.0,,N,,F,451,,723.0,Mus musculus,1,,,NIH3T3
,6277,1,BAO_0000219,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,80951,,,CHEMBL615683,Intermediate,10090.0,,N,,F,452,,723.0,Mus musculus,1,,,NIH3T3
,17780,1,BAO_0000218,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,80951,,,CHEMBL615684,Expert,10090.0,,N,,F,453,,723.0,Mus musculus,1,,,NIH3T3
,12751,7,BAO_0000219,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,104860,,,CHEMBL615685,Autocuration,10090.0,,D,,F,454,,,Mus musculus,1,,,
,12380,1,BAO_0000219,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,80951,,,CHEMBL615686,Expert,10090.0,,N,,F,455,,723.0,Mus musculus,1,,,NIH3T3
,14892,1,BAO_0000219,Inhibitory activity against 3T3 cell line,80951,,,CHEMBL615687,Intermediate,10090.0,,N,,F,456,,723.0,Mus musculus,1,,,NIH3T3
,12695,1,BAO_0000219,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,80951,,,CHEMBL884523,Intermediate,10090.0,,N,,F,457,,723.0,Mus musculus,1,,,NIH3T3
,12695,8,BAO_0000019,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,11169,,,CHEMBL615688,Expert,,,H,,F,458,,,,1,,,
,12695,1,BAO_0000219,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,80951,,,CHEMBL615689,Intermediate,10090.0,,N,,F,459,,723.0,Mus musculus,1,,,NIH3T3
,12695,1,BAO_0000219,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,80951,,,CHEMBL615690,Intermediate,10090.0,,N,,F,460,,723.0,Mus musculus,1,,,NIH3T3
,12695,8,BAO_0000019,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,11169,,,CHEMBL615691,Expert,,,H,,F,461,,,,1,,,
,12695,8,BAO_0000019,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,11169,,,CHEMBL615692,Expert,,,H,,F,462,,,,1,,,
,6277,1,BAO_0000219,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,80951,,,CHEMBL615693,Intermediate,10090.0,,N,,F,463,,723.0,Mus musculus,1,,,NIH3T3
,6277,1,BAO_0000219,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,80951,,,CHEMBL615324,Expert,10090.0,,N,,F,464,,723.0,Mus musculus,1,,,NIH3T3
,4959,9,BAO_0000219,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,9,,,CHEMBL615325,Expert,9606.0,,D,,F,465,,723.0,Homo sapiens,1,,,NIH3T3
,4959,9,BAO_0000219,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),9,,,CHEMBL615490,Expert,9606.0,,D,,F,466,,723.0,Homo sapiens,1,,,NIH3T3
,4959,9,BAO_0000219,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,188,,,CHEMBL615491,Expert,9606.0,,D,,F,467,,723.0,Homo sapiens,1,,,NIH3T3
,4959,9,BAO_0000219,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),188,,,CHEMBL615492,Expert,9606.0,,D,,F,468,,723.0,Homo sapiens,1,,,NIH3T3
,12082,1,BAO_0000219,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,80951,,,CHEMBL615493,Intermediate,10090.0,,N,,F,469,,723.0,Mus musculus,1,,,NIH3T3
,12082,1,BAO_0000219,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,80951,,,CHEMBL615494,Intermediate,10090.0,,N,,F,470,,723.0,Mus musculus,1,,,NIH3T3
,12082,1,BAO_0000219,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,80951,,,CHEMBL615495,Intermediate,10090.0,,N,,F,471,,723.0,Mus musculus,1,,,NIH3T3
,12082,1,BAO_0000219,Inhibitory concentration was calculated on 3T3 cells by using growth assay,80951,,,CHEMBL615496,Intermediate,10090.0,,N,,F,472,,723.0,Mus musculus,1,,,NIH3T3
,2643,1,BAO_0000219,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,80951,,,CHEMBL615497,Intermediate,10090.0,,N,,F,473,,723.0,Mus musculus,1,,,NIH3T3
,11926,1,BAO_0000219,Inhibition of Swiss 3T3 mouse fibroblast proliferation,80951,,,CHEMBL615498,Expert,10090.0,,N,,F,474,,723.0,Mus musculus,1,,,NIH3T3
,15204,1,BAO_0000219,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,80951,,,CHEMBL615499,Intermediate,10090.0,,N,,A,475,,723.0,Mus musculus,1,,,NIH3T3
,15992,1,BAO_0000219,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,80951,,,CHEMBL835522,Expert,10090.0,,N,,F,476,,723.0,Mus musculus,1,,,NIH3T3
,16279,1,BAO_0000219,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,80951,,,CHEMBL615500,Intermediate,10090.0,,N,,F,477,,723.0,Mus musculus,1,,,NIH3T3
,16279,1,BAO_0000219,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,,,CHEMBL615501,Intermediate,10090.0,,N,,F,478,,723.0,Mus musculus,1,,,NIH3T3
,16279,1,BAO_0000219,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,,,CHEMBL615502,Intermediate,10090.0,,N,,F,479,,723.0,Mus musculus,1,,,NIH3T3
,16279,1,BAO_0000219,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,,,CHEMBL615503,Intermediate,10090.0,,N,,F,480,,723.0,Mus musculus,1,,,NIH3T3
,16279,1,BAO_0000219,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,,,CHEMBL615504,Intermediate,10090.0,,N,,F,481,,723.0,Mus musculus,1,,,NIH3T3
,16279,1,BAO_0000219,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,,,CHEMBL615505,Intermediate,10090.0,,N,,F,482,,723.0,Mus musculus,1,,,NIH3T3
,12831,1,BAO_0000219,Inhibition of swiss 3T3 mouse fibroblast proliferation,80951,,,CHEMBL615506,Expert,10090.0,,N,,F,483,,723.0,Mus musculus,1,,,NIH3T3
,13497,1,BAO_0000219,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,80951,,,CHEMBL615507,Intermediate,10090.0,,N,,F,484,,723.0,Mus musculus,1,,,NIH3T3
,13715,1,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,80006,,,CHEMBL615508,Intermediate,,,N,,F,485,,620.0,,1,,,3T3-L1
,13618,1,BAO_0000219,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,80006,,,CHEMBL615509,Intermediate,10090.0,,N,,F,486,,620.0,Mus musculus,1,,,3T3-L1
,11902,1,BAO_0000219,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,80006,,,CHEMBL615510,Intermediate,10090.0,,N,,F,487,,620.0,Mus musculus,1,,,3T3-L1
,11902,1,BAO_0000219,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,80006,,,CHEMBL615511,Intermediate,10090.0,,N,,F,488,,620.0,Mus musculus,1,,,3T3-L1
,11902,1,BAO_0000219,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,80006,,,CHEMBL615512,Intermediate,10090.0,,N,,F,489,,620.0,Mus musculus,1,,,3T3-L1
,14840,1,BAO_0000218,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",80006,,,CHEMBL615513,Intermediate,10090.0,,N,,F,490,,620.0,Mus musculus,1,,,3T3-L1
,14840,1,BAO_0000218,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",80006,,,CHEMBL615514,Intermediate,10090.0,,N,,F,491,,620.0,Mus musculus,1,,,3T3-L1
,13715,1,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,80006,,,CHEMBL615515,Intermediate,,,N,,F,492,,620.0,,1,,,3T3-L1
,13715,1,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,80006,,,CHEMBL615516,Intermediate,,,N,,F,493,,620.0,,1,,,3T3-L1
,13715,1,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,80006,,,CHEMBL615517,Intermediate,,,N,,F,494,,620.0,,1,,,3T3-L1
,13715,1,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,80006,,,CHEMBL615518,Intermediate,,,N,,F,495,,620.0,,1,,,3T3-L1
,13715,1,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,80006,,,CHEMBL615519,Intermediate,,,N,,F,496,,620.0,,1,,,3T3-L1
,13715,1,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,80006,,,CHEMBL615520,Intermediate,,,N,,F,497,,620.0,,1,,,3T3-L1
,13715,1,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,80006,,,CHEMBL615521,Intermediate,,,N,,F,498,,620.0,,1,,,3T3-L1
,13715,1,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,80006,,,CHEMBL615522,Intermediate,,,N,,F,499,,620.0,,1,,,3T3-L1
,13715,1,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,80006,,,CHEMBL615523,Intermediate,,,N,,F,500,,620.0,,1,,,3T3-L1
,13715,1,BAO_0000218,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,80006,,,CHEMBL615524,Expert,,,N,,F,501,,620.0,,1,,,3T3-L1
,13715,1,BAO_0000218,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,80006,,,CHEMBL615525,Expert,,,N,,F,502,,620.0,,1,,,3T3-L1
,13715,1,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,80006,,,CHEMBL615526,Intermediate,,,N,,F,503,,620.0,,1,,,3T3-L1
,13715,1,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,80006,,,CHEMBL615527,Intermediate,,,N,,F,504,,620.0,,1,,,3T3-L1
,13715,1,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,80006,,,CHEMBL615528,Intermediate,,,N,,F,505,,620.0,,1,,,3T3-L1
,13715,1,BAO_0000218,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,80006,,,CHEMBL615529,Expert,,,N,,F,506,,620.0,,1,,,3T3-L1
,13715,1,BAO_0000218,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,80006,,,CHEMBL615530,Expert,,,N,,F,507,,620.0,,1,,,3T3-L1
,13715,1,BAO_0000218,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,80006,,,CHEMBL615531,Expert,,,N,,F,508,,620.0,,1,,,3T3-L1
,13715,1,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,80006,,,CHEMBL615532,Intermediate,,,N,,F,509,,620.0,,1,,,3T3-L1
,13715,1,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,80006,,,CHEMBL615533,Intermediate,,,N,,F,510,,620.0,,1,,,3T3-L1
,13715,1,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,80006,,,CHEMBL615534,Intermediate,,,N,,F,511,,620.0,,1,,,3T3-L1
,13715,1,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,80006,,,CHEMBL615535,Intermediate,,,N,,F,512,,620.0,,1,,,3T3-L1
,13715,1,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,80006,,,CHEMBL615536,Intermediate,,,N,,F,513,,620.0,,1,,,3T3-L1
,13715,1,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,80006,,,CHEMBL615537,Intermediate,,,N,,F,514,,620.0,,1,,,3T3-L1
,13715,1,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,80006,,,CHEMBL615538,Intermediate,,,N,,F,515,,620.0,,1,,,3T3-L1
,13715,1,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,80006,,,CHEMBL836166,Intermediate,,,N,,F,516,,620.0,,1,,,3T3-L1
,6411,8,BAO_0000219,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,11214,,,CHEMBL615539,Expert,,,H,,F,517,,620.0,,1,,,3T3-L1
,6411,1,BAO_0000219,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,80006,,,CHEMBL615540,Intermediate,10090.0,,N,,F,518,,620.0,Mus musculus,1,,,3T3-L1
,6411,8,BAO_0000219,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,11214,,,CHEMBL615541,Expert,,,H,,F,519,,620.0,,1,,,3T3-L1
,3966,1,BAO_0000219,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,80006,,,CHEMBL615542,Expert,10090.0,,N,,F,520,,620.0,Mus musculus,1,,,3T3-L1
,3966,1,BAO_0000219,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,80006,,,CHEMBL615543,Intermediate,10090.0,,N,,F,521,,620.0,Mus musculus,1,,,3T3-L1
,15556,1,BAO_0000219,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,80006,,,CHEMBL615544,Expert,10090.0,,N,,F,522,,620.0,Mus musculus,1,,,3T3-L1
,5845,1,BAO_0000219,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,80006,,,CHEMBL615545,Expert,10090.0,,N,,F,523,,620.0,Mus musculus,1,,,3T3-L1
,14422,1,BAO_0000219,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,80006,,,CHEMBL615546,Expert,10090.0,,N,,F,524,,620.0,Mus musculus,1,,,3T3-L1
,5845,1,BAO_0000219,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,80006,,,CHEMBL615547,Expert,10090.0,,N,,F,525,,620.0,Mus musculus,1,,,3T3-L1
,14508,1,BAO_0000219,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,80006,,,CHEMBL615548,Expert,10090.0,,N,,F,526,,620.0,Mus musculus,1,,,3T3-L1
,14508,1,BAO_0000219,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,80006,,,CHEMBL615549,Expert,10090.0,,N,,F,527,,620.0,Mus musculus,1,,,3T3-L1
,14508,1,BAO_0000219,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,80006,,,CHEMBL615550,Expert,10090.0,,N,,F,528,,620.0,Mus musculus,1,,,3T3-L1
,6349,1,BAO_0000219,Inhibitory activity against rat fibroblast (3Y1) cell line,80622,,,CHEMBL615551,Intermediate,10116.0,,N,,F,529,,1118.0,Rattus norvegicus,1,,,3Y1 cell line
,15899,1,BAO_0000219,Mean concentration causing inhibition of cell growth in 3Y1 cells.,80622,,,CHEMBL615552,Expert,10116.0,,N,,F,530,,1118.0,Rattus norvegicus,1,,,3Y1 cell line
,15899,1,BAO_0000219,Cytotoxicity in 3Y1 cells.,80622,,,CHEMBL615553,Expert,10116.0,,N,,F,531,,1118.0,Rattus norvegicus,1,,,3Y1 cell line
,15899,1,BAO_0000219,Cytostatic effect in 3Y1 cells.,80622,,,CHEMBL615554,Expert,10116.0,,N,,F,532,,1118.0,Rattus norvegicus,1,,,3Y1 cell line
,15899,1,BAO_0000219,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",80622,,,CHEMBL615555,Intermediate,10116.0,,N,,F,533,,1118.0,Rattus norvegicus,1,,,3Y1 cell line
,17038,1,BAO_0000219,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,80622,,,CHEMBL615556,Expert,10116.0,,N,,F,534,,1118.0,Rattus norvegicus,1,,,3Y1 cell line
,12421,0,BAO_0000019,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,22226,,,CHEMBL615557,Autocuration,,,U,,B,535,,,,1,,,
,12947,0,BAO_0000019,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,22226,,,CHEMBL615558,Autocuration,,,U,,B,536,,,,1,,,
,12947,0,BAO_0000019,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,22226,,,CHEMBL872066,Autocuration,,,U,,B,537,,,,1,,,
,4896,9,BAO_0000019,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,11607,,,CHEMBL615559,Expert,9823.0,,D,,B,538,,,Sus scrofa,1,,,
,6148,8,BAO_0000019,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,11607,,,CHEMBL615560,Autocuration,,,H,,B,539,,,,1,,,
,16432,8,BAO_0000019,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,11607,,,CHEMBL615561,Autocuration,,,H,,B,540,,,,1,,,
,4978,8,BAO_0000019,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,11607,,,CHEMBL857062,Expert,,,H,,B,541,,,,1,,,
,4978,8,BAO_0000019,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),11607,,,CHEMBL615562,Expert,,,H,,B,542,,,,1,,,
,3723,8,BAO_0000019,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,11607,,,CHEMBL615563,Autocuration,,,H,,B,543,,,,1,,,
,3518,8,BAO_0000357,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),11607,,,CHEMBL615564,Autocuration,,,H,,B,544,,,,1,,,
,4164,8,BAO_0000019,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,11607,,,CHEMBL615565,Autocuration,,,H,,B,545,,,,1,,,
,3518,8,BAO_0000019,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,11607,,,CHEMBL615566,Autocuration,,,H,,B,546,,,,1,,,
,4164,9,BAO_0000019,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,11607,,,CHEMBL615567,Expert,9823.0,,D,,B,547,,,Sus scrofa,1,,,
,3518,8,BAO_0000019,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,11607,,,CHEMBL615568,Autocuration,,,H,,B,548,,,,1,,,
,3518,8,BAO_0000357,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),11607,,,CHEMBL615569,Autocuration,,,H,,B,549,,,,1,,,
,4978,8,BAO_0000019,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,11607,,,CHEMBL615570,Autocuration,,,H,,B,550,,,,1,,,
,4978,8,BAO_0000019,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),11607,,,CHEMBL615571,Autocuration,,,H,,B,551,,,,1,,,
,6455,4,BAO_0000224,Binding affinity against melatonin (MT1) receptor (pC1),104733,,,CHEMBL615572,Autocuration,,,H,,B,552,,,,1,,,
,2222,0,BAO_0000019,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,22226,,,CHEMBL615573,Autocuration,,,U,,B,553,,,,1,,,
,13020,0,BAO_0000019,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,22226,,,CHEMBL615574,Autocuration,,,U,,B,554,,,,1,,,
,13021,0,BAO_0000019,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,22226,,,CHEMBL615575,Autocuration,,,U,,B,555,,,,1,,,
,14532,8,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,10619,,,CHEMBL615576,Autocuration,,,H,,B,556,,,,1,,,
,14118,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,10619,,,CHEMBL615577,Autocuration,,,H,,B,557,,,,1,,,
,11884,8,BAO_0000221,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,51,,Hippocampus,CHEMBL615578,Autocuration,,,H,,B,558,,,,1,,10000000.0,
,13969,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,51,,,CHEMBL615579,Expert,,,H,,B,559,,,,1,,,
,13392,8,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor,51,,,CHEMBL615580,Expert,,,H,,B,560,,,,1,,,
,14430,8,BAO_0000019,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,51,,,CHEMBL615581,Expert,,,H,,B,561,,,,1,,,
,12248,8,BAO_0000221,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,,Hippocampus,CHEMBL615582,Autocuration,,,H,,B,562,,,,1,,10000000.0,
,12249,8,BAO_0000221,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,,Hippocampus,CHEMBL615583,Autocuration,,,H,,B,563,,,,1,,10000000.0,
,9995,8,BAO_0000221,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,Hippocampus,CHEMBL615584,Autocuration,,,H,,B,564,,,,1,,10000000.0,
,9995,8,BAO_0000221,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,Hippocampus,CHEMBL833691,Autocuration,,,H,,B,565,,,,1,,10000000.0,
,9995,8,BAO_0000221,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,Hippocampus,CHEMBL615585,Autocuration,,,H,,B,566,,,,1,,10000000.0,
,9995,8,BAO_0000221,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,Hippocampus,CHEMBL615586,Autocuration,,,H,,B,567,,,,1,,10000000.0,
,9995,8,BAO_0000221,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,Hippocampus,CHEMBL884524,Autocuration,,,H,,B,568,,,,1,,10000000.0,
,12249,8,BAO_0000221,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,,Hippocampus,CHEMBL615587,Autocuration,,,H,,B,569,,,,1,,10000000.0,
,11799,8,BAO_0000221,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",51,,Hippocampus,CHEMBL615588,Autocuration,,,H,,B,570,,,,1,,10000000.0,
,14331,9,BAO_0000249,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,10576,,,CHEMBL615589,Expert,10116.0,Membranes,D,,B,571,,,Rattus norvegicus,1,,,
,11884,8,BAO_0000221,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,51,,Hippocampus,CHEMBL615442,Expert,9913.0,,H,,B,572,,,Bos taurus,1,,10000000.0,
,14331,8,BAO_0000221,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,51,,Hippocampus,CHEMBL615443,Autocuration,,,H,,B,573,,,,1,,10000000.0,
,11701,8,BAO_0000221,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,51,,Hippocampus,CHEMBL615444,Autocuration,,,H,,B,574,,,,1,,10000000.0,
,11701,8,BAO_0000221,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,51,,Hippocampus,CHEMBL615445,Expert,,,H,,B,575,,,,1,,10000000.0,
,12248,8,BAO_0000221,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,51,,Hippocampus,CHEMBL615446,Autocuration,,,H,,B,576,,,,1,,10000000.0,
,12248,8,BAO_0000219,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,51,,,CHEMBL615447,Autocuration,,,H,,B,577,,449.0,,1,,,CHO
,12248,8,BAO_0000221,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,,Hippocampus,CHEMBL615448,Expert,,,H,,B,578,,,,1,,10000000.0,
,12249,8,BAO_0000221,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,,Hippocampus,CHEMBL615449,Expert,,,H,,B,579,,,,1,,10000000.0,
,12248,8,BAO_0000219,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,51,,,CHEMBL615450,Autocuration,,,H,,B,580,,449.0,,1,,,CHO
,11799,8,BAO_0000221,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",51,,Hippocampus,CHEMBL615451,Expert,,,H,,B,581,,,,1,,10000000.0,
,634,8,BAO_0000357,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,51,,,CHEMBL615452,Autocuration,,,H,,B,582,,,,1,,,
,9995,8,BAO_0000221,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,Hippocampus,CHEMBL615453,Autocuration,,,H,,B,583,,,,1,,10000000.0,
,9995,8,BAO_0000221,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,Hippocampus,CHEMBL615454,Autocuration,,,H,,B,584,,,,1,,10000000.0,
,9995,8,BAO_0000221,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,Hippocampus,CHEMBL615455,Autocuration,,,H,,B,585,,,,1,,10000000.0,
,9995,8,BAO_0000221,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,Hippocampus,CHEMBL615456,Autocuration,,,H,,B,586,,,,1,,10000000.0,
,9995,8,BAO_0000221,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,Hippocampus,CHEMBL615457,Autocuration,,,H,,B,587,,,,1,,10000000.0,
,12210,8,BAO_0000218,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,51,,Hippocampus,CHEMBL615458,Expert,,,H,,B,588,,,,1,,10000000.0,
,13311,8,BAO_0000221,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,Hippocampus,CHEMBL615459,Expert,,,H,,B,589,,,,1,,10000000.0,
,2331,9,BAO_0000219,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",51,,,CHEMBL615460,Expert,9606.0,,D,,B,590,,449.0,Homo sapiens,1,,,CHO
,1375,8,BAO_0000019,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,51,,,CHEMBL615461,Autocuration,10141.0,,H,,F,591,,,Cavia porcellus,1,,,
,1375,8,BAO_0000019,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,51,,,CHEMBL615462,Autocuration,10141.0,,H,,F,592,,,Cavia porcellus,1,,,
,11574,8,BAO_0000221,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,51,,Hippocampus,CHEMBL615463,Autocuration,10141.0,,H,,F,593,,,Cavia porcellus,1,,10000000.0,
,12867,8,BAO_0000221,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,51,,Ileum,CHEMBL615464,Autocuration,10141.0,,H,,B,594,,,Cavia porcellus,1,,2116.0,
,12867,8,BAO_0000221,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,51,,Ileum,CHEMBL615465,Autocuration,10141.0,,H,,B,595,,,Cavia porcellus,1,,2116.0,
,12867,8,BAO_0000221,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,51,,Ileum,CHEMBL615466,Autocuration,10141.0,,H,,B,596,,,Cavia porcellus,1,,2116.0,
,12867,8,BAO_0000221,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,51,,Ileum,CHEMBL615467,Autocuration,10141.0,,H,,B,597,,,Cavia porcellus,1,,2116.0,
,12867,8,BAO_0000221,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,51,,Ileum,CHEMBL615468,Autocuration,10141.0,,H,,B,598,,,Cavia porcellus,1,,2116.0,
,12867,8,BAO_0000221,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,51,,Ileum,CHEMBL615469,Autocuration,10141.0,,H,,B,599,,,Cavia porcellus,1,,2116.0,
,11574,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,51,,,CHEMBL615470,Autocuration,10141.0,,H,,B,600,,,Cavia porcellus,1,,,
,13114,8,BAO_0000357,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,51,,,CHEMBL615471,Autocuration,10141.0,,H,,B,601,,,Cavia porcellus,1,,,
,13181,8,BAO_0000357,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,51,,,CHEMBL615472,Autocuration,10141.0,,H,,B,602,,,Cavia porcellus,1,,,
,10639,8,BAO_0000221,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,106,,Hippocampus,CHEMBL883242,Autocuration,10141.0,,H,,B,603,,,Cavia porcellus,1,,10000000.0,
,10639,8,BAO_0000221,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,106,,Hippocampus,CHEMBL615473,Autocuration,10141.0,,H,,F,604,,,Cavia porcellus,1,,10000000.0,
,11883,8,BAO_0000218,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),11863,,,CHEMBL615474,Autocuration,10029.0,,H,,B,605,,449.0,Cricetulus griseus,1,,,CHO
,17785,8,BAO_0000357,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,51,,,CHEMBL615475,Autocuration,,,H,,B,606,,,,1,,,
,1558,8,BAO_0000219,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,51,,,CHEMBL615476,Autocuration,,,H,,F,607,,308.0,,1,,,HeLa
,1558,8,BAO_0000219,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,51,,,CHEMBL615477,Autocuration,,,H,,F,608,,308.0,,1,,,HeLa
,15740,8,BAO_0000019,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,51,,,CHEMBL615478,Autocuration,,,H,,F,609,,,,1,,,
,17624,8,BAO_0000219,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL615160,Autocuration,,,H,,F,610,,449.0,,1,,,CHO
,17624,8,BAO_0000219,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL615161,Expert,,,H,,F,611,,449.0,,1,,,CHO
,17624,8,BAO_0000219,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,51,,,CHEMBL615162,Autocuration,,,H,,F,612,,449.0,,1,,,CHO
,17624,8,BAO_0000219,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,51,,,CHEMBL615163,Autocuration,,,H,,F,613,,449.0,,1,,,CHO
,17624,8,BAO_0000219,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,,,CHEMBL615164,Expert,,,H,,B,614,,449.0,,1,,,CHO
,17624,8,BAO_0000219,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,,,CHEMBL615165,Expert,,,H,,B,615,,449.0,,1,,,CHO
,17624,8,BAO_0000219,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,51,,,CHEMBL615166,Autocuration,,,H,,B,616,,449.0,,1,,,CHO
,14256,8,BAO_0000219,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,51,,,CHEMBL615167,Autocuration,,,H,,F,617,,,,1,,,
,3445,9,BAO_0000219,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,51,,,CHEMBL615168,Expert,9606.0,,D,,B,618,,308.0,Homo sapiens,1,,,HeLa
,3445,9,BAO_0000219,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,51,,,CHEMBL615169,Expert,9606.0,,D,,B,619,,308.0,Homo sapiens,1,,,HeLa
,17200,9,BAO_0000219,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL615170,Expert,9606.0,,D,,B,620,,449.0,Homo sapiens,1,,,CHO
,17200,9,BAO_0000219,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,51,,,CHEMBL615171,Expert,9606.0,,D,,B,621,,449.0,Homo sapiens,1,,,CHO
,15180,8,BAO_0000019,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,51,,,CHEMBL615694,Autocuration,,,H,,F,622,,,,1,,,
,15180,8,BAO_0000019,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,51,,,CHEMBL615695,Autocuration,,,H,,F,623,,,,1,,,
,16026,8,BAO_0000019,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",51,,,CHEMBL615696,Autocuration,,,H,,F,624,,,,1,,,
,2759,8,BAO_0000219,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,51,,,CHEMBL615697,Autocuration,,,H,,F,625,,449.0,,1,,,CHO
,2759,9,BAO_0000219,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),51,,,CHEMBL859410,Expert,9606.0,,D,,F,626,,449.0,Homo sapiens,1,,,CHO
,2759,8,BAO_0000219,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),51,,,CHEMBL615841,Autocuration,,,H,,F,627,,449.0,,1,,,CHO
,2759,9,BAO_0000219,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),51,,,CHEMBL615842,Expert,9606.0,,D,,F,628,,449.0,Homo sapiens,1,,,CHO
,2759,8,BAO_0000219,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,51,,,CHEMBL835003,Autocuration,,,H,,F,629,,449.0,,1,,,CHO
,2759,8,BAO_0000219,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),51,,,CHEMBL615843,Autocuration,,,H,,F,630,,449.0,,1,,,CHO
,2759,9,BAO_0000219,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),51,,,CHEMBL615979,Expert,9606.0,,D,,F,631,,449.0,Homo sapiens,1,,,CHO
,2759,8,BAO_0000219,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),51,,,CHEMBL615980,Autocuration,,,H,,F,632,,449.0,,1,,,CHO
,2759,9,BAO_0000219,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),51,,,CHEMBL615981,Expert,9606.0,,D,,F,633,,449.0,Homo sapiens,1,,,CHO
,3445,9,BAO_0000019,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,51,,,CHEMBL615982,Expert,9606.0,,D,,F,634,,,Homo sapiens,1,,,
,5272,9,BAO_0000019,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",51,,,CHEMBL615983,Expert,9606.0,,D,,F,635,,,Homo sapiens,1,,,
,5272,9,BAO_0000019,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",51,,,CHEMBL615984,Expert,9606.0,,D,,F,636,,,Homo sapiens,1,,,
,5272,9,BAO_0000019,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",51,,,CHEMBL615985,Expert,9606.0,,D,,F,637,,,Homo sapiens,1,,,
,17624,8,BAO_0000219,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,51,,,CHEMBL615986,Autocuration,,,H,,F,638,,449.0,,1,,,CHO
,17624,8,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,51,,,CHEMBL615987,Autocuration,,,H,,F,639,,449.0,,1,,,CHO
,17624,8,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,51,,,CHEMBL615988,Autocuration,,,H,,F,640,,449.0,,1,,,CHO
,17624,8,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,51,,,CHEMBL615989,Expert,,,H,,F,641,,449.0,,1,,,CHO
,17624,8,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,51,,,CHEMBL615990,Autocuration,,,H,,F,642,,449.0,,1,,,CHO
,17624,8,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,51,,,CHEMBL615991,Autocuration,,,H,,F,643,,449.0,,1,,,CHO
,17624,8,BAO_0000219,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,51,,,CHEMBL615992,Autocuration,,,H,,F,644,,449.0,,1,,,CHO
,17624,8,BAO_0000219,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,51,,,CHEMBL615993,Autocuration,,,H,,F,645,,449.0,,1,,,CHO
,17624,8,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,51,,,CHEMBL615994,Expert,,,H,,F,646,,449.0,,1,,,CHO
,17624,8,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,51,,,CHEMBL615995,Autocuration,,,H,,F,647,,449.0,,1,,,CHO
,17624,8,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,51,,,CHEMBL615996,Autocuration,,,H,,F,648,,449.0,,1,,,CHO
,17624,8,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,51,,,CHEMBL615997,Autocuration,,,H,,F,649,,449.0,,1,,,CHO
,6563,8,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,,,CHEMBL615998,Autocuration,,,H,,F,650,,,,1,,,
,6563,8,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,,,CHEMBL615999,Autocuration,,,H,,F,651,,,,1,,,
,6563,8,BAO_0000019,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,51,,,CHEMBL616000,Autocuration,,,H,,F,652,,,,1,,,
,17296,8,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,,,CHEMBL616001,Autocuration,,,H,,F,653,,722.0,,1,,,HEK293
,6876,9,BAO_0000019,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",51,,,CHEMBL616002,Expert,9606.0,,D,,F,654,,,Homo sapiens,1,,,
,6876,8,BAO_0000019,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",51,,,CHEMBL616003,Expert,,,H,,F,655,,,,1,,,
,5272,9,BAO_0000019,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616004,Expert,9606.0,,D,,F,656,,,Homo sapiens,1,,,
,5272,9,BAO_0000019,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,51,,,CHEMBL616005,Expert,9606.0,,D,,F,657,,,Homo sapiens,1,,,
,5548,8,BAO_0000019,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",51,,,CHEMBL616006,Autocuration,,,H,,F,658,,,,1,,,
,5548,8,BAO_0000019,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",51,,,CHEMBL616007,Expert,,,H,,F,659,,,,1,,,
,5548,8,BAO_0000019,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",51,,,CHEMBL616008,Autocuration,,,H,,F,660,,,,1,,,
,5548,8,BAO_0000019,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",51,,,CHEMBL616009,Autocuration,,,H,,F,661,,,,1,,,
,5929,8,BAO_0000019,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",51,,,CHEMBL616010,Expert,,,H,,F,662,,,,1,,,
,5929,9,BAO_0000019,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",51,,,CHEMBL616011,Expert,9606.0,,D,,F,663,,,Homo sapiens,1,,,
,5929,9,BAO_0000019,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",51,,,CHEMBL615740,Expert,9606.0,,D,,F,664,,,Homo sapiens,1,,,
,16245,8,BAO_0000019,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",51,,,CHEMBL615741,Autocuration,,,H,,F,665,,,,1,,,
,5640,8,BAO_0000019,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",51,,,CHEMBL615742,Expert,,,H,,F,666,,,,1,,,
,5640,8,BAO_0000019,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",51,,,CHEMBL615743,Autocuration,,,H,,F,667,,,,1,,,
,14509,8,BAO_0000219,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,51,,,CHEMBL615744,Autocuration,,,H,,F,668,,449.0,,1,,,CHO
,14509,8,BAO_0000219,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,51,,,CHEMBL615745,Expert,,,H,,F,669,,449.0,,1,,,CHO
,15331,8,BAO_0000357,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,51,,,CHEMBL615746,Autocuration,,,H,,B,670,,,,1,,,
,15331,8,BAO_0000357,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,51,,,CHEMBL615747,Autocuration,,,H,,B,671,,,,1,,,
,6563,8,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,,,CHEMBL615748,Autocuration,,,H,,F,672,,,,1,,,
,6563,8,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",51,,,CHEMBL615749,Autocuration,,,H,,F,673,,,,1,,,
,6563,8,BAO_0000019,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,51,,,CHEMBL615750,Autocuration,,,H,,F,674,,,,1,,,
,6563,9,BAO_0000019,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616259,Expert,9606.0,,D,,F,675,,,Homo sapiens,1,,,
,6563,8,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,,,CHEMBL616260,Autocuration,,,H,,F,676,,,,1,,,
,5272,9,BAO_0000019,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,51,,,CHEMBL616261,Expert,9606.0,,D,,F,677,,,Homo sapiens,1,,,
,5272,9,BAO_0000019,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",51,,,CHEMBL616262,Expert,9606.0,,D,,F,678,,,Homo sapiens,1,,,
,5272,9,BAO_0000019,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",51,,,CHEMBL616263,Expert,9606.0,,D,,F,679,,,Homo sapiens,1,,,
,5272,9,BAO_0000019,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,51,,,CHEMBL616264,Expert,9606.0,,D,,F,680,,,Homo sapiens,1,,,
,5272,9,BAO_0000019,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,51,,,CHEMBL616265,Expert,9606.0,,D,,F,681,,,Homo sapiens,1,,,
,5272,9,BAO_0000019,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",51,,,CHEMBL616266,Expert,9606.0,,D,,F,682,,,Homo sapiens,1,,,
,5272,9,BAO_0000019,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",51,,,CHEMBL616267,Expert,9606.0,,D,,F,683,,,Homo sapiens,1,,,
,5272,9,BAO_0000019,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,51,,,CHEMBL616268,Expert,9606.0,,D,,F,684,,,Homo sapiens,1,,,
,16146,9,BAO_0000357,Inhibition of human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616269,Expert,9606.0,,D,,B,685,,,Homo sapiens,1,,,
,17624,8,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,,,CHEMBL884528,Autocuration,,,H,,B,686,,449.0,,1,,,CHO
,13706,9,BAO_0000219,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,105,,,CHEMBL616270,Expert,,,D,,B,687,,722.0,,1,,,HEK293
,15250,8,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,51,,,CHEMBL616271,Autocuration,,,H,,B,688,,449.0,,1,,,CHO
,17624,8,BAO_0000219,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616272,Autocuration,,,H,,F,689,,449.0,,1,,,CHO
,6861,8,BAO_0000357,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,51,,,CHEMBL616273,Expert,,,H,,B,690,,,,1,,,
,17200,9,BAO_0000357,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616274,Expert,9606.0,,D,,B,691,,,Homo sapiens,1,,,
,17624,8,BAO_0000219,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,51,,,CHEMBL616275,Autocuration,,,H,,B,692,,449.0,,1,,,CHO
,17624,8,BAO_0000219,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,,,CHEMBL616276,Autocuration,,,H,,B,693,,449.0,,1,,,CHO
,12058,0,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,22226,In vivo,,CHEMBL616277,Autocuration,10116.0,,U,,F,694,,,Rattus norvegicus,1,,,
,12058,0,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,22226,In vivo,,CHEMBL616278,Autocuration,10116.0,,U,,F,695,,,Rattus norvegicus,1,,,
,12058,0,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,22226,In vivo,,CHEMBL616279,Autocuration,10116.0,,U,,F,696,,,Rattus norvegicus,1,,,
,12058,0,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,22226,In vivo,,CHEMBL616280,Autocuration,10116.0,,U,,F,697,,,Rattus norvegicus,1,,,
,12058,0,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,22226,In vivo,,CHEMBL616281,Autocuration,10116.0,,U,,F,698,,,Rattus norvegicus,1,,,
,12058,0,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,22226,In vivo,,CHEMBL616282,Autocuration,10116.0,,U,,F,699,,,Rattus norvegicus,1,,,
,12058,0,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,22226,In vivo,,CHEMBL616283,Autocuration,10116.0,,U,,F,700,,,Rattus norvegicus,1,,,
,12058,0,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,22226,In vivo,,CHEMBL616284,Autocuration,10116.0,,U,,F,701,,,Rattus norvegicus,1,,,
,12058,0,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,22226,In vivo,,CHEMBL616285,Autocuration,10116.0,,U,,F,702,,,Rattus norvegicus,1,,,
,12058,0,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,22226,In vivo,,CHEMBL616286,Autocuration,10116.0,,U,,F,703,,,Rattus norvegicus,1,,,
,12058,0,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,22226,In vivo,,CHEMBL616287,Autocuration,10116.0,,U,,F,704,,,Rattus norvegicus,1,,,
,12058,0,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,22226,In vivo,,CHEMBL616288,Autocuration,10116.0,,U,,F,705,,,Rattus norvegicus,1,,,
,12058,0,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,22226,In vivo,,CHEMBL616289,Autocuration,10116.0,,U,,F,706,,,Rattus norvegicus,1,,,
,12058,0,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,22226,In vivo,,CHEMBL615610,Autocuration,10116.0,,U,,F,707,,,Rattus norvegicus,1,,,
,12058,0,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,22226,In vivo,,CHEMBL615611,Autocuration,10116.0,,U,,F,708,,,Rattus norvegicus,1,,,
,12058,0,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,22226,In vivo,,CHEMBL615612,Autocuration,10116.0,,U,,F,709,,,Rattus norvegicus,1,,,
,12058,0,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,22226,In vivo,,CHEMBL615613,Autocuration,10116.0,,U,,F,710,,,Rattus norvegicus,1,,,
,12058,0,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,22226,In vivo,,CHEMBL615614,Autocuration,10116.0,,U,,F,711,,,Rattus norvegicus,1,,,
,12058,0,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,22226,In vivo,,CHEMBL615615,Autocuration,10116.0,,U,,F,712,,,Rattus norvegicus,1,,,
,11440,4,BAO_0000019,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,105093,,,CHEMBL615616,Autocuration,,,H,,B,713,,,,1,,,
,6238,8,BAO_0000249,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,11923,,Hypothalamus,CHEMBL615617,Autocuration,,,H,,B,714,,,,1,,1898.0,
,10046,8,BAO_0000019,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,10577,,,CHEMBL615618,Autocuration,,,H,,B,715,,,,1,,,
,10046,8,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,10577,,,CHEMBL615619,Autocuration,,,H,,B,716,,,,1,,,
,10046,8,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,10577,,,CHEMBL615620,Expert,,,H,,B,717,,,,1,,,
,167,8,BAO_0000357,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",55,,,CHEMBL615621,Autocuration,,,H,,B,718,,,,1,,,
,167,8,BAO_0000357,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",55,,,CHEMBL615622,Autocuration,,,H,,B,719,,,,1,,,
,11520,8,BAO_0000019,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),12166,,,CHEMBL615623,Autocuration,,,H,,F,720,,,,1,,,
,11520,8,BAO_0000019,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,12166,,,CHEMBL615624,Autocuration,,,H,,F,721,,,,1,,,
,11520,8,BAO_0000019,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,12166,,,CHEMBL615625,Autocuration,,,H,,F,722,,,,1,,,
,11520,8,BAO_0000019,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,12166,,,CHEMBL767045,Autocuration,,,H,,F,723,,,,1,,,
,135,8,BAO_0000019,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,55,,,CHEMBL615626,Autocuration,10141.0,,H,,F,724,,,Cavia porcellus,1,,,
,135,8,BAO_0000019,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,55,,,CHEMBL615627,Autocuration,10141.0,,H,,F,725,,,Cavia porcellus,1,,,
,11311,8,BAO_0000019,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,55,,,CHEMBL615628,Autocuration,10141.0,,H,,B,726,,,Cavia porcellus,1,,,
,10193,8,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,55,,,CHEMBL615629,Autocuration,10141.0,,H,,B,727,,,Cavia porcellus,1,,,
,12281,9,BAO_0000357,Inhibitory concentration against 5-lipoxygenase from human whole blood,55,,,CHEMBL615630,Expert,9606.0,,D,,B,728,,,Homo sapiens,1,,,
,11311,8,BAO_0000219,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],55,,,CHEMBL615631,Autocuration,,,H,,B,729,,,,1,,,
,12576,8,BAO_0000218,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,17087,,,CHEMBL615632,Autocuration,,,H,,F,730,,,,1,,,
,12281,8,BAO_0000357,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,17087,,,CHEMBL615633,Autocuration,,,H,,B,731,,,,1,,,
,12576,8,BAO_0000218,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,17087,,,CHEMBL615634,Autocuration,,,H,,F,732,,,,1,,,
,11089,8,BAO_0000019,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,55,,,CHEMBL615635,Expert,9823.0,,H,,B,733,,,Sus scrofa,1,,,
,11006,8,BAO_0000357,In vitro inhibition of rat 5-Lipoxygenase,12166,,,CHEMBL615636,Expert,,,H,,B,734,,,,1,,,
,11481,9,BAO_0000357,Inhibitory activity against 5-Lipoxygenase,12166,,,CHEMBL615637,Expert,10116.0,,D,,B,735,,,Rattus norvegicus,1,,,
,10864,8,BAO_0000219,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,12166,,,CHEMBL615638,Expert,,,H,,B,736,,702.0,,1,,,RBL-1
,3595,8,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),12166,,,CHEMBL615639,Autocuration,,,H,,B,737,,702.0,,1,,,RBL-1
,11311,8,BAO_0000219,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,12166,,,CHEMBL615640,Autocuration,,,H,,B,738,,702.0,,1,,,RBL-1
,11311,8,BAO_0000019,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,12166,,,CHEMBL615796,Autocuration,,,H,,B,739,,,,1,,,
,11311,8,BAO_0000219,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],12166,,,CHEMBL615845,Autocuration,,,H,,B,740,,,,1,,,
,11006,8,BAO_0000357,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,12166,,,CHEMBL615846,Autocuration,,,H,,B,741,,,,1,,,
,3595,8,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,12166,,,CHEMBL615847,Autocuration,,,H,,B,742,,702.0,,1,,,RBL-1
,11311,8,BAO_0000357,The compound was tested for inhibition of isolated 5-Lipoxygenase,12166,,,CHEMBL615848,Autocuration,,,H,,B,743,,,,1,,,
,11481,0,BAO_0000019,Ratio of IC50 against 5-LO and COX,22226,,,CHEMBL615849,Autocuration,10116.0,,U,,B,744,,,Rattus norvegicus,1,,,
,11006,8,BAO_0000357,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,12166,,,CHEMBL615850,Autocuration,,,H,,B,745,,,,1,,,
,11006,8,BAO_0000357,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,12166,,,CHEMBL615851,Autocuration,,,H,,B,746,,,,1,,,
,11311,8,BAO_0000219,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,12166,,,CHEMBL615852,Autocuration,,,H,,B,747,,,,1,,,
,11006,8,BAO_0000019,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,12166,,,CHEMBL615853,Autocuration,,,H,,F,748,,,,1,,,
,4288,8,BAO_0000357,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,120,,Prostate gland,CHEMBL884527,Autocuration,,,H,,B,749,,,,1,,2367.0,
,7587,0,BAO_0000019,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,22226,,,CHEMBL872871,Autocuration,8932.0,,U,,B,750,,,Columba livia,1,,,
,7587,0,BAO_0000019,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,22226,,,CHEMBL615854,Autocuration,8932.0,,U,,B,751,,,Columba livia,1,,,
,7587,0,BAO_0000019,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,22226,,,CHEMBL767046,Autocuration,8932.0,,U,,B,752,,,Columba livia,1,,,
,11249,8,BAO_0000357,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,10732,,,CHEMBL615855,Autocuration,,,H,,B,753,,,,1,,,
,8003,9,BAO_0000019,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,12198,,,CHEMBL615856,Expert,10116.0,,D,,F,754,,,Rattus norvegicus,1,,,
,8003,9,BAO_0000019,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),12198,,,CHEMBL615857,Expert,10116.0,,D,,F,755,,,Rattus norvegicus,1,,,
,8003,9,BAO_0000019,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),12198,,,CHEMBL615858,Expert,10116.0,,D,,F,756,,,Rattus norvegicus,1,,,
,12416,8,BAO_0000221,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,10576,,Hippocampus,CHEMBL615859,Expert,,,H,,B,757,,,,1,,10000000.0,
,16293,8,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1 receptor,51,,,CHEMBL615860,Autocuration,,,H,,B,758,,,,1,,,
,13047,0,BAO_0000019,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,22226,,,CHEMBL615861,Autocuration,9986.0,,U,,B,759,,,Oryctolagus cuniculus,1,,,
,13047,0,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,22226,,,CHEMBL615862,Autocuration,9986.0,,U,,B,760,,,Oryctolagus cuniculus,1,,,
,13047,0,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,22226,,,CHEMBL615863,Autocuration,9986.0,,U,,B,761,,,Oryctolagus cuniculus,1,,,
,13047,0,BAO_0000019,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,22226,,,CHEMBL615864,Autocuration,9986.0,,U,,B,762,,,Oryctolagus cuniculus,1,,,
,10085,4,BAO_0000221,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,104744,,Hippocampus,CHEMBL615865,Autocuration,,,H,,B,763,,,,1,,10000000.0,
,10085,4,BAO_0000221,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,104744,,Hippocampus,CHEMBL615866,Autocuration,,,H,,B,764,,,,1,,10000000.0,
,10085,4,BAO_0000221,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,104744,,Hippocampus,CHEMBL615867,Autocuration,,,H,,B,765,,,,1,,10000000.0,
,9841,4,BAO_0000249,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,104744,,,CHEMBL615868,Autocuration,,Membranes,H,,B,766,,,,1,,,
,8822,5,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,104744,,,CHEMBL615869,Autocuration,10116.0,,D,,B,767,,,Rattus norvegicus,1,,,
,9806,5,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,104744,,,CHEMBL615870,Autocuration,10116.0,,D,,B,768,,,Rattus norvegicus,1,,,
,9806,5,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,104744,,,CHEMBL615871,Autocuration,10116.0,,D,,B,769,,,Rattus norvegicus,1,,,
,8868,4,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,104744,,,CHEMBL615872,Autocuration,,,H,,B,770,,,,1,,,
,9036,4,BAO_0000221,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,104744,,Hippocampus,CHEMBL833492,Autocuration,,,H,,B,771,,,,1,,10000000.0,
,11374,4,BAO_0000221,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,104744,,Hippocampus,CHEMBL615873,Autocuration,,,H,,B,772,,,,1,,10000000.0,
,10881,4,BAO_0000224,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,104744,,,CHEMBL615479,Autocuration,,,H,,B,773,,,,1,,,
,8822,4,BAO_0000019,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,104744,,,CHEMBL615480,Autocuration,,,H,,B,774,,,,1,,,
,9806,5,BAO_0000249,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,104744,,,CHEMBL615481,Autocuration,10116.0,,D,,B,775,,,Rattus norvegicus,1,,,
,15463,4,BAO_0000019,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,,,CHEMBL872869,Autocuration,,,H,,B,776,,,,1,,,
,15463,4,BAO_0000019,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,,,CHEMBL615482,Autocuration,,,H,,B,777,,,,1,,,
,14542,4,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,104744,,Brain,CHEMBL615483,Autocuration,,,H,,B,778,,,,1,,955.0,
,14542,4,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,104744,,Brain,CHEMBL615484,Autocuration,,,H,,B,779,,,,1,,955.0,
,8569,4,BAO_0000019,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,104744,,,CHEMBL615485,Autocuration,,,H,,B,780,,,,1,,,
,10062,5,BAO_0000224,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,104744,,,CHEMBL615486,Autocuration,10116.0,,D,,B,781,,,Rattus norvegicus,1,,,
,4771,4,BAO_0000224,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,104744,,,CHEMBL615487,Autocuration,,,H,,B,782,,,,1,,,
,10062,4,BAO_0000224,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,104744,,,CHEMBL615488,Autocuration,,,H,,B,783,,,,1,,,
,10062,4,BAO_0000224,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,104744,,,CHEMBL615489,Autocuration,,,H,,B,784,,,,1,,,
,10062,4,BAO_0000224,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,104744,,,CHEMBL615389,Autocuration,,,H,,B,785,,,,1,,,
,15463,4,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,104744,,,CHEMBL615390,Autocuration,,,H,,B,786,,,,1,,,
,15463,4,BAO_0000019,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,104744,,,CHEMBL615391,Autocuration,,,H,,B,787,,,,1,,,
,9098,4,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,104744,,,CHEMBL615392,Autocuration,,,H,,B,788,,,,1,,,
,3070,0,BAO_0000019,Affinity for 5-hydroxytryptamine 1 receptor,22226,,,CHEMBL615393,Autocuration,10116.0,,U,,B,789,,,Rattus norvegicus,1,,,
,14542,4,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,104744,,Brain,CHEMBL615394,Autocuration,,,H,,B,790,,,,1,,955.0,
,14542,4,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,104744,,Brain,CHEMBL615395,Autocuration,,,H,,B,791,,,,1,,955.0,
,6398,4,BAO_0000224,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,104744,,,CHEMBL615396,Autocuration,,,H,,B,792,,,,1,,,
,1344,4,BAO_0000221,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,104744,,Brain,CHEMBL615397,Autocuration,,,H,,B,793,,,,1,,955.0,
,11963,4,BAO_0000019,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,,,CHEMBL615398,Autocuration,,,H,,B,794,,,,1,,,
,8908,0,BAO_0000019,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,22226,,,CHEMBL615399,Autocuration,10116.0,,U,,B,795,,,Rattus norvegicus,1,,,
,9098,4,BAO_0000019,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,104744,,,CHEMBL615400,Autocuration,,,H,,B,796,,,,1,,,
,8841,5,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,104744,,,CHEMBL615401,Autocuration,10116.0,,D,,B,797,,,Rattus norvegicus,1,,,
,8814,0,BAO_0000019,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,22226,,,CHEMBL615402,Autocuration,10116.0,,U,,B,798,,,Rattus norvegicus,1,,,
,11752,4,BAO_0000019,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,104744,,,CHEMBL615403,Autocuration,,,H,,B,799,,,,1,,,
,11642,4,BAO_0000221,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,104744,,Brain,CHEMBL615404,Autocuration,,,H,,B,800,,,,1,,955.0,
,11642,4,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,104744,,,CHEMBL615781,Autocuration,,,H,,B,801,,,,1,,,
,9231,4,BAO_0000220,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,104744,,Brain,CHEMBL615782,Autocuration,,,H,,B,802,,,,1,,955.0,
,11351,4,BAO_0000221,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,104744,,Brain,CHEMBL615783,Autocuration,,,H,,B,803,,,,1,,955.0,
,4639,0,BAO_0000019,Compound was tested for binding affinity against 5-HT1 receptor,22226,,,CHEMBL873481,Autocuration,,,U,,B,804,,,,1,,,
,1205,0,BAO_0000019,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,22226,,,CHEMBL615784,Autocuration,,,U,,B,805,,,,1,,,
,10025,8,BAO_0000357,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,10576,,,CHEMBL615785,Expert,,,H,,B,806,,,,1,,,
,13241,8,BAO_0000249,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",10576,,,CHEMBL615786,Autocuration,,,H,,F,807,,,,1,,,
,16245,8,BAO_0000218,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,10576,In vivo,,CHEMBL615787,Autocuration,,,H,,F,808,,,,1,,,
,16245,8,BAO_0000218,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,10576,In vivo,,CHEMBL615788,Autocuration,,,H,,F,809,,,,1,,,
,12438,8,BAO_0000019,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL767044,Autocuration,,,H,,F,810,,,,1,,,
,16245,8,BAO_0000218,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,10576,In vivo,,CHEMBL615789,Autocuration,,,H,,F,811,,,,1,,,
,16245,8,BAO_0000218,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,10576,In vivo,,CHEMBL615790,Autocuration,,,H,,F,812,,,,1,,,
,15740,8,BAO_0000019,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,10576,,,CHEMBL615813,Autocuration,,,H,,F,813,,,,1,,,
,15535,8,BAO_0000219,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,10576,,,CHEMBL615814,Autocuration,,,H,,F,814,,,,1,,,
,15535,8,BAO_0000219,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,51,,,CHEMBL615815,Expert,,,H,,F,815,,,,1,,,
,15535,8,BAO_0000219,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,10576,,,CHEMBL615816,Autocuration,,,H,,F,816,,,,1,,,
,9888,8,BAO_0000249,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,10576,,,CHEMBL615817,Expert,,,H,,B,817,,,,1,,,
,10085,8,BAO_0000221,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,10576,,Hippocampus,CHEMBL615818,Autocuration,,,H,,B,818,,,,1,,10000000.0,
,10085,8,BAO_0000221,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,10576,,Hippocampus,CHEMBL615819,Autocuration,,,H,,B,819,,,,1,,10000000.0,
,17331,8,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,10576,,,CHEMBL615820,Expert,,Membranes,H,,B,820,,,,1,,,
,10845,9,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,10576,,Hippocampus,CHEMBL615821,Expert,10116.0,,D,,B,821,,,Rattus norvegicus,1,,10000000.0,
,10845,9,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10576,,Hippocampus,CHEMBL615822,Expert,10116.0,,D,,B,822,,,Rattus norvegicus,1,,10000000.0,
,10845,8,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,10576,,Hippocampus,CHEMBL615823,Expert,,,H,,B,823,,,,1,,10000000.0,
,10845,9,BAO_0000221,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,10576,,Hippocampus,CHEMBL615824,Expert,10116.0,,D,,B,824,,,Rattus norvegicus,1,,10000000.0,
,10845,9,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10576,,Hippocampus,CHEMBL615825,Expert,10116.0,,D,,B,825,,,Rattus norvegicus,1,,10000000.0,
,13730,8,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,10576,,,CHEMBL615826,Expert,,,H,,B,826,,,,1,,,
,13508,8,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,10576,,,CHEMBL615827,Expert,,,H,,B,827,,,,1,,,
,13508,8,BAO_0000249,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,10576,,Hippocampus,CHEMBL615828,Expert,,,H,,B,828,,,,1,,10000000.0,
,12073,8,BAO_0000221,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,Hippocampus,CHEMBL615829,Expert,,,H,,B,829,,,,1,,10000000.0,
,4671,8,BAO_0000221,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,10576,,Hippocampus,CHEMBL615830,Autocuration,,,H,,B,830,,,,1,,10000000.0,
,13631,8,BAO_0000221,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,10576,,Hippocampus,CHEMBL615831,Expert,,,H,,B,831,,,,1,,10000000.0,
,12438,8,BAO_0000357,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL615832,Autocuration,,,H,,B,832,,,,1,,,
,10483,8,BAO_0000019,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,10576,,,CHEMBL615833,Autocuration,,,H,,B,833,,,,1,,,
,10483,8,BAO_0000221,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,10576,,Hippocampus,CHEMBL615834,Autocuration,,,H,,B,834,,,,1,,10000000.0,
,12352,8,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,10576,,,CHEMBL615835,Intermediate,,,H,,B,835,,,,1,,,
,14732,8,BAO_0000249,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,10576,,Hippocampus,CHEMBL615836,Autocuration,,,H,,B,836,,,,1,,10000000.0,
,11049,9,BAO_0000019,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,10576,,,CHEMBL615837,Expert,10116.0,,D,,B,837,,,Rattus norvegicus,1,,,
,11049,9,BAO_0000019,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,10576,,,CHEMBL615838,Expert,10116.0,,D,,B,838,,,Rattus norvegicus,1,,,
,13657,8,BAO_0000249,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",10576,,,CHEMBL615839,Expert,,,H,,B,839,,,,1,,,
,11473,8,BAO_0000019,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,10576,,,CHEMBL884525,Autocuration,,,H,,B,840,,,,1,,,
,2014,8,BAO_0000249,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,10576,,,CHEMBL615840,Autocuration,,,H,,B,841,,,,1,,,
,3086,8,BAO_0000221,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,Hippocampus,CHEMBL615405,Expert,,,H,,B,842,,,,1,,10000000.0,
,15854,8,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,10576,,,CHEMBL615406,Expert,,,H,,B,843,,,,1,,,
,10922,8,BAO_0000221,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,10576,,Hippocampus,CHEMBL615900,Expert,,,H,,B,844,,,,1,,10000000.0,
,13346,8,BAO_0000221,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,10576,,Hippocampus,CHEMBL615901,Expert,,,H,,B,845,,,,1,,10000000.0,
,15311,8,BAO_0000357,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,10576,,,CHEMBL615902,Expert,,,H,,B,846,,,,1,,,
,10922,8,BAO_0000221,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,10576,,Hippocampus,CHEMBL615903,Autocuration,,,H,,B,847,,,,1,,10000000.0,
,10025,8,BAO_0000357,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,10576,,,CHEMBL615904,Autocuration,,,H,,B,848,,,,1,,,
,10025,8,BAO_0000357,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,10576,,,CHEMBL615905,Expert,,,H,,B,849,,,,1,,,
,9742,8,BAO_0000019,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,10576,,,CHEMBL615906,Autocuration,,,H,,B,850,,,,1,,,
,9742,8,BAO_0000019,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,10576,,,CHEMBL615907,Autocuration,,,H,,F,851,,,,1,,,
,12304,8,BAO_0000019,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,10576,,,CHEMBL615908,Expert,,,H,,B,852,,,,1,,,
,15789,8,BAO_0000221,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,10576,,Hippocampus,CHEMBL615909,Autocuration,,,H,,B,853,,,,1,,10000000.0,
,9912,8,BAO_0000019,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",10576,,,CHEMBL615910,Autocuration,,,H,,B,854,,,,1,,,
,9912,8,BAO_0000019,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",10576,,,CHEMBL615911,Autocuration,,,H,,B,855,,,,1,,,
,9912,8,BAO_0000019,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",10576,,,CHEMBL615912,Autocuration,,,H,,B,856,,,,1,,,
,16693,8,BAO_0000019,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,10576,,,CHEMBL615913,Expert,,,H,,B,857,,,,1,,,
,13276,8,BAO_0000357,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,10576,,,CHEMBL615914,Expert,,,H,,B,858,,,,1,,,
,12678,8,BAO_0000221,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,10576,,Hippocampus,CHEMBL615915,Autocuration,,,H,,B,859,,,,1,,10000000.0,
,11825,8,BAO_0000357,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,10576,,,CHEMBL615916,Autocuration,,,H,,B,860,,,,1,,,
,12443,8,BAO_0000357,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,10576,,,CHEMBL615917,Expert,,,H,,B,861,,,,1,,,
,13830,8,BAO_0000357,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL615918,Expert,,,H,,B,862,,,,1,,,
,14286,8,BAO_0000249,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,10576,,Hippocampus,CHEMBL615919,Expert,,,H,,B,863,,,,1,,10000000.0,
,14356,9,BAO_0000221,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10576,,Hippocampus,CHEMBL615920,Expert,10116.0,,D,,B,864,,,Rattus norvegicus,1,,10000000.0,
,15306,8,BAO_0000357,Inhibition concentration against 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL615921,Autocuration,,,H,,B,865,,,,1,,,
,15306,8,BAO_0000357,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),10576,,,CHEMBL615922,Expert,,,H,,B,866,,,,1,,,
,16616,9,BAO_0000249,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",10576,,,CHEMBL881290,Expert,10116.0,,D,,F,867,,,Rattus norvegicus,1,,,
,3651,8,BAO_0000221,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",10576,,Hippocampus,CHEMBL615923,Autocuration,,,H,,B,868,,,,1,,10000000.0,
,14331,8,BAO_0000221,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,Hippocampus,CHEMBL615924,Autocuration,,,H,,F,869,,,,1,,10000000.0,
,14331,8,BAO_0000221,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,Hippocampus,CHEMBL615925,Autocuration,,,H,,F,870,,,,1,,10000000.0,
,14178,9,BAO_0000357,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL615926,Expert,10116.0,,D,,B,871,,,Rattus norvegicus,1,,,
,10639,9,BAO_0000019,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL615927,Expert,10116.0,,D,,B,872,,,Rattus norvegicus,1,,,
,12306,8,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,,Hippocampus,CHEMBL615928,Autocuration,,,H,,B,873,,,,1,,10000000.0,
,1348,9,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,10576,,,CHEMBL615929,Expert,10116.0,,D,,B,874,,,Rattus norvegicus,1,,,
,13605,8,BAO_0000221,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,10576,,Hippocampus,CHEMBL615930,Autocuration,,,H,,B,875,,,,1,,10000000.0,
,17624,8,BAO_0000219,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,,,CHEMBL615931,Autocuration,,,H,,B,876,,449.0,,1,,,CHO
,17624,8,BAO_0000219,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,51,,,CHEMBL615932,Autocuration,,,H,,F,877,,449.0,,1,,,CHO
,17624,8,BAO_0000219,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,51,,,CHEMBL615933,Autocuration,,,H,,F,878,,449.0,,1,,,CHO
,15267,8,BAO_0000357,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,51,,,CHEMBL615934,Autocuration,,,H,,B,879,,,,1,,,
,16532,8,BAO_0000357,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,51,,,CHEMBL615935,Autocuration,,,H,,B,880,,,,1,,,
,6563,8,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,,,CHEMBL615936,Autocuration,,,H,,F,881,,,,1,,,
,4751,8,BAO_0000219,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,51,,,CHEMBL615937,Autocuration,,,H,,B,882,,449.0,,1,,,CHO
,15463,8,BAO_0000357,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL615938,Autocuration,,,H,,B,883,,,,1,,,
,3805,8,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),51,,,CHEMBL615797,Autocuration,,,H,,B,884,,,,1,,,
,5640,8,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,CHEMBL615798,Autocuration,,,H,,B,885,,,,1,,,
,6563,8,BAO_0000357,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,51,,,CHEMBL872870,Autocuration,,,H,,B,886,,,,1,,,
,5548,8,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,51,,,CHEMBL615799,Autocuration,,,H,,B,887,,,,1,,,
,6347,8,BAO_0000357,Percent binding affinity against 5-hydroxytryptamine 1A receptor,51,,,CHEMBL615800,Autocuration,,,H,,B,888,,,,1,,,
,17296,8,BAO_0000219,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,,,CHEMBL615801,Autocuration,,,H,,F,889,,722.0,,1,,,HEK293
,13047,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,51,,,CHEMBL615802,Autocuration,,,H,,B,890,,,,1,,,
,15740,8,BAO_0000357,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,51,,,CHEMBL615803,Autocuration,,,H,,B,891,,,,1,,,
,5640,8,BAO_0000019,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",51,,,CHEMBL835002,Expert,,,H,,F,892,,,,1,,,
,5640,8,BAO_0000019,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",51,,,CHEMBL615804,Autocuration,,,H,,F,893,,,,1,,,
,17211,8,BAO_0000219,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL615805,Expert,,,H,,B,894,,308.0,,1,,,HeLa
,4751,8,BAO_0000219,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL615806,Autocuration,,,H,,B,895,,449.0,,1,,,CHO
,6491,9,BAO_0000357,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,51,,,CHEMBL615807,Expert,9606.0,,D,,B,896,,,Homo sapiens,1,,,
,4707,8,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,51,,,CHEMBL615808,Autocuration,,,H,,B,897,,,,1,,,
,13910,9,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,51,,,CHEMBL615809,Expert,9606.0,,D,,B,898,,,Homo sapiens,1,,,
,16190,8,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,51,,,CHEMBL615810,Autocuration,,,H,,B,899,,308.0,,1,,,HeLa
,16633,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,CHEMBL615811,Autocuration,,,H,,B,900,,,,1,,,
,11898,8,BAO_0000219,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,51,,,CHEMBL615812,Autocuration,,,H,,B,901,,449.0,,1,,,CHO
,11898,8,BAO_0000219,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,51,,,CHEMBL615751,Autocuration,,,H,,B,902,,449.0,,1,,,CHO
,14331,8,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL615752,Autocuration,,,H,,B,903,,,,1,,,
,17624,8,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,51,,,CHEMBL615753,Expert,,,H,,B,904,,449.0,,1,,,CHO
,17624,8,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,51,,,CHEMBL615754,Autocuration,,,H,,B,905,,449.0,,1,,,CHO
,3307,8,BAO_0000357,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL615755,Autocuration,,,H,,B,906,,,,1,,,
,6563,9,BAO_0000219,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,51,,,CHEMBL615756,Expert,9606.0,,D,,B,907,,449.0,Homo sapiens,1,,,CHO
,14165,8,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,51,,,CHEMBL615757,Autocuration,,,H,,B,908,,,,1,,,
,5732,8,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,51,,,CHEMBL615758,Autocuration,,,H,,B,909,,,,1,,,
,13366,8,BAO_0000357,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,51,,,CHEMBL615759,Expert,,,H,,B,910,,,,1,,,
,17626,8,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL615760,Autocuration,,,H,,B,911,,,,1,,,
,6588,8,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,51,,,CHEMBL615761,Expert,,,H,,B,912,,308.0,,1,,,HeLa
,16209,8,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,51,,,CHEMBL872104,Autocuration,,,H,,B,913,,,,1,,,
,15463,8,BAO_0000357,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,51,,,CHEMBL615762,Autocuration,,,H,,B,914,,,,1,,,
,15463,8,BAO_0000357,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,51,,,CHEMBL615763,Autocuration,,,H,,B,915,,,,1,,,
,14770,8,BAO_0000357,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,51,,,CHEMBL615764,Autocuration,,,H,,B,916,,,,1,,,
,16245,8,BAO_0000219,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),51,,,CHEMBL615765,Autocuration,,,H,,B,917,,1167.0,,1,,,Cell line
,16245,8,BAO_0000019,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),51,,,CHEMBL615766,Autocuration,,,H,,B,918,,,,1,,,
,5548,8,BAO_0000357,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,51,,,CHEMBL615767,Autocuration,,,H,,B,919,,,,1,,,
,5548,8,BAO_0000357,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,CHEMBL615768,Expert,,,H,,B,920,,,,1,,,
,5548,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,CHEMBL615769,Autocuration,,,H,,B,921,,,,1,,,
,6876,8,BAO_0000357,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,51,,,CHEMBL615770,Expert,,,H,,B,922,,,,1,,,
,2598,8,BAO_0000357,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,CHEMBL615771,Autocuration,,,H,,B,923,,,,1,,,
,17785,8,BAO_0000357,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,51,,,CHEMBL615772,Expert,,,H,,B,924,,,,1,,,
,6013,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,51,,,CHEMBL615773,Autocuration,,,H,,B,925,,,,1,,,
,5929,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,51,,,CHEMBL615774,Expert,,,H,,B,926,,,,1,,,
,16633,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,CHEMBL615775,Autocuration,,,H,,B,927,,,,1,,,
,1558,8,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,51,,,CHEMBL615776,Autocuration,,,H,,B,928,,,,1,,,
,16026,8,BAO_0000357,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,CHEMBL615777,Expert,,,H,,B,929,,,,1,,,
,12469,8,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,51,,,CHEMBL615778,Autocuration,,,H,,B,930,,,,1,,,
,15874,9,BAO_0000357,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,51,,,CHEMBL615779,Expert,9606.0,,D,,B,931,,,Homo sapiens,1,,,
,15874,8,BAO_0000357,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,51,,,CHEMBL615780,Autocuration,,,H,,B,932,,,,1,,,
,3935,8,BAO_0000357,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616298,Autocuration,,,H,,B,933,,,,1,,,
,15818,8,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616299,Autocuration,,,H,,B,934,,,,1,,,
,13706,8,BAO_0000219,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,51,,,CHEMBL616300,Autocuration,,,H,,B,935,,485.0,,1,,,CHO-K1
,13729,8,BAO_0000219,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,51,,,CHEMBL616301,Expert,,,H,,F,936,,485.0,,1,,,CHO-K1
,15413,8,BAO_0000019,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616302,Autocuration,,,H,,B,937,,,,1,,,
,15413,8,BAO_0000019,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),51,,,CHEMBL616117,Autocuration,,,H,,B,938,,,,1,,,
,15413,8,BAO_0000019,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),51,,,CHEMBL616118,Autocuration,,,H,,B,939,,,,1,,,
,15413,8,BAO_0000019,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,51,,,CHEMBL616119,Autocuration,,,H,,B,940,,,,1,,,
,3445,9,BAO_0000219,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,51,,,CHEMBL616120,Expert,9606.0,,D,,B,941,,308.0,Homo sapiens,1,,,HeLa
,15740,8,BAO_0000357,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616121,Autocuration,,,H,,B,942,,,,1,,,
,15740,8,BAO_0000357,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,51,,,CHEMBL616122,Autocuration,,,H,,B,943,,,,1,,,
,17626,8,BAO_0000357,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616123,Autocuration,,,H,,B,944,,,,1,,,
,4234,9,BAO_0000357,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616124,Expert,9606.0,,D,,B,945,,,Homo sapiens,1,,,
,5640,8,BAO_0000357,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,51,,,CHEMBL616125,Expert,,,H,,B,946,,,,1,,,
,5272,8,BAO_0000357,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,51,,,CHEMBL616126,Expert,10116.0,,H,,B,947,,,Rattus norvegicus,1,,,
,4622,8,BAO_0000219,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,51,,,CHEMBL616127,Autocuration,,,H,,B,948,,449.0,,1,,,CHO
,17085,8,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616128,Expert,,,H,,B,949,,,,1,,,
,3025,8,BAO_0000357,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,51,,,CHEMBL616129,Autocuration,,,H,,B,950,,,,1,,,
,15315,8,BAO_0000357,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616130,Expert,,,H,,B,951,,,,1,,,
,15267,8,BAO_0000357,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,51,,,CHEMBL616131,Autocuration,,,H,,B,952,,,,1,,,
,17158,8,BAO_0000219,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,51,,,CHEMBL616132,Autocuration,,,H,,B,953,,308.0,,1,,,HeLa
,14214,9,BAO_0000219,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,51,,,CHEMBL616133,Expert,9606.0,,D,,B,954,,308.0,Homo sapiens,1,,,HeLa
,17133,8,BAO_0000357,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,CHEMBL616134,Autocuration,,,H,,B,955,,,,1,,,
,16532,8,BAO_0000357,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,51,,,CHEMBL616135,Autocuration,,,H,,B,956,,,,1,,,
,2391,9,BAO_0000357,Affinity for 5-hydroxytryptamine 1A receptor subtype,51,,,CHEMBL616136,Expert,9606.0,,D,,B,957,,,Homo sapiens,1,,,
,14447,8,BAO_0000019,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,51,,,CHEMBL616137,Autocuration,,,H,,B,958,,,,1,,,
,14447,8,BAO_0000019,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,51,,,CHEMBL872105,Autocuration,,,H,,B,959,,,,1,,,
,15086,8,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,51,,,CHEMBL616138,Autocuration,,,H,,B,960,,,,1,,,
,13051,9,BAO_0000357,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616139,Expert,9606.0,,D,,B,961,,,Homo sapiens,1,,,
,16026,8,BAO_0000019,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",51,,,CHEMBL616140,Autocuration,,,H,,F,962,,,,1,,,
,17085,8,BAO_0000019,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,51,,,CHEMBL616141,Expert,,,H,,B,963,,,,1,,,
,17133,8,BAO_0000357,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,CHEMBL616142,Autocuration,,,H,,B,964,,,,1,,,
,17133,8,BAO_0000357,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,51,,,CHEMBL616143,Autocuration,,,H,,B,965,,,,1,,,
,17211,8,BAO_0000219,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,51,,,CHEMBL616144,Autocuration,,,H,,B,966,,308.0,,1,,,HeLa
,17211,8,BAO_0000219,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,51,,,CHEMBL616145,Autocuration,,,H,,B,967,,308.0,,1,,,HeLa
,17211,8,BAO_0000219,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,51,,,CHEMBL616012,Autocuration,,,H,,B,968,,308.0,,1,,,HeLa
,17211,8,BAO_0000219,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,51,,,CHEMBL616013,Autocuration,,,H,,B,969,,308.0,,1,,,HeLa
,16394,8,BAO_0000019,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",51,,,CHEMBL616014,Autocuration,,,H,,F,970,,,,1,,,
,16394,8,BAO_0000019,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",51,,,CHEMBL616015,Autocuration,,,H,,F,971,,,,1,,,
,16394,8,BAO_0000019,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",51,,,CHEMBL616016,Autocuration,,,H,,F,972,,,,1,,,
,16394,8,BAO_0000218,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,51,In vivo,,CHEMBL616017,Autocuration,,,H,,F,973,,,,1,,,
,16394,8,BAO_0000019,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,51,,,CHEMBL616018,Autocuration,,,H,,B,974,,,,1,,,
,15740,8,BAO_0000019,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,51,,,CHEMBL616019,Autocuration,,,H,,F,975,,,,1,,,
,15740,8,BAO_0000019,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,51,,,CHEMBL616020,Autocuration,,,H,,F,976,,,,1,,,
,15740,8,BAO_0000357,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL858018,Autocuration,,,H,,B,977,,,,1,,,
,17296,8,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,,,CHEMBL616021,Autocuration,,,H,,F,978,,722.0,,1,,,HEK293
,5640,8,BAO_0000019,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",51,,,CHEMBL616022,Expert,,,H,,F,979,,,,1,,,
,5640,8,BAO_0000019,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",51,,,CHEMBL616023,Autocuration,,,H,,F,980,,,,1,,,
,5640,8,BAO_0000019,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",51,,,CHEMBL616024,Autocuration,,,H,,F,981,,,,1,,,
,5640,8,BAO_0000019,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",51,,,CHEMBL616025,Autocuration,,,H,,F,982,,,,1,,,
,2759,8,BAO_0000219,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,51,,,CHEMBL616026,Autocuration,,,H,,F,983,,449.0,,1,,,CHO
,16394,8,BAO_0000019,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",51,,,CHEMBL616027,Autocuration,,,H,,F,984,,,,1,,,
,16394,9,BAO_0000019,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",51,,,CHEMBL616028,Expert,9606.0,,D,,F,985,,,Homo sapiens,1,,,
,3445,9,BAO_0000019,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,51,,,CHEMBL616029,Expert,9606.0,,D,,F,986,,,Homo sapiens,1,,,
,4316,8,BAO_0000219,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,51,,,CHEMBL616030,Expert,,,H,,B,987,,449.0,,1,,,CHO
,4316,8,BAO_0000019,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,51,,,CHEMBL616031,Expert,,,H,,B,988,,,,1,,,
,15180,9,BAO_0000019,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,51,,,CHEMBL616032,Expert,9606.0,,D,,F,989,,,Homo sapiens,1,,,
,15180,9,BAO_0000019,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,51,,,CHEMBL616033,Expert,9606.0,,D,,F,990,,,Homo sapiens,1,,,
,15042,8,BAO_0000019,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,,,CHEMBL616034,Autocuration,,,H,,F,991,,,,1,,,
,15042,8,BAO_0000019,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,,,CHEMBL616035,Autocuration,,,H,,F,992,,,,1,,,
,15042,8,BAO_0000019,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616036,Autocuration,,,H,,F,993,,,,1,,,
,15042,8,BAO_0000019,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,,,CHEMBL616037,Autocuration,,,H,,F,994,,,,1,,,
,15042,8,BAO_0000019,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,,,CHEMBL616038,Autocuration,,,H,,F,995,,,,1,,,
,15042,8,BAO_0000019,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,,,CHEMBL616039,Autocuration,,,H,,F,996,,,,1,,,
,15042,8,BAO_0000019,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616040,Autocuration,,,H,,F,997,,,,1,,,
,15180,9,BAO_0000219,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,51,,,CHEMBL616041,Expert,9606.0,,D,,F,998,,308.0,Homo sapiens,1,,,HeLa
,15180,9,BAO_0000219,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,51,,,CHEMBL616042,Expert,9606.0,,D,,F,999,,308.0,Homo sapiens,1,,,HeLa
,15180,9,BAO_0000219,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,51,,,CHEMBL616043,Expert,9606.0,,D,,F,1000,,308.0,Homo sapiens,1,,,HeLa
,16245,8,BAO_0000019,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",51,,,CHEMBL616044,Autocuration,,,H,,F,1001,,,,1,,,
,16026,8,BAO_0000019,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",51,,,CHEMBL616045,Autocuration,,,H,,F,1002,,,,1,,,
,17296,8,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,,,CHEMBL616046,Autocuration,,,H,,F,1003,,722.0,,1,,,HEK293
,2759,8,BAO_0000219,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),51,,,CHEMBL616047,Autocuration,,,H,,F,1004,,449.0,,1,,,CHO
,2759,8,BAO_0000219,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,51,,,CHEMBL616048,Autocuration,,,H,,F,1005,,449.0,,1,,,CHO
,2759,9,BAO_0000219,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),51,,,CHEMBL616049,Expert,9606.0,,D,,F,1006,,449.0,Homo sapiens,1,,,CHO
,2759,8,BAO_0000219,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),51,,,CHEMBL616050,Autocuration,,,H,,F,1007,,449.0,,1,,,CHO
,15419,8,BAO_0000219,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,51,,,CHEMBL616051,Expert,,,H,,F,1008,,,,1,,,
,15419,8,BAO_0000219,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,51,,,CHEMBL616212,Autocuration,,,H,,F,1009,,,,1,,,
,16026,8,BAO_0000019,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",51,,,CHEMBL616213,Autocuration,,,H,,F,1010,,,,1,,,
,1414,8,BAO_0000219,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,51,In vitro,,CHEMBL616214,Expert,,,H,,B,1011,,,,1,,,
,1414,8,BAO_0000219,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,51,In vitro,,CHEMBL616215,Expert,,,H,,B,1012,,,,1,,,
,12861,8,BAO_0000357,Binding activity radioligand.,51,,,CHEMBL616216,Autocuration,,,H,,B,1013,,,,1,,,
,12861,8,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,51,,,CHEMBL616217,Autocuration,,,H,,B,1014,,,,1,,,
,5104,8,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616218,Autocuration,,,H,,B,1015,,,,1,,,
,5105,8,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616219,Autocuration,,,H,,B,1016,,,,1,,,
,16312,8,BAO_0000357,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616220,Autocuration,,,H,,B,1017,,,,1,,,
,15180,9,BAO_0000357,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL833493,Expert,9606.0,,D,,B,1018,,,Homo sapiens,1,,,
,5033,8,BAO_0000357,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616221,Autocuration,,,H,,B,1019,,,,1,,,
,16909,9,BAO_0000219,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,51,,,CHEMBL616222,Expert,9606.0,,D,,B,1020,,449.0,Homo sapiens,1,,,CHO
,2590,8,BAO_0000019,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616223,Autocuration,,,H,,F,1021,,,,1,,,
,2590,8,BAO_0000019,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,51,,,CHEMBL616224,Autocuration,,,H,,F,1022,,,,1,,,
,16394,8,BAO_0000019,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,51,,,CHEMBL616225,Expert,,,H,,B,1023,,,,1,,,
,4540,9,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,51,,,CHEMBL616226,Expert,9606.0,,D,,B,1024,,722.0,Homo sapiens,1,,,HEK293
,17296,8,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,51,,,CHEMBL616227,Autocuration,,,H,,B,1025,,722.0,,1,,,HEK293
,17296,8,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,51,,,CHEMBL616228,Autocuration,,,H,,B,1026,,722.0,,1,,,HEK293
,15779,8,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,51,,,CHEMBL616229,Autocuration,,,H,,B,1027,,722.0,,1,,,HEK293
,15779,8,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,51,,,CHEMBL616230,Autocuration,,,H,,B,1028,,722.0,,1,,,HEK293
,15779,8,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,51,,,CHEMBL616231,Autocuration,,,H,,B,1029,,722.0,,1,,,HEK293
,6166,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,51,,,CHEMBL616232,Autocuration,,,H,,B,1030,,,,1,,,
,15779,8,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,51,,,CHEMBL616233,Autocuration,,,H,,B,1031,,722.0,,1,,,HEK293
,4199,8,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,51,,,CHEMBL857973,Autocuration,,,H,,B,1032,,722.0,,1,,,HEK293
,15316,8,BAO_0000219,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,51,,,CHEMBL616234,Autocuration,,,H,,B,1033,,,,1,,,
,14875,8,BAO_0000357,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616235,Autocuration,,,H,,B,1034,,,,1,,,
,14727,8,BAO_0000219,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,51,,,CHEMBL616236,Expert,,,H,,B,1035,,308.0,,1,,,HeLa
,14727,8,BAO_0000019,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,51,,,CHEMBL616237,Expert,,,H,,B,1036,,,,1,,,
,15146,8,BAO_0000219,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,51,,,CHEMBL616238,Autocuration,,,H,,B,1037,,722.0,,1,,,HEK293
,5213,8,BAO_0000219,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,51,,,CHEMBL616239,Autocuration,,,H,,B,1038,,722.0,,1,,,HEK293
,16429,8,BAO_0000219,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,51,,,CHEMBL616240,Autocuration,,,H,,B,1039,,,,1,,,
,15042,9,BAO_0000219,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,51,,,CHEMBL616241,Expert,9606.0,,D,,B,1040,,308.0,Homo sapiens,1,,,HeLa
,14818,8,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,51,,,CHEMBL616242,Autocuration,,,H,,B,1041,,722.0,,1,,,HEK293
,4829,8,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",51,,,CHEMBL616243,Autocuration,,,H,,B,1042,,722.0,,1,,,HEK293
,17200,9,BAO_0000357,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616244,Expert,,,D,,B,1043,,,,1,,,
,13051,9,BAO_0000357,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616245,Autocuration,9606.0,,D,,B,1044,,,Homo sapiens,1,,,
,5486,8,BAO_0000357,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,106,,,CHEMBL616246,Autocuration,,,H,,B,1045,,,,1,,,
,5254,8,BAO_0000357,Binding affinity against 5-HT1D receptor,105,,,CHEMBL616247,Autocuration,,,H,,B,1046,,,,1,,,
,5254,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,105,,,CHEMBL616248,Autocuration,,,H,,B,1047,,,,1,,,
,15331,8,BAO_0000357,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,107,,,CHEMBL616249,Autocuration,,,H,,B,1048,,,,1,,,
,13506,8,BAO_0000357,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,10576,,,CHEMBL616250,Autocuration,9606.0,,H,,B,1049,,,Homo sapiens,1,,,
,15267,8,BAO_0000357,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616251,Autocuration,,,H,,B,1050,,,,1,,,
,16616,8,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,11863,In vivo,,CHEMBL616252,Autocuration,,,H,,F,1051,,,,1,,,
,16616,8,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,11863,In vivo,,CHEMBL616253,Autocuration,,,H,,F,1052,,,,1,,,
,16616,8,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,11863,In vivo,,CHEMBL616254,Autocuration,,,H,,F,1053,,,,1,,,
,16616,9,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,11863,,,CHEMBL616255,Expert,10090.0,,D,,F,1054,,,Mus musculus,1,,,
,16616,9,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,11863,,,CHEMBL832872,Expert,10090.0,,D,,F,1055,,,Mus musculus,1,,,
,16616,9,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,11863,,,CHEMBL616256,Expert,10090.0,,D,,F,1056,,,Mus musculus,1,,,
,16616,9,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,11863,,,CHEMBL616257,Expert,10090.0,,D,,F,1057,,,Mus musculus,1,,,
,16616,9,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,11863,,,CHEMBL616258,Expert,10090.0,,D,,F,1058,,,Mus musculus,1,,,
,16616,9,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,11863,,,CHEMBL616384,Expert,10090.0,,D,,F,1059,,,Mus musculus,1,,,
,10297,8,BAO_0000221,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,11863,,Hippocampus,CHEMBL616385,Autocuration,,,H,,B,1060,,,,1,,10000000.0,
,13704,8,BAO_0000357,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,11863,,,CHEMBL616386,Expert,,,H,,B,1061,,,,1,,,
,10297,9,BAO_0000221,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,11863,,Hippocampus,CHEMBL616387,Expert,10090.0,,D,,B,1062,,,Mus musculus,1,,10000000.0,
,10297,8,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,11863,,Hippocampus,CHEMBL616388,Autocuration,,,H,,B,1063,,,,1,,10000000.0,
,10297,9,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,11863,,Hippocampus,CHEMBL616389,Expert,10090.0,,D,,B,1064,,,Mus musculus,1,,10000000.0,
,10297,8,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,11863,,Hippocampus,CHEMBL616390,Autocuration,,,H,,B,1065,,,,1,,10000000.0,
,217,8,BAO_0000357,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,11863,,,CHEMBL616391,Autocuration,,,H,,B,1066,,,,1,,,
,10297,9,BAO_0000221,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,11863,,Hippocampus,CHEMBL616392,Expert,10090.0,,D,,B,1067,,,Mus musculus,1,,10000000.0,
,4921,8,BAO_0000357,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616393,Autocuration,9823.0,,H,,B,1068,,,Sus scrofa,1,,,
,4921,8,BAO_0000357,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,51,,,CHEMBL616394,Autocuration,9823.0,,H,,B,1069,,,Sus scrofa,1,,,
,4996,8,BAO_0000019,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,51,,,CHEMBL616395,Autocuration,9823.0,,H,,B,1070,,,Sus scrofa,1,,,
,12918,8,BAO_0000357,Compound was evaluated for the binding affinity at 5- HT1A receptor,51,,,CHEMBL616396,Autocuration,9823.0,,H,,B,1071,,,Sus scrofa,1,,,
,5333,8,BAO_0000019,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,51,,,CHEMBL872907,Autocuration,9823.0,,H,,B,1072,,,Sus scrofa,1,,,
,4437,8,BAO_0000019,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,51,,,CHEMBL616397,Autocuration,9823.0,,H,,B,1073,,,Sus scrofa,1,,,
,1742,8,BAO_0000019,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,51,,,CHEMBL616398,Autocuration,9823.0,,H,,B,1074,,,Sus scrofa,1,,,
,16688,8,BAO_0000357,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616399,Expert,9823.0,,H,,B,1075,,,Sus scrofa,1,,,
,12861,8,BAO_0000357,Binding activity radioligand.,51,,,CHEMBL857065,Autocuration,9823.0,,H,,B,1076,,,Sus scrofa,1,,,
,12861,8,BAO_0000019,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,51,,,CHEMBL616400,Expert,9823.0,,H,,B,1077,,,Sus scrofa,1,,,
,12861,8,BAO_0000019,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,51,,,CHEMBL616401,Autocuration,9823.0,,H,,B,1078,,,Sus scrofa,1,,,
,12490,8,BAO_0000019,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,10624,,,CHEMBL616402,Expert,,,H,,B,1079,,,,1,,,
,11828,8,BAO_0000019,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616403,Expert,9823.0,,H,,B,1080,,,Sus scrofa,1,,,
,11866,8,BAO_0000221,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,51,,Hippocampus,CHEMBL616404,Autocuration,9823.0,,H,,B,1081,,,Sus scrofa,1,,10000000.0,
,12827,8,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,51,,,CHEMBL616405,Autocuration,9823.0,,H,,B,1082,,,Sus scrofa,1,,,
,12918,8,BAO_0000019,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,51,,,CHEMBL616406,Autocuration,9823.0,,H,,B,1083,,,Sus scrofa,1,,,
,12919,8,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,51,,,CHEMBL616407,Expert,9823.0,,H,,F,1084,,,Sus scrofa,1,,,
,13047,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,51,,,CHEMBL616408,Autocuration,9986.0,,H,,B,1085,,,Oryctolagus cuniculus,1,,,
,15796,9,BAO_0000249,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,10576,,,CHEMBL616409,Expert,10116.0,,D,,B,1086,,,Rattus norvegicus,1,,,
,3651,9,BAO_0000221,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",10576,,Hippocampus,CHEMBL616410,Expert,10116.0,,D,,B,1087,,,Rattus norvegicus,1,,10000000.0,
,188,8,BAO_0000357,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,10576,,,CHEMBL616411,Autocuration,,,H,,B,1088,,,,1,,,
,16616,9,BAO_0000249,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",10576,,,CHEMBL616412,Expert,10116.0,Membranes,D,,F,1089,,,Rattus norvegicus,1,,,
,16616,9,BAO_0000249,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",10576,,Hippocampus,CHEMBL616413,Expert,10116.0,Membranes,D,,F,1090,,,Rattus norvegicus,1,,10000000.0,
,12306,8,BAO_0000221,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,,Hippocampus,CHEMBL616414,Autocuration,,,H,,B,1091,,,,1,,10000000.0,
,17167,9,BAO_0000221,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,10576,,Hippocampus,CHEMBL616415,Expert,10116.0,,D,,B,1092,,,Rattus norvegicus,1,,10000000.0,
,14776,8,BAO_0000019,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,10576,,,CHEMBL616416,Autocuration,,,H,,B,1093,,,,1,,,
,12158,8,BAO_0000357,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,10576,,,CHEMBL616417,Expert,,,H,,B,1094,,,,1,,,
,13481,8,BAO_0000357,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,10576,,,CHEMBL616418,Autocuration,,,H,,B,1095,,,,1,,,
,13427,8,BAO_0000219,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,10576,In vitro,,CHEMBL616419,Autocuration,,,H,,B,1096,,,,1,,,
,10210,8,BAO_0000357,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,10576,,,CHEMBL616420,Autocuration,,,H,,B,1097,,,,1,,,
,10205,8,BAO_0000249,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,10576,,,CHEMBL616421,Autocuration,,Membranes,H,,B,1098,,,,1,,,
,10205,8,BAO_0000249,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,10576,,,CHEMBL616422,Autocuration,,Membranes,H,,B,1099,,,,1,,,
,10205,8,BAO_0000249,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,10576,,,CHEMBL616423,Expert,,Membranes,H,,B,1100,,,,1,,,
,12280,9,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,10576,,,CHEMBL616424,Expert,10116.0,,D,,B,1101,,,Rattus norvegicus,1,,,
,17386,8,BAO_0000357,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL616425,Expert,,,H,,B,1102,,,,1,,,
,13654,8,BAO_0000357,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,10576,,,CHEMBL616426,Expert,,,H,,B,1103,,,,1,,,
,14423,8,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,10576,,Hippocampus,CHEMBL616427,Autocuration,,,H,,B,1104,,,,1,,10000000.0,
,15412,8,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,10576,,Hippocampus,CHEMBL616428,Autocuration,,,H,,B,1105,,,,1,,10000000.0,
,12073,8,BAO_0000221,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,Hippocampus,CHEMBL616290,Autocuration,,,H,,B,1106,,,,1,,10000000.0,
,4101,9,BAO_0000357,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL616052,Expert,10116.0,,D,,B,1107,,,Rattus norvegicus,1,,,
,10062,8,BAO_0000357,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL616053,Autocuration,,,H,,B,1108,,,,1,,,
,6238,8,BAO_0000249,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,10576,,,CHEMBL616054,Autocuration,,,H,,B,1109,,,,1,,,
,16273,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL616055,Autocuration,,,H,,B,1110,,,,1,,,
,11139,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,10576,,,CHEMBL616056,Autocuration,,,H,,B,1111,,,,1,,,
,16796,8,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,10576,,,CHEMBL616057,Expert,,,H,,B,1112,,,,1,,,
,9548,9,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,10576,,Brain,CHEMBL616058,Expert,10116.0,,D,,B,1113,,,Rattus norvegicus,1,,955.0,
,10381,8,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,10576,,Brain,CHEMBL616059,Autocuration,,,H,,B,1114,,,,1,,955.0,
,13408,8,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,10576,,,CHEMBL616060,Autocuration,,,H,,B,1115,,,,1,,,
,13825,9,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,10576,,Hippocampus,CHEMBL616061,Expert,10116.0,,D,,B,1116,,,Rattus norvegicus,1,,10000000.0,
,11147,8,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,10576,,Hippocampus,CHEMBL616062,Expert,,,H,,B,1117,,,,1,,10000000.0,
,10552,8,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,10576,,,CHEMBL616063,Autocuration,,,H,,B,1118,,,,1,,,
,10552,8,BAO_0000249,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",10576,,Striatum,CHEMBL616064,Autocuration,,,H,,B,1119,,,,1,,2435.0,
,17136,9,BAO_0000249,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,10576,,,CHEMBL616065,Expert,10116.0,Membranes,D,,B,1120,,,Rattus norvegicus,1,,,
,5778,9,BAO_0000249,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,10576,,,CHEMBL616066,Expert,10116.0,Membranes,D,,B,1121,,,Rattus norvegicus,1,,,
,13481,8,BAO_0000221,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,10576,,Hippocampus,CHEMBL616067,Autocuration,,,H,,B,1122,,,,1,,10000000.0,
,13481,8,BAO_0000221,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,10576,,Hippocampus,CHEMBL616068,Autocuration,,,H,,B,1123,,,,1,,10000000.0,
,13630,8,BAO_0000221,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,10576,,Hippocampus,CHEMBL616069,Intermediate,,,H,,B,1124,,,,1,,10000000.0,
,16245,8,BAO_0000249,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,10576,,,CHEMBL616070,Expert,,,H,,B,1125,,,,1,,,
,14509,8,BAO_0000221,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,,Hippocampus,CHEMBL616071,Autocuration,,,H,,B,1126,,,,1,,10000000.0,
,14509,8,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,10576,,Hippocampus,CHEMBL616072,Expert,,,H,,B,1127,,,,1,,10000000.0,
,14509,8,BAO_0000221,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,10576,,Hippocampus,CHEMBL616073,Autocuration,,,H,,B,1128,,,,1,,10000000.0,
,14509,8,BAO_0000221,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,10576,,Hippocampus,CHEMBL616074,Autocuration,,,H,,B,1129,,,,1,,10000000.0,
,14256,8,BAO_0000019,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,10576,,,CHEMBL616075,Expert,,,H,,B,1130,,,,1,,,
,11139,8,BAO_0000357,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL616076,Autocuration,,,H,,B,1131,,,,1,,,
,11047,9,BAO_0000019,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,10576,,,CHEMBL616077,Expert,10116.0,,D,,B,1132,,,Rattus norvegicus,1,,,
,11047,9,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,10576,,,CHEMBL616078,Expert,10116.0,,D,,B,1133,,,Rattus norvegicus,1,,,
,11047,9,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,10576,,,CHEMBL616079,Expert,10116.0,,D,,B,1134,,,Rattus norvegicus,1,,,
,2395,9,BAO_0000219,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,10576,,,CHEMBL616080,Expert,10116.0,,D,,B,1135,,485.0,Rattus norvegicus,1,,,CHO-K1
,9699,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL616081,Autocuration,,,H,,B,1136,,,,1,,,
,12028,9,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,10576,,Hippocampus,CHEMBL616082,Expert,10116.0,,D,,B,1137,,,Rattus norvegicus,1,,10000000.0,
,12028,8,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,10576,,Hippocampus,CHEMBL616083,Autocuration,,,H,,B,1138,,,,1,,10000000.0,
,5815,8,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,10576,,,CHEMBL616084,Autocuration,,,H,,B,1139,,,,1,,,
,16616,8,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,10576,,,CHEMBL616085,Expert,,,H,,B,1140,,,,1,,,
,5815,8,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,10576,,,CHEMBL616086,Autocuration,,,H,,B,1141,,,,1,,,
,2761,8,BAO_0000221,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",10576,,Hippocampus,CHEMBL616087,Autocuration,,,H,,B,1142,,,,1,,10000000.0,
,13133,8,BAO_0000357,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,10576,,,CHEMBL616088,Expert,,,H,,B,1143,,,,1,,,
,10444,8,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,10576,,,CHEMBL616089,Autocuration,,,H,,B,1144,,,,1,,,
,13278,9,BAO_0000357,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,10576,,,CHEMBL616090,Expert,10116.0,,D,,B,1145,,,Rattus norvegicus,1,,,
,15874,8,BAO_0000357,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,10576,,,CHEMBL616091,Autocuration,,,H,,B,1146,,,,1,,,
,10552,8,BAO_0000249,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",10576,,Striatum,CHEMBL616092,Autocuration,,Membranes,H,,B,1147,,,,1,,2435.0,
,11130,8,BAO_0000357,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),10576,,,CHEMBL616093,Autocuration,,,H,,B,1148,,,,1,,,
,11130,8,BAO_0000218,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),10576,In vivo,,CHEMBL616094,Autocuration,,,H,,B,1149,,,,1,,,
,14542,8,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,10576,,Brain,CHEMBL616095,Autocuration,,,H,,B,1150,,,,1,,955.0,
,13670,9,BAO_0000357,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL616096,Expert,10116.0,,D,,B,1151,,,Rattus norvegicus,1,,,
,9888,8,BAO_0000249,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,10576,,,CHEMBL616097,Expert,,,H,,B,1152,,,,1,,,
,3678,9,BAO_0000249,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,10576,,,CHEMBL616098,Expert,10116.0,Membranes,D,,B,1153,,,Rattus norvegicus,1,,,
,11332,8,BAO_0000221,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,,Hippocampus,CHEMBL616099,Autocuration,,,H,,B,1154,,,,1,,10000000.0,
,11332,8,BAO_0000221,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,,Hippocampus,CHEMBL616100,Autocuration,,,H,,B,1155,,,,1,,10000000.0,
,1185,8,BAO_0000357,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL616101,Expert,,,H,,B,1156,,,,1,,,
,2014,8,BAO_0000249,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,10576,,,CHEMBL616102,Expert,,,H,,B,1157,,,,1,,,
,1185,8,BAO_0000357,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL616103,Autocuration,,,H,,B,1158,,,,1,,,
,14429,8,BAO_0000019,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,10576,,,CHEMBL616104,Expert,,,H,,B,1159,,,,1,,,
,16288,8,BAO_0000019,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",10576,,,CHEMBL616105,Expert,,,H,,B,1160,,,,1,,,
,5432,9,BAO_0000019,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL616106,Expert,10116.0,,D,,B,1161,,,Rattus norvegicus,1,,,
,14429,8,BAO_0000019,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,10576,,,CHEMBL616107,Autocuration,,,H,,B,1162,,,,1,,,
,13672,8,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,10576,,,CHEMBL616108,Expert,,,H,,B,1163,,,,1,,,
,11296,8,BAO_0000221,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10576,,Hippocampus,CHEMBL616109,Expert,,,H,,B,1164,,,,1,,10000000.0,
,11296,8,BAO_0000357,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,10576,,,CHEMBL616110,Autocuration,,,H,,B,1165,,,,1,,,
,14749,8,BAO_0000219,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,10576,,,CHEMBL616111,Expert,,,H,,B,1166,,449.0,,1,,,CHO
,15086,8,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,10576,,,CHEMBL616112,Expert,,,H,,B,1167,,,,1,,,
,13462,8,BAO_0000221,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,10576,,Hippocampus,CHEMBL616113,Autocuration,,,H,,B,1168,,,,1,,10000000.0,
,15363,8,BAO_0000019,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL616114,Autocuration,,,H,,B,1169,,,,1,,,
,15363,8,BAO_0000019,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL616115,Autocuration,,,H,,B,1170,,,,1,,,
,10796,8,BAO_0000357,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL616116,Autocuration,,,H,,B,1171,,,,1,,,
,12816,8,BAO_0000221,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,10576,,Brain,CHEMBL615844,Expert,,,H,,B,1172,,,,1,,955.0,
,13542,8,BAO_0000221,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10576,,Hippocampus,CHEMBL615939,Expert,,,H,,B,1173,,,,1,,10000000.0,
,13308,8,BAO_0000019,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,10576,,,CHEMBL615940,Expert,,,H,,B,1174,,,,1,,,
,13541,8,BAO_0000221,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,10576,,Hippocampus,CHEMBL615941,Expert,,,H,,B,1175,,,,1,,10000000.0,
,10058,8,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,10576,,Hippocampus,CHEMBL615942,Autocuration,,,H,,B,1176,,,,1,,10000000.0,
,10058,8,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,10576,,Hippocampus,CHEMBL615943,Autocuration,,,H,,B,1177,,,,1,,10000000.0,
,10058,8,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,10576,,Hippocampus,CHEMBL615944,Autocuration,,,H,,B,1178,,,,1,,10000000.0,
,10058,8,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,10576,,Hippocampus,CHEMBL615945,Autocuration,,,H,,B,1179,,,,1,,10000000.0,
,10058,8,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,10576,,Hippocampus,CHEMBL615946,Autocuration,,,H,,B,1180,,,,1,,10000000.0,
,10058,8,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,10576,,Hippocampus,CHEMBL615947,Autocuration,,,H,,B,1181,,,,1,,10000000.0,
,10058,8,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,10576,,Hippocampus,CHEMBL615948,Autocuration,,,H,,B,1182,,,,1,,10000000.0,
,10058,8,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,10576,,Hippocampus,CHEMBL615949,Autocuration,,,H,,B,1183,,,,1,,10000000.0,
,10058,8,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,10576,,Hippocampus,CHEMBL615950,Autocuration,,,H,,B,1184,,,,1,,10000000.0,
,10058,8,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,10576,,Hippocampus,CHEMBL615951,Autocuration,,,H,,B,1185,,,,1,,10000000.0,
,10058,8,BAO_0000221,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,10576,,Hippocampus,CHEMBL615952,Autocuration,,,H,,B,1186,,,,1,,10000000.0,
,10058,8,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,10576,,Hippocampus,CHEMBL615953,Autocuration,,,H,,B,1187,,,,1,,10000000.0,
,10058,8,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,10576,,Hippocampus,CHEMBL615954,Autocuration,,,H,,B,1188,,,,1,,10000000.0,
,10058,9,BAO_0000221,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,10576,,Hippocampus,CHEMBL615955,Expert,10116.0,,D,,B,1189,,,Rattus norvegicus,1,,10000000.0,
,10058,8,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,10576,,Hippocampus,CHEMBL615956,Autocuration,,,H,,B,1190,,,,1,,10000000.0,
,10058,8,BAO_0000221,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,10576,,Hippocampus,CHEMBL615957,Autocuration,,,H,,B,1191,,,,1,,10000000.0,
,12879,8,BAO_0000019,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,10576,,,CHEMBL615958,Expert,,,H,,B,1192,,,,1,,,
,11964,8,BAO_0000019,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,10576,,,CHEMBL615959,Expert,,,H,,B,1193,,,,1,,,
,11964,8,BAO_0000019,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),10576,,,CHEMBL615960,Autocuration,,,H,,B,1194,,,,1,,,
,11964,8,BAO_0000019,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),10576,,,CHEMBL615961,Autocuration,,,H,,B,1195,,,,1,,,
,9548,8,BAO_0000221,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,10576,,Brain,CHEMBL615962,Expert,,,H,,B,1196,,,,1,,955.0,
,9098,8,BAO_0000019,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,10576,,,CHEMBL615963,Expert,,,H,,B,1197,,,,1,,,
,9098,8,BAO_0000019,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,10576,,,CHEMBL615964,Autocuration,,,H,,B,1198,,,,1,,,
,9098,8,BAO_0000019,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,10576,,,CHEMBL615965,Autocuration,,,H,,B,1199,,,,1,,,
,13248,8,BAO_0000219,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,10576,,,CHEMBL615966,Expert,,,H,,B,1200,,449.0,,1,,,CHO
,3147,8,BAO_0000249,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,10576,,,CHEMBL615967,Expert,,,H,,B,1201,,,,1,,,
,13949,8,BAO_0000019,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,10576,,,CHEMBL615968,Expert,,,H,,B,1202,,,,1,,,
,11883,8,BAO_0000218,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),10576,,,CHEMBL615969,Autocuration,,,H,,B,1203,,449.0,,1,,,CHO
,11883,8,BAO_0000218,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),10576,,,CHEMBL615970,Autocuration,,,H,,B,1204,,,,1,,,
,11883,9,BAO_0000357,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,10576,,,CHEMBL615971,Expert,10116.0,,D,,B,1205,,,Rattus norvegicus,1,,,
,15535,8,BAO_0000249,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,10576,,,CHEMBL615972,Expert,,Membranes,H,,B,1206,,,,1,,,
,15535,8,BAO_0000249,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,10576,,,CHEMBL615973,Autocuration,,,H,,B,1207,,,,1,,,
,15535,8,BAO_0000249,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,10576,,,CHEMBL615974,Autocuration,,,H,,B,1208,,,,1,,,
,16372,9,BAO_0000219,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,51,,,CHEMBL615975,Expert,9606.0,,D,,B,1209,,449.0,Homo sapiens,1,,,CHO
,14608,8,BAO_0000249,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,10576,,,CHEMBL615976,Expert,,,H,,B,1210,,,,1,,,
,4795,9,BAO_0000221,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,10576,,Hippocampus,CHEMBL872106,Expert,10116.0,,D,,B,1211,,,Rattus norvegicus,1,,10000000.0,
,13863,8,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,10576,,,CHEMBL615977,Autocuration,,,H,,B,1212,,,,1,,,
,13863,8,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,10576,,,CHEMBL615978,Autocuration,,,H,,B,1213,,,,1,,,
,13863,8,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,10576,,,CHEMBL616166,Autocuration,,,H,,B,1214,,,,1,,,
,13863,8,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,10576,,,CHEMBL616167,Autocuration,,,H,,B,1215,,,,1,,,
,13863,8,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,10576,,,CHEMBL616168,Autocuration,,,H,,B,1216,,,,1,,,
,13863,8,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,10576,,,CHEMBL616169,Autocuration,,,H,,B,1217,,,,1,,,
,13863,8,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,10576,,,CHEMBL616170,Autocuration,,,H,,B,1218,,,,1,,,
,13863,8,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,10576,,,CHEMBL616171,Autocuration,,,H,,B,1219,,,,1,,,
,13863,8,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,10576,,,CHEMBL616172,Autocuration,,,H,,B,1220,,,,1,,,
,13863,8,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,10576,,,CHEMBL616173,Autocuration,,,H,,B,1221,,,,1,,,
,13863,8,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,10576,,,CHEMBL616174,Autocuration,,,H,,B,1222,,,,1,,,
,13863,8,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,10576,,,CHEMBL616175,Autocuration,,,H,,B,1223,,,,1,,,
,13863,8,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,10576,,,CHEMBL616176,Autocuration,,,H,,B,1224,,,,1,,,
,13863,8,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,10576,,,CHEMBL616177,Autocuration,,,H,,B,1225,,,,1,,,
,13863,8,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,10576,,,CHEMBL616178,Autocuration,,,H,,B,1226,,,,1,,,
,9742,8,BAO_0000019,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,10576,,,CHEMBL616179,Autocuration,,,H,,B,1227,,,,1,,,
,12073,8,BAO_0000357,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL616180,Autocuration,,,H,,B,1228,,,,1,,,
,4101,8,BAO_0000357,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,10576,,,CHEMBL616181,Autocuration,,,H,,B,1229,,,,1,,,
,15360,8,BAO_0000019,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,10576,,,CHEMBL616182,Autocuration,,,H,,B,1230,,,,1,,,
,11576,8,BAO_0000221,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10576,,Hippocampus,CHEMBL616183,Autocuration,,,H,,B,1231,,,,1,,10000000.0,
,5834,8,BAO_0000019,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,10576,,,CHEMBL615874,Expert,,,H,,B,1232,,,,1,,,
,2395,9,BAO_0000219,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,10576,,,CHEMBL615875,Expert,10116.0,,D,,B,1233,,485.0,Rattus norvegicus,1,,,CHO-K1
,1375,8,BAO_0000019,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,10576,,,CHEMBL615876,Autocuration,,,H,,B,1234,,,,1,,,
,1375,8,BAO_0000019,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,10576,,,CHEMBL615877,Autocuration,,,H,,B,1235,,,,1,,,
,3967,8,BAO_0000357,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),10576,,,CHEMBL615878,Autocuration,,,H,,B,1236,,,,1,,,
,12884,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,10576,,,CHEMBL615879,Expert,,,H,,B,1237,,,,1,,,
,2343,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,10576,,,CHEMBL615880,Expert,,,H,,B,1238,,,,1,,,
,11511,8,BAO_0000019,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",10576,,,CHEMBL615881,Autocuration,,,H,,B,1239,,,,1,,,
,11511,9,BAO_0000019,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",10576,,,CHEMBL615882,Expert,10116.0,,D,,B,1240,,,Rattus norvegicus,1,,,
,16394,8,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,10576,In vivo,,CHEMBL615883,Autocuration,,,H,,F,1241,,,,1,,,
,16394,8,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),10576,In vivo,,CHEMBL615884,Autocuration,,,H,,F,1242,,,,1,,,
,16394,8,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),10576,In vivo,,CHEMBL615885,Autocuration,,,H,,F,1243,,,,1,,,
,16394,8,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),10576,In vivo,,CHEMBL615886,Autocuration,,,H,,F,1244,,,,1,,,
,16394,8,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),10576,In vivo,,CHEMBL615887,Autocuration,,,H,,F,1245,,,,1,,,
,16394,8,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),10576,In vivo,,CHEMBL615888,Autocuration,,,H,,F,1246,,,,1,,,
,16394,8,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),10576,In vivo,,CHEMBL615889,Autocuration,,,H,,F,1247,,,,1,,,
,16394,8,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),10576,In vivo,,CHEMBL615890,Autocuration,,,H,,F,1248,,,,1,,,
,16394,8,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),10576,In vivo,,CHEMBL615891,Autocuration,,,H,,F,1249,,,,1,,,
,16394,8,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),10576,In vivo,,CHEMBL615892,Autocuration,,,H,,F,1250,,,,1,,,
,16394,8,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),10576,In vivo,,CHEMBL615893,Autocuration,,,H,,F,1251,,,,1,,,
,16394,8,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),10576,In vivo,,CHEMBL615894,Autocuration,,,H,,F,1252,,,,1,,,
,16394,8,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),10576,In vivo,,CHEMBL615895,Autocuration,,,H,,F,1253,,,,1,,,
,16394,8,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),10576,In vivo,,CHEMBL615896,Autocuration,,,H,,F,1254,,,,1,,,
,16394,8,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,10576,In vivo,,CHEMBL615897,Autocuration,,,H,,F,1255,,,,1,,,
,16616,9,BAO_0000249,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",10576,,,CHEMBL615898,Expert,10116.0,Membranes,D,,F,1256,,,Rattus norvegicus,1,,,
,16796,8,BAO_0000019,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,10576,,,CHEMBL615899,Autocuration,,,H,,B,1257,,,,1,,,
,16796,8,BAO_0000019,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,10576,,,CHEMBL616291,Autocuration,,,H,,B,1258,,,,1,,,
,15629,8,BAO_0000357,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,10576,,,CHEMBL616292,Autocuration,,,H,,B,1259,,,,1,,,
,13241,8,BAO_0000249,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",10576,,,CHEMBL616293,Autocuration,,,H,,F,1260,,,,1,,,
,12073,8,BAO_0000221,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,Hippocampus,CHEMBL616294,Expert,,,H,,B,1261,,,,1,,10000000.0,
,14286,8,BAO_0000249,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,10576,,Hippocampus,CHEMBL616295,Autocuration,,,H,,B,1262,,,,1,,10000000.0,
,14542,8,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,10576,,Brain,CHEMBL616296,Autocuration,,,H,,B,1263,,,,1,,955.0,
,13630,8,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,10576,,,CHEMBL616297,Autocuration,,,H,,F,1264,,,,1,,,
,13630,8,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,10576,,,CHEMBL616605,Autocuration,,,H,,F,1265,,,,1,,,
,13630,8,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,10576,,,CHEMBL616606,Autocuration,,,H,,F,1266,,,,1,,,
,13630,8,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,10576,,,CHEMBL616607,Autocuration,,,H,,F,1267,,,,1,,,
,13630,8,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,10576,,,CHEMBL616608,Expert,,,H,,F,1268,,,,1,,,
,13630,8,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,10576,,,CHEMBL616609,Autocuration,,,H,,F,1269,,,,1,,,
,13630,9,BAO_0000019,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,10576,,,CHEMBL616610,Expert,10116.0,,D,,F,1270,,,Rattus norvegicus,1,,,
,13630,8,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,10576,,,CHEMBL616611,Autocuration,,,H,,F,1271,,,,1,,,
,13630,8,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,10576,,,CHEMBL616612,Expert,,,H,,F,1272,,,,1,,,
,13630,8,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,10576,,,CHEMBL616613,Autocuration,,,H,,F,1273,,,,1,,,
,13630,8,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,10576,,,CHEMBL616614,Expert,,,H,,F,1274,,,,1,,,
,13630,8,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,10576,,,CHEMBL616615,Autocuration,,,H,,F,1275,,,,1,,,
,13630,8,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,10576,,,CHEMBL616616,Expert,,,H,,F,1276,,,,1,,,
,13630,8,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,10576,,,CHEMBL616617,Autocuration,,,H,,F,1277,,,,1,,,
,13630,8,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,10576,,,CHEMBL616618,Autocuration,,,H,,F,1278,,,,1,,,
,13630,8,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,10576,,,CHEMBL616619,Autocuration,,,H,,F,1279,,,,1,,,
,13630,8,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,10576,,,CHEMBL616620,Expert,,,H,,F,1280,,,,1,,,
,13630,8,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,10576,,,CHEMBL616621,Expert,,,H,,F,1281,,,,1,,,
,13630,8,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,10576,,,CHEMBL616622,Autocuration,,,H,,F,1282,,,,1,,,
,13630,8,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,10576,,,CHEMBL616146,Expert,,,H,,F,1283,,,,1,,,
,13630,8,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,10576,,,CHEMBL832873,Autocuration,,,H,,F,1284,,,,1,,,
,13630,8,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,10576,,,CHEMBL616147,Autocuration,,,H,,F,1285,,,,1,,,
,13630,8,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,10576,,,CHEMBL872872,Autocuration,,,H,,F,1286,,,,1,,,
,13630,8,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,10576,,,CHEMBL616148,Autocuration,,,H,,F,1287,,,,1,,,
,9783,8,BAO_0000221,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,10576,,Hippocampus,CHEMBL616149,Autocuration,,,H,,B,1288,,,,1,,10000000.0,
,9783,8,BAO_0000221,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,10576,,Hippocampus,CHEMBL616150,Expert,,,H,,B,1289,,,,1,,10000000.0,
,14331,9,BAO_0000249,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,10576,,,CHEMBL616151,Expert,10116.0,Membranes,D,,B,1290,,,Rattus norvegicus,1,,,
,15260,8,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,10576,,Hippocampus,CHEMBL872873,Expert,,,H,,B,1291,,,,1,,10000000.0,
,15260,8,BAO_0000221,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,10576,,Hippocampus,CHEMBL616670,Autocuration,,,H,,B,1292,,,,1,,10000000.0,
,15260,8,BAO_0000221,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,10576,,Hippocampus,CHEMBL616671,Autocuration,,,H,,B,1293,,,,1,,10000000.0,
,16616,9,BAO_0000249,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",10576,,,CHEMBL884861,Expert,10116.0,,D,,F,1294,,,Rattus norvegicus,1,,,
,15629,8,BAO_0000357,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,10576,,,CHEMBL616672,Autocuration,,,H,,B,1295,,,,1,,,
,15086,8,BAO_0000019,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,10576,,,CHEMBL616673,Autocuration,,,H,,B,1296,,,,1,,,
,5717,8,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,10576,,,CHEMBL616674,Expert,,,H,,F,1297,,,,1,,,
,12652,8,BAO_0000357,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,10576,,,CHEMBL616675,Autocuration,,,H,,B,1298,,,,1,,,
,14608,8,BAO_0000221,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,10576,,Hippocampus,CHEMBL616676,Autocuration,,,H,,B,1299,,,,1,,10000000.0,
,12306,8,BAO_0000221,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,,Hippocampus,CHEMBL616677,Autocuration,,,H,,B,1300,,,,1,,10000000.0,
,12306,8,BAO_0000221,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,,Hippocampus,CHEMBL616678,Autocuration,,,H,,B,1301,,,,1,,10000000.0,
,15247,9,BAO_0000357,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL616679,Expert,10116.0,,D,,B,1302,,,Rattus norvegicus,1,,,
,17529,8,BAO_0000221,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,10576,,Hippocampus,CHEMBL616680,Expert,,,H,,B,1303,,,,1,,10000000.0,
,14826,8,BAO_0000221,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,Hippocampus,CHEMBL616681,Autocuration,,,H,,B,1304,,,,1,,10000000.0,
,14826,8,BAO_0000221,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,Hippocampus,CHEMBL616682,Autocuration,,,H,,B,1305,,,,1,,10000000.0,
,13241,8,BAO_0000221,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10576,,Hippocampus,CHEMBL616683,Autocuration,,,H,,B,1306,,,,1,,10000000.0,
,14093,8,BAO_0000221,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,10576,,Hippocampus,CHEMBL616684,Autocuration,,,H,,B,1307,,,,1,,10000000.0,
,14093,8,BAO_0000221,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,10576,,Hippocampus,CHEMBL616685,Autocuration,,,H,,B,1308,,,,1,,10000000.0,
,14442,8,BAO_0000221,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,10576,,Brain,CHEMBL616686,Autocuration,,,H,,B,1309,,,,1,,955.0,
,9919,8,BAO_0000357,Affinity for 5-hydroxytryptamine 1A receptor site,10576,,,CHEMBL616687,Autocuration,,,H,,B,1310,,,,1,,,
,9919,8,BAO_0000357,Affinity for 5-hydroxytryptamine 1A receptor site,10576,,,CHEMBL616688,Autocuration,,,H,,B,1311,,,,1,,,
,11440,8,BAO_0000221,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,10576,,Hippocampus,CHEMBL616689,Autocuration,,,H,,B,1312,,,,1,,10000000.0,
,11257,8,BAO_0000357,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,10576,,,CHEMBL616690,Autocuration,,,H,,B,1313,,,,1,,,
,10330,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,10576,,,CHEMBL616691,Expert,,,H,,B,1314,,,,1,,,
,17331,9,BAO_0000221,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,10576,,Hippocampus,CHEMBL616692,Expert,10116.0,,D,,B,1315,,,Rattus norvegicus,1,,10000000.0,
,16567,8,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,10576,,,CHEMBL616693,Expert,,,H,,B,1316,,,,1,,,
,12058,9,BAO_0000019,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",10576,,,CHEMBL616694,Expert,10116.0,,D,,B,1317,,,Rattus norvegicus,1,,,
,9699,8,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,10576,,Hippocampus,CHEMBL616695,Autocuration,,,H,,B,1318,,,,1,,10000000.0,
,9547,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,10576,,,CHEMBL616696,Autocuration,,,H,,B,1319,,,,1,,,
,10330,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,10576,,,CHEMBL616697,Autocuration,,,H,,B,1320,,,,1,,,
,14331,8,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL616698,Autocuration,,,H,,B,1321,,,,1,,,
,14060,9,BAO_0000019,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL616949,Expert,10116.0,,D,,B,1322,,,Rattus norvegicus,1,,,
,14744,8,BAO_0000221,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,10576,,Hippocampus,CHEMBL616950,Autocuration,,,H,,B,1323,,,,1,,10000000.0,
,13506,8,BAO_0000357,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,10576,,,CHEMBL832875,Autocuration,,,H,,B,1324,,,,1,,,
,10862,8,BAO_0000221,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,10576,,Brain,CHEMBL616951,Expert,,,H,,B,1325,,,,1,,955.0,
,10862,8,BAO_0000221,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,10576,,Brain,CHEMBL616952,Expert,,,H,,B,1326,,,,1,,955.0,
,10062,8,BAO_0000357,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,10576,,,CHEMBL616953,Expert,,,H,,B,1327,,,,1,,,
,12073,8,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,10576,,,CHEMBL616954,Autocuration,,,H,,B,1328,,,,1,,,
,14875,8,BAO_0000357,GTPgammaS radioligand binding assay,106,,,CHEMBL616955,Autocuration,,,H,,B,1329,,,,1,,,
,2391,8,BAO_0000357,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,106,,,CHEMBL616956,Autocuration,,,H,,B,1330,,,,1,,,
,2391,8,BAO_0000019,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,106,,,CHEMBL616957,Autocuration,,,H,,F,1331,,,,1,,,
,2391,8,BAO_0000019,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,106,,,CHEMBL616958,Autocuration,,,H,,F,1332,,,,1,,,
,2391,8,BAO_0000357,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,106,,,CHEMBL616959,Autocuration,,,H,,B,1333,,,,1,,,
,2391,8,BAO_0000357,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,106,,,CHEMBL616960,Autocuration,,,H,,B,1334,,,,1,,,
,2391,8,BAO_0000019,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,106,,,CHEMBL616961,Autocuration,,,H,,F,1335,,,,1,,,
,17211,8,BAO_0000219,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,106,,,CHEMBL616962,Expert,,,H,,B,1336,,308.0,,1,,,HeLa
,17211,8,BAO_0000219,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,106,,,CHEMBL616963,Autocuration,,,H,,B,1337,,308.0,,1,,,HeLa
,6491,9,BAO_0000357,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,106,,,CHEMBL616524,Expert,9606.0,,D,,B,1338,,,Homo sapiens,1,,,
,16190,8,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,106,,,CHEMBL616525,Autocuration,,,H,,B,1339,,449.0,,1,,,CHO
,14165,8,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,106,,,CHEMBL872908,Autocuration,,,H,,B,1340,,,,1,,,
,14165,8,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,106,,,CHEMBL616526,Autocuration,,,H,,B,1341,,,,1,,,
,4234,9,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,106,,,CHEMBL616527,Expert,9606.0,,D,,B,1342,,,Homo sapiens,1,,,
,6328,8,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,106,,,CHEMBL616528,Expert,,,H,,B,1343,,,,1,,,
,14770,8,BAO_0000357,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,106,,,CHEMBL616529,Autocuration,,,H,,B,1344,,,,1,,,
,2598,8,BAO_0000357,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,106,,,CHEMBL616530,Autocuration,,,H,,B,1345,,,,1,,,
,6897,8,BAO_0000357,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,106,,,CHEMBL616531,Expert,,,H,,B,1346,,,,1,,,
,6897,8,BAO_0000357,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,106,,,CHEMBL616532,Autocuration,,,H,,B,1347,,,,1,,,
,6013,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor,106,,,CHEMBL616533,Autocuration,,,H,,B,1348,,,,1,,,
,5843,8,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,106,,,CHEMBL616534,Expert,,,H,,B,1349,,,,1,,,
,14454,8,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,106,,,CHEMBL616535,Expert,,,H,,B,1350,,,,1,,,
,16209,8,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,106,,,CHEMBL616536,Autocuration,,,H,,B,1351,,,,1,,,
,3935,8,BAO_0000357,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,106,,,CHEMBL616537,Autocuration,,,H,,B,1352,,,,1,,,
,13729,8,BAO_0000219,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,106,,,CHEMBL616538,Expert,,,H,,F,1353,,485.0,,1,,,CHO-K1
,14251,8,BAO_0000019,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,106,,,CHEMBL616539,Expert,,,H,,F,1354,,,,1,,,
,17085,8,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,106,,,CHEMBL616540,Expert,,,H,,B,1355,,,,1,,,
,3025,8,BAO_0000357,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,106,,,CHEMBL616429,Autocuration,,,H,,B,1356,,,,1,,,
,15315,8,BAO_0000357,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,106,,,CHEMBL616430,Expert,,,H,,B,1357,,,,1,,,
,14214,9,BAO_0000219,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,106,,,CHEMBL616431,Expert,9606.0,,D,,B,1358,,,Homo sapiens,1,,,
,3804,9,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,106,,,CHEMBL616432,Expert,9606.0,,D,,B,1359,,,Homo sapiens,1,,,
,2391,9,BAO_0000357,Affinity for 5-hydroxytryptamine 1B receptor subtype,106,,,CHEMBL616433,Expert,9606.0,,D,,B,1360,,,Homo sapiens,1,,,
,4175,9,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 1B receptor,106,,,CHEMBL616434,Expert,9606.0,,D,,B,1361,,,Homo sapiens,1,,,
,17296,8,BAO_0000219,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,106,,,CHEMBL616435,Autocuration,,,H,,B,1362,,449.0,,1,,,CHO
,17085,8,BAO_0000019,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,106,,,CHEMBL616436,Expert,,,H,,B,1363,,,,1,,,
,17211,8,BAO_0000219,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,106,,,CHEMBL616437,Autocuration,,,H,,B,1364,,308.0,,1,,,HeLa
,17211,8,BAO_0000219,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,106,,,CHEMBL616438,Autocuration,,,H,,B,1365,,308.0,,1,,,HeLa
,17211,8,BAO_0000219,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,106,,,CHEMBL616439,Autocuration,,,H,,B,1366,,308.0,,1,,,HeLa
,15926,9,BAO_0000357,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,106,,,CHEMBL616440,Expert,9606.0,,D,,B,1367,,,Homo sapiens,1,,,
,16312,8,BAO_0000219,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,106,,,CHEMBL616441,Autocuration,,,H,,B,1368,,485.0,,1,,,CHO-K1
,5843,8,BAO_0000357,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,106,,,CHEMBL616442,Expert,,,H,,B,1369,,,,1,,,
,5843,8,BAO_0000357,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,106,,,CHEMBL616443,Autocuration,,,H,,B,1370,,,,1,,,
,16312,8,BAO_0000219,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,106,,,CHEMBL616444,Expert,,,H,,B,1371,,485.0,,1,,,CHO-K1
,15926,9,BAO_0000357,Binding activity against human 5-hydroxytryptamine 1B receptor,106,,,CHEMBL616445,Expert,9606.0,,D,,B,1372,,,Homo sapiens,1,,,
,15926,9,BAO_0000357,Binding activity against human 5-hydroxytryptamine 1B receptor,106,,,CHEMBL616446,Expert,9606.0,,D,,B,1373,,,Homo sapiens,1,,,
,4540,9,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,106,,,CHEMBL616447,Expert,9606.0,,D,,B,1374,,449.0,Homo sapiens,1,,,CHO
,6166,8,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,106,,,CHEMBL616448,Autocuration,,,H,,B,1375,,,,1,,,
,17296,8,BAO_0000219,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,106,,,CHEMBL616449,Autocuration,,,H,,B,1376,,449.0,,1,,,CHO
,17296,8,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,106,,,CHEMBL616450,Autocuration,,,H,,B,1377,,449.0,,1,,,CHO
,17296,8,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,106,,,CHEMBL857974,Autocuration,,,H,,B,1378,,449.0,,1,,,CHO
,15779,8,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,106,,,CHEMBL616451,Autocuration,,,H,,B,1379,,449.0,,1,,,CHO
,15779,8,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,106,,,CHEMBL616452,Autocuration,,,H,,B,1380,,449.0,,1,,,CHO
,15779,8,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,106,,,CHEMBL616453,Autocuration,,,H,,B,1381,,449.0,,1,,,CHO
,4199,8,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,106,,,CHEMBL616454,Autocuration,,,H,,B,1382,,449.0,,1,,,CHO
,14875,9,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 1B receptor,106,,,CHEMBL616455,Expert,9606.0,,D,,B,1383,,,Homo sapiens,1,,,
,15146,8,BAO_0000219,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,106,,,CHEMBL616456,Autocuration,,,H,,B,1384,,449.0,,1,,,CHO
,5213,8,BAO_0000357,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,106,,,CHEMBL616457,Autocuration,,,H,,B,1385,,,,1,,,
,14818,8,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,106,,,CHEMBL616458,Autocuration,,,H,,B,1386,,449.0,,1,,,CHO
,4829,8,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",106,,,CHEMBL616459,Autocuration,,,H,,B,1387,,449.0,,1,,,CHO
,14454,8,BAO_0000019,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,106,,,CHEMBL616460,Expert,,,H,,F,1388,,,,1,,,
,14454,8,BAO_0000019,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,106,,,CHEMBL616461,Expert,,,H,,F,1389,,,,1,,,
,14875,8,BAO_0000219,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",106,,,CHEMBL616462,Autocuration,,,H,,F,1390,,449.0,,1,,,CHO
,14875,8,BAO_0000219,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",106,,,CHEMBL616463,Autocuration,,,H,,F,1391,,449.0,,1,,,CHO
,15250,8,BAO_0000019,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",105,,,CHEMBL616464,Autocuration,,,H,,F,1392,,,,1,,,
,15250,8,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,105,,,CHEMBL616465,Autocuration,,,H,,B,1393,,449.0,,1,,,CHO
,15086,8,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,17105,,,CHEMBL832874,Autocuration,,,H,,B,1394,,,,1,,,
,3025,8,BAO_0000019,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,106,,,CHEMBL616184,Autocuration,9986.0,,H,,F,1395,,,Oryctolagus cuniculus,1,,,
,14998,8,BAO_0000019,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,106,,,CHEMBL616185,Autocuration,9986.0,,H,,B,1396,,,Oryctolagus cuniculus,1,,,
,14998,8,BAO_0000019,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",106,,,CHEMBL616186,Intermediate,9986.0,,H,,B,1397,,,Oryctolagus cuniculus,1,,,
,14998,8,BAO_0000019,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,106,,,CHEMBL616187,Autocuration,9986.0,,H,,B,1398,,,Oryctolagus cuniculus,1,,,
,13969,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,10577,,,CHEMBL616188,Expert,,,H,,B,1399,,,,1,,,
,13392,9,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1B receptor,10577,,,CHEMBL873475,Intermediate,,,D,,B,1400,,,,1,,,
,3651,9,BAO_0000019,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,10577,,Striatum,CHEMBL616189,Expert,10116.0,,D,,B,1401,,,Rattus norvegicus,1,,2435.0,
,10025,8,BAO_0000357,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,10577,,,CHEMBL616190,Expert,,,H,,B,1402,,,,1,,,
,13863,8,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,10576,,,CHEMBL616191,Autocuration,,,H,,B,1403,,,,1,,,
,13863,8,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,10576,,,CHEMBL616192,Autocuration,,,H,,B,1404,,,,1,,,
,13863,8,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,10576,,,CHEMBL616193,Autocuration,,,H,,B,1405,,,,1,,,
,13863,8,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,10576,,,CHEMBL616194,Autocuration,,,H,,B,1406,,,,1,,,
,13863,8,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,10576,,,CHEMBL616195,Autocuration,,,H,,B,1407,,,,1,,,
,13863,8,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,10576,,,CHEMBL616196,Autocuration,,,H,,B,1408,,,,1,,,
,4622,8,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,10576,,Hippocampus,CHEMBL616197,Autocuration,,,H,,B,1409,,,,1,,10000000.0,
,14911,8,BAO_0000019,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,10576,,,CHEMBL616198,Intermediate,,,H,,B,1410,,,,1,,,
,12678,8,BAO_0000221,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,10576,,Hippocampus,CHEMBL616199,Autocuration,,,H,,B,1411,,,,1,,10000000.0,
,12678,8,BAO_0000221,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,10576,,Hippocampus,CHEMBL616200,Expert,,,H,,B,1412,,,,1,,10000000.0,
,14235,8,BAO_0000221,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,10576,,Hippocampus,CHEMBL616201,Expert,,,H,,B,1413,,,,1,,10000000.0,
,14949,8,BAO_0000221,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,10576,,Hippocampus,CHEMBL616202,Expert,,,H,,B,1414,,,,1,,10000000.0,
,14949,8,BAO_0000221,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,10576,,Hippocampus,CHEMBL616203,Expert,,,H,,B,1415,,,,1,,10000000.0,
,14949,8,BAO_0000221,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,10576,,Hippocampus,CHEMBL616204,Expert,,,H,,B,1416,,,,1,,10000000.0,
,14949,8,BAO_0000221,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,10576,,Hippocampus,CHEMBL616205,Expert,,,H,,B,1417,,,,1,,10000000.0,
,14949,8,BAO_0000221,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,10576,,Hippocampus,CHEMBL616206,Expert,,,H,,B,1418,,,,1,,10000000.0,
,16118,8,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,10576,,,CHEMBL616207,Expert,,,H,,B,1419,,,,1,,,
,3268,8,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,10576,,,CHEMBL616208,Autocuration,,,H,,B,1420,,,,1,,,
,3268,8,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,10576,,,CHEMBL616209,Autocuration,,,H,,B,1421,,,,1,,,
,16117,8,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,10576,,,CHEMBL616210,Expert,,,H,,B,1422,,,,1,,,
,9783,8,BAO_0000221,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,10576,,Hippocampus,CHEMBL616211,Expert,,,H,,B,1423,,,,1,,10000000.0,
,9783,8,BAO_0000221,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,10576,,Hippocampus,CHEMBL616504,Autocuration,,,H,,B,1424,,,,1,,10000000.0,
,14356,9,BAO_0000221,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,10576,,Hippocampus,CHEMBL616505,Expert,10116.0,,D,,B,1425,,,Rattus norvegicus,1,,10000000.0,
,15740,8,BAO_0000019,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL616506,Autocuration,,,H,,F,1426,,,,1,,,
,12306,8,BAO_0000221,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,,Hippocampus,CHEMBL872107,Autocuration,,,H,,B,1427,,,,1,,10000000.0,
,13348,9,BAO_0000221,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,10576,,Hippocampus,CHEMBL616507,Expert,10116.0,,D,,B,1428,,,Rattus norvegicus,1,,10000000.0,
,10394,8,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,10576,,,CHEMBL616303,Autocuration,,,H,,B,1429,,,,1,,,
,15260,8,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,10576,,Hippocampus,CHEMBL616304,Autocuration,,,H,,B,1430,,,,1,,10000000.0,
,10046,8,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10576,,Hippocampus,CHEMBL616305,Expert,,,H,,B,1431,,,,1,,10000000.0,
,15260,8,BAO_0000221,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,10576,,Hippocampus,CHEMBL616306,Intermediate,,,H,,F,1432,,,,1,,10000000.0,
,12851,8,BAO_0000357,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL616307,Autocuration,,,H,,B,1433,,,,1,,,
,2148,9,BAO_0000221,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,10576,,Hippocampus,CHEMBL881829,Expert,10116.0,,D,,B,1434,,,Rattus norvegicus,1,,10000000.0,
,13134,8,BAO_0000357,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,10576,,,CHEMBL616308,Expert,,,H,,B,1435,,,,1,,,
,12462,8,BAO_0000019,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,10576,,,CHEMBL616309,Autocuration,,,H,,B,1436,,,,1,,,
,12462,8,BAO_0000019,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,10576,,,CHEMBL616310,Expert,,,H,,B,1437,,,,1,,,
,12462,8,BAO_0000219,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,10576,,,CHEMBL616311,Autocuration,,,H,,B,1438,,449.0,,1,,,CHO
,11933,8,BAO_0000357,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,10576,,,CHEMBL616312,Expert,,,H,,B,1439,,,,1,,,
,11933,8,BAO_0000357,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,10576,,,CHEMBL616313,Autocuration,,,H,,B,1440,,,,1,,,
,403,9,BAO_0000221,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,10576,,Hippocampus,CHEMBL616314,Expert,10116.0,,D,,B,1441,,,Rattus norvegicus,1,,10000000.0,
,15538,8,BAO_0000221,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,Hippocampus,CHEMBL616315,Autocuration,,,H,,B,1442,,,,1,,10000000.0,
,15538,8,BAO_0000221,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,10576,,Hippocampus,CHEMBL616567,Autocuration,,,H,,B,1443,,,,1,,10000000.0,
,15538,8,BAO_0000221,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,10576,,Hippocampus,CHEMBL616568,Autocuration,,,H,,B,1444,,,,1,,10000000.0,
,12464,8,BAO_0000019,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,10576,,,CHEMBL616569,Intermediate,,,H,,B,1445,,,,1,,,
,1455,8,BAO_0000357,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,10576,,,CHEMBL616570,Expert,,,H,,B,1446,,,,1,,,
,12652,8,BAO_0000357,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,10576,,,CHEMBL616571,Autocuration,,,H,,B,1447,,,,1,,,
,12639,8,BAO_0000221,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,10576,,Hippocampus,CHEMBL616572,Autocuration,,,H,,B,1448,,,,1,,10000000.0,
,13949,8,BAO_0000249,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,10576,,,CHEMBL616573,Expert,,,H,,B,1449,,,,1,,,
,12463,9,BAO_0000357,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,10576,,,CHEMBL616574,Expert,10116.0,,D,,B,1450,,,Rattus norvegicus,1,,,
,14829,8,BAO_0000221,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,10576,,Hippocampus,CHEMBL616575,Expert,,,H,,B,1451,,,,1,,10000000.0,
,14829,8,BAO_0000221,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,10576,,Hippocampus,CHEMBL872108,Autocuration,,,H,,B,1452,,,,1,,10000000.0,
,12092,8,BAO_0000357,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,10576,,,CHEMBL616576,Autocuration,,,H,,B,1453,,,,1,,,
,403,8,BAO_0000249,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,10576,,,CHEMBL616577,Autocuration,,,H,,B,1454,,,,1,,,
,403,8,BAO_0000249,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,10576,,,CHEMBL616578,Autocuration,,,H,,B,1455,,,,1,,,
,3967,8,BAO_0000357,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,10576,,,CHEMBL616579,Expert,,,H,,B,1456,,,,1,,,
,12771,9,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,10576,,,CHEMBL616580,Expert,10116.0,,D,,B,1457,,,Rattus norvegicus,1,,,
,15086,8,BAO_0000019,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,10576,,,CHEMBL616581,Autocuration,,,H,,B,1458,,,,1,,,
,14909,8,BAO_0000221,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,Hippocampus,CHEMBL616582,Autocuration,,,H,,B,1459,,,,1,,10000000.0,
,14949,8,BAO_0000221,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,Hippocampus,CHEMBL616583,Expert,,,H,,B,1460,,,,1,,10000000.0,
,2309,9,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,10576,,Hippocampus,CHEMBL616584,Expert,10116.0,,D,,B,1461,,,Rattus norvegicus,1,,10000000.0,
,4170,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL616585,Expert,,,H,,B,1462,,,,1,,,
,11642,9,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,10576,,Hippocampus,CHEMBL616586,Expert,10116.0,,D,,B,1463,,,Rattus norvegicus,1,,10000000.0,
,11642,8,BAO_0000221,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,10576,,Hippocampus,CHEMBL616587,Autocuration,,,H,,B,1464,,,,1,,10000000.0,
,12953,8,BAO_0000221,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,10576,,Hippocampus,CHEMBL616588,Autocuration,,,H,,B,1465,,,,1,,10000000.0,
,12953,8,BAO_0000221,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,10576,,Hippocampus,CHEMBL616589,Autocuration,,,H,,B,1466,,,,1,,10000000.0,
,12953,8,BAO_0000221,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,,Hippocampus,CHEMBL616590,Expert,,,H,,B,1467,,,,1,,10000000.0,
,12903,8,BAO_0000219,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",10576,,,CHEMBL616591,Expert,,,H,,B,1468,,449.0,,1,,,CHO
,12536,8,BAO_0000357,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL616592,Expert,,,H,,B,1469,,,,1,,,
,10058,8,BAO_0000357,The inhibition activity of 5-HT1A at 1 uM,10576,,,CHEMBL616593,Autocuration,,,H,,B,1470,,,,1,,,
,12902,8,BAO_0000219,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",10576,,,CHEMBL616594,Expert,,,H,,B,1471,,485.0,,1,,,CHO-K1
,14057,8,BAO_0000249,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,10576,,,CHEMBL616595,Expert,,,H,,B,1472,,,,1,,,
,11296,8,BAO_0000357,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,10576,,,CHEMBL616596,Autocuration,,,H,,B,1473,,,,1,,,
,11296,8,BAO_0000221,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10576,,Hippocampus,CHEMBL616597,Autocuration,,,H,,B,1474,,,,1,,10000000.0,
,11296,8,BAO_0000221,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10576,,Hippocampus,CHEMBL616598,Expert,,,H,,B,1475,,,,1,,10000000.0,
,16616,9,BAO_0000249,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,10576,,,CHEMBL616599,Expert,10116.0,Membranes,D,,F,1476,,,Rattus norvegicus,1,,,
,16616,9,BAO_0000249,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",10576,,Hippocampus,CHEMBL616600,Expert,10116.0,Membranes,D,,F,1477,,,Rattus norvegicus,1,,10000000.0,
,16567,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,10576,,,CHEMBL616601,Autocuration,,,H,,B,1478,,,,1,,,
,16567,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,10576,,,CHEMBL616602,Autocuration,,,H,,B,1479,,,,1,,,
,16567,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,10576,,,CHEMBL616603,Autocuration,,,H,,B,1480,,,,1,,,
,16567,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,10576,,,CHEMBL616604,Autocuration,,,H,,B,1481,,,,1,,,
,17136,8,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,10576,,,CHEMBL616316,Autocuration,,,H,,B,1482,,,,1,,,
,17136,8,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,10576,,,CHEMBL616317,Autocuration,,,H,,B,1483,,,,1,,,
,16616,9,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,10576,,,CHEMBL616318,Expert,10116.0,,D,,B,1484,,,Rattus norvegicus,1,,,
,17331,8,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,10576,,Hippocampus,CHEMBL616319,Autocuration,,,H,,B,1485,,,,1,,10000000.0,
,17331,8,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,10576,,Hippocampus,CHEMBL616320,Autocuration,,,H,,B,1486,,,,1,,10000000.0,
,17167,9,BAO_0000221,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,10576,,Hippocampus,CHEMBL616321,Expert,10116.0,,D,,B,1487,,,Rattus norvegicus,1,,10000000.0,
,15740,8,BAO_0000019,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,10576,,,CHEMBL616322,Autocuration,,,H,,F,1488,,,,1,,,
,15740,8,BAO_0000019,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,10576,,,CHEMBL616323,Autocuration,,,H,,F,1489,,,,1,,,
,4671,8,BAO_0000357,Ratio of binding affinity to 5-HT 1A and D2 receptor,10576,,,CHEMBL616324,Autocuration,,,H,,B,1490,,,,1,,,
,10058,8,BAO_0000221,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,10576,,Hippocampus,CHEMBL616325,Autocuration,,,H,,B,1491,,,,1,,10000000.0,
,10058,8,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,10576,,Hippocampus,CHEMBL616326,Autocuration,,,H,,B,1492,,,,1,,10000000.0,
,10058,8,BAO_0000221,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,10576,,Hippocampus,CHEMBL616327,Autocuration,,,H,,B,1493,,,,1,,10000000.0,
,12073,8,BAO_0000357,Percentage inhibition against 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL616328,Autocuration,,,H,,B,1494,,,,1,,,
,2759,8,BAO_0000249,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),10576,,,CHEMBL858110,Autocuration,,,H,,B,1495,,,,1,,,
,2759,8,BAO_0000249,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),10576,,,CHEMBL616329,Autocuration,,,H,,F,1496,,,,1,,,
,2759,8,BAO_0000249,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),10576,,,CHEMBL616330,Autocuration,,,H,,B,1497,,,,1,,,
,2759,8,BAO_0000249,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),10576,,,CHEMBL616331,Autocuration,,,H,,F,1498,,,,1,,,
,2759,8,BAO_0000249,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,10576,,,CHEMBL616332,Autocuration,,,H,,F,1499,,,,1,,,
,9737,8,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,10576,,Brain,CHEMBL857063,Autocuration,,,H,,B,1500,,,,1,,955.0,
,9737,8,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,10576,,,CHEMBL616333,Autocuration,,,H,,B,1501,,,,1,,,
,5717,8,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,10576,,,CHEMBL616334,Expert,,,H,,F,1502,,,,1,,,
,12253,8,BAO_0000221,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10576,,Hippocampus,CHEMBL616335,Autocuration,,,H,,B,1503,,,,1,,10000000.0,
,14025,8,BAO_0000019,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,10576,,,CHEMBL616336,Autocuration,,,H,,B,1504,,,,1,,,
,10425,8,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,10576,,,CHEMBL616337,Expert,,,H,,B,1505,,,,1,,,
,14998,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,10576,,,CHEMBL616338,Autocuration,,,H,,B,1506,,,,1,,,
,13694,8,BAO_0000221,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,10576,,Hippocampus,CHEMBL616339,Autocuration,,,H,,B,1507,,,,1,,10000000.0,
,13694,8,BAO_0000221,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,10576,,Hippocampus,CHEMBL616340,Autocuration,,,H,,B,1508,,,,1,,10000000.0,
,4342,8,BAO_0000357,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,10576,,,CHEMBL616341,Autocuration,,,H,,B,1509,,,,1,,,
,12936,9,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL616342,Expert,10116.0,,D,,B,1510,,,Rattus norvegicus,1,,,
,13144,9,BAO_0000019,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,10576,,,CHEMBL616343,Expert,10116.0,,D,,B,1511,,,Rattus norvegicus,1,,,
,13343,8,BAO_0000019,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,10576,,,CHEMBL616344,Expert,,,H,,B,1512,,,,1,,,
,12132,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,10576,,,CHEMBL616345,Expert,,,H,,B,1513,,,,1,,,
,15419,8,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,10576,,,CHEMBL616346,Expert,,,H,,B,1514,,,,1,,,
,1479,8,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10576,,Hippocampus,CHEMBL616347,Autocuration,,,H,,B,1515,,,,1,,10000000.0,
,14287,8,BAO_0000019,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,10576,,,CHEMBL616348,Expert,,,H,,B,1516,,,,1,,,
,13116,8,BAO_0000357,Binding affinity at 5-hydroxytryptamine 1A receptor,10576,,,CHEMBL616349,Expert,,,H,,B,1517,,,,1,,,
,2759,9,BAO_0000249,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,10576,,,CHEMBL616152,Expert,10116.0,Membranes,D,,B,1518,,,Rattus norvegicus,1,,,
,2759,8,BAO_0000249,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,10576,,,CHEMBL616153,Autocuration,,,H,,B,1519,,,,1,,,
,14748,8,BAO_0000019,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",10576,,,CHEMBL616154,Expert,,,H,,B,1520,,,,1,,,
,12304,8,BAO_0000019,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,10576,,,CHEMBL616155,Autocuration,,,H,,B,1521,,,,1,,,
,12409,9,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,10576,,Hippocampus,CHEMBL616156,Expert,10116.0,,D,,B,1522,,,Rattus norvegicus,1,,10000000.0,
,12409,9,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,10576,,Hippocampus,CHEMBL616157,Expert,10116.0,,D,,B,1523,,,Rattus norvegicus,1,,10000000.0,
,13267,8,BAO_0000221,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,10576,,Hippocampus,CHEMBL616158,Autocuration,,,H,,B,1524,,,,1,,10000000.0,
,15194,8,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,10576,,,CHEMBL616159,Autocuration,,,H,,B,1525,,,,1,,,
,14256,8,BAO_0000357,pKi value against rat 5-hydroxytryptamine 1A receptor.,10576,,,CHEMBL616160,Expert,,,H,,B,1526,,,,1,,,
,16567,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,10576,,,CHEMBL616161,Autocuration,,,H,,B,1527,,,,1,,,
,15740,8,BAO_0000019,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,10576,,,CHEMBL616162,Autocuration,,,H,,F,1528,,,,1,,,
,13278,9,BAO_0000357,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,12687,,,CHEMBL616163,Expert,10116.0,,D,,B,1529,,,Rattus norvegicus,1,,,
,1970,8,BAO_0000249,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,10626,,,CHEMBL616164,Expert,,Membranes,H,,B,1530,,,,1,,,
,10034,8,BAO_0000221,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,10576,,Brain,CHEMBL616165,Autocuration,,,H,,B,1531,,,,1,,955.0,
,13348,8,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,51,,,CHEMBL616355,Autocuration,10116.0,,H,,B,1532,,,Rattus norvegicus,1,,,
,13630,8,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,10576,,,CHEMBL616356,Autocuration,,,H,,F,1533,,,,1,,,
,10862,8,BAO_0000221,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,10576,,Brain,CHEMBL616357,Autocuration,,,H,,B,1534,,,,1,,955.0,
,12058,8,BAO_0000019,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",10576,,,CHEMBL616358,Autocuration,,,H,,B,1535,,,,1,,,
,4639,8,BAO_0000357,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616359,Autocuration,,,H,,B,1536,,,,1,,,
,15453,8,BAO_0000357,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,51,,,CHEMBL616360,Expert,,,H,,B,1537,,,,1,,,
,4820,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616361,Expert,,,H,,B,1538,,,,1,,,
,1089,8,BAO_0000357,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616362,Autocuration,,,H,,B,1539,,,,1,,,
,386,8,BAO_0000249,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,51,,,CHEMBL616363,Autocuration,,Brain membranes,H,,B,1540,,,,1,,,
,6011,8,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,51,,,CHEMBL616364,Autocuration,,,H,,B,1541,,,,1,,,
,5014,8,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616365,Autocuration,,,H,,B,1542,,,,1,,,
,4402,8,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,51,,,CHEMBL616366,Expert,,,H,,B,1543,,,,1,,,
,17066,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,51,,,CHEMBL872906,Expert,,,H,,B,1544,,,,1,,,
,17515,8,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,51,,,CHEMBL616367,Autocuration,,,H,,B,1545,,,,1,,,
,2474,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616368,Autocuration,,,H,,B,1546,,,,1,,,
,4775,8,BAO_0000357,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,51,,,CHEMBL616369,Autocuration,,,H,,B,1547,,,,1,,,
,14294,9,BAO_0000357,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,51,,,CHEMBL616370,Expert,9606.0,,D,,B,1548,,,Homo sapiens,1,,,
,14294,9,BAO_0000357,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,51,,,CHEMBL616371,Expert,9606.0,,D,,B,1549,,,Homo sapiens,1,,,
,12249,8,BAO_0000219,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,51,,,CHEMBL616372,Autocuration,,,H,,B,1550,,449.0,,1,,,CHO
,11376,8,BAO_0000219,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,51,,,CHEMBL616373,Expert,,,H,,B,1551,,,,1,,,
,2474,8,BAO_0000218,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,In vivo,,CHEMBL616374,Autocuration,,,H,,B,1552,,,,1,,,
,13311,8,BAO_0000221,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,Hippocampus,CHEMBL616375,Autocuration,,,H,,B,1553,,,,1,,10000000.0,
,4373,8,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,51,,,CHEMBL616376,Autocuration,,,H,,B,1554,,,,1,,,
,1633,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,51,,,CHEMBL857064,Expert,,,H,,B,1555,,,,1,,,
,11866,8,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,51,,,CHEMBL616377,Autocuration,,,H,,B,1556,,,,1,,,
,4373,8,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,51,,,CHEMBL616378,Autocuration,,,H,,B,1557,,,,1,,,
,4687,8,BAO_0000357,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,51,,,CHEMBL616379,Autocuration,,,H,,B,1558,,,,1,,,
,16946,8,BAO_0000357,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,11863,,,CHEMBL616380,Autocuration,,,H,,B,1559,,,,1,,,
,13291,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,11863,,,CHEMBL616381,Autocuration,,,H,,B,1560,,,,1,,,
,14159,8,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,11863,,,CHEMBL616382,Autocuration,,,H,,B,1561,,,,1,,,
,10812,8,BAO_0000357,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,11863,,,CHEMBL616383,Autocuration,,,H,,B,1562,,,,1,,,
,3032,9,BAO_0000219,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,11863,,,CHEMBL616350,Expert,10090.0,,D,,B,1563,,449.0,Mus musculus,1,,,CHO
,16655,8,BAO_0000357,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,11863,,,CHEMBL616351,Autocuration,,,H,,B,1564,,,,1,,,
,14532,8,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,11863,,,CHEMBL616352,Autocuration,,,H,,B,1565,,,,1,,,
,13944,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,11863,,,CHEMBL616353,Autocuration,,,H,,B,1566,,,,1,,,
,13033,8,BAO_0000357,Binding affinity against serotonergic 5-HT1a receptor,11863,,,CHEMBL616354,Autocuration,,,H,,B,1567,,,,1,,,
,10321,8,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,11863,,,CHEMBL616508,Autocuration,,,H,,B,1568,,,,1,,,
,2968,9,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor,11863,,,CHEMBL616559,Expert,10090.0,,D,,B,1569,,,Mus musculus,1,,,
,13964,8,BAO_0000357,Binding affinity at 5-hydroxytryptamine 1A receptor,11863,,,CHEMBL616560,Autocuration,,,H,,B,1570,,,,1,,,
,15527,8,BAO_0000357,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",11863,,,CHEMBL616561,Autocuration,,,H,,B,1571,,,,1,,,
,12248,8,BAO_0000219,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,11863,,,CHEMBL616562,Autocuration,,,H,,B,1572,,449.0,,1,,,CHO
,12249,8,BAO_0000219,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,11863,,,CHEMBL616563,Autocuration,,,H,,B,1573,,449.0,,1,,,CHO
,15120,8,BAO_0000357,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,11863,,,CHEMBL616564,Autocuration,,,H,,B,1574,,,,1,,,
,13313,8,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,11863,,,CHEMBL616565,Autocuration,,,H,,B,1575,,,,1,,,
,2613,8,BAO_0000218,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,11863,,,CHEMBL616566,Autocuration,,,H,,B,1576,,,,1,,,
,16700,8,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,11863,,,CHEMBL616989,Autocuration,,,H,,B,1577,,,,1,,,
,2201,8,BAO_0000357,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,11863,,,CHEMBL857975,Autocuration,,,H,,B,1578,,,,1,,,
,1274,9,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,11863,,,CHEMBL616990,Expert,10090.0,,D,,B,1579,,,Mus musculus,1,,,
,1317,8,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,11863,,,CHEMBL616991,Autocuration,,,H,,B,1580,,,,1,,,
,12146,8,BAO_0000357,Tested against 5-hydroxytryptamine 1A receptor,11863,,,CHEMBL616992,Autocuration,,,H,,B,1581,,,,1,,,
,14059,8,BAO_0000357,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,11863,,,CHEMBL616993,Autocuration,,,H,,B,1582,,,,1,,,
,14025,8,BAO_0000019,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,106,,,CHEMBL616994,Expert,9986.0,,H,,B,1583,,,Oryctolagus cuniculus,1,,,
,14025,8,BAO_0000019,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,106,,,CHEMBL616995,Autocuration,9986.0,,H,,B,1584,,,Oryctolagus cuniculus,1,,,
,14447,9,BAO_0000219,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,105571,,,CHEMBL616996,Intermediate,9593.0,,D,,B,1585,,722.0,Gorilla gorilla,1,,,HEK293
,3025,8,BAO_0000218,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,106,In vivo,,CHEMBL616997,Autocuration,10141.0,,H,,F,1586,,,Cavia porcellus,1,,,
,3025,8,BAO_0000218,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,106,In vivo,,CHEMBL616998,Autocuration,10141.0,,H,,F,1587,,,Cavia porcellus,1,,,
,15329,8,BAO_0000019,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,106,,,CHEMBL616999,Autocuration,10141.0,,H,,F,1588,,,Cavia porcellus,1,,,
,15329,8,BAO_0000019,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,106,,,CHEMBL617000,Autocuration,10141.0,,H,,F,1589,,,Cavia porcellus,1,,,
,15847,8,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,106,,,CHEMBL617001,Autocuration,10141.0,,H,,F,1590,,,Cavia porcellus,1,,,
,15847,8,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,106,,,CHEMBL858111,Autocuration,10141.0,,H,,F,1591,,,Cavia porcellus,1,,,
,14165,8,BAO_0000019,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,106,,,CHEMBL617002,Autocuration,,,H,,F,1592,,,,1,,,
,14214,8,BAO_0000019,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),106,,,CHEMBL617003,Autocuration,,,H,,F,1593,,,,1,,,
,14214,8,BAO_0000019,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),106,,,CHEMBL617004,Autocuration,,,H,,F,1594,,,,1,,,
,14214,9,BAO_0000019,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,106,,,CHEMBL617005,Expert,9606.0,,D,,F,1595,,,Homo sapiens,1,,,
,13729,9,BAO_0000219,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,106,,,CHEMBL616623,Expert,9606.0,,D,,F,1596,,485.0,Homo sapiens,1,,,CHO-K1
,3025,8,BAO_0000219,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,106,,,CHEMBL616624,Autocuration,,,H,,F,1597,,449.0,,1,,,CHO
,2391,8,BAO_0000357,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,106,,,CHEMBL883243,Autocuration,,,H,,B,1598,,,,1,,,
,2391,8,BAO_0000019,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,106,,,CHEMBL616625,Autocuration,,,H,,F,1599,,,,1,,,
,14956,8,BAO_0000219,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",106,,,CHEMBL616626,Expert,,,H,,F,1600,,449.0,,1,,,CHO
,2598,8,BAO_0000219,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,106,,,CHEMBL616627,Autocuration,,,H,,F,1601,,449.0,,1,,,CHO
,2598,8,BAO_0000219,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,106,,,CHEMBL616628,Autocuration,,,H,,F,1602,,449.0,,1,,,CHO
,2598,8,BAO_0000219,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,106,,,CHEMBL616629,Autocuration,,,H,,F,1603,,449.0,,1,,,CHO
,2598,8,BAO_0000219,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,106,,,CHEMBL616630,Autocuration,,,H,,F,1604,,449.0,,1,,,CHO
,14956,8,BAO_0000019,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",106,,,CHEMBL616631,Expert,,,H,,F,1605,,,,1,,,
,14956,8,BAO_0000019,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",106,,,CHEMBL616632,Autocuration,,,H,,F,1606,,,,1,,,
,14214,9,BAO_0000357,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,106,,,CHEMBL616633,Expert,9606.0,,D,,B,1607,,,Homo sapiens,1,,,
,3463,8,BAO_0000219,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,106,,,CHEMBL616634,Expert,,,H,,B,1608,,449.0,,1,,,CHO
,15331,8,BAO_0000357,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,106,,,CHEMBL616635,Autocuration,,,H,,B,1609,,,,1,,,
,16146,9,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1B receptor,106,,,CHEMBL885358,Expert,9606.0,,D,,B,1610,,,Homo sapiens,1,,,
,14159,9,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,106,,,CHEMBL616636,Expert,9606.0,,D,,B,1611,,449.0,Homo sapiens,1,,,CHO
,14158,8,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,106,,,CHEMBL616637,Expert,,,H,,B,1612,,449.0,,1,,,CHO
,14159,8,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,106,,,CHEMBL616638,Autocuration,,,H,,B,1613,,,,1,,,
,15250,8,BAO_0000219,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,106,,,CHEMBL616639,Expert,,,H,,B,1614,,449.0,,1,,,CHO
,15250,8,BAO_0000219,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,106,,,CHEMBL616640,Expert,,,H,,B,1615,,449.0,,1,,,CHO
,15331,8,BAO_0000219,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,106,,,CHEMBL616641,Expert,,,H,,B,1616,,449.0,,1,,,CHO
,15332,8,BAO_0000219,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,106,,,CHEMBL616642,Expert,,,H,,B,1617,,449.0,,1,,,CHO
,14956,8,BAO_0000219,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,106,,,CHEMBL616643,Expert,,,H,,B,1618,,449.0,,1,,,CHO
,3805,8,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),106,,,CHEMBL616644,Autocuration,,,H,,B,1619,,,,1,,,
,14875,8,BAO_0000357,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,106,,,CHEMBL616645,Autocuration,,,H,,B,1620,,,,1,,,
,14454,8,BAO_0000019,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),105,,,CHEMBL616646,Autocuration,9986.0,,H,,F,1621,,,Oryctolagus cuniculus,1,,,
,14454,8,BAO_0000019,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),105,,,CHEMBL616647,Expert,9986.0,,H,,F,1622,,,Oryctolagus cuniculus,1,,,
,16288,8,BAO_0000357,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),105,,,CHEMBL616509,Autocuration,,,H,,B,1623,,,,1,,,
,16288,8,BAO_0000357,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),105,,,CHEMBL616510,Autocuration,,,H,,B,1624,,,,1,,,
,16312,8,BAO_0000357,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,105,,,CHEMBL616511,Autocuration,,,H,,B,1625,,,,1,,,
,1348,8,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,105,,,CHEMBL616512,Expert,9913.0,,H,,B,1626,,,Bos taurus,1,,,
,5834,8,BAO_0000357,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,105,,,CHEMBL616513,Autocuration,9913.0,,H,,B,1627,,,Bos taurus,1,,,
,13366,8,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,105,,Striatum,CHEMBL616514,Autocuration,9913.0,,H,,B,1628,,,Bos taurus,1,,2435.0,
,1414,8,BAO_0000357,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,105,,,CHEMBL616515,Expert,9913.0,,H,,B,1629,,,Bos taurus,1,,,
,14998,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,105,,,CHEMBL616516,Autocuration,9913.0,,H,,B,1630,,,Bos taurus,1,,,
,11473,8,BAO_0000357,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,105,,,CHEMBL616517,Autocuration,9913.0,,H,,B,1631,,,Bos taurus,1,,,
,11473,8,BAO_0000357,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,105,,,CHEMBL616518,Autocuration,9913.0,,H,,B,1632,,,Bos taurus,1,,,
,10639,8,BAO_0000357,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,105,,,CHEMBL616519,Autocuration,9913.0,,H,,B,1633,,,Bos taurus,1,,,
,10639,8,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,105,,,CHEMBL616520,Autocuration,9913.0,,H,,B,1634,,,Bos taurus,1,,,
,1375,8,BAO_0000357,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,105,,,CHEMBL616521,Autocuration,9913.0,,H,,B,1635,,,Bos taurus,1,,,
,1375,8,BAO_0000357,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,105,,,CHEMBL616522,Autocuration,9913.0,,H,,B,1636,,,Bos taurus,1,,,
,16532,8,BAO_0000357,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,105,,,CHEMBL884531,Autocuration,9913.0,,H,,B,1637,,,Bos taurus,1,,,
,11147,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,105,,,CHEMBL616523,Autocuration,9913.0,,H,,B,1638,,,Bos taurus,1,,,
,13366,8,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,105,,Striatum,CHEMBL616731,Autocuration,9913.0,,H,,B,1639,,,Bos taurus,1,,2435.0,
,10444,8,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,105,,,CHEMBL616732,Autocuration,9913.0,,H,,B,1640,,,Bos taurus,1,,,
,16532,8,BAO_0000357,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,105,,,CHEMBL616733,Autocuration,9913.0,,H,,B,1641,,,Bos taurus,1,,,
,16532,8,BAO_0000357,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,105,,,CHEMBL616734,Autocuration,9913.0,,H,,B,1642,,,Bos taurus,1,,,
,12827,8,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,105,,,CHEMBL616735,Autocuration,9913.0,,H,,B,1643,,,Bos taurus,1,,,
,12827,8,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,105,,,CHEMBL616736,Autocuration,9913.0,,H,,B,1644,,,Bos taurus,1,,,
,12919,8,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,,,CHEMBL616737,Expert,9913.0,,H,,F,1645,,,Bos taurus,1,,,
,14025,8,BAO_0000019,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,105,,,CHEMBL616738,Autocuration,9913.0,,H,,B,1646,,,Bos taurus,1,,,
,12919,8,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,,,CHEMBL616739,Expert,9913.0,,H,,F,1647,,,Bos taurus,1,,,
,12919,8,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,,,CHEMBL616740,Expert,9913.0,,H,,F,1648,,,Bos taurus,1,,,
,12919,8,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,,,CHEMBL616741,Expert,9913.0,,H,,F,1649,,,Bos taurus,1,,,
,14447,8,BAO_0000219,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,105,,,CHEMBL616742,Autocuration,9593.0,,H,,B,1650,,722.0,Gorilla gorilla,1,,,HEK293
,1375,9,BAO_0000019,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,105570,,,CHEMBL616743,Intermediate,10141.0,,D,,B,1651,,,Cavia porcellus,1,,,
,1375,9,BAO_0000019,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,105570,,,CHEMBL616744,Intermediate,10141.0,,D,,B,1652,,,Cavia porcellus,1,,,
,12409,9,BAO_0000019,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,105570,,,CHEMBL616745,Intermediate,10141.0,,D,,F,1653,,,Cavia porcellus,1,,,
,12409,9,BAO_0000019,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,,,CHEMBL616746,Intermediate,10141.0,,D,,F,1654,,,Cavia porcellus,1,,,
,12409,9,BAO_0000019,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,105570,,,CHEMBL616747,Intermediate,10141.0,,D,,F,1655,,,Cavia porcellus,1,,,
,12409,9,BAO_0000019,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,105570,,,CHEMBL616748,Intermediate,10141.0,,D,,F,1656,,,Cavia porcellus,1,,,
,12409,9,BAO_0000019,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,105570,,,CHEMBL616648,Intermediate,10141.0,,D,,F,1657,,,Cavia porcellus,1,,,
,11574,9,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor,105570,,,CHEMBL616649,Intermediate,10141.0,,D,,B,1658,,,Cavia porcellus,1,,,
,1558,9,BAO_0000357,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,105570,,,CHEMBL616650,Intermediate,10141.0,,D,,B,1659,,,Cavia porcellus,1,,,
,12409,9,BAO_0000218,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,,,CHEMBL616651,Intermediate,10141.0,,D,,F,1660,,,Cavia porcellus,1,,,
,12409,9,BAO_0000218,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,,,CHEMBL616652,Intermediate,10141.0,,D,,F,1661,,,Cavia porcellus,1,,,
,12409,9,BAO_0000218,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,,,CHEMBL616653,Intermediate,10141.0,,D,,F,1662,,,Cavia porcellus,1,,,
,12409,9,BAO_0000218,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,105570,,,CHEMBL616654,Intermediate,10141.0,,D,,F,1663,,,Cavia porcellus,1,,,
,12253,9,BAO_0000019,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,105570,,,CHEMBL616655,Intermediate,10141.0,,D,,B,1664,,,Cavia porcellus,1,,,
,12936,9,BAO_0000357,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,105570,,,CHEMBL616656,Intermediate,10141.0,,D,,B,1665,,,Cavia porcellus,1,,,
,13181,8,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,105,,,CHEMBL616657,Autocuration,10141.0,,H,,B,1666,,,Cavia porcellus,1,,,
,12409,9,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,105570,,Striatum,CHEMBL616658,Intermediate,10141.0,,D,,B,1667,,,Cavia porcellus,1,,2435.0,
,10639,9,BAO_0000357,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,105570,,,CHEMBL616659,Intermediate,10141.0,,D,,B,1668,,,Cavia porcellus,1,,,
,5254,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor,51,,,CHEMBL616660,Autocuration,,,H,,B,1669,,,,1,,,
,13051,8,BAO_0000357,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,106,,,CHEMBL616661,Autocuration,,,H,,B,1670,,,,1,,,
,3463,8,BAO_0000019,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,105,,,CHEMBL616662,Expert,,,H,,F,1671,,,,1,,,
,15315,8,BAO_0000019,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,105,,,CHEMBL616663,Autocuration,,,H,,F,1672,,,,1,,,
,6011,8,BAO_0000019,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,105,,,CHEMBL616664,Autocuration,,,H,,F,1673,,,,1,,,
,14159,9,BAO_0000219,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",105,,,CHEMBL881820,Expert,9606.0,,D,,F,1674,,449.0,Homo sapiens,1,,,CHO
,14159,8,BAO_0000219,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",105,,,CHEMBL616665,Autocuration,,,H,,F,1675,,449.0,,1,,,CHO
,15250,8,BAO_0000219,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,105,,,CHEMBL616666,Expert,,,H,,B,1676,,449.0,,1,,,CHO
,15250,8,BAO_0000219,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,105,,,CHEMBL616667,Autocuration,,,H,,B,1677,,449.0,,1,,,CHO
,15331,8,BAO_0000219,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",105,,,CHEMBL616668,Expert,,,H,,F,1678,,449.0,,1,,,CHO
,15332,9,BAO_0000219,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",105,,,CHEMBL616669,Expert,9606.0,,D,,F,1679,,449.0,Homo sapiens,1,,,CHO
,15332,8,BAO_0000219,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",105,,,CHEMBL617040,Expert,,,H,,F,1680,,449.0,,1,,,CHO
,3294,8,BAO_0000219,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",105,,,CHEMBL617041,Autocuration,,,H,,F,1681,,449.0,,1,,,CHO
,14158,8,BAO_0000219,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",105,,,CHEMBL617042,Expert,,,H,,F,1682,,449.0,,1,,,CHO
,14956,8,BAO_0000219,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",105,,,CHEMBL617043,Expert,,,H,,F,1683,,449.0,,1,,,CHO
,12469,8,BAO_0000019,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,105,,,CHEMBL617044,Autocuration,,,H,,F,1684,,,,1,,,
,3463,8,BAO_0000219,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,105,,,CHEMBL617045,Expert,,,H,,F,1685,,449.0,,1,,,CHO
,15250,9,BAO_0000219,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",105,,,CHEMBL617046,Expert,9606.0,,D,,F,1686,,449.0,Homo sapiens,1,,,CHO
,15250,9,BAO_0000219,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",105,,,CHEMBL617047,Expert,9606.0,,D,,F,1687,,449.0,Homo sapiens,1,,,CHO
,14956,8,BAO_0000019,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",105,,,CHEMBL617048,Expert,,,H,,F,1688,,,,1,,,
,14159,8,BAO_0000019,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",105,,,CHEMBL616897,Autocuration,,,H,,F,1689,,,,1,,,
,14159,9,BAO_0000019,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",105,,,CHEMBL616898,Expert,9606.0,,D,,F,1690,,,Homo sapiens,1,,,
,14499,9,BAO_0000219,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,105,,,CHEMBL858201,Expert,9606.0,,D,,F,1691,,449.0,Homo sapiens,1,,,CHO
,15315,8,BAO_0000019,Intrinsic activity for 5-hydroxytryptamine 1D receptor,105,,,CHEMBL616899,Autocuration,,,H,,F,1692,,,,1,,,
,3294,8,BAO_0000219,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),105,In vitro,,CHEMBL616900,Autocuration,,,H,,B,1693,,,,1,,,
,3463,8,BAO_0000219,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,105,,,CHEMBL616901,Expert,,,H,,B,1694,,449.0,,1,,,CHO
,15331,8,BAO_0000357,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,105,,,CHEMBL616902,Autocuration,,,H,,B,1695,,,,1,,,
,14159,9,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,,,CHEMBL616903,Expert,9606.0,,D,,B,1696,,449.0,Homo sapiens,1,,,CHO
,14158,8,BAO_0000219,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,105,,,CHEMBL616904,Expert,,,H,,B,1697,,449.0,,1,,,CHO
,14159,8,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,105,,,CHEMBL616905,Autocuration,,,H,,B,1698,,,,1,,,
,15250,8,BAO_0000219,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,105,,,CHEMBL616906,Expert,,,H,,B,1699,,449.0,,1,,,CHO
,15250,8,BAO_0000219,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,105,,,CHEMBL616907,Expert,,,H,,B,1700,,449.0,,1,,,CHO
,15331,8,BAO_0000219,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,105,,,CHEMBL616908,Expert,,,H,,B,1701,,449.0,,1,,,CHO
,15332,9,BAO_0000219,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,,,CHEMBL616909,Expert,9606.0,,D,,B,1702,,449.0,Homo sapiens,1,,,CHO
,14499,9,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,,,CHEMBL616910,Expert,9606.0,,D,,B,1703,,449.0,Homo sapiens,1,,,CHO
,15332,8,BAO_0000219,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,105,,,CHEMBL616911,Expert,,,H,,B,1704,,449.0,,1,,,CHO
,14956,8,BAO_0000219,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,,,CHEMBL616912,Expert,,,H,,B,1705,,449.0,,1,,,CHO
,3805,8,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),105,,,CHEMBL616913,Autocuration,,,H,,B,1706,,,,1,,,
,6011,9,BAO_0000219,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,105,,,CHEMBL616914,Expert,9606.0,,D,,B,1707,,449.0,Homo sapiens,1,,,CHO
,16190,8,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,105,,,CHEMBL616915,Autocuration,,,H,,B,1708,,449.0,,1,,,CHO
,14165,8,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,105,,,CHEMBL616916,Autocuration,,,H,,B,1709,,,,1,,,
,4234,9,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,105,,,CHEMBL616917,Expert,9606.0,,D,,B,1710,,,Homo sapiens,1,,,
,15527,8,BAO_0000357,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",105,,,CHEMBL616918,Autocuration,,,H,,B,1711,,,,1,,,
,6328,8,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,105,,,CHEMBL616919,Expert,,,H,,B,1712,,,,1,,,
,16209,8,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,105,,,CHEMBL616920,Autocuration,,,H,,B,1713,,,,1,,,
,14770,8,BAO_0000357,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,105,,,CHEMBL872914,Autocuration,,,H,,B,1714,,,,1,,,
,2598,8,BAO_0000357,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,105,,,CHEMBL616921,Autocuration,,,H,,B,1715,,,,1,,,
,6897,8,BAO_0000357,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,105,,,CHEMBL616922,Expert,,,H,,B,1716,,,,1,,,
,6013,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1D receptor,105,,,CHEMBL616923,Autocuration,,,H,,B,1717,,,,1,,,
,5843,8,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,105,,,CHEMBL616924,Expert,,,H,,B,1718,,,,1,,,
,14454,8,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,105,,,CHEMBL875909,Expert,,,H,,B,1719,,,,1,,,
,14454,8,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,105,,,CHEMBL616925,Autocuration,,,H,,B,1720,,,,1,,,
,14454,8,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,105,,,CHEMBL616926,Autocuration,,,H,,B,1721,,,,1,,,
,15818,8,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,105,,,CHEMBL616927,Autocuration,,,H,,B,1722,,,,1,,,
,13729,8,BAO_0000219,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,105,,,CHEMBL616928,Expert,,,H,,F,1723,,485.0,,1,,,CHO-K1
,6011,9,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),105,In vitro,,CHEMBL616929,Expert,9606.0,,D,,B,1724,,,Homo sapiens,1,,,
,4234,9,BAO_0000357,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,105,,,CHEMBL616930,Expert,9606.0,,D,,B,1725,,,Homo sapiens,1,,,
,17085,8,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,105,,,CHEMBL616931,Expert,,,H,,B,1726,,,,1,,,
,3025,8,BAO_0000357,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,105,,,CHEMBL616932,Autocuration,,,H,,B,1727,,,,1,,,
,15315,8,BAO_0000357,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,105,,,CHEMBL616933,Expert,,,H,,B,1728,,,,1,,,
,14214,9,BAO_0000219,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,105,,,CHEMBL616934,Expert,9606.0,,D,,B,1729,,,Homo sapiens,1,,,
,3804,9,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 1D receptor,105,,,CHEMBL616935,Expert,9606.0,,D,,B,1730,,,Homo sapiens,1,,,
,16700,8,BAO_0000357,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,105,,,CHEMBL616936,Autocuration,,,H,,B,1731,,,,1,,,
,2391,9,BAO_0000357,Affinity for 5-hydroxytryptamine 1D receptor subtype,105,,,CHEMBL616937,Expert,9606.0,,D,,B,1732,,,Homo sapiens,1,,,
,4175,9,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 1D receptor,105,,,CHEMBL616938,Expert,9606.0,,D,,B,1733,,,Homo sapiens,1,,,
,17085,8,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,105,,,CHEMBL616939,Autocuration,,,H,,B,1734,,,,1,,,
,17085,8,BAO_0000019,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,105,,,CHEMBL616940,Expert,,,H,,B,1735,,,,1,,,
,15926,9,BAO_0000357,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,105,,,CHEMBL616941,Expert,9606.0,,D,,B,1736,,,Homo sapiens,1,,,
,16312,8,BAO_0000219,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,105,,,CHEMBL616942,Autocuration,,,H,,B,1737,,485.0,,1,,,CHO-K1
,16312,8,BAO_0000219,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,105,,,CHEMBL616943,Autocuration,,,H,,B,1738,,485.0,,1,,,CHO-K1
,14956,4,BAO_0000219,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,104802,,,CHEMBL616944,Autocuration,,,H,,B,1739,,449.0,,1,,,CHO
,3294,8,BAO_0000019,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",105,,,CHEMBL616945,Autocuration,,,H,,F,1740,,,,1,,,
,12861,8,BAO_0000357,Binding activity radioligand.,105,,,CHEMBL616946,Autocuration,,,H,,B,1741,,,,1,,,
,12861,8,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,105,,,CHEMBL616947,Autocuration,,,H,,B,1742,,,,1,,,
,16312,8,BAO_0000219,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,105,,,CHEMBL616948,Expert,,,H,,B,1743,,485.0,,1,,,CHO-K1
,5104,8,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,105,,,CHEMBL616851,Autocuration,,,H,,B,1744,,,,1,,,
,5105,8,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,105,,,CHEMBL616852,Autocuration,,,H,,B,1745,,,,1,,,
,14499,8,BAO_0000357,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,105,,,CHEMBL616853,Autocuration,,,H,,B,1746,,,,1,,,
,15926,9,BAO_0000357,Binding activity against human 5-hydroxytryptamine 1D receptor,105,,,CHEMBL616854,Expert,9606.0,,D,,B,1747,,,Homo sapiens,1,,,
,4540,9,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,105,,,CHEMBL616855,Expert,9606.0,,D,,B,1748,,449.0,Homo sapiens,1,,,CHO
,15779,8,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,105,,,CHEMBL616856,Autocuration,,,H,,B,1749,,449.0,,1,,,CHO
,15779,8,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,105,,,CHEMBL616857,Autocuration,,,H,,B,1750,,449.0,,1,,,CHO
,6166,8,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,105,,,CHEMBL616858,Autocuration,,,H,,B,1751,,,,1,,,
,15779,8,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,105,,,CHEMBL616859,Autocuration,,,H,,B,1752,,449.0,,1,,,CHO
,15779,8,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,105,,,CHEMBL616860,Autocuration,,,H,,B,1753,,449.0,,1,,,CHO
,17451,8,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,105,,,CHEMBL616861,Autocuration,,,H,,B,1754,,722.0,,1,,,HEK293
,17451,8,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,105,,,CHEMBL616541,Autocuration,,,H,,B,1755,,722.0,,1,,,HEK293
,17451,8,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,105,,,CHEMBL616542,Autocuration,,,H,,B,1756,,722.0,,1,,,HEK293
,4199,8,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,105,,,CHEMBL616543,Autocuration,,,H,,B,1757,,449.0,,1,,,CHO
,14875,9,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 1D receptor,105,,,CHEMBL616544,Expert,9606.0,,D,,B,1758,,,Homo sapiens,1,,,
,15146,8,BAO_0000219,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,105,,,CHEMBL616545,Autocuration,,,H,,B,1759,,449.0,,1,,,CHO
,5213,8,BAO_0000357,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,105,,,CHEMBL616546,Autocuration,,,H,,B,1760,,,,1,,,
,14818,8,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,105,,,CHEMBL616547,Autocuration,,,H,,B,1761,,449.0,,1,,,CHO
,4829,8,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",105,,,CHEMBL616548,Autocuration,,,H,,B,1762,,449.0,,1,,,CHO
,14454,8,BAO_0000019,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,105,,,CHEMBL616549,Expert,,,H,,F,1763,,,,1,,,
,14454,8,BAO_0000019,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,105,,,CHEMBL616550,Expert,,,H,,F,1764,,,,1,,,
,5254,8,BAO_0000357,Binding affinity against 5-HT2C receptor,108,,,CHEMBL857066,Autocuration,,,H,,B,1765,,,,1,,,
,5254,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor,108,,,CHEMBL616551,Autocuration,,,H,,B,1766,,,,1,,,
,10639,8,BAO_0000357,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,10577,,,CHEMBL616552,Autocuration,,,H,,B,1767,,,,1,,,
,10639,8,BAO_0000019,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,10577,,,CHEMBL832876,Autocuration,,,H,,F,1768,,,,1,,,
,12352,8,BAO_0000019,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",10577,,,CHEMBL616553,Expert,,,H,,B,1769,,,,1,,,
,9098,8,BAO_0000357,Binding affinity towards 5-HT1B was determined,10577,,,CHEMBL616554,Autocuration,,,H,,B,1770,,,,1,,,
,14430,8,BAO_0000019,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,10577,,,CHEMBL616555,Expert,,,H,,B,1771,,,,1,,,
,13657,8,BAO_0000019,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",10577,,,CHEMBL616556,Expert,,,H,,B,1772,,,,1,,,
,13657,8,BAO_0000019,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",10577,,,CHEMBL616557,Autocuration,,,H,,B,1773,,,,1,,,
,15854,8,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,10577,,,CHEMBL616558,Expert,,,H,,B,1774,,,,1,,,
,10639,9,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,10577,,,CHEMBL616749,Expert,10116.0,,D,,B,1775,,,Rattus norvegicus,1,,,
,10025,8,BAO_0000357,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,10577,,,CHEMBL616750,Autocuration,,,H,,B,1776,,,,1,,,
,10025,8,BAO_0000357,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",10577,,,CHEMBL616751,Autocuration,,,H,,B,1777,,,,1,,,
,14286,8,BAO_0000249,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,10577,,,CHEMBL616752,Autocuration,,,H,,B,1778,,,,1,,,
,3651,8,BAO_0000019,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,10577,,Striatum,CHEMBL616753,Autocuration,,,H,,B,1779,,,,1,,2435.0,
,14178,9,BAO_0000357,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,10577,,,CHEMBL616754,Expert,10116.0,,D,,B,1780,,,Rattus norvegicus,1,,,
,10639,8,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,10577,,,CHEMBL616755,Autocuration,,,H,,B,1781,,,,1,,,
,13605,8,BAO_0000019,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,10577,,Striatum,CHEMBL616756,Autocuration,,,H,,B,1782,,,,1,,2435.0,
,5834,8,BAO_0000019,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,10577,,Striatum,CHEMBL616757,Autocuration,,,H,,B,1783,,,,1,,2435.0,
,10922,8,BAO_0000357,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,10577,,Striatum,CHEMBL616758,Autocuration,,,H,,B,1784,,,,1,,2435.0,
,14286,8,BAO_0000249,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,10577,,,CHEMBL616759,Autocuration,,,H,,B,1785,,,,1,,,
,11825,8,BAO_0000357,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,10577,,,CHEMBL616760,Autocuration,,,H,,B,1786,,,,1,,,
,14826,8,BAO_0000019,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,10577,,Striatum,CHEMBL616761,Autocuration,,,H,,B,1787,,,,1,,2435.0,
,9699,8,BAO_0000019,Binding affinity against 5-HT1B serotonin receptor in rat striatum,10577,,Striatum,CHEMBL616762,Autocuration,,,H,,B,1788,,,,1,,2435.0,
,14423,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,10577,,,CHEMBL616763,Autocuration,,,H,,B,1789,,,,1,,,
,10062,8,BAO_0000357,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,10577,,,CHEMBL872909,Expert,,,H,,B,1790,,,,1,,,
,10062,8,BAO_0000357,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,10577,,,CHEMBL616764,Autocuration,,,H,,B,1791,,,,1,,,
,12280,9,BAO_0000357,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,10577,,,CHEMBL616765,Expert,10116.0,,D,,B,1792,,,Rattus norvegicus,1,,,
,15412,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,10577,,Striatum,CHEMBL616766,Autocuration,,,H,,B,1793,,,,1,,2435.0,
,15412,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,10577,,Striatum,CHEMBL616767,Autocuration,,,H,,B,1794,,,,1,,2435.0,
,10062,8,BAO_0000357,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,10577,,,CHEMBL616768,Autocuration,,,H,,B,1795,,,,1,,,
,11147,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,10577,,,CHEMBL616769,Autocuration,,,H,,B,1796,,,,1,,,
,9547,8,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,10577,,,CHEMBL616770,Autocuration,,,H,,B,1797,,,,1,,,
,10444,8,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,10577,,,CHEMBL616771,Autocuration,,,H,,B,1798,,,,1,,,
,12469,8,BAO_0000019,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,10577,,Striatum,CHEMBL616772,Autocuration,,,H,,B,1799,,,,1,,2435.0,
,9098,8,BAO_0000019,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,10577,,,CHEMBL616773,Expert,,,H,,B,1800,,,,1,,,
,9098,8,BAO_0000019,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,10577,,,CHEMBL616774,Autocuration,,,H,,B,1801,,,,1,,,
,9699,8,BAO_0000357,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,10577,,,CHEMBL616775,Autocuration,,,H,,B,1802,,,,1,,,
,10394,8,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,10577,,,CHEMBL616776,Autocuration,,,H,,B,1803,,,,1,,,
,12092,8,BAO_0000357,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,10577,,,CHEMBL616777,Autocuration,,,H,,B,1804,,,,1,,,
,16700,8,BAO_0000357,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,10577,,,CHEMBL616778,Autocuration,,,H,,B,1805,,,,1,,,
,403,9,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,10577,,,CHEMBL616779,Expert,10116.0,,D,,B,1806,,,Rattus norvegicus,1,,,
,12771,9,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor,10577,,,CHEMBL616780,Expert,10116.0,,D,,B,1807,,,Rattus norvegicus,1,,,
,11642,8,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,10577,,,CHEMBL616781,Autocuration,,,H,,B,1808,,,,1,,,
,12953,8,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,10577,,,CHEMBL616782,Autocuration,,,H,,B,1809,,,,1,,,
,12953,8,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,10577,,,CHEMBL616783,Autocuration,,,H,,B,1810,,,,1,,,
,12953,8,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,10577,,Striatum,CHEMBL616784,Expert,,,H,,B,1811,,,,1,,2435.0,
,12953,8,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,10577,,,CHEMBL616785,Autocuration,,,H,,B,1812,,,,1,,,
,9737,8,BAO_0000249,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,10577,,Brain,CHEMBL857067,Autocuration,,,H,,B,1813,,,,1,,955.0,
,9737,8,BAO_0000019,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,10577,,,CHEMBL616786,Autocuration,,,H,,B,1814,,,,1,,,
,9737,8,BAO_0000249,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,10577,,Brain,CHEMBL616787,Autocuration,,,H,,B,1815,,,,1,,955.0,
,12827,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,10577,,,CHEMBL616788,Autocuration,,,H,,B,1816,,,,1,,,
,5033,8,BAO_0000357,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,10577,,,CHEMBL616789,Autocuration,,,H,,B,1817,,,,1,,,
,9786,9,BAO_0000019,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,10577,,,CHEMBL616790,Expert,10116.0,,D,,B,1818,,,Rattus norvegicus,1,,,
,13116,8,BAO_0000357,Binding affinity at 5-hydroxytryptamine 1B receptor,10577,,,CHEMBL616791,Expert,,,H,,B,1819,,,,1,,,
,16429,8,BAO_0000019,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,10577,,,CHEMBL616792,Autocuration,,,H,,B,1820,,,,1,,,
,12409,9,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,10577,,,CHEMBL616793,Expert,10116.0,,D,,B,1821,,,Rattus norvegicus,1,,,
,15194,8,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,10577,,,CHEMBL616794,Autocuration,,,H,,B,1822,,,,1,,,
,15194,8,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,10577,,,CHEMBL616795,Autocuration,,,H,,B,1823,,,,1,,,
,5486,4,BAO_0000019,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,104686,,,CHEMBL616796,Autocuration,,,H,,B,1824,,,,1,,,
,4639,8,BAO_0000357,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,106,,,CHEMBL616797,Autocuration,,,H,,B,1825,,,,1,,,
,386,8,BAO_0000249,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,106,,,CHEMBL616798,Autocuration,,Brain membranes,H,,B,1826,,,,1,,,
,2474,8,BAO_0000357,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,106,,,CHEMBL616799,Autocuration,,,H,,B,1827,,,,1,,,
,6011,8,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,106,,,CHEMBL616800,Autocuration,,,H,,B,1828,,,,1,,,
,5014,8,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,106,,,CHEMBL616801,Autocuration,,,H,,B,1829,,,,1,,,
,17515,8,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,106,,,CHEMBL616802,Autocuration,,,H,,B,1830,,,,1,,,
,4373,8,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,106,,,CHEMBL616803,Autocuration,,,H,,B,1831,,,,1,,,
,1633,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,106,,,CHEMBL857068,Expert,,,H,,B,1832,,,,1,,,
,1633,8,BAO_0000357,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,106,,,CHEMBL616804,Autocuration,,,H,,B,1833,,,,1,,,
,4373,8,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,106,,,CHEMBL616805,Autocuration,,,H,,B,1834,,,,1,,,
,4687,8,BAO_0000357,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,106,,,CHEMBL616806,Autocuration,,,H,,B,1835,,,,1,,,
,11574,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1B receptor,106,,,CHEMBL616807,Autocuration,,,H,,B,1836,,,,1,,,
,10321,8,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,106,,,CHEMBL616808,Autocuration,,,H,,B,1837,,,,1,,,
,15527,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,106,,,CHEMBL616809,Autocuration,,,H,,B,1838,,,,1,,,
,17200,8,BAO_0000357,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,106,,,CHEMBL616810,Autocuration,,,H,,B,1839,,,,1,,,
,14423,4,BAO_0000224,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,104802,,,CHEMBL616811,Autocuration,,,H,,B,1840,,,,1,,,
,5834,8,BAO_0000357,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,108,,,CHEMBL616812,Autocuration,9913.0,,H,,B,1841,,,Bos taurus,1,,,
,11473,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,108,,,CHEMBL616813,Autocuration,9823.0,,H,,B,1842,,,Sus scrofa,1,,,
,11473,8,BAO_0000357,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,108,,,CHEMBL616814,Autocuration,9823.0,,H,,B,1843,,,Sus scrofa,1,,,
,10639,8,BAO_0000357,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,108,,,CHEMBL616815,Autocuration,9823.0,,H,,B,1844,,,Sus scrofa,1,,,
,10639,8,BAO_0000357,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,108,,,CHEMBL616816,Autocuration,9823.0,,H,,B,1845,,,Sus scrofa,1,,,
,14331,8,BAO_0000357,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,108,,,CHEMBL616817,Autocuration,9823.0,,H,,B,1846,,,Sus scrofa,1,,,
,10796,8,BAO_0000357,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,108,,,CHEMBL616818,Autocuration,9823.0,,H,,B,1847,,,Sus scrofa,1,,,
,9098,8,BAO_0000357,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,108,,,CHEMBL616819,Expert,9823.0,,H,,B,1848,,,Sus scrofa,1,,,
,14331,8,BAO_0000357,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,108,,,CHEMBL616820,Expert,9823.0,,H,,B,1849,,,Sus scrofa,1,,,
,11828,8,BAO_0000019,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,108,,,CHEMBL616821,Expert,9823.0,,H,,B,1850,,,Sus scrofa,1,,,
,11866,8,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,108,,,CHEMBL616822,Autocuration,9823.0,,H,,B,1851,,,Sus scrofa,1,,,
,13047,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,108,,,CHEMBL616823,Autocuration,9986.0,,H,,B,1852,,,Oryctolagus cuniculus,1,,,
,188,9,BAO_0000357,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,12689,,,CHEMBL616824,Autocuration,10116.0,,D,,B,1853,,,Rattus norvegicus,1,,,
,11825,9,BAO_0000357,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,12689,,,CHEMBL616825,Autocuration,10116.0,,D,,B,1854,,,Rattus norvegicus,1,,,
,11825,9,BAO_0000357,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,12689,,,CHEMBL616826,Autocuration,10116.0,,D,,B,1855,,,Rattus norvegicus,1,,,
,11624,9,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,12689,,,CHEMBL616827,Expert,10116.0,,D,,B,1856,,,Rattus norvegicus,1,,,
,11139,9,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,12689,,,CHEMBL616828,Autocuration,10116.0,,D,,B,1857,,,Rattus norvegicus,1,,,
,11147,9,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,12689,,,CHEMBL616829,Autocuration,10116.0,,D,,B,1858,,,Rattus norvegicus,1,,,
,10444,9,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,12689,,,CHEMBL616830,Autocuration,10116.0,,D,,B,1859,,,Rattus norvegicus,1,,,
,11624,9,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1C receptor,12689,,,CHEMBL616831,Expert,10116.0,,D,,B,1860,,,Rattus norvegicus,1,,,
,11662,9,BAO_0000019,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,,,CHEMBL616832,Autocuration,10116.0,,D,,B,1861,,,Rattus norvegicus,1,,,
,11662,9,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,,,CHEMBL616833,Autocuration,10116.0,,D,,B,1862,,,Rattus norvegicus,1,,,
,11662,9,BAO_0000019,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,,,CHEMBL616834,Expert,10116.0,,D,,B,1863,,,Rattus norvegicus,1,,,
,11662,9,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,,,CHEMBL829595,Autocuration,10116.0,,D,,B,1864,,,Rattus norvegicus,1,,,
,9098,9,BAO_0000357,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,12689,,,CHEMBL616835,Autocuration,10116.0,,D,,B,1865,,,Rattus norvegicus,1,,,
,10394,9,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,12689,,,CHEMBL872910,Autocuration,10116.0,,D,,B,1866,,,Rattus norvegicus,1,,,
,11933,8,BAO_0000357,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,12689,,,CHEMBL616836,Expert,,,H,,B,1867,,,,1,,,
,12092,9,BAO_0000357,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,12689,,,CHEMBL616837,Autocuration,10116.0,,D,,B,1868,,,Rattus norvegicus,1,,,
,12253,9,BAO_0000019,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,12689,,,CHEMBL616466,Autocuration,10116.0,,D,,B,1869,,,Rattus norvegicus,1,,,
,12253,9,BAO_0000219,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,12689,,,CHEMBL616467,Autocuration,10116.0,,D,,B,1870,,722.0,Rattus norvegicus,1,,,HEK293
,1558,8,BAO_0000357,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,108,,,CHEMBL616468,Autocuration,,,H,,B,1871,,,,1,,,
,2474,8,BAO_0000357,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,108,,,CHEMBL616469,Autocuration,,,H,,B,1872,,,,1,,,
,2474,8,BAO_0000357,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,108,,,CHEMBL616470,Autocuration,,,H,,B,1873,,,,1,,,
,11574,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1C receptor,12689,,,CHEMBL616471,Autocuration,,,H,,B,1874,,,,1,,,
,1558,8,BAO_0000357,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,12689,,,CHEMBL616472,Autocuration,,,H,,B,1875,,,,1,,,
,13944,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1C receptor,12689,,,CHEMBL616473,Autocuration,,,H,,B,1876,,,,1,,,
,13033,8,BAO_0000357,Binding affinity against serotonergic 5-HT1c receptor,12689,,,CHEMBL616474,Autocuration,,,H,,B,1877,,,,1,,,
,10321,8,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,12689,,,CHEMBL616475,Autocuration,,,H,,B,1878,,,,1,,,
,11866,8,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,12689,,,CHEMBL616476,Autocuration,,,H,,B,1879,,,,1,,,
,14454,8,BAO_0000019,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),105,,,CHEMBL616477,Autocuration,9986.0,,H,,B,1880,,,Oryctolagus cuniculus,1,,,
,11574,4,BAO_0000224,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,104686,,,CHEMBL616478,Autocuration,,,H,,B,1881,,,,1,,,
,11574,4,BAO_0000224,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,104686,,,CHEMBL616479,Autocuration,,,H,,B,1882,,,,1,,,
,13631,4,BAO_0000019,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,104686,,,CHEMBL616480,Autocuration,,,H,,B,1883,,,,1,,,
,9630,5,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,104686,,,CHEMBL616481,Autocuration,10116.0,,D,,B,1884,,,Rattus norvegicus,1,,,
,8822,5,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,104686,,,CHEMBL616482,Autocuration,10116.0,,D,,B,1885,,,Rattus norvegicus,1,,,
,9064,5,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,104686,,Brain,CHEMBL884713,Autocuration,10116.0,,D,,B,1886,,,Rattus norvegicus,1,,955.0,
,8868,4,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,104686,,,CHEMBL616483,Autocuration,,,H,,B,1887,,,,1,,,
,9064,4,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,104686,,,CHEMBL616484,Autocuration,,,H,,B,1888,,,,1,,,
,9806,4,BAO_0000019,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,104686,,,CHEMBL616485,Autocuration,,,H,,B,1889,,,,1,,,
,9098,4,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,104686,,,CHEMBL616486,Autocuration,,,H,,B,1890,,,,1,,,
,8868,4,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,104686,,,CHEMBL616487,Autocuration,,,H,,B,1891,,,,1,,,
,12765,4,BAO_0000224,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,104686,,,CHEMBL616488,Autocuration,,,H,,B,1892,,,,1,,,
,11049,4,BAO_0000019,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,,,CHEMBL616489,Autocuration,,,H,,B,1893,,,,1,,,
,11049,4,BAO_0000019,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,,,CHEMBL616490,Autocuration,,,H,,B,1894,,,,1,,,
,11049,4,BAO_0000019,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,104686,,,CHEMBL616491,Autocuration,,,H,,B,1895,,,,1,,,
,11049,4,BAO_0000019,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,104686,,,CHEMBL616492,Autocuration,,,H,,B,1896,,,,1,,,
,11049,4,BAO_0000019,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,,,CHEMBL616493,Autocuration,,,H,,B,1897,,,,1,,,
,11473,4,BAO_0000019,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,104686,,,CHEMBL616494,Autocuration,,,H,,B,1898,,,,1,,,
,11473,4,BAO_0000019,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,104686,,,CHEMBL616495,Autocuration,,,H,,B,1899,,,,1,,,
,3086,4,BAO_0000019,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,104686,,,CHEMBL616496,Autocuration,,,H,,B,1900,,,,1,,,
,11049,4,BAO_0000019,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,,,CHEMBL616497,Autocuration,,,H,,B,1901,,,,1,,,
,11049,4,BAO_0000019,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,,,CHEMBL616498,Autocuration,,,H,,B,1902,,,,1,,,
,10639,4,BAO_0000019,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,104686,,,CHEMBL616499,Autocuration,,,H,,B,1903,,,,1,,,
,10922,4,BAO_0000019,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,104686,,,CHEMBL616500,Autocuration,,,H,,B,1904,,,,1,,,
,9064,5,BAO_0000221,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,104686,,Brain,CHEMBL616501,Autocuration,10116.0,,D,,B,1905,,,Rattus norvegicus,1,,955.0,
,10748,4,BAO_0000221,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,104686,,Brain,CHEMBL616502,Autocuration,,,H,,B,1906,,,,1,,955.0,
,11614,4,BAO_0000249,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,104686,,,CHEMBL884529,Autocuration,,Membranes,H,,B,1907,,,,1,,,
,11615,4,BAO_0000249,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,104686,,,CHEMBL616503,Autocuration,,Membranes,H,,B,1908,,,,1,,,
,11615,4,BAO_0000224,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL616964,Autocuration,,,H,,B,1909,,,,1,,,
,11614,4,BAO_0000249,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,104686,,,CHEMBL616965,Autocuration,,Membranes,H,,B,1910,,,,1,,,
,11702,4,BAO_0000224,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,104686,,,CHEMBL616966,Autocuration,,,H,,B,1911,,,,1,,,
,11702,4,BAO_0000224,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,104686,,,CHEMBL616967,Autocuration,,,H,,B,1912,,,,1,,,
,11702,5,BAO_0000224,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL616968,Autocuration,10116.0,,D,,B,1913,,,Rattus norvegicus,1,,,
,11702,4,BAO_0000224,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,104686,,,CHEMBL616969,Autocuration,,,H,,B,1914,,,,1,,,
,13346,4,BAO_0000019,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,104686,,,CHEMBL884530,Autocuration,,,H,,B,1915,,,,1,,,
,10025,4,BAO_0000224,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL616970,Autocuration,,,H,,B,1916,,,,1,,,
,10025,4,BAO_0000224,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,104686,,,CHEMBL616971,Autocuration,,,H,,B,1917,,,,1,,,
,10025,4,BAO_0000224,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",104686,,,CHEMBL616972,Autocuration,,,H,,B,1918,,,,1,,,
,9036,4,BAO_0000224,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,104686,,,CHEMBL616973,Autocuration,,,H,,B,1919,,,,1,,,
,9036,4,BAO_0000224,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,104686,,,CHEMBL616974,Autocuration,,,H,,B,1920,,,,1,,,
,9161,4,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,104686,,,CHEMBL616975,Autocuration,,,H,,B,1921,,,,1,,,
,12304,4,BAO_0000019,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,104686,,,CHEMBL616976,Autocuration,,,H,,B,1922,,,,1,,,
,13276,4,BAO_0000224,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,104686,,,CHEMBL616977,Autocuration,,,H,,B,1923,,,,1,,,
,11825,4,BAO_0000224,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,104686,,,CHEMBL616978,Autocuration,,,H,,B,1924,,,,1,,,
,12443,4,BAO_0000224,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,104686,,,CHEMBL616979,Autocuration,,,H,,B,1925,,,,1,,,
,13830,4,BAO_0000224,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL616980,Autocuration,,,H,,B,1926,,,,1,,,
,9592,4,BAO_0000249,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,104686,,,CHEMBL616981,Autocuration,,Membranes,H,,B,1927,,,,1,,,
,9592,4,BAO_0000249,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,104686,,,CHEMBL616982,Autocuration,,Membranes,H,,B,1928,,,,1,,,
,10881,4,BAO_0000224,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,104686,,,CHEMBL616983,Autocuration,,,H,,B,1929,,,,1,,,
,13605,4,BAO_0000019,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,104686,,,CHEMBL616984,Autocuration,,,H,,B,1930,,,,1,,,
,11624,5,BAO_0000224,Inhibitory activity against 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL616985,Autocuration,10116.0,,D,,B,1931,,,Rattus norvegicus,1,,,
,4101,4,BAO_0000224,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,104686,,,CHEMBL616986,Autocuration,,,H,,B,1932,,,,1,,,
,4101,4,BAO_0000224,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,104686,,,CHEMBL616987,Autocuration,,,H,,B,1933,,,,1,,,
,15360,4,BAO_0000019,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,104686,,,CHEMBL616988,Autocuration,,,H,,B,1934,,,,1,,,
,11576,4,BAO_0000019,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,104686,,,CHEMBL617243,Autocuration,,,H,,B,1935,,,,1,,,
,5834,4,BAO_0000019,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,104686,,,CHEMBL617244,Autocuration,,,H,,B,1936,,,,1,,,
,2395,5,BAO_0000219,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,104686,,,CHEMBL617245,Autocuration,10116.0,,D,,B,1937,,485.0,Rattus norvegicus,1,,,CHO-K1
,11965,4,BAO_0000249,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,104686,,,CHEMBL617246,Autocuration,,Membranes,H,,B,1938,,,,1,,,
,3967,4,BAO_0000224,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),104686,,,CHEMBL617546,Autocuration,,,H,,B,1939,,,,1,,,
,11130,4,BAO_0000249,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),104686,,,CHEMBL617547,Autocuration,,Brain membranes,H,,B,1940,,,,1,,,
,13427,4,BAO_0000219,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,104686,In vitro,,CHEMBL617548,Autocuration,,,H,,B,1941,,,,1,,,
,9443,4,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL617549,Autocuration,,,H,,B,1942,,,,1,,,
,9443,4,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,104686,,,CHEMBL617550,Autocuration,,,H,,B,1943,,,,1,,,
,11825,4,BAO_0000224,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,104686,,,CHEMBL617551,Autocuration,,,H,,B,1944,,,,1,,,
,12120,4,BAO_0000249,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,104686,,,CHEMBL617552,Autocuration,,Membranes,H,,B,1945,,,,1,,,
,12120,4,BAO_0000249,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,104686,,,CHEMBL617553,Autocuration,,Membranes,H,,B,1946,,,,1,,,
,11963,4,BAO_0000019,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,104686,,Thoracic aorta,CHEMBL617554,Autocuration,,,H,,F,1947,,,,1,,1515.0,
,9069,4,BAO_0000019,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL617555,Autocuration,,,H,,B,1948,,,,1,,,
,8868,4,BAO_0000224,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,104686,,,CHEMBL617556,Autocuration,,,H,,B,1949,,,,1,,,
,17200,8,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,10624,,,CHEMBL617557,Autocuration,,,H,,B,1950,,,,1,,,
,17200,8,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,10624,,,CHEMBL617558,Autocuration,,,H,,B,1951,,,,1,,,
,13969,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,17106,,,CHEMBL617559,Expert,,,H,,B,1952,,,,1,,,
,13392,9,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1D receptor,17106,,,CHEMBL617560,Expert,,,D,,B,1953,,,,1,,,
,1742,8,BAO_0000249,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,17106,,,CHEMBL617561,Autocuration,,,H,,B,1954,,,,1,,,
,1742,8,BAO_0000249,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,17106,,,CHEMBL617562,Autocuration,,,H,,B,1955,,,,1,,,
,14331,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,17106,,Striatum,CHEMBL617563,Autocuration,,,H,,B,1956,,,,1,,2435.0,
,12861,8,BAO_0000019,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,17106,,,CHEMBL617564,Autocuration,,,H,,F,1957,,,,1,,,
,12861,8,BAO_0000019,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,17106,,,CHEMBL617565,Expert,,,H,,B,1958,,,,1,,,
,12861,8,BAO_0000357,Binding activity radioligand.,17106,,,CHEMBL856076,Autocuration,,,H,,B,1959,,,,1,,,
,12861,8,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,17106,,,CHEMBL617566,Autocuration,,,H,,B,1960,,,,1,,,
,12861,8,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,17106,,,CHEMBL875911,Expert,,,H,,B,1961,,,,1,,,
,12861,8,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,17106,,,CHEMBL617567,Autocuration,,,H,,B,1962,,,,1,,,
,675,8,BAO_0000249,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,17106,,,CHEMBL617568,Autocuration,,,H,,B,1963,,,,1,,,
,12490,8,BAO_0000019,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,17106,,,CHEMBL617569,Expert,,,H,,B,1964,,,,1,,,
,11828,8,BAO_0000249,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,17106,,,CHEMBL617570,Expert,,,H,,B,1965,,,,1,,,
,11866,8,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,17106,,,CHEMBL617571,Autocuration,,,H,,B,1966,,,,1,,,
,773,8,BAO_0000357,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,105,,,CHEMBL617572,Autocuration,9823.0,,H,,B,1967,,,Sus scrofa,1,,,
,13047,8,BAO_0000357,The compound was tested for intrinsic activity against 5-HT1D receptor,105,,,CHEMBL617573,Expert,9986.0,,H,,B,1968,,,Oryctolagus cuniculus,1,,,
,13047,8,BAO_0000019,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,105,,,CHEMBL617574,Autocuration,9986.0,,H,,B,1969,,,Oryctolagus cuniculus,1,,,
,13047,8,BAO_0000357,The compound was tested for binding affinity against 5-HT1D receptor,105,,,CHEMBL617575,Expert,9986.0,,H,,B,1970,,,Oryctolagus cuniculus,1,,,
,188,8,BAO_0000357,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,10578,,,CHEMBL617576,Autocuration,,,H,,B,1971,,,,1,,,
,10639,8,BAO_0000019,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,10578,,,CHEMBL617577,Autocuration,,,H,,F,1972,,,,1,,,
,12438,8,BAO_0000019,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,10578,,,CHEMBL617578,Autocuration,,,H,,F,1973,,,,1,,,
,12438,8,BAO_0000357,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,10578,,,CHEMBL617579,Autocuration,,,H,,B,1974,,,,1,,,
,15854,8,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,10578,,,CHEMBL617580,Expert,,,H,,B,1975,,,,1,,,
,10394,8,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,10578,,,CHEMBL617581,Autocuration,,,H,,B,1976,,,,1,,,
,12092,8,BAO_0000357,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,10578,,,CHEMBL617582,Autocuration,,,H,,B,1977,,,,1,,,
,3389,8,BAO_0000019,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,10578,,,CHEMBL617583,Expert,,,H,,B,1978,,,,1,,,
,6011,8,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,105,,,CHEMBL617584,Autocuration,,,H,,B,1979,,,,1,,,
,4639,8,BAO_0000357,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,105,,,CHEMBL617585,Autocuration,,,H,,B,1980,,,,1,,,
,2474,8,BAO_0000357,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,105,,,CHEMBL875912,Autocuration,,,H,,B,1981,,,,1,,,
,5014,8,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,105,,,CHEMBL617586,Autocuration,,,H,,B,1982,,,,1,,,
,17515,8,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,105,,,CHEMBL617587,Autocuration,,,H,,B,1983,,,,1,,,
,11866,8,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,105,,,CHEMBL617588,Autocuration,,,H,,B,1984,,,,1,,,
,4687,8,BAO_0000357,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,105,,,CHEMBL857980,Autocuration,,,H,,B,1985,,,,1,,,
,12146,8,BAO_0000357,Tested against 5-hydroxytryptamine 1D receptor,105,,,CHEMBL617589,Autocuration,,,H,,B,1986,,,,1,,,
,10321,8,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,105,,,CHEMBL617590,Autocuration,,,H,,B,1987,,,,1,,,
,13267,8,BAO_0000219,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,105,,,CHEMBL617591,Autocuration,,,H,,B,1988,,722.0,,1,,,HEK293
,1274,9,BAO_0000357,Binding affinity against 5-Hydroxytryptamine 1D receptor,105,,,CHEMBL617592,Expert,9606.0,,D,,B,1989,,,Homo sapiens,1,,,
,15250,8,BAO_0000357,,105,,,CHEMBL617593,Autocuration,,,H,,B,1990,,,,1,,,
,13706,8,BAO_0000219,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,106,,,CHEMBL617594,Autocuration,,,H,,B,1991,,485.0,,1,,,CHO-K1
,13706,8,BAO_0000219,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,105,,,CHEMBL617595,Autocuration,,,H,,B,1992,,485.0,,1,,,CHO-K1
,13706,8,BAO_0000219,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,105,,,CHEMBL617596,Autocuration,,,H,,B,1993,,722.0,,1,,,HEK293
,13706,8,BAO_0000219,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,105,,,CHEMBL617597,Autocuration,,,H,,B,1994,,722.0,,1,,,HEK293
,13047,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,105,,,CHEMBL617598,Autocuration,,,H,,B,1995,,,,1,,,
,13366,8,BAO_0000357,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,105,,,CHEMBL872916,Autocuration,,,H,,B,1996,,,,1,,,
,13366,8,BAO_0000357,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,105,,,CHEMBL617599,Expert,,,H,,B,1997,,,,1,,,
,1558,8,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,105,,,CHEMBL617091,Autocuration,,,H,,B,1998,,,,1,,,
,12902,8,BAO_0000219,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",105,,,CHEMBL617092,Expert,,,H,,B,1999,,485.0,,1,,,CHO-K1
,13706,8,BAO_0000219,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,105,,,CHEMBL617093,Autocuration,,,H,,B,2000,,485.0,,1,,,CHO-K1
,13706,8,BAO_0000019,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,105,,,CHEMBL617094,Autocuration,,,H,,F,2001,,,,1,,,
,13706,8,BAO_0000019,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,105,,,CHEMBL617095,Autocuration,,,H,,F,2002,,,,1,,,
,14251,8,BAO_0000019,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,105,,,CHEMBL617096,Autocuration,,,H,,F,2003,,,,1,,,
,14251,8,BAO_0000019,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,105,,,CHEMBL617097,Autocuration,,,H,,F,2004,,,,1,,,
,14251,8,BAO_0000019,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,105,,,CHEMBL617098,Autocuration,,,H,,F,2005,,,,1,,,
,13313,8,BAO_0000357,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,105,,,CHEMBL617301,Autocuration,,,H,,B,2006,,,,1,,,
,13313,8,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,105,,,CHEMBL617302,Autocuration,,,H,,B,2007,,,,1,,,
,13366,8,BAO_0000357,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,105,,,CHEMBL617303,Autocuration,,,H,,B,2008,,,,1,,,
,13051,8,BAO_0000357,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,105,,,CHEMBL617304,Expert,,,H,,B,2009,,,,1,,,
,12903,8,BAO_0000219,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",105,,,CHEMBL617305,Expert,,,H,,B,2010,,449.0,,1,,,CHO
,12469,9,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,105,,,CHEMBL617306,Autocuration,9606.0,,D,,B,2011,,,Homo sapiens,1,,,
,5619,8,BAO_0000357,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,17106,,,CHEMBL617307,Autocuration,,,H,,B,2012,,,,1,,,
,13047,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,105,,,CHEMBL617308,Autocuration,9986.0,,H,,B,2013,,,Oryctolagus cuniculus,1,,,
,16633,8,BAO_0000357,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,105,,,CHEMBL617309,Autocuration,,,H,,B,2014,,,,1,,,
,16633,8,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,105,,,CHEMBL617310,Autocuration,,,H,,B,2015,,,,1,,,
,16633,8,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,105,,,CHEMBL617311,Autocuration,,,H,,B,2016,,,,1,,,
,16633,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,105,,,CHEMBL617312,Autocuration,,,H,,B,2017,,,,1,,,
,3269,8,BAO_0000357,Affinity against 5-hydroxytryptamine 1D receptor alpha,105,,,CHEMBL617313,Autocuration,,,H,,B,2018,,,,1,,,
,12409,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,105,,,CHEMBL617314,Expert,,,H,,B,2019,,,,1,,,
,13706,8,BAO_0000019,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,106,,,CHEMBL617315,Autocuration,,,H,,F,2020,,,,1,,,
,13706,8,BAO_0000219,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,106,,,CHEMBL617316,Autocuration,,,H,,B,2021,,722.0,,1,,,HEK293
,13706,8,BAO_0000219,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,106,,,CHEMBL617317,Autocuration,,,H,,B,2022,,722.0,,1,,,HEK293
,12903,8,BAO_0000219,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",106,,,CHEMBL617318,Autocuration,,,H,,B,2023,,449.0,,1,,,CHO
,13047,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,106,,,CHEMBL617319,Autocuration,,,H,,B,2024,,,,1,,,
,13366,9,BAO_0000357,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,106,,,CHEMBL617320,Expert,,,D,,B,2025,,,,1,,,
,13366,9,BAO_0000357,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,106,,,CHEMBL617321,Expert,,,D,,B,2026,,,,1,,,
,13366,9,BAO_0000357,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,106,,,CHEMBL617322,Expert,,,D,,B,2027,,,,1,,,
,13366,8,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,106,,,CHEMBL616862,Autocuration,,,H,,B,2028,,,,1,,,
,13366,8,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,106,,,CHEMBL616863,Autocuration,,,H,,B,2029,,,,1,,,
,12469,8,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,106,,,CHEMBL616864,Autocuration,,,H,,B,2030,,449.0,,1,,,CHO
,13706,8,BAO_0000219,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,106,,,CHEMBL616865,Autocuration,,,H,,B,2031,,485.0,,1,,,CHO-K1
,13706,8,BAO_0000219,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,106,,,CHEMBL616866,Autocuration,,,H,,B,2032,,485.0,,1,,,CHO-K1
,13706,8,BAO_0000019,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,106,,,CHEMBL616867,Autocuration,,,H,,F,2033,,,,1,,,
,12902,8,BAO_0000219,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",106,,,CHEMBL616868,Expert,,,H,,B,2034,,485.0,,1,,,CHO-K1
,13051,8,BAO_0000357,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,105,,,CHEMBL616869,Expert,,,H,,B,2035,,,,1,,,
,12903,8,BAO_0000219,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",106,,,CHEMBL616870,Expert,,,H,,B,2036,,449.0,,1,,,CHO
,1558,8,BAO_0000219,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,105,,,CHEMBL616871,Autocuration,,,H,,F,2037,,485.0,,1,,,CHO-K1
,1558,8,BAO_0000219,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,105,,,CHEMBL616872,Autocuration,,,H,,F,2038,,485.0,,1,,,CHO-K1
,1558,8,BAO_0000219,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,105,,,CHEMBL616873,Autocuration,,,H,,F,2039,,485.0,,1,,,CHO-K1
,1558,8,BAO_0000219,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,105,,,CHEMBL616838,Autocuration,,,H,,F,2040,,485.0,,1,,,CHO-K1
,1558,8,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,105,,,CHEMBL616839,Autocuration,,,H,,B,2041,,,,1,,,
,13047,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,106,,,CHEMBL616840,Autocuration,9986.0,,H,,B,2042,,,Oryctolagus cuniculus,1,,,
,13313,8,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,105,,,CHEMBL616841,Autocuration,,,H,,B,2043,,,,1,,,
,13313,8,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,105,,,CHEMBL616842,Autocuration,,,H,,B,2044,,,,1,,,
,12409,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor beta,105,,,CHEMBL857976,Expert,,,H,,B,2045,,,,1,,,
,15250,8,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,10618,,,CHEMBL616843,Autocuration,,,H,,B,2046,,449.0,,1,,,CHO
,1348,9,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,10618,,,CHEMBL616844,Expert,9606.0,,D,,B,2047,,,Homo sapiens,1,,,
,1348,8,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,10618,,,CHEMBL616845,Autocuration,,,H,,B,2048,,,,1,,,
,4234,9,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,10618,,,CHEMBL616846,Expert,9606.0,,D,,B,2049,,,Homo sapiens,1,,,
,16209,8,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,10618,,,CHEMBL616847,Autocuration,,,H,,B,2050,,,,1,,,
,10444,8,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,10618,,,CHEMBL616848,Autocuration,,,H,,B,2051,,,,1,,,
,3935,8,BAO_0000357,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,10618,,,CHEMBL616849,Autocuration,,,H,,B,2052,,,,1,,,
,15818,8,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,10618,,,CHEMBL872911,Autocuration,,,H,,B,2053,,,,1,,,
,17085,8,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,10618,,,CHEMBL616850,Autocuration,,,H,,B,2054,,,,1,,,
,12936,9,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,10618,,,CHEMBL616699,Expert,9606.0,,D,,B,2055,,449.0,Homo sapiens,1,,,CHO
,6166,8,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,10618,,,CHEMBL616700,Autocuration,,,H,,B,2056,,,,1,,,
,15779,8,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,10618,,,CHEMBL616701,Autocuration,,,H,,B,2057,,449.0,,1,,,CHO
,15779,8,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,10618,,,CHEMBL616702,Autocuration,,,H,,B,2058,,449.0,,1,,,CHO
,15779,8,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,10618,,,CHEMBL616703,Autocuration,,,H,,B,2059,,449.0,,1,,,CHO
,13181,8,BAO_0000357,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,10618,,,CHEMBL616704,Autocuration,,,H,,B,2060,,,,1,,,
,4199,8,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,10618,,,CHEMBL616705,Autocuration,,,H,,B,2061,,449.0,,1,,,CHO
,14875,8,BAO_0000357,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,10618,,,CHEMBL616706,Autocuration,,,H,,B,2062,,,,1,,,
,15146,8,BAO_0000219,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,10618,,,CHEMBL616707,Autocuration,,,H,,B,2063,,449.0,,1,,,CHO
,5213,8,BAO_0000357,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,10618,,,CHEMBL616708,Autocuration,,,H,,B,2064,,,,1,,,
,12146,8,BAO_0000357,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,10618,,,CHEMBL616709,Autocuration,,,H,,B,2065,,,,1,,,
,13267,8,BAO_0000219,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,10618,,,CHEMBL616710,Autocuration,,,H,,B,2066,,449.0,,1,,,CHO
,14818,8,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,10618,,,CHEMBL616711,Autocuration,,,H,,B,2067,,449.0,,1,,,CHO
,4829,8,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",10618,,,CHEMBL616712,Autocuration,,,H,,B,2068,,449.0,,1,,,CHO
,4373,8,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,10618,,,CHEMBL616713,Autocuration,,,H,,B,2069,,,,1,,,
,4373,8,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,10618,,,CHEMBL616714,Autocuration,,,H,,B,2070,,,,1,,,
,14159,8,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,10618,,,CHEMBL616715,Autocuration,,,H,,B,2071,,,,1,,,
,16633,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1E receptor,10618,,,CHEMBL616716,Autocuration,,,H,,B,2072,,,,1,,,
,17085,8,BAO_0000019,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",279,,,CHEMBL616717,Autocuration,,,H,,F,2073,,,,1,,,
,17085,8,BAO_0000019,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",279,,,CHEMBL616718,Expert,,,H,,F,2074,,,,1,,,
,16209,8,BAO_0000019,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,279,,,CHEMBL875905,Autocuration,,,H,,F,2075,,,,1,,,
,16209,8,BAO_0000019,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,279,,,CHEMBL616719,Autocuration,,,H,,F,2076,,,,1,,,
,17085,8,BAO_0000019,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",279,,,CHEMBL616720,Expert,,,H,,F,2077,,,,1,,,
,14159,8,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,279,,,CHEMBL616721,Autocuration,,,H,,B,2078,,,,1,,,
,15250,8,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,279,,,CHEMBL616722,Autocuration,,,H,,B,2079,,449.0,,1,,,CHO
,3805,8,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),279,,,CHEMBL616723,Autocuration,,,H,,B,2080,,,,1,,,
,16190,8,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,279,,,CHEMBL616724,Autocuration,,,H,,B,2081,,449.0,,1,,,CHO
,16190,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,279,,,CHEMBL616725,Autocuration,,,H,,B,2082,,,,1,,,
,16209,8,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1F receptor,279,,,CHEMBL616726,Autocuration,,,H,,B,2083,,,,1,,,
,16209,8,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,279,,,CHEMBL616727,Autocuration,,,H,,B,2084,,,,1,,,
,16209,8,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,279,,,CHEMBL616728,Autocuration,,,H,,B,2085,,,,1,,,
,6866,8,BAO_0000357,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,279,,,CHEMBL616729,Autocuration,,,H,,B,2086,,,,1,,,
,17085,8,BAO_0000019,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,279,,,CHEMBL616730,Expert,,,H,,B,2087,,,,1,,,
,16312,8,BAO_0000357,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,279,,,CHEMBL617125,Autocuration,,,H,,B,2088,,,,1,,,
,6166,8,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,279,,,CHEMBL857977,Autocuration,,,H,,B,2089,,,,1,,,
,15779,8,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,279,,,CHEMBL617126,Autocuration,,,H,,B,2090,,449.0,,1,,,CHO
,4199,8,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,279,,,CHEMBL617127,Autocuration,,,H,,B,2091,,449.0,,1,,,CHO
,14875,8,BAO_0000357,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,279,,,CHEMBL617128,Autocuration,,,H,,B,2092,,,,1,,,
,15146,8,BAO_0000219,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,279,,,CHEMBL617129,Autocuration,,,H,,B,2093,,449.0,,1,,,CHO
,5213,8,BAO_0000357,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,279,,,CHEMBL617130,Autocuration,,,H,,B,2094,,,,1,,,
,14818,8,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,279,,,CHEMBL617131,Autocuration,,,H,,B,2095,,449.0,,1,,,CHO
,4829,8,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",279,,,CHEMBL617132,Autocuration,,,H,,B,2096,,449.0,,1,,,CHO
,4829,8,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",279,,,CHEMBL617133,Autocuration,,,H,,B,2097,,449.0,,1,,,CHO
,4373,8,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,279,,,CHEMBL617134,Autocuration,,,H,,B,2098,,,,1,,,
,4373,8,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,279,,,CHEMBL617135,Autocuration,,,H,,B,2099,,,,1,,,
,5014,8,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,279,,,CHEMBL617136,Autocuration,,,H,,B,2100,,,,1,,,
,11662,4,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",104686,,,CHEMBL617137,Autocuration,,,H,,B,2101,,,,1,,,
,11662,4,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",104686,,,CHEMBL617138,Autocuration,,,H,,B,2102,,,,1,,,
,11662,4,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",104686,,,CHEMBL617139,Autocuration,,,H,,B,2103,,,,1,,,
,14093,8,BAO_0000019,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL617140,Autocuration,,,H,,B,2104,,,,1,,,
,11200,4,BAO_0000218,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",104686,In vivo,,CHEMBL617141,Autocuration,,,H,,F,2105,,,,1,,,
,11200,4,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,,,CHEMBL858112,Autocuration,,,H,,F,2106,,,,1,,,
,12352,8,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,17005,,,CHEMBL617142,Intermediate,,,H,,B,2107,,,,1,,,
,13657,0,BAO_0000019,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",22226,,,CHEMBL617143,Autocuration,9913.0,,U,,B,2108,,,Bos taurus,1,,,
,14331,0,BAO_0000019,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,22226,,,CHEMBL617144,Autocuration,9913.0,,U,,B,2109,,,Bos taurus,1,,,
,14331,0,BAO_0000019,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,22226,,,CHEMBL617145,Autocuration,9913.0,,U,,B,2110,,,Bos taurus,1,,,
,14331,0,BAO_0000019,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,22226,,,CHEMBL617146,Autocuration,,,U,,B,2111,,,,1,,,
,12685,4,BAO_0000019,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,104784,,,CHEMBL617147,Autocuration,10141.0,,H,,B,2112,,,Cavia porcellus,1,,,
,14389,4,BAO_0000019,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,104784,,,CHEMBL617148,Autocuration,10141.0,,H,,B,2113,,,Cavia porcellus,1,,,
,14386,4,BAO_0000019,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,104784,,,CHEMBL617149,Autocuration,10141.0,,H,,B,2114,,,Cavia porcellus,1,,,
,5732,4,BAO_0000224,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,104784,,,CHEMBL617150,Autocuration,,,H,,B,2115,,,,1,,,
,16293,4,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,104784,,,CHEMBL617151,Autocuration,,,H,,B,2116,,,,1,,,
,2078,4,BAO_0000224,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,104784,,,CHEMBL617201,Autocuration,,,H,,B,2117,,,,1,,,
,5486,8,BAO_0000357,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,10209,,,CHEMBL617202,Autocuration,,,H,,B,2118,,,,1,,,
,11820,4,BAO_0000218,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,104826,In vivo,,CHEMBL617203,Autocuration,,,H,,B,2119,,,,1,,,
,10297,4,BAO_0000019,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,104826,,,CHEMBL617204,Autocuration,,,H,,B,2120,,,,1,,,
,13704,4,BAO_0000224,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,104826,,,CHEMBL617205,Autocuration,,,H,,B,2121,,,,1,,,
,10297,5,BAO_0000019,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,104826,,,CHEMBL617206,Autocuration,10090.0,,D,,B,2122,,,Mus musculus,1,,,
,11820,4,BAO_0000218,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,104826,In vivo,,CHEMBL617207,Autocuration,,,H,,B,2123,,,,1,,,
,10297,5,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,104826,,,CHEMBL617208,Autocuration,10090.0,,D,,B,2124,,,Mus musculus,1,,,
,11555,4,BAO_0000224,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,104826,,,CHEMBL617209,Autocuration,,,H,,B,2125,,,,1,,,
,11555,4,BAO_0000224,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,104826,,,CHEMBL617210,Autocuration,,,H,,B,2126,,,,1,,,
,11555,4,BAO_0000224,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,104826,,,CHEMBL617211,Autocuration,,,H,,B,2127,,,,1,,,
,10297,5,BAO_0000019,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,104826,,,CHEMBL617212,Autocuration,10090.0,,D,,B,2128,,,Mus musculus,1,,,
,16688,4,BAO_0000224,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,104784,,,CHEMBL617213,Autocuration,9823.0,,H,,B,2129,,,Sus scrofa,1,,,
,16688,4,BAO_0000224,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,104784,,,CHEMBL617214,Autocuration,9823.0,,H,,B,2130,,,Sus scrofa,1,,,
,5333,0,BAO_0000221,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,22226,,,CHEMBL617215,Autocuration,,,U,,B,2131,,,,1,,,
,4437,0,BAO_0000221,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,22226,,,CHEMBL617216,Autocuration,,,U,,B,2132,,,,1,,,
,5033,8,BAO_0000357,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,17005,,,CHEMBL617217,Autocuration,9823.0,,H,,B,2133,,,Sus scrofa,1,,,
,15267,4,BAO_0000019,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL617218,Autocuration,,,H,,B,2134,,,,1,,,
,15267,4,BAO_0000019,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL872913,Autocuration,,,H,,B,2135,,,,1,,,
,11820,4,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,104826,,,CHEMBL617219,Autocuration,,,H,,B,2136,,,,1,,,
,9069,4,BAO_0000224,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL873482,Autocuration,,,H,,B,2137,,,,1,,,
,9162,5,BAO_0000019,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,104686,,,CHEMBL617220,Autocuration,10116.0,,D,,B,2138,,,Rattus norvegicus,1,,,
,9162,4,BAO_0000019,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,104686,,,CHEMBL617221,Autocuration,,,H,,B,2139,,,,1,,,
,9162,4,BAO_0000019,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,104686,,,CHEMBL617222,Autocuration,,,H,,B,2140,,,,1,,,
,10428,4,BAO_0000019,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,104686,,,CHEMBL875906,Autocuration,,,H,,F,2141,,,,1,,,
,9628,4,BAO_0000019,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,104686,,,CHEMBL617223,Autocuration,,,H,,B,2142,,,,1,,,
,12704,4,BAO_0000224,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL617224,Autocuration,,,H,,B,2143,,,,1,,,
,15453,5,BAO_0000224,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,104686,,,CHEMBL617225,Autocuration,10116.0,,D,,B,2144,,,Rattus norvegicus,1,,,
,188,4,BAO_0000224,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,104686,,,CHEMBL617226,Autocuration,,,H,,B,2145,,,,1,,,
,10349,4,BAO_0000224,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,104686,,,CHEMBL617227,Autocuration,,,H,,B,2146,,,,1,,,
,10349,4,BAO_0000224,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,104686,,,CHEMBL617228,Autocuration,,,H,,B,2147,,,,1,,,
,8868,4,BAO_0000224,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,104686,,,CHEMBL617229,Autocuration,,,H,,B,2148,,,,1,,,
,10025,4,BAO_0000224,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,104686,,,CHEMBL617230,Autocuration,,,H,,B,2149,,,,1,,,
,10025,4,BAO_0000224,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",104686,,,CHEMBL617231,Autocuration,,,H,,B,2150,,,,1,,,
,11702,4,BAO_0000224,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,104686,,,CHEMBL617232,Autocuration,,,H,,B,2151,,,,1,,,
,11702,4,BAO_0000224,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL617233,Autocuration,,,H,,B,2152,,,,1,,,
,11702,4,BAO_0000224,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,104686,,,CHEMBL617234,Autocuration,,,H,,B,2153,,,,1,,,
,11702,4,BAO_0000019,Compound was tested for the inhibition of quipazine induced head twitches in rats,104686,,,CHEMBL617235,Autocuration,,,H,,F,2154,,,,1,,,
,11702,4,BAO_0000019,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,104686,,,CHEMBL617236,Autocuration,,,H,,F,2155,,,,1,,,
,10085,4,BAO_0000221,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,104686,,Hippocampus,CHEMBL617237,Autocuration,,,H,,B,2156,,,,1,,10000000.0,
,10085,4,BAO_0000221,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,104686,,Hippocampus,CHEMBL617238,Autocuration,,,H,,B,2157,,,,1,,10000000.0,
,9630,5,BAO_0000221,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,104686,,Brain,CHEMBL617239,Autocuration,10116.0,,D,,B,2158,,,Rattus norvegicus,1,,955.0,
,11070,4,BAO_0000019,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,104686,,,CHEMBL617240,Autocuration,,,H,,B,2159,,,,1,,,
,9841,4,BAO_0000249,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,104686,,,CHEMBL617241,Autocuration,,Membranes,H,,B,2160,,,,1,,,
,9841,4,BAO_0000249,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,104686,,,CHEMBL875907,Autocuration,,Membranes,H,,B,2161,,,,1,,,
,13291,4,BAO_0000019,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,104686,,,CHEMBL617242,Autocuration,,,H,,B,2162,,,,1,,,
,10590,4,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,104686,,,CHEMBL617152,Autocuration,,,H,,F,2163,,,,1,,,
,9064,5,BAO_0000221,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,104686,,Brain,CHEMBL617153,Autocuration,10116.0,,D,,B,2164,,,Rattus norvegicus,1,,955.0,
,12268,5,BAO_0000249,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,104686,,,CHEMBL617154,Autocuration,10116.0,Membranes,D,,B,2165,,,Rattus norvegicus,1,,,
,13508,4,BAO_0000221,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,104686,,Brain,CHEMBL617155,Autocuration,,,H,,B,2166,,,,1,,955.0,
,11279,4,BAO_0000019,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,104686,,,CHEMBL617156,Autocuration,,,H,,F,2167,,,,1,,,
,11200,4,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,104686,,,CHEMBL617157,Autocuration,,,H,,F,2168,,,,1,,,
,11200,4,BAO_0000019,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,,,CHEMBL617158,Autocuration,,,H,,F,2169,,,,1,,,
,11200,4,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,104686,,,CHEMBL617159,Autocuration,,,H,,F,2170,,,,1,,,
,11200,4,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,104686,,,CHEMBL617160,Autocuration,,,H,,F,2171,,,,1,,,
,11200,4,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,,,CHEMBL858113,Autocuration,,,H,,F,2172,,,,1,,,
,9231,4,BAO_0000220,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,104686,,Brain,CHEMBL617247,Autocuration,,,H,,B,2173,,,,1,,955.0,
,9737,4,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,104686,,,CHEMBL617248,Autocuration,,,H,,B,2174,,,,1,,,
,9737,4,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,104686,,Brain,CHEMBL617249,Autocuration,,,H,,B,2175,,,,1,,955.0,
,9737,4,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,104686,,,CHEMBL617250,Autocuration,,,H,,B,2176,,,,1,,,
,9737,4,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,104686,,,CHEMBL617251,Autocuration,,,H,,B,2177,,,,1,,,
,11828,5,BAO_0000019,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL617252,Autocuration,10116.0,,D,,B,2178,,,Rattus norvegicus,1,,,
,12253,4,BAO_0000019,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,104686,,,CHEMBL617006,Autocuration,,,H,,B,2179,,,,1,,,
,12253,4,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,104686,,,CHEMBL617007,Autocuration,,,H,,B,2180,,,,1,,,
,11279,4,BAO_0000019,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",104686,,,CHEMBL617008,Autocuration,,,H,,F,2181,,,,1,,,
,11866,4,BAO_0000019,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,104686,,,CHEMBL617009,Autocuration,,,H,,B,2182,,,,1,,,
,14424,5,BAO_0000224,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,104686,,,CHEMBL617010,Autocuration,10116.0,,D,,B,2183,,,Rattus norvegicus,1,,,
,15180,5,BAO_0000019,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL857978,Autocuration,10116.0,,D,,B,2184,,,Rattus norvegicus,1,,,
,15180,5,BAO_0000019,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL617011,Autocuration,10116.0,,D,,B,2185,,,Rattus norvegicus,1,,,
,9786,5,BAO_0000019,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,104686,,,CHEMBL617012,Autocuration,10116.0,,D,,B,2186,,,Rattus norvegicus,1,,,
,12132,4,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,104686,,,CHEMBL617013,Autocuration,,,H,,B,2187,,,,1,,,
,5486,4,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,104686,,,CHEMBL617014,Autocuration,,,H,,B,2188,,,,1,,,
,15316,4,BAO_0000019,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL617015,Autocuration,,,H,,B,2189,,,,1,,,
,16429,4,BAO_0000019,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,104686,,,CHEMBL617016,Autocuration,,,H,,B,2190,,,,1,,,
,14617,4,BAO_0000224,pKi value for 5-hydroxytryptamine 2 receptor binding site,104686,,,CHEMBL617017,Autocuration,,,H,,B,2191,,,,1,,,
,11351,4,BAO_0000221,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,104686,,Brain,CHEMBL617018,Autocuration,,,H,,B,2192,,,,1,,955.0,
,11279,4,BAO_0000019,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,104686,,,CHEMBL617019,Autocuration,,,H,,F,2193,,,,1,,,
,9523,4,BAO_0000019,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,,CHEMBL617020,Autocuration,,,H,,B,2194,,,,1,,,
,9523,4,BAO_0000019,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,,CHEMBL617021,Autocuration,,,H,,B,2195,,,,1,,,
,9523,4,BAO_0000019,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,,CHEMBL617022,Autocuration,,,H,,B,2196,,,,1,,,
,9523,4,BAO_0000019,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,,CHEMBL617023,Autocuration,,,H,,B,2197,,,,1,,,
,9523,4,BAO_0000019,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,,CHEMBL617024,Autocuration,,,H,,B,2198,,,,1,,,
,9523,4,BAO_0000019,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,,CHEMBL617025,Autocuration,,,H,,B,2199,,,,1,,,
,9523,4,BAO_0000224,Hill coefficient of compound was determined,105075,,,CHEMBL617026,Autocuration,,,H,,B,2200,,,,1,,,
,4771,0,BAO_0000019,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,22226,,,CHEMBL617027,Autocuration,,,U,,B,2201,,,,1,,,
,5033,5,BAO_0000019,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,104686,,,CHEMBL617028,Autocuration,10116.0,,D,,B,2202,,,Rattus norvegicus,1,,,
,10845,8,BAO_0000019,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,12687,,,CHEMBL617029,Expert,,,H,,B,2203,,,,1,,,
,10845,8,BAO_0000019,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,12687,,,CHEMBL875908,Expert,,,H,,B,2204,,,,1,,,
,16288,8,BAO_0000357,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),12687,,,CHEMBL617030,Autocuration,,,H,,B,2205,,,,1,,,
,16288,8,BAO_0000019,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),12687,,,CHEMBL617031,Autocuration,,,H,,B,2206,,,,1,,,
,16190,8,BAO_0000019,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,12687,,,CHEMBL617032,Autocuration,,,H,,B,2207,,,,1,,,
,12463,5,BAO_0000224,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,104686,,,CHEMBL617033,Autocuration,10116.0,,D,,B,2208,,,Rattus norvegicus,1,,,
,9699,4,BAO_0000224,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",104686,,,CHEMBL617034,Autocuration,,,H,,B,2209,,,,1,,,
,9699,4,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,104686,,,CHEMBL617035,Autocuration,,,H,,B,2210,,,,1,,,
,11662,4,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",104686,,,CHEMBL617036,Autocuration,,,H,,B,2211,,,,1,,,
,1205,4,BAO_0000224,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,104784,,,CHEMBL617037,Autocuration,,,H,,B,2212,,,,1,,,
,11376,0,BAO_0000219,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,22226,,,CHEMBL617038,Autocuration,,,U,,B,2213,,,,1,,,
,11376,4,BAO_0000219,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",104784,,,CHEMBL617039,Autocuration,,,H,,B,2214,,,,1,,,
,4639,4,BAO_0000224,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,104784,,,CHEMBL617161,Autocuration,,,H,,B,2215,,,,1,,,
,2222,4,BAO_0000224,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,104784,,,CHEMBL617162,Autocuration,,,H,,B,2216,,,,1,,,
,1558,4,BAO_0000224,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,104784,,,CHEMBL617163,Autocuration,,,H,,B,2217,,,,1,,,
,1089,4,BAO_0000224,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,104784,,,CHEMBL617164,Autocuration,,,H,,B,2218,,,,1,,,
,386,4,BAO_0000249,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,104784,,,CHEMBL617165,Autocuration,,Brain membranes,H,,B,2219,,,,1,,,
,2474,4,BAO_0000224,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,104784,,,CHEMBL617166,Autocuration,,,H,,B,2220,,,,1,,,
,17066,4,BAO_0000224,Binding affinity towards 5-HT2 receptor,104784,,,CHEMBL617167,Autocuration,,,H,,B,2221,,,,1,,,
,959,4,BAO_0000224,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,104784,,,CHEMBL872912,Autocuration,,,H,,B,2222,,,,1,,,
,6398,4,BAO_0000224,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,104784,,,CHEMBL617168,Autocuration,,,H,,B,2223,,,,1,,,
,11889,4,BAO_0000224,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,104686,,,CHEMBL617169,Autocuration,,,H,,B,2224,,,,1,,,
,4221,4,BAO_0000224,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,104784,,,CHEMBL617170,Autocuration,,,H,,B,2225,,,,1,,,
,11026,4,BAO_0000224,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,104784,,,CHEMBL617171,Autocuration,,,H,,B,2226,,,,1,,,
,11866,4,BAO_0000224,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,104784,,,CHEMBL617172,Autocuration,,,H,,B,2227,,,,1,,,
,4221,4,BAO_0000224,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,104784,,,CHEMBL617173,Autocuration,,,H,,B,2228,,,,1,,,
,13950,0,BAO_0000019,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,22226,,,CHEMBL617174,Autocuration,,,U,,B,2229,,,,1,,,
,1263,4,BAO_0000224,5-hydroxytryptamine 2 receptor binding affinity,104784,,,CHEMBL617175,Autocuration,,,H,,B,2230,,,,1,,,
,13291,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,17005,,,CHEMBL617176,Autocuration,,,H,,B,2231,,,,1,,,
,10812,8,BAO_0000357,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,17005,,,CHEMBL617177,Autocuration,,,H,,B,2232,,,,1,,,
,13020,4,BAO_0000224,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,104784,,,CHEMBL617178,Autocuration,,,H,,B,2233,,,,1,,,
,13021,4,BAO_0000224,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,104784,,,CHEMBL617179,Autocuration,,,H,,B,2234,,,,1,,,
,13020,4,BAO_0000224,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,104784,,,CHEMBL617180,Autocuration,,,H,,B,2235,,,,1,,,
,14532,8,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,17005,,,CHEMBL617181,Autocuration,,,H,,B,2236,,,,1,,,
,13944,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2 receptor,17005,,,CHEMBL617182,Autocuration,,,H,,B,2237,,,,1,,,
,14331,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2 receptor,17005,,,CHEMBL617183,Autocuration,,,H,,B,2238,,,,1,,,
,14118,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,17005,,,CHEMBL617184,Autocuration,,,H,,B,2239,,,,1,,,
,13033,8,BAO_0000357,Binding affinity against serotonergic 5-HT2 receptor,17005,,,CHEMBL617185,Autocuration,,,H,,B,2240,,,,1,,,
,10321,8,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,17005,,,CHEMBL617186,Autocuration,,,H,,B,2241,,,,1,,,
,12918,8,BAO_0000357,Compound was evaluated for the binding affinity at 5- HT2 receptor,17005,,,CHEMBL617187,Autocuration,,,H,,B,2242,,,,1,,,
,15120,8,BAO_0000357,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,17005,,,CHEMBL617188,Autocuration,,,H,,B,2243,,,,1,,,
,2613,8,BAO_0000218,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,17005,,,CHEMBL617189,Autocuration,,,H,,B,2244,,,,1,,,
,13378,5,BAO_0000224,Inhibitory activity against cloned human 5-HT2 receptor,104784,,,CHEMBL617190,Autocuration,9606.0,,D,,B,2245,,,Homo sapiens,1,,,
,2331,5,BAO_0000219,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",104784,,,CHEMBL617191,Autocuration,9606.0,,D,,B,2246,,449.0,Homo sapiens,1,,,CHO
,2331,5,BAO_0000219,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",104784,,,CHEMBL617192,Autocuration,9606.0,,D,,B,2247,,449.0,Homo sapiens,1,,,CHO
,2331,5,BAO_0000219,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",104784,,,CHEMBL617193,Autocuration,9606.0,,D,,B,2248,,449.0,Homo sapiens,1,,,CHO
,2331,5,BAO_0000219,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",104784,,,CHEMBL617194,Autocuration,9606.0,,D,,B,2249,,449.0,Homo sapiens,1,,,CHO
,4170,4,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor,104784,,,CHEMBL617195,Autocuration,,,H,,B,2250,,,,1,,,
,15453,4,BAO_0000224,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,104784,,,CHEMBL881830,Autocuration,,,H,,B,2251,,,,1,,,
,1479,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2 receptor,17005,,,CHEMBL617196,Autocuration,,,H,,B,2252,,,,1,,,
,11139,4,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,104686,,,CHEMBL617197,Autocuration,,,H,,B,2253,,,,1,,,
,13969,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,17005,,,CHEMBL617198,Expert,,,H,,B,2254,,,,1,,,
,13392,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor,17005,,,CHEMBL873476,Expert,,,H,,B,2255,,,,1,,,
,14430,8,BAO_0000019,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,17005,,,CHEMBL617199,Expert,,,H,,B,2256,,,,1,,,
,13181,8,BAO_0000357,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617200,Autocuration,10141.0,,H,,B,2257,,,Cavia porcellus,1,,,
,17200,8,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,51,,,CHEMBL617484,Autocuration,,,H,,B,2258,,,,1,,,
,17200,8,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,107,,,CHEMBL617485,Autocuration,,,H,,B,2259,,,,1,,,
,17200,8,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,51,,,CHEMBL617486,Autocuration,,,H,,B,2260,,,,1,,,
,13463,8,BAO_0000357,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,107,,,CHEMBL858022,Autocuration,,,H,,B,2261,,,,1,,,
,6347,8,BAO_0000219,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,107,,,CHEMBL617049,Autocuration,,,H,,B,2262,,449.0,,1,,,CHO
,6857,9,BAO_0000219,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,107,,,CHEMBL617050,Expert,9606.0,,D,,F,2263,,449.0,Homo sapiens,1,,,CHO
,4176,8,BAO_0000219,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,107,,,CHEMBL617051,Autocuration,,,H,,F,2264,,,,1,,,
,4176,8,BAO_0000219,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,107,,,CHEMBL617052,Autocuration,,,H,,F,2265,,,,1,,,
,4176,8,BAO_0000219,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,107,,,CHEMBL617053,Autocuration,,,H,,F,2266,,,,1,,,
,6347,8,BAO_0000219,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",107,,,CHEMBL617054,Autocuration,,,H,,B,2267,,449.0,,1,,,CHO
,6347,8,BAO_0000219,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",107,,,CHEMBL617055,Autocuration,,,H,,B,2268,,449.0,,1,,,CHO
,15331,8,BAO_0000357,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,107,,,CHEMBL882924,Autocuration,,,H,,B,2269,,,,1,,,
,16146,9,BAO_0000357,Inhibition of human 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617056,Expert,9606.0,,D,,B,2270,,,Homo sapiens,1,,,
,15250,8,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,107,,,CHEMBL617057,Autocuration,,,H,,B,2271,,449.0,,1,,,CHO
,13631,8,BAO_0000219,Inhibitory concentration against human 5-HT2A receptor in BEK cells,107,,,CHEMBL617058,Expert,,,H,,B,2272,,,,1,,,
,3805,8,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),107,,,CHEMBL617059,Autocuration,,,H,,B,2273,,,,1,,,
,4011,8,BAO_0000219,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,107,,,CHEMBL617060,Autocuration,,,H,,B,2274,,449.0,,1,,,CHO
,4012,8,BAO_0000219,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,107,,,CHEMBL617061,Expert,,,H,,B,2275,,449.0,,1,,,CHO
,6366,8,BAO_0000219,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,107,,,CHEMBL617062,Expert,,,H,,B,2276,,307.0,,1,,,L929
,15949,8,BAO_0000219,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,107,,,CHEMBL617063,Expert,,,H,,B,2277,,449.0,,1,,,CHO
,14093,8,BAO_0000019,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,107,,,CHEMBL617064,Autocuration,,,H,,F,2278,,,,1,,,
,13481,8,BAO_0000019,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,107,,,CHEMBL617065,Autocuration,,,H,,F,2279,,,,1,,,
,6347,8,BAO_0000219,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,107,,,CHEMBL617066,Autocuration,,,H,,B,2280,,449.0,,1,,,CHO
,6347,8,BAO_0000219,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,107,,,CHEMBL617067,Autocuration,,,H,,B,2281,,449.0,,1,,,CHO
,14093,8,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,107,,,CHEMBL617068,Autocuration,,,H,,F,2282,,,,1,,,
,14093,8,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,107,,,CHEMBL617069,Autocuration,,,H,,F,2283,,,,1,,,
,13481,8,BAO_0000019,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,107,,,CHEMBL617070,Autocuration,,,H,,F,2284,,,,1,,,
,14442,8,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,107,,,CHEMBL617071,Autocuration,,,H,,B,2285,,,,1,,,
,14442,8,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,107,,,CHEMBL872915,Autocuration,,,H,,B,2286,,,,1,,,
,14755,8,BAO_0000357,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,107,,,CHEMBL617072,Autocuration,,,H,,B,2287,,,,1,,,
,16441,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,107,,,CHEMBL617073,Autocuration,,,H,,B,2288,,,,1,,,
,14744,8,BAO_0000357,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,107,,,CHEMBL617074,Autocuration,,,H,,B,2289,,,,1,,,
,16659,8,BAO_0000219,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,107,,,CHEMBL617075,Expert,,,H,,B,2290,,449.0,,1,,,CHO
,3307,8,BAO_0000357,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617076,Autocuration,,,H,,B,2291,,,,1,,,
,6857,9,BAO_0000019,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,107,,,CHEMBL617077,Expert,9606.0,,D,,B,2292,,,Homo sapiens,1,,,
,5635,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,107,,,CHEMBL617078,Expert,,,H,,B,2293,,,,1,,,
,4234,9,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617079,Expert,9606.0,,D,,B,2294,,,Homo sapiens,1,,,
,15527,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,107,,,CHEMBL617080,Autocuration,,,H,,B,2295,,,,1,,,
,6588,8,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,107,,,CHEMBL617081,Expert,,,H,,B,2296,,449.0,,1,,,CHO
,13631,8,BAO_0000219,Binding affinity towards human 5-HT2A receptor in BEK cells,107,,,CHEMBL617082,Expert,,,H,,B,2297,,,,1,,,
,17723,8,BAO_0000357,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617083,Autocuration,,,H,,B,2298,,,,1,,,
,14770,8,BAO_0000357,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,107,,,CHEMBL617084,Autocuration,,,H,,B,2299,,,,1,,,
,16293,9,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617085,Expert,9606.0,,D,,B,2300,,,Homo sapiens,1,,,
,16209,8,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,107,,,CHEMBL617086,Autocuration,,,H,,B,2301,,,,1,,,
,12469,8,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,107,,,CHEMBL617087,Autocuration,,,H,,B,2302,,,,1,,,
,15363,8,BAO_0000357,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617088,Autocuration,,,H,,B,2303,,,,1,,,
,15363,8,BAO_0000357,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617089,Autocuration,,,H,,B,2304,,,,1,,,
,16441,8,BAO_0000019,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",107,,,CHEMBL617090,Expert,,,H,,B,2305,,,,1,,,
,8,8,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,107,,,CHEMBL617513,Autocuration,,,H,,B,2306,,,,1,,,
,4176,8,BAO_0000219,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,107,,,CHEMBL617514,Autocuration,,,H,,B,2307,,722.0,,1,,,HEK293
,17085,8,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617515,Autocuration,,,H,,B,2308,,,,1,,,
,17200,8,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,107,,,CHEMBL617516,Autocuration,,,H,,B,2309,,,,1,,,
,17200,9,BAO_0000357,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,107,,,CHEMBL617517,Expert,9606.0,,D,,B,2310,,,Homo sapiens,1,,,
,4013,9,BAO_0000219,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,107,,,CHEMBL617518,Expert,9606.0,,D,,B,2311,,449.0,Homo sapiens,1,,,CHO
,5088,8,BAO_0000357,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617519,Autocuration,,,H,,B,2312,,,,1,,,
,5088,9,BAO_0000357,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617520,Expert,9606.0,,D,,B,2313,,,Homo sapiens,1,,,
,5088,8,BAO_0000357,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,107,,,CHEMBL617521,Autocuration,,,H,,B,2314,,,,1,,,
,5088,9,BAO_0000357,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617522,Expert,9606.0,,D,,B,2315,,,Homo sapiens,1,,,
,5088,8,BAO_0000357,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,107,,,CHEMBL617523,Autocuration,,,H,,B,2316,,,,1,,,
,5088,8,BAO_0000357,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,107,,,CHEMBL617524,Autocuration,,,H,,B,2317,,,,1,,,
,9786,4,BAO_0000019,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,104686,,,CHEMBL617525,Autocuration,,,H,,B,2318,,,,1,,,
,9205,5,BAO_0000019,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,104686,,,CHEMBL617526,Autocuration,10116.0,,D,,B,2319,,,Rattus norvegicus,1,,,
,11257,4,BAO_0000224,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,104686,,,CHEMBL617527,Autocuration,,,H,,B,2320,,,,1,,,
,9362,4,BAO_0000019,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,104686,,,CHEMBL617528,Autocuration,,,H,,B,2321,,,,1,,,
,9362,4,BAO_0000019,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,104686,,,CHEMBL617529,Autocuration,,,H,,B,2322,,,,1,,,
,10590,4,BAO_0000224,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,104686,,,CHEMBL617530,Autocuration,,,H,,B,2323,,,,1,,,
,10468,4,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,104686,,,CHEMBL617531,Autocuration,,,H,,B,2324,,,,1,,,
,13050,4,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,104686,,,CHEMBL617532,Autocuration,,,H,,B,2325,,,,1,,,
,11624,4,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,104686,,,CHEMBL617533,Autocuration,,,H,,B,2326,,,,1,,,
,10468,4,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,104686,,,CHEMBL617534,Autocuration,,,H,,B,2327,,,,1,,,
,10330,4,BAO_0000224,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,104686,,,CHEMBL617535,Autocuration,,,H,,B,2328,,,,1,,,
,10062,4,BAO_0000224,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,104686,,,CHEMBL617536,Autocuration,,,H,,B,2329,,,,1,,,
,11642,4,BAO_0000224,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL617537,Autocuration,,,H,,B,2330,,,,1,,,
,10062,4,BAO_0000224,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL617538,Autocuration,,,H,,B,2331,,,,1,,,
,13427,4,BAO_0000219,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,104686,In vitro,,CHEMBL617539,Autocuration,,,H,,B,2332,,,,1,,,
,12280,5,BAO_0000224,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL617540,Autocuration,10116.0,,D,,B,2333,,,Rattus norvegicus,1,,,
,4101,5,BAO_0000224,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,104686,,,CHEMBL617541,Autocuration,10116.0,,D,,B,2334,,,Rattus norvegicus,1,,,
,10062,4,BAO_0000224,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL617542,Autocuration,,,H,,B,2335,,,,1,,,
,11147,4,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,104686,,,CHEMBL617543,Autocuration,,,H,,B,2336,,,,1,,,
,2395,5,BAO_0000219,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,104686,,,CHEMBL617544,Autocuration,10116.0,,D,,B,2337,,485.0,Rattus norvegicus,1,,,CHO-K1
,2395,5,BAO_0000219,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,104686,,,CHEMBL617545,Autocuration,10116.0,,D,,B,2338,,485.0,Rattus norvegicus,1,,,CHO-K1
,9098,5,BAO_0000019,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,104686,,,CHEMBL617413,Autocuration,10116.0,,D,,B,2339,,,Rattus norvegicus,1,,,
,9098,4,BAO_0000019,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,104686,,,CHEMBL617414,Autocuration,,,H,,B,2340,,,,1,,,
,9098,5,BAO_0000019,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,104686,,,CHEMBL617415,Autocuration,10116.0,,D,,B,2341,,,Rattus norvegicus,1,,,
,9443,4,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL617416,Autocuration,,,H,,B,2342,,,,1,,,
,9443,4,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,104686,,,CHEMBL617417,Autocuration,,,H,,B,2343,,,,1,,,
,9699,4,BAO_0000019,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",104686,,,CHEMBL617418,Autocuration,,,H,,B,2344,,,,1,,,
,9699,4,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,104686,,,CHEMBL617419,Autocuration,,,H,,B,2345,,,,1,,,
,9098,4,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,104686,,,CHEMBL617420,Autocuration,,,H,,B,2346,,,,1,,,
,3070,5,BAO_0000224,Affinity for 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL617421,Autocuration,10116.0,,D,,B,2347,,,Rattus norvegicus,1,,,
,9547,4,BAO_0000224,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,104686,,,CHEMBL617422,Autocuration,,,H,,B,2348,,,,1,,,
,10444,4,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,104686,,,CHEMBL617423,Autocuration,,,H,,B,2349,,,,1,,,
,14617,4,BAO_0000019,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,104686,,,CHEMBL617424,Autocuration,,,H,,B,2350,,,,1,,,
,14617,4,BAO_0000019,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,104686,,,CHEMBL617425,Autocuration,,,H,,B,2351,,,,1,,,
,11130,4,BAO_0000224,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),104686,,,CHEMBL617426,Autocuration,,,H,,B,2352,,,,1,,,
,11130,4,BAO_0000218,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),104686,In vivo,,CHEMBL617427,Autocuration,,,H,,B,2353,,,,1,,,
,14542,4,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,104686,,Brain,CHEMBL617428,Autocuration,,,H,,B,2354,,,,1,,955.0,
,2797,4,BAO_0000224,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,104686,,,CHEMBL617429,Autocuration,,,H,,B,2355,,,,1,,,
,11332,4,BAO_0000019,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,104686,,,CHEMBL617430,Autocuration,,,H,,B,2356,,,,1,,,
,11332,4,BAO_0000019,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,104686,,,CHEMBL617431,Autocuration,,,H,,B,2357,,,,1,,,
,10752,4,BAO_0000019,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,104686,,Frontal cortex,CHEMBL617432,Autocuration,,,H,,B,2358,,,,1,,1870.0,
,1185,4,BAO_0000224,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL617433,Autocuration,,,H,,B,2359,,,,1,,,
,1185,4,BAO_0000224,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL617434,Autocuration,,,H,,B,2360,,,,1,,,
,11624,5,BAO_0000224,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,104686,,,CHEMBL617435,Autocuration,10116.0,,D,,B,2361,,,Rattus norvegicus,1,,,
,1344,4,BAO_0000019,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,104686,,,CHEMBL617436,Autocuration,,,H,,B,2362,,,,1,,,
,15453,5,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,104686,,Striatum,CHEMBL617437,Autocuration,10116.0,,D,,B,2363,,,Rattus norvegicus,1,,2435.0,
,11662,4,BAO_0000019,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",104686,,,CHEMBL617438,Autocuration,,,H,,B,2364,,,,1,,,
,11662,4,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",104686,,,CHEMBL617439,Autocuration,,,H,,B,2365,,,,1,,,
,10796,4,BAO_0000224,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL617440,Autocuration,,,H,,B,2366,,,,1,,,
,9069,4,BAO_0000224,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL617441,Autocuration,,,H,,B,2367,,,,1,,,
,8814,5,BAO_0000019,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,104686,,,CHEMBL872918,Autocuration,10116.0,,D,,B,2368,,,Rattus norvegicus,1,,,
,8908,5,BAO_0000019,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,104686,,,CHEMBL617442,Autocuration,10116.0,,D,,B,2369,,,Rattus norvegicus,1,,,
,9098,4,BAO_0000019,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,104686,,,CHEMBL617443,Autocuration,,,H,,B,2370,,,,1,,,
,9098,4,BAO_0000019,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,104686,,,CHEMBL617444,Autocuration,,,H,,B,2371,,,,1,,,
,9098,4,BAO_0000019,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,104686,,,CHEMBL617445,Autocuration,,,H,,B,2372,,,,1,,,
,9098,4,BAO_0000019,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,104686,,,CHEMBL617446,Autocuration,,,H,,B,2373,,,,1,,,
,9098,4,BAO_0000249,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,104686,,,CHEMBL617447,Autocuration,,,H,,B,2374,,,,1,,,
,9098,4,BAO_0000019,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,104686,,,CHEMBL617448,Autocuration,,,H,,B,2375,,,,1,,,
,9098,4,BAO_0000019,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,104686,,,CHEMBL617449,Autocuration,,,H,,B,2376,,,,1,,,
,9161,4,BAO_0000019,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,104686,,,CHEMBL617450,Autocuration,,,H,,B,2377,,,,1,,,
,9161,4,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,104686,,,CHEMBL617451,Autocuration,,,H,,B,2378,,,,1,,,
,9161,4,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,104686,,,CHEMBL617452,Autocuration,,,H,,B,2379,,,,1,,,
,9161,4,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,104686,,,CHEMBL617453,Autocuration,,,H,,B,2380,,,,1,,,
,9161,4,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,104686,,,CHEMBL617660,Autocuration,,,H,,B,2381,,,,1,,,
,9161,4,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,104686,,,CHEMBL617661,Autocuration,,,H,,B,2382,,,,1,,,
,9161,4,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,104686,,,CHEMBL617662,Autocuration,,,H,,B,2383,,,,1,,,
,9161,4,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,104686,,,CHEMBL872919,Autocuration,,,H,,B,2384,,,,1,,,
,9161,4,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,104686,,,CHEMBL617663,Autocuration,,,H,,B,2385,,,,1,,,
,9161,4,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,104686,,,CHEMBL617664,Autocuration,,,H,,B,2386,,,,1,,,
,9161,4,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,104686,,,CHEMBL617665,Autocuration,,,H,,B,2387,,,,1,,,
,9161,4,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,104686,,,CHEMBL617666,Autocuration,,,H,,B,2388,,,,1,,,
,12094,4,BAO_0000019,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,104686,,,CHEMBL617667,Autocuration,,,H,,B,2389,,,,1,,,
,12018,4,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,104686,,,CHEMBL617668,Autocuration,,,H,,B,2390,,,,1,,,
,10394,4,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,104686,,,CHEMBL617669,Autocuration,,,H,,B,2391,,,,1,,,
,15260,4,BAO_0000224,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL617670,Autocuration,,,H,,B,2392,,,,1,,,
,11624,5,BAO_0000224,Inhibitory constant against 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL617671,Autocuration,10116.0,,D,,B,2393,,,Rattus norvegicus,1,,,
,13654,4,BAO_0000224,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL617672,Autocuration,,,H,,B,2394,,,,1,,,
,9541,4,BAO_0000019,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,104686,,,CHEMBL617673,Autocuration,,,H,,B,2395,,,,1,,,
,11933,4,BAO_0000224,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,104686,,,CHEMBL617674,Autocuration,,,H,,B,2396,,,,1,,,
,15538,4,BAO_0000019,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,104686,,,CHEMBL617675,Autocuration,,,H,,B,2397,,,,1,,,
,15538,4,BAO_0000019,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,104686,,,CHEMBL617676,Autocuration,,,H,,B,2398,,,,1,,,
,15538,4,BAO_0000019,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,104686,,,CHEMBL617677,Autocuration,,,H,,B,2399,,,,1,,,
,8841,5,BAO_0000019,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL617678,Autocuration,,,D,,B,2400,,,,1,,,
,1455,4,BAO_0000224,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,104686,,,CHEMBL617679,Autocuration,,,H,,B,2401,,,,1,,,
,1455,4,BAO_0000224,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,104686,,,CHEMBL617680,Autocuration,,,H,,B,2402,,,,1,,,
,11752,4,BAO_0000019,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,104686,,,CHEMBL617681,Autocuration,,,H,,B,2403,,,,1,,,
,11642,4,BAO_0000221,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,104686,,Brain,CHEMBL617682,Autocuration,,,H,,B,2404,,,,1,,955.0,
,12092,4,BAO_0000224,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,104686,,,CHEMBL617683,Autocuration,,,H,,B,2405,,,,1,,,
,3967,4,BAO_0000224,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,104686,,,CHEMBL617684,Autocuration,,,H,,B,2406,,,,1,,,
,12771,5,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL617685,Autocuration,10116.0,,D,,B,2407,,,Rattus norvegicus,1,,,
,11642,4,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,104686,,,CHEMBL617686,Autocuration,,,H,,B,2408,,,,1,,,
,11628,4,BAO_0000224,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,104686,,,CHEMBL617687,Autocuration,,,H,,B,2409,,,,1,,,
,13654,4,BAO_0000224,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,104686,,,CHEMBL617688,Autocuration,,,H,,B,2410,,,,1,,,
,11200,4,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,,,CHEMBL617689,Autocuration,,,H,,F,2411,,,,1,,,
,11200,4,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,,,CHEMBL617690,Autocuration,,,H,,F,2412,,,,1,,,
,11200,4,BAO_0000218,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",104686,In vivo,,CHEMBL617691,Autocuration,,,H,,F,2413,,,,1,,,
,11200,4,BAO_0000218,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",104686,In vivo,,CHEMBL617692,Autocuration,,,H,,F,2414,,,,1,,,
,11200,4,BAO_0000218,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",104686,In vivo,,CHEMBL617693,Autocuration,,,H,,F,2415,,,,1,,,
,11200,4,BAO_0000218,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",104686,In vivo,,CHEMBL617694,Autocuration,,,H,,F,2416,,,,1,,,
,15436,8,BAO_0000221,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,12687,,Brain,CHEMBL857985,Expert,,,H,,B,2417,,,,1,,955.0,
,15436,9,BAO_0000019,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,12687,,,CHEMBL617695,Expert,10116.0,,D,,B,2418,,,Rattus norvegicus,1,,,
,14025,8,BAO_0000019,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,12687,,,CHEMBL617696,Autocuration,,,H,,B,2419,,,,1,,,
,4342,8,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,12687,,,CHEMBL617697,Autocuration,,,H,,B,2420,,,,1,,,
,13735,9,BAO_0000019,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,12687,,,CHEMBL617257,Expert,10116.0,,D,,B,2421,,,Rattus norvegicus,1,,,
,5816,9,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,12687,,,CHEMBL617258,Expert,10116.0,,D,,B,2422,,,Rattus norvegicus,1,,,
,14287,8,BAO_0000019,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,12687,,,CHEMBL617259,Expert,,,H,,B,2423,,,,1,,,
,15738,8,BAO_0000357,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,12687,,,CHEMBL617260,Autocuration,,,H,,B,2424,,,,1,,,
,15738,9,BAO_0000357,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL617261,Expert,10116.0,,D,,B,2425,,,Rattus norvegicus,1,,,
,15026,8,BAO_0000019,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,12687,,,CHEMBL617262,Autocuration,,,H,,B,2426,,,,1,,,
,16647,8,BAO_0000019,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,12687,,,CHEMBL617263,Expert,,,H,,B,2427,,,,1,,,
,16647,8,BAO_0000019,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,12687,,,CHEMBL617264,Autocuration,,,H,,B,2428,,,,1,,,
,13345,9,BAO_0000019,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL617265,Expert,10116.0,,D,,B,2429,,,Rattus norvegicus,1,,,
,1543,8,BAO_0000249,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL617266,Autocuration,,Membranes,H,,B,2430,,,,1,,,
,12444,8,BAO_0000019,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,12687,,,CHEMBL617267,Autocuration,,,H,,B,2431,,,,1,,,
,16404,8,BAO_0000019,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,12687,,,CHEMBL617268,Expert,,,H,,B,2432,,,,1,,,
,16404,8,BAO_0000219,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,12687,,,CHEMBL617269,Autocuration,,,H,,B,2433,,449.0,,1,,,CHO
,15577,8,BAO_0000357,Kinetic inhibition constant evaluated by measuring serotonergic activity,12687,,,CHEMBL617323,Expert,,,H,,B,2434,,,,1,,,
,15577,8,BAO_0000357,Serotonergic activity of the compound.,12687,,,CHEMBL617324,Autocuration,,,H,,B,2435,,,,1,,,
,2495,8,BAO_0000249,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,12687,,,CHEMBL617325,Autocuration,,,H,,B,2436,,,,1,,,
,15042,9,BAO_0000019,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,12687,,,CHEMBL617326,Expert,10116.0,,D,,B,2437,,,Rattus norvegicus,1,,,
,15026,8,BAO_0000249,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,12687,,,CHEMBL617327,Expert,,,H,,B,2438,,,,1,,,
,12919,9,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,,,CHEMBL617328,Expert,10116.0,,D,,F,2439,,,Rattus norvegicus,1,,,
,12919,9,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,,,CHEMBL617329,Expert,10116.0,,D,,F,2440,,,Rattus norvegicus,1,,,
,12919,9,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,,,CHEMBL617330,Expert,10116.0,,D,,F,2441,,,Rattus norvegicus,1,,,
,15194,8,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,,,CHEMBL617331,Autocuration,,,H,,B,2442,,,,1,,,
,15194,8,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,12687,,,CHEMBL617332,Autocuration,,,H,,B,2443,,,,1,,,
,4820,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617333,Expert,,,H,,B,2444,,,,1,,,
,6736,8,BAO_0000357,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,107,,,CHEMBL617334,Autocuration,,,H,,B,2445,,,,1,,,
,5163,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,107,,,CHEMBL617335,Autocuration,,,H,,B,2446,,,,1,,,
,5163,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,107,,,CHEMBL617336,Autocuration,,,H,,B,2447,,,,1,,,
,6011,8,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,107,,,CHEMBL617337,Autocuration,,,H,,B,2448,,,,1,,,
,14294,9,BAO_0000357,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,107,,,CHEMBL617338,Expert,9606.0,,D,,B,2449,,,Homo sapiens,1,,,
,5014,8,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617339,Autocuration,,,H,,B,2450,,,,1,,,
,17066,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617340,Expert,,,H,,B,2451,,,,1,,,
,17515,8,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,107,,,CHEMBL617341,Autocuration,,,H,,B,2452,,,,1,,,
,6736,8,BAO_0000357,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617342,Expert,,,H,,B,2453,,,,1,,,
,5163,8,BAO_0000357,Affinity for 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617343,Expert,,,H,,B,2454,,,,1,,,
,16911,8,BAO_0000219,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,107,,,CHEMBL617344,Expert,,,H,,B,2455,,723.0,,1,,,NIH3T3
,6841,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,107,,,CHEMBL617345,Expert,,,H,,B,2456,,,,1,,,
,6119,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,107,,,CHEMBL617346,Expert,,,H,,B,2457,,,,1,,,
,3962,8,BAO_0000357,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617347,Autocuration,,,H,,B,2458,,,,1,,,
,4373,8,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,107,,,CHEMBL617348,Autocuration,,,H,,B,2459,,,,1,,,
,4373,8,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,107,,,CHEMBL617349,Autocuration,,,H,,B,2460,,,,1,,,
,3962,8,BAO_0000019,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617350,Autocuration,,,H,,F,2461,,,,1,,,
,1633,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,107,,,CHEMBL872339,Expert,,,H,,B,2462,,,,1,,,
,4373,8,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,107,,,CHEMBL617351,Autocuration,,,H,,B,2463,,,,1,,,
,6576,8,BAO_0000357,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617352,Expert,,,H,,B,2464,,,,1,,,
,4687,8,BAO_0000357,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617353,Autocuration,,,H,,B,2465,,,,1,,,
,16946,8,BAO_0000357,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617354,Autocuration,,,H,,B,2466,,,,1,,,
,14159,8,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617355,Autocuration,,,H,,B,2467,,,,1,,,
,3032,8,BAO_0000219,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,107,,,CHEMBL617356,Expert,10090.0,,H,,B,2468,,449.0,Mus musculus,1,,,CHO
,16655,8,BAO_0000357,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617357,Autocuration,,,H,,B,2469,,,,1,,,
,13964,8,BAO_0000357,Binding affinity at 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617358,Autocuration,,,H,,B,2470,,,,1,,,
,16989,8,BAO_0000357,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617359,Expert,,,H,,B,2471,,,,1,,,
,16117,8,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,107,,,CHEMBL617360,Autocuration,,,H,,B,2472,,,,1,,,
,16700,8,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,107,,,CHEMBL875913,Autocuration,,,H,,B,2473,,,,1,,,
,3269,8,BAO_0000357,Affinity against 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617361,Autocuration,,,H,,B,2474,,,,1,,,
,1274,9,BAO_0000357,Binding affinity against 5-Hydroxytryptamine 2A receptor,107,,,CHEMBL617362,Expert,9606.0,,D,,B,2475,,,Homo sapiens,1,,,
,1317,8,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,107,,,CHEMBL617363,Autocuration,,,H,,B,2476,,,,1,,,
,12146,8,BAO_0000357,Tested against 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617364,Autocuration,,,H,,B,2477,,,,1,,,
,12652,4,BAO_0000224,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,105075,,,CHEMBL617365,Autocuration,,,H,,B,2478,,,,1,,,
,12652,4,BAO_0000224,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,105075,,,CHEMBL617366,Autocuration,,,H,,B,2479,,,,1,,,
,12652,4,BAO_0000224,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,105075,,,CHEMBL617367,Autocuration,,,H,,B,2480,,,,1,,,
,12652,4,BAO_0000224,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,105075,,,CHEMBL617368,Autocuration,,,H,,B,2481,,,,1,,,
,16647,8,BAO_0000357,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),107,,,CHEMBL617369,Autocuration,,,H,,B,2482,,,,1,,,
,15851,9,BAO_0000219,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,227,,,CHEMBL617370,Expert,9606.0,,D,,B,2483,,722.0,Homo sapiens,1,,,HEK293
,6857,9,BAO_0000219,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,227,,,CHEMBL617371,Expert,9606.0,,D,,F,2484,,449.0,Homo sapiens,1,,,CHO
,3805,8,BAO_0000357,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),227,,,CHEMBL617372,Autocuration,,,H,,B,2485,,,,1,,,
,6491,9,BAO_0000357,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,227,,,CHEMBL617373,Expert,9606.0,,D,,B,2486,,,Homo sapiens,1,,,
,14093,8,BAO_0000019,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,227,,,CHEMBL617374,Autocuration,,,H,,F,2487,,,,1,,,
,13481,8,BAO_0000019,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,227,,,CHEMBL617375,Autocuration,,,H,,F,2488,,,,1,,,
,14093,8,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,227,,,CHEMBL617376,Autocuration,,,H,,F,2489,,,,1,,,
,14093,8,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,227,,,CHEMBL617377,Autocuration,,,H,,F,2490,,,,1,,,
,14093,8,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,227,,,CHEMBL617378,Autocuration,,,H,,F,2491,,,,1,,,
,13481,8,BAO_0000019,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,227,,,CHEMBL617379,Autocuration,,,H,,F,2492,,,,1,,,
,14442,8,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,227,,,CHEMBL617380,Autocuration,,,H,,B,2493,,,,1,,,
,14442,8,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,227,,,CHEMBL617381,Autocuration,,,H,,B,2494,,,,1,,,
,14442,8,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,227,,,CHEMBL617382,Autocuration,,,H,,B,2495,,,,1,,,
,12369,8,BAO_0000357,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617383,Autocuration,,,H,,B,2496,,,,1,,,
,12369,8,BAO_0000357,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,107,,,CHEMBL617384,Expert,,,H,,B,2497,,,,1,,,
,12369,8,BAO_0000357,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,107,,,CHEMBL617385,Expert,,,H,,B,2498,,,,1,,,
,14447,8,BAO_0000019,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,107,,,CHEMBL617386,Autocuration,,,H,,B,2499,,,,1,,,
,14447,8,BAO_0000019,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,107,,,CHEMBL617387,Autocuration,,,H,,B,2500,,,,1,,,
,17451,8,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,107,,,CHEMBL617388,Autocuration,,,H,,B,2501,,723.0,,1,,,NIH3T3
,6857,8,BAO_0000219,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,107,,,CHEMBL617389,Autocuration,,,H,,F,2502,,449.0,,1,,,CHO
,6857,9,BAO_0000219,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,107,,,CHEMBL617390,Expert,9606.0,,D,,F,2503,,449.0,Homo sapiens,1,,,CHO
,5635,4,BAO_0000224,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,104817,,,CHEMBL617391,Autocuration,,,H,,B,2504,,,,1,,,
,12861,8,BAO_0000357,Binding activity radioligand.,107,,,CHEMBL617392,Autocuration,,,H,,B,2505,,,,1,,,
,12861,8,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,107,,,CHEMBL617393,Autocuration,,,H,,B,2506,,,,1,,,
,5105,8,BAO_0000219,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,107,,,CHEMBL617394,Autocuration,,,H,,B,2507,,307.0,,1,,,L929
,5104,8,BAO_0000219,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,107,,,CHEMBL617395,Expert,,,H,,B,2508,,307.0,,1,,,L929
,5105,8,BAO_0000219,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,107,,,CHEMBL617396,Expert,,,H,,B,2509,,307.0,,1,,,L929
,5105,8,BAO_0000219,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,107,,,CHEMBL617397,Autocuration,,,H,,B,2510,,307.0,,1,,,L929
,5254,8,BAO_0000357,Binding affinity against 5-HT2A receptor,107,,,CHEMBL617398,Autocuration,,,H,,B,2511,,,,1,,,
,5254,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor,107,,,CHEMBL617399,Autocuration,,,H,,B,2512,,,,1,,,
,13267,8,BAO_0000219,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,107,,,CHEMBL617400,Autocuration,,,H,,B,2513,,722.0,,1,,,HEK293
,13267,8,BAO_0000219,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,107,,,CHEMBL617401,Autocuration,,,H,,B,2514,,722.0,,1,,,HEK293
,14157,9,BAO_0000219,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,107,,,CHEMBL617402,Expert,9606.0,,D,,B,2515,,722.0,Homo sapiens,1,,,HEK293
,12936,9,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,,,CHEMBL617403,Expert,9606.0,,D,,B,2516,,722.0,Homo sapiens,1,,,HEK293
,14068,8,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,107,,,CHEMBL617404,Expert,,,H,,B,2517,,,,1,,,
,12936,9,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,,,CHEMBL857981,Expert,9606.0,,D,,B,2518,,722.0,Homo sapiens,1,,,HEK293
,12936,9,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,,,CHEMBL617405,Expert,9606.0,,D,,B,2519,,722.0,Homo sapiens,1,,,HEK293
,4540,9,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,107,,,CHEMBL617253,Expert,9606.0,,D,,B,2520,,722.0,Homo sapiens,1,,,HEK293
,6166,8,BAO_0000357,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,107,,,CHEMBL617254,Expert,,,H,,B,2521,,,,1,,,
,17296,8,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,107,,,CHEMBL617255,Autocuration,,,H,,B,2522,,722.0,,1,,,HEK293
,17296,8,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,107,,,CHEMBL617256,Autocuration,,,H,,B,2523,,722.0,,1,,,HEK293
,17296,8,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,107,,,CHEMBL616874,Autocuration,,,H,,B,2524,,722.0,,1,,,HEK293
,15779,9,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,107,,,CHEMBL616875,Expert,9606.0,,D,,B,2525,,722.0,Homo sapiens,1,,,HEK293
,14391,8,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,107,,,CHEMBL616876,Expert,,,H,,B,2526,,722.0,,1,,,HEK293
,15851,8,BAO_0000219,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",107,,,CHEMBL616877,Expert,,,H,,B,2527,,722.0,,1,,,HEK293
,15851,9,BAO_0000219,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,107,,,CHEMBL616878,Expert,9606.0,,D,,B,2528,,722.0,Homo sapiens,1,,,HEK293
,3832,8,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,107,,,CHEMBL616879,Expert,,,H,,B,2529,,722.0,,1,,,HEK293
,3833,8,BAO_0000219,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,107,,,CHEMBL616880,Expert,,,H,,B,2530,,722.0,,1,,,HEK293
,12936,9,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,,,CHEMBL616881,Expert,9606.0,,D,,B,2531,,722.0,Homo sapiens,1,,,HEK293
,17451,8,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,107,,,CHEMBL616882,Autocuration,,,H,,B,2532,,723.0,,1,,,NIH3T3
,17451,8,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,107,,,CHEMBL616883,Autocuration,,,H,,B,2533,,723.0,,1,,,NIH3T3
,17451,8,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,107,,,CHEMBL616884,Autocuration,,,H,,B,2534,,723.0,,1,,,NIH3T3
,4199,8,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,107,,,CHEMBL616885,Autocuration,,,H,,B,2535,,722.0,,1,,,HEK293
,1883,8,BAO_0000219,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,107,,,CHEMBL616886,Autocuration,,,H,,B,2536,,485.0,,1,,,CHO-K1
,1883,8,BAO_0000219,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,107,,,CHEMBL616887,Expert,,,H,,B,2537,,485.0,,1,,,CHO-K1
,14875,9,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 2A receptor,107,,,CHEMBL616888,Expert,9606.0,,D,,B,2538,,,Homo sapiens,1,,,
,15146,8,BAO_0000219,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,107,,,CHEMBL616889,Autocuration,,,H,,B,2539,,722.0,,1,,,HEK293
,5213,8,BAO_0000219,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,107,,,CHEMBL616890,Autocuration,,,H,,B,2540,,722.0,,1,,,HEK293
,16404,9,BAO_0000219,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,107,,,CHEMBL616891,Expert,9606.0,,D,,B,2541,,449.0,Homo sapiens,1,,,CHO
,14818,8,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,107,,,CHEMBL616892,Autocuration,,,H,,B,2542,,722.0,,1,,,HEK293
,4829,8,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",107,,,CHEMBL616893,Autocuration,,,H,,B,2543,,722.0,,1,,,HEK293
,12652,8,BAO_0000219,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,10620,,,CHEMBL616894,Autocuration,,,H,,F,2544,,723.0,,1,,,NIH3T3
,4682,8,BAO_0000219,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,107,,,CHEMBL616895,Expert,,,H,,B,2545,,723.0,,1,,,NIH3T3
,12652,8,BAO_0000019,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,10620,,,CHEMBL616896,Autocuration,,,H,,F,2546,,,,1,,,
,4921,8,BAO_0000357,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,10621,,,CHEMBL617099,Autocuration,,,H,,B,2547,,,,1,,,
,4921,8,BAO_0000357,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,10621,,,CHEMBL617100,Autocuration,,,H,,B,2548,,,,1,,,
,16312,8,BAO_0000357,Binding affinity against rabbit aorta 5-HT2A receptor,107,,,CHEMBL884532,Autocuration,9986.0,,H,,B,2549,,,Oryctolagus cuniculus,1,,,
,14998,8,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,107,,,CHEMBL617101,Expert,9986.0,,H,,B,2550,,,Oryctolagus cuniculus,1,,,
,14025,8,BAO_0000357,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,107,,,CHEMBL617102,Expert,9986.0,,H,,B,2551,,,Oryctolagus cuniculus,1,,,
,13047,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,107,,,CHEMBL617103,Autocuration,9986.0,,H,,B,2552,,,Oryctolagus cuniculus,1,,,
,13047,8,BAO_0000357,The compound was tested for binding affinity against 5-HT2A receptor,107,,,CHEMBL617104,Expert,9986.0,,H,,B,2553,,,Oryctolagus cuniculus,1,,,
,1883,8,BAO_0000219,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,10576,,,CHEMBL857979,Autocuration,,,H,,B,2554,,485.0,,1,,,CHO-K1
,13463,8,BAO_0000019,Binding affinity analysed towards 5-HT 2A in rat jugular vein,12687,,,CHEMBL857502,Autocuration,,,H,,B,2555,,,,1,,,
,13463,8,BAO_0000019,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,12687,,,CHEMBL617105,Autocuration,,,H,,B,2556,,,,1,,,
,13463,8,BAO_0000019,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,12687,,Stomach,CHEMBL858021,Autocuration,,,H,,B,2557,,,,1,,945.0,
,13463,9,BAO_0000019,Binding affinity for 5-HT 2A in rat stomach fundus,12687,,Stomach,CHEMBL875910,Expert,10116.0,,D,,B,2558,,,Rattus norvegicus,1,,945.0,
,13463,8,BAO_0000019,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,12687,,,CHEMBL617106,Autocuration,,,H,,B,2559,,,,1,,,
,16326,8,BAO_0000219,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL617107,Expert,,,H,,B,2560,,723.0,,1,,,NIH3T3
,14093,8,BAO_0000019,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL617108,Autocuration,,,H,,F,2561,,,,1,,,
,14093,8,BAO_0000019,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL617109,Autocuration,,,H,,F,2562,,,,1,,,
,15740,8,BAO_0000357,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL617110,Autocuration,,,H,,B,2563,,,,1,,,
,16633,8,BAO_0000357,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,12687,,,CHEMBL617111,Autocuration,,,H,,B,2564,,,,1,,,
,17200,9,BAO_0000019,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,12687,,,CHEMBL617112,Expert,10116.0,,D,,F,2565,,,Rattus norvegicus,1,,,
,17133,8,BAO_0000357,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL617113,Autocuration,,,H,,B,2566,,,,1,,,
,17133,8,BAO_0000357,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL617114,Autocuration,,,H,,B,2567,,,,1,,,
,17133,8,BAO_0000357,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL617115,Autocuration,,,H,,B,2568,,,,1,,,
,17200,8,BAO_0000219,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,12687,,,CHEMBL617116,Autocuration,,,H,,F,2569,,,,1,,,
,15363,8,BAO_0000019,Efficacy at 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL617117,Autocuration,,,H,,F,2570,,,,1,,,
,17200,8,BAO_0000357,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),12687,,,CHEMBL617118,Autocuration,,,H,,B,2571,,,,1,,,
,17200,9,BAO_0000357,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),12687,,,CHEMBL617119,Expert,10116.0,,D,,B,2572,,,Rattus norvegicus,1,,,
,17200,9,BAO_0000357,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),12687,,,CHEMBL617120,Expert,10116.0,,D,,B,2573,,,Rattus norvegicus,1,,,
,17200,9,BAO_0000219,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,12687,,,CHEMBL617121,Expert,10116.0,,D,,F,2574,,,Rattus norvegicus,1,,,
,17200,8,BAO_0000219,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,12687,,,CHEMBL617122,Autocuration,,,H,,F,2575,,,,1,,,
,17211,8,BAO_0000019,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL617123,Autocuration,,,H,,B,2576,,,,1,,,
,17331,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,12687,,,CHEMBL617124,Expert,,,H,,B,2577,,,,1,,,
,13565,8,BAO_0000249,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,12687,,,CHEMBL617600,Expert,,,H,,B,2578,,,,1,,,
,13730,8,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,12687,,,CHEMBL617601,Expert,,,H,,B,2579,,,,1,,,
,12416,8,BAO_0000019,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,12687,,,CHEMBL882923,Expert,,,H,,B,2580,,,,1,,,
,15295,8,BAO_0000357,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL617602,Autocuration,,,H,,B,2581,,,,1,,,
,1742,8,BAO_0000019,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,12687,,,CHEMBL617603,Autocuration,,,H,,B,2582,,,,1,,,
,15295,8,BAO_0000357,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL617604,Autocuration,,,H,,B,2583,,,,1,,,
,14970,8,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,12687,,,CHEMBL617605,Expert,,,H,,B,2584,,,,1,,,
,16693,8,BAO_0000019,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,12687,,,CHEMBL617606,Expert,,,H,,B,2585,,,,1,,,
,14776,9,BAO_0000019,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL617607,Expert,10116.0,,D,,B,2586,,,Rattus norvegicus,1,,,
,14286,8,BAO_0000249,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,,CHEMBL617455,Autocuration,,,H,,B,2587,,,,1,,,
,17200,9,BAO_0000019,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,12687,,,CHEMBL617456,Expert,10116.0,,D,,B,2588,,,Rattus norvegicus,1,,,
,15306,8,BAO_0000357,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),12687,,,CHEMBL617457,Expert,,,H,,B,2589,,,,1,,,
,14178,9,BAO_0000357,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL617458,Expert,10116.0,,D,,B,2590,,,Rattus norvegicus,1,,,
,14229,9,BAO_0000019,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,12687,,,CHEMBL617459,Expert,10116.0,,D,,B,2591,,,Rattus norvegicus,1,,,
,12884,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,12687,,,CHEMBL617460,Expert,,,H,,B,2592,,,,1,,,
,13149,8,BAO_0000357,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",12687,,,CHEMBL617461,Expert,,,H,,B,2593,,,,1,,,
,15295,9,BAO_0000019,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,12687,,,CHEMBL617462,Expert,10116.0,,D,,B,2594,,,Rattus norvegicus,1,,,
,15740,8,BAO_0000357,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,12687,,,CHEMBL617463,Autocuration,,,H,,B,2595,,,,1,,,
,15185,8,BAO_0000019,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",12687,,,CHEMBL617464,Autocuration,,,H,,B,2596,,,,1,,,
,15185,8,BAO_0000019,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",12687,,,CHEMBL617465,Autocuration,,,H,,B,2597,,,,1,,,
,17529,8,BAO_0000019,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,12687,,,CHEMBL617466,Expert,,,H,,B,2598,,,,1,,,
,14826,8,BAO_0000019,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,12687,,,CHEMBL617467,Autocuration,,,H,,B,2599,,,,1,,,
,17211,8,BAO_0000019,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,12687,,,CHEMBL617468,Expert,,,H,,B,2600,,,,1,,,
,14826,8,BAO_0000019,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,12687,,,CHEMBL617469,Autocuration,,,H,,B,2601,,,,1,,,
,14093,8,BAO_0000019,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL617470,Autocuration,,,H,,B,2602,,,,1,,,
,14093,8,BAO_0000019,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,12687,,,CHEMBL617471,Autocuration,,,H,,B,2603,,,,1,,,
,13246,8,BAO_0000219,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,12687,,,CHEMBL617472,Expert,,,H,,B,2604,,723.0,,1,,,NIH3T3
,13246,8,BAO_0000357,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,12687,,,CHEMBL617473,Expert,,,H,,B,2605,,,,1,,,
,15436,9,BAO_0000019,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,12687,,,CHEMBL617474,Expert,10116.0,,D,,B,2606,,,Rattus norvegicus,1,,,
,15436,9,BAO_0000019,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,12687,,,CHEMBL617475,Expert,10116.0,,D,,B,2607,,,Rattus norvegicus,1,,,
,14442,8,BAO_0000221,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,12687,,Brain,CHEMBL617476,Autocuration,,,H,,B,2608,,,,1,,955.0,
,12457,8,BAO_0000357,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL617477,Expert,,,H,,B,2609,,,,1,,,
,12457,8,BAO_0000219,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL617478,Expert,,,H,,B,2610,,723.0,,1,,,NIH3T3
,14755,8,BAO_0000221,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",12687,,,CHEMBL617479,Autocuration,,,H,,F,2611,,,,1,,,
,4707,8,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,12687,,,CHEMBL617480,Autocuration,,,H,,B,2612,,,,1,,,
,13297,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL617481,Expert,,,H,,B,2613,,,,1,,,
,17331,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,12687,,,CHEMBL617482,Expert,,,H,,B,2614,,,,1,,,
,4664,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,12687,,,CHEMBL617483,Autocuration,,,H,,B,2615,,,,1,,,
,16633,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,12687,,,CHEMBL621528,Autocuration,,,H,,B,2616,,,,1,,,
,4664,9,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,12687,,,CHEMBL621529,Expert,10116.0,,D,,B,2617,,723.0,Rattus norvegicus,1,,,NIH3T3
,16133,8,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,12687,,,CHEMBL621530,Expert,,,H,,B,2618,,,,1,,,
,16133,8,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,,,CHEMBL621531,Expert,,,H,,B,2619,,,,1,,,
,14060,9,BAO_0000019,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL621532,Expert,10116.0,,D,,B,2620,,,Rattus norvegicus,1,,,
,16326,8,BAO_0000357,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,12687,,,CHEMBL621533,Expert,,,H,,B,2621,,,,1,,,
,16659,8,BAO_0000219,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,12687,,,CHEMBL621534,Expert,,,H,,B,2622,,449.0,,1,,,CHO
,14776,8,BAO_0000019,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,12687,,,CHEMBL621535,Autocuration,,,H,,B,2623,,,,1,,,
,13481,8,BAO_0000357,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,12687,,,CHEMBL621536,Autocuration,,,H,,B,2624,,,,1,,,
,17386,8,BAO_0000357,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL621537,Autocuration,,,H,,B,2625,,,,1,,,
,6611,9,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL621538,Expert,10116.0,,D,,B,2626,,,Rattus norvegicus,1,,,
,14423,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,12687,,,CHEMBL621539,Autocuration,,,H,,B,2627,,,,1,,,
,15412,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,12687,,,CHEMBL621540,Autocuration,,,H,,B,2628,,,,1,,,
,15412,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,12687,,,CHEMBL621541,Autocuration,,,H,,B,2629,,,,1,,,
,6238,8,BAO_0000019,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,12687,,,CHEMBL621542,Autocuration,,,H,,B,2630,,,,1,,,
,6648,8,BAO_0000357,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,12687,,,CHEMBL621543,Expert,,,H,,B,2631,,,,1,,,
,5667,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,12687,,,CHEMBL621544,Expert,,,H,,B,2632,,,,1,,,
,6611,9,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,12687,,,CHEMBL621545,Expert,10116.0,,D,,B,2633,,,Rattus norvegicus,1,,,
,13481,8,BAO_0000357,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,,,CHEMBL621546,Autocuration,,,H,,B,2634,,,,1,,,
,13481,8,BAO_0000357,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,12687,,,CHEMBL621547,Autocuration,,,H,,B,2635,,,,1,,,
,15558,8,BAO_0000219,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL618692,Expert,,,H,,B,2636,,723.0,,1,,,NIH3T3
,6013,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL618693,Autocuration,,,H,,B,2637,,,,1,,,
,16633,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,12687,,,CHEMBL872922,Autocuration,,,H,,B,2638,,,,1,,,
,6013,8,BAO_0000357,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,12687,,,CHEMBL618694,Autocuration,,,H,,B,2639,,,,1,,,
,6013,9,BAO_0000357,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,12687,,,CHEMBL618695,Expert,10116.0,,D,,B,2640,,,Rattus norvegicus,1,,,
,6013,8,BAO_0000357,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,12687,,,CHEMBL618696,Autocuration,,,H,,B,2641,,,,1,,,
,6013,8,BAO_0000357,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,12687,,,CHEMBL618697,Expert,,,H,,B,2642,,,,1,,,
,6013,8,BAO_0000357,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,12687,,,CHEMBL618892,Autocuration,,,H,,B,2643,,,,1,,,
,6013,8,BAO_0000357,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,12687,,,CHEMBL618893,Autocuration,,,H,,B,2644,,,,1,,,
,16293,8,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL618894,Autocuration,,,H,,B,2645,,,,1,,,
,17175,8,BAO_0000219,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,12687,,,CHEMBL618895,Expert,,,H,,B,2646,,723.0,,1,,,NIH3T3
,13278,9,BAO_0000357,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,12687,,,CHEMBL618896,Expert,10116.0,,D,,B,2647,,,Rattus norvegicus,1,,,
,3682,8,BAO_0000019,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,12687,,Caudate-putamen,CHEMBL618897,Autocuration,,,H,,B,2648,,,,1,,5383.0,
,2014,8,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,12687,,,CHEMBL618898,Autocuration,,,H,,B,2649,,,,1,,,
,2014,8,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,12687,,,CHEMBL618899,Autocuration,,,H,,B,2650,,,,1,,,
,4932,8,BAO_0000357,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,12687,,,CHEMBL618900,Autocuration,,,H,,B,2651,,,,1,,,
,4932,8,BAO_0000019,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,12687,,,CHEMBL618901,Autocuration,,,H,,B,2652,,,,1,,,
,3935,8,BAO_0000357,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL618902,Autocuration,,,H,,B,2653,,,,1,,,
,5432,9,BAO_0000221,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,12687,,Hippocampus,CHEMBL618903,Expert,10116.0,,D,,B,2654,,,Rattus norvegicus,1,,10000000.0,
,15818,8,BAO_0000357,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL618904,Autocuration,,,H,,B,2655,,,,1,,,
,13672,8,BAO_0000357,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,12687,,,CHEMBL618905,Autocuration,,,H,,B,2656,,,,1,,,
,13672,8,BAO_0000357,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,12687,,,CHEMBL618906,Autocuration,,,H,,B,2657,,,,1,,,
,14749,8,BAO_0000219,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,12687,,,CHEMBL618907,Expert,,,H,,B,2658,,723.0,,1,,,NIH3T3
,13462,8,BAO_0000019,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,12687,,,CHEMBL618908,Autocuration,,,H,,B,2659,,,,1,,,
,15740,8,BAO_0000357,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL617909,Autocuration,,,H,,B,2660,,,,1,,,
,16647,8,BAO_0000019,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,12687,,,CHEMBL617910,Expert,,,H,,B,2661,,,,1,,,
,13345,8,BAO_0000221,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,12687,,Brain,CHEMBL617911,Autocuration,,,H,,B,2662,,,,1,,955.0,
,16740,8,BAO_0000249,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,,CHEMBL872923,Autocuration,,,H,,B,2663,,,,1,,,
,16740,8,BAO_0000249,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,,CHEMBL617912,Autocuration,,,H,,B,2664,,,,1,,,
,15535,9,BAO_0000019,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,12687,,,CHEMBL617913,Expert,10116.0,,D,,B,2665,,,Rattus norvegicus,1,,,
,16740,8,BAO_0000249,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,,CHEMBL617914,Expert,,,H,,B,2666,,,,1,,,
,16740,8,BAO_0000249,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,,CHEMBL617915,Autocuration,,,H,,B,2667,,,,1,,,
,16740,8,BAO_0000249,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,,CHEMBL617916,Autocuration,,,H,,B,2668,,,,1,,,
,4795,9,BAO_0000019,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL617917,Expert,10116.0,,D,,B,2669,,,Rattus norvegicus,1,,,
,8,8,BAO_0000019,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,12687,,,CHEMBL617918,Expert,,,H,,B,2670,,,,1,,,
,8,8,BAO_0000019,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,12687,,,CHEMBL617919,Autocuration,,,H,,B,2671,,,,1,,,
,17200,9,BAO_0000019,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,12687,,,CHEMBL617920,Expert,10116.0,,D,,B,2672,,,Rattus norvegicus,1,,,
,2148,9,BAO_0000019,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,12687,,,CHEMBL617921,Expert,10116.0,,D,,B,2673,,,Rattus norvegicus,1,,,
,13345,5,BAO_0000224,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",105102,,,CHEMBL617922,Expert,10116.0,,D,,B,2674,,,Rattus norvegicus,1,,,
,5088,8,BAO_0000357,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,12687,,,CHEMBL617923,Autocuration,,,H,,B,2675,,,,1,,,
,5088,8,BAO_0000357,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,,,CHEMBL617924,Autocuration,,,H,,B,2676,,,,1,,,
,17133,8,BAO_0000357,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,12687,,,CHEMBL617925,Autocuration,,,H,,B,2677,,,,1,,,
,17133,9,BAO_0000357,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,12687,,,CHEMBL617926,Expert,10116.0,,D,,B,2678,,,Rattus norvegicus,1,,,
,16532,8,BAO_0000357,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,12687,,,CHEMBL617927,Autocuration,,,H,,B,2679,,,,1,,,
,15086,8,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,12687,,,CHEMBL617928,Autocuration,,,H,,B,2680,,,,1,,,
,2309,9,BAO_0000019,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,,,CHEMBL617929,Expert,10116.0,,D,,B,2681,,,Rattus norvegicus,1,,,
,12953,8,BAO_0000019,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,12687,,,CHEMBL617930,Expert,,,H,,B,2682,,,,1,,,
,12953,8,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,12687,,,CHEMBL617931,Autocuration,,,H,,B,2683,,,,1,,,
,12953,8,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,12687,,,CHEMBL617932,Autocuration,,,H,,B,2684,,,,1,,,
,16659,8,BAO_0000219,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,12687,,,CHEMBL617933,Autocuration,,,H,,B,2685,,449.0,,1,,,CHO
,16740,8,BAO_0000019,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,12687,,,CHEMBL617934,Autocuration,,,H,,B,2686,,,,1,,,
,16740,8,BAO_0000019,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,12687,,,CHEMBL617935,Autocuration,,,H,,B,2687,,,,1,,,
,17133,8,BAO_0000357,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,12687,,,CHEMBL617936,Autocuration,,,H,,B,2688,,,,1,,,
,17211,8,BAO_0000019,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,12687,,,CHEMBL617937,Autocuration,,,H,,B,2689,,,,1,,,
,17331,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,12687,,,CHEMBL617938,Autocuration,,,H,,B,2690,,,,1,,,
,16633,8,BAO_0000218,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,12687,,,CHEMBL617939,Autocuration,,,H,,B,2691,,,,1,,,
,16633,8,BAO_0000218,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,12687,,,CHEMBL617940,Autocuration,,,H,,B,2692,,,,1,,,
,16633,8,BAO_0000218,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,12687,,,CHEMBL617941,Autocuration,,,H,,B,2693,,,,1,,,
,15026,8,BAO_0000357,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,12687,,,CHEMBL617942,Expert,,,H,,B,2694,,,,1,,,
,15026,8,BAO_0000357,Ratio of pKi of 5-HT2A to that of D2 receptor,12687,,,CHEMBL617943,Expert,,,H,,B,2695,,,,1,,,
,16404,4,BAO_0000224,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,105093,,,CHEMBL617944,Expert,,,H,,B,2696,,,,1,,,
,16404,4,BAO_0000224,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,105093,,,CHEMBL617945,Expert,,,H,,B,2697,,,,1,,,
,16404,4,BAO_0000224,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,105075,,,CHEMBL617946,Expert,,,H,,B,2698,,,,1,,,
,16404,8,BAO_0000357,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,12687,,,CHEMBL617947,Autocuration,,,H,,B,2699,,,,1,,,
,16326,8,BAO_0000357,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,12687,,,CHEMBL617948,Expert,,,H,,B,2700,,,,1,,,
,15847,8,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,12687,,,CHEMBL858116,Autocuration,,,H,,F,2701,,,,1,,,
,15847,8,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,12687,,,CHEMBL617949,Autocuration,,,H,,F,2702,,,,1,,,
,15329,8,BAO_0000019,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,12687,,,CHEMBL617950,Autocuration,,,H,,F,2703,,,,1,,,
,16404,8,BAO_0000019,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,12687,,Thoracic aorta,CHEMBL617951,Expert,,,H,,F,2704,,,,1,,1515.0,
,16404,8,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,12687,,Thoracic aorta,CHEMBL617952,Expert,,,H,,F,2705,,,,1,,1515.0,
,16404,8,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,12687,,Thoracic aorta,CHEMBL617953,Autocuration,,,H,,F,2706,,,,1,,1515.0,
,12861,8,BAO_0000357,Binding activity radioligand.,12687,,,CHEMBL617954,Autocuration,,,H,,B,2707,,,,1,,,
,12861,8,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,12687,,,CHEMBL617955,Expert,,,H,,B,2708,,,,1,,,
,12861,8,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,12687,,,CHEMBL857071,Autocuration,,,H,,B,2709,,,,1,,,
,12490,8,BAO_0000019,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,12687,,,CHEMBL617270,Expert,,,H,,B,2710,,,,1,,,
,12827,8,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,12687,,,CHEMBL617271,Autocuration,,,H,,B,2711,,339.0,,1,,,N1E-115
,12827,8,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,12687,,,CHEMBL617272,Autocuration,,,H,,B,2712,,339.0,,1,,,N1E-115
,12918,8,BAO_0000019,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,12687,,,CHEMBL617273,Autocuration,,,H,,B,2713,,,,1,,,
,12919,9,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,12687,,,CHEMBL617274,Expert,10116.0,,D,,F,2714,,,Rattus norvegicus,1,,,
,17723,8,BAO_0000357,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,108,,,CHEMBL617275,Autocuration,,,H,,B,2715,,,,1,,,
,6013,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor,108,,,CHEMBL617276,Autocuration,,,H,,B,2716,,,,1,,,
,16293,8,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 2C receptor,108,,,CHEMBL617277,Autocuration,,,H,,B,2717,,,,1,,,
,3857,8,BAO_0000019,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,108,,,CHEMBL617278,Expert,,,H,,B,2718,,,,1,,,
,3857,8,BAO_0000019,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,108,,,CHEMBL617279,Expert,,,H,,B,2719,,,,1,,,
,3857,8,BAO_0000019,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,108,,,CHEMBL617280,Expert,,,H,,B,2720,,,,1,,,
,15363,8,BAO_0000357,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,108,,,CHEMBL617281,Autocuration,,,H,,B,2721,,,,1,,,
,15363,8,BAO_0000357,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,108,,,CHEMBL617282,Autocuration,,,H,,B,2722,,,,1,,,
,16441,8,BAO_0000019,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,108,,,CHEMBL617283,Expert,,,H,,B,2723,,,,1,,,
,16441,8,BAO_0000019,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,108,,,CHEMBL617284,Expert,,,H,,B,2724,,,,1,,,
,4176,8,BAO_0000219,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,108,,,CHEMBL617285,Autocuration,,,H,,B,2725,,722.0,,1,,,HEK293
,17085,8,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,108,,,CHEMBL617286,Autocuration,,,H,,B,2726,,,,1,,,
,17200,9,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,108,,,CHEMBL617287,Expert,9606.0,,D,,B,2727,,,Homo sapiens,1,,,
,5088,8,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,108,,,CHEMBL617288,Expert,,,H,,B,2728,,,,1,,,
,5088,8,BAO_0000357,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,108,,,CHEMBL617289,Autocuration,,,H,,B,2729,,,,1,,,
,5088,8,BAO_0000357,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,108,,,CHEMBL872917,Autocuration,,,H,,B,2730,,,,1,,,
,5088,8,BAO_0000357,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,108,,,CHEMBL617290,Autocuration,,,H,,B,2731,,,,1,,,
,16659,8,BAO_0000219,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,108,,,CHEMBL617291,Autocuration,,,H,,B,2732,,449.0,,1,,,CHO
,16659,8,BAO_0000219,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,108,,,CHEMBL617292,Autocuration,,,H,,B,2733,,449.0,,1,,,CHO
,17451,8,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,108,,,CHEMBL617293,Autocuration,,,H,,B,2734,,723.0,,1,,,NIH3T3
,6857,9,BAO_0000219,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,108,,,CHEMBL617294,Expert,9606.0,,D,,F,2735,,449.0,Homo sapiens,1,,,CHO
,3857,8,BAO_0000019,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,108,,,CHEMBL617295,Expert,,,H,,B,2736,,,,1,,,
,12861,8,BAO_0000357,Binding activity radioligand.,108,,,CHEMBL617296,Autocuration,,,H,,B,2737,,,,1,,,
,12861,8,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,108,,,CHEMBL617297,Autocuration,,,H,,B,2738,,,,1,,,
,5104,8,BAO_0000219,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,108,,,CHEMBL617298,Expert,,,H,,B,2739,,449.0,,1,,,CHO
,5105,8,BAO_0000219,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,108,,,CHEMBL617299,Expert,,,H,,B,2740,,449.0,,1,,,CHO
,5105,8,BAO_0000219,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,108,,,CHEMBL617300,Autocuration,,,H,,B,2741,,449.0,,1,,,CHO
,5254,8,BAO_0000357,Binding affinity against 5-HT2C receptor,108,,,CHEMBL617454,Autocuration,,,H,,B,2742,,,,1,,,
,13267,8,BAO_0000219,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,108,,,CHEMBL617505,Autocuration,,,H,,B,2743,,722.0,,1,,,HEK293
,14157,9,BAO_0000219,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,108,,,CHEMBL617506,Expert,9606.0,,D,,B,2744,,722.0,Homo sapiens,1,,,HEK293
,12936,9,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,108,,,CHEMBL617507,Expert,9606.0,,D,,B,2745,,722.0,Homo sapiens,1,,,HEK293
,14068,8,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,108,,,CHEMBL617508,Expert,,,H,,B,2746,,,,1,,,
,12936,9,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,108,,,CHEMBL857982,Expert,9606.0,,D,,B,2747,,722.0,Homo sapiens,1,,,HEK293
,4540,9,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,108,,,CHEMBL617509,Expert,9606.0,,D,,B,2748,,722.0,Homo sapiens,1,,,HEK293
,4540,9,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,108,,,CHEMBL617510,Expert,9606.0,,D,,B,2749,,722.0,Homo sapiens,1,,,HEK293
,6166,8,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,108,,,CHEMBL617511,Autocuration,,,H,,B,2750,,,,1,,,
,17296,8,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,108,,,CHEMBL617512,Autocuration,,,H,,B,2751,,722.0,,1,,,HEK293
,17296,8,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,108,,,CHEMBL617749,Autocuration,,,H,,B,2752,,722.0,,1,,,HEK293
,15779,8,BAO_0000219,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,108,,,CHEMBL617750,Autocuration,,,H,,B,2753,,722.0,,1,,,HEK293
,15779,8,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,108,,,CHEMBL617751,Autocuration,,,H,,B,2754,,722.0,,1,,,HEK293
,14391,8,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,108,,,CHEMBL617752,Expert,,,H,,B,2755,,722.0,,1,,,HEK293
,15779,8,BAO_0000219,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",108,,,CHEMBL617753,Autocuration,,,H,,B,2756,,722.0,,1,,,HEK293
,15851,8,BAO_0000219,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",108,,,CHEMBL617754,Expert,,,H,,B,2757,,722.0,,1,,,HEK293
,15851,9,BAO_0000219,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,108,,,CHEMBL617755,Expert,9606.0,,D,,B,2758,,722.0,Homo sapiens,1,,,HEK293
,15779,8,BAO_0000219,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",108,,,CHEMBL617756,Autocuration,,,H,,B,2759,,722.0,,1,,,HEK293
,3832,8,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,108,,,CHEMBL617757,Expert,,,H,,B,2760,,722.0,,1,,,HEK293
,3833,8,BAO_0000219,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,108,,,CHEMBL617758,Expert,,,H,,B,2761,,722.0,,1,,,HEK293
,17451,8,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,108,,,CHEMBL617759,Autocuration,,,H,,B,2762,,723.0,,1,,,NIH3T3
,4199,8,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,108,,,CHEMBL617760,Autocuration,,,H,,B,2763,,722.0,,1,,,HEK293
,1883,8,BAO_0000219,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,108,,,CHEMBL617761,Expert,,,H,,B,2764,,485.0,,1,,,CHO-K1
,4321,9,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2C receptor,108,,,CHEMBL617762,Expert,9606.0,,D,,B,2765,,,Homo sapiens,1,,,
,14875,8,BAO_0000357,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,108,,,CHEMBL617763,Autocuration,,,H,,B,2766,,,,1,,,
,15146,8,BAO_0000219,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,108,,,CHEMBL857983,Autocuration,,,H,,B,2767,,722.0,,1,,,HEK293
,5213,8,BAO_0000219,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,108,,,CHEMBL617764,Autocuration,,,H,,B,2768,,722.0,,1,,,HEK293
,16404,8,BAO_0000219,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,108,,,CHEMBL617765,Autocuration,,,H,,B,2769,,308.0,,1,,,HeLa
,13267,8,BAO_0000019,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,108,,,CHEMBL617766,Autocuration,,,H,,F,2770,,,,1,,,
,13267,8,BAO_0000221,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,108,,Hippocampus,CHEMBL617767,Autocuration,,,H,,F,2771,,,,1,,10000000.0,
,14818,8,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,108,,,CHEMBL617768,Autocuration,,,H,,B,2772,,722.0,,1,,,HEK293
,4829,8,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",108,,,CHEMBL617769,Autocuration,,,H,,B,2773,,722.0,,1,,,HEK293
,13463,8,BAO_0000357,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,11864,,,CHEMBL858023,Autocuration,,,H,,B,2774,,,,1,,,
,13463,8,BAO_0000019,Binding affinity analysed on 5-HT 2C in rat stomach fundus,11864,,Stomach,CHEMBL617770,Autocuration,,,H,,B,2775,,,,1,,945.0,
,13463,8,BAO_0000019,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,11864,,Stomach,CHEMBL617771,Autocuration,,,H,,B,2776,,,,1,,945.0,
,12652,8,BAO_0000219,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,11864,,,CHEMBL617772,Autocuration,,,H,,F,2777,,625.0,,1,,,A9
,4682,8,BAO_0000219,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,11864,,,CHEMBL617773,Autocuration,,,H,,B,2778,,723.0,,1,,,NIH3T3
,4682,8,BAO_0000219,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,11864,,,CHEMBL617850,Autocuration,,,H,,B,2779,,723.0,,1,,,NIH3T3
,4682,8,BAO_0000219,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,11864,,,CHEMBL617851,Autocuration,,,H,,B,2780,,723.0,,1,,,NIH3T3
,12652,8,BAO_0000019,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,11864,,,CHEMBL617852,Autocuration,,,H,,F,2781,,,,1,,,
,13463,8,BAO_0000019,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,12689,,Stomach,CHEMBL858024,Autocuration,10090.0,,H,,B,2782,,,Mus musculus,1,,945.0,
,13463,9,BAO_0000019,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,12689,,Stomach,CHEMBL617853,Expert,10116.0,,D,,B,2783,,,Rattus norvegicus,1,,945.0,
,13969,8,BAO_0000357,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,108,,,CHEMBL617854,Expert,,,H,,B,2784,,,,1,,,
,13392,8,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2C receptor,108,,,CHEMBL873477,Expert,9823.0,,H,,B,2785,,,Sus scrofa,1,,,
,13392,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor,108,,,CHEMBL617855,Expert,,,H,,B,2786,,,,1,,,
,14430,8,BAO_0000019,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,108,,,CHEMBL617856,Expert,,,H,,B,2787,,,,1,,,
,1742,8,BAO_0000019,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,108,,,CHEMBL617857,Autocuration,,,H,,B,2788,,,,1,,,
,14286,8,BAO_0000249,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,108,,,CHEMBL617858,Autocuration,,,H,,B,2789,,,,1,,,
,5619,8,BAO_0000357,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,108,,,CHEMBL617859,Autocuration,,,H,,B,2790,,,,1,,,
,15086,8,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,108,,,CHEMBL617860,Autocuration,,,H,,B,2791,,,,1,,,
,12861,8,BAO_0000357,Binding activity radioligand.,108,,,CHEMBL617861,Autocuration,,,H,,B,2792,,,,1,,,
,12861,8,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,108,,,CHEMBL617862,Expert,,,H,,B,2793,,,,1,,,
,12861,8,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,108,,,CHEMBL617863,Autocuration,,,H,,B,2794,,,,1,,,
,12827,8,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,108,,,CHEMBL617864,Autocuration,,,H,,B,2795,,,,1,,,
,12827,8,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,108,,,CHEMBL617649,Autocuration,,,H,,B,2796,,,,1,,,
,12919,8,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,108,,,CHEMBL617650,Expert,9823.0,,H,,F,2797,,,Sus scrofa,1,,,
,12919,8,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,108,,,CHEMBL617651,Expert,9823.0,,H,,F,2798,,,Sus scrofa,1,,,
,16429,8,BAO_0000357,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,108,,,CHEMBL617652,Autocuration,9823.0,,H,,B,2799,,,Sus scrofa,1,,,
,773,8,BAO_0000019,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,108,,,CHEMBL857072,Autocuration,9823.0,,H,,B,2800,,,Sus scrofa,1,,,
,5033,8,BAO_0000357,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,108,,,CHEMBL617653,Autocuration,9823.0,,H,,B,2801,,,Sus scrofa,1,,,
,12861,8,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,12687,,,CHEMBL617654,Autocuration,,,H,,B,2802,,,,1,,,
,14093,8,BAO_0000019,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,12689,,,CHEMBL617655,Autocuration,,,H,,F,2803,,,,1,,,
,14970,8,BAO_0000357,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,12689,,,CHEMBL617656,Expert,,,H,,B,2804,,,,1,,,
,14970,8,BAO_0000357,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,12689,,,CHEMBL617657,Autocuration,,,H,,B,2805,,,,1,,,
,14970,8,BAO_0000357,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,12689,,,CHEMBL617658,Autocuration,,,H,,B,2806,,,,1,,,
,14178,9,BAO_0000357,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,12689,,,CHEMBL617659,Expert,10116.0,,D,,B,2807,,,Rattus norvegicus,1,,,
,14178,9,BAO_0000357,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,12689,,,CHEMBL617838,Expert,10116.0,,D,,B,2808,,,Rattus norvegicus,1,,,
,14229,9,BAO_0000249,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,12689,,,CHEMBL617839,Expert,10116.0,Brain membranes,D,,B,2809,,,Rattus norvegicus,1,,,
,16532,8,BAO_0000357,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,12689,,,CHEMBL617840,Autocuration,,,H,,B,2810,,,,1,,,
,14826,8,BAO_0000019,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,12689,,,CHEMBL617841,Autocuration,,,H,,B,2811,,,,1,,,
,17211,8,BAO_0000019,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,12689,,,CHEMBL875915,Autocuration,,,H,,B,2812,,,,1,,,
,17211,8,BAO_0000219,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,12689,In vitro,,CHEMBL617842,Expert,,,H,,B,2813,,,,1,,,
,13246,8,BAO_0000219,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,12689,,,CHEMBL617843,Expert,,,H,,B,2814,,723.0,,1,,,NIH3T3
,13246,8,BAO_0000357,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,12689,,,CHEMBL617844,Expert,,,H,,B,2815,,,,1,,,
,12457,8,BAO_0000357,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,12689,,,CHEMBL617845,Expert,,,H,,B,2816,,,,1,,,
,12457,8,BAO_0000219,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,12689,,,CHEMBL617846,Expert,,,H,,B,2817,,723.0,,1,,,NIH3T3
,4707,8,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,12689,,,CHEMBL617847,Autocuration,,,H,,B,2818,,,,1,,,
,13297,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2C receptor,12689,,,CHEMBL617848,Expert,,,H,,B,2819,,,,1,,,
,16633,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,12689,,,CHEMBL617849,Autocuration,,,H,,B,2820,,,,1,,,
,16133,8,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,12689,,,CHEMBL621507,Expert,,,H,,B,2821,,,,1,,,
,16326,8,BAO_0000357,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,12689,,,CHEMBL621508,Expert,,,H,,B,2822,,,,1,,,
,14423,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,12689,,,CHEMBL621509,Autocuration,,,H,,B,2823,,,,1,,,
,15412,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,12689,,,CHEMBL621510,Autocuration,,,H,,B,2824,,,,1,,,
,15412,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,12689,,,CHEMBL621511,Autocuration,,,H,,B,2825,,,,1,,,
,15558,8,BAO_0000219,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,12689,,,CHEMBL621512,Expert,,,H,,B,2826,,625.0,,1,,,A9
,16633,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,12689,,,CHEMBL621513,Autocuration,,,H,,B,2827,,,,1,,,
,6013,8,BAO_0000357,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,12689,,,CHEMBL621514,Expert,,,H,,B,2828,,,,1,,,
,17175,8,BAO_0000219,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,12689,In vitro,,CHEMBL621515,Expert,,,H,,B,2829,,,,1,,,
,12469,8,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,12689,,,CHEMBL621516,Autocuration,,,H,,B,2830,,,,1,,,
,3682,8,BAO_0000019,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,12689,,Caudate-putamen,CHEMBL621517,Autocuration,,,H,,B,2831,,,,1,,5383.0,
,4932,8,BAO_0000357,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,12689,,,CHEMBL621518,Autocuration,,,H,,B,2832,,,,1,,,
,4932,8,BAO_0000019,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,12689,,,CHEMBL621519,Autocuration,,,H,,B,2833,,,,1,,,
,3935,8,BAO_0000357,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,12689,,,CHEMBL621520,Autocuration,,,H,,B,2834,,,,1,,,
,15818,8,BAO_0000357,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,12689,,,CHEMBL621521,Autocuration,,,H,,B,2835,,,,1,,,
,15818,8,BAO_0000357,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,12689,,,CHEMBL621522,Autocuration,,,H,,B,2836,,,,1,,,
,14749,8,BAO_0000219,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,12689,,,CHEMBL621523,Expert,,,H,,B,2837,,,,1,,,
,15740,8,BAO_0000357,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,12689,,,CHEMBL621524,Autocuration,,,H,,B,2838,,,,1,,,
,17133,9,BAO_0000357,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,12689,,,CHEMBL621525,Expert,10116.0,,D,,B,2839,,,Rattus norvegicus,1,,,
,16532,8,BAO_0000357,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,12689,,,CHEMBL872921,Autocuration,,,H,,B,2840,,,,1,,,
,12369,8,BAO_0000357,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,12689,,,CHEMBL621526,Autocuration,,,H,,B,2841,,,,1,,,
,12369,8,BAO_0000219,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,12689,,,CHEMBL621527,Expert,,,H,,B,2842,,,,1,,,
,2309,9,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,12689,,,CHEMBL617865,Expert,10116.0,,D,,B,2843,,,Rattus norvegicus,1,,,
,12953,8,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,12689,,,CHEMBL617866,Autocuration,,,H,,B,2844,,,,1,,,
,12953,8,BAO_0000019,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,12689,,,CHEMBL617867,Autocuration,,,H,,B,2845,,,,1,,,
,12953,8,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,12689,,,CHEMBL617487,Autocuration,,,H,,B,2846,,,,1,,,
,12953,8,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2C receptor,12689,,,CHEMBL617488,Expert,,,H,,B,2847,,,,1,,,
,17133,8,BAO_0000357,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,12689,,,CHEMBL617489,Autocuration,,,H,,B,2848,,,,1,,,
,17211,8,BAO_0000019,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,12689,,,CHEMBL617490,Autocuration,,,H,,B,2849,,,,1,,,
,17211,8,BAO_0000019,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,12689,,,CHEMBL617491,Autocuration,,,H,,B,2850,,,,1,,,
,14025,8,BAO_0000019,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,12689,,,CHEMBL617492,Autocuration,,,H,,B,2851,,,,1,,,
,14998,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,12689,,,CHEMBL617493,Autocuration,,,H,,B,2852,,,,1,,,
,4342,8,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,12689,,,CHEMBL617494,Autocuration,,,H,,B,2853,,,,1,,,
,13735,9,BAO_0000019,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,12689,,,CHEMBL617495,Expert,10116.0,,D,,B,2854,,,Rattus norvegicus,1,,,
,13181,8,BAO_0000357,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,12689,,,CHEMBL617496,Autocuration,,,H,,B,2855,,,,1,,,
,1883,8,BAO_0000219,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,12689,,,CHEMBL617497,Autocuration,,,H,,B,2856,,485.0,,1,,,CHO-K1
,15194,8,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,12689,,,CHEMBL617498,Autocuration,,,H,,B,2857,,,,1,,,
,15194,8,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,12689,,,CHEMBL617499,Autocuration,,,H,,B,2858,,,,1,,,
,14579,8,BAO_0000019,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,12689,,,CHEMBL617500,Autocuration,,,H,,F,2859,,,,1,,,
,4639,8,BAO_0000357,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,108,,,CHEMBL617501,Autocuration,,,H,,B,2860,,,,1,,,
,4820,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor,108,,,CHEMBL617502,Expert,,,H,,B,2861,,,,1,,,
,14442,8,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,227,,,CHEMBL617503,Autocuration,,,H,,B,2862,,,,1,,,
,14755,8,BAO_0000357,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,227,,,CHEMBL617504,Autocuration,,,H,,B,2863,,,,1,,,
,14744,8,BAO_0000357,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,227,,,CHEMBL617406,Autocuration,,,H,,B,2864,,,,1,,,
,6857,9,BAO_0000019,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,227,,,CHEMBL617407,Expert,9606.0,,D,,B,2865,,,Homo sapiens,1,,,
,16209,8,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,227,,,CHEMBL617408,Autocuration,,,H,,B,2866,,,,1,,,
,15363,8,BAO_0000357,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,227,,,CHEMBL617409,Autocuration,,,H,,B,2867,,,,1,,,
,15363,8,BAO_0000357,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,227,,,CHEMBL617410,Autocuration,,,H,,B,2868,,,,1,,,
,15363,8,BAO_0000357,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,227,,,CHEMBL617411,Autocuration,,,H,,B,2869,,,,1,,,
,17085,8,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,227,,,CHEMBL617412,Autocuration,,,H,,B,2870,,,,1,,,
,17200,9,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,227,,,CHEMBL617774,Expert,9606.0,,D,,B,2871,,,Homo sapiens,1,,,
,15851,9,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,227,,,CHEMBL617775,Expert,9606.0,,D,,B,2872,,722.0,Homo sapiens,1,,,HEK293
,15851,9,BAO_0000219,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,227,,,CHEMBL617776,Expert,9606.0,,D,,B,2873,,722.0,Homo sapiens,1,,,HEK293
,6857,9,BAO_0000219,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,227,,,CHEMBL617777,Expert,9606.0,,D,,F,2874,,449.0,Homo sapiens,1,,,CHO
,6857,9,BAO_0000219,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,227,,,CHEMBL617778,Expert,9606.0,,D,,F,2875,,449.0,Homo sapiens,1,,,CHO
,15779,8,BAO_0000219,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",227,,,CHEMBL617779,Autocuration,,,H,,B,2876,,722.0,,1,,,HEK293
,15851,8,BAO_0000219,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,227,,,CHEMBL617780,Expert,,,H,,B,2877,,722.0,,1,,,HEK293
,15779,8,BAO_0000219,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",227,,,CHEMBL617781,Autocuration,,,H,,B,2878,,722.0,,1,,,HEK293
,14157,9,BAO_0000219,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,227,,,CHEMBL617782,Expert,9606.0,,D,,B,2879,,722.0,Homo sapiens,1,,,HEK293
,4540,9,BAO_0000219,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,227,,,CHEMBL617783,Expert,9606.0,,D,,B,2880,,722.0,Homo sapiens,1,,,HEK293
,6166,8,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,227,,,CHEMBL617784,Autocuration,,,H,,B,2881,,,,1,,,
,15779,8,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,227,,,CHEMBL617785,Autocuration,,,H,,B,2882,,722.0,,1,,,HEK293
,14391,8,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,227,,,CHEMBL857984,Expert,,,H,,B,2883,,722.0,,1,,,HEK293
,3832,8,BAO_0000219,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,227,,,CHEMBL617786,Expert,,,H,,B,2884,,722.0,,1,,,HEK293
,3833,8,BAO_0000219,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,227,,,CHEMBL617787,Expert,,,H,,B,2885,,722.0,,1,,,HEK293
,15851,9,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,227,,,CHEMBL617788,Expert,9606.0,,D,,B,2886,,722.0,Homo sapiens,1,,,HEK293
,15851,9,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,227,,,CHEMBL617789,Expert,9606.0,,D,,B,2887,,722.0,Homo sapiens,1,,,HEK293
,4199,8,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,227,,,CHEMBL617790,Autocuration,,,H,,B,2888,,722.0,,1,,,HEK293
,1883,8,BAO_0000219,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,227,,,CHEMBL617791,Expert,,,H,,B,2889,,485.0,,1,,,CHO-K1
,4321,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2B receptor,227,,,CHEMBL617608,Expert,,,H,,B,2890,,,,1,,,
,15146,8,BAO_0000219,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,227,,,CHEMBL617609,Autocuration,,,H,,B,2891,,722.0,,1,,,HEK293
,5213,8,BAO_0000219,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,227,,,CHEMBL617610,Autocuration,,,H,,B,2892,,722.0,,1,,,HEK293
,14818,8,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,227,,,CHEMBL617611,Autocuration,,,H,,B,2893,,722.0,,1,,,HEK293
,4829,8,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",227,,,CHEMBL617612,Autocuration,,,H,,B,2894,,722.0,,1,,,HEK293
,4829,8,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",227,,,CHEMBL617613,Autocuration,,,H,,B,2895,,722.0,,1,,,HEK293
,14025,8,BAO_0000019,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,227,,,CHEMBL617614,Autocuration,9986.0,,H,,B,2896,,,Oryctolagus cuniculus,1,,,
,13463,8,BAO_0000019,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,12688,,Stomach,CHEMBL617615,Expert,,,H,,B,2897,,,,1,,945.0,
,7259,8,BAO_0000357,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,12688,,Stomach,CHEMBL858114,Expert,,,H,,B,2898,,,,1,,945.0,
,7259,8,BAO_0000357,Affinity against serotonergic receptor in the isolated rat stomach fundus,12688,,Stomach,CHEMBL617616,Autocuration,,,H,,B,2899,,,,1,,945.0,
,7185,9,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,12688,,Stomach,CHEMBL617617,Expert,10116.0,,D,,F,2900,,,Rattus norvegicus,1,,945.0,
,7185,9,BAO_0000019,Antagonistic against 5-hydroxytryptamine 2B receptor,12688,,,CHEMBL875914,Expert,10116.0,,D,,F,2901,,,Rattus norvegicus,1,,,
,13267,8,BAO_0000019,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,12688,,Stomach,CHEMBL617618,Autocuration,,,H,,F,2902,,,,1,,945.0,
,13735,9,BAO_0000357,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,12688,,Stomach,CHEMBL617619,Expert,10116.0,,D,,B,2903,,,Rattus norvegicus,1,,945.0,
,15738,8,BAO_0000019,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,12688,,,CHEMBL617620,Autocuration,,,H,,F,2904,,,,1,,,
,15738,8,BAO_0000019,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,12688,,,CHEMBL617621,Autocuration,,,H,,F,2905,,,,1,,,
,15738,8,BAO_0000019,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,12688,,,CHEMBL617622,Autocuration,,,H,,F,2906,,,,1,,,
,12936,9,BAO_0000357,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,,Stomach,CHEMBL617623,Expert,10116.0,,D,,B,2907,,,Rattus norvegicus,1,,945.0,
,12936,9,BAO_0000357,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,,Stomach,CHEMBL617624,Expert,10116.0,,D,,B,2908,,,Rattus norvegicus,1,,945.0,
,12936,9,BAO_0000357,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,,Stomach,CHEMBL617625,Expert,10116.0,,D,,B,2909,,,Rattus norvegicus,1,,945.0,
,12936,9,BAO_0000357,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,,Stomach,CHEMBL617626,Expert,10116.0,,D,,B,2910,,,Rattus norvegicus,1,,945.0,
,16404,8,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,12688,,Stomach,CHEMBL617627,Autocuration,,,H,,F,2911,,,,1,,945.0,
,16404,8,BAO_0000019,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,12688,,Stomach,CHEMBL617628,Expert,,,H,,F,2912,,,,1,,945.0,
,16404,8,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,12688,,Stomach,CHEMBL617629,Autocuration,,,H,,F,2913,,,,1,,945.0,
,16404,8,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,12688,,Stomach,CHEMBL858115,Autocuration,,,H,,F,2914,,,,1,,945.0,
,16404,9,BAO_0000019,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,12688,,Stomach,CHEMBL617630,Expert,10116.0,,D,,F,2915,,,Rattus norvegicus,1,,945.0,
,16404,8,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,12688,,Thoracic aorta,CHEMBL617631,Autocuration,,,H,,F,2916,,,,1,,1515.0,
,7483,8,BAO_0000357,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,12688,,,CHEMBL617632,Autocuration,,,H,,B,2917,,,,1,,,
,7483,8,BAO_0000357,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,12688,,,CHEMBL617633,Expert,,,H,,B,2918,,,,1,,,
,7483,8,BAO_0000357,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,12688,,,CHEMBL617634,Autocuration,,,H,,B,2919,,,,1,,,
,7483,8,BAO_0000357,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,12688,,,CHEMBL617635,Autocuration,,,H,,B,2920,,,,1,,,
,16404,9,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,12688,,Stomach,CHEMBL617637,Autocuration,10116.0,,D,,F,2922,,,Rattus norvegicus,1,,945.0,
,6347,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,227,,,CHEMBL617638,Autocuration,,,H,,B,2923,,,,1,,,
,4373,8,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,227,,,CHEMBL617639,Autocuration,,,H,,B,2924,,,,1,,,
,4373,8,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,227,,,CHEMBL617640,Autocuration,,,H,,B,2925,,,,1,,,
,4687,8,BAO_0000357,Evaluated for the binding affinity to 5-HT 2B receptor,227,,,CHEMBL617641,Autocuration,,,H,,B,2926,,,,1,,,
,16946,8,BAO_0000357,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,227,,,CHEMBL617642,Autocuration,,,H,,B,2927,,,,1,,,
,16633,8,BAO_0000357,Binding affinities against 5-hydroxytryptamine 2B receptor,227,,,CHEMBL617643,Autocuration,,,H,,B,2928,,,,1,,,
,16633,8,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 2B receptor,227,,,CHEMBL617644,Autocuration,,,H,,B,2929,,,,1,,,
,16633,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,227,,,CHEMBL617645,Autocuration,,,H,,B,2930,,,,1,,,
,15026,8,BAO_0000357,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,108,,,CHEMBL617646,Expert,,,H,,B,2931,,,,1,,,
,15738,8,BAO_0000357,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,108,,,CHEMBL617647,Autocuration,9913.0,,H,,B,2932,,,Bos taurus,1,,,
,15738,8,BAO_0000357,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,108,,,CHEMBL617648,Autocuration,9913.0,,H,,B,2933,,,Bos taurus,1,,,
,15738,8,BAO_0000357,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,108,,,CHEMBL617875,Autocuration,9913.0,,H,,B,2934,,,Bos taurus,1,,,
,15738,8,BAO_0000357,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,108,,,CHEMBL617876,Autocuration,9913.0,,H,,B,2935,,,Bos taurus,1,,,
,16404,8,BAO_0000357,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,108,,,CHEMBL617877,Expert,9913.0,,H,,B,2936,,,Bos taurus,1,,,
,15026,8,BAO_0000357,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,108,,,CHEMBL617878,Expert,9913.0,,H,,B,2937,,,Bos taurus,1,,,
,15738,8,BAO_0000357,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,108,,,CHEMBL617879,Autocuration,9913.0,,H,,B,2938,,,Bos taurus,1,,,
,16312,8,BAO_0000019,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,108,,,CHEMBL617880,Autocuration,10141.0,,H,,B,2939,,,Cavia porcellus,1,,,
,5486,9,BAO_0000357,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,20033,,Striatum,CHEMBL617881,Intermediate,10141.0,,D,,B,2940,,,Cavia porcellus,1,,2435.0,
,5254,8,BAO_0000357,Binding affinity against 5-HT1A receptor,51,,,CHEMBL857073,Autocuration,,,H,,B,2941,,,,1,,,
,3857,8,BAO_0000219,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,108,,,CHEMBL617882,Expert,,,H,,F,2942,,449.0,,1,,,CHO
,6857,9,BAO_0000219,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,108,,,CHEMBL617883,Expert,9606.0,,D,,F,2943,,449.0,Homo sapiens,1,,,CHO
,4176,8,BAO_0000219,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,108,,,CHEMBL617884,Autocuration,,,H,,F,2944,,,,1,,,
,6347,8,BAO_0000219,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,108,,,CHEMBL617885,Autocuration,,,H,,B,2945,,449.0,,1,,,CHO
,6347,8,BAO_0000219,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",108,,,CHEMBL617886,Autocuration,,,H,,B,2946,,449.0,,1,,,CHO
,16146,9,BAO_0000357,Inhibition of human 5-hydroxytryptamine 2C receptor,108,,,CHEMBL617887,Expert,9606.0,,D,,B,2947,,,Homo sapiens,1,,,
,3805,8,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),108,,,CHEMBL617888,Autocuration,,,H,,B,2948,,,,1,,,
,3857,8,BAO_0000019,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,108,,,CHEMBL617889,Autocuration,,,H,,B,2949,,,,1,,,
,5635,8,BAO_0000357,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,108,,,CHEMBL617890,Autocuration,,,H,,B,2950,,,,1,,,
,5635,8,BAO_0000357,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,108,,,CHEMBL617891,Autocuration,,,H,,B,2951,,,,1,,,
,5635,8,BAO_0000357,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,108,,,CHEMBL617892,Autocuration,,,H,,B,2952,,,,1,,,
,4012,8,BAO_0000219,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,108,,,CHEMBL617893,Expert,,,H,,B,2953,,449.0,,1,,,CHO
,6366,8,BAO_0000219,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,108,,,CHEMBL617894,Expert,,,H,,B,2954,,449.0,,1,,,CHO
,15949,8,BAO_0000219,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,108,,,CHEMBL617895,Expert,,,H,,B,2955,,449.0,,1,,,CHO
,17211,8,BAO_0000219,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,108,,,CHEMBL617896,Autocuration,,,H,,B,2956,,449.0,,1,,,CHO
,6491,9,BAO_0000357,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,108,,,CHEMBL617897,Expert,9606.0,,D,,B,2957,,,Homo sapiens,1,,,
,14093,8,BAO_0000019,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,108,,,CHEMBL617898,Autocuration,,,H,,F,2958,,,,1,,,
,13481,8,BAO_0000019,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,108,,,CHEMBL617899,Autocuration,,,H,,F,2959,,,,1,,,
,6347,8,BAO_0000219,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,108,,,CHEMBL617900,Expert,10116.0,,H,,B,2960,,449.0,Rattus norvegicus,1,,,CHO
,14093,8,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,108,,,CHEMBL617901,Autocuration,,,H,,F,2961,,,,1,,,
,14093,8,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,108,,,CHEMBL617902,Autocuration,,,H,,F,2962,,,,1,,,
,13481,8,BAO_0000019,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,108,,,CHEMBL617903,Autocuration,,,H,,F,2963,,,,1,,,
,14442,8,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,108,,,CHEMBL617904,Autocuration,,,H,,B,2964,,,,1,,,
,14442,8,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,108,,,CHEMBL617905,Autocuration,,,H,,B,2965,,,,1,,,
,14442,8,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,108,,,CHEMBL617906,Autocuration,,,H,,B,2966,,,,1,,,
,14755,8,BAO_0000357,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,108,,,CHEMBL617907,Autocuration,,,H,,B,2967,,,,1,,,
,14744,8,BAO_0000357,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,108,,,CHEMBL617908,Autocuration,,,H,,B,2968,,,,1,,,
,16659,8,BAO_0000219,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,108,,,CHEMBL620617,Expert,,,H,,B,2969,,449.0,,1,,,CHO
,6857,9,BAO_0000019,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,108,,,CHEMBL620618,Expert,9606.0,,D,,B,2970,,,Homo sapiens,1,,,
,5635,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,108,,,CHEMBL620619,Expert,,,H,,B,2971,,,,1,,,
,4234,9,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,108,,,CHEMBL620620,Expert,9606.0,,D,,B,2972,,,Homo sapiens,1,,,
,16209,8,BAO_0000357,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,108,,,CHEMBL620621,Autocuration,,,H,,B,2973,,,,1,,,
,5778,7,BAO_0000249,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,104698,,,CHEMBL872920,Autocuration,10116.0,Membranes,D,,B,2974,,,Rattus norvegicus,1,,,
,5094,6,BAO_0000223,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,104698,,,CHEMBL620622,Autocuration,,,H,,B,2975,,,,1,,,
,809,7,BAO_0000019,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,104698,,,CHEMBL620623,Autocuration,10116.0,,D,,B,2976,,,Rattus norvegicus,1,,,
,1578,6,BAO_0000019,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,104698,,,CHEMBL620624,Autocuration,,,H,,B,2977,,,,1,,,
,809,6,BAO_0000019,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,104698,,,CHEMBL620625,Autocuration,,,H,,B,2978,,,,1,,,
,12469,6,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,104698,,,CHEMBL620626,Autocuration,,,H,,B,2979,,,,1,,,
,14290,6,BAO_0000019,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,104698,,,CHEMBL621307,Autocuration,,,H,,B,2980,,,,1,,,
,14290,6,BAO_0000019,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,104698,,,CHEMBL621308,Autocuration,,,H,,B,2981,,,,1,,,
,10609,6,BAO_0000223,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,104698,,,CHEMBL621309,Autocuration,,,H,,B,2982,,,,1,,,
,10609,6,BAO_0000223,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,104698,,,CHEMBL621310,Autocuration,,,H,,B,2983,,,,1,,,
,10609,6,BAO_0000223,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,104698,,,CHEMBL621311,Autocuration,,,H,,B,2984,,,,1,,,
,15253,6,BAO_0000249,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",104698,,,CHEMBL621502,Autocuration,,,H,,B,2985,,,,1,,,
,15253,6,BAO_0000249,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",104698,,,CHEMBL621503,Autocuration,,,H,,B,2986,,,,1,,,
,11683,6,BAO_0000249,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,104698,,,CHEMBL621504,Autocuration,,Membranes,H,,B,2987,,,,1,,,
,12092,6,BAO_0000223,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,104698,,,CHEMBL621505,Autocuration,,,H,,B,2988,,,,1,,,
,1946,6,BAO_0000019,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,104698,,,CHEMBL621506,Autocuration,,,H,,B,2989,,,,1,,,
,11623,6,BAO_0000223,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,104698,,,CHEMBL619781,Autocuration,,,H,,B,2990,,,,1,,,
,11623,6,BAO_0000223,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,104698,,,CHEMBL619782,Autocuration,,,H,,B,2991,,,,1,,,
,14788,6,BAO_0000019,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,104698,,,CHEMBL619783,Autocuration,,,H,,B,2992,,,,1,,,
,5432,7,BAO_0000019,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,104698,,,CHEMBL619784,Autocuration,10116.0,,D,,B,2993,,,Rattus norvegicus,1,,,
,14826,6,BAO_0000249,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,104698,,,CHEMBL619785,Autocuration,,,H,,B,2994,,,,1,,,
,2222,6,BAO_0000223,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,104698,,,CHEMBL619786,Autocuration,,,H,,B,2995,,,,1,,,
,11963,6,BAO_0000019,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,104698,,,CHEMBL619787,Autocuration,,,H,,B,2996,,,,1,,,
,14145,6,BAO_0000019,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,104698,,,CHEMBL872925,Autocuration,,,H,,B,2997,,,,1,,,
,17819,6,BAO_0000019,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,104698,,,CHEMBL619788,Autocuration,,,H,,B,2998,,,,1,,,
,10394,6,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,104698,,,CHEMBL619789,Autocuration,,,H,,B,2999,,,,1,,,
,10394,6,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,104698,,,CHEMBL619790,Autocuration,,,H,,B,3000,,,,1,,,
,15034,6,BAO_0000019,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,104698,,,CHEMBL619791,Autocuration,,,H,,B,3001,,,,1,,,
,691,6,BAO_0000019,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,104698,,,CHEMBL619792,Autocuration,,,H,,B,3002,,,,1,,,
,12092,6,BAO_0000249,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,104698,,,CHEMBL619793,Autocuration,,Membranes,H,,B,3003,,,,1,,,
,11752,7,BAO_0000223,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,104698,,,CHEMBL619794,Autocuration,10116.0,,D,,B,3004,,,Rattus norvegicus,1,,,
,11752,6,BAO_0000221,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,104698,,Brain,CHEMBL619795,Autocuration,,,H,,B,3005,,,,1,,955.0,
,301,6,BAO_0000019,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,104698,,,CHEMBL619796,Autocuration,,,H,,B,3006,,,,1,,,
,16532,6,BAO_0000223,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,104698,,,CHEMBL620448,Autocuration,,,H,,B,3007,,,,1,,,
,16532,6,BAO_0000223,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,104698,,,CHEMBL620449,Autocuration,,,H,,B,3008,,,,1,,,
,12092,6,BAO_0000223,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,104698,,,CHEMBL620450,Autocuration,,,H,,B,3009,,,,1,,,
,11684,6,BAO_0000223,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,104698,,,CHEMBL620451,Autocuration,,,H,,B,3010,,,,1,,,
,11684,6,BAO_0000223,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,104698,,,CHEMBL620631,Autocuration,,,H,,B,3011,,,,1,,,
,12953,6,BAO_0000019,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,104698,,,CHEMBL620632,Autocuration,,,H,,B,3012,,,,1,,,
,12953,6,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,104698,,,CHEMBL620633,Autocuration,,,H,,B,3013,,,,1,,,
,12953,6,BAO_0000223,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,104698,,,CHEMBL620634,Autocuration,,,H,,B,3014,,,,1,,,
,12861,6,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,104698,,,CHEMBL620635,Autocuration,,,H,,B,3015,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,In vivo,,CHEMBL620636,Autocuration,,,H,,F,3016,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,104698,In vivo,,CHEMBL620637,Autocuration,,,H,,F,3017,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,104698,In vivo,,CHEMBL620638,Autocuration,,,H,,F,3018,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,104698,In vivo,,CHEMBL620639,Autocuration,,,H,,F,3019,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,In vivo,,CHEMBL620640,Autocuration,,,H,,F,3020,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,104698,In vivo,,CHEMBL620641,Autocuration,,,H,,F,3021,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,104698,In vivo,,CHEMBL620642,Autocuration,,,H,,F,3022,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,104698,In vivo,,CHEMBL620643,Autocuration,,,H,,F,3023,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,104698,In vivo,,CHEMBL620644,Autocuration,,,H,,F,3024,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,In vivo,,CHEMBL620645,Autocuration,,,H,,F,3025,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,104698,In vivo,,CHEMBL620646,Autocuration,,,H,,F,3026,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,104698,In vivo,,CHEMBL620647,Autocuration,,,H,,F,3027,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,104698,In vivo,,CHEMBL620648,Autocuration,,,H,,F,3028,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,In vivo,,CHEMBL620649,Autocuration,,,H,,F,3029,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,104698,In vivo,,CHEMBL620650,Autocuration,,,H,,F,3030,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,104698,In vivo,,CHEMBL620651,Autocuration,,,H,,F,3031,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,104698,In vivo,,CHEMBL872875,Autocuration,,,H,,F,3032,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,104698,In vivo,,CHEMBL620652,Autocuration,,,H,,F,3033,,,,1,,,
,10609,6,BAO_0000019,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,104698,,,CHEMBL620653,Autocuration,,,H,,F,3034,,,,1,,,
,12861,6,BAO_0000019,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,104698,,,CHEMBL857076,Autocuration,,,H,,B,3035,,,,1,,,
,12861,7,BAO_0000019,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,104698,,,CHEMBL620654,Autocuration,10116.0,,D,,B,3036,,,Rattus norvegicus,1,,,
,12861,6,BAO_0000223,Binding activity radioligand.,104698,,,CHEMBL620655,Autocuration,,,H,,B,3037,,,,1,,,
,10728,6,BAO_0000249,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,104698,,,CHEMBL620656,Autocuration,,Brain membranes,H,,B,3038,,,,1,,,
,10728,6,BAO_0000249,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,104698,,,CHEMBL620657,Autocuration,,Brain membranes,H,,B,3039,,,,1,,,
,5163,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,108,,,CHEMBL620658,Autocuration,,,H,,B,3040,,,,1,,,
,5163,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,108,,,CHEMBL620659,Autocuration,,,H,,B,3041,,,,1,,,
,6011,8,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,108,,,CHEMBL620660,Autocuration,,,H,,B,3042,,,,1,,,
,5014,8,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,108,,,CHEMBL620661,Autocuration,,,H,,B,3043,,,,1,,,
,5635,8,BAO_0000357,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,108,,,CHEMBL620662,Autocuration,,,H,,B,3044,,,,1,,,
,5163,8,BAO_0000357,Affinity for 5-hydroxytryptamine 2C receptor,108,,,CHEMBL620663,Expert,,,H,,B,3045,,,,1,,,
,6841,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,108,,,CHEMBL620664,Autocuration,,,H,,B,3046,,,,1,,,
,6119,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,108,,,CHEMBL620665,Expert,,,H,,B,3047,,,,1,,,
,4373,8,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,108,,,CHEMBL620666,Autocuration,,,H,,B,3048,,,,1,,,
,1633,8,BAO_0000357,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,108,,,CHEMBL620667,Autocuration,,,H,,B,3049,,,,1,,,
,1633,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,108,,,CHEMBL620668,Expert,,,H,,B,3050,,,,1,,,
,4373,8,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,108,,,CHEMBL620669,Autocuration,,,H,,B,3051,,,,1,,,
,6576,8,BAO_0000357,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,108,,,CHEMBL620670,Expert,,,H,,B,3052,,,,1,,,
,4687,8,BAO_0000357,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,108,,,CHEMBL620671,Autocuration,,,H,,B,3053,,,,1,,,
,12146,8,BAO_0000357,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,108,,,CHEMBL620672,Autocuration,,,H,,B,3054,,,,1,,,
,12146,8,BAO_0000357,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,108,,,CHEMBL620673,Autocuration,,,H,,B,3055,,,,1,,,
,16946,8,BAO_0000357,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,108,,,CHEMBL620674,Autocuration,,,H,,B,3056,,,,1,,,
,14159,8,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,108,,,CHEMBL620675,Autocuration,,,H,,B,3057,,,,1,,,
,16700,8,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,108,,,CHEMBL620676,Autocuration,,,H,,B,3058,,,,1,,,
,3269,8,BAO_0000357,Affinity against 5-hydroxytryptamine 2C receptor,108,,,CHEMBL621382,Autocuration,,,H,,B,3059,,,,1,,,
,1274,9,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2C receptor,108,,,CHEMBL621383,Expert,9606.0,,D,,B,3060,,,Homo sapiens,1,,,
,1317,8,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,108,,,CHEMBL621384,Autocuration,,,H,,B,3061,,,,1,,,
,5834,8,BAO_0000357,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,144,,,CHEMBL621385,Autocuration,9913.0,,H,,B,3062,,,Bos taurus,1,,,
,11147,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,144,,,CHEMBL617989,Autocuration,9913.0,,H,,B,3063,,,Bos taurus,1,,,
,14145,4,BAO_0000019,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,104714,,,CHEMBL617990,Expert,10141.0,,H,,F,3064,,,Cavia porcellus,1,,,
,10561,4,BAO_0000221,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,104714,,Ileum,CHEMBL875085,Autocuration,10141.0,,H,,B,3065,,,Cavia porcellus,1,,2116.0,
,15847,4,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,104714,,,CHEMBL617991,Autocuration,10141.0,,H,,F,3066,,,Cavia porcellus,1,,,
,15847,4,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,104714,,,CHEMBL617992,Autocuration,10141.0,,H,,F,3067,,,Cavia porcellus,1,,,
,10561,4,BAO_0000221,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,104714,,Ileum,CHEMBL617993,Autocuration,10141.0,,H,,B,3068,,,Cavia porcellus,1,,2116.0,
,11454,4,BAO_0000221,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,104714,,Ileum,CHEMBL617994,Autocuration,10141.0,,H,,B,3069,,,Cavia porcellus,1,,2116.0,
,4639,4,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,104714,,,CHEMBL617995,Autocuration,10141.0,,H,,F,3070,,,Cavia porcellus,1,,,
,4639,4,BAO_0000019,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,104714,,,CHEMBL617996,Autocuration,10141.0,,H,,F,3071,,,Cavia porcellus,1,,,
,4639,4,BAO_0000019,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,104714,,,CHEMBL617997,Autocuration,10141.0,,H,,F,3072,,,Cavia porcellus,1,,,
,4639,4,BAO_0000019,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,104714,,,CHEMBL617998,Autocuration,10141.0,,H,,F,3073,,,Cavia porcellus,1,,,
,4639,4,BAO_0000019,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,104714,,,CHEMBL617999,Autocuration,10141.0,,H,,F,3074,,,Cavia porcellus,1,,,
,4639,4,BAO_0000019,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,104714,,,CHEMBL618000,Autocuration,10141.0,,H,,F,3075,,,Cavia porcellus,1,,,
,15253,4,BAO_0000221,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",104714,,Ileum,CHEMBL617815,Autocuration,10141.0,,H,,F,3076,,,Cavia porcellus,1,,2116.0,
,15253,4,BAO_0000221,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",104714,,Ileum,CHEMBL617816,Autocuration,10141.0,,H,,F,3077,,,Cavia porcellus,1,,2116.0,
,11963,4,BAO_0000221,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,104714,,Ileum,CHEMBL617817,Autocuration,10141.0,,H,,F,3078,,,Cavia porcellus,1,,2116.0,
,1946,4,BAO_0000221,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,104714,,Ileum,CHEMBL617818,Autocuration,10141.0,,H,,B,3079,,,Cavia porcellus,1,,2116.0,
,1946,4,BAO_0000221,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,104714,,Ileum,CHEMBL617819,Autocuration,10141.0,,H,,B,3080,,,Cavia porcellus,1,,2116.0,
,12045,4,BAO_0000223,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,104714,,,CHEMBL617820,Autocuration,10141.0,,H,,B,3081,,,Cavia porcellus,1,,,
,1559,4,BAO_0000221,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,104714,,Ileum,CHEMBL617821,Autocuration,10141.0,,H,,B,3082,,,Cavia porcellus,1,,2116.0,
,273,4,BAO_0000221,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),104714,,Ileum,CHEMBL617822,Autocuration,10141.0,,H,,F,3083,,,Cavia porcellus,1,,2116.0,
,273,4,BAO_0000221,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),104714,,Ileum,CHEMBL617823,Autocuration,10141.0,,H,,F,3084,,,Cavia porcellus,1,,2116.0,
,188,4,BAO_0000221,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,104714,,Ileum,CHEMBL617824,Autocuration,10141.0,,H,,F,3085,,,Cavia porcellus,1,,2116.0,
,12919,4,BAO_0000221,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,104714,,Ileum,CHEMBL617825,Autocuration,10141.0,,H,,F,3086,,,Cavia porcellus,1,,2116.0,
,12918,4,BAO_0000221,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,104714,,Ileum,CHEMBL617826,Autocuration,10141.0,,H,,F,3087,,,Cavia porcellus,1,,2116.0,
,1559,4,BAO_0000221,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,104714,,Ileum,CHEMBL617827,Autocuration,10141.0,,H,,B,3088,,,Cavia porcellus,1,,2116.0,
,273,4,BAO_0000221,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),104714,,Ileum,CHEMBL617828,Autocuration,10141.0,,H,,F,3089,,,Cavia porcellus,1,,2116.0,
,1559,4,BAO_0000221,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,104714,,Ileum,CHEMBL617829,Autocuration,10141.0,,H,,B,3090,,,Cavia porcellus,1,,2116.0,
,1559,4,BAO_0000221,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,104714,,Ileum,CHEMBL617830,Autocuration,10141.0,,H,,B,3091,,,Cavia porcellus,1,,2116.0,
,1559,4,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,104714,,Ileum,CHEMBL617831,Autocuration,10141.0,,H,,B,3092,,,Cavia porcellus,1,,2116.0,
,14424,4,BAO_0000221,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,104714,,Ileum,CHEMBL617832,Autocuration,10141.0,,H,,B,3093,,,Cavia porcellus,1,,2116.0,
,13181,0,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,22226,,,CHEMBL617833,Autocuration,10141.0,,U,,B,3094,,,Cavia porcellus,1,,,
,5486,8,BAO_0000357,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,51,,,CHEMBL617834,Autocuration,,,H,,B,3095,,,,1,,,
,6491,5,BAO_0000223,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,104714,,,CHEMBL617835,Expert,9606.0,,D,,B,3096,,,Homo sapiens,1,,,
,6013,4,BAO_0000223,Binding affinity towards 5-HT3 receptor,104714,,,CHEMBL617836,Autocuration,,,H,,B,3097,,,,1,,,
,12861,4,BAO_0000223,Binding activity radioligand.,104714,,,CHEMBL617837,Autocuration,,,H,,B,3098,,,,1,,,
,12861,4,BAO_0000019,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,104714,,,CHEMBL620392,Autocuration,,,H,,B,3099,,,,1,,,
,5104,4,BAO_0000223,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,104714,,,CHEMBL620393,Autocuration,,,H,,B,3100,,,,1,,,
,5105,4,BAO_0000223,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,104714,,,CHEMBL620394,Autocuration,,,H,,B,3101,,,,1,,,
,5104,4,BAO_0000223,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,104714,,,CHEMBL620395,Autocuration,,,H,,B,3102,,,,1,,,
,3935,0,BAO_0000019,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,22226,,,CHEMBL620396,Autocuration,,,U,,B,3103,,,,1,,,
,13657,4,BAO_0000219,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,105030,,,CHEMBL620582,Expert,,,H,,B,3104,,433.0,,1,,,NG108-15
,10369,4,BAO_0000218,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",105030,In vivo,,CHEMBL620583,Autocuration,,,H,,B,3105,,,,1,,,
,10369,4,BAO_0000019,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),105030,,,CHEMBL620584,Autocuration,,,H,,B,3106,,,,1,,,
,12918,4,BAO_0000224,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,105030,,,CHEMBL620585,Autocuration,,,H,,B,3107,,,,1,,,
,12918,4,BAO_0000224,Compound was evaluated for the binding affinity at 5- HT3 receptor,105030,,,CHEMBL620586,Autocuration,,,H,,B,3108,,,,1,,,
,10369,4,BAO_0000019,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),105030,,,CHEMBL620587,Autocuration,,,H,,B,3109,,,,1,,,
,773,4,BAO_0000019,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,105030,,,CHEMBL620588,Autocuration,,,H,,B,3110,,,,1,,,
,12918,4,BAO_0000218,5-hydroxytryptamine 3 receptor agonism in mouse,105030,,,CHEMBL620589,Autocuration,,,H,,F,3111,,,,1,,,
,10561,4,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,105030,,,CHEMBL620590,Autocuration,,,H,,B,3112,,,,1,,,
,12827,4,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,105030,,,CHEMBL617956,Autocuration,,,H,,B,3113,,,,1,,,
,12827,4,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,105030,,,CHEMBL617957,Autocuration,,,H,,B,3114,,,,1,,,
,12918,4,BAO_0000224,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,105030,,,CHEMBL617958,Autocuration,,,H,,B,3115,,,,1,,,
,273,4,BAO_0000219,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,105030,,,CHEMBL617959,Autocuration,,,H,,B,3116,,,,1,,,
,273,4,BAO_0000219,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,105030,,,CHEMBL617960,Autocuration,,,H,,B,3117,,,,1,,,
,10561,4,BAO_0000224,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,105030,,,CHEMBL617961,Autocuration,,,H,,B,3118,,,,1,,,
,5033,4,BAO_0000219,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,105030,In vitro,,CHEMBL617962,Autocuration,,,H,,B,3119,,,,1,,,
,16429,4,BAO_0000219,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,105030,,,CHEMBL617963,Autocuration,,,H,,B,3120,,339.0,,1,,,N1E-115
,10322,8,BAO_0000019,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,11765,,,CHEMBL617964,Autocuration,,,H,,B,3121,,,,1,,,
,14331,8,BAO_0000219,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,11765,,,CHEMBL617965,Autocuration,,,H,,B,3122,,,,1,,,
,13462,9,BAO_0000357,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,10630,,,CHEMBL617966,Autocuration,10090.0,,D,,B,3123,,,Mus musculus,1,,,
,12861,8,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,17106,,,CHEMBL857074,Autocuration,,,H,,B,3124,,,,1,,,
,15086,8,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,144,,,CHEMBL617967,Autocuration,9823.0,,H,,B,3125,,,Sus scrofa,1,,,
,12861,8,BAO_0000357,Binding activity radioligand.,144,,,CHEMBL617968,Autocuration,9823.0,,H,,B,3126,,,Sus scrofa,1,,,
,10561,4,BAO_0000223,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,104714,,,CHEMBL617969,Autocuration,9986.0,,H,,B,3127,,,Oryctolagus cuniculus,1,,,
,10561,4,BAO_0000223,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,104714,,,CHEMBL617970,Autocuration,9986.0,,H,,B,3128,,,Oryctolagus cuniculus,1,,,
,10561,4,BAO_0000223,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,104714,,,CHEMBL617971,Autocuration,9986.0,,H,,B,3129,,,Oryctolagus cuniculus,1,,,
,10561,4,BAO_0000019,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,104714,,,CHEMBL617972,Autocuration,9986.0,,H,,B,3130,,,Oryctolagus cuniculus,1,,,
,273,4,BAO_0000019,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),104714,,,CHEMBL617973,Autocuration,9986.0,,H,,F,3131,,,Oryctolagus cuniculus,1,,,
,273,4,BAO_0000019,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),104714,,,CHEMBL617974,Autocuration,9986.0,,H,,F,3132,,,Oryctolagus cuniculus,1,,,
,273,4,BAO_0000221,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),104714,,Ileum,CHEMBL617975,Autocuration,9986.0,,H,,F,3133,,,Oryctolagus cuniculus,1,,2116.0,
,273,4,BAO_0000019,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),104714,,,CHEMBL617976,Autocuration,9986.0,,H,,F,3134,,,Oryctolagus cuniculus,1,,,
,273,4,BAO_0000019,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),104714,,,CHEMBL617977,Autocuration,9986.0,,H,,F,3135,,,Oryctolagus cuniculus,1,,,
,273,4,BAO_0000019,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),104714,,,CHEMBL617978,Autocuration,9986.0,,H,,F,3136,,,Oryctolagus cuniculus,1,,,
,273,4,BAO_0000019,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),104714,,,CHEMBL617979,Autocuration,9986.0,,H,,F,3137,,,Oryctolagus cuniculus,1,,,
,13047,4,BAO_0000219,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,104714,,,CHEMBL617980,Autocuration,9986.0,,H,,B,3138,,449.0,Oryctolagus cuniculus,1,,,CHO
,1650,7,BAO_0000019,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,104698,,,CHEMBL617981,Autocuration,10116.0,,D,,B,3139,,,Rattus norvegicus,1,,,
,16288,8,BAO_0000019,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),12020,,,CHEMBL617982,Autocuration,,,H,,B,3140,,,,1,,,
,16288,8,BAO_0000357,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),12020,,,CHEMBL617983,Autocuration,,,H,,B,3141,,,,1,,,
,10254,7,BAO_0000019,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,104698,,,CHEMBL617984,Autocuration,10116.0,,D,,B,3142,,,Rattus norvegicus,1,,,
,14532,6,BAO_0000019,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",104698,,,CHEMBL617985,Autocuration,,,H,,B,3143,,,,1,,,
,13392,6,BAO_0000218,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",104698,In vivo,Heart,CHEMBL617986,Autocuration,,,H,,F,3144,,,,1,,948.0,
,13392,6,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",104698,,Heart,CHEMBL617987,Autocuration,,,H,,F,3145,,,,1,,948.0,
,13392,6,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",104698,,Heart,CHEMBL617988,Autocuration,,,H,,F,3146,,,,1,,948.0,
,13392,6,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",104698,,Heart,CHEMBL617792,Autocuration,,,H,,F,3147,,,,1,,948.0,
,13392,6,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",104698,,Heart,CHEMBL617793,Autocuration,,,H,,F,3148,,,,1,,948.0,
,13392,6,BAO_0000019,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",104698,,,CHEMBL617794,Autocuration,,,H,,F,3149,,,,1,,,
,13392,6,BAO_0000019,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",104698,,,CHEMBL617795,Autocuration,,,H,,F,3150,,,,1,,,
,13392,6,BAO_0000019,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",104698,,,CHEMBL617796,Autocuration,,,H,,F,3151,,,,1,,,
,13392,6,BAO_0000019,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",104698,,,CHEMBL617797,Autocuration,,,H,,F,3152,,,,1,,,
,1089,7,BAO_0000218,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),104698,In vivo,,CHEMBL617798,Autocuration,10116.0,,D,,F,3153,,,Rattus norvegicus,1,,,
,1089,6,BAO_0000218,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),104698,In vivo,,CHEMBL617799,Autocuration,,,H,,F,3154,,,,1,,,
,11454,7,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,In vivo,,CHEMBL617800,Autocuration,10116.0,,D,,F,3155,,,Rattus norvegicus,1,,,
,11454,7,BAO_0000019,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,104698,,,CHEMBL617801,Autocuration,10116.0,,D,,F,3156,,,Rattus norvegicus,1,,,
,12205,7,BAO_0000218,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,104698,In vivo,,CHEMBL617802,Autocuration,10116.0,,D,,F,3157,,,Rattus norvegicus,1,,,
,1089,7,BAO_0000019,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),104698,,,CHEMBL617803,Autocuration,10116.0,,D,,F,3158,,,Rattus norvegicus,1,,,
,5094,6,BAO_0000019,Binding affinity towards 5-HT3 receptor in rat was evaluated,104698,,,CHEMBL617804,Autocuration,,,H,,B,3159,,,,1,,,
,2622,7,BAO_0000019,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,104698,,,CHEMBL617805,Autocuration,10116.0,,D,,B,3160,,,Rattus norvegicus,1,,,
,245,6,BAO_0000223,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,104698,,,CHEMBL617806,Autocuration,,,H,,B,3161,,,,1,,,
,14788,6,BAO_0000019,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,104698,,,CHEMBL617807,Autocuration,,,H,,B,3162,,,,1,,,
,14788,6,BAO_0000019,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,104698,,,CHEMBL617808,Autocuration,,,H,,B,3163,,,,1,,,
,3020,6,BAO_0000249,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,104698,,,CHEMBL617809,Autocuration,,,H,,B,3164,,,,1,,,
,1742,6,BAO_0000019,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,104698,,,CHEMBL617810,Autocuration,,,H,,B,3165,,,,1,,,
,17394,6,BAO_0000249,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,104698,,Brain,CHEMBL617811,Autocuration,,,H,,B,3166,,,,1,,955.0,
,17394,6,BAO_0000221,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,104698,,Brain,CHEMBL617812,Autocuration,,,H,,B,3167,,,,1,,955.0,
,17394,6,BAO_0000249,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,104698,,,CHEMBL617813,Autocuration,,,H,,B,3168,,,,1,,,
,14286,6,BAO_0000249,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,104698,,,CHEMBL617814,Autocuration,,,H,,B,3169,,,,1,,,
,14178,6,BAO_0000019,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,104698,,,CHEMBL617698,Autocuration,,,H,,B,3170,,,,1,,,
,14178,7,BAO_0000019,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,104698,,,CHEMBL617699,Autocuration,10116.0,,D,,B,3171,,,Rattus norvegicus,1,,,
,14178,7,BAO_0000019,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,104698,,,CHEMBL617700,Autocuration,10116.0,,D,,B,3172,,,Rattus norvegicus,1,,,
,14178,7,BAO_0000223,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,104698,,,CHEMBL617701,Autocuration,10116.0,,D,,B,3173,,,Rattus norvegicus,1,,,
,15034,6,BAO_0000019,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,104698,,,CHEMBL617702,Autocuration,,,H,,B,3174,,,,1,,,
,1089,6,BAO_0000249,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",104698,,,CHEMBL617703,Autocuration,,Membranes,H,,B,3175,,,,1,,,
,1089,7,BAO_0000019,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,104698,,,CHEMBL617704,Autocuration,10116.0,,D,,B,3176,,,Rattus norvegicus,1,,,
,16532,6,BAO_0000223,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,104698,,,CHEMBL617705,Autocuration,,,H,,B,3177,,,,1,,,
,12801,7,BAO_0000223,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,104698,,,CHEMBL617706,Autocuration,10116.0,,D,,B,3178,,,Rattus norvegicus,1,,,
,15194,6,BAO_0000219,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),104698,,,CHEMBL617707,Autocuration,,,H,,B,3179,,433.0,,1,,,NG108-15
,15194,6,BAO_0000219,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,104698,,,CHEMBL617708,Autocuration,,,H,,B,3180,,433.0,,1,,,NG108-15
,15194,6,BAO_0000019,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,104698,,,CHEMBL617709,Autocuration,,,H,,B,3181,,,,1,,,
,15194,6,BAO_0000019,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,104698,,,CHEMBL617710,Autocuration,,,H,,B,3182,,,,1,,,
,15194,6,BAO_0000019,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,104698,,,CHEMBL882925,Autocuration,,,H,,B,3183,,,,1,,,
,15194,6,BAO_0000019,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,104698,,,CHEMBL617711,Autocuration,,,H,,B,3184,,,,1,,,
,10610,6,BAO_0000019,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,104698,,,CHEMBL617712,Autocuration,,,H,,F,3185,,,,1,,,
,10355,7,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,104698,,,CHEMBL617713,Autocuration,10116.0,,D,,F,3186,,,Rattus norvegicus,1,,,
,691,6,BAO_0000019,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",104698,,,CHEMBL617714,Autocuration,,,H,,F,3187,,,,1,,,
,10611,6,BAO_0000218,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,104698,,,CHEMBL617715,Autocuration,,,H,,F,3188,,,,1,,,
,12801,6,BAO_0000218,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,104698,In vivo,,CHEMBL617716,Autocuration,,,H,,F,3189,,,,1,,,
,10609,6,BAO_0000218,Inhibition of 5-HT evoked reflex bradycardia in rat.,104698,,,CHEMBL617717,Autocuration,,,H,,F,3190,,,,1,,,
,11454,6,BAO_0000218,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,In vivo,,CHEMBL617718,Autocuration,,,H,,F,3191,,,,1,,,
,11454,6,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,104698,In vivo,,CHEMBL617719,Autocuration,,,H,,F,3192,,,,1,,,
,11454,6,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),104698,In vivo,,CHEMBL617720,Autocuration,,,H,,F,3193,,,,1,,,
,11454,7,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,104698,In vivo,,CHEMBL617721,Autocuration,10116.0,,D,,F,3194,,,Rattus norvegicus,1,,,
,11454,6,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,In vivo,,CHEMBL617722,Autocuration,,,H,,F,3195,,,,1,,,
,11454,6,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,104698,In vivo,,CHEMBL617723,Autocuration,,,H,,F,3196,,,,1,,,
,11454,6,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,104698,In vivo,,CHEMBL617724,Autocuration,,,H,,F,3197,,,,1,,,
,11454,6,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,104698,In vivo,,CHEMBL617725,Autocuration,,,H,,F,3198,,,,1,,,
,11454,6,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,104698,In vivo,,CHEMBL617726,Autocuration,,,H,,F,3199,,,,1,,,
,11454,6,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,In vivo,,CHEMBL617727,Autocuration,,,H,,F,3200,,,,1,,,
,11454,6,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,104698,In vivo,,CHEMBL617728,Autocuration,,,H,,F,3201,,,,1,,,
,11454,6,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,104698,In vivo,,CHEMBL617729,Autocuration,,,H,,F,3202,,,,1,,,
,11454,6,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,104698,In vivo,,CHEMBL617730,Autocuration,,,H,,F,3203,,,,1,,,
,11454,6,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,In vivo,,CHEMBL617731,Autocuration,,,H,,F,3204,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,104698,In vivo,,CHEMBL617732,Autocuration,,,H,,F,3205,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,104698,In vivo,,CHEMBL617733,Autocuration,,,H,,F,3206,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,104698,In vivo,,CHEMBL617734,Autocuration,,,H,,F,3207,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,104698,In vivo,,CHEMBL872874,Autocuration,,,H,,F,3208,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,104698,In vivo,,CHEMBL617735,Autocuration,,,H,,F,3209,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,104698,In vivo,,CHEMBL617736,Autocuration,,,H,,F,3210,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,104698,In vivo,,CHEMBL617737,Autocuration,,,H,,F,3211,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,104698,In vivo,,CHEMBL617738,Autocuration,,,H,,F,3212,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,104698,In vivo,,CHEMBL617739,Autocuration,,,H,,F,3213,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,104698,In vivo,,CHEMBL617740,Autocuration,,,H,,F,3214,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,In vivo,,CHEMBL617741,Autocuration,,,H,,F,3215,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,104698,In vivo,,CHEMBL617742,Autocuration,,,H,,F,3216,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,104698,In vivo,,CHEMBL617743,Autocuration,,,H,,F,3217,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,104698,In vivo,,CHEMBL617744,Autocuration,,,H,,F,3218,,,,1,,,
,11454,6,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,104698,In vivo,,CHEMBL617745,Autocuration,,,H,,F,3219,,,,1,,,
,670,6,BAO_0000218,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",104698,,,CHEMBL617746,Autocuration,,,H,,F,3220,,,,1,,,
,670,6,BAO_0000218,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",104698,,,CHEMBL617747,Autocuration,,,H,,F,3221,,,,1,,,
,10321,6,BAO_0000218,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,104698,In vivo,,CHEMBL617748,Autocuration,,,H,,F,3222,,,,1,,,
,10321,6,BAO_0000218,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,104698,In vivo,,CHEMBL618909,Autocuration,,,H,,F,3223,,,,1,,,
,10321,6,BAO_0000218,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,104698,In vivo,,CHEMBL618910,Autocuration,,,H,,F,3224,,,,1,,,
,10321,6,BAO_0000218,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,104698,In vivo,,CHEMBL618911,Autocuration,,,H,,F,3225,,,,1,,,
,10321,6,BAO_0000218,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,104698,In vivo,,CHEMBL618912,Autocuration,,,H,,F,3226,,,,1,,,
,10322,6,BAO_0000218,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),104698,In vivo,,CHEMBL618913,Autocuration,,,H,,F,3227,,,,1,,,
,15412,6,BAO_0000019,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,104698,,,CHEMBL618914,Autocuration,,,H,,F,3228,,,,1,,,
,15412,6,BAO_0000019,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,104698,,,CHEMBL618915,Autocuration,,,H,,F,3229,,,,1,,,
,15412,7,BAO_0000223,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,104698,,,CHEMBL618916,Autocuration,10116.0,,D,,B,3230,,,Rattus norvegicus,1,,,
,15412,6,BAO_0000019,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,104698,,,CHEMBL618917,Autocuration,,,H,,F,3231,,,,1,,,
,15412,7,BAO_0000221,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,104698,,Hippocampus,CHEMBL618918,Intermediate,,,D,,B,3232,,,,1,,10000000.0,
,15412,7,BAO_0000019,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,104698,,,CHEMBL618919,Autocuration,10116.0,,D,,B,3233,,,Rattus norvegicus,1,,,
,17394,7,BAO_0000019,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,104698,,,CHEMBL618920,Autocuration,10116.0,,D,,B,3234,,,Rattus norvegicus,1,,,
,12457,6,BAO_0000223,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,104698,,,CHEMBL618921,Autocuration,,,H,,B,3235,,,,1,,,
,12457,6,BAO_0000019,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,104698,,,CHEMBL618922,Autocuration,,,H,,B,3236,,,,1,,,
,12205,6,BAO_0000019,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,104698,,,CHEMBL618923,Autocuration,,,H,,B,3237,,,,1,,,
,14532,6,BAO_0000019,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,104698,,,CHEMBL618924,Autocuration,,,H,,B,3238,,,,1,,,
,1122,6,BAO_0000019,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,104698,,,CHEMBL618925,Autocuration,,,H,,B,3239,,,,1,,,
,5094,6,BAO_0000019,Binding affinity towards 5-HT3 receptor in rat was evaluated,104698,,,CHEMBL618926,Autocuration,,,H,,B,3240,,,,1,,,
,809,9,BAO_0000221,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,20033,,Ileum,CHEMBL618927,Intermediate,10141.0,,D,,F,3241,,,Cavia porcellus,1,,2116.0,
,809,9,BAO_0000221,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,20033,,Ileum,CHEMBL618928,Intermediate,10141.0,,D,,F,3242,,,Cavia porcellus,1,,2116.0,
,14290,9,BAO_0000221,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",20033,,Ileum,CHEMBL618929,Intermediate,10141.0,,D,,F,3243,,,Cavia porcellus,1,,2116.0,
,14290,9,BAO_0000221,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",20033,,Ileum,CHEMBL618930,Intermediate,10141.0,,D,,F,3244,,,Cavia porcellus,1,,2116.0,
,14290,9,BAO_0000221,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",20033,,Ileum,CHEMBL618931,Intermediate,10141.0,,D,,F,3245,,,Cavia porcellus,1,,2116.0,
,14290,9,BAO_0000221,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",20033,,Ileum,CHEMBL619594,Intermediate,10141.0,,D,,F,3246,,,Cavia porcellus,1,,2116.0,
,14290,9,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",20033,,Ileum,CHEMBL619595,Intermediate,10141.0,,D,,F,3247,,,Cavia porcellus,1,,2116.0,
,13961,9,BAO_0000221,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,20033,,Ileum,CHEMBL619596,Intermediate,10141.0,,D,,F,3248,,,Cavia porcellus,1,,2116.0,
,13961,9,BAO_0000221,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,20033,,Ileum,CHEMBL619755,Intermediate,10141.0,,D,,F,3249,,,Cavia porcellus,1,,2116.0,
,809,9,BAO_0000221,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,20033,,Ileum,CHEMBL619756,Intermediate,10141.0,,D,,F,3250,,,Cavia porcellus,1,,2116.0,
,809,9,BAO_0000221,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,20033,,Ileum,CHEMBL619757,Intermediate,10141.0,,D,,F,3251,,,Cavia porcellus,1,,2116.0,
,809,9,BAO_0000221,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,20033,,Ileum,CHEMBL619758,Intermediate,10141.0,,D,,F,3252,,,Cavia porcellus,1,,2116.0,
,14290,9,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",20033,,Ileum,CHEMBL619759,Intermediate,10141.0,,D,,F,3253,,,Cavia porcellus,1,,2116.0,
,14290,9,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",20033,,Ileum,CHEMBL619760,Intermediate,10141.0,,D,,F,3254,,,Cavia porcellus,1,,2116.0,
,14290,9,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",20033,,Ileum,CHEMBL619761,Intermediate,10141.0,,D,,F,3255,,,Cavia porcellus,1,,2116.0,
,14290,9,BAO_0000221,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,20033,,Ileum,CHEMBL619762,Intermediate,10141.0,,D,,F,3256,,,Cavia porcellus,1,,2116.0,
,14290,9,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",20033,,Ileum,CHEMBL619763,Intermediate,10141.0,,D,,F,3257,,,Cavia porcellus,1,,2116.0,
,14290,9,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",20033,,Ileum,CHEMBL617868,Intermediate,10141.0,,D,,F,3258,,,Cavia porcellus,1,,2116.0,
,15034,9,BAO_0000357,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,20033,,,CHEMBL617869,Intermediate,10141.0,,D,,B,3259,,,Cavia porcellus,1,,,
,5094,9,BAO_0000249,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,,Striatum,CHEMBL882926,Intermediate,10141.0,,D,,B,3260,,,Cavia porcellus,1,,2435.0,
,5094,9,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,,Striatum,CHEMBL617870,Intermediate,10141.0,,D,,B,3261,,,Cavia porcellus,1,,2435.0,
,5399,9,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,20033,,Striatum,CHEMBL617871,Intermediate,10141.0,,D,,B,3262,,,Cavia porcellus,1,,2435.0,
,17394,9,BAO_0000357,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,20033,,Striatum,CHEMBL617872,Intermediate,10141.0,,D,,B,3263,,,Cavia porcellus,1,,2435.0,
,17394,9,BAO_0000357,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,20033,,Striatum,CHEMBL617873,Intermediate,10141.0,,D,,B,3264,,,Cavia porcellus,1,,2435.0,
,17394,9,BAO_0000357,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,20033,,Striatum,CHEMBL617874,Intermediate,10141.0,,D,,B,3265,,,Cavia porcellus,1,,2435.0,
,13961,9,BAO_0000221,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,20033,,Ileum,CHEMBL619067,Intermediate,10141.0,,D,,F,3266,,,Cavia porcellus,1,,2116.0,
,13961,9,BAO_0000221,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,20033,,Ileum,CHEMBL619068,Intermediate,10141.0,,D,,F,3267,,,Cavia porcellus,1,,2116.0,
,13961,9,BAO_0000221,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,20033,,Ileum,CHEMBL619069,Intermediate,10141.0,,D,,F,3268,,,Cavia porcellus,1,,2116.0,
,16946,9,BAO_0000357,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,20033,,,CHEMBL619070,Intermediate,10141.0,,D,,B,3269,,,Cavia porcellus,1,,,
,16946,9,BAO_0000357,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,20033,,,CHEMBL619071,Intermediate,10141.0,,D,,B,3270,,,Cavia porcellus,1,,,
,15034,9,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 4 receptor,20033,,,CHEMBL619072,Intermediate,10141.0,,D,,F,3271,,,Cavia porcellus,1,,,
,15034,9,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,20033,,,CHEMBL619073,Intermediate,10141.0,,D,,F,3272,,,Cavia porcellus,1,,,
,12918,9,BAO_0000019,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,20033,,,CHEMBL619074,Intermediate,10141.0,,D,,F,3273,,,Cavia porcellus,1,,,
,16946,9,BAO_0000357,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,20033,,,CHEMBL619075,Intermediate,10141.0,,D,,B,3274,,,Cavia porcellus,1,,,
,17394,9,BAO_0000357,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,20033,,Striatum,CHEMBL619076,Intermediate,10141.0,,D,,B,3275,,,Cavia porcellus,1,,2435.0,
,15034,9,BAO_0000357,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,20033,,Striatum,CHEMBL619077,Intermediate,10141.0,,D,,B,3276,,,Cavia porcellus,1,,2435.0,
,5094,9,BAO_0000249,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,,Striatum,CHEMBL619078,Intermediate,10141.0,,D,,B,3277,,,Cavia porcellus,1,,2435.0,
,5094,9,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,,Striatum,CHEMBL619079,Intermediate,10141.0,,D,,B,3278,,,Cavia porcellus,1,,2435.0,
,17358,9,BAO_0000221,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,20033,,Ileum,CHEMBL619080,Intermediate,10141.0,,D,,B,3279,,,Cavia porcellus,1,,2116.0,
,12953,9,BAO_0000357,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,20033,,,CHEMBL619081,Expert,10141.0,,D,,B,3280,,,Cavia porcellus,1,,,
,12953,9,BAO_0000357,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,20033,,,CHEMBL619082,Intermediate,10141.0,,D,,B,3281,,,Cavia porcellus,1,,,
,12953,9,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,20033,,,CHEMBL619083,Intermediate,10141.0,,D,,B,3282,,,Cavia porcellus,1,,,
,12953,9,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,20033,,,CHEMBL619084,Intermediate,10141.0,,D,,B,3283,,,Cavia porcellus,1,,,
,273,9,BAO_0000221,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,20033,,Ileum,CHEMBL859397,Intermediate,10141.0,,D,,F,3284,,,Cavia porcellus,1,,2116.0,
,12918,9,BAO_0000221,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,20033,,Ileum,CHEMBL619085,Intermediate,10141.0,,D,,F,3285,,,Cavia porcellus,1,,2116.0,
,12919,9,BAO_0000221,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,20033,,Ileum,CHEMBL619086,Intermediate,10141.0,,D,,F,3286,,,Cavia porcellus,1,,2116.0,
,273,9,BAO_0000221,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,20033,,Ileum,CHEMBL619087,Intermediate,10141.0,,D,,F,3287,,,Cavia porcellus,1,,2116.0,
,273,9,BAO_0000221,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,20033,,Ileum,CHEMBL619088,Intermediate,10141.0,,D,,F,3288,,,Cavia porcellus,1,,2116.0,
,13181,9,BAO_0000357,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,20033,,,CHEMBL619089,Intermediate,10141.0,,D,,B,3289,,,Cavia porcellus,1,,,
,13181,8,BAO_0000357,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,168,,,CHEMBL619090,Autocuration,10141.0,,H,,B,3290,,,Cavia porcellus,1,,,
,15034,9,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 4 receptor,20033,,,CHEMBL619091,Intermediate,10141.0,,D,,F,3291,,,Cavia porcellus,1,,,
,5033,9,BAO_0000357,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,20033,,,CHEMBL619092,Intermediate,10141.0,,D,,B,3292,,,Cavia porcellus,1,,,
,1980,9,BAO_0000019,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,20033,,,CHEMBL619093,Intermediate,10141.0,,D,,B,3293,,,Cavia porcellus,1,,,
,13181,8,BAO_0000219,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,168,,,CHEMBL619094,Autocuration,10141.0,,H,,B,3294,,722.0,Cavia porcellus,1,,,HEK293
,14287,9,BAO_0000019,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,20033,,,CHEMBL619095,Intermediate,10141.0,,D,,B,3295,,,Cavia porcellus,1,,,
,1317,9,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,20033,,,CHEMBL857988,Intermediate,10141.0,,D,,B,3296,,,Cavia porcellus,1,,,
,15316,9,BAO_0000357,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,20033,,,CHEMBL619096,Intermediate,10141.0,,D,,B,3297,,,Cavia porcellus,1,,,
,16429,9,BAO_0000357,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,20033,,Striatum,CHEMBL619097,Intermediate,10141.0,,D,,B,3298,,,Cavia porcellus,1,,2435.0,
,14818,9,BAO_0000221,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,20033,,Hippocampus,CHEMBL619098,Intermediate,10141.0,,D,,B,3299,,,Cavia porcellus,1,,10000000.0,
,15194,9,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,20033,,,CHEMBL619751,Intermediate,10141.0,,D,,B,3300,,,Cavia porcellus,1,,,
,15194,9,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,20033,,,CHEMBL619752,Intermediate,10141.0,,D,,B,3301,,,Cavia porcellus,1,,,
,13961,9,BAO_0000221,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,20033,,Ileum,CHEMBL875096,Intermediate,10141.0,,D,,F,3302,,,Cavia porcellus,1,,2116.0,
,5486,8,BAO_0000357,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,108,,,CHEMBL619004,Autocuration,,,H,,B,3303,,,,1,,,
,16209,8,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,168,,,CHEMBL619005,Autocuration,,,H,,B,3304,,,,1,,,
,17085,8,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,168,,,CHEMBL619006,Autocuration,,,H,,B,3305,,,,1,,,
,4199,8,BAO_0000219,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,168,,,CHEMBL619007,Autocuration,,,H,,B,3306,,308.0,,1,,,HeLa
,15146,8,BAO_0000357,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,168,,,CHEMBL619008,Autocuration,,,H,,B,3307,,,,1,,,
,5213,8,BAO_0000357,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,168,,,CHEMBL619009,Autocuration,,,H,,B,3308,,,,1,,,
,4829,8,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",168,,,CHEMBL619010,Autocuration,,,H,,B,3309,,308.0,,1,,,HeLa
,17358,8,BAO_0000357,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,10622,,,CHEMBL619011,Autocuration,,,H,,B,3310,,,,1,,,
,17358,8,BAO_0000357,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,10622,,,CHEMBL619012,Autocuration,,,H,,B,3311,,,,1,,,
,16946,8,BAO_0000219,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,10622,,,CHEMBL619013,Autocuration,,,H,,B,3312,,,,1,,,
,17358,8,BAO_0000357,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,10622,,,CHEMBL619014,Autocuration,,,H,,B,3313,,,,1,,,
,268,8,BAO_0000019,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,11249,,Cardiac atrium,CHEMBL857503,Autocuration,,,H,,F,3314,,,,1,,2081.0,
,268,8,BAO_0000019,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,11249,,Cardiac atrium,CHEMBL619015,Autocuration,,,H,,F,3315,,,,1,,2081.0,
,15086,8,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,11249,,,CHEMBL619016,Autocuration,,,H,,B,3316,,,,1,,,
,14875,8,BAO_0000221,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,11249,,Hippocampus,CHEMBL619017,Autocuration,,,H,,B,3317,,,,1,,10000000.0,
,13267,8,BAO_0000221,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,168,,Hippocampus,CHEMBL619018,Autocuration,9823.0,,H,,B,3318,,,Sus scrofa,1,,10000000.0,
,13047,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,168,,,CHEMBL619019,Autocuration,9986.0,,H,,B,3319,,,Oryctolagus cuniculus,1,,,
,1650,9,BAO_0000357,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,10623,,,CHEMBL619020,Expert,10116.0,,D,,B,3320,,,Rattus norvegicus,1,,,
,567,8,BAO_0000019,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,10623,,,CHEMBL619021,Autocuration,,,H,,F,3321,,,,1,,,
,17358,8,BAO_0000357,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,10623,,,CHEMBL619022,Autocuration,,,H,,B,3322,,,,1,,,
,188,8,BAO_0000357,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,10623,,,CHEMBL619023,Autocuration,,,H,,B,3323,,,,1,,,
,670,8,BAO_0000019,lntrinsic activity relative to 5-HT receptor,10623,,,CHEMBL619024,Autocuration,,,H,,F,3324,,,,1,,,
,204,8,BAO_0000019,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,10623,,,CHEMBL619025,Autocuration,,,H,,F,3325,,,,1,,,
,1946,8,BAO_0000019,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,10623,,,CHEMBL619026,Expert,,,H,,F,3326,,,,1,,,
,6398,8,BAO_0000019,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,10623,,,CHEMBL619027,Autocuration,,,H,,F,3327,,,,1,,,
,6398,8,BAO_0000019,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,10623,,,CHEMBL619028,Autocuration,,,H,,F,3328,,,,1,,,
,17358,8,BAO_0000019,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,10623,,,CHEMBL619029,Autocuration,,,H,,F,3329,,,,1,,,
,6398,8,BAO_0000019,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,10623,,,CHEMBL619030,Autocuration,,,H,,F,3330,,,,1,,,
,11752,8,BAO_0000357,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,10623,,,CHEMBL619031,Expert,,,H,,B,3331,,,,1,,,
,809,8,BAO_0000019,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,10623,,,CHEMBL619032,Autocuration,,,H,,F,3332,,,,1,,,
,14178,9,BAO_0000357,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,10623,,,CHEMBL619033,Expert,10116.0,,D,,B,3333,,,Rattus norvegicus,1,,,
,567,8,BAO_0000357,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,10623,,,CHEMBL619034,Autocuration,,,H,,B,3334,,,,1,,,
,1946,8,BAO_0000357,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,10623,,,CHEMBL619035,Autocuration,,,H,,B,3335,,,,1,,,
,1946,8,BAO_0000357,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,10623,,,CHEMBL619036,Autocuration,,,H,,B,3336,,,,1,,,
,13961,9,BAO_0000019,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,10623,,,CHEMBL619037,Expert,10116.0,,D,,B,3337,,,Rattus norvegicus,1,,,
,6238,8,BAO_0000249,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,10623,,Striatum,CHEMBL619038,Autocuration,,,H,,B,3338,,,,1,,2435.0,
,14290,8,BAO_0000249,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,10623,,,CHEMBL619039,Autocuration,,,H,,B,3339,,,,1,,,
,14290,8,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,10623,,,CHEMBL619040,Expert,,,H,,B,3340,,,,1,,,
,809,9,BAO_0000019,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,10623,,Striatum,CHEMBL619041,Expert,10116.0,,D,,B,3341,,,Rattus norvegicus,1,,2435.0,
,1578,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,10623,,Striatum,CHEMBL619042,Autocuration,,,H,,B,3342,,,,1,,2435.0,
,16709,8,BAO_0000249,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,10623,,Striatum,CHEMBL619043,Expert,,,H,,B,3343,,,,1,,2435.0,
,1946,8,BAO_0000019,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,10623,,Striatum,CHEMBL619044,Expert,,,H,,B,3344,,,,1,,2435.0,
,15253,8,BAO_0000249,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,10623,,Striatum,CHEMBL619045,Expert,,,H,,B,3345,,,,1,,2435.0,
,4535,8,BAO_0000249,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,10623,,Striatum,CHEMBL619046,Expert,,,H,,B,3346,,,,1,,2435.0,
,13961,8,BAO_0000249,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,10623,,,CHEMBL619047,Expert,,,H,,B,3347,,,,1,,,
,17358,8,BAO_0000221,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,10623,,Brain,CHEMBL619048,Autocuration,,,H,,F,3348,,,,1,,955.0,
,15847,8,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,10623,,,CHEMBL859398,Autocuration,,,H,,F,3349,,,,1,,,
,15847,8,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,10623,,,CHEMBL619049,Autocuration,,,H,,F,3350,,,,1,,,
,670,8,BAO_0000019,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,10623,,,CHEMBL857886,Autocuration,,,H,,F,3351,,,,1,,,
,670,8,BAO_0000019,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,10623,,,CHEMBL619050,Autocuration,,,H,,F,3352,,,,1,,,
,1317,8,BAO_0000019,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,10623,,,CHEMBL620591,Autocuration,,,H,,F,3353,,,,1,,,
,12936,9,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 4 receptor,10623,,,CHEMBL620592,Expert,10116.0,,D,,B,3354,,,Rattus norvegicus,1,,,
,4535,8,BAO_0000249,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,10623,,Striatum,CHEMBL620593,Expert,,,H,,B,3355,,,,1,,2435.0,
,14424,9,BAO_0000019,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,10623,,,CHEMBL620594,Expert,10116.0,,D,,F,3356,,,Rattus norvegicus,1,,,
,14424,8,BAO_0000019,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,10623,,,CHEMBL875079,Expert,,,H,,F,3357,,,,1,,,
,14424,8,BAO_0000019,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,10623,,,CHEMBL620595,Expert,,,H,,F,3358,,,,1,,,
,14424,9,BAO_0000019,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,10623,,,CHEMBL620596,Expert,10116.0,,D,,F,3359,,,Rattus norvegicus,1,,,
,14424,8,BAO_0000019,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,10623,,,CHEMBL620597,Autocuration,,,H,,F,3360,,,,1,,,
,14424,8,BAO_0000019,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,10623,,,CHEMBL620598,Expert,,,H,,F,3361,,,,1,,,
,14424,8,BAO_0000218,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),10623,,,CHEMBL620599,Expert,,,H,,F,3362,,,,1,,,
,14424,8,BAO_0000019,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,10623,,,CHEMBL620600,Autocuration,,,H,,F,3363,,,,1,,,
,1980,8,BAO_0000019,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,168,,,CHEMBL620601,Autocuration,10116.0,,H,,F,3364,,,Rattus norvegicus,1,,,
,4639,8,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,168,,,CHEMBL620602,Autocuration,,,H,,F,3365,,,,1,,,
,17358,8,BAO_0000357,Tested for affinity towards 5-hydroxytryptamine 4 receptor,168,,,CHEMBL620603,Autocuration,,,H,,B,3366,,,,1,,,
,17358,8,BAO_0000357,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,168,,,CHEMBL620604,Autocuration,,,H,,B,3367,,,,1,,,
,17358,8,BAO_0000357,Compound was tested for 5-hydroxytryptamine 4 binding affinity,168,,,CHEMBL620605,Autocuration,,,H,,B,3368,,,,1,,,
,1558,8,BAO_0000357,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,168,,,CHEMBL620606,Autocuration,,,H,,B,3369,,,,1,,,
,17358,8,BAO_0000019,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,168,,,CHEMBL620607,Autocuration,,,H,,F,3370,,,,1,,,
,16117,8,BAO_0000357,In vitro binding affinity towards 5-HT4 receptor was determined,168,,,CHEMBL620608,Autocuration,,,H,,B,3371,,,,1,,,
,17358,8,BAO_0000019,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,168,,,CHEMBL620609,Autocuration,,,H,,F,3372,,,,1,,,
,17358,8,BAO_0000019,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,168,,,CHEMBL620610,Autocuration,,,H,,F,3373,,,,1,,,
,17358,8,BAO_0000357,Tested for selectivity for 5-hydroxytryptamine 4 receptor,168,,,CHEMBL620611,Autocuration,,,H,,B,3374,,,,1,,,
,17358,8,BAO_0000357,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,168,,,CHEMBL620612,Autocuration,,,H,,B,3375,,,,1,,,
,17358,8,BAO_0000357,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,168,,,CHEMBL620613,Autocuration,,,H,,B,3376,,,,1,,,
,17358,8,BAO_0000357,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,168,,,CHEMBL620614,Autocuration,,,H,,B,3377,,,,1,,,
,1274,8,BAO_0000357,Binding affinity against 5-Hydroxytryptamine 4 receptor,168,,,CHEMBL620615,Expert,,,H,,B,3378,,,,1,,,
,10728,6,BAO_0000249,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,104698,,,CHEMBL857075,Autocuration,,Brain membranes,H,,B,3379,,,,1,,,
,11695,6,BAO_0000249,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,104698,,,CHEMBL620616,Autocuration,,Brain membranes,H,,B,3380,,,,1,,,
,11695,6,BAO_0000249,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,104698,,,CHEMBL619411,Autocuration,,Brain membranes,H,,B,3381,,,,1,,,
,12490,6,BAO_0000019,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,104698,,,CHEMBL619412,Autocuration,,,H,,B,3382,,,,1,,,
,11828,7,BAO_0000019,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,104698,,,CHEMBL619413,Autocuration,10116.0,,D,,B,3383,,,Rattus norvegicus,1,,,
,12253,6,BAO_0000221,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,104698,,Hippocampus,CHEMBL619414,Autocuration,,,H,,B,3384,,,,1,,10000000.0,
,10561,6,BAO_0000019,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,104698,,,CHEMBL619415,Autocuration,,,H,,B,3385,,,,1,,,
,10561,6,BAO_0000019,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,104698,,,CHEMBL619416,Autocuration,,,H,,B,3386,,,,1,,,
,14432,6,BAO_0000019,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,104698,,,CHEMBL619417,Autocuration,,,H,,F,3387,,,,1,,,
,12936,7,BAO_0000223,Binding affinity against rat 5-hydroxytryptamine 3 receptor,104698,,,CHEMBL619418,Autocuration,10116.0,,D,,B,3388,,,Rattus norvegicus,1,,,
,1274,7,BAO_0000223,Binding affinity against 5-Hydroxytryptamine 3 receptor,104698,,,CHEMBL619419,Autocuration,10116.0,,D,,B,3389,,,Rattus norvegicus,1,,,
,1980,6,BAO_0000019,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,104698,,,CHEMBL619420,Autocuration,,,H,,B,3390,,,,1,,,
,670,6,BAO_0000249,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,104698,,,CHEMBL619421,Autocuration,,,H,,B,3391,,,,1,,,
,968,7,BAO_0000019,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,104698,,,CHEMBL619422,Autocuration,10116.0,,D,,B,3392,,,Rattus norvegicus,1,,,
,14287,6,BAO_0000019,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,104698,,,CHEMBL619423,Autocuration,,,H,,B,3393,,,,1,,,
,567,6,BAO_0000019,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,104698,,,CHEMBL875080,Autocuration,,,H,,B,3394,,,,1,,,
,13267,6,BAO_0000019,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,104698,,,CHEMBL619424,Autocuration,,,H,,B,3395,,,,1,,,
,14826,6,BAO_0000249,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,104698,,,CHEMBL619425,Autocuration,,,H,,B,3396,,,,1,,,
,15194,6,BAO_0000223,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,104698,,,CHEMBL619426,Autocuration,,,H,,B,3397,,,,1,,,
,15194,6,BAO_0000223,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,104698,,,CHEMBL619427,Autocuration,,,H,,B,3398,,,,1,,,
,10394,7,BAO_0000223,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,104698,,,CHEMBL619645,Autocuration,10116.0,,D,,B,3399,,,Rattus norvegicus,1,,,
,13657,9,BAO_0000249,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",10576,,,CHEMBL619646,Expert,,,D,,B,3400,,,,1,,,
,1879,8,BAO_0000221,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,12020,,Brain,CHEMBL619647,Autocuration,,,H,,F,3401,,,,1,,955.0,
,1879,8,BAO_0000019,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,12020,,,CHEMBL619648,Autocuration,,,H,,F,3402,,,,1,,,
,1879,8,BAO_0000019,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,12020,,,CHEMBL619165,Autocuration,,,H,,F,3403,,,,1,,,
,204,8,BAO_0000218,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,12020,In vivo,,CHEMBL620719,Autocuration,,,H,,F,3404,,,,1,,,
,1879,8,BAO_0000019,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,12020,,,CHEMBL872924,Autocuration,,,H,,B,3405,,,,1,,,
,1879,8,BAO_0000357,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,12020,,,CHEMBL620720,Autocuration,,,H,,B,3406,,,,1,,,
,1879,8,BAO_0000019,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,12020,,,CHEMBL620721,Autocuration,,,H,,B,3407,,,,1,,,
,1879,8,BAO_0000019,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,12020,,,CHEMBL620722,Autocuration,,,H,,B,3408,,,,1,,,
,10641,6,BAO_0000019,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",104698,,,CHEMBL620723,Autocuration,,,H,,B,3409,,,,1,,,
,773,8,BAO_0000019,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,12020,,,CHEMBL620724,Autocuration,,,H,,B,3410,,,,1,,,
,11952,6,BAO_0000249,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,104698,,,CHEMBL620725,Autocuration,,,H,,B,3411,,,,1,,,
,14145,9,BAO_0000019,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,12020,,,CHEMBL620726,Autocuration,10116.0,,D,,F,3412,,,Rattus norvegicus,1,,,
,17066,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 3 receptor,144,,,CHEMBL620727,Expert,,,H,,B,3413,,,,1,,,
,6398,4,BAO_0000223,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,104714,,,CHEMBL620728,Autocuration,,,H,,B,3414,,,,1,,,
,10321,0,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,22226,,,CHEMBL620729,Autocuration,,,U,,B,3415,,,,1,,,
,511,4,BAO_0000019,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,104714,,,CHEMBL858288,Autocuration,,,H,,F,3416,,,,1,,,
,4639,4,BAO_0000223,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,104714,,,CHEMBL620730,Autocuration,,,H,,B,3417,,,,1,,,
,4639,4,BAO_0000223,Binding affinity towards 5-hydroxytryptamine 3 receptor,104714,,,CHEMBL620731,Autocuration,,,H,,B,3418,,,,1,,,
,4639,4,BAO_0000019,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,104714,,,CHEMBL620732,Autocuration,10141.0,,H,,F,3419,,,Cavia porcellus,1,,,
,4639,4,BAO_0000019,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,104714,,,CHEMBL618042,Autocuration,10141.0,,H,,F,3420,,,Cavia porcellus,1,,,
,4639,4,BAO_0000019,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,104714,,,CHEMBL618043,Autocuration,10141.0,,H,,F,3421,,,Cavia porcellus,1,,,
,1558,4,BAO_0000223,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,104714,,,CHEMBL618044,Autocuration,,,H,,B,3422,,,,1,,,
,268,4,BAO_0000019,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,104714,,,CHEMBL618045,Autocuration,,,H,,F,3423,,,,1,,,
,2474,4,BAO_0000223,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,104714,,,CHEMBL618046,Autocuration,,,H,,B,3424,,,,1,,,
,5067,4,BAO_0000019,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,104714,,,CHEMBL618047,Autocuration,,,H,,F,3425,,,,1,,,
,5067,4,BAO_0000019,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,104714,,,CHEMBL875084,Autocuration,,,H,,F,3426,,,,1,,,
,5067,4,BAO_0000019,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,104714,,,CHEMBL618048,Autocuration,,,H,,F,3427,,,,1,,,
,5067,4,BAO_0000223,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,104714,,,CHEMBL618049,Autocuration,,,H,,B,3428,,,,1,,,
,5067,4,BAO_0000019,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,104714,,,CHEMBL619764,Autocuration,,,H,,F,3429,,,,1,,,
,5067,4,BAO_0000019,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,104714,,,CHEMBL619765,Autocuration,,,H,,F,3430,,,,1,,,
,5067,4,BAO_0000019,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,104714,,,CHEMBL619766,Autocuration,,,H,,F,3431,,,,1,,,
,5067,4,BAO_0000223,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,104714,,,CHEMBL619767,Autocuration,,,H,,B,3432,,,,1,,,
,5067,4,BAO_0000223,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,104714,,,CHEMBL619768,Autocuration,,,H,,B,3433,,,,1,,,
,5067,4,BAO_0000019,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,104714,,,CHEMBL619769,Autocuration,,,H,,F,3434,,,,1,,,
,5067,4,BAO_0000223,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,104714,,,CHEMBL619770,Autocuration,,,H,,B,3435,,,,1,,,
,5067,4,BAO_0000223,Binding affinity towards 5-hydroxytryptamine 3 receptor,104714,,,CHEMBL619771,Autocuration,,,H,,B,3436,,,,1,,,
,14331,4,BAO_0000219,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,104714,,,CHEMBL619772,Autocuration,,,H,,B,3437,,,,1,,,
,5067,4,BAO_0000223,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,104714,,,CHEMBL619773,Autocuration,,,H,,B,3438,,,,1,,,
,6179,4,BAO_0000219,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,104714,,,CHEMBL619774,Autocuration,,,H,,B,3439,,433.0,,1,,,NG108-15
,4265,4,BAO_0000019,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,104714,,,CHEMBL875083,Autocuration,,,H,,B,3440,,,,1,,,
,4265,4,BAO_0000219,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,104714,,,CHEMBL620718,Autocuration,,,H,,B,3441,,433.0,,1,,,NG108-15
,17358,4,BAO_0000223,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,104714,,,CHEMBL618127,Autocuration,,,H,,B,3442,,,,1,,,
,17358,4,BAO_0000223,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,104714,,,CHEMBL618128,Autocuration,,,H,,B,3443,,,,1,,,
,13628,4,BAO_0000219,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,104714,In vitro,,CHEMBL618129,Autocuration,,,H,,B,3444,,,,1,,,
,4612,4,BAO_0000223,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,104714,,,CHEMBL618130,Autocuration,,,H,,B,3445,,,,1,,,
,17358,4,BAO_0000019,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,104714,,,CHEMBL618131,Autocuration,,,H,,F,3446,,,,1,,,
,4639,4,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,104714,,,CHEMBL618132,Autocuration,10141.0,,H,,F,3447,,,Cavia porcellus,1,,,
,4639,4,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,104714,,,CHEMBL618133,Autocuration,10141.0,,H,,F,3448,,,Cavia porcellus,1,,,
,4639,4,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,104714,,,CHEMBL618134,Autocuration,10141.0,,H,,F,3449,,,Cavia porcellus,1,,,
,4639,4,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,104714,,,CHEMBL618135,Autocuration,10141.0,,H,,F,3450,,,Cavia porcellus,1,,,
,511,4,BAO_0000223,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,104714,,,CHEMBL618136,Autocuration,,,H,,B,3451,,,,1,,,
,1479,4,BAO_0000223,Binding affinity towards 5-hydroxytryptamine 3 receptor,104714,,,CHEMBL618137,Autocuration,,,H,,B,3452,,,,1,,,
,1317,4,BAO_0000223,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,104714,,,CHEMBL618138,Autocuration,,,H,,B,3453,,,,1,,,
,12146,4,BAO_0000223,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,104714,,,CHEMBL618139,Autocuration,,,H,,B,3454,,,,1,,,
,12146,4,BAO_0000223,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,104714,,,CHEMBL618140,Autocuration,,,H,,B,3455,,,,1,,,
,13969,4,BAO_0000223,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,104714,,,CHEMBL618141,Autocuration,,,H,,B,3456,,,,1,,,
,13392,8,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2C receptor,108,,,CHEMBL873478,Expert,,,H,,B,3457,,,,1,,,
,13392,6,BAO_0000223,Binding affinity towards 5-hydroxytryptamine 3 receptor,104698,,,CHEMBL618142,Autocuration,,,H,,B,3458,,,,1,,,
,14159,8,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,144,,,CHEMBL618143,Autocuration,,,H,,B,3459,,,,1,,,
,1558,8,BAO_0000357,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,144,,,CHEMBL618144,Autocuration,,,H,,B,3460,,,,1,,,
,16655,8,BAO_0000357,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,144,,,CHEMBL618145,Autocuration,,,H,,B,3461,,,,1,,,
,13020,4,BAO_0000223,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,104714,,,CHEMBL618146,Autocuration,,,H,,B,3462,,,,1,,,
,13021,4,BAO_0000223,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,104714,,,CHEMBL618147,Autocuration,,,H,,B,3463,,,,1,,,
,13020,4,BAO_0000223,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,104714,,,CHEMBL618148,Autocuration,,,H,,B,3464,,,,1,,,
,10321,8,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,144,,,CHEMBL618149,Autocuration,,,H,,B,3465,,,,1,,,
,15818,8,BAO_0000357,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,144,,,CHEMBL872927,Autocuration,,,H,,B,3466,,,,1,,,
,15818,8,BAO_0000357,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,144,,,CHEMBL618150,Autocuration,,,H,,B,3467,,,,1,,,
,17358,8,BAO_0000357,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,144,,,CHEMBL618151,Autocuration,,,H,,B,3468,,,,1,,,
,2222,8,BAO_0000357,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,144,,,CHEMBL875094,Autocuration,,,H,,B,3469,,,,1,,,
,10322,8,BAO_0000019,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,144,,,CHEMBL618152,Autocuration,,,H,,B,3470,,,,1,,,
,16117,8,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,144,,,CHEMBL618153,Autocuration,,,H,,B,3471,,,,1,,,
,17200,8,BAO_0000357,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,144,,,CHEMBL618888,Autocuration,,,H,,B,3472,,,,1,,,
,17358,8,BAO_0000019,Tested for 5-hydroxytryptamine 3 receptor agonist activity,144,,,CHEMBL618889,Autocuration,,,H,,F,3473,,,,1,,,
,16700,8,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,144,,,CHEMBL618890,Autocuration,,,H,,B,3474,,,,1,,,
,1980,8,BAO_0000019,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,144,,,CHEMBL618891,Autocuration,,,H,,B,3475,,,,1,,,
,1980,8,BAO_0000019,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,144,,,CHEMBL619054,Autocuration,,,H,,B,3476,,,,1,,,
,12409,4,BAO_0000223,Binding affinity against the 5-hydroxytryptamine 3 receptor,104714,,,CHEMBL619055,Autocuration,,,H,,B,3477,,,,1,,,
,4365,8,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 3A receptor,144,,,CHEMBL619056,Autocuration,,,H,,B,3478,,,,1,,,
,4365,8,BAO_0000019,Percent efficacy against 5-hydroxytryptamine 3A receptor,144,,,CHEMBL619057,Autocuration,,,H,,F,3479,,,,1,,,
,4365,8,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 3A receptor,144,,,CHEMBL619058,Autocuration,,,H,,B,3480,,,,1,,,
,6769,9,BAO_0000219,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,12020,,,CHEMBL619059,Expert,10116.0,,D,,F,3481,,,Rattus norvegicus,1,,,Oocytes
,6769,9,BAO_0000219,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,12020,,,CHEMBL619060,Expert,10116.0,,D,,F,3482,,,Rattus norvegicus,1,,,Oocytes
,6769,9,BAO_0000219,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,12020,,,CHEMBL875095,Expert,10116.0,,D,,F,3483,,,Rattus norvegicus,1,,,Oocytes
,809,9,BAO_0000221,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,20033,,Ileum,CHEMBL619061,Intermediate,10141.0,,D,,F,3484,,,Cavia porcellus,1,,2116.0,
,809,9,BAO_0000221,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,20033,,Ileum,CHEMBL619062,Intermediate,10141.0,,D,,F,3485,,,Cavia porcellus,1,,2116.0,
,14290,9,BAO_0000019,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,20033,,,CHEMBL619063,Intermediate,10141.0,,D,,F,3486,,,Cavia porcellus,1,,,
,17358,9,BAO_0000221,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,20033,,Ileum,CHEMBL619064,Intermediate,10141.0,,D,,B,3487,,,Cavia porcellus,1,,2116.0,
,17358,9,BAO_0000357,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,20033,,,CHEMBL619065,Intermediate,10141.0,,D,,B,3488,,,Cavia porcellus,1,,,
,17358,9,BAO_0000221,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,20033,,Ileum,CHEMBL619066,Intermediate,10141.0,,D,,B,3489,,,Cavia porcellus,1,,2116.0,
,17386,8,BAO_0000221,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,10209,,Ileum,CHEMBL619775,Autocuration,,,H,,B,3490,,,,1,,2116.0,
,3269,8,BAO_0000357,Affinity against 5-hydroxytryptamine 7 receptor,10209,,,CHEMBL619776,Autocuration,,,H,,B,3491,,,,1,,,
,7721,4,BAO_0000224,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,104841,,,CHEMBL619777,Autocuration,10141.0,,H,,B,3492,,,Cavia porcellus,1,,,
,7721,4,BAO_0000224,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,104841,,,CHEMBL619778,Autocuration,10141.0,,H,,B,3493,,,Cavia porcellus,1,,,
,9117,4,BAO_0000221,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,104841,,Ileum,CHEMBL619779,Autocuration,10141.0,,H,,B,3494,,,Cavia porcellus,1,,2116.0,
,7721,4,BAO_0000224,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",104841,,,CHEMBL619780,Autocuration,10141.0,,H,,B,3495,,,Cavia porcellus,1,,,
,7721,4,BAO_0000224,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",104841,,,CHEMBL619166,Autocuration,10141.0,,H,,B,3496,,,Cavia porcellus,1,,,
,15796,4,BAO_0000019,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,104841,,,CHEMBL619167,Autocuration,10141.0,,H,,F,3497,,,Cavia porcellus,1,,,
,15796,4,BAO_0000019,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,104841,,,CHEMBL619168,Autocuration,10141.0,,H,,F,3498,,,Cavia porcellus,1,,,
,15650,9,BAO_0000219,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,168,,Cardiac atrium,CHEMBL619169,Expert,9606.0,,D,,B,3499,,,Homo sapiens,1,,2081.0,
,15650,9,BAO_0000219,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,168,,Cardiac atrium,CHEMBL619170,Expert,9606.0,,D,,B,3500,,,Homo sapiens,1,,2081.0,
,6866,5,BAO_0000019,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",104841,,,CHEMBL619171,Autocuration,9606.0,,D,,F,3501,,,Homo sapiens,1,,,
,15650,9,BAO_0000219,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",168,,Cardiac atrium,CHEMBL619172,Expert,9606.0,,D,,F,3502,,,Homo sapiens,1,,2081.0,
,10063,0,BAO_0000019,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,22226,,,CHEMBL619173,Autocuration,10090.0,,U,,B,3503,,,Mus musculus,1,,,
,12665,0,BAO_0000019,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,22226,,,CHEMBL619174,Autocuration,10090.0,,U,,B,3504,,,Mus musculus,1,,,
,7504,4,BAO_0000019,5-hydroxytryptamine receptor binding affinity was determined in rats,104705,,,CHEMBL619175,Autocuration,,,H,,B,3505,,,,1,,,
,7504,4,BAO_0000224,Binding affinity at rat 5-hydroxytryptamine receptor.,104705,,,CHEMBL619176,Autocuration,,,H,,B,3506,,,,1,,,
,7038,4,BAO_0000019,Affinity against 5-hydroxytryptamine receptors in rat fundus model,104705,,,CHEMBL619177,Autocuration,,,H,,B,3507,,,,1,,,
,7626,4,BAO_0000224,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,104705,,,CHEMBL619178,Autocuration,,,H,,B,3508,,,,1,,,
,7626,4,BAO_0000224,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,104705,,,CHEMBL619179,Autocuration,,,H,,B,3509,,,,1,,,
,7185,4,BAO_0000019,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,104705,,Stomach,CHEMBL619180,Autocuration,,,H,,F,3510,,,,1,,945.0,
,7185,4,BAO_0000019,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,104705,,Stomach,CHEMBL619181,Autocuration,,,H,,F,3511,,,,1,,945.0,
,7185,4,BAO_0000019,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,104705,,,CHEMBL619182,Autocuration,,,H,,F,3512,,,,1,,,
,6960,4,BAO_0000224,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,104705,,,CHEMBL619183,Autocuration,,,H,,B,3513,,,,1,,,
,6960,4,BAO_0000224,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",104705,,,CHEMBL619184,Autocuration,,,H,,B,3514,,,,1,,,
,12416,8,BAO_0000221,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,10576,,Hippocampus,CHEMBL619185,Autocuration,,,H,,B,3515,,,,1,,10000000.0,
,15753,8,BAO_0000357,Binding affinity for rat 5-hydroxytryptamine transporter.,12198,,,CHEMBL619186,Expert,,,H,,B,3516,,,,1,,,
,8062,4,BAO_0000019,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,104705,,,CHEMBL619187,Autocuration,,,H,,B,3517,,,,1,,,
,9036,5,BAO_0000019,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,104705,,,CHEMBL619188,Autocuration,10116.0,,D,,B,3518,,,Rattus norvegicus,1,,,
,15067,5,BAO_0000224,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,104705,,,CHEMBL619189,Autocuration,10116.0,,D,,B,3519,,,Rattus norvegicus,1,,,
,15753,9,BAO_0000019,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,12198,,Brain,CHEMBL619190,Expert,10116.0,,D,,F,3520,,,Rattus norvegicus,1,,955.0,
,15753,9,BAO_0000221,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,12198,,Cerebellum,CHEMBL619191,Expert,10116.0,,D,,F,3521,,,Rattus norvegicus,1,,2037.0,
,15295,5,BAO_0000019,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,104705,,,CHEMBL619192,Autocuration,10116.0,,D,,B,3522,,,Rattus norvegicus,1,,,
,6347,5,BAO_0000224,Percent binding affinity against 5-hydroxytryptamine receptor,104705,,,CHEMBL619193,Autocuration,10116.0,,D,,B,3523,,,Rattus norvegicus,1,,,
,6763,0,BAO_0000019,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,22226,,,CHEMBL619194,Autocuration,,,U,,B,3524,,,,1,,,
,12092,5,BAO_0000224,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,104705,,,CHEMBL619195,Autocuration,10116.0,,D,,B,3525,,,Rattus norvegicus,1,,,
,1579,5,BAO_0000224,Affinity against 5-hydroxytryptamine receptor was determined,104705,,,CHEMBL619196,Autocuration,10116.0,,D,,B,3526,,,Rattus norvegicus,1,,,
,1579,5,BAO_0000019,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,104705,,Stomach,CHEMBL619197,Autocuration,10116.0,,D,,B,3527,,,Rattus norvegicus,1,,945.0,
,5963,9,BAO_0000219,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,121,In vitro,,CHEMBL619198,Expert,9606.0,,D,,B,3528,,,Homo sapiens,1,,,
,5963,9,BAO_0000219,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,121,In vitro,,CHEMBL875081,Expert,9606.0,,D,,B,3529,,,Homo sapiens,1,,,
,5030,8,BAO_0000357,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,18065,,,CHEMBL884712,Autocuration,,,H,,B,3530,,,,1,,,
,15796,8,BAO_0000357,Inhibition of 5-hydroxytryptamine reuptake,121,,,CHEMBL884710,Expert,,,H,,B,3531,,,,1,,,
,15413,8,BAO_0000019,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",18065,,,CHEMBL619199,Autocuration,,,H,,F,3532,,,,1,,,
,15413,8,BAO_0000019,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",18065,,,CHEMBL619200,Autocuration,,,H,,F,3533,,,,1,,,
,15413,8,BAO_0000019,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",18065,,,CHEMBL619201,Autocuration,,,H,,F,3534,,,,1,,,
,12409,8,BAO_0000019,Tested for 5-hydroxytryptamine receptor uptake,18065,,,CHEMBL619202,Autocuration,,,H,,F,3535,,,,1,,,
,16909,9,BAO_0000219,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,51,,,CHEMBL619203,Expert,9606.0,,D,,B,3536,,449.0,Homo sapiens,1,,,CHO
,16909,9,BAO_0000019,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,51,,,CHEMBL619204,Expert,9606.0,,D,,F,3537,,,Homo sapiens,1,,,
,15629,8,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,10576,,,CHEMBL619205,Autocuration,9606.0,,H,,B,3538,,,Homo sapiens,1,,,
,15629,8,BAO_0000357,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,10576,,,CHEMBL619206,Autocuration,,,H,,B,3539,,,,1,,,
,15629,8,BAO_0000249,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,10576,,,CHEMBL619207,Expert,,,H,,B,3540,,,,1,,,
,10034,8,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,10825,,Striatum,CHEMBL619208,Autocuration,,,H,,F,3541,,,,1,,2435.0,
,10034,8,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,10825,,Striatum,CHEMBL619209,Autocuration,,,H,,F,3542,,,,1,,2435.0,
,10034,8,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,10825,,Striatum,CHEMBL619210,Autocuration,,,H,,F,3543,,,,1,,2435.0,
,10034,8,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,10825,,Striatum,CHEMBL619211,Autocuration,,,H,,F,3544,,,,1,,2435.0,
,10034,8,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,10825,,Striatum,CHEMBL619212,Autocuration,,,H,,F,3545,,,,1,,2435.0,
,10034,8,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,10825,,Striatum,CHEMBL620681,Autocuration,,,H,,F,3546,,,,1,,2435.0,
,10034,8,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,10825,,Striatum,CHEMBL620682,Autocuration,,,H,,F,3547,,,,1,,2435.0,
,10034,8,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,10825,,Striatum,CHEMBL620683,Autocuration,,,H,,F,3548,,,,1,,2435.0,
,10034,8,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,10825,,Striatum,CHEMBL620684,Autocuration,,,H,,F,3549,,,,1,,2435.0,
,10034,8,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,10825,,Striatum,CHEMBL620685,Autocuration,,,H,,F,3550,,,,1,,2435.0,
,10034,8,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,10825,,Striatum,CHEMBL620686,Autocuration,,,H,,F,3551,,,,1,,2435.0,
,10034,8,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,10825,,Limbic system,CHEMBL620687,Autocuration,,,H,,F,3552,,,,1,,349.0,
,10034,8,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,10825,,Limbic system,CHEMBL620688,Autocuration,,,H,,F,3553,,,,1,,349.0,
,10034,8,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,10825,,Limbic system,CHEMBL620689,Autocuration,,,H,,F,3554,,,,1,,349.0,
,10034,8,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,10825,,Limbic system,CHEMBL620690,Autocuration,,,H,,F,3555,,,,1,,349.0,
,10034,8,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,10825,,Limbic system,CHEMBL620691,Autocuration,,,H,,F,3556,,,,1,,349.0,
,10034,8,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,10825,,Limbic system,CHEMBL620692,Autocuration,,,H,,F,3557,,,,1,,349.0,
,10034,8,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,10825,,Limbic system,CHEMBL620693,Autocuration,,,H,,F,3558,,,,1,,349.0,
,1274,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 4 receptor,168,,,CHEMBL620694,Expert,,,H,,B,3559,,,,1,,,
,17358,8,BAO_0000019,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,168,,,CHEMBL857986,Autocuration,,,H,,F,3560,,,,1,,,
,14532,8,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,168,,,CHEMBL620695,Autocuration,,,H,,B,3561,,,,1,,,
,16989,8,BAO_0000357,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,168,,,CHEMBL620696,Expert,,,H,,B,3562,,,,1,,,
,17200,8,BAO_0000357,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,168,,,CHEMBL620697,Autocuration,,,H,,B,3563,,,,1,,,
,15779,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 4 receptor,168,,,CHEMBL620698,Autocuration,,,H,,B,3564,,,,1,,,
,15779,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,168,,,CHEMBL620699,Autocuration,,,H,,B,3565,,,,1,,,
,15779,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,168,,,CHEMBL620700,Autocuration,,,H,,B,3566,,,,1,,,
,15650,8,BAO_0000219,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,168,,,CHEMBL620701,Autocuration,,,H,,B,3567,,643.0,,1,,,COS-7
,15650,8,BAO_0000219,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,168,,,CHEMBL875082,Autocuration,,,H,,B,3568,,643.0,,1,,,COS-7
,15650,8,BAO_0000219,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,168,,,CHEMBL620702,Autocuration,,,H,,B,3569,,643.0,,1,,,COS-7
,15650,8,BAO_0000219,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,168,,,CHEMBL620703,Autocuration,,,H,,B,3570,,643.0,,1,,,COS-7
,17046,8,BAO_0000219,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,168,,,CHEMBL620704,Autocuration,,,H,,B,3571,,673.0,,1,,,C6
,17046,8,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,168,,,CHEMBL620705,Expert,,,H,,B,3572,,673.0,,1,,,C6
,15650,8,BAO_0000219,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,168,,,CHEMBL620706,Expert,,,H,,B,3573,,673.0,,1,,,C6
,17046,8,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,168,,,CHEMBL620707,Expert,,,H,,B,3574,,673.0,,1,,,C6
,17066,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 5 receptor,10624,,,CHEMBL620708,Expert,,,H,,B,3575,,,,1,,,
,17200,8,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,105,,,CHEMBL620709,Autocuration,,,H,,B,3576,,,,1,,,
,16146,9,BAO_0000357,Binding affinity against 5-hydroxytryptamine 5A receptor,10624,,,CHEMBL620710,Expert,9606.0,,D,,B,3577,,,Homo sapiens,1,,,
,15250,8,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,10624,,,CHEMBL620711,Autocuration,,,H,,B,3578,,449.0,,1,,,CHO
,6491,9,BAO_0000357,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,10624,,,CHEMBL620712,Expert,9606.0,,D,,B,3579,,,Homo sapiens,1,,,
,17066,9,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 5A receptor,10624,,,CHEMBL620713,Expert,9606.0,,D,,B,3580,,,Homo sapiens,1,,,
,17066,9,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,10624,,,CHEMBL620714,Expert,9606.0,,D,,B,3581,,,Homo sapiens,1,,,
,4234,9,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,10624,,,CHEMBL620715,Expert,9606.0,,D,,B,3582,,,Homo sapiens,1,,,
,6013,8,BAO_0000357,Binding affinity towards 5-HT5A receptor,10624,,,CHEMBL620716,Autocuration,,,H,,B,3583,,,,1,,,
,17175,8,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,10624,,,CHEMBL620717,Expert,,,H,,B,3584,,,,1,,,
,15818,8,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,10624,,,CHEMBL618072,Autocuration,,,H,,B,3585,,,,1,,,
,6166,8,BAO_0000357,Binding affinity towards cloned human 5-HT5A receptor was determined,10624,,,CHEMBL857987,Autocuration,,,H,,B,3586,,,,1,,,
,15779,8,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,10624,,,CHEMBL618073,Autocuration,,,H,,B,3587,,722.0,,1,,,HEK293
,15779,8,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,10624,,,CHEMBL618074,Autocuration,,,H,,B,3588,,722.0,,1,,,HEK293
,5213,8,BAO_0000219,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),10624,,,CHEMBL618075,Autocuration,,,H,,B,3589,,722.0,,1,,,HEK293
,17066,9,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,10625,,,CHEMBL618076,Expert,10090.0,,D,,B,3590,,,Mus musculus,1,,,
,17066,9,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,10625,,,CHEMBL618077,Expert,10090.0,,D,,B,3591,,,Mus musculus,1,,,
,17066,9,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,10625,,,CHEMBL618078,Expert,10090.0,,D,,B,3592,,,Mus musculus,1,,,
,17066,9,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,10625,,,CHEMBL881821,Expert,10090.0,,D,,B,3593,,,Mus musculus,1,,,
,17066,9,BAO_0000357,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,10625,,,CHEMBL618079,Expert,10090.0,,D,,B,3594,,,Mus musculus,1,,,
,17175,8,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,10625,,,CHEMBL618080,Expert,,,H,,B,3595,,,,1,,,
,16190,8,BAO_0000219,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,10576,,,CHEMBL618081,Autocuration,,,H,,B,3596,,722.0,,1,,,HEK293
,16190,8,BAO_0000219,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,10626,,,CHEMBL618082,Autocuration,,,H,,B,3597,,722.0,,1,,,HEK293
,4820,8,BAO_0000357,Binding affinity towards 5-HT5a receptor,10624,,,CHEMBL618083,Expert,,,H,,B,3598,,,,1,,,
,17066,9,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 5A receptor,10624,,,CHEMBL618084,Expert,9606.0,,D,,B,3599,,,Homo sapiens,1,,,
,17066,8,BAO_0000357,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,10624,,,CHEMBL618085,Expert,,,H,,B,3600,,,,1,,,
,17175,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,10624,,,CHEMBL618086,Expert,,,H,,B,3601,,,,1,,,
,16633,8,BAO_0000357,Binding affinities against 5-hydroxytryptamine 5A receptor,10624,,,CHEMBL875092,Autocuration,,,H,,B,3602,,,,1,,,
,16633,8,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 5A receptor,10624,,,CHEMBL618087,Autocuration,,,H,,B,3603,,,,1,,,
,16700,8,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,10624,,,CHEMBL872926,Autocuration,,,H,,B,3604,,,,1,,,
,4639,4,BAO_0000019,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,104714,,,CHEMBL618088,Autocuration,10141.0,,H,,F,3605,,,Cavia porcellus,1,,,
,5486,4,BAO_0000223,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,104714,,,CHEMBL618089,Autocuration,,,H,,B,3606,,,,1,,,
,16146,9,BAO_0000357,Inhibition of human 5-hydroxytryptamine 6 receptor,10627,,,CHEMBL618090,Expert,9606.0,,D,,B,3607,,,Homo sapiens,1,,,
,17273,9,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,10627,,,CHEMBL618091,Expert,9606.0,,D,,B,3608,,,Homo sapiens,1,,,
,17687,8,BAO_0000357,Inhibition against human 5-hydroxytryptamine 6 receptor,10627,,,CHEMBL618092,Autocuration,,,H,,B,3609,,,,1,,,
,6491,9,BAO_0000357,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,10627,,,CHEMBL618093,Expert,9606.0,,D,,B,3610,,,Homo sapiens,1,,,
,16190,8,BAO_0000219,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,10627,,,CHEMBL618094,Expert,,,H,,B,3611,,308.0,,1,,,HeLa
,17066,9,BAO_0000357,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,10627,,,CHEMBL618095,Expert,9606.0,,D,,B,3612,,,Homo sapiens,1,,,
,17066,9,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,,CHEMBL875093,Expert,9606.0,,D,,B,3613,,,Homo sapiens,1,,,
,17066,9,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,10627,,,CHEMBL618096,Expert,9606.0,,D,,B,3614,,,Homo sapiens,1,,,
,17066,9,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,10627,,,CHEMBL618118,Expert,9606.0,,D,,B,3615,,,Homo sapiens,1,,,
,3555,9,BAO_0000357,Binding affinity against 5-hydroxytryptamine 6 receptor,10627,,,CHEMBL618119,Expert,9606.0,,D,,B,3616,,,Homo sapiens,1,,,
,5808,8,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,,CHEMBL618120,Expert,,,H,,B,3617,,,,1,,,
,6013,8,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,,CHEMBL618121,Autocuration,,,H,,B,3618,,,,1,,,
,15818,8,BAO_0000219,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",10627,,,CHEMBL618122,Expert,,,H,,B,3619,,722.0,,1,,,HEK293
,16209,8,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,10627,,,CHEMBL618123,Autocuration,,,H,,B,3620,,,,1,,,
,3935,8,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,10627,,,CHEMBL618124,Expert,,,H,,B,3621,,722.0,,1,,,HEK293
,15818,8,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,,CHEMBL618125,Autocuration,,,H,,B,3622,,,,1,,,
,3805,9,BAO_0000219,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,10627,,,CHEMBL618126,Expert,9606.0,,D,,B,3623,,722.0,Homo sapiens,1,,,HEK293
,16441,8,BAO_0000019,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,10627,,,CHEMBL618236,Expert,,,H,,B,3624,,,,1,,,
,16441,8,BAO_0000019,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,10627,,,CHEMBL618237,Expert,,,H,,B,3625,,,,1,,,
,6786,8,BAO_0000219,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,10627,,,CHEMBL618238,Expert,,,H,,B,3626,,643.0,,1,,,COS-7
,4234,9,BAO_0000357,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,10627,,,CHEMBL618239,Expert,9606.0,,D,,B,3627,,,Homo sapiens,1,,,
,17085,8,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,10627,,,CHEMBL618240,Autocuration,,,H,,B,3628,,,,1,,,
,17200,8,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,10627,,,CHEMBL618241,Autocuration,,,H,,B,3629,,,,1,,,
,17451,8,BAO_0000219,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,10627,,,CHEMBL859399,Autocuration,,,H,,B,3630,,722.0,,1,,,HEK293
,3935,8,BAO_0000019,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,10627,,,CHEMBL618242,Autocuration,,,H,,F,3631,,,,1,,,
,5033,8,BAO_0000357,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,10627,,,CHEMBL857991,Autocuration,,,H,,B,3632,,,,1,,,
,4540,8,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 6 receptor,10627,,,CHEMBL619951,Expert,,,H,,B,3633,,,,1,,,
,4540,9,BAO_0000219,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,10627,,,CHEMBL619952,Expert,9606.0,,D,,B,3634,,308.0,Homo sapiens,1,,,HeLa
,4540,9,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,10627,,,CHEMBL619953,Expert,9606.0,,D,,B,3635,,308.0,Homo sapiens,1,,,HeLa
,17296,8,BAO_0000219,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,10627,,,CHEMBL619954,Autocuration,,,H,,B,3636,,308.0,,1,,,HeLa
,17296,8,BAO_0000219,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,10627,,,CHEMBL619955,Autocuration,,,H,,B,3637,,308.0,,1,,,HeLa
,17296,8,BAO_0000219,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,10627,,,CHEMBL619956,Autocuration,,,H,,B,3638,,308.0,,1,,,HeLa
,15779,8,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,10627,,,CHEMBL619957,Autocuration,,,H,,B,3639,,449.0,,1,,,CHO
,15779,8,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,10627,,,CHEMBL619958,Autocuration,,,H,,B,3640,,722.0,,1,,,HEK293
,15779,8,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,10627,,,CHEMBL620627,Autocuration,,,H,,B,3641,,722.0,,1,,,HEK293
,15779,8,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,10627,,,CHEMBL620628,Autocuration,,,H,,B,3642,,722.0,,1,,,HEK293
,15779,8,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,10627,,,CHEMBL620629,Autocuration,,,H,,B,3643,,308.0,,1,,,HeLa
,6166,8,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,,CHEMBL620630,Autocuration,,,H,,B,3644,,,,1,,,
,17451,8,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,10627,,,CHEMBL620782,Autocuration,,,H,,B,3645,,308.0,,1,,,HeLa
,15316,8,BAO_0000357,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,10627,,,CHEMBL620783,Autocuration,,,H,,B,3646,,,,1,,,
,4199,8,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 6 receptor,10627,,,CHEMBL620784,Expert,,,H,,B,3647,,,,1,,,
,15146,8,BAO_0000219,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,10627,,,CHEMBL620785,Expert,,,H,,B,3648,,308.0,,1,,,HeLa
,5213,8,BAO_0000357,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),10627,,,CHEMBL857992,Autocuration,,,H,,B,3649,,,,1,,,
,16429,8,BAO_0000219,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,10627,,,CHEMBL620786,Autocuration,,,H,,B,3650,,,,1,,,
,14818,8,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,10627,,,CHEMBL620787,Autocuration,,,H,,B,3651,,308.0,,1,,,HeLa
,4829,8,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",10627,,,CHEMBL620788,Autocuration,,,H,,B,3652,,308.0,,1,,,HeLa
,4829,8,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",10627,,,CHEMBL620789,Autocuration,,,H,,B,3653,,308.0,,1,,,HeLa
,4829,8,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",10627,,,CHEMBL620790,Autocuration,,,H,,B,3654,,308.0,,1,,,HeLa
,15250,8,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,10628,,,CHEMBL620791,Autocuration,,,H,,B,3655,,449.0,,1,,,CHO
,14423,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,10628,,,CHEMBL620792,Autocuration,,,H,,B,3656,,,,1,,,
,15086,8,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,10628,,,CHEMBL620793,Autocuration,,,H,,B,3657,,,,1,,,
,4342,8,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,10628,,,CHEMBL620794,Autocuration,,,H,,B,3658,,,,1,,,
,16190,9,BAO_0000219,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,10627,,,CHEMBL620795,Autocuration,9606.0,,D,,B,3659,,308.0,Homo sapiens,1,,,HeLa
,4820,8,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,,CHEMBL620796,Expert,,,H,,B,3660,,,,1,,,
,4639,8,BAO_0000357,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,10627,,,CHEMBL620797,Autocuration,,,H,,B,3661,,,,1,,,
,17066,9,BAO_0000019,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,10627,,,CHEMBL620798,Expert,9606.0,,D,,F,3662,,,Homo sapiens,1,,,
,6011,8,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,10627,,,CHEMBL620799,Autocuration,,,H,,B,3663,,,,1,,,
,17066,8,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,,CHEMBL620800,Expert,,,H,,B,3664,,,,1,,,
,17515,8,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,10627,,,CHEMBL620801,Autocuration,,,H,,B,3665,,,,1,,,
,5014,8,BAO_0000357,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,10627,,,CHEMBL875100,Autocuration,,,H,,B,3666,,,,1,,,
,4373,8,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,10627,,,CHEMBL620802,Autocuration,,,H,,B,3667,,,,1,,,
,17066,8,BAO_0000019,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,10627,,,CHEMBL620803,Expert,,,H,,F,3668,,,,1,,,
,17066,8,BAO_0000019,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,10627,,,CHEMBL620804,Expert,,,H,,F,3669,,,,1,,,
,4373,8,BAO_0000357,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,10627,,,CHEMBL620805,Autocuration,,,H,,B,3670,,,,1,,,
,4687,8,BAO_0000357,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,10627,,,CHEMBL620806,Autocuration,,,H,,B,3671,,,,1,,,
,16946,8,BAO_0000357,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,10627,,,CHEMBL620807,Autocuration,,,H,,B,3672,,,,1,,,
,16946,8,BAO_0000357,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,10627,,,CHEMBL620808,Autocuration,,,H,,B,3673,,,,1,,,
,16633,8,BAO_0000357,Binding affinities against 5-hydroxytryptamine 6 receptor,10627,,,CHEMBL620809,Autocuration,,,H,,B,3674,,,,1,,,
,16633,8,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 6 receptor,10627,,,CHEMBL620810,Autocuration,,,H,,B,3675,,,,1,,,
,17066,9,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 6 receptor,10627,,,CHEMBL620811,Expert,9606.0,,D,,B,3676,,,Homo sapiens,1,,,
,16700,8,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,10627,,,CHEMBL620812,Autocuration,,,H,,B,3677,,,,1,,,
,3269,8,BAO_0000357,Affinity against 5-hydroxytryptamine 6 receptor,10627,,,CHEMBL620813,Autocuration,,,H,,B,3678,,,,1,,,
,5486,8,BAO_0000357,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],10627,,,CHEMBL620814,Autocuration,,,H,,B,3679,,,,1,,,
,16146,9,BAO_0000357,Inhibition of human 5-hydroxytryptamine 7 receptor,10209,,,CHEMBL620815,Expert,9606.0,,D,,B,3680,,,Homo sapiens,1,,,
,5014,8,BAO_0000219,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,10209,,,CHEMBL620816,Autocuration,,,H,,B,3681,,722.0,,1,,,HEK293
,15463,8,BAO_0000357,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,10209,,,CHEMBL620817,Autocuration,,,H,,B,3682,,,,1,,,
,3805,8,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),10209,,,CHEMBL620818,Autocuration,,,H,,B,3683,,,,1,,,
,5014,8,BAO_0000219,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,10209,,,CHEMBL620819,Expert,,,H,,B,3684,,722.0,,1,,,HEK293
,6491,9,BAO_0000357,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,10209,,,CHEMBL620820,Expert,9606.0,,D,,B,3685,,,Homo sapiens,1,,,
,16190,8,BAO_0000219,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,10209,,,CHEMBL620821,Autocuration,,,H,,B,3686,,449.0,,1,,,CHO
,17066,9,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 7 receptor,10209,,,CHEMBL620822,Expert,9606.0,,D,,B,3687,,,Homo sapiens,1,,,
,17066,9,BAO_0000357,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,10209,,,CHEMBL620823,Expert,9606.0,,D,,B,3688,,,Homo sapiens,1,,,
,3555,9,BAO_0000357,Binding affinity against 5-hydroxytryptamine 7 receptor,10209,,,CHEMBL620824,Expert,9606.0,,D,,B,3689,,,Homo sapiens,1,,,
,6588,8,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,10209,,,CHEMBL620825,Expert,,,H,,B,3690,,449.0,,1,,,CHO
,15463,8,BAO_0000357,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,10209,,,CHEMBL872930,Autocuration,,,H,,B,3691,,,,1,,,
,6013,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 7 receptor,10209,,,CHEMBL620826,Autocuration,,,H,,B,3692,,,,1,,,
,16209,8,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,10209,,,CHEMBL620827,Autocuration,,,H,,B,3693,,,,1,,,
,3935,8,BAO_0000357,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,10209,,,CHEMBL620828,Autocuration,,,H,,B,3694,,,,1,,,
,15818,8,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,10209,,,CHEMBL620829,Autocuration,,,H,,B,3695,,,,1,,,
,5014,8,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,10209,,,CHEMBL620830,Expert,,,H,,B,3696,,722.0,,1,,,HEK293
,16441,8,BAO_0000019,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,10209,,,CHEMBL620831,Expert,,,H,,B,3697,,,,1,,,
,16441,8,BAO_0000019,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,10209,,,CHEMBL620832,Expert,,,H,,B,3698,,,,1,,,
,4234,9,BAO_0000357,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,10209,,,CHEMBL621548,Expert,9606.0,,D,,B,3699,,,Homo sapiens,1,,,
,17085,8,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,10209,,,CHEMBL621549,Autocuration,,,H,,B,3700,,,,1,,,
,17200,8,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,10209,,,CHEMBL621550,Autocuration,,,H,,B,3701,,,,1,,,
,17451,8,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,10209,,,CHEMBL621551,Autocuration,,,H,,B,3702,,449.0,,1,,,CHO
,17085,8,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,10209,,,CHEMBL621552,Autocuration,,,H,,B,3703,,,,1,,,
,5104,8,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,10209,,,CHEMBL857077,Autocuration,,,H,,B,3704,,,,1,,,
,5104,8,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,10209,,,CHEMBL618158,Autocuration,,,H,,B,3705,,,,1,,,
,5033,9,BAO_0000219,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,10209,,,CHEMBL618159,Expert,9606.0,,D,,B,3706,,643.0,Homo sapiens,1,,,COS-7
,5486,8,BAO_0000219,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,10209,,,CHEMBL875101,Autocuration,,,H,,B,3707,,643.0,,1,,,COS-7
,4540,9,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,10209,,,CHEMBL618160,Expert,9606.0,,D,,B,3708,,722.0,Homo sapiens,1,,,HEK293
,6166,8,BAO_0000357,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,10209,,,CHEMBL618161,Expert,,,H,,B,3709,,,,1,,,
,17342,8,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,10209,,,CHEMBL618162,Expert,,,H,,B,3710,,722.0,,1,,,HEK293
,17342,8,BAO_0000357,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,10209,,,CHEMBL618163,Expert,,,H,,B,3711,,,,1,,,
,17296,8,BAO_0000357,Binding affinity against 5-hydroxytryptamine 7 human receptors,10209,,,CHEMBL618164,Autocuration,,,H,,B,3712,,,,1,,,
,16429,8,BAO_0000219,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,10209,,,CHEMBL618165,Expert,,,H,,B,3713,,,,1,,,
,15779,8,BAO_0000219,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,10209,,,CHEMBL618166,Autocuration,,,H,,B,3714,,722.0,,1,,,HEK293
,15779,8,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,10209,,,CHEMBL857989,Autocuration,,,H,,B,3715,,722.0,,1,,,HEK293
,15779,8,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,10209,,,CHEMBL619888,Autocuration,,,H,,B,3716,,722.0,,1,,,HEK293
,15779,8,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,10209,,,CHEMBL619889,Autocuration,,,H,,B,3717,,722.0,,1,,,HEK293
,15779,8,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,10209,,,CHEMBL619890,Autocuration,,,H,,B,3718,,722.0,,1,,,HEK293
,17451,8,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,10209,,,CHEMBL619891,Autocuration,,,H,,B,3719,,449.0,,1,,,CHO
,4199,8,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),10209,,,CHEMBL619892,Autocuration,,,H,,B,3720,,722.0,,1,,,HEK293
,4199,9,BAO_0000219,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,10209,,,CHEMBL619893,Expert,,,D,,B,3721,,722.0,,1,,,HEK293
,4199,8,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),10209,,,CHEMBL619894,Autocuration,,,H,,B,3722,,722.0,,1,,,HEK293
,3680,9,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,10209,,,CHEMBL619895,Intermediate,,,D,,B,3723,,722.0,,1,,,HEK293
,3680,9,BAO_0000357,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,10209,,,CHEMBL619896,Intermediate,,,D,,B,3724,,,,1,,,
,15316,8,BAO_0000219,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,10209,,,CHEMBL619897,Autocuration,,,H,,B,3725,,643.0,,1,,,COS-7
,15146,8,BAO_0000219,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,10209,,,CHEMBL619898,Autocuration,,,H,,B,3726,,722.0,,1,,,HEK293
,5213,8,BAO_0000219,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,10209,,,CHEMBL619899,Expert,,,H,,B,3727,,722.0,,1,,,HEK293
,5213,8,BAO_0000219,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),10209,,,CHEMBL619900,Autocuration,,,H,,B,3728,,722.0,,1,,,HEK293
,14818,9,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,10209,,,CHEMBL619901,Expert,9606.0,,D,,B,3729,,722.0,Homo sapiens,1,,,HEK293
,14818,8,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,10209,,,CHEMBL620580,Autocuration,,,H,,B,3730,,722.0,,1,,,HEK293
,14818,8,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,10209,,,CHEMBL620581,Autocuration,,,H,,B,3731,,722.0,,1,,,HEK293
,4829,8,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",10209,,,CHEMBL620733,Autocuration,,,H,,B,3732,,722.0,,1,,,HEK293
,17200,9,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,10209,,,CHEMBL620734,Autocuration,9606.0,,D,,B,3733,,,Homo sapiens,1,,,
,17066,9,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,10022,,,CHEMBL620735,Expert,10090.0,,D,,B,3734,,,Mus musculus,1,,,
,14025,8,BAO_0000019,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,10209,,,CHEMBL620736,Autocuration,9986.0,,H,,B,3735,,,Oryctolagus cuniculus,1,,,
,15250,8,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,11923,,,CHEMBL620737,Autocuration,,,H,,B,3736,,449.0,,1,,,CHO
,16372,8,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,11923,,,CHEMBL620738,Autocuration,,,H,,B,3737,,449.0,,1,,,CHO
,16372,8,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,11923,,,CHEMBL620739,Autocuration,,,H,,B,3738,,449.0,,1,,,CHO
,16372,8,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,11923,,,CHEMBL620740,Autocuration,,,H,,B,3739,,449.0,,1,,,CHO
,16372,8,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,11923,,,CHEMBL620741,Autocuration,,,H,,B,3740,,449.0,,1,,,CHO
,16372,8,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,11923,,,CHEMBL620742,Autocuration,,,H,,B,3741,,449.0,,1,,,CHO
,16372,8,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,11923,,,CHEMBL620743,Autocuration,,,H,,B,3742,,449.0,,1,,,CHO
,16372,8,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,11923,,,CHEMBL620744,Autocuration,,,H,,B,3743,,449.0,,1,,,CHO
,16372,8,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,11923,,,CHEMBL620745,Autocuration,,,H,,B,3744,,449.0,,1,,,CHO
,16372,8,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,11923,,,CHEMBL620746,Autocuration,,,H,,B,3745,,449.0,,1,,,CHO
,16372,8,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,11923,,,CHEMBL620747,Autocuration,,,H,,B,3746,,449.0,,1,,,CHO
,16372,8,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,11923,,,CHEMBL620748,Autocuration,,,H,,B,3747,,449.0,,1,,,CHO
,16372,8,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,11923,,,CHEMBL620749,Autocuration,,,H,,B,3748,,449.0,,1,,,CHO
,17066,8,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,11923,,,CHEMBL620750,Expert,,,H,,B,3749,,,,1,,,
,17066,9,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,11923,,,CHEMBL620751,Expert,10116.0,,D,,B,3750,,,Rattus norvegicus,1,,,
,17386,8,BAO_0000357,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,11923,,,CHEMBL620752,Expert,,,H,,B,3751,,,,1,,,
,14423,8,BAO_0000019,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,11923,,,CHEMBL872929,Autocuration,,,H,,B,3752,,,,1,,,
,15874,9,BAO_0000357,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,11923,,,CHEMBL620753,Expert,10116.0,,D,,B,3753,,,Rattus norvegicus,1,,,
,15874,9,BAO_0000357,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,11923,,,CHEMBL620754,Expert,10116.0,,D,,B,3754,,,Rattus norvegicus,1,,,
,16372,9,BAO_0000219,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,11923,,,CHEMBL620755,Expert,10116.0,,D,,B,3755,,449.0,Rattus norvegicus,1,,,CHO
,4622,8,BAO_0000357,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,11923,,,CHEMBL620756,Autocuration,,,H,,B,3756,,,,1,,,
,15086,8,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,11923,,,CHEMBL620757,Autocuration,,,H,,B,3757,,,,1,,,
,16372,8,BAO_0000219,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",11923,,,CHEMBL620758,Autocuration,,,H,,B,3758,,449.0,,1,,,CHO
,16372,8,BAO_0000219,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",11923,,,CHEMBL620759,Autocuration,,,H,,B,3759,,449.0,,1,,,CHO
,16372,8,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,11923,,,CHEMBL620760,Autocuration,,,H,,B,3760,,449.0,,1,,,CHO
,16372,8,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,11923,,,CHEMBL620761,Autocuration,,,H,,B,3761,,449.0,,1,,,CHO
,17386,8,BAO_0000221,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,11923,,Ileum,CHEMBL620762,Autocuration,,,H,,F,3762,,,,1,,2116.0,
,17386,8,BAO_0000221,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,11923,,Ileum,CHEMBL620763,Autocuration,,,H,,F,3763,,,,1,,2116.0,
,17386,8,BAO_0000221,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,11923,,Ileum,CHEMBL620764,Autocuration,,,H,,F,3764,,,,1,,2116.0,
,5831,9,BAO_0000249,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,11923,,,CHEMBL857990,Expert,10116.0,Membranes,D,,B,3765,,,Rattus norvegicus,1,,,
,4342,8,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,11923,,,CHEMBL620765,Autocuration,,,H,,B,3766,,,,1,,,
,17319,8,BAO_0000357,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,11923,,,CHEMBL620766,Expert,,,H,,B,3767,,,,1,,,
,17342,8,BAO_0000019,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,11923,,Hypothalamus,CHEMBL620767,Expert,,,H,,B,3768,,,,1,,1898.0,
,17342,8,BAO_0000357,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,11923,,,CHEMBL620768,Autocuration,,,H,,B,3769,,,,1,,,
,3680,8,BAO_0000249,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,11923,,Hypothalamus,CHEMBL619051,Expert,,,H,,B,3770,,,,1,,1898.0,
,3680,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 7 receptor,11923,,,CHEMBL619052,Expert,,,H,,B,3771,,,,1,,,
,17319,9,BAO_0000219,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,11923,,,CHEMBL619053,Expert,10116.0,,D,,F,3772,,722.0,Rattus norvegicus,1,,,HEK293
,17319,9,BAO_0000219,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,11923,,,CHEMBL619703,Expert,10116.0,,D,,F,3773,,722.0,Rattus norvegicus,1,,,HEK293
,17319,9,BAO_0000219,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,11923,,,CHEMBL619704,Autocuration,10116.0,,D,,F,3774,,722.0,Rattus norvegicus,1,,,HEK293
,4820,8,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 7 receptor,10209,,,CHEMBL619851,Expert,,,H,,B,3775,,,,1,,,
,4639,8,BAO_0000357,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,10209,,,CHEMBL619852,Autocuration,,,H,,B,3776,,,,1,,,
,6011,8,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,10209,,,CHEMBL619853,Autocuration,,,H,,B,3777,,,,1,,,
,17066,9,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 7 receptor,10209,,,CHEMBL619854,Expert,9606.0,,D,,B,3778,,,Homo sapiens,1,,,
,17066,8,BAO_0000357,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,10209,,,CHEMBL619855,Expert,,,H,,B,3779,,,,1,,,
,17515,8,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,10209,,,CHEMBL619856,Autocuration,,,H,,B,3780,,,,1,,,
,4373,8,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,10209,,,CHEMBL619857,Autocuration,,,H,,B,3781,,,,1,,,
,17066,8,BAO_0000019,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,10209,,,CHEMBL619858,Expert,,,H,,F,3782,,,,1,,,
,4373,8,BAO_0000357,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,10209,,,CHEMBL619859,Autocuration,,,H,,B,3783,,,,1,,,
,4373,8,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,10209,,,CHEMBL619860,Autocuration,,,H,,B,3784,,,,1,,,
,4687,8,BAO_0000357,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,10209,,,CHEMBL619861,Autocuration,,,H,,B,3785,,,,1,,,
,17342,8,BAO_0000357,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,10209,,,CHEMBL619862,Expert,,,H,,B,3786,,,,1,,,
,16946,8,BAO_0000357,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,10209,,,CHEMBL619863,Autocuration,,,H,,B,3787,,,,1,,,
,16946,8,BAO_0000357,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,10209,,,CHEMBL619864,Autocuration,,,H,,B,3788,,,,1,,,
,16633,8,BAO_0000357,Binding affinities against 5-hydroxytryptamine 7 receptor,10209,,,CHEMBL872928,Autocuration,,,H,,B,3789,,,,1,,,
,16633,8,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 7 receptor,10209,,,CHEMBL619865,Autocuration,,,H,,B,3790,,,,1,,,
,17066,8,BAO_0000357,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,10209,,,CHEMBL619866,Expert,,,H,,B,3791,,,,1,,,
,16700,8,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,10209,,,CHEMBL619867,Autocuration,,,H,,B,3792,,,,1,,,
,17386,8,BAO_0000221,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,10209,,Ileum,CHEMBL619868,Autocuration,,,H,,B,3793,,,,1,,2116.0,
,14080,8,BAO_0000019,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,55,,,CHEMBL619869,Autocuration,,,H,,F,3794,,,,1,,,
,14080,9,BAO_0000019,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,55,,,CHEMBL619870,Expert,9606.0,,D,,F,3795,,,Homo sapiens,1,,,
,409,8,BAO_0000357,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,55,,,CHEMBL619871,Autocuration,,,H,,B,3796,,,,1,,,
,409,8,BAO_0000357,In vitro inhibition of human recombinant lipoxygenase enzyme,55,,,CHEMBL619872,Autocuration,,,H,,B,3797,,,,1,,,
,409,8,BAO_0000357,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,55,,,CHEMBL619873,Autocuration,,,H,,B,3798,,,,1,,,
,11090,8,BAO_0000357,Inhibition of 5-lipoxygenase in human whole blood.,55,,Blood,CHEMBL619874,Expert,,,H,,B,3799,,,,1,,178.0,
,11090,8,BAO_0000357,Inhibition of 5-lipoxygenase in human whole blood.,55,,Blood,CHEMBL619875,Expert,,,H,,B,3800,,,,1,,178.0,
,948,8,BAO_0000357,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,55,,,CHEMBL619876,Autocuration,,,H,,B,3801,,,,1,,,
,948,8,BAO_0000357,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),55,,,CHEMBL619877,Autocuration,,,H,,B,3802,,,,1,,,
,13622,8,BAO_0000219,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,55,,,CHEMBL619878,Expert,,,H,,F,3803,,,,1,,,
,13622,8,BAO_0000019,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,55,,Blood,CHEMBL619879,Autocuration,,,H,,F,3804,,,,1,,178.0,
,9637,8,BAO_0000357,In vitro inhibition of 5-lipoxygenase from human polymorphs,55,,,CHEMBL619880,Autocuration,,,H,,B,3805,,,,1,,,
,11320,8,BAO_0000357,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),55,,,CHEMBL619881,Autocuration,,,H,,B,3806,,,,1,,,
,11320,8,BAO_0000357,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,55,,,CHEMBL619882,Expert,,,H,,B,3807,,,,1,,,
,6838,8,BAO_0000357,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,55,,,CHEMBL619883,Autocuration,,,H,,B,3808,,,,1,,,
,17667,9,BAO_0000357,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),55,,Blood,CHEMBL619884,Expert,9606.0,,D,,B,3809,,,Homo sapiens,1,,178.0,
,12703,8,BAO_0000357,In vitro potency against human 5-Lipoxygenase,55,,,CHEMBL619885,Autocuration,,,H,,B,3810,,,,1,,,
,14312,9,BAO_0000019,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,55,,,CHEMBL619886,Expert,9606.0,,D,,F,3811,,,Homo sapiens,1,,,
,14312,8,BAO_0000019,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,55,,Blood,CHEMBL619887,Autocuration,,,H,,F,3812,,,,1,,178.0,
,5364,8,BAO_0000019,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,55,,,CHEMBL875097,Autocuration,,,H,,F,3813,,,,1,,,
,951,8,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,55,,,CHEMBL618001,Autocuration,,,H,,B,3814,,,,1,,,
,951,8,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,55,,,CHEMBL618002,Autocuration,,,H,,B,3815,,,,1,,,
,951,8,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,55,,,CHEMBL618003,Autocuration,,,H,,B,3816,,,,1,,,
,951,8,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,55,,,CHEMBL618004,Autocuration,,,H,,B,3817,,,,1,,,
,12365,8,BAO_0000219,Inhibition of human 5-lipoxygenase in human cells,55,,,CHEMBL618005,Autocuration,,,H,,B,3818,,,,1,,,
,10603,8,BAO_0000357,Inhibition of human neutrophil 5-lipoxygenase,55,,,CHEMBL618006,Expert,,,H,,B,3819,,,,1,,,
,10501,8,BAO_0000019,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,55,,,CHEMBL875086,Autocuration,,,H,,B,3820,,,,1,,,
,12281,8,BAO_0000357,Inhibition of 5-lipoxygenase from human whole blood,55,,Blood,CHEMBL618007,Expert,,,H,,B,3821,,,,1,,178.0,
,2567,8,BAO_0000357,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,55,,,CHEMBL618008,Autocuration,,,H,,B,3822,,,,1,,,
,2567,8,BAO_0000219,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,55,,,CHEMBL618009,Autocuration,,,H,,B,3823,,,,1,,,
,10193,8,BAO_0000357,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,55,,,CHEMBL618010,Expert,,,H,,B,3824,,,,1,,,
,10193,8,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,55,,,CHEMBL618011,Autocuration,,,H,,B,3825,,,,1,,,
,13623,8,BAO_0000357,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,55,,,CHEMBL618012,Expert,,,H,,B,3826,,,,1,,,
,12780,8,BAO_0000357,Tested against 5-lipoxygenase,55,,,CHEMBL882927,Autocuration,,,H,,B,3827,,,,1,,,
,12780,8,BAO_0000357,Tested for activity against 5-Lipoxygenase (5-LO),55,,,CHEMBL618013,Autocuration,,,H,,B,3828,,,,1,,,
,12780,8,BAO_0000357,Tested for activity against 5-lipoxygenase,55,,,CHEMBL618014,Autocuration,,,H,,B,3829,,,,1,,,
,11966,8,BAO_0000357,Tested for inhibition of 5-HPETE production by human 5-LO,55,,,CHEMBL618015,Autocuration,,,H,,B,3830,,,,1,,,
,5364,8,BAO_0000019,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,55,,,CHEMBL618016,Autocuration,,,H,,F,3831,,,,1,,,
,13165,8,BAO_0000357,Inhibition of Human 5-lipoxygenase,55,,,CHEMBL618017,Expert,,,H,,B,3832,,,,1,,,
,5364,8,BAO_0000019,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,55,,,CHEMBL618018,Autocuration,,,H,,B,3833,,,,1,,,
,11311,8,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],55,,,CHEMBL875087,Autocuration,,,H,,B,3834,,,,1,,,
,11311,8,BAO_0000219,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],55,,,CHEMBL618019,Autocuration,,,H,,B,3835,,,,1,,,
,14863,8,BAO_0000019,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,55,,,CHEMBL618020,Autocuration,,,H,,B,3836,,,,1,,,
,14863,8,BAO_0000019,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,55,,,CHEMBL618021,Autocuration,,,H,,B,3837,,,,1,,,
,11087,8,BAO_0000357,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),55,,Blood,CHEMBL618022,Autocuration,,,H,,B,3838,,,,1,,178.0,
,455,8,BAO_0000357,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,55,,,CHEMBL618023,Autocuration,,,H,,B,3839,,,,1,,,
,13183,8,BAO_0000357,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),55,,,CHEMBL618024,Autocuration,,,H,,B,3840,,,,1,,,
,10319,8,BAO_0000019,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,55,,,CHEMBL873950,Expert,,,H,,B,3841,,,,1,,,
,10193,8,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,55,,,CHEMBL618025,Autocuration,,,H,,B,3842,,,,1,,,
,951,8,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,55,,,CHEMBL618026,Autocuration,,,H,,B,3843,,,,1,,,
,951,8,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,55,,,CHEMBL618027,Autocuration,,,H,,B,3844,,,,1,,,
,951,8,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,55,,,CHEMBL618028,Autocuration,,,H,,B,3845,,,,1,,,
,951,8,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,55,,,CHEMBL618029,Autocuration,,,H,,B,3846,,,,1,,,
,9859,8,BAO_0000357,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,55,,,CHEMBL618030,Expert,,,H,,B,3847,,,,1,,,
,9859,8,BAO_0000357,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,55,,,CHEMBL618031,Expert,,,H,,B,3848,,,,1,,,
,9859,8,BAO_0000357,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,55,,,CHEMBL618032,Autocuration,,,H,,B,3849,,,,1,,,
,2567,8,BAO_0000357,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,55,,,CHEMBL618033,Autocuration,,,H,,B,3850,,,,1,,,
,10193,8,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,55,,,CHEMBL618034,Autocuration,,,H,,B,3851,,,,1,,,
,10193,8,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,55,,,CHEMBL875088,Autocuration,,,H,,B,3852,,,,1,,,
,949,8,BAO_0000019,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,55,,,CHEMBL618035,Autocuration,,,H,,B,3853,,,,1,,,
,949,8,BAO_0000019,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,55,,,CHEMBL618036,Autocuration,,,H,,B,3854,,,,1,,,
,10603,8,BAO_0000357,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,55,,,CHEMBL618037,Expert,,,H,,B,3855,,,,1,,,
,10603,8,BAO_0000357,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,55,,,CHEMBL618038,Expert,,,H,,B,3856,,,,1,,,
,10603,8,BAO_0000019,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,55,,,CHEMBL618761,Autocuration,,,H,,F,3857,,,,1,,,
,10603,8,BAO_0000357,Inhibition of lipoxygenase at the concentration of 0.1 uM,55,,,CHEMBL618762,Expert,,,H,,B,3858,,,,1,,,
,10603,8,BAO_0000357,Inhibition of lipoxygenase at the concentration of 1 uM,55,,,CHEMBL618763,Expert,,,H,,B,3859,,,,1,,,
,10193,8,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,55,,,CHEMBL618764,Autocuration,,,H,,B,3860,,,,1,,,
,14580,9,BAO_0000357,Inhibition of 5-Lipoxygenase (5-LOX),55,,,CHEMBL618765,Expert,9606.0,,D,,B,3861,,,Homo sapiens,1,,,
,11090,8,BAO_0000357,Inhibition of 5-lipoxygenase in mouse macrophages.,17087,,,CHEMBL618766,Expert,,,H,,B,3862,,,,1,,,
,11090,8,BAO_0000357,Inhibition of 5-lipoxygenase in mouse macrophages.,17087,,,CHEMBL618767,Expert,,,H,,B,3863,,,,1,,,
,6339,8,BAO_0000357,Inhibitory activity against lipoxygenase-2 in mice,17087,,,CHEMBL619380,Autocuration,,,H,,B,3864,,,,1,,,
,6339,8,BAO_0000357,Inhibitory activity against murine lipoxygenase-2.,17087,,,CHEMBL619381,Expert,,,H,,B,3865,,,,1,,,
,12281,9,BAO_0000357,Inhibition of 5-lipoxygenase from mouse macrophage,17087,,,CHEMBL619382,Expert,10090.0,,D,,B,3866,,,Mus musculus,1,,,
,11311,8,BAO_0000357,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,17087,,,CHEMBL619383,Autocuration,,,H,,B,3867,,,,1,,,
,11089,8,BAO_0000019,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,55,,,CHEMBL619384,Autocuration,9823.0,,H,,B,3868,,,Sus scrofa,1,,,
,10091,8,BAO_0000019,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,55,,,CHEMBL619385,Autocuration,9823.0,,H,,B,3869,,,Sus scrofa,1,,,
,14352,8,BAO_0000019,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,55,,,CHEMBL882928,Autocuration,9986.0,,H,,B,3870,,,Oryctolagus cuniculus,1,,,
,13329,9,BAO_0000019,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,12166,,,CHEMBL619386,Expert,10116.0,,D,,B,3871,,,Rattus norvegicus,1,,,
,13329,8,BAO_0000019,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",12166,,,CHEMBL619387,Autocuration,,,H,,B,3872,,,,1,,,
,13329,8,BAO_0000019,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",12166,,,CHEMBL619388,Autocuration,,,H,,B,3873,,,,1,,,
,13329,8,BAO_0000019,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",12166,,,CHEMBL619389,Autocuration,,,H,,B,3874,,,,1,,,
,13329,8,BAO_0000019,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),12166,,,CHEMBL619390,Expert,,,H,,B,3875,,,,1,,,
,13329,8,BAO_0000019,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",12166,,,CHEMBL619391,Expert,,,H,,B,3876,,,,1,,,
,13329,8,BAO_0000019,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,12166,,,CHEMBL619392,Autocuration,,,H,,B,3877,,,,1,,,
,11311,8,BAO_0000019,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),12166,,,CHEMBL619393,Autocuration,,,H,,B,3878,,,,1,,,
,11311,8,BAO_0000019,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,12166,,,CHEMBL619394,Autocuration,,,H,,B,3879,,,,1,,,
,105,8,BAO_0000219,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",12166,,,CHEMBL619395,Autocuration,,,H,,B,3880,,702.0,,1,,,RBL-1
,105,8,BAO_0000219,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",12166,,,CHEMBL619396,Autocuration,,,H,,B,3881,,702.0,,1,,,RBL-1
,9138,8,BAO_0000357,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),12166,,,CHEMBL619397,Autocuration,,,H,,B,3882,,,,1,,,
,9138,8,BAO_0000357,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",12166,,,CHEMBL619398,Autocuration,,,H,,B,3883,,,,1,,,
,9138,8,BAO_0000357,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",12166,,,CHEMBL619399,Autocuration,,,H,,B,3884,,,,1,,,
,14427,8,BAO_0000357,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,12166,,,CHEMBL619400,Autocuration,,,H,,B,3885,,,,1,,,
,13329,8,BAO_0000019,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",12166,,,CHEMBL619401,Autocuration,,,H,,B,3886,,,,1,,,
,13329,8,BAO_0000019,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",12166,,,CHEMBL619402,Autocuration,,,H,,B,3887,,,,1,,,
,14427,9,BAO_0000219,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,12166,,,CHEMBL619403,Expert,10116.0,,D,,B,3888,,663.0,Rattus norvegicus,1,,,RBL-2H3
,14427,8,BAO_0000357,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,12166,,,CHEMBL619404,Autocuration,,,H,,B,3889,,,,1,,,
,14427,8,BAO_0000357,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,12166,,,CHEMBL619405,Autocuration,,,H,,B,3890,,,,1,,,
,10293,8,BAO_0000219,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,12166,,,CHEMBL619406,Expert,,,H,,B,3891,,702.0,,1,,,RBL-1
,338,9,BAO_0000219,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,12166,,,CHEMBL619407,Expert,10116.0,,D,,B,3892,,702.0,Rattus norvegicus,1,,,RBL-1
,303,8,BAO_0000357,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),12166,,,CHEMBL619408,Autocuration,,,H,,B,3893,,,,1,,,
,303,8,BAO_0000219,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,12166,,,CHEMBL619409,Autocuration,,,H,,B,3894,,702.0,,1,,,RBL-1
,9247,8,BAO_0000219,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,12166,,,CHEMBL619410,Expert,,,H,,B,3895,,702.0,,1,,,RBL-1
,9247,8,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,12166,,,CHEMBL619753,Autocuration,,,H,,B,3896,,702.0,,1,,,RBL-1
,137,8,BAO_0000219,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,12166,,,CHEMBL619754,Autocuration,,,H,,B,3897,,702.0,,1,,,RBL-1
,11481,8,BAO_0000357,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,12166,,,CHEMBL619903,Expert,,,H,,B,3898,,,,1,,,
,11481,8,BAO_0000357,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",12166,,,CHEMBL619904,Expert,,,H,,B,3899,,,,1,,,
,9029,8,BAO_0000357,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,12166,,,CHEMBL619905,Expert,,,H,,B,3900,,,,1,,,
,1701,8,BAO_0000019,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,12166,,,CHEMBL619906,Autocuration,,,H,,B,3901,,,,1,,,
,1701,8,BAO_0000019,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,12166,,,CHEMBL619907,Autocuration,,,H,,B,3902,,,,1,,,
,1701,8,BAO_0000019,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,12166,,,CHEMBL619908,Autocuration,,,H,,B,3903,,,,1,,,
,1701,8,BAO_0000019,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,12166,,,CHEMBL619909,Autocuration,,,H,,B,3904,,,,1,,,
,13358,8,BAO_0000219,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,12166,,,CHEMBL619910,Expert,,,H,,F,3905,,702.0,,1,,,RBL-1
,1175,8,BAO_0000219,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,12166,,,CHEMBL882929,Expert,,,H,,B,3906,,702.0,,1,,,RBL-1
,8797,8,BAO_0000219,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,12166,,,CHEMBL619911,Expert,,,H,,B,3907,,702.0,,1,,,RBL-1
,8797,8,BAO_0000019,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,12166,,,CHEMBL619912,Autocuration,,,H,,B,3908,,,,1,,,
,577,9,BAO_0000357,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,12166,,,CHEMBL619913,Expert,10116.0,,D,,B,3909,,,Rattus norvegicus,1,,,
,9295,8,BAO_0000219,In vitro inhibitory activity against RBL-1 5-LO,12166,,,CHEMBL619914,Expert,,,H,,B,3910,,702.0,,1,,,RBL-1
,9295,8,BAO_0000219,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),12166,,,CHEMBL619915,Autocuration,,,H,,B,3911,,702.0,,1,,,RBL-1
,9295,8,BAO_0000219,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),12166,,,CHEMBL619916,Autocuration,,,H,,B,3912,,702.0,,1,,,RBL-1
,9295,8,BAO_0000218,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,12166,,,CHEMBL619917,Autocuration,,,H,,B,3913,,,,1,,,
,9295,8,BAO_0000357,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,12166,,,CHEMBL619918,Autocuration,,,H,,B,3914,,,,1,,,
,216,8,BAO_0000218,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,12166,,,CHEMBL619919,Autocuration,,,H,,B,3915,,,,1,,,
,11090,8,BAO_0000219,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,12166,,,CHEMBL883710,Autocuration,,,H,,B,3916,,702.0,,1,,,RBL-1
,11090,8,BAO_0000019,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,12166,,Blood,CHEMBL619920,Autocuration,,,H,,B,3917,,,,1,,178.0,
,10091,8,BAO_0000357,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,12166,,,CHEMBL619921,Expert,,,H,,B,3918,,,,1,,,
,10274,8,BAO_0000019,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,12166,,,CHEMBL619922,Autocuration,,,H,,F,3919,,,,1,,,
,13622,8,BAO_0000219,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,12166,,,CHEMBL619923,Autocuration,,,H,,F,3920,,,,1,,,
,12118,8,BAO_0000219,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,12166,,,CHEMBL619924,Expert,,,H,,B,3921,,702.0,,1,,,RBL-1
,12576,8,BAO_0000357,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,12166,,,CHEMBL619925,Expert,,,H,,B,3922,,,,1,,,
,9546,8,BAO_0000219,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,12166,,,CHEMBL619926,Expert,,,H,,B,3923,,702.0,,1,,,RBL-1
,9521,8,BAO_0000219,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,12166,,,CHEMBL619927,Autocuration,,,H,,B,3924,,702.0,,1,,,RBL-1
,10626,8,BAO_0000219,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,12166,,,CHEMBL619928,Expert,,,H,,B,3925,,702.0,,1,,,RBL-1
,9225,8,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase,12166,,,CHEMBL619929,Autocuration,,,H,,B,3926,,702.0,,1,,,RBL-1
,9225,8,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,12166,,,CHEMBL875089,Autocuration,,,H,,B,3927,,702.0,,1,,,RBL-1
,9225,8,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,12166,,,CHEMBL619930,Autocuration,,,H,,B,3928,,702.0,,1,,,RBL-1
,9225,8,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,12166,,,CHEMBL619931,Autocuration,,,H,,B,3929,,702.0,,1,,,RBL-1
,9225,8,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,12166,,,CHEMBL619932,Autocuration,,,H,,B,3930,,702.0,,1,,,RBL-1
,9225,8,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,12166,,,CHEMBL619933,Autocuration,,,H,,B,3931,,702.0,,1,,,RBL-1
,9225,8,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,12166,,,CHEMBL619934,Autocuration,,,H,,B,3932,,702.0,,1,,,RBL-1
,9225,8,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,12166,,,CHEMBL619935,Autocuration,,,H,,B,3933,,702.0,,1,,,RBL-1
,9225,8,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,12166,,,CHEMBL619936,Autocuration,,,H,,B,3934,,702.0,,1,,,RBL-1
,9225,8,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,12166,,,CHEMBL619937,Autocuration,,,H,,B,3935,,702.0,,1,,,RBL-1
,9225,8,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,12166,,,CHEMBL619938,Autocuration,,,H,,B,3936,,702.0,,1,,,RBL-1
,9225,8,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,12166,,,CHEMBL619939,Autocuration,,,H,,B,3937,,702.0,,1,,,RBL-1
,9225,8,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,12166,,,CHEMBL619940,Autocuration,,,H,,B,3938,,702.0,,1,,,RBL-1
,9225,8,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,12166,,,CHEMBL875090,Autocuration,,,H,,B,3939,,702.0,,1,,,RBL-1
,9225,8,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,12166,,,CHEMBL619941,Autocuration,,,H,,B,3940,,702.0,,1,,,RBL-1
,9225,8,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,12166,,,CHEMBL619942,Autocuration,,,H,,B,3941,,702.0,,1,,,RBL-1
,9225,8,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,12166,,,CHEMBL883711,Autocuration,,,H,,B,3942,,702.0,,1,,,RBL-1
,9225,8,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,12166,,,CHEMBL619943,Autocuration,,,H,,B,3943,,702.0,,1,,,RBL-1
,9225,8,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,12166,,,CHEMBL619944,Autocuration,,,H,,B,3944,,702.0,,1,,,RBL-1
,9225,8,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,12166,,,CHEMBL619945,Autocuration,,,H,,B,3945,,702.0,,1,,,RBL-1
,9225,8,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,12166,,,CHEMBL619946,Autocuration,,,H,,B,3946,,702.0,,1,,,RBL-1
,9225,8,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,12166,,,CHEMBL619947,Autocuration,,,H,,B,3947,,702.0,,1,,,RBL-1
,9225,8,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,12166,,,CHEMBL619948,Autocuration,,,H,,B,3948,,702.0,,1,,,RBL-1
,9225,8,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,12166,,,CHEMBL619949,Autocuration,,,H,,B,3949,,702.0,,1,,,RBL-1
,9401,8,BAO_0000019,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,12166,,,CHEMBL619950,Expert,,,H,,B,3950,,,,1,,,
,10325,8,BAO_0000019,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,12166,,,CHEMBL618050,Autocuration,,,H,,B,3951,,,,1,,,
,1556,8,BAO_0000219,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,12166,,,CHEMBL875091,Expert,,,H,,F,3952,,663.0,,1,,,RBL-2H3
,1556,8,BAO_0000219,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,12166,,,CHEMBL618051,Expert,,,H,,F,3953,,663.0,,1,,,RBL-2H3
,961,9,BAO_0000219,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,12166,,,CHEMBL618052,Expert,10116.0,,D,,B,3954,,702.0,Rattus norvegicus,1,,,RBL-1
,6838,8,BAO_0000019,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,12166,,,CHEMBL618053,Autocuration,,,H,,B,3955,,,,1,,,
,10325,8,BAO_0000019,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),12166,,,CHEMBL618054,Expert,,,H,,B,3956,,,,1,,,
,9209,9,BAO_0000219,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,12166,,,CHEMBL618055,Expert,10116.0,,D,,B,3957,,702.0,Rattus norvegicus,1,,,RBL-1
,11520,8,BAO_0000219,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,12166,,,CHEMBL618056,Expert,,,H,,B,3958,,702.0,,1,,,RBL-1
,137,8,BAO_0000357,In vitro inhibitory activity against 5-lipoxygenase was determined,12166,,,CHEMBL618057,Autocuration,,,H,,B,3959,,,,1,,,
,4717,8,BAO_0000219,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,12166,,,CHEMBL618058,Autocuration,,,H,,B,3960,,702.0,,1,,,RBL-1
,10636,8,BAO_0000219,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,12166,,,CHEMBL618059,Expert,,,H,,B,3961,,702.0,,1,,,RBL-1
,14312,9,BAO_0000019,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,12166,,,CHEMBL618060,Expert,10116.0,,D,,F,3962,,,Rattus norvegicus,1,,,
,1203,8,BAO_0000219,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,12166,,,CHEMBL618061,Autocuration,,,H,,B,3963,,702.0,,1,,,RBL-1
,1203,8,BAO_0000019,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,12166,,,CHEMBL618062,Autocuration,,,H,,B,3964,,,,1,,,
,13622,8,BAO_0000219,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,12166,,,CHEMBL618063,Expert,,,H,,B,3965,,702.0,,1,,,RBL-1
,9793,8,BAO_0000357,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,12166,,,CHEMBL618064,Autocuration,,,H,,B,3966,,,,1,,,
,1143,9,BAO_0000219,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,12166,,,CHEMBL618065,Expert,10116.0,,D,,B,3967,,702.0,Rattus norvegicus,1,,,RBL-1
,11854,9,BAO_0000219,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,12166,,,CHEMBL618066,Expert,10116.0,,D,,B,3968,,702.0,Rattus norvegicus,1,,,RBL-1
,3595,8,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),12166,,,CHEMBL618067,Autocuration,,,H,,B,3969,,702.0,,1,,,RBL-1
,3595,8,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),12166,,,CHEMBL618068,Autocuration,,,H,,B,3970,,702.0,,1,,,RBL-1
,10501,9,BAO_0000219,Inhibition of 5-lipoxygenase in rat RBL-1 cells,12166,,,CHEMBL618069,Expert,10116.0,,D,,B,3971,,702.0,Rattus norvegicus,1,,,RBL-1
,12526,8,BAO_0000219,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12166,,,CHEMBL618070,Expert,,,H,,B,3972,,702.0,,1,,,RBL-1
,10034,8,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,10825,,Limbic system,CHEMBL618071,Autocuration,,,H,,F,3973,,,,1,,349.0,
,10034,8,BAO_0000019,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,10825,,Limbic system,CHEMBL619247,Autocuration,,,H,,F,3974,,,,1,,349.0,
,10034,8,BAO_0000019,Approximate dose levels for a half maximal reduction of 5-HTP levels,10825,,,CHEMBL619248,Autocuration,,,H,,F,3975,,,,1,,,
,10046,8,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10576,,Hippocampus,CHEMBL619249,Autocuration,,,H,,B,3976,,,,1,,10000000.0,
,10046,8,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10576,,Hippocampus,CHEMBL619250,Autocuration,,,H,,B,3977,,,,1,,10000000.0,
,10046,8,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,10577,,,CHEMBL619251,Autocuration,,,H,,B,3978,,,,1,,,
,12079,8,BAO_0000019,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,55,,Blood,CHEMBL619252,Autocuration,9615.0,,H,,F,3979,,,Canis lupus familiaris,1,,178.0,
,12079,8,BAO_0000019,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,55,,Blood,CHEMBL619253,Autocuration,,,H,,F,3980,,,,1,,178.0,
,11311,8,BAO_0000219,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],12166,,,CHEMBL619254,Autocuration,,,H,,B,3981,,,,1,,,
,12338,8,BAO_0000219,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,17140,,,CHEMBL619255,Expert,,,H,,B,3982,,,,1,,,
,12143,8,BAO_0000219,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,17140,,,CHEMBL619256,Expert,,,H,,B,3983,,,,1,,,
,12143,8,BAO_0000219,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),17140,,,CHEMBL875418,Autocuration,,,H,,B,3984,,,,1,,,
,12143,8,BAO_0000219,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,17140,,,CHEMBL619257,Expert,,,H,,B,3985,,,,1,,,
,12143,8,BAO_0000219,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,17140,,,CHEMBL619258,Autocuration,,,H,,B,3986,,,,1,,,
,12365,8,BAO_0000357,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,17140,,,CHEMBL619259,Expert,,,H,,B,3987,,,,1,,,
,13500,8,BAO_0000357,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,17140,,,CHEMBL619260,Expert,,,H,,B,3988,,,,1,,,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL619261,Autocuration,9615.0,,H,,F,3989,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL619263,Autocuration,9615.0,,H,,F,3990,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL619264,Autocuration,9615.0,,H,,F,3991,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL619265,Autocuration,9615.0,,H,,F,3992,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL619266,Autocuration,9615.0,,H,,F,3993,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL619902,Autocuration,9615.0,,H,,F,3994,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL620058,Autocuration,9615.0,,H,,F,3995,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL620059,Autocuration,9615.0,,H,,F,3996,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL620060,Autocuration,9615.0,,H,,F,3997,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL620061,Autocuration,9615.0,,H,,F,3998,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",55,In vivo,Blood,CHEMBL620062,Autocuration,9615.0,,H,,F,3999,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL620063,Autocuration,9615.0,,H,,F,4000,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",55,In vivo,Blood,CHEMBL620064,Autocuration,9615.0,,H,,F,4001,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL620065,Autocuration,9615.0,,H,,F,4002,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",55,In vivo,Blood,CHEMBL620066,Autocuration,9615.0,,H,,F,4003,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL620067,Autocuration,9615.0,,H,,F,4004,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",55,In vivo,Blood,CHEMBL620068,Autocuration,9615.0,,H,,F,4005,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL620069,Autocuration,9615.0,,H,,F,4006,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",55,In vivo,Blood,CHEMBL620070,Autocuration,9615.0,,H,,F,4007,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL620071,Autocuration,9615.0,,H,,F,4008,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",55,In vivo,Blood,CHEMBL620072,Autocuration,9615.0,,H,,F,4009,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL620036,Autocuration,9615.0,,H,,F,4010,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",55,In vivo,Blood,CHEMBL857702,Autocuration,9615.0,,H,,F,4011,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL620037,Autocuration,9615.0,,H,,F,4012,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",55,In vivo,Blood,CHEMBL620038,Autocuration,9615.0,,H,,F,4013,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL620039,Autocuration,9615.0,,H,,F,4014,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",55,In vivo,Blood,CHEMBL620040,Autocuration,9615.0,,H,,F,4015,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL620041,Autocuration,9615.0,,H,,F,4016,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",55,In vivo,Blood,CHEMBL620042,Autocuration,9615.0,,H,,F,4017,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL620043,Autocuration,9615.0,,H,,F,4018,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",55,In vivo,Blood,CHEMBL620044,Autocuration,9615.0,,H,,F,4019,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL620045,Autocuration,9615.0,,H,,F,4020,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",55,In vivo,Blood,CHEMBL620046,Autocuration,9615.0,,H,,F,4021,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL620047,Autocuration,9615.0,,H,,F,4022,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",55,In vivo,Blood,CHEMBL620048,Autocuration,9615.0,,H,,F,4023,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL857703,Autocuration,9615.0,,H,,F,4024,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",55,In vivo,Blood,CHEMBL620049,Autocuration,9615.0,,H,,F,4025,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL620050,Autocuration,9615.0,,H,,F,4026,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL620051,Autocuration,9615.0,,H,,F,4027,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL619213,Autocuration,9615.0,,H,,F,4028,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL619214,Autocuration,9615.0,,H,,F,4029,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL619804,Autocuration,9615.0,,H,,F,4030,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL619805,Autocuration,9615.0,,H,,F,4031,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL619806,Autocuration,9615.0,,H,,F,4032,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL619807,Autocuration,9615.0,,H,,F,4033,,,Canis lupus familiaris,1,,178.0,
,12832,8,BAO_0000218,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",55,In vivo,Blood,CHEMBL619808,Autocuration,9615.0,,H,,F,4034,,,Canis lupus familiaris,1,,178.0,
,3595,8,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,55,,,CHEMBL619809,Autocuration,9615.0,,H,,B,4035,,,Canis lupus familiaris,1,,,
,3595,8,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,55,,,CHEMBL619810,Autocuration,9615.0,,H,,B,4036,,,Canis lupus familiaris,1,,,
,3595,8,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,55,,,CHEMBL619811,Autocuration,9615.0,,H,,B,4037,,,Canis lupus familiaris,1,,,
,3595,8,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,55,,,CHEMBL620769,Autocuration,9615.0,,H,,B,4038,,,Canis lupus familiaris,1,,,
,3595,8,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,55,,,CHEMBL620770,Autocuration,9615.0,,H,,B,4039,,,Canis lupus familiaris,1,,,
,3595,8,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,55,,,CHEMBL620771,Autocuration,9615.0,,H,,B,4040,,,Canis lupus familiaris,1,,,
,3595,8,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,55,,,CHEMBL620772,Autocuration,9615.0,,H,,B,4041,,,Canis lupus familiaris,1,,,
,3595,8,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,55,,,CHEMBL620773,Autocuration,9615.0,,H,,B,4042,,,Canis lupus familiaris,1,,,
,9203,8,BAO_0000357,Ability to inhibit 5-lipoxygenase in guinea pig,55,,,CHEMBL620774,Autocuration,10141.0,,H,,B,4043,,,Cavia porcellus,1,,,
,82,8,BAO_0000357,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),55,,,CHEMBL620775,Expert,10141.0,,H,,B,4044,,,Cavia porcellus,1,,,
,11090,8,BAO_0000357,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,55,,,CHEMBL620776,Autocuration,10141.0,,H,,B,4045,,,Cavia porcellus,1,,,
,12832,8,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",55,,Blood,CHEMBL620777,Autocuration,10141.0,,H,,B,4046,,,Cavia porcellus,1,,178.0,
,1065,8,BAO_0000357,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,55,,,CHEMBL620778,Autocuration,10141.0,,H,,B,4047,,,Cavia porcellus,1,,,
,1065,8,BAO_0000357,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,55,,,CHEMBL620779,Autocuration,10141.0,,H,,B,4048,,,Cavia porcellus,1,,,
,12832,8,BAO_0000019,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,55,,,CHEMBL621500,Expert,10141.0,,H,,B,4049,,,Cavia porcellus,1,,,
,12832,8,BAO_0000019,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,55,,,CHEMBL621501,Expert,10141.0,,H,,B,4050,,,Cavia porcellus,1,,,
,12832,8,BAO_0000019,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,55,,,CHEMBL618098,Autocuration,10141.0,,H,,B,4051,,,Cavia porcellus,1,,,
,10504,8,BAO_0000019,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,55,,,CHEMBL618099,Autocuration,10141.0,,H,,B,4052,,,Cavia porcellus,1,,,
,7788,8,BAO_0000357,Inhibitory activity against 5-lipoxygenase,55,,,CHEMBL618100,Autocuration,10141.0,,H,,B,4053,,,Cavia porcellus,1,,,
,10001,8,BAO_0000357,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,55,,,CHEMBL618101,Autocuration,10141.0,,H,,B,4054,,,Cavia porcellus,1,,,
,10193,8,BAO_0000357,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,55,,,CHEMBL618102,Autocuration,10141.0,,H,,B,4055,,,Cavia porcellus,1,,,
,13243,8,BAO_0000357,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,55,,,CHEMBL618103,Autocuration,10141.0,,H,,B,4056,,,Cavia porcellus,1,,,
,13243,8,BAO_0000357,Inhibitory activity uM,55,,,CHEMBL618104,Autocuration,10141.0,,H,,B,4057,,,Cavia porcellus,1,,,
,969,8,BAO_0000219,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,55,,,CHEMBL883712,Autocuration,10141.0,,H,,B,4058,,,Cavia porcellus,1,,,
,10001,8,BAO_0000357,Inhibitory activity against 5-lipoxygenase at 10 uM,55,,,CHEMBL618105,Autocuration,10141.0,,H,,B,4059,,,Cavia porcellus,1,,,
,7788,8,BAO_0000357,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,55,,,CHEMBL618106,Autocuration,10141.0,,H,,B,4060,,,Cavia porcellus,1,,,
,10001,8,BAO_0000357,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,55,,,CHEMBL618107,Autocuration,10141.0,,H,,B,4061,,,Cavia porcellus,1,,,
,10193,8,BAO_0000357,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,55,,,CHEMBL618108,Autocuration,10141.0,,H,,B,4062,,,Cavia porcellus,1,,,
,13243,8,BAO_0000357,Inhibitory activity uM,55,,,CHEMBL618109,Autocuration,10141.0,,H,,B,4063,,,Cavia porcellus,1,,,
,13243,8,BAO_0000357,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,55,,,CHEMBL618110,Autocuration,10141.0,,H,,B,4064,,,Cavia porcellus,1,,,
,13243,8,BAO_0000357,Inhibitory activity uM,55,,,CHEMBL618111,Expert,10141.0,,H,,B,4065,,,Cavia porcellus,1,,,
,13243,8,BAO_0000019,Inhibitory activity uM,55,,,CHEMBL618112,Autocuration,10141.0,,H,,F,4066,,,Cavia porcellus,1,,,
,10504,8,BAO_0000019,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,55,,,CHEMBL618113,Autocuration,10141.0,,H,,B,4067,,,Cavia porcellus,1,,,
,7788,8,BAO_0000357,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,55,,,CHEMBL618114,Autocuration,10141.0,,H,,B,4068,,,Cavia porcellus,1,,,
,10546,8,BAO_0000221,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,55,,Ileum,CHEMBL620871,Expert,10141.0,,H,,F,4069,,,Cavia porcellus,1,,2116.0,
,13183,8,BAO_0000357,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),55,,,CHEMBL620872,Autocuration,,,H,,B,4070,,,,1,,,
,13183,8,BAO_0000357,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),55,,,CHEMBL620873,Autocuration,,,H,,B,4071,,,,1,,,
,2578,8,BAO_0000357,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),55,,,CHEMBL620874,Autocuration,,,H,,B,4072,,,,1,,,
,12780,8,BAO_0000357,In vitro inhibition of human 5-Lipoxygenase.,55,,,CHEMBL620875,Expert,,,H,,B,4073,,,,1,,,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,22226,,Liver,CHEMBL620876,Autocuration,10116.0,Microsomes,U,,B,4074,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,22226,,Liver,CHEMBL620877,Autocuration,10116.0,Microsomes,U,,B,4075,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,22226,,Liver,CHEMBL857854,Autocuration,10116.0,Microsomes,U,,B,4076,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,22226,,Liver,CHEMBL620878,Autocuration,10116.0,Microsomes,U,,B,4077,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,22226,,Liver,CHEMBL620879,Autocuration,10116.0,Microsomes,U,,B,4078,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,22226,,Liver,CHEMBL620880,Autocuration,10116.0,Microsomes,U,,B,4079,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,22226,,Liver,CHEMBL620881,Autocuration,10116.0,Microsomes,U,,B,4080,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,22226,,Liver,CHEMBL620882,Autocuration,10116.0,Microsomes,U,,B,4081,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,22226,,Liver,CHEMBL620883,Autocuration,10116.0,Microsomes,U,,B,4082,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,22226,,Liver,CHEMBL620884,Autocuration,10116.0,Microsomes,U,,B,4083,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,22226,,Liver,CHEMBL620885,Autocuration,10116.0,Microsomes,U,,B,4084,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,22226,,Liver,CHEMBL620886,Autocuration,10116.0,Microsomes,U,,B,4085,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,22226,,Liver,CHEMBL620887,Autocuration,10116.0,Microsomes,U,,B,4086,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,22226,,Liver,CHEMBL618039,Autocuration,10116.0,Microsomes,U,,B,4087,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,22226,,Liver,CHEMBL618040,Autocuration,10116.0,Microsomes,U,,B,4088,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,22226,,Liver,CHEMBL618041,Autocuration,10116.0,Microsomes,U,,B,4089,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",22226,,Liver,CHEMBL618216,Autocuration,10116.0,Microsomes,U,,B,4090,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",22226,,Liver,CHEMBL618217,Autocuration,10116.0,Microsomes,U,,B,4091,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,22226,,Liver,CHEMBL618218,Autocuration,10116.0,Microsomes,U,,B,4092,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,22226,,Liver,CHEMBL618219,Autocuration,10116.0,Microsomes,U,,B,4093,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,22226,,Liver,CHEMBL618220,Autocuration,10116.0,Microsomes,U,,B,4094,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,22226,,Liver,CHEMBL618221,Autocuration,10116.0,Microsomes,U,,B,4095,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,22226,,Liver,CHEMBL618222,Autocuration,10116.0,Microsomes,U,,B,4096,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,22226,,Liver,CHEMBL618223,Autocuration,10116.0,Microsomes,U,,B,4097,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,22226,,Liver,CHEMBL618224,Autocuration,10116.0,Microsomes,U,,B,4098,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,22226,,Liver,CHEMBL618225,Autocuration,10116.0,Microsomes,U,,B,4099,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,22226,,Liver,CHEMBL618226,Autocuration,10116.0,Microsomes,U,,B,4100,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,22226,,Liver,CHEMBL618227,Autocuration,10116.0,Microsomes,U,,B,4101,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,22226,,Liver,CHEMBL618228,Autocuration,10116.0,Microsomes,U,,B,4102,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,22226,,Liver,CHEMBL618229,Autocuration,10116.0,Microsomes,U,,B,4103,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,22226,,Liver,CHEMBL618230,Autocuration,10116.0,Microsomes,U,,B,4104,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,22226,,Liver,CHEMBL618231,Autocuration,10116.0,Microsomes,U,,B,4105,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,22226,,Liver,CHEMBL618232,Autocuration,10116.0,Microsomes,U,,B,4106,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,22226,,Liver,CHEMBL618233,Autocuration,10116.0,Microsomes,U,,B,4107,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,22226,,Liver,CHEMBL618234,Autocuration,10116.0,Microsomes,U,,B,4108,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,22226,,Liver,CHEMBL618235,Autocuration,10116.0,Microsomes,U,,B,4109,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,22226,,Liver,CHEMBL618115,Autocuration,10116.0,Microsomes,U,,B,4110,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,22226,,Liver,CHEMBL618116,Autocuration,10116.0,Microsomes,U,,B,4111,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,22226,,Liver,CHEMBL618117,Autocuration,10116.0,Microsomes,U,,B,4112,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,22226,,Liver,CHEMBL619968,Autocuration,10116.0,Microsomes,U,,B,4113,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,22226,,Liver,CHEMBL619969,Autocuration,10116.0,Microsomes,U,,B,4114,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,22226,,Liver,CHEMBL619970,Autocuration,10116.0,Microsomes,U,,B,4115,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,22226,,Liver,CHEMBL619971,Autocuration,10116.0,Microsomes,U,,B,4116,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,22226,,Liver,CHEMBL619972,Autocuration,10116.0,Microsomes,U,,B,4117,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,22226,,Liver,CHEMBL619973,Autocuration,10116.0,Microsomes,U,,B,4118,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,22226,,Liver,CHEMBL619974,Autocuration,10116.0,Microsomes,U,,B,4119,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,22226,,Liver,CHEMBL619975,Autocuration,10116.0,Microsomes,U,,B,4120,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,22226,,,CHEMBL619976,Autocuration,10116.0,Microsomes,U,,B,4121,,,Rattus norvegicus,1,,,
,7411,0,BAO_0000251,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",22226,,Liver,CHEMBL619977,Autocuration,10116.0,Microsomes,U,,B,4122,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",22226,,Liver,CHEMBL619978,Autocuration,10116.0,Microsomes,U,,B,4123,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",22226,,Liver,CHEMBL619979,Autocuration,10116.0,Microsomes,U,,B,4124,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",22226,,Liver,CHEMBL619980,Autocuration,10116.0,Microsomes,U,,B,4125,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",22226,,Liver,CHEMBL619981,Autocuration,10116.0,Microsomes,U,,B,4126,,,Rattus norvegicus,1,,2107.0,
,10797,1,BAO_0000219,In vitro inhibition of 7226/S myeloma cancer cell line,80433,,,CHEMBL619982,Intermediate,9606.0,,N,,F,4127,,741.0,Homo sapiens,1,,,RPMI-8226
,6881,1,BAO_0000219,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),80698,,,CHEMBL619983,Intermediate,9606.0,,N,,F,4128,,993.0,Homo sapiens,1,,,BEL-7404 tumor cell line
,3838,1,BAO_0000219,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,80640,,,CHEMBL620031,Intermediate,9606.0,,N,,F,4129,,391.0,Homo sapiens,1,,,786-0
,3838,1,BAO_0000219,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,80640,,,CHEMBL620032,Intermediate,9606.0,,N,,F,4130,,391.0,Homo sapiens,1,,,786-0
,12981,1,BAO_0000219,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,81264,,,CHEMBL620033,Expert,10029.0,,N,,F,4131,,505.0,Cricetulus griseus,1,,,V79
,12981,1,BAO_0000219,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,81264,,,CHEMBL620034,Expert,10029.0,,N,,F,4132,,505.0,Cricetulus griseus,1,,,V79
,7653,1,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,80635,,,CHEMBL620035,Intermediate,10116.0,,N,,F,4133,,1119.0,Rattus norvegicus,1,,,7800C1 cell line
,7653,1,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,80635,,,CHEMBL618318,Intermediate,10116.0,,N,,F,4134,,1119.0,Rattus norvegicus,1,,,7800C1 cell line
,7653,1,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,80635,,,CHEMBL618319,Intermediate,10116.0,,N,,F,4135,,1119.0,Rattus norvegicus,1,,,7800C1 cell line
,7653,1,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,80635,,,CHEMBL618320,Intermediate,10116.0,,N,,F,4136,,1119.0,Rattus norvegicus,1,,,7800C1 cell line
,7653,1,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,80635,,,CHEMBL618321,Intermediate,10116.0,,N,,F,4137,,1119.0,Rattus norvegicus,1,,,7800C1 cell line
,7653,1,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,80635,,,CHEMBL883118,Intermediate,10116.0,,N,,F,4138,,1119.0,Rattus norvegicus,1,,,7800C1 cell line
,17229,1,BAO_0000219,In vitro antitumor activity against renal 786-0 tumor cell lines,80640,,,CHEMBL883795,Intermediate,9606.0,,N,,F,4139,,391.0,Homo sapiens,1,,,786-0
,12858,1,BAO_0000219,Cytotoxic activity against 786-0 Renal cancer cell line,80640,,,CHEMBL618322,Intermediate,9606.0,,N,,F,4140,,391.0,Homo sapiens,1,,,786-0
,16325,1,BAO_0000219,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,80640,,,CHEMBL618323,Intermediate,9606.0,,N,,F,4141,,391.0,Homo sapiens,1,,,786-0
,16325,1,BAO_0000219,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,80640,,,CHEMBL618324,Intermediate,9606.0,,N,,F,4142,,391.0,Homo sapiens,1,,,786-0
,5858,1,BAO_0000219,In vitro antitumor activity against human renal 786-0 cell line,80640,,,CHEMBL618325,Intermediate,9606.0,,N,,F,4143,,391.0,Homo sapiens,1,,,786-0
,16325,1,BAO_0000219,Inhibition of Renal cancer in 786-0 cancer cell lines,80640,,,CHEMBL875416,Intermediate,9606.0,,N,,F,4144,,391.0,Homo sapiens,1,,,786-0
,14696,1,BAO_0000219,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,80640,,,CHEMBL618326,Intermediate,9606.0,,N,,F,4145,,391.0,Homo sapiens,1,,,786-0
,3786,1,BAO_0000219,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,80640,,,CHEMBL618327,Intermediate,9606.0,,N,,F,4146,,391.0,Homo sapiens,1,,,786-0
,14696,1,BAO_0000219,inhibition of the growth of renal cancer(786-0) cell line,80640,,,CHEMBL619215,Intermediate,9606.0,,N,,F,4147,,391.0,Homo sapiens,1,,,786-0
,14769,1,BAO_0000219,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),80640,,,CHEMBL619216,Intermediate,9606.0,,N,,F,4148,,391.0,Homo sapiens,1,,,786-0
,15354,1,BAO_0000219,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,80640,,,CHEMBL619217,Intermediate,9606.0,,N,,F,4149,,391.0,Homo sapiens,1,,,786-0
,14255,1,BAO_0000219,The IC50 value was measured on 786-0 cell line in ovarian tumor,80640,,,CHEMBL619218,Intermediate,9606.0,,N,,F,4150,,391.0,Homo sapiens,1,,,786-0
,14255,1,BAO_0000219,The IC50 value was measured on 786-0 cell line in ovarian tumor t,80640,,,CHEMBL619219,Intermediate,9606.0,,N,,F,4151,,391.0,Homo sapiens,1,,,786-0
,14255,1,BAO_0000219,The IC50 value was measured on 786-0 cell line in renal tumor type.,80640,,,CHEMBL619220,Intermediate,9606.0,,N,,F,4152,,391.0,Homo sapiens,1,,,786-0
,14696,1,BAO_0000219,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,80640,,,CHEMBL619221,Intermediate,9606.0,,N,,F,4153,,391.0,Homo sapiens,1,,,786-0
,12016,1,BAO_0000219,Tested for cytotoxic activity against renal cancer 786-0 cell line,80640,,,CHEMBL619222,Intermediate,9606.0,,N,,F,4154,,391.0,Homo sapiens,1,,,786-0
,2597,1,BAO_0000219,Compound was tested for growth inhibitory activity against 786-0 cell line,80640,,,CHEMBL857454,Intermediate,9606.0,,N,,F,4155,,391.0,Homo sapiens,1,,,786-0
,12526,8,BAO_0000219,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,12166,,,CHEMBL619223,Autocuration,,,H,,B,4156,,702.0,,1,,,RBL-1
,12526,8,BAO_0000219,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,12166,,,CHEMBL619224,Autocuration,,,H,,B,4157,,702.0,,1,,,RBL-1
,14799,8,BAO_0000019,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,12166,,,CHEMBL619225,Autocuration,,,H,,B,4158,,,,1,,,
,3595,8,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),12166,,,CHEMBL619226,Expert,,,H,,B,4159,,702.0,,1,,,RBL-1
,3595,8,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),12166,,,CHEMBL619227,Expert,,,H,,B,4160,,702.0,,1,,,RBL-1
,12767,8,BAO_0000357,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,12166,,,CHEMBL619228,Autocuration,,,H,,B,4161,,,,1,,,
,10997,8,BAO_0000219,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,12166,,,CHEMBL619229,Autocuration,,,H,,B,4162,,,,1,,,
,11388,8,BAO_0000219,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,12166,,,CHEMBL619230,Autocuration,,,H,,B,4163,,702.0,,1,,,RBL-1
,167,8,BAO_0000357,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,12166,,,CHEMBL619231,Autocuration,,,H,,B,4164,,,,1,,,
,167,8,BAO_0000357,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",12166,,,CHEMBL619232,Autocuration,,,H,,B,4165,,,,1,,,
,13744,8,BAO_0000357,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,12166,,,CHEMBL619233,Expert,,,H,,B,4166,,,,1,,,
,1630,8,BAO_0000357,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,12166,,,CHEMBL619234,Autocuration,,,H,,B,4167,,,,1,,,
,1630,8,BAO_0000357,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),12166,,,CHEMBL619235,Autocuration,,,H,,B,4168,,,,1,,,
,969,9,BAO_0000019,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",12166,,,CHEMBL619236,Expert,10116.0,,D,,B,4169,,,Rattus norvegicus,1,,,
,13621,8,BAO_0000219,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,12166,,,CHEMBL619237,Autocuration,,,H,,B,4170,,702.0,,1,,,RBL-1
,10089,8,BAO_0000357,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,12166,,,CHEMBL619238,Autocuration,,,H,,B,4171,,,,1,,,
,10193,8,BAO_0000357,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,12166,,,CHEMBL619239,Expert,,,H,,B,4172,,,,1,,,
,11966,8,BAO_0000357,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,12166,,,CHEMBL619240,Autocuration,,,H,,B,4173,,,,1,,,
,12251,8,BAO_0000019,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,12166,,,CHEMBL875417,Autocuration,,,H,,B,4174,,,,1,,,
,211,8,BAO_0000219,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),12166,,,CHEMBL619241,Autocuration,,,H,,B,4175,,702.0,,1,,,RBL-1
,12251,8,BAO_0000019,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,12166,,,CHEMBL619242,Expert,,,H,,F,4176,,,,1,,,
,12495,8,BAO_0000219,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,12166,,,CHEMBL883796,Autocuration,,,H,,B,4177,,702.0,,1,,,RBL-1
,414,8,BAO_0000357,Tested for its inhibitory activity against 5-lipoxygenase,12166,,,CHEMBL619243,Autocuration,,,H,,B,4178,,,,1,,,
,414,8,BAO_0000357,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,12166,,,CHEMBL619244,Autocuration,,,H,,B,4179,,,,1,,,
,10325,8,BAO_0000019,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",12166,,,CHEMBL619245,Expert,,,H,,B,4180,,,,1,,,
,11966,8,BAO_0000019,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,12166,,,CHEMBL619246,Expert,,,H,,B,4181,,,,1,,,
,165,8,BAO_0000219,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,12166,,,CHEMBL619984,Expert,,,H,,B,4182,,702.0,,1,,,RBL-1
,165,8,BAO_0000219,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,12166,,,CHEMBL619985,Autocuration,,,H,,B,4183,,702.0,,1,,,RBL-1
,165,8,BAO_0000219,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,12166,,,CHEMBL619986,Autocuration,,,H,,B,4184,,702.0,,1,,,RBL-1
,165,8,BAO_0000219,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,12166,,,CHEMBL619987,Expert,,,H,,B,4185,,702.0,,1,,,RBL-1
,11311,8,BAO_0000218,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,12166,,,CHEMBL619988,Autocuration,,,H,,B,4186,,,,1,,,
,11311,8,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,12166,,,CHEMBL619989,Autocuration,,,H,,B,4187,,702.0,,1,,,RBL-1
,11311,8,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,12166,,,CHEMBL619990,Autocuration,,,H,,B,4188,,702.0,,1,,,RBL-1
,11311,8,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],12166,,,CHEMBL619991,Autocuration,,,H,,B,4189,,,,1,,,
,11311,8,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),12166,,,CHEMBL619992,Autocuration,,,H,,B,4190,,,,1,,,
,11311,8,BAO_0000218,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),12166,In vivo,,CHEMBL619993,Autocuration,,,H,,B,4191,,,,1,,,
,11311,8,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,12166,,,CHEMBL619994,Autocuration,,,H,,F,4192,,663.0,,1,,,RBL-2H3
,11311,8,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,12166,,,CHEMBL619995,Autocuration,,,H,,F,4193,,663.0,,1,,,RBL-2H3
,11311,8,BAO_0000019,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],12166,,,CHEMBL619996,Autocuration,,,H,,B,4194,,,,1,,,
,11732,8,BAO_0000019,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,12166,,,CHEMBL619997,Autocuration,,,H,,B,4195,,,,1,,,
,11732,8,BAO_0000019,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,12166,,,CHEMBL619998,Expert,,,H,,B,4196,,,,1,,,
,11087,8,BAO_0000019,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,12166,,,CHEMBL619999,Expert,,,H,,B,4197,,,,1,,,
,11087,8,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,12166,,,CHEMBL620000,Autocuration,,,H,,B,4198,,,,1,,,
,11087,8,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,12166,,,CHEMBL620001,Autocuration,,,H,,B,4199,,702.0,,1,,,RBL-1
,11087,9,BAO_0000357,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,12166,,,CHEMBL620002,Expert,10116.0,,D,,B,4200,,,Rattus norvegicus,1,,,
,496,8,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,12166,,,CHEMBL620003,Autocuration,,,H,,B,4201,,702.0,,1,,,RBL-1
,13986,8,BAO_0000219,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,12166,,,CHEMBL620004,Expert,,,H,,F,4202,,702.0,,1,,,RBL-1
,11520,8,BAO_0000357,Compound was evaluated for the inhibition of 5-lipoxygenase,12166,,,CHEMBL874063,Autocuration,,,H,,B,4203,,,,1,,,
,10293,8,BAO_0000219,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,12166,,,CHEMBL620005,Autocuration,,,H,,B,4204,,702.0,,1,,,RBL-1
,303,8,BAO_0000219,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,12166,,,CHEMBL620006,Autocuration,,,H,,B,4205,,702.0,,1,,,RBL-1
,303,8,BAO_0000219,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,12166,,,CHEMBL620007,Autocuration,,,H,,B,4206,,702.0,,1,,,RBL-1
,9247,8,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,12166,,,CHEMBL620008,Autocuration,,,H,,B,4207,,702.0,,1,,,RBL-1
,9247,9,BAO_0000219,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,12166,,,CHEMBL620009,Expert,10116.0,,D,,B,4208,,702.0,Rattus norvegicus,1,,,RBL-1
,9247,8,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,12166,,,CHEMBL620010,Autocuration,,,H,,B,4209,,702.0,,1,,,RBL-1
,9247,8,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,12166,,,CHEMBL620011,Autocuration,,,H,,B,4210,,702.0,,1,,,RBL-1
,9247,8,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,12166,,,CHEMBL620677,Autocuration,,,H,,B,4211,,702.0,,1,,,RBL-1
,9247,8,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,12166,,,CHEMBL620678,Autocuration,,,H,,B,4212,,702.0,,1,,,RBL-1
,9247,8,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,12166,,,CHEMBL620679,Autocuration,,,H,,B,4213,,702.0,,1,,,RBL-1
,9247,8,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,12166,,,CHEMBL620680,Autocuration,,,H,,B,4214,,702.0,,1,,,RBL-1
,11481,9,BAO_0000357,Inhibitory activity against 5-lipoxygenase at 10 uM,12166,,,CHEMBL620838,Expert,10116.0,,D,,B,4215,,,Rattus norvegicus,1,,,
,105,8,BAO_0000357,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,12166,,,CHEMBL620839,Autocuration,,,H,,B,4216,,,,1,,,
,9029,8,BAO_0000357,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,12166,,,CHEMBL620840,Expert,,,H,,B,4217,,,,1,,,
,1175,8,BAO_0000219,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,12166,,,CHEMBL620841,Expert,,,H,,B,4218,,702.0,,1,,,RBL-1
,12118,8,BAO_0000219,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,12166,,,CHEMBL620842,Autocuration,,,H,,B,4219,,702.0,,1,,,RBL-1
,12118,8,BAO_0000219,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,12166,,,CHEMBL620843,Autocuration,,,H,,B,4220,,702.0,,1,,,RBL-1
,12118,8,BAO_0000219,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,12166,,,CHEMBL620844,Autocuration,,,H,,B,4221,,702.0,,1,,,RBL-1
,9225,8,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,12166,,,CHEMBL620845,Autocuration,,,H,,B,4222,,702.0,,1,,,RBL-1
,9401,8,BAO_0000019,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,12166,,,CHEMBL620846,Autocuration,,,H,,B,4223,,,,1,,,
,137,8,BAO_0000357,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,12166,,,CHEMBL873951,Autocuration,,,H,,B,4224,,,,1,,,
,137,8,BAO_0000357,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,12166,,,CHEMBL620847,Autocuration,,,H,,B,4225,,,,1,,,
,4717,8,BAO_0000219,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,12166,,,CHEMBL620848,Autocuration,,,H,,B,4226,,702.0,,1,,,RBL-1
,3595,8,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,12166,,,CHEMBL620849,Autocuration,,,H,,B,4227,,702.0,,1,,,RBL-1
,10501,8,BAO_0000219,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,12166,,,CHEMBL620850,Autocuration,,,H,,B,4228,,702.0,,1,,,RBL-1
,10501,8,BAO_0000219,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,12166,,,CHEMBL620851,Autocuration,,,H,,B,4229,,702.0,,1,,,RBL-1
,10501,8,BAO_0000219,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,12166,,,CHEMBL620852,Autocuration,,,H,,B,4230,,702.0,,1,,,RBL-1
,12526,8,BAO_0000219,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12166,,,CHEMBL875098,Autocuration,,,H,,B,4231,,702.0,,1,,,RBL-1
,14799,9,BAO_0000219,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,12166,,,CHEMBL620853,Expert,10116.0,,D,,B,4232,,702.0,Rattus norvegicus,1,,,RBL-1
,14799,8,BAO_0000019,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,12166,,,CHEMBL620854,Autocuration,,,H,,B,4233,,,,1,,,
,3595,8,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,12166,,,CHEMBL620855,Autocuration,,,H,,B,4234,,702.0,,1,,,RBL-1
,3595,8,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,12166,,,CHEMBL839884,Expert,,,H,,B,4235,,702.0,,1,,,RBL-1
,12526,8,BAO_0000219,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12166,,,CHEMBL620856,Autocuration,,,H,,B,4236,,702.0,,1,,,RBL-1
,12526,8,BAO_0000219,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12166,,,CHEMBL620857,Autocuration,,,H,,B,4237,,702.0,,1,,,RBL-1
,10193,8,BAO_0000019,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,12166,,,CHEMBL620858,Autocuration,,,H,,B,4238,,,,1,,,
,10193,8,BAO_0000019,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,12166,,,CHEMBL620859,Autocuration,,,H,,B,4239,,,,1,,,
,10193,8,BAO_0000019,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,12166,,,CHEMBL620860,Autocuration,,,H,,B,4240,,,,1,,,
,10193,8,BAO_0000019,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,12166,,,CHEMBL620861,Autocuration,,,H,,B,4241,,,,1,,,
,9138,8,BAO_0000357,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),12166,,,CHEMBL620862,Expert,,,H,,B,4242,,,,1,,,
,9138,8,BAO_0000357,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,12166,,,CHEMBL620863,Autocuration,,,H,,B,4243,,,,1,,,
,11966,8,BAO_0000019,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,12166,,,CHEMBL620864,Autocuration,,,H,,B,4244,,,,1,,,
,165,8,BAO_0000219,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,12166,,,CHEMBL620865,Autocuration,,,H,,B,4245,,702.0,,1,,,RBL-1
,165,8,BAO_0000219,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,12166,,,CHEMBL620866,Autocuration,,,H,,B,4246,,702.0,,1,,,RBL-1
,11311,8,BAO_0000219,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,12166,,,CHEMBL620867,Autocuration,,,H,,B,4247,,663.0,,1,,,RBL-2H3
,11311,8,BAO_0000219,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,12166,,,CHEMBL620868,Autocuration,,,H,,B,4248,,663.0,,1,,,RBL-2H3
,11311,8,BAO_0000219,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,12166,,,CHEMBL620869,Autocuration,,,H,,F,4249,,663.0,,1,,,RBL-2H3
,11311,8,BAO_0000019,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,12166,,,CHEMBL873952,Autocuration,,,H,,F,4250,,,,1,,,
,11311,8,BAO_0000357,The compound was tested for inhibition of isolated 5-lipoxygenase,12166,,,CHEMBL875099,Autocuration,,,H,,B,4251,,,,1,,,
,11311,8,BAO_0000219,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,12166,,,CHEMBL620870,Autocuration,,,H,,F,4252,,663.0,,1,,,RBL-2H3
,11087,8,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,12166,,,CHEMBL618261,Autocuration,,,H,,B,4253,,,,1,,,
,11087,8,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,12166,,,CHEMBL618262,Autocuration,,,H,,B,4254,,,,1,,,
,11087,8,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,12166,,,CHEMBL619428,Autocuration,,,H,,B,4255,,,,1,,,
,11087,8,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,12166,,,CHEMBL619429,Autocuration,,,H,,B,4256,,,,1,,,
,11087,8,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,12166,,,CHEMBL619430,Autocuration,,,H,,B,4257,,,,1,,,
,496,8,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,12166,,,CHEMBL620017,Autocuration,,,H,,B,4258,,702.0,,1,,,RBL-1
,496,8,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,12166,,,CHEMBL620018,Autocuration,,,H,,B,4259,,702.0,,1,,,RBL-1
,13986,8,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,12166,,,CHEMBL620019,Autocuration,,,H,,F,4260,,702.0,,1,,,RBL-1
,13986,8,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,12166,,,CHEMBL620020,Autocuration,,,H,,F,4261,,702.0,,1,,,RBL-1
,13986,8,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,12166,,,CHEMBL620021,Autocuration,,,H,,F,4262,,702.0,,1,,,RBL-1
,13986,8,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,12166,,,CHEMBL620022,Autocuration,,,H,,F,4263,,702.0,,1,,,RBL-1
,13986,8,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,12166,,,CHEMBL620023,Autocuration,,,H,,F,4264,,702.0,,1,,,RBL-1
,13986,8,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,12166,,,CHEMBL620024,Autocuration,,,H,,F,4265,,702.0,,1,,,RBL-1
,13986,8,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,12166,,,CHEMBL620025,Autocuration,,,H,,F,4266,,702.0,,1,,,RBL-1
,13986,8,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,12166,,,CHEMBL620026,Autocuration,,,H,,F,4267,,702.0,,1,,,RBL-1
,13986,8,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,12166,,,CHEMBL620027,Autocuration,,,H,,F,4268,,702.0,,1,,,RBL-1
,13986,9,BAO_0000019,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,12166,,,CHEMBL620028,Expert,10116.0,,D,,F,4269,,,Rattus norvegicus,1,,,
,10193,8,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,12166,,,CHEMBL620029,Autocuration,,,H,,B,4270,,,,1,,,
,9295,8,BAO_0000357,Compound was tested for the percent of inhibition against 5-LO at 10 uM,12166,,,CHEMBL620030,Autocuration,,,H,,B,4271,,,,1,,,
,4717,8,BAO_0000219,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,12166,,,CHEMBL875415,Autocuration,,,H,,B,4272,,702.0,,1,,,RBL-1
,4717,8,BAO_0000219,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,12166,,,CHEMBL618256,Autocuration,,,H,,B,4273,,702.0,,1,,,RBL-1
,11854,8,BAO_0000219,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,12166,,,CHEMBL618257,Autocuration,,,H,,B,4274,,702.0,,1,,,RBL-1
,11854,8,BAO_0000219,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,12166,,,CHEMBL618258,Autocuration,,,H,,B,4275,,702.0,,1,,,RBL-1
,11854,8,BAO_0000219,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,12166,,,CHEMBL618259,Autocuration,,,H,,B,4276,,702.0,,1,,,RBL-1
,10193,8,BAO_0000019,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,12166,,,CHEMBL618260,Autocuration,,,H,,B,4277,,,,1,,,
,9295,8,BAO_0000219,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,12166,,,CHEMBL618215,Autocuration,,,H,,B,4278,,702.0,,1,,,RBL-1
,9295,8,BAO_0000219,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,12166,,,CHEMBL618390,Autocuration,,,H,,B,4279,,702.0,,1,,,RBL-1
,9295,8,BAO_0000219,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,12166,,,CHEMBL618391,Autocuration,,,H,,B,4280,,702.0,,1,,,RBL-1
,9295,8,BAO_0000219,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,12166,,,CHEMBL618392,Autocuration,,,H,,B,4281,,702.0,,1,,,RBL-1
,165,8,BAO_0000219,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,12166,,,CHEMBL618393,Autocuration,,,H,,B,4282,,702.0,,1,,,RBL-1
,11311,8,BAO_0000219,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,12166,,,CHEMBL618394,Autocuration,,,H,,B,4283,,,,1,,,
,10489,8,BAO_0000219,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),12166,,,CHEMBL618395,Expert,9606.0,,H,,B,4284,,702.0,Homo sapiens,1,,,RBL-1
,10489,9,BAO_0000219,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),12166,,,CHEMBL618396,Expert,10116.0,,D,,B,4285,,702.0,Rattus norvegicus,1,,,RBL-1
,10489,9,BAO_0000219,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),12166,,,CHEMBL858253,Expert,10116.0,,D,,B,4286,,702.0,Rattus norvegicus,1,,,RBL-1
,14799,9,BAO_0000019,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,12166,,,CHEMBL618397,Autocuration,10116.0,,D,,B,4287,,,Rattus norvegicus,1,,,
,9295,8,BAO_0000357,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),12054,,,CHEMBL618398,Autocuration,3847.0,,H,,B,4288,,,Glycine max,1,,,
,16811,0,BAO_0000019,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",22226,,,CHEMBL618399,Autocuration,,,U,,B,4289,,,,1,,,
,168,8,BAO_0000357,In vitro inhibition of 5-Lipoxygenase; Inactive.,55,,,CHEMBL618400,Expert,,,H,,B,4290,,,,1,,,
,6309,8,BAO_0000357,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,55,,,CHEMBL618401,Autocuration,,,H,,B,4291,,,,1,,,
,6309,8,BAO_0000357,Inhibitory concentration against 5-lipoxygenase; No inhibition,55,,,CHEMBL618402,Autocuration,,,H,,B,4292,,,,1,,,
,3092,8,BAO_0000219,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,55,,,CHEMBL876400,Autocuration,,,H,,B,4293,,702.0,,1,,,RBL-1
,168,8,BAO_0000357,Inhibitory activity against 5-lipoxygenase.,55,,,CHEMBL618403,Expert,,,H,,B,4294,,,,1,,,
,168,8,BAO_0000357,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,55,,,CHEMBL618404,Autocuration,,,H,,B,4295,,,,1,,,
,168,8,BAO_0000357,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,55,,,CHEMBL618405,Autocuration,,,H,,B,4296,,,,1,,,
,168,8,BAO_0000357,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,55,,,CHEMBL618406,Autocuration,,,H,,B,4297,,,,1,,,
,12338,8,BAO_0000019,Inhibitory concentration against arachidonic acid 5-lipoxygenation,55,,,CHEMBL618407,Expert,,,H,,F,4298,,,,1,,,
,4501,8,BAO_0000357,Tested for the inhibitory activity against 5-lipoxygenase,55,,,CHEMBL618408,Autocuration,,,H,,B,4299,,,,1,,,
,1132,8,BAO_0000357,Compound was tested for its inhibitory activity against 5-lipoxygenase,55,,,CHEMBL618409,Autocuration,,,H,,B,4300,,,,1,,,
,2117,8,BAO_0000357,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,55,,,CHEMBL618410,Autocuration,,,H,,B,4301,,,,1,,,
,168,8,BAO_0000357,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,55,,,CHEMBL618411,Autocuration,,,H,,B,4302,,,,1,,,
,168,8,BAO_0000357,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,55,,,CHEMBL618412,Autocuration,,,H,,B,4303,,,,1,,,
,13575,8,BAO_0000219,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,12166,,,CHEMBL618413,Autocuration,,,H,,B,4304,,702.0,,1,,,RBL-1
,11089,8,BAO_0000357,,12166,,,CHEMBL618414,Autocuration,,,H,,B,4305,,,,1,,,
,216,8,BAO_0000357,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),10102,,,CHEMBL618415,Autocuration,,,H,,B,4306,,,,1,,,
,13165,8,BAO_0000019,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,10102,,,CHEMBL618416,Autocuration,,,H,,B,4307,,,,1,,,
,3278,8,BAO_0000357,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,10102,,,CHEMBL876401,Autocuration,,,H,,B,4308,,,,1,,,
,3278,8,BAO_0000357,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,10102,,,CHEMBL618417,Expert,,,H,,B,4309,,,,1,,,
,11966,8,BAO_0000357,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,10102,,,CHEMBL618418,Autocuration,,,H,,B,4310,,,,1,,,
,175,8,BAO_0000357,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",10102,,,CHEMBL618419,Autocuration,,,H,,B,4311,,,,1,,,
,175,8,BAO_0000357,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",10102,,,CHEMBL618420,Autocuration,,,H,,B,4312,,,,1,,,
,13449,8,BAO_0000357,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,10102,,,CHEMBL618421,Autocuration,,,H,,B,4313,,,,1,,,
,12014,8,BAO_0000019,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,11238,,,CHEMBL618422,Autocuration,,,H,,B,4314,,,,1,,,
,12014,8,BAO_0000019,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),11238,,,CHEMBL618423,Autocuration,,,H,,B,4315,,,,1,,,
,12014,8,BAO_0000019,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),11238,,,CHEMBL618424,Autocuration,,,H,,B,4316,,,,1,,,
,99,2,BAO_0000220,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,100284,,,CHEMBL618425,Intermediate,,,S,,B,4317,,,,1,,,
,4349,0,BAO_0000019,The dark toxicity against 543 human galactophore carcinoma cells,22226,,,CHEMBL618426,Autocuration,9606.0,,U,,F,4318,,,Homo sapiens,1,,,
,4071,1,BAO_0000219,Tested in vitro for cytotoxicity against 56 human tumor cell lines,80623,,,CHEMBL618427,Expert,9606.0,,N,,F,4319,,390.0,Homo sapiens,1,,,Panel (56 tumour cell lines)
,17589,1,BAO_0000219,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,80008,,,CHEMBL618428,Expert,9606.0,,N,,F,4320,,345.0,Homo sapiens,1,,,5637
,15002,1,BAO_0000219,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,80008,,,CHEMBL618429,Intermediate,9606.0,,N,,F,4321,,345.0,Homo sapiens,1,,,5637
,13958,1,BAO_0000219,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",80008,,,CHEMBL618430,Intermediate,9606.0,,N,,F,4322,,345.0,Homo sapiens,1,,,5637
,17589,1,BAO_0000219,Growth inhibition against human 5637 cell lines,80008,,,CHEMBL618431,Expert,9606.0,,N,,F,4323,,345.0,Homo sapiens,1,,,5637
,16748,1,BAO_0000219,Antitumor activity against human bladder carcinoma 5637 cells.,80008,,,CHEMBL883799,Expert,9606.0,,N,,F,4324,,345.0,Homo sapiens,1,,,5637
,16747,1,BAO_0000219,Antitumor activity against human bladder carcinoma 5637 cells,80008,,,CHEMBL618432,Intermediate,9606.0,,N,,F,4325,,345.0,Homo sapiens,1,,,5637
,16747,1,BAO_0000219,Antitumor activity against human bladder carcinoma 5637 cells,80008,,,CHEMBL618433,Intermediate,9606.0,,N,,F,4326,,345.0,Homo sapiens,1,,,5637
,15285,9,BAO_0000357,In vitro inhibition of bovine trypsin(Trp).,10443,,,CHEMBL618434,Expert,9913.0,,D,,B,4327,,,Bos taurus,1,,,
,3726,8,BAO_0000219,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,240,,,CHEMBL618435,Expert,9527.0,,H,,B,4328,,407.0,Cercopithecidae,1,,,CV-1
,5033,8,BAO_0000357,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,10577,,,CHEMBL876402,Autocuration,,,H,,B,4329,,,,1,,,
,11756,6,BAO_0000019,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,104698,,,CHEMBL618436,Autocuration,,,H,,F,4330,,,,1,,,
,11953,0,BAO_0000218,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,22226,In vivo,,CHEMBL618437,Autocuration,,,U,,F,4331,,,,1,,,
,5033,9,BAO_0000357,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,20033,,,CHEMBL618438,Intermediate,10141.0,,D,,B,4332,,,Cavia porcellus,1,,,
,11347,8,BAO_0000251,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,17045,,,CHEMBL883800,Expert,10116.0,Microsomes,H,,A,4333,,,Rattus norvegicus,1,,,
,11347,8,BAO_0000251,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,17045,,,CHEMBL618439,Expert,10116.0,Microsomes,H,,A,4334,,,Rattus norvegicus,1,,,
,1229,0,BAO_0000019,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,22226,,,CHEMBL618440,Intermediate,,,U,,F,4335,,,,1,,,
,1229,0,BAO_0000019,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,22226,,,CHEMBL618441,Intermediate,,,U,,F,4336,,,,1,,,
,17588,8,BAO_0000019,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,11938,,,CHEMBL618442,Expert,5691.0,,H,,B,4337,,,Trypanosoma brucei,1,,,
,17588,8,BAO_0000019,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,11938,,,CHEMBL618443,Autocuration,5691.0,,H,,B,4338,,,Trypanosoma brucei,1,,,
,17588,8,BAO_0000019,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,11938,,,CHEMBL619158,Expert,9940.0,,H,,B,4339,,,Ovis aries,1,,,
,17588,8,BAO_0000019,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,11938,,,CHEMBL620974,Autocuration,9940.0,,H,,B,4340,,,Ovis aries,1,,,
,16485,8,BAO_0000357,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,11938,,,CHEMBL620975,Autocuration,,,H,,B,4341,,,,1,,,
,4337,0,BAO_0000019,Average inhibitory concentration against 60 human cell lines was reported,22226,,,CHEMBL620976,Intermediate,9606.0,,U,,F,4342,,,Homo sapiens,1,,,
,4112,0,BAO_0000019,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,22226,,,CHEMBL620977,Expert,9606.0,,U,,F,4343,,,Homo sapiens,1,,,
,16160,1,BAO_0000219,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,80315,,,CHEMBL620978,Intermediate,9606.0,,N,,F,4344,,542.0,Homo sapiens,1,,,Panel NCI-60 (60 carcinoma cell lines)
,16160,1,BAO_0000219,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,80315,,,CHEMBL620979,Intermediate,9606.0,,N,,F,4345,,542.0,Homo sapiens,1,,,Panel NCI-60 (60 carcinoma cell lines)
,17376,1,BAO_0000219,In vitro mean growth inhibitory activity against 60-cell panel,80315,,,CHEMBL620980,Expert,,,N,,F,4346,,542.0,,1,,,Panel NCI-60 (60 carcinoma cell lines)
,17376,1,BAO_0000219,In vitro mean growth lethal concentration against 60-cell panel,80315,,,CHEMBL620981,Expert,,,N,,F,4347,,542.0,,1,,,Panel NCI-60 (60 carcinoma cell lines)
,17376,1,BAO_0000219,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,80315,,,CHEMBL620982,Expert,,,N,,F,4348,,542.0,,1,,,Panel NCI-60 (60 carcinoma cell lines)
,17376,1,BAO_0000219,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,80315,,,CHEMBL620983,Expert,,,N,,F,4349,,542.0,,1,,,Panel NCI-60 (60 carcinoma cell lines)
,3241,4,BAO_0000019,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,104775,,,CHEMBL620984,Autocuration,,,H,,F,4350,,,,1,,,
,3241,4,BAO_0000019,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,104775,,,CHEMBL620985,Autocuration,,,H,,F,4351,,,,1,,,
,3725,8,BAO_0000357,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,275,,,CHEMBL620986,Expert,,,H,,B,4352,,,,1,,,
,10805,1,BAO_0000218,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,50425,,,CHEMBL620987,Expert,5833.0,,N,,F,4353,,,Plasmodium falciparum,1,,,
,10805,1,BAO_0000218,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,50425,,,CHEMBL620988,Expert,5833.0,,N,,F,4354,,,Plasmodium falciparum,1,,,
,10805,1,BAO_0000218,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,50425,,,CHEMBL620989,Expert,5833.0,,N,,F,4355,,,Plasmodium falciparum,1,,,
,10805,1,BAO_0000218,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,50425,,,CHEMBL620990,Expert,5833.0,,N,,F,4356,,,Plasmodium falciparum,1,,,
,10805,1,BAO_0000218,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,50425,,,CHEMBL620991,Intermediate,5833.0,,N,,F,4357,,,Plasmodium falciparum,1,,,
,10144,1,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,80628,,,CHEMBL620992,Intermediate,10090.0,,N,,F,4358,,850.0,Mus musculus,1,,,6C3HED
,10144,1,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,80628,,,CHEMBL620993,Intermediate,10090.0,,N,,F,4359,,850.0,Mus musculus,1,,,6C3HED
,10144,1,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,80628,,,CHEMBL620994,Intermediate,10090.0,,N,,F,4360,,850.0,Mus musculus,1,,,6C3HED
,10144,1,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,80628,,,CHEMBL620995,Intermediate,10090.0,,N,,F,4361,,850.0,Mus musculus,1,,,6C3HED
,10144,1,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,80628,,,CHEMBL620996,Intermediate,10090.0,,N,,F,4362,,850.0,Mus musculus,1,,,6C3HED
,10144,1,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,80628,,,CHEMBL875581,Intermediate,10090.0,,N,,F,4363,,850.0,Mus musculus,1,,,6C3HED
,10685,0,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,22224,In vivo,,CHEMBL620997,Autocuration,10090.0,,U,,F,4364,,,Mus musculus,1,,,
,10685,0,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,22224,In vivo,,CHEMBL620998,Autocuration,10090.0,,U,,F,4365,,,Mus musculus,1,,,
,10685,0,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),22224,In vivo,,CHEMBL620999,Autocuration,10090.0,,U,,F,4366,,,Mus musculus,1,,,
,10685,0,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,22224,In vivo,,CHEMBL621000,Autocuration,10090.0,,U,,F,4367,,,Mus musculus,1,,,
,10685,0,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,22224,In vivo,,CHEMBL621001,Autocuration,10090.0,,U,,F,4368,,,Mus musculus,1,,,
,10685,0,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,22224,In vivo,,CHEMBL621002,Autocuration,10090.0,,U,,F,4369,,,Mus musculus,1,,,
,10685,0,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,22224,In vivo,,CHEMBL621003,Autocuration,10090.0,,U,,F,4370,,,Mus musculus,1,,,
,10685,0,BAO_0000218,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",22224,In vivo,,CHEMBL621004,Autocuration,10090.0,,U,,F,4371,,,Mus musculus,1,,,
,10685,0,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),22224,In vivo,,CHEMBL621005,Autocuration,10090.0,,U,,F,4372,,,Mus musculus,1,,,
,10685,0,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),22224,In vivo,,CHEMBL621006,Autocuration,10090.0,,U,,F,4373,,,Mus musculus,1,,,
,10685,0,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,22224,In vivo,,CHEMBL621007,Autocuration,10090.0,,U,,F,4374,,,Mus musculus,1,,,
,10144,0,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,22224,,,CHEMBL621008,Autocuration,10090.0,,U,,F,4375,,,Mus musculus,1,,,
,10144,0,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,22224,,,CHEMBL621009,Autocuration,10090.0,,U,,F,4376,,,Mus musculus,1,,,
,10144,0,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,22224,,,CHEMBL857705,Autocuration,10090.0,,U,,F,4377,,,Mus musculus,1,,,
,10144,0,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,22224,,,CHEMBL619828,Autocuration,10090.0,,U,,F,4378,,,Mus musculus,1,,,
,10685,0,BAO_0000218,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,22224,,,CHEMBL619829,Autocuration,10090.0,,U,,F,4379,,,Mus musculus,1,,,
,10685,0,BAO_0000218,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,22224,,,CHEMBL619830,Autocuration,10090.0,,U,,F,4380,,,Mus musculus,1,,,
,10685,0,BAO_0000218,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,22224,,,CHEMBL619831,Autocuration,10090.0,,U,,F,4381,,,Mus musculus,1,,,
,10685,0,BAO_0000218,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,22224,,,CHEMBL619832,Autocuration,10090.0,,U,,F,4382,,,Mus musculus,1,,,
,10685,0,BAO_0000218,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,22224,,,CHEMBL619833,Autocuration,10090.0,,U,,A,4383,,,Mus musculus,1,,,
,10685,0,BAO_0000218,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,22224,,,CHEMBL619834,Autocuration,10090.0,,U,,A,4384,,,Mus musculus,1,,,
,10685,0,BAO_0000218,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,22224,,,CHEMBL619835,Autocuration,10090.0,,U,,A,4385,,,Mus musculus,1,,,
,10685,0,BAO_0000218,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,22224,,,CHEMBL619836,Autocuration,10090.0,,U,,A,4386,,,Mus musculus,1,,,
,8831,1,BAO_0000218,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",80628,,,CHEMBL619837,Intermediate,10090.0,,N,,F,4387,,850.0,Mus musculus,1,,,6C3HED
,11704,0,BAO_0000218,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,22224,In vivo,,CHEMBL619838,Autocuration,,,U,,F,4388,,,,1,,,
,11704,1,BAO_0000218,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,50594,,,CHEMBL619839,Intermediate,10090.0,,N,,A,4389,,,Mus musculus,1,,,
,10685,1,BAO_0000218,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,80628,In vivo,,CHEMBL619840,Intermediate,10090.0,,N,,F,4390,,850.0,Mus musculus,1,,,6C3HED
,10685,1,BAO_0000218,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,80628,In vivo,,CHEMBL619841,Intermediate,10090.0,,N,,F,4391,,850.0,Mus musculus,1,,,6C3HED
,11368,1,BAO_0000218,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),80628,,,CHEMBL857704,Expert,10090.0,,N,,F,4392,,850.0,Mus musculus,1,,,6C3HED
,11368,1,BAO_0000218,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),80628,,,CHEMBL619842,Intermediate,10090.0,,N,,F,4393,,850.0,Mus musculus,1,,,6C3HED
,11368,1,BAO_0000218,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),80628,,,CHEMBL619843,Expert,10090.0,,N,,F,4394,,850.0,Mus musculus,1,,,6C3HED
,17763,0,BAO_0000019,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",22226,,,CHEMBL619844,Autocuration,1280.0,,U,,B,4395,,,Staphylococcus aureus,1,,,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,22226,,Liver,CHEMBL857855,Autocuration,10116.0,Microsomes,U,,B,4396,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,22226,,Liver,CHEMBL619845,Autocuration,10116.0,Microsomes,U,,B,4397,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,22226,,Liver,CHEMBL619846,Autocuration,10116.0,Microsomes,U,,B,4398,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,22226,,Liver,CHEMBL619847,Autocuration,10116.0,Microsomes,U,,B,4399,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,22226,,Liver,CHEMBL619848,Autocuration,10116.0,Microsomes,U,,B,4400,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,22226,,Liver,CHEMBL620893,Autocuration,10116.0,Microsomes,U,,B,4401,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,22226,,Liver,CHEMBL620894,Autocuration,10116.0,Microsomes,U,,B,4402,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,22226,,Liver,CHEMBL620895,Autocuration,10116.0,Microsomes,U,,B,4403,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,22226,,Liver,CHEMBL620896,Autocuration,10116.0,Microsomes,U,,B,4404,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,22226,,Liver,CHEMBL620897,Autocuration,10116.0,Microsomes,U,,B,4405,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,22226,,Liver,CHEMBL620898,Autocuration,10116.0,Microsomes,U,,B,4406,,,Rattus norvegicus,1,,2107.0,
,7411,0,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,22226,,Liver,CHEMBL620899,Autocuration,10116.0,Microsomes,U,,B,4407,,,Rattus norvegicus,1,,2107.0,
,347,0,BAO_0000218,The apparent total plasma clearance in monkey,22224,In vivo,Plasma,CHEMBL620900,Autocuration,9527.0,,U,,A,4408,,,Cercopithecidae,1,,1969.0,
,3341,0,BAO_0000218,Compound was evaluated for Hepatic clearance in monkey,22224,In vivo,,CHEMBL620901,Autocuration,9527.0,,U,,A,4409,,,Cercopithecidae,1,,,
,17853,0,BAO_0000218,Lower clearance in monkey (i.v.) at 0.5 mpk,22224,In vivo,,CHEMBL620902,Autocuration,9527.0,,U,,A,4410,,,Cercopithecidae,1,,,
,4514,0,BAO_0000218,Plasma clearance in rhesus monkey,22224,In vivo,,CHEMBL620903,Autocuration,9527.0,,U,,A,4411,,,Cercopithecidae,1,,,
,6062,0,BAO_0000218,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,22224,In vivo,,CHEMBL620904,Autocuration,9527.0,,U,,A,4412,,,Cercopithecidae,1,,,
,6821,0,BAO_0000218,Plasma clearance of compound was determined in monkey,22224,In vivo,,CHEMBL620905,Autocuration,9527.0,,U,,A,4413,,,Cercopithecidae,1,,,
,6057,0,BAO_0000218,Plasma clearance was calculated in rhesus monkey,22224,In vivo,,CHEMBL620906,Autocuration,9527.0,,U,,A,4414,,,Cercopithecidae,1,,,
,5145,0,BAO_0000218,Plasma clearance in rhesus monkey,22224,In vivo,,CHEMBL875420,Autocuration,9527.0,,U,,A,4415,,,Cercopithecidae,1,,,
,6641,0,BAO_0000218,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),22224,In vivo,,CHEMBL620907,Autocuration,9527.0,,U,,A,4416,,,Cercopithecidae,1,,,
,5472,0,BAO_0000218,Plasma clearance was evaluated in rhesus,22224,In vivo,,CHEMBL620908,Autocuration,9527.0,,U,,A,4417,,,Cercopithecidae,1,,,
,4257,0,BAO_0000218,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,22224,In vivo,,CHEMBL620909,Autocuration,9527.0,,U,,A,4418,,,Cercopithecidae,1,,,
,5546,0,BAO_0000218,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,22224,In vivo,,CHEMBL620910,Autocuration,9527.0,,U,,A,4419,,,Cercopithecidae,1,,,
,5334,0,BAO_0000218,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),22224,In vivo,,CHEMBL620911,Autocuration,9527.0,,U,,A,4420,,,Cercopithecidae,1,,,
,5334,0,BAO_0000218,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),22224,In vivo,,CHEMBL620912,Autocuration,9527.0,,U,,A,4421,,,Cercopithecidae,1,,,
,17509,0,BAO_0000218,Cmax 24 hr after 2 mg/kg oral administration in monkeys,22224,In vivo,,CHEMBL620913,Autocuration,9527.0,,U,,A,4422,,,Cercopithecidae,1,,,
,6535,0,BAO_0000218,Cmax in monkey after administration of 1 mg/kg iv,22224,In vivo,,CHEMBL620914,Autocuration,9527.0,,U,,A,4423,,,Cercopithecidae,1,,,
,5668,0,BAO_0000218,Cmax was determine after peroral administration at 10 mpk in Rhesus,22224,In vivo,,CHEMBL620915,Autocuration,9527.0,,U,,A,4424,,,Cercopithecidae,1,,,
,5922,0,BAO_0000218,Cmax in cynomolgus monkey by iv administration,22224,In vivo,,CHEMBL620916,Autocuration,9527.0,,U,,A,4425,,,Cercopithecidae,1,,,
,5922,0,BAO_0000218,Cmax in cynomolgus monkey by po administration,22224,In vivo,,CHEMBL620917,Autocuration,9527.0,,U,,A,4426,,,Cercopithecidae,1,,,
,6078,0,BAO_0000218,Cmax value evaluated in monkey,22224,In vivo,,CHEMBL620918,Autocuration,9527.0,,U,,A,4427,,,Cercopithecidae,1,,,
,2661,0,BAO_0000218,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,22224,In vivo,,CHEMBL620919,Autocuration,9527.0,,U,,A,4428,,,Cercopithecidae,1,,,
,3249,0,BAO_0000218,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,22224,In vivo,Plasma,CHEMBL620920,Autocuration,9527.0,,U,,A,4429,,,Cercopithecidae,1,,1969.0,
,3249,0,BAO_0000218,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,22224,In vivo,Plasma,CHEMBL620921,Autocuration,9527.0,,U,,A,4430,,,Cercopithecidae,1,,1969.0,
,5553,0,BAO_0000218,Maximal plasma concentration in squirrel monkeys,22224,In vivo,Plasma,CHEMBL620922,Autocuration,9527.0,,U,,A,4431,,,Cercopithecidae,1,,1969.0,
,1916,0,BAO_0000218,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,In vivo,,CHEMBL620923,Autocuration,9527.0,,U,,A,4432,,,Cercopithecidae,1,,,
,6227,0,BAO_0000218,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,22224,In vivo,Plasma,CHEMBL620924,Autocuration,9527.0,,U,,A,4433,,,Cercopithecidae,1,,1969.0,
,4809,0,BAO_0000218,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),22224,In vivo,,CHEMBL620925,Autocuration,9527.0,,U,,A,4434,,,Cercopithecidae,1,,,
,5355,0,BAO_0000218,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,22224,In vivo,,CHEMBL620926,Autocuration,9527.0,,U,,A,4435,,,Cercopithecidae,1,,,
,5355,0,BAO_0000218,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,22224,In vivo,,CHEMBL620927,Autocuration,9527.0,,U,,A,4436,,,Cercopithecidae,1,,,
,5355,0,BAO_0000218,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,22224,In vivo,,CHEMBL620928,Autocuration,9527.0,,U,,A,4437,,,Cercopithecidae,1,,,
,5355,0,BAO_0000218,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,22224,In vivo,,CHEMBL620929,Autocuration,9527.0,,U,,A,4438,,,Cercopithecidae,1,,,
,6221,0,BAO_0000218,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,22224,In vivo,Plasma,CHEMBL620930,Autocuration,9527.0,,U,,A,4439,,,Cercopithecidae,1,,1969.0,
,167,0,BAO_0000218,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,22224,,,CHEMBL620931,Autocuration,9527.0,,U,,A,4440,,,Cercopithecidae,1,,,
,167,0,BAO_0000218,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,22224,,,CHEMBL620932,Autocuration,9527.0,,U,,A,4441,,,Cercopithecidae,1,,,
,4257,0,BAO_0000218,Absolute bioavailability was evaluated in monkey,22224,In vivo,,CHEMBL620933,Autocuration,9443.0,,U,,A,4442,,,monkey,1,,,
,6221,0,BAO_0000218,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,22224,In vivo,,CHEMBL620934,Autocuration,9443.0,,U,,A,4443,,,monkey,1,,,
,17667,0,BAO_0000218,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,22224,In vivo,,CHEMBL620935,Autocuration,9443.0,,U,,A,4444,,,monkey,1,,,
,17267,0,BAO_0000218,Bioavailability of compound was determined in rhesus monkey,22224,In vivo,,CHEMBL620936,Autocuration,9544.0,,U,,A,4445,,,Macaca mulatta,1,,,
,4256,0,BAO_0000218,Bioavailability determined after oral administration in marmoset,22224,In vivo,,CHEMBL620937,Autocuration,38020.0,,U,,A,4446,,,marmosets,1,,,
,4256,0,BAO_0000218,Oral bioavailability in cynomolgus monkey,22224,In vivo,,CHEMBL620938,Autocuration,9541.0,,U,,A,4447,,,Macaca fascicularis,1,,,
,17853,0,BAO_0000218,Bioavailability in monkey (p.o.) at 2.0 mpk,22224,In vivo,,CHEMBL620939,Autocuration,9443.0,,U,,A,4448,,,monkey,1,,,
,16365,0,BAO_0000218,Bioavailability was evaluated after oral administration in monkey,22224,In vivo,,CHEMBL620940,Autocuration,9443.0,,U,,A,4449,,,monkey,1,,,
,1916,0,BAO_0000218,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,In vivo,,CHEMBL620941,Autocuration,9541.0,,U,,A,4450,,,Macaca fascicularis,1,,,
,5334,0,BAO_0000218,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),22224,In vivo,,CHEMBL620942,Autocuration,9544.0,,U,,A,4451,,,Macaca mulatta,1,,,
,5334,0,BAO_0000218,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),22224,In vivo,,CHEMBL620943,Autocuration,9544.0,,U,,A,4452,,,Macaca mulatta,1,,,
,17592,0,BAO_0000218,Bioavailability of the compound was determined in monkey,22224,In vivo,,CHEMBL620944,Autocuration,9443.0,,U,,A,4453,,,monkey,1,,,
,1399,0,BAO_0000218,Bioavailability in squirrel monkey (dose 5 mg/kg),22224,In vivo,,CHEMBL620945,Autocuration,9521.0,,U,,A,4454,,,Saimiri sciureus,1,,,
,4809,0,BAO_0000218,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),22224,In vivo,,CHEMBL620946,Autocuration,9443.0,,U,,A,4455,,,monkey,1,,,
,3341,0,BAO_0000218,Oral bioavailability in monkey,22224,In vivo,,CHEMBL620947,Autocuration,9443.0,,U,,A,4456,,,monkey,1,,,
,64,0,BAO_0000218,Compound was tested for bioavailability in squirrel monkey,22224,In vivo,,CHEMBL620948,Autocuration,9521.0,,U,,A,4457,,,Saimiri sciureus,1,,,
,5005,0,BAO_0000218,Oral bioavailability in Rhesus monkey,22224,In vivo,,CHEMBL620949,Autocuration,9544.0,,U,,A,4458,,,Macaca mulatta,1,,,
,5005,0,BAO_0000218,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),22224,In vivo,,CHEMBL620950,Autocuration,9544.0,,U,,A,4459,,,Macaca mulatta,1,,,
,5237,0,BAO_0000218,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,22224,In vivo,,CHEMBL620951,Autocuration,9541.0,,U,,A,4460,,,Macaca fascicularis,1,,,
,5237,0,BAO_0000218,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,22224,In vivo,,CHEMBL620952,Autocuration,9541.0,,U,,A,4461,,,Macaca fascicularis,1,,,
,5302,0,BAO_0000218,Oral bioavailability in monkey (dose 5 mg/kg),22224,In vivo,,CHEMBL875421,Autocuration,9443.0,,U,,A,4462,,,monkey,1,,,
,17667,0,BAO_0000218,Oral bioavailability of compound at 5 mg/kg in monkey,22224,In vivo,,CHEMBL620953,Autocuration,9443.0,,U,,A,4463,,,monkey,1,,,
,6161,1,BAO_0000218,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,50588,In vivo,,CHEMBL873491,Intermediate,9615.0,,N,,A,4464,,,Canis lupus familiaris,1,,,
,6161,1,BAO_0000218,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,50588,In vivo,,CHEMBL620954,Intermediate,9615.0,,N,,A,4465,,,Canis lupus familiaris,1,,,
,3854,1,BAO_0000218,Plasma half life determined,50588,,Plasma,CHEMBL620955,Intermediate,9615.0,,N,,A,4466,,,Canis lupus familiaris,1,,1969.0,
,993,1,BAO_0000218,Plasma half life in dog,50588,,Plasma,CHEMBL618097,Intermediate,9615.0,,N,,A,4467,,,Canis lupus familiaris,1,,1969.0,
,4514,1,BAO_0000218,Plasma half-life in Beagle dogs,50588,,Plasma,CHEMBL618268,Intermediate,9615.0,,N,,A,4468,,,Canis lupus familiaris,1,,1969.0,
,5334,1,BAO_0000218,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),50588,In vivo,Plasma,CHEMBL618269,Intermediate,9615.0,,N,,A,4469,,,Canis lupus familiaris,1,,1969.0,
,5334,1,BAO_0000218,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),50588,In vivo,Plasma,CHEMBL618270,Intermediate,9615.0,,N,,A,4470,,,Canis lupus familiaris,1,,1969.0,
,1466,1,BAO_0000218,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,50588,In vivo,,CHEMBL618271,Intermediate,9615.0,,N,,A,4471,,,Canis lupus familiaris,1,,,
,1466,1,BAO_0000218,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,50588,In vivo,,CHEMBL873493,Intermediate,9615.0,,N,,A,4472,,,Canis lupus familiaris,1,,,
,5313,1,BAO_0000218,Tested for the half life period in dog,50588,,,CHEMBL621031,Intermediate,9615.0,,N,,A,4473,,,Canis lupus familiaris,1,,,
,5313,1,BAO_0000218,Tested for the half life period in dog at dosage of 10 mpk,50588,In vivo,,CHEMBL621032,Intermediate,9615.0,,N,,A,4474,,,Canis lupus familiaris,1,,,
,3880,1,BAO_0000218,The compound was tested for half life in dog,50588,,,CHEMBL621033,Intermediate,9615.0,,N,,A,4475,,,Canis lupus familiaris,1,,,
,3639,1,BAO_0000218,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",50588,,Plasma,CHEMBL621034,Intermediate,9615.0,,N,,A,4476,,,Canis lupus familiaris,1,,1969.0,
,3880,1,BAO_0000218,The half life was determined,50588,,,CHEMBL621035,Intermediate,9615.0,,N,,A,4477,,,Canis lupus familiaris,1,,,
,3918,1,BAO_0000218,The plasma half-life in dogs,50588,,Plasma,CHEMBL621036,Intermediate,9615.0,,N,,A,4478,,,Canis lupus familiaris,1,,1969.0,
,16452,1,BAO_0000218,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,50588,,Plasma,CHEMBL621037,Intermediate,9615.0,,N,,A,4479,,,Canis lupus familiaris,1,,1969.0,
,17796,1,BAO_0000218,Half life in dog,50588,,,CHEMBL619812,Intermediate,9615.0,,N,,A,4480,,,Canis lupus familiaris,1,,,
,5983,1,BAO_0000218,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,50588,In vivo,,CHEMBL619813,Intermediate,9615.0,,N,,A,4481,,,Canis lupus familiaris,1,,,
,1466,1,BAO_0000218,tmax upon peroral administration of 10.0 mg/Kg dose in dog,50588,In vivo,,CHEMBL873335,Intermediate,9615.0,,N,,A,4482,,,Canis lupus familiaris,1,,,
,16456,1,BAO_0000218,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,50588,In vivo,,CHEMBL619814,Intermediate,9615.0,,N,,A,4483,,,Canis lupus familiaris,1,,,
,6113,1,BAO_0000218,Cmax in ferrets after 30 mg/kg oral dose,50506,In vivo,,CHEMBL619815,Expert,9669.0,,N,,A,4484,,,Mustela putorius furo,1,,,
,6113,1,BAO_0000218,Emesis in ferrets at 30 mg/kg oral dose,50506,In vivo,,CHEMBL619816,Expert,9669.0,,N,,F,4485,,,Mustela putorius furo,1,,,
,17796,0,BAO_0000218,Bioavailability in cynomolgus monkey,22224,In vivo,,CHEMBL619817,Autocuration,9541.0,,U,,A,4486,,,Macaca fascicularis,1,,,
,17796,1,BAO_0000218,Volume of distribution in cynomolgus,100710,In vivo,,CHEMBL619818,Intermediate,9541.0,,N,,A,4487,,,Macaca fascicularis,1,,,
,5308,0,BAO_0000218,AUC tested in guinea pig when 3 mg/kg dose was given perorally,22224,,Plasma,CHEMBL619819,Autocuration,10141.0,,U,,A,4488,,,Cavia porcellus,1,,1969.0,
,4877,0,BAO_0000218,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,22224,,,CHEMBL619820,Autocuration,10141.0,,U,,A,4489,,,Cavia porcellus,1,,,
,4876,0,BAO_0000218,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",22224,,,CHEMBL875419,Autocuration,10141.0,,U,,A,4490,,,Cavia porcellus,1,,,
,4878,0,BAO_0000218,AUC in guinea pig after 3mg/kg oral dose,22224,In vivo,Plasma,CHEMBL619821,Autocuration,10141.0,,U,,A,4491,,,Cavia porcellus,1,,1969.0,
,5308,0,BAO_0000218,Bioavailability in guinea pig was tested,22224,In vivo,,CHEMBL619822,Autocuration,10141.0,,U,,A,4492,,,Cavia porcellus,1,,,
,4877,0,BAO_0000218,Tested for oral bioavailability in guinea pig at 5 mg/kg,22224,In vivo,,CHEMBL619823,Autocuration,10141.0,,U,,A,4493,,,Cavia porcellus,1,,,
,4876,0,BAO_0000218,Tested for the oral bioavailability of the compound,22224,In vivo,,CHEMBL619824,Autocuration,10141.0,,U,,A,4494,,,Cavia porcellus,1,,,
,4876,0,BAO_0000218,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,22224,In vivo,,CHEMBL619825,Autocuration,10141.0,,U,,A,4495,,,Cavia porcellus,1,,,
,5308,0,BAO_0000218,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,22224,In vivo,,CHEMBL619826,Autocuration,10141.0,,U,,A,4496,,,Cavia porcellus,1,,,
,4877,0,BAO_0000218,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,22224,In vivo,Lung,CHEMBL619827,Autocuration,10141.0,,U,,A,4497,,,Cavia porcellus,1,,2048.0,
,4878,0,BAO_0000218,Cmax in guinea pig after 3mg/kg oral dose,22224,In vivo,,CHEMBL618167,Autocuration,10141.0,,U,,A,4498,,,Cavia porcellus,1,,,
,5689,0,BAO_0000019,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,22224,,Blood,CHEMBL618168,Autocuration,10141.0,,U,,A,4499,,,Cavia porcellus,1,,178.0,
,5689,0,BAO_0000019,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,22224,,Brain,CHEMBL618169,Autocuration,10141.0,,U,,A,4500,,,Cavia porcellus,1,,955.0,
,5689,0,BAO_0000019,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,22224,,,CHEMBL618170,Autocuration,10141.0,,U,,A,4501,,,Cavia porcellus,1,,,
,5689,0,BAO_0000019,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,22224,,Intestine,CHEMBL618171,Autocuration,10141.0,,U,,A,4502,,,Cavia porcellus,1,,160.0,
,5689,0,BAO_0000019,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,22224,,Kidney,CHEMBL618172,Autocuration,10141.0,,U,,A,4503,,,Cavia porcellus,1,,2113.0,
,5689,0,BAO_0000019,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,22224,,Liver,CHEMBL618173,Autocuration,10141.0,,U,,A,4504,,,Cavia porcellus,1,,2107.0,
,5689,0,BAO_0000019,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,22224,,,CHEMBL618174,Autocuration,10141.0,,U,,A,4505,,,Cavia porcellus,1,,,
,5689,0,BAO_0000019,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,22224,,Spleen,CHEMBL875408,Autocuration,10141.0,,U,,A,4506,,,Cavia porcellus,1,,2106.0,
,14465,0,BAO_0000218,Elimination T1/2 in Guinea pig (PO dose),22224,In vivo,,CHEMBL839827,Autocuration,10141.0,,U,,A,4507,,,Cavia porcellus,1,,,
,5689,0,BAO_0000019,Partition coefficient was measured as -log (counts per min ),22224,,,CHEMBL618175,Autocuration,10141.0,,U,,A,4508,,,Cavia porcellus,1,,,
,611,0,BAO_0000218,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,22224,In vivo,,CHEMBL618176,Autocuration,10141.0,,U,,A,4509,,,Cavia porcellus,1,,,
,611,0,BAO_0000218,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,22224,In vivo,,CHEMBL618177,Autocuration,10141.0,,U,,A,4510,,,Cavia porcellus,1,,,
,14465,0,BAO_0000218,Elimination T1/2 in Guinea pig (PO dose),22224,In vivo,,CHEMBL618178,Autocuration,10141.0,,U,,A,4511,,,Cavia porcellus,1,,,
,4876,0,BAO_0000218,"Tested for the half life period of the compound, intravenously",22224,In vivo,,CHEMBL618179,Autocuration,10141.0,,U,,A,4512,,,Cavia porcellus,1,,,
,5689,0,BAO_0000019,Half-life was measured,22224,,,CHEMBL873489,Autocuration,10141.0,,U,,A,4513,,,Cavia porcellus,1,,,
,7515,0,BAO_0000019,The time required for onset of inotropy after addition of a single dose of delta F75,22224,,,CHEMBL618180,Autocuration,10141.0,,U,,A,4514,,,Cavia porcellus,1,,,
,17667,0,BAO_0000218,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,22224,In vivo,,CHEMBL618181,Autocuration,10141.0,,U,,A,4515,,,Cavia porcellus,1,,,
,17667,0,BAO_0000218,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,22224,In vivo,,CHEMBL618182,Autocuration,10141.0,,U,,A,4516,,,Cavia porcellus,1,,,
,4727,0,BAO_0000218,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,22224,In vivo,,CHEMBL618183,Autocuration,10029.0,,U,,A,4517,,,Cricetulus griseus,1,,,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,In vivo,,CHEMBL618184,Intermediate,10090.0,,N,,A,4518,,,Mus musculus,1,,,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,In vivo,,CHEMBL618185,Intermediate,10090.0,,N,,A,4519,,,Mus musculus,1,,,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,In vivo,,CHEMBL618186,Intermediate,10090.0,,N,,A,4520,,,Mus musculus,1,,,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,In vivo,,CHEMBL618187,Intermediate,10090.0,,N,,A,4521,,,Mus musculus,1,,,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,50594,In vivo,,CHEMBL618188,Intermediate,10090.0,,N,,A,4522,,,Mus musculus,1,,,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,In vivo,,CHEMBL875409,Intermediate,10090.0,,N,,A,4523,,,Mus musculus,1,,,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,In vivo,,CHEMBL618189,Intermediate,10090.0,,N,,A,4524,,,Mus musculus,1,,,
,3655,1,BAO_0000218,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,50594,In vivo,Blood,CHEMBL618190,Intermediate,10090.0,,N,,A,4525,,,Mus musculus,1,,178.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,50594,In vivo,Blood,CHEMBL618191,Intermediate,10090.0,,N,,A,4526,,,Mus musculus,1,,178.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,50594,In vivo,Blood,CHEMBL618192,Intermediate,10090.0,,N,,A,4527,,,Mus musculus,1,,178.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,50594,In vivo,Bone,CHEMBL618193,Intermediate,10090.0,,N,,A,4528,,,Mus musculus,1,,10000001.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,50594,In vivo,Bone,CHEMBL618194,Intermediate,10090.0,,N,,A,4529,,,Mus musculus,1,,10000001.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,50594,In vivo,Bone,CHEMBL618195,Intermediate,10090.0,,N,,A,4530,,,Mus musculus,1,,10000001.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,50594,In vivo,Brain,CHEMBL618196,Intermediate,10090.0,,N,,A,4531,,,Mus musculus,1,,955.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,50594,In vivo,Brain,CHEMBL618197,Intermediate,10090.0,,N,,A,4532,,,Mus musculus,1,,955.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,50594,In vivo,Brain,CHEMBL618198,Intermediate,10090.0,,N,,A,4533,,,Mus musculus,1,,955.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,50594,In vivo,Heart,CHEMBL618199,Intermediate,10090.0,,N,,A,4534,,,Mus musculus,1,,948.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,50594,In vivo,Heart,CHEMBL618200,Intermediate,10090.0,,N,,A,4535,,,Mus musculus,1,,948.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,50594,In vivo,Heart,CHEMBL618201,Intermediate,10090.0,,N,,A,4536,,,Mus musculus,1,,948.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,50594,In vivo,Intestine,CHEMBL618202,Intermediate,10090.0,,N,,A,4537,,,Mus musculus,1,,160.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,50594,In vivo,Intestine,CHEMBL618203,Intermediate,10090.0,,N,,A,4538,,,Mus musculus,1,,160.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,50594,In vivo,Intestine,CHEMBL618204,Intermediate,10090.0,,N,,A,4539,,,Mus musculus,1,,160.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,50594,In vivo,Kidney,CHEMBL618205,Intermediate,10090.0,,N,,A,4540,,,Mus musculus,1,,2113.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,50594,In vivo,Kidney,CHEMBL618206,Intermediate,10090.0,,N,,A,4541,,,Mus musculus,1,,2113.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,50594,In vivo,Kidney,CHEMBL618207,Intermediate,10090.0,,N,,A,4542,,,Mus musculus,1,,2113.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,50594,In vivo,Liver,CHEMBL618208,Intermediate,10090.0,,N,,A,4543,,,Mus musculus,1,,2107.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,50594,In vivo,Liver,CHEMBL618932,Intermediate,10090.0,,N,,A,4544,,,Mus musculus,1,,2107.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,50594,In vivo,Liver,CHEMBL618933,Intermediate,10090.0,,N,,A,4545,,,Mus musculus,1,,2107.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,50594,In vivo,Lung,CHEMBL618934,Intermediate,10090.0,,N,,A,4546,,,Mus musculus,1,,2048.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,50594,In vivo,Lung,CHEMBL618935,Intermediate,10090.0,,N,,A,4547,,,Mus musculus,1,,2048.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,50594,In vivo,Lung,CHEMBL618936,Intermediate,10090.0,,N,,A,4548,,,Mus musculus,1,,2048.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,50594,In vivo,Muscle tissue,CHEMBL618937,Intermediate,10090.0,,N,,A,4549,,,Mus musculus,1,,2385.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,50594,In vivo,Muscle tissue,CHEMBL618938,Intermediate,10090.0,,N,,A,4550,,,Mus musculus,1,,2385.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,50594,In vivo,Muscle tissue,CHEMBL619104,Intermediate,10090.0,,N,,A,4551,,,Mus musculus,1,,2385.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,50594,In vivo,Spleen,CHEMBL619105,Intermediate,10090.0,,N,,A,4552,,,Mus musculus,1,,2106.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,50594,In vivo,Spleen,CHEMBL619106,Intermediate,10090.0,,N,,A,4553,,,Mus musculus,1,,2106.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,50594,In vivo,Spleen,CHEMBL619107,Intermediate,10090.0,,N,,A,4554,,,Mus musculus,1,,2106.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,50594,In vivo,Stomach,CHEMBL875410,Intermediate,10090.0,,N,,A,4555,,,Mus musculus,1,,945.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,50594,In vivo,Stomach,CHEMBL619108,Intermediate,10090.0,,N,,A,4556,,,Mus musculus,1,,945.0,
,3655,1,BAO_0000218,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,50594,In vivo,Stomach,CHEMBL619109,Intermediate,10090.0,,N,,A,4557,,,Mus musculus,1,,945.0,
,16597,1,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,50594,In vivo,,CHEMBL619110,Intermediate,10090.0,,N,,A,4558,,,Mus musculus,1,,,
,16597,1,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,50594,In vivo,,CHEMBL619111,Intermediate,10090.0,,N,,F,4559,,,Mus musculus,1,,,
,16597,1,BAO_0000218,MRT value at a dose of 10 mg/kg intravenous administration in mice.,50594,In vivo,,CHEMBL619112,Intermediate,10090.0,,N,,A,4560,,,Mus musculus,1,,,
,16597,1,BAO_0000218,MRT value at a dose of 10 mg/kg peroral administration in mice.,50594,In vivo,,CHEMBL619113,Intermediate,10090.0,,N,,A,4561,,,Mus musculus,1,,,
,17764,1,BAO_0000218,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,50594,In vivo,,CHEMBL619114,Intermediate,10090.0,,N,,A,4562,,,Mus musculus,1,,,
,17764,1,BAO_0000218,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,50594,In vivo,,CHEMBL619115,Intermediate,10090.0,,N,,F,4563,,,Mus musculus,1,,,
,3830,1,BAO_0000219,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,81034,,,CHEMBL619116,Intermediate,9606.0,,N,,F,4564,,478.0,Homo sapiens,1,,,A2780
,3829,1,BAO_0000219,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,81034,,,CHEMBL619117,Intermediate,9606.0,,N,,F,4565,,478.0,Homo sapiens,1,,,A2780
,2040,1,BAO_0000219,Compound was evaluated for cytotoxicity against A2780 cell lines.,81034,,,CHEMBL619118,Intermediate,9606.0,,N,,F,4566,,478.0,Homo sapiens,1,,,A2780
,15684,1,BAO_0000219,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,81034,,,CHEMBL619119,Intermediate,9606.0,,N,,F,4567,,478.0,Homo sapiens,1,,,A2780
,15684,1,BAO_0000219,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,81034,,,CHEMBL619120,Intermediate,9606.0,,N,,F,4568,,478.0,Homo sapiens,1,,,A2780
,15684,1,BAO_0000219,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,81034,,,CHEMBL619121,Intermediate,9606.0,,N,,F,4569,,478.0,Homo sapiens,1,,,A2780
,15684,1,BAO_0000219,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,81034,,,CHEMBL619122,Intermediate,9606.0,,N,,F,4570,,478.0,Homo sapiens,1,,,A2780
,15684,1,BAO_0000219,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,81034,,,CHEMBL619123,Intermediate,9606.0,,N,,F,4571,,478.0,Homo sapiens,1,,,A2780
,15684,1,BAO_0000219,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,81034,,,CHEMBL619124,Intermediate,9606.0,,N,,F,4572,,478.0,Homo sapiens,1,,,A2780
,2859,1,BAO_0000219,Compound was evaluated for cytotoxicity against A2780 cell line,81034,,,CHEMBL619125,Intermediate,9606.0,,N,,F,4573,,478.0,Homo sapiens,1,,,A2780
,5618,1,BAO_0000219,In vitro inhibitory activity against human tumor cell line A2780,81034,,,CHEMBL875411,Intermediate,9606.0,,N,,F,4574,,478.0,Homo sapiens,1,,,A2780
,15684,1,BAO_0000219,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,81034,,,CHEMBL619126,Intermediate,9606.0,,N,,F,4575,,478.0,Homo sapiens,1,,,A2780
,15684,1,BAO_0000219,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,81034,,,CHEMBL619127,Intermediate,9606.0,,N,,F,4576,,478.0,Homo sapiens,1,,,A2780
,15684,1,BAO_0000219,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,81034,,,CHEMBL619128,Intermediate,9606.0,,N,,F,4577,,478.0,Homo sapiens,1,,,A2780
,15684,1,BAO_0000219,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,81034,,,CHEMBL619129,Intermediate,9606.0,,N,,F,4578,,478.0,Homo sapiens,1,,,A2780
,2113,1,BAO_0000219,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,81034,,,CHEMBL619130,Intermediate,9606.0,,N,,F,4579,,478.0,Homo sapiens,1,,,A2780
,2113,1,BAO_0000219,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,81034,,,CHEMBL619131,Intermediate,9606.0,,N,,F,4580,,478.0,Homo sapiens,1,,,A2780
,16745,1,BAO_0000219,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,81034,,,CHEMBL619132,Intermediate,9606.0,,N,,F,4581,,478.0,Homo sapiens,1,,,A2780
,16597,1,BAO_0000218,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,81034,,,CHEMBL619133,Expert,9606.0,,N,,F,4582,,478.0,Homo sapiens,1,,,A2780
,15684,1,BAO_0000219,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,81034,,,CHEMBL619134,Intermediate,9606.0,,N,,F,4583,,478.0,Homo sapiens,1,,,A2780
,15684,1,BAO_0000219,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,81034,,,CHEMBL619135,Intermediate,9606.0,,N,,F,4584,,478.0,Homo sapiens,1,,,A2780
,2040,1,BAO_0000219,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,81034,,,CHEMBL619136,Intermediate,9606.0,,N,,F,4585,,478.0,Homo sapiens,1,,,A2780
,2040,1,BAO_0000219,Relative resistance factor in A2780 cisplatin-resistant line,81034,,,CHEMBL619137,Intermediate,9606.0,,N,,F,4586,,478.0,Homo sapiens,1,,,A2780
,16165,1,BAO_0000219,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,81034,,,CHEMBL883713,Intermediate,9606.0,,N,,F,4587,,478.0,Homo sapiens,1,,,A2780
,16165,1,BAO_0000219,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,81034,,,CHEMBL875412,Intermediate,9606.0,,N,,F,4588,,478.0,Homo sapiens,1,,,A2780
,16597,1,BAO_0000218,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,81034,,,CHEMBL619138,Expert,9606.0,,N,,F,4589,,478.0,Homo sapiens,1,,,A2780
,16597,1,BAO_0000218,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,81034,,,CHEMBL619262,Expert,9606.0,,N,,F,4590,,478.0,Homo sapiens,1,,,A2780
,3992,1,BAO_0000219,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,81034,,,CHEMBL619139,Intermediate,9606.0,,N,,F,4591,,478.0,Homo sapiens,1,,,A2780
,10553,1,BAO_0000219,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,81034,,,CHEMBL619140,Intermediate,9606.0,,N,,F,4592,,478.0,Homo sapiens,1,,,A2780
,15608,1,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,81034,,,CHEMBL619141,Intermediate,9606.0,,N,,F,4593,,478.0,Homo sapiens,1,,,A2780
,15608,1,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,81034,,,CHEMBL619142,Intermediate,9606.0,,N,,F,4594,,478.0,Homo sapiens,1,,,A2780
,15608,1,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,81034,,,CHEMBL619143,Intermediate,9606.0,,N,,F,4595,,478.0,Homo sapiens,1,,,A2780
,15608,1,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,81034,,,CHEMBL619144,Intermediate,9606.0,,N,,F,4596,,478.0,Homo sapiens,1,,,A2780
,15608,1,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,81034,,,CHEMBL619145,Intermediate,9606.0,,N,,F,4597,,478.0,Homo sapiens,1,,,A2780
,15608,1,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,81034,,,CHEMBL619146,Intermediate,9606.0,,N,,F,4598,,478.0,Homo sapiens,1,,,A2780
,15569,1,BAO_0000219,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,81034,,,CHEMBL619147,Intermediate,9606.0,,N,,F,4599,,478.0,Homo sapiens,1,,,A2780
,17420,1,BAO_0000219,Antiproliferative effect of compound on A2780/DX cell line,81034,,,CHEMBL619148,Intermediate,9606.0,,N,,F,4600,,478.0,Homo sapiens,1,,,A2780
,17420,1,BAO_0000219,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,81034,,,CHEMBL619149,Intermediate,9606.0,,N,,F,4601,,478.0,Homo sapiens,1,,,A2780
,15099,1,BAO_0000219,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),81034,,,CHEMBL619150,Intermediate,9606.0,,N,,F,4602,,478.0,Homo sapiens,1,,,A2780
,15099,1,BAO_0000219,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),81034,,,CHEMBL619151,Intermediate,9606.0,,N,,F,4603,,478.0,Homo sapiens,1,,,A2780
,17672,1,BAO_0000219,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,81034,,,CHEMBL883794,Intermediate,9606.0,,N,,F,4604,,478.0,Homo sapiens,1,,,A2780
,17672,1,BAO_0000219,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,81034,,,CHEMBL619152,Intermediate,9606.0,,N,,F,4605,,478.0,Homo sapiens,1,,,A2780
,17270,1,BAO_0000219,In vitro cytotoxicity against A2780ADR cell line,81034,,,CHEMBL619153,Intermediate,9606.0,,N,,F,4606,,478.0,Homo sapiens,1,,,A2780
,17270,1,BAO_0000219,In vitro cytotoxicity against A2780CIS cell line,81034,,,CHEMBL619154,Intermediate,9606.0,,N,,F,4607,,478.0,Homo sapiens,1,,,A2780
,5574,1,BAO_0000219,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,81034,,,CHEMBL619155,Intermediate,9606.0,,N,,F,4608,,478.0,Homo sapiens,1,,,A2780
,2113,1,BAO_0000219,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,81034,,,CHEMBL619156,Intermediate,9606.0,,N,,F,4609,,478.0,Homo sapiens,1,,,A2780
,16913,1,BAO_0000219,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",81034,,,CHEMBL619157,Intermediate,9606.0,,N,,F,4610,,478.0,Homo sapiens,1,,,A2780
,16913,1,BAO_0000219,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",81034,,,CHEMBL619797,Intermediate,9606.0,,N,,F,4611,,478.0,Homo sapiens,1,,,A2780
,17839,0,BAO_0000218,Oral bioavailability of compound in rhesus macaques,22224,In vivo,,CHEMBL619798,Autocuration,9544.0,,U,,A,4612,,,Macaca mulatta,1,,,
,6821,0,BAO_0000218,Oral bioavailability in monkey,22224,In vivo,,CHEMBL619799,Autocuration,9443.0,,U,,A,4613,,,monkey,1,,,
,6078,0,BAO_0000218,Oral bioavailability evaluated in monkey,22224,In vivo,,CHEMBL619800,Autocuration,9443.0,,U,,A,4614,,,monkey,1,,,
,6535,0,BAO_0000218,Oral bioavailability in monkey (dose 1 mg/kg p.o.),22224,In vivo,,CHEMBL619801,Autocuration,9443.0,,U,,A,4615,,,monkey,1,,,
,4449,0,BAO_0000218,Oral bioavailability in Rhesus monkey,22224,In vivo,,CHEMBL619802,Autocuration,9544.0,,U,,A,4616,,,Macaca mulatta,1,,,
,6057,0,BAO_0000218,Oral bioavailability was calculated in rhesus monkey,22224,In vivo,,CHEMBL619803,Autocuration,9544.0,,U,,A,4617,,,Macaca mulatta,1,,,
,5922,0,BAO_0000218,Oral bioavailability in cynomolgus monkey,22224,In vivo,,CHEMBL619965,Autocuration,9541.0,,U,,A,4618,,,Macaca fascicularis,1,,,
,5940,0,BAO_0000218,Oral bioavailability in monkey,22224,In vivo,,CHEMBL619966,Autocuration,9443.0,,U,,A,4619,,,monkey,1,,,
,6265,0,BAO_0000218,Oral bioavailability in monkey,22224,In vivo,,CHEMBL619967,Autocuration,9443.0,,U,,A,4620,,,monkey,1,,,
,6265,0,BAO_0000218,Oral bioavailability in monkey (dose 1 mg/kg),22224,In vivo,,CHEMBL620073,Autocuration,9443.0,,U,,A,4621,,,monkey,1,,,
,6265,0,BAO_0000218,Oral bioavailability in monkey (dose 5 mg/kg),22224,In vivo,,CHEMBL620074,Autocuration,9443.0,,U,,A,4622,,,monkey,1,,,
,5940,0,BAO_0000218,Oral bioavailability in monkey,22224,In vivo,,CHEMBL620075,Autocuration,9443.0,,U,,A,4623,,,monkey,1,,,
,5940,0,BAO_0000218,Oral bioavailability in monkey,22224,In vivo,,CHEMBL620076,Autocuration,9443.0,,U,,A,4624,,,monkey,1,,,
,4514,0,BAO_0000218,Oral bioavailability in rhesus monkey,22224,In vivo,,CHEMBL620077,Autocuration,9544.0,,U,,A,4625,,,Macaca mulatta,1,,,
,5546,0,BAO_0000218,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,22224,In vivo,,CHEMBL620078,Autocuration,9544.0,,U,,A,4626,,,Macaca mulatta,1,,,
,5553,0,BAO_0000218,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,22224,In vivo,,CHEMBL620079,Autocuration,9521.0,,U,,A,4627,,,Saimiri sciureus,1,,,
,6641,0,BAO_0000218,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),22224,In vivo,,CHEMBL620080,Autocuration,9443.0,,U,,A,4628,,,monkey,1,,,
,5472,0,BAO_0000218,Oral bioavailability in Rhesus monkey,22224,In vivo,,CHEMBL620081,Autocuration,9544.0,,U,,A,4629,,,Macaca mulatta,1,,,
,5668,0,BAO_0000218,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),22224,In vivo,,CHEMBL620082,Autocuration,9544.0,,U,,A,4630,,,Macaca mulatta,1,,,
,5711,0,BAO_0000218,Oral bioavailability in monkey at 10 mg/kg of the compound,22224,In vivo,,CHEMBL620083,Autocuration,9443.0,,U,,A,4631,,,monkey,1,,,
,5145,0,BAO_0000218,Bioavailability in Rhesus monkey,22224,In vivo,,CHEMBL620084,Autocuration,9544.0,,U,,A,4632,,,Macaca mulatta,1,,,
,3443,0,BAO_0000218,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,,,CHEMBL620085,Autocuration,9527.0,,U,,A,4633,,,Cercopithecidae,1,,,
,3443,0,BAO_0000218,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,,,CHEMBL874595,Autocuration,9527.0,,U,,A,4634,,,Cercopithecidae,1,,,
,3249,0,BAO_0000218,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,22224,In vivo,,CHEMBL873352,Autocuration,9527.0,,U,,A,4635,,,Cercopithecidae,1,,,
,3249,0,BAO_0000218,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,22224,In vivo,,CHEMBL620086,Autocuration,9527.0,,U,,A,4636,,,Cercopithecidae,1,,,
,5355,0,BAO_0000218,Mean residence time was determined after intravenous administration in cynomolgus monkeys,22224,In vivo,,CHEMBL620087,Autocuration,9527.0,,U,,A,4637,,,Cercopithecidae,1,,,
,5355,0,BAO_0000218,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,22224,In vivo,,CHEMBL620088,Autocuration,9527.0,,U,,A,4638,,,Cercopithecidae,1,,,
,5355,0,BAO_0000218,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,22224,In vivo,,CHEMBL620089,Autocuration,9527.0,,U,,A,4639,,,Cercopithecidae,1,,,
,4809,0,BAO_0000218,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),22224,In vivo,,CHEMBL620090,Autocuration,9527.0,,U,,A,4640,,,Cercopithecidae,1,,,
,4809,0,BAO_0000218,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),22224,In vivo,,CHEMBL620091,Autocuration,9527.0,,U,,A,4641,,,Cercopithecidae,1,,,
,14294,0,BAO_0000251,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),22224,,,CHEMBL620092,Autocuration,9527.0,Microsomes,U,,A,4642,,,Cercopithecidae,1,,,
,14294,0,BAO_0000251,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),22224,,,CHEMBL620093,Autocuration,9527.0,Microsomes,U,,A,4643,,,Cercopithecidae,1,,,
,14294,0,BAO_0000251,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),22224,,,CHEMBL620094,Autocuration,9527.0,Microsomes,U,,A,4644,,,Cercopithecidae,1,,,
,14294,0,BAO_0000251,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),22224,,,CHEMBL620095,Autocuration,9527.0,Microsomes,U,,A,4645,,,Cercopithecidae,1,,,
,3443,0,BAO_0000218,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,In vivo,,CHEMBL620096,Autocuration,9527.0,,U,,A,4646,,,Cercopithecidae,1,,,
,3443,0,BAO_0000218,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,In vivo,,CHEMBL620097,Autocuration,9527.0,,U,,A,4647,,,Cercopithecidae,1,,,
,11271,0,BAO_0000019,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,22224,,,CHEMBL620098,Autocuration,9527.0,,U,,A,4648,,,Cercopithecidae,1,,,
,3443,0,BAO_0000218,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,,,CHEMBL620099,Autocuration,9527.0,,U,,A,4649,,,Cercopithecidae,1,,,
,3443,0,BAO_0000218,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,,,CHEMBL620100,Autocuration,9527.0,,U,,A,4650,,,Cercopithecidae,1,,,
,6821,0,BAO_0000019,Elimination Half-life of compound was determined in monkey,22224,,,CHEMBL620101,Autocuration,9527.0,,U,,A,4651,,,Cercopithecidae,1,,,
,17267,0,BAO_0000019,Half life of compound was determined in rhesus monkey,22224,,,CHEMBL620102,Autocuration,9527.0,,U,,A,4652,,,Cercopithecidae,1,,,
,5819,0,BAO_0000366,Half life in monkey plasma,22224,,Plasma,CHEMBL620103,Autocuration,9527.0,,U,,A,4653,,,Cercopithecidae,1,,1969.0,
,5819,0,BAO_0000366,Half life in monkey plasma; Not detected,22224,,Plasma,CHEMBL620104,Autocuration,9527.0,,U,,A,4654,,,Cercopithecidae,1,,1969.0,
,1916,0,BAO_0000218,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,In vivo,,CHEMBL874596,Autocuration,9527.0,,U,,A,4655,,,Cercopithecidae,1,,,
,17509,0,BAO_0000218,Half-life 24 hr after 2 mg/kg iv administration in monkeys,22224,In vivo,,CHEMBL873490,Autocuration,9527.0,,U,,A,4656,,,Cercopithecidae,1,,,
,1399,0,BAO_0000019,Terminal half life of the compound.,22224,,,CHEMBL620105,Autocuration,9527.0,,U,,A,4657,,,Cercopithecidae,1,,,
,1916,0,BAO_0000218,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,In vivo,,CHEMBL620780,Autocuration,9527.0,,U,,A,4658,,,Cercopithecidae,1,,,
,4809,0,BAO_0000218,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),22224,In vivo,,CHEMBL620781,Autocuration,9527.0,,U,,A,4659,,,Cercopithecidae,1,,,
,5546,0,BAO_0000218,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,22224,,,CHEMBL620956,Autocuration,9527.0,,U,,A,4660,,,Cercopithecidae,1,,,
,3443,0,BAO_0000218,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,,Urine,CHEMBL620957,Autocuration,9527.0,,U,,A,4661,,,Cercopithecidae,1,,1088.0,
,3443,0,BAO_0000218,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,,Urine,CHEMBL620958,Autocuration,9527.0,,U,,A,4662,,,Cercopithecidae,1,,1088.0,
,4257,0,BAO_0000218,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,22224,In vivo,,CHEMBL620959,Autocuration,9527.0,,U,,A,4663,,,Cercopithecidae,1,,,
,6221,0,BAO_0000218,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,22224,In vivo,,CHEMBL620960,Autocuration,9527.0,,U,,A,4664,,,Cercopithecidae,1,,,
,5472,0,BAO_0000218,Volume of distribution was evaluated in rhesus,22224,In vivo,,CHEMBL620961,Autocuration,9527.0,,U,,A,4665,,,Cercopithecidae,1,,,
,4727,0,BAO_0000218,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,22224,In vivo,,CHEMBL620962,Autocuration,10029.0,,U,,A,4666,,,Cricetulus griseus,1,,,
,4727,0,BAO_0000218,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,22224,In vivo,,CHEMBL620963,Autocuration,10029.0,,U,,A,4667,,,Cricetulus griseus,1,,,
,4727,0,BAO_0000218,Bioavailability in hamster was determined,22224,In vivo,,CHEMBL620964,Autocuration,10029.0,,U,,A,4668,,,Cricetulus griseus,1,,,
,4727,0,BAO_0000218,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,22224,In vivo,,CHEMBL620965,Autocuration,10029.0,,U,,A,4669,,,Cricetulus griseus,1,,,
,4727,0,BAO_0000218,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,22224,In vivo,,CHEMBL620966,Autocuration,10029.0,,U,,A,4670,,,Cricetulus griseus,1,,,
,4727,0,BAO_0000221,Half life of compound was determined in hamster blood,22224,,Blood,CHEMBL620967,Autocuration,10029.0,,U,,A,4671,,,Cricetulus griseus,1,,178.0,
,1452,0,BAO_0000019,Michaelis-Menten constant of the compound.,22224,,,CHEMBL620968,Autocuration,9823.0,,U,,A,4672,,,Sus scrofa,1,,,
,1452,0,BAO_0000019,Vmax value was measured at 0 uM concentration of silyl ether.,22224,,,CHEMBL874597,Autocuration,9823.0,,U,,A,4673,,,Sus scrofa,1,,,
,1452,0,BAO_0000019,Vmax value was measured at 10 uM concentration of silyl ether.,22224,,,CHEMBL620969,Autocuration,9823.0,,U,,A,4674,,,Sus scrofa,1,,,
,1452,0,BAO_0000019,Vmax value was measured at 5 uM concentration of silyl ether.,22224,,,CHEMBL620970,Autocuration,9823.0,,U,,A,4675,,,Sus scrofa,1,,,
,11706,9,BAO_0000357,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,235,,,CHEMBL620971,Expert,9606.0,,D,,B,4676,,,Homo sapiens,1,,,
,1916,0,BAO_0000218,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,22224,,,CHEMBL620972,Autocuration,9606.0,,U,,A,4677,,,Homo sapiens,1,,,
,17791,0,BAO_0000019,Compound was evaluated for area under the curve expressed as (h*ug/ml),22224,,,CHEMBL620973,Autocuration,9606.0,,U,,A,4678,,,Homo sapiens,1,,,
,7766,0,BAO_0000019,Active metabolite of ifosfamide determined in humans; A-Active,22224,,,CHEMBL618243,Autocuration,9606.0,,U,,A,4679,,,Homo sapiens,1,,,
,6567,0,BAO_0000019,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,22224,,,CHEMBL618244,Autocuration,9606.0,,U,,A,4680,,,Homo sapiens,1,,,
,6567,0,BAO_0000019,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,22224,,,CHEMBL618245,Autocuration,9606.0,,U,,A,4681,,,Homo sapiens,1,,,
,6567,0,BAO_0000019,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,22224,,,CHEMBL618246,Autocuration,9606.0,,U,,A,4682,,,Homo sapiens,1,,,
,6567,0,BAO_0000019,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,22224,,,CHEMBL618247,Autocuration,9606.0,,U,,A,4683,,,Homo sapiens,1,,,
,17791,0,BAO_0000218,Compound was evaluated for oral bioavailability in human,22224,,,CHEMBL618248,Autocuration,9606.0,,U,,A,4684,,,Homo sapiens,1,,,
,7766,0,BAO_0000019,Metabolite of ifosfamide determined in urine; NF-Not found,22224,,Urine,CHEMBL618249,Autocuration,9606.0,,U,,A,4685,,,Homo sapiens,1,,1088.0,
,6852,0,BAO_0000019,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),22224,,,CHEMBL618250,Autocuration,9606.0,,U,,A,4686,,,Homo sapiens,1,,,
,6852,0,BAO_0000019,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,22224,,,CHEMBL874598,Autocuration,9606.0,,U,,A,4687,,,Homo sapiens,1,,,
,6852,0,BAO_0000019,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,22224,,,CHEMBL618251,Autocuration,9606.0,,U,,A,4688,,,Homo sapiens,1,,,
,6852,0,BAO_0000019,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,22224,,,CHEMBL618252,Autocuration,9606.0,,U,,A,4689,,,Homo sapiens,1,,,
,6852,0,BAO_0000019,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,22224,,,CHEMBL618253,Autocuration,9606.0,,U,,A,4690,,,Homo sapiens,1,,,
,6852,0,BAO_0000019,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),22224,,,CHEMBL618254,Autocuration,9606.0,,U,,A,4691,,,Homo sapiens,1,,,
,6852,0,BAO_0000019,Percent of compound in healthy individuals (Group D),22224,,,CHEMBL618255,Autocuration,9606.0,,U,,A,4692,,,Homo sapiens,1,,,
,4397,0,BAO_0000251,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,22224,,Liver,CHEMBL618983,Autocuration,9606.0,Microsomes,U,,A,4693,,,Homo sapiens,1,,2107.0,
,17409,0,BAO_0000019,Binding towards human plasma protein at 10 uM,22224,,,CHEMBL618984,Autocuration,9606.0,,U,,A,4694,,,Homo sapiens,1,,,
,17409,0,BAO_0000019,Binding towards human plasma protein at 100 uM,22224,,,CHEMBL618985,Autocuration,9606.0,,U,,A,4695,,,Homo sapiens,1,,,
,17176,0,BAO_0000019,Human plasma protein binding activity was determined,22224,,,CHEMBL618986,Autocuration,9606.0,,U,,A,4696,,,Homo sapiens,1,,,
,15444,0,BAO_0000019,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),22224,,,CHEMBL618987,Autocuration,9606.0,,U,,A,4697,,,Homo sapiens,1,,,
,17267,0,BAO_0000019,Percent binding of compound towards human plasma protein was determined,22224,,,CHEMBL618988,Autocuration,9606.0,,U,,A,4698,,,Homo sapiens,1,,,
,5944,0,BAO_0000251,Plasma clearance in human liver microsomes,22224,In vitro,Liver,CHEMBL618989,Autocuration,9606.0,Microsomes,U,,A,4699,,,Homo sapiens,1,,2107.0,
,5668,0,BAO_0000251,In vitro intrinsic clearance in human liver microsome,22224,In vitro,Liver,CHEMBL618990,Autocuration,9606.0,Microsomes,U,,A,4700,,,Homo sapiens,1,,2107.0,
,5669,0,BAO_0000251,In vitro intrinsic clearance in human liver microsome,22224,In vitro,Liver,CHEMBL618991,Autocuration,9606.0,Microsomes,U,,A,4701,,,Homo sapiens,1,,2107.0,
,5041,0,BAO_0000251,In vitro microsome metabolism clearance in human was determined,22224,In vitro,,CHEMBL876725,Autocuration,9606.0,Microsomes,U,,A,4702,,,Homo sapiens,1,,,
,5041,0,BAO_0000251,In vitro microsome metabolism clearance in human was determined; High,22224,In vitro,,CHEMBL618992,Autocuration,9606.0,Microsomes,U,,A,4703,,,Homo sapiens,1,,,
,5041,0,BAO_0000251,In vitro microsome metabolism clearance in human was determined; ND denotes no data,22224,In vitro,,CHEMBL618993,Autocuration,9606.0,Microsomes,U,,A,4704,,,Homo sapiens,1,,,
,5676,0,BAO_0000251,Pharmacokinetic property (clearance) in human liver microsome,22224,In vitro,Liver,CHEMBL618994,Autocuration,9606.0,Microsomes,U,,A,4705,,,Homo sapiens,1,,2107.0,
,5944,0,BAO_0000251,Plasma clearance in human liver microsomes,22224,In vitro,Liver,CHEMBL618995,Autocuration,9606.0,Microsomes,U,,A,4706,,,Homo sapiens,1,,2107.0,
,17538,0,BAO_0000251,In vitro clearance in human liver microsomes,22224,In vitro,Liver,CHEMBL618996,Autocuration,9606.0,Microsomes,U,,A,4707,,,Homo sapiens,1,,2107.0,
,6331,0,BAO_0000251,Intrinsic clearance in human liver microsomes was determined,22224,In vitro,Liver,CHEMBL618997,Autocuration,9606.0,Microsomes,U,,A,4708,,,Homo sapiens,1,,2107.0,
,5948,0,BAO_0000251,Intrinsic clearance in human liver microsomes was determined,22224,In vitro,Liver,CHEMBL618998,Autocuration,9606.0,Microsomes,U,,A,4709,,,Homo sapiens,1,,2107.0,
,5965,0,BAO_0000218,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,22224,In vivo,,CHEMBL618999,Autocuration,9606.0,,U,,A,4710,,,Homo sapiens,1,,,
,1916,0,BAO_0000218,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,22224,In vivo,,CHEMBL620223,Autocuration,9606.0,,U,,A,4711,,,Homo sapiens,1,,,
,5965,0,BAO_0000218,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,22224,,,CHEMBL620224,Autocuration,9606.0,,U,,A,4712,,,Homo sapiens,1,,,
,1299,0,BAO_0000019,Stability in human plasma 2 hr after incubation expressed as percent concentration,22224,,,CHEMBL620225,Autocuration,9606.0,,U,,A,4713,,,Homo sapiens,1,,,
,1299,0,BAO_0000019,Stability in human plasma 4 hr after incubation expressed as percent concentration,22224,,,CHEMBL620226,Autocuration,9606.0,,U,,A,4714,,,Homo sapiens,1,,,
,7766,0,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,,Urine,CHEMBL620227,Autocuration,9606.0,,U,,A,4715,,,Homo sapiens,1,,1088.0,
,7766,0,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,,Urine,CHEMBL876726,Autocuration,9606.0,,U,,A,4716,,,Homo sapiens,1,,1088.0,
,7766,0,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,,Urine,CHEMBL620228,Autocuration,9606.0,,U,,A,4717,,,Homo sapiens,1,,1088.0,
,7766,0,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,,Urine,CHEMBL620229,Autocuration,9606.0,,U,,A,4718,,,Homo sapiens,1,,1088.0,
,17764,1,BAO_0000218,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,50594,In vivo,,CHEMBL620230,Intermediate,10090.0,,N,,F,4719,,,Mus musculus,1,,,
,17764,1,BAO_0000218,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,50594,In vivo,,CHEMBL620231,Intermediate,10090.0,,N,,F,4720,,,Mus musculus,1,,,
,17764,1,BAO_0000218,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,50594,In vivo,,CHEMBL620232,Intermediate,10090.0,,N,,F,4721,,,Mus musculus,1,,,
,17764,1,BAO_0000218,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,50594,In vivo,,CHEMBL620233,Intermediate,10090.0,,N,,F,4722,,,Mus musculus,1,,,
,14294,1,BAO_0000218,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),50594,,,CHEMBL620234,Intermediate,10090.0,,N,,A,4723,,,Mus musculus,1,,,
,14294,1,BAO_0000218,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),50594,,,CHEMBL620235,Intermediate,10090.0,,N,,A,4724,,,Mus musculus,1,,,
,14294,1,BAO_0000218,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),50594,,,CHEMBL620236,Intermediate,10090.0,,N,,A,4725,,,Mus musculus,1,,,
,6251,1,BAO_0000218,In vitro metabolic potential in mouse liver microsomes,50594,,Liver,CHEMBL620237,Intermediate,10090.0,,N,,A,4726,,,Mus musculus,1,,2107.0,
,17582,1,BAO_0000218,Ability of compound to bind to plasma protein was evaluated in HSA cells,50594,,,CHEMBL620238,Intermediate,10090.0,,N,,A,4727,,,Mus musculus,1,,,
,17811,1,BAO_0000218,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),50594,,Adrenal gland,CHEMBL620239,Intermediate,10090.0,,N,,A,4728,,,Mus musculus,1,,2369.0,
,17811,1,BAO_0000218,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,50594,,Brain,CHEMBL620240,Intermediate,10090.0,,N,,A,4729,,,Mus musculus,1,,955.0,
,17811,1,BAO_0000218,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,50594,,Brain,CHEMBL620241,Intermediate,10090.0,,N,,A,4730,,,Mus musculus,1,,955.0,
,17811,1,BAO_0000218,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),50594,,,CHEMBL876727,Intermediate,10090.0,,N,,A,4731,,,Mus musculus,1,,,
,17811,1,BAO_0000218,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),50594,,Kidney,CHEMBL620242,Intermediate,10090.0,,N,,A,4732,,,Mus musculus,1,,2113.0,
,17811,1,BAO_0000218,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),50594,,,CHEMBL620243,Intermediate,10090.0,,N,,A,4733,,,Mus musculus,1,,,
,5288,1,BAO_0000218,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,50594,,,CHEMBL620244,Intermediate,10090.0,,N,,A,4734,,,Mus musculus,1,,,
,2717,1,BAO_0000218,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,50594,,Serum,CHEMBL620245,Intermediate,10090.0,,N,,A,4735,,,Mus musculus,1,,1977.0,
,2717,1,BAO_0000218,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,50594,,Serum,CHEMBL620246,Intermediate,10090.0,,N,,A,4736,,,Mus musculus,1,,1977.0,
,2717,1,BAO_0000218,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,50594,,Serum,CHEMBL620247,Intermediate,10090.0,,N,,A,4737,,,Mus musculus,1,,1977.0,
,17753,1,BAO_0000218,Half life of compound was determined in plasma of mice at 24 mg/Kg,50594,In vivo,Plasma,CHEMBL620248,Intermediate,10090.0,,N,,A,4738,,,Mus musculus,1,,1969.0,
,17753,1,BAO_0000218,Half life of compound was determined in plasma of mice at 40 mg/Kg,50594,In vivo,Plasma,CHEMBL873497,Intermediate,10090.0,,N,,A,4739,,,Mus musculus,1,,1969.0,
,17753,1,BAO_0000218,Half life of compound was determined in plasma of mice at 5 mg/Kg,50594,In vivo,Plasma,CHEMBL620249,Intermediate,10090.0,,N,,A,4740,,,Mus musculus,1,,1969.0,
,17764,1,BAO_0000218,Half life after intraperitoneal administration in mice at 18 uM/kg,50594,In vivo,,CHEMBL620250,Intermediate,10090.0,,N,,F,4741,,,Mus musculus,1,,,
,17764,1,BAO_0000218,Half life after intraperitoneal administration in mice at 23 uM/kg,50594,In vivo,,CHEMBL620251,Intermediate,10090.0,,N,,F,4742,,,Mus musculus,1,,,
,17764,1,BAO_0000218,Half life after intraperitoneal administration in mice at 25 uM/kg,50594,In vivo,,CHEMBL620252,Intermediate,10090.0,,N,,F,4743,,,Mus musculus,1,,,
,17764,1,BAO_0000218,Half life after intraperitoneal administration in mice at 26 uM/kg,50594,In vivo,,CHEMBL620253,Intermediate,10090.0,,N,,F,4744,,,Mus musculus,1,,,
,17764,1,BAO_0000218,Half life after intravenous administration in mice at 23 uM/kg,50594,In vivo,,CHEMBL620254,Intermediate,10090.0,,N,,F,4745,,,Mus musculus,1,,,
,17764,1,BAO_0000218,Half life after intravenous administration in mice at 24 uM/kg,50594,In vivo,,CHEMBL620255,Intermediate,10090.0,,N,,A,4746,,,Mus musculus,1,,,
,16597,1,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,50594,In vivo,,CHEMBL620256,Intermediate,10090.0,,N,,A,4747,,,Mus musculus,1,,,
,2675,1,BAO_0000218,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,50594,In vivo,,CHEMBL876728,Intermediate,10090.0,,N,,A,4748,,,Mus musculus,1,,,
,2675,1,BAO_0000218,Maximum time required to reach Cp max was evaluated in mice after oral administration,50594,In vivo,,CHEMBL620257,Intermediate,10090.0,,N,,A,4749,,,Mus musculus,1,,,
,16597,1,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),50594,In vivo,,CHEMBL620258,Intermediate,10090.0,,N,,A,4750,,,Mus musculus,1,,,
,4890,1,BAO_0000218,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",50594,In vivo,,CHEMBL620259,Intermediate,10090.0,,N,,A,4751,,,Mus musculus,1,,,
,429,1,BAO_0000218,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,50594,In vivo,,CHEMBL620260,Intermediate,10090.0,,N,,A,4752,,,Mus musculus,1,,,
,17837,1,BAO_0000218,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,50594,In vivo,Blood,CHEMBL620261,Intermediate,10090.0,,N,,A,4753,,,Mus musculus,1,,178.0,
,16597,1,BAO_0000218,Half life at a dose of 10 mg/kg intravenous administration in mice.,50594,In vivo,,CHEMBL620262,Intermediate,10090.0,,N,,A,4754,,,Mus musculus,1,,,
,16597,1,BAO_0000218,Half life at a dose of 10 mg/kg peroral administration in mice.,50594,In vivo,,CHEMBL620263,Intermediate,10090.0,,N,,A,4755,,,Mus musculus,1,,,
,6619,1,BAO_0000218,Half life in ob/ob mice,50594,,,CHEMBL620264,Intermediate,10090.0,,N,,A,4756,,,Mus musculus,1,,,
,4066,1,BAO_0000218,Half-life at a single subcutaneous administration of 40 mg/kg in mice,50594,In vivo,,CHEMBL620265,Intermediate,10090.0,,N,,A,4757,,,Mus musculus,1,,,
,4239,1,BAO_0000218,Half-life was measured in mouse,50594,,,CHEMBL620266,Intermediate,10090.0,,N,,A,4758,,,Mus musculus,1,,,
,5969,1,BAO_0000218,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,50594,In vivo,,CHEMBL620267,Intermediate,10090.0,,N,,A,4759,,,Mus musculus,1,,,
,8999,1,BAO_0000218,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,50594,,,CHEMBL619364,Intermediate,10090.0,,N,,A,4760,,,Mus musculus,1,,,
,8999,1,BAO_0000218,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,50594,,,CHEMBL619365,Intermediate,10090.0,,N,,A,4761,,,Mus musculus,1,,,
,17641,1,BAO_0000218,T2 in brain of mice at the oral dose of 50 mg/kg,50594,,Brain,CHEMBL619366,Intermediate,10090.0,,N,,A,4762,,,Mus musculus,1,,955.0,
,17641,1,BAO_0000218,T2 in kidney of mice at the oral dose of 50 mg/kg,50594,,Kidney,CHEMBL619367,Intermediate,10090.0,,N,,A,4763,,,Mus musculus,1,,2113.0,
,17641,1,BAO_0000218,T2 in liver of mice at the oral dose of 50 mg/kg,50594,,Liver,CHEMBL619368,Intermediate,10090.0,,N,,A,4764,,,Mus musculus,1,,2107.0,
,17641,1,BAO_0000218,T2 in lungs of mice at the oral dose of 50 mg/kg,50594,,Lung,CHEMBL619369,Intermediate,10090.0,,N,,A,4765,,,Mus musculus,1,,2048.0,
,17641,1,BAO_0000218,T2 in spleen of mice at the oral dose of 50 mg/kg,50594,,Spleen,CHEMBL876729,Intermediate,10090.0,,N,,A,4766,,,Mus musculus,1,,2106.0,
,16597,1,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,50594,In vivo,,CHEMBL619370,Intermediate,10090.0,,N,,A,4767,,,Mus musculus,1,,,
,4890,1,BAO_0000218,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",50594,In vivo,,CHEMBL619371,Intermediate,10090.0,,N,,A,4768,,,Mus musculus,1,,,
,429,1,BAO_0000218,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,50594,In vivo,,CHEMBL619372,Intermediate,10090.0,,N,,A,4769,,,Mus musculus,1,,,
,429,1,BAO_0000218,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,50594,In vivo,,CHEMBL620012,Intermediate,10090.0,,N,,A,4770,,,Mus musculus,1,,,
,5969,1,BAO_0000218,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,50594,In vivo,,CHEMBL620013,Intermediate,10090.0,,N,,A,4771,,,Mus musculus,1,,,
,16913,1,BAO_0000219,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",81034,,,CHEMBL620014,Intermediate,9606.0,,N,,F,4772,,478.0,Homo sapiens,1,,,A2780
,16913,1,BAO_0000219,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",81034,,,CHEMBL620015,Intermediate,9606.0,,N,,F,4773,,478.0,Homo sapiens,1,,,A2780
,16913,1,BAO_0000219,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",81034,,,CHEMBL621010,Intermediate,9606.0,,N,,F,4774,,478.0,Homo sapiens,1,,,A2780
,16913,1,BAO_0000219,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",81034,,,CHEMBL621011,Intermediate,9606.0,,N,,F,4775,,478.0,Homo sapiens,1,,,A2780
,16913,1,BAO_0000219,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",81034,,,CHEMBL621012,Intermediate,9606.0,,N,,F,4776,,478.0,Homo sapiens,1,,,A2780
,16913,1,BAO_0000219,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",81034,,,CHEMBL621013,Intermediate,9606.0,,N,,F,4777,,478.0,Homo sapiens,1,,,A2780
,17270,1,BAO_0000219,In vitro cytotoxicity against A2780TAX cell line,81034,,,CHEMBL621014,Intermediate,9606.0,,N,,F,4778,,478.0,Homo sapiens,1,,,A2780
,5618,1,BAO_0000219,In vitro inhibitory activity against human tumor cell line A2780cis,80017,,,CHEMBL618154,Intermediate,9606.0,,N,,F,4779,,481.0,Homo sapiens,1,,,A2780cisR
,17777,1,BAO_0000219,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,81034,,,CHEMBL618155,Expert,9606.0,,N,,F,4780,,478.0,Homo sapiens,1,,,A2780
,16112,1,BAO_0000219,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,80017,,,CHEMBL618156,Intermediate,9606.0,,N,,F,4781,,481.0,Homo sapiens,1,,,A2780cisR
,15748,1,BAO_0000219,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),80017,,,CHEMBL618157,Intermediate,9606.0,,N,,F,4782,,481.0,Homo sapiens,1,,,A2780cisR
,6633,1,BAO_0000219,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,81034,,,CHEMBL618328,Intermediate,9606.0,,N,,F,4783,,478.0,Homo sapiens,1,,,A2780
,16930,1,BAO_0000219,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,81034,,,CHEMBL618329,Intermediate,9606.0,,N,,F,4784,,478.0,Homo sapiens,1,,,A2780
,17496,1,BAO_0000219,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,81034,,,CHEMBL618330,Intermediate,9606.0,,N,,F,4785,,478.0,Homo sapiens,1,,,A2780
,12989,1,BAO_0000219,In vitro antitumor activity against A2780cisR cell line.,81034,,,CHEMBL618331,Expert,9606.0,,N,,F,4786,,478.0,Homo sapiens,1,,,A2780
,4840,1,BAO_0000219,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),81034,,,CHEMBL618332,Intermediate,9606.0,,N,,F,4787,,478.0,Homo sapiens,1,,,A2780
,12989,1,BAO_0000219,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,81034,,,CHEMBL618333,Expert,9606.0,,N,,F,4788,,478.0,Homo sapiens,1,,,A2780
,16745,1,BAO_0000219,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,80017,,,CHEMBL618334,Intermediate,9606.0,,N,,F,4789,,481.0,Homo sapiens,1,,,A2780cisR
,16597,1,BAO_0000219,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,81034,,,CHEMBL618335,Expert,9606.0,,N,,F,4790,,478.0,Homo sapiens,1,,,A2780
,16547,9,BAO_0000019,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,11736,,,CHEMBL618336,Expert,10116.0,,D,,B,4791,,,Rattus norvegicus,1,,,
,16547,8,BAO_0000019,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),11736,,,CHEMBL618337,Expert,,,H,,F,4792,,,,1,,,
,16547,9,BAO_0000019,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),11736,,,CHEMBL618338,Expert,10116.0,,D,,F,4793,,,Rattus norvegicus,1,,,
,15856,9,BAO_0000219,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,278,,,CHEMBL618339,Expert,9606.0,,D,,F,4794,,722.0,Homo sapiens,1,,,HEK293
,15856,9,BAO_0000219,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,278,,,CHEMBL618340,Expert,9606.0,,D,,F,4795,,722.0,Homo sapiens,1,,,HEK293
,16547,9,BAO_0000019,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,11831,,,CHEMBL618341,Expert,10090.0,,D,,B,4796,,,Mus musculus,1,,,
,16547,8,BAO_0000019,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),11831,,,CHEMBL618342,Expert,,,H,,F,4797,,,,1,,,
,16547,9,BAO_0000019,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),11831,,,CHEMBL618343,Expert,10090.0,,D,,F,4798,,,Mus musculus,1,,,
,17402,8,BAO_0000357,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,280,,,CHEMBL621038,Expert,,,H,,B,4799,,,,1,,,
,11746,0,BAO_0000219,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),22226,,,CHEMBL621039,Autocuration,9606.0,,U,,F,4800,,574.0,Homo sapiens,1,,,T-cells
,11746,0,BAO_0000219,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,22226,,,CHEMBL621040,Autocuration,9606.0,,U,,F,4801,,574.0,Homo sapiens,1,,,T-cells
,5455,1,BAO_0000219,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,80018,,,CHEMBL621041,Intermediate,9606.0,,N,,F,4802,,455.0,Homo sapiens,1,,,A-375
,2068,1,BAO_0000219,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,80018,,,CHEMBL621042,Intermediate,9606.0,,N,,F,4803,,455.0,Homo sapiens,1,,,A-375
,2683,1,BAO_0000219,In vitro antitumor activity against A375cell line extracted form melanoma,80018,,,CHEMBL621043,Intermediate,9606.0,,N,,F,4804,,455.0,Homo sapiens,1,,,A-375
,15313,1,BAO_0000219,Inhibition of cell growth in (A375) melan cell line,80018,,,CHEMBL621044,Expert,9606.0,,N,,F,4805,,455.0,Homo sapiens,1,,,A-375
,13739,1,BAO_0000219,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,80018,,,CHEMBL621045,Intermediate,9606.0,,N,,F,4806,,455.0,Homo sapiens,1,,,A-375
,13739,1,BAO_0000219,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,80018,,,CHEMBL621046,Intermediate,9606.0,,N,,F,4807,,455.0,Homo sapiens,1,,,A-375
,14750,1,BAO_0000219,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,80018,,,CHEMBL621047,Intermediate,9606.0,,N,,F,4808,,455.0,Homo sapiens,1,,,A-375
,14777,1,BAO_0000219,Antiproliferative activity measured against A427 human lung carcinoma,80019,,,CHEMBL621048,Intermediate,9606.0,,N,,F,4809,,797.0,Homo sapiens,1,,,A-427
,14777,1,BAO_0000219,Antiproliferative activity measured against A427 human lung carcinoma,80019,,,CHEMBL883798,Intermediate,9606.0,,N,,F,4810,,797.0,Homo sapiens,1,,,A-427
,17672,1,BAO_0000219,Cytotoxicity against lung carcinoma A427 tumor cell lines,80019,,,CHEMBL621049,Intermediate,9606.0,,N,,F,4811,,797.0,Homo sapiens,1,,,A-427
,14368,1,BAO_0000219,Inhibition of large cell lung carcinoma (A427),80019,,,CHEMBL621050,Intermediate,9606.0,,N,,F,4812,,797.0,Homo sapiens,1,,,A-427
,14368,1,BAO_0000219,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,80019,,,CHEMBL621051,Intermediate,9606.0,,N,,F,4813,,797.0,Homo sapiens,1,,,A-427
,13866,1,BAO_0000219,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,80019,,,CHEMBL621052,Intermediate,9606.0,,N,,F,4814,,797.0,Homo sapiens,1,,,A-427
,2545,1,BAO_0000219,Inhibitory concentration in human lung carcinoma A427 cell line,80019,,,CHEMBL621053,Intermediate,9606.0,,N,,F,4815,,797.0,Homo sapiens,1,,,A-427
,2545,1,BAO_0000219,Inhibitory concentration in human lung carcinoma A427/VCR cell line,80019,,,CHEMBL621054,Intermediate,9606.0,,N,,F,4816,,797.0,Homo sapiens,1,,,A-427
,6062,0,BAO_0000218,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,22224,In vivo,,CHEMBL621055,Autocuration,9527.0,,U,,A,4817,,,Cercopithecidae,1,,,
,4578,0,BAO_0000218,Tested for volume of distribution upon iv administration to african green monkey,22224,In vivo,,CHEMBL876398,Autocuration,9527.0,,U,,A,4818,,,Cercopithecidae,1,,,
,17592,0,BAO_0000218,Volume of distribution in monkey,22224,In vivo,,CHEMBL621056,Autocuration,9527.0,,U,,A,4819,,,Cercopithecidae,1,,,
,5005,0,BAO_0000218,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,In vivo,,CHEMBL621057,Autocuration,9544.0,,U,,A,4820,,,Macaca mulatta,1,,,
,5005,0,BAO_0000218,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,22224,In vivo,,CHEMBL621058,Autocuration,9544.0,,U,,A,4821,,,Macaca mulatta,1,,,
,5922,0,BAO_0000218,Pharmacokinetic property(Vdss) in cynomolgus monkey,22224,In vivo,,CHEMBL621059,Autocuration,9527.0,,U,,A,4822,,,Cercopithecidae,1,,,
,5355,0,BAO_0000218,The distribution volume after intravenous administration in cynomolgus monkeys,22224,In vivo,,CHEMBL621060,Autocuration,9527.0,,U,,A,4823,,,Cercopithecidae,1,,,
,5355,0,BAO_0000218,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,22224,In vivo,,CHEMBL621061,Autocuration,9527.0,,U,,A,4824,,,Cercopithecidae,1,,,
,5355,0,BAO_0000218,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,22224,In vivo,,CHEMBL621062,Autocuration,9527.0,,U,,A,4825,,,Cercopithecidae,1,,,
,6057,0,BAO_0000218,Volume displacement was calculated in rhesus monkey,22224,In vivo,,CHEMBL621063,Autocuration,9527.0,,U,,A,4826,,,Cercopithecidae,1,,,
,5145,0,BAO_0000218,Volume of distribution in steady state was determined in rhesus monkey,22224,In vivo,,CHEMBL621064,Autocuration,9527.0,,U,,A,4827,,,Cercopithecidae,1,,,
,6821,0,BAO_0000218,Volume of distribution of compound was determined in monkey,22224,In vivo,,CHEMBL621065,Autocuration,9527.0,,U,,A,4828,,,Cercopithecidae,1,,,
,5334,0,BAO_0000218,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),22224,In vivo,,CHEMBL621066,Autocuration,9527.0,,U,,A,4829,,,Cercopithecidae,1,,,
,5334,0,BAO_0000218,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),22224,In vivo,,CHEMBL621067,Autocuration,9527.0,,U,,A,4830,,,Cercopithecidae,1,,,
,6641,0,BAO_0000218,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),22224,In vivo,,CHEMBL621068,Autocuration,9527.0,,U,,A,4831,,,Cercopithecidae,1,,,
,2661,0,BAO_0000218,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,22224,In vivo,,CHEMBL876399,Autocuration,9527.0,,U,,A,4832,,,Cercopithecidae,1,,,
,6535,0,BAO_0000218,Volume distribution in monkey after administration of 1 mg/kg iv,22224,In vivo,,CHEMBL621069,Autocuration,9527.0,,U,,A,4833,,,Cercopithecidae,1,,,
,4809,0,BAO_0000218,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),22224,In vivo,,CHEMBL621070,Autocuration,9527.0,,U,,A,4834,,,Cercopithecidae,1,,,
,6062,0,BAO_0000218,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,22224,In vivo,,CHEMBL621071,Autocuration,9527.0,,U,,A,4835,,,Cercopithecidae,1,,,
,3443,0,BAO_0000218,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,In vivo,,CHEMBL621072,Autocuration,9527.0,,U,,A,4836,,,Cercopithecidae,1,,,
,4578,0,BAO_0000218,Oral systemic bioavailability upon iv administration to african green monkey,22224,In vivo,,CHEMBL618209,Autocuration,9527.0,,U,,A,4837,,,Cercopithecidae,1,,,
,4809,0,BAO_0000218,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),22224,In vivo,,CHEMBL618210,Autocuration,9527.0,,U,,A,4838,,,Cercopithecidae,1,,,
,11271,0,BAO_0000019,Baboon plasma free fraction. ,22224,,,CHEMBL618211,Autocuration,9527.0,,U,,A,4839,,,Cercopithecidae,1,,,
,6057,0,BAO_0000218,Area under the curve was calculated in rhesus monkey after iv administration,22224,,,CHEMBL618212,Autocuration,9527.0,,U,,A,4840,,,Cercopithecidae,1,,,
,6057,0,BAO_0000019,Area under the curve was calculated in rhesus monkey after peroral administration,22224,,,CHEMBL618213,Autocuration,9527.0,,U,,A,4841,,,Cercopithecidae,1,,,
,17853,0,BAO_0000019,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,22224,,,CHEMBL618214,Autocuration,9527.0,,U,,A,4842,,,Cercopithecidae,1,,,
,5302,0,BAO_0000218,Half life period in monkey after 5 mg/kg dose,22224,In vivo,,CHEMBL873492,Autocuration,9527.0,,U,,A,4843,,,Cercopithecidae,1,,,
,4257,0,BAO_0000218,Half-life was determined in monkey after 3 mg/kg of i.v. dose,22224,In vivo,,CHEMBL618272,Autocuration,9527.0,,U,,A,4844,,,Cercopithecidae,1,,,
,4257,0,BAO_0000218,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,22224,In vivo,,CHEMBL618273,Autocuration,9527.0,,U,,A,4845,,,Cercopithecidae,1,,,
,13501,0,BAO_0000218,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,22224,In vivo,Plasma,CHEMBL618274,Autocuration,9527.0,,U,,A,4846,,,Cercopithecidae,1,,1969.0,
,5394,0,BAO_0000218,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,22224,In vivo,,CHEMBL618275,Autocuration,9527.0,,U,,A,4847,,,Cercopithecidae,1,,,
,2661,0,BAO_0000218,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,22224,In vivo,,CHEMBL618276,Autocuration,9527.0,,U,,A,4848,,,Cercopithecidae,1,,,
,3341,0,BAO_0000019,Compound was evaluated for terminal half life in monkey,22224,,,CHEMBL618277,Autocuration,9527.0,,U,,A,4849,,,Cercopithecidae,1,,,
,3045,0,BAO_0000218,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,22224,In vivo,,CHEMBL618278,Autocuration,9527.0,,U,,A,4850,,,Cercopithecidae,1,,,
,5005,0,BAO_0000218,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,In vivo,Plasma,CHEMBL618279,Autocuration,9544.0,,U,,A,4851,,,Macaca mulatta,1,,1969.0,
,4847,0,BAO_0000019,Half life of compound was determined in squirrel monkey,22224,,,CHEMBL618280,Autocuration,9527.0,,U,,A,4852,,,Cercopithecidae,1,,,
,4256,0,BAO_0000218,Half life after iv administration in cynomolgus monkey,22224,In vivo,,CHEMBL618281,Autocuration,9541.0,,U,,A,4853,,,Macaca fascicularis,1,,,
,6535,0,BAO_0000218,Half life in monkey plasma after administration of 1 mg/kg iv,22224,In vivo,Plasma,CHEMBL618282,Autocuration,9527.0,,U,,A,4854,,,Cercopithecidae,1,,1969.0,
,6057,0,BAO_0000019,Half life was calculated in rhesus monkey,22224,,,CHEMBL618283,Autocuration,9527.0,,U,,A,4855,,,Cercopithecidae,1,,,
,17592,0,BAO_0000019,Half life in monkey,22224,,,CHEMBL618284,Autocuration,9527.0,,U,,A,4856,,,Cercopithecidae,1,,,
,6641,0,BAO_0000218,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),22224,In vivo,,CHEMBL618285,Autocuration,9527.0,,U,,A,4857,,,Cercopithecidae,1,,,
,5472,0,BAO_0000019,Half life was evaluated in rhesus,22224,,,CHEMBL618286,Autocuration,9527.0,,U,,A,4858,,,Cercopithecidae,1,,,
,6221,0,BAO_0000218,Half life period after oral administration (2.5 mg/kg) in monkey was determined,22224,In vivo,,CHEMBL618287,Autocuration,9527.0,,U,,A,4859,,,Cercopithecidae,1,,,
,5668,0,BAO_0000218,Half life period was determine after peroral administration at 10 mpk in Rhesus,22224,In vivo,,CHEMBL618288,Autocuration,9527.0,,U,,A,4860,,,Cercopithecidae,1,,,
,4809,0,BAO_0000218,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),22224,In vivo,,CHEMBL876393,Autocuration,9527.0,,U,,A,4861,,,Cercopithecidae,1,,,
,5546,0,BAO_0000218,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,22224,In vivo,,CHEMBL618289,Autocuration,9527.0,,U,,A,4862,,,Cercopithecidae,1,,,
,5553,0,BAO_0000218,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,22224,In vivo,,CHEMBL618290,Autocuration,9527.0,,U,,A,4863,,,Cercopithecidae,1,,,
,6078,0,BAO_0000019,Half-life was calculated in monkey,22224,,,CHEMBL618291,Autocuration,9527.0,,U,,A,4864,,,Cercopithecidae,1,,,
,5147,0,BAO_0000019,Half-life in Squirrel monkey,22224,,,CHEMBL618292,Autocuration,9527.0,,U,,A,4865,,,Cercopithecidae,1,,,
,5145,0,BAO_0000019,Half-life in rhesus monkey,22224,,,CHEMBL618293,Autocuration,9527.0,,U,,A,4866,,,Cercopithecidae,1,,,
,6062,0,BAO_0000218,Half-life was measured in monkey after an iv dose of 1 mg/kg,22224,In vivo,,CHEMBL618294,Autocuration,9527.0,,U,,A,4867,,,Cercopithecidae,1,,,
,5355,0,BAO_0000218,Half-life period after intravenous administration in cynomolgus monkeys,22224,In vivo,,CHEMBL618295,Autocuration,9527.0,,U,,A,4868,,,Cercopithecidae,1,,,
,5355,0,BAO_0000218,Half-life period after oral administration in cynomolgus monkeys,22224,In vivo,,CHEMBL618296,Autocuration,9527.0,,U,,A,4869,,,Cercopithecidae,1,,,
,5355,0,BAO_0000218,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,22224,In vivo,,CHEMBL618297,Autocuration,9527.0,,U,,A,4870,,,Cercopithecidae,1,,,
,7766,0,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,,Urine,CHEMBL618298,Autocuration,9606.0,,U,,A,4871,,,Homo sapiens,1,,1088.0,
,7766,0,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,,Urine,CHEMBL618299,Autocuration,9606.0,,U,,A,4872,,,Homo sapiens,1,,1088.0,
,7766,0,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,,Urine,CHEMBL618300,Autocuration,9606.0,,U,,A,4873,,,Homo sapiens,1,,1088.0,
,7766,0,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,,Urine,CHEMBL618301,Autocuration,9606.0,,U,,A,4874,,,Homo sapiens,1,,1088.0,
,7766,0,BAO_0000019,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,22224,,Urine,CHEMBL618302,Autocuration,9606.0,,U,,A,4875,,,Homo sapiens,1,,1088.0,
,7766,0,BAO_0000019,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,22224,,Urine,CHEMBL876394,Autocuration,9606.0,,U,,A,4876,,,Homo sapiens,1,,1088.0,
,7766,0,BAO_0000019,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,22224,,Urine,CHEMBL618303,Autocuration,9606.0,,U,,A,4877,,,Homo sapiens,1,,1088.0,
,7766,0,BAO_0000019,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,22224,,Urine,CHEMBL618304,Autocuration,9606.0,,U,,A,4878,,,Homo sapiens,1,,1088.0,
,1916,0,BAO_0000218,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,22224,In vivo,,CHEMBL618305,Autocuration,9606.0,,U,,A,4879,,,Homo sapiens,1,,,
,16643,0,BAO_0000218,Oral bioavailability in human,22224,In vivo,,CHEMBL618306,Autocuration,9606.0,,U,,A,4880,,,Homo sapiens,1,,,
,17248,0,BAO_0000019,Compound was tested for human plasma protein binding,22224,,,CHEMBL618307,Autocuration,9606.0,,U,,A,4881,,,Homo sapiens,1,,,
,17248,0,BAO_0000019,Compound was tested for human plasma protein binding; Not determined,22224,,,CHEMBL618308,Autocuration,9606.0,,U,,A,4882,,,Homo sapiens,1,,,
,6241,0,BAO_0000019,Protein binding activity of compound in human plasma; % Free,22224,,,CHEMBL618309,Autocuration,9606.0,,U,,A,4883,,,Homo sapiens,1,,,
,17716,0,BAO_0000019,Unbound fraction (plasma),22224,,,CHEMBL618310,Autocuration,9606.0,,U,,A,4884,,,Homo sapiens,1,,,
,17605,0,BAO_0000366,Half life for the hydrolysis of compound in human blood serum,22224,,Plasma,CHEMBL873353,Autocuration,9606.0,,U,,A,4885,,,Homo sapiens,1,,1969.0,
,17625,0,BAO_0000366,Half life period in human plasma using phosphate buffer (0.08 M),22224,,Plasma,CHEMBL618311,Autocuration,9606.0,,U,,A,4886,,,Homo sapiens,1,,1969.0,
,17625,0,BAO_0000366,Half life period in human plasma using phosphate buffer (0.1 M),22224,,Plasma,CHEMBL618312,Autocuration,9606.0,,U,,A,4887,,,Homo sapiens,1,,1969.0,
,17747,0,BAO_0000366,Half-life in human plasma was determined,22224,,Plasma,CHEMBL618313,Autocuration,9606.0,,U,,A,4888,,,Homo sapiens,1,,1969.0,
,15613,0,BAO_0000019,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,22224,,,CHEMBL618314,Autocuration,9606.0,,U,,A,4889,,,Homo sapiens,1,,,
,354,0,BAO_0000019,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),22224,,,CHEMBL618315,Autocuration,9606.0,,U,,A,4890,,,Homo sapiens,1,,,
,3741,0,BAO_0000019,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",22224,,,CHEMBL618316,Autocuration,9606.0,,U,,A,4891,,,Homo sapiens,1,,,
,3741,0,BAO_0000019,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",22224,,,CHEMBL618317,Autocuration,9606.0,,U,,A,4892,,,Homo sapiens,1,,,
,3741,0,BAO_0000019,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",22224,,,CHEMBL620138,Autocuration,9606.0,,U,,A,4893,,,Homo sapiens,1,,,
,17599,0,BAO_0000019,Partition coefficient (logP),22224,,,CHEMBL858280,Autocuration,9606.0,,U,,A,4894,,,Homo sapiens,1,,,
,5486,0,BAO_0000019,In vitro metabolic stability in human was measured as pmol/min/mg/protein,22224,,,CHEMBL620139,Autocuration,9606.0,,U,,A,4895,,,Homo sapiens,1,,,
,5600,0,BAO_0000251,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,22224,,,CHEMBL620140,Autocuration,9606.0,Microsomes,U,,A,4896,,,Homo sapiens,1,,,
,14294,0,BAO_0000019,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),22224,,,CHEMBL620141,Autocuration,9606.0,,U,,A,4897,,,Homo sapiens,1,,,
,14294,0,BAO_0000019,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),22224,,,CHEMBL620142,Autocuration,9606.0,,U,,A,4898,,,Homo sapiens,1,,,
,14294,0,BAO_0000019,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),22224,,,CHEMBL620143,Autocuration,9606.0,,U,,A,4899,,,Homo sapiens,1,,,
,14294,0,BAO_0000251,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),22224,,,CHEMBL620144,Autocuration,9606.0,Microsomes,U,,A,4900,,,Homo sapiens,1,,,
,14294,0,BAO_0000251,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),22224,,,CHEMBL620145,Autocuration,9606.0,Microsomes,U,,A,4901,,,Homo sapiens,1,,,
,14294,0,BAO_0000251,Metabolism of compound in human microsomes; Trace,22224,,,CHEMBL620146,Autocuration,9606.0,Microsomes,U,,A,4902,,,Homo sapiens,1,,,
,6260,0,BAO_0000251,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,22224,,Liver,CHEMBL620147,Autocuration,9606.0,Microsomes,U,,A,4903,,,Homo sapiens,1,,2107.0,
,6187,0,BAO_0000251,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,22224,,,CHEMBL620148,Autocuration,9606.0,Microsomes,U,,A,4904,,,Homo sapiens,1,,,
,6251,0,BAO_0000251,In vitro metabolic potential in human liver microsomes,22224,,Liver,CHEMBL620149,Autocuration,9606.0,Microsomes,U,,A,4905,,,Homo sapiens,1,,2107.0,
,3246,0,BAO_0000019,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,22224,,,CHEMBL876412,Autocuration,9606.0,,U,,A,4906,,,Homo sapiens,1,,,
,17313,0,BAO_0000019,Tested for human plasma protein binding of the compound; Not tested,22224,,,CHEMBL619352,Autocuration,9606.0,,U,,A,4907,,,Homo sapiens,1,,,
,6227,0,BAO_0000019,Compound was tested for percent protein binding (PB) in human,22224,,,CHEMBL619353,Autocuration,9606.0,,U,,A,4908,,,Homo sapiens,1,,,
,5530,0,BAO_0000019,Protein binding in human plasma,22224,,Plasma,CHEMBL619354,Autocuration,9606.0,,U,,A,4909,,,Homo sapiens,1,,1969.0,
,6108,0,BAO_0000019,Permeability coefficient (B to A) in Caco-2 cell,22224,,,CHEMBL619355,Autocuration,9606.0,,U,,A,4910,,,Homo sapiens,1,,,
,6108,0,BAO_0000019,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,22224,,,CHEMBL619356,Autocuration,9606.0,,U,,A,4911,,,Homo sapiens,1,,,
,2774,0,BAO_0000019,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),22224,,,CHEMBL619357,Autocuration,9606.0,,U,,A,4912,,,Homo sapiens,1,,,
,16643,0,BAO_0000019,In vitro rate of absorption observed as Caco-2 permeability in humans,22224,,,CHEMBL619358,Autocuration,9606.0,,U,,A,4913,,,Homo sapiens,1,,,
,17582,0,BAO_0000219,Cellular permeability of compound was determined in Caco-2 cells; High,22224,,,CHEMBL619359,Autocuration,9606.0,,U,,A,4914,,495.0,Homo sapiens,1,,,Caco-2
,6838,0,BAO_0000219,Permeability in Caco-2 cells of compound,22224,,,CHEMBL619360,Autocuration,9606.0,,U,,A,4915,,495.0,Homo sapiens,1,,,Caco-2
,6108,0,BAO_0000019,Permeability coefficient (A to B) in Caco-2 cell,22224,,,CHEMBL619361,Autocuration,9606.0,,U,,A,4916,,,Homo sapiens,1,,,
,6108,0,BAO_0000019,Permeability coefficient (B to A) in Caco-2 cell,22224,,,CHEMBL619362,Autocuration,9606.0,,U,,A,4917,,,Homo sapiens,1,,,
,6108,0,BAO_0000019,Permeability coefficient (Papp) (Caco-2 cell monolayer),22224,,,CHEMBL619363,Autocuration,9606.0,,U,,A,4918,,,Homo sapiens,1,,,
,2146,0,BAO_0000019,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,22224,,,CHEMBL618942,Autocuration,9606.0,,U,,A,4919,,,Homo sapiens,1,,,
,4514,0,BAO_0000019,Compound was tested for protein binding in human plasma,22224,,,CHEMBL618943,Autocuration,9606.0,,U,,A,4920,,,Homo sapiens,1,,,
,6108,0,BAO_0000019,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,22224,,,CHEMBL618944,Autocuration,9606.0,,U,,A,4921,,,Homo sapiens,1,,,
,7766,0,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,22224,,Urine,CHEMBL618945,Autocuration,9606.0,,U,,A,4922,,,Homo sapiens,1,,1088.0,
,5969,1,BAO_0000218,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,50594,In vivo,,CHEMBL618946,Intermediate,10090.0,,N,,A,4923,,,Mus musculus,1,,,
,3277,1,BAO_0000218,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),50594,In vivo,,CHEMBL876413,Intermediate,10090.0,,N,,A,4924,,,Mus musculus,1,,,
,3802,1,BAO_0000218,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,50594,In vivo,,CHEMBL618947,Intermediate,10090.0,,N,,A,4925,,,Mus musculus,1,,,
,2862,1,BAO_0000218,Time taken to reach maximum concentration in plasma upon oral administration in mouse,50594,In vivo,Plasma,CHEMBL618948,Intermediate,10090.0,,N,,A,4926,,,Mus musculus,1,,1969.0,
,6348,1,BAO_0000218,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,In vivo,Plasma,CHEMBL618949,Intermediate,10090.0,,N,,A,4927,,,Mus musculus,1,,1969.0,
,17764,1,BAO_0000218,Tmax after intraperitoneal administration in mice at 23 uM/kg,50594,In vivo,,CHEMBL618950,Intermediate,10090.0,,N,,F,4928,,,Mus musculus,1,,,
,5781,1,BAO_0000218,Tmax after oral administration at 30 mg/kg in ICR mouse,50594,In vivo,,CHEMBL618951,Intermediate,10090.0,,N,,A,4929,,,Mus musculus,1,,,
,17764,1,BAO_0000218,Tmax after peroral administration in mice at 2.4 uM/kg,50594,In vivo,,CHEMBL618952,Intermediate,10090.0,,N,,A,4930,,,Mus musculus,1,,,
,4066,1,BAO_0000218,Tmax at a single subcutaneous administration of 40 mg/kg in mice,50594,In vivo,,CHEMBL618953,Intermediate,10090.0,,N,,A,4931,,,Mus musculus,1,,,
,17641,1,BAO_0000218,Tmax in brain of mice at the oral dose of 50 mg/kg,50594,In vivo,Brain,CHEMBL618954,Intermediate,10090.0,,N,,A,4932,,,Mus musculus,1,,955.0,
,17641,1,BAO_0000218,Tmax in kidney of mice at the oral dose of 50 mg/kg,50594,In vivo,Kidney,CHEMBL618955,Intermediate,10090.0,,N,,A,4933,,,Mus musculus,1,,2113.0,
,17641,1,BAO_0000218,Tmax in liver of mice at the oral dose of 50 mg/kg,50594,In vivo,Liver,CHEMBL618956,Intermediate,10090.0,,N,,A,4934,,,Mus musculus,1,,2107.0,
,17641,1,BAO_0000218,Tmax in lungs of mice at the oral dose of 50 mg/kg,50594,In vivo,Lung,CHEMBL618957,Intermediate,10090.0,,N,,A,4935,,,Mus musculus,1,,2048.0,
,17764,1,BAO_0000218,Tmax in mice at 18 uM/kg i.p. administration,50594,In vivo,,CHEMBL618958,Intermediate,10090.0,,N,,F,4936,,,Mus musculus,1,,,
,17764,1,BAO_0000218,Tmax in mice at 23 uM/kg i.v. administration,50594,In vivo,,CHEMBL618959,Intermediate,10090.0,,N,,F,4937,,,Mus musculus,1,,,
,17764,1,BAO_0000218,Tmax in mice at 25 uM/kg i.p. administration,50594,In vivo,,CHEMBL618960,Intermediate,10090.0,,N,,F,4938,,,Mus musculus,1,,,
,17764,1,BAO_0000218,Tmax in mice at 26 uM/kg i.p. administration,50594,In vivo,,CHEMBL876723,Intermediate,10090.0,,N,,F,4939,,,Mus musculus,1,,,
,17641,1,BAO_0000218,Tmax in spleen of mice at the oral dose of 50 mg/kg,50594,In vivo,Spleen,CHEMBL618961,Intermediate,10090.0,,N,,A,4940,,,Mus musculus,1,,2106.0,
,16597,1,BAO_0000218,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,50594,In vivo,,CHEMBL618962,Intermediate,10090.0,,N,,A,4941,,,Mus musculus,1,,,
,16597,1,BAO_0000218,Tmax value at a dose of 10 mg/kg peroral administration in mice.,50594,In vivo,,CHEMBL618963,Intermediate,10090.0,,N,,A,4942,,,Mus musculus,1,,,
,5951,1,BAO_0000218,Tmax value in IRC mice,50594,,,CHEMBL618964,Intermediate,10090.0,,N,,A,4943,,,Mus musculus,1,,,
,5506,1,BAO_0000218,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,50594,In vivo,,CHEMBL618965,Intermediate,10090.0,,N,,A,4944,,,Mus musculus,1,,,
,5506,1,BAO_0000218,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,50594,In vivo,,CHEMBL618966,Intermediate,10090.0,,N,,A,4945,,,Mus musculus,1,,,
,429,1,BAO_0000218,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),50594,,Urine,CHEMBL618967,Intermediate,10090.0,,N,,A,4946,,,Mus musculus,1,,1088.0,
,429,1,BAO_0000218,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),50594,,Urine,CHEMBL618968,Intermediate,10090.0,,N,,A,4947,,,Mus musculus,1,,1088.0,
,4066,1,BAO_0000218,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),50594,,Urine,CHEMBL618969,Intermediate,10090.0,,N,,A,4948,,,Mus musculus,1,,1088.0,
,17734,1,BAO_0000218,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,50594,,,CHEMBL618970,Intermediate,10090.0,,N,,A,4949,,,Mus musculus,1,,,
,17734,1,BAO_0000218,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,50594,,,CHEMBL618971,Intermediate,10090.0,,N,,A,4950,,,Mus musculus,1,,,
,6062,1,BAO_0000218,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,50594,In vivo,,CHEMBL618972,Intermediate,10090.0,,N,,A,4951,,,Mus musculus,1,,,
,5969,1,BAO_0000218,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,50594,In vivo,,CHEMBL618973,Intermediate,10090.0,,N,,A,4952,,,Mus musculus,1,,,
,5969,1,BAO_0000218,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,50594,In vivo,,CHEMBL618974,Intermediate,10090.0,,N,,A,4953,,,Mus musculus,1,,,
,5969,1,BAO_0000218,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,50594,In vivo,,CHEMBL618975,Intermediate,10090.0,,N,,A,4954,,,Mus musculus,1,,,
,5980,1,BAO_0000218,Vd in mice,50594,In vivo,,CHEMBL618976,Intermediate,10090.0,,N,,A,4955,,,Mus musculus,1,,,
,17592,1,BAO_0000218,Volume of distribution in mouse,50594,In vivo,,CHEMBL618977,Intermediate,10090.0,,N,,A,4956,,,Mus musculus,1,,,
,6348,1,BAO_0000218,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,In vivo,,CHEMBL876724,Intermediate,10090.0,,N,,A,4957,,,Mus musculus,1,,,
,17753,1,BAO_0000218,Volume of distribution of compound in plasma was determined at 24 mg/Kg,50594,In vivo,,CHEMBL618978,Intermediate,10090.0,,N,,A,4958,,,Mus musculus,1,,,
,17753,1,BAO_0000218,Volume of distribution of compound in plasma was determined at 40 mg/Kg,50594,In vivo,,CHEMBL618979,Intermediate,10090.0,,N,,A,4959,,,Mus musculus,1,,,
,17753,1,BAO_0000218,Volume of distribution of compound in plasma was determined at 5 mg/Kg,50594,In vivo,,CHEMBL618980,Intermediate,10090.0,,N,,A,4960,,,Mus musculus,1,,,
,4239,1,BAO_0000218,Pharmacokinetic property (vdss) was measured in mouse,50594,In vivo,,CHEMBL618981,Intermediate,10090.0,,N,,A,4961,,,Mus musculus,1,,,
,2862,1,BAO_0000218,Value distribution upon iv administration in mouse,50594,In vivo,,CHEMBL618982,Intermediate,10090.0,,N,,A,4962,,,Mus musculus,1,,,
,17734,1,BAO_0000218,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,50594,In vivo,,CHEMBL620150,Intermediate,10090.0,,N,,A,4963,,,Mus musculus,1,,,
,2675,1,BAO_0000218,Volume of distribution was evaluated in mice after intravenous administration,50594,In vivo,,CHEMBL620151,Intermediate,10090.0,,N,,A,4964,,,Mus musculus,1,,,
,2675,1,BAO_0000218,Volume of distribution was evaluated in mice after oral administration,50594,In vivo,,CHEMBL620152,Intermediate,10090.0,,N,,A,4965,,,Mus musculus,1,,,
,17837,1,BAO_0000218,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,50594,In vivo,,CHEMBL620153,Intermediate,10090.0,,N,,A,4966,,,Mus musculus,1,,,
,5727,1,BAO_0000218,Steady state volume of distribution was determined in mice,50594,In vivo,,CHEMBL876395,Intermediate,10090.0,,N,,A,4967,,,Mus musculus,1,,,
,17852,1,BAO_0000218,Volume distribution (steady state) of compound was determined in mouse,50594,In vivo,,CHEMBL620154,Intermediate,10090.0,,N,,A,4968,,,Mus musculus,1,,,
,17764,1,BAO_0000218,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,50594,In vivo,,CHEMBL620155,Intermediate,10090.0,,N,,A,4969,,,Mus musculus,1,,,
,16597,1,BAO_0000218,Vss value at a dose of 10 mg/kg intravenous administration in mice.,50594,In vivo,,CHEMBL620156,Intermediate,10090.0,,N,,A,4970,,,Mus musculus,1,,,
,6062,1,BAO_0000218,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,50594,In vivo,,CHEMBL620157,Intermediate,10090.0,,N,,A,4971,,,Mus musculus,1,,,
,16438,1,BAO_0000218,Biodistribution of compound (oxidized form) in in kidney tissue,50594,In vivo,Kidney,CHEMBL620158,Intermediate,10090.0,,N,,A,4972,,,Mus musculus,1,,2113.0,
,16438,1,BAO_0000218,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,50594,In vivo,Blood,CHEMBL620159,Intermediate,10090.0,,N,,A,4973,,,Mus musculus,1,,178.0,
,16438,1,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",50594,In vivo,Blood,CHEMBL620160,Intermediate,10090.0,,N,,A,4974,,,Mus musculus,1,,178.0,
,16438,1,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,In vivo,Blood,CHEMBL620161,Intermediate,10090.0,,N,,A,4975,,,Mus musculus,1,,178.0,
,10708,1,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,80019,,,CHEMBL620162,Intermediate,9606.0,,N,,F,4976,,797.0,Homo sapiens,1,,,A-427
,16597,1,BAO_0000219,Inhibition of A431 human squamous cell carcinoma cell proliferation,80852,,,CHEMBL620163,Expert,9606.0,,N,,F,4977,,500.0,Homo sapiens,1,,,A-431
,16062,1,BAO_0000219,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,80852,,,CHEMBL620833,Expert,9606.0,,N,,F,4978,,500.0,Homo sapiens,1,,,A-431
,16062,1,BAO_0000219,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,80852,,,CHEMBL876396,Expert,9606.0,,N,,F,4979,,500.0,Homo sapiens,1,,,A-431
,16958,1,BAO_0000219,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,80852,,,CHEMBL620834,Expert,9606.0,,N,,F,4980,,500.0,Homo sapiens,1,,,A-431
,6700,1,BAO_0000219,Inhibition of A431 human carcinoma cell proliferation,80852,,,CHEMBL620835,Expert,9606.0,,N,,F,4981,,500.0,Homo sapiens,1,,,A-431
,17226,1,BAO_0000219,In vitro inhibition of A431 (human carcinoma) cell basal growth.,80852,,,CHEMBL620836,Expert,9606.0,,N,,F,4982,,500.0,Homo sapiens,1,,,A-431
,6828,1,BAO_0000219,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,80852,,,CHEMBL620837,Intermediate,9606.0,,N,,F,4983,,500.0,Homo sapiens,1,,,A-431
,12314,1,BAO_0000219,In vitro cytotoxicity against epidermoid carcinoma cell line,80852,,,CHEMBL621017,Intermediate,9606.0,,N,,F,4984,,500.0,Homo sapiens,1,,,A-431
,13412,9,BAO_0000218,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",9,,,CHEMBL621018,Expert,9606.0,,D,,F,4985,,500.0,Homo sapiens,1,,,A-431
,13299,1,BAO_0000219,Antiproliferative activity of compound was measured on human tumor cell line A431.,80852,,,CHEMBL621019,Intermediate,9606.0,,N,,F,4986,,500.0,Homo sapiens,1,,,A-431
,17420,1,BAO_0000219,Antiproliferative effect of compound on A431 cell line expressing mutant p53,80852,,,CHEMBL621020,Intermediate,9606.0,,N,,F,4987,,500.0,Homo sapiens,1,,,A-431
,13678,1,BAO_0000219,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,80852,,,CHEMBL621021,Intermediate,9606.0,,N,,F,4988,,500.0,Homo sapiens,1,,,A-431
,14171,8,BAO_0000219,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,9,,,CHEMBL621022,Expert,,,H,,F,4989,,500.0,,1,,,A-431
,6333,1,BAO_0000219,Tested for antiproliferative activity against human A431 cells,80852,,,CHEMBL621023,Expert,9606.0,,N,,F,4990,,500.0,Homo sapiens,1,,,A-431
,2356,9,BAO_0000219,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,9,,,CHEMBL621024,Expert,9606.0,,D,,F,4991,,500.0,Homo sapiens,1,,,A-431
,15578,1,BAO_0000219,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,80852,,,CHEMBL621025,Expert,9606.0,,N,,F,4992,,500.0,Homo sapiens,1,,,A-431
,5126,1,BAO_0000219,Inhibition of A431 cell proliferation,80852,,,CHEMBL621026,Expert,9606.0,,N,,F,4993,,500.0,Homo sapiens,1,,,A-431
,6844,1,BAO_0000219,Cytotoxic effect on A431 human epidermoid carcinoma cells,80852,,,CHEMBL621027,Expert,9606.0,,N,,F,4994,,500.0,Homo sapiens,1,,,A-431
,6844,1,BAO_0000219,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),80852,,,CHEMBL876397,Expert,9606.0,,N,,F,4995,,500.0,Homo sapiens,1,,,A-431
,4925,1,BAO_0000219,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,80852,,,CHEMBL883797,Intermediate,9606.0,,N,,F,4996,,500.0,Homo sapiens,1,,,A-431
,4925,1,BAO_0000219,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,80852,,,CHEMBL621028,Intermediate,9606.0,,N,,F,4997,,500.0,Homo sapiens,1,,,A-431
,13978,1,BAO_0000219,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,80852,,,CHEMBL621029,Intermediate,9606.0,,N,,F,4998,,500.0,Homo sapiens,1,,,A-431
,16786,1,BAO_0000219,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,80852,,,CHEMBL621030,Intermediate,9606.0,,N,,F,4999,,500.0,Homo sapiens,1,,,A-431
,13412,8,BAO_0000219,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,9,,,CHEMBL621147,Expert,,,H,,F,5000,,500.0,,1,,,A-431
,17824,1,BAO_0000218,In vivo antiproliferative activity against A431 cell line,80852,,,CHEMBL621148,Intermediate,9606.0,,N,,F,5001,,500.0,Homo sapiens,1,,,A-431
,12751,9,BAO_0000219,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,9,,,CHEMBL621149,Expert,9606.0,,D,,F,5002,,500.0,Homo sapiens,1,,,A-431
,12380,1,BAO_0000219,Inhibition of A431 human epidermoid carcinoma cell proliferation,80852,,,CHEMBL621150,Expert,9606.0,,N,,F,5003,,500.0,Homo sapiens,1,,,A-431
,4959,9,BAO_0000219,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,9,,,CHEMBL621151,Expert,9606.0,,D,,F,5004,,500.0,Homo sapiens,1,,,A-431
,6333,1,BAO_0000219,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),80852,,,CHEMBL621152,Intermediate,9606.0,,N,,F,5005,,500.0,Homo sapiens,1,,,A-431
,6333,1,BAO_0000219,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),80852,,,CHEMBL621153,Intermediate,9606.0,,N,,F,5006,,500.0,Homo sapiens,1,,,A-431
,6333,1,BAO_0000219,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),80852,,,CHEMBL884000,Intermediate,9606.0,,N,,F,5007,,500.0,Homo sapiens,1,,,A-431
,5296,9,BAO_0000019,Inhibition of EGFR overexpressing A431 cell proliferation,9,,,CHEMBL621154,Expert,9606.0,,D,,F,5008,,,Homo sapiens,1,,,
,12624,1,BAO_0000219,Inhibition of A431 cell proliferation,80852,,,CHEMBL621155,Expert,9606.0,,N,,F,5009,,500.0,Homo sapiens,1,,,A-431
,14926,9,BAO_0000219,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,9,,,CHEMBL621156,Expert,9606.0,,D,,F,5010,,500.0,Homo sapiens,1,,,A-431
,14926,9,BAO_0000219,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",9,,,CHEMBL621157,Expert,9606.0,,D,,F,5011,,500.0,Homo sapiens,1,,,A-431
,14926,8,BAO_0000219,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),9,,,CHEMBL621158,Expert,,,H,,F,5012,,500.0,,1,,,A-431
,15144,1,BAO_0000219,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,80852,,,CHEMBL621159,Intermediate,9606.0,,N,,F,5013,,500.0,Homo sapiens,1,,,A-431
,15144,1,BAO_0000219,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,80852,,,CHEMBL621160,Intermediate,9606.0,,N,,F,5014,,500.0,Homo sapiens,1,,,A-431
,5245,1,BAO_0000219,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,80852,,,CHEMBL621161,Intermediate,9606.0,,N,,F,5015,,500.0,Homo sapiens,1,,,A-431
,5245,1,BAO_0000219,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,80852,,,CHEMBL621162,Intermediate,9606.0,,N,,F,5016,,500.0,Homo sapiens,1,,,A-431
,5245,1,BAO_0000219,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,80852,,,CHEMBL621163,Intermediate,9606.0,,N,,F,5017,,500.0,Homo sapiens,1,,,A-431
,5245,1,BAO_0000219,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,80852,,,CHEMBL621164,Intermediate,9606.0,,N,,F,5018,,500.0,Homo sapiens,1,,,A-431
,5245,1,BAO_0000219,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,80852,,,CHEMBL621165,Intermediate,9606.0,,N,,F,5019,,500.0,Homo sapiens,1,,,A-431
,5922,0,BAO_0000019,Half-life period in cynomolgus monkey,22224,,,CHEMBL619159,Autocuration,9527.0,,U,,A,5020,,,Cercopithecidae,1,,,
,1116,0,BAO_0000366,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",22224,In vitro,Plasma,CHEMBL619160,Autocuration,9527.0,,U,,A,5021,,,Cercopithecidae,1,,1969.0,
,17853,0,BAO_0000218,Longer half-life in monkey (i.v.) at 0.5 mpk,22224,In vivo,,CHEMBL619161,Autocuration,9527.0,,U,,A,5022,,,Cercopithecidae,1,,,
,993,0,BAO_0000366,Plasma half life in monkey,22224,,Plasma,CHEMBL619162,Autocuration,9527.0,,U,,A,5023,,,Cercopithecidae,1,,1969.0,
,4514,0,BAO_0000366,Plasma half-life in rhesus monkey,22224,,Plasma,CHEMBL619163,Autocuration,9527.0,,U,,A,5024,,,Cercopithecidae,1,,1969.0,
,5334,0,BAO_0000218,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),22224,In vivo,Plasma,CHEMBL619164,Autocuration,9527.0,,U,,A,5025,,,Cercopithecidae,1,,1969.0,
,5334,0,BAO_0000218,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),22224,In vivo,Plasma,CHEMBL619320,Autocuration,9527.0,,U,,A,5026,,,Cercopithecidae,1,,1969.0,
,4578,0,BAO_0000218,Tested for half life upon iv administration to african green monkey,22224,In vivo,,CHEMBL619321,Autocuration,9527.0,,U,,A,5027,,,Cercopithecidae,1,,,
,2661,0,BAO_0000218,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,22224,In vivo,,CHEMBL873336,Autocuration,9527.0,,U,,A,5028,,,Cercopithecidae,1,,,
,5355,0,BAO_0000218,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,22224,In vivo,,CHEMBL619322,Autocuration,9527.0,,U,,A,5029,,,Cercopithecidae,1,,,
,5355,0,BAO_0000218,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,22224,In vivo,,CHEMBL619323,Autocuration,9527.0,,U,,A,5030,,,Cercopithecidae,1,,,
,5355,0,BAO_0000218,The time for peak concentration value after oral administration in cynomolgus monkeys,22224,In vivo,,CHEMBL619324,Autocuration,9527.0,,U,,A,5031,,,Cercopithecidae,1,,,
,11271,0,BAO_0000019,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,22224,,,CHEMBL619325,Autocuration,9527.0,,U,,A,5032,,,Cercopithecidae,1,,,
,11271,0,BAO_0000019,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,22224,,,CHEMBL876411,Autocuration,9527.0,,U,,A,5033,,,Cercopithecidae,1,,,
,11271,0,BAO_0000019,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,22224,,,CHEMBL619326,Autocuration,9527.0,,U,,A,5034,,,Cercopithecidae,1,,,
,11271,0,BAO_0000019,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,22224,,,CHEMBL619327,Autocuration,9527.0,,U,,A,5035,,,Cercopithecidae,1,,,
,11271,0,BAO_0000019,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,22224,,,CHEMBL619328,Autocuration,9527.0,,U,,A,5036,,,Cercopithecidae,1,,,
,11271,0,BAO_0000019,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,22224,,,CHEMBL619329,Autocuration,9527.0,,U,,A,5037,,,Cercopithecidae,1,,,
,11271,0,BAO_0000019,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,22224,,,CHEMBL619330,Autocuration,9527.0,,U,,A,5038,,,Cercopithecidae,1,,,
,11271,0,BAO_0000019,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,22224,,,CHEMBL619331,Autocuration,9527.0,,U,,A,5039,,,Cercopithecidae,1,,,
,11271,0,BAO_0000019,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,22224,,,CHEMBL619332,Autocuration,9527.0,,U,,A,5040,,,Cercopithecidae,1,,,
,11271,0,BAO_0000019,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,22224,,,CHEMBL619333,Autocuration,9527.0,,U,,A,5041,,,Cercopithecidae,1,,,
,11271,0,BAO_0000019,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,22224,,,CHEMBL619334,Autocuration,9527.0,,U,,A,5042,,,Cercopithecidae,1,,,
,11271,0,BAO_0000019,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,22224,,,CHEMBL619335,Autocuration,9527.0,,U,,A,5043,,,Cercopithecidae,1,,,
,11271,0,BAO_0000019,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,22224,,,CHEMBL619336,Autocuration,9527.0,,U,,A,5044,,,Cercopithecidae,1,,,
,11271,0,BAO_0000019,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,22224,,,CHEMBL619337,Autocuration,9527.0,,U,,A,5045,,,Cercopithecidae,1,,,
,11271,0,BAO_0000019,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,22224,,,CHEMBL619338,Autocuration,9527.0,,U,,A,5046,,,Cercopithecidae,1,,,
,11271,0,BAO_0000019,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,22224,,,CHEMBL619339,Autocuration,9527.0,,U,,A,5047,,,Cercopithecidae,1,,,
,5809,1,BAO_0000218,Bioavailability in rat (cannulated) (dose 2 mg/kg),50597,In vivo,,CHEMBL619340,Intermediate,10116.0,,N,,A,5048,,,Rattus norvegicus,1,,,
,17720,1,BAO_0000218,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,In vivo,Plasma,CHEMBL873496,Intermediate,10116.0,,N,,A,5049,,,Rattus norvegicus,1,,1969.0,
,3546,1,BAO_0000218,AUC value in rat after IV administration at a dose of 10 mg/kg,50597,,Plasma,CHEMBL619341,Intermediate,10116.0,,N,,A,5050,,,Rattus norvegicus,1,,1969.0,
,3546,1,BAO_0000218,AUC value in rat after oral administration at a dose of 10 mg/kg,50597,,Plasma,CHEMBL619342,Intermediate,10116.0,,N,,A,5051,,,Rattus norvegicus,1,,1969.0,
,3546,1,BAO_0000218,Cmax value in rat after oral administration at a dose of 10 mg/kg,50597,In vivo,,CHEMBL619343,Intermediate,10116.0,,N,,A,5052,,,Rattus norvegicus,1,,,
,3546,1,BAO_0000218,Bioavailability in rat after oral administration at a dose of 10 mg/kg,50597,In vivo,,CHEMBL619344,Intermediate,10116.0,,N,,A,5053,,,Rattus norvegicus,1,,,
,3546,1,BAO_0000218,Tmax value in rat after oral administration at a dose of 10 mg/kg,50597,In vivo,,CHEMBL619345,Intermediate,10116.0,,N,,A,5054,,,Rattus norvegicus,1,,,
,3546,1,BAO_0000218,Vc value in rat after IV administration at a dose of 10 mg/kg,50597,,,CHEMBL619346,Intermediate,10116.0,,N,,A,5055,,,Rattus norvegicus,1,,,
,3546,1,BAO_0000218,Half life period in rat after IV administration at a dose of 10 mg/kg,50597,In vivo,,CHEMBL619347,Intermediate,10116.0,,N,,A,5056,,,Rattus norvegicus,1,,,
,10625,0,BAO_0000019,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,22224,,,CHEMBL619348,Autocuration,9557.0,,U,,A,5057,,,Papio hamadryas,1,,,
,10625,0,BAO_0000019,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),22224,,,CHEMBL619349,Autocuration,9557.0,,U,,A,5058,,,Papio hamadryas,1,,,
,10625,0,BAO_0000019,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),22224,,,CHEMBL619350,Autocuration,9557.0,,U,,A,5059,,,Papio hamadryas,1,,,
,10625,0,BAO_0000019,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,22224,,,CHEMBL619351,Autocuration,9557.0,,U,,A,5060,,,Papio hamadryas,1,,,
,10625,0,BAO_0000019,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,22224,,,CHEMBL875953,Autocuration,9557.0,,U,,A,5061,,,Papio hamadryas,1,,,
,10625,0,BAO_0000019,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,22224,,,CHEMBL621716,Autocuration,9557.0,,U,,A,5062,,,Papio hamadryas,1,,,
,10625,0,BAO_0000019,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,22224,,,CHEMBL621717,Autocuration,9557.0,,U,,A,5063,,,Papio hamadryas,1,,,
,10625,0,BAO_0000019,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,22224,,,CHEMBL621718,Autocuration,9557.0,,U,,A,5064,,,Papio hamadryas,1,,,
,3510,0,BAO_0000019,Area under curve after 1 mpk peroral administration to beagles,22224,,,CHEMBL621719,Autocuration,9615.0,,U,,A,5065,,,beagle,1,,,
,3510,0,BAO_0000019,Area under curve after 2 mpk peroral administration to beagles,22224,,,CHEMBL621720,Autocuration,9615.0,,U,,A,5066,,,beagle,1,,,
,3510,0,BAO_0000218,Cmax value after 1 mpk peroral administration to beagles,22224,In vivo,,CHEMBL621721,Autocuration,9615.0,,U,,A,5067,,,beagle,1,,,
,7766,0,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,22224,,Urine,CHEMBL621722,Autocuration,9606.0,,U,,A,5068,,,Homo sapiens,1,,1088.0,
,7766,0,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,22224,,Urine,CHEMBL621723,Autocuration,9606.0,,U,,A,5069,,,Homo sapiens,1,,1088.0,
,7766,0,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,22224,,Urine,CHEMBL621724,Autocuration,9606.0,,U,,A,5070,,,Homo sapiens,1,,1088.0,
,7766,0,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,22224,,Urine,CHEMBL623443,Autocuration,9606.0,,U,,A,5071,,,Homo sapiens,1,,1088.0,
,7766,0,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,22224,,Urine,CHEMBL623444,Autocuration,9606.0,,U,,A,5072,,,Homo sapiens,1,,1088.0,
,7766,0,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,22224,,Urine,CHEMBL623445,Autocuration,9606.0,,U,,A,5073,,,Homo sapiens,1,,1088.0,
,7766,0,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,22224,,Urine,CHEMBL623446,Autocuration,9606.0,,U,,A,5074,,,Homo sapiens,1,,1088.0,
,16643,0,BAO_0000251,Metabolic stability observed at 30 min after administration in human liver microsomes,22224,,Liver,CHEMBL623447,Autocuration,9606.0,Microsomes,U,,A,5075,,,Homo sapiens,1,,2107.0,
,6852,0,BAO_0000019,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,22224,,,CHEMBL623448,Autocuration,9606.0,,U,,A,5076,,,Homo sapiens,1,,,
,6852,0,BAO_0000019,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,22224,,,CHEMBL623449,Autocuration,9606.0,,U,,A,5077,,,Homo sapiens,1,,,
,6852,0,BAO_0000019,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,22224,,,CHEMBL623450,Autocuration,9606.0,,U,,A,5078,,,Homo sapiens,1,,,
,6567,0,BAO_0000251,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",22224,,Liver,CHEMBL623451,Autocuration,9606.0,Microsomes,U,,A,5079,,,Homo sapiens,1,,2107.0,
,6570,0,BAO_0000019,Metabolic stability (% remaining at 30 mins) in human S9.,22224,,,CHEMBL623452,Autocuration,9606.0,,U,,A,5080,,,Homo sapiens,1,,,
,6570,0,BAO_0000019,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,22224,,,CHEMBL623453,Autocuration,9606.0,,U,,A,5081,,,Homo sapiens,1,,,
,5237,0,BAO_0000251,Percent parent compound remaining after 20 min incubation with human liver microsomes,22224,,Liver,CHEMBL623454,Autocuration,9606.0,Microsomes,U,,A,5082,,,Homo sapiens,1,,2107.0,
,5237,0,BAO_0000251,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,22224,,Liver,CHEMBL623455,Autocuration,9606.0,Microsomes,U,,A,5083,,,Homo sapiens,1,,2107.0,
,5237,0,BAO_0000251,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,22224,,Liver,CHEMBL624371,Autocuration,9606.0,Microsomes,U,,A,5084,,,Homo sapiens,1,,2107.0,
,5202,0,BAO_0000218,First pass metabolism and metabolic bioavailability using human hepatic microsomes,22224,,,CHEMBL624372,Autocuration,9606.0,,U,,A,5085,,,Homo sapiens,1,,,
,5481,0,BAO_0000019,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,22224,,,CHEMBL624373,Autocuration,9606.0,,U,,A,5086,,,Homo sapiens,1,,,
,5481,0,BAO_0000019,Percent remaining in human plasma after incubation for 60 min at 37 C.,22224,,,CHEMBL624374,Autocuration,9606.0,,U,,A,5087,,,Homo sapiens,1,,,
,3956,0,BAO_0000019,The percent remaining in human plasma after 30 min was determined,22224,,,CHEMBL624556,Autocuration,9606.0,,U,,A,5088,,,Homo sapiens,1,,,
,5074,0,BAO_0000366,Conversion rate of the prodrug in human plasma,22224,,Plasma,CHEMBL624557,Autocuration,9606.0,,U,,A,5089,,,Homo sapiens,1,,1969.0,
,5074,0,BAO_0000366,Conversion rate of the prodrug in human plasma; ND means no data,22224,,Plasma,CHEMBL624558,Autocuration,9606.0,,U,,A,5090,,,Homo sapiens,1,,1969.0,
,4727,0,BAO_0000221,Half life of compound was determined in human blood,22224,,Blood,CHEMBL624559,Autocuration,9606.0,,U,,A,5091,,,Homo sapiens,1,,178.0,
,5965,0,BAO_0000019,Half life of compound was determined in man with once daily dosing,22224,,,CHEMBL624560,Autocuration,9606.0,,U,,A,5092,,,Homo sapiens,1,,,
,5732,0,BAO_0000251,Half life in human microsomes,22224,In vitro,,CHEMBL624561,Autocuration,9606.0,Microsomes,U,,A,5093,,,Homo sapiens,1,,,
,5819,0,BAO_0000366,Half life in human plasma,22224,,Plasma,CHEMBL624562,Autocuration,9606.0,,U,,A,5094,,,Homo sapiens,1,,1969.0,
,5819,0,BAO_0000366,Half life in human plasma; Not detected,22224,,Plasma,CHEMBL624563,Autocuration,9606.0,,U,,A,5095,,,Homo sapiens,1,,1969.0,
,1916,0,BAO_0000218,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,22224,In vivo,,CHEMBL624564,Autocuration,9606.0,,U,,A,5096,,,Homo sapiens,1,,,
,6597,0,BAO_0000251,Half-life for oxidative metabolic stability was determined using rat liver microsomes,22224,In vitro,Liver,CHEMBL624565,Autocuration,9606.0,Microsomes,U,,A,5097,,,Homo sapiens,1,,2107.0,
,5229,0,BAO_0000366,Half-life in human plasma,22224,,Plasma,CHEMBL875152,Autocuration,9606.0,,U,,A,5098,,,Homo sapiens,1,,1969.0,
,5229,0,BAO_0000366,Half-life of the parent prodrug in plasma,22224,,Plasma,CHEMBL624566,Autocuration,9606.0,,U,,A,5099,,,Homo sapiens,1,,1969.0,
,2192,0,BAO_0000366,In vitro half life in human plasma was determined,22224,In vitro,Plasma,CHEMBL873805,Autocuration,9606.0,,U,,A,5100,,,Homo sapiens,1,,1969.0,
,3032,0,BAO_0000251,The compound was tested In Vitro for half life in human liver microsomes.,22224,In vitro,Liver,CHEMBL624567,Autocuration,9606.0,Microsomes,U,,A,5101,,,Homo sapiens,1,,2107.0,
,1916,0,BAO_0000218,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,22224,In vivo,,CHEMBL624568,Autocuration,9606.0,,U,,A,5102,,,Homo sapiens,1,,,
,17716,0,BAO_0000218,Observed volume of distribution,22224,In vivo,,CHEMBL624569,Autocuration,9606.0,,U,,A,5103,,,Homo sapiens,1,,,
,15778,0,BAO_0000218,Oral bioavailability in human,22224,In vivo,,CHEMBL624570,Autocuration,9606.0,,U,,A,5104,,,Homo sapiens,1,,,
,17313,0,BAO_0000019,Tested for human plasma protein binding of the compound,22224,,,CHEMBL624571,Autocuration,9606.0,,U,,A,5105,,,Homo sapiens,1,,,
,4231,0,BAO_0000019,"First order rate constant, k was determined in human plasma",22224,,,CHEMBL624572,Autocuration,9606.0,,U,,A,5106,,,Homo sapiens,1,,,
,4755,0,BAO_0000019,Observed rate constant in 80% human plasma at 37 degree Centigrade,22224,,,CHEMBL624573,Autocuration,9606.0,,U,,A,5107,,,Homo sapiens,1,,,
,4755,0,BAO_0000019,Observed rate constant in 80% human plasma at 37 degree Centigrade,22224,,,CHEMBL875153,Autocuration,9606.0,,U,,A,5108,,,Homo sapiens,1,,,
,16907,0,BAO_0000251,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,22224,,Liver,CHEMBL624574,Autocuration,9606.0,Microsomes,U,,A,5109,,,Homo sapiens,1,,2107.0,
,10839,0,BAO_0000019,The compound was tested for the plasma binding in human,22224,,,CHEMBL624575,Autocuration,9606.0,,U,,A,5110,,,Homo sapiens,1,,,
,10839,0,BAO_0000019,Plasma protein binding (human),22224,,,CHEMBL624576,Autocuration,9606.0,,U,,A,5111,,,Homo sapiens,1,,,
,3199,0,BAO_0000251,Compound was evaluated for half-life in human liver microsomes,22224,In vitro,Liver,CHEMBL624577,Autocuration,9606.0,Microsomes,U,,A,5112,,,Homo sapiens,1,,2107.0,
,1345,0,BAO_0000221,Half life measured in vitro for its stability in human blood,22224,In vitro,Blood,CHEMBL624578,Autocuration,9606.0,,U,,A,5113,,,Homo sapiens,1,,178.0,
,4297,0,BAO_0000019,Half life in human serum,22224,,Serum,CHEMBL622796,Autocuration,9606.0,,U,,A,5114,,,Homo sapiens,1,,1977.0,
,4297,0,BAO_0000019,Half life in human serum; ND=not determined,22224,,Serum,CHEMBL622797,Autocuration,9606.0,,U,,A,5115,,,Homo sapiens,1,,1977.0,
,4297,0,BAO_0000019,Half life were determined in CEM-SS cell extract in decomposition step 1,22224,,,CHEMBL622798,Autocuration,9606.0,,U,,A,5116,,,Homo sapiens,1,,,
,4297,0,BAO_0000019,Half life were determined in CEM-SS cell extract in decomposition step 2,22224,,,CHEMBL622799,Autocuration,9606.0,,U,,A,5117,,,Homo sapiens,1,,,
,4231,0,BAO_0000366,Half life of the in human plasma,22224,,Plasma,CHEMBL622800,Autocuration,9606.0,,U,,A,5118,,,Homo sapiens,1,,1969.0,
,5633,0,BAO_0000220,Half life period in human hepatic S9 fraction was determined,22224,In vitro,,CHEMBL622801,Autocuration,9606.0,S9,U,,A,5119,,,Homo sapiens,1,,,
,5633,0,BAO_0000251,Half life period in human liver microsome was determined,22224,In vitro,Liver,CHEMBL622802,Autocuration,9606.0,Microsomes,U,,A,5120,,,Homo sapiens,1,,2107.0,
,17791,0,BAO_0000019,Half life period was determined; 6-7,22224,,,CHEMBL622803,Autocuration,9606.0,,U,,A,5121,,,Homo sapiens,1,,,
,17791,0,BAO_0000019,Half life period was evaluated in human,22224,,,CHEMBL875154,Autocuration,9606.0,,U,,A,5122,,,Homo sapiens,1,,,
,3160,0,BAO_0000366,Half life time in human plasma,22224,,Plasma,CHEMBL622804,Autocuration,9606.0,,U,,A,5123,,,Homo sapiens,1,,1969.0,
,16438,1,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,In vivo,Brain,CHEMBL622805,Intermediate,10090.0,,N,,A,5124,,,Mus musculus,1,,955.0,
,16438,1,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,In vivo,Heart,CHEMBL622611,Intermediate,10090.0,,N,,A,5125,,,Mus musculus,1,,948.0,
,16438,1,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,In vivo,Heart,CHEMBL622612,Intermediate,10090.0,,N,,A,5126,,,Mus musculus,1,,948.0,
,16438,1,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,In vivo,Kidney,CHEMBL875160,Intermediate,10090.0,,N,,A,5127,,,Mus musculus,1,,2113.0,
,16438,1,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",50594,In vivo,Kidney,CHEMBL622613,Intermediate,10090.0,,N,,A,5128,,,Mus musculus,1,,2113.0,
,16438,1,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,In vivo,Kidney,CHEMBL622614,Intermediate,10090.0,,N,,A,5129,,,Mus musculus,1,,2113.0,
,16438,1,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,In vivo,Liver,CHEMBL622615,Intermediate,10090.0,,N,,A,5130,,,Mus musculus,1,,2107.0,
,16438,1,BAO_0000218,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,50594,In vivo,Liver,CHEMBL622616,Intermediate,10090.0,,N,,A,5131,,,Mus musculus,1,,2107.0,
,16438,1,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,In vivo,Liver,CHEMBL622617,Intermediate,10090.0,,N,,A,5132,,,Mus musculus,1,,2107.0,
,16438,1,BAO_0000218,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,50594,In vivo,Spleen,CHEMBL622618,Intermediate,10090.0,,N,,A,5133,,,Mus musculus,1,,2106.0,
,16438,1,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",50594,In vivo,Spleen,CHEMBL622619,Intermediate,10090.0,,N,,A,5134,,,Mus musculus,1,,2106.0,
,16438,1,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,In vivo,Spleen,CHEMBL622620,Intermediate,10090.0,,N,,A,5135,,,Mus musculus,1,,2106.0,
,16438,1,BAO_0000218,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,In vivo,Brain,CHEMBL622621,Intermediate,10090.0,,N,,A,5136,,,Mus musculus,1,,955.0,
,16438,1,BAO_0000218,Biodistribution of compound (oxidized form) in blood tissue,50594,In vivo,Blood,CHEMBL622622,Intermediate,10090.0,,N,,A,5137,,,Mus musculus,1,,178.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,In vivo,Blood,CHEMBL622623,Intermediate,10090.0,,N,,A,5138,,,Mus musculus,1,,178.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",50594,In vivo,Blood,CHEMBL622624,Intermediate,10090.0,,N,,A,5139,,,Mus musculus,1,,178.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,In vivo,Blood,CHEMBL622625,Intermediate,10090.0,,N,,A,5140,,,Mus musculus,1,,178.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,In vivo,Blood,CHEMBL622626,Intermediate,10090.0,,N,,A,5141,,,Mus musculus,1,,178.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,In vivo,Blood,CHEMBL622627,Intermediate,10090.0,,N,,A,5142,,,Mus musculus,1,,178.0,
,16438,1,BAO_0000218,Biodistribution of compound (oxidized form) in brain tissue of mice,50594,In vivo,Brain,CHEMBL622628,Intermediate,10090.0,,N,,A,5143,,,Mus musculus,1,,955.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,In vivo,Brain,CHEMBL622629,Intermediate,10090.0,,N,,A,5144,,,Mus musculus,1,,955.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",50594,In vivo,Brain,CHEMBL622630,Intermediate,10090.0,,N,,A,5145,,,Mus musculus,1,,955.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,In vivo,Brain,CHEMBL622631,Intermediate,10090.0,,N,,A,5146,,,Mus musculus,1,,955.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,In vivo,Brain,CHEMBL622632,Intermediate,10090.0,,N,,A,5147,,,Mus musculus,1,,955.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",50594,In vivo,Brain,CHEMBL622633,Intermediate,10090.0,,N,,A,5148,,,Mus musculus,1,,955.0,
,16438,1,BAO_0000218,Biodistribution of compound (oxidized form) in heart tissue of mice,50594,In vivo,Heart,CHEMBL622634,Intermediate,10090.0,,N,,A,5149,,,Mus musculus,1,,948.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,In vivo,Heart,CHEMBL622635,Intermediate,10090.0,,N,,A,5150,,,Mus musculus,1,,948.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,In vivo,Heart,CHEMBL875161,Intermediate,10090.0,,N,,A,5151,,,Mus musculus,1,,948.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",50594,In vivo,Heart,CHEMBL622636,Intermediate,10090.0,,N,,A,5152,,,Mus musculus,1,,948.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,In vivo,Heart,CHEMBL623335,Intermediate,10090.0,,N,,A,5153,,,Mus musculus,1,,948.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,In vivo,Heart,CHEMBL623336,Intermediate,10090.0,,N,,A,5154,,,Mus musculus,1,,948.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,In vivo,Kidney,CHEMBL623337,Intermediate,10090.0,,N,,A,5155,,,Mus musculus,1,,2113.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",50594,In vivo,Kidney,CHEMBL623338,Intermediate,10090.0,,N,,A,5156,,,Mus musculus,1,,2113.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",50594,In vivo,Kidney,CHEMBL623339,Intermediate,10090.0,,N,,A,5157,,,Mus musculus,1,,2113.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,In vivo,Kidney,CHEMBL623524,Intermediate,10090.0,,N,,A,5158,,,Mus musculus,1,,2113.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,In vivo,Kidney,CHEMBL623525,Intermediate,10090.0,,N,,A,5159,,,Mus musculus,1,,2113.0,
,16438,1,BAO_0000218,Biodistribution of compound (oxidized form) in liver tissue,50594,In vivo,Liver,CHEMBL623526,Intermediate,10090.0,,N,,A,5160,,,Mus musculus,1,,2107.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,In vivo,Liver,CHEMBL623527,Intermediate,10090.0,,N,,A,5161,,,Mus musculus,1,,2107.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,In vivo,Liver,CHEMBL623528,Intermediate,10090.0,,N,,A,5162,,,Mus musculus,1,,2107.0,
,5245,1,BAO_0000219,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,80852,,,CHEMBL624615,Intermediate,9606.0,,N,,F,5163,,500.0,Homo sapiens,1,,,A-431
,5245,1,BAO_0000219,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,80852,,,CHEMBL621672,Intermediate,9606.0,,N,,F,5164,,500.0,Homo sapiens,1,,,A-431
,16289,1,BAO_0000218,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",80852,,,CHEMBL621673,Expert,,,N,,F,5165,,500.0,,1,,,A-431
,16289,1,BAO_0000218,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",80852,,,CHEMBL621674,Expert,,,N,,F,5166,,500.0,,1,,,A-431
,16093,9,BAO_0000219,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,9,,,CHEMBL884002,Expert,9606.0,,D,,F,5167,,500.0,Homo sapiens,1,,,A-431
,16825,1,BAO_0000219,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",80852,,,CHEMBL621850,Intermediate,9606.0,,N,,F,5168,,500.0,Homo sapiens,1,,,A-431
,4848,1,BAO_0000219,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,80852,,,CHEMBL621851,Intermediate,9606.0,,N,,F,5169,,500.0,Homo sapiens,1,,,A-431
,14827,9,BAO_0000219,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,9,,,CHEMBL621852,Expert,9606.0,,D,,F,5170,,500.0,Homo sapiens,1,,,A-431
,14827,9,BAO_0000219,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,9,,,CHEMBL621853,Expert,9606.0,,D,,F,5171,,500.0,Homo sapiens,1,,,A-431
,16289,1,BAO_0000218,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",80852,,,CHEMBL621854,Expert,,,N,,F,5172,,500.0,,1,,,A-431
,16289,1,BAO_0000218,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",80852,,,CHEMBL621855,Expert,,,N,,F,5173,,500.0,,1,,,A-431
,16289,1,BAO_0000218,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",80852,,,CHEMBL623724,Expert,,,N,,F,5174,,500.0,,1,,,A-431
,16289,1,BAO_0000218,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",80852,,,CHEMBL623725,Expert,,,N,,F,5175,,500.0,,1,,,A-431
,16289,1,BAO_0000218,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",80852,,,CHEMBL623726,Expert,,,N,,F,5176,,500.0,,1,,,A-431
,16289,9,BAO_0000219,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",9,,,CHEMBL623727,Expert,9606.0,,D,,F,5177,,500.0,Homo sapiens,1,,,A-431
,16289,8,BAO_0000219,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,9,,,CHEMBL623728,Expert,,,H,,F,5178,,500.0,,1,,,A-431
,16289,1,BAO_0000218,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",80852,,,CHEMBL623729,Expert,,,N,,F,5179,,500.0,,1,,,A-431
,16289,1,BAO_0000218,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",80852,,,CHEMBL623730,Expert,,,N,,F,5180,,500.0,,1,,,A-431
,16289,1,BAO_0000218,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",80852,,,CHEMBL623731,Expert,,,N,,F,5181,,500.0,,1,,,A-431
,14555,1,BAO_0000218,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",80852,,,CHEMBL623732,Expert,10090.0,,N,,F,5182,,500.0,Mus musculus,1,,,A-431
,14555,1,BAO_0000218,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",80852,,,CHEMBL623733,Expert,10090.0,,N,,F,5183,,500.0,Mus musculus,1,,,A-431
,14555,1,BAO_0000218,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",80852,,,CHEMBL623734,Expert,10090.0,,N,,F,5184,,500.0,Mus musculus,1,,,A-431
,14555,1,BAO_0000218,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",80852,,,CHEMBL623735,Expert,10090.0,,N,,F,5185,,500.0,Mus musculus,1,,,A-431
,1937,1,BAO_0000219,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,80852,,,CHEMBL623736,Expert,9606.0,,N,,F,5186,,500.0,Homo sapiens,1,,,A-431
,13739,1,BAO_0000219,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,80852,,,CHEMBL623737,Intermediate,9606.0,,N,,F,5187,,500.0,Homo sapiens,1,,,A-431
,3558,1,BAO_0000219,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,80852,,,CHEMBL623738,Intermediate,9606.0,,N,,F,5188,,500.0,Homo sapiens,1,,,A-431
,3558,1,BAO_0000219,Dose giving a 50% decrease in the living cell number (A437 cells),80852,,,CHEMBL875168,Intermediate,9606.0,,N,,F,5189,,500.0,Homo sapiens,1,,,A-431
,17686,1,BAO_0000219,In vitro inhibitory concentration against proliferation of A459 cell line.,80682,,,CHEMBL623739,Expert,9606.0,,N,,F,5190,,646.0,Homo sapiens,1,,,A549
,5305,1,BAO_0000219,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,80682,,,CHEMBL623740,Intermediate,9606.0,,N,,F,5191,,646.0,Homo sapiens,1,,,A549
,3614,1,BAO_0000219,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,80682,,,CHEMBL624424,Intermediate,9606.0,,N,,F,5192,,646.0,Homo sapiens,1,,,A549
,17229,1,BAO_0000219,In vitro antitumor activity against renal A498 tumor cell lines,80021,,,CHEMBL624425,Intermediate,9606.0,,N,,F,5193,,624.0,Homo sapiens,1,,,A498
,15935,1,BAO_0000219,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",80021,,,CHEMBL624426,Intermediate,9606.0,,N,,F,5194,,624.0,Homo sapiens,1,,,A498
,15935,1,BAO_0000219,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",80021,,,CHEMBL624427,Intermediate,9606.0,,N,,F,5195,,624.0,Homo sapiens,1,,,A498
,15560,1,BAO_0000219,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,80021,,,CHEMBL624428,Intermediate,9606.0,,N,,F,5196,,624.0,Homo sapiens,1,,,A498
,13891,1,BAO_0000219,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,80021,,,CHEMBL624429,Intermediate,9606.0,,N,,F,5197,,624.0,Homo sapiens,1,,,A498
,13891,1,BAO_0000219,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,80021,,,CHEMBL624620,Intermediate,9606.0,,N,,F,5198,,624.0,Homo sapiens,1,,,A498
,13788,1,BAO_0000219,Cytotoxicity on kidney carcinoma (A-498) cell line,80021,,,CHEMBL624621,Intermediate,9606.0,,N,,F,5199,,624.0,Homo sapiens,1,,,A498
,15403,1,BAO_0000219,Compound was evaluated against Human cell line renal A498,80021,,,CHEMBL624622,Intermediate,9606.0,,N,,F,5200,,624.0,Homo sapiens,1,,,A498
,1009,1,BAO_0000219,Compound was tested for inhibition of A498 human renal cancer cell line,80021,,,CHEMBL624623,Intermediate,9606.0,,N,,F,5201,,624.0,Homo sapiens,1,,,A498
,1043,1,BAO_0000219,Growth inhibitory activity against A498 human cancer cell line,80021,,,CHEMBL874365,Intermediate,9606.0,,N,,F,5202,,624.0,Homo sapiens,1,,,A498
,5858,1,BAO_0000219,In vitro antitumor activity against human renal A498 cell line,80021,,,CHEMBL624624,Intermediate,9606.0,,N,,F,5203,,624.0,Homo sapiens,1,,,A498
,5958,1,BAO_0000219,In vitro cytotoxic activity against renal (A498) cell line,80021,,,CHEMBL624625,Intermediate,9606.0,,N,,F,5204,,624.0,Homo sapiens,1,,,A498
,5506,1,BAO_0000219,In vitro cytotoxic activity against human renal cancer (A498) cell line,80021,,,CHEMBL624626,Intermediate,9606.0,,N,,F,5205,,624.0,Homo sapiens,1,,,A498
,12781,1,BAO_0000219,Tested for cytostatic activity against renal A498 cell line,80021,,,CHEMBL624627,Intermediate,9606.0,,N,,F,5206,,624.0,Homo sapiens,1,,,A498
,14399,1,BAO_0000219,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,80021,,,CHEMBL883157,Intermediate,9606.0,,N,,F,5207,,624.0,Homo sapiens,1,,,A498
,5958,1,BAO_0000219,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,80021,,,CHEMBL624628,Expert,9606.0,,N,,F,5208,,624.0,Homo sapiens,1,,,A498
,3510,0,BAO_0000218,Cmax value after 2 mpk peroral administration to beagles,22224,In vivo,,CHEMBL624629,Autocuration,9615.0,,U,,A,5209,,,beagle,1,,,
,3510,0,BAO_0000218,Bioavailability,22224,In vivo,,CHEMBL623551,Autocuration,9615.0,,U,,A,5210,beagle,,Canis lupus familiaris,1,,,
,3510,0,BAO_0000218,Bioavailability after 1 mpk peroral administration to beagles,22224,In vivo,,CHEMBL623552,Autocuration,9615.0,,U,,A,5211,beagle,,Canis lupus familiaris,1,,,
,3510,0,BAO_0000218,Bioavailability after 2 mpk peroral administration to beagles,22224,In vivo,,CHEMBL623553,Autocuration,9615.0,,U,,A,5212,beagle,,Canis lupus familiaris,1,,,
,3085,0,BAO_0000019,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,22224,,,CHEMBL623554,Autocuration,9913.0,,U,,A,5213,,,Bos taurus,1,,,
,3085,0,BAO_0000019,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,22224,,,CHEMBL623555,Autocuration,9913.0,,U,,A,5214,,,Bos taurus,1,,,
,3085,0,BAO_0000019,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,22224,,,CHEMBL623556,Autocuration,9913.0,,U,,A,5215,,,Bos taurus,1,,,
,9372,0,BAO_0000019,Solubility against bovine alpha-chymotrypsin,22224,,,CHEMBL623557,Autocuration,9913.0,,U,,A,5216,,,Bos taurus,1,,,
,3085,0,BAO_0000019,Rate constant of the bovine serum albumin catalyzed reaction of the compound,22224,,,CHEMBL623558,Autocuration,9913.0,,U,,A,5217,,,Bos taurus,1,,,
,3085,0,BAO_0000019,Rate constant of the bovine serum albumin catalyzed reaction of the compound,22224,,,CHEMBL623559,Autocuration,9913.0,,U,,A,5218,,,Bos taurus,1,,,
,1469,0,BAO_0000221,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,22224,,Spleen,CHEMBL623560,Autocuration,9913.0,,U,,A,5219,,,Bos taurus,1,,2106.0,
,4297,0,BAO_0000019,Half life in culture medium containing 10% of heat inactivated foetal calf serum,22224,,,CHEMBL623561,Autocuration,9913.0,,U,,A,5220,,,Bos taurus,1,,,
,4297,0,BAO_0000019,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,22224,,,CHEMBL623562,Autocuration,9913.0,,U,,A,5221,,,Bos taurus,1,,,
,17585,0,BAO_0000019,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,22224,,,CHEMBL623563,Autocuration,9913.0,,U,,A,5222,,,Bos taurus,1,,,
,1336,0,BAO_0000221,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,22224,,Spleen,CHEMBL623564,Autocuration,9913.0,,U,,A,5223,,,Bos taurus,1,,2106.0,
,3085,0,BAO_0000019,Half life in presence of 2 mg/mL BSA at pH 8.8,22224,,,CHEMBL873806,Autocuration,9913.0,,U,,A,5224,,,Bos taurus,1,,,
,2857,0,BAO_0000019,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,22224,,,CHEMBL623565,Autocuration,9913.0,,U,,A,5225,,,Bos taurus,1,,,
,2857,0,BAO_0000019,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,22224,,,CHEMBL623566,Autocuration,9913.0,,U,,A,5226,,,Bos taurus,1,,,
,2857,0,BAO_0000019,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,22224,,,CHEMBL623567,Autocuration,9913.0,,U,,A,5227,,,Bos taurus,1,,,
,1540,0,BAO_0000019,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),22224,,,CHEMBL623568,Autocuration,9913.0,,U,,A,5228,,,Bos taurus,1,,,
,6316,1,BAO_0000218,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,50588,,Plasma,CHEMBL623569,Intermediate,9615.0,,N,,A,5229,,,Canis lupus familiaris,1,,1969.0,
,17594,1,BAO_0000218,AUC after administration at 100 mg/kg/day in dogs,50588,,Plasma,CHEMBL623570,Intermediate,9615.0,,N,,A,5230,,,Canis lupus familiaris,1,,1969.0,
,4953,1,BAO_0000218,AUC in dog at 0-24 hr by peroral administration at 3 mpk,50588,,Plasma,CHEMBL624254,Intermediate,9615.0,,N,,A,5231,,,Canis lupus familiaris,1,,1969.0,
,16907,1,BAO_0000218,AUC value after 15 mg/kg iv dose in Dogs,50588,,Plasma,CHEMBL624255,Intermediate,9615.0,,N,,A,5232,,,Canis lupus familiaris,1,,1969.0,
,16907,1,BAO_0000218,AUC value after 30 mg/kg po dose in Dogs,50588,,Plasma,CHEMBL624256,Intermediate,9615.0,,N,,A,5233,,,Canis lupus familiaris,1,,1969.0,
,2959,1,BAO_0000218,AUC value after administration of 4 mg/Kg oral dose in dog,50588,,Plasma,CHEMBL624257,Intermediate,9615.0,,N,,A,5234,,,Canis lupus familiaris,1,,1969.0,
,17594,1,BAO_0000218,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,50588,,Plasma,CHEMBL624258,Intermediate,9615.0,,N,,A,5235,,,Canis lupus familiaris,1,,1969.0,
,5356,1,BAO_0000218,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,50588,,,CHEMBL875277,Intermediate,9615.0,,N,,A,5236,,,Canis lupus familiaris,1,,,
,16807,1,BAO_0000218,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,50588,,,CHEMBL622667,Intermediate,9615.0,,N,,A,5237,,,Canis lupus familiaris,1,,,
,4527,1,BAO_0000218,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,50588,,,CHEMBL622668,Intermediate,9615.0,,N,,A,5238,,,Canis lupus familiaris,1,,,
,4527,1,BAO_0000218,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,50588,,,CHEMBL622669,Intermediate,9615.0,,N,,A,5239,,,Canis lupus familiaris,1,,,
,15660,1,BAO_0000218,Area under curve determined in dogs after intravenous administration of 3 mg/kg,50588,,,CHEMBL622670,Intermediate,9615.0,,N,,A,5240,,,Canis lupus familiaris,1,,,
,15660,1,BAO_0000218,Area under curve determined in dogs after oral administration of 10 mg/kg,50588,,,CHEMBL622671,Intermediate,9615.0,,N,,A,5241,,,Canis lupus familiaris,1,,,
,5802,1,BAO_0000218,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,50588,,,CHEMBL622672,Intermediate,9615.0,,N,,A,5242,,,Canis lupus familiaris,1,,,
,3598,1,BAO_0000218,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,,,CHEMBL622673,Expert,9615.0,,N,,A,5243,,,Canis lupus familiaris,1,,,
,3598,1,BAO_0000218,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,50588,,,CHEMBL622674,Expert,9615.0,,N,,A,5244,,,Canis lupus familiaris,1,,,
,5944,1,BAO_0000218,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),50588,,,CHEMBL622675,Intermediate,9615.0,,N,,A,5245,,,Canis lupus familiaris,1,,,
,5944,1,BAO_0000218,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,50588,,,CHEMBL622676,Intermediate,9615.0,,N,,A,5246,,,Canis lupus familiaris,1,,,
,5944,1,BAO_0000218,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),50588,,,CHEMBL622677,Intermediate,9615.0,,N,,A,5247,,,Canis lupus familiaris,1,,,
,5944,1,BAO_0000218,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,50588,,,CHEMBL622678,Intermediate,9615.0,,N,,A,5248,,,Canis lupus familiaris,1,,,
,4186,1,BAO_0000218,Area under curve in dog after administration of 20 mg/kg dose through peroral route,50588,,,CHEMBL622679,Intermediate,9615.0,,N,,A,5249,,,Canis lupus familiaris,1,,,
,5007,1,BAO_0000218,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),50588,,,CHEMBL622680,Intermediate,9615.0,,N,,A,5250,,,Canis lupus familiaris,1,,,
,5668,1,BAO_0000218,Area under curve was determine after peroral administration at 10 mpk in dog,50588,,,CHEMBL622681,Intermediate,9615.0,,N,,A,5251,,,Canis lupus familiaris,1,,,
,5668,1,BAO_0000218,Area under curve was determine after peroral administration at 5 mpk in dog,50588,,,CHEMBL875278,Intermediate,9615.0,,N,,A,5252,,,Canis lupus familiaris,1,,,
,5006,1,BAO_0000218,Area under curve was determined,50588,,,CHEMBL622682,Intermediate,9615.0,,N,,A,5253,,,Canis lupus familiaris,1,,,
,5006,1,BAO_0000218,Area under curve in dogs,50588,,,CHEMBL622683,Intermediate,9615.0,,N,,A,5254,,,Canis lupus familiaris,1,,,
,3771,1,BAO_0000218,Area under curve in dogs at 10 mg/kg dose fo oral administration,50588,,,CHEMBL622684,Intermediate,9615.0,,N,,A,5255,,,Canis lupus familiaris,1,,,
,3771,1,BAO_0000218,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),50588,,,CHEMBL622685,Intermediate,9615.0,,N,,A,5256,,,Canis lupus familiaris,1,,,
,3771,1,BAO_0000218,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,50588,,,CHEMBL622686,Intermediate,9615.0,,N,,A,5257,,,Canis lupus familiaris,1,,,
,1916,1,BAO_0000218,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,,,CHEMBL618344,Intermediate,9615.0,,N,,A,5258,,,Canis lupus familiaris,1,,,
,5302,1,BAO_0000218,Area under curve value in dog at a dose of 5 mg/kg,50588,,,CHEMBL875582,Intermediate,9615.0,,N,,A,5259,,,Canis lupus familiaris,1,,,
,5600,1,BAO_0000218,Area under curve was determined after 0.1 mg/kg iv administration in dog,50588,,,CHEMBL618345,Intermediate,9615.0,,N,,A,5260,,,Canis lupus familiaris,1,,,
,5600,1,BAO_0000218,Area under curve was determined after 0.3 mg/kg po administration in dog,50588,,,CHEMBL618346,Intermediate,9615.0,,N,,A,5261,,,Canis lupus familiaris,1,,,
,17764,1,BAO_0000218,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,50588,,,CHEMBL618347,Intermediate,9615.0,,N,,A,5262,,,Canis lupus familiaris,1,,,
,4368,1,BAO_0000218,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,50588,,,CHEMBL618348,Intermediate,9615.0,,N,,A,5263,,,Canis lupus familiaris,1,,,
,5318,0,BAO_0000019,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,22224,,,CHEMBL618349,Autocuration,9606.0,,U,,A,5264,,,Homo sapiens,1,,,
,5318,0,BAO_0000019,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,22224,,,CHEMBL618350,Autocuration,9606.0,,U,,A,5265,,,Homo sapiens,1,,,
,5318,0,BAO_0000019,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,22224,,,CHEMBL618351,Autocuration,9606.0,,U,,A,5266,,,Homo sapiens,1,,,
,5318,0,BAO_0000019,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,22224,,,CHEMBL618352,Autocuration,9606.0,,U,,A,5267,,,Homo sapiens,1,,,
,14518,0,BAO_0000221,Time taken to reduce 50% of the concentration of compound in blood plasma,22224,,Blood,CHEMBL873494,Autocuration,9606.0,,U,,A,5268,,,Homo sapiens,1,,178.0,
,2209,0,BAO_0000366,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",22224,,Plasma,CHEMBL618353,Autocuration,9606.0,,U,,A,5269,,,Homo sapiens,1,,1969.0,
,6787,0,BAO_0000366,Half life in human plasma,22224,,Plasma,CHEMBL618354,Autocuration,9606.0,,U,,A,5270,,,Homo sapiens,1,,1969.0,
,4898,0,BAO_0000366,Half life in human plasma was reported,22224,,Plasma,CHEMBL875583,Autocuration,9606.0,,U,,A,5271,,,Homo sapiens,1,,1969.0,
,6072,0,BAO_0000019,Half life in human serum,22224,,Serum,CHEMBL618355,Autocuration,9606.0,,U,,A,5272,,,Homo sapiens,1,,1977.0,
,16907,0,BAO_0000366,Half life upon exposure to human plasma,22224,,Plasma,CHEMBL618356,Autocuration,9606.0,,U,,A,5273,,,Homo sapiens,1,,1969.0,
,5656,0,BAO_0000251,t1/2 in human microsomes,22224,In vitro,,CHEMBL618357,Autocuration,9606.0,Microsomes,U,,A,5274,,,Homo sapiens,1,,,
,4755,0,BAO_0000366,Half life period in 80% human plasma at 37 degree Centigrade,22224,,Plasma,CHEMBL618358,Autocuration,9606.0,,U,,A,5275,,,Homo sapiens,1,,1969.0,
,17503,0,BAO_0000221,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),22224,,Zone of skin,CHEMBL618359,Autocuration,9606.0,,U,,A,5276,,,Homo sapiens,1,,14.0,
,12357,0,BAO_0000366,Half-life measured in in vitro Cathepsin B assay in human plasma,22224,In vitro,Plasma,CHEMBL618360,Autocuration,9606.0,,U,,A,5277,,,Homo sapiens,1,,1969.0,
,3076,0,BAO_0000019,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,22224,,,CHEMBL618361,Autocuration,9606.0,,U,,A,5278,,,Homo sapiens,1,,,
,6410,0,BAO_0000251,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,22224,In vitro,Liver,CHEMBL618362,Autocuration,9606.0,Microsomes,U,,A,5279,,,Homo sapiens,1,,2107.0,
,3741,0,BAO_0000366,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",22224,,Plasma,CHEMBL618363,Autocuration,9606.0,,U,,A,5280,,,Homo sapiens,1,,1969.0,
,3741,0,BAO_0000366,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",22224,,Plasma,CHEMBL618364,Autocuration,9606.0,,U,,A,5281,,,Homo sapiens,1,,1969.0,
,3741,0,BAO_0000366,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",22224,,Plasma,CHEMBL875584,Autocuration,9606.0,,U,,A,5282,,,Homo sapiens,1,,1969.0,
,1540,0,BAO_0000019,Half-life in the CEM cell extracts,22224,,,CHEMBL618365,Autocuration,9606.0,,U,,A,5283,,,Homo sapiens,1,,,
,2905,0,BAO_0000366,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,22224,,Plasma,CHEMBL873495,Autocuration,9606.0,,U,,A,5284,,,Homo sapiens,1,,1969.0,
,2905,0,BAO_0000366,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,22224,,Plasma,CHEMBL618366,Autocuration,9606.0,,U,,A,5285,,,Homo sapiens,1,,1969.0,
,5523,0,BAO_0000019,Half-life was determined,22224,,,CHEMBL618367,Autocuration,9606.0,,U,,A,5286,,,Homo sapiens,1,,,
,1499,0,BAO_0000221,Half-life (human blood stability),22224,,Blood,CHEMBL618368,Autocuration,9606.0,,U,,A,5287,,,Homo sapiens,1,,178.0,
,1499,0,BAO_0000221,Half-life (human blood stability); no data,22224,,Blood,CHEMBL618369,Autocuration,9606.0,,U,,A,5288,,,Homo sapiens,1,,178.0,
,17065,0,BAO_0000366,Half-life in human plasma,22224,,Plasma,CHEMBL618370,Autocuration,9606.0,,U,,A,5289,,,Homo sapiens,1,,1969.0,
,6861,0,BAO_0000019,CYP3A4 metabolism half-life (t1/2),22224,,,CHEMBL618371,Autocuration,9606.0,,U,,A,5290,,,Homo sapiens,1,,,
,1499,0,BAO_0000221,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),22224,,Blood,CHEMBL618372,Autocuration,9606.0,,U,,A,5291,,,Homo sapiens,1,,178.0,
,530,0,BAO_0000366,In vitro half life in human plasma,22224,In vitro,Plasma,CHEMBL618373,Autocuration,9606.0,,U,,A,5292,,,Homo sapiens,1,,1969.0,
,1116,0,BAO_0000366,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",22224,In vitro,Plasma,CHEMBL618374,Autocuration,9606.0,,U,,A,5293,,,Homo sapiens,1,,1969.0,
,6695,0,BAO_0000366,In vitro hydrolysis in human plasma,22224,In vitro,Plasma,CHEMBL618375,Autocuration,9606.0,,U,,A,5294,,,Homo sapiens,1,,1969.0,
,6695,0,BAO_0000366,In vitro hydrolysis in human plasma; no data,22224,In vitro,Plasma,CHEMBL618376,Autocuration,9606.0,,U,,A,5295,,,Homo sapiens,1,,1969.0,
,10,0,BAO_0000251,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,22224,In vitro,Liver,CHEMBL618377,Autocuration,9606.0,Microsomes,U,,A,5296,,,Homo sapiens,1,,2107.0,
,993,0,BAO_0000366,Plasma half life in human,22224,,Plasma,CHEMBL618378,Autocuration,9606.0,,U,,A,5297,,,Homo sapiens,1,,1969.0,
,15429,0,BAO_0000366,Stability after incubation with human plasma (at 37 degree C),22224,,Plasma,CHEMBL618379,Autocuration,9606.0,,U,,A,5298,,,Homo sapiens,1,,1969.0,
,1675,0,BAO_0000366,T1/2 was evaluated in human plasma,22224,,Plasma,CHEMBL618380,Autocuration,9606.0,,U,,A,5299,,,Homo sapiens,1,,1969.0,
,2209,0,BAO_0000366,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",22224,,Plasma,CHEMBL618381,Autocuration,9606.0,,U,,A,5300,,,Homo sapiens,1,,1969.0,
,2209,0,BAO_0000366,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",22224,,Plasma,CHEMBL618382,Autocuration,9606.0,,U,,A,5301,,,Homo sapiens,1,,1969.0,
,5318,0,BAO_0000019,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,22224,,,CHEMBL618383,Autocuration,9606.0,,U,,A,5302,,,Homo sapiens,1,,,
,2412,0,BAO_0000019,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,22224,In vitro,,CHEMBL618384,Autocuration,9606.0,,U,,A,5303,,,Homo sapiens,1,,,
,2412,0,BAO_0000019,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,22224,In vitro,,CHEMBL618385,Autocuration,9606.0,,U,,A,5304,,,Homo sapiens,1,,,
,2906,0,BAO_0000366,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,22224,,Plasma,CHEMBL619099,Autocuration,9606.0,,U,,A,5305,,,Homo sapiens,1,,1969.0,
,2906,0,BAO_0000366,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,22224,,Plasma,CHEMBL619100,Autocuration,9606.0,,U,,A,5306,,,Homo sapiens,1,,1969.0,
,5495,0,BAO_0000019,Time taken for 50% to be consumed by serum PON1 was determined,22224,,,CHEMBL619101,Autocuration,9606.0,,U,,A,5307,,,Homo sapiens,1,,,
,5495,0,BAO_0000019,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,22224,,,CHEMBL619102,Autocuration,9606.0,,U,,A,5308,,,Homo sapiens,1,,,
,4397,0,BAO_0000251,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,22224,,Liver,CHEMBL619103,Autocuration,9606.0,Microsomes,U,,A,5309,,,Homo sapiens,1,,2107.0,
,2413,0,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,,,CHEMBL619268,Autocuration,10095.0,,U,,A,5310,,,Mus sp.,1,,,
,2413,0,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,,,CHEMBL619269,Autocuration,10095.0,,U,,A,5311,,,Mus sp.,1,,,
,2413,0,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,,,CHEMBL619270,Autocuration,10095.0,,U,,A,5312,,,Mus sp.,1,,,
,2413,0,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,,,CHEMBL619271,Autocuration,10095.0,,U,,A,5313,,,Mus sp.,1,,,
,2413,0,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,,,CHEMBL875585,Autocuration,10095.0,,U,,A,5314,,,Mus sp.,1,,,
,2413,0,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,,,CHEMBL619272,Autocuration,10095.0,,U,,A,5315,,,Mus sp.,1,,,
,6058,1,BAO_0000219,Compound tested for growth inhibition of renal cancer cell line 786-0,80640,,,CHEMBL619273,Intermediate,9606.0,,N,,F,5316,,391.0,Homo sapiens,1,,,786-0
,17708,1,BAO_0000219,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,80640,,,CHEMBL619274,Intermediate,9606.0,,N,,F,5317,,391.0,Homo sapiens,1,,,786-0
,14017,1,BAO_0000219,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,80640,,,CHEMBL619275,Expert,9606.0,,N,,F,5318,,391.0,Homo sapiens,1,,,786-0
,16818,1,BAO_0000219,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",80640,,,CHEMBL619276,Intermediate,9606.0,,N,,F,5319,,391.0,Homo sapiens,1,,,786-0
,16818,1,BAO_0000219,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",80640,,,CHEMBL619277,Intermediate,9606.0,,N,,F,5320,,391.0,Homo sapiens,1,,,786-0
,16818,1,BAO_0000219,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",80640,,,CHEMBL619278,Intermediate,9606.0,,N,,F,5321,,391.0,Homo sapiens,1,,,786-0
,11970,1,BAO_0000219,Tested for cytotoxicity against 786-0 cell lines in renal cancer,80640,,,CHEMBL619279,Intermediate,9606.0,,N,,F,5322,,391.0,Homo sapiens,1,,,786-0
,12400,1,BAO_0000219,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,80640,,,CHEMBL858458,Intermediate,9606.0,,N,,F,5323,,391.0,Homo sapiens,1,,,786-0
,12888,1,BAO_0000219,Cytotoxic effect on renal cancer line 786-0,80640,,,CHEMBL619280,Expert,9606.0,,N,,F,5324,,391.0,Homo sapiens,1,,,786-0
,15300,1,BAO_0000219,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,80640,,,CHEMBL619281,Intermediate,9606.0,,N,,F,5325,,391.0,Homo sapiens,1,,,786-0
,14769,1,BAO_0000219,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),80640,,,CHEMBL619282,Intermediate,9606.0,,N,,F,5326,,391.0,Homo sapiens,1,,,786-0
,15895,1,BAO_0000219,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",80640,,,CHEMBL619283,Intermediate,9606.0,,N,,F,5327,,391.0,Homo sapiens,1,,,786-0
,17376,1,BAO_0000219,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,80640,,,CHEMBL619284,Intermediate,9606.0,,N,,F,5328,,391.0,Homo sapiens,1,,,786-0
,14882,1,BAO_0000219,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,80640,,,CHEMBL619285,Intermediate,9606.0,,N,,F,5329,,391.0,Homo sapiens,1,,,786-0
,14882,1,BAO_0000219,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),80640,,,CHEMBL619286,Intermediate,9606.0,,N,,F,5330,,391.0,Homo sapiens,1,,,786-0
,15176,1,BAO_0000219,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,80640,,,CHEMBL619287,Intermediate,9606.0,,N,,F,5331,,391.0,Homo sapiens,1,,,786-0
,12696,1,BAO_0000219,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,80640,,,CHEMBL857455,Intermediate,9606.0,,N,,F,5332,,391.0,Homo sapiens,1,,,786-0
,2496,1,BAO_0000219,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),80640,,,CHEMBL883801,Intermediate,9606.0,,N,,F,5333,,391.0,Homo sapiens,1,,,786-0
,11831,1,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,80641,,,CHEMBL619288,Intermediate,9606.0,,N,,F,5334,,972.0,Homo sapiens,1,,,791T cell line
,11831,1,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),80641,,,CHEMBL619289,Intermediate,9606.0,,N,,F,5335,,972.0,Homo sapiens,1,,,791T cell line
,11831,1,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,80641,,,CHEMBL619290,Intermediate,9606.0,,N,,F,5336,,972.0,Homo sapiens,1,,,791T cell line
,11831,1,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),80641,,,CHEMBL619291,Intermediate,9606.0,,N,,F,5337,,972.0,Homo sapiens,1,,,791T cell line
,11831,1,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),80641,,,CHEMBL619292,Intermediate,9606.0,,N,,F,5338,,972.0,Homo sapiens,1,,,791T cell line
,11831,1,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,80641,,,CHEMBL619293,Intermediate,9606.0,,N,,F,5339,,972.0,Homo sapiens,1,,,791T cell line
,11831,1,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),80641,,,CHEMBL619294,Intermediate,9606.0,,N,,F,5340,,972.0,Homo sapiens,1,,,791T cell line
,11831,1,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),80641,,,CHEMBL619295,Intermediate,9606.0,,N,,F,5341,,972.0,Homo sapiens,1,,,791T cell line
,11831,1,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),80641,,,CHEMBL619296,Intermediate,9606.0,,N,,F,5342,,972.0,Homo sapiens,1,,,791T cell line
,11831,1,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,80641,,,CHEMBL619297,Intermediate,9606.0,,N,,F,5343,,972.0,Homo sapiens,1,,,791T cell line
,12782,1,BAO_0000219,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,80640,,,CHEMBL619298,Intermediate,9606.0,,N,,F,5344,,391.0,Homo sapiens,1,,,786-0
,1229,0,BAO_0000019,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,22226,,,CHEMBL619299,Intermediate,,,U,,F,5345,,,,1,,,
,15313,1,BAO_0000219,Inhibition of cell growth in drug resistant 8226 myeloma cell line,80433,,,CHEMBL619300,Expert,9606.0,,N,,F,5346,,741.0,Homo sapiens,1,,,RPMI-8226
,15313,1,BAO_0000219,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,80433,,,CHEMBL619301,Expert,9606.0,,N,,F,5347,,741.0,Homo sapiens,1,,,RPMI-8226
,11544,1,BAO_0000219,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,80433,,,CHEMBL619302,Intermediate,9606.0,,N,,F,5348,,741.0,Homo sapiens,1,,,RPMI-8226
,9424,1,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,80433,,,CHEMBL619303,Intermediate,9606.0,,N,,F,5349,,741.0,Homo sapiens,1,,,RPMI-8226
,9424,1,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,80433,,,CHEMBL619304,Intermediate,9606.0,,N,,F,5350,,741.0,Homo sapiens,1,,,RPMI-8226
,9424,1,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),80433,,,CHEMBL857706,Intermediate,9606.0,,N,,F,5351,,741.0,Homo sapiens,1,,,RPMI-8226
,9424,1,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),80433,,,CHEMBL619305,Intermediate,9606.0,,N,,F,5352,,741.0,Homo sapiens,1,,,RPMI-8226
,9424,1,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),80433,,,CHEMBL619306,Intermediate,9606.0,,N,,F,5353,,741.0,Homo sapiens,1,,,RPMI-8226
,9424,1,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),80433,,,CHEMBL619307,Intermediate,9606.0,,N,,F,5354,,741.0,Homo sapiens,1,,,RPMI-8226
,9424,1,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),80433,,,CHEMBL619308,Intermediate,9606.0,,N,,F,5355,,741.0,Homo sapiens,1,,,RPMI-8226
,9424,1,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),80433,,,CHEMBL619309,Intermediate,9606.0,,N,,F,5356,,741.0,Homo sapiens,1,,,RPMI-8226
,9424,1,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),80433,,,CHEMBL619310,Intermediate,9606.0,,N,,F,5357,,741.0,Homo sapiens,1,,,RPMI-8226
,14769,1,BAO_0000219,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),80021,,,CHEMBL619311,Intermediate,9606.0,,N,,F,5358,,624.0,Homo sapiens,1,,,A498
,15354,1,BAO_0000219,Compound was tested for the growth inhibition of A498 renal tumor cell line,80021,,,CHEMBL619312,Intermediate,9606.0,,N,,F,5359,,624.0,Homo sapiens,1,,,A498
,17445,1,BAO_0000219,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),80021,,,CHEMBL619313,Intermediate,9606.0,,N,,F,5360,,624.0,Homo sapiens,1,,,A498
,4337,1,BAO_0000219,In vitro inhibitory concentration against renal cancer cell line A498,80021,,,CHEMBL619314,Intermediate,9606.0,,N,,F,5361,,624.0,Homo sapiens,1,,,A498
,15277,1,BAO_0000219,Cytotoxicity against A 498 tumor cell line,80021,,,CHEMBL619959,Intermediate,9606.0,,N,,F,5362,,624.0,Homo sapiens,1,,,A498
,4812,1,BAO_0000219,In vitro antitumor activity against A498 human cancer cell line,80021,,,CHEMBL619960,Intermediate,9606.0,,N,,F,5363,,624.0,Homo sapiens,1,,,A498
,4812,1,BAO_0000219,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),80021,,,CHEMBL619961,Intermediate,9606.0,,N,,F,5364,,624.0,Homo sapiens,1,,,A498
,4995,1,BAO_0000219,Inhibitory dose required against A498 human tumor cell lines,80021,,,CHEMBL619962,Intermediate,9606.0,,N,,F,5365,,624.0,Homo sapiens,1,,,A498
,5847,1,BAO_0000219,Anticancer activity against one renal cancer (A498 cell line),80021,,,CHEMBL875586,Intermediate,9606.0,,N,,F,5366,,624.0,Homo sapiens,1,,,A498
,6557,1,BAO_0000219,In vitro cytotoxicity against melanoma A498 cell line,80021,,,CHEMBL619963,Intermediate,9606.0,,N,,F,5367,,624.0,Homo sapiens,1,,,A498
,2597,1,BAO_0000219,Compound was tested for growth inhibitory activity against A498 cell line,80021,,,CHEMBL619964,Intermediate,9606.0,,N,,F,5368,,624.0,Homo sapiens,1,,,A498
,6058,1,BAO_0000219,Compound tested for growth inhibition of renal cancer cell line A498,80021,,,CHEMBL620108,Intermediate,9606.0,,N,,F,5369,,624.0,Homo sapiens,1,,,A498
,17708,1,BAO_0000219,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,80021,,,CHEMBL620109,Intermediate,9606.0,,N,,F,5370,,624.0,Homo sapiens,1,,,A498
,15176,1,BAO_0000219,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,80021,,,CHEMBL620110,Intermediate,9606.0,,N,,F,5371,,624.0,Homo sapiens,1,,,A498
,15300,1,BAO_0000219,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,80021,,,CHEMBL620111,Intermediate,9606.0,,N,,F,5372,,624.0,Homo sapiens,1,,,A498
,11970,1,BAO_0000219,Tested for cytotoxicity against A498 cell lines in renal cancer,80021,,,CHEMBL620112,Intermediate,9606.0,,N,,F,5373,,624.0,Homo sapiens,1,,,A498
,12400,1,BAO_0000219,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,80021,,,CHEMBL620113,Intermediate,9606.0,,N,,F,5374,,624.0,Homo sapiens,1,,,A498
,12888,1,BAO_0000219,Cytotoxic effect on renal cancer lines A498,80021,,,CHEMBL620114,Expert,9606.0,,N,,F,5375,,624.0,Homo sapiens,1,,,A498
,3030,1,BAO_0000219,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,80021,,,CHEMBL620115,Intermediate,9606.0,,N,,F,5376,,624.0,Homo sapiens,1,,,A498
,14769,1,BAO_0000219,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),80021,,,CHEMBL620116,Intermediate,9606.0,,N,,F,5377,,624.0,Homo sapiens,1,,,A498
,17376,1,BAO_0000219,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,80021,,,CHEMBL620117,Intermediate,9606.0,,N,,F,5378,,624.0,Homo sapiens,1,,,A498
,16558,1,BAO_0000219,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,80021,,,CHEMBL620118,Intermediate,9606.0,,N,,F,5379,,624.0,Homo sapiens,1,,,A498
,5194,1,BAO_0000219,Cytotoxicity against human kidney carcinoma cell lines A4982LM,80021,,,CHEMBL620119,Intermediate,9606.0,,N,,F,5380,,624.0,Homo sapiens,1,,,A498
,10708,1,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,80021,,,CHEMBL620120,Intermediate,9606.0,,N,,F,5381,,624.0,Homo sapiens,1,,,A498
,16880,1,BAO_0000219,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,80682,,,CHEMBL620121,Expert,9606.0,,N,,F,5382,,646.0,Homo sapiens,1,,,A549
,10196,1,BAO_0000219,Antitumor activity against A549 human lung carcinoma cell line,80682,,,CHEMBL620122,Intermediate,9606.0,,N,,F,5383,,646.0,Homo sapiens,1,,,A549
,10196,1,BAO_0000219,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,80682,,,CHEMBL620123,Intermediate,9606.0,,N,,F,5384,,646.0,Homo sapiens,1,,,A549
,10196,1,BAO_0000219,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,80682,,,CHEMBL620124,Intermediate,9606.0,,N,,F,5385,,646.0,Homo sapiens,1,,,A549
,12083,1,BAO_0000219,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",80682,,,CHEMBL620125,Intermediate,9606.0,,N,,F,5386,,646.0,Homo sapiens,1,,,A549
,16464,1,BAO_0000219,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,80682,,,CHEMBL620126,Expert,9606.0,,N,,F,5387,,646.0,Homo sapiens,1,,,A549
,16464,1,BAO_0000219,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80682,,,CHEMBL883027,Intermediate,9606.0,,N,,F,5388,,646.0,Homo sapiens,1,,,A549
,16470,1,BAO_0000219,In vitro cytotoxic activity against human lung A549 cell line,80682,,,CHEMBL620127,Expert,9606.0,,N,,F,5389,,646.0,Homo sapiens,1,,,A549
,16470,1,BAO_0000219,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),80682,,,CHEMBL620128,Intermediate,9606.0,,N,,F,5390,,646.0,Homo sapiens,1,,,A549
,16470,1,BAO_0000219,In vitro cytotoxic activity against human lung A549 cell line),80682,,,CHEMBL620129,Intermediate,9606.0,,N,,F,5391,,646.0,Homo sapiens,1,,,A549
,16470,1,BAO_0000219,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,80682,,,CHEMBL620130,Intermediate,9606.0,,N,,F,5392,,646.0,Homo sapiens,1,,,A549
,16582,1,BAO_0000219,In vitro cytotoxicity against human non small-cell-lung cell line A549.,80682,,,CHEMBL620131,Expert,9606.0,,N,,F,5393,,646.0,Homo sapiens,1,,,A549
,15935,1,BAO_0000219,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",80682,,,CHEMBL620132,Intermediate,9606.0,,N,,F,5394,,646.0,Homo sapiens,1,,,A549
,15935,1,BAO_0000219,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",80682,,,CHEMBL620133,Intermediate,9606.0,,N,,F,5395,,646.0,Homo sapiens,1,,,A549
,16597,1,BAO_0000219,Inhibition of A549 human lung carcinoma cell proliferation,80682,,,CHEMBL620134,Expert,9606.0,,N,,F,5396,,646.0,Homo sapiens,1,,,A549
,17376,1,BAO_0000219,Inhibitory activity against A549 lung adenocarcinoma cell line,80682,,,CHEMBL620135,Intermediate,9606.0,,N,,F,5397,,646.0,Homo sapiens,1,,,A549
,16496,1,BAO_0000219,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,80682,,,CHEMBL620136,Intermediate,9606.0,,N,,F,5398,,646.0,Homo sapiens,1,,,A549
,16152,1,BAO_0000219,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,80682,,,CHEMBL620137,Intermediate,9606.0,,N,,F,5399,,646.0,Homo sapiens,1,,,A549
,16152,1,BAO_0000219,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,80682,,,CHEMBL620268,Intermediate,9606.0,,N,,F,5400,,646.0,Homo sapiens,1,,,A549
,16464,1,BAO_0000219,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80682,,,CHEMBL620269,Intermediate,9606.0,,N,,F,5401,,646.0,Homo sapiens,1,,,A549
,2288,1,BAO_0000219,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,80682,,,CHEMBL620270,Intermediate,9606.0,,N,,F,5402,,646.0,Homo sapiens,1,,,A549
,17350,1,BAO_0000219,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,80682,,,CHEMBL620271,Intermediate,9606.0,,N,,F,5403,,646.0,Homo sapiens,1,,,A549
,4090,1,BAO_0000219,Inhibition of A549 cancer cell proliferation,80682,,,CHEMBL620272,Expert,9606.0,,N,,F,5404,,646.0,Homo sapiens,1,,,A549
,4090,1,BAO_0000219,Inhibition of A549 cancer cell proliferation (Not tested),80682,,,CHEMBL620273,Expert,9606.0,,N,,F,5405,,646.0,Homo sapiens,1,,,A549
,17350,1,BAO_0000219,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,80682,,,CHEMBL620274,Intermediate,9606.0,,N,,F,5406,,646.0,Homo sapiens,1,,,A549
,4197,1,BAO_0000219,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,80682,,,CHEMBL620275,Intermediate,9606.0,,N,,F,5407,,646.0,Homo sapiens,1,,,A549
,17072,1,BAO_0000219,Antiproliferative potency determined as inhibitory concentration against A549 cells,80682,,,CHEMBL620276,Intermediate,9606.0,,N,,F,5408,,646.0,Homo sapiens,1,,,A549
,17072,1,BAO_0000219,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,80682,,,CHEMBL620277,Intermediate,9606.0,,N,,F,5409,,646.0,Homo sapiens,1,,,A549
,5194,1,BAO_0000219,Cytotoxicity against Renal cell lines A549 was determined,80682,,,CHEMBL620278,Intermediate,9606.0,,N,,F,5410,,646.0,Homo sapiens,1,,,A549
,4257,1,BAO_0000218,Area under curve was determined in dog after a 3 mg/kg of oral dose,50588,,,CHEMBL620279,Intermediate,9615.0,,N,,A,5411,,,Canis lupus familiaris,1,,,
,6123,1,BAO_0000218,Area under curve was determined in dog after oral administration at 1 mg/kg,50588,,,CHEMBL620280,Intermediate,9615.0,,N,,A,5412,,,Canis lupus familiaris,1,,,
,1337,1,BAO_0000218,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,50588,,,CHEMBL620281,Intermediate,9615.0,,N,,A,5413,,,Canis lupus familiaris,1,,,
,1337,1,BAO_0000218,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,50588,,,CHEMBL620282,Intermediate,9615.0,,N,,A,5414,,,Canis lupus familiaris,1,,,
,8833,1,BAO_0000218,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),50588,,,CHEMBL621134,Intermediate,9615.0,,N,,A,5415,,,Canis lupus familiaris,1,,,
,8833,1,BAO_0000218,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),50588,,,CHEMBL621135,Intermediate,9615.0,,N,,A,5416,,,Canis lupus familiaris,1,,,
,8833,1,BAO_0000218,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),50588,,,CHEMBL621136,Intermediate,9615.0,,N,,A,5417,,,Canis lupus familiaris,1,,,
,8833,1,BAO_0000218,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),50588,,,CHEMBL621137,Intermediate,9615.0,,N,,A,5418,,,Canis lupus familiaris,1,,,
,17657,1,BAO_0000218,Area under plasma concentration time curve in dog upon oral administration,50588,,Plasma,CHEMBL621138,Intermediate,9615.0,,N,,A,5419,,,Canis lupus familiaris,1,,1969.0,
,17650,1,BAO_0000218,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,50588,,Plasma,CHEMBL875587,Intermediate,9615.0,,N,,A,5420,,,Canis lupus familiaris,1,,1969.0,
,1977,1,BAO_0000218,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,50588,,,CHEMBL621139,Intermediate,9615.0,,N,,A,5421,,,Canis lupus familiaris,1,,,
,1977,1,BAO_0000218,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,50588,,,CHEMBL621140,Intermediate,9615.0,,N,,A,5422,,,Canis lupus familiaris,1,,,
,3132,1,BAO_0000218,Area under the curve for the compound was obtained when tested in dog,50588,,,CHEMBL621141,Intermediate,9615.0,,N,,A,5423,,,Canis lupus familiaris,1,,,
,5473,1,BAO_0000218,Area under the curve at a dose of 1 mg/kg,50588,,,CHEMBL621142,Intermediate,9615.0,,N,,A,5424,,,Canis lupus familiaris,1,,,
,5474,1,BAO_0000218,Area under the curve at a dose of 1 mg/kg (oral),50588,,,CHEMBL621143,Intermediate,9615.0,,N,,A,5425,,,Canis lupus familiaris,1,,,
,5474,1,BAO_0000218,Area under the curve at i.v. dose of 0.2 mg/kg,50588,,,CHEMBL621144,Intermediate,9615.0,,N,,A,5426,,,Canis lupus familiaris,1,,,
,6062,1,BAO_0000218,Area under the curve was measured in dog after an iv dose of 1 mg/kg,50588,,,CHEMBL621145,Intermediate,9615.0,,N,,A,5427,,,Canis lupus familiaris,1,,,
,4709,1,BAO_0000218,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,50588,,,CHEMBL621146,Intermediate,9615.0,,N,,A,5428,,,Canis lupus familiaris,1,,,
,2652,1,BAO_0000218,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,50588,,,CHEMBL622567,Intermediate,9615.0,,N,,A,5429,,,Canis lupus familiaris,1,,,
,2652,1,BAO_0000218,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,50588,,,CHEMBL622568,Intermediate,9615.0,,N,,A,5430,,,Canis lupus familiaris,1,,,
,2877,1,BAO_0000218,Compound was evaluated for area under the curve in dog blood.,50588,,,CHEMBL622569,Intermediate,9615.0,,N,,A,5431,,,Canis lupus familiaris,1,,,
,5444,1,BAO_0000218,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,50588,,,CHEMBL622570,Intermediate,9615.0,,N,,A,5432,,,Canis lupus familiaris,1,,,
,5130,1,BAO_0000218,AUC in dog after oral dose (1 mg/kg),50588,,Plasma,CHEMBL622571,Intermediate,9615.0,,N,,A,5433,,,Canis lupus familiaris,1,,1969.0,
,6265,1,BAO_0000218,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,50588,,,CHEMBL622572,Intermediate,9615.0,,N,,A,5434,,,Canis lupus familiaris,1,,,
,4657,1,BAO_0000218,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",50588,,,CHEMBL622573,Intermediate,9615.0,,N,,A,5435,,,Canis lupus familiaris,1,,,
,16367,1,BAO_0000218,Pharmacokinetic parameter AUC after intravenous administration to dogs,50588,,,CHEMBL622574,Intermediate,9615.0,,N,,A,5436,,,Canis lupus familiaris,1,,,
,16367,1,BAO_0000218,Pharmacokinetic parameter AUC after oral administration to dogs,50588,,,CHEMBL622575,Intermediate,9615.0,,N,,A,5437,,,Canis lupus familiaris,1,,,
,9579,1,BAO_0000218,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,50588,,,CHEMBL622576,Intermediate,9615.0,,N,,A,5438,,,Canis lupus familiaris,1,,,
,9579,1,BAO_0000218,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,50588,,,CHEMBL622577,Intermediate,9615.0,,N,,A,5439,,,Canis lupus familiaris,1,,,
,5983,1,BAO_0000218,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,50588,,,CHEMBL622578,Intermediate,9615.0,,N,,A,5440,,,Canis lupus familiaris,1,,,
,6241,1,BAO_0000218,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,50588,,,CHEMBL622579,Intermediate,9615.0,,N,,A,5441,,,Canis lupus familiaris,1,,,
,5313,1,BAO_0000218,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",50588,,,CHEMBL622580,Intermediate,9615.0,,N,,A,5442,,,Canis lupus familiaris,1,,,
,5313,1,BAO_0000218,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",50588,,,CHEMBL622581,Intermediate,9615.0,,N,,A,5443,,,Canis lupus familiaris,1,,,
,6642,1,BAO_0000218,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,,,CHEMBL622582,Intermediate,9615.0,,N,,A,5444,,,Canis lupus familiaris,1,,,
,6642,1,BAO_0000218,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,,,CHEMBL622583,Intermediate,9615.0,,N,,A,5445,,,Canis lupus familiaris,1,,,
,6641,1,BAO_0000218,Oral AUCN in dog (dosed at 0.5 mpk iv ),50588,,,CHEMBL622584,Intermediate,9615.0,,N,,A,5446,,,Canis lupus familiaris,1,,,
,6642,1,BAO_0000218,Oral AUCN in dog (dosed at 0.5 mpk iv ),50588,,,CHEMBL622585,Intermediate,9615.0,,N,,A,5447,,,Canis lupus familiaris,1,,,
,17791,1,BAO_0000218,Compound was evaluated for oral bioavailability in dog; 90-100,50588,,,CHEMBL622586,Intermediate,9615.0,,N,,A,5448,,,Canis lupus familiaris,1,,,
,17655,1,BAO_0000218,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,50588,,,CHEMBL623281,Intermediate,9615.0,,N,,A,5449,,,Canis lupus familiaris,1,,,
,17655,1,BAO_0000218,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,50588,,,CHEMBL623282,Intermediate,9615.0,,N,,A,5450,,,Canis lupus familiaris,1,,,
,6596,1,BAO_0000218,PAPP (membrane permeability) in dog kidney cell monolayer assay,50588,,,CHEMBL623283,Intermediate,9615.0,,N,,A,5451,,,Canis lupus familiaris,1,,,
,3880,1,BAO_0000218,Oral bioavailability in dog,50588,,,CHEMBL623284,Intermediate,9615.0,,N,,A,5452,,,Canis lupus familiaris,1,,,
,16367,1,BAO_0000218,Bioavailability administered orally at a dose of 10 mg/kg to dogs,50588,,,CHEMBL623285,Intermediate,9615.0,,N,,A,5453,,,Canis lupus familiaris,1,,,
,17409,1,BAO_0000218,Plasma protein binding towards dog plasma at 10 uM,50588,,Plasma,CHEMBL623463,Intermediate,9615.0,,N,,A,5454,,,Canis lupus familiaris,1,,1969.0,
,17409,1,BAO_0000218,Plasma protein binding towards dog plasma at 100 uM,50588,,Plasma,CHEMBL875952,Intermediate,9615.0,,N,,A,5455,,,Canis lupus familiaris,1,,1969.0,
,2959,1,BAO_0000218,Bioavailability in dog (dose 4 mg/kg p.o.),50588,In vivo,,CHEMBL621705,Intermediate,9615.0,,N,,A,5456,,,Canis lupus familiaris,1,,,
,13501,1,BAO_0000218,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,50588,In vivo,,CHEMBL621706,Intermediate,9615.0,,N,,A,5457,,,Canis lupus familiaris,1,,,
,4527,1,BAO_0000218,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,50588,In vivo,,CHEMBL621707,Intermediate,9615.0,,N,,A,5458,,,Canis lupus familiaris,1,,,
,15145,1,BAO_0000218,Bioavailability in dogs,50588,In vivo,,CHEMBL621708,Intermediate,9615.0,,N,,A,5459,,,Canis lupus familiaris,1,,,
,4219,1,BAO_0000218,Bioavailability,50588,In vivo,,CHEMBL621709,Intermediate,9615.0,,N,,A,5460,,,Canis lupus familiaris,1,,,
,17538,1,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),50588,In vivo,,CHEMBL621710,Intermediate,9615.0,,N,,A,5461,,,Canis lupus familiaris,1,,,
,17538,1,BAO_0000218,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,50588,In vivo,,CHEMBL621711,Intermediate,9615.0,,N,,A,5462,,,Canis lupus familiaris,1,,,
,1466,1,BAO_0000218,Bioavailability in dog (dose 10.0 mg/kg p.o.),50588,In vivo,,CHEMBL621712,Intermediate,9615.0,,N,,A,5463,,,Canis lupus familiaris,1,,,
,17650,1,BAO_0000218,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,50588,In vivo,,CHEMBL621713,Intermediate,9615.0,,N,,A,5464,,,Canis lupus familiaris,1,,,
,3132,1,BAO_0000218,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,50588,In vivo,,CHEMBL621714,Intermediate,9615.0,,N,,A,5465,,,Canis lupus familiaris,1,,,
,2413,0,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,,,CHEMBL621715,Autocuration,10095.0,,U,,A,5466,,,Mus sp.,1,,,
,2413,0,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,,Liver,CHEMBL623717,Autocuration,10095.0,,U,,A,5467,,,Mus sp.,1,,2107.0,
,2413,0,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,,Liver,CHEMBL623718,Autocuration,10095.0,,U,,A,5468,,,Mus sp.,1,,2107.0,
,2413,0,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,,Liver,CHEMBL623719,Autocuration,10095.0,,U,,A,5469,,,Mus sp.,1,,2107.0,
,2413,0,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,,,CHEMBL623720,Autocuration,10095.0,,U,,A,5470,,,Mus sp.,1,,,
,2413,0,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,,,CHEMBL623721,Autocuration,10095.0,,U,,A,5471,,,Mus sp.,1,,,
,2413,0,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,,Muscle tissue,CHEMBL623722,Autocuration,10095.0,,U,,A,5472,,,Mus sp.,1,,2385.0,
,2413,0,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,,Muscle tissue,CHEMBL623723,Autocuration,10095.0,,U,,A,5473,,,Mus sp.,1,,2385.0,
,2413,0,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,,Muscle tissue,CHEMBL618543,Autocuration,10095.0,,U,,A,5474,,,Mus sp.,1,,2385.0,
,2413,0,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,,Spleen,CHEMBL618544,Autocuration,10095.0,,U,,A,5475,,,Mus sp.,1,,2106.0,
,2413,0,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,,Spleen,CHEMBL875155,Autocuration,10095.0,,U,,A,5476,,,Mus sp.,1,,2106.0,
,2413,0,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,,,CHEMBL618545,Autocuration,10095.0,,U,,A,5477,,,Mus sp.,1,,,
,2413,0,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,,,CHEMBL618546,Autocuration,10095.0,,U,,A,5478,,,Mus sp.,1,,,
,2413,0,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,,,CHEMBL623529,Autocuration,10095.0,,U,,A,5479,,,Mus sp.,1,,,
,2413,0,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,,,CHEMBL623530,Autocuration,10095.0,,U,,A,5480,,,Mus sp.,1,,,
,2413,0,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,,,CHEMBL621764,Autocuration,10095.0,,U,,A,5481,,,Mus sp.,1,,,
,17827,0,BAO_0000019,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),22224,,,CHEMBL621765,Autocuration,9527.0,,U,,A,5482,,,Cercopithecidae,1,,,
,17827,0,BAO_0000019,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),22224,,Cerebellum,CHEMBL621766,Autocuration,9527.0,,U,,A,5483,,,Cercopithecidae,1,,2037.0,
,17827,0,BAO_0000019,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),22224,,Frontal cortex,CHEMBL621767,Autocuration,9527.0,,U,,A,5484,,,Cercopithecidae,1,,1870.0,
,17827,0,BAO_0000019,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),22224,,,CHEMBL621768,Autocuration,9527.0,,U,,A,5485,,,Cercopithecidae,1,,,
,17827,0,BAO_0000019,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),22224,,Striatum,CHEMBL621769,Autocuration,9527.0,,U,,A,5486,,,Cercopithecidae,1,,2435.0,
,17827,0,BAO_0000019,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),22224,,,CHEMBL621770,Autocuration,9527.0,,U,,A,5487,,,Cercopithecidae,1,,,
,17827,0,BAO_0000019,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),22224,,Cerebellum,CHEMBL621771,Autocuration,9527.0,,U,,A,5488,,,Cercopithecidae,1,,2037.0,
,17827,0,BAO_0000019,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),22224,,Frontal cortex,CHEMBL621772,Autocuration,9527.0,,U,,A,5489,,,Cercopithecidae,1,,1870.0,
,17827,0,BAO_0000019,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),22224,,,CHEMBL621773,Autocuration,9527.0,,U,,A,5490,,,Cercopithecidae,1,,,
,17827,0,BAO_0000019,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),22224,,Striatum,CHEMBL621774,Autocuration,9527.0,,U,,A,5491,,,Cercopithecidae,1,,2435.0,
,17791,0,BAO_0000218,Compound was evaluated for oral bioavailability in rats,22224,,,CHEMBL621775,Autocuration,9527.0,,U,,A,5492,,,Cercopithecidae,1,,,
,17667,0,BAO_0000218,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,22224,In vivo,Plasma,CHEMBL621776,Autocuration,9527.0,,U,,A,5493,,,Cercopithecidae,1,,1969.0,
,17791,0,BAO_0000019,Half life period was evaluated in monkey,22224,,,CHEMBL621777,Autocuration,9527.0,,U,,A,5494,,,Cercopithecidae,1,,,
,110,0,BAO_0000218,Half-life in rhesus monkeys by intravenous administration of dose,22224,In vivo,,CHEMBL875162,Autocuration,9527.0,,U,,A,5495,,,Cercopithecidae,1,,,
,5781,1,BAO_0000218,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,50594,,Plasma,CHEMBL621778,Intermediate,10090.0,,N,,A,5496,,,Mus musculus,1,,1969.0,
,17734,1,BAO_0000218,AUC after intraperitoneal administration of 100 mg/kg in mice,50594,,Plasma,CHEMBL621779,Intermediate,10090.0,,N,,A,5497,,,Mus musculus,1,,1969.0,
,17718,1,BAO_0000218,AUC value was determined after oral administration,50594,,Plasma,CHEMBL622479,Intermediate,10090.0,,N,,A,5498,,,Mus musculus,1,,1969.0,
,4573,1,BAO_0000218,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,50594,,,CHEMBL622480,Intermediate,10090.0,,N,,A,5499,,,Mus musculus,1,,,
,3277,1,BAO_0000218,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),50594,,,CHEMBL622481,Intermediate,10090.0,,N,,A,5500,,,Mus musculus,1,,,
,2862,1,BAO_0000218,Area under curve by ioral administration in mouse,50594,,,CHEMBL622482,Intermediate,10090.0,,N,,A,5501,,,Mus musculus,1,,,
,2862,1,BAO_0000218,Area under curve by iv administration in mouse,50594,,,CHEMBL622483,Intermediate,10090.0,,N,,A,5502,,,Mus musculus,1,,,
,5951,1,BAO_0000218,Area under curve at 0-8 hr in IRC mice after peroral administration,50594,,,CHEMBL622484,Intermediate,10090.0,,N,,A,5503,,,Mus musculus,1,,,
,17729,1,BAO_0000218,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,50594,,,CHEMBL622641,Intermediate,10090.0,,N,,A,5504,,,Mus musculus,1,,,
,17728,1,BAO_0000218,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,50594,,,CHEMBL622642,Intermediate,10090.0,,N,,A,5505,,,Mus musculus,1,,,
,17728,1,BAO_0000218,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,50594,,,CHEMBL622643,Intermediate,10090.0,,N,,A,5506,,,Mus musculus,1,,,
,17729,1,BAO_0000218,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,50594,,,CHEMBL622644,Intermediate,10090.0,,N,,A,5507,,,Mus musculus,1,,,
,9424,1,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,80433,,,CHEMBL622645,Intermediate,9606.0,,N,,F,5508,,741.0,Homo sapiens,1,,,RPMI-8226
,9424,1,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,80433,,,CHEMBL622646,Intermediate,9606.0,,N,,F,5509,,741.0,Homo sapiens,1,,,RPMI-8226
,9424,1,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),80433,,,CHEMBL621238,Intermediate,9606.0,,N,,F,5510,,741.0,Homo sapiens,1,,,RPMI-8226
,9424,1,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),80433,,,CHEMBL621239,Intermediate,9606.0,,N,,F,5511,,741.0,Homo sapiens,1,,,RPMI-8226
,9424,1,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),80433,,,CHEMBL621240,Intermediate,9606.0,,N,,F,5512,,741.0,Homo sapiens,1,,,RPMI-8226
,9424,1,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),80433,,,CHEMBL621241,Intermediate,9606.0,,N,,F,5513,,741.0,Homo sapiens,1,,,RPMI-8226
,9424,1,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),80433,,,CHEMBL621242,Intermediate,9606.0,,N,,F,5514,,741.0,Homo sapiens,1,,,RPMI-8226
,9424,1,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),80433,,,CHEMBL620350,Intermediate,9606.0,,N,,F,5515,,741.0,Homo sapiens,1,,,RPMI-8226
,9424,1,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,80433,,,CHEMBL620351,Intermediate,9606.0,,N,,F,5516,,741.0,Homo sapiens,1,,,RPMI-8226
,9424,1,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,80433,,,CHEMBL620352,Intermediate,9606.0,,N,,F,5517,,741.0,Homo sapiens,1,,,RPMI-8226
,9424,1,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),80433,,,CHEMBL620353,Intermediate,9606.0,,N,,F,5518,,741.0,Homo sapiens,1,,,RPMI-8226
,9424,1,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),80433,,,CHEMBL620354,Intermediate,9606.0,,N,,F,5519,,741.0,Homo sapiens,1,,,RPMI-8226
,9424,1,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),80433,,,CHEMBL620355,Intermediate,9606.0,,N,,F,5520,,741.0,Homo sapiens,1,,,RPMI-8226
,9424,1,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),80433,,,CHEMBL620356,Intermediate,9606.0,,N,,F,5521,,741.0,Homo sapiens,1,,,RPMI-8226
,9424,1,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),80433,,,CHEMBL620357,Intermediate,9606.0,,N,,F,5522,,741.0,Homo sapiens,1,,,RPMI-8226
,9424,1,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),80433,,,CHEMBL620358,Intermediate,9606.0,,N,,F,5523,,741.0,Homo sapiens,1,,,RPMI-8226
,9424,1,BAO_0000219,In vitro inhibition of human 8226 myeloma tumor cell line growth.,80433,,,CHEMBL620359,Expert,9606.0,,N,,F,5524,,741.0,Homo sapiens,1,,,RPMI-8226
,11544,1,BAO_0000219,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,80433,,,CHEMBL620360,Intermediate,9606.0,,N,,F,5525,,741.0,Homo sapiens,1,,,RPMI-8226
,17378,1,BAO_0000219,Cytotoxicity of compound against 8226/DOX1V cells,80433,,,CHEMBL620361,Intermediate,9606.0,,N,,F,5526,,741.0,Homo sapiens,1,,,RPMI-8226
,17378,1,BAO_0000219,Cytotoxicity of compound against 8226/S cells,80433,,,CHEMBL620362,Intermediate,9606.0,,N,,F,5527,,741.0,Homo sapiens,1,,,RPMI-8226
,17079,1,BAO_0000219,Inhibitory concentration against 8226 myeloma cancer cell line,80433,,,CHEMBL620363,Intermediate,9606.0,,N,,F,5528,,741.0,Homo sapiens,1,,,RPMI-8226
,17079,1,BAO_0000219,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,80433,,,CHEMBL620364,Intermediate,9606.0,,N,,F,5529,,741.0,Homo sapiens,1,,,RPMI-8226
,13466,1,BAO_0000219,Inhibition of cell growth was studied in human teratocarcinoma (833K).,80647,,,CHEMBL620365,Intermediate,9606.0,,N,,F,5530,,854.0,Homo sapiens,1,,,833K
,13466,1,BAO_0000219,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',80647,,,CHEMBL620366,Intermediate,9606.0,,N,,F,5531,,854.0,Homo sapiens,1,,,833K
,2392,1,BAO_0000219,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,80647,,,CHEMBL620367,Expert,9606.0,,N,,F,5532,,854.0,Homo sapiens,1,,,833K
,2392,1,BAO_0000219,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,80647,,,CHEMBL620368,Intermediate,9606.0,,N,,F,5533,,854.0,Homo sapiens,1,,,833K
,6608,0,BAO_0000019,Inhibitory activity against caspase-1,22226,,,CHEMBL620369,Autocuration,,,U,,B,5534,,,,1,,,
,10199,8,BAO_0000357,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,45,,,CHEMBL620370,Autocuration,1351.0,,H,,B,5535,,,Enterococcus faecalis,1,,,
,17749,1,BAO_0000219,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,80648,,,CHEMBL620371,Intermediate,9606.0,,N,,F,5536,,705.0,Homo sapiens,1,,,8701-BC
,17749,1,BAO_0000219,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,80648,,,CHEMBL620372,Intermediate,9606.0,,N,,F,5537,,705.0,Homo sapiens,1,,,8701-BC
,1229,0,BAO_0000019,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,22226,,,CHEMBL876492,Intermediate,,,U,,F,5538,,,,1,,,
,1229,0,BAO_0000019,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,22226,,,CHEMBL620373,Intermediate,,,U,,F,5539,,,,1,,,
,1229,0,BAO_0000019,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,22226,,,CHEMBL620374,Intermediate,,,U,,F,5540,,,,1,,,
,6390,0,BAO_0000019,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,22226,,,CHEMBL620375,Autocuration,,,U,,B,5541,,,,1,,,
,16219,0,BAO_0000019,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,22226,,,CHEMBL857902,Autocuration,1314.0,,U,,F,5542,,,Streptococcus pyogenes,1,,,
,16219,0,BAO_0000019,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,22226,,,CHEMBL620376,Autocuration,1314.0,,U,,F,5543,,,Streptococcus pyogenes,1,,,
,17043,8,BAO_0000357,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,11922,,,CHEMBL620377,Autocuration,,,H,,B,5544,,,,1,,,
,6929,1,BAO_0000219,Tested for in vitro cytotoxic potency of compound in 9KB assay,81115,,,CHEMBL620378,Intermediate,9606.0,,N,,F,5545,,324.0,Homo sapiens,1,,,KB 
,6929,1,BAO_0000219,Tested for in vitro cytotoxic potency of compound in 9KB assay,81115,,,CHEMBL620379,Intermediate,9606.0,,N,,A,5546,,324.0,Homo sapiens,1,,,KB 
,7083,0,BAO_0000219,In vitro cytotoxicity of compound was tested against 9KB cells.,22226,,,CHEMBL620380,Autocuration,9606.0,,U,,F,5547,,,Homo sapiens,1,,,
,12446,1,BAO_0000219,Cytotoxic concentration against 9L cells was determined on day 3,80653,,,CHEMBL884006,Intermediate,10116.0,,N,,F,5548,,392.0,Rattus norvegicus,1,,,9L
,15345,1,BAO_0000219,Tested in vitro for anticancer activity against 9L cells,80653,,,CHEMBL620381,Expert,10116.0,,N,,F,5549,,392.0,Rattus norvegicus,1,,,9L
,15345,1,BAO_0000219,Tested in vitro for anticancer activity against 9L cells; Not determined,80653,,,CHEMBL620382,Expert,10116.0,,N,,F,5550,,392.0,Rattus norvegicus,1,,,9L
,6301,1,BAO_0000219,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,80682,,,CHEMBL620383,Intermediate,9606.0,,N,,F,5551,,646.0,Homo sapiens,1,,,A549
,4833,1,BAO_0000219,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,80682,,,CHEMBL876493,Intermediate,9606.0,,N,,F,5552,,646.0,Homo sapiens,1,,,A549
,4833,1,BAO_0000219,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,80682,,,CHEMBL620384,Intermediate,9606.0,,N,,F,5553,,646.0,Homo sapiens,1,,,A549
,4833,1,BAO_0000219,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,80682,,,CHEMBL620385,Intermediate,9606.0,,N,,F,5554,,646.0,Homo sapiens,1,,,A549
,13330,1,BAO_0000219,Cytotoxicity against human lung carcinoma A549 cell line,80682,,,CHEMBL620386,Expert,9606.0,,N,,F,5555,,646.0,Homo sapiens,1,,,A549
,17517,9,BAO_0000219,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,25,,,CHEMBL620387,Expert,9606.0,,D,,F,5556,,646.0,Homo sapiens,1,,,A549
,17517,9,BAO_0000219,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",25,,,CHEMBL621404,Expert,9606.0,,D,,F,5557,,646.0,Homo sapiens,1,,,A549
,14425,1,BAO_0000219,"In vitro growth inhibition of A549, lung carcinoma",80682,,,CHEMBL621405,Intermediate,9606.0,,N,,F,5558,,646.0,Homo sapiens,1,,,A549
,14425,1,BAO_0000219,"In vitro growth inhibition of A549, lung carcinoma.",80682,,,CHEMBL621406,Intermediate,9606.0,,N,,F,5559,,646.0,Homo sapiens,1,,,A549
,5228,1,BAO_0000219,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,80682,,,CHEMBL621407,Expert,9606.0,,N,,F,5560,,646.0,Homo sapiens,1,,,A549
,5351,1,BAO_0000219,Cytotoxic activity against human lung cancer A549 cell line was determined,80682,,,CHEMBL621408,Intermediate,9606.0,,N,,F,5561,,646.0,Homo sapiens,1,,,A549
,12198,1,BAO_0000219,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,80682,,,CHEMBL885345,Expert,9606.0,,N,,F,5562,,646.0,Homo sapiens,1,,,A549
,13891,1,BAO_0000219,Cytotoxicity concentration against human lung carcinoma A-549 cell line,80682,,,CHEMBL621409,Intermediate,9606.0,,N,,F,5563,,646.0,Homo sapiens,1,,,A549
,5677,1,BAO_0000219,Cytotoxicity in A549 (human carcinoma) cell line.,80682,,,CHEMBL876034,Expert,9606.0,,N,,F,5564,,646.0,Homo sapiens,1,,,A549
,13788,1,BAO_0000219,Cytotoxicity on lung carcinoma (A-549) cell line,80682,,,CHEMBL621410,Intermediate,9606.0,,N,,F,5565,,646.0,Homo sapiens,1,,,A549
,13384,1,BAO_0000219,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,80682,,,CHEMBL621411,Expert,9606.0,,N,,F,5566,,646.0,Homo sapiens,1,,,A549
,6726,1,BAO_0000219,Effective dose of compound against replication of A549 cell line was evaluated,80682,,,CHEMBL621412,Intermediate,9606.0,,N,,F,5567,,646.0,Homo sapiens,1,,,A549
,3455,1,BAO_0000219,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,80682,,,CHEMBL621413,Expert,9606.0,,N,,F,5568,,646.0,Homo sapiens,1,,,A549
,5726,1,BAO_0000219,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),80682,,,CHEMBL621414,Intermediate,9606.0,,N,,F,5569,,646.0,Homo sapiens,1,,,A549
,5726,1,BAO_0000219,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,80682,,,CHEMBL621415,Intermediate,9606.0,,N,,F,5570,,646.0,Homo sapiens,1,,,A549
,3936,1,BAO_0000219,The compound was evaluated for antiproliferative activity against A549 cell line,80682,,,CHEMBL621416,Intermediate,9606.0,,N,,F,5571,,646.0,Homo sapiens,1,,,A549
,14991,1,BAO_0000219,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,80682,,,CHEMBL621417,Intermediate,9606.0,,N,,F,5572,,646.0,Homo sapiens,1,,,A549
,5243,1,BAO_0000219,Concentration required for growth inhibition of human lung carcinoma cell line A549,80682,,,CHEMBL621418,Intermediate,9606.0,,N,,F,5573,,646.0,Homo sapiens,1,,,A549
,12858,1,BAO_0000219,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,80682,,,CHEMBL621419,Intermediate,9606.0,,N,,F,5574,,646.0,Homo sapiens,1,,,A549
,6776,1,BAO_0000219,Growth inhibition against A549 cell line was evaluated,80682,,,CHEMBL621420,Intermediate,9606.0,,N,,F,5575,,646.0,Homo sapiens,1,,,A549
,16558,1,BAO_0000219,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,80682,,,CHEMBL875823,Intermediate,9606.0,,N,,F,5576,,646.0,Homo sapiens,1,,,A549
,4583,1,BAO_0000219,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,80682,,,CHEMBL621421,Expert,9606.0,,N,,F,5577,,646.0,Homo sapiens,1,,,A549
,13514,1,BAO_0000219,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,80682,,,CHEMBL621422,Intermediate,9606.0,,N,,F,5578,,646.0,Homo sapiens,1,,,A549
,15166,1,BAO_0000219,Chemosensitivity against DT-diaphorase rich A549 cell lines,80682,,,CHEMBL884014,Expert,9606.0,,N,,F,5579,,646.0,Homo sapiens,1,,,A549
,13873,1,BAO_0000219,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,80682,,,CHEMBL621423,Intermediate,9606.0,,N,,F,5580,,646.0,Homo sapiens,1,,,A549
,6447,1,BAO_0000219,In vitro cytotoxicity against human A549 (lung cancer) cell line.,80682,,,CHEMBL621424,Expert,9606.0,,N,,F,5581,,646.0,Homo sapiens,1,,,A549
,2068,1,BAO_0000219,In vitro antitumor activity against A549 (lung) human tumor cell lines.,80682,,,CHEMBL621425,Intermediate,9606.0,,N,,F,5582,,646.0,Homo sapiens,1,,,A549
,1863,1,BAO_0000219,In vitro cytotoxic activity against human lung carcinoma A549 cell line,80682,,,CHEMBL621426,Expert,9606.0,,N,,F,5583,,646.0,Homo sapiens,1,,,A549
,13873,1,BAO_0000219,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,80682,,,CHEMBL621427,Intermediate,9606.0,,N,,F,5584,,646.0,Homo sapiens,1,,,A549
,13873,1,BAO_0000219,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,80682,,,CHEMBL621428,Intermediate,9606.0,,N,,F,5585,,646.0,Homo sapiens,1,,,A549
,13873,1,BAO_0000219,Tested against A549 lung carcinoma in the sulforhodamine B assay.,80682,,,CHEMBL621429,Expert,9606.0,,N,,F,5586,,646.0,Homo sapiens,1,,,A549
,579,1,BAO_0000219,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),80682,,,CHEMBL621430,Intermediate,9606.0,,N,,F,5587,,646.0,Homo sapiens,1,,,A549
,579,1,BAO_0000219,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,80682,,,CHEMBL621431,Intermediate,9606.0,,N,,F,5588,,646.0,Homo sapiens,1,,,A549
,4584,1,BAO_0000219,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,80682,,,CHEMBL621432,Intermediate,9606.0,,N,,F,5589,,646.0,Homo sapiens,1,,,A549
,5421,1,BAO_0000219,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,80682,,,CHEMBL621433,Expert,9606.0,,N,,F,5590,,646.0,Homo sapiens,1,,,A549
,5421,1,BAO_0000219,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,80682,,,CHEMBL875824,Intermediate,9606.0,,N,,F,5591,,646.0,Homo sapiens,1,,,A549
,5421,1,BAO_0000219,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,80682,,,CHEMBL621434,Intermediate,9606.0,,N,,F,5592,,646.0,Homo sapiens,1,,,A549
,5421,1,BAO_0000219,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,80682,,,CHEMBL621435,Intermediate,9606.0,,N,,F,5593,,646.0,Homo sapiens,1,,,A549
,14188,1,BAO_0000219,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,80682,,,CHEMBL621436,Intermediate,9606.0,,N,,F,5594,,646.0,Homo sapiens,1,,,A549
,14188,1,BAO_0000219,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,80682,,,CHEMBL621437,Intermediate,9606.0,,N,,F,5595,,646.0,Homo sapiens,1,,,A549
,15354,1,BAO_0000219,Compound was tested for the growth inhibition of A549 lung tumor cell line,80682,,,CHEMBL621438,Intermediate,9606.0,,N,,F,5596,,646.0,Homo sapiens,1,,,A549
,14253,1,BAO_0000219,Growth inhibition of human non-small-lung carcinoma (A549) cell line,80682,,,CHEMBL621439,Expert,9606.0,,N,,F,5597,,646.0,Homo sapiens,1,,,A549
,13873,1,BAO_0000219,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,80682,,,CHEMBL621440,Intermediate,9606.0,,N,,F,5598,,646.0,Homo sapiens,1,,,A549
,3043,1,BAO_0000218,Oral bioavailability in dog (conscious),50588,In vivo,,CHEMBL621441,Intermediate,9615.0,,N,,A,5599,,,Canis lupus familiaris,1,,,
,3045,1,BAO_0000218,Compound was evaluated for the oral bioavailability after oral administration in dog.,50588,In vivo,,CHEMBL621442,Intermediate,9615.0,,N,,A,5600,,,Canis lupus familiaris,1,,,
,3022,1,BAO_0000218,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,50588,In vivo,,CHEMBL621443,Intermediate,9615.0,,N,,A,5601,,,Canis lupus familiaris,1,,,
,4453,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL621444,Intermediate,9615.0,,N,,A,5602,,,Canis lupus familiaris,1,,,
,1696,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL625133,Intermediate,9615.0,,N,,A,5603,,,Canis lupus familiaris,1,,,
,5045,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL625134,Intermediate,9615.0,,N,,A,5604,,,Canis lupus familiaris,1,,,
,5356,1,BAO_0000218,Oral bioavailability in dog (fasted),50588,In vivo,,CHEMBL625135,Intermediate,9615.0,,N,,A,5605,,,Canis lupus familiaris,1,,,
,17764,1,BAO_0000218,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,50588,In vivo,,CHEMBL625136,Intermediate,9615.0,,N,,A,5606,,,Canis lupus familiaris,1,,,
,6448,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL625137,Intermediate,9615.0,,N,,A,5607,,,Canis lupus familiaris,1,,,
,1475,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL625138,Intermediate,9615.0,,N,,A,5608,,,Canis lupus familiaris,1,,,
,3788,1,BAO_0000218,Percent bioavailability in dog,50588,In vivo,,CHEMBL625139,Intermediate,9615.0,,N,,A,5609,,,Canis lupus familiaris,1,,,
,3639,1,BAO_0000218,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,50588,In vivo,,CHEMBL872264,Intermediate,9615.0,,N,,A,5610,,,Canis lupus familiaris,1,,,
,13397,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL625140,Intermediate,9615.0,,N,,A,5611,,,Canis lupus familiaris,1,,,
,2137,1,BAO_0000218,The compound was evaluated for bioavailability in dogs; 34-44,50588,In vivo,,CHEMBL624436,Intermediate,9615.0,,N,,A,5612,,,Canis lupus familiaris,1,,,
,2959,1,BAO_0000218,Bioavailability in dog (dose 4 mg/kg p.o.),50588,In vivo,,CHEMBL624437,Intermediate,9615.0,,N,,A,5613,,,Canis lupus familiaris,1,,,
,6448,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL872261,Intermediate,9615.0,,N,,A,5614,,,Canis lupus familiaris,1,,,
,6084,1,BAO_0000218,8 hour trough Blood level in dog was measured after administration of compound,50588,,,CHEMBL624438,Intermediate,9615.0,,N,,A,5615,,,Canis lupus familiaris,1,,,
,3639,1,BAO_0000218,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,50588,In vivo,Plasma,CHEMBL624439,Intermediate,9615.0,,N,,A,5616,,,Canis lupus familiaris,1,,1969.0,
,6316,1,BAO_0000218,C24 after oral administration at 5 mg/kg,50588,,,CHEMBL624440,Intermediate,9615.0,,N,,A,5617,,,Canis lupus familiaris,1,,,
,5238,1,BAO_0000218,Clearance after oral and iv dosing in dogs,50588,,,CHEMBL624441,Intermediate,9615.0,,N,,A,5618,,,Canis lupus familiaris,1,,,
,17796,1,BAO_0000218,Clearance of the drug was measured in the plasma of dog,50588,,Plasma,CHEMBL624442,Intermediate,9615.0,,N,,A,5619,,,Canis lupus familiaris,1,,1969.0,
,2652,1,BAO_0000218,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,50588,,,CHEMBL624443,Intermediate,9615.0,,N,,A,5620,,,Canis lupus familiaris,1,,,
,5654,1,BAO_0000218,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,50588,In vivo,,CHEMBL624444,Intermediate,9615.0,,N,,A,5621,,,Canis lupus familiaris,1,,,
,6621,1,BAO_0000218,Clearance of compound was determined in dogs,50588,In vivo,,CHEMBL624445,Intermediate,9615.0,,N,,A,5622,,,Canis lupus familiaris,1,,,
,6505,1,BAO_0000218,Clearance on i.v. administration of 2 mg/kg was measured in dog,50588,In vivo,,CHEMBL624446,Intermediate,9615.0,,N,,A,5623,,,Canis lupus familiaris,1,,,
,5802,1,BAO_0000218,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,50588,In vivo,,CHEMBL624447,Intermediate,9615.0,,N,,A,5624,,,Canis lupus familiaris,1,,,
,17267,1,BAO_0000218,Plasma clearance in dog was determined,50588,In vivo,,CHEMBL624448,Intermediate,9615.0,,N,,A,5625,,,Canis lupus familiaris,1,,,
,4521,1,BAO_0000218,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,50588,In vivo,,CHEMBL624449,Intermediate,9615.0,,N,,A,5626,,,Canis lupus familiaris,1,,,
,6535,1,BAO_0000218,Plasma clearance in dog after administration of 0.25 mg/kg iv,50588,In vivo,,CHEMBL624450,Intermediate,9615.0,,N,,A,5627,,,Canis lupus familiaris,1,,,
,6535,1,BAO_0000218,Plasma clearance in dog after administration of 1 mg/kg iv,50588,In vivo,,CHEMBL875942,Intermediate,9615.0,,N,,A,5628,,,Canis lupus familiaris,1,,,
,6535,1,BAO_0000218,Plasma clearance in dogs,50588,In vivo,,CHEMBL624451,Intermediate,9615.0,,N,,A,5629,,,Canis lupus familiaris,1,,,
,5542,1,BAO_0000218,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,50588,In vivo,,CHEMBL624452,Intermediate,9615.0,,N,,A,5630,,,Canis lupus familiaris,1,,,
,5199,1,BAO_0000218,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,50588,In vivo,,CHEMBL624453,Intermediate,9615.0,,N,,A,5631,,,Canis lupus familiaris,1,,,
,16907,1,BAO_0000218,Plasma clearance after 15 mg/kg iv dose in Dogs,50588,In vivo,,CHEMBL624454,Intermediate,9615.0,,N,,A,5632,,,Canis lupus familiaris,1,,,
,16907,1,BAO_0000218,Plasma clearance after 30 mg/kg po dose in Dogs,50588,In vivo,,CHEMBL624455,Intermediate,9615.0,,N,,A,5633,,,Canis lupus familiaris,1,,,
,16367,1,BAO_0000218,Plasma administration to dogs,50588,In vivo,,CHEMBL624456,Intermediate,9615.0,,N,,A,5634,,,Canis lupus familiaris,1,,,
,5505,1,BAO_0000218,Plasma clearance was determined,50588,In vivo,,CHEMBL624457,Intermediate,9615.0,,N,,A,5635,,,Canis lupus familiaris,1,,,
,6215,1,BAO_0000218,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,50588,In vivo,,CHEMBL624458,Intermediate,9615.0,,N,,A,5636,,,Canis lupus familiaris,1,,,
,1466,1,BAO_0000218,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,50588,In vivo,,CHEMBL624459,Intermediate,9615.0,,N,,A,5637,,,Canis lupus familiaris,1,,,
,5007,2,BAO_0000251,Intrinsic clearance in human liver microsomes,102164,In vitro,Liver,CHEMBL624460,Intermediate,9606.0,Microsomes,S,,A,5638,,,Homo sapiens,1,,2107.0,
,5007,2,BAO_0000251,Intrinsic clearance in human liver microsomes,102164,In vitro,Liver,CHEMBL624461,Intermediate,9606.0,Microsomes,S,,A,5639,,,Homo sapiens,1,,2107.0,
,16452,1,BAO_0000218,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,50588,In vivo,,CHEMBL875943,Intermediate,9615.0,,N,,A,5640,,,Canis lupus familiaris,1,,,
,16452,1,BAO_0000218,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,50588,In vivo,,CHEMBL624462,Intermediate,9615.0,,N,,A,5641,,,Canis lupus familiaris,1,,,
,16452,1,BAO_0000218,Clearance in dog (dose 1 mg/kg i.v.),50588,In vivo,,CHEMBL624463,Intermediate,9615.0,,N,,A,5642,,,Canis lupus familiaris,1,,,
,6221,1,BAO_0000218,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,50588,In vivo,,CHEMBL624464,Intermediate,9615.0,,N,,A,5643,,,Canis lupus familiaris,1,,,
,5007,1,BAO_0000218,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),50588,In vivo,,CHEMBL624465,Intermediate,9615.0,,N,,A,5644,,,Canis lupus familiaris,1,,,
,5668,1,BAO_0000218,Plasma clearance after peroral administration at 10 mpk in dog,50588,In vivo,,CHEMBL624466,Intermediate,9615.0,,N,,A,5645,,,Canis lupus familiaris,1,,,
,5668,1,BAO_0000218,Plasma clearance after peroral administration at 5 mpk in dog,50588,In vivo,,CHEMBL624467,Intermediate,9615.0,,N,,A,5646,,,Canis lupus familiaris,1,,,
,5668,1,BAO_0000218,Plasma clearance after peroral administration at 5 mg/kg in dog,50588,In vivo,,CHEMBL624468,Intermediate,9615.0,,N,,A,5647,,,Canis lupus familiaris,1,,,
,15660,1,BAO_0000218,Plasma clearance was measured in dog,50588,In vivo,,CHEMBL624469,Intermediate,9615.0,,N,,A,5648,,,Canis lupus familiaris,1,,,
,15660,1,BAO_0000218,Plasma clearance was measured in dog,50588,In vivo,,CHEMBL624470,Intermediate,9615.0,,N,,A,5649,,,Canis lupus familiaris,1,,,
,5983,1,BAO_0000218,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,50588,In vivo,,CHEMBL624471,Intermediate,9615.0,,N,,A,5650,,,Canis lupus familiaris,1,,,
,5600,1,BAO_0000218,Total clearance was determined after 0.1 mg/kg iv administration in dog,50588,In vivo,,CHEMBL624472,Intermediate,9615.0,,N,,A,5651,,,Canis lupus familiaris,1,,,
,17764,1,BAO_0000218,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,50588,In vivo,,CHEMBL622775,Intermediate,9615.0,,N,,A,5652,,,Canis lupus familiaris,1,,,
,6039,1,BAO_0000218,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,50588,In vivo,,CHEMBL622776,Intermediate,9615.0,,N,,A,5653,,,Canis lupus familiaris,1,,,
,6039,1,BAO_0000218,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,50588,In vivo,,CHEMBL622777,Intermediate,9615.0,,N,,A,5654,,,Canis lupus familiaris,1,,,
,6039,1,BAO_0000218,Clearance after peroral administration of 0.2 mg/kg in dog was determined,50588,In vivo,,CHEMBL622778,Intermediate,9615.0,,N,,A,5655,,,Canis lupus familiaris,1,,,
,4368,1,BAO_0000218,Clearance by intravenous administration of 1.2 mg/kg in dog,50588,In vivo,,CHEMBL622779,Intermediate,9615.0,,N,,A,5656,,,Canis lupus familiaris,1,,,
,4305,1,BAO_0000218,Clearance by iv administration in dogs at a dose of 1 mg/kg,50588,In vivo,,CHEMBL622780,Intermediate,9615.0,,N,,A,5657,,,Canis lupus familiaris,1,,,
,1918,1,BAO_0000218,Clearance value was evaluated in dog plasma,50588,In vivo,Plasma,CHEMBL622781,Intermediate,9615.0,,N,,A,5658,,,Canis lupus familiaris,1,,1969.0,
,6005,1,BAO_0000218,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,50588,In vivo,,CHEMBL622782,Intermediate,9615.0,,N,,A,5659,,,Canis lupus familiaris,1,,,
,4839,1,BAO_0000218,Compound was tested for plasma clearance in dog,50588,In vivo,Plasma,CHEMBL622783,Intermediate,9615.0,,N,,A,5660,,,Canis lupus familiaris,1,,1969.0,
,4239,1,BAO_0000218,Pharmacokinetic property (Plasma clearance) was measured in dog,50588,In vivo,,CHEMBL622784,Intermediate,9615.0,,N,,A,5661,,,Canis lupus familiaris,1,,,
,17729,1,BAO_0000218,Area under curve when injected perorally in mice at a dose of 50 mg/kg,50594,,,CHEMBL622785,Intermediate,10090.0,,N,,A,5662,,,Mus musculus,1,,,
,17728,1,BAO_0000218,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,50594,,,CHEMBL622786,Intermediate,10090.0,,N,,A,5663,,,Mus musculus,1,,,
,5302,1,BAO_0000218,Area under curve value in mouse at a dose of 10 mg/kg,50594,,,CHEMBL622787,Intermediate,10090.0,,N,,A,5664,,,Mus musculus,1,,,
,5506,1,BAO_0000218,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,50594,,,CHEMBL875949,Intermediate,10090.0,,N,,A,5665,,,Mus musculus,1,,,
,5506,1,BAO_0000218,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,50594,,,CHEMBL622788,Intermediate,10090.0,,N,,A,5666,,,Mus musculus,1,,,
,17764,1,BAO_0000218,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,50594,,,CHEMBL622789,Intermediate,10090.0,,N,,F,5667,,,Mus musculus,1,,,
,17764,1,BAO_0000218,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,50594,,,CHEMBL622790,Intermediate,10090.0,,N,,F,5668,,,Mus musculus,1,,,
,17764,1,BAO_0000218,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,50594,,,CHEMBL622791,Intermediate,10090.0,,N,,F,5669,,,Mus musculus,1,,,
,17764,1,BAO_0000218,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,50594,,,CHEMBL622792,Intermediate,10090.0,,N,,F,5670,,,Mus musculus,1,,,
,17764,1,BAO_0000218,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,50594,,,CHEMBL622793,Intermediate,10090.0,,N,,A,5671,,,Mus musculus,1,,,
,17753,1,BAO_0000218,Area under curve was determined for the compound at 24 mg/Kg,50594,,,CHEMBL622794,Intermediate,10090.0,,N,,A,5672,,,Mus musculus,1,,,
,17753,1,BAO_0000218,Area under curve was determined for the compound at 40 mg/Kg,50594,,,CHEMBL622795,Intermediate,10090.0,,N,,A,5673,,,Mus musculus,1,,,
,17753,1,BAO_0000218,Area under curve was determined for the compound at 5 mg/Kg,50594,,,CHEMBL621803,Intermediate,10090.0,,N,,A,5674,,,Mus musculus,1,,,
,3132,1,BAO_0000218,Area under the curve for the compound is obtained at dose 25 mg/kg,50594,,,CHEMBL621804,Intermediate,10090.0,,N,,A,5675,,,Mus musculus,1,,,
,3132,1,BAO_0000218,Area under the curve for the compound was obtained when tested in mouse,50594,,,CHEMBL621805,Intermediate,10090.0,,N,,A,5676,,,Mus musculus,1,,,
,17837,1,BAO_0000218,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,50594,,,CHEMBL621806,Intermediate,10090.0,,N,,A,5677,,,Mus musculus,1,,,
,17837,1,BAO_0000218,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,50594,,,CHEMBL621807,Intermediate,10090.0,,N,,A,5678,,,Mus musculus,1,,,
,6062,1,BAO_0000218,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,50594,,,CHEMBL621808,Intermediate,10090.0,,N,,A,5679,,,Mus musculus,1,,,
,4066,1,BAO_0000218,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,50594,,,CHEMBL621809,Intermediate,10090.0,,N,,A,5680,,,Mus musculus,1,,,
,16597,1,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),50594,,,CHEMBL621810,Intermediate,10090.0,,N,,A,5681,,,Mus musculus,1,,,
,14239,1,BAO_0000218,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,50594,,,CHEMBL875164,Intermediate,10090.0,,N,,A,5682,,,Mus musculus,1,,,
,14239,1,BAO_0000218,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,50594,,,CHEMBL621811,Intermediate,10090.0,,N,,A,5683,,,Mus musculus,1,,,
,4890,1,BAO_0000218,"Compound was evaluated for the pharmacokinetic parameter, area under curve",50594,,,CHEMBL621812,Intermediate,10090.0,,N,,A,5684,,,Mus musculus,1,,,
,429,1,BAO_0000218,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),50594,,,CHEMBL621813,Intermediate,10090.0,,N,,A,5685,,,Mus musculus,1,,,
,429,1,BAO_0000218,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),50594,,,CHEMBL621814,Intermediate,10090.0,,N,,A,5686,,,Mus musculus,1,,,
,5969,1,BAO_0000218,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,50594,,,CHEMBL621815,Intermediate,10090.0,,N,,A,5687,,,Mus musculus,1,,,
,5969,1,BAO_0000218,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,50594,,,CHEMBL621816,Intermediate,10090.0,,N,,A,5688,,,Mus musculus,1,,,
,5969,1,BAO_0000218,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,50594,,,CHEMBL621817,Intermediate,10090.0,,N,,A,5689,,,Mus musculus,1,,,
,6091,1,BAO_0000218,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,50594,,,CHEMBL621818,Intermediate,10090.0,,N,,A,5690,,,Mus musculus,1,,,
,6091,1,BAO_0000218,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,50594,,,CHEMBL621819,Intermediate,10090.0,,N,,A,5691,,,Mus musculus,1,,,
,6091,1,BAO_0000218,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,50594,,,CHEMBL621820,Intermediate,10090.0,,N,,A,5692,,,Mus musculus,1,,,
,6091,1,BAO_0000218,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,50594,,,CHEMBL621821,Intermediate,10090.0,,N,,A,5693,,,Mus musculus,1,,,
,6178,1,BAO_0000218,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,50594,,,CHEMBL621822,Intermediate,10090.0,,N,,A,5694,,,Mus musculus,1,,,
,6178,1,BAO_0000218,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,50594,,,CHEMBL619474,Intermediate,10090.0,,N,,A,5695,,,Mus musculus,1,,,
,6619,1,BAO_0000218,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",50594,,,CHEMBL619475,Intermediate,10090.0,,N,,A,5696,,,Mus musculus,1,,,
,6619,1,BAO_0000218,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",50594,,,CHEMBL619476,Intermediate,10090.0,,N,,A,5697,,,Mus musculus,1,,,
,3760,1,BAO_0000218,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",50594,,,CHEMBL619477,Intermediate,10090.0,,N,,A,5698,,,Mus musculus,1,,,
,3760,1,BAO_0000218,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",50594,,,CHEMBL619478,Intermediate,10090.0,,N,,A,5699,,,Mus musculus,1,,,
,3760,1,BAO_0000218,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",50594,,,CHEMBL619479,Intermediate,10090.0,,N,,A,5700,,,Mus musculus,1,,,
,3760,1,BAO_0000218,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",50594,,,CHEMBL619480,Intermediate,10090.0,,N,,A,5701,,,Mus musculus,1,,,
,3192,1,BAO_0000218,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,50594,,,CHEMBL619481,Intermediate,10090.0,,N,,A,5702,,,Mus musculus,1,,,
,3192,1,BAO_0000218,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,50594,,,CHEMBL619482,Intermediate,10090.0,,N,,A,5703,,,Mus musculus,1,,,
,2675,1,BAO_0000218,Area under the curve was evaluated in mice after intravenous administration,50594,,,CHEMBL619483,Intermediate,10090.0,,N,,A,5704,,,Mus musculus,1,,,
,2675,1,BAO_0000218,Area under the curve was evaluated in mice after oral administration,50594,,,CHEMBL619484,Intermediate,10090.0,,N,,A,5705,,,Mus musculus,1,,,
,16597,1,BAO_0000218,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,50594,,Plasma,CHEMBL619485,Intermediate,10090.0,,N,,A,5706,,,Mus musculus,1,,1969.0,
,16597,1,BAO_0000218,AUC total value at a dose of 10 mg/kg peroral administration in mice.,50594,,Plasma,CHEMBL619486,Intermediate,10090.0,,N,,A,5707,,,Mus musculus,1,,1969.0,
,16597,1,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),50594,,,CHEMBL619487,Intermediate,10090.0,,N,,A,5708,,,Mus musculus,1,,,
,17734,1,BAO_0000218,AUMC after intraperitoneal administration of 100 mg/kg in mice,50594,,,CHEMBL619488,Intermediate,10090.0,,N,,A,5709,,,Mus musculus,1,,,
,7767,1,BAO_0000218,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,50594,In vivo,Blood,CHEMBL620106,Intermediate,10090.0,,N,,A,5710,,,Mus musculus,1,,178.0,
,15345,1,BAO_0000219,The compound was tested in vitro for anticancer activity against 9L cells,80653,,,CHEMBL620107,Intermediate,,,N,,F,5711,,392.0,,1,,,9L
,2181,0,BAO_0000019,Anti proliferation activity determined; Weak effect,22226,,,CHEMBL620283,Autocuration,10116.0,,U,,F,5712,,,Rattus norvegicus,1,,,
,2181,0,BAO_0000219,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,22226,,,CHEMBL875176,Autocuration,10116.0,,U,,F,5713,,,Rattus norvegicus,1,,,
,2181,0,BAO_0000219,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,22226,,,CHEMBL620284,Autocuration,10116.0,,U,,F,5714,,,Rattus norvegicus,1,,,
,2181,0,BAO_0000219,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,22226,,,CHEMBL623515,Autocuration,10116.0,,U,,F,5715,,,Rattus norvegicus,1,,,
,10486,0,BAO_0000019,The cytotoxic activity was in vitro tested by 9PS assay method,22226,,,CHEMBL623516,Autocuration,10090.0,,U,,F,5716,,,Mus musculus,1,,,
,10486,0,BAO_0000019,The cytotoxic activity was in vitro tested by 9PS assay method.,22226,,,CHEMBL623517,Autocuration,10090.0,,U,,F,5717,,,Mus musculus,1,,,
,15508,0,BAO_0000019,Partition coefficient (logD6.5),22224,,,CHEMBL857878,Autocuration,,,U,,A,5718,,,,1,,,
,5242,1,BAO_0000219,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,81034,,,CHEMBL623518,Expert,9606.0,,N,,F,5719,,478.0,Homo sapiens,1,,,A2780
,16167,1,BAO_0000219,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),80018,,,CHEMBL624195,Intermediate,9606.0,,N,,F,5720,,455.0,Homo sapiens,1,,,A-375
,4782,1,BAO_0000219,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,80852,,,CHEMBL624196,Expert,9606.0,,N,,F,5721,,500.0,Homo sapiens,1,,,A-431
,16093,9,BAO_0000219,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,9,,,CHEMBL624197,Expert,9606.0,,D,,F,5722,,500.0,Homo sapiens,1,,,A-431
,2596,1,BAO_0000219,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,80021,,,CHEMBL624198,Intermediate,9606.0,,N,,F,5723,,624.0,Homo sapiens,1,,,A498
,2596,1,BAO_0000219,in vitro cytotoxicity against A 498 cancer cell line,80021,,,CHEMBL621287,Intermediate,9606.0,,N,,F,5724,,624.0,Homo sapiens,1,,,A498
,3239,1,BAO_0000219,In vitro cytotoxic activity against renal (A 498) cancer cell line.,80021,,,CHEMBL621288,Intermediate,9606.0,,N,,F,5725,,624.0,Homo sapiens,1,,,A498
,1847,1,BAO_0000219,Cytotoxic activity against A 498 renal cancer cell lines.,80021,,,CHEMBL876496,Intermediate,9606.0,,N,,F,5726,,624.0,Homo sapiens,1,,,A498
,10553,1,BAO_0000219,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,80021,,,CHEMBL621289,Intermediate,9606.0,,N,,F,5727,,624.0,Homo sapiens,1,,,A498
,16219,0,BAO_0000019,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,22226,,,CHEMBL621290,Autocuration,1280.0,,U,,F,5728,,,Staphylococcus aureus,1,,,
,16219,0,BAO_0000019,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,22226,,,CHEMBL621291,Autocuration,1280.0,,U,,F,5729,,,Staphylococcus aureus,1,,,
,16219,0,BAO_0000019,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,22226,,,CHEMBL621292,Autocuration,1280.0,,U,,F,5730,,,Staphylococcus aureus,1,,,
,16219,0,BAO_0000019,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,22226,,,CHEMBL621293,Autocuration,1280.0,,U,,F,5731,,,Staphylococcus aureus,1,,,
,4782,1,BAO_0000219,Inhibitory concentration required against A 549 lung cancer cell line,80682,,,CHEMBL621294,Intermediate,9606.0,,N,,F,5732,,646.0,Homo sapiens,1,,,A549
,11805,1,BAO_0000219,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,80682,,,CHEMBL621295,Intermediate,9606.0,,N,,F,5733,,646.0,Homo sapiens,1,,,A549
,11805,1,BAO_0000219,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,80682,,,CHEMBL884007,Intermediate,9606.0,,N,,F,5734,,646.0,Homo sapiens,1,,,A549
,2007,1,BAO_0000219,In vitro cytotoxicity against lung cancer A 549 cell lines,80682,,,CHEMBL621296,Intermediate,9606.0,,N,,F,5735,,646.0,Homo sapiens,1,,,A549
,4594,1,BAO_0000219,Compound was tested for its cytotoxicity against A 549 cell line,80682,,,CHEMBL621297,Intermediate,9606.0,,N,,F,5736,,646.0,Homo sapiens,1,,,A549
,6018,1,BAO_0000219,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",80682,,,CHEMBL839828,Expert,9606.0,,N,,F,5737,,646.0,Homo sapiens,1,,,A549
,6018,1,BAO_0000219,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",80682,,,CHEMBL620397,Intermediate,9606.0,,N,,F,5738,,646.0,Homo sapiens,1,,,A549
,3599,1,BAO_0000219,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,80682,,,CHEMBL620398,Expert,9606.0,,N,,F,5739,,646.0,Homo sapiens,1,,,A549
,2551,1,BAO_0000219,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,80682,,,CHEMBL620399,Intermediate,9606.0,,N,,F,5740,,646.0,Homo sapiens,1,,,A549
,16132,1,BAO_0000219,In vitro inhibition of A549 (human lung cancer) cell growth.,80682,,,CHEMBL620400,Expert,9606.0,,N,,F,5741,,646.0,Homo sapiens,1,,,A549
,16132,1,BAO_0000219,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,80682,,,CHEMBL620401,Intermediate,9606.0,,N,,F,5742,,646.0,Homo sapiens,1,,,A549
,2551,1,BAO_0000219,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,80682,,,CHEMBL620402,Expert,9606.0,,N,,F,5743,,646.0,Homo sapiens,1,,,A549
,2551,1,BAO_0000219,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),80682,,,CHEMBL620403,Expert,9606.0,,N,,F,5744,,646.0,Homo sapiens,1,,,A549
,11913,0,BAO_0000218,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,22226,,,CHEMBL620404,Autocuration,,,U,,F,5745,,,,1,,,
,12621,4,BAO_0000218,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,104694,In vivo,,CHEMBL620405,Autocuration,,,H,,F,5746,,,,1,,,
,12621,4,BAO_0000218,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,104694,In vivo,,CHEMBL620406,Autocuration,,,H,,F,5747,,,,1,,,
,12621,4,BAO_0000218,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,104694,In vivo,,CHEMBL620407,Autocuration,,,H,,F,5748,,,,1,,,
,12621,4,BAO_0000218,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,104694,In vivo,,CHEMBL620408,Autocuration,,,H,,F,5749,,,,1,,,
,12621,4,BAO_0000218,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,104694,In vivo,,CHEMBL620409,Autocuration,,,H,,F,5750,,,,1,,,
,3600,1,BAO_0000219,Inhibition of A-498 human Renal cell proliferation,80021,,,CHEMBL620410,Expert,9606.0,,N,,F,5751,,624.0,Homo sapiens,1,,,A498
,1796,0,BAO_0000019,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",22226,,,CHEMBL620411,Autocuration,10116.0,,U,,F,5752,,,Rattus norvegicus,1,,,
,1796,0,BAO_0000019,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",22226,,,CHEMBL620412,Autocuration,10116.0,,U,,F,5753,,,Rattus norvegicus,1,,,
,1796,0,BAO_0000019,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",22226,,,CHEMBL876596,Autocuration,10116.0,,U,,F,5754,,,Rattus norvegicus,1,,,
,16464,1,BAO_0000219,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,80012,,,CHEMBL620413,Expert,9606.0,,N,,F,5755,,622.0,Homo sapiens,1,,,A 172
,16464,1,BAO_0000219,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80012,,,CHEMBL620414,Intermediate,9606.0,,N,,F,5756,,622.0,Homo sapiens,1,,,A 172
,16464,1,BAO_0000219,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80012,,,CHEMBL620415,Intermediate,9606.0,,N,,F,5757,,622.0,Homo sapiens,1,,,A 172
,13617,1,BAO_0000219,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,80682,,,CHEMBL620416,Expert,9606.0,,N,,F,5758,,646.0,Homo sapiens,1,,,A549
,4584,1,BAO_0000219,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,80682,,,CHEMBL620417,Intermediate,9606.0,,N,,F,5759,,646.0,Homo sapiens,1,,,A549
,13799,1,BAO_0000219,Cytotoxic activity evaluated against A549 tumor cells,80682,,,CHEMBL620418,Expert,9606.0,,N,,F,5760,,646.0,Homo sapiens,1,,,A549
,16726,1,BAO_0000219,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,80682,,,CHEMBL620419,Intermediate,9606.0,,N,,F,5761,,646.0,Homo sapiens,1,,,A549
,16109,1,BAO_0000219,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,80682,,,CHEMBL620420,Intermediate,9606.0,,N,,F,5762,,646.0,Homo sapiens,1,,,A549
,16109,1,BAO_0000219,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,80682,,,CHEMBL620421,Intermediate,9606.0,,N,,F,5763,,646.0,Homo sapiens,1,,,A549
,15474,1,BAO_0000219,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,80682,,,CHEMBL620422,Intermediate,9606.0,,N,,F,5764,,646.0,Homo sapiens,1,,,A549
,6851,1,BAO_0000219,Cytotoxicity of compound against A549 cell line,80682,,,CHEMBL620423,Intermediate,9606.0,,N,,F,5765,,646.0,Homo sapiens,1,,,A549
,17534,1,BAO_0000219,Cytotoxicity against human lung cell carcinoma A549 cell line,80682,,,CHEMBL620424,Expert,9606.0,,N,,F,5766,,646.0,Homo sapiens,1,,,A549
,2621,1,BAO_0000219,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,80682,,,CHEMBL620425,Intermediate,9606.0,,N,,F,5767,,646.0,Homo sapiens,1,,,A549
,830,1,BAO_0000219,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,80682,,,CHEMBL620426,Intermediate,9606.0,,N,,F,5768,,646.0,Homo sapiens,1,,,A549
,14255,1,BAO_0000219,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,80682,,,CHEMBL620427,Intermediate,9606.0,,N,,F,5769,,646.0,Homo sapiens,1,,,A549
,14255,1,BAO_0000219,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,80682,,,CHEMBL620428,Intermediate,9606.0,,N,,F,5770,,646.0,Homo sapiens,1,,,A549
,1590,1,BAO_0000219,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,80682,,,CHEMBL620429,Intermediate,9606.0,,N,,F,5771,,646.0,Homo sapiens,1,,,A549
,6146,1,BAO_0000219,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,80682,,,CHEMBL620430,Expert,9606.0,,N,,F,5772,,646.0,Homo sapiens,1,,,A549
,17427,1,BAO_0000219,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,80682,,,CHEMBL839887,Expert,9606.0,,N,,F,5773,,646.0,Homo sapiens,1,,,A549
,5280,1,BAO_0000219,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,80682,,,CHEMBL620431,Intermediate,9606.0,,N,,F,5774,,646.0,Homo sapiens,1,,,A549
,16786,1,BAO_0000219,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,80682,,,CHEMBL884010,Intermediate,9606.0,,N,,F,5775,,646.0,Homo sapiens,1,,,A549
,5895,1,BAO_0000219,In vitro cytotoxicity against A549 (human lung cancer),80682,,,CHEMBL620538,Intermediate,9606.0,,N,,F,5776,,646.0,Homo sapiens,1,,,A549
,14297,1,BAO_0000219,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,80682,,,CHEMBL620539,Expert,9606.0,,N,,F,5777,,646.0,Homo sapiens,1,,,A549
,17824,1,BAO_0000218,In vivo antiproliferative activity against A549 cell line,80682,,,CHEMBL623373,Intermediate,9606.0,,N,,F,5778,,646.0,Homo sapiens,1,,,A549
,14368,1,BAO_0000219,Inhibition of non-small-cell lung adenocarcinoma (A549),80682,,,CHEMBL623374,Intermediate,9606.0,,N,,F,5779,,646.0,Homo sapiens,1,,,A549
,14368,1,BAO_0000219,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,80682,,,CHEMBL623375,Intermediate,9606.0,,N,,F,5780,,646.0,Homo sapiens,1,,,A549
,14254,1,BAO_0000219,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,80682,,,CHEMBL623376,Intermediate,9606.0,,N,,F,5781,,646.0,Homo sapiens,1,,,A549
,15897,1,BAO_0000219,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),80682,,,CHEMBL623377,Intermediate,9606.0,,N,,F,5782,,646.0,Homo sapiens,1,,,A549
,13866,1,BAO_0000219,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,80682,,,CHEMBL623378,Intermediate,9606.0,,N,,F,5783,,646.0,Homo sapiens,1,,,A549
,13370,1,BAO_0000219,Inhibitory activity of compound against human A549 lung carcinoma cell line.,80682,,,CHEMBL623379,Intermediate,9606.0,,N,,F,5784,,646.0,Homo sapiens,1,,,A549
,4862,1,BAO_0000219,Inhibitory activity against A549 lung cancer cell line,80682,,,CHEMBL623380,Intermediate,9606.0,,N,,F,5785,,646.0,Homo sapiens,1,,,A549
,4862,1,BAO_0000219,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,80682,,,CHEMBL623381,Intermediate,9606.0,,N,,F,5786,,646.0,Homo sapiens,1,,,A549
,4862,1,BAO_0000219,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,80682,,,CHEMBL623382,Intermediate,9606.0,,N,,F,5787,,646.0,Homo sapiens,1,,,A549
,15970,1,BAO_0000219,Inhibitory concentration against A549 (lung cancer) cell line,80682,,,CHEMBL623383,Intermediate,9606.0,,N,,F,5788,,646.0,Homo sapiens,1,,,A549
,17713,1,BAO_0000219,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,80682,,,CHEMBL623384,Expert,9606.0,,N,,F,5789,,646.0,Homo sapiens,1,,,A549
,4833,1,BAO_0000219,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,80682,,,CHEMBL623385,Intermediate,9606.0,,N,,F,5790,,646.0,Homo sapiens,1,,,A549
,13736,1,BAO_0000219,Activity against A549 cancer cell line.,80682,,,CHEMBL623386,Expert,9606.0,,N,,F,5791,,646.0,Homo sapiens,1,,,A549
,4312,1,BAO_0000219,The compound was evaluated for cytotoxicity against A549 cell line,80682,,,CHEMBL884105,Intermediate,9606.0,,N,,F,5792,,646.0,Homo sapiens,1,,,A549
,5421,1,BAO_0000219,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,80682,,,CHEMBL623387,Intermediate,9606.0,,N,,F,5793,,646.0,Homo sapiens,1,,,A549
,5421,1,BAO_0000219,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,80682,,,CHEMBL621568,Intermediate,9606.0,,N,,F,5794,,646.0,Homo sapiens,1,,,A549
,14717,1,BAO_0000219,Growth inhibitory activity was measured for human A549 tumor cell line.,80682,,,CHEMBL621569,Intermediate,9606.0,,N,,F,5795,,646.0,Homo sapiens,1,,,A549
,4634,1,BAO_0000219,Inhibitory activity against A549 lung cancer cell line,80682,,,CHEMBL621570,Intermediate,9606.0,,N,,F,5796,,646.0,Homo sapiens,1,,,A549
,1149,1,BAO_0000219,Inhibitory activity against A549 cell line; inactive,80682,,,CHEMBL621571,Intermediate,9606.0,,N,,F,5797,,646.0,Homo sapiens,1,,,A549
,5421,1,BAO_0000219,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,80682,,,CHEMBL621572,Expert,9606.0,,N,,F,5798,,646.0,Homo sapiens,1,,,A549
,5421,1,BAO_0000219,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,80682,,,CHEMBL621573,Expert,9606.0,,N,,F,5799,,646.0,Homo sapiens,1,,,A549
,5421,1,BAO_0000219,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,80682,,,CHEMBL621574,Intermediate,9606.0,,N,,F,5800,,646.0,Homo sapiens,1,,,A549
,3320,1,BAO_0000219,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),80682,,,CHEMBL621575,Intermediate,9606.0,,N,,F,5801,,646.0,Homo sapiens,1,,,A549
,3320,1,BAO_0000219,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),80682,,,CHEMBL621576,Intermediate,9606.0,,N,,F,5802,,646.0,Homo sapiens,1,,,A549
,3320,1,BAO_0000219,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),80682,,,CHEMBL621577,Intermediate,9606.0,,N,,F,5803,,646.0,Homo sapiens,1,,,A549
,3320,1,BAO_0000219,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),80682,,,CHEMBL621578,Intermediate,9606.0,,N,,F,5804,,646.0,Homo sapiens,1,,,A549
,3320,1,BAO_0000219,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),80682,,,CHEMBL621579,Intermediate,9606.0,,N,,F,5805,,646.0,Homo sapiens,1,,,A549
,5726,1,BAO_0000219,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,80682,,,CHEMBL621580,Intermediate,9606.0,,N,,F,5806,,646.0,Homo sapiens,1,,,A549
,17800,1,BAO_0000218,Plasma clearance (in vivo) in mongrel dogs was determined,50588,In vivo,,CHEMBL621581,Intermediate,9615.0,,N,,A,5807,,,Canis lupus familiaris,1,,,
,5985,1,BAO_0000218,Plasma clearance was measured in dog,50588,In vivo,,CHEMBL621582,Intermediate,9615.0,,N,,A,5808,,,Canis lupus familiaris,1,,,
,5530,1,BAO_0000218,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,50588,In vivo,,CHEMBL621583,Intermediate,9615.0,,N,,A,5809,,,Canis lupus familiaris,1,,,
,5530,1,BAO_0000218,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,50588,In vivo,,CHEMBL621584,Intermediate,9615.0,,N,,A,5810,,,Canis lupus familiaris,1,,,
,4839,1,BAO_0000218,Tested for plasma clearance in dog,50588,In vivo,Plasma,CHEMBL621585,Intermediate,9615.0,,N,,A,5811,,,Canis lupus familiaris,1,,1969.0,
,3639,1,BAO_0000218,The compound was tested for clearance in dog plasma.,50588,In vivo,,CHEMBL621586,Intermediate,9615.0,,N,,A,5812,,,Canis lupus familiaris,1,,,
,4838,1,BAO_0000218,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",50588,In vivo,,CHEMBL875835,Intermediate,9615.0,,N,,A,5813,,,Canis lupus familiaris,1,,,
,4137,1,BAO_0000218,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,50588,In vivo,,CHEMBL621587,Intermediate,9615.0,,N,,A,5814,,,Canis lupus familiaris,1,,,
,5017,1,BAO_0000218,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),50588,In vivo,Plasma,CHEMBL621588,Intermediate,9615.0,,N,,A,5815,,,Canis lupus familiaris,1,,1969.0,
,17538,1,BAO_0000218,In vitro clearance in dog liver microsomes,50588,In vitro,Liver,CHEMBL621589,Intermediate,9615.0,Microsomes,N,,A,5816,,,Canis lupus familiaris,1,,2107.0,
,6161,1,BAO_0000218,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,50588,In vivo,,CHEMBL621590,Intermediate,9615.0,,N,,A,5817,,,Canis lupus familiaris,1,,,
,6161,1,BAO_0000218,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,50588,In vivo,,CHEMBL621591,Intermediate,9615.0,,N,,A,5818,,,Canis lupus familiaris,1,,,
,1696,1,BAO_0000218,Plasma clearance in dog,50588,In vivo,,CHEMBL621592,Intermediate,9615.0,,N,,A,5819,,,Canis lupus familiaris,1,,,
,6762,1,BAO_0000218,Clearance rate in dog,50588,In vivo,,CHEMBL621593,Intermediate,9615.0,,N,,A,5820,,,Canis lupus familiaris,1,,,
,5932,1,BAO_0000218,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,50588,In vivo,Plasma,CHEMBL621594,Intermediate,9615.0,,N,,A,5821,,,Canis lupus familiaris,1,,1969.0,
,6305,1,BAO_0000218,Clearance in dogs,50588,In vivo,,CHEMBL621595,Intermediate,9615.0,,N,,A,5822,,,Canis lupus familiaris,1,,,
,4942,1,BAO_0000218,Plasma clearance in dogs,50588,In vivo,,CHEMBL621596,Intermediate,9615.0,,N,,A,5823,,,Canis lupus familiaris,1,,,
,4219,1,BAO_0000218,Plasma clearance was determined,50588,In vivo,,CHEMBL621597,Intermediate,9615.0,,N,,A,5824,,,Canis lupus familiaris,1,,,
,17853,1,BAO_0000218,Lower clearance in dog (i.v.) at 0.5 mpk,50588,In vivo,,CHEMBL621598,Intermediate,9615.0,,N,,A,5825,,,Canis lupus familiaris,1,,,
,4514,1,BAO_0000218,Plasma clearance in Beagle dogs,50588,In vivo,,CHEMBL621599,Intermediate,9615.0,,N,,A,5826,,,Canis lupus familiaris,1,,,
,6448,1,BAO_0000218,Plasma clearance (Clp) in dog,50588,In vivo,,CHEMBL875836,Intermediate,9615.0,,N,,A,5827,,,Canis lupus familiaris,1,,,
,6227,1,BAO_0000218,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,50588,In vivo,,CHEMBL621600,Intermediate,9615.0,,N,,A,5828,,,Canis lupus familiaris,1,,,
,6227,1,BAO_0000218,Plasma clearance (pharmacokinetic parameter) in dog was determined,50588,In vivo,,CHEMBL621601,Intermediate,9615.0,,N,,A,5829,,,Canis lupus familiaris,1,,,
,6062,1,BAO_0000218,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,50588,In vivo,,CHEMBL618474,Intermediate,9615.0,,N,,A,5830,,,Canis lupus familiaris,1,,,
,6821,1,BAO_0000218,Plasma clearance of compound was determined in dog,50588,In vivo,,CHEMBL618475,Intermediate,9615.0,,N,,A,5831,,,Canis lupus familiaris,1,,,
,4709,1,BAO_0000218,Plasma clearance after intravenous administration of 1 mg/kg in dog,50588,In vivo,,CHEMBL624524,Intermediate,9615.0,,N,,A,5832,,,Canis lupus familiaris,1,,,
,4521,1,BAO_0000218,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,50588,In vivo,,CHEMBL624525,Intermediate,9615.0,,N,,A,5833,,,Canis lupus familiaris,1,,,
,5374,1,BAO_0000218,Plasma clearance in dog was determined,50588,In vivo,,CHEMBL624526,Intermediate,9615.0,,N,,A,5834,,,Canis lupus familiaris,1,,,
,6057,1,BAO_0000218,Plasma clearance was calculated in dog,50588,In vivo,,CHEMBL624527,Intermediate,9615.0,,N,,A,5835,,,Canis lupus familiaris,1,,,
,4727,1,BAO_0000218,Plasma clearance at the dose of 2 mg/kg in dog,50588,In vivo,,CHEMBL624528,Intermediate,9615.0,,N,,A,5836,,,Canis lupus familiaris,1,,,
,5145,1,BAO_0000218,Plasma clearance in dog,50588,In vivo,,CHEMBL624529,Intermediate,9615.0,,N,,A,5837,,,Canis lupus familiaris,1,,,
,17657,1,BAO_0000218,Plasma clearance in dog,50588,In vivo,,CHEMBL624530,Intermediate,9615.0,,N,,A,5838,,,Canis lupus familiaris,1,,,
,17657,1,BAO_0000218,Plasma clearance in dog; Unable to calculate,50588,In vivo,,CHEMBL624531,Intermediate,9615.0,,N,,A,5839,,,Canis lupus familiaris,1,,,
,5145,1,BAO_0000218,Plasma clearance in rhesus monkey,50588,In vivo,,CHEMBL624532,Intermediate,9615.0,,N,,A,5840,,,Canis lupus familiaris,1,,,
,6642,1,BAO_0000218,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,In vivo,,CHEMBL624533,Intermediate,9615.0,,N,,A,5841,,,Canis lupus familiaris,1,,,
,6641,1,BAO_0000218,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,In vivo,,CHEMBL624534,Intermediate,9615.0,,N,,A,5842,,,Canis lupus familiaris,1,,,
,6642,1,BAO_0000218,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,In vivo,,CHEMBL624535,Intermediate,9615.0,,N,,A,5843,,,Canis lupus familiaris,1,,,
,5472,1,BAO_0000218,Plasma clearance was evaluated in dog,50588,In vivo,,CHEMBL624536,Intermediate,9615.0,,N,,A,5844,,,Canis lupus familiaris,1,,,
,5472,1,BAO_0000218,Plasma clearance was evaluated in dog; Not tested,50588,In vivo,,CHEMBL624537,Intermediate,9615.0,,N,,A,5845,,,Canis lupus familiaris,1,,,
,5472,1,BAO_0000218,Plasma clearance was evaluated in rhesus,50588,In vivo,,CHEMBL624538,Intermediate,9615.0,,N,,A,5846,,,Canis lupus familiaris,1,,,
,5472,1,BAO_0000218,Plasma clearance was evaluated in rhesus; Not tested,50588,In vivo,,CHEMBL624539,Intermediate,9615.0,,N,,A,5847,,,Canis lupus familiaris,1,,,
,4257,1,BAO_0000218,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,50588,In vivo,,CHEMBL624540,Intermediate,9615.0,,N,,A,5848,,,Canis lupus familiaris,1,,,
,6679,1,BAO_0000218,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50588,In vivo,,CHEMBL624541,Intermediate,9615.0,,N,,A,5849,,,Canis lupus familiaris,1,,,
,5546,1,BAO_0000218,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,50588,In vivo,,CHEMBL624542,Intermediate,9615.0,,N,,A,5850,,,Canis lupus familiaris,1,,,
,6348,1,BAO_0000218,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,In vivo,,CHEMBL624543,Intermediate,9615.0,,N,,A,5851,,,Canis lupus familiaris,1,,,
,5474,1,BAO_0000218,Clearance value at a dose of 0.2 mg/kg i.v.,50588,In vivo,,CHEMBL624544,Intermediate,9615.0,,N,,A,5852,,,Canis lupus familiaris,1,,,
,6316,1,BAO_0000218,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,50588,In vivo,Plasma,CHEMBL624545,Intermediate,9615.0,,N,,A,5853,,,Canis lupus familiaris,1,,1969.0,
,17594,1,BAO_0000218,Cmax after oral dose of compound at 3 mg/kg in dogs,50588,In vivo,,CHEMBL624546,Intermediate,9615.0,,N,,A,5854,,,Canis lupus familiaris,1,,,
,17594,1,BAO_0000218,Cmax after single intravenous bolus of 1 mg/kg in dogs,50588,In vivo,,CHEMBL875957,Intermediate,9615.0,,N,,A,5855,,,Canis lupus familiaris,1,,,
,5802,1,BAO_0000218,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,50588,In vivo,,CHEMBL624547,Intermediate,9615.0,,N,,A,5856,,,Canis lupus familiaris,1,,,
,6535,1,BAO_0000218,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,50588,In vivo,,CHEMBL624548,Intermediate,9615.0,,N,,A,5857,,,Canis lupus familiaris,1,,,
,6535,1,BAO_0000218,Cmax in dog after administration of 1 mg/kg iv,50588,In vivo,,CHEMBL624549,Intermediate,9615.0,,N,,A,5858,,,Canis lupus familiaris,1,,,
,1466,1,BAO_0000218,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,50588,In vivo,Plasma,CHEMBL624550,Intermediate,9615.0,,N,,A,5859,,,Canis lupus familiaris,1,,1969.0,
,6505,1,BAO_0000218,Cmax on p.o. administration of 10 mg/kg was measured in dog,50588,In vivo,,CHEMBL621613,Intermediate,9615.0,,N,,A,5860,,,Canis lupus familiaris,1,,,
,5668,1,BAO_0000218,Cmax was determine after peroral administration at 10 mpk in dog,50588,In vivo,,CHEMBL621614,Intermediate,9615.0,,N,,A,5861,,,Canis lupus familiaris,1,,,
,5668,1,BAO_0000218,Cmax was determine after peroral administration at 5 mpk in dog,50588,In vivo,,CHEMBL623431,Intermediate,9615.0,,N,,A,5862,,,Canis lupus familiaris,1,,,
,5668,1,BAO_0000218,Cmax was determine after peroral administration at 5 mg/kg in dog,50588,In vivo,,CHEMBL623432,Intermediate,9615.0,,N,,A,5863,,,Canis lupus familiaris,1,,,
,5600,1,BAO_0000218,Cmax after 0.3 mg/kg po administration in dog,50588,In vivo,,CHEMBL623433,Intermediate,9615.0,,N,,A,5864,,,Canis lupus familiaris,1,,,
,17764,1,BAO_0000218,Cmax after peroral administration in dogs at 2.4 uM/kg,50588,In vivo,,CHEMBL623434,Intermediate,9615.0,,N,,A,5865,,,Canis lupus familiaris,1,,,
,6123,1,BAO_0000218,Cmax in dog after oral administration at 1 mg/kg,50588,In vivo,,CHEMBL623435,Intermediate,9615.0,,N,,A,5866,,,Canis lupus familiaris,1,,,
,6123,1,BAO_0000218,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,50588,In vivo,,CHEMBL623436,Intermediate,9615.0,,N,,A,5867,,,Canis lupus familiaris,1,,,
,6757,1,BAO_0000218,Cmax upon oral administration in male Beagle dog at 10 mg/kg,50588,In vivo,,CHEMBL875958,Intermediate,9615.0,,N,,A,5868,,,Canis lupus familiaris,1,,,
,16907,1,BAO_0000218,Cmax value after 15 mg/kg iv dose in Dogs,50588,In vivo,,CHEMBL623437,Intermediate,9615.0,,N,,A,5869,,,Canis lupus familiaris,1,,,
,7767,1,BAO_0000218,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,In vivo,Blood,CHEMBL623438,Intermediate,10090.0,,N,,A,5870,,,Mus musculus,1,,178.0,
,7767,1,BAO_0000218,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,In vivo,Blood,CHEMBL623439,Intermediate,10090.0,,N,,A,5871,,,Mus musculus,1,,178.0,
,7767,1,BAO_0000218,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,In vivo,Bone,CHEMBL623440,Intermediate,10090.0,,N,,A,5872,,,Mus musculus,1,,10000001.0,
,7767,1,BAO_0000218,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,In vivo,Bone,CHEMBL623441,Intermediate,10090.0,,N,,A,5873,,,Mus musculus,1,,10000001.0,
,7767,1,BAO_0000218,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,In vivo,Bone,CHEMBL623442,Intermediate,10090.0,,N,,A,5874,,,Mus musculus,1,,10000001.0,
,7767,1,BAO_0000218,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,In vivo,,CHEMBL623469,Intermediate,10090.0,,N,,A,5875,,,Mus musculus,1,,,
,7767,1,BAO_0000218,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,In vivo,,CHEMBL623470,Intermediate,10090.0,,N,,A,5876,,,Mus musculus,1,,,
,7767,1,BAO_0000218,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,In vivo,,CHEMBL623471,Intermediate,10090.0,,N,,A,5877,,,Mus musculus,1,,,
,7767,1,BAO_0000218,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,In vivo,Heart,CHEMBL623472,Intermediate,10090.0,,N,,A,5878,,,Mus musculus,1,,948.0,
,7767,1,BAO_0000218,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,In vivo,Heart,CHEMBL623473,Intermediate,10090.0,,N,,A,5879,,,Mus musculus,1,,948.0,
,7767,1,BAO_0000218,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,In vivo,Heart,CHEMBL623474,Intermediate,10090.0,,N,,A,5880,,,Mus musculus,1,,948.0,
,7767,1,BAO_0000218,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,In vivo,Kidney,CHEMBL623475,Intermediate,10090.0,,N,,A,5881,,,Mus musculus,1,,2113.0,
,7767,1,BAO_0000218,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,In vivo,Kidney,CHEMBL623476,Intermediate,10090.0,,N,,A,5882,,,Mus musculus,1,,2113.0,
,7767,1,BAO_0000218,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,In vivo,Kidney,CHEMBL623477,Intermediate,10090.0,,N,,A,5883,,,Mus musculus,1,,2113.0,
,7767,1,BAO_0000218,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,In vivo,Intestine,CHEMBL621896,Intermediate,10090.0,,N,,A,5884,,,Mus musculus,1,,160.0,
,7767,1,BAO_0000218,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,In vivo,Intestine,CHEMBL621897,Intermediate,10090.0,,N,,A,5885,,,Mus musculus,1,,160.0,
,7767,1,BAO_0000218,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,In vivo,Intestine,CHEMBL621898,Intermediate,10090.0,,N,,A,5886,,,Mus musculus,1,,160.0,
,7767,1,BAO_0000218,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,In vivo,Liver,CHEMBL621899,Intermediate,10090.0,,N,,A,5887,,,Mus musculus,1,,2107.0,
,7767,1,BAO_0000218,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,In vivo,Liver,CHEMBL621900,Intermediate,10090.0,,N,,A,5888,,,Mus musculus,1,,2107.0,
,7767,1,BAO_0000218,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,In vivo,Liver,CHEMBL621901,Intermediate,10090.0,,N,,A,5889,,,Mus musculus,1,,2107.0,
,7767,1,BAO_0000218,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,In vivo,Lung,CHEMBL621902,Intermediate,10090.0,,N,,A,5890,,,Mus musculus,1,,2048.0,
,7767,1,BAO_0000218,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,In vivo,Lung,CHEMBL621903,Intermediate,10090.0,,N,,A,5891,,,Mus musculus,1,,2048.0,
,7767,1,BAO_0000218,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,In vivo,Lung,CHEMBL622587,Intermediate,10090.0,,N,,A,5892,,,Mus musculus,1,,2048.0,
,7767,1,BAO_0000218,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,In vivo,Muscle tissue,CHEMBL620285,Intermediate,10090.0,,N,,A,5893,,,Mus musculus,1,,2385.0,
,7767,1,BAO_0000218,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,In vivo,Muscle tissue,CHEMBL875285,Intermediate,10090.0,,N,,A,5894,,,Mus musculus,1,,2385.0,
,7767,1,BAO_0000218,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,In vivo,Muscle tissue,CHEMBL620286,Intermediate,10090.0,,N,,A,5895,,,Mus musculus,1,,2385.0,
,7767,1,BAO_0000218,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,In vivo,,CHEMBL620287,Intermediate,10090.0,,N,,A,5896,,,Mus musculus,1,,,
,7767,1,BAO_0000218,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,In vivo,,CHEMBL620288,Intermediate,10090.0,,N,,A,5897,,,Mus musculus,1,,,
,7767,1,BAO_0000218,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,In vivo,,CHEMBL620289,Intermediate,10090.0,,N,,A,5898,,,Mus musculus,1,,,
,7767,1,BAO_0000218,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,In vivo,Intestine,CHEMBL620290,Intermediate,10090.0,,N,,A,5899,,,Mus musculus,1,,160.0,
,7767,1,BAO_0000218,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,In vivo,Intestine,CHEMBL620291,Intermediate,10090.0,,N,,A,5900,,,Mus musculus,1,,160.0,
,7767,1,BAO_0000218,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,In vivo,Intestine,CHEMBL620292,Intermediate,10090.0,,N,,A,5901,,,Mus musculus,1,,160.0,
,7767,1,BAO_0000218,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,In vivo,Spleen,CHEMBL620293,Intermediate,10090.0,,N,,A,5902,,,Mus musculus,1,,2106.0,
,7767,1,BAO_0000218,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,In vivo,Spleen,CHEMBL620294,Intermediate,10090.0,,N,,A,5903,,,Mus musculus,1,,2106.0,
,7767,1,BAO_0000218,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,In vivo,Spleen,CHEMBL618614,Intermediate,10090.0,,N,,A,5904,,,Mus musculus,1,,2106.0,
,7767,1,BAO_0000218,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,In vivo,Stomach,CHEMBL618615,Intermediate,10090.0,,N,,A,5905,,,Mus musculus,1,,945.0,
,7767,1,BAO_0000218,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,In vivo,Stomach,CHEMBL618616,Intermediate,10090.0,,N,,A,5906,,,Mus musculus,1,,945.0,
,2036,1,BAO_0000219,Cytotoxicity against A-172 human tumor cell lines,80012,,,CHEMBL618617,Expert,9606.0,,N,,F,5907,,622.0,Homo sapiens,1,,,A 172
,2357,1,BAO_0000219,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,80012,,,CHEMBL618618,Intermediate,9606.0,,N,,F,5908,,622.0,Homo sapiens,1,,,A 172
,1457,1,BAO_0000219,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,80014,,,CHEMBL618619,Intermediate,9606.0,,N,,F,5909,,623.0,Homo sapiens,1,,,A204
,4379,1,BAO_0000219,Tested for antiproliferative activity against A-2780 tumoral cell line,81034,,,CHEMBL618620,Intermediate,9606.0,,N,,F,5910,,478.0,Homo sapiens,1,,,A2780
,1093,1,BAO_0000219,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,80018,,,CHEMBL618621,Intermediate,9606.0,,N,,F,5911,,455.0,Homo sapiens,1,,,A-375
,12152,1,BAO_0000219,Tested in vitro against A-375 cell line human melanoma,80018,,,CHEMBL618622,Intermediate,9606.0,,N,,F,5912,,455.0,Homo sapiens,1,,,A-375
,16464,1,BAO_0000219,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,80019,,,CHEMBL618623,Expert,9606.0,,N,,F,5913,,797.0,Homo sapiens,1,,,A-427
,16464,1,BAO_0000219,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80019,,,CHEMBL618624,Intermediate,9606.0,,N,,F,5914,,797.0,Homo sapiens,1,,,A-427
,16582,1,BAO_0000219,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,80019,,,CHEMBL618625,Expert,9606.0,,N,,F,5915,,797.0,Homo sapiens,1,,,A-427
,16464,1,BAO_0000219,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80019,,,CHEMBL618626,Intermediate,9606.0,,N,,F,5916,,797.0,Homo sapiens,1,,,A-427
,10413,1,BAO_0000219,Antitumor activity on A-427 lung carcinoma cell lines,80019,,,CHEMBL618627,Intermediate,9606.0,,N,,F,5917,,797.0,Homo sapiens,1,,,A-427
,6418,1,BAO_0000219,Cytotoxic activity against human A-427 lung tumor cell line,80019,,,CHEMBL618628,Intermediate,9606.0,,N,,F,5918,,797.0,Homo sapiens,1,,,A-427
,17134,1,BAO_0000219,In vitro antitumor effects against human A-427 cell lines.,80019,,,CHEMBL618629,Expert,9606.0,,N,,F,5919,,797.0,Homo sapiens,1,,,A-427
,16132,1,BAO_0000219,In vitro inhibition of A-427 (human lung cancer) cell growth.,80019,,,CHEMBL618630,Expert,9606.0,,N,,F,5920,,797.0,Homo sapiens,1,,,A-427
,16132,1,BAO_0000219,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,80019,,,CHEMBL618631,Intermediate,9606.0,,N,,F,5921,,797.0,Homo sapiens,1,,,A-427
,16780,1,BAO_0000219,Cytotoxic activity of compound against A-427 lung human tumor cell line,80019,,,CHEMBL618632,Intermediate,9606.0,,N,,F,5922,,797.0,Homo sapiens,1,,,A-427
,4085,1,BAO_0000219,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,80852,,,CHEMBL618633,Expert,9606.0,,N,,F,5923,,500.0,Homo sapiens,1,,,A-431
,1276,1,BAO_0000219,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,80021,,,CHEMBL619315,Intermediate,9606.0,,N,,F,5924,,624.0,Homo sapiens,1,,,A498
,3498,1,BAO_0000219,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,80021,,,CHEMBL619316,Expert,9606.0,,N,,F,5925,,624.0,Homo sapiens,1,,,A498
,1169,1,BAO_0000219,Cytotoxicity against human kidney carcinoma A-498cell lines,80021,,,CHEMBL619317,Intermediate,9606.0,,N,,F,5926,,624.0,Homo sapiens,1,,,A498
,4450,1,BAO_0000219,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,80021,,,CHEMBL619318,Intermediate,9606.0,,N,,F,5927,,624.0,Homo sapiens,1,,,A498
,3311,1,BAO_0000219,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,80021,,,CHEMBL619319,Intermediate,9606.0,,N,,F,5928,,624.0,Homo sapiens,1,,,A498
,4461,1,BAO_0000219,Antitumor cytotoxic activity against A-498 cell line was determined,80021,,,CHEMBL619739,Intermediate,9606.0,,N,,F,5929,,624.0,Homo sapiens,1,,,A498
,3311,1,BAO_0000219,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,80021,,,CHEMBL619740,Intermediate,9606.0,,N,,F,5930,,624.0,Homo sapiens,1,,,A498
,3311,1,BAO_0000219,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,80021,,,CHEMBL883158,Intermediate,9606.0,,N,,F,5931,,624.0,Homo sapiens,1,,,A498
,1457,1,BAO_0000219,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,80021,,,CHEMBL884012,Intermediate,9606.0,,N,,F,5932,,624.0,Homo sapiens,1,,,A498
,3664,1,BAO_0000219,In vitro inhibitory activity against A-498 ovarian cancer cell lines,80021,,,CHEMBL619741,Intermediate,9606.0,,N,,F,5933,,624.0,Homo sapiens,1,,,A498
,15895,1,BAO_0000219,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",80021,,,CHEMBL619742,Intermediate,9606.0,,N,,F,5934,,624.0,Homo sapiens,1,,,A498
,11843,1,BAO_0000219,Inhibition of growth lung non-small cell carcinoma A-549 cell line,80682,,,CHEMBL876610,Intermediate,9606.0,,N,,F,5935,,646.0,Homo sapiens,1,,,A549
,11843,1,BAO_0000219,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,80682,,,CHEMBL619743,Intermediate,9606.0,,N,,F,5936,,646.0,Homo sapiens,1,,,A549
,17705,1,BAO_0000219,In vitro antiproliferative activity against human A-549 NSCL cell line,80682,,,CHEMBL619744,Intermediate,9606.0,,N,,F,5937,,646.0,Homo sapiens,1,,,A549
,17705,1,BAO_0000219,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,80682,,,CHEMBL619745,Intermediate,9606.0,,N,,F,5938,,646.0,Homo sapiens,1,,,A549
,4369,1,BAO_0000219,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,80682,,,CHEMBL619746,Intermediate,9606.0,,N,,F,5939,,646.0,Homo sapiens,1,,,A549
,4369,1,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,80682,,,CHEMBL619747,Intermediate,9606.0,,N,,F,5940,,646.0,Homo sapiens,1,,,A549
,4369,1,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,80682,,,CHEMBL619748,Intermediate,9606.0,,N,,F,5941,,646.0,Homo sapiens,1,,,A549
,4369,1,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,80682,,,CHEMBL619749,Intermediate,9606.0,,N,,F,5942,,646.0,Homo sapiens,1,,,A549
,4369,1,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,80682,,,CHEMBL619750,Intermediate,9606.0,,N,,F,5943,,646.0,Homo sapiens,1,,,A549
,4369,1,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,80682,,,CHEMBL624014,Intermediate,9606.0,,N,,F,5944,,646.0,Homo sapiens,1,,,A549
,4369,1,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,80682,,,CHEMBL624015,Intermediate,9606.0,,N,,F,5945,,646.0,Homo sapiens,1,,,A549
,4787,1,BAO_0000219,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,80682,,,CHEMBL885344,Expert,9606.0,,N,,F,5946,,646.0,Homo sapiens,1,,,A549
,4787,1,BAO_0000219,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,80682,,,CHEMBL623224,Intermediate,9606.0,,N,,F,5947,,646.0,Homo sapiens,1,,,A549
,6513,1,BAO_0000219,Cytotoxic activity against A-549 cell line,80682,,,CHEMBL623225,Intermediate,9606.0,,N,,F,5948,,646.0,Homo sapiens,1,,,A549
,6690,1,BAO_0000219,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,80682,,,CHEMBL622698,Intermediate,9606.0,,N,,F,5949,,646.0,Homo sapiens,1,,,A549
,6690,1,BAO_0000219,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,80682,,,CHEMBL622699,Intermediate,9606.0,,N,,F,5950,,646.0,Homo sapiens,1,,,A549
,12263,1,BAO_0000219,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",80682,,,CHEMBL622700,Expert,9606.0,,N,,F,5951,,646.0,Homo sapiens,1,,,A549
,1054,1,BAO_0000219,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),80682,,,CHEMBL622701,Intermediate,9606.0,,N,,F,5952,,646.0,Homo sapiens,1,,,A549
,1359,1,BAO_0000219,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),80682,,,CHEMBL622702,Intermediate,9606.0,,N,,F,5953,,646.0,Homo sapiens,1,,,A549
,3547,1,BAO_0000219,Cytotoxic activity against human lung carcinoma (A-549) cell line,80682,,,CHEMBL622703,Intermediate,9606.0,,N,,F,5954,,646.0,Homo sapiens,1,,,A549
,5771,1,BAO_0000219,Cytotoxic activity towards A-549 cells,80682,,,CHEMBL622704,Expert,9606.0,,N,,F,5955,,646.0,Homo sapiens,1,,,A549
,14425,1,BAO_0000219,"In vitro percent inhibition of A549, lung carcinoma.",80682,,,CHEMBL622705,Intermediate,9606.0,,N,,F,5956,,646.0,Homo sapiens,1,,,A549
,14425,1,BAO_0000219,"In vitro percent inhibition of A549, lung carcinoma",80682,,,CHEMBL622706,Intermediate,9606.0,,N,,F,5957,,646.0,Homo sapiens,1,,,A549
,14425,1,BAO_0000219,"In vitro percent inhibition of A549, lung carcinoma.",80682,,,CHEMBL622707,Intermediate,9606.0,,N,,F,5958,,646.0,Homo sapiens,1,,,A549
,14425,1,BAO_0000219,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",80682,,,CHEMBL622708,Intermediate,9606.0,,N,,F,5959,,646.0,Homo sapiens,1,,,A549
,5280,1,BAO_0000219,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,80682,,,CHEMBL622709,Intermediate,9606.0,,N,,F,5960,,646.0,Homo sapiens,1,,,A549
,15176,1,BAO_0000219,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,80682,,,CHEMBL622710,Intermediate,9606.0,,N,,F,5961,,646.0,Homo sapiens,1,,,A549
,15300,1,BAO_0000219,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,80682,,,CHEMBL622711,Intermediate,9606.0,,N,,F,5962,,646.0,Homo sapiens,1,,,A549
,17824,1,BAO_0000218,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,,,CHEMBL622712,Intermediate,9606.0,,N,,F,5963,,646.0,Homo sapiens,1,,,A549
,17824,1,BAO_0000218,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,,,CHEMBL622713,Intermediate,9606.0,,N,,F,5964,,646.0,Homo sapiens,1,,,A549
,17824,1,BAO_0000218,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,,,CHEMBL622714,Intermediate,9606.0,,N,,F,5965,,646.0,Homo sapiens,1,,,A549
,17824,1,BAO_0000218,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,,,CHEMBL622715,Intermediate,9606.0,,N,,F,5966,,646.0,Homo sapiens,1,,,A549
,17824,1,BAO_0000218,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,,,CHEMBL622716,Intermediate,9606.0,,N,,F,5967,,646.0,Homo sapiens,1,,,A549
,17824,1,BAO_0000219,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",80682,,,CHEMBL622717,Intermediate,9606.0,,N,,F,5968,,646.0,Homo sapiens,1,,,A549
,17528,1,BAO_0000218,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),80682,,,CHEMBL622718,Intermediate,9606.0,,N,,F,5969,,646.0,Homo sapiens,1,,,A549
,6870,1,BAO_0000219,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,80682,,,CHEMBL622719,Expert,9606.0,,N,,F,5970,,646.0,Homo sapiens,1,,,A549
,6870,1,BAO_0000219,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,80682,,,CHEMBL622720,Intermediate,9606.0,,N,,F,5971,,646.0,Homo sapiens,1,,,A549
,6870,1,BAO_0000219,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,80682,,,CHEMBL622721,Intermediate,9606.0,,N,,F,5972,,646.0,Homo sapiens,1,,,A549
,6870,1,BAO_0000219,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,80682,,,CHEMBL622722,Intermediate,9606.0,,N,,F,5973,,646.0,Homo sapiens,1,,,A549
,16726,1,BAO_0000219,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,80682,,,CHEMBL876030,Intermediate,9606.0,,N,,F,5974,,646.0,Homo sapiens,1,,,A549
,6170,1,BAO_0000219,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",80682,,,CHEMBL620206,Intermediate,9606.0,,N,,F,5975,,646.0,Homo sapiens,1,,,A549
,6583,1,BAO_0000219,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,80682,,,CHEMBL620207,Expert,9606.0,,N,,F,5976,,646.0,Homo sapiens,1,,,A549
,6583,1,BAO_0000219,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,80682,,,CHEMBL620208,Expert,9606.0,,N,,F,5977,,646.0,Homo sapiens,1,,,A549
,6583,1,BAO_0000219,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,80682,,,CHEMBL620209,Expert,9606.0,,N,,F,5978,,646.0,Homo sapiens,1,,,A549
,6583,1,BAO_0000219,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,80682,,,CHEMBL620210,Expert,9606.0,,N,,F,5979,,646.0,Homo sapiens,1,,,A549
,6583,1,BAO_0000219,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,80682,,,CHEMBL621639,Expert,9606.0,,N,,F,5980,,646.0,Homo sapiens,1,,,A549
,17321,1,BAO_0000219,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,80682,,,CHEMBL621640,Intermediate,9606.0,,N,,F,5981,,646.0,Homo sapiens,1,,,A549
,17528,1,BAO_0000219,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,80682,,,CHEMBL621641,Expert,9606.0,,N,,F,5982,,646.0,Homo sapiens,1,,,A549
,12888,1,BAO_0000219,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,80682,,,CHEMBL621642,Expert,9606.0,,N,,F,5983,,646.0,Homo sapiens,1,,,A549
,4312,1,BAO_0000219,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,80682,,,CHEMBL621643,Intermediate,9606.0,,N,,F,5984,,646.0,Homo sapiens,1,,,A549
,4312,1,BAO_0000219,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,80682,,,CHEMBL621644,Intermediate,9606.0,,N,,F,5985,,646.0,Homo sapiens,1,,,A549
,4312,1,BAO_0000219,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,80682,,,CHEMBL621645,Intermediate,9606.0,,N,,F,5986,,646.0,Homo sapiens,1,,,A549
,17737,1,BAO_0000219,In vitro antiproliferative activity against A549 cell line,80682,,,CHEMBL621646,Intermediate,10090.0,,N,,F,5987,,646.0,Mus musculus,1,,,A549
,6630,1,BAO_0000219,Synergism with indomethacin in A549 cells,80682,,,CHEMBL621647,Intermediate,,,N,,F,5988,,646.0,,1,,,A549
,6630,1,BAO_0000219,Synergism with tolmetin in A549 cells,80682,,,CHEMBL621648,Intermediate,,,N,,F,5989,,646.0,,1,,,A549
,6630,1,BAO_0000219,Synergism with sulindac in A549 cells,80682,,,CHEMBL621649,Intermediate,,,N,,F,5990,,646.0,,1,,,A549
,6630,1,BAO_0000219,Antagonism of indomethacin in A549 cells,80682,,,CHEMBL621650,Intermediate,,,N,,F,5991,,646.0,,1,,,A549
,6630,1,BAO_0000219,Antagonism of sulindac in A549 cells,80682,,,CHEMBL621651,Intermediate,,,N,,F,5992,,646.0,,1,,,A549
,6630,1,BAO_0000219,Antagonism of tolmetin in A549 cells,80682,,,CHEMBL621652,Intermediate,,,N,,F,5993,,646.0,,1,,,A549
,6630,1,BAO_0000219,Synergism with indomethacin in A549 cells,80682,,,CHEMBL621653,Intermediate,,,N,,F,5994,,646.0,,1,,,A549
,6630,1,BAO_0000219,Synergism with sulindac in A549 cells,80682,,,CHEMBL621654,Intermediate,,,N,,F,5995,,646.0,,1,,,A549
,6630,1,BAO_0000219,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,80682,,,CHEMBL621655,Intermediate,,,N,,F,5996,,646.0,,1,,,A549
,16907,1,BAO_0000218,Cmax value after 30 mg/kg po dose in Dogs,50588,In vivo,,CHEMBL621656,Intermediate,9615.0,,N,,A,5997,,,Canis lupus familiaris,1,,,
,5944,1,BAO_0000218,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),50588,In vivo,,CHEMBL621657,Intermediate,9615.0,,N,,A,5998,,,Canis lupus familiaris,1,,,
,5944,1,BAO_0000218,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,50588,In vivo,,CHEMBL621658,Intermediate,9615.0,,N,,A,5999,,,Canis lupus familiaris,1,,,
,5944,1,BAO_0000218,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),50588,In vivo,,CHEMBL621659,Intermediate,9615.0,,N,,A,6000,,,Canis lupus familiaris,1,,,
,5944,1,BAO_0000218,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,50588,In vivo,,CHEMBL621660,Intermediate,9615.0,,N,,A,6001,,,Canis lupus familiaris,1,,,
,2959,1,BAO_0000218,Cmax value after administration of 4 mg/Kg oral dose in dog,50588,In vivo,,CHEMBL621661,Intermediate,9615.0,,N,,A,6002,,,Canis lupus familiaris,1,,,
,6241,1,BAO_0000218,Cmax value in dog,50588,In vivo,,CHEMBL621662,Intermediate,9615.0,,N,,A,6003,,,Canis lupus familiaris,1,,,
,6241,1,BAO_0000218,Cmax value in dogs after oral administration at 1 mg/kg,50588,In vivo,,CHEMBL621663,Intermediate,9615.0,,N,,A,6004,,,Canis lupus familiaris,1,,,
,2652,1,BAO_0000218,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,50588,In vivo,,CHEMBL621664,Intermediate,9615.0,,N,,A,6005,,,Canis lupus familiaris,1,,,
,1806,1,BAO_0000218,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,50588,In vivo,Plasma,CHEMBL621665,Intermediate,9615.0,,N,,A,6006,,,Canis lupus familiaris,1,,1969.0,
,1806,1,BAO_0000218,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,50588,In vivo,Plasma,CHEMBL621666,Intermediate,9615.0,,N,,A,6007,,,Canis lupus familiaris,1,,1969.0,
,1021,1,BAO_0000218,Concentration maxima after oral dosing in dogs,50588,In vivo,,CHEMBL621667,Intermediate,9615.0,,N,,A,6008,,,Canis lupus familiaris,1,,,
,1021,1,BAO_0000218,Concentration maxima after oral dosing in dogs; not available,50588,In vivo,,CHEMBL876738,Intermediate,9615.0,,N,,A,6009,,,Canis lupus familiaris,1,,,
,1021,1,BAO_0000218,Concentration maxima after oral dosing in dogs; not available,50588,In vivo,,CHEMBL621668,Intermediate,9615.0,,N,,A,6010,,,Canis lupus familiaris,1,,,
,5444,1,BAO_0000218,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,50588,In vivo,,CHEMBL621669,Intermediate,9615.0,,N,,A,6011,,,Canis lupus familiaris,1,,,
,5444,1,BAO_0000218,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,50588,In vivo,,CHEMBL621670,Intermediate,9615.0,,N,,A,6012,,,Canis lupus familiaris,1,,,
,5444,1,BAO_0000218,In vivo maximal concentration was calculated at 1 mg/kg in dog,50588,In vivo,,CHEMBL621671,Intermediate,9615.0,,N,,A,6013,,,Canis lupus familiaris,1,,,
,5444,1,BAO_0000218,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,50588,In vivo,,CHEMBL622360,Intermediate,9615.0,,N,,A,6014,,,Canis lupus familiaris,1,,,
,5444,1,BAO_0000218,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,50588,In vivo,,CHEMBL622361,Intermediate,9615.0,,N,,A,6015,,,Canis lupus familiaris,1,,,
,5130,1,BAO_0000218,Cmax in dog plasma after oral dose (1 mg/kg),50588,In vivo,Plasma,CHEMBL622362,Intermediate,9615.0,,N,,A,6016,,,Canis lupus familiaris,1,,1969.0,
,3249,1,BAO_0000218,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,50588,In vivo,Plasma,CHEMBL622363,Intermediate,9615.0,,N,,A,6017,,,Canis lupus familiaris,1,,1969.0,
,5473,1,BAO_0000218,Maximal plasma concentration at a dose of 1 mg/kg,50588,In vivo,Plasma,CHEMBL622364,Intermediate,9615.0,,N,,A,6018,,,Canis lupus familiaris,1,,1969.0,
,5474,1,BAO_0000218,Maximal plasma concentration at a dose of 1 mg/kg (oral),50588,In vivo,Plasma,CHEMBL622365,Intermediate,9615.0,,N,,A,6019,,,Canis lupus familiaris,1,,1969.0,
,4657,1,BAO_0000218,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,50588,In vivo,Plasma,CHEMBL622533,Intermediate,9615.0,,N,,A,6020,,,Canis lupus familiaris,1,,1969.0,
,3031,1,BAO_0000218,Maximum concentration of compound in dog was evaluated.,50588,In vivo,,CHEMBL622534,Intermediate,9615.0,,N,,A,6021,,,Canis lupus familiaris,1,,,
,4527,1,BAO_0000218,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,50588,In vivo,,CHEMBL622535,Intermediate,9615.0,,N,,A,6022,,,Canis lupus familiaris,1,,,
,4186,1,BAO_0000218,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,50588,In vivo,,CHEMBL876739,Intermediate,9615.0,,N,,A,6023,,,Canis lupus familiaris,1,,,
,5007,1,BAO_0000218,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),50588,In vivo,,CHEMBL622536,Intermediate,9615.0,,N,,A,6024,,,Canis lupus familiaris,1,,,
,3132,1,BAO_0000218,Maximum concentration obtained in dog plasma was determined,50588,In vivo,Plasma,CHEMBL622537,Intermediate,9615.0,,N,,A,6025,,,Canis lupus familiaris,1,,1969.0,
,5006,1,BAO_0000218,Maximum concentration was determined,50588,In vivo,,CHEMBL622538,Intermediate,9615.0,,N,,A,6026,,,Canis lupus familiaris,1,,,
,4727,1,BAO_0000218,Maximum concentration at the dose of 2 mg/kg in dog,50588,In vivo,,CHEMBL627867,Intermediate,9615.0,,N,,A,6027,,,Canis lupus familiaris,1,,,
,1916,1,BAO_0000218,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,In vivo,,CHEMBL627868,Intermediate,9615.0,,N,,A,6028,,,Canis lupus familiaris,1,,,
,1918,1,BAO_0000218,Maximum concentration was evaluated in dog plasma,50588,In vivo,Plasma,CHEMBL627869,Intermediate,9615.0,,N,,A,6029,,,Canis lupus familiaris,1,,1969.0,
,3045,1,BAO_0000218,Maximum concentration was evaluated after 75 min after administration in dog,50588,In vivo,,CHEMBL627870,Intermediate,9615.0,,N,,A,6030,,,Canis lupus familiaris,1,,,
,9579,1,BAO_0000218,Maximum plasma concentration determined in dog after oral administration of 17b,50588,In vivo,Plasma,CHEMBL627871,Intermediate,9615.0,,N,,A,6031,,,Canis lupus familiaris,1,,1969.0,
,9579,1,BAO_0000218,Maximum plasma concentration determined in dog after oral administration of 2b,50588,In vivo,Plasma,CHEMBL627872,Intermediate,9615.0,,N,,A,6032,,,Canis lupus familiaris,1,,1969.0,
,933,1,BAO_0000218,Maximum plasma concentration in dog,50588,In vivo,Plasma,CHEMBL627873,Intermediate,9615.0,,N,,A,6033,,,Canis lupus familiaris,1,,1969.0,
,17839,1,BAO_0000218,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,50588,In vivo,Plasma,CHEMBL627874,Intermediate,9615.0,,N,,A,6034,,,Canis lupus familiaris,1,,1969.0,
,17839,1,BAO_0000218,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,50588,In vivo,Plasma,CHEMBL627875,Intermediate,9615.0,,N,,A,6035,,,Canis lupus familiaris,1,,1969.0,
,17839,1,BAO_0000218,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,50588,In vivo,Plasma,CHEMBL627876,Intermediate,9615.0,,N,,A,6036,,,Canis lupus familiaris,1,,1969.0,
,17839,1,BAO_0000218,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,50588,In vivo,Plasma,CHEMBL627877,Intermediate,9615.0,,N,,A,6037,,,Canis lupus familiaris,1,,1969.0,
,6348,1,BAO_0000218,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,In vivo,Plasma,CHEMBL627878,Intermediate,9615.0,,N,,A,6038,,,Canis lupus familiaris,1,,1969.0,
,16367,1,BAO_0000218,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,50588,In vivo,Plasma,CHEMBL627879,Intermediate,9615.0,,N,,A,6039,,,Canis lupus familiaris,1,,1969.0,
,1337,1,BAO_0000218,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,50588,In vivo,Plasma,CHEMBL875355,Intermediate,9615.0,,N,,A,6040,,,Canis lupus familiaris,1,,1969.0,
,1337,1,BAO_0000218,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,50588,In vivo,Plasma,CHEMBL627880,Intermediate,9615.0,,N,,A,6041,,,Canis lupus familiaris,1,,1969.0,
,5199,1,BAO_0000218,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,50588,In vivo,Plasma,CHEMBL627881,Intermediate,9615.0,,N,,A,6042,,,Canis lupus familiaris,1,,1969.0,
,17650,1,BAO_0000218,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,50588,In vivo,Plasma,CHEMBL627882,Intermediate,9615.0,,N,,A,6043,,,Canis lupus familiaris,1,,1969.0,
,6679,1,BAO_0000218,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,50588,In vivo,Plasma,CHEMBL627883,Intermediate,9615.0,,N,,A,6044,,,Canis lupus familiaris,1,,1969.0,
,5356,1,BAO_0000218,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,50588,In vivo,Plasma,CHEMBL628526,Intermediate,9615.0,,N,,A,6045,,,Canis lupus familiaris,1,,1969.0,
,5356,1,BAO_0000218,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,50588,In vivo,Plasma,CHEMBL628527,Intermediate,9615.0,,N,,A,6046,,,Canis lupus familiaris,1,,1969.0,
,6227,1,BAO_0000218,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,50588,In vivo,Plasma,CHEMBL628528,Intermediate,9615.0,,N,,A,6047,,,Canis lupus familiaris,1,,1969.0,
,6227,1,BAO_0000218,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,50588,In vivo,Plasma,CHEMBL628529,Intermediate,9615.0,,N,,A,6048,,,Canis lupus familiaris,1,,1969.0,
,6227,1,BAO_0000218,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,50588,In vivo,Plasma,CHEMBL628530,Intermediate,9615.0,,N,,A,6049,,,Canis lupus familiaris,1,,1969.0,
,6227,1,BAO_0000218,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,50588,In vivo,Plasma,CHEMBL625243,Intermediate,9615.0,,N,,A,6050,,,Canis lupus familiaris,1,,1969.0,
,3598,1,BAO_0000218,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,In vivo,Plasma,CHEMBL625244,Expert,9615.0,,N,,A,6051,,,Canis lupus familiaris,1,,1969.0,
,4368,1,BAO_0000218,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,50588,In vivo,,CHEMBL625245,Intermediate,9615.0,,N,,A,6052,,,Canis lupus familiaris,1,,,
,6265,1,BAO_0000218,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,50588,In vivo,,CHEMBL625246,Intermediate,9615.0,,N,,A,6053,,,Canis lupus familiaris,1,,,
,7767,1,BAO_0000218,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,In vivo,Stomach,CHEMBL625247,Intermediate,10090.0,,N,,A,6054,,,Mus musculus,1,,945.0,
,7767,1,BAO_0000218,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,In vivo,Urine,CHEMBL625248,Intermediate,10090.0,,N,,A,6055,,,Mus musculus,1,,1088.0,
,7767,1,BAO_0000218,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,50594,In vivo,Urine,CHEMBL625249,Intermediate,10090.0,,N,,A,6056,,,Mus musculus,1,,1088.0,
,7767,1,BAO_0000218,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,50594,In vivo,Urine,CHEMBL625250,Intermediate,10090.0,,N,,A,6057,,,Mus musculus,1,,1088.0,
,17811,1,BAO_0000218,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,50594,,,CHEMBL625251,Intermediate,10090.0,,N,,A,6058,,,Mus musculus,1,,,
,17811,1,BAO_0000218,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,50594,,,CHEMBL875356,Intermediate,10090.0,,N,,A,6059,,,Mus musculus,1,,,
,17827,1,BAO_0000218,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),50594,,,CHEMBL625252,Intermediate,10090.0,,N,,A,6060,,,Mus musculus,1,,,
,17827,1,BAO_0000218,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),50594,,Blood,CHEMBL625253,Intermediate,10090.0,,N,,A,6061,,,Mus musculus,1,,178.0,
,17827,1,BAO_0000218,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),50594,,,CHEMBL625254,Intermediate,10090.0,,N,,A,6062,,,Mus musculus,1,,,
,17827,1,BAO_0000218,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),50594,,,CHEMBL625255,Intermediate,10090.0,,N,,A,6063,,,Mus musculus,1,,,
,17827,1,BAO_0000218,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),50594,,,CHEMBL625256,Intermediate,10090.0,,N,,A,6064,,,Mus musculus,1,,,
,17827,1,BAO_0000218,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),50594,,Blood,CHEMBL625257,Intermediate,10090.0,,N,,A,6065,,,Mus musculus,1,,178.0,
,17827,1,BAO_0000218,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),50594,,Blood,CHEMBL625258,Intermediate,10090.0,,N,,A,6066,,,Mus musculus,1,,178.0,
,17827,1,BAO_0000218,Compound was evaluated for washout rate in mice (Radiolabeled compound),50594,,,CHEMBL625259,Intermediate,10090.0,,N,,A,6067,,,Mus musculus,1,,,
,17827,1,BAO_0000218,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,50594,,,CHEMBL625260,Intermediate,10090.0,,N,,A,6068,,,Mus musculus,1,,,
,17827,1,BAO_0000218,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",50594,,,CHEMBL625261,Intermediate,10090.0,,N,,A,6069,,,Mus musculus,1,,,
,17827,1,BAO_0000218,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",50594,,,CHEMBL625262,Intermediate,10090.0,,N,,A,6070,,,Mus musculus,1,,,
,17827,1,BAO_0000218,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",50594,,,CHEMBL622639,Intermediate,10090.0,,N,,A,6071,,,Mus musculus,1,,,
,17257,1,BAO_0000218,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,50594,,,CHEMBL622640,Intermediate,10090.0,,N,,A,6072,,,Mus musculus,1,,,
,17257,1,BAO_0000218,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,50594,,,CHEMBL622812,Intermediate,10090.0,,N,,A,6073,,,Mus musculus,1,,,
,17257,1,BAO_0000218,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,50594,,,CHEMBL622813,Intermediate,10090.0,,N,,A,6074,,,Mus musculus,1,,,
,17257,1,BAO_0000218,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,50594,,,CHEMBL622814,Intermediate,10090.0,,N,,A,6075,,,Mus musculus,1,,,
,17827,1,BAO_0000218,Time at maximum activity in mice (Radiolabeled compound),50594,,,CHEMBL622815,Intermediate,10090.0,,N,,A,6076,,,Mus musculus,1,,,
,3760,1,BAO_0000218,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,50594,,,CHEMBL625342,Intermediate,10090.0,,N,,A,6077,,,Mus musculus,1,,,
,3760,1,BAO_0000218,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,50594,,,CHEMBL625343,Intermediate,10090.0,,N,,A,6078,,,Mus musculus,1,,,
,17409,1,BAO_0000218,Binding towards mouse plasma protein at 10 uM,50594,,,CHEMBL877591,Intermediate,10090.0,,N,,A,6079,,,Mus musculus,1,,,
,17409,1,BAO_0000218,Binding towards mouse plasma protein at 100 uM,50594,,,CHEMBL625344,Intermediate,10090.0,,N,,A,6080,,,Mus musculus,1,,,
,2675,1,BAO_0000218,Bioavailability was evaluated in mice after intravenous administration,50594,In vivo,,CHEMBL625345,Intermediate,10090.0,,N,,A,6081,,,Mus musculus,1,,,
,2675,1,BAO_0000218,Bioavailability was evaluated in mice after oral administration,50594,In vivo,,CHEMBL625346,Intermediate,10090.0,,N,,A,6082,,,Mus musculus,1,,,
,3132,1,BAO_0000218,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,50594,In vivo,,CHEMBL625347,Intermediate,10090.0,,N,,A,6083,,,Mus musculus,1,,,
,3132,1,BAO_0000218,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,50594,In vivo,,CHEMBL625348,Intermediate,10090.0,,N,,A,6084,,,Mus musculus,1,,,
,16597,1,BAO_0000218,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,50594,In vivo,,CHEMBL625349,Intermediate,10090.0,,N,,A,6085,,,Mus musculus,1,,,
,2862,1,BAO_0000218,Oral bioavailability in mouse,50594,In vivo,,CHEMBL625350,Intermediate,10090.0,,N,,A,6086,,,Mus musculus,1,,,
,17764,1,BAO_0000218,Oral bioavailability after intravenous administration in mice at 24 uM/kg,50594,In vivo,,CHEMBL882952,Intermediate,10090.0,,N,,A,6087,,,Mus musculus,1,,,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Brain,CHEMBL625351,Intermediate,10090.0,,N,,A,6088,,,Mus musculus,1,,955.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Brain,CHEMBL625352,Intermediate,10090.0,,N,,A,6089,,,Mus musculus,1,,955.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Brain,CHEMBL877592,Intermediate,10090.0,,N,,A,6090,,,Mus musculus,1,,955.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Brain,CHEMBL625353,Intermediate,10090.0,,N,,A,6091,,,Mus musculus,1,,955.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Brain,CHEMBL625354,Intermediate,10090.0,,N,,A,6092,,,Mus musculus,1,,955.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Brain,CHEMBL626019,Intermediate,10090.0,,N,,A,6093,,,Mus musculus,1,,955.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Heart,CHEMBL626020,Intermediate,10090.0,,N,,A,6094,,,Mus musculus,1,,948.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Heart,CHEMBL626021,Intermediate,10090.0,,N,,A,6095,,,Mus musculus,1,,948.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Heart,CHEMBL626022,Intermediate,10090.0,,N,,A,6096,,,Mus musculus,1,,948.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Heart,CHEMBL626192,Intermediate,10090.0,,N,,A,6097,,,Mus musculus,1,,948.0,
,1276,1,BAO_0000219,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),80682,,,CHEMBL626193,Intermediate,9606.0,,N,,F,6098,,646.0,Homo sapiens,1,,,A549
,3498,1,BAO_0000219,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,80682,,,CHEMBL626194,Expert,9606.0,,N,,F,6099,,646.0,Homo sapiens,1,,,A549
,1169,1,BAO_0000219,Cytotoxicity against human lung carcinoma A-549 cell lines,80682,,,CHEMBL626195,Intermediate,9606.0,,N,,F,6100,,646.0,Homo sapiens,1,,,A549
,4450,1,BAO_0000219,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,80682,,,CHEMBL626196,Intermediate,9606.0,,N,,F,6101,,646.0,Homo sapiens,1,,,A549
,358,1,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549,80682,,,CHEMBL626197,Intermediate,9606.0,,N,,F,6102,,646.0,Homo sapiens,1,,,A549
,358,1,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,80682,,,CHEMBL626198,Intermediate,9606.0,,N,,F,6103,,646.0,Homo sapiens,1,,,A549
,358,1,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,80682,,,CHEMBL626199,Intermediate,9606.0,,N,,F,6104,,646.0,Homo sapiens,1,,,A549
,358,1,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,80682,,,CHEMBL626200,Intermediate,9606.0,,N,,F,6105,,646.0,Homo sapiens,1,,,A549
,358,1,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,80682,,,CHEMBL626201,Intermediate,9606.0,,N,,F,6106,,646.0,Homo sapiens,1,,,A549
,358,1,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,80682,,,CHEMBL626202,Intermediate,9606.0,,N,,F,6107,,646.0,Homo sapiens,1,,,A549
,358,1,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,80682,,,CHEMBL626203,Intermediate,9606.0,,N,,F,6108,,646.0,Homo sapiens,1,,,A549
,15167,1,BAO_0000219,In vitro cytotoxicity against A-549 human lung cancer cells,80682,,,CHEMBL626204,Intermediate,9606.0,,N,,F,6109,,646.0,Homo sapiens,1,,,A549
,4139,1,BAO_0000219,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,80682,,,CHEMBL624701,Intermediate,9606.0,,N,,F,6110,,646.0,Homo sapiens,1,,,A549
,833,1,BAO_0000219,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,80682,,,CHEMBL624702,Intermediate,9606.0,,N,,F,6111,,646.0,Homo sapiens,1,,,A549
,15718,1,BAO_0000219,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,80682,,,CHEMBL624703,Expert,9606.0,,N,,F,6112,,646.0,Homo sapiens,1,,,A549
,12373,1,BAO_0000219,Tested in vitro for cytotoxicity against A-549 lung cancer cells,80682,,,CHEMBL624704,Intermediate,9606.0,,N,,F,6113,,646.0,Homo sapiens,1,,,A549
,637,1,BAO_0000219,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,80682,,,CHEMBL624705,Intermediate,9606.0,,N,,F,6114,,646.0,Homo sapiens,1,,,A549
,14867,1,BAO_0000219,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,80682,,,CHEMBL624706,Expert,9606.0,,N,,F,6115,,646.0,Homo sapiens,1,,,A549
,4461,1,BAO_0000219,Antitumor cytotoxic activity against A-549 cell line was determined,80682,,,CHEMBL624707,Intermediate,9606.0,,N,,F,6116,,646.0,Homo sapiens,1,,,A549
,5406,1,BAO_0000219,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",80682,,,CHEMBL624708,Intermediate,9606.0,,N,,F,6117,,646.0,Homo sapiens,1,,,A549
,4457,1,BAO_0000219,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,80682,,,CHEMBL624709,Intermediate,9606.0,,N,,F,6118,,646.0,Homo sapiens,1,,,A549
,1386,1,BAO_0000219,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,80682,,,CHEMBL884107,Expert,9606.0,,N,,F,6119,,646.0,Homo sapiens,1,,,A549
,3265,1,BAO_0000219,Antitumoral activity was assayed against A-549 cell line,80682,,,CHEMBL624710,Intermediate,9606.0,,N,,F,6120,,646.0,Homo sapiens,1,,,A549
,2359,1,BAO_0000219,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,80682,,,CHEMBL624711,Intermediate,9606.0,,N,,F,6121,,646.0,Homo sapiens,1,,,A549
,4457,1,BAO_0000219,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,80682,,,CHEMBL624712,Intermediate,9606.0,,N,,F,6122,,646.0,Homo sapiens,1,,,A549
,12454,1,BAO_0000219,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,80682,,,CHEMBL624713,Expert,9606.0,,N,,F,6123,,646.0,Homo sapiens,1,,,A549
,1481,1,BAO_0000219,Compound was tested for inhibition of cell growth of A-549 cells,80682,,,CHEMBL624714,Intermediate,9606.0,,N,,F,6124,,646.0,Homo sapiens,1,,,A549
,1750,1,BAO_0000219,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,80682,,,CHEMBL624715,Intermediate,9606.0,,N,,F,6125,,646.0,Homo sapiens,1,,,A549
,5065,1,BAO_0000219,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,80682,,,CHEMBL624716,Intermediate,9606.0,,N,,F,6126,,646.0,Homo sapiens,1,,,A549
,808,1,BAO_0000219,In vitro cytotoxicity against A549-human lung carcinoma cells.,80682,,,CHEMBL619505,Expert,9606.0,,N,,F,6127,,646.0,Homo sapiens,1,,,A549
,16364,1,BAO_0000219,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,80682,,,CHEMBL619506,Expert,9606.0,,N,,F,6128,,646.0,Homo sapiens,1,,,A549
,1847,1,BAO_0000219,Cytotoxic activity against A-549 cell lines.,80682,,,CHEMBL619507,Intermediate,9606.0,,N,,F,6129,,646.0,Homo sapiens,1,,,A549
,1747,1,BAO_0000219,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,80682,,,CHEMBL619508,Expert,9606.0,,N,,F,6130,,646.0,Homo sapiens,1,,,A549
,1003,1,BAO_0000219,Cytotoxicity against human A549 non small cell lung cell lines,80682,,,CHEMBL619509,Intermediate,9606.0,,N,,F,6131,,646.0,Homo sapiens,1,,,A549
,15313,1,BAO_0000219,Inhibition of cell growth in (A-549) lung cell line,80682,,,CHEMBL619510,Expert,9606.0,,N,,F,6132,,646.0,Homo sapiens,1,,,A549
,3122,1,BAO_0000219,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,80682,,,CHEMBL619511,Intermediate,9606.0,,N,,F,6133,,646.0,Homo sapiens,1,,,A549
,16049,1,BAO_0000219,In vitro antitumor activity against A-549 tumor cells.,80682,,,CHEMBL619512,Intermediate,9606.0,,N,,F,6134,,646.0,Homo sapiens,1,,,A549
,17134,1,BAO_0000219,In vitro antitumor effects against human A-549 cell lines.,80682,,,CHEMBL619513,Expert,9606.0,,N,,F,6135,,646.0,Homo sapiens,1,,,A549
,6406,1,BAO_0000219,In vitro cytotoxic activity of compound against A-549 cell line,80682,,,CHEMBL619514,Intermediate,9606.0,,N,,F,6136,,646.0,Homo sapiens,1,,,A549
,627,1,BAO_0000219,In vitro cytotoxicity against human lung carcinoma A-549 cell line,80682,,,CHEMBL619515,Intermediate,9606.0,,N,,F,6137,,646.0,Homo sapiens,1,,,A549
,12307,1,BAO_0000219,In vitro cytotoxicity against human non-small cell lung carcinoma A549,80682,,,CHEMBL619516,Intermediate,9606.0,,N,,F,6138,,646.0,Homo sapiens,1,,,A549
,17861,1,BAO_0000219,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,80682,,,CHEMBL884005,Intermediate,9606.0,,N,,F,6139,,646.0,Homo sapiens,1,,,A549
,6682,1,BAO_0000219,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,80682,,,CHEMBL619517,Expert,9606.0,,N,,F,6140,,646.0,Homo sapiens,1,,,A549
,6663,1,BAO_0000219,Inhibitory concentration of compound against A-549 cell line,80682,,,CHEMBL619518,Intermediate,9606.0,,N,,F,6141,,646.0,Homo sapiens,1,,,A549
,2454,1,BAO_0000219,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,80682,,,CHEMBL619519,Intermediate,9606.0,,N,,F,6142,,646.0,Homo sapiens,1,,,A549
,14709,1,BAO_0000219,cytotoxic activity against leukemia (A-549) cancer cell line,80682,,,CHEMBL876489,Intermediate,9606.0,,N,,F,6143,,646.0,Homo sapiens,1,,,A549
,15718,1,BAO_0000219,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,80682,,,CHEMBL619520,Expert,9606.0,,N,,F,6144,,646.0,Homo sapiens,1,,,A549
,15718,1,BAO_0000219,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,80682,,,CHEMBL619521,Intermediate,9606.0,,N,,F,6145,,646.0,Homo sapiens,1,,,A549
,17130,1,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),80682,,,CHEMBL619522,Intermediate,9606.0,,N,,F,6146,,646.0,Homo sapiens,1,,,A549
,17130,1,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),80682,,,CHEMBL619523,Intermediate,9606.0,,N,,F,6147,,646.0,Homo sapiens,1,,,A549
,17130,1,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),80682,,,CHEMBL619524,Intermediate,9606.0,,N,,F,6148,,646.0,Homo sapiens,1,,,A549
,17130,1,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),80682,,,CHEMBL619525,Intermediate,9606.0,,N,,F,6149,,646.0,Homo sapiens,1,,,A549
,6630,1,BAO_0000219,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,80682,,,CHEMBL619526,Intermediate,,,N,,F,6150,,646.0,,1,,,A549
,16726,1,BAO_0000219,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,80682,,,CHEMBL619527,Intermediate,9606.0,,N,,F,6151,,646.0,Homo sapiens,1,,,A549
,17846,1,BAO_0000219,Cytotoxicity against A549 cells; No cytotoxicity,80682,,,CHEMBL619528,Intermediate,9606.0,,N,,F,6152,,646.0,Homo sapiens,1,,,A549
,3415,1,BAO_0000219,Cytotoxicity against human lung carcinoma (A549) cell lines,80682,,,CHEMBL619529,Expert,9606.0,,N,,F,6153,,646.0,Homo sapiens,1,,,A549
,3415,1,BAO_0000219,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,80682,,,CHEMBL619530,Expert,9606.0,,N,,F,6154,,646.0,Homo sapiens,1,,,A549
,5609,1,BAO_0000219,In vitro anticancer activity against human lung (A549) cell line,80682,,,CHEMBL876490,Intermediate,9606.0,,N,,F,6155,,646.0,Homo sapiens,1,,,A549
,17206,1,BAO_0000219,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,80682,,,CHEMBL619531,Intermediate,9606.0,,N,,F,6156,,646.0,Homo sapiens,1,,,A549
,17206,1,BAO_0000219,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,80682,,,CHEMBL619532,Intermediate,9606.0,,N,,F,6157,,646.0,Homo sapiens,1,,,A549
,17206,1,BAO_0000219,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,80682,,,CHEMBL619533,Intermediate,9606.0,,N,,F,6158,,646.0,Homo sapiens,1,,,A549
,17206,1,BAO_0000219,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,80682,,,CHEMBL619534,Intermediate,9606.0,,N,,F,6159,,646.0,Homo sapiens,1,,,A549
,17206,1,BAO_0000219,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,80682,,,CHEMBL620164,Intermediate,9606.0,,N,,F,6160,,646.0,Homo sapiens,1,,,A549
,17206,1,BAO_0000219,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,80682,,,CHEMBL620165,Intermediate,9606.0,,N,,F,6161,,646.0,Homo sapiens,1,,,A549
,16295,1,BAO_0000219,Inhibition of A549 human lung tumor cell proliferation,80682,,,CHEMBL620166,Expert,9606.0,,N,,F,6162,,646.0,Homo sapiens,1,,,A549
,16825,1,BAO_0000219,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",80682,,,CHEMBL620167,Intermediate,9606.0,,N,,F,6163,,646.0,Homo sapiens,1,,,A549
,3439,1,BAO_0000219,In vitro cytotoxicity against human tumor cell line A549,80682,,,CHEMBL620168,Expert,9606.0,,N,,F,6164,,646.0,Homo sapiens,1,,,A549
,10870,1,BAO_0000219,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,80682,,,CHEMBL620338,Intermediate,9606.0,,N,,F,6165,,646.0,Homo sapiens,1,,,A549
,4845,1,BAO_0000219,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,80682,,,CHEMBL620339,Intermediate,9606.0,,N,,F,6166,,646.0,Homo sapiens,1,,,A549
,5822,1,BAO_0000219,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,80682,,,CHEMBL620340,Intermediate,9606.0,,N,,F,6167,,646.0,Homo sapiens,1,,,A549
,5822,1,BAO_0000219,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,80682,,,CHEMBL620341,Intermediate,9606.0,,N,,F,6168,,646.0,Homo sapiens,1,,,A549
,5822,1,BAO_0000219,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,80682,,,CHEMBL876491,Intermediate,9606.0,,N,,F,6169,,646.0,Homo sapiens,1,,,A549
,16381,1,BAO_0000219,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,80682,,,CHEMBL620342,Intermediate,9606.0,,N,,F,6170,,646.0,Homo sapiens,1,,,A549
,16381,1,BAO_0000219,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,80682,,,CHEMBL620343,Intermediate,9606.0,,N,,F,6171,,646.0,Homo sapiens,1,,,A549
,16381,1,BAO_0000219,% inhibition against A549 cells (lung cancer) at 4 ug/mL,80682,,,CHEMBL620344,Intermediate,9606.0,,N,,F,6172,,646.0,Homo sapiens,1,,,A549
,5609,1,BAO_0000219,In vitro anticancer activity against human lung (A549) cell line,80682,,,CHEMBL620345,Intermediate,9606.0,,N,,F,6173,,646.0,Homo sapiens,1,,,A549
,4644,1,BAO_0000219,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,80682,,,CHEMBL620346,Intermediate,9606.0,,N,,F,6174,,646.0,Homo sapiens,1,,,A549
,4644,1,BAO_0000219,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,80682,,,CHEMBL620347,Intermediate,9606.0,,N,,F,6175,,646.0,Homo sapiens,1,,,A549
,4644,1,BAO_0000219,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,80682,,,CHEMBL620348,Intermediate,9606.0,,N,,F,6176,,646.0,Homo sapiens,1,,,A549
,4644,1,BAO_0000219,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,80682,,,CHEMBL620349,Intermediate,9606.0,,N,,F,6177,,646.0,Homo sapiens,1,,,A549
,5822,1,BAO_0000219,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,80682,,,CHEMBL618667,Intermediate,9606.0,,N,,F,6178,,646.0,Homo sapiens,1,,,A549
,3415,1,BAO_0000219,Percentage inhibition of human lung carcinoma (A549) cell lines,80682,,,CHEMBL618668,Expert,9606.0,,N,,F,6179,,646.0,Homo sapiens,1,,,A549
,16726,1,BAO_0000219,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,80682,,,CHEMBL876031,Intermediate,9606.0,,N,,F,6180,,646.0,Homo sapiens,1,,,A549
,17206,1,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",80682,,,CHEMBL618759,Intermediate,9606.0,,N,,F,6181,,646.0,Homo sapiens,1,,,A549
,17206,1,BAO_0000219,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,80682,,,CHEMBL618760,Intermediate,9606.0,,N,,F,6182,,646.0,Homo sapiens,1,,,A549
,17206,1,BAO_0000219,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,80682,,,CHEMBL619000,Intermediate,9606.0,,N,,F,6183,,646.0,Homo sapiens,1,,,A549
,17206,1,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",80682,,,CHEMBL619001,Intermediate,9606.0,,N,,F,6184,,646.0,Homo sapiens,1,,,A549
,17206,1,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",80682,,,CHEMBL619002,Intermediate,9606.0,,N,,F,6185,,646.0,Homo sapiens,1,,,A549
,17206,1,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",80682,,,CHEMBL619003,Intermediate,9606.0,,N,,F,6186,,646.0,Homo sapiens,1,,,A549
,17206,1,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",80682,,,CHEMBL619597,Intermediate,9606.0,,N,,F,6187,,646.0,Homo sapiens,1,,,A549
,17206,1,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",80682,,,CHEMBL619598,Intermediate,9606.0,,N,,F,6188,,646.0,Homo sapiens,1,,,A549
,17206,1,BAO_0000219,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,80682,,,CHEMBL619599,Intermediate,9606.0,,N,,F,6189,,646.0,Homo sapiens,1,,,A549
,17206,1,BAO_0000219,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,80682,,,CHEMBL619600,Intermediate,9606.0,,N,,F,6190,,646.0,Homo sapiens,1,,,A549
,16726,1,BAO_0000219,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,80682,,,CHEMBL619601,Intermediate,9606.0,,N,,F,6191,,646.0,Homo sapiens,1,,,A549
,17206,1,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,80682,,,CHEMBL619602,Intermediate,9606.0,,N,,F,6192,,646.0,Homo sapiens,1,,,A549
,17206,1,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,80682,,,CHEMBL619603,Intermediate,9606.0,,N,,F,6193,,646.0,Homo sapiens,1,,,A549
,17206,1,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,80682,,,CHEMBL619604,Intermediate,9606.0,,N,,F,6194,,646.0,Homo sapiens,1,,,A549
,17206,1,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,80682,,,CHEMBL619605,Intermediate,9606.0,,N,,F,6195,,646.0,Homo sapiens,1,,,A549
,6084,1,BAO_0000218,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,50588,In vivo,,CHEMBL619606,Intermediate,9615.0,,N,,A,6196,,,Canis lupus familiaris,1,,,
,6084,1,BAO_0000218,Pharmacokinetic activity (Cmax) in dog,50588,In vivo,,CHEMBL876032,Intermediate,9615.0,,N,,A,6197,,,Canis lupus familiaris,1,,,
,4809,1,BAO_0000218,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),50588,In vivo,,CHEMBL619607,Intermediate,9615.0,,N,,A,6198,,,Canis lupus familiaris,1,,,
,5983,1,BAO_0000218,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,50588,In vivo,,CHEMBL619608,Intermediate,9615.0,,N,,A,6199,,,Canis lupus familiaris,1,,,
,6251,1,BAO_0000218,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,50588,In vivo,,CHEMBL619609,Intermediate,9615.0,,N,,A,6200,,,Canis lupus familiaris,1,,,
,5932,1,BAO_0000218,Cmax in dog plasma after 30mg/kg oral dose,50588,In vivo,Plasma,CHEMBL619610,Intermediate,9615.0,,N,,A,6201,,,Canis lupus familiaris,1,,1969.0,
,4273,1,BAO_0000218,Tested for the peak blood level in dog,50588,In vivo,Blood,CHEMBL619611,Intermediate,9615.0,,N,,A,6202,,,Canis lupus familiaris,1,,178.0,
,5313,1,BAO_0000218,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",50588,In vivo,,CHEMBL619612,Intermediate,9615.0,,N,,A,6203,,,Canis lupus familiaris,1,,,
,5313,1,BAO_0000218,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",50588,In vivo,,CHEMBL619613,Intermediate,9615.0,,N,,A,6204,,,Canis lupus familiaris,1,,,
,6221,1,BAO_0000218,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,50588,In vivo,Blood,CHEMBL619614,Intermediate,9615.0,,N,,A,6205,,,Canis lupus familiaris,1,,178.0,
,4709,1,BAO_0000218,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,50588,,,CHEMBL619615,Intermediate,9615.0,,N,,A,6206,,,Canis lupus familiaris,1,,,
,167,1,BAO_0000218,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,50588,,,CHEMBL619616,Intermediate,9615.0,,N,,A,6207,,,Canis lupus familiaris,1,,,
,6241,1,BAO_0000218,Final plasma concentration in dogs after oral administration at 1 mg/kg,50588,,Plasma,CHEMBL619617,Intermediate,9615.0,,N,,A,6208,,,Canis lupus familiaris,1,,1969.0,
,344,1,BAO_0000218,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,50588,,,CHEMBL619618,Intermediate,9615.0,,N,,A,6209,,,Canis lupus familiaris,1,,,
,344,1,BAO_0000218,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,50588,,,CHEMBL876033,Intermediate,9615.0,,N,,A,6210,,,Canis lupus familiaris,1,,,
,344,1,BAO_0000218,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,50588,,,CHEMBL619619,Intermediate,9615.0,,N,,A,6211,,,Canis lupus familiaris,1,,,
,2189,1,BAO_0000218,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,50588,,,CHEMBL619620,Intermediate,9615.0,,N,,A,6212,,,Canis lupus familiaris,1,,,
,2189,1,BAO_0000218,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,50588,,Urine,CHEMBL619621,Intermediate,9615.0,,N,,A,6213,,,Canis lupus familiaris,1,,1088.0,
,2189,1,BAO_0000218,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,50588,,Urine,CHEMBL619622,Intermediate,9615.0,,N,,A,6214,,,Canis lupus familiaris,1,,1088.0,
,2189,1,BAO_0000218,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,50588,,Urine,CHEMBL618874,Intermediate,9615.0,,N,,A,6215,,,Canis lupus familiaris,1,,1088.0,
,4257,1,BAO_0000218,Absolute bioavailability was evaluated in dog,50588,In vivo,,CHEMBL618875,Intermediate,9615.0,,N,,A,6216,,,Canis lupus familiaris,1,,,
,6221,1,BAO_0000218,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,50588,In vivo,,CHEMBL618876,Intermediate,9615.0,,N,,A,6217,,,Canis lupus familiaris,1,,,
,6215,1,BAO_0000218,Bioavailability after peroral administration (1 mg/kg) was determined in dog,50588,In vivo,,CHEMBL618877,Intermediate,9615.0,,N,,A,6218,,,Canis lupus familiaris,1,,,
,17267,1,BAO_0000218,Bioavailability in dog,50588,In vivo,,CHEMBL618878,Intermediate,9615.0,,N,,A,6219,,,Canis lupus familiaris,1,,,
,6621,1,BAO_0000218,Bioavailability in dog,50588,In vivo,,CHEMBL618879,Intermediate,9615.0,,N,,A,6220,,,Canis lupus familiaris,1,,,
,3854,1,BAO_0000218,Bioavailability after intravenous administration in dogs,50588,In vivo,,CHEMBL618880,Intermediate,9615.0,,N,,A,6221,,,Canis lupus familiaris,1,,,
,3854,1,BAO_0000218,Bioavailability after peroral administration in dogs,50588,In vivo,,CHEMBL618881,Intermediate,9615.0,,N,,A,6222,,,Canis lupus familiaris,1,,,
,5007,1,BAO_0000218,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),50588,In vivo,,CHEMBL618882,Intermediate,9615.0,,N,,A,6223,,,Canis lupus familiaris,1,,,
,4333,1,BAO_0000218,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,50588,In vivo,,CHEMBL624226,Intermediate,9615.0,,N,,A,6224,,,Canis lupus familiaris,1,,,
,4333,1,BAO_0000218,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,50588,In vivo,Plasma,CHEMBL624227,Intermediate,9615.0,,N,,A,6225,,,Canis lupus familiaris,1,,1969.0,
,5006,1,BAO_0000218,Bioavailability,50588,In vivo,,CHEMBL624228,Intermediate,9615.0,,N,,A,6226,,,Canis lupus familiaris,1,,,
,5199,1,BAO_0000218,Bioavailability,50588,In vivo,,CHEMBL624229,Intermediate,9615.0,,N,,A,6227,,,Canis lupus familiaris,1,,,
,4368,1,BAO_0000218,Bioavailability by intravenous administration of 1.2 mg/kg in dog,50588,In vivo,,CHEMBL624230,Intermediate,9615.0,,N,,A,6228,,,Canis lupus familiaris,1,,,
,3771,1,BAO_0000218,Bioavailability in dog,50588,In vivo,,CHEMBL624231,Intermediate,9615.0,,N,,A,6229,,,Canis lupus familiaris,1,,,
,4953,1,BAO_0000218,Bioavailability in dog,50588,In vivo,,CHEMBL624232,Intermediate,9615.0,,N,,A,6230,,,Canis lupus familiaris,1,,,
,5064,1,BAO_0000218,Bioavailability in dog,50588,In vivo,,CHEMBL625127,Intermediate,9615.0,,N,,A,6231,,,Canis lupus familiaris,1,,,
,17657,1,BAO_0000218,Bioavailability in dog,50588,In vivo,,CHEMBL625128,Intermediate,9615.0,,N,,A,6232,,,Canis lupus familiaris,1,,,
,17796,1,BAO_0000218,Bioavailability in dog,50588,In vivo,,CHEMBL621675,Intermediate,9615.0,,N,,A,6233,,,Canis lupus familiaris,1,,,
,17853,1,BAO_0000218,Bioavailability in dog (p.o.) at 2.0 mpk,50588,In vivo,,CHEMBL621676,Intermediate,9615.0,,N,,A,6234,,,Canis lupus familiaris,1,,,
,4521,1,BAO_0000218,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),50588,In vivo,,CHEMBL621677,Intermediate,9615.0,,N,,A,6235,,,Canis lupus familiaris,1,,,
,4521,1,BAO_0000218,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,50588,In vivo,,CHEMBL621678,Intermediate,9615.0,,N,,A,6236,,,Canis lupus familiaris,1,,,
,5006,1,BAO_0000218,Bioavailability in dog,50588,In vivo,,CHEMBL621679,Intermediate,9615.0,,N,,A,6237,,,Canis lupus familiaris,1,,,
,16365,1,BAO_0000218,Bioavailability was evaluated after oral administration in dog,50588,In vivo,,CHEMBL621680,Intermediate,9615.0,,N,,A,6238,,,Canis lupus familiaris,1,,,
,1916,1,BAO_0000218,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,In vivo,,CHEMBL621681,Intermediate,9615.0,,N,,A,6239,,,Canis lupus familiaris,1,,,
,1918,1,BAO_0000218,Bioavailability was evaluated in dog,50588,In vivo,,CHEMBL876740,Intermediate,9615.0,,N,,A,6240,,,Canis lupus familiaris,1,,,
,4239,1,BAO_0000218,Bioavailability in dog,50588,In vivo,,CHEMBL621682,Intermediate,9615.0,,N,,A,6241,,,Canis lupus familiaris,1,,,
,6505,1,BAO_0000218,Bioavailability in dog,50588,In vivo,,CHEMBL621683,Intermediate,9615.0,,N,,A,6242,,,Canis lupus familiaris,1,,,
,5334,1,BAO_0000218,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),50588,In vivo,,CHEMBL621684,Intermediate,9615.0,,N,,A,6243,,,Canis lupus familiaris,1,,,
,5334,1,BAO_0000218,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),50588,In vivo,,CHEMBL621685,Intermediate,9615.0,,N,,A,6244,,,Canis lupus familiaris,1,,,
,4809,1,BAO_0000218,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),50588,In vivo,,CHEMBL621686,Intermediate,9615.0,,N,,A,6245,,,Canis lupus familiaris,1,,,
,6348,1,BAO_0000218,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,In vivo,,CHEMBL621687,Intermediate,9615.0,,N,,A,6246,,,Canis lupus familiaris,1,,,
,6005,1,BAO_0000218,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,50588,In vivo,,CHEMBL621688,Intermediate,9615.0,,N,,A,6247,,,Canis lupus familiaris,1,,,
,17804,1,BAO_0000218,Bioavailability of compound in dog was determined after peroral administration,50588,In vivo,,CHEMBL621689,Intermediate,9615.0,,N,,A,6248,,,Canis lupus familiaris,1,,,
,3184,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL621690,Intermediate,9615.0,,N,,A,6249,,,Canis lupus familiaris,1,,,
,1806,1,BAO_0000218,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,50588,In vivo,,CHEMBL621691,Intermediate,9615.0,,N,,A,6250,,,Canis lupus familiaris,1,,,
,1806,1,BAO_0000218,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,50588,In vivo,,CHEMBL875941,Intermediate,9615.0,,N,,A,6251,,,Canis lupus familiaris,1,,,
,1806,1,BAO_0000218,Compound was evaluated for oral bioavailability in dogs; 37-38 %,50588,In vivo,,CHEMBL621692,Intermediate,9615.0,,N,,A,6252,,,Canis lupus familiaris,1,,,
,4839,1,BAO_0000218,Bioavailability in dog,50588,In vivo,,CHEMBL621693,Intermediate,9615.0,,N,,A,6253,,,Canis lupus familiaris,1,,,
,5017,1,BAO_0000218,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),50588,In vivo,,CHEMBL621694,Intermediate,9615.0,,N,,A,6254,,,Canis lupus familiaris,1,,,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Heart,CHEMBL621695,Intermediate,10090.0,,N,,A,6255,,,Mus musculus,1,,948.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Heart,CHEMBL621696,Intermediate,10090.0,,N,,A,6256,,,Mus musculus,1,,948.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Kidney,CHEMBL621697,Intermediate,10090.0,,N,,A,6257,,,Mus musculus,1,,2113.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Kidney,CHEMBL621698,Intermediate,10090.0,,N,,A,6258,,,Mus musculus,1,,2113.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Kidney,CHEMBL623420,Intermediate,10090.0,,N,,A,6259,,,Mus musculus,1,,2113.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Kidney,CHEMBL623421,Intermediate,10090.0,,N,,A,6260,,,Mus musculus,1,,2113.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Kidney,CHEMBL623422,Intermediate,10090.0,,N,,A,6261,,,Mus musculus,1,,2113.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Kidney,CHEMBL623423,Intermediate,10090.0,,N,,A,6262,,,Mus musculus,1,,2113.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Liver,CHEMBL623424,Intermediate,10090.0,,N,,A,6263,,,Mus musculus,1,,2107.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Liver,CHEMBL623425,Intermediate,10090.0,,N,,A,6264,,,Mus musculus,1,,2107.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Liver,CHEMBL623426,Intermediate,10090.0,,N,,A,6265,,,Mus musculus,1,,2107.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Liver,CHEMBL623427,Intermediate,10090.0,,N,,A,6266,,,Mus musculus,1,,2107.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Liver,CHEMBL623428,Intermediate,10090.0,,N,,A,6267,,,Mus musculus,1,,2107.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Liver,CHEMBL875947,Intermediate,10090.0,,N,,A,6268,,,Mus musculus,1,,2107.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Lung,CHEMBL623429,Intermediate,10090.0,,N,,A,6269,,,Mus musculus,1,,2048.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Lung,CHEMBL623430,Intermediate,10090.0,,N,,A,6270,,,Mus musculus,1,,2048.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Lung,CHEMBL622588,Intermediate,10090.0,,N,,A,6271,,,Mus musculus,1,,2048.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Lung,CHEMBL622589,Intermediate,10090.0,,N,,A,6272,,,Mus musculus,1,,2048.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Lung,CHEMBL622751,Intermediate,10090.0,,N,,A,6273,,,Mus musculus,1,,2048.0,
,846,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,In vivo,Lung,CHEMBL622752,Intermediate,10090.0,,N,,A,6274,,,Mus musculus,1,,2048.0,
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,50594,,,CHEMBL622753,Intermediate,10090.0,,N,,A,6275,,42.0,Mus musculus,1,,,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,50594,,,CHEMBL622647,Intermediate,10090.0,,N,,A,6276,,42.0,Mus musculus,1,,,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,50594,,,CHEMBL875163,Intermediate,10090.0,,N,,A,6277,,42.0,Mus musculus,1,,,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,50594,,,CHEMBL622648,Intermediate,10090.0,,N,,A,6278,,42.0,Mus musculus,1,,,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,50594,,,CHEMBL622649,Intermediate,10090.0,,N,,A,6279,,42.0,Mus musculus,1,,,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,50594,,Brain,CHEMBL622650,Intermediate,10090.0,,N,,A,6280,,42.0,Mus musculus,1,,955.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,50594,,Brain,CHEMBL622651,Intermediate,10090.0,,N,,A,6281,,42.0,Mus musculus,1,,955.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,50594,,Brain,CHEMBL622652,Intermediate,10090.0,,N,,A,6282,,42.0,Mus musculus,1,,955.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,50594,,Brain,CHEMBL622653,Intermediate,10090.0,,N,,A,6283,,42.0,Mus musculus,1,,955.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,50594,,Brain,CHEMBL622654,Intermediate,10090.0,,N,,A,6284,,42.0,Mus musculus,1,,955.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,50594,,Heart,CHEMBL622655,Intermediate,10090.0,,N,,A,6285,,42.0,Mus musculus,1,,948.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,50594,,Heart,CHEMBL622656,Intermediate,10090.0,,N,,A,6286,,42.0,Mus musculus,1,,948.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,50594,,Heart,CHEMBL622657,Intermediate,10090.0,,N,,A,6287,,42.0,Mus musculus,1,,948.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,50594,,Heart,CHEMBL622658,Intermediate,10090.0,,N,,A,6288,,42.0,Mus musculus,1,,948.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,50594,,Heart,CHEMBL622659,Intermediate,10090.0,,N,,A,6289,,42.0,Mus musculus,1,,948.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,50594,,Kidney,CHEMBL624630,Intermediate,10090.0,,N,,A,6290,,42.0,Mus musculus,1,,2113.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,50594,,Kidney,CHEMBL624631,Intermediate,10090.0,,N,,A,6291,,42.0,Mus musculus,1,,2113.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,50594,,Kidney,CHEMBL624632,Intermediate,10090.0,,N,,A,6292,,42.0,Mus musculus,1,,2113.0,CCRF S-180
,17130,1,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,80682,,,CHEMBL624633,Intermediate,9606.0,,N,,F,6293,,646.0,Homo sapiens,1,,,A549
,17130,1,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,80682,,,CHEMBL624634,Intermediate,9606.0,,N,,F,6294,,646.0,Homo sapiens,1,,,A549
,17130,1,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),80682,,,CHEMBL624635,Intermediate,9606.0,,N,,F,6295,,646.0,Homo sapiens,1,,,A549
,17130,1,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),80682,,,CHEMBL624636,Intermediate,9606.0,,N,,F,6296,,646.0,Homo sapiens,1,,,A549
,3263,1,BAO_0000219,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,80682,,,CHEMBL857055,Expert,9606.0,,N,,F,6297,,646.0,Homo sapiens,1,,,A549
,6663,1,BAO_0000219,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,80682,,,CHEMBL624637,Expert,9606.0,,N,,F,6298,,646.0,Homo sapiens,1,,,A549
,6663,1,BAO_0000219,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,80682,,,CHEMBL624638,Expert,9606.0,,N,,F,6299,,646.0,Homo sapiens,1,,,A549
,6663,1,BAO_0000219,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,80682,,,CHEMBL874366,Expert,9606.0,,N,,F,6300,,646.0,Homo sapiens,1,,,A549
,6663,1,BAO_0000219,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,80682,,,CHEMBL624639,Expert,9606.0,,N,,F,6301,,646.0,Homo sapiens,1,,,A549
,6663,1,BAO_0000219,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,80682,,,CHEMBL624640,Expert,9606.0,,N,,F,6302,,646.0,Homo sapiens,1,,,A549
,6663,1,BAO_0000219,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,80682,,,CHEMBL624641,Intermediate,9606.0,,N,,F,6303,,646.0,Homo sapiens,1,,,A549
,6663,1,BAO_0000219,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,80682,,,CHEMBL624642,Intermediate,9606.0,,N,,F,6304,,646.0,Homo sapiens,1,,,A549
,6663,1,BAO_0000219,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,80682,,,CHEMBL624643,Intermediate,9606.0,,N,,F,6305,,646.0,Homo sapiens,1,,,A549
,6663,1,BAO_0000219,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,80682,,,CHEMBL624644,Intermediate,9606.0,,N,,F,6306,,646.0,Homo sapiens,1,,,A549
,6663,1,BAO_0000219,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,80682,,,CHEMBL624645,Intermediate,9606.0,,N,,F,6307,,646.0,Homo sapiens,1,,,A549
,3983,1,BAO_0000219,The compound was evaluated for its cytotoxic potency against A-549 cell line,80682,,,CHEMBL619445,Intermediate,9606.0,,N,,F,6308,,646.0,Homo sapiens,1,,,A549
,11141,1,BAO_0000219,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,80682,,,CHEMBL839886,Expert,9606.0,,N,,F,6309,,646.0,Homo sapiens,1,,,A549
,5076,1,BAO_0000219,Cytotoxic activity of compound against A-549 tumor cell line.,80682,,,CHEMBL619446,Intermediate,9606.0,,N,,F,6310,,646.0,Homo sapiens,1,,,A549
,3311,1,BAO_0000219,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,80682,,,CHEMBL619447,Intermediate,9606.0,,N,,F,6311,,646.0,Homo sapiens,1,,,A549
,3311,1,BAO_0000219,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,80682,,,CHEMBL619448,Intermediate,9606.0,,N,,F,6312,,646.0,Homo sapiens,1,,,A549
,3311,1,BAO_0000219,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,80682,,,CHEMBL619449,Intermediate,9606.0,,N,,F,6313,,646.0,Homo sapiens,1,,,A549
,5076,1,BAO_0000219,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,80682,,,CHEMBL619450,Intermediate,9606.0,,N,,F,6314,,646.0,Homo sapiens,1,,,A549
,4150,1,BAO_0000219,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),80682,,,CHEMBL619451,Intermediate,9606.0,,N,,F,6315,,646.0,Homo sapiens,1,,,A549
,2150,1,BAO_0000219,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,80682,,,CHEMBL619452,Expert,9606.0,,N,,F,6316,,646.0,Homo sapiens,1,,,A549
,4644,1,BAO_0000219,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,80682,,,CHEMBL619453,Intermediate,9606.0,,N,,F,6317,,646.0,Homo sapiens,1,,,A549
,263,1,BAO_0000219,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,80682,,,CHEMBL874367,Intermediate,9606.0,,N,,F,6318,,646.0,Homo sapiens,1,,,A549
,11333,1,BAO_0000219,Cytotoxic concentration against A-549 tumor cells.,80682,,,CHEMBL619454,Intermediate,9606.0,,N,,F,6319,,646.0,Homo sapiens,1,,,A549
,11333,1,BAO_0000219,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,80682,,,CHEMBL619455,Intermediate,9606.0,,N,,F,6320,,646.0,Homo sapiens,1,,,A549
,15895,1,BAO_0000219,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",80682,,,CHEMBL619456,Intermediate,9606.0,,N,,F,6321,,646.0,Homo sapiens,1,,,A549
,16677,1,BAO_0000218,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,50191,,,CHEMBL619457,Expert,470.0,,N,,F,6322,,,Acinetobacter baumannii,1,,,
,10624,1,BAO_0000218,Activity against Acinetobacter calcoaceticus (AC54),50192,,,CHEMBL619458,Intermediate,471.0,,N,,F,6323,,,Acinetobacter calcoaceticus,1,,,
,16717,1,BAO_0000218,In vitro antifungal activity against Aspergillus flavus CM74,50274,,,CHEMBL619459,Expert,5059.0,,N,,F,6324,,,Aspergillus flavus,1,,,
,16717,1,BAO_0000218,In vitro antifungal activity against Aspergillus flavus CM74,50274,,,CHEMBL619460,Expert,5059.0,,N,,F,6325,,,Aspergillus flavus,1,,,
,5513,1,BAO_0000218,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,50416,,,CHEMBL619461,Intermediate,746128.0,,N,,F,6326,,,Aspergillus fumigatus,1,,,
,15962,1,BAO_0000218,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),50416,,,CHEMBL619462,Intermediate,746128.0,,N,,F,6327,,,Aspergillus fumigatus,1,,,
,15962,1,BAO_0000218,Antimicrobial activity against Aspergillus fumigatus (MIC),50416,,,CHEMBL620388,Intermediate,746128.0,,N,,F,6328,,,Aspergillus fumigatus,1,,,
,15962,1,BAO_0000218,Antimicrobial activity against Aspergillus fumigatus (MIC),50416,,,CHEMBL620389,Intermediate,746128.0,,N,,F,6329,,,Aspergillus fumigatus,1,,,
,15962,1,BAO_0000218,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),50416,,,CHEMBL620390,Intermediate,746128.0,,N,,F,6330,,,Aspergillus fumigatus,1,,,
,16717,1,BAO_0000218,In vitro antifungal activity against Aspergillus fumigatus 48238E,50416,,,CHEMBL620391,Expert,746128.0,,N,,F,6331,,,Aspergillus fumigatus,1,,,
,16717,1,BAO_0000218,In vitro antifungal activity against Aspergillus fumigatus 48238E,50416,,,CHEMBL621073,Expert,746128.0,,N,,F,6332,,,Aspergillus fumigatus,1,,,
,8117,1,BAO_0000218,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,50296,,,CHEMBL621074,Intermediate,1655.0,,N,,F,6333,,,Actinomyces naeslundii,1,,,
,8117,1,BAO_0000218,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,50366,,,CHEMBL621075,Intermediate,1656.0,,N,,F,6334,,,Actinomyces viscosus,1,,,
,15472,1,BAO_0000218,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),50535,,,CHEMBL619554,Intermediate,6277.0,,N,,F,6335,,,Acanthocheilonema viteae,1,,,
,15472,1,BAO_0000218,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),50535,,,CHEMBL619555,Intermediate,6277.0,,N,,F,6336,,,Acanthocheilonema viteae,1,,,
,16443,1,BAO_0000218,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,50169,,,CHEMBL619556,Intermediate,714.0,,N,,F,6337,,,Aggregatibacter actinomycetemcomitans,1,,,
,16443,1,BAO_0000218,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,50169,,,CHEMBL619557,Intermediate,714.0,,N,,F,6338,,,Aggregatibacter actinomycetemcomitans,1,,,
,16443,1,BAO_0000218,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,50169,,,CHEMBL619558,Intermediate,714.0,,N,,F,6339,,,Aggregatibacter actinomycetemcomitans,1,,,
,17206,1,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,80682,,,CHEMBL619559,Intermediate,9606.0,,N,,F,6340,,646.0,Homo sapiens,1,,,A549
,17206,1,BAO_0000219,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,80682,,,CHEMBL619560,Intermediate,9606.0,,N,,F,6341,,646.0,Homo sapiens,1,,,A549
,16381,1,BAO_0000219,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,80682,,,CHEMBL619561,Intermediate,9606.0,,N,,F,6342,,646.0,Homo sapiens,1,,,A549
,16381,1,BAO_0000219,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,80682,,,CHEMBL619562,Intermediate,9606.0,,N,,F,6343,,646.0,Homo sapiens,1,,,A549
,16381,1,BAO_0000219,% inhibition against A549 cells (lung cancer) at 4 ug/mL,80682,,,CHEMBL619563,Intermediate,9606.0,,N,,F,6344,,646.0,Homo sapiens,1,,,A549
,16381,1,BAO_0000219,GI values against A549 cells (lung cancer),80682,,,CHEMBL857457,Intermediate,9606.0,,N,,F,6345,,646.0,Homo sapiens,1,,,A549
,17206,1,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,80682,,,CHEMBL619564,Intermediate,9606.0,,N,,F,6346,,646.0,Homo sapiens,1,,,A549
,16325,1,BAO_0000219,Inhibitory activity against A549 human adenocarcinoma,80682,,,CHEMBL619565,Intermediate,9606.0,,N,,F,6347,,646.0,Homo sapiens,1,,,A549
,10708,1,BAO_0000218,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,80682,,,CHEMBL619566,Intermediate,9606.0,,N,,F,6348,,646.0,Homo sapiens,1,,,A549
,10708,1,BAO_0000218,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,80682,,,CHEMBL619567,Intermediate,9606.0,,N,,F,6349,,646.0,Homo sapiens,1,,,A549
,17376,1,BAO_0000219,Inhibitory activity against A549 lung adenocarcinoma cell line,80682,,,CHEMBL619568,Intermediate,9606.0,,N,,F,6350,,646.0,Homo sapiens,1,,,A549
,17376,1,BAO_0000219,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,80682,,,CHEMBL619569,Intermediate,9606.0,,N,,F,6351,,646.0,Homo sapiens,1,,,A549
,17488,1,BAO_0000219,Cytotoxicity against human A549 lung cells,80682,,,CHEMBL619570,Intermediate,9606.0,,N,,F,6352,,646.0,Homo sapiens,1,,,A549
,17404,1,BAO_0000218,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,80682,,,CHEMBL619571,Intermediate,9606.0,,N,,F,6353,,646.0,Homo sapiens,1,,,A549
,10958,1,BAO_0000219,Growth inhibition of A549 (human lung carcinoma) cell line.,80682,,,CHEMBL619572,Expert,9606.0,,N,,F,6354,,646.0,Homo sapiens,1,,,A549
,17099,1,BAO_0000219,Effective dose required for inhibitory activity against A549 human tumor cell line.,80682,,,CHEMBL619573,Expert,9606.0,,N,,F,6355,,646.0,Homo sapiens,1,,,A549
,17099,1,BAO_0000219,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,80682,,,CHEMBL619574,Intermediate,9606.0,,N,,F,6356,,646.0,Homo sapiens,1,,,A549
,4096,1,BAO_0000219,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,80682,,,CHEMBL619575,Intermediate,9606.0,,N,,F,6357,,646.0,Homo sapiens,1,,,A549
,4096,1,BAO_0000219,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,80682,,,CHEMBL619576,Expert,9606.0,,N,,F,6358,,646.0,Homo sapiens,1,,,A549
,4096,1,BAO_0000219,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,80682,,,CHEMBL619577,Intermediate,9606.0,,N,,F,6359,,646.0,Homo sapiens,1,,,A549
,2525,1,BAO_0000219,In vitro inhibitory activity against A549 tumor cell culture,80682,,,CHEMBL619578,Intermediate,9606.0,,N,,F,6360,,646.0,Homo sapiens,1,,,A549
,2525,1,BAO_0000219,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,80682,,,CHEMBL884009,Intermediate,9606.0,,N,,F,6361,,646.0,Homo sapiens,1,,,A549
,5302,1,BAO_0000219,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),80682,,,CHEMBL619579,Intermediate,9606.0,,N,,F,6362,,646.0,Homo sapiens,1,,,A549
,16325,1,BAO_0000219,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,80682,,,CHEMBL619580,Intermediate,9606.0,,N,,F,6363,,646.0,Homo sapiens,1,,,A549
,16939,1,BAO_0000219,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,80682,,,CHEMBL619581,Intermediate,9606.0,,N,,F,6364,,646.0,Homo sapiens,1,,,A549
,17229,1,BAO_0000219,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,80682,,,CHEMBL619582,Intermediate,9606.0,,N,,F,6365,,646.0,Homo sapiens,1,,,A549
,17380,1,BAO_0000219,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,80682,,,CHEMBL619583,Intermediate,9606.0,,N,,F,6366,,646.0,Homo sapiens,1,,,A549
,17380,1,BAO_0000219,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,80682,,,CHEMBL876502,Intermediate,9606.0,,N,,F,6367,,646.0,Homo sapiens,1,,,A549
,1903,1,BAO_0000219,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,80682,,,CHEMBL619584,Intermediate,9606.0,,N,,F,6368,,646.0,Homo sapiens,1,,,A549
,3838,1,BAO_0000219,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,80682,,,CHEMBL619585,Intermediate,9606.0,,N,,F,6369,,646.0,Homo sapiens,1,,,A549
,14696,1,BAO_0000219,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,80682,,,CHEMBL619586,Intermediate,9606.0,,N,,F,6370,,646.0,Homo sapiens,1,,,A549
,3838,1,BAO_0000219,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,80682,,,CHEMBL619587,Intermediate,9606.0,,N,,F,6371,,646.0,Homo sapiens,1,,,A549
,1522,1,BAO_0000219,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,80682,,,CHEMBL619588,Intermediate,9606.0,,N,,F,6372,,646.0,Homo sapiens,1,,,A549
,12400,1,BAO_0000219,Tested in vitro for cytotoxicity in A549/ATCC cell lines,80682,,,CHEMBL619589,Intermediate,9606.0,,N,,F,6373,,646.0,Homo sapiens,1,,,A549
,14696,1,BAO_0000219,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,80682,,,CHEMBL619590,Intermediate,9606.0,,N,,F,6374,,646.0,Homo sapiens,1,,,A549
,14769,1,BAO_0000219,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),80682,,,CHEMBL619591,Intermediate,9606.0,,N,,F,6375,,646.0,Homo sapiens,1,,,A549
,14696,1,BAO_0000219,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,80682,,,CHEMBL619592,Intermediate,9606.0,,N,,F,6376,,646.0,Homo sapiens,1,,,A549
,1888,1,BAO_0000219,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,80682,,,CHEMBL619593,Intermediate,9606.0,,N,,F,6377,,646.0,Homo sapiens,1,,,A549
,12016,1,BAO_0000219,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,80682,,,CHEMBL620217,Intermediate,9606.0,,N,,F,6378,,646.0,Homo sapiens,1,,,A549
,6058,1,BAO_0000219,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,80682,,,CHEMBL620218,Intermediate,9606.0,,N,,F,6379,,646.0,Homo sapiens,1,,,A549
,17708,1,BAO_0000219,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,80682,,,CHEMBL620219,Intermediate,9606.0,,N,,F,6380,,646.0,Homo sapiens,1,,,A549
,12301,1,BAO_0000219,Antitumor activity against A549/ATCC cell line,80682,,,CHEMBL620220,Intermediate,9606.0,,N,,F,6381,,646.0,Homo sapiens,1,,,A549
,11970,1,BAO_0000219,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,80682,,,CHEMBL625141,Intermediate,9606.0,,N,,F,6382,,646.0,Homo sapiens,1,,,A549
,11818,1,BAO_0000219,In vitro cytotoxicity against A549/ATCC cell line.,80682,,,CHEMBL625142,Expert,9606.0,,N,,F,6383,,646.0,Homo sapiens,1,,,A549
,12400,1,BAO_0000219,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,80682,,,CHEMBL625143,Intermediate,9606.0,,N,,F,6384,,646.0,Homo sapiens,1,,,A549
,3381,1,BAO_0000219,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,80682,,,CHEMBL625144,Intermediate,9606.0,,N,,F,6385,,646.0,Homo sapiens,1,,,A549
,17376,1,BAO_0000219,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,80682,,,CHEMBL622474,Intermediate,9606.0,,N,,F,6386,,646.0,Homo sapiens,1,,,A549
,10708,1,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,80682,,,CHEMBL884104,Intermediate,9606.0,,N,,F,6387,,646.0,Homo sapiens,1,,,A549
,2964,0,BAO_0000219,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,22226,,,CHEMBL622475,Autocuration,9606.0,,U,,F,6388,,,Homo sapiens,1,,,
,5005,0,BAO_0000218,Compound was tested for oral bioavailability in dogs,22224,In vivo,,CHEMBL622476,Intermediate,9615.0,,U,,A,6389,,,Canis lupus familiaris,1,,,
,6229,1,BAO_0000218,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,50588,In vivo,,CHEMBL875831,Intermediate,9615.0,,N,,A,6390,,,Canis lupus familiaris,1,,,
,6229,1,BAO_0000218,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,50588,In vivo,,CHEMBL622477,Intermediate,9615.0,,N,,A,6391,,,Canis lupus familiaris,1,,,
,5374,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL622478,Intermediate,9615.0,,N,,A,6392,,,Canis lupus familiaris,1,,,
,5374,1,BAO_0000218,Compound was tested for the oral bioavailability in dog; No availability,50588,In vivo,,CHEMBL623172,Intermediate,9615.0,,N,,A,6393,,,Canis lupus familiaris,1,,,
,6265,1,BAO_0000218,Oral bioavailability in dog (dose 5 mg/kg),50588,In vivo,,CHEMBL623173,Intermediate,9615.0,,N,,A,6394,,,Canis lupus familiaris,1,,,
,5654,1,BAO_0000218,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,50588,In vivo,,CHEMBL623174,Intermediate,9615.0,,N,,A,6395,,,Canis lupus familiaris,1,,,
,5654,1,BAO_0000218,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,50588,In vivo,,CHEMBL623175,Intermediate,9615.0,,N,,A,6396,,,Canis lupus familiaris,1,,,
,16456,1,BAO_0000218,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),50588,In vivo,,CHEMBL623340,Intermediate,9615.0,,N,,A,6397,,,Canis lupus familiaris,1,,,
,5302,1,BAO_0000218,Oral bioavailability in dog (dose 5 mg/kg),50588,In vivo,,CHEMBL623341,Intermediate,9615.0,,N,,A,6398,,,Canis lupus familiaris,1,,,
,3624,1,BAO_0000218,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),50588,In vivo,,CHEMBL623342,Intermediate,9615.0,,N,,A,6399,,,Canis lupus familiaris,1,,,
,16452,1,BAO_0000218,Oral bioavailability of active FTIs in dogs,50588,In vivo,,CHEMBL623343,Intermediate,9615.0,,N,,A,6400,,,Canis lupus familiaris,1,,,
,5802,1,BAO_0000218,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),50588,In vivo,,CHEMBL623344,Intermediate,9615.0,,N,,A,6401,,,Canis lupus familiaris,1,,,
,3598,1,BAO_0000218,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,In vivo,,CHEMBL623345,Expert,9615.0,,N,,A,6402,,,Canis lupus familiaris,1,,,
,17839,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL875832,Intermediate,9615.0,,N,,A,6403,,,Canis lupus familiaris,1,,,
,6762,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL623346,Intermediate,9615.0,,N,,A,6404,,,Canis lupus familiaris,1,,,
,6821,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL623347,Intermediate,9615.0,,N,,A,6405,,,Canis lupus familiaris,1,,,
,6821,1,BAO_0000218,Oral bioavailability of compound was determined in dog; Not tested,50588,In vivo,,CHEMBL623348,Intermediate,9615.0,,N,,A,6406,,,Canis lupus familiaris,1,,,
,5210,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL623349,Intermediate,9615.0,,N,,A,6407,,,Canis lupus familiaris,1,,,
,6227,1,BAO_0000218,Oral bioavailability (10 mg/kg) was determined in dog,50588,In vivo,,CHEMBL623350,Intermediate,9615.0,,N,,A,6408,,,Canis lupus familiaris,1,,,
,761,1,BAO_0000218,Oral bioavailability,50588,In vivo,,CHEMBL623351,Intermediate,9615.0,,N,,A,6409,,,Canis lupus familiaris,1,,,
,761,1,BAO_0000218,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),50588,In vivo,,CHEMBL623352,Intermediate,9615.0,,N,,A,6410,,,Canis lupus familiaris,1,,,
,761,1,BAO_0000218,Oral bioavailability administered in solution in rats,50588,In vivo,,CHEMBL623353,Intermediate,9615.0,,N,,A,6411,,,Canis lupus familiaris,1,,,
,16907,1,BAO_0000218,Oral bioavailability after 30 mg/kg po dose in Dogs,50588,In vivo,,CHEMBL875833,Intermediate,9615.0,,N,,A,6412,,,Canis lupus familiaris,1,,,
,5474,1,BAO_0000218,Oral bioavailability at a dose of 1 mg/kg in dogs,50588,In vivo,,CHEMBL623354,Intermediate,9615.0,,N,,A,6413,,,Canis lupus familiaris,1,,,
,6535,1,BAO_0000218,Oral bioavailability in dog (dose 1 mg/kg p.o.),50588,In vivo,,CHEMBL623355,Intermediate,9615.0,,N,,A,6414,,,Canis lupus familiaris,1,,,
,6535,1,BAO_0000218,Oral bioavailability in Dog; ND = not determined,50588,In vivo,,CHEMBL623356,Intermediate,9615.0,,N,,A,6415,,,Canis lupus familiaris,1,,,
,3352,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL623357,Intermediate,9615.0,,N,,A,6416,,,Canis lupus familiaris,1,,,
,6168,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL623358,Intermediate,9615.0,,N,,A,6417,,,Canis lupus familiaris,1,,,
,5988,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL623359,Intermediate,9615.0,,N,,A,6418,,,Canis lupus familiaris,1,,,
,4942,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL623360,Intermediate,9615.0,,N,,A,6419,,,Canis lupus familiaris,1,,,
,4942,1,BAO_0000218,Oral bioavailability in dogs; No data,50588,In vivo,,CHEMBL623361,Intermediate,9615.0,,N,,A,6420,,,Canis lupus familiaris,1,,,
,14541,1,BAO_0000218,Oral bioavailability measured in dogs,50588,In vivo,,CHEMBL623362,Intermediate,9615.0,,N,,A,6421,,,Canis lupus familiaris,1,,,
,4449,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL623363,Intermediate,9615.0,,N,,A,6422,,,Canis lupus familiaris,1,,,
,6057,1,BAO_0000218,Oral bioavailability was calculated in dog,50588,In vivo,,CHEMBL623364,Intermediate,9615.0,,N,,A,6423,,,Canis lupus familiaris,1,,,
,5600,1,BAO_0000218,Oral bioavailability after 0.3 mg/kg po administration in dog,50588,In vivo,,CHEMBL875834,Intermediate,9615.0,,N,,A,6424,,,Canis lupus familiaris,1,,,
,5542,1,BAO_0000218,Oral bioavailability in dog (i.v. dosing),50588,In vivo,,CHEMBL623365,Intermediate,9615.0,,N,,A,6425,,,Canis lupus familiaris,1,,,
,5542,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL623366,Intermediate,9615.0,,N,,A,6426,,,Canis lupus familiaris,1,,,
,5546,1,BAO_0000218,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,50588,In vivo,,CHEMBL623367,Intermediate,9615.0,,N,,A,6427,,,Canis lupus familiaris,1,,,
,4514,1,BAO_0000218,Oral bioavailability in Beagle dogs,50588,In vivo,,CHEMBL623368,Intermediate,9615.0,,N,,A,6428,,,Canis lupus familiaris,1,,,
,3624,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL623369,Intermediate,9615.0,,N,,A,6429,,,Canis lupus familiaris,1,,,
,3854,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL623370,Intermediate,9615.0,,N,,A,6430,,,Canis lupus familiaris,1,,,
,5836,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL623371,Intermediate,9615.0,,N,,A,6431,,,Canis lupus familiaris,1,,,
,5940,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL623372,Intermediate,9615.0,,N,,A,6432,,,Canis lupus familiaris,1,,,
,6168,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL621351,Intermediate,9615.0,,N,,A,6433,,,Canis lupus familiaris,1,,,
,6227,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL621352,Intermediate,9615.0,,N,,A,6434,,,Canis lupus familiaris,1,,,
,6251,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL621353,Intermediate,9615.0,,N,,A,6435,,,Canis lupus familiaris,1,,,
,6448,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL621354,Intermediate,9615.0,,N,,A,6436,,,Canis lupus familiaris,1,,,
,6647,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL621355,Intermediate,9615.0,,N,,A,6437,,,Canis lupus familiaris,1,,,
,5940,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL621356,Intermediate,9615.0,,N,,A,6438,,,Canis lupus familiaris,1,,,
,933,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL621357,Intermediate,9615.0,,N,,A,6439,,,Canis lupus familiaris,1,,,
,5210,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL621358,Intermediate,9615.0,,N,,A,6440,,,Canis lupus familiaris,1,,,
,6642,1,BAO_0000218,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),50588,In vivo,,CHEMBL621359,Intermediate,9615.0,,N,,A,6441,,,Canis lupus familiaris,1,,,
,6641,1,BAO_0000218,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),50588,In vivo,,CHEMBL621360,Intermediate,9615.0,,N,,A,6442,,,Canis lupus familiaris,1,,,
,6642,1,BAO_0000218,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),50588,In vivo,,CHEMBL621361,Intermediate,9615.0,,N,,A,6443,,,Canis lupus familiaris,1,,,
,5472,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL621362,Intermediate,9615.0,,N,,A,6444,,,Canis lupus familiaris,1,,,
,5985,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL621363,Intermediate,9615.0,,N,,A,6445,,,Canis lupus familiaris,1,,,
,15660,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL621364,Intermediate,9615.0,,N,,A,6446,,,Canis lupus familiaris,1,,,
,5530,1,BAO_0000218,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),50588,In vivo,,CHEMBL621166,Intermediate,9615.0,,N,,A,6447,,,Canis lupus familiaris,1,,,
,5530,1,BAO_0000218,Oral bioavailability in dog (dose 1 mg/kg i.v.),50588,In vivo,,CHEMBL621167,Intermediate,9615.0,,N,,A,6448,,,Canis lupus familiaris,1,,,
,6305,1,BAO_0000218,Oral bioavailability (F) in dogs,50588,In vivo,,CHEMBL621168,Intermediate,9615.0,,N,,A,6449,,,Canis lupus familiaris,1,,,
,5210,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL621169,Intermediate,9615.0,,N,,A,6450,,,Canis lupus familiaris,1,,,
,5238,1,BAO_0000218,Bioavailability in dog,50588,In vivo,,CHEMBL875950,Intermediate,9615.0,,N,,A,6451,,,Canis lupus familiaris,1,,,
,5668,1,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),50588,In vivo,,CHEMBL621170,Intermediate,9615.0,,N,,A,6452,,,Canis lupus familiaris,1,,,
,5668,1,BAO_0000218,Oral bioavailability after peroral administration at 5 mpk in Dog,50588,In vivo,,CHEMBL621171,Intermediate,9615.0,,N,,A,6453,,,Canis lupus familiaris,1,,,
,5668,1,BAO_0000218,Oral bioavailability in dog (dose 5 mg/kg),50588,In vivo,,CHEMBL621172,Intermediate,9615.0,,N,,A,6454,,,Canis lupus familiaris,1,,,
,6084,1,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),50588,In vivo,,CHEMBL621173,Intermediate,9615.0,,N,,A,6455,,,Canis lupus familiaris,1,,,
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,50594,,Kidney,CHEMBL621174,Intermediate,10090.0,,N,,A,6456,,42.0,Mus musculus,1,,2113.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,50594,,Kidney,CHEMBL621175,Intermediate,10090.0,,N,,A,6457,,42.0,Mus musculus,1,,2113.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,50594,,Liver,CHEMBL621176,Intermediate,10090.0,,N,,A,6458,,42.0,Mus musculus,1,,2107.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,50594,,Liver,CHEMBL621177,Intermediate,10090.0,,N,,A,6459,,42.0,Mus musculus,1,,2107.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,50594,,Liver,CHEMBL621178,Intermediate,10090.0,,N,,A,6460,,42.0,Mus musculus,1,,2107.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,50594,,Liver,CHEMBL621179,Intermediate,10090.0,,N,,A,6461,,42.0,Mus musculus,1,,2107.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,50594,,Liver,CHEMBL621180,Intermediate,10090.0,,N,,A,6462,,42.0,Mus musculus,1,,2107.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,50594,,Lung,CHEMBL875951,Intermediate,10090.0,,N,,A,6463,,42.0,Mus musculus,1,,2048.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,50594,,Lung,CHEMBL621181,Intermediate,10090.0,,N,,A,6464,,42.0,Mus musculus,1,,2048.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,50594,,Lung,CHEMBL621182,Intermediate,10090.0,,N,,A,6465,,42.0,Mus musculus,1,,2048.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,50594,,Lung,CHEMBL621183,Intermediate,10090.0,,N,,A,6466,,42.0,Mus musculus,1,,2048.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,50594,,Lung,CHEMBL621184,Intermediate,10090.0,,N,,A,6467,,42.0,Mus musculus,1,,2048.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,50594,,,CHEMBL621185,Intermediate,10090.0,,N,,A,6468,,42.0,Mus musculus,1,,,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,50594,,,CHEMBL621186,Intermediate,10090.0,,N,,A,6469,,42.0,Mus musculus,1,,,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,50594,,,CHEMBL621187,Intermediate,10090.0,,N,,A,6470,,42.0,Mus musculus,1,,,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,50594,,,CHEMBL621188,Intermediate,10090.0,,N,,A,6471,,42.0,Mus musculus,1,,,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,50594,,,CHEMBL621189,Intermediate,10090.0,,N,,A,6472,,42.0,Mus musculus,1,,,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,50594,,Spleen,CHEMBL621190,Intermediate,10090.0,,N,,A,6473,,42.0,Mus musculus,1,,2106.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,50594,,Spleen,CHEMBL618520,Intermediate,10090.0,,N,,A,6474,,42.0,Mus musculus,1,,2106.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,50594,,Spleen,CHEMBL621739,Intermediate,10090.0,,N,,A,6475,,42.0,Mus musculus,1,,2106.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,50594,,Spleen,CHEMBL621740,Intermediate,10090.0,,N,,A,6476,,42.0,Mus musculus,1,,2106.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,50594,,Spleen,CHEMBL621741,Intermediate,10090.0,,N,,A,6477,,42.0,Mus musculus,1,,2106.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,50594,,,CHEMBL621742,Intermediate,10090.0,,N,,A,6478,,42.0,Mus musculus,1,,,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,50594,,,CHEMBL621743,Intermediate,10090.0,,N,,A,6479,,42.0,Mus musculus,1,,,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,50594,,,CHEMBL621744,Intermediate,10090.0,,N,,A,6480,,42.0,Mus musculus,1,,,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,50594,,,CHEMBL621745,Intermediate,10090.0,,N,,A,6481,,42.0,Mus musculus,1,,,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,50594,,,CHEMBL621746,Intermediate,10090.0,,N,,A,6482,,42.0,Mus musculus,1,,,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,50594,,,CHEMBL621747,Intermediate,10090.0,,N,,A,6483,,42.0,Mus musculus,1,,,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,50594,,,CHEMBL621748,Intermediate,10090.0,,N,,A,6484,,42.0,Mus musculus,1,,,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,50594,,,CHEMBL621749,Intermediate,10090.0,,N,,A,6485,,42.0,Mus musculus,1,,,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,50594,,,CHEMBL621750,Intermediate,10090.0,,N,,A,6486,,42.0,Mus musculus,1,,,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,50594,,,CHEMBL621751,Intermediate,10090.0,,N,,A,6487,,42.0,Mus musculus,1,,,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,50594,,Heart,CHEMBL621752,Intermediate,10090.0,,N,,A,6488,,42.0,Mus musculus,1,,948.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,50594,,Heart,CHEMBL621753,Intermediate,10090.0,,N,,A,6489,,42.0,Mus musculus,1,,948.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,50594,,Heart,CHEMBL875955,Intermediate,10090.0,,N,,A,6490,,42.0,Mus musculus,1,,948.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,50594,,Heart,CHEMBL621754,Intermediate,10090.0,,N,,A,6491,,42.0,Mus musculus,1,,948.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,50594,,Heart,CHEMBL621755,Intermediate,10090.0,,N,,A,6492,,42.0,Mus musculus,1,,948.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,50594,,Liver,CHEMBL621756,Intermediate,10090.0,,N,,A,6493,,42.0,Mus musculus,1,,2107.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,50594,,Liver,CHEMBL624199,Intermediate,10090.0,,N,,A,6494,,42.0,Mus musculus,1,,2107.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,50594,,Liver,CHEMBL624200,Intermediate,10090.0,,N,,A,6495,,42.0,Mus musculus,1,,2107.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,50594,,Liver,CHEMBL624375,Intermediate,10090.0,,N,,A,6496,,42.0,Mus musculus,1,,2107.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,50594,,Liver,CHEMBL624376,Intermediate,10090.0,,N,,A,6497,,42.0,Mus musculus,1,,2107.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,50594,,Lung,CHEMBL624377,Intermediate,10090.0,,N,,A,6498,,42.0,Mus musculus,1,,2048.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,50594,,Lung,CHEMBL624378,Intermediate,10090.0,,N,,A,6499,,42.0,Mus musculus,1,,2048.0,CCRF S-180
,12269,1,BAO_0000218,Compound tested for the antimicrobial activity against Acinetobacter anitratus,50067,,,CHEMBL857901,Intermediate,107673.0,,N,,F,6500,,,aeinetobacter anitrotap,1,,,
,12269,1,BAO_0000218,Compound tested for the antimicrobial activity against Acinetobacter anitratus,50067,,,CHEMBL875274,Intermediate,107673.0,,N,,F,6501,,,Acinetobacter calcoaceticus subsp. anitratus,1,,,
,12269,1,BAO_0000218,Compound tested for the antimicrobial activity against Acinetobacter anitratus,50067,,,CHEMBL624379,Intermediate,107673.0,,N,,F,6502,,,Acinetobacter calcoaceticus subsp. anitratus,1,,,
,12269,1,BAO_0000218,Compound tested for the antimicrobial activity against Acinetobacter anitratus,50067,,,CHEMBL624380,Intermediate,107673.0,,N,,F,6503,,,aeinetobacter anitrotap,1,,,
,10624,1,BAO_0000218,Activity against Acinetobacter calcoaceticus (AC54),50192,,,CHEMBL624381,Intermediate,471.0,,N,,F,6504,,,Acinetobacter calcoaceticus,1,,,
,17216,1,BAO_0000218,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,50714,,,CHEMBL624382,Intermediate,28377.0,,N,,F,6505,,,Anolis carolinensis,1,,,
,17216,1,BAO_0000218,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,50714,,,CHEMBL624383,Intermediate,28377.0,,N,,F,6506,,,Anolis carolinensis,1,,,
,9560,1,BAO_0000218,Chlorohexidine coefficient for Actinomyces naeslundii 631,50296,,,CHEMBL624384,Intermediate,1655.0,,N,,F,6507,,,Actinomyces naeslundii,1,,,
,9560,1,BAO_0000218,Chlorohexidine coefficient for Actinomyces naeslundii B74,50296,,,CHEMBL624385,Intermediate,1655.0,,N,,F,6508,,,Actinomyces naeslundii,1,,,
,9560,1,BAO_0000218,Chlorohexidine coefficient for Actinomyces naeslundii N/3,50296,,,CHEMBL624386,Intermediate,1655.0,,N,,F,6509,,,Actinomyces naeslundii,1,,,
,9560,1,BAO_0000218,Chlorohexidine coefficient for Actinomyces naeslundii N/9,50296,,,CHEMBL624387,Intermediate,1655.0,,N,,F,6510,,,Actinomyces naeslundii,1,,,
,9560,1,BAO_0000218,Plaque bactericidal index against Actinomyces naeslundii 631,50296,,,CHEMBL624388,Intermediate,1655.0,,N,,F,6511,,,Actinomyces naeslundii,1,,,
,9560,1,BAO_0000218,Plaque bactericidal index against Actinomyces naeslundii N/9,50296,,,CHEMBL624389,Intermediate,1655.0,,N,,F,6512,,,Actinomyces naeslundii,1,,,
,9560,1,BAO_0000218,Plaque bactericidal index against Actinomyces naeslundii B74,50296,,,CHEMBL624390,Intermediate,1655.0,,N,,F,6513,,,Actinomyces naeslundii,1,,,
,9560,1,BAO_0000218,Plaque bactericidal index against Actinomyces naeslundii N/3,50296,,,CHEMBL875275,Intermediate,1655.0,,N,,F,6514,,,Actinomyces naeslundii,1,,,
,114,1,BAO_0000218,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,50056,,,CHEMBL624391,Intermediate,85549.0,,N,,F,6515,,,Artemia salina,1,,,
,114,1,BAO_0000218,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",50056,,,CHEMBL623636,Intermediate,85549.0,,N,,F,6516,,,Artemia salina,1,,,
,10841,1,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,50532,,,CHEMBL623637,Intermediate,6253.0,,N,,F,6517,,,Ascaris suum,1,,,
,10841,1,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,50532,,,CHEMBL623638,Intermediate,6253.0,,N,,F,6518,,,Ascaris suum,1,,,
,10841,1,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,50532,,,CHEMBL623639,Intermediate,6253.0,,N,,F,6519,,,Ascaris suum,1,,,
,10841,1,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,50532,,,CHEMBL623640,Intermediate,6253.0,,N,,F,6520,,,Ascaris suum,1,,,
,10841,1,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,50532,,,CHEMBL623641,Intermediate,6253.0,,N,,F,6521,,,Ascaris suum,1,,,
,10841,1,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,50532,,,CHEMBL623642,Intermediate,6253.0,,N,,F,6522,,,Ascaris suum,1,,,
,10841,1,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,50532,,,CHEMBL623643,Intermediate,6253.0,,N,,F,6523,,,Ascaris suum,1,,,
,10841,1,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,50532,,,CHEMBL623644,Intermediate,6253.0,,N,,F,6524,,,Ascaris suum,1,,,
,10841,1,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,50532,,,CHEMBL623645,Intermediate,6253.0,,N,,F,6525,,,Ascaris suum,1,,,
,10841,1,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,50532,,,CHEMBL623646,Intermediate,6253.0,,N,,F,6526,,,Ascaris suum,1,,,
,10841,1,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,50532,,,CHEMBL623647,Intermediate,6253.0,,N,,F,6527,,,Ascaris suum,1,,,
,10841,1,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,50532,,,CHEMBL623648,Intermediate,6253.0,,N,,F,6528,,,Ascaris suum,1,,,
,8117,1,BAO_0000218,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,50366,,,CHEMBL623649,Intermediate,1656.0,,N,,F,6529,,,Actinomyces viscosus,1,,,
,8117,1,BAO_0000218,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,50366,,,CHEMBL623650,Intermediate,1656.0,,N,,F,6530,,,Actinomyces viscosus,1,,,
,9560,1,BAO_0000218,Chlorohexidine coefficient for Actinomyces viscosus 8A06,50366,,,CHEMBL623651,Intermediate,1656.0,,N,,F,6531,,,Actinomyces viscosus,1,,,
,9560,1,BAO_0000218,Chlorohexidine coefficient for Actinomyces viscosus M-100,50366,,,CHEMBL623652,Expert,1656.0,,N,,F,6532,,,Actinomyces viscosus,1,,,
,9560,1,BAO_0000218,Chlorohexidine coefficient for Actinomyces viscosus M-626,50366,,,CHEMBL623653,Intermediate,1656.0,,N,,F,6533,,,Actinomyces viscosus,1,,,
,9560,1,BAO_0000218,Chlorohexidine coefficient for Actinomyces viscosus T14V,50366,,,CHEMBL623654,Intermediate,1656.0,,N,,F,6534,,,Actinomyces viscosus,1,,,
,9560,1,BAO_0000218,Plaque bactericidal index against Actinomyces viscosus 8A06,50366,,,CHEMBL623655,Intermediate,1656.0,,N,,F,6535,,,Actinomyces viscosus,1,,,
,9560,1,BAO_0000218,Plaque bactericidal index against Actinomyces viscosus M-100,50366,,,CHEMBL623656,Intermediate,1656.0,,N,,F,6536,,,Actinomyces viscosus,1,,,
,9560,1,BAO_0000218,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,50366,,,CHEMBL623657,Expert,1656.0,,N,,F,6537,,,Actinomyces viscosus,1,,,
,9560,1,BAO_0000218,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",50366,,,CHEMBL623658,Intermediate,1656.0,,N,,F,6538,,,Actinomyces viscosus,1,,,
,9560,1,BAO_0000218,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",50366,,,CHEMBL623659,Intermediate,1656.0,,N,,F,6539,,,Actinomyces viscosus,1,,,
,9560,1,BAO_0000218,Plaque bactericidal index against Actinomyces viscosus 626,50366,,,CHEMBL623660,Intermediate,1656.0,,N,,F,6540,,,Actinomyces viscosus,1,,,
,9560,1,BAO_0000218,Plaque bactericidal index against Actinomyces viscosus T14V,50366,,,CHEMBL623661,Intermediate,1656.0,,N,,F,6541,,,Actinomyces viscosus,1,,,
,10986,1,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,50535,,,CHEMBL875281,Intermediate,6277.0,,N,,F,6542,,,Acanthocheilonema viteae,1,,,
,10986,1,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,50535,,,CHEMBL623662,Intermediate,6277.0,,N,,F,6543,,,Acanthocheilonema viteae,1,,,
,10986,1,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,50535,,,CHEMBL623663,Intermediate,6277.0,,N,,F,6544,,,Acanthocheilonema viteae,1,,,
,10986,1,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,50535,,,CHEMBL623664,Intermediate,6277.0,,N,,F,6545,,,Acanthocheilonema viteae,1,,,
,10986,1,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,50535,,,CHEMBL623665,Intermediate,6277.0,,N,,F,6546,,,Acanthocheilonema viteae,1,,,
,10708,1,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,80023,,,CHEMBL621856,Intermediate,9606.0,,N,,F,6547,,165.0,Homo sapiens,1,,,A673
,10708,1,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,80661,,,CHEMBL620432,Intermediate,9606.0,,N,,F,6548,,645.0,Homo sapiens,1,,,A704
,416,0,BAO_0000219,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,22226,,,CHEMBL620433,Autocuration,10116.0,,U,,F,6549,,,Rattus norvegicus,1,,,
,14354,1,BAO_0000219,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,80024,,,CHEMBL620434,Intermediate,10090.0,,N,,F,6550,,625.0,Mus musculus,1,,,A9
,14354,1,BAO_0000219,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,80024,,,CHEMBL620435,Intermediate,10090.0,,N,,F,6551,,625.0,Mus musculus,1,,,A9
,5116,1,BAO_0000219,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,80024,,,CHEMBL620436,Intermediate,9606.0,,N,,F,6552,,625.0,Homo sapiens,1,,,A9
,5116,1,BAO_0000219,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,80024,,,CHEMBL876597,Intermediate,9606.0,,N,,F,6553,,625.0,Homo sapiens,1,,,A9
,15694,1,BAO_0000219,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,81037,,,CHEMBL620437,Expert,9606.0,,N,,F,6554,,874.0,Homo sapiens,1,,,Human ovarian carcinoma cell line
,13038,1,BAO_0000219,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",80024,,,CHEMBL620438,Expert,10090.0,,N,,F,6555,,625.0,Mus musculus,1,,,A9
,13038,1,BAO_0000219,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,80024,,,CHEMBL620439,Expert,10090.0,,N,,F,6556,,625.0,Mus musculus,1,,,A9
,10923,1,BAO_0000219,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,80024,,,CHEMBL619657,Expert,10090.0,,N,,F,6557,,625.0,Mus musculus,1,,,A9
,10923,1,BAO_0000219,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,80024,,,CHEMBL619658,Intermediate,10090.0,,N,,F,6558,,625.0,Mus musculus,1,,,A9
,10923,1,BAO_0000219,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,80024,,,CHEMBL619659,Intermediate,10090.0,,N,,F,6559,,625.0,Mus musculus,1,,,A9
,10923,8,BAO_0000019,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",10649,,,CHEMBL619660,Expert,,,H,,F,6560,,,,1,,,
,10923,1,BAO_0000219,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,80024,,,CHEMBL619661,Intermediate,10090.0,,N,,F,6561,,625.0,Mus musculus,1,,,A9
,10923,1,BAO_0000219,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,80024,,,CHEMBL619662,Intermediate,10090.0,,N,,F,6562,,625.0,Mus musculus,1,,,A9
,8158,1,BAO_0000219,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,80663,,,CHEMBL619663,Intermediate,10029.0,,N,,F,6563,,975.0,Cricetulus griseus,1,,,AA6
,15494,0,BAO_0000219,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,22226,,,CHEMBL619664,Autocuration,9606.0,,U,,F,6564,,,Homo sapiens,1,,,
,15494,0,BAO_0000219,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",22226,,,CHEMBL619665,Autocuration,9606.0,,U,,F,6565,,,Homo sapiens,1,,,
,12348,1,BAO_0000219,Anti -HIV activity was measured against AA5/HIV-1(IIIB),80662,,,CHEMBL883244,Intermediate,9606.0,,N,,F,6566,,974.0,Homo sapiens,1,,,AA5
,12348,1,BAO_0000219,Cytotoxicity was measured against AA5/HIV-1(IIIB),80662,,,CHEMBL884011,Intermediate,9606.0,,N,,F,6567,,974.0,Homo sapiens,1,,,AA5
,2726,1,BAO_0000219,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,80662,,,CHEMBL619666,Intermediate,9606.0,,N,,F,6568,,974.0,Homo sapiens,1,,,AA5
,2726,1,BAO_0000219,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,80566,,,CHEMBL619667,Intermediate,9606.0,,N,,F,6569,,379.0,Homo sapiens,1,,,U-937
,10747,1,BAO_0000219,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,80578,,,CHEMBL619668,Intermediate,10029.0,,N,,F,6570,,274.0,Cricetulus griseus,1,,,UV4
,11005,1,BAO_0000219,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",80089,,,CHEMBL619669,Expert,10029.0,,N,,F,6571,,185.0,Cricetulus griseus,1,,,CHO-AA8
,12687,1,BAO_0000219,Average intracellular compound concentration when the hypoxic SER=1.6,80089,,,CHEMBL876608,Intermediate,10029.0,,N,,F,6572,,185.0,Cricetulus griseus,1,,,CHO-AA8
,12687,1,BAO_0000219,Average intracellular compound concentration when the hypoxic SER=1.6.,80089,,,CHEMBL619670,Intermediate,10029.0,,N,,F,6573,,185.0,Cricetulus griseus,1,,,CHO-AA8
,12687,1,BAO_0000219,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,80089,,,CHEMBL619671,Intermediate,10029.0,,N,,F,6574,,185.0,Cricetulus griseus,1,,,CHO-AA8
,12687,1,BAO_0000219,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,80089,,,CHEMBL619672,Intermediate,10029.0,,N,,F,6575,,185.0,Cricetulus griseus,1,,,CHO-AA8
,12687,1,BAO_0000219,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,80089,,,CHEMBL619673,Intermediate,10029.0,,N,,F,6576,,185.0,Cricetulus griseus,1,,,CHO-AA8
,13436,1,BAO_0000219,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",80089,,,CHEMBL619674,Intermediate,10029.0,,N,,F,6577,,185.0,Cricetulus griseus,1,,,CHO-AA8
,13435,1,BAO_0000219,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",80089,,,CHEMBL619675,Intermediate,10029.0,,N,,F,6578,,185.0,Cricetulus griseus,1,,,CHO-AA8
,13302,1,BAO_0000219,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,80089,,,CHEMBL619676,Intermediate,10029.0,,N,,F,6579,,185.0,Cricetulus griseus,1,,,CHO-AA8
,12687,1,BAO_0000219,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,80089,,,CHEMBL619677,Intermediate,10029.0,,N,,F,6580,,185.0,Cricetulus griseus,1,,,CHO-AA8
,12687,1,BAO_0000219,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,80089,,,CHEMBL619678,Intermediate,10029.0,,N,,A,6581,,185.0,Cricetulus griseus,1,,,CHO-AA8
,12687,1,BAO_0000219,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,80089,,,CHEMBL619679,Intermediate,10029.0,,N,,A,6582,,185.0,Cricetulus griseus,1,,,CHO-AA8
,12878,1,BAO_0000219,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,80089,,,CHEMBL619680,Expert,10029.0,,N,,A,6583,,185.0,Cricetulus griseus,1,,,CHO-AA8
,12878,1,BAO_0000219,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,80089,,,CHEMBL621457,Intermediate,10029.0,,N,,A,6584,,185.0,Cricetulus griseus,1,,,CHO-AA8
,14367,1,BAO_0000219,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,80089,,,CHEMBL876609,Expert,10029.0,,N,,F,6585,,185.0,Cricetulus griseus,1,,,CHO-AA8
,14367,1,BAO_0000219,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,80089,,,CHEMBL621458,Intermediate,10029.0,,N,,F,6586,,185.0,Cricetulus griseus,1,,,CHO-AA8
,12398,1,BAO_0000219,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,80089,,,CHEMBL621459,Expert,36483.0,,N,,F,6587,,185.0,hampster,1,,,CHO-AA8
,12878,1,BAO_0000219,Aerobic growth inhibition in Chinese hamster cell line AA8,80089,,,CHEMBL621460,Expert,10029.0,,N,,F,6588,,185.0,Cricetulus griseus,1,,,CHO-AA8
,13820,1,BAO_0000219,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,80089,,,CHEMBL621461,Expert,10029.0,,N,,F,6589,,185.0,Cricetulus griseus,1,,,CHO-AA8
,13436,1,BAO_0000219,Inhibition of growth under aerobic conditions in AA8 cells,80089,,,CHEMBL621462,Expert,10029.0,,N,,F,6590,,185.0,Cricetulus griseus,1,,,CHO-AA8
,6084,1,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),50588,In vivo,,CHEMBL621463,Intermediate,9615.0,,N,,A,6591,,,Canis lupus familiaris,1,,,
,5711,1,BAO_0000218,Oral bioavailability in dog at 10 mg/kg of the compound,50588,In vivo,,CHEMBL621464,Intermediate,9615.0,,N,,A,6592,,,Canis lupus familiaris,1,,,
,4353,1,BAO_0000218,Oral bioavailability in dog (dose 5 uM/kg),50588,In vivo,,CHEMBL621465,Intermediate,9615.0,,N,,A,6593,,,Canis lupus familiaris,1,,,
,4353,1,BAO_0000218,Oral bioavailability in dog (dose 5 uM/kg),50588,In vivo,,CHEMBL621466,Intermediate,9615.0,,N,,A,6594,,,Canis lupus familiaris,1,,,
,17800,1,BAO_0000218,Oral bioavailability in dog (mongrel),50588,In vivo,,CHEMBL621467,Intermediate,9615.0,,N,,A,6595,,,Canis lupus familiaris,1,,,
,3994,1,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),50588,In vivo,,CHEMBL621468,Intermediate,9615.0,,N,,A,6596,,,Canis lupus familiaris,1,,,
,3994,1,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),50588,In vivo,,CHEMBL876734,Intermediate,9615.0,,N,,F,6597,,,Canis lupus familiaris,1,,,
,5145,1,BAO_0000218,Bioavailability in dog,50588,In vivo,,CHEMBL618476,Intermediate,9615.0,,N,,A,6598,,,Canis lupus familiaris,1,,,
,16452,1,BAO_0000218,Bioavailability in dog (dose 1 mg/kg i.v.),50588,In vivo,,CHEMBL618477,Intermediate,9615.0,,N,,A,6599,,,Canis lupus familiaris,1,,,
,16452,1,BAO_0000218,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),50588,In vivo,,CHEMBL618478,Intermediate,9615.0,,N,,A,6600,,,Canis lupus familiaris,1,,,
,5983,1,BAO_0000218,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,50588,In vivo,,CHEMBL618479,Intermediate,9615.0,,N,,A,6601,,,Canis lupus familiaris,1,,,
,4273,1,BAO_0000218,Bioavailability in dog,50588,In vivo,,CHEMBL618480,Intermediate,9615.0,,N,,A,6602,,,Canis lupus familiaris,1,,,
,12500,1,BAO_0000218,Bioavailability in dog (dose 3-10 mg/kg),50588,In vivo,,CHEMBL618481,Intermediate,9615.0,,N,,A,6603,,,Canis lupus familiaris,1,,,
,12500,1,BAO_0000218,The compound was tested for bioavailability of compound in plasma of dog; Complete,50588,In vivo,Plasma,CHEMBL618482,Intermediate,9615.0,,N,,A,6604,,,Canis lupus familiaris,1,,1969.0,
,3639,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL618483,Intermediate,9615.0,,N,,A,6605,,,Canis lupus familiaris,1,,,
,3880,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL618484,Intermediate,9615.0,,N,,A,6606,,,Canis lupus familiaris,1,,,
,4838,1,BAO_0000218,Bioavailability in dog,50588,In vivo,,CHEMBL618485,Intermediate,9615.0,,N,,A,6607,,,Canis lupus familiaris,1,,,
,15600,1,BAO_0000218,oral bioavailability was measured in dogs,50588,In vivo,,CHEMBL618486,Intermediate,9615.0,,N,,A,6608,,,Canis lupus familiaris,1,,,
,17248,1,BAO_0000218,Compound was tested for plasma protein binding in dog; Not determined,50588,,,CHEMBL618487,Intermediate,9615.0,,N,,A,6609,,,Canis lupus familiaris,1,,,
,17248,1,BAO_0000218,Compound was tested for plasma protein binding of dog,50588,,,CHEMBL618488,Intermediate,9615.0,,N,,A,6610,,,Canis lupus familiaris,1,,,
,17248,1,BAO_0000218,Compound was tested for plasma protein binding of dog; Not determined,50588,,,CHEMBL876735,Intermediate,9615.0,,N,,A,6611,,,Canis lupus familiaris,1,,,
,17443,1,BAO_0000218,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,50588,,,CHEMBL618489,Intermediate,9615.0,,N,,A,6612,,,Canis lupus familiaris,1,,,
,4186,1,BAO_0000218,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,50588,In vivo,,CHEMBL618490,Intermediate,9615.0,,N,,A,6613,,,Canis lupus familiaris,1,,,
,3749,1,BAO_0000218,Half life was determined,50588,,,CHEMBL618491,Intermediate,9615.0,,N,,A,6614,,,Canis lupus familiaris,1,,,
,3249,1,BAO_0000218,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,50588,In vivo,,CHEMBL618492,Intermediate,9615.0,,N,,A,6615,,,Canis lupus familiaris,1,,,
,3022,1,BAO_0000218,Half life was evaluated in dog,50588,,,CHEMBL873354,Intermediate,9615.0,,N,,A,6616,,,Canis lupus familiaris,1,,,
,3749,1,BAO_0000218,Half life was determined,50588,,,CHEMBL618493,Intermediate,9615.0,,N,,A,6617,,,Canis lupus familiaris,1,,,
,2517,1,BAO_0000218,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,In vivo,,CHEMBL618494,Intermediate,9615.0,,N,,A,6618,,,Canis lupus familiaris,1,,,
,2517,1,BAO_0000218,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,In vivo,Heart,CHEMBL618495,Intermediate,9615.0,,N,,A,6619,,,Canis lupus familiaris,1,,948.0,
,2517,1,BAO_0000218,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,In vivo,Kidney,CHEMBL618496,Intermediate,9615.0,,N,,A,6620,,,Canis lupus familiaris,1,,2113.0,
,2517,1,BAO_0000218,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,In vivo,Liver,CHEMBL618497,Intermediate,9615.0,,N,,A,6621,,,Canis lupus familiaris,1,,2107.0,
,2517,1,BAO_0000218,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,In vivo,Lung,CHEMBL618498,Intermediate,9615.0,,N,,A,6622,,,Canis lupus familiaris,1,,2048.0,
,2517,1,BAO_0000218,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,In vivo,Spleen,CHEMBL618499,Intermediate,9615.0,,N,,A,6623,,,Canis lupus familiaris,1,,2106.0,
,3639,1,BAO_0000218,LogP in dog,50588,,,CHEMBL876736,Intermediate,9615.0,,N,,A,6624,,,Canis lupus familiaris,1,,,
,6227,1,BAO_0000218,Partition coefficient (logP),50588,,,CHEMBL618500,Intermediate,9615.0,,N,,A,6625,,,Canis lupus familiaris,1,,,
,6227,1,BAO_0000218,Partition coefficient in dog,50588,,,CHEMBL857831,Intermediate,9615.0,,N,,A,6626,,,Canis lupus familiaris,1,,,
,17764,1,BAO_0000218,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,50588,In vivo,,CHEMBL618501,Intermediate,9615.0,,N,,A,6627,,,Canis lupus familiaris,1,,,
,4809,1,BAO_0000218,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),50588,In vivo,,CHEMBL618502,Intermediate,9615.0,,N,,A,6628,,,Canis lupus familiaris,1,,,
,5600,1,BAO_0000218,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,50588,,,CHEMBL618503,Intermediate,9615.0,,N,,A,6629,,,Canis lupus familiaris,1,,,
,14294,1,BAO_0000218,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),50588,,,CHEMBL618504,Intermediate,9615.0,,N,,A,6630,,,Canis lupus familiaris,1,,,
,14294,1,BAO_0000218,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),50588,,,CHEMBL618505,Intermediate,9615.0,,N,,A,6631,,,Canis lupus familiaris,1,,,
,14294,1,BAO_0000218,Metabolism of compound in dog S9 microsomes; Trace,50588,,,CHEMBL618506,Intermediate,9615.0,,N,,A,6632,,,Canis lupus familiaris,1,,,
,6251,1,BAO_0000218,In vitro metabolic potential in dog liver microsomes,50588,,Liver,CHEMBL618507,Intermediate,9615.0,,N,,A,6633,,,Canis lupus familiaris,1,,2107.0,
,3748,1,BAO_0000218,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,50588,In vivo,,CHEMBL876737,Intermediate,9615.0,,N,,A,6634,,,Canis lupus familiaris,1,,,
,2713,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL618508,Intermediate,9615.0,,N,,A,6635,,,Canis lupus familiaris,1,,,
,6512,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL618509,Intermediate,9615.0,,N,,A,6636,,,Canis lupus familiaris,1,,,
,6679,1,BAO_0000218,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50588,In vivo,,CHEMBL618510,Intermediate,9615.0,,N,,A,6637,,,Canis lupus familiaris,1,,,
,3749,1,BAO_0000218,The compound was tested for bioavailability in dogs,50588,In vivo,,CHEMBL618511,Intermediate,9615.0,,N,,A,6638,,,Canis lupus familiaris,1,,,
,3749,1,BAO_0000218,The compound was tested for oral bioavailability in dogs,50588,In vivo,,CHEMBL618512,Intermediate,9615.0,,N,,A,6639,,,Canis lupus familiaris,1,,,
,6742,1,BAO_0000218,Oral bioavailability in dog,50588,In vivo,,CHEMBL618513,Intermediate,9615.0,,N,,A,6640,,,Canis lupus familiaris,1,,,
,6227,1,BAO_0000218,Compound was tested for percent protein binding (PB) in dog,50588,,,CHEMBL618514,Intermediate,9615.0,,N,,A,6641,,,Canis lupus familiaris,1,,,
,6874,1,BAO_0000218,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,50588,,,CHEMBL620052,Intermediate,9615.0,,N,,A,6642,,,Canis lupus familiaris,1,,,
,2877,1,BAO_0000218,Compound was evaluated for plasma clearance.,50588,In vivo,Plasma,CHEMBL620053,Intermediate,9615.0,,N,,A,6643,,,Canis lupus familiaris,1,,1969.0,
,12500,1,BAO_0000218,The compound was tested for plasma clearance in dog,50588,In vivo,Plasma,CHEMBL620054,Intermediate,9615.0,,N,,A,6644,,,Canis lupus familiaris,1,,1969.0,
,12500,1,BAO_0000218,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,50588,In vivo,Plasma,CHEMBL620055,Intermediate,9615.0,,N,,A,6645,,,Canis lupus familiaris,1,,1969.0,
,4709,1,BAO_0000218,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,50588,,,CHEMBL620056,Intermediate,9615.0,,N,,A,6646,,,Canis lupus familiaris,1,,,
,5542,1,BAO_0000218,In vitro relative rate of metabolism was determined in dog liver microsomes,50588,,Liver,CHEMBL620057,Intermediate,9615.0,,N,,A,6647,,,Canis lupus familiaris,1,,2107.0,
,17594,1,BAO_0000218,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,50588,In vivo,,CHEMBL618939,Intermediate,9615.0,,N,,A,6648,,,Canis lupus familiaris,1,,,
,2652,1,BAO_0000218,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,50588,In vivo,,CHEMBL618940,Intermediate,9615.0,,N,,A,6649,,,Canis lupus familiaris,1,,,
,17764,1,BAO_0000218,Half life after intravenous administration in dogs at 1.2 uM/kg,50588,In vivo,,CHEMBL618941,Intermediate,9615.0,,N,,A,6650,,,Canis lupus familiaris,1,,,
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,50594,,Lung,CHEMBL624473,Intermediate,10090.0,,N,,A,6651,,42.0,Mus musculus,1,,2048.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,50594,,Lung,CHEMBL624474,Intermediate,10090.0,,N,,A,6652,,42.0,Mus musculus,1,,2048.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,50594,,Lung,CHEMBL624475,Intermediate,10090.0,,N,,A,6653,,42.0,Mus musculus,1,,2048.0,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,50594,,,CHEMBL624476,Intermediate,10090.0,,N,,A,6654,,42.0,Mus musculus,1,,,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,50594,,,CHEMBL623478,Intermediate,10090.0,,N,,A,6655,,42.0,Mus musculus,1,,,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,50594,,,CHEMBL623479,Intermediate,10090.0,,N,,A,6656,,42.0,Mus musculus,1,,,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,50594,,,CHEMBL623480,Intermediate,10090.0,,N,,A,6657,,42.0,Mus musculus,1,,,CCRF S-180
,6599,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,50594,,,CHEMBL623481,Intermediate,10090.0,,N,,A,6658,,42.0,Mus musculus,1,,,CCRF S-180
,17641,1,BAO_0000218,C2 in brain of mice at the oral dose of 50 mg/kg,50594,,Brain,CHEMBL623482,Intermediate,10090.0,,N,,A,6659,,,Mus musculus,1,,955.0,
,17641,1,BAO_0000218,C2 in kidney of mice at the oral dose of 50 mg/kg,50594,,Kidney,CHEMBL623483,Intermediate,10090.0,,N,,A,6660,,,Mus musculus,1,,2113.0,
,17641,1,BAO_0000218,C2 in liver of mice at the oral dose of 50 mg/kg,50594,,Liver,CHEMBL623484,Intermediate,10090.0,,N,,A,6661,,,Mus musculus,1,,2107.0,
,17641,1,BAO_0000218,C2 in lungs of mice at the oral dose of 50 mg/kg,50594,,Lung,CHEMBL623485,Intermediate,10090.0,,N,,A,6662,,,Mus musculus,1,,2048.0,
,17641,1,BAO_0000218,C2 in spleen of mice at the oral dose of 50 mg/kg,50594,,Spleen,CHEMBL623486,Intermediate,10090.0,,N,,A,6663,,,Mus musculus,1,,2106.0,
,17852,1,BAO_0000218,Plasma clearance in mouse,50594,In vivo,,CHEMBL623487,Intermediate,10090.0,,N,,A,6664,,,Mus musculus,1,,,
,17764,1,BAO_0000218,Clearance of compound after intravenous administration in mice at 24 uM/kg,50594,In vivo,,CHEMBL623488,Intermediate,10090.0,,N,,A,6665,,,Mus musculus,1,,,
,17837,1,BAO_0000218,Clearance from mouse blood following i.v. administration of 10 mg/kg,50594,In vivo,,CHEMBL623489,Intermediate,10090.0,,N,,A,6666,,,Mus musculus,1,,,
,2675,1,BAO_0000218,Clearance was evaluated in mice after intravenous administration,50594,In vivo,,CHEMBL875157,Intermediate,10090.0,,N,,A,6667,,,Mus musculus,1,,,
,2675,1,BAO_0000218,Clearance was evaluated in mice after oral administration,50594,In vivo,,CHEMBL623490,Intermediate,10090.0,,N,,A,6668,,,Mus musculus,1,,,
,4239,1,BAO_0000218,Pharmacokinetic property (Plasma clearance) was measured in mouse,50594,In vivo,,CHEMBL623491,Intermediate,10090.0,,N,,A,6669,,,Mus musculus,1,,,
,17753,1,BAO_0000218,Plasma clearance of compound was determined at 40 mg/Kg,50594,In vivo,,CHEMBL623492,Intermediate,10090.0,,N,,A,6670,,,Mus musculus,1,,,
,17753,1,BAO_0000218,Plasma clearance of at 24 mg/Kg,50594,In vivo,,CHEMBL623493,Intermediate,10090.0,,N,,A,6671,,,Mus musculus,1,,,
,17753,1,BAO_0000218,Plasma clearance at 24 mg/Kg,50594,In vivo,,CHEMBL623494,Intermediate,10090.0,,N,,A,6672,,,Mus musculus,1,,,
,17753,1,BAO_0000218,Plasma clearance at 5 mg/Kg,50594,In vivo,,CHEMBL623495,Intermediate,10090.0,,N,,A,6673,,,Mus musculus,1,,,
,5727,1,BAO_0000218,Plasma clearance in mice,50594,In vivo,,CHEMBL623496,Intermediate,10090.0,,N,,A,6674,,,Mus musculus,1,,,
,2862,1,BAO_0000218,Plasma clearance value upon iv administration in mouse,50594,In vivo,,CHEMBL623497,Intermediate,10090.0,,N,,A,6675,,,Mus musculus,1,,,
,5980,1,BAO_0000218,Total plasma clearance in mice,50594,In vivo,Plasma,CHEMBL623498,Intermediate,10090.0,,N,,A,6676,,,Mus musculus,1,,1969.0,
,17592,1,BAO_0000218,Clearance in mouse,50594,In vivo,,CHEMBL623499,Intermediate,10090.0,,N,,A,6677,,,Mus musculus,1,,,
,17718,1,BAO_0000218,Clearance value was determined,50594,In vivo,,CHEMBL623500,Intermediate,10090.0,,N,,A,6678,,,Mus musculus,1,,,
,16597,1,BAO_0000218,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,50594,In vivo,,CHEMBL623501,Intermediate,10090.0,,N,,A,6679,,,Mus musculus,1,,,
,17384,0,BAO_0000100,Calculated partition coefficient (clogP),22229,,,CHEMBL875158,Intermediate,,,U,,P,6680,,,,1,,,
,6062,1,BAO_0000218,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,50594,In vivo,,CHEMBL623502,Intermediate,10090.0,,N,,A,6681,,,Mus musculus,1,,,
,17734,1,BAO_0000218,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,50594,In vivo,,CHEMBL623503,Intermediate,10090.0,,N,,A,6682,,,Mus musculus,1,,,
,6348,1,BAO_0000218,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,In vivo,,CHEMBL623504,Intermediate,10090.0,,N,,A,6683,,,Mus musculus,1,,,
,5969,1,BAO_0000218,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,50594,In vivo,,CHEMBL623505,Intermediate,10090.0,,N,,A,6684,,,Mus musculus,1,,,
,5969,1,BAO_0000218,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,50594,In vivo,,CHEMBL623506,Intermediate,10090.0,,N,,A,6685,,,Mus musculus,1,,,
,5969,1,BAO_0000218,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,50594,In vivo,,CHEMBL623507,Intermediate,10090.0,,N,,A,6686,,,Mus musculus,1,,,
,16597,1,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,50594,In vivo,,CHEMBL623508,Intermediate,10090.0,,N,,A,6687,,,Mus musculus,1,,,
,5781,1,BAO_0000218,Cmax after oral administration at 30 mg/kg in ICR mouse,50594,In vivo,,CHEMBL623509,Intermediate,10090.0,,N,,A,6688,,,Mus musculus,1,,,
,17764,1,BAO_0000218,Cmax after peroral administration in mice at 2.4 uM/kg,50594,In vivo,,CHEMBL875159,Intermediate,10090.0,,N,,A,6689,,,Mus musculus,1,,,
,17641,1,BAO_0000218,Cmax in brain of mice at the oral dose of 50 mg/kg,50594,In vivo,Brain,CHEMBL623510,Intermediate,10090.0,,N,,A,6690,,,Mus musculus,1,,955.0,
,17641,1,BAO_0000218,Cmax in kidney of mice at the oral dose of 50 mg/kg,50594,In vivo,Kidney,CHEMBL623511,Intermediate,10090.0,,N,,A,6691,,,Mus musculus,1,,2113.0,
,17641,1,BAO_0000218,Cmax in liver of mice at the oral dose of 50 mg/kg,50594,In vivo,Liver,CHEMBL623512,Intermediate,10090.0,,N,,A,6692,,,Mus musculus,1,,2107.0,
,17641,1,BAO_0000218,Cmax in lungs of mice at the oral dose of 50 mg/kg,50594,In vivo,Lung,CHEMBL623513,Intermediate,10090.0,,N,,A,6693,,,Mus musculus,1,,2048.0,
,17764,1,BAO_0000218,Cmax in mice at 18 uM/kg i.p. administration,50594,In vivo,,CHEMBL623514,Intermediate,10090.0,,N,,F,6694,,,Mus musculus,1,,,
,17764,1,BAO_0000218,Cmax in mice at 23 uM/kg i.v. administration,50594,In vivo,,CHEMBL622609,Intermediate,10090.0,,N,,F,6695,,,Mus musculus,1,,,
,17764,1,BAO_0000218,Cmax in mice at 24 uM/kg i.p. administration,50594,In vivo,,CHEMBL622610,Intermediate,10090.0,,N,,F,6696,,,Mus musculus,1,,,
,17764,1,BAO_0000218,Cmax in mice at 25 uM/kg i.p. administration,50594,In vivo,,CHEMBL621823,Intermediate,10090.0,,N,,F,6697,,,Mus musculus,1,,,
,17764,1,BAO_0000218,Cmax in mice at 26 uM/kg i.p. administration,50594,In vivo,,CHEMBL621824,Intermediate,10090.0,,N,,F,6698,,,Mus musculus,1,,,
,17641,1,BAO_0000218,Cmax in spleen of mice at the oral dose of 50 mg/kg,50594,In vivo,Spleen,CHEMBL621825,Intermediate,10090.0,,N,,A,6699,,,Mus musculus,1,,2106.0,
,16597,1,BAO_0000218,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,50594,In vivo,,CHEMBL621826,Intermediate,10090.0,,N,,A,6700,,,Mus musculus,1,,,
,16597,1,BAO_0000218,Cmax value at a dose of 10 mg/kg peroral administration in mice.,50594,In vivo,,CHEMBL621827,Intermediate,10090.0,,N,,A,6701,,,Mus musculus,1,,,
,5727,1,BAO_0000218,Cmax value was determined,50594,In vivo,,CHEMBL621828,Intermediate,10090.0,,N,,A,6702,,,Mus musculus,1,,,
,5951,1,BAO_0000218,Cmax value in IRC mice,50594,In vivo,,CHEMBL621829,Intermediate,10090.0,,N,,A,6703,,,Mus musculus,1,,,
,5506,1,BAO_0000218,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,50594,In vivo,,CHEMBL621830,Intermediate,10090.0,,N,,A,6704,,,Mus musculus,1,,,
,5506,1,BAO_0000218,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,50594,In vivo,,CHEMBL621831,Intermediate,10090.0,,N,,A,6705,,,Mus musculus,1,,,
,14239,1,BAO_0000218,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,50594,In vivo,Plasma,CHEMBL621832,Intermediate,10090.0,,N,,A,6706,,,Mus musculus,1,,1969.0,
,4890,1,BAO_0000218,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",50594,In vivo,Plasma,CHEMBL624579,Intermediate,10090.0,,N,,A,6707,,,Mus musculus,1,,1969.0,
,429,1,BAO_0000218,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,50594,In vivo,,CHEMBL624580,Intermediate,10090.0,,N,,A,6708,,,Mus musculus,1,,,
,10986,1,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,50535,,,CHEMBL624581,Intermediate,6277.0,,N,,F,6709,,,Acanthocheilonema viteae,1,,,
,10986,1,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,50535,,,CHEMBL624582,Intermediate,6277.0,,N,,F,6710,,,Acanthocheilonema viteae,1,,,
,10986,1,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,50535,,,CHEMBL624583,Intermediate,6277.0,,N,,F,6711,,,Acanthocheilonema viteae,1,,,
,13227,1,BAO_0000219,Inhibitory activity against human tumor cell line A0375 melanoma.,80018,,,CHEMBL624584,Intermediate,9606.0,,N,,F,6712,,455.0,Homo sapiens,1,,,A-375
,4481,9,BAO_0000249,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,12512,,,CHEMBL624585,Expert,10116.0,Brain membranes,D,,B,6713,,,Rattus norvegicus,1,,,
,16931,9,BAO_0000019,Forskolin-induced cAMP production at human A1 adenosine receptor,114,,,CHEMBL875165,Expert,9606.0,,D,,F,6714,,,Homo sapiens,1,,,
,3850,8,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,114,,,CHEMBL619490,Autocuration,,,H,,F,6715,,449.0,,1,,,CHO
,3850,8,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,114,,,CHEMBL619491,Autocuration,,,H,,F,6716,,449.0,,1,,,CHO
,3850,8,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,114,,,CHEMBL619492,Expert,,,H,,F,6717,,449.0,,1,,,CHO
,3850,8,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,114,,,CHEMBL619493,Expert,,,H,,F,6718,,449.0,,1,,,CHO
,3850,8,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,114,,,CHEMBL619494,Autocuration,,,H,,F,6719,,449.0,,1,,,CHO
,3850,8,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,114,,,CHEMBL619495,Autocuration,,,H,,F,6720,,449.0,,1,,,CHO
,3850,8,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,114,,,CHEMBL619496,Autocuration,,,H,,F,6721,,449.0,,1,,,CHO
,3850,9,BAO_0000219,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,114,,,CHEMBL619497,Expert,9606.0,,D,,F,6722,,449.0,Homo sapiens,1,,,CHO
,3850,8,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,114,,,CHEMBL619498,Autocuration,,,H,,F,6723,,449.0,,1,,,CHO
,3850,8,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,114,,,CHEMBL619499,Autocuration,,,H,,F,6724,,449.0,,1,,,CHO
,3850,8,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,114,,,CHEMBL619500,Expert,,,H,,F,6725,,449.0,,1,,,CHO
,3850,8,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,114,,,CHEMBL619501,Autocuration,,,H,,F,6726,,449.0,,1,,,CHO
,3850,8,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,114,,,CHEMBL619502,Expert,,,H,,F,6727,,449.0,,1,,,CHO
,3850,8,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,114,,,CHEMBL619503,Autocuration,,,H,,F,6728,,449.0,,1,,,CHO
,3850,8,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,114,,,CHEMBL619504,Autocuration,,,H,,F,6729,,449.0,,1,,,CHO
,3850,8,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,114,,,CHEMBL621298,Autocuration,,,H,,F,6730,,449.0,,1,,,CHO
,3850,8,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,114,,,CHEMBL621299,Expert,,,H,,F,6731,,449.0,,1,,,CHO
,3850,8,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,114,,,CHEMBL621300,Autocuration,,,H,,F,6732,,449.0,,1,,,CHO
,3850,8,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,114,,,CHEMBL621301,Autocuration,,,H,,F,6733,,449.0,,1,,,CHO
,3850,8,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,114,,,CHEMBL621302,Expert,,,H,,F,6734,,449.0,,1,,,CHO
,12680,1,BAO_0000219,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,80013,,,CHEMBL621303,Intermediate,9986.0,,N,,F,6735,,164.0,Oryctolagus cuniculus,1,,,A10
,1313,0,BAO_0000219,In vitro potassium channel opening activity in A10 (smooth muscle) cells,22226,,,CHEMBL621304,Autocuration,10116.0,,U,,F,6736,,164.0,Rattus norvegicus,1,,,A10
,1313,0,BAO_0000219,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,22226,,,CHEMBL621305,Autocuration,10116.0,,U,,F,6737,,164.0,Rattus norvegicus,1,,,A10
,17567,1,BAO_0000219,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,80013,,,CHEMBL621306,Intermediate,10116.0,,N,,F,6738,,164.0,Rattus norvegicus,1,,,A10
,17567,1,BAO_0000219,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,80013,,,CHEMBL618444,Intermediate,10116.0,,N,,F,6739,,164.0,Rattus norvegicus,1,,,A10
,11819,1,BAO_0000219,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,80013,,,CHEMBL618445,Intermediate,10116.0,,N,,F,6740,,164.0,Rattus norvegicus,1,,,A10
,13436,1,BAO_0000219,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,80089,,,CHEMBL618446,Intermediate,10029.0,,N,,F,6741,,185.0,Cricetulus griseus,1,,,CHO-AA8
,12687,1,BAO_0000219,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,80089,,,CHEMBL618447,Intermediate,10029.0,,N,,F,6742,,185.0,Cricetulus griseus,1,,,CHO-AA8
,12651,1,BAO_0000219,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,80089,,,CHEMBL618448,Intermediate,10029.0,,N,,F,6743,,185.0,Cricetulus griseus,1,,,CHO-AA8
,13300,1,BAO_0000219,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,80089,,,CHEMBL618449,Intermediate,10029.0,,N,,F,6744,,185.0,Cricetulus griseus,1,,,CHO-AA8
,15296,1,BAO_0000219,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,80089,,,CHEMBL618637,Intermediate,10029.0,,N,,F,6745,,185.0,Cricetulus griseus,1,,,CHO-AA8
,15328,1,BAO_0000219,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",80089,,,CHEMBL618638,Intermediate,10029.0,,N,,F,6746,,185.0,Cricetulus griseus,1,,,CHO-AA8
,13302,1,BAO_0000219,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),80089,,,CHEMBL618639,Intermediate,10029.0,,N,,F,6747,,185.0,Cricetulus griseus,1,,,CHO-AA8
,14367,1,BAO_0000219,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",80089,,,CHEMBL618640,Expert,10029.0,,N,,F,6748,,185.0,Cricetulus griseus,1,,,CHO-AA8
,17002,1,BAO_0000219,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,80089,,,CHEMBL618641,Expert,10029.0,,N,,F,6749,,185.0,Cricetulus griseus,1,,,CHO-AA8
,13436,1,BAO_0000219,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,80089,,,CHEMBL618642,Intermediate,10029.0,,N,,F,6750,,185.0,Cricetulus griseus,1,,,CHO-AA8
,13435,1,BAO_0000219,Inhibitory activity against aerobic growth of AA8 cells.,80089,,,CHEMBL618643,Intermediate,10029.0,,N,,F,6751,,185.0,Cricetulus griseus,1,,,CHO-AA8
,10503,1,BAO_0000219,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,80089,,,CHEMBL884013,Intermediate,10029.0,,N,,A,6752,,185.0,Cricetulus griseus,1,,,CHO-AA8
,10503,1,BAO_0000219,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,80089,,,CHEMBL622723,Expert,10029.0,,N,,F,6753,,185.0,Cricetulus griseus,1,,,CHO-AA8
,10503,1,BAO_0000219,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,80089,,,CHEMBL622724,Intermediate,10029.0,,N,,F,6754,,185.0,Cricetulus griseus,1,,,CHO-AA8
,15090,1,BAO_0000219,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,80089,,,CHEMBL622725,Expert,10029.0,,N,,F,6755,,185.0,Cricetulus griseus,1,,,CHO-AA8
,10368,1,BAO_0000219,Cytotoxicity against AA8 cell line,80089,,,CHEMBL622726,Expert,10029.0,,N,,F,6756,,185.0,Cricetulus griseus,1,,,CHO-AA8
,12651,1,BAO_0000219,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),80089,,,CHEMBL622727,Intermediate,10029.0,,N,,F,6757,,185.0,Cricetulus griseus,1,,,CHO-AA8
,12687,1,BAO_0000219,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),80089,,,CHEMBL622728,Intermediate,10029.0,,N,,A,6758,,185.0,Cricetulus griseus,1,,,CHO-AA8
,12687,1,BAO_0000219,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),80089,,,CHEMBL622729,Intermediate,10029.0,,N,,F,6759,,185.0,Cricetulus griseus,1,,,CHO-AA8
,12687,1,BAO_0000219,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),80089,,,CHEMBL622730,Intermediate,10029.0,,N,,A,6760,,185.0,Cricetulus griseus,1,,,CHO-AA8
,1890,1,BAO_0000219,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,80089,,,CHEMBL622731,Intermediate,10029.0,,N,,F,6761,,185.0,Cricetulus griseus,1,,,CHO-AA8
,10747,1,BAO_0000219,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,80089,,,CHEMBL622732,Intermediate,10029.0,,N,,F,6762,,185.0,Cricetulus griseus,1,,,CHO-AA8
,10747,1,BAO_0000219,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,80089,,,CHEMBL622733,Intermediate,10029.0,,N,,F,6763,,185.0,Cricetulus griseus,1,,,CHO-AA8
,11616,0,BAO_0000218,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),22224,,,CHEMBL622734,Autocuration,10029.0,,U,,F,6764,,,Cricetulus griseus,1,,,
,11616,1,BAO_0000219,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,80089,,,CHEMBL622735,Expert,10029.0,,N,,F,6765,,185.0,Cricetulus griseus,1,,,CHO-AA8
,3471,0,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,22224,,,CHEMBL618746,Autocuration,10029.0,,U,,F,6766,,185.0,Cricetulus griseus,1,,,CHO-AA8
,3471,0,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,22224,,,CHEMBL618747,Autocuration,10029.0,,U,,F,6767,,185.0,Cricetulus griseus,1,,,CHO-AA8
,3471,0,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,22224,,,CHEMBL620540,Autocuration,10029.0,,U,,F,6768,,185.0,Cricetulus griseus,1,,,CHO-AA8
,3471,0,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,22224,,,CHEMBL620541,Autocuration,10029.0,,U,,F,6769,,185.0,Cricetulus griseus,1,,,CHO-AA8
,3471,0,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,22224,,,CHEMBL620542,Autocuration,10029.0,,U,,F,6770,,185.0,Cricetulus griseus,1,,,CHO-AA8
,3471,0,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,22224,,,CHEMBL620543,Autocuration,10029.0,,U,,F,6771,,185.0,Cricetulus griseus,1,,,CHO-AA8
,3471,0,BAO_0000219,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,22224,,,CHEMBL618832,Autocuration,10029.0,,U,,F,6772,,185.0,Cricetulus griseus,1,,,CHO-AA8
,11616,1,BAO_0000219,Concentration required to reduce AA8 cell survival by 10%,80089,,,CHEMBL618833,Expert,10029.0,,N,,F,6773,,185.0,Cricetulus griseus,1,,,CHO-AA8
,2656,0,BAO_0000219,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",22224,,,CHEMBL618834,Autocuration,10029.0,,U,,F,6774,,185.0,Cricetulus griseus,1,,,CHO-AA8
,10518,0,BAO_0000219,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,22224,,,CHEMBL618835,Autocuration,10029.0,,U,,F,6775,,185.0,Cricetulus griseus,1,,,CHO-AA8
,10518,0,BAO_0000219,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,22224,,,CHEMBL618836,Autocuration,10029.0,,U,,F,6776,,185.0,Cricetulus griseus,1,,,CHO-AA8
,10518,0,BAO_0000219,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,22224,,,CHEMBL618837,Autocuration,10029.0,,U,,F,6777,,185.0,Cricetulus griseus,1,,,CHO-AA8
,10518,0,BAO_0000219,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,22224,,,CHEMBL618838,Autocuration,10029.0,,U,,F,6778,,185.0,Cricetulus griseus,1,,,CHO-AA8
,16156,0,BAO_0000219,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,22224,,,CHEMBL618839,Autocuration,10029.0,,U,,F,6779,,185.0,Cricetulus griseus,1,,,CHO-AA8
,2656,0,BAO_0000219,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,22224,,,CHEMBL618840,Autocuration,10029.0,,U,,F,6780,,185.0,Cricetulus griseus,1,,,CHO-AA8
,11005,0,BAO_0000019,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",22224,,,CHEMBL618841,Autocuration,10029.0,,U,,F,6781,,,Cricetulus griseus,1,,,
,11942,0,BAO_0000219,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,22224,,,CHEMBL618842,Autocuration,10029.0,,U,,F,6782,,185.0,Cricetulus griseus,1,,,CHO-AA8
,2128,0,BAO_0000219,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,22224,,,CHEMBL618843,Autocuration,10029.0,,U,,F,6783,,185.0,Cricetulus griseus,1,,,CHO-AA8
,16907,1,BAO_0000218,Half life period after 15 mg/kg iv dose in Dogs,50588,In vivo,,CHEMBL618844,Intermediate,9615.0,,N,,A,6784,,,Canis lupus familiaris,1,,,
,16907,1,BAO_0000218,Half life period after 30 mg/kg po dose in Dogs,50588,In vivo,,CHEMBL618845,Intermediate,9615.0,,N,,A,6785,,,Canis lupus familiaris,1,,,
,9579,1,BAO_0000218,Half life was measured after oral 2b administration (tested in 6 dogs),50588,In vivo,,CHEMBL618846,Intermediate,9615.0,,N,,A,6786,,,Canis lupus familiaris,1,,,
,9579,1,BAO_0000218,Half life was measured in dog after oral 17b administration,50588,In vivo,,CHEMBL618847,Intermediate,9615.0,,N,,A,6787,,,Canis lupus familiaris,1,,,
,9579,1,BAO_0000218,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,50588,In vivo,,CHEMBL618848,Intermediate,9615.0,,N,,A,6788,,,Canis lupus familiaris,1,,,
,9579,1,BAO_0000218,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,50588,In vivo,,CHEMBL618849,Intermediate,9615.0,,N,,A,6789,,,Canis lupus familiaris,1,,,
,16907,1,BAO_0000218,Tmax value after 15 mg/kg iv dose in Dogs,50588,In vivo,,CHEMBL618850,Intermediate,9615.0,,N,,A,6790,,,Canis lupus familiaris,1,,,
,16907,1,BAO_0000218,Tmax value after 30 mg/kg po dose in Dogs,50588,In vivo,,CHEMBL618851,Intermediate,9615.0,,N,,A,6791,,,Canis lupus familiaris,1,,,
,3184,1,BAO_0000218,Compound was evaluated for its half life when administered intravenously in dog,50588,In vivo,,CHEMBL873815,Intermediate,9615.0,,N,,A,6792,,,Canis lupus familiaris,1,,,
,5017,1,BAO_0000218,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),50588,In vivo,Plasma,CHEMBL618852,Intermediate,9615.0,,N,,A,6793,,,Canis lupus familiaris,1,,1969.0,
,6821,1,BAO_0000218,Elimination Half-life of compound was determined in dog,50588,,,CHEMBL618853,Intermediate,9615.0,,N,,A,6794,,,Canis lupus familiaris,1,,,
,17839,1,BAO_0000218,Half life of compound in dog following oral administration,50588,In vivo,,CHEMBL618854,Intermediate,9615.0,,N,,A,6795,,,Canis lupus familiaris,1,,,
,17267,1,BAO_0000218,Half life of compound was determined in dog,50588,,,CHEMBL618855,Intermediate,9615.0,,N,,A,6796,,,Canis lupus familiaris,1,,,
,4727,1,BAO_0000218,Half life of compound was determined in dog blood,50588,,Blood,CHEMBL618856,Intermediate,9615.0,,N,,A,6797,,,Canis lupus familiaris,1,,178.0,
,5238,1,BAO_0000218,Half life after oral and iv dosing in dogs,50588,In vivo,,CHEMBL875827,Intermediate,9615.0,,N,,A,6798,,,Canis lupus familiaris,1,,,
,4942,1,BAO_0000218,Half life in dogs in hours,50588,,,CHEMBL618857,Intermediate,9615.0,,N,,A,6799,,,Canis lupus familiaris,1,,,
,6505,1,BAO_0000218,Half life on i.v. administration of 2 mg/kg was measured in dog,50588,In vivo,,CHEMBL618858,Intermediate,9615.0,,N,,A,6800,,,Canis lupus familiaris,1,,,
,5130,1,BAO_0000218,t1/2 in dog after oral dose (1 mg/kg),50588,In vivo,,CHEMBL618859,Intermediate,9615.0,,N,,A,6801,,,Canis lupus familiaris,1,,,
,1475,1,BAO_0000218,Half life was evaluated in dog,50588,,,CHEMBL618860,Intermediate,9615.0,,N,,A,6802,,,Canis lupus familiaris,1,,,
,17804,1,BAO_0000218,Half life period of compound was determined after intravenous administration at 2 mg/kg,50588,In vivo,,CHEMBL618861,Intermediate,9615.0,,N,,A,6803,,,Canis lupus familiaris,1,,,
,17804,1,BAO_0000218,Half life period of compound was determined after peroral administration at 2 mg/kg,50588,In vivo,,CHEMBL622539,Intermediate,9615.0,,N,,A,6804,,,Canis lupus familiaris,1,,,
,6084,1,BAO_0000218,Half life period (10 mg/kg) was determined in dog,50588,In vivo,,CHEMBL622540,Intermediate,9615.0,,N,,A,6805,,,Canis lupus familiaris,1,,,
,6084,1,BAO_0000218,Half life period (10 mg/kg) was determined in dog,50588,In vivo,,CHEMBL873803,Intermediate,9615.0,,N,,A,6806,,,Canis lupus familiaris,1,,,
,5542,1,BAO_0000218,Half life period by iv administration in dog at a dose of 0.3 mg/kg,50588,In vivo,,CHEMBL873804,Intermediate,9615.0,,N,,A,6807,,,Canis lupus familiaris,1,,,
,5542,1,BAO_0000218,Half life period by po administration in dog at a dose of 0.3 mg/kg,50588,In vivo,,CHEMBL624311,Intermediate,9615.0,,N,,A,6808,,,Canis lupus familiaris,1,,,
,6084,1,BAO_0000218,Half life period in dog,50588,,,CHEMBL624312,Intermediate,9615.0,,N,,A,6809,,,Canis lupus familiaris,1,,,
,6241,1,BAO_0000218,Half life period in dogs after oral administration at 1 mg/kg,50588,In vivo,,CHEMBL624313,Intermediate,9615.0,,N,,A,6810,,,Canis lupus familiaris,1,,,
,1916,1,BAO_0000218,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,In vivo,,CHEMBL624314,Intermediate,9615.0,,N,,A,6811,,,Canis lupus familiaris,1,,,
,6621,1,BAO_0000218,Half-life of compound was determined in dogs,50588,,,CHEMBL624315,Intermediate,9615.0,,N,,A,6812,,,Canis lupus familiaris,1,,,
,1696,1,BAO_0000218,Half-life in dog plasma,50588,,Plasma,CHEMBL624316,Intermediate,9615.0,,N,,A,6813,,,Canis lupus familiaris,1,,1969.0,
,17800,1,BAO_0000218,Half-life in mongrel dogs was determined,50588,,,CHEMBL624317,Intermediate,9615.0,,N,,A,6814,,,Canis lupus familiaris,1,,,
,17657,1,BAO_0000218,Half-life in dog upon oral administration,50588,In vivo,,CHEMBL624318,Intermediate,9615.0,,N,,A,6815,,,Canis lupus familiaris,1,,,
,17657,1,BAO_0000218,Half-life in dog upon oral administration; Unable to calculate,50588,In vivo,,CHEMBL624319,Intermediate,9615.0,,N,,A,6816,,,Canis lupus familiaris,1,,,
,4239,1,BAO_0000218,Half-life was measured in dog,50588,,,CHEMBL624496,Intermediate,9615.0,,N,,A,6817,,,Canis lupus familiaris,1,,,
,5985,1,BAO_0000218,Half-life was measured in dog,50588,,,CHEMBL624497,Intermediate,9615.0,,N,,A,6818,,,Canis lupus familiaris,1,,,
,9932,1,BAO_0000218,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,50588,,,CHEMBL624498,Intermediate,9615.0,,N,,A,6819,,,Canis lupus familiaris,1,,,
,5199,1,BAO_0000218,Oral half life was determined,50588,In vivo,,CHEMBL624499,Intermediate,9615.0,,N,,A,6820,,,Canis lupus familiaris,1,,,
,5199,1,BAO_0000218,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,50588,In vivo,Plasma,CHEMBL624500,Intermediate,9615.0,,N,,A,6821,,,Canis lupus familiaris,1,,1969.0,
,1475,1,BAO_0000218,Plasma half life was evaluated,50588,,Plasma,CHEMBL624501,Intermediate,9615.0,,N,,A,6822,,,Canis lupus familiaris,1,,1969.0,
,1475,1,BAO_0000218,Plasma half life was evaluated in Dog,50588,,Plasma,CHEMBL623666,Intermediate,9615.0,,N,,A,6823,,,Canis lupus familiaris,1,,1969.0,
,1475,1,BAO_0000218,Plasma half life was evaluated in dog,50588,,Plasma,CHEMBL623667,Intermediate,9615.0,,N,,A,6824,,,Canis lupus familiaris,1,,1969.0,
,6316,1,BAO_0000218,T1/2 (Half-life) was after oral administration at 5 mg/kg,50588,In vivo,,CHEMBL623668,Intermediate,9615.0,,N,,A,6825,,,Canis lupus familiaris,1,,,
,4883,1,BAO_0000218,Tested for the half life value in dog,50588,,,CHEMBL623669,Intermediate,9615.0,,N,,A,6826,,,Canis lupus familiaris,1,,,
,4727,1,BAO_0000218,Maximum time at the dose of 2 mg/kg in dog,50588,In vivo,,CHEMBL623670,Intermediate,9615.0,,N,,A,6827,,,Canis lupus familiaris,1,,,
,1916,1,BAO_0000218,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,In vivo,,CHEMBL623671,Intermediate,9615.0,,N,,A,6828,,,Canis lupus familiaris,1,,,
,1337,1,BAO_0000218,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,50588,In vivo,Blood,CHEMBL875945,Intermediate,9615.0,,N,,A,6829,,,Canis lupus familiaris,1,,178.0,
,1337,1,BAO_0000218,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,50588,In vivo,Blood,CHEMBL623672,Intermediate,9615.0,,N,,A,6830,,,Canis lupus familiaris,1,,178.0,
,6265,1,BAO_0000218,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,50588,In vivo,,CHEMBL623673,Intermediate,9615.0,,N,,A,6831,,,Canis lupus familiaris,1,,,
,4809,1,BAO_0000218,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),50588,In vivo,,CHEMBL623674,Intermediate,9615.0,,N,,A,6832,,,Canis lupus familiaris,1,,,
,5983,1,BAO_0000218,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,50588,In vivo,,CHEMBL623675,Intermediate,9615.0,,N,,A,6833,,,Canis lupus familiaris,1,,,
,5313,1,BAO_0000218,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",50588,,,CHEMBL872526,Intermediate,9615.0,,N,,A,6834,,,Canis lupus familiaris,1,,,
,5313,1,BAO_0000218,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",50588,In vivo,,CHEMBL623676,Intermediate,9615.0,,N,,A,6835,,,Canis lupus familiaris,1,,,
,17650,1,BAO_0000218,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,50588,In vivo,Plasma,CHEMBL623677,Intermediate,9615.0,,N,,A,6836,,,Canis lupus familiaris,1,,1969.0,
,5199,1,BAO_0000218,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,50588,In vivo,Plasma,CHEMBL623678,Intermediate,9615.0,,N,,A,6837,,,Canis lupus familiaris,1,,1969.0,
,933,1,BAO_0000218,Time taken for maximum plasma concentration in dog,50588,,Plasma,CHEMBL623679,Intermediate,9615.0,,N,,A,6838,,,Canis lupus familiaris,1,,1969.0,
,16367,1,BAO_0000218,Time to reach Cmax after oral administration to dogs,50588,In vivo,,CHEMBL623680,Intermediate,9615.0,,N,,A,6839,,,Canis lupus familiaris,1,,,
,6348,1,BAO_0000218,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,In vivo,Plasma,CHEMBL623681,Intermediate,9615.0,,N,,A,6840,,,Canis lupus familiaris,1,,1969.0,
,6316,1,BAO_0000218,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,50588,In vivo,,CHEMBL623682,Intermediate,9615.0,,N,,A,6841,,,Canis lupus familiaris,1,,,
,6215,1,BAO_0000218,Tmax after peroral administration (1 mg/kg) was determined in dog,50588,In vivo,,CHEMBL623683,Intermediate,9615.0,,N,,A,6842,,,Canis lupus familiaris,1,,,
,3598,1,BAO_0000218,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,In vivo,,CHEMBL623684,Expert,9615.0,,N,,A,6843,,,Canis lupus familiaris,1,,,
,4527,1,BAO_0000218,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,50588,In vivo,,CHEMBL622745,Intermediate,9615.0,,N,,A,6844,,,Canis lupus familiaris,1,,,
,17764,1,BAO_0000218,Tmax after peroral administration in dogs at 2.4 uM/kg,50588,In vivo,,CHEMBL622746,Intermediate,9615.0,,N,,A,6845,,,Canis lupus familiaris,1,,,
,5969,1,BAO_0000218,In vivo Cmax in mice at dose of 100 mg/kg,50594,In vivo,,CHEMBL622747,Intermediate,10090.0,,N,,A,6846,,,Mus musculus,1,,,
,5969,1,BAO_0000218,In vivo Cmax in mice at dose of 50 mg/kg,50594,In vivo,,CHEMBL622748,Intermediate,10090.0,,N,,A,6847,,,Mus musculus,1,,,
,4573,1,BAO_0000218,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,50594,In vivo,,CHEMBL622749,Intermediate,10090.0,,N,,A,6848,,,Mus musculus,1,,,
,3277,1,BAO_0000218,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),50594,In vivo,Plasma,CHEMBL622750,Intermediate,10090.0,,N,,A,6849,,,Mus musculus,1,,1969.0,
,17734,1,BAO_0000218,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,50594,In vivo,Plasma,CHEMBL623411,Intermediate,10090.0,,N,,A,6850,,,Mus musculus,1,,1969.0,
,3132,1,BAO_0000218,Maximum concentration obtained in mouse plasma was determined,50594,In vivo,Plasma,CHEMBL875946,Intermediate,10090.0,,N,,A,6851,,,Mus musculus,1,,1969.0,
,3132,1,BAO_0000218,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,50594,In vivo,Plasma,CHEMBL623412,Intermediate,10090.0,,N,,A,6852,,,Mus musculus,1,,1969.0,
,6348,1,BAO_0000218,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,In vivo,Plasma,CHEMBL623413,Intermediate,10090.0,,N,,A,6853,,,Mus musculus,1,,1969.0,
,17729,1,BAO_0000218,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,50594,In vivo,Plasma,CHEMBL623414,Intermediate,10090.0,,N,,A,6854,,,Mus musculus,1,,1969.0,
,17729,1,BAO_0000218,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,50594,In vivo,Plasma,CHEMBL623415,Intermediate,10090.0,,N,,A,6855,,,Mus musculus,1,,1969.0,
,17729,1,BAO_0000218,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,50594,In vivo,Plasma,CHEMBL623416,Intermediate,10090.0,,N,,A,6856,,,Mus musculus,1,,1969.0,
,17728,1,BAO_0000218,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,50594,In vivo,Plasma,CHEMBL623417,Intermediate,10090.0,,N,,A,6857,,,Mus musculus,1,,1969.0,
,17728,1,BAO_0000218,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,50594,In vivo,Plasma,CHEMBL623418,Intermediate,10090.0,,N,,A,6858,,,Mus musculus,1,,1969.0,
,17728,1,BAO_0000218,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,50594,In vivo,Plasma,CHEMBL623419,Intermediate,10090.0,,N,,A,6859,,,Mus musculus,1,,1969.0,
,4066,1,BAO_0000218,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,50594,In vivo,,CHEMBL622816,Intermediate,10090.0,,N,,A,6860,,,Mus musculus,1,,,
,6178,1,BAO_0000218,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,50594,In vivo,,CHEMBL623313,Intermediate,10090.0,,N,,A,6861,,,Mus musculus,1,,,
,6178,1,BAO_0000218,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,50594,In vivo,,CHEMBL623314,Intermediate,10090.0,,N,,A,6862,,,Mus musculus,1,,,
,3760,1,BAO_0000218,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,50594,In vivo,,CHEMBL876788,Intermediate,10090.0,,N,,A,6863,,,Mus musculus,1,,,
,3760,1,BAO_0000218,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,50594,In vivo,,CHEMBL623315,Intermediate,10090.0,,N,,A,6864,,,Mus musculus,1,,,
,3760,1,BAO_0000218,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,50594,In vivo,,CHEMBL623316,Intermediate,10090.0,,N,,A,6865,,,Mus musculus,1,,,
,3760,1,BAO_0000218,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,50594,In vivo,,CHEMBL623317,Intermediate,10090.0,,N,,A,6866,,,Mus musculus,1,,,
,5961,1,BAO_0000218,Cmax in male mice after 2 mg/kg oral dose,50594,In vivo,,CHEMBL623319,Intermediate,10090.0,,N,,A,6868,,,Mus musculus,1,,,
,6137,1,BAO_0000218,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,50594,In vivo,,CHEMBL623320,Intermediate,10090.0,,N,,A,6869,,,Mus musculus,1,,,
,3802,1,BAO_0000218,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,50594,In vivo,,CHEMBL623321,Intermediate,10090.0,,N,,A,6870,,,Mus musculus,1,,,
,3535,1,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,50594,,,CHEMBL623322,Intermediate,10090.0,,N,,A,6871,,,Mus musculus,1,,,
,3535,1,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,50594,,,CHEMBL623323,Intermediate,10090.0,,N,,A,6872,,,Mus musculus,1,,,
,3535,1,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,50594,,,CHEMBL623324,Intermediate,10090.0,,N,,A,6873,,,Mus musculus,1,,,
,3535,1,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,50594,,,CHEMBL623325,Intermediate,10090.0,,N,,A,6874,,,Mus musculus,1,,,
,3535,1,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,50594,,,CHEMBL623326,Intermediate,10090.0,,N,,A,6875,,,Mus musculus,1,,,
,3535,1,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,50594,,,CHEMBL623327,Intermediate,10090.0,,N,,A,6876,,,Mus musculus,1,,,
,2862,1,BAO_0000218,Maximum concentration in plasma upon oral administration in mouse,50594,,Plasma,CHEMBL623328,Intermediate,10090.0,,N,,A,6877,,,Mus musculus,1,,1969.0,
,2675,1,BAO_0000218,Maximum plasma concentration was evaluated in mice after oral administration,50594,,Plasma,CHEMBL623329,Intermediate,10090.0,,N,,A,6878,,,Mus musculus,1,,1969.0,
,2675,1,BAO_0000218,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,50594,In vivo,Plasma,CHEMBL623330,Intermediate,10090.0,,N,,A,6879,,,Mus musculus,1,,1969.0,
,5399,1,BAO_0000218,Dose at which the compound induced fecal excretion in mice,50594,,,CHEMBL876789,Intermediate,10090.0,,N,,A,6880,,,Mus musculus,1,,,
,11819,1,BAO_0000219,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,80013,,,CHEMBL623333,Expert,10116.0,,N,,F,6893,,164.0,Rattus norvegicus,1,,,A10
,11819,1,BAO_0000219,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,80013,,,CHEMBL623334,Expert,10116.0,,N,,F,6894,,164.0,Rattus norvegicus,1,,,A10
,11819,1,BAO_0000219,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,80013,,,CHEMBL627536,Expert,10116.0,,N,,F,6895,,164.0,Rattus norvegicus,1,,,A10
,11819,1,BAO_0000219,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,80013,,,CHEMBL627537,Expert,10116.0,,N,,F,6896,,164.0,Rattus norvegicus,1,,,A10
,16361,1,BAO_0000219,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),80013,,,CHEMBL627538,Intermediate,10116.0,,N,,F,6897,,164.0,Rattus norvegicus,1,,,A10
,2288,1,BAO_0000219,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,80655,,,CHEMBL884106,Intermediate,9606.0,,N,,F,6898,,393.0,Homo sapiens,1,,,A121
,10404,1,BAO_0000219,Anticancer activity against human ovarian carcinoma A121 cells,80655,,,CHEMBL625294,Intermediate,9606.0,,N,,F,6899,,393.0,Homo sapiens,1,,,A121
,14790,1,BAO_0000219,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,80655,,,CHEMBL625295,Intermediate,9606.0,,N,,F,6900,,393.0,Homo sapiens,1,,,A121
,14790,1,BAO_0000219,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,80655,,,CHEMBL625296,Intermediate,9606.0,,N,,F,6901,,393.0,Homo sapiens,1,,,A121
,14253,1,BAO_0000219,Growth inhibition of human ovarian carcinoma (A121) cell line,80655,,,CHEMBL625297,Expert,9606.0,,N,,F,6902,,393.0,Homo sapiens,1,,,A121
,13617,1,BAO_0000219,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,80655,,,CHEMBL625298,Expert,9606.0,,N,,F,6903,,393.0,Homo sapiens,1,,,A121
,1003,1,BAO_0000219,Cytotoxicity against human A121 ovarian cells,80655,,,CHEMBL625960,Intermediate,9606.0,,N,,F,6904,,393.0,Homo sapiens,1,,,A121
,830,1,BAO_0000219,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,80655,,,CHEMBL625961,Intermediate,9606.0,,N,,F,6905,,393.0,Homo sapiens,1,,,A121
,12307,1,BAO_0000219,In vitro cytotoxicity against human ovarian carcinoma A21,80655,,,CHEMBL625962,Intermediate,9606.0,,N,,F,6906,,393.0,Homo sapiens,1,,,A121
,14254,1,BAO_0000219,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,80655,,,CHEMBL624717,Intermediate,9606.0,,N,,F,6907,,393.0,Homo sapiens,1,,,A121
,13370,1,BAO_0000219,Inhibitory activity of compound against human A121 ovarian cell line.,80655,,,CHEMBL624718,Intermediate,9606.0,,N,,F,6908,,393.0,Homo sapiens,1,,,A121
,14790,1,BAO_0000219,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,80655,,,CHEMBL624719,Intermediate,9606.0,,N,,F,6909,,393.0,Homo sapiens,1,,,A121
,3614,1,BAO_0000219,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,80655,,,CHEMBL624720,Intermediate,9606.0,,N,,F,6910,,393.0,Homo sapiens,1,,,A121
,2664,1,BAO_0000219,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,80012,,,CHEMBL624721,Intermediate,9606.0,,N,,F,6911,,622.0,Homo sapiens,1,,,A 172
,2037,1,BAO_0000219,In vitro cytotoxicity against A172 human tumor cell lines.,80012,,,CHEMBL624722,Expert,9606.0,,N,,F,6912,,622.0,Homo sapiens,1,,,A 172
,14539,1,BAO_0000219,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,80012,,,CHEMBL877597,Intermediate,9606.0,,N,,F,6913,,622.0,Homo sapiens,1,,,A 172
,2836,1,BAO_0000219,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,80012,,,CHEMBL624723,Intermediate,9606.0,,N,,F,6914,,622.0,Homo sapiens,1,,,A 172
,10708,1,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,80012,,,CHEMBL624724,Intermediate,9606.0,,N,,F,6915,,622.0,Homo sapiens,1,,,A 172
,8975,4,BAO_0000224,Association constant against A2 adenosine receptor,104729,,,CHEMBL624725,Autocuration,9615.0,,H,,B,6916,,,Canis lupus familiaris,1,,,
,7645,1,BAO_0000219,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,80656,,,CHEMBL624726,Intermediate,,,N,,F,6917,,1085.0,fish,1,,,A2
,11377,5,BAO_0000224,Ratio of Ki for adenosine A2 and A1 receptor binding,104713,,,CHEMBL857535,Autocuration,10116.0,,D,,B,6918,,,Rattus norvegicus,1,,,
,13528,1,BAO_0000219,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,80014,,,CHEMBL624727,Expert,9606.0,,N,,F,6919,,623.0,Homo sapiens,1,,,A204
,10160,1,BAO_0000219,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,80014,,,CHEMBL624728,Expert,9606.0,,N,,F,6920,,623.0,Homo sapiens,1,,,A204
,15144,1,BAO_0000219,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,80015,,,CHEMBL624729,Intermediate,9606.0,,N,,F,6921,,404.0,Homo sapiens,1,,,A2058
,13160,1,BAO_0000219,Growth inhibition against Human squamous cell line(A 253),80657,,,CHEMBL624730,Intermediate,9606.0,,N,,F,6922,,973.0,Homo sapiens,1,,,A253 cell line
,12898,1,BAO_0000219,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,80657,,,CHEMBL624731,Intermediate,9606.0,,N,,F,6923,,973.0,Homo sapiens,1,,,A253 cell line
,13069,1,BAO_0000219,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,80657,,,CHEMBL624732,Intermediate,9606.0,,N,,F,6924,,973.0,Homo sapiens,1,,,A253 cell line
,15984,1,BAO_0000219,Growth inhibition of A253 cell lines.,80657,,,CHEMBL883245,Intermediate,9606.0,,N,,F,6925,,973.0,Homo sapiens,1,,,A253 cell line
,15564,1,BAO_0000219,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),80657,,,CHEMBL624733,Intermediate,9606.0,,N,,F,6926,,973.0,Homo sapiens,1,,,A253 cell line
,15564,1,BAO_0000219,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,80657,,,CHEMBL624734,Intermediate,9606.0,,N,,F,6927,,973.0,Homo sapiens,1,,,A253 cell line
,15564,1,BAO_0000219,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,80657,,,CHEMBL624735,Intermediate,9606.0,,N,,F,6928,,973.0,Homo sapiens,1,,,A253 cell line
,4720,1,BAO_0000219,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,81034,,,CHEMBL621780,Intermediate,9606.0,,N,,F,6929,,478.0,Homo sapiens,1,,,A2780
,16112,1,BAO_0000219,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,81034,,,CHEMBL877598,Intermediate,9606.0,,N,,F,6930,,478.0,Homo sapiens,1,,,A2780
,16597,1,BAO_0000219,Cytotoxic activity against A2780 human ovarian carcinoma cell line,81034,,,CHEMBL621781,Expert,9606.0,,N,,F,6931,,478.0,Homo sapiens,1,,,A2780
,16378,1,BAO_0000219,Cytotoxicity against human cancer cell lines A2780 (ovarian),81034,,,CHEMBL621782,Intermediate,9606.0,,N,,F,6932,,478.0,Homo sapiens,1,,,A2780
,16085,1,BAO_0000219,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,81034,,,CHEMBL621783,Expert,9606.0,,N,,F,6933,,478.0,Homo sapiens,1,,,A2780
,16317,1,BAO_0000219,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,81034,,,CHEMBL621784,Intermediate,9606.0,,N,,F,6934,,478.0,Homo sapiens,1,,,A2780
,15748,1,BAO_0000219,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),81034,,,CHEMBL621785,Intermediate,9606.0,,N,,F,6935,,478.0,Homo sapiens,1,,,A2780
,16597,1,BAO_0000219,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,81034,,,CHEMBL621968,Expert,9606.0,,N,,F,6936,,478.0,Homo sapiens,1,,,A2780
,16597,1,BAO_0000219,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,81034,,,CHEMBL621969,Expert,9606.0,,N,,F,6937,,478.0,Homo sapiens,1,,,A2780
,16597,1,BAO_0000219,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,81034,,,CHEMBL621970,Expert,9606.0,,N,,F,6938,,478.0,Homo sapiens,1,,,A2780
,15608,1,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,81034,,,CHEMBL621971,Intermediate,9606.0,,N,,F,6939,,478.0,Homo sapiens,1,,,A2780
,15608,1,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,81034,,,CHEMBL621972,Intermediate,9606.0,,N,,F,6940,,478.0,Homo sapiens,1,,,A2780
,15608,1,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,81034,,,CHEMBL884108,Intermediate,9606.0,,N,,F,6941,,478.0,Homo sapiens,1,,,A2780
,15296,0,BAO_0000019,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,22224,,,CHEMBL623826,Autocuration,10029.0,,U,,F,6942,,,Cricetulus griseus,1,,,
,10251,0,BAO_0000219,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,22224,,,CHEMBL623827,Autocuration,10029.0,,U,,A,6943,,185.0,Cricetulus griseus,1,,,CHO-AA8
,10251,0,BAO_0000219,Evaluated for growth inhibition of AA8 cells under aerobic conditions,22224,,,CHEMBL623828,Autocuration,10029.0,,U,,F,6944,,185.0,Cricetulus griseus,1,,,CHO-AA8
,10251,0,BAO_0000219,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,22224,,,CHEMBL623829,Autocuration,10029.0,,U,,F,6945,,185.0,Cricetulus griseus,1,,,CHO-AA8
,10251,0,BAO_0000219,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),22224,,,CHEMBL623830,Autocuration,10029.0,,U,,F,6946,,185.0,Cricetulus griseus,1,,,CHO-AA8
,11858,0,BAO_0000019,Growth inhibition against CHO-derived cell line AA8,22224,,,CHEMBL623831,Autocuration,10029.0,,U,,F,6947,,,Cricetulus griseus,1,,,
,11858,0,BAO_0000219,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],22224,,,CHEMBL623832,Autocuration,10029.0,,U,,F,6948,,185.0,Cricetulus griseus,1,,,CHO-AA8
,11616,1,BAO_0000219,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,80089,,,CHEMBL623833,Expert,36483.0,,N,,F,6949,,185.0,hampster,1,,,CHO-AA8
,11616,1,BAO_0000219,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,80089,,,CHEMBL623834,Expert,10029.0,,N,,F,6950,,185.0,Cricetulus griseus,1,,,CHO-AA8
,10518,0,BAO_0000219,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,22224,,,CHEMBL623835,Autocuration,10029.0,,U,,F,6951,,185.0,Cricetulus griseus,1,,,CHO-AA8
,11396,0,BAO_0000219,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,22224,,,CHEMBL623836,Autocuration,10029.0,,U,,F,6952,,185.0,Cricetulus griseus,1,,,CHO-AA8
,10518,0,BAO_0000219,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,22224,,,CHEMBL623837,Autocuration,10029.0,,U,,F,6953,,185.0,Cricetulus griseus,1,,,CHO-AA8
,11616,1,BAO_0000219,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,80089,,,CHEMBL623838,Expert,10029.0,,N,,F,6954,,185.0,Cricetulus griseus,1,,,CHO-AA8
,14837,8,BAO_0000019,compound was evaluated for association constant (Ka) of isolated serum protein AAG,12675,,,CHEMBL623839,Autocuration,,,H,,F,6955,,,,1,,,
,14837,8,BAO_0000019,Number of binding sites (n) of isolated serum protein AAG,12675,,,CHEMBL623840,Autocuration,,,H,,F,6956,,,,1,,,
,16037,3,BAO_0000225,Association constant for binding to AATT duplex,22222,,,CHEMBL623841,Intermediate,,,M,,B,6957,,,,1,,,
,16597,1,BAO_0000219,Inhibition of ABAE human fibroblast cell proliferation,100090,,,CHEMBL623842,Expert,9606.0,,N,,F,6958,,416.0,Homo sapiens,1,,,ABAE
,8831,1,BAO_0000218,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",80668,,,CHEMBL623843,Intermediate,10090.0,,N,,F,6959,,1064.0,Mus musculus,1,,,AC755
,13419,9,BAO_0000218,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,102444,,,CHEMBL618669,Expert,9986.0,,D,,F,6960,,,Oryctolagus cuniculus,1,,,
,13419,9,BAO_0000218,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,102444,In vivo,,CHEMBL618670,Expert,9986.0,,D,,F,6961,,,Oryctolagus cuniculus,1,,,
,15778,8,BAO_0000357,Inhibitory activity against angiotensin-converting enzyme (ACE).,69,,,CHEMBL618671,Autocuration,,,H,,B,6962,,,,1,,,
,15778,8,BAO_0000357,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,69,,,CHEMBL618672,Autocuration,,,H,,B,6963,,,,1,,,
,12988,1,BAO_0000219,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,80669,,,CHEMBL618673,Intermediate,9606.0,,N,,F,6964,,978.0,Homo sapiens,1,,,ACH-2 cell line
,12988,1,BAO_0000219,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),80669,,,CHEMBL618674,Intermediate,9606.0,,N,,F,6965,,978.0,Homo sapiens,1,,,ACH-2 cell line
,12988,0,BAO_0000219,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,22224,,,CHEMBL618675,Autocuration,11676.0,,U,,F,6966,,998.0,Human immunodeficiency virus 1,1,,,T cell line
,12988,0,BAO_0000219,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),22224,,,CHEMBL618676,Autocuration,11676.0,,U,,F,6967,,998.0,Human immunodeficiency virus 1,1,,,T cell line
,12988,0,BAO_0000219,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),22224,,,CHEMBL618677,Autocuration,11676.0,,U,,F,6968,,998.0,Human immunodeficiency virus 1,1,,,T cell line
,11843,1,BAO_0000219,Inhibition of growth of renal cancer ACHN cell line,80025,,,CHEMBL618678,Intermediate,9606.0,,N,,F,6969,,626.0,Homo sapiens,1,,,ACHN
,16939,1,BAO_0000219,Inhibition of growth of ACHN renal cancer cell line,80025,,,CHEMBL618679,Intermediate,9606.0,,N,,F,6970,,626.0,Homo sapiens,1,,,ACHN
,4782,1,BAO_0000219,Inhibitory concentration required against ACHN renal cancer cell line,80025,,,CHEMBL618680,Intermediate,9606.0,,N,,F,6971,,626.0,Homo sapiens,1,,,ACHN
,6310,1,BAO_0000219,Concentration required to inhibit growth of human renal (ACHN) cell line,80025,,,CHEMBL618681,Expert,9606.0,,N,,F,6972,,626.0,Homo sapiens,1,,,ACHN
,6310,1,BAO_0000219,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,80025,,,CHEMBL618682,Intermediate,9606.0,,N,,F,6973,,626.0,Homo sapiens,1,,,ACHN
,12858,1,BAO_0000219,Cytotoxic activity against ACHN Renal cancer cell line,80025,,,CHEMBL618683,Intermediate,9606.0,,N,,F,6974,,626.0,Homo sapiens,1,,,ACHN
,17380,1,BAO_0000219,Cytotoxicity evaluation against ACHN renal cancer cells,80025,,,CHEMBL618684,Intermediate,9606.0,,N,,F,6975,,626.0,Homo sapiens,1,,,ACHN
,5858,1,BAO_0000219,In vitro antitumor activity against human renal ACHN cell line,80025,,,CHEMBL618685,Intermediate,9606.0,,N,,F,6976,,626.0,Homo sapiens,1,,,ACHN
,3838,1,BAO_0000219,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,80025,,,CHEMBL876499,Intermediate,9606.0,,N,,F,6977,,626.0,Homo sapiens,1,,,ACHN
,3838,1,BAO_0000219,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,80025,,,CHEMBL618686,Intermediate,9606.0,,N,,F,6978,,626.0,Homo sapiens,1,,,ACHN
,5406,1,BAO_0000219,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",80025,,,CHEMBL618687,Intermediate,9606.0,,N,,F,6979,,626.0,Homo sapiens,1,,,ACHN
,4071,1,BAO_0000219,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,80025,,,CHEMBL618688,Intermediate,9606.0,,N,,F,6980,,626.0,Homo sapiens,1,,,ACHN
,4071,1,BAO_0000219,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,80025,,,CHEMBL618689,Expert,9606.0,,N,,F,6981,,626.0,Homo sapiens,1,,,ACHN
,4071,1,BAO_0000219,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,80025,,,CHEMBL618690,Intermediate,9606.0,,N,,F,6982,,626.0,Homo sapiens,1,,,ACHN
,15002,1,BAO_0000219,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,80025,,,CHEMBL618691,Intermediate,9606.0,,N,,F,6983,,626.0,Homo sapiens,1,,,ACHN
,14769,1,BAO_0000219,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),80025,,,CHEMBL619373,Intermediate,9606.0,,N,,F,6984,,626.0,Homo sapiens,1,,,ACHN
,13958,1,BAO_0000219,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",80025,,,CHEMBL884008,Intermediate,9606.0,,N,,F,6985,,626.0,Homo sapiens,1,,,ACHN
,1665,1,BAO_0000219,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,80025,,,CHEMBL619374,Intermediate,9606.0,,N,,F,6986,,626.0,Homo sapiens,1,,,ACHN
,15354,1,BAO_0000219,Compound was tested for the growth inhibition of ACHN renal tumor cell line,80025,,,CHEMBL619375,Intermediate,9606.0,,N,,F,6987,,626.0,Homo sapiens,1,,,ACHN
,15354,1,BAO_0000219,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,80025,,,CHEMBL619376,Intermediate,9606.0,,N,,F,6988,,626.0,Homo sapiens,1,,,ACHN
,13978,1,BAO_0000219,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,80025,,,CHEMBL619377,Intermediate,9606.0,,N,,F,6989,,626.0,Homo sapiens,1,,,ACHN
,6798,1,BAO_0000219,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,80025,,,CHEMBL619378,Intermediate,9606.0,,N,,F,6990,,626.0,Homo sapiens,1,,,ACHN
,2959,1,BAO_0000218,Tmax value after administration of 4 mg/Kg oral dose in dog,50588,In vivo,,CHEMBL872527,Intermediate,9615.0,,N,,A,6991,,,Canis lupus familiaris,1,,,
,9932,1,BAO_0000218,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",50588,,,CHEMBL876500,Intermediate,9615.0,,N,,A,6992,,,Canis lupus familiaris,1,,,
,5546,1,BAO_0000218,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,50588,,,CHEMBL619379,Intermediate,9615.0,,N,,A,6993,,,Canis lupus familiaris,1,,,
,16907,1,BAO_0000218,Volume distribution after 15 mg/kg iv dose in Dogs,50588,In vivo,,CHEMBL619538,Intermediate,9615.0,,N,,A,6994,,,Canis lupus familiaris,1,,,
,16907,1,BAO_0000218,Volume distribution after 30 mg/kg po dose in Dogs,50588,In vivo,,CHEMBL619539,Intermediate,9615.0,,N,,A,6995,,,Canis lupus familiaris,1,,,
,4257,1,BAO_0000218,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,50588,In vivo,,CHEMBL619540,Intermediate,9615.0,,N,,A,6996,,,Canis lupus familiaris,1,,,
,4305,1,BAO_0000218,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,50588,In vivo,,CHEMBL619541,Intermediate,9615.0,,N,,A,6997,,,Canis lupus familiaris,1,,,
,5472,1,BAO_0000218,Volume of distribution was evaluated in dog,50588,In vivo,,CHEMBL619542,Intermediate,9615.0,,N,,A,6998,,,Canis lupus familiaris,1,,,
,6062,1,BAO_0000218,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,50588,In vivo,,CHEMBL619543,Intermediate,9615.0,,N,,A,6999,,,Canis lupus familiaris,1,,,
,3598,1,BAO_0000218,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,,,CHEMBL619544,Expert,9615.0,,N,,A,7000,,,Canis lupus familiaris,1,,,
,12500,1,BAO_0000218,The compound was tested for volume of distribution in dog,50588,In vivo,,CHEMBL619545,Intermediate,9615.0,,N,,A,7001,,,Canis lupus familiaris,1,,,
,12500,1,BAO_0000218,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,50588,In vivo,,CHEMBL619546,Intermediate,9615.0,,N,,A,7002,,,Canis lupus familiaris,1,,,
,6227,1,BAO_0000218,Vd (1 mg/kg) was determined in dog (in vivo),50588,In vivo,,CHEMBL619547,Intermediate,9615.0,,N,,A,7003,,,Canis lupus familiaris,1,,,
,6227,1,BAO_0000218,Vd in dog,50588,In vivo,,CHEMBL619548,Intermediate,9615.0,,N,,A,7004,,,Canis lupus familiaris,1,,,
,4219,1,BAO_0000218,Volume distribution was determined,50588,In vivo,,CHEMBL619549,Intermediate,9615.0,,N,,A,7005,,,Canis lupus familiaris,1,,,
,1696,1,BAO_0000218,Volume of distribution in dog,50588,In vivo,,CHEMBL619550,Intermediate,9615.0,,N,,A,7006,,,Canis lupus familiaris,1,,,
,5542,1,BAO_0000218,Volume of distribution by as 4 fold increase by iv administration in dogs,50588,In vivo,,CHEMBL876501,Intermediate,9615.0,,N,,A,7007,,,Canis lupus familiaris,1,,,
,5199,1,BAO_0000218,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,50588,In vivo,,CHEMBL619551,Intermediate,9615.0,,N,,A,7008,,,Canis lupus familiaris,1,,,
,6348,1,BAO_0000218,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,In vivo,,CHEMBL619552,Intermediate,9615.0,,N,,A,7009,,,Canis lupus familiaris,1,,,
,4727,1,BAO_0000218,Volume distribution at the dose of 2 mg/kg in dog,50588,In vivo,,CHEMBL619553,Intermediate,9615.0,,N,,A,7010,,,Canis lupus familiaris,1,,,
,16367,1,BAO_0000218,Steady state volume of distribution was determined,50588,In vivo,,CHEMBL618722,Intermediate,9615.0,,N,,A,7011,,,Canis lupus familiaris,1,,,
,2652,1,BAO_0000218,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,50588,In vivo,,CHEMBL618723,Intermediate,9615.0,,N,,A,7012,,,Canis lupus familiaris,1,,,
,16452,1,BAO_0000218,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,50588,In vivo,,CHEMBL618724,Intermediate,9615.0,,N,,A,7013,,,Canis lupus familiaris,1,,,
,16452,1,BAO_0000218,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,50588,In vivo,,CHEMBL618725,Intermediate,9615.0,,N,,A,7014,,,Canis lupus familiaris,1,,,
,16452,1,BAO_0000218,Bioavailability in dog (dose 1 mg/kg i.v.),50588,In vivo,,CHEMBL618726,Intermediate,9615.0,,N,,A,7015,,,Canis lupus familiaris,1,,,
,5334,1,BAO_0000218,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),50588,In vivo,,CHEMBL618727,Intermediate,9615.0,,N,,A,7016,,,Canis lupus familiaris,1,,,
,4239,1,BAO_0000218,Pharmacokinetic property (vdss) was measured in dog,50588,In vivo,,CHEMBL624233,Intermediate,9615.0,,N,,A,7017,,,Canis lupus familiaris,1,,,
,4709,1,BAO_0000218,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,50588,In vivo,,CHEMBL624234,Intermediate,9615.0,,N,,A,7018,,,Canis lupus familiaris,1,,,
,5600,1,BAO_0000218,Vdss was determined after iv 0.1 mg/kg administration in dog,50588,In vivo,,CHEMBL624235,Intermediate,9615.0,,N,,A,7019,,,Canis lupus familiaris,1,,,
,6057,1,BAO_0000218,Volume displacement was calculated in dog,50588,In vivo,,CHEMBL624236,Intermediate,9615.0,,N,,A,7020,,,Canis lupus familiaris,1,,,
,5654,1,BAO_0000218,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,50588,In vivo,,CHEMBL624237,Intermediate,9615.0,,N,,A,7021,,,Canis lupus familiaris,1,,,
,5505,1,BAO_0000218,Volume distribution constant was determined,50588,In vivo,,CHEMBL624238,Intermediate,9615.0,,N,,A,7022,,,Canis lupus familiaris,1,,,
,4527,1,BAO_0000218,Volume distribution at a dose of 1 uM/kg in dog was determined,50588,In vivo,,CHEMBL624239,Intermediate,9615.0,,N,,A,7023,,,Canis lupus familiaris,1,,,
,4521,1,BAO_0000218,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,50588,In vivo,,CHEMBL875829,Intermediate,9615.0,,N,,A,7024,,,Canis lupus familiaris,1,,,
,4521,1,BAO_0000218,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,50588,In vivo,,CHEMBL624240,Intermediate,9615.0,,N,,A,7025,,,Canis lupus familiaris,1,,,
,15660,1,BAO_0000218,Volume distribution (Vdss) was measured in dog,50588,In vivo,,CHEMBL624241,Intermediate,9615.0,,N,,A,7026,,,Canis lupus familiaris,1,,,
,15660,1,BAO_0000218,Volume distribution (Vdss) was measured in dog,50588,In vivo,,CHEMBL624242,Intermediate,9615.0,,N,,A,7027,,,Canis lupus familiaris,1,,,
,6679,1,BAO_0000218,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50588,In vivo,,CHEMBL624243,Intermediate,9615.0,,N,,A,7028,,,Canis lupus familiaris,1,,,
,5145,1,BAO_0000218,Volume of distribution in steady state was determined in dog,50588,In vivo,,CHEMBL624244,Intermediate,9615.0,,N,,A,7029,,,Canis lupus familiaris,1,,,
,6821,1,BAO_0000218,Volume of distribution of compound was determined in dog,50588,In vivo,,CHEMBL624245,Intermediate,9615.0,,N,,A,7030,,,Canis lupus familiaris,1,,,
,4137,1,BAO_0000218,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,50588,In vivo,,CHEMBL624246,Intermediate,9615.0,,N,,A,7031,,,Canis lupus familiaris,1,,,
,5334,1,BAO_0000218,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),50588,In vivo,,CHEMBL624247,Intermediate,9615.0,,N,,A,7032,,,Canis lupus familiaris,1,,,
,15660,1,BAO_0000218,Volume of distribution (Vdss) was measured in dog,50588,In vivo,,CHEMBL624248,Intermediate,9615.0,,N,,A,7033,,,Canis lupus familiaris,1,,,
,6642,1,BAO_0000218,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,In vivo,,CHEMBL624249,Intermediate,9615.0,,N,,A,7034,,,Canis lupus familiaris,1,,,
,6641,1,BAO_0000218,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,In vivo,,CHEMBL624250,Intermediate,9615.0,,N,,A,7035,,,Canis lupus familiaris,1,,,
,6642,1,BAO_0000218,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,In vivo,,CHEMBL624251,Intermediate,9615.0,,N,,A,7036,,,Canis lupus familiaris,1,,,
,11659,1,BAO_0000218,Maximum rate of depolarization of the upstroke of the action potential,50588,,,CHEMBL624252,Intermediate,9615.0,,N,,A,7037,,,Canis lupus familiaris,1,,,
,6448,1,BAO_0000218,Steady state volume distribution in dog,50588,In vivo,,CHEMBL624253,Intermediate,9615.0,,N,,A,7038,,,Canis lupus familiaris,1,,,
,5474,1,BAO_0000218,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,50588,In vivo,,CHEMBL624950,Intermediate,9615.0,,N,,A,7039,,,Canis lupus familiaris,1,,,
,1466,1,BAO_0000218,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,50588,In vivo,,CHEMBL624951,Intermediate,9615.0,,N,,A,7040,,,Canis lupus familiaris,1,,,
,6535,1,BAO_0000218,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,50588,In vivo,,CHEMBL875830,Intermediate,9615.0,,N,,A,7041,,,Canis lupus familiaris,1,,,
,6535,1,BAO_0000218,Volume distribution in dog after administration of 1 mg/kg iv,50588,In vivo,,CHEMBL624952,Intermediate,9615.0,,N,,A,7042,,,Canis lupus familiaris,1,,,
,17764,1,BAO_0000218,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,50588,In vivo,,CHEMBL624953,Intermediate,9615.0,,N,,A,7043,,,Canis lupus familiaris,1,,,
,6215,1,BAO_0000218,Vss after intravenous administration (0.5 mg/kg) was determined in dog,50588,In vivo,,CHEMBL624954,Intermediate,9615.0,,N,,A,7044,,,Canis lupus familiaris,1,,,
,6505,1,BAO_0000218,Vss on i.v. administration of 2 mg/kg was measured in dog,50588,In vivo,,CHEMBL624955,Intermediate,9615.0,,N,,A,7045,,,Canis lupus familiaris,1,,,
,3639,1,BAO_0000218,Vss was determined,50588,,,CHEMBL624956,Intermediate,9615.0,,N,,A,7046,,,Canis lupus familiaris,1,,,
,3639,1,BAO_0000218,Vss in dog,50588,,,CHEMBL625129,Intermediate,9615.0,,N,,A,7047,,,Canis lupus familiaris,1,,,
,6062,1,BAO_0000218,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,50588,In vivo,,CHEMBL625130,Intermediate,9615.0,,N,,A,7048,,,Canis lupus familiaris,1,,,
,4942,1,BAO_0000218,Volume distribution in dogs,50588,In vivo,,CHEMBL625131,Intermediate,9615.0,,N,,A,7049,,,Canis lupus familiaris,1,,,
,17796,1,BAO_0000218,Volume of distribution in dog,50588,In vivo,,CHEMBL625132,Intermediate,9615.0,,N,,A,7050,,,Canis lupus familiaris,1,,,
,4883,1,BAO_0000218,Tested for the oral bioavailability in dog,50588,In vivo,,CHEMBL872263,Intermediate,9615.0,,N,,A,7051,,,Canis lupus familiaris,1,,,
,17837,1,BAO_0000218,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,50594,In vivo,,CHEMBL624336,Intermediate,10090.0,,N,,A,7060,,,Mus musculus,1,,,
,17729,1,BAO_0000218,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,50594,In vivo,,CHEMBL624337,Intermediate,10090.0,,N,,A,7061,,,Mus musculus,1,,,
,17729,1,BAO_0000218,Bioavailability after peroral administration of 50 mg/kg of dose in mice,50594,In vivo,,CHEMBL624338,Intermediate,10090.0,,N,,A,7062,,,Mus musculus,1,,,
,4239,1,BAO_0000218,Bioavailability was measured in mouse,50594,In vivo,,CHEMBL624339,Intermediate,10090.0,,N,,A,7063,,,Mus musculus,1,,,
,17592,1,BAO_0000218,Bioavailability in mouse,50594,In vivo,,CHEMBL624340,Intermediate,10090.0,,N,,A,7064,,,Mus musculus,1,,,
,6348,1,BAO_0000218,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,In vivo,,CHEMBL624341,Intermediate,10090.0,,N,,A,7065,,,Mus musculus,1,,,
,2801,1,BAO_0000218,Bioavailability in mouse,50594,In vivo,,CHEMBL624342,Intermediate,10090.0,,N,,A,7066,,,Mus musculus,1,,,
,2801,1,BAO_0000218,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,50594,In vivo,,CHEMBL624343,Intermediate,10090.0,,N,,A,7067,,,Mus musculus,1,,,
,17718,1,BAO_0000218,Oral bioavailability in mouse,50594,In vivo,,CHEMBL624344,Intermediate,10090.0,,N,,A,7068,,,Mus musculus,1,,,
,5727,1,BAO_0000218,Oral availability at 50 mg/kg po in male mice,50594,In vivo,,CHEMBL624345,Intermediate,10090.0,,N,,A,7069,,,Mus musculus,1,,,
,5302,1,BAO_0000218,Oral bioavailability in mouse (dose 10 mg/kg),50594,In vivo,,CHEMBL624346,Intermediate,10090.0,,N,,A,7070,,,Mus musculus,1,,,
,3598,1,BAO_0000218,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,50594,In vivo,,CHEMBL624347,Expert,10090.0,,N,,A,7071,,,Mus musculus,1,,,
,5961,1,BAO_0000218,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",50594,In vivo,,CHEMBL624348,Intermediate,10090.0,,N,,A,7072,,,Mus musculus,1,,,
,6091,1,BAO_0000218,Oral bioavailability in mouse,50594,In vivo,,CHEMBL622754,Intermediate,10090.0,,N,,A,7074,,,Mus musculus,1,,,
,6091,1,BAO_0000218,Oral bioavailability in vivo in mice;ND=Not determined,50594,In vivo,,CHEMBL622755,Intermediate,10090.0,,N,,A,7075,,,Mus musculus,1,,,
,5711,1,BAO_0000218,Oral bioavailability in mouse at 10 mg/kg of the compound,50594,In vivo,,CHEMBL622756,Intermediate,10090.0,,N,,A,7076,,,Mus musculus,1,,,
,17728,1,BAO_0000218,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),50594,In vivo,,CHEMBL622757,Intermediate,10090.0,,N,,A,7077,,,Mus musculus,1,,,
,17728,1,BAO_0000218,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),50594,In vivo,,CHEMBL622758,Intermediate,10090.0,,N,,A,7078,,,Mus musculus,1,,,
,3802,1,BAO_0000218,Tested for bioavailability of the compound,50594,In vivo,,CHEMBL622759,Intermediate,10090.0,,N,,A,7079,,,Mus musculus,1,,,
,3802,1,BAO_0000218,Tested for half life at the dose of 10 mg/kg when administered intravenously,50594,In vivo,,CHEMBL622760,Intermediate,10090.0,,N,,A,7080,,,Mus musculus,1,,,
,14029,1,BAO_0000218,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,50594,,Plasma,CHEMBL622761,Intermediate,10090.0,,N,,A,7081,,,Mus musculus,1,,1969.0,
,14029,1,BAO_0000218,The plasma half life of compound was determined on heparin prepared by human plasma. ,50594,,Plasma,CHEMBL622762,Intermediate,10090.0,,N,,A,7082,,,Mus musculus,1,,1969.0,
,14029,1,BAO_0000218,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,50594,,Plasma,CHEMBL622763,Intermediate,10090.0,,N,,A,7083,,,Mus musculus,1,,1969.0,
,14029,1,BAO_0000218,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,50594,,Plasma,CHEMBL622764,Intermediate,10090.0,,N,,A,7084,,,Mus musculus,1,,1969.0,
,14029,1,BAO_0000218,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,50594,,Plasma,CHEMBL622765,Intermediate,10090.0,,N,,A,7085,,,Mus musculus,1,,1969.0,
,17753,1,BAO_0000218,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,50594,,,CHEMBL622766,Intermediate,10090.0,,N,,F,7086,,,Mus musculus,1,,,
,17753,1,BAO_0000218,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,50594,,,CHEMBL622767,Intermediate,10090.0,,N,,A,7087,,,Mus musculus,1,,,
,17753,1,BAO_0000218,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,50594,,,CHEMBL622768,Intermediate,10090.0,,N,,A,7088,,,Mus musculus,1,,,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,In vivo,Blood,CHEMBL875948,Intermediate,10090.0,,N,,A,7089,,,Mus musculus,1,,178.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,In vivo,Blood,CHEMBL622769,Intermediate,10090.0,,N,,A,7090,,,Mus musculus,1,,178.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,In vivo,Blood,CHEMBL622770,Intermediate,10090.0,,N,,A,7091,,,Mus musculus,1,,178.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,In vivo,Blood,CHEMBL622771,Intermediate,10090.0,,N,,A,7092,,,Mus musculus,1,,178.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,In vivo,Blood,CHEMBL622772,Intermediate,10090.0,,N,,A,7093,,,Mus musculus,1,,178.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,In vivo,Blood,CHEMBL622773,Intermediate,10090.0,,N,,A,7094,,,Mus musculus,1,,178.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,In vivo,Blood,CHEMBL622774,Intermediate,10090.0,,N,,A,7095,,,Mus musculus,1,,178.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,In vivo,Bone,CHEMBL621725,Intermediate,10090.0,,N,,A,7096,,,Mus musculus,1,,10000001.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,50594,In vivo,Bone,CHEMBL621726,Intermediate,10090.0,,N,,A,7097,,,Mus musculus,1,,10000001.0,
,15608,1,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,81034,,,CHEMBL621727,Intermediate,9606.0,,N,,F,7098,,478.0,Homo sapiens,1,,,A2780
,3290,1,BAO_0000219,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,81034,,,CHEMBL622413,Expert,9606.0,,N,,F,7099,,478.0,Homo sapiens,1,,,A2780
,2859,1,BAO_0000219,Compound was evaluated for cytotoxicity against A2780 cell line,81034,,,CHEMBL622414,Intermediate,9606.0,,N,,F,7100,,478.0,Homo sapiens,1,,,A2780
,15688,1,BAO_0000219,Inhibition of A2780 cell clonogenic assay,81034,,,CHEMBL622415,Expert,9606.0,,N,,F,7101,,478.0,Homo sapiens,1,,,A2780
,5642,1,BAO_0000219,Cytotoxic effect on ovarian cancer cell line (A2780),81034,,,CHEMBL884001,Expert,9606.0,,N,,F,7102,,478.0,Homo sapiens,1,,,A2780
,6633,1,BAO_0000219,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,81034,,,CHEMBL622416,Intermediate,9606.0,,N,,F,7103,,478.0,Homo sapiens,1,,,A2780
,3906,1,BAO_0000219,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",81034,,,CHEMBL622417,Intermediate,9606.0,,N,,F,7104,,478.0,Homo sapiens,1,,,A2780
,6788,1,BAO_0000219,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,81034,,,CHEMBL622590,Expert,9606.0,,N,,F,7105,,478.0,Homo sapiens,1,,,A2780
,17582,1,BAO_0000219,Antiproliferative activity against human A2780 cells,81034,,,CHEMBL622591,Expert,9606.0,,N,,F,7106,,478.0,Homo sapiens,1,,,A2780
,17764,1,BAO_0000219,Inhibition of human A2780 cell proliferation,81034,,,CHEMBL622592,Expert,9606.0,,N,,F,7107,,478.0,Homo sapiens,1,,,A2780
,17764,1,BAO_0000219,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,81034,,,CHEMBL622593,Expert,9606.0,,N,,F,7108,,478.0,Homo sapiens,1,,,A2780
,17764,1,BAO_0000219,Inhibition of human A2780 cell proliferation (No data),81034,,,CHEMBL622594,Expert,9606.0,,N,,F,7109,,478.0,Homo sapiens,1,,,A2780
,2815,1,BAO_0000219,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,81034,,,CHEMBL622595,Intermediate,9606.0,,N,,F,7110,,478.0,Homo sapiens,1,,,A2780
,16930,1,BAO_0000219,Compound was evaluated against human Ovarian carcinoma cell line A2780,81034,,,CHEMBL622596,Intermediate,9606.0,,N,,F,7111,,478.0,Homo sapiens,1,,,A2780
,17777,1,BAO_0000219,Growth inhibition against A2780 wild-type ovarian cell lines,81034,,,CHEMBL622597,Expert,9606.0,,N,,F,7112,,478.0,Homo sapiens,1,,,A2780
,17777,1,BAO_0000219,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,81034,,,CHEMBL622598,Intermediate,9606.0,,N,,F,7113,,478.0,Homo sapiens,1,,,A2780
,16936,5,BAO_0000019,Inhibition of tubulin polymerization in human ovarian cancer cell lines,104766,,,CHEMBL622599,Autocuration,9606.0,,D,,F,7114,,,Homo sapiens,1,,,
,13759,1,BAO_0000219,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,81034,,,CHEMBL622600,Intermediate,9606.0,,N,,F,7115,,478.0,Homo sapiens,1,,,A2780
,13759,1,BAO_0000219,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,81034,,,CHEMBL622601,Intermediate,9606.0,,N,,F,7116,,478.0,Homo sapiens,1,,,A2780
,13759,1,BAO_0000219,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,81034,,,CHEMBL622602,Intermediate,9606.0,,N,,F,7117,,478.0,Homo sapiens,1,,,A2780
,13759,1,BAO_0000219,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,81034,,,CHEMBL622603,Intermediate,9606.0,,N,,F,7118,,478.0,Homo sapiens,1,,,A2780
,15292,1,BAO_0000219,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,81034,,,CHEMBL622604,Intermediate,9606.0,,N,,F,7119,,478.0,Homo sapiens,1,,,A2780
,15292,1,BAO_0000219,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,81034,,,CHEMBL622605,Intermediate,9606.0,,N,,F,7120,,478.0,Homo sapiens,1,,,A2780
,15069,1,BAO_0000219,In vitro inhibition of human ovarian cell line A2780,81034,,,CHEMBL622606,Expert,9606.0,,N,,F,7121,,478.0,Homo sapiens,1,,,A2780
,15069,1,BAO_0000219,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",81034,,,CHEMBL619463,Expert,9606.0,,N,,F,7122,,478.0,Homo sapiens,1,,,A2780
,14073,1,BAO_0000219,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),81034,,,CHEMBL619464,Intermediate,9606.0,,N,,F,7123,,478.0,Homo sapiens,1,,,A2780
,14553,1,BAO_0000219,Concentration required to inhibit A2780-cell growth by 50%,81034,,,CHEMBL619465,Expert,9606.0,,N,,F,7124,,478.0,Homo sapiens,1,,,A2780
,13040,1,BAO_0000219,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,81034,,,CHEMBL619466,Expert,9606.0,,N,,F,7125,,478.0,Homo sapiens,1,,,A2780
,6891,1,BAO_0000219,Cytotoxic effect on human ovarian (A2780) cancer cell line,81034,,,CHEMBL619467,Expert,9606.0,,N,,F,7126,,478.0,Homo sapiens,1,,,A2780
,15569,1,BAO_0000219,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,81034,,,CHEMBL619468,Intermediate,9606.0,,N,,F,7127,,478.0,Homo sapiens,1,,,A2780
,14190,1,BAO_0000219,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,81034,,,CHEMBL619469,Expert,9606.0,,N,,F,7128,,478.0,Homo sapiens,1,,,A2780
,15014,1,BAO_0000219,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,81034,,,CHEMBL619470,Expert,9606.0,,N,,F,7129,,478.0,Homo sapiens,1,,,A2780
,15014,1,BAO_0000219,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,81034,,,CHEMBL619471,Intermediate,9606.0,,N,,F,7130,,478.0,Homo sapiens,1,,,A2780
,17496,1,BAO_0000219,Cytotoxicity against human ovarian carcinoma A2780 cell line,81034,,,CHEMBL619472,Intermediate,9606.0,,N,,F,7131,,478.0,Homo sapiens,1,,,A2780
,13617,1,BAO_0000219,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",81034,,,CHEMBL619473,Intermediate,9606.0,,N,,F,7132,,478.0,Homo sapiens,1,,,A2780
,13617,1,BAO_0000219,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",81034,,,CHEMBL874368,Intermediate,9606.0,,N,,F,7133,,478.0,Homo sapiens,1,,,A2780
,13617,1,BAO_0000219,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",81034,,,CHEMBL884003,Intermediate,9606.0,,N,,F,7134,,478.0,Homo sapiens,1,,,A2780
,13617,1,BAO_0000219,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",81034,,,CHEMBL622690,Intermediate,9606.0,,N,,F,7135,,478.0,Homo sapiens,1,,,A2780
,17672,1,BAO_0000219,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,81034,,,CHEMBL622691,Intermediate,9606.0,,N,,F,7136,,478.0,Homo sapiens,1,,,A2780
,4544,1,BAO_0000219,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,81034,,,CHEMBL622692,Intermediate,9606.0,,N,,F,7137,,478.0,Homo sapiens,1,,,A2780
,4544,1,BAO_0000219,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,81034,,,CHEMBL623406,Intermediate,9606.0,,N,,F,7138,,478.0,Homo sapiens,1,,,A2780
,16317,1,BAO_0000219,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",81034,,,CHEMBL884004,Intermediate,9606.0,,N,,F,7139,,478.0,Homo sapiens,1,,,A2780
,15099,1,BAO_0000219,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,81034,,,CHEMBL623407,Intermediate,9606.0,,N,,F,7140,,478.0,Homo sapiens,1,,,A2780
,13978,1,BAO_0000219,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,81034,,,CHEMBL623408,Intermediate,9606.0,,N,,F,7141,,478.0,Homo sapiens,1,,,A2780
,12989,1,BAO_0000219,In vitro antitumor activity against A2780 cell line.,81034,,,CHEMBL623409,Expert,9606.0,,N,,F,7142,,478.0,Homo sapiens,1,,,A2780
,5574,1,BAO_0000219,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,81034,,,CHEMBL623410,Intermediate,9606.0,,N,,F,7143,,478.0,Homo sapiens,1,,,A2780
,13528,1,BAO_0000219,In vitro cytotoxicity against A2780 human ovarian cancer cell line,81034,,,CHEMBL623576,Expert,9606.0,,N,,F,7144,,478.0,Homo sapiens,1,,,A2780
,12782,1,BAO_0000219,Inhibitory activity against kidney A-CHN tumor cell growth in culture,80025,,,CHEMBL623577,Intermediate,9606.0,,N,,F,7145,,626.0,Homo sapiens,1,,,ACHN
,14255,1,BAO_0000219,The IC50 value was measured on ACHN cell line in renal tumor type.,80025,,,CHEMBL623578,Intermediate,9606.0,,N,,F,7146,,626.0,Homo sapiens,1,,,ACHN
,16364,1,BAO_0000219,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,80025,,,CHEMBL623579,Intermediate,9606.0,,N,,F,7147,,626.0,Homo sapiens,1,,,ACHN
,17376,1,BAO_0000219,In vitro lethal concentration against most sensitive ACHN cell line,80025,,,CHEMBL623580,Expert,9606.0,,N,,F,7148,,626.0,Homo sapiens,1,,,ACHN
,12016,1,BAO_0000219,Tested for cytotoxic activity against renal cancer ACHN cell line,80025,,,CHEMBL623581,Intermediate,9606.0,,N,,F,7149,,626.0,Homo sapiens,1,,,ACHN
,6058,1,BAO_0000219,Compound tested for growth inhibition of renal cancer cell line ACHN,80025,,,CHEMBL857456,Intermediate,9606.0,,N,,F,7150,,626.0,Homo sapiens,1,,,ACHN
,17708,1,BAO_0000219,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,80025,,,CHEMBL623582,Intermediate,9606.0,,N,,F,7151,,626.0,Homo sapiens,1,,,ACHN
,15176,1,BAO_0000219,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,80025,,,CHEMBL623583,Intermediate,9606.0,,N,,F,7152,,626.0,Homo sapiens,1,,,ACHN
,2806,1,BAO_0000219,In vitro anticancer activity against ACHN renal cancer cell line,80025,,,CHEMBL623584,Intermediate,9606.0,,N,,F,7153,,626.0,Homo sapiens,1,,,ACHN
,15300,1,BAO_0000219,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,80025,,,CHEMBL623585,Intermediate,9606.0,,N,,F,7154,,626.0,Homo sapiens,1,,,ACHN
,16364,1,BAO_0000219,Percent selectivity was evaluated in renal ACHN cell lines,80025,,,CHEMBL623586,Intermediate,9606.0,,N,,F,7155,,626.0,Homo sapiens,1,,,ACHN
,13859,1,BAO_0000219,In vitro inhibitory activity against renal ACHN cancer cell line,80025,,,CHEMBL623587,Intermediate,9606.0,,N,,F,7156,,626.0,Homo sapiens,1,,,ACHN
,11970,1,BAO_0000219,Tested for cytotoxicity against ACHN cell lines in renal cancer,80025,,,CHEMBL875279,Intermediate,9606.0,,N,,F,7157,,626.0,Homo sapiens,1,,,ACHN
,2450,1,BAO_0000219,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,80025,,,CHEMBL623588,Intermediate,9606.0,,N,,F,7158,,626.0,Homo sapiens,1,,,ACHN
,12696,1,BAO_0000219,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,80025,,,CHEMBL623589,Intermediate,9606.0,,N,,F,7159,,626.0,Homo sapiens,1,,,ACHN
,12400,1,BAO_0000219,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,80025,,,CHEMBL623590,Intermediate,9606.0,,N,,F,7160,,626.0,Homo sapiens,1,,,ACHN
,12888,1,BAO_0000219,Cytotoxic effect on renal cancer line ACHN,80025,,,CHEMBL623591,Expert,9606.0,,N,,F,7161,,626.0,Homo sapiens,1,,,ACHN
,3156,1,BAO_0000219,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,80025,,,CHEMBL623592,Intermediate,9606.0,,N,,F,7162,,626.0,Homo sapiens,1,,,ACHN
,3381,1,BAO_0000219,In vitro inhibition of Renal Cancer ACHN cell lines,80025,,,CHEMBL623593,Intermediate,9606.0,,N,,F,7163,,626.0,Homo sapiens,1,,,ACHN
,16747,1,BAO_0000219,Antitumor activity against human renal adenocarcinoma ACHN cells,80025,,,CHEMBL623594,Intermediate,9606.0,,N,,F,7164,,626.0,Homo sapiens,1,,,ACHN
,16748,1,BAO_0000219,Antitumor activity against human renal adenocarcinoma ACHN cells.,80025,,,CHEMBL621833,Expert,9606.0,,N,,F,7165,,626.0,Homo sapiens,1,,,ACHN
,12062,1,BAO_0000219,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,80025,,,CHEMBL621834,Intermediate,9606.0,,N,,F,7166,,626.0,Homo sapiens,1,,,ACHN
,14769,1,BAO_0000219,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),80025,,,CHEMBL621835,Intermediate,9606.0,,N,,F,7167,,626.0,Homo sapiens,1,,,ACHN
,15895,1,BAO_0000219,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",80025,,,CHEMBL621836,Intermediate,9606.0,,N,,F,7168,,626.0,Homo sapiens,1,,,ACHN
,17376,1,BAO_0000219,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,80025,,,CHEMBL621837,Intermediate,9606.0,,N,,F,7169,,626.0,Homo sapiens,1,,,ACHN
,14882,1,BAO_0000219,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,80025,,,CHEMBL875280,Intermediate,9606.0,,N,,F,7170,,626.0,Homo sapiens,1,,,ACHN
,14882,1,BAO_0000219,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,80025,,,CHEMBL621838,Intermediate,9606.0,,N,,F,7171,,626.0,Homo sapiens,1,,,ACHN
,15661,1,BAO_0000219,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,80025,,,CHEMBL621839,Intermediate,9606.0,,N,,F,7172,,626.0,Homo sapiens,1,,,ACHN
,9680,0,BAO_0000019,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,22224,,,CHEMBL621840,Autocuration,,,U,,A,7173,,,,1,,,
,14579,8,BAO_0000019,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,10647,,,CHEMBL621841,Autocuration,,,H,,F,7174,,,,1,,,
,17290,1,BAO_0000218,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,50529,,,CHEMBL622979,Expert,10358.0,,N,,F,7175,,468.0,Cytomegalovirus,1,,,HEL
,17290,1,BAO_0000218,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,50529,,,CHEMBL876595,Intermediate,10358.0,,N,,F,7176,,,Cytomegalovirus,1,,,
,15891,8,BAO_0000357,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),12159,,,CHEMBL620221,Autocuration,,,H,,B,7177,,,,1,,,
,15890,8,BAO_0000357,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),12159,,,CHEMBL620222,Autocuration,,,H,,B,7178,,,,1,,,
,3801,1,BAO_0000219,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,80670,,,CHEMBL620506,Intermediate,9913.0,,N,,F,7179,,979.0,Bos taurus,1,,,ADDP cell line
,9222,1,BAO_0000219,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,80671,,,CHEMBL620507,Intermediate,10090.0,,N,,F,7180,,980.0,Mus musculus,1,,,ADJ/PC6
,9222,1,BAO_0000219,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,80671,,,CHEMBL620508,Intermediate,10090.0,,N,,F,7181,,980.0,Mus musculus,1,,,ADJ/PC6
,7257,1,BAO_0000219,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",80671,,,CHEMBL620509,Intermediate,10090.0,,N,,F,7182,,980.0,Mus musculus,1,,,ADJ/PC6
,7257,1,BAO_0000219,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,80671,,,CHEMBL620510,Intermediate,10090.0,,N,,F,7183,,980.0,Mus musculus,1,,,ADJ/PC6
,7257,1,BAO_0000219,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,80671,,,CHEMBL620511,Intermediate,10090.0,,N,,A,7184,,980.0,Mus musculus,1,,,ADJ/PC6
,8084,1,BAO_0000219,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,80671,,,CHEMBL620512,Intermediate,10090.0,,N,,F,7185,,980.0,Mus musculus,1,,,ADJ/PC6
,14943,0,BAO_0000019,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,22224,,,CHEMBL620513,Autocuration,10090.0,,U,,F,7186,,,Mus musculus,1,,,
,14943,0,BAO_0000019,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,22224,,,CHEMBL620514,Autocuration,10090.0,,U,,F,7187,,,Mus musculus,1,,,
,14943,0,BAO_0000019,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,22224,,,CHEMBL620515,Autocuration,10090.0,,U,,F,7188,,,Mus musculus,1,,,
,10524,0,BAO_0000218,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),22224,In vivo,,CHEMBL620516,Autocuration,1423.0,,U,,A,7189,,,Bacillus subtilis,1,,,
,3546,1,BAO_0000218,AUC value in dog after IV administration at a dose of 5 mg/kg,50588,,Plasma,CHEMBL620517,Intermediate,9615.0,,N,,A,7190,,,Canis lupus familiaris,1,,1969.0,
,3546,1,BAO_0000218,AUC value in dog after oral administration at a dose of 5 mg/kg,50588,,Plasma,CHEMBL620518,Intermediate,9615.0,,N,,A,7191,,,Canis lupus familiaris,1,,1969.0,
,3546,1,BAO_0000218,Cmax value in dog after oral administration at a dose of 5 mg/kg,50588,In vivo,,CHEMBL620519,Intermediate,9615.0,,N,,A,7192,,,Canis lupus familiaris,1,,,
,3546,1,BAO_0000218,Bioavailability in dog after oral administration at a dose of 5 mg/kg,50588,In vivo,,CHEMBL621386,Intermediate,9615.0,,N,,A,7193,,,Canis lupus familiaris,1,,,
,3546,1,BAO_0000218,Tmax value in dog after oral administration at a dose of 5 mg/kg,50588,In vivo,,CHEMBL621387,Intermediate,9615.0,,N,,A,7194,,,Canis lupus familiaris,1,,,
,3184,1,BAO_0000218,Compound was evaluated for its clearance when administered intravenously in dog,50588,In vivo,,CHEMBL621388,Intermediate,9615.0,,N,,A,7195,,,Canis lupus familiaris,1,,,
,16456,1,BAO_0000218,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,50588,In vivo,,CHEMBL621389,Intermediate,9615.0,,N,,A,7196,,,Canis lupus familiaris,1,,,
,4809,1,BAO_0000218,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),50588,In vivo,,CHEMBL621390,Intermediate,9615.0,,N,,A,7197,,,Canis lupus familiaris,1,,,
,4219,0,BAO_0000100,Calculated partition coefficient (clogP),22229,,,CHEMBL621391,Intermediate,,,U,,P,7198,,,,1,,,
,3748,1,BAO_0000218,Half life in dog,50588,,,CHEMBL621392,Intermediate,9615.0,,N,,A,7199,,,Canis lupus familiaris,1,,,
,3132,1,BAO_0000218,Time taken for EC90 was determined when tested in dog,50588,,,CHEMBL621393,Intermediate,9615.0,,N,,A,7200,,,Canis lupus familiaris,1,,,
,4219,1,BAO_0000218,Half life (iv) was determined,50588,,,CHEMBL621394,Intermediate,9615.0,,N,,A,7201,,,Canis lupus familiaris,1,,,
,16907,1,BAO_0000218,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,50588,,Liver,CHEMBL621395,Intermediate,9615.0,,N,,A,7202,,,Canis lupus familiaris,1,,2107.0,
,6057,1,BAO_0000218,Area under the curve was calculated in dog after iv administration,50588,,,CHEMBL621396,Intermediate,9615.0,,N,,A,7203,,,Canis lupus familiaris,1,,,
,6057,1,BAO_0000218,Area under the curve was calculated in dog after peroral administration,50588,,,CHEMBL621397,Intermediate,9615.0,,N,,A,7204,,,Canis lupus familiaris,1,,,
,17853,1,BAO_0000218,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,50588,,,CHEMBL621398,Intermediate,9615.0,,N,,A,7205,,,Canis lupus familiaris,1,,,
,3639,1,BAO_0000218,pKa was evaluated in dog,50588,,,CHEMBL618818,Intermediate,9615.0,,N,,A,7206,,,Canis lupus familiaris,1,,,
,14541,1,BAO_0000218,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,50588,,,CHEMBL618819,Intermediate,9615.0,,N,,A,7207,,,Canis lupus familiaris,1,,,
,16456,1,BAO_0000218,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,50588,In vivo,,CHEMBL618820,Intermediate,9615.0,,N,,A,7208,,,Canis lupus familiaris,1,,,
,16456,1,BAO_0000218,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,50588,In vivo,,CHEMBL873810,Intermediate,9615.0,,N,,A,7209,,,Canis lupus familiaris,1,,,
,2652,1,BAO_0000218,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,50588,In vivo,,CHEMBL876606,Intermediate,9615.0,,N,,A,7210,,,Canis lupus familiaris,1,,,
,3624,1,BAO_0000218,Compound was evaluated for the half-life (t 1/2) in hours,50588,,,CHEMBL618821,Intermediate,9615.0,,N,,A,7211,,,Canis lupus familiaris,1,,,
,1337,1,BAO_0000218,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,50588,In vivo,Blood,CHEMBL618822,Intermediate,9615.0,,N,,A,7212,,,Canis lupus familiaris,1,,178.0,
,1337,1,BAO_0000218,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,50588,In vivo,Blood,CHEMBL618823,Intermediate,9615.0,,N,,A,7213,,,Canis lupus familiaris,1,,178.0,
,4709,1,BAO_0000218,Half life after intravenous administration of 1 mg/kg in dog,50588,In vivo,,CHEMBL618824,Intermediate,9615.0,,N,,A,7214,,,Canis lupus familiaris,1,,,
,15660,1,BAO_0000218,Half life was measured in dog,50588,,,CHEMBL618825,Intermediate,9615.0,,N,,A,7215,,,Canis lupus familiaris,1,,,
,5302,1,BAO_0000218,Half life period in dog after 5 mg/kg dose,50588,In vivo,,CHEMBL618826,Intermediate,9615.0,,N,,A,7216,,,Canis lupus familiaris,1,,,
,17791,1,BAO_0000218,Half life period was evaluated in dog; 4-4.8,50588,,,CHEMBL618827,Intermediate,9615.0,,N,,A,7217,,,Canis lupus familiaris,1,,,
,6348,1,BAO_0000218,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,In vivo,,CHEMBL618828,Intermediate,9615.0,,N,,A,7218,,,Canis lupus familiaris,1,,,
,4257,1,BAO_0000218,Half-life was determined in dog after a3 mg/kg of iv dose,50588,In vivo,,CHEMBL618829,Intermediate,9615.0,,N,,A,7219,,,Canis lupus familiaris,1,,,
,3771,1,BAO_0000218,Half-life was determined,50588,,,CHEMBL618830,Intermediate,9615.0,,N,,A,7220,,,Canis lupus familiaris,1,,,
,6305,1,BAO_0000218,Half life in dogs,50588,,,CHEMBL618831,Intermediate,9615.0,,N,,A,7221,,,Canis lupus familiaris,1,,,
,13501,1,BAO_0000218,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,50588,In vivo,Plasma,CHEMBL619489,Intermediate,9615.0,,N,,A,7222,,,Canis lupus familiaris,1,,1969.0,
,17594,1,BAO_0000218,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,50588,In vivo,,CHEMBL619649,Intermediate,9615.0,,N,,A,7223,,,Canis lupus familiaris,1,,,
,3045,1,BAO_0000218,Compound was evaluated for the half life period after iv administration in Beagle dog.,50588,In vivo,,CHEMBL876607,Intermediate,9615.0,,N,,A,7224,,,Canis lupus familiaris,1,,,
,3043,1,BAO_0000218,Compound was evaluated for the half life period after oral administration in conscious dog.,50588,In vivo,,CHEMBL619650,Intermediate,9615.0,,N,,A,7225,,,Canis lupus familiaris,1,,,
,4839,1,BAO_0000218,Compound was tested for half life in dog,50588,,,CHEMBL619651,Intermediate,9615.0,,N,,A,7226,,,Canis lupus familiaris,1,,,
,4839,1,BAO_0000218,Compound was tested for its half life in dog,50588,,,CHEMBL619652,Intermediate,9615.0,,N,,A,7227,,,Canis lupus familiaris,1,,,
,5802,1,BAO_0000218,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,50588,In vivo,,CHEMBL619653,Intermediate,9615.0,,N,,A,7228,,,Canis lupus familiaris,1,,,
,17839,1,BAO_0000218,Half life of compound in dog was determined,50588,,,CHEMBL619654,Intermediate,9615.0,,N,,A,7229,,,Canis lupus familiaris,1,,,
,4219,1,BAO_0000218,Half life (iv) was determined,50588,In vivo,,CHEMBL619655,Intermediate,9615.0,,N,,A,7230,,,Canis lupus familiaris,1,,,
,13966,1,BAO_0000218,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),50588,,Blood,CHEMBL619656,Intermediate,9615.0,,N,,A,7231,,,Canis lupus familiaris,1,,178.0,
,3994,1,BAO_0000218,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,50588,In vivo,Plasma,CHEMBL873812,Intermediate,9615.0,,N,,A,7232,,,Canis lupus familiaris,1,,1969.0,
,3994,1,BAO_0000218,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,50588,In vivo,Plasma,CHEMBL621365,Intermediate,9615.0,,N,,F,7233,,,Canis lupus familiaris,1,,1969.0,
,4453,1,BAO_0000218,Half life in dog,50588,,,CHEMBL621366,Intermediate,9615.0,,N,,A,7234,,,Canis lupus familiaris,1,,,
,6535,1,BAO_0000218,Half life in dog plasma,50588,,Plasma,CHEMBL621367,Intermediate,9615.0,,N,,A,7235,,,Canis lupus familiaris,1,,1969.0,
,6535,1,BAO_0000218,Half life in dog plasma after administration of 0.25 mg/kg iv,50588,In vivo,Plasma,CHEMBL621368,Intermediate,9615.0,,N,,A,7236,,,Canis lupus familiaris,1,,1969.0,
,6535,1,BAO_0000218,Half life in dog plasma after administration of 1 mg/kg iv,50588,In vivo,Plasma,CHEMBL621369,Intermediate,9615.0,,N,,A,7237,,,Canis lupus familiaris,1,,1969.0,
,3132,1,BAO_0000218,Half life in dog plasma was determined at dose 10 mg/kg,50588,In vivo,Plasma,CHEMBL621370,Intermediate,9615.0,,N,,A,7238,,,Canis lupus familiaris,1,,1969.0,
,5374,1,BAO_0000218,Half life in dog was determined,50588,,,CHEMBL621371,Intermediate,9615.0,,N,,A,7239,,,Canis lupus familiaris,1,,,
,5007,1,BAO_0000218,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),50588,In vivo,,CHEMBL621372,Intermediate,9615.0,,N,,A,7240,,,Canis lupus familiaris,1,,,
,16907,1,BAO_0000218,Half life upon exposure to human plasma,50588,,Plasma,CHEMBL621373,Intermediate,9615.0,,N,,A,7241,,,Canis lupus familiaris,1,,1969.0,
,6057,1,BAO_0000218,Half life was calculated in dog,50588,,,CHEMBL621374,Intermediate,9615.0,,N,,A,7242,,,Canis lupus familiaris,1,,,
,5006,1,BAO_0000218,Half life was determined,50588,,,CHEMBL621375,Intermediate,9615.0,,N,,A,7243,,,Canis lupus familiaris,1,,,
,5473,1,BAO_0000218,Half life was determined,50588,,,CHEMBL621376,Intermediate,9615.0,,N,,A,7244,,,Canis lupus familiaris,1,,,
,4368,1,BAO_0000218,Half life by intravenous administration of 1.2 mg/kg in dog,50588,In vivo,,CHEMBL619624,Intermediate,9615.0,,N,,A,7245,,,Canis lupus familiaris,1,,,
,6448,1,BAO_0000218,Half life in dog,50588,,,CHEMBL875840,Intermediate,9615.0,,N,,A,7246,,,Canis lupus familiaris,1,,,
,4353,1,BAO_0000218,Half life in dog after intra venous administration of the compound,50588,,,CHEMBL619625,Intermediate,9615.0,,N,,A,7247,,,Canis lupus familiaris,1,,,
,4353,1,BAO_0000218,Half life in dog after intra venous administration of the compound; ND means Not determined,50588,,,CHEMBL619626,Intermediate,9615.0,,N,,A,7248,,,Canis lupus familiaris,1,,,
,4353,1,BAO_0000218,Half life in dog after po administration of the compound,50588,In vivo,,CHEMBL619627,Intermediate,9615.0,,N,,A,7249,,,Canis lupus familiaris,1,,,
,4353,1,BAO_0000218,Half life in dog after po administration of the compound; ND means Not determined,50588,In vivo,,CHEMBL873817,Intermediate,9615.0,,N,,A,7250,,,Canis lupus familiaris,1,,,
,6265,1,BAO_0000218,Half life in dog at the single oral dose of 1 mg/kg,50588,In vivo,,CHEMBL619628,Intermediate,9615.0,,N,,A,7251,,,Canis lupus familiaris,1,,,
,5006,1,BAO_0000218,Half life in dogs,50588,,,CHEMBL619629,Intermediate,9615.0,,N,,A,7252,,,Canis lupus familiaris,1,,,
,5356,1,BAO_0000218,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,50588,In vivo,,CHEMBL619630,Intermediate,9615.0,,N,,A,7253,,,Canis lupus familiaris,1,,,
,405,1,BAO_0000218,Half life in rat,50588,,,CHEMBL619631,Intermediate,9615.0,,N,,A,7254,,,Canis lupus familiaris,1,,,
,6642,1,BAO_0000218,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,In vivo,,CHEMBL619632,Intermediate,9615.0,,N,,A,7255,,,Canis lupus familiaris,1,,,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,In vivo,Bone,CHEMBL619633,Intermediate,10090.0,,N,,A,7256,,,Mus musculus,1,,10000001.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,In vivo,Bone,CHEMBL875841,Intermediate,10090.0,,N,,A,7257,,,Mus musculus,1,,10000001.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,In vivo,Bone,CHEMBL619634,Intermediate,10090.0,,N,,A,7258,,,Mus musculus,1,,10000001.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,In vivo,Bone,CHEMBL619635,Intermediate,10090.0,,N,,A,7259,,,Mus musculus,1,,10000001.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,In vivo,Bone,CHEMBL619636,Intermediate,10090.0,,N,,A,7260,,,Mus musculus,1,,10000001.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,In vivo,Gut,CHEMBL619637,Intermediate,10090.0,,N,,A,7261,,,Mus musculus,1,,10000004.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,In vivo,Gut,CHEMBL619638,Intermediate,10090.0,,N,,A,7262,,,Mus musculus,1,,10000004.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,In vivo,Gut,CHEMBL619639,Intermediate,10090.0,,N,,A,7263,,,Mus musculus,1,,10000004.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,In vivo,Gut,CHEMBL619640,Intermediate,10090.0,,N,,A,7264,,,Mus musculus,1,,10000004.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,In vivo,Gut,CHEMBL619641,Intermediate,10090.0,,N,,A,7265,,,Mus musculus,1,,10000004.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,In vivo,Gut,CHEMBL619642,Intermediate,10090.0,,N,,A,7266,,,Mus musculus,1,,10000004.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,In vivo,Gut,CHEMBL619643,Intermediate,10090.0,,N,,A,7267,,,Mus musculus,1,,10000004.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,In vivo,Heart,CHEMBL619644,Intermediate,10090.0,,N,,A,7268,,,Mus musculus,1,,948.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,In vivo,Heart,CHEMBL621112,Intermediate,10090.0,,N,,A,7269,,,Mus musculus,1,,948.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,In vivo,Heart,CHEMBL621113,Intermediate,10090.0,,N,,A,7270,,,Mus musculus,1,,948.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,In vivo,Heart,CHEMBL621114,Intermediate,10090.0,,N,,A,7271,,,Mus musculus,1,,948.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,In vivo,Heart,CHEMBL621115,Intermediate,10090.0,,N,,A,7272,,,Mus musculus,1,,948.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,In vivo,Heart,CHEMBL621116,Intermediate,10090.0,,N,,A,7273,,,Mus musculus,1,,948.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,In vivo,Heart,CHEMBL621117,Intermediate,10090.0,,N,,A,7274,,,Mus musculus,1,,948.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,In vivo,Kidney,CHEMBL621118,Intermediate,10090.0,,N,,A,7275,,,Mus musculus,1,,2113.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,50594,In vivo,Kidney,CHEMBL621119,Intermediate,10090.0,,N,,A,7276,,,Mus musculus,1,,2113.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,In vivo,Kidney,CHEMBL621120,Intermediate,10090.0,,N,,A,7277,,,Mus musculus,1,,2113.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,In vivo,Kidney,CHEMBL621757,Intermediate,10090.0,,N,,A,7278,,,Mus musculus,1,,2113.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,In vivo,Kidney,CHEMBL621758,Intermediate,10090.0,,N,,A,7279,,,Mus musculus,1,,2113.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,In vivo,Kidney,CHEMBL621759,Intermediate,10090.0,,N,,A,7280,,,Mus musculus,1,,2113.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,In vivo,Kidney,CHEMBL621760,Intermediate,10090.0,,N,,A,7281,,,Mus musculus,1,,2113.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,In vivo,Liver,CHEMBL621761,Intermediate,10090.0,,N,,A,7282,,,Mus musculus,1,,2107.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,In vivo,Liver,CHEMBL621762,Intermediate,10090.0,,N,,A,7283,,,Mus musculus,1,,2107.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,In vivo,Liver,CHEMBL621763,Intermediate,10090.0,,N,,A,7284,,,Mus musculus,1,,2107.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,In vivo,Liver,CHEMBL624502,Intermediate,10090.0,,N,,A,7285,,,Mus musculus,1,,2107.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,In vivo,Liver,CHEMBL624503,Intermediate,10090.0,,N,,A,7286,,,Mus musculus,1,,2107.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,In vivo,Liver,CHEMBL624504,Intermediate,10090.0,,N,,A,7287,,,Mus musculus,1,,2107.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,In vivo,Liver,CHEMBL624505,Intermediate,10090.0,,N,,A,7288,,,Mus musculus,1,,2107.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,In vivo,Lung,CHEMBL624506,Intermediate,10090.0,,N,,A,7289,,,Mus musculus,1,,2048.0,
,5895,1,BAO_0000219,In vitro cytotoxicity against A2780 (human ovarian cancer),81034,,,CHEMBL624507,Intermediate,9606.0,,N,,F,7290,,478.0,Homo sapiens,1,,,A2780
,6338,1,BAO_0000219,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,81034,,,CHEMBL624508,Intermediate,9606.0,,N,,F,7291,,478.0,Homo sapiens,1,,,A2780
,15163,1,BAO_0000219,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,81034,,,CHEMBL624509,Intermediate,9606.0,,N,,F,7292,,478.0,Homo sapiens,1,,,A2780
,15163,1,BAO_0000219,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,81034,,,CHEMBL624510,Intermediate,9606.0,,N,,F,7293,,478.0,Homo sapiens,1,,,A2780
,15000,1,BAO_0000219,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,81034,,,CHEMBL875956,Expert,9606.0,,N,,F,7294,,478.0,Homo sapiens,1,,,A2780
,15000,1,BAO_0000219,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,81034,,,CHEMBL839885,Expert,9606.0,,N,,F,7295,,478.0,Homo sapiens,1,,,A2780
,14729,1,BAO_0000219,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,81034,,,CHEMBL624511,Expert,9606.0,,N,,F,7296,,478.0,Homo sapiens,1,,,A2780
,17270,1,BAO_0000219,In vitro cytotoxicity against A2780 cell line,81034,,,CHEMBL624512,Intermediate,9606.0,,N,,F,7297,,478.0,Homo sapiens,1,,,A2780
,5685,1,BAO_0000219,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,81034,,,CHEMBL624513,Intermediate,9606.0,,N,,F,7298,,478.0,Homo sapiens,1,,,A2780
,3563,1,BAO_0000219,In vitro inhibitory activity against human ovarian cancer A2780 cell line,81034,,,CHEMBL624514,Intermediate,9606.0,,N,,F,7299,,478.0,Homo sapiens,1,,,A2780
,17753,1,BAO_0000218,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,81034,,,CHEMBL618547,Intermediate,9606.0,,N,,F,7300,,478.0,Homo sapiens,1,,,A2780
,16317,1,BAO_0000219,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",81034,,,CHEMBL618548,Intermediate,9606.0,,N,,F,7301,,478.0,Homo sapiens,1,,,A2780
,16936,1,BAO_0000219,Inhibition of tubulin polymerization in analogy of ca.,81034,,,CHEMBL618549,Intermediate,9606.0,,N,,F,7302,,478.0,Homo sapiens,1,,,A2780
,3801,1,BAO_0000219,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,81034,,,CHEMBL618550,Intermediate,9606.0,,N,,F,7303,,478.0,Homo sapiens,1,,,A2780
,6181,1,BAO_0000219,Cytotoxic effect in ovarian cancer cell line (A2780),81034,,,CHEMBL618551,Expert,9606.0,,N,,F,7304,,478.0,Homo sapiens,1,,,A2780
,5318,1,BAO_0000219,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,81034,,,CHEMBL618552,Intermediate,9606.0,,N,,F,7305,,478.0,Homo sapiens,1,,,A2780
,4840,1,BAO_0000219,Tested for the cytotoxicity in A2780 ovarian cell line,81034,,,CHEMBL618553,Intermediate,9606.0,,N,,F,7306,,478.0,Homo sapiens,1,,,A2780
,15748,1,BAO_0000219,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),81034,,,CHEMBL618554,Intermediate,9606.0,,N,,F,7307,,478.0,Homo sapiens,1,,,A2780
,15748,1,BAO_0000219,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,81034,,,CHEMBL618555,Intermediate,9606.0,,N,,F,7308,,478.0,Homo sapiens,1,,,A2780
,15748,1,BAO_0000219,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,80017,,,CHEMBL618556,Intermediate,,,N,,F,7309,,481.0,,1,,,A2780cisR
,15748,1,BAO_0000219,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),80017,,,CHEMBL618557,Intermediate,,,N,,F,7310,,481.0,,1,,,A2780cisR
,15748,1,BAO_0000219,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,80017,,,CHEMBL618558,Intermediate,,,N,,F,7311,,481.0,,1,,,A2780cisR
,15748,1,BAO_0000219,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),80017,,,CHEMBL618559,Intermediate,,,N,,F,7312,,481.0,,1,,,A2780cisR
,17753,1,BAO_0000218,In vivo log of cells killed after administration of compound in A2780 cell line,81034,,,CHEMBL618560,Intermediate,9606.0,,N,,F,7313,,478.0,Homo sapiens,1,,,A2780
,17753,1,BAO_0000218,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,81034,In vivo,,CHEMBL618561,Intermediate,9606.0,,N,,F,7314,,478.0,Homo sapiens,1,,,A2780
,16936,1,BAO_0000219,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,81034,,,CHEMBL618562,Intermediate,9606.0,,N,,F,7315,,478.0,Homo sapiens,1,,,A2780
,16936,1,BAO_0000219,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,81034,,,CHEMBL618563,Intermediate,9606.0,,N,,F,7316,,478.0,Homo sapiens,1,,,A2780
,16936,1,BAO_0000219,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,81034,,,CHEMBL618564,Intermediate,9606.0,,N,,F,7317,,478.0,Homo sapiens,1,,,A2780
,16936,1,BAO_0000219,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,81034,,,CHEMBL618565,Intermediate,9606.0,,N,,F,7318,,478.0,Homo sapiens,1,,,A2780
,17528,1,BAO_0000218,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),81034,,,CHEMBL618566,Intermediate,9606.0,,N,,F,7319,,478.0,Homo sapiens,1,,,A2780
,6633,1,BAO_0000219,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,81034,,,CHEMBL618567,Intermediate,9606.0,,N,,F,7320,,478.0,Homo sapiens,1,,,A2780
,15000,1,BAO_0000219,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,81034,,,CHEMBL618568,Expert,9606.0,,N,,F,7321,,478.0,Homo sapiens,1,,,A2780
,17528,1,BAO_0000219,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,81034,,,CHEMBL618569,Expert,9606.0,,N,,F,7322,,478.0,Homo sapiens,1,,,A2780
,16936,1,BAO_0000219,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,81034,,,CHEMBL621857,Intermediate,9606.0,,N,,F,7323,,478.0,Homo sapiens,1,,,A2780
,16936,1,BAO_0000219,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,81034,,,CHEMBL621858,Intermediate,9606.0,,N,,F,7324,,478.0,Homo sapiens,1,,,A2780
,16936,1,BAO_0000219,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,81034,,,CHEMBL621859,Intermediate,9606.0,,N,,F,7325,,478.0,Homo sapiens,1,,,A2780
,16936,1,BAO_0000219,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",81034,,,CHEMBL621860,Intermediate,9606.0,,N,,F,7326,,478.0,Homo sapiens,1,,,A2780
,16936,1,BAO_0000219,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),81034,,,CHEMBL621861,Intermediate,9606.0,,N,,F,7327,,478.0,Homo sapiens,1,,,A2780
,16936,1,BAO_0000219,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",81034,,,CHEMBL621862,Expert,9606.0,,N,,F,7328,,478.0,Homo sapiens,1,,,A2780
,16936,1,BAO_0000219,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),81034,,,CHEMBL621863,Intermediate,9606.0,,N,,F,7329,,478.0,Homo sapiens,1,,,A2780
,16936,1,BAO_0000219,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),81034,,,CHEMBL621864,Intermediate,9606.0,,N,,F,7330,,478.0,Homo sapiens,1,,,A2780
,16936,1,BAO_0000219,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),81034,,,CHEMBL621865,Intermediate,9606.0,,N,,F,7331,,478.0,Homo sapiens,1,,,A2780
,17737,1,BAO_0000219,In vitro antiproliferative activity against A2780 cell line,81034,,,CHEMBL621866,Intermediate,10090.0,,N,,F,7332,,478.0,Mus musculus,1,,,A2780
,17764,1,BAO_0000219,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,81034,,,CHEMBL621867,Expert,10090.0,,N,,F,7333,,478.0,Mus musculus,1,,,A2780
,3830,1,BAO_0000219,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,81034,,,CHEMBL621868,Intermediate,9606.0,,N,,F,7334,,478.0,Homo sapiens,1,,,A2780
,3829,1,BAO_0000219,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,81034,,,CHEMBL875282,Intermediate,9606.0,,N,,F,7335,,478.0,Homo sapiens,1,,,A2780
,3546,1,BAO_0000218,Vc value in dog after IV administration at a dose of 5 mg/kg,50588,,,CHEMBL621869,Intermediate,9615.0,,N,,A,7336,,,Canis lupus familiaris,1,,,
,3546,1,BAO_0000218,Half life period in dog after IV administration at a dose of 5 mg/kg,50588,In vivo,,CHEMBL621870,Intermediate,9615.0,,N,,A,7337,,,Canis lupus familiaris,1,,,
,5668,0,BAO_0000019,Area under curve was determine after peroral administration at 10 mpk in Rhesus,22224,,,CHEMBL621871,Autocuration,9527.0,,U,,A,7338,,,Cercopithecidae,1,,,
,3443,0,BAO_0000218,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,,Plasma,CHEMBL621243,Autocuration,9527.0,,U,,A,7339,,,Cercopithecidae,1,,1969.0,
,3443,0,BAO_0000218,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,,Plasma,CHEMBL621244,Autocuration,9527.0,,U,,A,7340,,,Cercopithecidae,1,,1969.0,
,4256,0,BAO_0000218,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,22224,In vivo,,CHEMBL621245,Autocuration,9541.0,,U,,A,7341,,,Macaca fascicularis,1,,,
,4256,0,BAO_0000218,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,22224,In vivo,,CHEMBL621246,Autocuration,9541.0,,U,,A,7342,,,Macaca fascicularis,1,,,
,4256,0,BAO_0000218,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,22224,In vivo,,CHEMBL621247,Autocuration,9541.0,,U,,A,7343,,,Macaca fascicularis,1,,,
,4256,0,BAO_0000218,Oral Bioavailability in rat,22224,In vivo,,CHEMBL618386,Autocuration,10116.0,,U,,A,7344,,,Rattus norvegicus,1,,,
,1916,0,BAO_0000218,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,,,CHEMBL618387,Autocuration,9527.0,,U,,A,7345,,,Cercopithecidae,1,,,
,5302,0,BAO_0000218,Area under curve value in monkey at a dose of 5 mg/kg,22224,,,CHEMBL618388,Autocuration,9527.0,,U,,A,7346,,,Cercopithecidae,1,,,
,4257,0,BAO_0000218,Area under curve was determined in monkey after a 3 mg/kg of oral dose,22224,,,CHEMBL618389,Autocuration,9527.0,,U,,A,7347,,,Cercopithecidae,1,,,
,5355,0,BAO_0000019,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,22224,,,CHEMBL618574,Autocuration,9527.0,,U,,A,7348,,,Cercopithecidae,1,,,
,5355,0,BAO_0000019,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,22224,,,CHEMBL618575,Autocuration,9527.0,,U,,A,7349,,,Cercopithecidae,1,,,
,5355,0,BAO_0000019,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,22224,,,CHEMBL618576,Autocuration,9527.0,,U,,A,7350,,,Cercopithecidae,1,,,
,6078,0,BAO_0000218,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,22224,,,CHEMBL618577,Autocuration,9527.0,,U,,A,7351,,,Cercopithecidae,1,,,
,6078,0,BAO_0000218,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,22224,,,CHEMBL876487,Autocuration,9527.0,,U,,A,7352,,,Cercopithecidae,1,,,
,6062,0,BAO_0000218,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,22224,,,CHEMBL618578,Autocuration,9527.0,,U,,A,7353,,,Cercopithecidae,1,,,
,2661,0,BAO_0000218,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,22224,,,CHEMBL618579,Autocuration,9527.0,,U,,A,7354,,,Cercopithecidae,1,,,
,2661,0,BAO_0000019,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,22224,,,CHEMBL618580,Autocuration,9527.0,,U,,A,7355,,,Cercopithecidae,1,,,
,5394,0,BAO_0000218,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,22224,,,CHEMBL618581,Autocuration,9527.0,,U,,A,7356,,,Cercopithecidae,1,,,
,4397,0,BAO_0000218,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,22224,,,CHEMBL618582,Autocuration,9527.0,,U,,A,7357,,,Cercopithecidae,1,,,
,17509,0,BAO_0000218,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,22224,,,CHEMBL618583,Autocuration,9527.0,,U,,A,7358,,,Cercopithecidae,1,,,
,17509,0,BAO_0000218,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,22224,,,CHEMBL618584,Autocuration,9527.0,,U,,A,7359,,,Cercopithecidae,1,,,
,6641,0,BAO_0000218,Oral AUCN in monkey (dosed at 0.5 mpk iv ),22224,In vivo,,CHEMBL618585,Autocuration,9527.0,,U,,A,7360,,,Cercopithecidae,1,,,
,5355,0,BAO_0000218,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),22224,,,CHEMBL618586,Autocuration,9527.0,,U,,A,7361,,,Cercopithecidae,1,,,
,3443,0,BAO_0000218,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,In vivo,,CHEMBL618587,Autocuration,9527.0,,U,,A,7362,,,Cercopithecidae,1,,,
,3443,0,BAO_0000218,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,In vivo,,CHEMBL618588,Autocuration,9527.0,,U,,A,7363,,,Cercopithecidae,1,,,
,17409,0,BAO_0000019,Binding towards monkey plasma protein at 10 uM,22224,,,CHEMBL618589,Autocuration,9527.0,,U,,A,7364,,,Cercopithecidae,1,,,
,17409,0,BAO_0000019,Binding towards monkey plasma protein at 100 uM,22224,,,CHEMBL618590,Autocuration,9527.0,,U,,A,7365,,,Cercopithecidae,1,,,
,1052,0,BAO_0000218,Apparent bioavailability in squirrel monkey was determined,22224,In vivo,,CHEMBL872262,Autocuration,9527.0,,U,,A,7366,,,Cercopithecidae,1,,,
,13501,0,BAO_0000218,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,22224,In vivo,,CHEMBL618591,Autocuration,9527.0,,U,,A,7367,,,Cercopithecidae,1,,,
,17509,0,BAO_0000218,Bioavailability in monkey (dose 2 mg/kg),22224,In vivo,,CHEMBL618592,Autocuration,9443.0,,U,,A,7368,,,monkey,1,,,
,5394,0,BAO_0000218,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,22224,In vivo,,CHEMBL876488,Autocuration,9527.0,,U,,A,7369,,,Cercopithecidae,1,,,
,2661,0,BAO_0000218,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,22224,In vivo,,CHEMBL618593,Autocuration,9527.0,,U,,A,7370,,,Cercopithecidae,1,,,
,11219,0,BAO_0000218,Bioavailability in monkey (i.d. dosing),22224,In vivo,,CHEMBL618594,Autocuration,9443.0,,U,,A,7371,,,monkey,1,,,
,3045,0,BAO_0000218,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,22224,In vivo,,CHEMBL618595,Autocuration,9527.0,,U,,A,7372,,,Cercopithecidae,1,,,
,17796,0,BAO_0000019,Clearance of the drug was measured in cynomolgus,22224,,,CHEMBL621469,Autocuration,9527.0,,U,,A,7373,,,Cercopithecidae,1,,,
,1399,0,BAO_0000218,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,22224,In vivo,,CHEMBL621470,Autocuration,9527.0,,U,,A,7374,,,Cercopithecidae,1,,,
,2661,0,BAO_0000218,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,22224,In vivo,,CHEMBL621471,Autocuration,9527.0,,U,,A,7375,,,Cercopithecidae,1,,,
,5005,0,BAO_0000218,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,In vivo,Plasma,CHEMBL621472,Autocuration,9544.0,,U,,A,7376,,,Macaca mulatta,1,,1969.0,
,17267,0,BAO_0000218,Plasma clearance in rhesus monkey was determined,22224,In vivo,,CHEMBL621473,Autocuration,9527.0,,U,,A,7377,,,Cercopithecidae,1,,,
,6535,0,BAO_0000218,Plasma clearance in monkey after administration of 1 mg/kg iv,22224,In vivo,,CHEMBL621474,Autocuration,9527.0,,U,,A,7378,,,Cercopithecidae,1,,,
,5922,0,BAO_0000218,Plasma clearance in cynomolgus monkey,22224,In vivo,,CHEMBL621475,Autocuration,9527.0,,U,,A,7379,,,Cercopithecidae,1,,,
,6221,0,BAO_0000218,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,22224,In vivo,,CHEMBL621476,Autocuration,9527.0,,U,,A,7380,,,Cercopithecidae,1,,,
,5668,0,BAO_0000218,Plasma clearance after peroral administration at 10 mpk in Rhesus,22224,In vivo,,CHEMBL624290,Autocuration,9527.0,,U,,A,7381,,,Cercopithecidae,1,,,
,5355,0,BAO_0000218,The total clearance was determined after intravenous administration in cynomolgus monkeys,22224,In vivo,,CHEMBL624291,Autocuration,9527.0,,U,,A,7382,,,Cercopithecidae,1,,,
,5355,0,BAO_0000218,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,22224,In vivo,,CHEMBL624292,Autocuration,9527.0,,U,,A,7383,,,Cercopithecidae,1,,,
,5355,0,BAO_0000218,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,22224,In vivo,,CHEMBL624293,Autocuration,9527.0,,U,,A,7384,,,Cercopithecidae,1,,,
,4578,0,BAO_0000218,Tested for Clearance upon iv administration to african green monkey,22224,In vivo,,CHEMBL624294,Autocuration,9527.0,,U,,A,7385,,,Cercopithecidae,1,,,
,17592,0,BAO_0000218,Clearance in monkey,22224,In vivo,,CHEMBL624295,Autocuration,9527.0,,U,,A,7386,,,Cercopithecidae,1,,,
,6641,1,BAO_0000218,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,In vivo,,CHEMBL624296,Intermediate,9615.0,,N,,A,7387,,,Canis lupus familiaris,1,,,
,6642,1,BAO_0000218,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,In vivo,,CHEMBL624297,Intermediate,9615.0,,N,,A,7388,,,Canis lupus familiaris,1,,,
,16367,1,BAO_0000218,Half life was evaluated after intravenous administration to dogs,50588,In vivo,,CHEMBL624298,Intermediate,9615.0,,N,,A,7389,,,Canis lupus familiaris,1,,,
,5472,1,BAO_0000218,Half life was evaluated in dog,50588,,,CHEMBL624299,Intermediate,9615.0,,N,,A,7390,,,Canis lupus familiaris,1,,,
,5474,1,BAO_0000218,Half life was evaluated in dog,50588,,,CHEMBL624300,Intermediate,9615.0,,N,,A,7391,,,Canis lupus familiaris,1,,,
,5654,1,BAO_0000218,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,50588,In vivo,,CHEMBL624301,Intermediate,9615.0,,N,,A,7392,,,Canis lupus familiaris,1,,,
,6227,1,BAO_0000218,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),50588,In vivo,,CHEMBL624302,Intermediate,9615.0,,N,,A,7393,,,Canis lupus familiaris,1,,,
,6227,1,BAO_0000218,Half life period after intravenous administration in dog,50588,In vivo,,CHEMBL876026,Intermediate,9615.0,,N,,A,7394,,,Canis lupus familiaris,1,,,
,6221,1,BAO_0000218,Half life period after oral administration (2.5 mg/kg) in dog was determined,50588,In vivo,,CHEMBL624303,Intermediate,9615.0,,N,,A,7395,,,Canis lupus familiaris,1,,,
,4527,1,BAO_0000218,Half life period at a dose of 1 uM/kg in dog was determined,50588,,,CHEMBL624304,Intermediate,9615.0,,N,,A,7396,,,Canis lupus familiaris,1,,,
,5668,1,BAO_0000218,Half life period was determine after peroral administration at 10 mpk in dog,50588,In vivo,,CHEMBL624305,Intermediate,9615.0,,N,,A,7397,,,Canis lupus familiaris,1,,,
,5668,1,BAO_0000218,Half life period was determine after peroral administration at 5 mpk in dog,50588,In vivo,,CHEMBL624306,Intermediate,9615.0,,N,,A,7398,,,Canis lupus familiaris,1,,,
,3854,1,BAO_0000218,Half life period was determined,50588,,,CHEMBL624307,Intermediate,9615.0,,N,,A,7399,,,Canis lupus familiaris,1,,,
,5505,1,BAO_0000218,Half life period was determined,50588,,,CHEMBL624308,Intermediate,9615.0,,N,,A,7400,,,Canis lupus familiaris,1,,,
,6251,1,BAO_0000218,Half life period by iv administration in dog at a dose of 6 mg/kg,50588,In vivo,,CHEMBL624309,Intermediate,9615.0,,N,,A,7401,,,Canis lupus familiaris,1,,,
,1918,1,BAO_0000218,Half life period was evaluated in dog,50588,,,CHEMBL624310,Intermediate,9615.0,,N,,A,7402,,,Canis lupus familiaris,1,,,
,5546,1,BAO_0000218,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,50588,In vivo,,CHEMBL625003,Intermediate,9615.0,,N,,A,7403,,,Canis lupus familiaris,1,,,
,4809,1,BAO_0000218,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),50588,In vivo,,CHEMBL625004,Intermediate,9615.0,,N,,A,7404,,,Canis lupus familiaris,1,,,
,6215,1,BAO_0000218,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,50588,In vivo,,CHEMBL625005,Intermediate,9615.0,,N,,A,7405,,,Canis lupus familiaris,1,,,
,4527,1,BAO_0000218,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,50588,In vivo,,CHEMBL873813,Intermediate,9615.0,,N,,A,7406,,,Canis lupus familiaris,1,,,
,17594,1,BAO_0000218,Half-life after oral dose of compound at 3 mg/kg in dogs,50588,In vivo,,CHEMBL625006,Intermediate,9615.0,,N,,A,7407,,,Canis lupus familiaris,1,,,
,17839,1,BAO_0000218,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,50588,In vivo,,CHEMBL625007,Intermediate,9615.0,,N,,A,7408,,,Canis lupus familiaris,1,,,
,17839,1,BAO_0000218,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,50588,In vivo,,CHEMBL876027,Intermediate,9615.0,,N,,A,7409,,,Canis lupus familiaris,1,,,
,17839,1,BAO_0000218,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,50588,In vivo,,CHEMBL625008,Intermediate,9615.0,,N,,A,7410,,,Canis lupus familiaris,1,,,
,17839,1,BAO_0000218,Half-life of compound in dog following p.o. administration of 1 mg/kg,50588,In vivo,,CHEMBL625009,Intermediate,9615.0,,N,,A,7411,,,Canis lupus familiaris,1,,,
,5210,1,BAO_0000218,Half-life of compound in plasma of dog was determined,50588,,Plasma,CHEMBL625010,Intermediate,9615.0,,N,,A,7412,,,Canis lupus familiaris,1,,1969.0,
,5210,1,BAO_0000218,Half-life of compound was determined in dogs,50588,,,CHEMBL625011,Intermediate,9615.0,,N,,A,7413,,,Canis lupus familiaris,1,,,
,2959,1,BAO_0000218,Half-life after administration of 4 mg/Kg oral dose in dog,50588,In vivo,,CHEMBL621553,Intermediate,9615.0,,N,,A,7414,,,Canis lupus familiaris,1,,,
,4137,1,BAO_0000218,Half-life after intravenous administration of 1 mg/kg/h in dog,50588,In vivo,,CHEMBL621554,Intermediate,9615.0,,N,,A,7415,,,Canis lupus familiaris,1,,,
,5064,1,BAO_0000218,Half-life in Dog,50588,,,CHEMBL621555,Intermediate,9615.0,,N,,A,7416,,,Canis lupus familiaris,1,,,
,5147,1,BAO_0000218,Half-life in Dog,50588,,,CHEMBL621556,Intermediate,9615.0,,N,,A,7417,,,Canis lupus familiaris,1,,,
,5145,1,BAO_0000218,Half-life in dog,50588,,,CHEMBL621557,Intermediate,9615.0,,N,,A,7418,,,Canis lupus familiaris,1,,,
,6123,1,BAO_0000218,Half-life in dog after oral administration at 1 mg/kg,50588,In vivo,,CHEMBL621558,Intermediate,9615.0,,N,,A,7419,,,Canis lupus familiaris,1,,,
,6123,1,BAO_0000218,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,50588,In vivo,,CHEMBL621559,Intermediate,9615.0,,N,,A,7420,,,Canis lupus familiaris,1,,,
,4333,1,BAO_0000218,Half-life in dogs,50588,,,CHEMBL621560,Intermediate,9615.0,,N,,A,7421,,,Canis lupus familiaris,1,,,
,4333,1,BAO_0000218,Half-life in dogs; ND indicates not determined,50588,,,CHEMBL876028,Intermediate,9615.0,,N,,A,7422,,,Canis lupus familiaris,1,,,
,12500,1,BAO_0000218,Half-life in plasma of dog,50588,,Plasma,CHEMBL621561,Intermediate,9615.0,,N,,A,7423,,,Canis lupus familiaris,1,,1969.0,
,12500,1,BAO_0000218,Half-life in plasma of dog at dose of 3-10 mgkg,50588,,Plasma,CHEMBL621562,Intermediate,9615.0,,N,,A,7424,,,Canis lupus familiaris,1,,1969.0,
,6005,1,BAO_0000218,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,50588,In vivo,,CHEMBL621563,Intermediate,9615.0,,N,,A,7425,,,Canis lupus familiaris,1,,,
,6062,1,BAO_0000218,Half-life was measured in dog after an iv dose of 1 mg/kg,50588,In vivo,,CHEMBL621564,Intermediate,9615.0,,N,,A,7426,,,Canis lupus familiaris,1,,,
,17650,1,BAO_0000218,Half-life was measured in dogs after an oral dose of 10 uM/kg,50588,In vivo,,CHEMBL621565,Intermediate,9615.0,,N,,A,7427,,,Canis lupus familiaris,1,,,
,5530,1,BAO_0000218,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,50588,In vivo,,CHEMBL621566,Intermediate,9615.0,,N,,A,7428,,,Canis lupus familiaris,1,,,
,5530,1,BAO_0000218,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,50588,In vivo,,CHEMBL621567,Intermediate,9615.0,,N,,A,7429,,,Canis lupus familiaris,1,,,
,5600,1,BAO_0000218,Half-life of the compound after 0.3 mg/kg po administration in dog,50588,In vivo,,CHEMBL622978,Intermediate,9615.0,,N,,A,7430,,,Canis lupus familiaris,1,,,
,6039,1,BAO_0000218,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,50588,In vivo,,CHEMBL873814,Intermediate,9615.0,,N,,A,7431,,,Canis lupus familiaris,1,,,
,6039,1,BAO_0000218,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,50588,In vivo,,CHEMBL623219,Intermediate,9615.0,,N,,A,7432,,,Canis lupus familiaris,1,,,
,6039,1,BAO_0000218,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,50588,In vivo,,CHEMBL624477,Intermediate,9615.0,,N,,A,7433,,,Canis lupus familiaris,1,,,
,6227,1,BAO_0000218,t1/2 in dog,50588,,,CHEMBL624478,Intermediate,9615.0,,N,,A,7434,,,Canis lupus familiaris,1,,,
,14541,1,BAO_0000218,Half-life period measured in dogs,50588,,,CHEMBL624479,Intermediate,9615.0,,N,,A,7435,,,Canis lupus familiaris,1,,,
,4521,1,BAO_0000218,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,50588,In vivo,,CHEMBL624480,Intermediate,9615.0,,N,,A,7436,,,Canis lupus familiaris,1,,,
,4521,1,BAO_0000218,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,50588,In vivo,,CHEMBL623595,Intermediate,9615.0,,N,,A,7437,,,Canis lupus familiaris,1,,,
,6679,1,BAO_0000218,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50588,In vivo,,CHEMBL623596,Intermediate,9615.0,,N,,A,7438,,,Canis lupus familiaris,1,,,
,1116,1,BAO_0000218,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",50588,In vitro,Plasma,CHEMBL623597,Intermediate,9615.0,,N,,A,7439,,,Canis lupus familiaris,1,,1969.0,
,5444,1,BAO_0000218,In vivo half life period was calculated at 1 mg/kg in dog,50588,In vivo,,CHEMBL623598,Intermediate,9615.0,,N,,A,7440,,,Canis lupus familiaris,1,,,
,5444,1,BAO_0000218,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,50588,In vivo,,CHEMBL623599,Intermediate,9615.0,,N,,A,7441,,,Canis lupus familiaris,1,,,
,17853,1,BAO_0000218,Longer half-life in dog (i.v.) at 0.5 mpk,50588,In vivo,,CHEMBL623600,Intermediate,9615.0,,N,,A,7442,,,Canis lupus familiaris,1,,,
,4353,1,BAO_0000218,Oral bioavailability in dog (dose 5 uM/kg),50588,In vivo,,CHEMBL623601,Intermediate,9615.0,,N,,A,7443,,,Canis lupus familiaris,1,,,
,16452,1,BAO_0000218,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,50588,In vivo,,CHEMBL623602,Intermediate,9615.0,,N,,A,7444,,,Canis lupus familiaris,1,,,
,16452,1,BAO_0000218,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,50588,In vivo,,CHEMBL623603,Intermediate,9615.0,,N,,A,7445,,,Canis lupus familiaris,1,,,
,16452,1,BAO_0000218,Bioavailability in dog (dose 1 mg/kg i.v.),50588,In vivo,,CHEMBL623604,Intermediate,9615.0,,N,,A,7446,,,Canis lupus familiaris,1,,,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,50594,In vivo,Lung,CHEMBL623605,Intermediate,10090.0,,N,,A,7447,,,Mus musculus,1,,2048.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,In vivo,Lung,CHEMBL623606,Intermediate,10090.0,,N,,A,7448,,,Mus musculus,1,,2048.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,In vivo,Lung,CHEMBL623607,Intermediate,10090.0,,N,,A,7449,,,Mus musculus,1,,2048.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,In vivo,Lung,CHEMBL623608,Intermediate,10090.0,,N,,A,7450,,,Mus musculus,1,,2048.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,In vivo,Lung,CHEMBL623609,Intermediate,10090.0,,N,,A,7451,,,Mus musculus,1,,2048.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,In vivo,Lung,CHEMBL623610,Intermediate,10090.0,,N,,A,7452,,,Mus musculus,1,,2048.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,In vivo,Muscle tissue,CHEMBL623611,Intermediate,10090.0,,N,,A,7453,,,Mus musculus,1,,2385.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,50594,In vivo,Muscle tissue,CHEMBL623612,Intermediate,10090.0,,N,,A,7454,,,Mus musculus,1,,2385.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,In vivo,Muscle tissue,CHEMBL623613,Intermediate,10090.0,,N,,A,7455,,,Mus musculus,1,,2385.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,In vivo,Muscle tissue,CHEMBL623614,Intermediate,10090.0,,N,,A,7456,,,Mus musculus,1,,2385.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,In vivo,Muscle tissue,CHEMBL623615,Intermediate,10090.0,,N,,A,7457,,,Mus musculus,1,,2385.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,In vivo,Muscle tissue,CHEMBL623616,Intermediate,10090.0,,N,,A,7458,,,Mus musculus,1,,2385.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,In vivo,Muscle tissue,CHEMBL623617,Intermediate,10090.0,,N,,A,7459,,,Mus musculus,1,,2385.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,In vivo,Zone of skin,CHEMBL875944,Intermediate,10090.0,,N,,A,7460,,,Mus musculus,1,,14.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,In vivo,Zone of skin,CHEMBL623618,Intermediate,10090.0,,N,,A,7461,,,Mus musculus,1,,14.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,In vivo,Zone of skin,CHEMBL623619,Intermediate,10090.0,,N,,A,7462,,,Mus musculus,1,,14.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,In vivo,Zone of skin,CHEMBL623620,Intermediate,10090.0,,N,,A,7463,,,Mus musculus,1,,14.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,In vivo,Zone of skin,CHEMBL623621,Intermediate,10090.0,,N,,A,7464,,,Mus musculus,1,,14.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,In vivo,Zone of skin,CHEMBL623622,Intermediate,10090.0,,N,,A,7465,,,Mus musculus,1,,14.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,In vivo,Zone of skin,CHEMBL623623,Intermediate,10090.0,,N,,A,7466,,,Mus musculus,1,,14.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,In vivo,Spleen,CHEMBL623624,Intermediate,10090.0,,N,,A,7467,,,Mus musculus,1,,2106.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,In vivo,Spleen,CHEMBL618521,Intermediate,10090.0,,N,,A,7468,,,Mus musculus,1,,2106.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,In vivo,Spleen,CHEMBL618522,Intermediate,10090.0,,N,,A,7469,,,Mus musculus,1,,2106.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,In vivo,Spleen,CHEMBL618523,Intermediate,10090.0,,N,,A,7470,,,Mus musculus,1,,2106.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,In vivo,Spleen,CHEMBL618524,Intermediate,10090.0,,N,,A,7471,,,Mus musculus,1,,2106.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,In vivo,Spleen,CHEMBL618525,Intermediate,10090.0,,N,,A,7472,,,Mus musculus,1,,2106.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,In vivo,Spleen,CHEMBL624586,Intermediate,10090.0,,N,,A,7473,,,Mus musculus,1,,2106.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,In vivo,Stomach,CHEMBL624587,Intermediate,10090.0,,N,,A,7474,,,Mus musculus,1,,945.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,In vivo,Stomach,CHEMBL624588,Intermediate,10090.0,,N,,A,7475,,,Mus musculus,1,,945.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,In vivo,Stomach,CHEMBL624589,Intermediate,10090.0,,N,,A,7476,,,Mus musculus,1,,945.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,In vivo,Stomach,CHEMBL624590,Intermediate,10090.0,,N,,A,7477,,,Mus musculus,1,,945.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,In vivo,Stomach,CHEMBL624591,Intermediate,10090.0,,N,,A,7478,,,Mus musculus,1,,945.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,In vivo,Stomach,CHEMBL624592,Intermediate,10090.0,,N,,A,7479,,,Mus musculus,1,,945.0,
,10107,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,In vivo,Stomach,CHEMBL624593,Intermediate,10090.0,,N,,A,7480,,,Mus musculus,1,,945.0,
,4689,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL624594,Intermediate,10116.0,,N,,A,7481,,,Rattus norvegicus,1,,,
,4950,1,BAO_0000218,Tested for the bioavailability in rat,50597,In vivo,,CHEMBL624595,Intermediate,10116.0,,N,,A,7482,,,Rattus norvegicus,1,,,
,5328,1,BAO_0000218,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),50597,In vivo,,CHEMBL624596,Intermediate,10116.0,,N,,A,7483,,,Rattus norvegicus,1,,,
,406,1,BAO_0000218,Bioavailability in rat,50597,In vivo,,CHEMBL624597,Intermediate,10116.0,,N,,A,7484,,,Rattus norvegicus,1,,,
,12500,1,BAO_0000218,Bioavailability in rat,50597,In vivo,,CHEMBL624598,Intermediate,10116.0,,N,,A,7485,,,Rattus norvegicus,1,,,
,12500,1,BAO_0000218,Bioavailability in rat (dose 3-10 mg/kg),50597,In vivo,,CHEMBL624599,Intermediate,10116.0,,N,,A,7486,,,Rattus norvegicus,1,,,
,5247,1,BAO_0000218,Bioavailability in rat,50597,In vivo,,CHEMBL875166,Intermediate,10116.0,,N,,A,7487,,,Rattus norvegicus,1,,,
,4186,1,BAO_0000218,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,50597,In vivo,Plasma,CHEMBL624600,Intermediate,10116.0,,N,,A,7488,,,Rattus norvegicus,1,,1969.0,
,4186,1,BAO_0000218,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,50597,In vivo,Plasma,CHEMBL624601,Intermediate,10116.0,,N,,A,7489,,,Rattus norvegicus,1,,1969.0,
,6647,1,BAO_0000218,Half life after oral administration was determined in rats at 6 mg/kg,50597,In vivo,,CHEMBL624602,Intermediate,10116.0,,N,,A,7490,,,Rattus norvegicus,1,,,
,6484,1,BAO_0000218,Half life was determined,50597,,,CHEMBL624603,Intermediate,10116.0,,N,,A,7491,,,Rattus norvegicus,1,,,
,3249,1,BAO_0000218,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,50597,In vivo,,CHEMBL624604,Intermediate,10116.0,,N,,A,7492,,,Rattus norvegicus,1,,,
,6281,1,BAO_0000218,Plasma half life in rat at oral dose 2.8 mg/mk body weight,50597,In vivo,Plasma,CHEMBL624605,Intermediate,10116.0,,N,,A,7493,,,Rattus norvegicus,1,,1969.0,
,3307,1,BAO_0000218,Half life in rats,50597,,,CHEMBL624606,Intermediate,10116.0,,N,,A,7494,,,Rattus norvegicus,1,,,
,12058,1,BAO_0000218,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,50597,In vivo,Blood,CHEMBL624607,Intermediate,10116.0,,N,,A,7495,,,Rattus norvegicus,1,,178.0,
,8833,1,BAO_0000218,Hill coefficient of the compound,50597,,,CHEMBL624608,Intermediate,10116.0,,N,,A,7496,,,Rattus norvegicus,1,,,
,3193,1,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,50597,,Blood,CHEMBL624609,Intermediate,10116.0,,N,,A,7497,,,Rattus norvegicus,1,,178.0,
,3193,1,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,50597,,Blood,CHEMBL624610,Intermediate,10116.0,,N,,A,7498,,,Rattus norvegicus,1,,178.0,
,3193,1,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,50597,,Blood,CHEMBL624611,Intermediate,10116.0,,N,,A,7499,,,Rattus norvegicus,1,,178.0,
,3193,1,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,50597,,Blood,CHEMBL624612,Intermediate,10116.0,,N,,A,7500,,,Rattus norvegicus,1,,178.0,
,3193,1,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,50597,,Blood,CHEMBL875167,Intermediate,10116.0,,N,,A,7501,,,Rattus norvegicus,1,,178.0,
,3193,1,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,50597,,Blood,CHEMBL624613,Intermediate,10116.0,,N,,A,7502,,,Rattus norvegicus,1,,178.0,
,3193,1,BAO_0000218,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",50597,,Blood,CHEMBL624614,Intermediate,10116.0,,N,,A,7503,,,Rattus norvegicus,1,,178.0,
,5960,1,BAO_0000218,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,50597,,,CHEMBL624392,Intermediate,10116.0,,N,,A,7504,,,Rattus norvegicus,1,,,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,50597,In vivo,Brain,CHEMBL624393,Intermediate,10116.0,,N,,A,7505,,,Rattus norvegicus,1,,955.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,50597,In vivo,Brain,CHEMBL624394,Intermediate,10116.0,,N,,A,7506,,,Rattus norvegicus,1,,955.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,50597,In vivo,Brain,CHEMBL624395,Intermediate,10116.0,,N,,A,7507,,,Rattus norvegicus,1,,955.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,50597,In vivo,Brain,CHEMBL624396,Intermediate,10116.0,,N,,A,7508,,,Rattus norvegicus,1,,955.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,50597,In vivo,Brain,CHEMBL624397,Intermediate,10116.0,,N,,A,7509,,,Rattus norvegicus,1,,955.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,50597,In vivo,Thyroid gland,CHEMBL624398,Intermediate,10116.0,,N,,A,7510,,,Rattus norvegicus,1,,2046.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,50597,In vivo,Thyroid gland,CHEMBL624399,Intermediate,10116.0,,N,,A,7511,,,Rattus norvegicus,1,,2046.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,50597,In vivo,Thyroid gland,CHEMBL624400,Intermediate,10116.0,,N,,A,7512,,,Rattus norvegicus,1,,2046.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,50597,In vivo,Thyroid gland,CHEMBL624401,Intermediate,10116.0,,N,,A,7513,,,Rattus norvegicus,1,,2046.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,50597,In vivo,Thyroid gland,CHEMBL624402,Intermediate,10116.0,,N,,A,7514,,,Rattus norvegicus,1,,2046.0,
,9866,1,BAO_0000218,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,In vivo,Blood,CHEMBL624403,Intermediate,10116.0,,N,,A,7515,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,50597,In vivo,Blood,CHEMBL624404,Intermediate,10116.0,,N,,A,7516,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,50597,In vivo,Blood,CHEMBL624405,Intermediate,10116.0,,N,,A,7517,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,In vivo,Bone,CHEMBL624406,Intermediate,10116.0,,N,,A,7518,,,Rattus norvegicus,1,,10000001.0,
,9866,1,BAO_0000218,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,50597,In vivo,Bone,CHEMBL624407,Intermediate,10116.0,,N,,A,7519,,,Rattus norvegicus,1,,10000001.0,
,9866,1,BAO_0000218,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,50597,In vivo,Bone,CHEMBL624408,Intermediate,10116.0,,N,,A,7520,,,Rattus norvegicus,1,,10000001.0,
,9866,1,BAO_0000218,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,In vivo,Heart,CHEMBL618644,Intermediate,10116.0,,N,,A,7521,,,Rattus norvegicus,1,,948.0,
,9866,1,BAO_0000218,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,50597,In vivo,Heart,CHEMBL618645,Intermediate,10116.0,,N,,A,7522,,,Rattus norvegicus,1,,948.0,
,9866,1,BAO_0000218,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,50597,In vivo,Heart,CHEMBL618646,Intermediate,10116.0,,N,,A,7523,,,Rattus norvegicus,1,,948.0,
,9866,1,BAO_0000218,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,In vivo,Kidney,CHEMBL618647,Intermediate,10116.0,,N,,A,7524,,,Rattus norvegicus,1,,2113.0,
,9866,1,BAO_0000218,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,50597,In vivo,Kidney,CHEMBL618648,Intermediate,10116.0,,N,,A,7525,,,Rattus norvegicus,1,,2113.0,
,9866,1,BAO_0000218,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,50597,In vivo,Kidney,CHEMBL618649,Intermediate,10116.0,,N,,A,7526,,,Rattus norvegicus,1,,2113.0,
,9866,1,BAO_0000218,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,In vivo,Liver,CHEMBL618650,Intermediate,10116.0,,N,,A,7527,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,50597,In vivo,Liver,CHEMBL618651,Intermediate,10116.0,,N,,A,7528,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,50597,In vivo,Liver,CHEMBL876497,Intermediate,10116.0,,N,,A,7529,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,In vivo,Lung,CHEMBL618652,Intermediate,10116.0,,N,,A,7530,,,Rattus norvegicus,1,,2048.0,
,9866,1,BAO_0000218,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,50597,In vivo,Lung,CHEMBL618653,Intermediate,10116.0,,N,,A,7531,,,Rattus norvegicus,1,,2048.0,
,9866,1,BAO_0000218,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,50597,In vivo,Lung,CHEMBL618654,Intermediate,10116.0,,N,,A,7532,,,Rattus norvegicus,1,,2048.0,
,6351,1,BAO_0000218,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,50597,,,CHEMBL618655,Intermediate,10116.0,,N,,A,7533,,,Rattus norvegicus,1,,,
,1465,1,BAO_0000218,Compound was tested for solubility in water,50597,,,CHEMBL618656,Intermediate,10116.0,,N,,A,7534,,,Rattus norvegicus,1,,,
,5182,0,BAO_0000100,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),22229,,,CHEMBL618657,Intermediate,,,U,,P,7535,,,,1,,,
,17847,1,BAO_0000218,Solubility was determined,50597,,,CHEMBL618658,Intermediate,10116.0,,N,,A,7536,,,Rattus norvegicus,1,,,
,15339,1,BAO_0000218,solubility in water (ug/mL) at 37 degree C.,50597,,,CHEMBL618659,Intermediate,10116.0,,N,,A,7537,,,Rattus norvegicus,1,,,
,5202,1,BAO_0000218,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,50597,,,CHEMBL618660,Intermediate,10116.0,,N,,A,7538,,,Rattus norvegicus,1,,,
,1088,1,BAO_0000218,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,50597,,,CHEMBL618661,Intermediate,10116.0,,N,,A,7539,,,Rattus norvegicus,1,,,
,3169,1,BAO_0000218,Half life in rats,50597,,,CHEMBL873807,Intermediate,10116.0,,N,,A,7540,,,Rattus norvegicus,1,,,
,5353,1,BAO_0000218,Half life in Dawley rat,50597,,,CHEMBL618662,Intermediate,10116.0,,N,,A,7541,,,Rattus norvegicus,1,,,
,2864,1,BAO_0000218,Half life period after 3 mg/kg iv administration,50597,In vivo,,CHEMBL618663,Intermediate,10116.0,,N,,A,7542,,,Rattus norvegicus,1,,,
,2864,1,BAO_0000218,Half life period after 3 mg/kg iv administration in rat,50597,In vivo,,CHEMBL618664,Intermediate,10116.0,,N,,A,7543,,,Rattus norvegicus,1,,,
,2864,1,BAO_0000218,Half life period after 3 mg/kg iv administration in the rat,50597,In vivo,,CHEMBL618665,Intermediate,10116.0,,N,,A,7544,,,Rattus norvegicus,1,,,
,6362,1,BAO_0000218,Half life period in female Sprague-Dawley rats,50597,,,CHEMBL876498,Intermediate,10116.0,,N,,A,7545,,,Rattus norvegicus,1,,,
,6249,1,BAO_0000218,Half life period in rat,50597,,,CHEMBL618666,Intermediate,10116.0,,N,,A,7546,,,Rattus norvegicus,1,,,
,3169,1,BAO_0000218,Half-life in rats was determined,50597,,,CHEMBL620440,Intermediate,10116.0,,N,,A,7547,,,Rattus norvegicus,1,,,
,3169,1,BAO_0000218,Half-life in rats with metabolic oxidation,50597,,,CHEMBL620441,Intermediate,10116.0,,N,,A,7548,,,Rattus norvegicus,1,,,
,3169,1,BAO_0000218,Half-life in rats,50597,,,CHEMBL620442,Intermediate,10116.0,,N,,A,7549,,,Rattus norvegicus,1,,,
,17260,1,BAO_0000218,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,50597,In vivo,,CHEMBL620443,Intermediate,10116.0,,N,,A,7550,,,Rattus norvegicus,1,,,
,17260,1,BAO_0000218,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,50597,In vivo,,CHEMBL620444,Intermediate,10116.0,,N,,A,7551,,,Rattus norvegicus,1,,,
,17260,1,BAO_0000218,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,50597,In vivo,,CHEMBL620445,Intermediate,10116.0,,N,,A,7552,,,Rattus norvegicus,1,,,
,17260,1,BAO_0000218,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,50597,In vivo,,CHEMBL620446,Intermediate,10116.0,,N,,A,7553,,,Rattus norvegicus,1,,,
,2879,1,BAO_0000218,Biological half-life measured in plasma of rat,50597,,Plasma,CHEMBL620447,Intermediate,10116.0,,N,,A,7554,,,Rattus norvegicus,1,,1969.0,
,2879,1,BAO_0000218,Biological half-life measured in plasma of rat; 22-25,50597,,Plasma,CHEMBL621129,Intermediate,10116.0,,N,,A,7555,,,Rattus norvegicus,1,,1969.0,
,2879,1,BAO_0000218,Biological half-life measured in plasma of rat; 9-16,50597,,Plasma,CHEMBL621130,Intermediate,10116.0,,N,,A,7556,,,Rattus norvegicus,1,,1969.0,
,3184,1,BAO_0000218,Compound was evaluated for its half life when administered intravenously in rat,50597,In vivo,,CHEMBL873808,Intermediate,10116.0,,N,,A,7557,,,Rattus norvegicus,1,,,
,4891,1,BAO_0000218,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,50597,In vivo,,CHEMBL876598,Intermediate,10116.0,,N,,A,7558,,,Rattus norvegicus,1,,,
,429,1,BAO_0000218,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,50597,In vivo,,CHEMBL621131,Intermediate,10116.0,,N,,A,7559,,,Rattus norvegicus,1,,,
,5656,1,BAO_0000218,Half life (T1/2) after oral administration in rat,50597,In vivo,,CHEMBL621132,Intermediate,10116.0,,N,,A,7560,,,Rattus norvegicus,1,,,
,4413,1,BAO_0000218,Half life of compound after iv administration of 20 mg/kg dose in rat,50597,In vivo,,CHEMBL621133,Intermediate,10116.0,,N,,A,7561,,,Rattus norvegicus,1,,,
,3598,1,BAO_0000218,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,In vivo,,CHEMBL621312,Expert,10116.0,,N,,A,7562,,,Rattus norvegicus,1,,,
,17267,1,BAO_0000218,Half life of compound was determined in rat,50597,,,CHEMBL621313,Intermediate,10116.0,,N,,A,7563,,,Rattus norvegicus,1,,,
,4727,1,BAO_0000218,Half life of compound was determined in rat blood,50597,,Blood,CHEMBL621314,Intermediate,10116.0,,N,,A,7564,,,Rattus norvegicus,1,,178.0,
,17651,1,BAO_0000218,Half life at 1 mg/kg was determined in rat,50597,In vivo,,CHEMBL621315,Intermediate,10116.0,,N,,A,7565,,,Rattus norvegicus,1,,,
,17651,1,BAO_0000218,Half life at 10 mg/kg was determined in rat,50597,In vivo,,CHEMBL621316,Intermediate,10116.0,,N,,A,7566,,,Rattus norvegicus,1,,,
,401,1,BAO_0000218,Half life in rats,50597,,,CHEMBL621317,Intermediate,10116.0,,N,,A,7567,,,Rattus norvegicus,1,,,
,4942,1,BAO_0000218,Half life in rats in hours,50597,,,CHEMBL621318,Intermediate,10116.0,,N,,A,7568,,,Rattus norvegicus,1,,,
,17735,1,BAO_0000218,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,50597,In vivo,,CHEMBL621319,Intermediate,10116.0,,N,,A,7569,,,Rattus norvegicus,1,,,
,6056,1,BAO_0000218,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,50597,In vivo,,CHEMBL621377,Intermediate,10116.0,,N,,A,7570,,,Rattus norvegicus,1,,,
,5213,1,BAO_0000218,Half life was determined,50597,,,CHEMBL621378,Intermediate,10116.0,,N,,A,7571,,,Rattus norvegicus,1,,,
,6616,1,BAO_0000218,Half life after i.v. administration,50597,In vivo,,CHEMBL876599,Intermediate,10116.0,,N,,A,7572,,,Rattus norvegicus,1,,,
,5937,1,BAO_0000218,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,50597,In vivo,,CHEMBL621379,Intermediate,10116.0,,N,,A,7573,,,Rattus norvegicus,1,,,
,5819,1,BAO_0000218,Half life in rat plasma,50597,,Plasma,CHEMBL621380,Intermediate,10116.0,,N,,A,7574,,,Rattus norvegicus,1,,1969.0,
,5819,1,BAO_0000218,Half life in rat plasma; Not detected,50597,,Plasma,CHEMBL621381,Intermediate,10116.0,,N,,A,7575,,,Rattus norvegicus,1,,1969.0,
,6803,1,BAO_0000218,Half life in rats,50597,,,CHEMBL618515,Intermediate,10116.0,,N,,A,7576,,,Rattus norvegicus,1,,,
,17804,1,BAO_0000218,Half life period of compound was determined after peroral administration,50597,In vivo,,CHEMBL618516,Intermediate,10116.0,,N,,A,7577,,,Rattus norvegicus,1,,,
,17804,1,BAO_0000218,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,50597,In vivo,,CHEMBL618517,Intermediate,10116.0,,N,,A,7578,,,Rattus norvegicus,1,,,
,5948,1,BAO_0000218,Half life period in rat,50597,,,CHEMBL618518,Intermediate,10116.0,,N,,A,7579,,,Rattus norvegicus,1,,,
,1916,1,BAO_0000218,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,50597,In vivo,,CHEMBL618519,Intermediate,10116.0,,N,,A,7580,,,Rattus norvegicus,1,,,
,1916,1,BAO_0000218,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,50597,In vivo,,CHEMBL618698,Intermediate,10116.0,,N,,A,7581,,,Rattus norvegicus,1,,,
,1916,1,BAO_0000218,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,50597,In vivo,,CHEMBL618862,Intermediate,10116.0,,N,,A,7582,,,Rattus norvegicus,1,,,
,4890,1,BAO_0000218,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,50597,In vivo,,CHEMBL618863,Intermediate,10116.0,,N,,A,7583,,,Rattus norvegicus,1,,,
,17764,1,BAO_0000218,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,50597,In vivo,,CHEMBL618864,Intermediate,10116.0,,N,,A,7584,,,Rattus norvegicus,1,,,
,4727,1,BAO_0000218,Half life time in rat the dose of 2 mg/kg,50597,In vivo,,CHEMBL618865,Intermediate,10116.0,,N,,A,7585,,,Rattus norvegicus,1,,,
,17509,1,BAO_0000218,Half-life 24 hr after 10 mg/kg iv administration in rats,50597,In vivo,,CHEMBL618866,Intermediate,10116.0,,N,,A,7586,,,Rattus norvegicus,1,,,
,17509,1,BAO_0000218,Half-life 24 hr after 2 mg/kg iv administration in rats,50597,In vivo,,CHEMBL618867,Intermediate,10116.0,,N,,A,7587,,,Rattus norvegicus,1,,,
,6597,1,BAO_0000218,Half-life consistent with the observed metabolic steady state in rats,50597,,,CHEMBL875828,Intermediate,10116.0,,N,,A,7588,,,Rattus norvegicus,1,,,
,17735,1,BAO_0000218,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,50597,In vivo,,CHEMBL618868,Intermediate,10116.0,,N,,A,7589,,,Rattus norvegicus,1,,,
,6597,1,BAO_0000218,Half-life for oxidative metabolic stability was determined using male human,50597,,,CHEMBL618869,Intermediate,10116.0,,N,,A,7590,,,Rattus norvegicus,1,,,
,17670,1,BAO_0000218,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",50597,In vivo,,CHEMBL618870,Intermediate,10116.0,,N,,A,7591,,,Rattus norvegicus,1,,,
,1696,1,BAO_0000218,Half-life in rat plasma,50597,,Plasma,CHEMBL618871,Intermediate,10116.0,,N,,A,7592,,,Rattus norvegicus,1,,1969.0,
,1742,1,BAO_0000218,Half-life in rat plasma was determined,50597,,Plasma,CHEMBL618872,Intermediate,10116.0,,N,,A,7593,,,Rattus norvegicus,1,,1969.0,
,17800,1,BAO_0000218,Half-life in rats was determined,50597,,,CHEMBL873816,Intermediate,10116.0,,N,,A,7594,,,Rattus norvegicus,1,,,
,12923,0,BAO_0000218,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,22224,,,CHEMBL618873,Autocuration,,,U,,A,7595,,,,1,,,
,11954,0,BAO_0000019,Area under curve after oral dose of 0.1 mg//kg,22224,,,CHEMBL621602,Autocuration,,,U,,A,7596,,,,1,,,
,11954,0,BAO_0000218,Area under curve after oral dose of 0.3 mg/kg,22224,,,CHEMBL621603,Autocuration,,,U,,A,7597,,,,1,,,
,11954,0,BAO_0000218,Area under curve after oral dose of 1 mg/kg,22224,,,CHEMBL621604,Autocuration,,,U,,A,7598,,,,1,,,
,11954,0,BAO_0000218,Area under curve after oral dose of 10 mg/kg,22224,,,CHEMBL621605,Autocuration,,,U,,A,7599,,,,1,,,
,11954,0,BAO_0000218,Area under curve after oral dose of 23.4 mg/kg,22224,,,CHEMBL621606,Autocuration,,,U,,A,7600,,,,1,,,
,11954,0,BAO_0000218,Area under curve after oral dose of 3 mg/kg,22224,,,CHEMBL621607,Autocuration,,,U,,A,7601,,,,1,,,
,11954,0,BAO_0000218,Area under curve after oral dose of 3.87 mg/kg,22224,,,CHEMBL621608,Autocuration,,,U,,A,7602,,,,1,,,
,5237,0,BAO_0000019,Area under curve was determined,22224,,,CHEMBL621609,Autocuration,,,U,,A,7603,,,,1,,,
,4026,0,BAO_0000218,Area under curve at a dose of 10 mg/kg,22224,,,CHEMBL621610,Autocuration,,,U,,A,7604,,,,1,,,
,5237,1,BAO_0000218,Area under curve was determined; ND=No data,50597,,,CHEMBL621611,Intermediate,10116.0,,N,,A,7605,,,Rattus norvegicus,1,,,
,14793,1,BAO_0000218,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,50597,,,CHEMBL621612,Intermediate,10116.0,,N,,A,7606,,,Rattus norvegicus,1,,,
,14793,1,BAO_0000218,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,50597,,,CHEMBL622308,Intermediate,10116.0,,N,,A,7607,,,Rattus norvegicus,1,,,
,14793,1,BAO_0000218,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,50597,,,CHEMBL622309,Intermediate,10116.0,,N,,A,7608,,,Rattus norvegicus,1,,,
,14793,1,BAO_0000218,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,50597,,,CHEMBL622310,Intermediate,10116.0,,N,,A,7609,,,Rattus norvegicus,1,,,
,14793,1,BAO_0000218,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,50597,,,CHEMBL622311,Intermediate,10116.0,,N,,A,7610,,,Rattus norvegicus,1,,,
,14793,1,BAO_0000218,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,50597,,,CHEMBL622312,Intermediate,10116.0,,N,,A,7611,,,Rattus norvegicus,1,,,
,14793,1,BAO_0000218,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,50597,,,CHEMBL622931,Intermediate,10116.0,,N,,A,7612,,,Rattus norvegicus,1,,,
,14793,1,BAO_0000218,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,50597,,,CHEMBL622932,Intermediate,10116.0,,N,,A,7613,,,Rattus norvegicus,1,,,
,14793,1,BAO_0000218,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,50597,,Plasma,CHEMBL622736,Intermediate,10116.0,,N,,A,7614,,,Rattus norvegicus,1,,1969.0,
,14793,1,BAO_0000218,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,50597,,Plasma,CHEMBL622737,Intermediate,10116.0,,N,,A,7615,,,Rattus norvegicus,1,,1969.0,
,14793,1,BAO_0000218,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,50597,,Plasma,CHEMBL622738,Intermediate,10116.0,,N,,A,7616,,,Rattus norvegicus,1,,1969.0,
,14793,1,BAO_0000218,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,50597,,Plasma,CHEMBL622739,Intermediate,10116.0,,N,,A,7617,,,Rattus norvegicus,1,,1969.0,
,14793,1,BAO_0000218,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,50597,,Plasma,CHEMBL622740,Intermediate,10116.0,,N,,A,7618,,,Rattus norvegicus,1,,1969.0,
,14793,1,BAO_0000218,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,50597,,Plasma,CHEMBL622741,Intermediate,10116.0,,N,,A,7619,,,Rattus norvegicus,1,,1969.0,
,14793,1,BAO_0000218,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,50597,,Plasma,CHEMBL622742,Intermediate,10116.0,,N,,A,7620,,,Rattus norvegicus,1,,1969.0,
,14793,1,BAO_0000218,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,50597,,Plasma,CHEMBL622743,Intermediate,10116.0,,N,,A,7621,,,Rattus norvegicus,1,,1969.0,
,11637,1,BAO_0000218,AUC in mice,50594,,Plasma,CHEMBL622744,Intermediate,10090.0,,N,,A,7622,,,Mus musculus,1,,1969.0,
,11149,0,BAO_0000019,Area under curve was measured from the graph obtained from concentration Vs time,22224,,,CHEMBL624134,Autocuration,,,U,,A,7623,,,,1,,,
,10016,0,BAO_0000019,Area under curve value of compound per hour after oral administration,22224,,,CHEMBL624135,Autocuration,,,U,,A,7624,,,,1,,,
,17796,1,BAO_0000218,Area under curve was determined after oral administration in rats,50597,,,CHEMBL624136,Intermediate,10116.0,,N,,A,7625,,,Rattus norvegicus,1,,,
,17796,1,BAO_0000218,Area under curve was determined after oral administration in rats; No data,50597,,,CHEMBL624137,Intermediate,10116.0,,N,,A,7626,,,Rattus norvegicus,1,,,
,17796,1,BAO_0000218,Area under curve was determined after oral administration in rats;No data,50597,,,CHEMBL624320,Intermediate,10116.0,,N,,A,7627,,,Rattus norvegicus,1,,,
,12923,1,BAO_0000218,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,50588,,,CHEMBL624321,Intermediate,9615.0,,N,,A,7628,,,Canis lupus familiaris,1,,,
,15372,1,BAO_0000218,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,50597,,,CHEMBL624322,Intermediate,10116.0,,N,,A,7629,,,Rattus norvegicus,1,,,
,15372,1,BAO_0000218,Area under curve was determined for the compound after iv dose of 5.06 in rats,50597,,,CHEMBL624323,Intermediate,10116.0,,N,,A,7630,,,Rattus norvegicus,1,,,
,15372,1,BAO_0000218,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,50597,,,CHEMBL624324,Intermediate,10116.0,,N,,A,7631,,,Rattus norvegicus,1,,,
,15372,1,BAO_0000218,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,50597,,,CHEMBL624325,Intermediate,10116.0,,N,,A,7632,,,Rattus norvegicus,1,,,
,15372,1,BAO_0000218,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,50597,,,CHEMBL624326,Intermediate,10116.0,,N,,A,7633,,,Rattus norvegicus,1,,,
,15372,1,BAO_0000218,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,50597,,,CHEMBL624327,Intermediate,10116.0,,N,,A,7634,,,Rattus norvegicus,1,,,
,15372,1,BAO_0000218,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,50597,,,CHEMBL624328,Intermediate,10116.0,,N,,A,7635,,,Rattus norvegicus,1,,,
,14169,1,BAO_0000218,Area under curve was determined in Dogs after peroral administration,50588,,,CHEMBL627848,Intermediate,9615.0,,N,,A,7636,,,Canis lupus familiaris,1,,,
,14169,1,BAO_0000218,Area under curve was determined in Rats after peroral administration,50597,,,CHEMBL627849,Intermediate,10116.0,,N,,A,7637,,,Rattus norvegicus,1,,,
,14258,1,BAO_0000218,Area under curve was determined in carotid blood of rat when administered intradermally,50597,,,CHEMBL627850,Intermediate,10116.0,,N,,A,7638,,,Rattus norvegicus,1,,,
,14258,1,BAO_0000218,Area under curve was determined in portal blood of rat when administered intradermally,50597,,,CHEMBL627851,Intermediate,10116.0,,N,,A,7639,,,Rattus norvegicus,1,,,
,15011,1,BAO_0000218,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,50594,,,CHEMBL627852,Intermediate,10090.0,,N,,A,7640,,,Mus musculus,1,,,
,15011,1,BAO_0000218,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,50594,,,CHEMBL627853,Intermediate,10090.0,,N,,A,7641,,,Mus musculus,1,,,
,15011,1,BAO_0000218,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),50594,,,CHEMBL627854,Intermediate,10090.0,,N,,A,7642,,,Mus musculus,1,,,
,15011,1,BAO_0000218,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,50594,,,CHEMBL627855,Intermediate,10090.0,,N,,A,7643,,,Mus musculus,1,,,
,15011,1,BAO_0000218,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),50594,,,CHEMBL627856,Intermediate,10090.0,,N,,A,7644,,,Mus musculus,1,,,
,15011,1,BAO_0000218,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,50594,,,CHEMBL875339,Intermediate,10090.0,,N,,A,7645,,,Mus musculus,1,,,
,15011,1,BAO_0000218,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),50594,,,CHEMBL627857,Intermediate,10090.0,,N,,A,7646,,,Mus musculus,1,,,
,11195,1,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,50597,In vivo,Spleen,CHEMBL627858,Intermediate,10116.0,,N,,A,7647,,,Rattus norvegicus,1,,2106.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,50597,,Blood,CHEMBL627859,Intermediate,10116.0,,N,,A,7648,,,Rattus norvegicus,1,,178.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,50597,,Brain,CHEMBL627860,Intermediate,10116.0,,N,,A,7649,,,Rattus norvegicus,1,,955.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,50597,,Heart,CHEMBL627019,Intermediate,10116.0,,N,,A,7650,,,Rattus norvegicus,1,,948.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,50597,,Liver,CHEMBL627020,Intermediate,10116.0,,N,,A,7651,,,Rattus norvegicus,1,,2107.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,50597,,Lung,CHEMBL627021,Intermediate,10116.0,,N,,A,7652,,,Rattus norvegicus,1,,2048.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,50597,,Muscle tissue,CHEMBL627022,Intermediate,10116.0,,N,,A,7653,,,Rattus norvegicus,1,,2385.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,50597,,,CHEMBL627023,Intermediate,10116.0,,N,,A,7654,,,Rattus norvegicus,1,,,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,50597,,Spleen,CHEMBL627024,Intermediate,10116.0,,N,,A,7655,,,Rattus norvegicus,1,,2106.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,50597,,Thyroid gland,CHEMBL627025,Intermediate,10116.0,,N,,A,7656,,,Rattus norvegicus,1,,2046.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,50597,,Kidney,CHEMBL627026,Intermediate,10116.0,,N,,A,7657,,,Rattus norvegicus,1,,2113.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,50597,,Blood,CHEMBL627027,Intermediate,10116.0,,N,,A,7658,,,Rattus norvegicus,1,,178.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,50597,,Brain,CHEMBL627028,Intermediate,10116.0,,N,,A,7659,,,Rattus norvegicus,1,,955.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,50597,,Heart,CHEMBL627029,Intermediate,10116.0,,N,,A,7660,,,Rattus norvegicus,1,,948.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,50597,,Kidney,CHEMBL627030,Intermediate,10116.0,,N,,A,7661,,,Rattus norvegicus,1,,2113.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,50597,,Liver,CHEMBL627031,Intermediate,10116.0,,N,,A,7662,,,Rattus norvegicus,1,,2107.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,50597,,Lung,CHEMBL627032,Intermediate,10116.0,,N,,A,7663,,,Rattus norvegicus,1,,2048.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,50597,,Muscle tissue,CHEMBL627033,Intermediate,10116.0,,N,,A,7664,,,Rattus norvegicus,1,,2385.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,50597,,,CHEMBL627034,Intermediate,10116.0,,N,,A,7665,,,Rattus norvegicus,1,,,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,50597,,Spleen,CHEMBL627035,Intermediate,10116.0,,N,,A,7666,,,Rattus norvegicus,1,,2106.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,50597,,Thyroid gland,CHEMBL627036,Intermediate,10116.0,,N,,A,7667,,,Rattus norvegicus,1,,2046.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,50597,,Blood,CHEMBL875340,Intermediate,10116.0,,N,,A,7668,,,Rattus norvegicus,1,,178.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,50597,,Heart,CHEMBL627037,Intermediate,10116.0,,N,,A,7669,,,Rattus norvegicus,1,,948.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,50597,,Kidney,CHEMBL627038,Intermediate,10116.0,,N,,A,7670,,,Rattus norvegicus,1,,2113.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,50597,,Liver,CHEMBL627039,Intermediate,10116.0,,N,,A,7671,,,Rattus norvegicus,1,,2107.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,50597,,Muscle tissue,CHEMBL627040,Intermediate,10116.0,,N,,A,7672,,,Rattus norvegicus,1,,2385.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,50597,,Spleen,CHEMBL624663,Intermediate,10116.0,,N,,A,7673,,,Rattus norvegicus,1,,2106.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,50597,,Thyroid gland,CHEMBL625963,Intermediate,10116.0,,N,,A,7674,,,Rattus norvegicus,1,,2046.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,50597,,Brain,CHEMBL876799,Intermediate,10116.0,,N,,A,7675,,,Rattus norvegicus,1,,955.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,50597,,Lung,CHEMBL626133,Intermediate,10116.0,,N,,A,7676,,,Rattus norvegicus,1,,2048.0,
,10130,1,BAO_0000218,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,50597,,,CHEMBL626134,Intermediate,10116.0,,N,,A,7677,,,Rattus norvegicus,1,,,
,6295,1,BAO_0000218,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,50597,,,CHEMBL626135,Intermediate,10116.0,,N,,A,7678,,,Rattus norvegicus,1,,,
,6296,1,BAO_0000218,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,50597,,,CHEMBL626136,Intermediate,10116.0,,N,,A,7679,,,Rattus norvegicus,1,,,
,6296,1,BAO_0000218,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,50597,,,CHEMBL626137,Intermediate,10116.0,,N,,A,7680,,,Rattus norvegicus,1,,,
,6295,1,BAO_0000218,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,50597,,,CHEMBL626138,Intermediate,10116.0,,N,,A,7681,,,Rattus norvegicus,1,,,
,6296,1,BAO_0000218,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,50597,,,CHEMBL626139,Intermediate,10116.0,,N,,A,7682,,,Rattus norvegicus,1,,,
,17260,1,BAO_0000218,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,50597,In vivo,,CHEMBL626140,Intermediate,10116.0,,N,,A,7683,,,Rattus norvegicus,1,,,
,17260,1,BAO_0000218,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,50597,In vivo,,CHEMBL626141,Intermediate,10116.0,,N,,A,7684,,,Rattus norvegicus,1,,,
,17686,1,BAO_0000218,C24h in rat p.o. at 20 mg/kg concentration,50597,,,CHEMBL626142,Intermediate,10116.0,,N,,A,7685,,,Rattus norvegicus,1,,,
,9866,1,BAO_0000218,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,In vivo,Muscle tissue,CHEMBL627930,Intermediate,10116.0,,N,,A,7686,,,Rattus norvegicus,1,,2385.0,
,9866,1,BAO_0000218,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,50597,In vivo,Muscle tissue,CHEMBL627931,Intermediate,10116.0,,N,,A,7687,,,Rattus norvegicus,1,,2385.0,
,9866,1,BAO_0000218,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,50597,In vivo,Muscle tissue,CHEMBL627932,Intermediate,10116.0,,N,,A,7688,,,Rattus norvegicus,1,,2385.0,
,9866,1,BAO_0000218,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,In vivo,Spleen,CHEMBL627933,Intermediate,10116.0,,N,,A,7689,,,Rattus norvegicus,1,,2106.0,
,9866,1,BAO_0000218,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,50597,In vivo,Spleen,CHEMBL627934,Intermediate,10116.0,,N,,A,7690,,,Rattus norvegicus,1,,2106.0,
,9866,1,BAO_0000218,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,50597,In vivo,Spleen,CHEMBL627935,Intermediate,10116.0,,N,,A,7691,,,Rattus norvegicus,1,,2106.0,
,9866,1,BAO_0000218,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,50597,In vivo,Blood,CHEMBL627936,Intermediate,10116.0,,N,,A,7692,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,50597,In vivo,Blood,CHEMBL627937,Intermediate,10116.0,,N,,A,7693,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,50597,In vivo,Blood,CHEMBL627938,Intermediate,10116.0,,N,,A,7694,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,50597,In vivo,Blood,CHEMBL627939,Intermediate,10116.0,,N,,A,7695,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,50597,In vivo,Blood,CHEMBL627940,Intermediate,10116.0,,N,,A,7696,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,50597,In vivo,Blood,CHEMBL627941,Intermediate,10116.0,,N,,A,7697,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,50597,In vivo,Blood,CHEMBL876800,Intermediate,10116.0,,N,,A,7698,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,50597,In vivo,Blood,CHEMBL627942,Intermediate,10116.0,,N,,A,7699,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,50597,In vivo,Blood,CHEMBL627943,Intermediate,10116.0,,N,,A,7700,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,50597,In vivo,Blood,CHEMBL627944,Intermediate,10116.0,,N,,A,7701,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,50597,In vivo,Blood,CHEMBL627945,Intermediate,10116.0,,N,,A,7702,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,50597,In vivo,Blood,CHEMBL628584,Intermediate,10116.0,,N,,A,7703,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in rat blood in the presence of GdDTPA at 15 min,50597,In vivo,Blood,CHEMBL628585,Intermediate,10116.0,,N,,A,7704,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,50597,In vivo,Blood,CHEMBL628586,Intermediate,10116.0,,N,,A,7705,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in rat blood in the presence of GdDTPA at 30 min,50597,In vivo,Blood,CHEMBL628587,Intermediate,10116.0,,N,,A,7706,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,50597,In vivo,Blood,CHEMBL628588,Intermediate,10116.0,,N,,A,7707,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,50597,In vivo,Blood,CHEMBL628589,Intermediate,10116.0,,N,,A,7708,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,50597,In vivo,Blood,CHEMBL625304,Intermediate,10116.0,,N,,A,7709,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,50597,In vivo,Blood,CHEMBL625305,Intermediate,10116.0,,N,,A,7710,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,50597,In vivo,Blood,CHEMBL625306,Intermediate,10116.0,,N,,A,7711,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,50597,In vivo,Blood,CHEMBL625307,Intermediate,10116.0,,N,,A,7712,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,50597,In vivo,Blood,CHEMBL625308,Intermediate,10116.0,,N,,A,7713,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,50597,In vivo,Blood,CHEMBL627740,Intermediate,10116.0,,N,,A,7714,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,50597,In vivo,Blood,CHEMBL627741,Intermediate,10116.0,,N,,A,7715,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,50597,In vivo,Blood,CHEMBL627742,Intermediate,10116.0,,N,,A,7716,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,50597,In vivo,Blood,CHEMBL627743,Intermediate,10116.0,,N,,A,7717,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,50597,In vivo,Blood,CHEMBL627744,Intermediate,10116.0,,N,,A,7718,,,Rattus norvegicus,1,,178.0,
,9866,1,BAO_0000218,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,50597,In vivo,Bone,CHEMBL627745,Intermediate,10116.0,,N,,A,7719,,,Rattus norvegicus,1,,10000001.0,
,9866,1,BAO_0000218,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,50597,In vivo,Bone,CHEMBL627746,Intermediate,10116.0,,N,,A,7720,,,Rattus norvegicus,1,,10000001.0,
,9866,1,BAO_0000218,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,50597,In vivo,Bone,CHEMBL627747,Intermediate,10116.0,,N,,A,7721,,,Rattus norvegicus,1,,10000001.0,
,9866,1,BAO_0000218,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,50597,In vivo,Bone,CHEMBL876810,Intermediate,10116.0,,N,,A,7722,,,Rattus norvegicus,1,,10000001.0,
,9866,1,BAO_0000218,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,50597,In vivo,Bone,CHEMBL627748,Intermediate,10116.0,,N,,A,7723,,,Rattus norvegicus,1,,10000001.0,
,9866,1,BAO_0000218,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,50597,In vivo,Bone,CHEMBL627749,Intermediate,10116.0,,N,,A,7724,,,Rattus norvegicus,1,,10000001.0,
,9866,1,BAO_0000218,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,50597,In vivo,Bone,CHEMBL627750,Intermediate,10116.0,,N,,A,7725,,,Rattus norvegicus,1,,10000001.0,
,9866,1,BAO_0000218,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,50597,In vivo,Bone,CHEMBL618728,Intermediate,10116.0,,N,,A,7726,,,Rattus norvegicus,1,,10000001.0,
,9866,1,BAO_0000218,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,50597,In vivo,Bone,CHEMBL618729,Intermediate,10116.0,,N,,A,7727,,,Rattus norvegicus,1,,10000001.0,
,9866,1,BAO_0000218,Biodistribution in rat bone in the presence of GdDTPA at 15 min,50597,In vivo,Bone,CHEMBL618730,Intermediate,10116.0,,N,,A,7728,,,Rattus norvegicus,1,,10000001.0,
,9866,1,BAO_0000218,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,50597,In vivo,Bone,CHEMBL618731,Intermediate,10116.0,,N,,A,7729,,,Rattus norvegicus,1,,10000001.0,
,9866,1,BAO_0000218,Biodistribution in rat bone in the presence of GdDTPA at 30 min,50597,In vivo,Bone,CHEMBL618732,Intermediate,10116.0,,N,,A,7730,,,Rattus norvegicus,1,,10000001.0,
,9866,1,BAO_0000218,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,50597,In vivo,Bone,CHEMBL618733,Intermediate,10116.0,,N,,A,7731,,,Rattus norvegicus,1,,10000001.0,
,9866,1,BAO_0000218,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,50597,In vivo,Bone,CHEMBL618734,Intermediate,10116.0,,N,,A,7732,,,Rattus norvegicus,1,,10000001.0,
,9866,1,BAO_0000218,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,50597,In vivo,Bone,CHEMBL618735,Intermediate,10116.0,,N,,A,7733,,,Rattus norvegicus,1,,10000001.0,
,9866,1,BAO_0000218,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,50597,In vivo,Bone,CHEMBL876602,Intermediate,10116.0,,N,,A,7734,,,Rattus norvegicus,1,,10000001.0,
,9866,1,BAO_0000218,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,50597,In vivo,Bone,CHEMBL618736,Intermediate,10116.0,,N,,A,7735,,,Rattus norvegicus,1,,10000001.0,
,9866,1,BAO_0000218,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,50597,In vivo,Bone,CHEMBL618737,Intermediate,10116.0,,N,,A,7736,,,Rattus norvegicus,1,,10000001.0,
,9866,1,BAO_0000218,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,50597,In vivo,Bone,CHEMBL618738,Intermediate,10116.0,,N,,A,7737,,,Rattus norvegicus,1,,10000001.0,
,9866,1,BAO_0000218,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,50597,In vivo,Bone,CHEMBL618739,Intermediate,10116.0,,N,,A,7738,,,Rattus norvegicus,1,,10000001.0,
,9866,1,BAO_0000218,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,50597,In vivo,Bone,CHEMBL618740,Intermediate,10116.0,,N,,A,7739,,,Rattus norvegicus,1,,10000001.0,
,9866,1,BAO_0000218,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,50597,In vivo,Bone,CHEMBL618741,Intermediate,10116.0,,N,,A,7740,,,Rattus norvegicus,1,,10000001.0,
,9866,1,BAO_0000218,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,50597,In vivo,Bone,CHEMBL618742,Intermediate,10116.0,,N,,A,7741,,,Rattus norvegicus,1,,10000001.0,
,9866,1,BAO_0000218,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,50597,In vivo,Bone,CHEMBL618743,Intermediate,10116.0,,N,,A,7742,,,Rattus norvegicus,1,,10000001.0,
,17752,1,BAO_0000218,Half-life from rat plasma at a single oral dose of 25 mg/kg,50597,In vivo,Plasma,CHEMBL618744,Intermediate,10116.0,,N,,A,7743,,,Rattus norvegicus,1,,1969.0,
,5610,1,BAO_0000218,Half-life in male rat,50597,,,CHEMBL618745,Intermediate,10116.0,,N,,A,7744,,,Rattus norvegicus,1,,,
,5939,1,BAO_0000218,Half-life in rat after peroral administration at 10 mg/kg concentration,50597,In vivo,,CHEMBL620479,Intermediate,10116.0,,N,,A,7745,,,Rattus norvegicus,1,,,
,5939,1,BAO_0000218,Half-life in rat after peroral administration at 5 mg/kg concentration,50597,In vivo,,CHEMBL620480,Intermediate,10116.0,,N,,A,7746,,,Rattus norvegicus,1,,,
,17771,1,BAO_0000218,Half-life in rat at a dose of 3 mg/kg,50597,In vivo,,CHEMBL620481,Intermediate,10116.0,,N,,A,7747,,,Rattus norvegicus,1,,,
,1974,1,BAO_0000218,Half-life was evaluated in rats,50597,,,CHEMBL620482,Intermediate,10116.0,,N,,A,7748,,,Rattus norvegicus,1,,,
,4239,1,BAO_0000218,Half-life was measured in rat,50597,,,CHEMBL876603,Intermediate,10116.0,,N,,A,7749,,,Rattus norvegicus,1,,,
,6681,1,BAO_0000218,Half-life period for the compound was determined in rats at 50 mg/kg dose,50597,In vivo,,CHEMBL620483,Intermediate,10116.0,,N,,A,7750,,,Rattus norvegicus,1,,,
,17752,1,BAO_0000218,Half-life period in rats after intravenous administration at 5 mg/kg,50597,In vivo,,CHEMBL620484,Intermediate,10116.0,,N,,A,7751,,,Rattus norvegicus,1,,,
,6046,1,BAO_0000218,Half-life period in rat at 10 mg/kg,50597,In vivo,,CHEMBL620485,Intermediate,10116.0,,N,,A,7752,,,Rattus norvegicus,1,,,
,6685,1,BAO_0000218,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",50597,In vivo,,CHEMBL620486,Intermediate,10116.0,,N,,A,7753,,,Rattus norvegicus,1,,,
,6685,1,BAO_0000218,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",50597,In vivo,,CHEMBL620487,Intermediate,10116.0,,N,,A,7754,,,Rattus norvegicus,1,,,
,6685,1,BAO_0000218,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",50597,In vivo,,CHEMBL620488,Intermediate,10116.0,,N,,A,7755,,,Rattus norvegicus,1,,,
,4727,1,BAO_0000218,Half-life time in rat the dose of 2 mg/kg,50597,In vivo,,CHEMBL620489,Intermediate,10116.0,,N,,A,7756,,,Rattus norvegicus,1,,,
,1088,1,BAO_0000218,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,50597,In vivo,,CHEMBL620490,Intermediate,10116.0,,N,,A,7757,,,Rattus norvegicus,1,,,
,5610,1,BAO_0000218,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,50597,In vivo,,CHEMBL620491,Intermediate,10116.0,,N,,A,7758,,,Rattus norvegicus,1,,,
,3032,1,BAO_0000218,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",50597,In vivo,Plasma,CHEMBL876604,Intermediate,10116.0,,N,,A,7759,,,Rattus norvegicus,1,,1969.0,
,5199,1,BAO_0000218,Oral half life was determined,50597,In vivo,,CHEMBL620492,Intermediate,10116.0,,N,,A,7760,,,Rattus norvegicus,1,,,
,14941,1,BAO_0000218,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",50597,In vivo,,CHEMBL620493,Intermediate,10116.0,,N,,A,7761,,,Rattus norvegicus,1,,,
,4408,1,BAO_0000218,Pharmacokinetic property (t1/2) in rat,50597,In vivo,,CHEMBL620494,Intermediate,10116.0,,N,,A,7762,,,Rattus norvegicus,1,,,
,2552,1,BAO_0000218,Plasma elimination half-life was determined,50597,,Plasma,CHEMBL620495,Intermediate,10116.0,,N,,A,7763,,,Rattus norvegicus,1,,1969.0,
,5199,1,BAO_0000218,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,50597,In vivo,Plasma,CHEMBL620496,Intermediate,10116.0,,N,,A,7764,,,Rattus norvegicus,1,,1969.0,
,15662,1,BAO_0000218,Plasma half life was observed after intravenous administration in rat,50597,In vivo,Plasma,CHEMBL620497,Intermediate,10116.0,,N,,A,7765,,,Rattus norvegicus,1,,1969.0,
,1465,1,BAO_0000218,Plasma half-life was determined,50597,,Plasma,CHEMBL620498,Intermediate,10116.0,,N,,A,7766,,,Rattus norvegicus,1,,1969.0,
,1446,1,BAO_0000218,Plasma half-life following oral administration in Fisher rats,50597,In vivo,Plasma,CHEMBL620499,Intermediate,10116.0,,N,,A,7767,,,Rattus norvegicus,1,,1969.0,
,6824,1,BAO_0000218,Plasma half-life in rat,50597,,Plasma,CHEMBL620500,Intermediate,10116.0,,N,,A,7768,,,Rattus norvegicus,1,,1969.0,
,17533,1,BAO_0000218,Plasmatic Half-life after intravenous administration to rat,50597,In vivo,Plasma,CHEMBL873809,Intermediate,10116.0,,N,,A,7769,,,Rattus norvegicus,1,,1969.0,
,5979,1,BAO_0000218,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,50597,In vivo,,CHEMBL620501,Intermediate,10116.0,,N,,A,7770,,,Rattus norvegicus,1,,,
,4689,1,BAO_0000218,Terminal half life after intravenous administration (1 mg/kg) in rat,50597,In vivo,,CHEMBL620502,Intermediate,10116.0,,N,,A,7771,,,Rattus norvegicus,1,,,
,4689,1,BAO_0000218,Terminal half life in Rat at a oral dose of 5 mg/kg,50597,In vivo,,CHEMBL620503,Intermediate,10116.0,,N,,A,7772,,,Rattus norvegicus,1,,,
,2463,1,BAO_0000218,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,50597,In vivo,,CHEMBL620504,Intermediate,10116.0,,N,,A,7773,,,Rattus norvegicus,1,,,
,4883,1,BAO_0000218,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,50597,In vivo,,CHEMBL876605,Intermediate,10116.0,,N,,A,7774,,,Rattus norvegicus,1,,,
,4883,1,BAO_0000218,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,50597,In vivo,,CHEMBL620505,Intermediate,10116.0,,N,,A,7775,,,Rattus norvegicus,1,,,
,15662,1,BAO_0000218,plasma half life was observed after intravenous administration in rat,50597,In vivo,Plasma,CHEMBL873811,Intermediate,10116.0,,N,,A,7776,,,Rattus norvegicus,1,,1969.0,
,3598,1,BAO_0000218,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,In vivo,,CHEMBL624016,Expert,10116.0,,N,,A,7777,,,Rattus norvegicus,1,,,
,4576,1,BAO_0000218,Half life of compound determined in rat,50597,,,CHEMBL624017,Intermediate,10116.0,,N,,A,7778,,,Rattus norvegicus,1,,,
,4576,1,BAO_0000218,Mean residence time determined in rat,50597,,,CHEMBL624018,Intermediate,10116.0,,N,,A,7779,,,Rattus norvegicus,1,,,
,4576,1,BAO_0000218,Plasma half life determined in rat,50597,,,CHEMBL624019,Intermediate,10116.0,,N,,A,7780,,,Rattus norvegicus,1,,,
,4910,1,BAO_0000218,Compound was evaluated for Tmax in brain after intravenous administration in male rats,50597,In vivo,Brain,CHEMBL624020,Intermediate,10116.0,,N,,A,7781,,,Rattus norvegicus,1,,955.0,
,4891,1,BAO_0000218,Compound was evaluated for pharmacokinetic parameter maximum time period,50597,In vivo,,CHEMBL624201,Intermediate,10116.0,,N,,A,7782,,,Rattus norvegicus,1,,,
,429,1,BAO_0000218,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,50597,In vivo,,CHEMBL872528,Intermediate,10116.0,,N,,A,7783,,,Rattus norvegicus,1,,,
,5974,1,BAO_0000218,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,In vivo,,CHEMBL624202,Intermediate,10116.0,,N,,A,7784,,,Rattus norvegicus,1,,,
,5974,1,BAO_0000218,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,In vivo,,CHEMBL624203,Intermediate,10116.0,,N,,A,7785,,,Rattus norvegicus,1,,,
,5974,1,BAO_0000218,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,50597,In vivo,,CHEMBL624350,Intermediate,10116.0,,N,,A,7786,,,Rattus norvegicus,1,,,
,5974,1,BAO_0000218,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,In vivo,,CHEMBL621320,Intermediate,10116.0,,N,,A,7787,,,Rattus norvegicus,1,,,
,17582,1,BAO_0000218,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,50597,In vivo,,CHEMBL621321,Intermediate,10116.0,,N,,A,7788,,,Rattus norvegicus,1,,,
,4026,1,BAO_0000218,Maximum time (Tmax) required to reach Cmax in rats,50597,,,CHEMBL621322,Intermediate,10116.0,,N,,A,7789,,,Rattus norvegicus,1,,,
,4890,1,BAO_0000218,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,50597,In vivo,,CHEMBL621323,Intermediate,10116.0,,N,,A,7790,,,Rattus norvegicus,1,,,
,6571,1,BAO_0000218,Maximum time of clearance of compound in rats after peroral administration,50597,In vivo,,CHEMBL621324,Intermediate,10116.0,,N,,A,7791,,,Rattus norvegicus,1,,,
,4727,1,BAO_0000218,Maximum time at the dose of 2 mg/kg in rat,50597,,,CHEMBL621325,Intermediate,10116.0,,N,,A,7792,,,Rattus norvegicus,1,,,
,17651,1,BAO_0000218,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,50597,In vivo,Plasma,CHEMBL875837,Intermediate,10116.0,,N,,A,7793,,,Rattus norvegicus,1,,1969.0,
,17651,1,BAO_0000218,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,50597,In vivo,Plasma,CHEMBL621326,Intermediate,10116.0,,N,,A,7794,,,Rattus norvegicus,1,,1969.0,
,14465,1,BAO_0000218,Tmax in Guinea pig (PO dose),50597,In vivo,,CHEMBL621327,Intermediate,10116.0,,N,,A,7795,,,Rattus norvegicus,1,,,
,14941,1,BAO_0000218,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",50597,In vivo,,CHEMBL621328,Intermediate,10116.0,,N,,A,7796,,,Rattus norvegicus,1,,,
,5960,1,BAO_0000218,Pharmacokinetic parameter (Tmax) in rat,50597,In vivo,,CHEMBL621329,Intermediate,10116.0,,N,,A,7797,,,Rattus norvegicus,1,,,
,5022,1,BAO_0000218,Pharmacokinetic parameter (Tmax) was estimated,50597,In vivo,,CHEMBL621330,Intermediate,10116.0,,N,,A,7798,,,Rattus norvegicus,1,,,
,4408,1,BAO_0000218,Pharmacokinetic property (Tmax) in rat,50597,In vivo,,CHEMBL621331,Intermediate,10116.0,,N,,A,7799,,,Rattus norvegicus,1,,,
,5983,1,BAO_0000218,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,50597,In vivo,,CHEMBL621332,Intermediate,10116.0,,N,,A,7800,,,Rattus norvegicus,1,,,
,4689,1,BAO_0000218,T max in Rat at a oral dose of 5 mg/kg,50597,In vivo,,CHEMBL621333,Intermediate,10116.0,,N,,A,7801,,,Rattus norvegicus,1,,,
,2792,1,BAO_0000218,T max was determined at 10 mg/kg po dose in rats,50597,In vivo,,CHEMBL621334,Intermediate,10116.0,,N,,A,7802,,,Rattus norvegicus,1,,,
,15011,1,BAO_0000218,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),50594,,,CHEMBL621335,Intermediate,10090.0,,N,,A,7803,,,Mus musculus,1,,,
,14180,1,BAO_0000218,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,50588,,,CHEMBL621336,Intermediate,9615.0,,N,,A,7804,,,Canis lupus familiaris,1,,,
,14180,1,BAO_0000218,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,50597,,,CHEMBL621337,Intermediate,10116.0,,N,,A,7805,,,Rattus norvegicus,1,,,
,14599,1,BAO_0000218,Area under curve was measured after i.v. administration into Beagle dog.,50588,,,CHEMBL621338,Intermediate,9615.0,,N,,A,7806,,,Canis lupus familiaris,1,,,
,14599,1,BAO_0000218,Area under curve was measured after iv administration into Beagle dog,50588,,,CHEMBL875838,Intermediate,9615.0,,N,,A,7807,,,Canis lupus familiaris,1,,,
,14599,1,BAO_0000218,Area under curve was measured after po administration into Beagle dog,50588,,,CHEMBL621339,Intermediate,9615.0,,N,,A,7808,,,Canis lupus familiaris,1,,,
,14599,1,BAO_0000218,Area under curve was measured after po administration into Beagle dog.,50588,,,CHEMBL621340,Intermediate,9615.0,,N,,A,7809,,,Canis lupus familiaris,1,,,
,15675,0,BAO_0000218,Area under curve was measured at peroral dose of 3 mg/kg,22224,,,CHEMBL621341,Autocuration,,,U,,A,7810,,,,1,,,
,12706,0,BAO_0000019,Area under curve was measured by using concentration Vs time,22224,,,CHEMBL621342,Autocuration,,,U,,A,7811,,,,1,,,
,12706,0,BAO_0000019,Area under curve was measured by using concentration Vs time; not tested,22224,,,CHEMBL621343,Autocuration,,,U,,A,7812,,,,1,,,
,9750,1,BAO_0000218,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),50594,,,CHEMBL621344,Intermediate,10090.0,,N,,A,7813,,,Mus musculus,1,,,
,9750,1,BAO_0000218,Area under curve(AUC) was measured in mice after oral administration.,50594,,,CHEMBL621345,Intermediate,10090.0,,N,,A,7814,,,Mus musculus,1,,,
,14691,0,BAO_0000019,Area under curve(AUC) value of the compound,22224,,,CHEMBL621346,Autocuration,,,U,,A,7815,,,,1,,,
,14691,0,BAO_0000218,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,22224,,,CHEMBL621347,Autocuration,,,U,,A,7816,,,,1,,,
,14691,1,BAO_0000218,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,50588,,,CHEMBL621348,Intermediate,9615.0,,N,,A,7817,,,Canis lupus familiaris,1,,,
,2939,0,BAO_0000019,Area under curve(carotid artery) was determined by the availability in blood,22224,,Blood,CHEMBL621349,Autocuration,,,U,,A,7818,,,,1,,178.0,
,2939,0,BAO_0000019,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,22224,,Blood,CHEMBL621350,Autocuration,,,U,,A,7819,,,,1,,178.0,
,2939,0,BAO_0000019,Area under curve(carotid artery) was determined by the availability in blood; No data,22224,,Blood,CHEMBL875839,Autocuration,,,U,,A,7820,,,,1,,178.0,
,2939,0,BAO_0000019,Area under curve(portal vein) was determined by the availability in blood,22224,,Blood,CHEMBL620211,Autocuration,,,U,,A,7821,,,,1,,178.0,
,2939,0,BAO_0000019,Area under curve(portal vein) was determined by the availability in blood; ND means no data,22224,,Blood,CHEMBL620212,Autocuration,,,U,,A,7822,,,,1,,178.0,
,2939,0,BAO_0000019,Area under curve(portal vein) was determined by the availability in blood; No data,22224,,Blood,CHEMBL620213,Autocuration,,,U,,A,7823,,,,1,,178.0,
,9552,1,BAO_0000218,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",50797,,Plasma,CHEMBL620214,Intermediate,9544.0,,N,,A,7824,,,Macaca mulatta,1,,1969.0,
,9552,1,BAO_0000218,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",50797,,Plasma,CHEMBL620215,Intermediate,9544.0,,N,,A,7825,,,Macaca mulatta,1,,1969.0,
,9552,1,BAO_0000218,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,50797,,Plasma,CHEMBL620216,Intermediate,9544.0,,N,,A,7826,,,Macaca mulatta,1,,1969.0,
,9552,1,BAO_0000218,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",50588,,Plasma,CHEMBL620888,Intermediate,9615.0,,N,,A,7827,,,Canis lupus familiaris,1,,1969.0,
,9552,1,BAO_0000218,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",50588,,Plasma,CHEMBL620889,Intermediate,9615.0,,N,,A,7828,,,Canis lupus familiaris,1,,1969.0,
,9552,0,BAO_0000019,Area under plasma concentration vs time curve observed in rats for 0-3 h,22224,,Plasma,CHEMBL620890,Autocuration,,,U,,A,7829,,,,1,,1969.0,
,11911,1,BAO_0000218,Area under plasma time curve determined in male rat,50597,,Plasma,CHEMBL620891,Intermediate,10116.0,,N,,A,7830,,,Rattus norvegicus,1,,1969.0,
,16618,0,BAO_0000019,Area under the MAP curve measured over 5 min.,22224,,,CHEMBL620892,Autocuration,,,U,,A,7831,,,,1,,,
,14387,1,BAO_0000218,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,50594,,,CHEMBL621079,Intermediate,10090.0,,N,,A,7832,,,Mus musculus,1,,,
,14387,1,BAO_0000218,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,50594,,,CHEMBL621080,Intermediate,10090.0,,N,,A,7833,,,Mus musculus,1,,,
,12836,1,BAO_0000218,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,50588,,,CHEMBL621081,Intermediate,9615.0,,N,,A,7834,,,Canis lupus familiaris,1,,,
,12836,1,BAO_0000218,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,100712,,,CHEMBL621082,Intermediate,10026.0,,N,,A,7835,,,Cricetinae,1,,,
,12836,1,BAO_0000218,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,50597,,,CHEMBL621083,Intermediate,10116.0,,N,,A,7836,,,Rattus norvegicus,1,,,
,14339,1,BAO_0000218,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,50588,,,CHEMBL621084,Intermediate,9615.0,,N,,A,7837,,,Canis lupus familiaris,1,,,
,14339,1,BAO_0000218,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,50588,,,CHEMBL621085,Intermediate,9615.0,,N,,A,7838,,,Canis lupus familiaris,1,,,
,14339,1,BAO_0000218,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,50588,,,CHEMBL621086,Intermediate,9615.0,,N,,A,7839,,,Canis lupus familiaris,1,,,
,10524,1,BAO_0000218,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),50588,,,CHEMBL621087,Intermediate,9615.0,,N,,A,7840,,,Canis lupus familiaris,1,,,
,9994,1,BAO_0000218,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),50588,,,CHEMBL622607,Intermediate,9615.0,,N,,A,7841,,,Canis lupus familiaris,1,,,
,11325,1,BAO_0000218,Serum AUC in marmosets (IV dose),50588,,,CHEMBL622608,Intermediate,9615.0,,N,,A,7842,,,Canis lupus familiaris,1,,,
,12536,0,BAO_0000019,Area under the curve after intravenous administration at a dose of 10 umol/kg,22224,,,CHEMBL624481,Autocuration,,,U,,A,7843,,,,1,,,
,12536,0,BAO_0000019,Area under the curve after intravenous administration at a dose of 2 umol/kg,22224,,,CHEMBL624482,Autocuration,,,U,,A,7844,,,,1,,,
,12536,0,BAO_0000019,Area under the curve after intravenous administration at a dose of 4 umol/kg,22224,,,CHEMBL624483,Autocuration,,,U,,A,7845,,,,1,,,
,12536,0,BAO_0000019,Area under the curve after intravenous administration at a dose of 40 umol/kg,22224,,,CHEMBL624484,Autocuration,,,U,,A,7846,,,,1,,,
,12536,0,BAO_0000019,Area under the curve after intravenous administration at a dose of 5 umol/kg,22224,,,CHEMBL624485,Autocuration,,,U,,A,7847,,,,1,,,
,15556,1,BAO_0000218,Area under the curve for fumarate salt was evaluated in F344 Rats.,50597,,,CHEMBL624486,Intermediate,10116.0,,N,,A,7848,,,Rattus norvegicus,1,,,
,2809,0,BAO_0000019,Area under the curve for the compound was calculated.,22224,,,CHEMBL624487,Autocuration,,,U,,A,7849,,,,1,,,
,9511,0,BAO_0000019,Area under the curve in concentration/ time,22224,,,CHEMBL624488,Autocuration,,,U,,A,7850,,,,1,,,
,12818,1,BAO_0000218,Area under the curve administered intraintestinal in rats.,50597,,,CHEMBL624489,Intermediate,10116.0,,N,,A,7851,,,Rattus norvegicus,1,,,
,12818,1,BAO_0000218,Area under the curve administered intravenously in rats.,50597,,,CHEMBL625184,Intermediate,10116.0,,N,,A,7852,,,Rattus norvegicus,1,,,
,15118,0,BAO_0000019,Area under the curve during intravenous administration,22224,,,CHEMBL625185,Autocuration,,,U,,A,7853,,,,1,,,
,15118,0,BAO_0000019,Area under the curve during intravenous administration; Not determined,22224,,,CHEMBL875954,Autocuration,,,U,,A,7854,,,,1,,,
,15118,0,BAO_0000019,Area under the curve during systemic administration,22224,,,CHEMBL625186,Autocuration,,,U,,A,7855,,,,1,,,
,15118,0,BAO_0000019,Area under the curve during systemic administration; Not determined,22224,,,CHEMBL625187,Autocuration,,,U,,A,7856,,,,1,,,
,2632,0,BAO_0000019,Area under the curve was calculated for the compound.,22224,,,CHEMBL625188,Autocuration,,,U,,A,7857,,,,1,,,
,14346,1,BAO_0000218,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,50588,,,CHEMBL625189,Intermediate,9615.0,,N,,A,7858,,,Canis lupus familiaris,1,,,
,14346,1,BAO_0000218,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,50588,,,CHEMBL625190,Intermediate,9615.0,,N,,A,7859,,,Canis lupus familiaris,1,,,
,14346,1,BAO_0000218,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,50597,,,CHEMBL621733,Intermediate,10116.0,,N,,A,7860,,,Rattus norvegicus,1,,,
,14346,1,BAO_0000218,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,50597,,,CHEMBL621734,Intermediate,10116.0,,N,,A,7861,,,Rattus norvegicus,1,,,
,11149,1,BAO_0000218,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,50597,,,CHEMBL621735,Intermediate,10116.0,,N,,A,7862,,,Rattus norvegicus,1,,,
,17796,1,BAO_0000218,Clearance of the drug was measured in the plasma of rat; No data,50597,,Plasma,CHEMBL621736,Intermediate,10116.0,,N,,A,7863,,,Rattus norvegicus,1,,1969.0,
,5247,1,BAO_0000218,The pharmacokinetic parameter plasma clearance in vivo in rats,50597,,Plasma,CHEMBL621737,Intermediate,10116.0,,N,,A,7864,,,Rattus norvegicus,1,,1969.0,
,4727,1,BAO_0000218,Plasma clearance at the dose of 2 mg/kg in rat,50597,,,CHEMBL621738,Intermediate,10116.0,,N,,A,7865,,,Rattus norvegicus,1,,,
,5654,1,BAO_0000218,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,50597,In vivo,,CHEMBL622806,Intermediate,10116.0,,N,,A,7866,,,Rattus norvegicus,1,,,
,5654,1,BAO_0000218,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,50597,In vivo,,CHEMBL623519,Intermediate,10116.0,,N,,A,7867,,,Rattus norvegicus,1,,,
,17260,1,BAO_0000218,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,50597,In vivo,,CHEMBL623520,Intermediate,10116.0,,N,,A,7868,,,Rattus norvegicus,1,,,
,17065,1,BAO_0000218,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,50597,In vivo,,CHEMBL623521,Intermediate,10116.0,,N,,A,7869,,,Rattus norvegicus,1,,,
,17671,1,BAO_0000218,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,50597,In vivo,,CHEMBL623522,Intermediate,10116.0,,N,,A,7870,,,Rattus norvegicus,1,,,
,6672,1,BAO_0000218,Clearance rate in rat,50597,In vivo,,CHEMBL623523,Intermediate,10116.0,,N,,A,7871,,,Rattus norvegicus,1,,,
,6673,1,BAO_0000218,Clearance rate in rat,50597,In vivo,,CHEMBL623690,Intermediate,10116.0,,N,,A,7872,,,Rattus norvegicus,1,,,
,5978,1,BAO_0000218,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,In vivo,,CHEMBL623691,Intermediate,10116.0,,N,,A,7873,,,Rattus norvegicus,1,,,
,5978,1,BAO_0000218,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,In vivo,,CHEMBL623692,Intermediate,10116.0,,N,,A,7874,,,Rattus norvegicus,1,,,
,5978,1,BAO_0000218,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,In vivo,,CHEMBL623693,Intermediate,10116.0,,N,,A,7875,,,Rattus norvegicus,1,,,
,5978,1,BAO_0000218,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,In vivo,,CHEMBL623694,Intermediate,10116.0,,N,,A,7876,,,Rattus norvegicus,1,,,
,4413,1,BAO_0000218,Clearance of compound after iv administration of 20 mg/kg dose in rat,50597,In vivo,,CHEMBL623695,Intermediate,10116.0,,N,,A,7877,,,Rattus norvegicus,1,,,
,2661,1,BAO_0000218,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,50597,In vivo,,CHEMBL623696,Intermediate,10116.0,,N,,A,7878,,,Rattus norvegicus,1,,,
,2661,1,BAO_0000218,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,50597,In vivo,,CHEMBL623697,Intermediate,10116.0,,N,,A,7879,,,Rattus norvegicus,1,,,
,5005,0,BAO_0000218,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,In vivo,Plasma,CHEMBL623698,Intermediate,9544.0,,U,,A,7880,,,Macaca mulatta,1,,1969.0,
,5005,0,BAO_0000218,Compound was tested for its plasma clearance rate in Sprague Dawley rats,22224,In vivo,Plasma,CHEMBL623699,Intermediate,10116.0,,U,,A,7881,,,Rattus norvegicus,1,,1969.0,
,15765,1,BAO_0000218,Mean (%CV) PK parameters for CL(mL/min/kg).,50597,In vivo,,CHEMBL623700,Intermediate,10116.0,,N,,A,7882,,,Rattus norvegicus,1,,,
,3747,1,BAO_0000218,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,50597,In vivo,,CHEMBL623701,Intermediate,10116.0,,N,,A,7883,,,Rattus norvegicus,1,,,
,16366,1,BAO_0000218,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,50597,In vivo,Plasma,CHEMBL623702,Intermediate,10116.0,,N,,A,7884,,,Rattus norvegicus,1,,1969.0,
,4199,1,BAO_0000218,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,50597,In vivo,,CHEMBL623703,Intermediate,10116.0,,N,,A,7885,,,Rattus norvegicus,1,,,
,17267,1,BAO_0000218,Plasma clearance in rat was determined,50597,In vivo,,CHEMBL623704,Intermediate,10116.0,,N,,A,7886,,,Rattus norvegicus,1,,,
,6535,1,BAO_0000218,Plasma clearance in rat after administration of 2 mg/kg iv,50597,In vivo,,CHEMBL623705,Intermediate,10116.0,,N,,A,7887,,,Rattus norvegicus,1,,,
,6535,1,BAO_0000218,Plasma clearance in rat after administration of 2 mg/kg iv,50597,In vivo,,CHEMBL623706,Intermediate,10116.0,,N,,A,7888,,,Rattus norvegicus,1,,,
,5041,1,BAO_0000218,Plasma clearance was determined,50597,In vivo,,CHEMBL623707,Intermediate,10116.0,,N,,A,7889,,,Rattus norvegicus,1,,,
,5960,1,BAO_0000218,Plasma clearance in rat,50597,In vivo,,CHEMBL623708,Intermediate,10116.0,,N,,A,7890,,,Rattus norvegicus,1,,,
,5937,1,BAO_0000218,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,50597,In vivo,,CHEMBL623709,Intermediate,10116.0,,N,,A,7891,,,Rattus norvegicus,1,,,
,5871,1,BAO_0000218,Plasma clearance in rat by iv administration,50597,In vivo,,CHEMBL623710,Intermediate,10116.0,,N,,A,7892,,,Rattus norvegicus,1,,,
,5874,1,BAO_0000218,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,50597,In vivo,,CHEMBL623711,Intermediate,10116.0,,N,,A,7893,,,Rattus norvegicus,1,,,
,6504,1,BAO_0000218,Plasma clearance in rat p.o.,50597,In vivo,,CHEMBL623712,Intermediate,10116.0,,N,,A,7894,,,Rattus norvegicus,1,,,
,6803,1,BAO_0000218,Plasma clearance in rats,50597,In vivo,,CHEMBL623713,Intermediate,10116.0,,N,,A,7895,,,Rattus norvegicus,1,,,
,5041,1,BAO_0000218,Plasma clearance was determined; ND denotes no data,50597,In vivo,,CHEMBL623714,Intermediate,10116.0,,N,,A,7896,,,Rattus norvegicus,1,,,
,5041,1,BAO_0000218,Plasma clearance was determined; ND denotes not determined,50597,In vivo,,CHEMBL623715,Intermediate,10116.0,,N,,A,7897,,,Rattus norvegicus,1,,,
,1916,1,BAO_0000218,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,50597,In vivo,,CHEMBL623716,Intermediate,10116.0,,N,,A,7898,,,Rattus norvegicus,1,,,
,5199,1,BAO_0000218,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,50597,In vivo,,CHEMBL622980,Intermediate,10116.0,,N,,A,7899,,,Rattus norvegicus,1,,,
,16367,1,BAO_0000218,Plasma administration to rats,50597,In vivo,,CHEMBL622981,Intermediate,10116.0,,N,,A,7900,,,Rattus norvegicus,1,,,
,6362,1,BAO_0000218,Plasma clearance of the compound in female Sprague-Dawley rats,50597,In vivo,,CHEMBL622982,Intermediate,10116.0,,N,,A,7901,,,Rattus norvegicus,1,,,
,15662,1,BAO_0000218,Plasma clearance was observed after intravenous administration in rat,50597,In vivo,,CHEMBL622983,Intermediate,10116.0,,N,,A,7902,,,Rattus norvegicus,1,,,
,6215,1,BAO_0000218,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,50597,In vivo,,CHEMBL622984,Intermediate,10116.0,,N,,A,7903,,,Rattus norvegicus,1,,,
,1466,1,BAO_0000218,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,50597,In vivo,,CHEMBL622985,Intermediate,10116.0,,N,,A,7904,,,Rattus norvegicus,1,,,
,15662,1,BAO_0000218,plasma clearance was observed after intravenous administration in rat,50597,In vivo,Plasma,CHEMBL623631,Intermediate,10116.0,,N,,A,7905,,,Rattus norvegicus,1,,1969.0,
,4723,1,BAO_0000218,In vivo CL/F determined,50597,In vivo,,CHEMBL623632,Intermediate,10116.0,,N,,A,7906,,,Rattus norvegicus,1,,,
,2792,1,BAO_0000218,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,50597,In vivo,Plasma,CHEMBL623633,Intermediate,10116.0,,N,,A,7907,,,Rattus norvegicus,1,,1969.0,
,2792,1,BAO_0000218,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,50597,In vivo,Plasma,CHEMBL623634,Intermediate,10116.0,,N,,A,7908,,,Rattus norvegicus,1,,1969.0,
,5213,1,BAO_0000218,Compound was tested for the lower blood clearance in rat,50597,In vivo,,CHEMBL623635,Intermediate,10116.0,,N,,A,7909,,,Rattus norvegicus,1,,,
,4687,1,BAO_0000218,Evaluated for the low clearance in rat (in vivo),50597,In vivo,,CHEMBL621195,Intermediate,10116.0,,N,,A,7910,,,Rattus norvegicus,1,,,
,3371,1,BAO_0000218,Pharmacokinetic property (CLb)of the compound was determined in rat,50597,In vivo,,CHEMBL621196,Intermediate,10116.0,,N,,A,7911,,,Rattus norvegicus,1,,,
,4690,1,BAO_0000218,Rapid clearance after intravenous administration in rat was determined,50597,In vivo,,CHEMBL875287,Intermediate,10116.0,,N,,A,7912,,,Rattus norvegicus,1,,,
,5702,1,BAO_0000218,Clearance measured in rat,50597,In vivo,,CHEMBL621197,Intermediate,10116.0,,N,,A,7913,,,Rattus norvegicus,1,,,
,740,1,BAO_0000218,Compound was evaluated for plasma clearance in rat,50597,In vivo,Plasma,CHEMBL621198,Intermediate,10116.0,,N,,A,7914,,,Rattus norvegicus,1,,1969.0,
,4853,1,BAO_0000218,Low plasma clearance was calculated in rat,50597,In vivo,Plasma,CHEMBL621199,Intermediate,10116.0,,N,,A,7915,,,Rattus norvegicus,1,,1969.0,
,5789,1,BAO_0000218,Pharmacokinetic property (Clp) in rat,50597,In vivo,,CHEMBL621200,Intermediate,10116.0,,N,,A,7916,,,Rattus norvegicus,1,,,
,4527,1,BAO_0000218,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,50597,In vivo,,CHEMBL621201,Intermediate,10116.0,,N,,A,7917,,,Rattus norvegicus,1,,,
,4527,1,BAO_0000218,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,50597,In vivo,,CHEMBL621202,Intermediate,10116.0,,N,,A,7918,,,Rattus norvegicus,1,,,
,6518,1,BAO_0000218,Plasma clearance after IV dosing at 0.5 mg/kg in rat,50597,In vivo,,CHEMBL621203,Intermediate,10116.0,,N,,A,7919,,,Rattus norvegicus,1,,,
,6518,1,BAO_0000218,Plasma clearance after IV dosing at 1 mg/kg in rat,50597,In vivo,,CHEMBL621204,Intermediate,10116.0,,N,,A,7920,,,Rattus norvegicus,1,,,
,9866,1,BAO_0000218,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,50597,In vivo,Heart,CHEMBL621205,Intermediate,10116.0,,N,,A,7921,,,Rattus norvegicus,1,,948.0,
,9866,1,BAO_0000218,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,50597,In vivo,Heart,CHEMBL621206,Intermediate,10116.0,,N,,A,7922,,,Rattus norvegicus,1,,948.0,
,9866,1,BAO_0000218,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,50597,In vivo,Heart,CHEMBL621207,Intermediate,10116.0,,N,,A,7923,,,Rattus norvegicus,1,,948.0,
,9866,1,BAO_0000218,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,50597,In vivo,Heart,CHEMBL621208,Intermediate,10116.0,,N,,A,7924,,,Rattus norvegicus,1,,948.0,
,9866,1,BAO_0000218,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,50597,In vivo,Heart,CHEMBL621209,Intermediate,10116.0,,N,,A,7925,,,Rattus norvegicus,1,,948.0,
,9866,1,BAO_0000218,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,50597,In vivo,Heart,CHEMBL876484,Intermediate,10116.0,,N,,A,7926,,,Rattus norvegicus,1,,948.0,
,9866,1,BAO_0000218,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,50597,In vivo,Heart,CHEMBL621210,Intermediate,10116.0,,N,,A,7927,,,Rattus norvegicus,1,,948.0,
,9866,1,BAO_0000218,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,50597,In vivo,Heart,CHEMBL621211,Intermediate,10116.0,,N,,A,7928,,,Rattus norvegicus,1,,948.0,
,9866,1,BAO_0000218,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,50597,In vivo,Heart,CHEMBL621212,Intermediate,10116.0,,N,,A,7929,,,Rattus norvegicus,1,,948.0,
,9866,1,BAO_0000218,Biodistribution in rat heart in the presence of GdDTPA at 15 min,50597,In vivo,Heart,CHEMBL621213,Intermediate,10116.0,,N,,A,7930,,,Rattus norvegicus,1,,948.0,
,9866,1,BAO_0000218,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,50597,In vivo,Heart,CHEMBL621214,Intermediate,10116.0,,N,,A,7931,,,Rattus norvegicus,1,,948.0,
,9866,1,BAO_0000218,Biodistribution in rat heart in the presence of GdDTPA at 30 min,50597,In vivo,Heart,CHEMBL621215,Intermediate,10116.0,,N,,A,7932,,,Rattus norvegicus,1,,948.0,
,9866,1,BAO_0000218,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,50597,In vivo,Heart,CHEMBL621216,Intermediate,10116.0,,N,,A,7933,,,Rattus norvegicus,1,,948.0,
,9866,1,BAO_0000218,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,50597,In vivo,Heart,CHEMBL621217,Intermediate,10116.0,,N,,A,7934,,,Rattus norvegicus,1,,948.0,
,9866,1,BAO_0000218,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,50597,In vivo,Heart,CHEMBL621218,Intermediate,10116.0,,N,,A,7935,,,Rattus norvegicus,1,,948.0,
,9866,1,BAO_0000218,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,50597,In vivo,Heart,CHEMBL621219,Intermediate,10116.0,,N,,A,7936,,,Rattus norvegicus,1,,948.0,
,9866,1,BAO_0000218,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,50597,In vivo,Heart,CHEMBL621220,Intermediate,10116.0,,N,,A,7937,,,Rattus norvegicus,1,,948.0,
,9866,1,BAO_0000218,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,50597,In vivo,Heart,CHEMBL621221,Intermediate,10116.0,,N,,A,7938,,,Rattus norvegicus,1,,948.0,
,9866,1,BAO_0000218,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,50597,In vivo,Heart,CHEMBL621222,Intermediate,10116.0,,N,,A,7939,,,Rattus norvegicus,1,,948.0,
,9866,1,BAO_0000218,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,50597,In vivo,Heart,CHEMBL621223,Intermediate,10116.0,,N,,A,7940,,,Rattus norvegicus,1,,948.0,
,9866,1,BAO_0000218,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,50597,In vivo,Heart,CHEMBL876485,Intermediate,10116.0,,N,,A,7941,,,Rattus norvegicus,1,,948.0,
,9866,1,BAO_0000218,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,50597,In vivo,Heart,CHEMBL621224,Intermediate,10116.0,,N,,A,7942,,,Rattus norvegicus,1,,948.0,
,9866,1,BAO_0000218,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,50597,In vivo,Heart,CHEMBL621225,Intermediate,10116.0,,N,,A,7943,,,Rattus norvegicus,1,,948.0,
,9866,1,BAO_0000218,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,50597,In vivo,Heart,CHEMBL621226,Intermediate,10116.0,,N,,A,7944,,,Rattus norvegicus,1,,948.0,
,9866,1,BAO_0000218,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,50597,In vivo,Kidney,CHEMBL621227,Intermediate,10116.0,,N,,A,7945,,,Rattus norvegicus,1,,2113.0,
,9866,1,BAO_0000218,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,50597,In vivo,Kidney,CHEMBL621228,Intermediate,10116.0,,N,,A,7946,,,Rattus norvegicus,1,,2113.0,
,9866,1,BAO_0000218,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,50597,In vivo,Kidney,CHEMBL621229,Intermediate,10116.0,,N,,A,7947,,,Rattus norvegicus,1,,2113.0,
,9866,1,BAO_0000218,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,50597,In vivo,Kidney,CHEMBL621230,Intermediate,10116.0,,N,,A,7948,,,Rattus norvegicus,1,,2113.0,
,9866,1,BAO_0000218,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,50597,In vivo,Kidney,CHEMBL621231,Intermediate,10116.0,,N,,A,7949,,,Rattus norvegicus,1,,2113.0,
,9866,1,BAO_0000218,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,50597,In vivo,Kidney,CHEMBL621232,Intermediate,10116.0,,N,,A,7950,,,Rattus norvegicus,1,,2113.0,
,9866,1,BAO_0000218,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,50597,In vivo,Kidney,CHEMBL621233,Intermediate,10116.0,,N,,A,7951,,,Rattus norvegicus,1,,2113.0,
,9866,1,BAO_0000218,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,50597,In vivo,Kidney,CHEMBL621234,Intermediate,10116.0,,N,,A,7952,,,Rattus norvegicus,1,,2113.0,
,9866,1,BAO_0000218,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,50597,In vivo,Kidney,CHEMBL621235,Intermediate,10116.0,,N,,A,7953,,,Rattus norvegicus,1,,2113.0,
,9866,1,BAO_0000218,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,50597,In vivo,Kidney,CHEMBL621236,Intermediate,10116.0,,N,,A,7954,,,Rattus norvegicus,1,,2113.0,
,9866,1,BAO_0000218,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,50597,In vivo,Kidney,CHEMBL621237,Intermediate,10116.0,,N,,A,7955,,,Rattus norvegicus,1,,2113.0,
,9866,1,BAO_0000218,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,50597,In vivo,Kidney,CHEMBL876486,Intermediate,10116.0,,N,,A,7956,,,Rattus norvegicus,1,,2113.0,
,9866,1,BAO_0000218,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,50597,In vivo,Intestine,CHEMBL622436,Intermediate,10116.0,,N,,A,7957,,,Rattus norvegicus,1,,160.0,
,9866,1,BAO_0000218,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,50597,In vivo,Intestine,CHEMBL622437,Intermediate,10116.0,,N,,A,7958,,,Rattus norvegicus,1,,160.0,
,9866,1,BAO_0000218,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,50597,In vivo,Intestine,CHEMBL622438,Intermediate,10116.0,,N,,A,7959,,,Rattus norvegicus,1,,160.0,
,9866,1,BAO_0000218,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,50597,In vivo,Liver,CHEMBL622439,Intermediate,10116.0,,N,,A,7960,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,50597,In vivo,Liver,CHEMBL622440,Intermediate,10116.0,,N,,A,7961,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,50597,In vivo,Liver,CHEMBL622441,Intermediate,10116.0,,N,,A,7962,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,50597,In vivo,Liver,CHEMBL622442,Intermediate,10116.0,,N,,A,7963,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,50597,In vivo,Liver,CHEMBL622443,Intermediate,10116.0,,N,,A,7964,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,50597,In vivo,Liver,CHEMBL622444,Intermediate,10116.0,,N,,A,7965,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,50597,In vivo,Liver,CHEMBL622445,Intermediate,10116.0,,N,,A,7966,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,50597,In vivo,Liver,CHEMBL622446,Intermediate,10116.0,,N,,A,7967,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,50597,In vivo,Liver,CHEMBL622447,Intermediate,10116.0,,N,,A,7968,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,50597,In vivo,Liver,CHEMBL622448,Intermediate,10116.0,,N,,A,7969,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,50597,In vivo,Liver,CHEMBL622449,Intermediate,10116.0,,N,,A,7970,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,50597,In vivo,Liver,CHEMBL622450,Intermediate,10116.0,,N,,A,7971,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,50597,In vivo,Liver,CHEMBL622451,Intermediate,10116.0,,N,,A,7972,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in rat liver in the presence of GdDTPA at 15 min,50597,In vivo,Liver,CHEMBL622452,Intermediate,10116.0,,N,,A,7973,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,50597,In vivo,Liver,CHEMBL622453,Intermediate,10116.0,,N,,A,7974,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in rat liver in the presence of GdDTPA at 30 min,50597,In vivo,Liver,CHEMBL622454,Intermediate,10116.0,,N,,A,7975,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,50597,In vivo,Liver,CHEMBL622455,Intermediate,10116.0,,N,,A,7976,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,50597,In vivo,Liver,CHEMBL876024,Intermediate,10116.0,,N,,A,7977,,,Rattus norvegicus,1,,2107.0,
,2792,1,BAO_0000218,T max was determined at 3 mg/kg po dose in rats,50597,In vivo,,CHEMBL622456,Intermediate,10116.0,,N,,A,7978,,,Rattus norvegicus,1,,,
,15078,1,BAO_0000218,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",50597,In vivo,,CHEMBL622457,Intermediate,10116.0,,N,,A,7979,,,Rattus norvegicus,1,,,
,15078,1,BAO_0000218,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",50597,In vivo,,CHEMBL622458,Intermediate,10116.0,,N,,A,7980,,,Rattus norvegicus,1,,,
,15022,1,BAO_0000218,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,50597,,,CHEMBL622459,Intermediate,10116.0,,N,,A,7981,,,Rattus norvegicus,1,,,
,15022,1,BAO_0000218,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,50597,,,CHEMBL873343,Intermediate,10116.0,,N,,A,7982,,,Rattus norvegicus,1,,,
,15022,1,BAO_0000218,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,50597,,,CHEMBL622460,Intermediate,10116.0,,N,,A,7983,,,Rattus norvegicus,1,,,
,4576,1,BAO_0000218,Time for maximum plasma concentration determined in rat,50597,,Plasma,CHEMBL622461,Intermediate,10116.0,,N,,A,7984,,,Rattus norvegicus,1,,1969.0,
,6681,1,BAO_0000218,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,50597,In vivo,Plasma,CHEMBL622462,Intermediate,10116.0,,N,,A,7985,,,Rattus norvegicus,1,,1969.0,
,16365,1,BAO_0000218,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,50597,In vivo,,CHEMBL622463,Intermediate,10116.0,,N,,A,7986,,,Rattus norvegicus,1,,,
,16365,1,BAO_0000218,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,50597,In vivo,,CHEMBL622464,Intermediate,10116.0,,N,,A,7987,,,Rattus norvegicus,1,,,
,16365,1,BAO_0000218,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,50597,In vivo,,CHEMBL622465,Intermediate,10116.0,,N,,A,7988,,,Rattus norvegicus,1,,,
,16365,1,BAO_0000218,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,50597,In vivo,,CHEMBL622466,Intermediate,10116.0,,N,,A,7989,,,Rattus norvegicus,1,,,
,16365,1,BAO_0000218,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,50597,In vivo,,CHEMBL622467,Intermediate,10116.0,,N,,A,7990,,,Rattus norvegicus,1,,,
,6824,1,BAO_0000218,Time of maximum plasma concentration in rat,50597,,Plasma,CHEMBL622468,Intermediate,10116.0,,N,,A,7991,,,Rattus norvegicus,1,,1969.0,
,6685,1,BAO_0000218,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",50597,,Plasma,CHEMBL876025,Intermediate,10116.0,,N,,A,7992,,,Rattus norvegicus,1,,1969.0,
,6685,1,BAO_0000218,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",50597,,Plasma,CHEMBL622469,Intermediate,10116.0,,N,,A,7993,,,Rattus norvegicus,1,,1969.0,
,6685,1,BAO_0000218,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",50597,,Plasma,CHEMBL622470,Intermediate,10116.0,,N,,A,7994,,,Rattus norvegicus,1,,1969.0,
,15662,1,BAO_0000218,Time required to reach maximum concentration (Cmax) after oral administration in rat,50597,In vivo,,CHEMBL622471,Intermediate,10116.0,,N,,A,7995,,,Rattus norvegicus,1,,,
,1742,1,BAO_0000218,Time required to reach maximum concentration in rat plasma,50597,,Plasma,CHEMBL622472,Intermediate,10116.0,,N,,A,7996,,,Rattus norvegicus,1,,1969.0,
,2774,1,BAO_0000218,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,50597,In vivo,Plasma,CHEMBL622473,Intermediate,10116.0,,N,,A,7997,,,Rattus norvegicus,1,,1969.0,
,5199,1,BAO_0000218,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,50597,In vivo,Plasma,CHEMBL624282,Intermediate,10116.0,,N,,A,7998,,,Rattus norvegicus,1,,1969.0,
,12873,1,BAO_0000218,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,50597,In vivo,Plasma,CHEMBL624283,Intermediate,10116.0,,N,,A,7999,,,Rattus norvegicus,1,,1969.0,
,12873,1,BAO_0000218,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,50597,In vivo,Plasma,CHEMBL624284,Intermediate,10116.0,,N,,A,8000,,,Rattus norvegicus,1,,1969.0,
,1916,1,BAO_0000218,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,50597,In vivo,Plasma,CHEMBL624285,Intermediate,10116.0,,N,,A,8001,,,Rattus norvegicus,1,,1969.0,
,16367,1,BAO_0000218,Time to reach Cmax after oral administration to rats,50597,In vivo,,CHEMBL624286,Intermediate,10116.0,,N,,A,8002,,,Rattus norvegicus,1,,,
,16366,1,BAO_0000218,Time to reach Cmax when a dose of 1 mg/kg is administered orally,50597,In vivo,,CHEMBL624287,Intermediate,10116.0,,N,,A,8003,,,Rattus norvegicus,1,,,
,216,1,BAO_0000218,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,50597,,,CHEMBL624288,Intermediate,10116.0,,N,,A,8004,,,Rattus norvegicus,1,,,
,6410,1,BAO_0000218,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,50597,In vivo,Plasma,CHEMBL624289,Intermediate,10116.0,,N,,A,8005,,,Rattus norvegicus,1,,1969.0,
,6410,1,BAO_0000218,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,50597,In vivo,Plasma,CHEMBL873344,Intermediate,10116.0,,N,,A,8006,,,Rattus norvegicus,1,,1969.0,
,6215,1,BAO_0000218,Tmax after peroral administration (10 mg/kg) was determined in rat,50597,In vivo,,CHEMBL619623,Intermediate,10116.0,,N,,A,8007,,,Rattus norvegicus,1,,,
,3598,1,BAO_0000218,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,In vivo,,CHEMBL621399,Expert,10116.0,,N,,A,8008,,,Rattus norvegicus,1,,,
,4527,1,BAO_0000218,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,50597,In vivo,,CHEMBL621400,Intermediate,10116.0,,N,,A,8009,,,Rattus norvegicus,1,,,
,17670,1,BAO_0000218,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",50597,In vivo,,CHEMBL621401,Intermediate,10116.0,,N,,A,8010,,,Rattus norvegicus,1,,,
,1465,1,BAO_0000218,Tmax was determined,50597,,,CHEMBL621402,Intermediate,10116.0,,N,,A,8011,,,Rattus norvegicus,1,,,
,2552,1,BAO_0000218,Tmax was determined,50597,,,CHEMBL621403,Intermediate,10116.0,,N,,A,8012,,,Rattus norvegicus,1,,,
,5656,1,BAO_0000218,Tmax after oral administration in rat,50597,In vivo,,CHEMBL621121,Intermediate,10116.0,,N,,A,8013,,,Rattus norvegicus,1,,,
,17764,1,BAO_0000218,Tmax after peroral administration in rats at 2.4 uM/kg,50597,In vivo,,CHEMBL872525,Intermediate,10116.0,,N,,A,8014,,,Rattus norvegicus,1,,,
,5610,1,BAO_0000218,Tmax in male rat,50597,,,CHEMBL621122,Intermediate,10116.0,,N,,A,8015,,,Rattus norvegicus,1,,,
,6046,1,BAO_0000218,Tmax in rat at 10 mg/kg,50597,In vivo,,CHEMBL621123,Intermediate,10116.0,,N,,A,8016,,,Rattus norvegicus,1,,,
,5874,1,BAO_0000218,Tmax in rat by po administration at a dose of 40 mg/kg,50597,In vivo,,CHEMBL621124,Intermediate,10116.0,,N,,A,8017,,,Rattus norvegicus,1,,,
,17596,1,BAO_0000218,Tmax in rats,50597,,,CHEMBL621125,Intermediate,10116.0,,N,,A,8018,,,Rattus norvegicus,1,,,
,17804,1,BAO_0000218,Tmax was measured in rats after peroral administration at 5 mg/kg,50597,In vivo,,CHEMBL621126,Intermediate,10116.0,,N,,A,8019,,,Rattus norvegicus,1,,,
,1908,1,BAO_0000218,Tmax value after oral dose at a dose of 10 mg/kg in rats.,50597,In vivo,,CHEMBL621127,Intermediate,10116.0,,N,,A,8020,,,Rattus norvegicus,1,,,
,2959,1,BAO_0000218,Tmax value after administration of 20 mg/Kg oral dose in rat,50597,In vivo,,CHEMBL621128,Intermediate,10116.0,,N,,A,8021,,,Rattus norvegicus,1,,,
,6757,1,BAO_0000218,Tmax value at a dose of 10 mg/kg in male SD rats,50597,In vivo,,CHEMBL618263,Intermediate,10116.0,,N,,A,8022,,,Rattus norvegicus,1,,,
,6757,1,BAO_0000218,Tmax value at a dose of 100 mg/kg in male SD rats,50597,In vivo,,CHEMBL618264,Intermediate,10116.0,,N,,A,8023,,,Rattus norvegicus,1,,,
,6757,1,BAO_0000218,Tmax value at a dose of 50 mg/kg in male SD rats,50597,In vivo,,CHEMBL618265,Intermediate,10116.0,,N,,A,8024,,,Rattus norvegicus,1,,,
,4186,1,BAO_0000218,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,50597,In vivo,Plasma,CHEMBL618266,Intermediate,10116.0,,N,,A,8025,,,Rattus norvegicus,1,,1969.0,
,15662,1,BAO_0000218,time required to reach maximum concentration (Cmax) after oral administration in rat,50597,In vivo,,CHEMBL618267,Intermediate,10116.0,,N,,A,8026,,,Rattus norvegicus,1,,,
,429,1,BAO_0000218,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),50597,,Urine,CHEMBL618450,Intermediate,10116.0,,N,,A,8027,,,Rattus norvegicus,1,,1088.0,
,429,1,BAO_0000218,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),50597,,Urine,CHEMBL618451,Intermediate,10116.0,,N,,A,8028,,,Rattus norvegicus,1,,1088.0,
,5546,1,BAO_0000218,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,50597,,,CHEMBL618452,Intermediate,10116.0,,N,,A,8029,,,Rattus norvegicus,1,,,
,3173,1,BAO_0000218,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,50597,,Urine,CHEMBL618453,Intermediate,10116.0,,N,,A,8030,,,Rattus norvegicus,1,,1088.0,
,3173,1,BAO_0000218,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,50597,,Urine,CHEMBL618454,Intermediate,10116.0,,N,,A,8031,,,Rattus norvegicus,1,,1088.0,
,3173,1,BAO_0000218,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,50597,,Urine,CHEMBL618455,Intermediate,10116.0,,N,,A,8032,,,Rattus norvegicus,1,,1088.0,
,4257,1,BAO_0000218,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,50597,In vivo,,CHEMBL618456,Intermediate,10116.0,,N,,A,8033,,,Rattus norvegicus,1,,,
,6011,1,BAO_0000218,Compound distribution in rat tissues was determined,50597,In vivo,,CHEMBL618457,Intermediate,10116.0,,N,,A,8034,,,Rattus norvegicus,1,,,
,5472,1,BAO_0000218,Volume of distribution was evaluated in rat,50597,In vivo,,CHEMBL618458,Intermediate,10116.0,,N,,A,8035,,,Rattus norvegicus,1,,,
,14346,1,BAO_0000218,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,50597,,,CHEMBL618459,Intermediate,10116.0,,N,,A,8036,,,Rattus norvegicus,1,,,
,14346,1,BAO_0000218,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,50597,,,CHEMBL876733,Intermediate,10116.0,,N,,A,8037,,,Rattus norvegicus,1,,,
,14346,1,BAO_0000218,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,50588,,,CHEMBL618460,Intermediate,9615.0,,N,,A,8038,,,Canis lupus familiaris,1,,,
,14346,1,BAO_0000218,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,50597,,,CHEMBL618461,Intermediate,10116.0,,N,,A,8039,,,Rattus norvegicus,1,,,
,15469,0,BAO_0000019,Area under the curve was determined after oral administration (300 uM/Kg),22224,,,CHEMBL618462,Autocuration,,,U,,A,8040,,,,1,,,
,14346,1,BAO_0000218,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,50597,,,CHEMBL618463,Intermediate,10116.0,,N,,A,8041,,,Rattus norvegicus,1,,,
,14346,1,BAO_0000218,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,50597,,,CHEMBL618464,Intermediate,10116.0,,N,,A,8042,,,Rattus norvegicus,1,,,
,14346,1,BAO_0000218,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,50597,,,CHEMBL618465,Intermediate,10116.0,,N,,A,8043,,,Rattus norvegicus,1,,,
,14346,1,BAO_0000218,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,50597,,,CHEMBL618466,Intermediate,10116.0,,N,,A,8044,,,Rattus norvegicus,1,,,
,14346,1,BAO_0000218,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,50597,,,CHEMBL618467,Intermediate,10116.0,,N,,A,8045,,,Rattus norvegicus,1,,,
,15372,1,BAO_0000218,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,50597,,,CHEMBL618468,Intermediate,10116.0,,N,,A,8046,,,Rattus norvegicus,1,,,
,12935,1,BAO_0000218,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,50588,,Plasma,CHEMBL618469,Intermediate,9615.0,,N,,A,8047,,,Canis lupus familiaris,1,,1969.0,
,12935,1,BAO_0000218,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,50588,,Plasma,CHEMBL618470,Intermediate,9615.0,,N,,A,8048,,,Canis lupus familiaris,1,,1969.0,
,14813,0,BAO_0000218,Plasma drug AUC in rat (PO dose),22224,,,CHEMBL618471,Autocuration,,,U,,A,8049,,,,1,,,
,15792,1,BAO_0000218,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,50594,,,CHEMBL618472,Intermediate,10090.0,,N,,A,8050,,,Mus musculus,1,,,
,3579,0,BAO_0000218,Area under was determined at a dose of 30 mg/kg,22224,,,CHEMBL618473,Autocuration,,,U,,A,8051,,,,1,,,
,12487,1,BAO_0000218,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,50506,,,CHEMBL621699,Intermediate,9669.0,,N,,A,8052,,,Mustela putorius furo,1,,,
,12487,1,BAO_0000218,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,50597,,,CHEMBL621700,Intermediate,10116.0,,N,,A,8053,,,Rattus norvegicus,1,,,
,12487,1,BAO_0000218,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,50597,,,CHEMBL621701,Intermediate,10116.0,,N,,A,8054,,,Rattus norvegicus,1,,,
,12487,1,BAO_0000218,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,50506,,,CHEMBL621702,Intermediate,9669.0,,N,,A,8055,,,Mustela putorius furo,1,,,
,12487,1,BAO_0000218,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,50588,,,CHEMBL621703,Intermediate,9615.0,,N,,A,8056,,,Canis lupus familiaris,1,,,
,12487,1,BAO_0000218,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,50588,,,CHEMBL621704,Intermediate,9615.0,,N,,A,8057,,,Canis lupus familiaris,1,,,
,12902,1,BAO_0000218,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",50597,,,CHEMBL624259,Intermediate,10116.0,,N,,A,8058,,,Rattus norvegicus,1,,,
,12902,1,BAO_0000218,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",50597,,,CHEMBL624260,Intermediate,10116.0,,N,,A,8059,,,Rattus norvegicus,1,,,
,12902,1,BAO_0000218,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",50597,,,CHEMBL624430,Intermediate,10116.0,,N,,A,8060,,,Rattus norvegicus,1,,,
,12902,1,BAO_0000218,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",50597,,,CHEMBL624431,Intermediate,10116.0,,N,,A,8061,,,Rattus norvegicus,1,,,
,12902,1,BAO_0000218,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",50597,,,CHEMBL624432,Intermediate,10116.0,,N,,A,8062,,,Rattus norvegicus,1,,,
,12902,1,BAO_0000218,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",50597,,,CHEMBL624433,Intermediate,10116.0,,N,,A,8063,,,Rattus norvegicus,1,,,
,12902,1,BAO_0000218,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",50597,,,CHEMBL624434,Intermediate,10116.0,,N,,A,8064,,,Rattus norvegicus,1,,,
,12902,1,BAO_0000218,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",50597,,,CHEMBL624435,Intermediate,10116.0,,N,,A,8065,,,Rattus norvegicus,1,,,
,12745,1,BAO_0000218,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,50594,,,CHEMBL618570,Intermediate,10090.0,,N,,A,8066,,,Mus musculus,1,,,
,12745,1,BAO_0000218,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),50594,,,CHEMBL618571,Intermediate,10090.0,,N,,A,8067,,,Mus musculus,1,,,
,12745,1,BAO_0000218,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,50594,,,CHEMBL618572,Intermediate,10090.0,,N,,A,8068,,,Mus musculus,1,,,
,12745,1,BAO_0000218,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),50594,,,CHEMBL618573,Intermediate,10090.0,,N,,A,8069,,,Mus musculus,1,,,
,12745,1,BAO_0000218,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,50594,,,CHEMBL619267,Intermediate,10090.0,,N,,A,8070,,,Mus musculus,1,,,
,12745,1,BAO_0000218,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),50594,,,CHEMBL619431,Intermediate,10090.0,,N,,A,8071,,,Mus musculus,1,,,
,12745,1,BAO_0000218,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,50594,,,CHEMBL619432,Intermediate,10090.0,,N,,A,8072,,,Mus musculus,1,,,
,12745,1,BAO_0000218,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),50594,,,CHEMBL619433,Intermediate,10090.0,,N,,A,8073,,,Mus musculus,1,,,
,13298,0,BAO_0000218,AUC in mice after oral dose (50 mg/kg),22224,,Plasma,CHEMBL619434,Autocuration,,,U,,A,8074,,,,1,,1969.0,
,12226,1,BAO_0000218,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,50594,,Serum,CHEMBL619435,Intermediate,10090.0,,N,,A,8075,,,Mus musculus,1,,1977.0,
,12634,0,BAO_0000019,AUC (0-4 hr) ug/ml/h,22224,,Plasma,CHEMBL619436,Autocuration,,,U,,A,8076,,,,1,,1969.0,
,14810,1,BAO_0000218,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,50597,,,CHEMBL619437,Intermediate,10116.0,,N,,A,8077,,,Rattus norvegicus,1,,,
,13889,0,BAO_0000218,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,22224,,,CHEMBL619438,Autocuration,,,U,,A,8078,,,,1,,,
,10018,1,BAO_0000218,Compound was evaluated for Area under curve in mice,50594,,,CHEMBL619439,Intermediate,10090.0,,N,,A,8079,,,Mus musculus,1,,,
,8758,1,BAO_0000218,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,50597,,,CHEMBL619440,Intermediate,10116.0,,N,,A,8080,,,Rattus norvegicus,1,,,
,8758,0,BAO_0000218,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,22224,,,CHEMBL619441,Autocuration,,,U,,F,8081,,,,1,,,
,8758,1,BAO_0000218,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,50597,,,CHEMBL619442,Intermediate,10116.0,,N,,A,8082,,,Rattus norvegicus,1,,,
,2249,0,BAO_0000019,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,22224,,,CHEMBL875156,Autocuration,,,U,,A,8083,,,,1,,,
,2249,0,BAO_0000019,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,22224,,,CHEMBL619443,Autocuration,,,U,,A,8084,,,,1,,,
,2249,0,BAO_0000019,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,22224,,,CHEMBL619444,Autocuration,,,U,,A,8085,,,,1,,,
,2249,0,BAO_0000019,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,22224,,,CHEMBL623464,Autocuration,,,U,,A,8086,,,,1,,,
,15115,1,BAO_0000218,Compound was evaluated for area under curve when administered through oral route in mouse,50594,,,CHEMBL623465,Intermediate,10090.0,,N,,A,8087,,,Mus musculus,1,,,
,6518,1,BAO_0000218,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,50597,In vivo,,CHEMBL623466,Intermediate,10116.0,,N,,A,8088,,,Rattus norvegicus,1,,,
,6518,1,BAO_0000218,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,50597,In vivo,,CHEMBL623467,Intermediate,10116.0,,N,,A,8089,,,Rattus norvegicus,1,,,
,6249,1,BAO_0000218,Plasma clearance in rat,50597,In vivo,,CHEMBL623468,Intermediate,10116.0,,N,,A,8090,,,Rattus norvegicus,1,,,
,2463,1,BAO_0000218,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,50597,In vivo,,CHEMBL622660,Intermediate,10116.0,,N,,A,8091,,,Rattus norvegicus,1,,,
,4969,1,BAO_0000218,Plasma clearance rate in Sprague-Dawley rats,50597,In vivo,,CHEMBL622661,Intermediate,10116.0,,N,,A,8092,,,Rattus norvegicus,1,,,
,17720,1,BAO_0000218,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,In vivo,,CHEMBL622662,Intermediate,10116.0,,N,,F,8093,,,Rattus norvegicus,1,,,
,3457,1,BAO_0000218,Pharmacokinetic property (total body clearance) in rat,50597,In vivo,,CHEMBL622663,Intermediate,10116.0,,N,,A,8094,,,Rattus norvegicus,1,,,
,5983,1,BAO_0000218,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,50597,In vivo,,CHEMBL622664,Intermediate,10116.0,,N,,A,8095,,,Rattus norvegicus,1,,,
,6295,1,BAO_0000218,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,50597,,,CHEMBL622665,Intermediate,10116.0,,N,,A,8096,,,Rattus norvegicus,1,,,
,6296,1,BAO_0000218,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,50597,,,CHEMBL622666,Intermediate,10116.0,,N,,A,8097,,,Rattus norvegicus,1,,,
,17686,1,BAO_0000218,Cl in rat i.v. at 2 mg/kg concentration,50597,In vivo,,CHEMBL621615,Intermediate,10116.0,,N,,A,8098,,,Rattus norvegicus,1,,,
,17764,1,BAO_0000218,Clearance of compound after intravenous administration in rats at 24 uM/kg,50597,In vivo,,CHEMBL621616,Intermediate,10116.0,,N,,A,8099,,,Rattus norvegicus,1,,,
,5503,1,BAO_0000218,Clearance was determined,50597,In vivo,,CHEMBL621617,Intermediate,10116.0,,N,,A,8100,,,Rattus norvegicus,1,,,
,4368,1,BAO_0000218,Clearance by intravenous administration of 3.4 mg/kg in rat,50597,In vivo,,CHEMBL621618,Intermediate,10116.0,,N,,A,8101,,,Rattus norvegicus,1,,,
,6005,1,BAO_0000218,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,50597,In vivo,,CHEMBL621619,Intermediate,10116.0,,N,,A,8102,,,Rattus norvegicus,1,,,
,5031,1,BAO_0000218,Clearance rate after i.v. administration in rats,50597,In vivo,,CHEMBL621620,Intermediate,10116.0,,N,,A,8103,,,Rattus norvegicus,1,,,
,4890,1,BAO_0000218,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,50597,In vivo,,CHEMBL621786,Intermediate,10116.0,,N,,A,8104,,,Rattus norvegicus,1,,,
,5182,1,BAO_0000218,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,50597,In vivo,,CHEMBL621787,Intermediate,10116.0,,N,,A,8105,,,Rattus norvegicus,1,,,
,5979,1,BAO_0000218,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,50597,In vivo,,CHEMBL621788,Intermediate,10116.0,,N,,A,8106,,,Rattus norvegicus,1,,,
,5656,1,BAO_0000218,Clearance (Cl) after oral administration in rat,50597,In vivo,,CHEMBL621789,Intermediate,10116.0,,N,,A,8107,,,Rattus norvegicus,1,,,
,17804,1,BAO_0000218,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,50597,In vivo,,CHEMBL621790,Intermediate,10116.0,,N,,A,8108,,,Rattus norvegicus,1,,,
,4839,1,BAO_0000218,Compound was tested for plasma clearance in rat,50597,In vivo,Plasma,CHEMBL621791,Intermediate,10116.0,,N,,A,8109,,,Rattus norvegicus,1,,1969.0,
,5041,1,BAO_0000218,In vitro microsome metabolism clearance in rat was determined,50597,In vitro,,CHEMBL621792,Intermediate,10116.0,Microsomes,N,,A,8110,,,Rattus norvegicus,1,,,
,5041,1,BAO_0000218,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,50597,In vitro,,CHEMBL621793,Intermediate,10116.0,Microsomes,N,,A,8111,,,Rattus norvegicus,1,,,
,5974,1,BAO_0000218,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,In vivo,,CHEMBL621794,Intermediate,10116.0,,N,,A,8112,,,Rattus norvegicus,1,,,
,5496,1,BAO_0000218,In vivo plasma clearance was determined,50597,In vivo,Plasma,CHEMBL621795,Intermediate,10116.0,,N,,A,8113,,,Rattus norvegicus,1,,1969.0,
,5739,1,BAO_0000218,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,50597,In vivo,,CHEMBL621796,Intermediate,10116.0,,N,,A,8114,,,Rattus norvegicus,1,,,
,5676,1,BAO_0000218,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,50597,In vivo,Liver,CHEMBL621797,Intermediate,10116.0,,N,,A,8115,,401.0,Rattus norvegicus,1,,2107.0,Hepatocyte
,4239,1,BAO_0000218,Pharmacokinetic property (Plasma clearance) was measured in rat,50597,In vivo,,CHEMBL621798,Intermediate,10116.0,,N,,A,8116,,,Rattus norvegicus,1,,,
,5676,1,BAO_0000218,Pharmacokinetic property (clearance) in rat i.v.,50597,In vivo,,CHEMBL621799,Intermediate,10116.0,,N,,A,8117,,,Rattus norvegicus,1,,,
,1918,1,BAO_0000218,"Plasma Clearance was evaluated in rats, iv",50597,In vivo,,CHEMBL621800,Intermediate,10116.0,,N,,A,8118,,,Rattus norvegicus,1,,,
,17800,1,BAO_0000218,Plasma clearance (in vivo) in rats was determined,50597,In vivo,,CHEMBL621801,Intermediate,10116.0,,N,,A,8119,,,Rattus norvegicus,1,,,
,6056,1,BAO_0000218,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,50597,In vivo,,CHEMBL621802,Intermediate,10116.0,,N,,A,8120,,,Rattus norvegicus,1,,,
,5496,1,BAO_0000218,Plasma clearance was determined,50597,In vivo,,CHEMBL618596,Intermediate,10116.0,,N,,A,8121,,,Rattus norvegicus,1,,,
,5939,1,BAO_0000218,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,50597,In vivo,,CHEMBL618597,Intermediate,10116.0,,N,,A,8122,,,Rattus norvegicus,1,,,
,5939,1,BAO_0000218,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,50597,In vivo,,CHEMBL618598,Intermediate,10116.0,,N,,A,8123,,,Rattus norvegicus,1,,,
,17752,1,BAO_0000218,Plasma clearance in rats,50597,In vivo,,CHEMBL618599,Intermediate,10116.0,,N,,A,8124,,,Rattus norvegicus,1,,,
,4576,1,BAO_0000218,Plasma clearance rate determined in rat,50597,In vivo,,CHEMBL618600,Intermediate,10116.0,,N,,A,8125,,,Rattus norvegicus,1,,,
,6011,1,BAO_0000218,Plasma clearance was determined in rat,50597,In vivo,,CHEMBL618601,Intermediate,10116.0,,N,,A,8126,,,Rattus norvegicus,1,,,
,5510,1,BAO_0000218,Plasma clearance was determined,50597,In vivo,,CHEMBL618602,Intermediate,10116.0,,N,,A,8127,,,Rattus norvegicus,1,,,
,5948,1,BAO_0000218,Plasma clearance value in rat,50597,In vivo,,CHEMBL618603,Intermediate,10116.0,,N,,A,8128,,,Rattus norvegicus,1,,,
,6125,1,BAO_0000218,Clearance rate constant using isolated perfused rat liver (IPRL) assay,50597,Ex vivo,Liver,CHEMBL618604,Intermediate,10116.0,,N,,A,8129,,,Rattus norvegicus,1,,2107.0,
,4839,1,BAO_0000218,Clearance in rat,50597,In vivo,,CHEMBL618605,Intermediate,10116.0,,N,,A,8130,,,Rattus norvegicus,1,,,
,17686,1,BAO_0000218,Total body clearance in rat i.v. at 2 mg/kg concentration,50597,In vivo,,CHEMBL618606,Intermediate,10116.0,,N,,A,8131,,,Rattus norvegicus,1,,,
,6571,1,BAO_0000218,Clearance of compound in rats after intravenous administration,50597,In vivo,,CHEMBL618607,Intermediate,10116.0,,N,,A,8132,,,Rattus norvegicus,1,,,
,3364,1,BAO_0000218,Clearance after iv administration to rats,50597,In vivo,,CHEMBL618608,Intermediate,10116.0,,N,,A,8133,,,Rattus norvegicus,1,,,
,13569,1,BAO_0000218,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,50597,In vivo,,CHEMBL618609,Intermediate,10116.0,,N,,A,8134,,,Rattus norvegicus,1,,,
,13569,1,BAO_0000218,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,50597,In vivo,,CHEMBL618610,Intermediate,10116.0,,N,,A,8135,,,Rattus norvegicus,1,,,
,13569,1,BAO_0000218,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,50597,In vivo,,CHEMBL618611,Intermediate,10116.0,,N,,A,8136,,,Rattus norvegicus,1,,,
,13569,1,BAO_0000218,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,50597,In vivo,,CHEMBL618612,Intermediate,10116.0,,N,,A,8137,,,Rattus norvegicus,1,,,
,13569,1,BAO_0000218,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,50597,In vivo,,CHEMBL618613,Intermediate,10116.0,,N,,A,8138,,,Rattus norvegicus,1,,,
,13569,1,BAO_0000218,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,50597,In vivo,,CHEMBL621076,Intermediate,10116.0,,N,,A,8139,,,Rattus norvegicus,1,,,
,13569,1,BAO_0000218,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,50597,In vivo,,CHEMBL621077,Intermediate,10116.0,,N,,A,8140,,,Rattus norvegicus,1,,,
,17670,1,BAO_0000218,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",50597,In vivo,,CHEMBL621078,Intermediate,10116.0,,N,,A,8141,,,Rattus norvegicus,1,,,
,5970,1,BAO_0000218,Clearance in rat,50597,In vivo,,CHEMBL621251,Intermediate,10116.0,,N,,A,8142,,,Rattus norvegicus,1,,,
,6495,1,BAO_0000218,Clearance in rat after oral administration at 10 mg/kg,50597,In vivo,,CHEMBL621252,Intermediate,10116.0,,N,,A,8143,,,Rattus norvegicus,1,,,
,4590,1,BAO_0000218,Clearance in rat.,50597,In vivo,,CHEMBL621253,Intermediate,10116.0,,N,,A,8144,,,Rattus norvegicus,1,,,
,6193,1,BAO_0000218,Clearance rate following an oral dose of 20 mg/kg in rats,50597,In vivo,,CHEMBL621254,Intermediate,10116.0,,N,,A,8145,,,Rattus norvegicus,1,,,
,2832,1,BAO_0000218,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,50597,In vivo,,CHEMBL621255,Intermediate,10116.0,,N,,A,8146,,,Rattus norvegicus,1,,,
,1052,1,BAO_0000218,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,50597,In vivo,Plasma,CHEMBL621256,Intermediate,10116.0,,N,,A,8147,,,Rattus norvegicus,1,,1969.0,
,9866,1,BAO_0000218,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,50597,In vivo,Liver,CHEMBL621257,Intermediate,10116.0,,N,,A,8148,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,50597,In vivo,Liver,CHEMBL621258,Intermediate,10116.0,,N,,A,8149,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,50597,In vivo,Liver,CHEMBL621259,Intermediate,10116.0,,N,,A,8150,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,50597,In vivo,Liver,CHEMBL621260,Intermediate,10116.0,,N,,A,8151,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,50597,In vivo,Liver,CHEMBL876494,Intermediate,10116.0,,N,,A,8152,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,50597,In vivo,Liver,CHEMBL621261,Intermediate,10116.0,,N,,A,8153,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,50597,In vivo,Liver,CHEMBL621262,Intermediate,10116.0,,N,,A,8154,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,50597,In vivo,Liver,CHEMBL621263,Intermediate,10116.0,,N,,A,8155,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,50597,In vivo,Liver,CHEMBL621264,Intermediate,10116.0,,N,,A,8156,,,Rattus norvegicus,1,,2107.0,
,9866,1,BAO_0000218,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,50597,In vivo,Muscle tissue,CHEMBL621265,Intermediate,10116.0,,N,,A,8157,,,Rattus norvegicus,1,,2385.0,
,9866,1,BAO_0000218,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,50597,In vivo,Muscle tissue,CHEMBL621266,Intermediate,10116.0,,N,,A,8158,,,Rattus norvegicus,1,,2385.0,
,9866,1,BAO_0000218,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,50597,In vivo,Muscle tissue,CHEMBL621267,Intermediate,10116.0,,N,,A,8159,,,Rattus norvegicus,1,,2385.0,
,9866,1,BAO_0000218,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,50597,In vivo,Muscle tissue,CHEMBL621268,Intermediate,10116.0,,N,,A,8160,,,Rattus norvegicus,1,,2385.0,
,9866,1,BAO_0000218,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,50597,In vivo,Muscle tissue,CHEMBL621269,Intermediate,10116.0,,N,,A,8161,,,Rattus norvegicus,1,,2385.0,
,9866,1,BAO_0000218,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,50597,In vivo,Muscle tissue,CHEMBL621270,Intermediate,10116.0,,N,,A,8162,,,Rattus norvegicus,1,,2385.0,
,9866,1,BAO_0000218,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,50597,In vivo,Muscle tissue,CHEMBL621271,Intermediate,10116.0,,N,,A,8163,,,Rattus norvegicus,1,,2385.0,
,9866,1,BAO_0000218,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,50597,In vivo,Muscle tissue,CHEMBL621272,Intermediate,10116.0,,N,,A,8164,,,Rattus norvegicus,1,,2385.0,
,9866,1,BAO_0000218,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,50597,In vivo,Muscle tissue,CHEMBL621273,Intermediate,10116.0,,N,,A,8165,,,Rattus norvegicus,1,,2385.0,
,9866,1,BAO_0000218,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,50597,In vivo,Muscle tissue,CHEMBL621274,Intermediate,10116.0,,N,,A,8166,,,Rattus norvegicus,1,,2385.0,
,9866,1,BAO_0000218,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,50597,In vivo,Muscle tissue,CHEMBL876495,Intermediate,10116.0,,N,,A,8167,,,Rattus norvegicus,1,,2385.0,
,9866,1,BAO_0000218,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,50597,In vivo,Muscle tissue,CHEMBL621275,Intermediate,10116.0,,N,,A,8168,,,Rattus norvegicus,1,,2385.0,
,9866,1,BAO_0000218,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,50597,In vivo,Muscle tissue,CHEMBL621276,Intermediate,10116.0,,N,,A,8169,,,Rattus norvegicus,1,,2385.0,
,9866,1,BAO_0000218,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,50597,In vivo,Muscle tissue,CHEMBL621277,Intermediate,10116.0,,N,,A,8170,,,Rattus norvegicus,1,,2385.0,
,9866,1,BAO_0000218,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,50597,In vivo,Intestine,CHEMBL621278,Intermediate,10116.0,,N,,A,8171,,,Rattus norvegicus,1,,160.0,
,9866,1,BAO_0000218,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,50597,In vivo,Intestine,CHEMBL621279,Intermediate,10116.0,,N,,A,8172,,,Rattus norvegicus,1,,160.0,
,9866,1,BAO_0000218,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),50597,In vivo,Intestine,CHEMBL621280,Intermediate,10116.0,,N,,A,8173,,,Rattus norvegicus,1,,160.0,
,9866,1,BAO_0000218,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,50597,In vivo,Spleen,CHEMBL621281,Intermediate,10116.0,,N,,A,8174,,,Rattus norvegicus,1,,2106.0,
,9866,1,BAO_0000218,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,50597,In vivo,Spleen,CHEMBL621282,Intermediate,10116.0,,N,,A,8175,,,Rattus norvegicus,1,,2106.0,
,9866,1,BAO_0000218,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,50597,In vivo,Spleen,CHEMBL621283,Intermediate,10116.0,,N,,A,8176,,,Rattus norvegicus,1,,2106.0,
,9866,1,BAO_0000218,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,50597,In vivo,Spleen,CHEMBL621284,Intermediate,10116.0,,N,,A,8177,,,Rattus norvegicus,1,,2106.0,
,9866,1,BAO_0000218,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,50597,In vivo,Spleen,CHEMBL621285,Intermediate,10116.0,,N,,A,8178,,,Rattus norvegicus,1,,2106.0,
,9866,1,BAO_0000218,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,50597,In vivo,Spleen,CHEMBL621286,Intermediate,10116.0,,N,,A,8179,,,Rattus norvegicus,1,,2106.0,
,9866,1,BAO_0000218,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,50597,In vivo,Spleen,CHEMBL623220,Intermediate,10116.0,,N,,A,8180,,,Rattus norvegicus,1,,2106.0,
,9866,1,BAO_0000218,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,50597,In vivo,Spleen,CHEMBL623221,Intermediate,10116.0,,N,,A,8181,,,Rattus norvegicus,1,,2106.0,
,9866,1,BAO_0000218,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,50597,In vivo,Spleen,CHEMBL876029,Intermediate,10116.0,,N,,A,8182,,,Rattus norvegicus,1,,2106.0,
,9866,1,BAO_0000218,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,50597,In vivo,Stomach,CHEMBL623222,Intermediate,10116.0,,N,,A,8183,,,Rattus norvegicus,1,,945.0,
,9866,1,BAO_0000218,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,50597,In vivo,Stomach,CHEMBL623223,Intermediate,10116.0,,N,,A,8184,,,Rattus norvegicus,1,,945.0,
,9866,1,BAO_0000218,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,50597,In vivo,Stomach,CHEMBL621445,Intermediate,10116.0,,N,,A,8185,,,Rattus norvegicus,1,,945.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Blood,CHEMBL621446,Intermediate,10116.0,,N,,A,8186,,,Rattus norvegicus,1,,178.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Blood,CHEMBL621447,Intermediate,10116.0,,N,,A,8187,,,Rattus norvegicus,1,,178.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Blood,CHEMBL619681,Intermediate,10116.0,,N,,A,8188,,,Rattus norvegicus,1,,178.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Blood,CHEMBL619682,Intermediate,10116.0,,N,,A,8189,,,Rattus norvegicus,1,,178.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Blood,CHEMBL619683,Intermediate,10116.0,,N,,A,8190,,,Rattus norvegicus,1,,178.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Brain,CHEMBL619684,Intermediate,10116.0,,N,,A,8191,,,Rattus norvegicus,1,,955.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Brain,CHEMBL619685,Intermediate,10116.0,,N,,A,8192,,,Rattus norvegicus,1,,955.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Brain,CHEMBL619686,Intermediate,10116.0,,N,,A,8193,,,Rattus norvegicus,1,,955.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Brain,CHEMBL619687,Intermediate,10116.0,,N,,A,8194,,,Rattus norvegicus,1,,955.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Brain,CHEMBL619688,Intermediate,10116.0,,N,,A,8195,,,Rattus norvegicus,1,,955.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Heart,CHEMBL619689,Intermediate,10116.0,,N,,A,8196,,,Rattus norvegicus,1,,948.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Heart,CHEMBL619690,Intermediate,10116.0,,N,,A,8197,,,Rattus norvegicus,1,,948.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Heart,CHEMBL619691,Intermediate,10116.0,,N,,A,8198,,,Rattus norvegicus,1,,948.0,
,6062,1,BAO_0000218,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,50597,In vivo,,CHEMBL619692,Intermediate,10116.0,,N,,A,8199,,,Rattus norvegicus,1,,,
,3598,1,BAO_0000218,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,,,CHEMBL619693,Expert,10116.0,,N,,A,8200,,,Rattus norvegicus,1,,,
,1908,1,BAO_0000218,Vc value after IV dose at a dose of 5 mg/kg in rats.,50597,In vivo,,CHEMBL619694,Intermediate,10116.0,,N,,A,8201,,,Rattus norvegicus,1,,,
,17596,1,BAO_0000218,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,50597,In vivo,,CHEMBL619695,Intermediate,10116.0,,N,,A,8202,,,Rattus norvegicus,1,,,
,4891,1,BAO_0000218,Compound was evaluated for pharmacokinetic parameter volume of distribution,50597,In vivo,,CHEMBL619696,Intermediate,10116.0,,N,,A,8203,,,Rattus norvegicus,1,,,
,740,1,BAO_0000218,Compound was evaluated for volume of distribution in rat,50597,In vivo,,CHEMBL619697,Intermediate,10116.0,,N,,A,8204,,,Rattus norvegicus,1,,,
,16366,1,BAO_0000218,Steady state volume distribution was determined; steady state(ss),50597,In vivo,,CHEMBL619698,Intermediate,10116.0,,N,,A,8205,,,Rattus norvegicus,1,,,
,3364,1,BAO_0000218,Steady state volume of distribution after iv administration to rats,50597,In vivo,,CHEMBL619699,Intermediate,10116.0,,N,,A,8206,,,Rattus norvegicus,1,,,
,2552,1,BAO_0000218,Steady state volume of distribution dosing at 3 mg/kg iv,50597,In vivo,,CHEMBL619700,Intermediate,10116.0,,N,,A,8207,,,Rattus norvegicus,1,,,
,406,1,BAO_0000218,The compound was evaluated for volume of distribution in rat,50597,In vivo,,CHEMBL619701,Intermediate,10116.0,,N,,A,8208,,,Rattus norvegicus,1,,,
,12500,1,BAO_0000218,The compound was tested for volume of distribution in rat,50597,In vivo,,CHEMBL619702,Intermediate,10116.0,,N,,A,8209,,,Rattus norvegicus,1,,,
,12500,1,BAO_0000218,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,50597,In vivo,,CHEMBL620335,Intermediate,10116.0,,N,,A,8210,,,Rattus norvegicus,1,,,
,5656,1,BAO_0000218,Volume distribution (VD) after oral administration in rat,50597,In vivo,,CHEMBL620336,Intermediate,10116.0,,N,,A,8211,,,Rattus norvegicus,1,,,
,17671,1,BAO_0000218,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,50597,In vivo,,CHEMBL620337,Intermediate,10116.0,,N,,A,8212,,,Rattus norvegicus,1,,,
,1094,1,BAO_0000218,Volume distribution in rat,50597,In vivo,,CHEMBL620520,Intermediate,10116.0,,N,,A,8213,,,Rattus norvegicus,1,,,
,5833,1,BAO_0000218,Volume distribution in rat,50597,In vivo,,CHEMBL620521,Intermediate,10116.0,,N,,A,8214,,,Rattus norvegicus,1,,,
,5939,1,BAO_0000218,Volume distribution in rat after peroral administration at 10 mg/kg,50597,In vivo,,CHEMBL875825,Intermediate,10116.0,,N,,A,8215,,,Rattus norvegicus,1,,,
,5939,1,BAO_0000218,Volume distribution in rat after peroral administration at 5 mg/kg,50597,In vivo,,CHEMBL620522,Intermediate,10116.0,,N,,A,8216,,,Rattus norvegicus,1,,,
,6005,1,BAO_0000218,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,50597,In vivo,,CHEMBL620523,Intermediate,10116.0,,N,,A,8217,,,Rattus norvegicus,1,,,
,1696,1,BAO_0000218,Volume of distribution in rat.,50597,In vivo,,CHEMBL620524,Intermediate,10116.0,,N,,A,8218,,,Rattus norvegicus,1,,,
,6672,1,BAO_0000218,Volume of distribution in rat,50597,In vivo,,CHEMBL620525,Intermediate,10116.0,,N,,A,8219,,,Rattus norvegicus,1,,,
,6673,1,BAO_0000218,Volume of distribution in rat,50597,In vivo,,CHEMBL620526,Intermediate,10116.0,,N,,A,8220,,,Rattus norvegicus,1,,,
,5871,1,BAO_0000218,Volume of distribution in rat by iv administration,50597,In vivo,,CHEMBL620527,Intermediate,10116.0,,N,,A,8221,,,Rattus norvegicus,1,,,
,6803,1,BAO_0000218,Volume of distribution in rats,50597,In vivo,,CHEMBL620528,Intermediate,10116.0,,N,,A,8222,,,Rattus norvegicus,1,,,
,5199,1,BAO_0000218,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,50597,In vivo,,CHEMBL620529,Intermediate,10116.0,,N,,A,8223,,,Rattus norvegicus,1,,,
,4727,1,BAO_0000218,Volume distribution at the dose of 2 mg/kg in rat,50597,,,CHEMBL620530,Intermediate,10116.0,,N,,A,8224,,,Rattus norvegicus,1,,,
,16367,1,BAO_0000218,Steady state volume of distribution was determined,50597,In vivo,,CHEMBL620531,Intermediate,10116.0,,N,,A,8225,,,Rattus norvegicus,1,,,
,5005,0,BAO_0000218,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,In vivo,,CHEMBL620532,Intermediate,9544.0,,U,,A,8226,,,Macaca mulatta,1,,,
,5005,0,BAO_0000218,Compound was tested for its plasma volume distribution in Sprague Dawley rats,22224,In vivo,,CHEMBL620533,Intermediate,10116.0,,U,,A,8227,,,Rattus norvegicus,1,,,
,5005,0,BAO_0000218,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,22224,In vivo,,CHEMBL620534,Intermediate,10116.0,,U,,A,8228,,,Rattus norvegicus,1,,,
,15765,1,BAO_0000218,Mean (%CV) PK parameters for Vdss(mL/kg).,50597,In vivo,,CHEMBL620535,Intermediate,10116.0,,N,,A,8229,,,Rattus norvegicus,1,,,
,2792,1,BAO_0000218,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,50597,In vivo,,CHEMBL875826,Intermediate,10116.0,,N,,A,8230,,,Rattus norvegicus,1,,,
,2792,1,BAO_0000218,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,50597,In vivo,,CHEMBL620536,Intermediate,10116.0,,N,,A,8231,,,Rattus norvegicus,1,,,
,5334,1,BAO_0000218,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,50597,In vivo,,CHEMBL620537,Intermediate,10116.0,,N,,A,8232,,,Rattus norvegicus,1,,,
,5334,1,BAO_0000218,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,50597,In vivo,,CHEMBL618526,Intermediate,10116.0,,N,,A,8233,,,Rattus norvegicus,1,,,
,5739,1,BAO_0000218,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,50597,In vivo,,CHEMBL618527,Intermediate,10116.0,,N,,A,8234,,,Rattus norvegicus,1,,,
,5789,1,BAO_0000218,Pharmacokinetic property (Vdss) in rat,50597,In vivo,,CHEMBL618528,Intermediate,10116.0,,N,,A,8235,,,Rattus norvegicus,1,,,
,4239,1,BAO_0000218,Pharmacokinetic property (vdss) was measured in rat,50597,In vivo,,CHEMBL618529,Intermediate,10116.0,,N,,A,8236,,,Rattus norvegicus,1,,,
,4709,1,BAO_0000218,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,50597,In vivo,,CHEMBL618530,Intermediate,10116.0,,N,,A,8237,,,Rattus norvegicus,1,,,
,6642,1,BAO_0000218,Volume of distribution in rat,50597,In vivo,,CHEMBL618531,Intermediate,10116.0,,N,,A,8238,,,Rattus norvegicus,1,,,
,5247,1,BAO_0000218,The pharmacokinetic parameter volume of distribution in vivo in rats,50597,In vivo,,CHEMBL618532,Intermediate,10116.0,,N,,A,8239,,,Rattus norvegicus,1,,,
,17720,1,BAO_0000218,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,In vivo,,CHEMBL618533,Intermediate,10116.0,,N,,F,8240,,,Rattus norvegicus,1,,,
,17686,1,BAO_0000218,Vdss in rat i.v. at 2 mg/kg concentration,50597,In vivo,,CHEMBL618534,Intermediate,10116.0,,N,,A,8241,,,Rattus norvegicus,1,,,
,4689,1,BAO_0000218,Volume distribution after intravenous administration (1 mg/kg) in rat,50597,In vivo,,CHEMBL618535,Intermediate,10116.0,,N,,A,8242,,,Rattus norvegicus,1,,,
,5654,1,BAO_0000218,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,50597,In vivo,,CHEMBL618536,Intermediate,10116.0,,N,,A,8243,,,Rattus norvegicus,1,,,
,5654,1,BAO_0000218,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,50597,In vivo,,CHEMBL618537,Intermediate,10116.0,,N,,A,8244,,,Rattus norvegicus,1,,,
,4527,1,BAO_0000218,Volume distribution at a dose of 10 uM/kg in rat was determined,50597,In vivo,,CHEMBL618538,Intermediate,10116.0,,N,,A,8245,,,Rattus norvegicus,1,,,
,4521,1,BAO_0000218,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,50597,In vivo,,CHEMBL618539,Intermediate,10116.0,,N,,A,8246,,,Rattus norvegicus,1,,,
,6057,1,BAO_0000218,Volume distribution was calculated in rat,50597,In vivo,,CHEMBL618540,Intermediate,10116.0,,N,,A,8247,,,Rattus norvegicus,1,,,
,5510,1,BAO_0000218,Volume distribution was determined,50597,In vivo,,CHEMBL618541,Intermediate,10116.0,,N,,A,8248,,,Rattus norvegicus,1,,,
,2938,1,BAO_0000218,Volume of distribution after intravenous administration was evaluated in rat,50597,In vivo,,CHEMBL618542,Intermediate,10116.0,,N,,A,8249,,,Rattus norvegicus,1,,,
,6679,1,BAO_0000218,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50597,In vivo,,CHEMBL622544,Intermediate,10116.0,,N,,A,8250,,,Rattus norvegicus,1,,,
,6685,1,BAO_0000218,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",50597,In vivo,,CHEMBL622545,Intermediate,10116.0,,N,,A,8251,,,Rattus norvegicus,1,,,
,6685,1,BAO_0000218,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",50597,In vivo,,CHEMBL622546,Intermediate,10116.0,,N,,A,8252,,,Rattus norvegicus,1,,,
,6685,1,BAO_0000218,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",50597,In vivo,,CHEMBL622547,Intermediate,10116.0,,N,,A,8253,,,Rattus norvegicus,1,,,
,5145,1,BAO_0000218,Volume of distribution in steady state was determined in rat,50597,In vivo,,CHEMBL622548,Intermediate,10116.0,,N,,A,8254,,,Rattus norvegicus,1,,,
,6467,1,BAO_0000218,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,50597,In vivo,,CHEMBL622549,Intermediate,10116.0,,N,,A,8255,,,Rattus norvegicus,1,,,
,6467,1,BAO_0000218,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,50597,In vivo,,CHEMBL622550,Intermediate,10116.0,,N,,A,8256,,,Rattus norvegicus,1,,,
,15115,1,BAO_0000218,Compound was evaluated for area under curve when administered through oral route to mouse,50594,,,CHEMBL622551,Intermediate,10090.0,,N,,A,8257,,,Mus musculus,1,,,
,8758,1,BAO_0000218,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,50597,,,CHEMBL622552,Intermediate,10116.0,,N,,A,8258,,,Rattus norvegicus,1,,,
,8758,1,BAO_0000218,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,50597,,,CHEMBL622553,Intermediate,10116.0,,N,,A,8259,,,Rattus norvegicus,1,,,
,8267,0,BAO_0000218,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,22224,In vivo,,CHEMBL622554,Autocuration,,,U,,F,8260,,,,1,,,
,8267,1,BAO_0000218,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,50588,,,CHEMBL622555,Intermediate,9615.0,,N,,A,8261,,,Canis lupus familiaris,1,,,
,14239,1,BAO_0000218,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,50594,,,CHEMBL622556,Intermediate,10090.0,,N,,A,8262,,,Mus musculus,1,,,
,14239,1,BAO_0000218,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,50594,,,CHEMBL622557,Intermediate,10090.0,,N,,A,8263,,,Mus musculus,1,,,
,10754,1,BAO_0000218,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,50594,,Blood,CHEMBL622558,Intermediate,10090.0,,N,,A,8264,,,Mus musculus,1,,178.0,
,10754,1,BAO_0000218,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,50594,,Blood,CHEMBL622559,Intermediate,10090.0,,N,,A,8265,,,Mus musculus,1,,178.0,
,10754,1,BAO_0000218,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,50588,,,CHEMBL622560,Intermediate,9615.0,,N,,A,8266,,,Canis lupus familiaris,1,,,
,14681,1,BAO_0000218,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,50597,,,CHEMBL622561,Intermediate,10116.0,,N,,A,8267,,,Rattus norvegicus,1,,,
,14681,1,BAO_0000218,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,50597,,,CHEMBL622562,Intermediate,10116.0,,N,,A,8268,,,Rattus norvegicus,1,,,
,14681,1,BAO_0000218,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,50597,,,CHEMBL622563,Intermediate,10116.0,,N,,A,8269,,,Rattus norvegicus,1,,,
,13118,0,BAO_0000019,Concentration of compound in Central nervous system,22224,,,CHEMBL622564,Autocuration,,,U,,A,8270,,,,1,,,
,13118,0,BAO_0000019,Concentration of compound in Central nervous system; Not detectable,22224,,,CHEMBL622565,Autocuration,,,U,,A,8271,,,,1,,,
,13318,1,BAO_0000218,"Concentration of diester in the blood, following oral administration in mice",50594,,,CHEMBL622566,Intermediate,10090.0,,N,,A,8272,,,Mus musculus,1,,,
,13318,1,BAO_0000218,"Concentration of monoester in the blood, following oral administration in mice",50594,,,CHEMBL624515,Intermediate,10090.0,,N,,A,8273,,,Mus musculus,1,,,
,13318,1,BAO_0000218,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,50594,,,CHEMBL624516,Intermediate,10090.0,,N,,A,8274,,,Mus musculus,1,,,
,15692,0,BAO_0000019,Evaluated for Pharmacokinetic property: Area under the curve,22224,,,CHEMBL624517,Autocuration,,,U,,A,8275,,,,1,,,
,14839,1,BAO_0000218,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,50594,,,CHEMBL624518,Intermediate,10090.0,,N,,A,8276,,,Mus musculus,1,,,
,14839,1,BAO_0000218,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,100710,,,CHEMBL624519,Intermediate,9541.0,,N,,A,8277,,,Macaca fascicularis,1,,,
,14839,1,BAO_0000218,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,100710,,,CHEMBL624520,Intermediate,9541.0,,N,,A,8278,,,Macaca fascicularis,1,,,
,14839,1,BAO_0000218,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,100710,,,CHEMBL624521,Intermediate,9541.0,,N,,A,8279,,,Macaca fascicularis,1,,,
,14839,1,BAO_0000218,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,100710,,,CHEMBL624522,Intermediate,9541.0,,N,,A,8280,,,Macaca fascicularis,1,,,
,14839,1,BAO_0000218,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,100710,,,CHEMBL624523,Intermediate,9541.0,,N,,A,8281,,,Macaca fascicularis,1,,,
,14839,1,BAO_0000218,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",100710,,,CHEMBL624409,Intermediate,9541.0,,N,,A,8282,,,Macaca fascicularis,1,,,
,14839,1,BAO_0000218,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",100710,,,CHEMBL624410,Intermediate,9541.0,,N,,A,8283,,,Macaca fascicularis,1,,,
,14839,1,BAO_0000218,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",100710,,,CHEMBL624411,Intermediate,9541.0,,N,,A,8284,,,Macaca fascicularis,1,,,
,14839,1,BAO_0000218,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",100710,,,CHEMBL623531,Intermediate,9541.0,,N,,A,8285,,,Macaca fascicularis,1,,,
,14839,1,BAO_0000218,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",100710,,,CHEMBL623532,Intermediate,9541.0,,N,,A,8286,,,Macaca fascicularis,1,,,
,14839,1,BAO_0000218,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",100710,,,CHEMBL623533,Intermediate,9541.0,,N,,A,8287,,,Macaca fascicularis,1,,,
,14839,1,BAO_0000218,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",100710,,,CHEMBL623534,Intermediate,9541.0,,N,,A,8288,,,Macaca fascicularis,1,,,
,14839,1,BAO_0000218,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,50594,,,CHEMBL623535,Intermediate,10090.0,,N,,A,8289,,,Mus musculus,1,,,
,14839,1,BAO_0000218,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,50594,,,CHEMBL623536,Intermediate,10090.0,,N,,A,8290,,,Mus musculus,1,,,
,14839,1,BAO_0000218,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,50594,,,CHEMBL623537,Intermediate,10090.0,,N,,A,8291,,,Mus musculus,1,,,
,14839,1,BAO_0000218,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,50594,,,CHEMBL623538,Intermediate,10090.0,,N,,A,8292,,,Mus musculus,1,,,
,14839,1,BAO_0000218,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,50594,,,CHEMBL623539,Intermediate,10090.0,,N,,A,8293,,,Mus musculus,1,,,
,14839,1,BAO_0000218,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,50594,,,CHEMBL623540,Intermediate,10090.0,,N,,A,8294,,,Mus musculus,1,,,
,14839,1,BAO_0000218,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",50594,,,CHEMBL623541,Intermediate,10090.0,,N,,A,8295,,,Mus musculus,1,,,
,14839,1,BAO_0000218,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",50594,,,CHEMBL623542,Intermediate,10090.0,,N,,A,8296,,,Mus musculus,1,,,
,14839,1,BAO_0000218,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",50594,,,CHEMBL623543,Intermediate,10090.0,,N,,A,8297,,,Mus musculus,1,,,
,14839,1,BAO_0000218,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",50594,,,CHEMBL623544,Intermediate,10090.0,,N,,A,8298,,,Mus musculus,1,,,
,14839,1,BAO_0000218,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",50594,,,CHEMBL623545,Intermediate,10090.0,,N,,A,8299,,,Mus musculus,1,,,
,14839,1,BAO_0000218,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",50594,,,CHEMBL623546,Intermediate,10090.0,,N,,A,8300,,,Mus musculus,1,,,
,5408,1,BAO_0000218,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,50597,In vivo,Plasma,CHEMBL623547,Intermediate,10116.0,,N,,A,8301,,,Rattus norvegicus,1,,1969.0,
,6827,1,BAO_0000218,High i.v. clearance in Dawley rats,50597,In vivo,,CHEMBL623548,Intermediate,10116.0,,N,,A,8302,,,Rattus norvegicus,1,,,
,17538,1,BAO_0000218,In vitro clearance in rat liver microsomes,50597,In vitro,Liver,CHEMBL623549,Intermediate,10116.0,Microsomes,N,,A,8303,,,Rattus norvegicus,1,,2107.0,
,6331,1,BAO_0000218,Intrinsic clearance in rat liver microsomes was determined,50597,In vitro,Liver,CHEMBL623550,Intermediate,10116.0,Microsomes,N,,A,8304,,,Rattus norvegicus,1,,2107.0,
,5948,1,BAO_0000218,Intrinsic clearance in rat hepatocytes was determined,50597,In vitro,Liver,CHEMBL875276,Intermediate,10116.0,,N,,A,8305,,401.0,Rattus norvegicus,1,,2107.0,Hepatocyte
,4026,1,BAO_0000218,Plasma Clearance was determined,50597,In vivo,,CHEMBL621872,Intermediate,10116.0,,N,,A,8306,,,Rattus norvegicus,1,,,
,6647,1,BAO_0000218,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,50597,In vivo,,CHEMBL621873,Intermediate,10116.0,,N,,A,8307,,,Rattus norvegicus,1,,,
,1696,1,BAO_0000218,Plasma clearance in rat.,50597,In vivo,,CHEMBL621874,Intermediate,10116.0,,N,,A,8308,,,Rattus norvegicus,1,,,
,6597,1,BAO_0000218,Plasma clearance in rats,50597,In vivo,,CHEMBL621875,Intermediate,10116.0,,N,,A,8309,,,Rattus norvegicus,1,,,
,347,1,BAO_0000218,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,50597,In vivo,,CHEMBL621876,Intermediate,10116.0,,N,,A,8310,,,Rattus norvegicus,1,,,
,16423,1,BAO_0000218,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,50597,In vivo,,CHEMBL621877,Intermediate,10116.0,,N,,A,8311,,,Rattus norvegicus,1,,,
,2879,1,BAO_0000218,Plasma clearance was measured in rat,50597,In vivo,,CHEMBL621878,Intermediate,10116.0,,N,,A,8312,,,Rattus norvegicus,1,,,
,4883,1,BAO_0000218,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,50597,In vivo,,CHEMBL621879,Intermediate,10116.0,,N,,A,8313,,,Rattus norvegicus,1,,,
,5328,1,BAO_0000218,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",50597,In vivo,Plasma,CHEMBL621880,Intermediate,10116.0,,N,,A,8314,,,Rattus norvegicus,1,,1969.0,
,5160,1,BAO_0000218,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,50597,In vivo,,CHEMBL621881,Intermediate,10116.0,,N,,A,8315,,,Rattus norvegicus,1,,,
,17582,1,BAO_0000218,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,50597,In vivo,,CHEMBL621882,Intermediate,10116.0,,N,,A,8316,,,Rattus norvegicus,1,,,
,17651,1,BAO_0000218,Total clearance at 1 mg/kg was determined in rat,50597,In vivo,,CHEMBL875283,Intermediate,10116.0,,N,,A,8317,,,Rattus norvegicus,1,,,
,17651,1,BAO_0000218,Total clearance at 10 mg/kg was determined in rat,50597,In vivo,,CHEMBL621883,Intermediate,10116.0,,N,,A,8318,,,Rattus norvegicus,1,,,
,6596,1,BAO_0000218,Clearance in rat,50597,In vivo,,CHEMBL621884,Intermediate,10116.0,,N,,A,8319,,,Rattus norvegicus,1,,,
,4796,1,BAO_0000218,Plasma clearance rate determined in rats,50597,In vivo,,CHEMBL621885,Intermediate,10116.0,,N,,A,8320,,,Rattus norvegicus,1,,,
,6850,1,BAO_0000218,Clearance of compound in rat was evaluated,50597,In vivo,,CHEMBL621886,Intermediate,10116.0,,N,,A,8321,,,Rattus norvegicus,1,,,
,5932,1,BAO_0000218,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,50597,In vivo,Plasma,CHEMBL621887,Intermediate,10116.0,,N,,A,8322,,,Rattus norvegicus,1,,1969.0,
,3371,1,BAO_0000218,Pharmacokinetic property (blood clearance) in rat,50597,In vivo,,CHEMBL621888,Intermediate,10116.0,,N,,A,8323,,,Rattus norvegicus,1,,,
,2083,1,BAO_0000218,Plasma clearance in rat,50597,In vivo,,CHEMBL621889,Intermediate,10116.0,,N,,A,8324,,,Rattus norvegicus,1,,,
,4942,1,BAO_0000218,Plasma clearance in rats,50597,In vivo,,CHEMBL621890,Intermediate,10116.0,,N,,A,8325,,,Rattus norvegicus,1,,,
,6838,1,BAO_0000218,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,50597,In vitro,Liver,CHEMBL621891,Intermediate,10116.0,Microsomes,N,,A,8326,,,Rattus norvegicus,1,,2107.0,
,5353,1,BAO_0000218,Clearance in Dawley rat,50597,In vivo,,CHEMBL621892,Intermediate,10116.0,,N,,A,8327,,,Rattus norvegicus,1,,,
,6641,1,BAO_0000218,Clearance rat,50597,In vivo,,CHEMBL621893,Intermediate,10116.0,,N,,A,8328,,,Rattus norvegicus,1,,,
,6641,1,BAO_0000218,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),50597,In vivo,,CHEMBL621894,Intermediate,10116.0,,N,,A,8329,,,Rattus norvegicus,1,,,
,6641,1,BAO_0000218,Clearance rat; Not determined,50597,In vivo,,CHEMBL621895,Intermediate,10116.0,,N,,A,8330,,,Rattus norvegicus,1,,,
,6444,1,BAO_0000218,Clearance rate was determined in rat at a dose of 1 mpk i.v.,50597,In vivo,,CHEMBL875284,Intermediate,10116.0,,N,,A,8331,,,Rattus norvegicus,1,,,
,6444,1,BAO_0000218,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,50597,In vivo,,CHEMBL618699,Intermediate,10116.0,,N,,A,8332,,,Rattus norvegicus,1,,,
,6444,1,BAO_0000218,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,50597,In vivo,,CHEMBL618700,Intermediate,10116.0,,N,,A,8333,,,Rattus norvegicus,1,,,
,6211,1,BAO_0000218,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,50597,In vivo,,CHEMBL618701,Intermediate,10116.0,,N,,A,8334,,,Rattus norvegicus,1,,,
,12873,1,BAO_0000218,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",50597,In vivo,Plasma,CHEMBL876600,Intermediate,10116.0,,N,,A,8335,,,Rattus norvegicus,1,,1969.0,
,6570,1,BAO_0000218,Clearance of compound in rat after 1 mg/kg i.v. administration,50597,In vivo,,CHEMBL618702,Intermediate,10116.0,,N,,A,8336,,,Rattus norvegicus,1,,,
,3341,1,BAO_0000218,Compound was evaluated for Hepatic clearance in rat,50597,In vivo,,CHEMBL618703,Intermediate,10116.0,,N,,A,8337,,,Rattus norvegicus,1,,,
,4891,1,BAO_0000218,In vivo clearance after 5 mg/kg dose,50597,In vivo,,CHEMBL618704,Intermediate,10116.0,,N,,A,8338,,,Rattus norvegicus,1,,,
,1094,1,BAO_0000218,Compound was tested for plasma clearance in rats,50597,In vivo,Plasma,CHEMBL618705,Intermediate,10116.0,,N,,A,8339,,,Rattus norvegicus,1,,1969.0,
,2938,1,BAO_0000218,Hepatic clearance after intravenous administration was evaluated in rat,50597,In vivo,,CHEMBL618706,Intermediate,10116.0,,N,,A,8340,,,Rattus norvegicus,1,,,
,17853,1,BAO_0000218,Lower clearance in rat (i.v.) at 0.5 mpk,50597,In vivo,,CHEMBL618707,Intermediate,10116.0,,N,,A,8341,,,Rattus norvegicus,1,,,
,6049,1,BAO_0000218,Pharmacokinetic parameter expressed as plasma clearance in rat,50597,In vivo,Plasma,CHEMBL618708,Intermediate,10116.0,,N,,A,8342,,,Rattus norvegicus,1,,1969.0,
,5789,1,BAO_0000218,Pharmacokinetic property (Clp) in rat,50597,In vivo,,CHEMBL618709,Intermediate,10116.0,,N,,A,8343,,,Rattus norvegicus,1,,,
,4514,1,BAO_0000218,Plasma clearance in Sprague-Dawley rats,50597,In vivo,,CHEMBL618710,Intermediate,10116.0,,N,,A,8344,,,Rattus norvegicus,1,,,
,6448,1,BAO_0000218,Plasma clearance (Clp) in rat,50597,In vivo,,CHEMBL618711,Intermediate,10116.0,,N,,A,8345,,,Rattus norvegicus,1,,,
,6062,1,BAO_0000218,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,50597,In vivo,,CHEMBL618712,Intermediate,10116.0,,N,,A,8346,,,Rattus norvegicus,1,,,
,5710,1,BAO_0000218,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,50597,In vivo,,CHEMBL618713,Intermediate,10116.0,,N,,A,8347,,,Rattus norvegicus,1,,,
,4709,1,BAO_0000218,Plasma clearance after intravenous administration of 1 mg/kg in rat,50597,In vivo,,CHEMBL618714,Intermediate,10116.0,,N,,A,8348,,,Rattus norvegicus,1,,,
,4521,1,BAO_0000218,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,50597,In vivo,,CHEMBL618715,Intermediate,10116.0,,N,,A,8349,,,Rattus norvegicus,1,,,
,1742,1,BAO_0000218,Plasma clearance in rat was determined,50597,In vivo,,CHEMBL618716,Intermediate,10116.0,,N,,A,8350,,,Rattus norvegicus,1,,,
,6057,1,BAO_0000218,Plasma clearance measured in rat,50597,In vivo,,CHEMBL876601,Intermediate,10116.0,,N,,A,8351,,,Rattus norvegicus,1,,,
,6057,1,BAO_0000218,Plasma clearance was calculated in rat,50597,In vivo,,CHEMBL618717,Intermediate,10116.0,,N,,A,8352,,,Rattus norvegicus,1,,,
,5145,1,BAO_0000218,Plasma clearance in rat,50597,In vivo,,CHEMBL618718,Intermediate,10116.0,,N,,A,8353,,,Rattus norvegicus,1,,,
,5833,1,BAO_0000218,Plasma clearance in rat,50597,In vivo,,CHEMBL618719,Intermediate,10116.0,,N,,A,8354,,,Rattus norvegicus,1,,,
,6453,1,BAO_0000218,Plasma clearance in rat,50597,In vivo,,CHEMBL618720,Intermediate,10116.0,,N,,A,8355,,,Rattus norvegicus,1,,,
,6640,1,BAO_0000218,Plasma clearance in rat,50597,In vivo,,CHEMBL618721,Intermediate,10116.0,,N,,A,8356,,,Rattus norvegicus,1,,,
,6305,1,BAO_0000218,Plasma clearance in rats,50597,In vivo,,CHEMBL621477,Intermediate,10116.0,,N,,A,8357,,,Rattus norvegicus,1,,,
,6642,1,BAO_0000218,Plasma clearance in rat,50597,In vivo,,CHEMBL621478,Intermediate,10116.0,,N,,A,8358,,,Rattus norvegicus,1,,,
,5472,1,BAO_0000218,Plasma clearance was evaluated in rat,50597,In vivo,,CHEMBL621479,Intermediate,10116.0,,N,,A,8359,,,Rattus norvegicus,1,,,
,5472,1,BAO_0000218,Plasma clearance was evaluated in rat; Not tested,50597,In vivo,,CHEMBL621480,Intermediate,10116.0,,N,,A,8360,,,Rattus norvegicus,1,,,
,5144,1,BAO_0000218,Plasma clearance rate was determined for the compound in rat,50597,In vivo,,CHEMBL621481,Intermediate,10116.0,,N,,A,8361,,,Rattus norvegicus,1,,,
,6685,1,BAO_0000218,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",50597,In vivo,,CHEMBL621482,Intermediate,10116.0,,N,,A,8362,,,Rattus norvegicus,1,,,
,6685,1,BAO_0000218,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",50597,In vivo,,CHEMBL621483,Intermediate,10116.0,,N,,A,8363,,,Rattus norvegicus,1,,,
,6685,1,BAO_0000218,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",50597,In vivo,,CHEMBL621484,Intermediate,10116.0,,N,,A,8364,,,Rattus norvegicus,1,,,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Heart,CHEMBL621485,Intermediate,10116.0,,N,,A,8365,,,Rattus norvegicus,1,,948.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Heart,CHEMBL621486,Intermediate,10116.0,,N,,A,8366,,,Rattus norvegicus,1,,948.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Intestine,CHEMBL621487,Intermediate,10116.0,,N,,A,8367,,,Rattus norvegicus,1,,160.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Intestine,CHEMBL621488,Intermediate,10116.0,,N,,A,8368,,,Rattus norvegicus,1,,160.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Intestine,CHEMBL621489,Intermediate,10116.0,,N,,A,8369,,,Rattus norvegicus,1,,160.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Intestine,CHEMBL621490,Intermediate,10116.0,,N,,A,8370,,,Rattus norvegicus,1,,160.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Intestine,CHEMBL621491,Intermediate,10116.0,,N,,A,8371,,,Rattus norvegicus,1,,160.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Kidney,CHEMBL621492,Intermediate,10116.0,,N,,A,8372,,,Rattus norvegicus,1,,2113.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,50597,In vivo,Kidney,CHEMBL621493,Intermediate,10116.0,,N,,A,8373,,,Rattus norvegicus,1,,2113.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Kidney,CHEMBL621494,Intermediate,10116.0,,N,,A,8374,,,Rattus norvegicus,1,,2113.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Kidney,CHEMBL621495,Intermediate,10116.0,,N,,A,8375,,,Rattus norvegicus,1,,2113.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Kidney,CHEMBL621496,Intermediate,10116.0,,N,,A,8376,,,Rattus norvegicus,1,,2113.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Liver,CHEMBL621497,Intermediate,10116.0,,N,,A,8377,,,Rattus norvegicus,1,,2107.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Liver,CHEMBL621498,Intermediate,10116.0,,N,,A,8378,,,Rattus norvegicus,1,,2107.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Liver,CHEMBL621499,Intermediate,10116.0,,N,,A,8379,,,Rattus norvegicus,1,,2107.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,50597,In vivo,Liver,CHEMBL618634,Intermediate,10116.0,,N,,A,8380,,,Rattus norvegicus,1,,2107.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Liver,CHEMBL618635,Intermediate,10116.0,,N,,A,8381,,,Rattus norvegicus,1,,2107.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Lung,CHEMBL618636,Intermediate,10116.0,,N,,A,8382,,,Rattus norvegicus,1,,2048.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Lung,CHEMBL619737,Intermediate,10116.0,,N,,A,8383,,,Rattus norvegicus,1,,2048.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Lung,CHEMBL619738,Intermediate,10116.0,,N,,A,8384,,,Rattus norvegicus,1,,2048.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Lung,CHEMBL624329,Intermediate,10116.0,,N,,A,8385,,,Rattus norvegicus,1,,2048.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Lung,CHEMBL624330,Intermediate,10116.0,,N,,A,8386,,,Rattus norvegicus,1,,2048.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Muscle tissue,CHEMBL624331,Intermediate,10116.0,,N,,A,8387,,,Rattus norvegicus,1,,2385.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Muscle tissue,CHEMBL624332,Intermediate,10116.0,,N,,A,8388,,,Rattus norvegicus,1,,2385.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Muscle tissue,CHEMBL624333,Intermediate,10116.0,,N,,A,8389,,,Rattus norvegicus,1,,2385.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Muscle tissue,CHEMBL624334,Intermediate,10116.0,,N,,A,8390,,,Rattus norvegicus,1,,2385.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Muscle tissue,CHEMBL624335,Intermediate,10116.0,,N,,A,8391,,,Rattus norvegicus,1,,2385.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Spleen,CHEMBL620016,Intermediate,10116.0,,N,,A,8392,,,Rattus norvegicus,1,,2106.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Spleen,CHEMBL620169,Intermediate,10116.0,,N,,A,8393,,,Rattus norvegicus,1,,2106.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Spleen,CHEMBL620170,Intermediate,10116.0,,N,,A,8394,,,Rattus norvegicus,1,,2106.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,50597,In vivo,Spleen,CHEMBL620171,Intermediate,10116.0,,N,,A,8395,,,Rattus norvegicus,1,,2106.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Spleen,CHEMBL620172,Intermediate,10116.0,,N,,A,8396,,,Rattus norvegicus,1,,2106.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Stomach,CHEMBL620173,Intermediate,10116.0,,N,,A,8397,,,Rattus norvegicus,1,,945.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,50597,In vivo,Stomach,CHEMBL620174,Intermediate,10116.0,,N,,A,8398,,,Rattus norvegicus,1,,945.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Stomach,CHEMBL620175,Intermediate,10116.0,,N,,A,8399,,,Rattus norvegicus,1,,945.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Stomach,CHEMBL620176,Intermediate,10116.0,,N,,A,8400,,,Rattus norvegicus,1,,945.0,
,13950,1,BAO_0000218,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,In vivo,Stomach,CHEMBL620177,Intermediate,10116.0,,N,,A,8401,,,Rattus norvegicus,1,,945.0,
,13950,1,BAO_0000218,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,,Cerebellum,CHEMBL620178,Intermediate,10116.0,,N,,A,8402,,,Rattus norvegicus,1,,2037.0,
,13950,1,BAO_0000218,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,,Cerebellum,CHEMBL620179,Intermediate,10116.0,,N,,A,8403,,,Rattus norvegicus,1,,2037.0,
,13950,1,BAO_0000218,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,,,CHEMBL620180,Intermediate,10116.0,,N,,A,8404,,,Rattus norvegicus,1,,,
,6570,1,BAO_0000218,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,50597,In vivo,,CHEMBL620181,Intermediate,10116.0,,N,,A,8405,,,Rattus norvegicus,1,,,
,6571,1,BAO_0000218,Volume of distribution of compound in rats after intravenous administration,50597,In vivo,,CHEMBL620182,Intermediate,10116.0,,N,,A,8406,,,Rattus norvegicus,1,,,
,6453,1,BAO_0000218,Volume of distribution in rat,50597,In vivo,,CHEMBL620183,Intermediate,10116.0,,N,,A,8407,,,Rattus norvegicus,1,,,
,6444,1,BAO_0000218,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,50597,In vivo,,CHEMBL620184,Intermediate,10116.0,,N,,A,8408,,,Rattus norvegicus,1,,,
,6444,1,BAO_0000218,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,50597,In vivo,,CHEMBL620185,Intermediate,10116.0,,N,,A,8409,,,Rattus norvegicus,1,,,
,6444,1,BAO_0000218,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,50597,In vivo,,CHEMBL620186,Intermediate,10116.0,,N,,A,8410,,,Rattus norvegicus,1,,,
,5353,1,BAO_0000218,Volume of distribution was determined in Dawley rat,50597,In vivo,,CHEMBL620187,Intermediate,10116.0,,N,,A,8411,,,Rattus norvegicus,1,,,
,5334,1,BAO_0000218,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,50597,In vivo,,CHEMBL620188,Intermediate,10116.0,,N,,A,8412,,,Rattus norvegicus,1,,,
,5334,1,BAO_0000218,Volume of distribution was reported in Sprague-Dawley rat,50597,In vivo,,CHEMBL620189,Intermediate,10116.0,,N,,A,8413,,,Rattus norvegicus,1,,,
,6641,1,BAO_0000218,Volumes of distribution in rat after peroral administration,50597,In vivo,,CHEMBL620190,Intermediate,10116.0,,N,,A,8414,,,Rattus norvegicus,1,,,
,6641,1,BAO_0000218,Volumes of distribution in rat after po administration,50597,In vivo,,CHEMBL620191,Intermediate,10116.0,,N,,A,8415,,,Rattus norvegicus,1,,,
,6641,1,BAO_0000218,Volumes of distribution in rat after po administration; Not determined,50597,In vivo,,CHEMBL620192,Intermediate,10116.0,,N,,A,8416,,,Rattus norvegicus,1,,,
,5676,1,BAO_0000218,Pharmacokinetic property (Volume) in rat i.v.,50597,In vivo,,CHEMBL620193,Intermediate,10116.0,,N,,A,8417,,,Rattus norvegicus,1,,,
,6410,1,BAO_0000218,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,50597,In vivo,,CHEMBL620194,Intermediate,10116.0,,N,,A,8418,,,Rattus norvegicus,1,,,
,17670,1,BAO_0000218,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",50597,In vivo,,CHEMBL876730,Intermediate,10116.0,,N,,A,8419,,,Rattus norvegicus,1,,,
,6495,1,BAO_0000218,Volume distribution in rat after oral administration at 10 mg/kg,50597,In vivo,,CHEMBL620195,Intermediate,10116.0,,N,,A,8420,,,Rattus norvegicus,1,,,
,5408,1,BAO_0000218,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,50597,In vivo,,CHEMBL620196,Intermediate,10116.0,,N,,A,8421,,,Rattus norvegicus,1,,,
,4883,1,BAO_0000218,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,50597,In vivo,,CHEMBL620197,Intermediate,10116.0,,N,,A,8422,,,Rattus norvegicus,1,,,
,6647,1,BAO_0000218,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,50597,In vivo,,CHEMBL620198,Intermediate,10116.0,,N,,A,8423,,,Rattus norvegicus,1,,,
,6495,1,BAO_0000218,Volume of distribution in rats,50597,In vivo,,CHEMBL620199,Intermediate,10116.0,,N,,A,8424,,,Rattus norvegicus,1,,,
,2661,1,BAO_0000218,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,50597,In vivo,,CHEMBL620200,Intermediate,10116.0,,N,,A,8425,,,Rattus norvegicus,1,,,
,2661,1,BAO_0000218,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,50597,In vivo,,CHEMBL620201,Intermediate,10116.0,,N,,A,8426,,,Rattus norvegicus,1,,,
,5974,1,BAO_0000218,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,In vivo,,CHEMBL620202,Intermediate,10116.0,,N,,A,8427,,,Rattus norvegicus,1,,,
,5974,1,BAO_0000218,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,In vivo,,CHEMBL620203,Intermediate,10116.0,,N,,A,8428,,,Rattus norvegicus,1,,,
,5974,1,BAO_0000218,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,50597,In vivo,,CHEMBL620204,Intermediate,10116.0,,N,,A,8429,,,Rattus norvegicus,1,,,
,5974,1,BAO_0000218,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,In vivo,,CHEMBL620205,Intermediate,10116.0,,N,,A,8430,,,Rattus norvegicus,1,,,
,5960,1,BAO_0000218,Pharmacokinetic parameter (Vss) in rat,50597,In vivo,,CHEMBL624664,Intermediate,10116.0,,N,,A,8431,,,Rattus norvegicus,1,,,
,5676,1,BAO_0000218,Pharmacokinetic property (Volume) in rat i.v.,50597,In vivo,,CHEMBL624665,Intermediate,10116.0,,N,,A,8432,,,Rattus norvegicus,1,,,
,5948,1,BAO_0000218,Pharmacokinetic property (Vss) in rat,50597,,,CHEMBL624666,Intermediate,10116.0,,N,,A,8433,,,Rattus norvegicus,1,,,
,5979,1,BAO_0000218,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,50597,In vivo,,CHEMBL624667,Intermediate,10116.0,,N,,A,8434,,,Rattus norvegicus,1,,,
,5978,1,BAO_0000218,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,50597,In vivo,,CHEMBL624668,Intermediate,10116.0,,N,,A,8435,,,Rattus norvegicus,1,,,
,5978,1,BAO_0000218,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,In vivo,,CHEMBL624669,Intermediate,10116.0,,N,,A,8436,,,Rattus norvegicus,1,,,
,5978,1,BAO_0000218,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,In vivo,,CHEMBL624670,Intermediate,10116.0,,N,,A,8437,,,Rattus norvegicus,1,,,
,5978,1,BAO_0000218,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,In vivo,,CHEMBL624671,Intermediate,10116.0,,N,,A,8438,,,Rattus norvegicus,1,,,
,6448,1,BAO_0000218,Steady state volume distribution in rat,50597,In vivo,,CHEMBL624672,Intermediate,10116.0,,N,,A,8439,,,Rattus norvegicus,1,,,
,12873,1,BAO_0000218,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",50597,In vivo,Plasma,CHEMBL624673,Intermediate,10116.0,,N,,A,8440,,,Rattus norvegicus,1,,1969.0,
,4576,1,BAO_0000218,Steady state volume of distribution determined in rat,50597,In vivo,,CHEMBL624674,Intermediate,10116.0,,N,,A,8441,,,Rattus norvegicus,1,,,
,17582,1,BAO_0000218,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,50597,In vivo,,CHEMBL624675,Intermediate,10116.0,,N,,A,8442,,,Rattus norvegicus,1,,,
,1466,1,BAO_0000218,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,50597,In vivo,,CHEMBL621728,Intermediate,10116.0,,N,,A,8443,,,Rattus norvegicus,1,,,
,5182,1,BAO_0000218,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,50597,,,CHEMBL621729,Intermediate,10116.0,,N,,A,8444,,,Rattus norvegicus,1,,,
,5182,1,BAO_0000218,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,50597,,,CHEMBL621730,Intermediate,10116.0,,N,,A,8445,,,Rattus norvegicus,1,,,
,6535,1,BAO_0000218,Volume distribution in rat after administration of 2 mg/kg iv,50597,In vivo,,CHEMBL621731,Intermediate,10116.0,,N,,A,8446,,,Rattus norvegicus,1,,,
,6535,1,BAO_0000218,Volume distribution in rat after administration of 2 mg/kg iv,50597,In vivo,,CHEMBL621732,Intermediate,10116.0,,N,,A,8447,,,Rattus norvegicus,1,,,
,5041,1,BAO_0000218,Volume in steady state distribution value was determined,50597,In vivo,,CHEMBL621908,Intermediate,10116.0,,N,,A,8448,,,Rattus norvegicus,1,,,
,5041,1,BAO_0000218,Volume in steady state distribution value was determined; ND denotes no data,50597,In vivo,,CHEMBL875347,Intermediate,10116.0,,N,,A,8449,,,Rattus norvegicus,1,,,
,5041,1,BAO_0000218,Volume in steady state distribution value was determined; ND denotes not determined,50597,In vivo,,CHEMBL621909,Intermediate,10116.0,,N,,A,8450,,,Rattus norvegicus,1,,,
,17065,1,BAO_0000218,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,50597,In vivo,,CHEMBL621910,Intermediate,10116.0,,N,,A,8451,,,Rattus norvegicus,1,,,
,6597,1,BAO_0000218,Volume of distribution at steady state was evaluated in rats,50597,In vivo,,CHEMBL621911,Intermediate,10116.0,,N,,A,8452,,,Rattus norvegicus,1,,,
,15662,1,BAO_0000218,Volume of distribution at steady state was observed after intravenous administration in rat,50597,In vivo,,CHEMBL621912,Intermediate,10116.0,,N,,A,8453,,,Rattus norvegicus,1,,,
,6485,1,BAO_0000218,Volume of distribution in steady state was determined in rat,50597,In vivo,,CHEMBL621913,Intermediate,10116.0,,N,,A,8454,,,Rattus norvegicus,1,,,
,17655,1,BAO_0000218,Volume of distribution in steady state was determined in rat,50597,In vivo,,CHEMBL621914,Intermediate,10116.0,,N,,A,8455,,,Rattus norvegicus,1,,,
,6616,1,BAO_0000218,Volume of distribution after i.v. administration,50597,In vivo,,CHEMBL621915,Intermediate,10116.0,,N,,A,8456,,,Rattus norvegicus,1,,,
,1916,1,BAO_0000218,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,50597,In vivo,,CHEMBL621916,Intermediate,10116.0,,N,,A,8457,,,Rattus norvegicus,1,,,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,In vivo,Liver,CHEMBL621917,Intermediate,10090.0,,N,,A,8458,,,Mus musculus,1,,2107.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,In vivo,Liver,CHEMBL621918,Intermediate,10090.0,,N,,A,8459,,,Mus musculus,1,,2107.0,
,16438,1,BAO_0000218,Biodistribution of compound (oxidized form) in spleen tissue,50594,In vivo,Spleen,CHEMBL621919,Intermediate,10090.0,,N,,A,8460,,,Mus musculus,1,,2106.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,In vivo,Spleen,CHEMBL621920,Intermediate,10090.0,,N,,A,8461,,,Mus musculus,1,,2106.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",50594,In vivo,Spleen,CHEMBL621921,Intermediate,10090.0,,N,,A,8462,,,Mus musculus,1,,2106.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,In vivo,Spleen,CHEMBL622401,Intermediate,10090.0,,N,,A,8463,,,Mus musculus,1,,2106.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,In vivo,Spleen,CHEMBL875348,Intermediate,10090.0,,N,,A,8464,,,Mus musculus,1,,2106.0,
,16438,1,BAO_0000218,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,In vivo,Spleen,CHEMBL622402,Intermediate,10090.0,,N,,A,8465,,,Mus musculus,1,,2106.0,
,16438,1,BAO_0000218,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,50594,In vivo,Blood,CHEMBL622403,Intermediate,10090.0,,N,,A,8466,,,Mus musculus,1,,178.0,
,16438,1,BAO_0000218,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,In vivo,Blood,CHEMBL622404,Intermediate,10090.0,,N,,A,8467,,,Mus musculus,1,,178.0,
,16438,1,BAO_0000218,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,50594,In vivo,Brain,CHEMBL622405,Intermediate,10090.0,,N,,A,8468,,,Mus musculus,1,,955.0,
,16438,1,BAO_0000218,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",50594,In vivo,Brain,CHEMBL622406,Intermediate,10090.0,,N,,A,8469,,,Mus musculus,1,,955.0,
,16438,1,BAO_0000218,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,In vivo,Brain,CHEMBL622407,Intermediate,10090.0,,N,,A,8470,,,Mus musculus,1,,955.0,
,16438,1,BAO_0000218,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,50594,In vivo,Heart,CHEMBL622408,Intermediate,10090.0,,N,,A,8471,,,Mus musculus,1,,948.0,
,16438,1,BAO_0000218,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",50594,In vivo,Heart,CHEMBL622409,Intermediate,10090.0,,N,,A,8472,,,Mus musculus,1,,948.0,
,16438,1,BAO_0000218,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,In vivo,Heart,CHEMBL622410,Intermediate,10090.0,,N,,A,8473,,,Mus musculus,1,,948.0,
,16438,1,BAO_0000218,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,50594,In vivo,Kidney,CHEMBL622411,Intermediate,10090.0,,N,,A,8474,,,Mus musculus,1,,2113.0,
,16438,1,BAO_0000218,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",50594,In vivo,Kidney,CHEMBL627864,Intermediate,10090.0,,N,,A,8475,,,Mus musculus,1,,2113.0,
,16438,1,BAO_0000218,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,In vivo,Kidney,CHEMBL627865,Intermediate,10090.0,,N,,A,8476,,,Mus musculus,1,,2113.0,
,16438,1,BAO_0000218,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,50594,In vivo,Liver,CHEMBL627866,Intermediate,10090.0,,N,,A,8477,,,Mus musculus,1,,2107.0,
,16438,1,BAO_0000218,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,In vivo,Liver,CHEMBL627751,Intermediate,10090.0,,N,,A,8478,,,Mus musculus,1,,2107.0,
,16438,1,BAO_0000218,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,50594,In vivo,Spleen,CHEMBL627752,Intermediate,10090.0,,N,,A,8479,,,Mus musculus,1,,2106.0,
,16438,1,BAO_0000218,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",50594,In vivo,Spleen,CHEMBL627753,Intermediate,10090.0,,N,,A,8480,,,Mus musculus,1,,2106.0,
,16438,1,BAO_0000218,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,In vivo,Spleen,CHEMBL627754,Intermediate,10090.0,,N,,A,8481,,,Mus musculus,1,,2106.0,
,12467,1,BAO_0000218,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,50594,,,CHEMBL627755,Intermediate,10090.0,,N,,A,8482,,,Mus musculus,1,,,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),50594,In vivo,Brain,CHEMBL627756,Intermediate,10090.0,,N,,A,8483,,,Mus musculus,1,,955.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),50594,In vivo,Brain,CHEMBL627757,Intermediate,10090.0,,N,,A,8484,,,Mus musculus,1,,955.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,In vivo,Brain,CHEMBL627758,Intermediate,10090.0,,N,,A,8485,,,Mus musculus,1,,955.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),50594,In vivo,Brain,CHEMBL627759,Intermediate,10090.0,,N,,A,8486,,,Mus musculus,1,,955.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,In vivo,Brain,CHEMBL627760,Intermediate,10090.0,,N,,A,8487,,,Mus musculus,1,,955.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),50594,In vivo,Brain,CHEMBL627761,Intermediate,10090.0,,N,,A,8488,,,Mus musculus,1,,955.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),50594,In vivo,Heart,CHEMBL876811,Intermediate,10090.0,,N,,A,8489,,,Mus musculus,1,,948.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),50594,In vivo,Heart,CHEMBL627762,Intermediate,10090.0,,N,,A,8490,,,Mus musculus,1,,948.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,In vivo,Heart,CHEMBL627763,Intermediate,10090.0,,N,,A,8491,,,Mus musculus,1,,948.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),50594,In vivo,Heart,CHEMBL627764,Intermediate,10090.0,,N,,A,8492,,,Mus musculus,1,,948.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,In vivo,Heart,CHEMBL627765,Intermediate,10090.0,,N,,A,8493,,,Mus musculus,1,,948.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),50594,In vivo,Heart,CHEMBL627766,Intermediate,10090.0,,N,,A,8494,,,Mus musculus,1,,948.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),50594,In vivo,Kidney,CHEMBL627767,Intermediate,10090.0,,N,,A,8495,,,Mus musculus,1,,2113.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),50594,In vivo,Kidney,CHEMBL627768,Intermediate,10090.0,,N,,A,8496,,,Mus musculus,1,,2113.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,In vivo,Kidney,CHEMBL628422,Intermediate,10090.0,,N,,A,8497,,,Mus musculus,1,,2113.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),50594,In vivo,Kidney,CHEMBL628423,Intermediate,10090.0,,N,,A,8498,,,Mus musculus,1,,2113.0,
,5089,1,BAO_0000218,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,50597,In vivo,,CHEMBL628424,Intermediate,10116.0,,N,,A,8499,,,Rattus norvegicus,1,,,
,5089,1,BAO_0000218,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,50597,In vivo,,CHEMBL628425,Intermediate,10116.0,,N,,A,8500,,,Rattus norvegicus,1,,,
,4257,1,BAO_0000218,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,50597,In vivo,,CHEMBL628426,Intermediate,10116.0,,N,,A,8501,,,Rattus norvegicus,1,,,
,6679,1,BAO_0000218,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50597,In vivo,,CHEMBL628427,Intermediate,10116.0,,N,,A,8502,,,Rattus norvegicus,1,,,
,5546,1,BAO_0000218,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,50597,In vivo,,CHEMBL626938,Intermediate,10116.0,,N,,A,8503,,,Rattus norvegicus,1,,,
,6141,1,BAO_0000218,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,50597,In vivo,,CHEMBL626939,Intermediate,10116.0,,N,,A,8504,,,Rattus norvegicus,1,,,
,5334,1,BAO_0000218,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,50597,In vivo,,CHEMBL626940,Intermediate,10116.0,,N,,A,8505,,,Rattus norvegicus,1,,,
,5334,1,BAO_0000218,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,50597,In vivo,,CHEMBL626941,Intermediate,10116.0,,N,,A,8506,,,Rattus norvegicus,1,,,
,5334,1,BAO_0000218,Plasma clearance was reported in Sprague-Dawley rat,50597,In vivo,,CHEMBL626942,Intermediate,10116.0,,N,,A,8507,,,Rattus norvegicus,1,,,
,4689,1,BAO_0000218,Plasma clearance after intravenous administration (1 mg/kg) in rat,50597,In vivo,,CHEMBL876812,Intermediate,10116.0,,N,,A,8508,,,Rattus norvegicus,1,,,
,6848,1,BAO_0000218,Plasma clearance of compound in rats was evaluated,50597,In vivo,,CHEMBL626943,Intermediate,10116.0,,N,,A,8509,,,Rattus norvegicus,1,,,
,6848,1,BAO_0000218,Plasma clearance of compound in rats was evaluated; ND indicates not determined,50597,In vivo,,CHEMBL626944,Intermediate,10116.0,,N,,A,8510,,,Rattus norvegicus,1,,,
,6467,1,BAO_0000218,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,50597,In vivo,,CHEMBL626945,Intermediate,10116.0,,N,,A,8511,,,Rattus norvegicus,1,,,
,6467,1,BAO_0000218,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,50597,In vivo,,CHEMBL626946,Intermediate,10116.0,,N,,A,8512,,,Rattus norvegicus,1,,,
,4956,1,BAO_0000218,Plasma clearance rate in Sprague-Dawley rats,50597,In vivo,,CHEMBL626856,Intermediate,10116.0,,N,,A,8513,,,Rattus norvegicus,1,,,
,5529,1,BAO_0000218,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),50597,In vivo,,CHEMBL626857,Intermediate,10116.0,,N,,A,8514,,,Rattus norvegicus,1,,,
,406,1,BAO_0000218,The compound was evaluated for plasma clearance in rat,50597,In vivo,Plasma,CHEMBL626858,Intermediate,10116.0,,N,,A,8515,,,Rattus norvegicus,1,,1969.0,
,17655,1,BAO_0000218,Total plasma clearance in rat,50597,In vivo,Plasma,CHEMBL627018,Intermediate,10116.0,,N,,A,8516,,,Rattus norvegicus,1,,1969.0,
,3293,1,BAO_0000218,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,50597,In vivo,Blood,CHEMBL625331,Intermediate,10116.0,,N,,A,8517,,,Rattus norvegicus,1,,178.0,
,4075,1,BAO_0000218,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,50597,In vivo,Blood,CHEMBL625332,Intermediate,10116.0,,N,,A,8518,,,Rattus norvegicus,1,,178.0,
,2792,1,BAO_0000218,C max was determined at 10 mg/kg po dose in rats,50597,In vivo,,CHEMBL877590,Intermediate,10116.0,,N,,A,8519,,,Rattus norvegicus,1,,,
,2792,1,BAO_0000218,C max was determined at 3 mg/kg po dose in rats,50597,In vivo,,CHEMBL625333,Intermediate,10116.0,,N,,A,8520,,,Rattus norvegicus,1,,,
,17594,1,BAO_0000218,Cmax after repeated oral dose of compound at 1 mg/kg in rats,50597,In vivo,,CHEMBL625334,Intermediate,10116.0,,N,,A,8521,,,Rattus norvegicus,1,,,
,17594,1,BAO_0000218,Cmax after single intravenous bolus of 1 mg/kg in rats,50597,In vivo,,CHEMBL625335,Intermediate,10116.0,,N,,A,8522,,,Rattus norvegicus,1,,,
,4762,1,BAO_0000218,Cmax of compound at 5 mg/kg after po administration was determined in rat,50597,In vivo,,CHEMBL625336,Intermediate,10116.0,,N,,A,8523,,,Rattus norvegicus,1,,,
,17509,1,BAO_0000218,Cmax 24 hr after 10 mg/kg oral administration in rats,50597,In vivo,,CHEMBL625337,Intermediate,10116.0,,N,,A,8524,,,Rattus norvegicus,1,,,
,17509,1,BAO_0000218,Cmax 24 hr after 2 mg/kg oral administration in rats,50597,In vivo,,CHEMBL625338,Intermediate,10116.0,,N,,A,8525,,,Rattus norvegicus,1,,,
,1466,1,BAO_0000218,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,50597,In vivo,Plasma,CHEMBL625339,Intermediate,10116.0,,N,,A,8526,,,Rattus norvegicus,1,,1969.0,
,6535,1,BAO_0000218,Cmax in rat after administration of 2 mg/kg iv,50597,In vivo,,CHEMBL625340,Intermediate,10116.0,,N,,A,8527,,,Rattus norvegicus,1,,,
,6535,1,BAO_0000218,Cmax in rat after administration of 2 mg/kg iv,50597,In vivo,,CHEMBL625341,Intermediate,10116.0,,N,,A,8528,,,Rattus norvegicus,1,,,
,3169,1,BAO_0000218,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,50597,In vivo,,CHEMBL622687,Intermediate,10116.0,,N,,A,8529,,,Rattus norvegicus,1,,,
,6515,1,BAO_0000218,Cmax wa determined in rat plasma at 30 mg/kg after po administration,50597,In vivo,Plasma,CHEMBL622688,Intermediate,10116.0,,N,,A,8530,,,Rattus norvegicus,1,,1969.0,
,11149,1,BAO_0000218,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,50597,In vivo,Blood,CHEMBL622689,Intermediate,10116.0,,N,,A,8531,,,Rattus norvegicus,1,,178.0,
,11149,1,BAO_0000218,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,50597,In vivo,Blood,CHEMBL620295,Intermediate,10116.0,,N,,A,8532,,,Rattus norvegicus,1,,178.0,
,17858,1,BAO_0000218,Cmax after 10 mg/kg oral administration in rat,50597,In vivo,,CHEMBL620296,Intermediate,10116.0,,N,,A,8533,,,Rattus norvegicus,1,,,
,6518,1,BAO_0000218,Cmax after IV dosing at 0.5 mg/kg in rat; no data,50597,In vivo,,CHEMBL620297,Intermediate,10116.0,,N,,A,8534,,,Rattus norvegicus,1,,,
,6518,1,BAO_0000218,Cmax after IV dosing at 1 mg/kg in rat; no data,50597,In vivo,,CHEMBL620298,Intermediate,10116.0,,N,,A,8535,,,Rattus norvegicus,1,,,
,4426,1,BAO_0000218,Cmax after oral administration at 20 mpk in rats,50597,In vivo,,CHEMBL620299,Intermediate,10116.0,,N,,A,8536,,,Rattus norvegicus,1,,,
,4426,1,BAO_0000218,Cmax after oral administration at 20 mpk in rats; Not performed.,50597,In vivo,,CHEMBL620300,Intermediate,10116.0,,N,,A,8537,,,Rattus norvegicus,1,,,
,4426,1,BAO_0000218,Cmax after oral administration at 20 mpk in rats d; Not performed.,50597,In vivo,,CHEMBL620301,Intermediate,10116.0,,N,,A,8538,,,Rattus norvegicus,1,,,
,5656,1,BAO_0000218,Cmax after oral administration in rat,50597,In vivo,,CHEMBL620302,Intermediate,10116.0,,N,,A,8539,,,Rattus norvegicus,1,,,
,6518,1,BAO_0000218,Cmax after oral administration at a dose of 2 mg/kg in rat,50597,In vivo,,CHEMBL620303,Intermediate,10116.0,,N,,A,8540,,,Rattus norvegicus,1,,,
,6518,1,BAO_0000218,Cmax after oral administration at a dose of 4 mg/kg in rat,50597,In vivo,,CHEMBL620304,Intermediate,10116.0,,N,,A,8541,,,Rattus norvegicus,1,,,
,6113,1,BAO_0000218,Cmax in rats after 20 mg/kg oral dose,50597,In vivo,,CHEMBL620305,Intermediate,10116.0,,N,,A,8542,,,Rattus norvegicus,1,,,
,17764,1,BAO_0000218,Cmax after peroral administration in rats at 2.4 uM/kg,50597,In vivo,,CHEMBL620306,Intermediate,10116.0,,N,,A,8543,,,Rattus norvegicus,1,,,
,4756,1,BAO_0000218,Cmax at the dose of 2 mg/Kg administered perorally in rats,50597,In vivo,,CHEMBL620307,Intermediate,10116.0,,N,,A,8544,,,Rattus norvegicus,1,,,
,4756,1,BAO_0000218,Cmax at the dose of 5 mg/Kg administered perorally in rats,50597,In vivo,,CHEMBL620308,Intermediate,10116.0,,N,,A,8545,,,Rattus norvegicus,1,,,
,6402,1,BAO_0000218,Cmax by administering at 20 mg/kg p.o. in rats,50597,In vivo,,CHEMBL620309,Intermediate,10116.0,,N,,A,8546,,,Rattus norvegicus,1,,,
,5610,1,BAO_0000218,Cmax in male rat,50597,In vivo,,CHEMBL620310,Intermediate,10116.0,,N,,A,8547,,,Rattus norvegicus,1,,,
,5207,1,BAO_0000218,Cmax in rat,50597,In vivo,,CHEMBL620311,Intermediate,10116.0,,N,,A,8548,,,Rattus norvegicus,1,,,
,6011,1,BAO_0000218,Cmax in rat,50597,In vivo,,CHEMBL620312,Intermediate,10116.0,,N,,A,8549,,,Rattus norvegicus,1,,,
,6504,1,BAO_0000218,Cmax in rat,50597,In vivo,,CHEMBL620313,Intermediate,10116.0,,N,,A,8550,,,Rattus norvegicus,1,,,
,6046,1,BAO_0000218,Cmax in rat at 10 mg/kg,50597,In vivo,,CHEMBL620314,Intermediate,10116.0,,N,,A,8551,,,Rattus norvegicus,1,,,
,6504,1,BAO_0000218,Cmax in rat at the dose of 1 mg/kg i.v.,50597,In vivo,,CHEMBL620315,Intermediate,10116.0,,N,,A,8552,,,Rattus norvegicus,1,,,
,5874,1,BAO_0000218,Cmax in rat by po administration at a dose of 40 mg/kg,50597,In vivo,,CHEMBL620316,Intermediate,10116.0,,N,,A,8553,,,Rattus norvegicus,1,,,
,17686,1,BAO_0000218,Cmax in rat p.o. at 20 mg/kg concentration,50597,In vivo,,CHEMBL620317,Intermediate,10116.0,,N,,A,8554,,,Rattus norvegicus,1,,,
,5836,1,BAO_0000218,Cmax in rats,50597,In vivo,,CHEMBL620318,Intermediate,10116.0,,N,,A,8555,,,Rattus norvegicus,1,,,
,17596,1,BAO_0000218,Cmax in rats,50597,In vivo,,CHEMBL620319,Intermediate,10116.0,,N,,A,8556,,,Rattus norvegicus,1,,,
,16423,1,BAO_0000218,Cmax was evaluated after 20 uM/kg of peroral administration,50597,In vivo,,CHEMBL620320,Intermediate,10116.0,,N,,A,8557,,,Rattus norvegicus,1,,,
,17804,1,BAO_0000218,Cmax was measured in rats after peroral administration at 3 mg/kg,50597,In vivo,,CHEMBL620321,Intermediate,10116.0,,N,,A,8558,,,Rattus norvegicus,1,,,
,1908,1,BAO_0000218,Cmax value after oral dose at a dose of 10 mg/kg in rats.,50597,In vivo,,CHEMBL620322,Intermediate,10116.0,,N,,A,8559,,,Rattus norvegicus,1,,,
,13950,1,BAO_0000218,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,,,CHEMBL620323,Intermediate,10116.0,,N,,A,8560,,,Rattus norvegicus,1,,,
,13950,1,BAO_0000218,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,,Frontal cortex,CHEMBL620324,Intermediate,10116.0,,N,,A,8561,,,Rattus norvegicus,1,,1870.0,
,13950,1,BAO_0000218,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,,Frontal cortex,CHEMBL620325,Intermediate,10116.0,,N,,A,8562,,,Rattus norvegicus,1,,1870.0,
,13950,1,BAO_0000218,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,,Hippocampus,CHEMBL620326,Intermediate,10116.0,,N,,A,8563,,,Rattus norvegicus,1,,10000000.0,
,13950,1,BAO_0000218,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,,Hippocampus,CHEMBL620327,Intermediate,10116.0,,N,,A,8564,,,Rattus norvegicus,1,,10000000.0,
,13950,1,BAO_0000218,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,,,CHEMBL620328,Intermediate,10116.0,,N,,A,8565,,,Rattus norvegicus,1,,,
,13950,1,BAO_0000218,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,,,CHEMBL620329,Intermediate,10116.0,,N,,A,8566,,,Rattus norvegicus,1,,,
,13950,1,BAO_0000218,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,,Midbrain,CHEMBL620330,Intermediate,10116.0,,N,,A,8567,,,Rattus norvegicus,1,,1891.0,
,13950,1,BAO_0000218,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,,Midbrain,CHEMBL875286,Intermediate,10116.0,,N,,A,8568,,,Rattus norvegicus,1,,1891.0,
,13950,1,BAO_0000218,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,,,CHEMBL620331,Intermediate,10116.0,,N,,A,8569,,,Rattus norvegicus,1,,,
,13950,1,BAO_0000218,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,,,CHEMBL620332,Intermediate,10116.0,,N,,A,8570,,,Rattus norvegicus,1,,,
,13950,1,BAO_0000218,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,,Striatum,CHEMBL620333,Intermediate,10116.0,,N,,A,8571,,,Rattus norvegicus,1,,2435.0,
,13950,1,BAO_0000218,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,,Striatum,CHEMBL620334,Intermediate,10116.0,,N,,A,8572,,,Rattus norvegicus,1,,2435.0,
,16434,1,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,,Blood,CHEMBL621015,Intermediate,10116.0,,N,,A,8573,,,Rattus norvegicus,1,,178.0,
,16434,1,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,,Blood,CHEMBL621016,Intermediate,10116.0,,N,,A,8574,,,Rattus norvegicus,1,,178.0,
,16434,1,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,,Blood,CHEMBL621191,Intermediate,10116.0,,N,,A,8575,,,Rattus norvegicus,1,,178.0,
,16434,1,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,,Blood,CHEMBL621192,Intermediate,10116.0,,N,,A,8576,,,Rattus norvegicus,1,,178.0,
,16434,1,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,,Blood,CHEMBL621193,Intermediate,10116.0,,N,,A,8577,,,Rattus norvegicus,1,,178.0,
,16434,1,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,,Blood,CHEMBL621194,Intermediate,10116.0,,N,,A,8578,,,Rattus norvegicus,1,,178.0,
,16434,1,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,,Blood,CHEMBL624204,Intermediate,10116.0,,N,,A,8579,,,Rattus norvegicus,1,,178.0,
,16434,1,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,,Blood,CHEMBL624205,Intermediate,10116.0,,N,,A,8580,,,Rattus norvegicus,1,,178.0,
,16435,1,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,,Blood,CHEMBL624206,Intermediate,10116.0,,N,,A,8581,,,Rattus norvegicus,1,,178.0,
,16435,1,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,,Blood,CHEMBL624207,Intermediate,10116.0,,N,,A,8582,,,Rattus norvegicus,1,,178.0,
,16435,1,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,,Blood,CHEMBL624208,Intermediate,10116.0,,N,,A,8583,,,Rattus norvegicus,1,,178.0,
,16435,1,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,,Blood,CHEMBL624209,Intermediate,10116.0,,N,,A,8584,,,Rattus norvegicus,1,,178.0,
,16435,1,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,,Blood,CHEMBL624210,Intermediate,10116.0,,N,,A,8585,,,Rattus norvegicus,1,,178.0,
,16435,1,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,,Blood,CHEMBL624211,Intermediate,10116.0,,N,,A,8586,,,Rattus norvegicus,1,,178.0,
,16435,1,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,,Blood,CHEMBL624212,Intermediate,10116.0,,N,,A,8587,,,Rattus norvegicus,1,,178.0,
,16435,1,BAO_0000218,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,,Blood,CHEMBL624213,Intermediate,10116.0,,N,,A,8588,,,Rattus norvegicus,1,,178.0,
,16434,1,BAO_0000218,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,,Blood,CHEMBL876611,Intermediate,10116.0,,N,,A,8589,,,Rattus norvegicus,1,,178.0,
,16434,1,BAO_0000218,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,,Blood,CHEMBL624214,Intermediate,10116.0,,N,,A,8590,,,Rattus norvegicus,1,,178.0,
,16434,1,BAO_0000218,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,,Blood,CHEMBL624215,Intermediate,10116.0,,N,,A,8591,,,Rattus norvegicus,1,,178.0,
,16435,1,BAO_0000218,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,,Blood,CHEMBL624216,Intermediate,10116.0,,N,,A,8592,,,Rattus norvegicus,1,,178.0,
,16435,1,BAO_0000218,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,,Blood,CHEMBL624217,Intermediate,10116.0,,N,,A,8593,,,Rattus norvegicus,1,,178.0,
,16435,1,BAO_0000218,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,,Blood,CHEMBL624218,Intermediate,10116.0,,N,,A,8594,,,Rattus norvegicus,1,,178.0,
,16435,1,BAO_0000218,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,,Blood,CHEMBL624219,Intermediate,10116.0,,N,,A,8595,,,Rattus norvegicus,1,,178.0,
,16435,1,BAO_0000218,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,,Blood,CHEMBL624220,Intermediate,10116.0,,N,,A,8596,,,Rattus norvegicus,1,,178.0,
,16435,1,BAO_0000218,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,,Blood,CHEMBL624221,Intermediate,10116.0,,N,,A,8597,,,Rattus norvegicus,1,,178.0,
,16434,1,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,,,CHEMBL624222,Intermediate,10116.0,,N,,A,8598,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,,,CHEMBL624223,Intermediate,10116.0,,N,,A,8599,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,,,CHEMBL624224,Intermediate,10116.0,,N,,A,8600,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,,,CHEMBL624225,Intermediate,10116.0,,N,,A,8601,,,Rattus norvegicus,1,,,
,17764,1,BAO_0000218,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,50597,In vivo,,CHEMBL622420,Intermediate,10116.0,,N,,A,8602,,,Rattus norvegicus,1,,,
,5031,1,BAO_0000218,Volume of steady state distribution after i.v. administration in rats,50597,In vivo,,CHEMBL622421,Intermediate,10116.0,,N,,A,8603,,,Rattus norvegicus,1,,,
,6215,1,BAO_0000218,Vss after intravenous administration (5.0 mg/kg) was determined in rat,50597,In vivo,,CHEMBL622422,Intermediate,10116.0,,N,,A,8604,,,Rattus norvegicus,1,,,
,17671,1,BAO_0000218,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,50597,In vivo,,CHEMBL622423,Intermediate,10116.0,,N,,A,8605,,,Rattus norvegicus,1,,,
,17752,1,BAO_0000218,Vss was determined,50597,In vivo,,CHEMBL622424,Intermediate,10116.0,,N,,A,8606,,,Rattus norvegicus,1,,,
,6596,1,BAO_0000218,Vss in rat,50597,In vivo,,CHEMBL622425,Intermediate,10116.0,,N,,A,8607,,,Rattus norvegicus,1,,,
,16423,1,BAO_0000218,Vss was evaluated after 10 uM/kg of intra arterial administration,50597,In vivo,,CHEMBL876612,Intermediate,10116.0,,N,,A,8608,,,Rattus norvegicus,1,,,
,15662,1,BAO_0000218,volume of distribution at steady state was observed after intravenous administration in rat,50597,In vivo,,CHEMBL622426,Intermediate,10116.0,,N,,A,8609,,,Rattus norvegicus,1,,,
,6062,1,BAO_0000218,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,50597,In vivo,,CHEMBL622427,Intermediate,10116.0,,N,,A,8610,,,Rattus norvegicus,1,,,
,5874,1,BAO_0000218,Pharmacokinetic (PK) parameter Vz in rat,50597,In vivo,,CHEMBL622428,Intermediate,10116.0,,N,,A,8611,,,Rattus norvegicus,1,,,
,4942,1,BAO_0000218,Volume distribution in rats,50597,In vivo,,CHEMBL622429,Intermediate,10116.0,,N,,A,8612,,,Rattus norvegicus,1,,,
,17796,1,BAO_0000218,Volume of distribution in rat; No data,50597,In vivo,,CHEMBL622430,Intermediate,10116.0,,N,,A,8613,,,Rattus norvegicus,1,,,
,4890,1,BAO_0000218,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,50597,In vivo,,CHEMBL622431,Intermediate,10116.0,,N,,A,8614,,,Rattus norvegicus,1,,,
,15765,1,BAO_0000218,% absorption predicted from in vitro rat ileum transport studies,50597,,Ileum,CHEMBL622432,Intermediate,10116.0,,N,,A,8615,,,Rattus norvegicus,1,,2116.0,
,13569,1,BAO_0000218,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,50597,In vivo,,CHEMBL622433,Intermediate,10116.0,,N,,A,8616,,,Rattus norvegicus,1,,,
,13569,1,BAO_0000218,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,50597,In vivo,,CHEMBL622434,Intermediate,10116.0,,N,,A,8617,,,Rattus norvegicus,1,,,
,13569,1,BAO_0000218,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,50597,In vivo,,CHEMBL622435,Intermediate,10116.0,,N,,A,8618,,,Rattus norvegicus,1,,,
,13569,1,BAO_0000218,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),50597,In vivo,,CHEMBL618748,Intermediate,10116.0,,N,,A,8619,,,Rattus norvegicus,1,,,
,13569,1,BAO_0000218,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,50597,In vivo,,CHEMBL618749,Intermediate,10116.0,,N,,A,8620,,,Rattus norvegicus,1,,,
,13569,1,BAO_0000218,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,50597,In vivo,,CHEMBL618750,Intermediate,10116.0,,N,,A,8621,,,Rattus norvegicus,1,,,
,13569,1,BAO_0000218,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,50597,In vivo,,CHEMBL618751,Intermediate,10116.0,,N,,A,8622,,,Rattus norvegicus,1,,,
,13569,1,BAO_0000218,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,50597,In vivo,,CHEMBL618752,Intermediate,10116.0,,N,,A,8623,,,Rattus norvegicus,1,,,
,4576,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL618753,Intermediate,10116.0,,N,,A,8624,,,Rattus norvegicus,1,,,
,750,1,BAO_0000218,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,50597,In vivo,Plasma,CHEMBL618754,Intermediate,10116.0,,N,,A,8625,,,Rattus norvegicus,1,,1969.0,
,750,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL618755,Intermediate,10116.0,,N,,A,8626,,,Rattus norvegicus,1,,,
,4590,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL618756,Intermediate,10116.0,,N,,A,8627,,,Rattus norvegicus,1,,,
,1716,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL618757,Intermediate,10116.0,,N,,A,8628,,,Rattus norvegicus,1,,,
,1974,1,BAO_0000218,Bioavailability in rat,50597,In vivo,,CHEMBL618758,Intermediate,10116.0,,N,,A,8629,,,Rattus norvegicus,1,,,
,4502,1,BAO_0000218,Oral bioavailability in rat (dose 30 mg/kg),50597,In vivo,,CHEMBL621088,Intermediate,10116.0,,N,,A,8630,,,Rattus norvegicus,1,,,
,3371,1,BAO_0000218,Pharmacokinetic property (cLogP) in rat,50597,,,CHEMBL621089,Intermediate,10116.0,,N,,A,8631,,,Rattus norvegicus,1,,,
,9099,1,BAO_0000218,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,50597,,Blood,CHEMBL621090,Intermediate,10116.0,,N,,F,8632,,,Rattus norvegicus,1,,178.0,
,9099,1,BAO_0000218,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,50597,,Blood,CHEMBL621091,Intermediate,10116.0,,N,,F,8633,,,Rattus norvegicus,1,,178.0,
,4590,1,BAO_0000218,Clearance in rat.,50597,In vivo,,CHEMBL876731,Intermediate,10116.0,,N,,A,8634,,,Rattus norvegicus,1,,,
,3184,1,BAO_0000218,Compound was evaluated for its clearance when administered intravenously in rat,50597,In vivo,,CHEMBL621092,Intermediate,10116.0,,N,,A,8635,,,Rattus norvegicus,1,,,
,16456,1,BAO_0000218,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,50597,In vivo,,CHEMBL621093,Intermediate,10116.0,,N,,A,8636,,,Rattus norvegicus,1,,,
,4199,1,BAO_0000218,Blood: Brain distribution ratio is determined in rat,50597,,,CHEMBL621094,Intermediate,10116.0,,N,,A,8637,,,Rattus norvegicus,1,,,
,4199,1,BAO_0000218,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,50597,,,CHEMBL621095,Intermediate,10116.0,,N,,A,8638,,,Rattus norvegicus,1,,,
,4199,1,BAO_0000218,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,50597,,,CHEMBL621096,Intermediate,10116.0,,N,,A,8639,,,Rattus norvegicus,1,,,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,In vivo,Kidney,CHEMBL621097,Intermediate,10116.0,,N,,A,8640,,,Rattus norvegicus,1,,2113.0,
,7449,1,BAO_0000218,Percent dose excreted in 0-48 hours administered ip to male rat,50597,,,CHEMBL621098,Intermediate,10116.0,,N,,F,8641,,,Rattus norvegicus,1,,,
,11977,1,BAO_0000218,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,,Cerebellum,CHEMBL621099,Intermediate,10116.0,,N,,A,8642,,,Rattus norvegicus,1,,2037.0,
,11977,1,BAO_0000218,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,,Cerebellum,CHEMBL621100,Intermediate,10116.0,,N,,A,8643,,,Rattus norvegicus,1,,2037.0,
,11977,1,BAO_0000218,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,,Cerebellum,CHEMBL621101,Intermediate,10116.0,,N,,A,8644,,,Rattus norvegicus,1,,2037.0,
,11977,1,BAO_0000218,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,,Cerebellum,CHEMBL621102,Intermediate,10116.0,,N,,A,8645,,,Rattus norvegicus,1,,2037.0,
,11977,1,BAO_0000218,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,,Cerebellum,CHEMBL876732,Intermediate,10116.0,,N,,A,8646,,,Rattus norvegicus,1,,2037.0,
,11977,1,BAO_0000218,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,,,CHEMBL621103,Intermediate,10116.0,,N,,A,8647,,,Rattus norvegicus,1,,,
,11977,1,BAO_0000218,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,,,CHEMBL621104,Intermediate,10116.0,,N,,A,8648,,,Rattus norvegicus,1,,,
,11977,1,BAO_0000218,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,,,CHEMBL621105,Intermediate,10116.0,,N,,A,8649,,,Rattus norvegicus,1,,,
,11977,1,BAO_0000218,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,,,CHEMBL621106,Intermediate,10116.0,,N,,A,8650,,,Rattus norvegicus,1,,,
,11977,1,BAO_0000218,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,,,CHEMBL621107,Intermediate,10116.0,,N,,A,8651,,,Rattus norvegicus,1,,,
,11977,1,BAO_0000218,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,,,CHEMBL621108,Intermediate,10116.0,,N,,A,8652,,,Rattus norvegicus,1,,,
,11977,1,BAO_0000218,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,,,CHEMBL621109,Intermediate,10116.0,,N,,A,8653,,,Rattus norvegicus,1,,,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,In vivo,Kidney,CHEMBL621110,Intermediate,10090.0,,N,,A,8654,,,Mus musculus,1,,2113.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),50594,In vivo,Kidney,CHEMBL621111,Intermediate,10090.0,,N,,A,8655,,,Mus musculus,1,,2113.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),50594,In vivo,Liver,CHEMBL622541,Intermediate,10090.0,,N,,A,8656,,,Mus musculus,1,,2107.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),50594,In vivo,Liver,CHEMBL622542,Intermediate,10090.0,,N,,A,8657,,,Mus musculus,1,,2107.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,In vivo,Liver,CHEMBL622543,Intermediate,10090.0,,N,,A,8658,,,Mus musculus,1,,2107.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),50594,In vivo,Liver,CHEMBL624412,Intermediate,10090.0,,N,,A,8659,,,Mus musculus,1,,2107.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,In vivo,Liver,CHEMBL624413,Intermediate,10090.0,,N,,A,8660,,,Mus musculus,1,,2107.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),50594,In vivo,Liver,CHEMBL624414,Intermediate,10090.0,,N,,A,8661,,,Mus musculus,1,,2107.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),50594,In vivo,Lung,CHEMBL624415,Intermediate,10090.0,,N,,A,8662,,,Mus musculus,1,,2048.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),50594,In vivo,Lung,CHEMBL624416,Intermediate,10090.0,,N,,A,8663,,,Mus musculus,1,,2048.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,In vivo,Lung,CHEMBL624417,Intermediate,10090.0,,N,,A,8664,,,Mus musculus,1,,2048.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),50594,In vivo,Lung,CHEMBL624418,Intermediate,10090.0,,N,,A,8665,,,Mus musculus,1,,2048.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,In vivo,Lung,CHEMBL624419,Intermediate,10090.0,,N,,A,8666,,,Mus musculus,1,,2048.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),50594,In vivo,Lung,CHEMBL624420,Intermediate,10090.0,,N,,A,8667,,,Mus musculus,1,,2048.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),50594,In vivo,Muscle tissue,CHEMBL624421,Intermediate,10090.0,,N,,A,8668,,,Mus musculus,1,,2385.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),50594,In vivo,Muscle tissue,CHEMBL624422,Intermediate,10090.0,,N,,A,8669,,,Mus musculus,1,,2385.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,In vivo,Muscle tissue,CHEMBL624423,Intermediate,10090.0,,N,,A,8670,,,Mus musculus,1,,2385.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),50594,In vivo,Muscle tissue,CHEMBL625123,Intermediate,10090.0,,N,,A,8671,,,Mus musculus,1,,2385.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,In vivo,Muscle tissue,CHEMBL625124,Intermediate,10090.0,,N,,A,8672,,,Mus musculus,1,,2385.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),50594,In vivo,Muscle tissue,CHEMBL625125,Intermediate,10090.0,,N,,A,8673,,,Mus musculus,1,,2385.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),50594,In vivo,Zone of skin,CHEMBL625126,Intermediate,10090.0,,N,,A,8674,,,Mus musculus,1,,14.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),50594,In vivo,Zone of skin,CHEMBL626947,Intermediate,10090.0,,N,,A,8675,,,Mus musculus,1,,14.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,In vivo,Zone of skin,CHEMBL626948,Intermediate,10090.0,,N,,A,8676,,,Mus musculus,1,,14.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),50594,In vivo,Zone of skin,CHEMBL626949,Intermediate,10090.0,,N,,A,8677,,,Mus musculus,1,,14.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,In vivo,Zone of skin,CHEMBL626950,Intermediate,10090.0,,N,,A,8678,,,Mus musculus,1,,14.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),50594,In vivo,Zone of skin,CHEMBL626951,Intermediate,10090.0,,N,,A,8679,,,Mus musculus,1,,14.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),50594,In vivo,Spleen,CHEMBL626952,Intermediate,10090.0,,N,,A,8680,,,Mus musculus,1,,2106.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),50594,In vivo,Spleen,CHEMBL626953,Intermediate,10090.0,,N,,A,8681,,,Mus musculus,1,,2106.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,In vivo,Spleen,CHEMBL626954,Intermediate,10090.0,,N,,A,8682,,,Mus musculus,1,,2106.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),50594,In vivo,Spleen,CHEMBL626955,Intermediate,10090.0,,N,,A,8683,,,Mus musculus,1,,2106.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,In vivo,Spleen,CHEMBL626956,Intermediate,10090.0,,N,,A,8684,,,Mus musculus,1,,2106.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),50594,In vivo,Spleen,CHEMBL626957,Intermediate,10090.0,,N,,A,8685,,,Mus musculus,1,,2106.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),50594,In vivo,Blood,CHEMBL626958,Intermediate,10090.0,,N,,A,8686,,,Mus musculus,1,,178.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),50594,In vivo,Blood,CHEMBL626959,Intermediate,10090.0,,N,,A,8687,,,Mus musculus,1,,178.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,In vivo,Blood,CHEMBL626960,Intermediate,10090.0,,N,,A,8688,,,Mus musculus,1,,178.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),50594,In vivo,Blood,CHEMBL626961,Intermediate,10090.0,,N,,A,8689,,,Mus musculus,1,,178.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,In vivo,Blood,CHEMBL627589,Intermediate,10090.0,,N,,A,8690,,,Mus musculus,1,,178.0,
,17208,1,BAO_0000218,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),50594,In vivo,Blood,CHEMBL627590,Intermediate,10090.0,,N,,A,8691,,,Mus musculus,1,,178.0,
,3132,1,BAO_0000218,Time taken for EC90 was determined when tested in mouse,50594,,,CHEMBL627591,Intermediate,10090.0,,N,,A,8692,,,Mus musculus,1,,,
,3132,1,BAO_0000218,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,50594,,,CHEMBL627592,Intermediate,10090.0,,N,,A,8693,,,Mus musculus,1,,,
,16597,1,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),50594,In vivo,,CHEMBL627593,Intermediate,10090.0,,N,,A,8694,,,Mus musculus,1,,,
,5727,1,BAO_0000218,Half life in mice,50594,,,CHEMBL627594,Intermediate,10090.0,,N,,A,8695,,,Mus musculus,1,,,
,5302,1,BAO_0000218,Half life period in mouse after 10 mg/Kg dose,50594,In vivo,,CHEMBL876813,Intermediate,10090.0,,N,,A,8696,,,Mus musculus,1,,,
,5302,1,BAO_0000218,Half life period in mouse after 10 mg/kg dose,50594,In vivo,,CHEMBL627595,Intermediate,10090.0,,N,,A,8697,,,Mus musculus,1,,,
,6348,1,BAO_0000218,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,In vivo,,CHEMBL627596,Intermediate,10090.0,,N,,A,8698,,,Mus musculus,1,,,
,5964,1,BAO_0000218,Cmax value at 5 mg/kg po was determined in rat,50597,In vivo,,CHEMBL627597,Intermediate,10116.0,,N,,A,8699,,,Rattus norvegicus,1,,,
,6078,1,BAO_0000218,Cmax value evaluated in rat,50597,In vivo,,CHEMBL627598,Intermediate,10116.0,,N,,A,8700,,,Rattus norvegicus,1,,,
,5206,1,BAO_0000218,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,50597,In vivo,Brain,CHEMBL627599,Intermediate,10116.0,,N,,A,8701,,,Rattus norvegicus,1,,955.0,
,2959,1,BAO_0000218,Cmax value after administration of 20 mg/Kg oral dose in rat,50597,In vivo,,CHEMBL627600,Intermediate,10116.0,,N,,A,8702,,,Rattus norvegicus,1,,,
,5964,1,BAO_0000218,Cmax value at 1 mg/kg po in rat,50597,In vivo,,CHEMBL627601,Intermediate,10116.0,,N,,A,8703,,,Rattus norvegicus,1,,,
,5964,1,BAO_0000218,Cmax value at 5 mg/kg po in rat,50597,In vivo,,CHEMBL627776,Intermediate,10116.0,,N,,A,8704,,,Rattus norvegicus,1,,,
,6757,1,BAO_0000218,Cmax value at a dose of 10 mg/kg in male SD rats,50597,In vivo,,CHEMBL627777,Intermediate,10116.0,,N,,A,8705,,,Rattus norvegicus,1,,,
,6757,1,BAO_0000218,Cmax value at a dose of 100 mg/kg in male SD rats,50597,In vivo,,CHEMBL627778,Intermediate,10116.0,,N,,A,8706,,,Rattus norvegicus,1,,,
,6757,1,BAO_0000218,Cmax value at a dose of 50 mg/kg in male SD rats,50597,In vivo,,CHEMBL627779,Intermediate,10116.0,,N,,A,8707,,,Rattus norvegicus,1,,,
,17617,1,BAO_0000218,Cmax value in rats at 10 mg/kg,50597,In vivo,,CHEMBL876814,Intermediate,10116.0,,N,,A,8708,,,Rattus norvegicus,1,,,
,1445,1,BAO_0000218,Cmax value was evaluated in rats at a dose of 20 mg/kg,50597,In vivo,,CHEMBL627780,Intermediate,10116.0,,N,,A,8709,,,Rattus norvegicus,1,,,
,6082,1,BAO_0000218,Cmax value was determined after peroral administration of 20 mg/kg in rat,50597,In vivo,,CHEMBL627781,Intermediate,10116.0,,N,,A,8710,,,Rattus norvegicus,1,,,
,1446,1,BAO_0000218,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,50597,In vivo,,CHEMBL627782,Intermediate,10116.0,,N,,A,8711,,,Rattus norvegicus,1,,,
,5407,1,BAO_0000218,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,50597,In vivo,Plasma,CHEMBL627783,Intermediate,10116.0,,N,,A,8712,,,Rattus norvegicus,1,,1969.0,
,2690,1,BAO_0000218,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,50597,In vivo,Plasma,CHEMBL627784,Intermediate,10116.0,,N,,A,8713,,,Rattus norvegicus,1,,1969.0,
,2661,1,BAO_0000218,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,50597,In vivo,,CHEMBL627785,Intermediate,10116.0,,N,,A,8714,,,Rattus norvegicus,1,,,
,2661,1,BAO_0000218,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,50597,In vivo,,CHEMBL627786,Intermediate,10116.0,,N,,A,8715,,,Rattus norvegicus,1,,,
,4891,1,BAO_0000218,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,50597,In vivo,Plasma,CHEMBL627787,Intermediate,10116.0,,N,,A,8716,,,Rattus norvegicus,1,,1969.0,
,2807,1,BAO_0000218,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,50597,In vivo,Plasma,CHEMBL627788,Intermediate,10116.0,,N,,A,8717,,,Rattus norvegicus,1,,1969.0,
,2807,1,BAO_0000218,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,50597,In vivo,Plasma,CHEMBL626579,Intermediate,10116.0,,N,,A,8718,,,Rattus norvegicus,1,,1969.0,
,2807,1,BAO_0000218,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,50597,In vivo,Plasma,CHEMBL626580,Intermediate,10116.0,,N,,A,8719,,,Rattus norvegicus,1,,1969.0,
,3634,1,BAO_0000218,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,50597,In vivo,,CHEMBL876815,Intermediate,10116.0,,N,,A,8720,,,Rattus norvegicus,1,,,
,1881,1,BAO_0000218,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,50597,In vivo,Plasma,CHEMBL626581,Intermediate,10116.0,,N,,A,8721,,,Rattus norvegicus,1,,1969.0,
,1881,1,BAO_0000218,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,50597,In vivo,Plasma,CHEMBL626582,Intermediate,10116.0,,N,,A,8722,,,Rattus norvegicus,1,,1969.0,
,429,1,BAO_0000218,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,50597,In vivo,,CHEMBL626583,Intermediate,10116.0,,N,,A,8723,,,Rattus norvegicus,1,,,
,5974,1,BAO_0000218,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,In vivo,,CHEMBL626205,Intermediate,10116.0,,N,,A,8724,,,Rattus norvegicus,1,,,
,5974,1,BAO_0000218,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,In vivo,,CHEMBL626206,Intermediate,10116.0,,N,,A,8725,,,Rattus norvegicus,1,,,
,5974,1,BAO_0000218,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,50597,In vivo,,CHEMBL626207,Intermediate,10116.0,,N,,A,8726,,,Rattus norvegicus,1,,,
,5974,1,BAO_0000218,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,In vivo,,CHEMBL623882,Intermediate,10116.0,,N,,A,8727,,,Rattus norvegicus,1,,,
,17582,1,BAO_0000218,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,50597,In vivo,,CHEMBL623883,Intermediate,10116.0,,N,,A,8728,,,Rattus norvegicus,1,,,
,17582,1,BAO_0000218,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,50597,In vivo,,CHEMBL623884,Intermediate,10116.0,,N,,A,8729,,,Rattus norvegicus,1,,,
,3032,1,BAO_0000218,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",50597,In vivo,Plasma,CHEMBL623885,Intermediate,10116.0,,N,,A,8730,,,Rattus norvegicus,1,,1969.0,
,6295,1,BAO_0000218,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,50597,In vivo,Plasma,CHEMBL623886,Intermediate,10116.0,,N,,A,8731,,,Rattus norvegicus,1,,1969.0,
,6619,1,BAO_0000218,Maximal concentration in rat was determined,50597,In vivo,,CHEMBL623887,Intermediate,10116.0,,N,,A,8732,,,Rattus norvegicus,1,,,
,6616,1,BAO_0000218,Maximal concentration after i.v. administration,50597,In vivo,,CHEMBL623888,Intermediate,10116.0,,N,,A,8733,,,Rattus norvegicus,1,,,
,3249,1,BAO_0000218,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,50597,In vivo,Plasma,CHEMBL623889,Intermediate,10116.0,,N,,A,8734,,,Rattus norvegicus,1,,1969.0,
,17791,1,BAO_0000218,Maximal plasma concentration in rat after oral administration at 50 mg/kg,50597,In vivo,Plasma,CHEMBL623890,Intermediate,10116.0,,N,,A,8735,,,Rattus norvegicus,1,,1969.0,
,17791,1,BAO_0000218,Cmax in rat plasma after oral dose (50 mg/Kg),50597,In vivo,Plasma,CHEMBL623891,Intermediate,10116.0,,N,,A,8736,,,Rattus norvegicus,1,,1969.0,
,1360,1,BAO_0000218,Maximal plasma concentration was determined.,50597,In vivo,Plasma,CHEMBL623892,Intermediate,10116.0,,N,,A,8737,,,Rattus norvegicus,1,,1969.0,
,2552,1,BAO_0000218,Maximal plasma drug concentration was determined,50597,In vivo,Plasma,CHEMBL623893,Intermediate,10116.0,,N,,A,8738,,,Rattus norvegicus,1,,1969.0,
,6571,1,BAO_0000218,Maximal concentration in rats after peroral administration,50597,In vivo,,CHEMBL877616,Intermediate,10116.0,,N,,A,8739,,,Rattus norvegicus,1,,,
,6570,1,BAO_0000218,Maximum concentration in rat after 2 mg/kg peroral administration,50597,In vivo,,CHEMBL623894,Intermediate,10116.0,,N,,A,8740,,,Rattus norvegicus,1,,,
,6567,1,BAO_0000218,Maximum concentration in rat plasma after 5 mg/kg oral gavage,50597,In vivo,Plasma,CHEMBL623895,Intermediate,10116.0,,N,,A,8741,,,Rattus norvegicus,1,,1969.0,
,3031,1,BAO_0000218,Maximum concentration of compound in rat was evaluated.,50597,In vivo,,CHEMBL623896,Intermediate,10116.0,,N,,A,8742,,,Rattus norvegicus,1,,,
,3436,1,BAO_0000218,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,50597,In vivo,,CHEMBL623897,Intermediate,10116.0,,N,,A,8743,,,Rattus norvegicus,1,,,
,3436,1,BAO_0000218,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,50597,In vivo,,CHEMBL623898,Intermediate,10116.0,,N,,A,8744,,,Rattus norvegicus,1,,,
,2083,1,BAO_0000218,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,50597,In vivo,,CHEMBL623899,Intermediate,10116.0,,N,,A,8745,,,Rattus norvegicus,1,,,
,3436,1,BAO_0000218,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,50597,In vivo,,CHEMBL623900,Intermediate,10116.0,,N,,A,8746,,,Rattus norvegicus,1,,,
,4527,1,BAO_0000218,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,50597,In vivo,,CHEMBL623901,Intermediate,10116.0,,N,,A,8747,,,Rattus norvegicus,1,,,
,1974,1,BAO_0000218,Maximum concentration was evaluated in rats,50597,In vivo,,CHEMBL623902,Intermediate,10116.0,,N,,A,8748,,,Rattus norvegicus,1,,,
,3307,1,BAO_0000218,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,50597,In vivo,Cerebrospinal fluid,CHEMBL623903,Intermediate,10116.0,,N,,A,8749,,,Rattus norvegicus,1,,1359.0,
,3307,1,BAO_0000218,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,50597,In vivo,Plasma,CHEMBL623904,Intermediate,10116.0,,N,,A,8750,,,Rattus norvegicus,1,,1969.0,
,1916,1,BAO_0000218,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,50597,In vivo,Plasma,CHEMBL877617,Intermediate,10116.0,,N,,A,8751,,,Rattus norvegicus,1,,1969.0,
,1500,1,BAO_0000218,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,50597,In vivo,,CHEMBL623905,Intermediate,10116.0,,N,,A,8752,,,Rattus norvegicus,1,,,
,1500,1,BAO_0000218,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,50597,In vivo,,CHEMBL623906,Intermediate,10116.0,,N,,A,8753,,,Rattus norvegicus,1,,,
,4186,1,BAO_0000218,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,50597,In vivo,Plasma,CHEMBL623907,Intermediate,10116.0,,N,,A,8754,,,Rattus norvegicus,1,,1969.0,
,16434,1,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,,,CHEMBL623908,Intermediate,10116.0,,N,,A,8755,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,50597,,,CHEMBL623909,Intermediate,10116.0,,N,,A,8756,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,,,CHEMBL623910,Intermediate,10116.0,,N,,A,8757,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,,,CHEMBL623911,Intermediate,10116.0,,N,,A,8758,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,,,CHEMBL623912,Intermediate,10116.0,,N,,A,8759,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,,,CHEMBL624616,Intermediate,10116.0,,N,,A,8760,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,,,CHEMBL624617,Intermediate,10116.0,,N,,A,8761,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,,,CHEMBL624618,Intermediate,10116.0,,N,,A,8762,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,,,CHEMBL624619,Intermediate,10116.0,,N,,A,8763,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,,,CHEMBL624794,Intermediate,10116.0,,N,,A,8764,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,,,CHEMBL624795,Intermediate,10116.0,,N,,A,8765,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,,,CHEMBL623921,Intermediate,10116.0,,N,,A,8766,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,,,CHEMBL623922,Intermediate,10116.0,,N,,A,8767,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,,,CHEMBL623923,Intermediate,10116.0,,N,,A,8768,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,,,CHEMBL623924,Intermediate,10116.0,,N,,A,8769,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,,,CHEMBL623925,Intermediate,10116.0,,N,,A,8770,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,,,CHEMBL623926,Intermediate,10116.0,,N,,A,8771,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,,,CHEMBL623927,Intermediate,10116.0,,N,,A,8772,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,,,CHEMBL623928,Intermediate,10116.0,,N,,A,8773,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,,,CHEMBL623929,Intermediate,10116.0,,N,,A,8774,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,,,CHEMBL623930,Intermediate,10116.0,,N,,A,8775,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,,Brain,CHEMBL623931,Intermediate,10116.0,,N,,A,8776,,,Rattus norvegicus,1,,955.0,
,16434,1,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,,Brain,CHEMBL622165,Intermediate,10116.0,,N,,A,8777,,,Rattus norvegicus,1,,955.0,
,16434,1,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,,Brain,CHEMBL621249,Intermediate,10116.0,,N,,A,8778,,,Rattus norvegicus,1,,955.0,
,16434,1,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,,Brain,CHEMBL621250,Intermediate,10116.0,,N,,A,8779,,,Rattus norvegicus,1,,955.0,
,16434,1,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,,Brain,CHEMBL621448,Intermediate,10116.0,,N,,A,8780,,,Rattus norvegicus,1,,955.0,
,16434,1,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,,Brain,CHEMBL621449,Intermediate,10116.0,,N,,A,8781,,,Rattus norvegicus,1,,955.0,
,16434,1,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,,Brain,CHEMBL621450,Intermediate,10116.0,,N,,A,8782,,,Rattus norvegicus,1,,955.0,
,16434,1,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,,Brain,CHEMBL621451,Intermediate,10116.0,,N,,A,8783,,,Rattus norvegicus,1,,955.0,
,16435,1,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,,Brain,CHEMBL621452,Intermediate,10116.0,,N,,A,8784,,,Rattus norvegicus,1,,955.0,
,16435,1,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,,Brain,CHEMBL621453,Intermediate,10116.0,,N,,A,8785,,,Rattus norvegicus,1,,955.0,
,16435,1,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,,Brain,CHEMBL621454,Intermediate,10116.0,,N,,A,8786,,,Rattus norvegicus,1,,955.0,
,16435,1,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,,Brain,CHEMBL621455,Intermediate,10116.0,,N,,A,8787,,,Rattus norvegicus,1,,955.0,
,16435,1,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,,Brain,CHEMBL621456,Intermediate,10116.0,,N,,A,8788,,,Rattus norvegicus,1,,955.0,
,16435,1,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,,Brain,CHEMBL625145,Intermediate,10116.0,,N,,A,8789,,,Rattus norvegicus,1,,955.0,
,16435,1,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,,Brain,CHEMBL875847,Intermediate,10116.0,,N,,A,8790,,,Rattus norvegicus,1,,955.0,
,16435,1,BAO_0000218,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,,Brain,CHEMBL625146,Intermediate,10116.0,,N,,A,8791,,,Rattus norvegicus,1,,955.0,
,16434,1,BAO_0000218,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,,Brain,CHEMBL625147,Intermediate,10116.0,,N,,A,8792,,,Rattus norvegicus,1,,955.0,
,16434,1,BAO_0000218,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,,Brain,CHEMBL625148,Intermediate,10116.0,,N,,A,8793,,,Rattus norvegicus,1,,955.0,
,16434,1,BAO_0000218,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,,Brain,CHEMBL625149,Intermediate,10116.0,,N,,A,8794,,,Rattus norvegicus,1,,955.0,
,16435,1,BAO_0000218,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,,Brain,CHEMBL625150,Intermediate,10116.0,,N,,A,8795,,,Rattus norvegicus,1,,955.0,
,16435,1,BAO_0000218,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,,Brain,CHEMBL625151,Intermediate,10116.0,,N,,A,8796,,,Rattus norvegicus,1,,955.0,
,16435,1,BAO_0000218,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,,Brain,CHEMBL625152,Intermediate,10116.0,,N,,A,8797,,,Rattus norvegicus,1,,955.0,
,16435,1,BAO_0000218,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,,Brain,CHEMBL625153,Intermediate,10116.0,,N,,A,8798,,,Rattus norvegicus,1,,955.0,
,16435,1,BAO_0000218,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,,Brain,CHEMBL625154,Intermediate,10116.0,,N,,A,8799,,,Rattus norvegicus,1,,955.0,
,16435,1,BAO_0000218,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,,Brain,CHEMBL625155,Intermediate,10116.0,,N,,A,8800,,,Rattus norvegicus,1,,955.0,
,11977,1,BAO_0000218,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,,,CHEMBL625156,Intermediate,10116.0,,N,,A,8801,,,Rattus norvegicus,1,,,
,11977,1,BAO_0000218,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,,,CHEMBL624354,Intermediate,10116.0,,N,,A,8802,,,Rattus norvegicus,1,,,
,11977,1,BAO_0000218,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,,Hippocampus,CHEMBL624355,Intermediate,10116.0,,N,,A,8803,,,Rattus norvegicus,1,,10000000.0,
,11977,1,BAO_0000218,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,,Hippocampus,CHEMBL624356,Intermediate,10116.0,,N,,A,8804,,,Rattus norvegicus,1,,10000000.0,
,11977,1,BAO_0000218,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,,Hippocampus,CHEMBL624357,Intermediate,10116.0,,N,,A,8805,,,Rattus norvegicus,1,,10000000.0,
,11977,1,BAO_0000218,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,,Hippocampus,CHEMBL624358,Intermediate,10116.0,,N,,A,8806,,,Rattus norvegicus,1,,10000000.0,
,11977,1,BAO_0000218,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,,Striatum,CHEMBL624359,Intermediate,10116.0,,N,,A,8807,,,Rattus norvegicus,1,,2435.0,
,11977,1,BAO_0000218,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,,Striatum,CHEMBL624360,Intermediate,10116.0,,N,,A,8808,,,Rattus norvegicus,1,,2435.0,
,11977,1,BAO_0000218,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,,Striatum,CHEMBL624361,Intermediate,10116.0,,N,,A,8809,,,Rattus norvegicus,1,,2435.0,
,11977,1,BAO_0000218,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,,Striatum,CHEMBL624362,Intermediate,10116.0,,N,,A,8810,,,Rattus norvegicus,1,,2435.0,
,11977,1,BAO_0000218,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,,Striatum,CHEMBL624363,Intermediate,10116.0,,N,,A,8811,,,Rattus norvegicus,1,,2435.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Blood,CHEMBL624364,Intermediate,10116.0,,N,,A,8812,,,Rattus norvegicus,1,,178.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Blood,CHEMBL624365,Intermediate,10116.0,,N,,A,8813,,,Rattus norvegicus,1,,178.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Blood,CHEMBL624366,Intermediate,10116.0,,N,,A,8814,,,Rattus norvegicus,1,,178.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Blood,CHEMBL624367,Intermediate,10116.0,,N,,A,8815,,,Rattus norvegicus,1,,178.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Brain,CHEMBL624368,Intermediate,10116.0,,N,,A,8816,,,Rattus norvegicus,1,,955.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Brain,CHEMBL624369,Intermediate,10116.0,,N,,A,8817,,,Rattus norvegicus,1,,955.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,In vivo,Brain,CHEMBL624370,Intermediate,10116.0,,N,,A,8818,,,Rattus norvegicus,1,,955.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Brain,CHEMBL625069,Intermediate,10116.0,,N,,A,8819,,,Rattus norvegicus,1,,955.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Brain,CHEMBL625070,Intermediate,10116.0,,N,,A,8820,,,Rattus norvegicus,1,,955.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Heart,CHEMBL626051,Intermediate,10116.0,,N,,A,8821,,,Rattus norvegicus,1,,948.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Heart,CHEMBL626052,Intermediate,10116.0,,N,,A,8822,,,Rattus norvegicus,1,,948.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,In vivo,Heart,CHEMBL626053,Intermediate,10116.0,,N,,A,8823,,,Rattus norvegicus,1,,948.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Heart,CHEMBL626054,Intermediate,10116.0,,N,,A,8824,,,Rattus norvegicus,1,,948.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Heart,CHEMBL626055,Intermediate,10116.0,,N,,A,8825,,,Rattus norvegicus,1,,948.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Kidney,CHEMBL626056,Intermediate,10116.0,,N,,A,8826,,,Rattus norvegicus,1,,2113.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Kidney,CHEMBL626057,Intermediate,10116.0,,N,,A,8827,,,Rattus norvegicus,1,,2113.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Kidney,CHEMBL625193,Intermediate,10116.0,,N,,A,8828,,,Rattus norvegicus,1,,2113.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Kidney,CHEMBL625194,Intermediate,10116.0,,N,,A,8829,,,Rattus norvegicus,1,,2113.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Liver,CHEMBL625195,Intermediate,10116.0,,N,,A,8830,,,Rattus norvegicus,1,,2107.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Liver,CHEMBL625196,Intermediate,10116.0,,N,,A,8831,,,Rattus norvegicus,1,,2107.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,In vivo,Liver,CHEMBL625197,Intermediate,10116.0,,N,,A,8832,,,Rattus norvegicus,1,,2107.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Liver,CHEMBL625198,Intermediate,10116.0,,N,,A,8833,,,Rattus norvegicus,1,,2107.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Liver,CHEMBL627929,Intermediate,10116.0,,N,,A,8834,,,Rattus norvegicus,1,,2107.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Lung,CHEMBL627074,Intermediate,10116.0,,N,,A,8835,,,Rattus norvegicus,1,,2048.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Lung,CHEMBL627075,Intermediate,10116.0,,N,,A,8836,,,Rattus norvegicus,1,,2048.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,In vivo,Lung,CHEMBL627076,Intermediate,10116.0,,N,,A,8837,,,Rattus norvegicus,1,,2048.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Lung,CHEMBL627077,Intermediate,10116.0,,N,,A,8838,,,Rattus norvegicus,1,,2048.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Lung,CHEMBL627078,Intermediate,10116.0,,N,,A,8839,,,Rattus norvegicus,1,,2048.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),50597,In vivo,Muscle tissue,CHEMBL627079,Intermediate,10116.0,,N,,A,8840,,,Rattus norvegicus,1,,2385.0,
,4573,1,BAO_0000218,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,50594,In vivo,,CHEMBL873824,Intermediate,10090.0,,N,,A,8841,,,Mus musculus,1,,,
,3132,1,BAO_0000218,Half life in mouse plasma was determined at dose 25 mg/kg,50594,In vivo,Plasma,CHEMBL627080,Intermediate,10090.0,,N,,A,8842,,,Mus musculus,1,,1969.0,
,17718,1,BAO_0000218,Half life was determined,50594,,,CHEMBL627081,Intermediate,10090.0,,N,,A,8843,,,Mus musculus,1,,,
,17728,1,BAO_0000218,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,50594,In vivo,,CHEMBL627082,Intermediate,10090.0,,N,,A,8844,,,Mus musculus,1,,,
,5961,1,BAO_0000218,Half-life in male mice after 1 mg/kg intravenous dose,50594,In vivo,,CHEMBL627083,Intermediate,10090.0,,N,,A,8845,,,Mus musculus,1,,,
,17731,1,BAO_0000218,Half life in mice plasma,50594,,Plasma,CHEMBL627085,Intermediate,10090.0,,N,,A,8847,,,Mus musculus,1,,1969.0,
,17592,1,BAO_0000218,Half life in mouse,50594,,,CHEMBL627086,Intermediate,10090.0,,N,,A,8848,,,Mus musculus,1,,,
,3132,1,BAO_0000218,Half life in mouse plasma at dose 25 mg/kg,50594,In vivo,Plasma,CHEMBL627087,Intermediate,10090.0,,N,,A,8849,,,Mus musculus,1,,1969.0,
,17729,1,BAO_0000218,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,50594,In vivo,,CHEMBL627088,Intermediate,10090.0,,N,,A,8850,,,Mus musculus,1,,,
,17729,1,BAO_0000218,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,50594,In vivo,,CHEMBL627089,Intermediate,10090.0,,N,,A,8851,,,Mus musculus,1,,,
,17729,1,BAO_0000218,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,50594,In vivo,,CHEMBL627090,Intermediate,10090.0,,N,,A,8852,,,Mus musculus,1,,,
,3277,1,BAO_0000218,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),50594,In vivo,,CHEMBL627091,Intermediate,10090.0,,N,,A,8853,,,Mus musculus,1,,,
,3760,1,BAO_0000218,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",50594,In vivo,,CHEMBL627092,Intermediate,10090.0,,N,,A,8854,,,Mus musculus,1,,,
,3760,1,BAO_0000218,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",50594,In vivo,,CHEMBL876785,Intermediate,10090.0,,N,,A,8855,,,Mus musculus,1,,,
,2862,1,BAO_0000218,Half-life by iv administration in mouse,50594,In vivo,,CHEMBL627093,Intermediate,10090.0,,N,,A,8856,,,Mus musculus,1,,,
,2862,1,BAO_0000218,Half-life by oral administration in mouse,50594,In vivo,,CHEMBL627094,Intermediate,10090.0,,N,,A,8857,,,Mus musculus,1,,,
,5980,1,BAO_0000218,Half-life in mice,50594,,,CHEMBL627095,Intermediate,10090.0,,N,,A,8858,,,Mus musculus,1,,,
,6159,1,BAO_0000218,Half-life using mouse brain homogenate,50594,,Brain,CHEMBL627096,Intermediate,10090.0,,N,,A,8859,,,Mus musculus,1,,955.0,
,6254,1,BAO_0000218,Half-life was measured in mice,50594,,,CHEMBL627097,Intermediate,10090.0,,N,,A,8860,,,Mus musculus,1,,,
,6062,1,BAO_0000218,Half-life was measured in mouse after an iv dose of 1 mg/kg,50594,In vivo,,CHEMBL627098,Intermediate,10090.0,,N,,A,8861,,,Mus musculus,1,,,
,1574,1,BAO_0000218,Half-life period was determined in mouse blood,50594,,Blood,CHEMBL627099,Intermediate,10090.0,,N,,A,8862,,,Mus musculus,1,,178.0,
,56,1,BAO_0000218,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",50594,,Brain,CHEMBL627100,Intermediate,10090.0,,N,,A,8863,,,Mus musculus,1,,955.0,
,993,1,BAO_0000218,Plasma half life in mouse,50594,,Plasma,CHEMBL627101,Intermediate,10090.0,,N,,A,8864,,,Mus musculus,1,,1969.0,
,6652,1,BAO_0000218,Stability of the peptide in the presence of mouse serum,50594,,,CHEMBL627102,Intermediate,10090.0,,N,,A,8865,,,Mus musculus,1,,,
,17852,1,BAO_0000218,Terminal half life of compound was determined in mouse,50594,,,CHEMBL627103,Intermediate,10090.0,,N,,A,8866,,,Mus musculus,1,,,
,2675,1,BAO_0000218,Terminal half life was evaluated in mice after intravenous administration,50594,In vivo,,CHEMBL627104,Intermediate,10090.0,,N,,A,8867,,,Mus musculus,1,,,
,2675,1,BAO_0000218,Terminal half life was evaluated in mice after oral administration,50594,In vivo,,CHEMBL627105,Intermediate,10090.0,,N,,A,8868,,,Mus musculus,1,,,
,499,1,BAO_0000218,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,50594,,,CHEMBL876786,Intermediate,10090.0,,N,,A,8869,,,Mus musculus,1,,,
,499,1,BAO_0000218,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,50594,,,CHEMBL873825,Intermediate,10090.0,,N,,A,8870,,,Mus musculus,1,,,
,499,1,BAO_0000218,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,50594,,,CHEMBL627106,Intermediate,10090.0,,N,,A,8871,,,Mus musculus,1,,,
,14239,1,BAO_0000218,half life period is evaluated by administering intravenously at 25 mg/kg in mice,50594,In vivo,,CHEMBL626336,Intermediate,10090.0,,N,,A,8872,,,Mus musculus,1,,,
,5506,1,BAO_0000218,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",50594,In vivo,,CHEMBL877462,Intermediate,10090.0,,N,,A,8873,,,Mus musculus,1,,,
,5506,1,BAO_0000218,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",50594,In vivo,,CHEMBL626337,Intermediate,10090.0,,N,,A,8874,,,Mus musculus,1,,,
,17734,1,BAO_0000218,Half life after intraperitoneal administration of 100 mg/kg in mice,50594,,,CHEMBL626338,Intermediate,10090.0,,N,,A,8875,,,Mus musculus,1,,,
,17728,1,BAO_0000218,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,50594,In vivo,,CHEMBL626339,Intermediate,10090.0,,N,,A,8876,,,Mus musculus,1,,,
,17728,1,BAO_0000218,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,50594,In vivo,,CHEMBL626340,Intermediate,10090.0,,N,,A,8877,,,Mus musculus,1,,,
,17728,1,BAO_0000218,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,50594,In vivo,,CHEMBL625377,Intermediate,10090.0,,N,,A,8878,,,Mus musculus,1,,,
,17728,1,BAO_0000218,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,50594,In vivo,,CHEMBL625378,Intermediate,10090.0,,N,,A,8879,,,Mus musculus,1,,,
,17728,1,BAO_0000218,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,50594,In vivo,,CHEMBL625379,Intermediate,10090.0,,N,,A,8880,,,Mus musculus,1,,,
,14294,0,BAO_0000251,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),22224,,,CHEMBL625380,Autocuration,9823.0,Microsomes,U,,A,8881,,,Sus scrofa,1,,,
,14294,0,BAO_0000251,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),22224,,,CHEMBL625381,Autocuration,9823.0,Microsomes,U,,A,8882,,,Sus scrofa,1,,,
,6056,0,BAO_0000019,Stability to porcine renal DHP-I,22224,,,CHEMBL625382,Autocuration,9823.0,,U,,A,8883,,,Sus scrofa,1,,,
,1317,0,BAO_0000218,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,22224,In vivo,,CHEMBL873828,Autocuration,9823.0,,U,,A,8884,,,Sus scrofa,1,,,
,1317,0,BAO_0000218,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,22224,In vivo,,CHEMBL625383,Autocuration,9823.0,,U,,A,8885,,,Sus scrofa,1,,,
,5229,0,BAO_0000019,Half-life of the parent prodrug in porcine esterase solution,22224,,,CHEMBL625384,Autocuration,9823.0,,U,,A,8886,,,Sus scrofa,1,,,
,4231,0,BAO_0000019,"First order rate constant, k was determined in in pig liver Esterase",22224,,,CHEMBL625385,Autocuration,9823.0,,U,,A,8887,,,Sus scrofa,1,,,
,4231,0,BAO_0000221,Half life of the in pig liver Esterase,22224,,Liver,CHEMBL625386,Autocuration,9823.0,,U,,A,8888,,,Sus scrofa,1,,2107.0,
,5318,0,BAO_0000221,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,22224,,Liver,CHEMBL623571,Autocuration,9823.0,,U,,A,8889,,,Sus scrofa,1,,2107.0,
,5318,0,BAO_0000221,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,22224,,Liver,CHEMBL623572,Autocuration,9823.0,,U,,A,8890,,,Sus scrofa,1,,2107.0,
,5318,0,BAO_0000221,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,22224,,Liver,CHEMBL623573,Autocuration,9823.0,,U,,A,8891,,,Sus scrofa,1,,2107.0,
,3305,0,BAO_0000221,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,22224,,Liver,CHEMBL623574,Autocuration,9823.0,,U,,A,8892,,,Sus scrofa,1,,2107.0,
,3305,0,BAO_0000221,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,22224,,Liver,CHEMBL623575,Autocuration,9823.0,,U,,A,8893,,,Sus scrofa,1,,2107.0,
,2842,0,BAO_0000221,Half-life in the presence of pig liver esterase(PLE) was evaluated.,22224,,Liver,CHEMBL623749,Autocuration,9823.0,,U,,A,8894,,,Sus scrofa,1,,2107.0,
,2842,0,BAO_0000221,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,22224,,Liver,CHEMBL623750,Autocuration,9823.0,,U,,A,8895,,,Sus scrofa,1,,2107.0,
,889,0,BAO_0000221,Half-life in vitro in pig liver,22224,In vitro,Liver,CHEMBL623751,Autocuration,9823.0,,U,,A,8896,,,Sus scrofa,1,,2107.0,
,1904,0,BAO_0000221,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,22224,,Liver,CHEMBL623752,Autocuration,9823.0,,U,,A,8897,,,Sus scrofa,1,,2107.0,
,4186,1,BAO_0000218,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,50597,In vivo,Plasma,CHEMBL623753,Intermediate,10116.0,,N,,A,8898,,,Rattus norvegicus,1,,1969.0,
,2774,1,BAO_0000218,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,50597,In vivo,Plasma,CHEMBL623754,Intermediate,10116.0,,N,,A,8899,,,Rattus norvegicus,1,,1969.0,
,1742,1,BAO_0000218,Maximum concentration in rat plasma was determined,50597,In vivo,Plasma,CHEMBL623755,Intermediate,10116.0,,N,,A,8900,,,Rattus norvegicus,1,,1969.0,
,3169,1,BAO_0000218,Maximum concentration in rats,50597,In vivo,,CHEMBL623756,Intermediate,10116.0,,N,,A,8901,,,Rattus norvegicus,1,,,
,3169,1,BAO_0000218,Maximum concentration in rats at 1-2 hours,50597,In vivo,,CHEMBL623757,Intermediate,10116.0,,N,,A,8902,,,Rattus norvegicus,1,,,
,2081,1,BAO_0000218,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,50597,In vivo,,CHEMBL623758,Intermediate,10116.0,,N,,A,8903,,,Rattus norvegicus,1,,,
,3307,1,BAO_0000218,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,50597,In vivo,Brain,CHEMBL623759,Intermediate,10116.0,,N,,A,8904,,,Rattus norvegicus,1,,955.0,
,4727,1,BAO_0000218,Maximum concentration at the dose of 2 mg/kg in rat,50597,In vivo,,CHEMBL623760,Intermediate,10116.0,,N,,A,8905,,,Rattus norvegicus,1,,,
,6597,1,BAO_0000218,Maximum concentration was evaluated in rats,50597,In vivo,,CHEMBL623761,Intermediate,10116.0,,N,,A,8906,,,Rattus norvegicus,1,,,
,16365,1,BAO_0000218,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,50597,In vivo,Plasma,CHEMBL623762,Intermediate,10116.0,,N,,A,8907,,,Rattus norvegicus,1,,1969.0,
,16365,1,BAO_0000218,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,50597,In vivo,Plasma,CHEMBL877594,Intermediate,10116.0,,N,,A,8908,,,Rattus norvegicus,1,,1969.0,
,16365,1,BAO_0000218,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,50597,In vivo,Plasma,CHEMBL623763,Intermediate,10116.0,,N,,A,8909,,,Rattus norvegicus,1,,1969.0,
,16365,1,BAO_0000218,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,50597,In vivo,Plasma,CHEMBL623764,Intermediate,10116.0,,N,,A,8910,,,Rattus norvegicus,1,,1969.0,
,16365,1,BAO_0000218,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,50597,In vivo,Plasma,CHEMBL623765,Intermediate,10116.0,,N,,A,8911,,,Rattus norvegicus,1,,1969.0,
,2591,1,BAO_0000218,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,50597,In vivo,Blood,CHEMBL623766,Intermediate,10116.0,,N,,A,8912,,,Rattus norvegicus,1,,178.0,
,2591,1,BAO_0000218,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,50597,In vivo,Blood,CHEMBL623767,Intermediate,10116.0,,N,,A,8913,,,Rattus norvegicus,1,,178.0,
,2591,1,BAO_0000218,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,50597,In vivo,Blood,CHEMBL623768,Intermediate,10116.0,,N,,A,8914,,,Rattus norvegicus,1,,178.0,
,5978,1,BAO_0000218,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,50597,In vivo,Plasma,CHEMBL623769,Intermediate,10116.0,,N,,A,8915,,,Rattus norvegicus,1,,1969.0,
,5978,1,BAO_0000218,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,50597,In vivo,Plasma,CHEMBL623770,Intermediate,10116.0,,N,,A,8916,,,Rattus norvegicus,1,,1969.0,
,5978,1,BAO_0000218,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,50597,In vivo,Plasma,CHEMBL623771,Intermediate,10116.0,,N,,A,8917,,,Rattus norvegicus,1,,1969.0,
,5978,1,BAO_0000218,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,50597,In vivo,Plasma,CHEMBL623772,Intermediate,10116.0,,N,,A,8918,,,Rattus norvegicus,1,,1969.0,
,5978,1,BAO_0000218,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,50597,In vivo,Plasma,CHEMBL623773,Intermediate,10116.0,,N,,A,8919,,,Rattus norvegicus,1,,1969.0,
,5978,1,BAO_0000218,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,50597,In vivo,Plasma,CHEMBL623774,Intermediate,10116.0,,N,,A,8920,,,Rattus norvegicus,1,,1969.0,
,5978,1,BAO_0000218,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,50597,In vivo,Plasma,CHEMBL623775,Intermediate,10116.0,,N,,A,8921,,,Rattus norvegicus,1,,1969.0,
,14465,1,BAO_0000218,Cmax in rat (PO dose),50597,In vivo,,CHEMBL623776,Intermediate,10116.0,,N,,A,8922,,,Rattus norvegicus,1,,,
,4723,1,BAO_0000218,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,In vivo,Plasma,CHEMBL622191,Intermediate,10116.0,,N,,A,8923,,,Rattus norvegicus,1,,1969.0,
,4723,1,BAO_0000218,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,In vivo,Plasma,CHEMBL622192,Intermediate,10116.0,,N,,A,8924,,,Rattus norvegicus,1,,1969.0,
,4576,1,BAO_0000218,Maximum plasma concentration determined in rat,50597,In vivo,Plasma,CHEMBL622193,Intermediate,10116.0,,N,,A,8925,,,Rattus norvegicus,1,,1969.0,
,12873,1,BAO_0000218,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,50597,In vivo,Plasma,CHEMBL622194,Intermediate,10116.0,,N,,A,8926,,,Rattus norvegicus,1,,1969.0,
,12873,1,BAO_0000218,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,50597,In vivo,Plasma,CHEMBL622195,Intermediate,10116.0,,N,,A,8927,,,Rattus norvegicus,1,,1969.0,
,6824,1,BAO_0000218,Maximum plasma concentration in rat,50597,In vivo,Plasma,CHEMBL622196,Intermediate,10116.0,,N,,A,8928,,,Rattus norvegicus,1,,1969.0,
,17065,1,BAO_0000218,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,50597,In vivo,Plasma,CHEMBL622197,Intermediate,10116.0,,N,,A,8929,,,Rattus norvegicus,1,,1969.0,
,2932,1,BAO_0000218,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,50597,In vivo,Plasma,CHEMBL622198,Intermediate,10116.0,,N,,A,8930,,,Rattus norvegicus,1,,1969.0,
,2932,1,BAO_0000218,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,50597,In vivo,Plasma,CHEMBL622199,Intermediate,10116.0,,N,,A,8931,,,Rattus norvegicus,1,,1969.0,
,2879,1,BAO_0000218,Maximum plasma concentration of compound was measured in rat,50597,In vivo,Plasma,CHEMBL622200,Intermediate,10116.0,,N,,A,8932,,,Rattus norvegicus,1,,1969.0,
,2864,1,BAO_0000218,Maximum plasma concentration after 20 mg/kg oral administration in rat,50597,In vivo,Plasma,CHEMBL622201,Intermediate,10116.0,,N,,A,8933,,,Rattus norvegicus,1,,1969.0,
,16367,1,BAO_0000218,Maximum plasma concentration after oral administration to rats,50597,In vivo,Plasma,CHEMBL623990,Intermediate,10116.0,,N,,A,8934,,,Rattus norvegicus,1,,1969.0,
,17717,1,BAO_0000218,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,In vivo,Plasma,CHEMBL623991,Intermediate,10116.0,,N,,A,8935,,,Rattus norvegicus,1,,1969.0,
,17717,1,BAO_0000218,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",50597,In vivo,Plasma,CHEMBL623992,Intermediate,10116.0,,N,,A,8936,,,Rattus norvegicus,1,,1969.0,
,17717,1,BAO_0000218,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,In vivo,Plasma,CHEMBL623993,Intermediate,10116.0,,N,,A,8937,,,Rattus norvegicus,1,,1969.0,
,17717,1,BAO_0000218,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,50597,In vivo,Plasma,CHEMBL623994,Intermediate,10116.0,,N,,A,8938,,,Rattus norvegicus,1,,1969.0,
,17720,1,BAO_0000218,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,50597,In vivo,Plasma,CHEMBL623995,Intermediate,10116.0,,N,,F,8939,,,Rattus norvegicus,1,,1969.0,
,17720,1,BAO_0000218,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,In vivo,Plasma,CHEMBL623996,Intermediate,10116.0,,N,,F,8940,,,Rattus norvegicus,1,,1969.0,
,17720,1,BAO_0000218,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,50597,In vivo,Plasma,CHEMBL623997,Intermediate,10116.0,,N,,F,8941,,,Rattus norvegicus,1,,1969.0,
,4516,1,BAO_0000218,Maximum plasma concentration dosed orally in rats,50597,In vivo,Plasma,CHEMBL623998,Intermediate,10116.0,,N,,A,8942,,,Rattus norvegicus,1,,1969.0,
,4516,1,BAO_0000218,Maximum plasma concentration dosed orally in rats after 6 hours,50597,In vivo,Plasma,CHEMBL623999,Intermediate,10116.0,,N,,A,8943,,,Rattus norvegicus,1,,1969.0,
,4516,1,BAO_0000218,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,50597,In vivo,Plasma,CHEMBL624000,Intermediate,10116.0,,N,,A,8944,,,Rattus norvegicus,1,,1969.0,
,5199,1,BAO_0000218,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,50597,In vivo,Plasma,CHEMBL624001,Intermediate,10116.0,,N,,A,8945,,,Rattus norvegicus,1,,1969.0,
,17538,1,BAO_0000218,Maximum plasma concentration in rat after po administration,50597,In vivo,Plasma,CHEMBL624002,Intermediate,10116.0,,N,,A,8946,,,Rattus norvegicus,1,,1969.0,
,6685,1,BAO_0000218,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",50597,In vivo,Plasma,CHEMBL624003,Intermediate,10116.0,,N,,A,8947,,,Rattus norvegicus,1,,1969.0,
,6685,1,BAO_0000218,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",50597,In vivo,Plasma,CHEMBL624004,Intermediate,10116.0,,N,,A,8948,,,Rattus norvegicus,1,,1969.0,
,16434,1,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,,Heart,CHEMBL624005,Intermediate,10116.0,,N,,A,8949,,,Rattus norvegicus,1,,948.0,
,16434,1,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,,Heart,CHEMBL624006,Intermediate,10116.0,,N,,A,8950,,,Rattus norvegicus,1,,948.0,
,16434,1,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,,Heart,CHEMBL624007,Intermediate,10116.0,,N,,A,8951,,,Rattus norvegicus,1,,948.0,
,16434,1,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,,Heart,CHEMBL624008,Intermediate,10116.0,,N,,A,8952,,,Rattus norvegicus,1,,948.0,
,16434,1,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,,Heart,CHEMBL624009,Intermediate,10116.0,,N,,A,8953,,,Rattus norvegicus,1,,948.0,
,16434,1,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,,Heart,CHEMBL874387,Intermediate,10116.0,,N,,A,8954,,,Rattus norvegicus,1,,948.0,
,16434,1,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,,Heart,CHEMBL624010,Intermediate,10116.0,,N,,A,8955,,,Rattus norvegicus,1,,948.0,
,16434,1,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,50597,,Heart,CHEMBL624011,Intermediate,10116.0,,N,,A,8956,,,Rattus norvegicus,1,,948.0,
,16435,1,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,,Heart,CHEMBL624012,Intermediate,10116.0,,N,,A,8957,,,Rattus norvegicus,1,,948.0,
,16435,1,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,,Heart,CHEMBL624013,Intermediate,10116.0,,N,,A,8958,,,Rattus norvegicus,1,,948.0,
,16435,1,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,,Heart,CHEMBL624736,Intermediate,10116.0,,N,,A,8959,,,Rattus norvegicus,1,,948.0,
,16435,1,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,,Heart,CHEMBL624737,Intermediate,10116.0,,N,,A,8960,,,Rattus norvegicus,1,,948.0,
,16434,1,BAO_0000218,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,,Heart,CHEMBL624738,Intermediate,10116.0,,N,,A,8961,,,Rattus norvegicus,1,,948.0,
,16434,1,BAO_0000218,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,,Heart,CHEMBL624739,Intermediate,10116.0,,N,,A,8962,,,Rattus norvegicus,1,,948.0,
,16434,1,BAO_0000218,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,,Heart,CHEMBL624740,Intermediate,10116.0,,N,,A,8963,,,Rattus norvegicus,1,,948.0,
,16435,1,BAO_0000218,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,,Heart,CHEMBL624896,Intermediate,10116.0,,N,,A,8964,,,Rattus norvegicus,1,,948.0,
,16435,1,BAO_0000218,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,,Heart,CHEMBL624897,Intermediate,10116.0,,N,,A,8965,,,Rattus norvegicus,1,,948.0,
,16435,1,BAO_0000218,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,,Heart,CHEMBL624108,Intermediate,10116.0,,N,,A,8966,,,Rattus norvegicus,1,,948.0,
,16435,1,BAO_0000218,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,,Heart,CHEMBL624109,Intermediate,10116.0,,N,,A,8967,,,Rattus norvegicus,1,,948.0,
,16435,1,BAO_0000218,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,,Heart,CHEMBL624110,Intermediate,10116.0,,N,,A,8968,,,Rattus norvegicus,1,,948.0,
,16435,1,BAO_0000218,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,,Heart,CHEMBL624111,Intermediate,10116.0,,N,,A,8969,,,Rattus norvegicus,1,,948.0,
,16435,1,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,,Heart,CHEMBL624112,Intermediate,10116.0,,N,,A,8970,,,Rattus norvegicus,1,,948.0,
,16435,1,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,,Heart,CHEMBL624113,Intermediate,10116.0,,N,,A,8971,,,Rattus norvegicus,1,,948.0,
,16435,1,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,,Heart,CHEMBL619709,Intermediate,10116.0,,N,,A,8972,,,Rattus norvegicus,1,,948.0,
,16435,1,BAO_0000218,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,,Heart,CHEMBL619710,Intermediate,10116.0,,N,,A,8973,,,Rattus norvegicus,1,,948.0,
,16434,1,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,,Kidney,CHEMBL619711,Intermediate,10116.0,,N,,A,8974,,,Rattus norvegicus,1,,2113.0,
,16434,1,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,,Kidney,CHEMBL619712,Intermediate,10116.0,,N,,A,8975,,,Rattus norvegicus,1,,2113.0,
,16434,1,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,,Kidney,CHEMBL619713,Intermediate,10116.0,,N,,A,8976,,,Rattus norvegicus,1,,2113.0,
,16434,1,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,,Kidney,CHEMBL619714,Intermediate,10116.0,,N,,A,8977,,,Rattus norvegicus,1,,2113.0,
,16434,1,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,,Kidney,CHEMBL619715,Intermediate,10116.0,,N,,A,8978,,,Rattus norvegicus,1,,2113.0,
,16434,1,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,,Kidney,CHEMBL619716,Intermediate,10116.0,,N,,A,8979,,,Rattus norvegicus,1,,2113.0,
,16434,1,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,,Kidney,CHEMBL619717,Intermediate,10116.0,,N,,A,8980,,,Rattus norvegicus,1,,2113.0,
,16434,1,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,,Kidney,CHEMBL619718,Intermediate,10116.0,,N,,A,8981,,,Rattus norvegicus,1,,2113.0,
,16435,1,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,,Kidney,CHEMBL619719,Intermediate,10116.0,,N,,A,8982,,,Rattus norvegicus,1,,2113.0,
,16435,1,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,,Kidney,CHEMBL875329,Intermediate,10116.0,,N,,A,8983,,,Rattus norvegicus,1,,2113.0,
,16435,1,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,,Kidney,CHEMBL619720,Intermediate,10116.0,,N,,A,8984,,,Rattus norvegicus,1,,2113.0,
,16435,1,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,,Kidney,CHEMBL619721,Intermediate,10116.0,,N,,A,8985,,,Rattus norvegicus,1,,2113.0,
,16435,1,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,,Kidney,CHEMBL619722,Intermediate,10116.0,,N,,A,8986,,,Rattus norvegicus,1,,2113.0,
,16435,1,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,,Kidney,CHEMBL619723,Intermediate,10116.0,,N,,A,8987,,,Rattus norvegicus,1,,2113.0,
,16435,1,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,,Kidney,CHEMBL619724,Intermediate,10116.0,,N,,A,8988,,,Rattus norvegicus,1,,2113.0,
,16435,1,BAO_0000218,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,,Kidney,CHEMBL619725,Intermediate,10116.0,,N,,A,8989,,,Rattus norvegicus,1,,2113.0,
,16434,1,BAO_0000218,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,,Kidney,CHEMBL619726,Intermediate,10116.0,,N,,A,8990,,,Rattus norvegicus,1,,2113.0,
,16434,1,BAO_0000218,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,,Kidney,CHEMBL619727,Intermediate,10116.0,,N,,A,8991,,,Rattus norvegicus,1,,2113.0,
,16434,1,BAO_0000218,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,,Kidney,CHEMBL619728,Intermediate,10116.0,,N,,A,8992,,,Rattus norvegicus,1,,2113.0,
,16435,1,BAO_0000218,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,,Kidney,CHEMBL619729,Intermediate,10116.0,,N,,A,8993,,,Rattus norvegicus,1,,2113.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Muscle tissue,CHEMBL619730,Intermediate,10116.0,,N,,A,8994,,,Rattus norvegicus,1,,2385.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Muscle tissue,CHEMBL619731,Intermediate,10116.0,,N,,A,8995,,,Rattus norvegicus,1,,2385.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,In vivo,Muscle tissue,CHEMBL619732,Intermediate,10116.0,,N,,A,8996,,,Rattus norvegicus,1,,2385.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Muscle tissue,CHEMBL619733,Intermediate,10116.0,,N,,A,8997,,,Rattus norvegicus,1,,2385.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Muscle tissue,CHEMBL619734,Intermediate,10116.0,,N,,A,8998,,,Rattus norvegicus,1,,2385.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Zone of skin,CHEMBL619735,Intermediate,10116.0,,N,,A,8999,,,Rattus norvegicus,1,,14.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Zone of skin,CHEMBL875330,Intermediate,10116.0,,N,,A,9000,,,Rattus norvegicus,1,,14.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,In vivo,Zone of skin,CHEMBL628465,Intermediate,10116.0,,N,,A,9001,,,Rattus norvegicus,1,,14.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Zone of skin,CHEMBL628466,Intermediate,10116.0,,N,,A,9002,,,Rattus norvegicus,1,,14.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Zone of skin,CHEMBL628467,Intermediate,10116.0,,N,,A,9003,,,Rattus norvegicus,1,,14.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Spleen,CHEMBL628468,Intermediate,10116.0,,N,,A,9004,,,Rattus norvegicus,1,,2106.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Spleen,CHEMBL628469,Intermediate,10116.0,,N,,A,9005,,,Rattus norvegicus,1,,2106.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,In vivo,Spleen,CHEMBL628470,Intermediate,10116.0,,N,,A,9006,,,Rattus norvegicus,1,,2106.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Spleen,CHEMBL628471,Intermediate,10116.0,,N,,A,9007,,,Rattus norvegicus,1,,2106.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Spleen,CHEMBL628472,Intermediate,10116.0,,N,,A,9008,,,Rattus norvegicus,1,,2106.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Thyroid gland,CHEMBL625191,Intermediate,10116.0,,N,,A,9009,,,Rattus norvegicus,1,,2046.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Thyroid gland,CHEMBL625192,Intermediate,10116.0,,N,,A,9010,,,Rattus norvegicus,1,,2046.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,In vivo,Thyroid gland,CHEMBL875337,Intermediate,10116.0,,N,,A,9011,,,Rattus norvegicus,1,,2046.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Thyroid gland,CHEMBL626341,Intermediate,10116.0,,N,,A,9012,,,Rattus norvegicus,1,,2046.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Thyroid gland,CHEMBL626342,Intermediate,10116.0,,N,,A,9013,,,Rattus norvegicus,1,,2046.0,
,11977,1,BAO_0000218,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,In vivo,Liver,CHEMBL621943,Intermediate,10116.0,,N,,A,9014,,,Rattus norvegicus,1,,2107.0,
,3748,1,BAO_0000218,Half life in rats,50597,,,CHEMBL621944,Intermediate,10116.0,,N,,A,9015,,,Rattus norvegicus,1,,,
,15765,1,BAO_0000218,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,50597,,,CHEMBL621945,Intermediate,10116.0,,N,,A,9016,,,Rattus norvegicus,1,,,
,4871,1,BAO_0000218,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),50597,,,CHEMBL621946,Intermediate,10116.0,,N,,A,9017,,,Rattus norvegicus,1,,,
,4871,1,BAO_0000218,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,50597,,,CHEMBL621947,Intermediate,10116.0,,N,,A,9018,,,Rattus norvegicus,1,,,
,4872,1,BAO_0000218,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),50597,,,CHEMBL621948,Intermediate,10116.0,,N,,A,9019,,,Rattus norvegicus,1,,,
,4872,1,BAO_0000218,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,50597,,,CHEMBL621949,Intermediate,10116.0,,N,,A,9020,,,Rattus norvegicus,1,,,
,5413,1,BAO_0000218,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),50597,,,CHEMBL621950,Intermediate,10116.0,,N,,A,9021,,,Rattus norvegicus,1,,,
,5413,1,BAO_0000218,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,50597,,,CHEMBL621951,Intermediate,10116.0,,N,,A,9022,,,Rattus norvegicus,1,,,
,15272,1,BAO_0000218,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,50597,In vivo,Blood,CHEMBL621952,Intermediate,10116.0,,N,,A,9023,,,Rattus norvegicus,1,,178.0,
,4689,1,BAO_0000218,Stability (%) in rat liver microsomes,50597,,Liver,CHEMBL621953,Intermediate,10116.0,,N,,A,9024,,,Rattus norvegicus,1,,2107.0,
,6057,1,BAO_0000218,Area under curve was calculated after intravenous administration,50597,,,CHEMBL621954,Intermediate,10116.0,,N,,A,9025,,,Rattus norvegicus,1,,,
,6057,1,BAO_0000218,Area under the curve was calculated after iv administration in rat,50597,,,CHEMBL621955,Intermediate,10116.0,,N,,A,9026,,,Rattus norvegicus,1,,,
,6057,1,BAO_0000218,Area under the curve was calculated in rat after peroral administration,50597,,,CHEMBL621956,Intermediate,10116.0,,N,,A,9027,,,Rattus norvegicus,1,,,
,6211,1,BAO_0000218,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,50597,,,CHEMBL621957,Intermediate,10116.0,,N,,A,9028,,,Rattus norvegicus,1,,,
,5710,1,BAO_0000218,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,50597,,,CHEMBL621958,Intermediate,10116.0,,N,,A,9029,,,Rattus norvegicus,1,,,
,5710,1,BAO_0000218,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,50597,,,CHEMBL621959,Intermediate,10116.0,,N,,A,9030,,,Rattus norvegicus,1,,,
,17853,1,BAO_0000218,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,50597,,,CHEMBL621960,Intermediate,10116.0,,N,,A,9031,,,Rattus norvegicus,1,,,
,17853,1,BAO_0000218,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,50597,,,CHEMBL621961,Intermediate,10116.0,,N,,A,9032,,,Rattus norvegicus,1,,,
,15765,1,BAO_0000218,p value of the compound,50597,,,CHEMBL621962,Intermediate,10116.0,,N,,A,9033,,,Rattus norvegicus,1,,,
,15765,1,BAO_0000218,p value of the compound,50597,,,CHEMBL876787,Intermediate,10116.0,,N,,F,9034,,,Rattus norvegicus,1,,,
,15765,1,BAO_0000218,p value of the compound,50597,,,CHEMBL621963,Intermediate,10116.0,,N,,A,9035,,,Rattus norvegicus,1,,,
,6175,1,BAO_0000218,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,,Stomach,CHEMBL622637,Intermediate,10116.0,,N,,A,9036,,,Rattus norvegicus,1,,945.0,
,6175,1,BAO_0000218,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,,Stomach,CHEMBL622638,Intermediate,10116.0,,N,,A,9037,,,Rattus norvegicus,1,,945.0,
,6175,1,BAO_0000218,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,,Stomach,CHEMBL626561,Intermediate,10116.0,,N,,A,9038,,,Rattus norvegicus,1,,945.0,
,7991,0,BAO_0000019,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),22224,,,CHEMBL626562,Autocuration,9986.0,,U,,F,9039,,,Oryctolagus cuniculus,1,,,
,429,0,BAO_0000218,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),22224,,,CHEMBL626563,Autocuration,9986.0,,U,,A,9040,,,Oryctolagus cuniculus,1,,,
,429,0,BAO_0000218,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),22224,,,CHEMBL626564,Autocuration,9986.0,,U,,A,9041,,,Oryctolagus cuniculus,1,,,
,6253,0,BAO_0000218,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,22224,In vivo,,CHEMBL626565,Autocuration,9986.0,,U,,A,9042,,,Oryctolagus cuniculus,1,,,
,6253,0,BAO_0000218,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,22224,In vivo,,CHEMBL626566,Autocuration,9986.0,,U,,A,9043,,,Oryctolagus cuniculus,1,,,
,3615,0,BAO_0000218,Clearance rate in rabbits,22224,In vivo,,CHEMBL626567,Autocuration,9986.0,,U,,A,9044,,,Oryctolagus cuniculus,1,,,
,4059,0,BAO_0000218,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,22224,In vivo,,CHEMBL626568,Autocuration,9986.0,,U,,A,9045,,,Oryctolagus cuniculus,1,,,
,5124,0,BAO_0000218,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,22224,In vivo,,CHEMBL626569,Autocuration,9986.0,,U,,A,9046,,,Oryctolagus cuniculus,1,,,
,5124,0,BAO_0000218,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,22224,In vivo,,CHEMBL626570,Autocuration,9986.0,,U,,A,9047,,,Oryctolagus cuniculus,1,,,
,5124,0,BAO_0000218,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,22224,In vivo,,CHEMBL626571,Autocuration,9986.0,,U,,A,9048,,,Oryctolagus cuniculus,1,,,
,429,0,BAO_0000218,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,22224,In vivo,,CHEMBL626572,Autocuration,9986.0,,U,,A,9049,,,Oryctolagus cuniculus,1,,,
,4059,0,BAO_0000218,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,22224,In vivo,Plasma,CHEMBL626573,Autocuration,9986.0,,U,,A,9050,,,Oryctolagus cuniculus,1,,1969.0,
,9659,0,BAO_0000251,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,22224,,Liver,CHEMBL626574,Autocuration,9986.0,Microsomes,U,,A,9051,,,Oryctolagus cuniculus,1,,2107.0,
,9659,0,BAO_0000251,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,22224,,Liver,CHEMBL626575,Autocuration,9986.0,Microsomes,U,,A,9052,,,Oryctolagus cuniculus,1,,2107.0,
,3639,0,BAO_0000218,Dose at which bioavailability of intravenously administered compound was tested in rabbit,22224,,,CHEMBL626576,Autocuration,9986.0,,U,,A,9053,,,Oryctolagus cuniculus,1,,,
,3639,0,BAO_0000218,Dose at which bioavailability of perorally administered compound was tested in rabbit,22224,,,CHEMBL626577,Autocuration,9986.0,,U,,A,9054,,,Oryctolagus cuniculus,1,,,
,3639,0,BAO_0000218,The compound was tested for its bioavailability in rabbit (by oral dosage).,22224,In vivo,,CHEMBL626578,Autocuration,9986.0,,U,,A,9055,,,Oryctolagus cuniculus,1,,,
,5124,0,BAO_0000218,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,22224,In vivo,,CHEMBL625263,Autocuration,9986.0,,U,,A,9056,,,Oryctolagus cuniculus,1,,,
,5124,0,BAO_0000218,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,22224,In vivo,,CHEMBL625264,Autocuration,9986.0,,U,,A,9057,,,Oryctolagus cuniculus,1,,,
,5124,0,BAO_0000218,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,22224,In vivo,,CHEMBL625265,Autocuration,9986.0,,U,,A,9058,,,Oryctolagus cuniculus,1,,,
,14294,0,BAO_0000251,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),22224,,,CHEMBL625266,Autocuration,9986.0,Microsomes,U,,A,9059,,,Oryctolagus cuniculus,1,,,
,14294,0,BAO_0000251,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),22224,,,CHEMBL876796,Autocuration,9986.0,Microsomes,U,,A,9060,,,Oryctolagus cuniculus,1,,,
,429,0,BAO_0000218,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,22224,In vivo,,CHEMBL625267,Autocuration,9986.0,,U,,A,9061,,,Oryctolagus cuniculus,1,,,
,5124,0,BAO_0000218,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,22224,In vivo,Plasma,CHEMBL625268,Autocuration,9986.0,,U,,A,9062,,,Oryctolagus cuniculus,1,,1969.0,
,5124,0,BAO_0000218,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,22224,In vivo,Plasma,CHEMBL625269,Autocuration,9986.0,,U,,A,9063,,,Oryctolagus cuniculus,1,,1969.0,
,5124,0,BAO_0000218,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,22224,In vivo,Plasma,CHEMBL624689,Autocuration,9986.0,,U,,A,9064,,,Oryctolagus cuniculus,1,,1969.0,
,429,0,BAO_0000218,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,22224,In vivo,,CHEMBL624690,Autocuration,9986.0,,U,,A,9065,,,Oryctolagus cuniculus,1,,,
,429,0,BAO_0000218,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),22224,,Urine,CHEMBL624691,Autocuration,9986.0,,U,,A,9066,,,Oryctolagus cuniculus,1,,1088.0,
,429,0,BAO_0000218,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),22224,,Urine,CHEMBL624692,Autocuration,9986.0,,U,,A,9067,,,Oryctolagus cuniculus,1,,1088.0,
,4059,0,BAO_0000218,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,22224,In vivo,,CHEMBL624693,Autocuration,9986.0,,U,,A,9068,,,Oryctolagus cuniculus,1,,,
,4137,0,BAO_0000218,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,22224,In vivo,,CHEMBL624694,Autocuration,9986.0,,U,,A,9069,,,Oryctolagus cuniculus,1,,,
,11672,0,BAO_0000221,In vitro Biological half-life in crude homogenate of rabbit renal cortex,22224,In vitro,,CHEMBL877596,Autocuration,9986.0,,U,,A,9070,,,Oryctolagus cuniculus,1,,,
,12886,0,BAO_0000019,Time within which only 10% of the drug was degraded,22224,,,CHEMBL624695,Autocuration,9986.0,,U,,A,9071,,,Oryctolagus cuniculus,1,,,
,3853,0,BAO_0000221,Half life period in rabbit liver homogenate,22224,,Liver,CHEMBL624696,Autocuration,9986.0,,U,,A,9072,,,Oryctolagus cuniculus,1,,2107.0,
,3615,0,BAO_0000019,Half life value in rabbits,22224,,,CHEMBL624697,Autocuration,9986.0,,U,,A,9073,,,Oryctolagus cuniculus,1,,,
,6253,0,BAO_0000218,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,22224,In vivo,Blood,CHEMBL624698,Autocuration,9986.0,,U,,A,9074,,,Oryctolagus cuniculus,1,,178.0,
,6253,0,BAO_0000218,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,22224,In vivo,Blood,CHEMBL624699,Autocuration,9986.0,,U,,A,9075,,,Oryctolagus cuniculus,1,,178.0,
,6077,0,BAO_0000218,Half-life period in rabbits following intravenous administration at 2 mg/kg,22224,In vivo,,CHEMBL624700,Autocuration,9986.0,,U,,A,9076,,,Oryctolagus cuniculus,1,,,
,17617,1,BAO_0000218,AUC 0-8 hr value in rats at 10 mg/kg,50597,,Plasma,CHEMBL622903,Intermediate,10116.0,,N,,A,9077,,,Rattus norvegicus,1,,1969.0,
,17594,1,BAO_0000218,AUC after administration at 2000 mg/kg/day in rats,50597,,Plasma,CHEMBL622904,Intermediate,10116.0,,N,,A,9078,,,Rattus norvegicus,1,,1969.0,
,6149,1,BAO_0000218,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,50597,,Plasma,CHEMBL622905,Intermediate,10116.0,,N,,A,9079,,,Rattus norvegicus,1,,1969.0,
,17260,1,BAO_0000218,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,50597,,Plasma,CHEMBL622906,Intermediate,10116.0,,N,,A,9080,,,Rattus norvegicus,1,,1969.0,
,17260,1,BAO_0000218,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,50597,,Plasma,CHEMBL622907,Intermediate,10116.0,,N,,A,9081,,,Rattus norvegicus,1,,1969.0,
,6644,1,BAO_0000218,AUC in rat after oral administration at 10.5 mg/kg dose,50597,,Plasma,CHEMBL622908,Intermediate,10116.0,,N,,A,9082,,,Rattus norvegicus,1,,1969.0,
,6644,1,BAO_0000218,AUC in rat after oral administration at 11.2 mg/kg dose,50597,,Plasma,CHEMBL622909,Intermediate,10116.0,,N,,A,9083,,,Rattus norvegicus,1,,1969.0,
,6644,1,BAO_0000218,AUC in rat after oral administration at 9.7 mg/kg dose,50597,,Plasma,CHEMBL622910,Intermediate,10116.0,,N,,A,9084,,,Rattus norvegicus,1,,1969.0,
,6495,1,BAO_0000218,AUC in rat brain after oral administration at 10 mg/kg,50597,,Brain,CHEMBL622911,Intermediate,10116.0,,N,,A,9085,,,Rattus norvegicus,1,,955.0,
,6504,1,BAO_0000218,AUC in rat p.o.,50597,,Plasma,CHEMBL622912,Intermediate,10116.0,,N,,A,9086,,,Rattus norvegicus,1,,1969.0,
,17686,1,BAO_0000218,AUC in rat p.o. at 20 mg/kg concentration,50597,,Plasma,CHEMBL622913,Intermediate,10116.0,,N,,A,9087,,,Rattus norvegicus,1,,1969.0,
,6495,1,BAO_0000218,AUC in rat plasma after oral administration at 10 mg/kg,50597,,Plasma,CHEMBL622914,Intermediate,10116.0,,N,,A,9088,,,Rattus norvegicus,1,,1969.0,
,216,1,BAO_0000218,AUC in rats,50597,,Plasma,CHEMBL622915,Intermediate,10116.0,,N,,A,9089,,,Rattus norvegicus,1,,1969.0,
,1908,1,BAO_0000218,AUC value after IV dose at a dose of 5 mg/kg in rats.,50597,,Plasma,CHEMBL622916,Intermediate,10116.0,,N,,A,9090,,,Rattus norvegicus,1,,1969.0,
,1908,1,BAO_0000218,AUC value after oral dose at a dose of 10 mg/kg in rats.,50597,,Plasma,CHEMBL622917,Intermediate,10116.0,,N,,A,9091,,,Rattus norvegicus,1,,1969.0,
,6685,1,BAO_0000218,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",50597,In vivo,Plasma,CHEMBL622918,Intermediate,10116.0,,N,,A,9092,,,Rattus norvegicus,1,,1969.0,
,216,1,BAO_0000218,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,50597,In vivo,Plasma,CHEMBL622919,Intermediate,10116.0,,N,,A,9093,,,Rattus norvegicus,1,,1969.0,
,6049,1,BAO_0000218,Maximum plasma concentration was evaluated in rat,50597,In vivo,Plasma,CHEMBL622920,Intermediate,10116.0,,N,,A,9094,,,Rattus norvegicus,1,,1969.0,
,2463,1,BAO_0000218,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,50597,In vivo,Plasma,CHEMBL622921,Intermediate,10116.0,,N,,A,9095,,,Rattus norvegicus,1,,1969.0,
,6679,1,BAO_0000218,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,50597,In vivo,Plasma,CHEMBL622922,Intermediate,10116.0,,N,,A,9096,,,Rattus norvegicus,1,,1969.0,
,6681,1,BAO_0000218,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,50597,In vivo,Plasma,CHEMBL622923,Intermediate,10116.0,,N,,A,9097,,,Rattus norvegicus,1,,1969.0,
,4890,1,BAO_0000218,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,50597,In vivo,Plasma,CHEMBL877604,Intermediate,10116.0,,N,,A,9098,,,Rattus norvegicus,1,,1969.0,
,6410,1,BAO_0000218,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,50597,In vivo,Plasma,CHEMBL622924,Intermediate,10116.0,,N,,A,9099,,,Rattus norvegicus,1,,1969.0,
,6410,1,BAO_0000218,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,50597,In vivo,Plasma,CHEMBL622925,Intermediate,10116.0,,N,,A,9100,,,Rattus norvegicus,1,,1969.0,
,16366,1,BAO_0000218,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,50597,In vivo,Plasma,CHEMBL622926,Intermediate,10116.0,,N,,A,9101,,,Rattus norvegicus,1,,1969.0,
,6227,1,BAO_0000218,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,50597,In vivo,Plasma,CHEMBL623625,Intermediate,10116.0,,N,,A,9102,,,Rattus norvegicus,1,,1969.0,
,3598,1,BAO_0000218,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,In vivo,Plasma,CHEMBL623626,Expert,10116.0,,N,,A,9103,,,Rattus norvegicus,1,,1969.0,
,1465,1,BAO_0000218,Maximum plasma drug concentration was determined,50597,In vivo,Plasma,CHEMBL623627,Intermediate,10116.0,,N,,A,9104,,,Rattus norvegicus,1,,1969.0,
,4368,1,BAO_0000218,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,50597,In vivo,,CHEMBL623628,Intermediate,10116.0,,N,,A,9105,,,Rattus norvegicus,1,,,
,15662,1,BAO_0000218,Mean peak plasma concentration was observed after intravenous administration in rat,50597,In vivo,Plasma,CHEMBL623629,Intermediate,10116.0,,N,,A,9106,,,Rattus norvegicus,1,,1969.0,
,15662,1,BAO_0000218,Mean peak plasma concentration was observed after oral administration in rat,50597,In vivo,Plasma,CHEMBL623630,Intermediate,10116.0,,N,,A,9107,,,Rattus norvegicus,1,,1969.0,
,5355,1,BAO_0000218,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,50597,In vivo,,CHEMBL623804,Intermediate,10116.0,,N,,A,9108,,,Rattus norvegicus,1,,,
,5355,1,BAO_0000218,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,50597,In vivo,,CHEMBL623805,Intermediate,10116.0,,N,,A,9109,,,Rattus norvegicus,1,,,
,1567,1,BAO_0000218,Peak oral plasma concentration was determined in rats by oral administration,50597,In vivo,Plasma,CHEMBL623806,Intermediate,10116.0,,N,,A,9110,,,Rattus norvegicus,1,,1969.0,
,4026,1,BAO_0000218,Peak plasma concentration (Cmax) was determined,50597,In vivo,Plasma,CHEMBL623807,Intermediate,10116.0,,N,,A,9111,,,Rattus norvegicus,1,,1969.0,
,6193,1,BAO_0000218,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,50597,In vivo,Plasma,CHEMBL623808,Intermediate,10116.0,,N,,A,9112,,,Rattus norvegicus,1,,1969.0,
,4026,1,BAO_0000218,Peak plasma concentration (Cmax) in rats,50597,In vivo,Plasma,CHEMBL623809,Intermediate,10116.0,,N,,A,9113,,,Rattus norvegicus,1,,1969.0,
,6485,1,BAO_0000218,Peak plasma concentration at 1 mg/kg peroral administration,50597,In vivo,Plasma,CHEMBL623810,Intermediate,10116.0,,N,,A,9114,,,Rattus norvegicus,1,,1969.0,
,17655,1,BAO_0000218,Peak plasma concentration in rat,50597,In vivo,Plasma,CHEMBL623811,Intermediate,10116.0,,N,,A,9115,,,Rattus norvegicus,1,,1969.0,
,14941,1,BAO_0000218,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",50597,In vivo,Plasma,CHEMBL623812,Intermediate,10116.0,,N,,A,9116,,,Rattus norvegicus,1,,1969.0,
,5394,1,BAO_0000218,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,50597,In vivo,,CHEMBL877605,Intermediate,10116.0,,N,,A,9117,,,Rattus norvegicus,1,,,
,4408,1,BAO_0000218,Pharmacokinetic property (Cmax) in rat,50597,In vivo,,CHEMBL623813,Intermediate,10116.0,,N,,A,9118,,,Rattus norvegicus,1,,,
,5983,1,BAO_0000218,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,50597,In vivo,,CHEMBL623814,Intermediate,10116.0,,N,,A,9119,,,Rattus norvegicus,1,,,
,4878,1,BAO_0000218,Cmax in rat after 3mg/kg oral dose,50597,In vivo,,CHEMBL623815,Intermediate,10116.0,,N,,A,9120,,,Rattus norvegicus,1,,,
,5862,1,BAO_0000218,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,50597,In vivo,,CHEMBL623816,Intermediate,10116.0,,N,,A,9121,Sprague-Dawley,,Rattus norvegicus,1,,,
,4517,1,BAO_0000218,Cmax in rats after 20 mg/kg oral dose,50597,In vivo,,CHEMBL623145,Intermediate,10116.0,,N,,A,9122,,,Rattus norvegicus,1,,,
,5932,1,BAO_0000218,Cmax in rat plasma after 30mg/kg oral dose,50597,In vivo,Plasma,CHEMBL623146,Intermediate,10116.0,,N,,A,9123,,,Rattus norvegicus,1,,1969.0,
,5436,1,BAO_0000218,Plasma concentration after oral administration of 100 mg/kg to rats,50597,In vivo,Plasma,CHEMBL623147,Intermediate,10116.0,,N,,A,9124,,,Rattus norvegicus,1,,1969.0,
,4910,1,BAO_0000218,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,50597,In vivo,Brain,CHEMBL623042,Intermediate,10116.0,,N,,A,9125,,,Rattus norvegicus,1,,955.0,
,4950,1,BAO_0000218,Tested for the Cmax in rat at 10 mg/kg per orally,50597,In vivo,,CHEMBL623043,Intermediate,10116.0,,N,,A,9126,,,Rattus norvegicus,1,,,
,15078,1,BAO_0000218,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",50597,In vivo,,CHEMBL623044,Intermediate,10116.0,,N,,A,9127,,,Rattus norvegicus,1,,,
,15078,1,BAO_0000218,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",50597,In vivo,,CHEMBL623045,Intermediate,10116.0,,N,,A,9128,,,Rattus norvegicus,1,,,
,3360,1,BAO_0000218,Bioavailability as oral Cmax in rats at 30 mins,50597,In vivo,,CHEMBL623046,Intermediate,10116.0,,N,,A,9129,,,Rattus norvegicus,1,,,
,3360,1,BAO_0000218,Bioavailability as oral Cmax in rats at 6hr,50597,In vivo,,CHEMBL623226,Intermediate,10116.0,,N,,A,9130,,,Rattus norvegicus,1,,,
,15022,1,BAO_0000218,The maximum concentration of compound was measured at the dose of 100 umol/kg,50597,In vivo,,CHEMBL623227,Intermediate,10116.0,,N,,A,9131,,,Rattus norvegicus,1,,,
,15022,1,BAO_0000218,The maximum concentration of compound was measured at the dose of 300 umol/kg,50597,In vivo,,CHEMBL623228,Intermediate,10116.0,,N,,A,9132,,,Rattus norvegicus,1,,,
,15022,1,BAO_0000218,The maximum concentration of compound was measured at the dose of 30 umol/kg,50597,In vivo,,CHEMBL623229,Intermediate,10116.0,,N,,A,9133,,,Rattus norvegicus,1,,,
,5160,1,BAO_0000218,The maximum plasma levels for the compounds were determined by LC-MS.,50597,In vivo,Plasma,CHEMBL623230,Intermediate,10116.0,,N,,A,9134,,,Rattus norvegicus,1,,1969.0,
,15662,1,BAO_0000218,mean peak plasma concentration was observed after intravenous administration in rat,50597,In vivo,Plasma,CHEMBL623231,Intermediate,10116.0,,N,,A,9135,,,Rattus norvegicus,1,,1969.0,
,15662,1,BAO_0000218,mean peak plasma concentration was observed after oral administration in rat,50597,In vivo,Plasma,CHEMBL623232,Intermediate,10116.0,,N,,A,9136,,,Rattus norvegicus,1,,1969.0,
,4709,1,BAO_0000218,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,50597,,,CHEMBL623233,Intermediate,10116.0,,N,,A,9137,,,Rattus norvegicus,1,,,
,3535,1,BAO_0000218,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,50597,,,CHEMBL623234,Intermediate,10116.0,,N,,A,9138,,,Rattus norvegicus,1,,,
,3535,1,BAO_0000218,Concentration in plasma (portal) following oral dose in rats at 1 hr,50597,,,CHEMBL623235,Intermediate,10116.0,,N,,A,9139,,,Rattus norvegicus,1,,,
,3535,1,BAO_0000218,Concentration in plasma (portal) following oral dose in rats at 2 hr,50597,,,CHEMBL623236,Intermediate,10116.0,,N,,A,9140,,,Rattus norvegicus,1,,,
,3535,1,BAO_0000218,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,50597,,,CHEMBL623237,Intermediate,10116.0,,N,,A,9141,,,Rattus norvegicus,1,,,
,3535,1,BAO_0000218,Concentration in plasma (systemic) following oral dose in rats at 1 hr,50597,,,CHEMBL623238,Intermediate,10116.0,,N,,A,9142,,,Rattus norvegicus,1,,,
,3535,1,BAO_0000218,Concentration in plasma (systemic) following oral dose in rats at 2 hr,50597,,,CHEMBL623239,Intermediate,10116.0,,N,,A,9143,,,Rattus norvegicus,1,,,
,5005,0,BAO_0000218,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,22224,In vivo,Plasma,CHEMBL623240,Intermediate,10116.0,,U,,A,9144,,,Rattus norvegicus,1,,1969.0,
,6326,1,BAO_0000218,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",50597,,Hypothalamus,CHEMBL623241,Intermediate,10116.0,,N,,A,9145,,,Rattus norvegicus,1,,1898.0,
,6326,1,BAO_0000218,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",50597,,Hypothalamus,CHEMBL623242,Intermediate,10116.0,,N,,A,9146,,,Rattus norvegicus,1,,1898.0,
,6326,1,BAO_0000218,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",50597,,,CHEMBL874394,Intermediate,10116.0,,N,,A,9147,,,Rattus norvegicus,1,,,
,6326,1,BAO_0000218,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",50597,,,CHEMBL623243,Intermediate,10116.0,,N,,A,9148,,,Rattus norvegicus,1,,,
,17411,1,BAO_0000218,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,,,CHEMBL623244,Intermediate,10116.0,,N,,A,9149,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,,Kidney,CHEMBL623245,Intermediate,10116.0,,N,,A,9150,,,Rattus norvegicus,1,,2113.0,
,16435,1,BAO_0000218,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,,Kidney,CHEMBL623246,Intermediate,10116.0,,N,,A,9151,,,Rattus norvegicus,1,,2113.0,
,16435,1,BAO_0000218,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,,Kidney,CHEMBL623247,Intermediate,10116.0,,N,,A,9152,,,Rattus norvegicus,1,,2113.0,
,16435,1,BAO_0000218,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,,Kidney,CHEMBL623248,Intermediate,10116.0,,N,,A,9153,,,Rattus norvegicus,1,,2113.0,
,16435,1,BAO_0000218,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,,Kidney,CHEMBL623249,Intermediate,10116.0,,N,,A,9154,,,Rattus norvegicus,1,,2113.0,
,16434,1,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,,Liver,CHEMBL625072,Intermediate,10116.0,,N,,A,9155,,,Rattus norvegicus,1,,2107.0,
,16434,1,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,,Liver,CHEMBL625073,Intermediate,10116.0,,N,,A,9156,,,Rattus norvegicus,1,,2107.0,
,16434,1,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,,Liver,CHEMBL625074,Intermediate,10116.0,,N,,A,9157,,,Rattus norvegicus,1,,2107.0,
,16434,1,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,,Liver,CHEMBL625075,Intermediate,10116.0,,N,,A,9158,,,Rattus norvegicus,1,,2107.0,
,16434,1,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,50597,,Liver,CHEMBL625076,Intermediate,10116.0,,N,,A,9159,,,Rattus norvegicus,1,,2107.0,
,16434,1,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,,Liver,CHEMBL625077,Intermediate,10116.0,,N,,A,9160,,,Rattus norvegicus,1,,2107.0,
,16434,1,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,,Liver,CHEMBL625078,Intermediate,10116.0,,N,,A,9161,,,Rattus norvegicus,1,,2107.0,
,16434,1,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,,Liver,CHEMBL874395,Intermediate,10116.0,,N,,A,9162,,,Rattus norvegicus,1,,2107.0,
,16435,1,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,,Liver,CHEMBL625079,Intermediate,10116.0,,N,,A,9163,,,Rattus norvegicus,1,,2107.0,
,16435,1,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,,Liver,CHEMBL625080,Intermediate,10116.0,,N,,A,9164,,,Rattus norvegicus,1,,2107.0,
,16435,1,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,,Liver,CHEMBL625081,Intermediate,10116.0,,N,,A,9165,,,Rattus norvegicus,1,,2107.0,
,16435,1,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,,Liver,CHEMBL625082,Intermediate,10116.0,,N,,A,9166,,,Rattus norvegicus,1,,2107.0,
,16435,1,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,,Liver,CHEMBL625083,Intermediate,10116.0,,N,,A,9167,,,Rattus norvegicus,1,,2107.0,
,16435,1,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,,Liver,CHEMBL625084,Intermediate,10116.0,,N,,A,9168,,,Rattus norvegicus,1,,2107.0,
,16435,1,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,,Liver,CHEMBL625085,Intermediate,10116.0,,N,,A,9169,,,Rattus norvegicus,1,,2107.0,
,16435,1,BAO_0000218,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,,Liver,CHEMBL625086,Intermediate,10116.0,,N,,A,9170,,,Rattus norvegicus,1,,2107.0,
,16434,1,BAO_0000218,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,,Liver,CHEMBL625087,Intermediate,10116.0,,N,,A,9171,,,Rattus norvegicus,1,,2107.0,
,16434,1,BAO_0000218,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,,Liver,CHEMBL625088,Intermediate,10116.0,,N,,A,9172,,,Rattus norvegicus,1,,2107.0,
,16434,1,BAO_0000218,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,,Liver,CHEMBL622205,Intermediate,10116.0,,N,,A,9173,,,Rattus norvegicus,1,,2107.0,
,16435,1,BAO_0000218,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,,Liver,CHEMBL622206,Intermediate,10116.0,,N,,A,9174,,,Rattus norvegicus,1,,2107.0,
,16435,1,BAO_0000218,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,,Liver,CHEMBL622207,Intermediate,10116.0,,N,,A,9175,,,Rattus norvegicus,1,,2107.0,
,16435,1,BAO_0000218,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,,Liver,CHEMBL622366,Intermediate,10116.0,,N,,A,9176,,,Rattus norvegicus,1,,2107.0,
,16435,1,BAO_0000218,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,,Liver,CHEMBL622367,Intermediate,10116.0,,N,,A,9177,,,Rattus norvegicus,1,,2107.0,
,16435,1,BAO_0000218,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,,Liver,CHEMBL875331,Intermediate,10116.0,,N,,A,9178,,,Rattus norvegicus,1,,2107.0,
,16435,1,BAO_0000218,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,,Liver,CHEMBL622368,Intermediate,10116.0,,N,,A,9179,,,Rattus norvegicus,1,,2107.0,
,16434,1,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,,Lung,CHEMBL622369,Intermediate,10116.0,,N,,A,9180,,,Rattus norvegicus,1,,2048.0,
,16434,1,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,,Lung,CHEMBL622370,Intermediate,10116.0,,N,,A,9181,,,Rattus norvegicus,1,,2048.0,
,16434,1,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,,Lung,CHEMBL622371,Intermediate,10116.0,,N,,A,9182,,,Rattus norvegicus,1,,2048.0,
,16434,1,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,,Lung,CHEMBL622372,Intermediate,10116.0,,N,,A,9183,,,Rattus norvegicus,1,,2048.0,
,16434,1,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,,Lung,CHEMBL622373,Intermediate,10116.0,,N,,A,9184,,,Rattus norvegicus,1,,2048.0,
,16434,1,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,,Lung,CHEMBL622374,Intermediate,10116.0,,N,,A,9185,,,Rattus norvegicus,1,,2048.0,
,16434,1,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,,Lung,CHEMBL622375,Intermediate,10116.0,,N,,A,9186,,,Rattus norvegicus,1,,2048.0,
,16434,1,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,50597,,Lung,CHEMBL622376,Intermediate,10116.0,,N,,A,9187,,,Rattus norvegicus,1,,2048.0,
,16435,1,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,,Lung,CHEMBL622377,Intermediate,10116.0,,N,,A,9188,,,Rattus norvegicus,1,,2048.0,
,16435,1,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,,Lung,CHEMBL622378,Intermediate,10116.0,,N,,A,9189,,,Rattus norvegicus,1,,2048.0,
,16435,1,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,,Lung,CHEMBL622379,Intermediate,10116.0,,N,,A,9190,,,Rattus norvegicus,1,,2048.0,
,16435,1,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,,Lung,CHEMBL622380,Intermediate,10116.0,,N,,A,9191,,,Rattus norvegicus,1,,2048.0,
,16435,1,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,,Lung,CHEMBL622381,Intermediate,10116.0,,N,,A,9192,,,Rattus norvegicus,1,,2048.0,
,16435,1,BAO_0000218,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,,Lung,CHEMBL622382,Intermediate,10116.0,,N,,A,9193,,,Rattus norvegicus,1,,2048.0,
,16434,1,BAO_0000218,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,50597,,Lung,CHEMBL622383,Intermediate,10116.0,,N,,A,9194,,,Rattus norvegicus,1,,2048.0,
,6175,1,BAO_0000218,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,,Stomach,CHEMBL875332,Intermediate,10116.0,,N,,A,9195,,,Rattus norvegicus,1,,945.0,
,6175,1,BAO_0000218,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,,Stomach,CHEMBL622384,Intermediate,10116.0,,N,,A,9196,,,Rattus norvegicus,1,,945.0,
,6175,1,BAO_0000218,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,,Stomach,CHEMBL622385,Intermediate,10116.0,,N,,A,9197,,,Rattus norvegicus,1,,945.0,
,6175,1,BAO_0000218,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,,Stomach,CHEMBL622386,Intermediate,10116.0,,N,,A,9198,,,Rattus norvegicus,1,,945.0,
,10839,1,BAO_0000218,The compound was tested for the plasma binding in rat,50597,,,CHEMBL622387,Intermediate,10116.0,,N,,A,9199,,,Rattus norvegicus,1,,,
,16459,1,BAO_0000218,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",50597,,,CHEMBL622388,Intermediate,10116.0,,N,,A,9200,,,Rattus norvegicus,1,,,
,16459,1,BAO_0000218,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",50597,,,CHEMBL622389,Intermediate,10116.0,,N,,A,9201,,,Rattus norvegicus,1,,,
,16459,1,BAO_0000218,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",50597,,,CHEMBL622390,Intermediate,10116.0,,N,,A,9202,,,Rattus norvegicus,1,,,
,16459,1,BAO_0000218,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),50597,,,CHEMBL622391,Intermediate,10116.0,,N,,A,9203,,,Rattus norvegicus,1,,,
,16459,1,BAO_0000218,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),50597,,,CHEMBL622392,Intermediate,10116.0,,N,,A,9204,,,Rattus norvegicus,1,,,
,16459,1,BAO_0000218,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),50597,,,CHEMBL622393,Intermediate,10116.0,,N,,A,9205,,,Rattus norvegicus,1,,,
,3278,1,BAO_0000218,Plasma level at 2 hr after administration of the compound,50597,,,CHEMBL622394,Intermediate,10116.0,,N,,A,9206,,,Rattus norvegicus,1,,,
,3278,1,BAO_0000218,plasma level at 2 hr after administration of the compound,50597,,,CHEMBL622395,Intermediate,10116.0,,N,,A,9207,,,Rattus norvegicus,1,,,
,4684,1,BAO_0000218,Stability in rat serum measured as % recovery at 1 min,50597,,Serum,CHEMBL622396,Intermediate,10116.0,,N,,A,9208,,,Rattus norvegicus,1,,1977.0,
,4684,1,BAO_0000218,Stability in rat serum measured as % recovery at 10 min,50597,,Serum,CHEMBL624894,Intermediate,10116.0,,N,,A,9209,,,Rattus norvegicus,1,,1977.0,
,4684,1,BAO_0000218,Stability in rat serum measured as % recovery at 10 mins,50597,,Serum,CHEMBL624895,Intermediate,10116.0,,N,,A,9210,,,Rattus norvegicus,1,,1977.0,
,4684,1,BAO_0000218,Stability in rat serum measured as % recovery at 2 hr,50597,,Serum,CHEMBL624058,Intermediate,10116.0,,N,,A,9211,,,Rattus norvegicus,1,,1977.0,
,4684,1,BAO_0000218,Stability in rat serum measured as % recovery at 3 min,50597,,Serum,CHEMBL624059,Intermediate,10116.0,,N,,A,9212,,,Rattus norvegicus,1,,1977.0,
,4684,1,BAO_0000218,Stability in rat serum measured as % recovery at 3 mins,50597,,Serum,CHEMBL624060,Intermediate,10116.0,,N,,A,9213,,,Rattus norvegicus,1,,1977.0,
,4684,1,BAO_0000218,Stability in rat serum measured as % recovery at 5 min,50597,,Serum,CHEMBL624061,Intermediate,10116.0,,N,,A,9214,,,Rattus norvegicus,1,,1977.0,
,4684,1,BAO_0000218,Stability in rat serum measured as % recovery at 5 mins,50597,,Serum,CHEMBL624062,Intermediate,10116.0,,N,,A,9215,,,Rattus norvegicus,1,,1977.0,
,16456,1,BAO_0000218,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,50597,In vivo,,CHEMBL624063,Intermediate,10116.0,,N,,A,9216,,,Rattus norvegicus,1,,,
,16456,1,BAO_0000218,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,50597,In vivo,,CHEMBL624064,Intermediate,10116.0,,N,,A,9217,,,Rattus norvegicus,1,,,
,723,1,BAO_0000218,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,50597,,Plasma,CHEMBL624065,Intermediate,10116.0,,N,,A,9218,,,Rattus norvegicus,1,,1969.0,
,723,1,BAO_0000218,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,50597,,Plasma,CHEMBL624066,Intermediate,10116.0,,N,,A,9219,,,Rattus norvegicus,1,,1969.0,
,5160,1,BAO_0000218,Half life tested in mature male rat at a dose of 30 mg/kg,50597,In vivo,,CHEMBL877490,Intermediate,10116.0,,N,,A,9220,,,Rattus norvegicus,1,,,
,4709,1,BAO_0000218,Half life after intravenous administration of 1 mg/kg in rat,50597,In vivo,,CHEMBL874442,Intermediate,10116.0,,N,,A,9221,,,Rattus norvegicus,1,,,
,5633,1,BAO_0000218,Half life period after administration (30 mg/kg) in rat,50597,In vivo,,CHEMBL626890,Intermediate,10116.0,,N,,A,9222,,,Rattus norvegicus,1,,,
,5302,1,BAO_0000218,Half life period in rat after 5 mg/Kg dose,50597,In vivo,,CHEMBL626891,Intermediate,10116.0,,N,,A,9223,,,Rattus norvegicus,1,,,
,5302,1,BAO_0000218,Half life period in rat after 5 mg/kg dose,50597,In vivo,,CHEMBL626892,Intermediate,10116.0,,N,,A,9224,,,Rattus norvegicus,1,,,
,17791,1,BAO_0000218,Half life period was determined,50597,,,CHEMBL626893,Intermediate,10116.0,,N,,A,9225,,,Rattus norvegicus,1,,,
,17791,1,BAO_0000218,Half life period was evaluated in rat,50597,,,CHEMBL626894,Intermediate,10116.0,,N,,A,9226,,,Rattus norvegicus,1,,,
,17791,1,BAO_0000218,Half life period was evaluated in rat; 0.5-1.0,50597,,,CHEMBL626895,Intermediate,10116.0,,N,,A,9227,,,Rattus norvegicus,1,,,
,17791,1,BAO_0000218,Half life period was evaluated in rat; 5.9-7.5,50597,,,CHEMBL626896,Intermediate,10116.0,,N,,A,9228,,,Rattus norvegicus,1,,,
,14512,1,BAO_0000218,Half-life in rat plasma,50597,,Plasma,CHEMBL626897,Intermediate,10116.0,,N,,A,9229,,,Rattus norvegicus,1,,1969.0,
,6230,1,BAO_0000218,Half-life time in rat was determined,50597,,,CHEMBL626898,Intermediate,10116.0,,N,,A,9230,,,Rattus norvegicus,1,,,
,3364,1,BAO_0000218,Terminal half-life after iv administration to rats,50597,In vivo,,CHEMBL626899,Intermediate,10116.0,,N,,A,9231,,,Rattus norvegicus,1,,,
,6874,1,BAO_0000218,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,50597,In vivo,,CHEMBL626900,Intermediate,10116.0,,N,,A,9232,,,Rattus norvegicus,1,,,
,857,1,BAO_0000218,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,50597,,,CHEMBL626901,Intermediate,10116.0,,N,,A,9233,,,Rattus norvegicus,1,,,
,858,1,BAO_0000218,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),50597,In vivo,,CHEMBL626902,Intermediate,10116.0,,N,,A,9234,,,Rattus norvegicus,1,,,
,858,1,BAO_0000218,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),50597,In vivo,,CHEMBL626903,Intermediate,10116.0,,N,,A,9235,,,Rattus norvegicus,1,,,
,5355,1,BAO_0000218,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,50597,In vivo,,CHEMBL874443,Intermediate,10116.0,,N,,A,9236,,,Rattus norvegicus,1,,,
,5355,1,BAO_0000218,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,50597,In vivo,,CHEMBL626904,Intermediate,10116.0,,N,,A,9237,,,Rattus norvegicus,1,,,
,6305,1,BAO_0000218,Half life in rats,50597,,,CHEMBL626905,Intermediate,10116.0,,N,,A,9238,,,Rattus norvegicus,1,,,
,13501,1,BAO_0000218,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,50597,In vivo,Plasma,CHEMBL873830,Intermediate,10116.0,,N,,A,9239,,,Rattus norvegicus,1,,1969.0,
,17594,1,BAO_0000218,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,50597,In vivo,,CHEMBL626906,Intermediate,10116.0,,N,,A,9240,,,Rattus norvegicus,1,,,
,4186,1,BAO_0000218,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,50597,In vivo,Plasma,CHEMBL631076,Intermediate,10116.0,,N,,A,9241,,,Rattus norvegicus,1,,1969.0,
,2932,1,BAO_0000218,Biological half-life was measured in plasma of rats,50597,,Plasma,CHEMBL631077,Intermediate,10116.0,,N,,A,9242,,,Rattus norvegicus,1,,1969.0,
,17065,1,BAO_0000218,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,50597,In vivo,,CHEMBL631078,Intermediate,10116.0,,N,,A,9243,,,Rattus norvegicus,1,,,
,15765,1,BAO_0000218,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,50597,In vivo,,CHEMBL631079,Intermediate,10116.0,,N,,A,9244,,,Rattus norvegicus,1,,,
,2713,1,BAO_0000218,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,50597,In vivo,,CHEMBL631080,Intermediate,10116.0,,N,,A,9245,,,Rattus norvegicus,1,,,
,2661,1,BAO_0000218,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,50597,In vivo,,CHEMBL631081,Intermediate,10116.0,,N,,A,9246,,,Rattus norvegicus,1,,,
,2661,1,BAO_0000218,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,50597,In vivo,,CHEMBL631239,Intermediate,10116.0,,N,,A,9247,,,Rattus norvegicus,1,,,
,740,1,BAO_0000218,Compound was evaluated for plasma half life in rat,50597,,Plasma,CHEMBL631240,Intermediate,10116.0,,N,,A,9248,,,Rattus norvegicus,1,,1969.0,
,6597,1,BAO_0000218,AUC value at a dose of 5 mg/kg (p.o.) in rats,50597,,Plasma,CHEMBL631241,Intermediate,10116.0,,N,,A,9249,,,Rattus norvegicus,1,,1969.0,
,2959,1,BAO_0000218,AUC value after administration of 20 mg/Kg oral dose in rat,50597,,Plasma,CHEMBL631242,Intermediate,10116.0,,N,,A,9250,,,Rattus norvegicus,1,,1969.0,
,17594,1,BAO_0000218,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,50597,,Plasma,CHEMBL631243,Intermediate,10116.0,,N,,A,9251,,,Rattus norvegicus,1,,1969.0,
,17596,1,BAO_0000218,AUC0-96 after administration at 50 mg/kg,50597,,Plasma,CHEMBL874444,Intermediate,10116.0,,N,,A,9252,,,Rattus norvegicus,1,,1969.0,
,17594,1,BAO_0000218,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,50597,,Plasma,CHEMBL631244,Intermediate,10116.0,,N,,A,9253,,,Rattus norvegicus,1,,1969.0,
,3293,1,BAO_0000218,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",50597,,,CHEMBL631245,Intermediate,10116.0,,N,,A,9254,,,Rattus norvegicus,1,,,
,6757,1,BAO_0000218,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,50597,,,CHEMBL627162,Intermediate,10116.0,,N,,A,9255,,,Rattus norvegicus,1,,,
,6757,1,BAO_0000218,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,50597,,,CHEMBL627163,Intermediate,10116.0,,N,,A,9256,,,Rattus norvegicus,1,,,
,6757,1,BAO_0000218,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,50597,,,CHEMBL627164,Intermediate,10116.0,,N,,A,9257,,,Rattus norvegicus,1,,,
,5979,1,BAO_0000218,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,50597,,Kidney,CHEMBL627165,Intermediate,10116.0,,N,,A,9258,,,Rattus norvegicus,1,,2113.0,
,5979,1,BAO_0000218,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,50597,,,CHEMBL627166,Intermediate,10116.0,,N,,A,9259,,,Rattus norvegicus,1,,,
,5979,1,BAO_0000218,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,50597,,,CHEMBL627167,Intermediate,10116.0,,N,,A,9260,,,Rattus norvegicus,1,,,
,4026,1,BAO_0000218,Area under curve (AUC) at a dose of 30 mg/kg in rats,50597,,,CHEMBL627822,Intermediate,10116.0,,N,,A,9261,,,Rattus norvegicus,1,,,
,5355,1,BAO_0000218,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,50597,,,CHEMBL627823,Intermediate,10116.0,,N,,A,9262,,,Rattus norvegicus,1,,,
,5355,1,BAO_0000218,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,50597,,,CHEMBL627824,Intermediate,10116.0,,N,,A,9263,,,Rattus norvegicus,1,,,
,5355,1,BAO_0000218,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,50597,,,CHEMBL627825,Intermediate,10116.0,,N,,A,9264,,,Rattus norvegicus,1,,,
,5633,1,BAO_0000218,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,50597,,,CHEMBL627826,Intermediate,10116.0,,N,,A,9265,,,Rattus norvegicus,1,,,
,1716,1,BAO_0000218,Area under curve (Pharmacokinetic property) was determined,50597,,,CHEMBL627827,Intermediate,10116.0,,N,,A,9266,,,Rattus norvegicus,1,,,
,1716,1,BAO_0000218,Area under curve (Pharmacokinetic property) of the compound; Not determined,50597,,,CHEMBL627828,Intermediate,10116.0,,N,,A,9267,,,Rattus norvegicus,1,,,
,4689,1,BAO_0000218,Area under curve after intravenous administration (1 mg/kg) in rat,50597,,,CHEMBL627829,Intermediate,10116.0,,N,,A,9268,,,Rattus norvegicus,1,,,
,4527,1,BAO_0000218,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,50597,,,CHEMBL627830,Intermediate,10116.0,,N,,A,9269,,,Rattus norvegicus,1,,,
,4527,1,BAO_0000218,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,50597,,,CHEMBL627831,Intermediate,10116.0,,N,,A,9270,,,Rattus norvegicus,1,,,
,15662,1,BAO_0000218,Area under curve in male SD rats was observed after oral administration in rat,50597,,,CHEMBL627832,Intermediate,10116.0,,N,,A,9271,,,Rattus norvegicus,1,,,
,4413,1,BAO_0000218,Area under curve of compound after iv administration of 20 mg/kg dose in rat,50597,,,CHEMBL627833,Intermediate,10116.0,,N,,A,9272,,,Rattus norvegicus,1,,,
,3598,1,BAO_0000218,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,,,CHEMBL627834,Expert,10116.0,,N,,A,9273,,,Rattus norvegicus,1,,,
,3598,1,BAO_0000218,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,50597,,,CHEMBL628004,Expert,10116.0,,N,,A,9274,,,Rattus norvegicus,1,,,
,5964,1,BAO_0000218,Area under curve at 5 mg/kg po was determined in rat,50597,,,CHEMBL628005,Intermediate,10116.0,,N,,A,9275,,,Rattus norvegicus,1,,,
,4689,1,BAO_0000218,Area under curve in Rat at a oral dose of 5 mg/kg,50597,,,CHEMBL628006,Intermediate,10116.0,,N,,A,9276,,,Rattus norvegicus,1,,,
,4186,1,BAO_0000218,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,50597,,,CHEMBL628007,Intermediate,10116.0,,N,,A,9277,,,Rattus norvegicus,1,,,
,5510,1,BAO_0000218,Area under curve was determined,50597,,,CHEMBL625676,Intermediate,10116.0,,N,,A,9278,,,Rattus norvegicus,1,,,
,17858,1,BAO_0000218,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,50597,,,CHEMBL631309,Intermediate,10116.0,,N,,A,9279,,,Rattus norvegicus,1,,,
,17804,1,BAO_0000218,Area under curve after intravenous administration at 3 mg/kg,50597,,,CHEMBL631310,Intermediate,10116.0,,N,,A,9280,,,Rattus norvegicus,1,,,
,6106,1,BAO_0000218,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,50597,,,CHEMBL631311,Intermediate,10116.0,,N,,A,9281,,,Rattus norvegicus,1,,,
,5964,1,BAO_0000218,Area under curve at 4 hr in rat,50597,,,CHEMBL631312,Intermediate,10116.0,,N,,A,9282,,,Rattus norvegicus,1,,,
,4026,1,BAO_0000218,Area under curve at a dose of 30 mg/kg,50597,,,CHEMBL631313,Intermediate,10116.0,,N,,A,9283,,,Rattus norvegicus,1,,,
,4756,1,BAO_0000218,Area under curve at the dose of 2 mg/Kg administered perorally in rats,50597,,,CHEMBL631314,Intermediate,10116.0,,N,,A,9284,,,Rattus norvegicus,1,,,
,4756,1,BAO_0000218,Area under curve at the dose of 5 mg/Kg administered perorally in rats,50597,,,CHEMBL631315,Intermediate,10116.0,,N,,A,9285,,,Rattus norvegicus,1,,,
,5862,1,BAO_0000218,Area under curve for a 2-mpk po dose in SD rats,50597,,,CHEMBL631316,Intermediate,10116.0,,N,,A,9286,,,Rattus norvegicus,1,,,
,5862,1,BAO_0000218,Area under curve in SD rats,50597,,,CHEMBL631317,Intermediate,10116.0,,N,,A,9287,,,Rattus norvegicus,1,,,
,6644,1,BAO_0000218,Area under curve in rat after oral administration at 13 mg/kg dose,50597,,,CHEMBL874471,Intermediate,10116.0,,N,,A,9288,,,Rattus norvegicus,1,,,
,5871,1,BAO_0000218,Area under curve in rat by po administration at 0-24 hr,50597,,,CHEMBL631318,Intermediate,10116.0,,N,,A,9289,,,Rattus norvegicus,1,,,
,5919,1,BAO_0000218,Area under curve in rat plasma,50597,,Plasma,CHEMBL631319,Intermediate,10116.0,,N,,A,9290,,,Rattus norvegicus,1,,1969.0,
,5939,1,BAO_0000218,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,50597,,,CHEMBL631320,Intermediate,10116.0,,N,,A,9291,,,Rattus norvegicus,1,,,
,5939,1,BAO_0000218,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,50597,,,CHEMBL631321,Intermediate,10116.0,,N,,A,9292,,,Rattus norvegicus,1,,,
,10,1,BAO_0000218,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,50597,,,CHEMBL631322,Intermediate,10116.0,,N,,A,9293,,,Rattus norvegicus,1,,,
,11149,1,BAO_0000218,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,50597,,,CHEMBL631323,Intermediate,10116.0,,N,,A,9294,,,Rattus norvegicus,1,,,
,5302,1,BAO_0000218,Area under curve value in rat at a dose of 5 mg/kg,50597,,,CHEMBL631324,Intermediate,10116.0,,N,,A,9295,,,Rattus norvegicus,1,,,
,17796,1,BAO_0000218,Area under curve was determined after oral administration in rats,50597,,,CHEMBL631325,Intermediate,10116.0,,N,,A,9296,,,Rattus norvegicus,1,,,
,4890,1,BAO_0000218,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,50597,,,CHEMBL631326,Intermediate,10116.0,,N,,A,9297,,,Rattus norvegicus,1,,,
,6011,1,BAO_0000218,Area under curve was determined after peroral administration in rat,50597,,,CHEMBL631327,Intermediate,10116.0,,N,,A,9298,,,Rattus norvegicus,1,,,
,5375,1,BAO_0000218,Area under curve was determined at a dose 30 mpk administered orally.,50597,,,CHEMBL631328,Intermediate,10116.0,,N,,A,9299,,,Rattus norvegicus,1,,,
,17764,1,BAO_0000218,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,50597,,,CHEMBL631329,Intermediate,10116.0,,N,,A,9300,,,Rattus norvegicus,1,,,
,4368,1,BAO_0000218,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,50597,,,CHEMBL627217,Intermediate,10116.0,,N,,A,9301,,,Rattus norvegicus,1,,,
,5610,1,BAO_0000218,Area under curve was determined in male rat,50597,,,CHEMBL626352,Intermediate,10116.0,,N,,A,9302,,,Rattus norvegicus,1,,,
,5833,1,BAO_0000218,Area under curve was determined in rat after PO administration,50597,,,CHEMBL626353,Intermediate,10116.0,,N,,A,9303,,,Rattus norvegicus,1,,,
,4257,1,BAO_0000218,Area under curve was determined in rat after a 3 mg/kg of oral dose,50597,,,CHEMBL626354,Intermediate,10116.0,,N,,A,9304,,,Rattus norvegicus,1,,,
,5937,1,BAO_0000218,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,50597,,,CHEMBL626355,Intermediate,10116.0,,N,,A,9305,,,Rattus norvegicus,1,,,
,5932,1,BAO_0000218,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,50597,,,CHEMBL626356,Intermediate,10116.0,,N,,A,9306,,,Rattus norvegicus,1,,,
,5932,1,BAO_0000218,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,50597,,,CHEMBL626357,Intermediate,10116.0,,N,,A,9307,,,Rattus norvegicus,1,,,
,17411,1,BAO_0000218,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,,,CHEMBL626358,Intermediate,10116.0,,N,,A,9308,,,Rattus norvegicus,1,,,
,17411,1,BAO_0000218,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,,,CHEMBL626359,Intermediate,10116.0,,N,,A,9309,,,Rattus norvegicus,1,,,
,17771,1,BAO_0000218,Peak plasma concentration in rat at a dose of 3 mg/kg,50597,,Plasma,CHEMBL626360,Intermediate,10116.0,,N,,A,9310,,,Rattus norvegicus,1,,1969.0,
,1628,1,BAO_0000218,Plasma concentration at 2 hr in rats was evaluated.,50597,,,CHEMBL626361,Intermediate,10116.0,,N,,A,9311,,,Rattus norvegicus,1,,,
,1628,1,BAO_0000218,Plasma concentration at 2 hr in rats was evaluated; Not available,50597,,,CHEMBL626362,Intermediate,10116.0,,N,,A,9312,,,Rattus norvegicus,1,,,
,17411,1,BAO_0000218,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,,,CHEMBL626363,Intermediate,10116.0,,N,,A,9313,,,Rattus norvegicus,1,,,
,4910,1,BAO_0000218,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,50597,,,CHEMBL626970,Intermediate,10116.0,,N,,A,9314,,,Rattus norvegicus,1,,,
,4910,1,BAO_0000218,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,50597,,,CHEMBL626971,Intermediate,10116.0,,N,,A,9315,,,Rattus norvegicus,1,,,
,4910,1,BAO_0000218,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,50597,,Plasma,CHEMBL626972,Intermediate,10116.0,,N,,A,9316,,,Rattus norvegicus,1,,1969.0,
,4910,1,BAO_0000218,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,50597,,Plasma,CHEMBL626973,Intermediate,10116.0,,N,,A,9317,,,Rattus norvegicus,1,,1969.0,
,4910,1,BAO_0000218,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,50597,,Plasma,CHEMBL626974,Intermediate,10116.0,,N,,A,9318,,,Rattus norvegicus,1,,1969.0,
,4910,1,BAO_0000218,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,50597,,Plasma,CHEMBL874592,Intermediate,10116.0,,N,,A,9319,,,Rattus norvegicus,1,,1969.0,
,5510,1,BAO_0000218,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,50597,,,CHEMBL626975,Intermediate,10116.0,,N,,A,9320,,,Rattus norvegicus,1,,,
,5510,1,BAO_0000218,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,50597,,,CHEMBL626976,Intermediate,10116.0,,N,,A,9321,,,Rattus norvegicus,1,,,
,5510,1,BAO_0000218,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,50597,,,CHEMBL626977,Intermediate,10116.0,,N,,A,9322,,,Rattus norvegicus,1,,,
,5510,1,BAO_0000218,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,50597,,,CHEMBL626978,Intermediate,10116.0,,N,,A,9323,,,Rattus norvegicus,1,,,
,16427,1,BAO_0000218,PK study was carried to determine the relative absorption ranking in rat.,50597,,,CHEMBL626979,Intermediate,10116.0,,N,,A,9324,,,Rattus norvegicus,1,,,
,4689,1,BAO_0000218,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,50597,In vivo,Plasma,CHEMBL626980,Intermediate,10116.0,,N,,A,9325,,,Rattus norvegicus,1,,1969.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",50597,,Blood,CHEMBL626981,Intermediate,10116.0,,N,,A,9326,,,Rattus norvegicus,1,,178.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",50597,,Blood,CHEMBL626982,Intermediate,10116.0,,N,,A,9327,,,Rattus norvegicus,1,,178.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",50597,,Blood,CHEMBL626983,Intermediate,10116.0,,N,,A,9328,,,Rattus norvegicus,1,,178.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",50597,,Blood,CHEMBL622522,Intermediate,10116.0,,N,,A,9329,,,Rattus norvegicus,1,,178.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",50597,,Blood,CHEMBL622523,Intermediate,10116.0,,N,,A,9330,,,Rattus norvegicus,1,,178.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",50597,,Blood,CHEMBL622524,Intermediate,10116.0,,N,,A,9331,,,Rattus norvegicus,1,,178.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",50597,,Brain,CHEMBL622525,Intermediate,10116.0,,N,,A,9332,,,Rattus norvegicus,1,,955.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",50597,,Brain,CHEMBL622526,Intermediate,10116.0,,N,,A,9333,,,Rattus norvegicus,1,,955.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",50597,,Brain,CHEMBL619849,Intermediate,10116.0,,N,,A,9334,,,Rattus norvegicus,1,,955.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",50597,,Brain,CHEMBL619850,Intermediate,10116.0,,N,,A,9335,,,Rattus norvegicus,1,,955.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",50597,,Brain,CHEMBL623864,Intermediate,10116.0,,N,,A,9336,,,Rattus norvegicus,1,,955.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",50597,,Brain,CHEMBL623865,Intermediate,10116.0,,N,,A,9337,,,Rattus norvegicus,1,,955.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",50597,,Heart,CHEMBL623866,Intermediate,10116.0,,N,,A,9338,,,Rattus norvegicus,1,,948.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",50597,,Heart,CHEMBL623867,Intermediate,10116.0,,N,,A,9339,,,Rattus norvegicus,1,,948.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",50597,,Heart,CHEMBL877615,Intermediate,10116.0,,N,,A,9340,,,Rattus norvegicus,1,,948.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",50597,,Heart,CHEMBL623868,Intermediate,10116.0,,N,,A,9341,,,Rattus norvegicus,1,,948.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",50597,,Heart,CHEMBL623869,Intermediate,10116.0,,N,,A,9342,,,Rattus norvegicus,1,,948.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",50597,,Heart,CHEMBL623870,Intermediate,10116.0,,N,,A,9343,,,Rattus norvegicus,1,,948.0,
,16434,1,BAO_0000218,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,50597,,Lung,CHEMBL623871,Intermediate,10116.0,,N,,A,9344,,,Rattus norvegicus,1,,2048.0,
,16434,1,BAO_0000218,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,,Lung,CHEMBL623872,Intermediate,10116.0,,N,,A,9345,,,Rattus norvegicus,1,,2048.0,
,16435,1,BAO_0000218,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,,Lung,CHEMBL622129,Intermediate,10116.0,,N,,A,9346,,,Rattus norvegicus,1,,2048.0,
,16435,1,BAO_0000218,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,,Lung,CHEMBL622130,Intermediate,10116.0,,N,,A,9347,,,Rattus norvegicus,1,,2048.0,
,16435,1,BAO_0000218,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,,Lung,CHEMBL622131,Intermediate,10116.0,,N,,A,9348,,,Rattus norvegicus,1,,2048.0,
,16435,1,BAO_0000218,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,,Lung,CHEMBL622132,Intermediate,10116.0,,N,,A,9349,,,Rattus norvegicus,1,,2048.0,
,16435,1,BAO_0000218,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,,Lung,CHEMBL622133,Intermediate,10116.0,,N,,A,9350,,,Rattus norvegicus,1,,2048.0,
,16435,1,BAO_0000218,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,,Lung,CHEMBL622134,Intermediate,10116.0,,N,,A,9351,,,Rattus norvegicus,1,,2048.0,
,16435,1,BAO_0000218,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,,Lung,CHEMBL622135,Intermediate,10116.0,,N,,A,9352,,,Rattus norvegicus,1,,2048.0,
,16435,1,BAO_0000218,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,,Lung,CHEMBL622136,Intermediate,10116.0,,N,,A,9353,,,Rattus norvegicus,1,,2048.0,
,16434,1,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,,Muscle tissue,CHEMBL622137,Intermediate,10116.0,,N,,A,9354,,,Rattus norvegicus,1,,2385.0,
,16434,1,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,,Muscle tissue,CHEMBL622138,Intermediate,10116.0,,N,,A,9355,,,Rattus norvegicus,1,,2385.0,
,16434,1,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,,Muscle tissue,CHEMBL623017,Intermediate,10116.0,,N,,A,9356,,,Rattus norvegicus,1,,2385.0,
,16434,1,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,,Muscle tissue,CHEMBL623018,Intermediate,10116.0,,N,,A,9357,,,Rattus norvegicus,1,,2385.0,
,16434,1,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,,Muscle tissue,CHEMBL623019,Intermediate,10116.0,,N,,A,9358,,,Rattus norvegicus,1,,2385.0,
,16434,1,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,,Muscle tissue,CHEMBL623020,Intermediate,10116.0,,N,,A,9359,,,Rattus norvegicus,1,,2385.0,
,16434,1,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,50597,,Muscle tissue,CHEMBL623021,Intermediate,10116.0,,N,,A,9360,,,Rattus norvegicus,1,,2385.0,
,16434,1,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,50597,,Muscle tissue,CHEMBL623022,Intermediate,10116.0,,N,,A,9361,,,Rattus norvegicus,1,,2385.0,
,16435,1,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,,Muscle tissue,CHEMBL623023,Intermediate,10116.0,,N,,A,9362,,,Rattus norvegicus,1,,2385.0,
,16435,1,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,,Muscle tissue,CHEMBL623024,Intermediate,10116.0,,N,,A,9363,,,Rattus norvegicus,1,,2385.0,
,16435,1,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,,Muscle tissue,CHEMBL623025,Intermediate,10116.0,,N,,A,9364,,,Rattus norvegicus,1,,2385.0,
,16435,1,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,,Muscle tissue,CHEMBL620545,Intermediate,10116.0,,N,,A,9365,,,Rattus norvegicus,1,,2385.0,
,16435,1,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,,Muscle tissue,CHEMBL620546,Intermediate,10116.0,,N,,A,9366,,,Rattus norvegicus,1,,2385.0,
,16435,1,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,,Muscle tissue,CHEMBL620547,Intermediate,10116.0,,N,,A,9367,,,Rattus norvegicus,1,,2385.0,
,16435,1,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,,Muscle tissue,CHEMBL620548,Intermediate,10116.0,,N,,A,9368,,,Rattus norvegicus,1,,2385.0,
,16435,1,BAO_0000218,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,,Muscle tissue,CHEMBL620549,Intermediate,10116.0,,N,,A,9369,,,Rattus norvegicus,1,,2385.0,
,16434,1,BAO_0000218,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,,Muscle tissue,CHEMBL620550,Intermediate,10116.0,,N,,A,9370,,,Rattus norvegicus,1,,2385.0,
,16434,1,BAO_0000218,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,50597,,Muscle tissue,CHEMBL620551,Intermediate,10116.0,,N,,A,9371,,,Rattus norvegicus,1,,2385.0,
,16434,1,BAO_0000218,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,,Muscle tissue,CHEMBL620552,Intermediate,10116.0,,N,,A,9372,,,Rattus norvegicus,1,,2385.0,
,16435,1,BAO_0000218,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,,Muscle tissue,CHEMBL620553,Intermediate,10116.0,,N,,A,9373,,,Rattus norvegicus,1,,2385.0,
,16435,1,BAO_0000218,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,,Muscle tissue,CHEMBL620554,Intermediate,10116.0,,N,,A,9374,,,Rattus norvegicus,1,,2385.0,
,16435,1,BAO_0000218,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,,Muscle tissue,CHEMBL875845,Intermediate,10116.0,,N,,A,9375,,,Rattus norvegicus,1,,2385.0,
,16435,1,BAO_0000218,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,,Muscle tissue,CHEMBL620555,Intermediate,10116.0,,N,,A,9376,,,Rattus norvegicus,1,,2385.0,
,16435,1,BAO_0000218,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,,Muscle tissue,CHEMBL620556,Intermediate,10116.0,,N,,A,9377,,,Rattus norvegicus,1,,2385.0,
,16435,1,BAO_0000218,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,,Muscle tissue,CHEMBL620557,Intermediate,10116.0,,N,,A,9378,,,Rattus norvegicus,1,,2385.0,
,16434,1,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,,,CHEMBL620558,Intermediate,10116.0,,N,,A,9379,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,,,CHEMBL620559,Intermediate,10116.0,,N,,A,9380,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,,,CHEMBL622939,Intermediate,10116.0,,N,,A,9381,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,,,CHEMBL622940,Intermediate,10116.0,,N,,A,9382,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,,,CHEMBL622941,Intermediate,10116.0,,N,,A,9383,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,,,CHEMBL622942,Intermediate,10116.0,,N,,A,9384,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,,,CHEMBL622943,Intermediate,10116.0,,N,,A,9385,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,,,CHEMBL622944,Intermediate,10116.0,,N,,A,9386,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,,,CHEMBL622945,Intermediate,10116.0,,N,,A,9387,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,,,CHEMBL622946,Intermediate,10116.0,,N,,A,9388,,,Rattus norvegicus,1,,,
,3341,1,BAO_0000218,Compound was evaluated for terminal half life in rat,50597,,,CHEMBL622947,Intermediate,10116.0,,N,,A,9389,,,Rattus norvegicus,1,,,
,3634,1,BAO_0000218,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,50597,In vivo,Plasma,CHEMBL622948,Intermediate,10116.0,,N,,A,9390,,,Rattus norvegicus,1,,1969.0,
,3634,1,BAO_0000218,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,50597,In vivo,Plasma,CHEMBL622949,Intermediate,10116.0,,N,,A,9391,,,Rattus norvegicus,1,,1969.0,
,4839,1,BAO_0000218,Compound was tested for its half life in rat,50597,,,CHEMBL622950,Intermediate,10116.0,,N,,A,9392,,,Rattus norvegicus,1,,,
,5005,0,BAO_0000218,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,22224,In vivo,Plasma,CHEMBL622951,Intermediate,9544.0,,U,,A,9393,,,Macaca mulatta,1,,1969.0,
,5005,0,BAO_0000366,Compound was tested for its plasma half life in Sprague Dawley rats,22224,,Plasma,CHEMBL622952,Intermediate,10116.0,,U,,A,9394,,,Rattus norvegicus,1,,1969.0,
,5005,0,BAO_0000366,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,22224,,Plasma,CHEMBL622953,Intermediate,10116.0,,U,,A,9395,,,Rattus norvegicus,1,,1969.0,
,1094,1,BAO_0000218,Compound was tested for plasma half-life period in rat,50597,,Plasma,CHEMBL873818,Intermediate,10116.0,,N,,A,9396,,,Rattus norvegicus,1,,1969.0,
,5031,1,BAO_0000218,Elimination half life after i.v. administration of compound in rats,50597,In vivo,,CHEMBL622954,Intermediate,10116.0,,N,,A,9397,,,Rattus norvegicus,1,,,
,6518,1,BAO_0000218,Elimination half-life after IV dosing at 0.5 mg/kg in rat,50597,In vivo,,CHEMBL622955,Intermediate,10116.0,,N,,A,9398,,,Rattus norvegicus,1,,,
,6518,1,BAO_0000218,Elimination half-life after IV dosing at 1 mg/kg in rat,50597,In vivo,,CHEMBL875229,Intermediate,10116.0,,N,,A,9399,,,Rattus norvegicus,1,,,
,6518,1,BAO_0000218,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,50597,In vivo,,CHEMBL622956,Intermediate,10116.0,,N,,A,9400,,,Rattus norvegicus,1,,,
,6518,1,BAO_0000218,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,50597,In vivo,,CHEMBL622957,Intermediate,10116.0,,N,,A,9401,,,Rattus norvegicus,1,,,
,5408,1,BAO_0000218,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,50597,In vivo,Brain,CHEMBL622958,Intermediate,10116.0,,N,,A,9402,,,Rattus norvegicus,1,,955.0,
,5408,1,BAO_0000218,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,50597,In vivo,Plasma,CHEMBL622959,Intermediate,10116.0,,N,,A,9403,,,Rattus norvegicus,1,,1969.0,
,5408,1,BAO_0000218,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,50597,In vivo,Brain,CHEMBL622960,Intermediate,10116.0,,N,,A,9404,,,Rattus norvegicus,1,,955.0,
,5408,1,BAO_0000218,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,50597,In vivo,Plasma,CHEMBL622961,Intermediate,10116.0,,N,,A,9405,,,Rattus norvegicus,1,,1969.0,
,4687,1,BAO_0000218,Evaluated for the half life in rat (in vivo),50597,In vivo,,CHEMBL622962,Intermediate,10116.0,,N,,A,9406,,,Rattus norvegicus,1,,,
,6640,1,BAO_0000218,Hafl life in rat,50597,,,CHEMBL622963,Intermediate,10116.0,,N,,A,9407,,,Rattus norvegicus,1,,,
,6640,1,BAO_0000218,Hafl life rat,50597,,,CHEMBL622964,Intermediate,10116.0,,N,,A,9408,,,Rattus norvegicus,1,,,
,6641,1,BAO_0000218,Hafl life rat,50597,,,CHEMBL622965,Intermediate,10116.0,,N,,A,9409,,,Rattus norvegicus,1,,,
,6640,1,BAO_0000218,Hafl life rat; Not determined,50597,,,CHEMBL622966,Intermediate,10116.0,,N,,A,9410,,,Rattus norvegicus,1,,,
,6641,1,BAO_0000218,Hafl life rat; Not determined,50597,,,CHEMBL622967,Intermediate,10116.0,,N,,A,9411,,,Rattus norvegicus,1,,,
,17411,1,BAO_0000218,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,In vivo,Kidney,CHEMBL622968,Intermediate,10116.0,,N,,A,9412,,,Rattus norvegicus,1,,2113.0,
,17411,1,BAO_0000218,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,In vivo,Liver,CHEMBL622969,Intermediate,10116.0,,N,,A,9413,,,Rattus norvegicus,1,,2107.0,
,17411,1,BAO_0000218,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,In vivo,Lung,CHEMBL875327,Intermediate,10116.0,,N,,A,9414,,,Rattus norvegicus,1,,2048.0,
,6570,1,BAO_0000218,Half life in rat after 1 mg/kg i.v. administration,50597,In vivo,,CHEMBL628638,Intermediate,10116.0,,N,,A,9415,,,Rattus norvegicus,1,,,
,6570,1,BAO_0000218,Half life in rat after 2 mg/kg peroral administration,50597,In vivo,,CHEMBL628639,Intermediate,10116.0,,N,,A,9416,,,Rattus norvegicus,1,,,
,17411,1,BAO_0000218,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,In vivo,,CHEMBL625840,Intermediate,10116.0,,N,,A,9417,,,Rattus norvegicus,1,,,
,4722,1,BAO_0000218,Half life of 10 mg/kg oral dose determined in rats,50597,In vivo,,CHEMBL625841,Intermediate,10116.0,,N,,A,9418,,,Rattus norvegicus,1,,,
,5978,1,BAO_0000218,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,In vivo,,CHEMBL625842,Intermediate,10116.0,,N,,A,9419,,,Rattus norvegicus,1,,,
,5978,1,BAO_0000218,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,In vivo,,CHEMBL625843,Intermediate,10116.0,,N,,A,9420,,,Rattus norvegicus,1,,,
,5978,1,BAO_0000218,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,In vivo,,CHEMBL625844,Intermediate,10116.0,,N,,A,9421,,,Rattus norvegicus,1,,,
,5978,1,BAO_0000218,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,In vivo,,CHEMBL873822,Intermediate,10116.0,,N,,A,9422,,,Rattus norvegicus,1,,,
,5978,1,BAO_0000218,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,In vivo,,CHEMBL625845,Intermediate,10116.0,,N,,A,9423,,,Rattus norvegicus,1,,,
,5978,1,BAO_0000218,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,In vivo,,CHEMBL627059,Intermediate,10116.0,,N,,A,9424,,,Rattus norvegicus,1,,,
,5978,1,BAO_0000218,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,In vivo,,CHEMBL627060,Intermediate,10116.0,,N,,A,9425,,,Rattus norvegicus,1,,,
,5978,1,BAO_0000218,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,In vivo,,CHEMBL627061,Intermediate,10116.0,,N,,A,9426,,,Rattus norvegicus,1,,,
,4762,1,BAO_0000218,Half life of compound at 5 mg/kg after po administration was determined in rat,50597,In vivo,,CHEMBL627709,Intermediate,10116.0,,N,,A,9427,,,Rattus norvegicus,1,,,
,5327,1,BAO_0000218,Half life of compound determined after intravenous administration to rat,50597,In vivo,,CHEMBL627710,Intermediate,10116.0,,N,,A,9428,,,Rattus norvegicus,1,,,
,4847,1,BAO_0000218,Half life of compound was determined in rat,50597,,,CHEMBL627711,Intermediate,10116.0,,N,,A,9429,,,Rattus norvegicus,1,,,
,17720,1,BAO_0000218,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,In vivo,Plasma,CHEMBL627712,Intermediate,10116.0,,N,,A,9430,,,Rattus norvegicus,1,,1969.0,
,4723,1,BAO_0000218,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,In vivo,,CHEMBL627713,Intermediate,10116.0,,N,,A,9431,,,Rattus norvegicus,1,,,
,4723,1,BAO_0000218,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,In vivo,,CHEMBL627714,Intermediate,10116.0,,N,,A,9432,,,Rattus norvegicus,1,,,
,4256,0,BAO_0000218,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,22224,In vivo,,CHEMBL627889,Intermediate,9541.0,,U,,A,9433,,,Macaca fascicularis,1,,,
,4256,0,BAO_0000218,Half life determined in rat by intravenous administration,22224,In vivo,,CHEMBL627890,Intermediate,10116.0,,U,,A,9434,,,Rattus norvegicus,1,,,
,4722,1,BAO_0000218,Half life determined in rats after iv administration,50597,In vivo,,CHEMBL627891,Intermediate,10116.0,,N,,A,9435,,,Rattus norvegicus,1,,,
,6535,1,BAO_0000218,Half life in rat plasma after administration of 2 mg/kg iv,50597,In vivo,Plasma,CHEMBL627892,Intermediate,10116.0,,N,,A,9436,,,Rattus norvegicus,1,,1969.0,
,6535,1,BAO_0000218,Half life in rat plasma after administration of 2 mg/kg iv,50597,In vivo,Plasma,CHEMBL627893,Intermediate,10116.0,,N,,A,9437,,,Rattus norvegicus,1,,1969.0,
,1435,1,BAO_0000218,Half life in rat plasma was determined,50597,,Plasma,CHEMBL627894,Intermediate,10116.0,,N,,A,9438,,,Rattus norvegicus,1,,1969.0,
,1435,1,BAO_0000218,Half life in rat plasma was determined; NA means not applicable,50597,,Plasma,CHEMBL627895,Intermediate,10116.0,,N,,A,9439,,,Rattus norvegicus,1,,1969.0,
,5206,1,BAO_0000218,Half life in rat was tested,50597,,,CHEMBL627896,Intermediate,10116.0,,N,,A,9440,,,Rattus norvegicus,1,,,
,6080,1,BAO_0000218,Half life measured in rat plasma,50597,,Plasma,CHEMBL627897,Intermediate,10116.0,,N,,A,9441,,,Rattus norvegicus,1,,1969.0,
,4449,1,BAO_0000218,Half life recorded in rats,50597,,,CHEMBL627898,Intermediate,10116.0,,N,,A,9442,,,Rattus norvegicus,1,,,
,6057,1,BAO_0000218,Half life was calculated,50597,,,CHEMBL627899,Intermediate,10116.0,,N,,A,9443,,,Rattus norvegicus,1,,,
,6057,1,BAO_0000218,Half life was calculated in rat,50597,,,CHEMBL873823,Intermediate,10116.0,,N,,A,9444,,,Rattus norvegicus,1,,,
,3747,1,BAO_0000218,Half life was determined,50597,,,CHEMBL627900,Intermediate,10116.0,,N,,A,9445,,,Rattus norvegicus,1,,,
,17858,1,BAO_0000218,Half life after 10 mg/kg oral administration in rat,50597,In vivo,,CHEMBL627901,Intermediate,10116.0,,N,,A,9446,,,Rattus norvegicus,1,,,
,16365,1,BAO_0000218,Half life after administering orally a dose of 10 mg/kg to a fasting rat,50597,In vivo,,CHEMBL627902,Intermediate,10116.0,,N,,A,9447,,,Rattus norvegicus,1,,,
,16365,1,BAO_0000218,Half life after administering orally a dose of 30 mg/kg,50597,In vivo,,CHEMBL627903,Intermediate,10116.0,,N,,A,9448,,,Rattus norvegicus,1,,,
,5031,1,BAO_0000218,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,50597,,,CHEMBL627904,Intermediate,10116.0,,N,,A,9449,,,Rattus norvegicus,1,,,
,4722,1,BAO_0000218,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,50597,,,CHEMBL627905,Intermediate,10116.0,,N,,A,9450,,,Rattus norvegicus,1,,,
,6078,1,BAO_0000218,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,50597,,,CHEMBL627906,Intermediate,10116.0,,N,,A,9451,,,Rattus norvegicus,1,,,
,6078,1,BAO_0000218,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,50597,,,CHEMBL627907,Intermediate,10116.0,,N,,A,9452,,,Rattus norvegicus,1,,,
,6078,1,BAO_0000218,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,50597,,,CHEMBL876783,Intermediate,10116.0,,N,,A,9453,,,Rattus norvegicus,1,,,
,6078,1,BAO_0000218,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,50597,,,CHEMBL627908,Intermediate,10116.0,,N,,A,9454,,,Rattus norvegicus,1,,,
,17065,1,BAO_0000218,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,50597,,,CHEMBL627909,Intermediate,10116.0,,N,,A,9455,,,Rattus norvegicus,1,,,
,1353,1,BAO_0000218,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,50597,,,CHEMBL627910,Intermediate,10116.0,,N,,A,9456,,,Rattus norvegicus,1,,,
,1353,1,BAO_0000218,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),50597,,,CHEMBL627911,Intermediate,10116.0,,N,,A,9457,,,Rattus norvegicus,1,,,
,1353,1,BAO_0000218,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),50597,,,CHEMBL627912,Intermediate,10116.0,,N,,A,9458,,,Rattus norvegicus,1,,,
,1353,1,BAO_0000218,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),50597,,,CHEMBL627913,Intermediate,10116.0,,N,,A,9459,,,Rattus norvegicus,1,,,
,1353,1,BAO_0000218,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),50597,,,CHEMBL627914,Intermediate,10116.0,,N,,A,9460,,,Rattus norvegicus,1,,,
,16423,1,BAO_0000218,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,50597,,,CHEMBL627915,Intermediate,10116.0,,N,,A,9461,,,Rattus norvegicus,1,,,
,16423,1,BAO_0000218,Area under the curve was evaluated after 20 uM/kg of peroral administration,50597,,,CHEMBL627916,Intermediate,10116.0,,N,,A,9462,,,Rattus norvegicus,1,,,
,6062,1,BAO_0000218,Area under the curve was measured in rat after an iv dose of 1 mg/kg,50597,,,CHEMBL627917,Intermediate,10116.0,,N,,A,9463,,,Rattus norvegicus,1,,,
,6056,1,BAO_0000218,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,50597,,,CHEMBL627918,Intermediate,10116.0,,N,,A,9464,,,Rattus norvegicus,1,,,
,5182,1,BAO_0000218,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,50597,,,CHEMBL627919,Intermediate,10116.0,,N,,A,9465,,,Rattus norvegicus,1,,,
,6410,1,BAO_0000218,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,50597,,,CHEMBL627920,Intermediate,10116.0,,N,,A,9466,,,Rattus norvegicus,1,,,
,6410,1,BAO_0000218,Area under the curve was evaluated at an oral dose of 30 mg/kg,50597,,,CHEMBL627921,Intermediate,10116.0,,N,,A,9467,,,Rattus norvegicus,1,,,
,4723,1,BAO_0000218,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,,,CHEMBL627922,Intermediate,10116.0,,N,,A,9468,,,Rattus norvegicus,1,,,
,4723,1,BAO_0000218,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,,,CHEMBL876784,Intermediate,10116.0,,N,,A,9469,,,Rattus norvegicus,1,,,
,4723,1,BAO_0000218,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,,,CHEMBL627923,Intermediate,10116.0,,N,,A,9470,,,Rattus norvegicus,1,,,
,4723,1,BAO_0000218,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,,,CHEMBL626208,Intermediate,10116.0,,N,,A,9471,,,Rattus norvegicus,1,,,
,4723,1,BAO_0000218,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,,,CHEMBL626209,Intermediate,10116.0,,N,,A,9472,,,Rattus norvegicus,1,,,
,4723,1,BAO_0000218,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,,,CHEMBL626210,Intermediate,10116.0,,N,,A,9473,,,Rattus norvegicus,1,,,
,2463,1,BAO_0000218,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,50597,,Plasma,CHEMBL627994,Intermediate,10116.0,,N,,A,9474,,,Rattus norvegicus,1,,1969.0,
,4709,1,BAO_0000218,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,50597,,,CHEMBL627995,Intermediate,10116.0,,N,,A,9475,,,Rattus norvegicus,1,,,
,4075,1,BAO_0000218,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,50597,,,CHEMBL627996,Intermediate,10116.0,,N,,A,9476,,,Rattus norvegicus,1,,,
,5394,1,BAO_0000218,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,50597,,,CHEMBL627997,Intermediate,10116.0,,N,,A,9477,,,Rattus norvegicus,1,,,
,2661,1,BAO_0000218,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,50597,,,CHEMBL627998,Intermediate,10116.0,,N,,A,9478,,,Rattus norvegicus,1,,,
,2661,1,BAO_0000218,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,50597,,,CHEMBL628640,Intermediate,10116.0,,N,,A,9479,,,Rattus norvegicus,1,,,
,2661,1,BAO_0000218,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,50597,,,CHEMBL628641,Intermediate,10116.0,,N,,A,9480,,,Rattus norvegicus,1,,,
,2661,1,BAO_0000218,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,50597,,,CHEMBL628642,Intermediate,10116.0,,N,,A,9481,,,Rattus norvegicus,1,,,
,17791,1,BAO_0000218,Compound was evaluated for area under the curve expressed as (h*ug/ml),50597,,,CHEMBL628643,Intermediate,10116.0,,N,,A,9482,,,Rattus norvegicus,1,,,
,2591,1,BAO_0000218,Compound was tested for area under curve in rat,50597,,,CHEMBL628644,Intermediate,10116.0,,N,,A,9483,,,Rattus norvegicus,1,,,
,6567,1,BAO_0000218,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,50597,,,CHEMBL628645,Intermediate,10116.0,,N,,A,9484,,,Rattus norvegicus,1,,,
,6211,1,BAO_0000218,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,50597,,,CHEMBL628646,Intermediate,10116.0,,N,,A,9485,,,Rattus norvegicus,1,,,
,5529,1,BAO_0000218,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),50597,,,CHEMBL628647,Intermediate,10116.0,,N,,A,9486,,,Rattus norvegicus,1,,,
,5408,1,BAO_0000218,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,50597,,,CHEMBL628648,Intermediate,10116.0,,N,,A,9487,,,Rattus norvegicus,1,,,
,5408,1,BAO_0000218,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,50597,,,CHEMBL625358,Intermediate,10116.0,,N,,A,9488,,,Rattus norvegicus,1,,,
,5408,1,BAO_0000218,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,50597,,,CHEMBL625359,Intermediate,10116.0,,N,,A,9489,,,Rattus norvegicus,1,,,
,5408,1,BAO_0000218,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,50597,,,CHEMBL625360,Intermediate,10116.0,,N,,A,9490,,,Rattus norvegicus,1,,,
,429,1,BAO_0000218,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),50597,,,CHEMBL625361,Intermediate,10116.0,,N,,A,9491,,,Rattus norvegicus,1,,,
,429,1,BAO_0000218,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),50597,,,CHEMBL625362,Intermediate,10116.0,,N,,A,9492,,,Rattus norvegicus,1,,,
,429,1,BAO_0000218,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),50597,,,CHEMBL625363,Intermediate,10116.0,,N,,A,9493,,,Rattus norvegicus,1,,,
,4796,1,BAO_0000218,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,50597,,,CHEMBL625364,Intermediate,10116.0,,N,,A,9494,,,Rattus norvegicus,1,,,
,5974,1,BAO_0000218,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,,,CHEMBL625365,Intermediate,10116.0,,N,,A,9495,,,Rattus norvegicus,1,,,
,5974,1,BAO_0000218,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,,,CHEMBL625366,Intermediate,10116.0,,N,,A,9496,,,Rattus norvegicus,1,,,
,5974,1,BAO_0000218,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,50597,,,CHEMBL625367,Intermediate,10116.0,,N,,A,9497,,,Rattus norvegicus,1,,,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",50597,,Kidney,CHEMBL625368,Intermediate,10116.0,,N,,A,9498,,,Rattus norvegicus,1,,2113.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",50597,,Kidney,CHEMBL625369,Intermediate,10116.0,,N,,A,9499,,,Rattus norvegicus,1,,2113.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",50597,,Kidney,CHEMBL625370,Intermediate,10116.0,,N,,A,9500,,,Rattus norvegicus,1,,2113.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",50597,,Kidney,CHEMBL625371,Intermediate,10116.0,,N,,A,9501,,,Rattus norvegicus,1,,2113.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",50597,,Kidney,CHEMBL625372,Intermediate,10116.0,,N,,A,9502,,,Rattus norvegicus,1,,2113.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",50597,,Kidney,CHEMBL625373,Intermediate,10116.0,,N,,A,9503,,,Rattus norvegicus,1,,2113.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",50597,,Liver,CHEMBL625374,Intermediate,10116.0,,N,,A,9504,,,Rattus norvegicus,1,,2107.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",50597,,Liver,CHEMBL877593,Intermediate,10116.0,,N,,A,9505,,,Rattus norvegicus,1,,2107.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",50597,,Liver,CHEMBL625375,Intermediate,10116.0,,N,,A,9506,,,Rattus norvegicus,1,,2107.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",50597,,Liver,CHEMBL625376,Intermediate,10116.0,,N,,A,9507,,,Rattus norvegicus,1,,2107.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",50597,,Liver,CHEMBL621973,Intermediate,10116.0,,N,,A,9508,,,Rattus norvegicus,1,,2107.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",50597,,Liver,CHEMBL621974,Intermediate,10116.0,,N,,A,9509,,,Rattus norvegicus,1,,2107.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",50597,,Lung,CHEMBL621975,Intermediate,10116.0,,N,,A,9510,,,Rattus norvegicus,1,,2048.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",50597,,Lung,CHEMBL622166,Intermediate,10116.0,,N,,A,9511,,,Rattus norvegicus,1,,2048.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",50597,,Lung,CHEMBL622167,Intermediate,10116.0,,N,,A,9512,,,Rattus norvegicus,1,,2048.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",50597,,Lung,CHEMBL622168,Intermediate,10116.0,,N,,A,9513,,,Rattus norvegicus,1,,2048.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",50597,,Lung,CHEMBL622169,Intermediate,10116.0,,N,,A,9514,,,Rattus norvegicus,1,,2048.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",50597,,Lung,CHEMBL622170,Intermediate,10116.0,,N,,A,9515,,,Rattus norvegicus,1,,2048.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",50597,,Thyroid gland,CHEMBL622171,Intermediate,10116.0,,N,,A,9516,,,Rattus norvegicus,1,,2046.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",50597,,Thyroid gland,CHEMBL622172,Intermediate,10116.0,,N,,A,9517,,,Rattus norvegicus,1,,2046.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",50597,,Thyroid gland,CHEMBL622173,Intermediate,10116.0,,N,,A,9518,,,Rattus norvegicus,1,,2046.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",50597,,Thyroid gland,CHEMBL622174,Intermediate,10116.0,,N,,A,9519,,,Rattus norvegicus,1,,2046.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",50597,,Thyroid gland,CHEMBL622175,Intermediate,10116.0,,N,,A,9520,,,Rattus norvegicus,1,,2046.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",50597,,Thyroid gland,CHEMBL622176,Intermediate,10116.0,,N,,A,9521,,,Rattus norvegicus,1,,2046.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",50597,,Thyroid gland,CHEMBL622177,Intermediate,10116.0,,N,,A,9522,,,Rattus norvegicus,1,,2046.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",50597,,Thyroid gland,CHEMBL622178,Intermediate,10116.0,,N,,A,9523,,,Rattus norvegicus,1,,2046.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",50597,,Thyroid gland,CHEMBL622179,Intermediate,10116.0,,N,,A,9524,,,Rattus norvegicus,1,,2046.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",50597,,Thyroid gland,CHEMBL622180,Intermediate,10116.0,,N,,A,9525,,,Rattus norvegicus,1,,2046.0,
,16435,1,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,,,CHEMBL622181,Intermediate,10116.0,,N,,A,9526,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,,,CHEMBL622182,Intermediate,10116.0,,N,,A,9527,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,,,CHEMBL622183,Intermediate,10116.0,,N,,A,9528,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,,,CHEMBL622184,Intermediate,10116.0,,N,,A,9529,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,,,CHEMBL622185,Intermediate,10116.0,,N,,A,9530,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,,,CHEMBL622186,Intermediate,10116.0,,N,,A,9531,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,,,CHEMBL622187,Intermediate,10116.0,,N,,A,9532,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,50597,,,CHEMBL625002,Intermediate,10116.0,,N,,A,9533,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,50597,,,CHEMBL622090,Intermediate,10116.0,,N,,A,9534,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,,,CHEMBL622091,Intermediate,10116.0,,N,,A,9535,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,,,CHEMBL622092,Intermediate,10116.0,,N,,A,9536,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,,,CHEMBL622093,Intermediate,10116.0,,N,,A,9537,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,,,CHEMBL622094,Intermediate,10116.0,,N,,A,9538,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,,,CHEMBL622095,Intermediate,10116.0,,N,,A,9539,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,,,CHEMBL622264,Intermediate,10116.0,,N,,A,9540,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,,Spleen,CHEMBL622265,Intermediate,10116.0,,N,,A,9541,,,Rattus norvegicus,1,,2106.0,
,16434,1,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,,Spleen,CHEMBL622266,Intermediate,10116.0,,N,,A,9542,,,Rattus norvegicus,1,,2106.0,
,16434,1,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,,Spleen,CHEMBL622267,Intermediate,10116.0,,N,,A,9543,,,Rattus norvegicus,1,,2106.0,
,16434,1,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,,Spleen,CHEMBL622268,Intermediate,10116.0,,N,,A,9544,,,Rattus norvegicus,1,,2106.0,
,16434,1,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,,Spleen,CHEMBL622269,Intermediate,10116.0,,N,,A,9545,,,Rattus norvegicus,1,,2106.0,
,16434,1,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,,Spleen,CHEMBL625071,Intermediate,10116.0,,N,,A,9546,,,Rattus norvegicus,1,,2106.0,
,16434,1,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,,Spleen,CHEMBL621621,Intermediate,10116.0,,N,,A,9547,,,Rattus norvegicus,1,,2106.0,
,16434,1,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,,Spleen,CHEMBL621622,Intermediate,10116.0,,N,,A,9548,,,Rattus norvegicus,1,,2106.0,
,16435,1,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,,Spleen,CHEMBL621623,Intermediate,10116.0,,N,,A,9549,,,Rattus norvegicus,1,,2106.0,
,16435,1,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,,Spleen,CHEMBL621624,Intermediate,10116.0,,N,,A,9550,,,Rattus norvegicus,1,,2106.0,
,16435,1,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,,Spleen,CHEMBL621625,Intermediate,10116.0,,N,,A,9551,,,Rattus norvegicus,1,,2106.0,
,16435,1,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,,Spleen,CHEMBL621626,Intermediate,10116.0,,N,,A,9552,,,Rattus norvegicus,1,,2106.0,
,16435,1,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,,Spleen,CHEMBL621627,Intermediate,10116.0,,N,,A,9553,,,Rattus norvegicus,1,,2106.0,
,16435,1,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,,Spleen,CHEMBL621628,Intermediate,10116.0,,N,,A,9554,,,Rattus norvegicus,1,,2106.0,
,16435,1,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,,Spleen,CHEMBL875328,Intermediate,10116.0,,N,,A,9555,,,Rattus norvegicus,1,,2106.0,
,16435,1,BAO_0000218,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,,Spleen,CHEMBL621629,Intermediate,10116.0,,N,,A,9556,,,Rattus norvegicus,1,,2106.0,
,16434,1,BAO_0000218,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,,Spleen,CHEMBL621630,Intermediate,10116.0,,N,,A,9557,,,Rattus norvegicus,1,,2106.0,
,16434,1,BAO_0000218,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,,Spleen,CHEMBL621631,Intermediate,10116.0,,N,,A,9558,,,Rattus norvegicus,1,,2106.0,
,16434,1,BAO_0000218,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,,Spleen,CHEMBL621632,Intermediate,10116.0,,N,,A,9559,,,Rattus norvegicus,1,,2106.0,
,16435,1,BAO_0000218,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,,Spleen,CHEMBL621633,Intermediate,10116.0,,N,,A,9560,,,Rattus norvegicus,1,,2106.0,
,16435,1,BAO_0000218,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,,Spleen,CHEMBL621634,Intermediate,10116.0,,N,,A,9561,,,Rattus norvegicus,1,,2106.0,
,16435,1,BAO_0000218,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,,Spleen,CHEMBL621635,Intermediate,10116.0,,N,,A,9562,,,Rattus norvegicus,1,,2106.0,
,16435,1,BAO_0000218,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,,Spleen,CHEMBL621636,Intermediate,10116.0,,N,,A,9563,,,Rattus norvegicus,1,,2106.0,
,16435,1,BAO_0000218,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,,Spleen,CHEMBL621637,Intermediate,10116.0,,N,,A,9564,,,Rattus norvegicus,1,,2106.0,
,16435,1,BAO_0000218,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,,Spleen,CHEMBL621638,Intermediate,10116.0,,N,,A,9565,,,Rattus norvegicus,1,,2106.0,
,16434,1,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,,,CHEMBL618883,Intermediate,10116.0,,N,,A,9566,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,,,CHEMBL618884,Intermediate,10116.0,,N,,A,9567,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,,,CHEMBL628627,Intermediate,10116.0,,N,,A,9568,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,,,CHEMBL628628,Intermediate,10116.0,,N,,A,9569,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,,,CHEMBL628629,Intermediate,10116.0,,N,,A,9570,,,Rattus norvegicus,1,,,
,16365,1,BAO_0000218,Half life after administering orally a dose of 3 mg/kg,50597,In vivo,,CHEMBL628630,Intermediate,10116.0,,N,,A,9571,,,Rattus norvegicus,1,,,
,16365,1,BAO_0000218,Half life after administering orally a dose of 3 mg/kg to a fasting rat,50597,In vivo,,CHEMBL628631,Intermediate,10116.0,,N,,A,9572,,,Rattus norvegicus,1,,,
,16365,1,BAO_0000218,Half life after administering intravenously a dose of 1 mg/kg,50597,In vivo,,CHEMBL628632,Intermediate,10116.0,,N,,A,9573,,,Rattus norvegicus,1,,,
,526,1,BAO_0000218,Half life after oral dosing in rats,50597,In vivo,,CHEMBL628633,Intermediate,10116.0,,N,,A,9574,,,Rattus norvegicus,1,,,
,16365,1,BAO_0000218,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,50597,In vivo,,CHEMBL628634,Intermediate,10116.0,,N,,A,9575,,,Rattus norvegicus,1,,,
,4368,1,BAO_0000218,Half life by intravenous administration of 3.4 mg/kg in rat,50597,In vivo,,CHEMBL627789,Intermediate,10116.0,,N,,A,9576,,,Rattus norvegicus,1,,,
,3371,1,BAO_0000218,Half life in rat,50597,,,CHEMBL627790,Intermediate,10116.0,,N,,A,9577,,,Rattus norvegicus,1,,,
,6448,1,BAO_0000218,Half life in rat,50597,,,CHEMBL627791,Intermediate,10116.0,,N,,A,9578,,,Rattus norvegicus,1,,,
,6453,1,BAO_0000218,Half life in rat,50597,,,CHEMBL627792,Intermediate,10116.0,,N,,A,9579,,,Rattus norvegicus,1,,,
,4353,1,BAO_0000218,Half life in rat after intravenous administration of the compound,50597,In vivo,,CHEMBL627793,Intermediate,10116.0,,N,,A,9580,,,Rattus norvegicus,1,,,
,4353,1,BAO_0000218,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,50597,In vivo,Plasma,CHEMBL627794,Intermediate,10116.0,,N,,A,9581,,,Rattus norvegicus,1,,1969.0,
,4353,1,BAO_0000218,Half life in rat after po administration of the compound,50597,In vivo,,CHEMBL627795,Intermediate,10116.0,,N,,A,9582,,,Rattus norvegicus,1,,,
,4353,1,BAO_0000218,Half life in rat after po administration of the compound; ND means Not determined,50597,In vivo,,CHEMBL627796,Intermediate,10116.0,,N,,A,9583,,,Rattus norvegicus,1,,,
,4353,1,BAO_0000218,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,50597,In vivo,Plasma,CHEMBL875335,Intermediate,10116.0,,N,,A,9584,,,Rattus norvegicus,1,,1969.0,
,4353,1,BAO_0000218,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,50597,In vivo,Plasma,CHEMBL627797,Intermediate,10116.0,,N,,A,9585,,,Rattus norvegicus,1,,1969.0,
,5789,1,BAO_0000218,Half life in rat i.v.,50597,In vivo,,CHEMBL627798,Intermediate,10116.0,,N,,A,9586,,,Rattus norvegicus,1,,,
,17686,1,BAO_0000218,Half life in rat i.v. at 2 mg/kg concentration,50597,In vivo,,CHEMBL627799,Intermediate,10116.0,,N,,A,9587,,,Rattus norvegicus,1,,,
,6495,1,BAO_0000218,Half life in rats,50597,,,CHEMBL627800,Intermediate,10116.0,,N,,A,9588,,,Rattus norvegicus,1,,,
,484,1,BAO_0000218,Half life in rats after intravenous administration,50597,In vivo,,CHEMBL627801,Intermediate,10116.0,,N,,A,9589,,,Rattus norvegicus,1,,,
,6467,1,BAO_0000218,Half life in rats at the dose of 1.0 mpk by i.v. administration,50597,In vivo,,CHEMBL627802,Intermediate,10116.0,,N,,A,9590,,,Rattus norvegicus,1,,,
,6642,1,BAO_0000218,Half life in rat,50597,,,CHEMBL627803,Expert,10116.0,,N,,A,9591,,,Rattus norvegicus,1,,,
,16367,1,BAO_0000218,Half life was evaluated after intravenous administration to rats,50597,In vivo,,CHEMBL873820,Intermediate,10116.0,,N,,A,9592,,,Rattus norvegicus,1,,,
,1369,1,BAO_0000218,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),50597,,,CHEMBL627804,Intermediate,10116.0,,N,,A,9593,,,Rattus norvegicus,1,,,
,5472,1,BAO_0000218,Half life was evaluated in rat,50597,,,CHEMBL627805,Intermediate,10116.0,,N,,A,9594,,,Rattus norvegicus,1,,,
,6049,1,BAO_0000218,Half life was evaluated in rat,50597,,,CHEMBL627806,Intermediate,10116.0,,N,,A,9595,,,Rattus norvegicus,1,,,
,5472,1,BAO_0000218,Half life was evaluated in rat; Not tested,50597,,,CHEMBL627107,Intermediate,10116.0,,N,,A,9596,,,Rattus norvegicus,1,,,
,16366,1,BAO_0000218,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,50597,In vivo,,CHEMBL627108,Intermediate,10116.0,,N,,A,9597,,,Rattus norvegicus,1,,,
,11149,1,BAO_0000218,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,50597,In vivo,,CHEMBL627109,Intermediate,10116.0,,N,,A,9598,,,Rattus norvegicus,1,,,
,11149,1,BAO_0000218,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,50597,In vivo,Blood,CHEMBL627110,Intermediate,10116.0,,N,,A,9599,,,Rattus norvegicus,1,,178.0,
,2891,0,BAO_0000218,Half life was measured in monkey at dose of 10 mg/kg by po administration,22224,In vivo,,CHEMBL627111,Intermediate,9443.0,,U,,A,9600,,,Primates,1,,,
,2891,0,BAO_0000218,Half life was measured in monkey at dose of 10 mg/kg by po administration,22224,In vivo,,CHEMBL627112,Intermediate,9443.0,,U,,A,9601,,,Primates,1,,,
,2891,0,BAO_0000218,Half life was measured in rat at dose of 30 mg/kg by iv administration,22224,In vivo,,CHEMBL627113,Intermediate,10116.0,,U,,A,9602,,,Rattus norvegicus,1,,,
,2891,0,BAO_0000218,Half life was measured in rat at dose of 30 mg/kg by po administration,22224,In vivo,,CHEMBL627114,Intermediate,10116.0,,U,,A,9603,,,Rattus norvegicus,1,,,
,4026,1,BAO_0000218,Half life (t1/2) was determined,50597,,,CHEMBL627115,Intermediate,10116.0,,N,,A,9604,,,Rattus norvegicus,1,,,
,4527,1,BAO_0000218,Half life period at a dose of 10 uM/kg in rat was determined,50597,,,CHEMBL627116,Intermediate,10116.0,,N,,A,9605,,,Rattus norvegicus,1,,,
,4527,1,BAO_0000218,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,50597,In vivo,,CHEMBL627117,Intermediate,10116.0,,N,,A,9606,,,Rattus norvegicus,1,,,
,5503,1,BAO_0000218,Half life period was determined,50597,,,CHEMBL627118,Intermediate,10116.0,,N,,A,9607,,,Rattus norvegicus,1,,,
,4426,1,BAO_0000218,Half life period after intravenous administration at 20 mpk in rats,50597,In vivo,,CHEMBL627119,Intermediate,10116.0,,N,,A,9608,,,Rattus norvegicus,1,,,
,4426,1,BAO_0000218,Half life period after intravenous administration at 20 mpk in rats; Not performed.,50597,In vivo,,CHEMBL627120,Intermediate,10116.0,,N,,A,9609,,,Rattus norvegicus,1,,,
,6109,1,BAO_0000218,Half life period after intravenous administration in rat,50597,In vivo,,CHEMBL626922,Intermediate,10116.0,,N,,A,9610,,,Rattus norvegicus,1,,,
,5654,1,BAO_0000218,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,50597,In vivo,,CHEMBL626923,Intermediate,10116.0,,N,,A,9611,,,Rattus norvegicus,1,,,
,5654,1,BAO_0000218,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,50597,In vivo,,CHEMBL626924,Intermediate,10116.0,,N,,A,9612,,,Rattus norvegicus,1,,,
,4755,1,BAO_0000218,Half life period in 80% rat plasma at 37 degree Centigrade,50597,,Plasma,CHEMBL626925,Intermediate,10116.0,,N,,A,9613,,,Rattus norvegicus,1,,1969.0,
,5862,1,BAO_0000218,Half life period in SD rats,50597,,,CHEMBL626926,Intermediate,10116.0,,N,,A,9614,,,Rattus norvegicus,1,,,
,1515,1,BAO_0000218,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),50597,,Plasma,CHEMBL626927,Intermediate,10116.0,,N,,A,9615,,,Rattus norvegicus,1,,1969.0,
,1515,1,BAO_0000218,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),50597,,Plasma,CHEMBL626928,Intermediate,10116.0,,N,,A,9616,,,Rattus norvegicus,1,,1969.0,
,1515,1,BAO_0000218,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,50597,,Plasma,CHEMBL626929,Intermediate,10116.0,,N,,A,9617,,,Rattus norvegicus,1,,1969.0,
,1515,1,BAO_0000218,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,50597,,Plasma,CHEMBL626930,Intermediate,10116.0,,N,,A,9618,,,Rattus norvegicus,1,,1969.0,
,5960,1,BAO_0000218,Half life period in rat,50597,,,CHEMBL626931,Intermediate,10116.0,,N,,A,9619,,,Rattus norvegicus,1,,,
,6103,1,BAO_0000218,Half life period in rat,50597,,,CHEMBL626932,Intermediate,10116.0,,N,,A,9620,,,Rattus norvegicus,1,,,
,6317,1,BAO_0000218,Half life period in rat,50597,,,CHEMBL626933,Intermediate,10116.0,,N,,A,9621,,,Rattus norvegicus,1,,,
,6644,1,BAO_0000218,Half life period in rat after oral administration at 10.5 mg/kg dose,50597,In vivo,,CHEMBL873826,Intermediate,10116.0,,N,,A,9622,,,Rattus norvegicus,1,,,
,6644,1,BAO_0000218,Half life period in rat after oral administration at 11.2 mg/kg dose,50597,In vivo,,CHEMBL626934,Intermediate,10116.0,,N,,A,9623,,,Rattus norvegicus,1,,,
,6644,1,BAO_0000218,Half life period in rat after oral administration at 13 mg/kg dose,50597,In vivo,,CHEMBL626935,Intermediate,10116.0,,N,,A,9624,,,Rattus norvegicus,1,,,
,6644,1,BAO_0000218,Half life period in rat after oral administration at 9.7 mg/kg dose,50597,In vivo,,CHEMBL626936,Intermediate,10116.0,,N,,A,9625,,,Rattus norvegicus,1,,,
,5974,1,BAO_0000218,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,,,CHEMBL626937,Intermediate,10116.0,,N,,A,9626,,,Rattus norvegicus,1,,,
,6295,1,BAO_0000218,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,50597,,,CHEMBL625906,Intermediate,10116.0,,N,,A,9627,,,Rattus norvegicus,1,,,
,6296,1,BAO_0000218,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,50597,,,CHEMBL625907,Intermediate,10116.0,,N,,A,9628,,,Rattus norvegicus,1,,,
,16427,1,BAO_0000218,PK study was carried to determine AUC (area under curve) value in rat,50597,,,CHEMBL625908,Intermediate,10116.0,,N,,A,9629,,,Rattus norvegicus,1,,,
,16367,1,BAO_0000218,Pharmacokinetic parameter AUC after intravenous administration to rats,50597,,,CHEMBL625909,Intermediate,10116.0,,N,,A,9630,,,Rattus norvegicus,1,,,
,16367,1,BAO_0000218,Pharmacokinetic parameter AUC after oral administration to rats,50597,,,CHEMBL625910,Intermediate,10116.0,,N,,A,9631,,,Rattus norvegicus,1,,,
,16365,1,BAO_0000218,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,50597,,,CHEMBL625911,Intermediate,10116.0,,N,,A,9632,,,Rattus norvegicus,1,,,
,16365,1,BAO_0000218,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,50597,,,CHEMBL625912,Intermediate,10116.0,,N,,A,9633,,,Rattus norvegicus,1,,,
,16365,1,BAO_0000218,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,50597,,,CHEMBL626538,Intermediate,10116.0,,N,,A,9634,,,Rattus norvegicus,1,,,
,16365,1,BAO_0000218,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,50597,,,CHEMBL876794,Intermediate,10116.0,,N,,A,9635,,,Rattus norvegicus,1,,,
,16365,1,BAO_0000218,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,50597,,,CHEMBL626539,Intermediate,10116.0,,N,,A,9636,,,Rattus norvegicus,1,,,
,16365,1,BAO_0000218,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,50597,,,CHEMBL626540,Intermediate,10116.0,,N,,A,9637,,,Rattus norvegicus,1,,,
,5394,1,BAO_0000218,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,50597,,,CHEMBL626541,Intermediate,10116.0,,N,,A,9638,,,Rattus norvegicus,1,,,
,5394,1,BAO_0000218,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,50597,,,CHEMBL626542,Intermediate,10116.0,,N,,A,9639,,,Rattus norvegicus,1,,,
,2792,1,BAO_0000218,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,50597,,,CHEMBL626543,Intermediate,10116.0,,N,,A,9640,,,Rattus norvegicus,1,,,
,2792,1,BAO_0000218,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,50597,,,CHEMBL626544,Intermediate,10116.0,,N,,A,9641,,,Rattus norvegicus,1,,,
,2792,1,BAO_0000218,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,50597,,,CHEMBL626545,Intermediate,10116.0,,N,,A,9642,,,Rattus norvegicus,1,,,
,2792,1,BAO_0000218,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,50597,,,CHEMBL626546,Intermediate,10116.0,,N,,A,9643,,,Rattus norvegicus,1,,,
,5334,1,BAO_0000218,Pharmacokinetic parameter area under curve was reported,50597,,,CHEMBL626547,Intermediate,10116.0,,N,,A,9644,,,Rattus norvegicus,1,,,
,4408,1,BAO_0000218,Pharmacokinetic property (AUC) in rat,50597,,,CHEMBL626548,Intermediate,10116.0,,N,,A,9645,,,Rattus norvegicus,1,,,
,5983,1,BAO_0000218,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,50597,,,CHEMBL626549,Intermediate,10116.0,,N,,A,9646,,,Rattus norvegicus,1,,,
,4397,1,BAO_0000218,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,50597,,,CHEMBL626550,Intermediate,10116.0,,N,,A,9647,,,Rattus norvegicus,1,,,
,4397,1,BAO_0000218,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,50597,,,CHEMBL626551,Intermediate,10116.0,,N,,A,9648,,,Rattus norvegicus,1,,,
,5491,1,BAO_0000218,Pharmacokinetic property was determined,50597,,,CHEMBL623777,Intermediate,10116.0,,N,,A,9649,,,Rattus norvegicus,1,,,
,5491,1,BAO_0000218,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,50597,,,CHEMBL623778,Intermediate,10116.0,,N,,A,9650,,,Rattus norvegicus,1,,,
,5491,1,BAO_0000218,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,50597,,,CHEMBL623779,Intermediate,10116.0,,N,,A,9651,,,Rattus norvegicus,1,,,
,4199,1,BAO_0000218,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,50597,,Plasma,CHEMBL623780,Intermediate,10116.0,,N,,A,9652,,,Rattus norvegicus,1,,1969.0,
,4199,1,BAO_0000218,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,50597,,Plasma,CHEMBL622015,Intermediate,10116.0,,N,,A,9653,,,Rattus norvegicus,1,,1969.0,
,4199,1,BAO_0000218,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,50597,,Plasma,CHEMBL622016,Intermediate,10116.0,,N,,A,9654,,,Rattus norvegicus,1,,1969.0,
,5173,1,BAO_0000218,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",50597,,,CHEMBL622017,Intermediate,10116.0,,N,,A,9655,,,Rattus norvegicus,1,,,
,5173,1,BAO_0000218,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",50597,,,CHEMBL622018,Intermediate,10116.0,,N,,A,9656,,,Rattus norvegicus,1,,,
,5173,1,BAO_0000218,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",50597,,,CHEMBL622019,Intermediate,10116.0,,N,,A,9657,,,Rattus norvegicus,1,,,
,5173,1,BAO_0000218,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",50597,,,CHEMBL622020,Intermediate,10116.0,,N,,A,9658,,,Rattus norvegicus,1,,,
,16366,1,BAO_0000218,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,50597,,,CHEMBL622021,Intermediate,10116.0,,N,,A,9659,,,Rattus norvegicus,1,,,
,16366,1,BAO_0000218,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,50597,,,CHEMBL622022,Intermediate,10116.0,,N,,A,9660,,,Rattus norvegicus,1,,,
,5327,1,BAO_0000218,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,50597,,,CHEMBL622023,Intermediate,10116.0,,N,,A,9661,,,Rattus norvegicus,1,,,
,6681,1,BAO_0000218,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,50597,,,CHEMBL622024,Intermediate,10116.0,,N,,A,9662,,,Rattus norvegicus,1,,,
,12873,1,BAO_0000218,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),50597,,,CHEMBL622693,Intermediate,10116.0,,N,,A,9663,,,Rattus norvegicus,1,,,
,12873,1,BAO_0000218,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),50597,,,CHEMBL622694,Intermediate,10116.0,,N,,A,9664,,,Rattus norvegicus,1,,,
,6685,1,BAO_0000218,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",50597,,,CHEMBL622695,Intermediate,10116.0,,N,,A,9665,,,Rattus norvegicus,1,,,
,6685,1,BAO_0000218,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",50597,,,CHEMBL622696,Intermediate,10116.0,,N,,A,9666,,,Rattus norvegicus,1,,,
,6685,1,BAO_0000218,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",50597,,,CHEMBL622697,Intermediate,10116.0,,N,,A,9667,,,Rattus norvegicus,1,,,
,6619,1,BAO_0000218,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",50597,,,CHEMBL622874,Intermediate,10116.0,,N,,A,9668,,,Rattus norvegicus,1,,,
,6619,1,BAO_0000218,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",50597,,,CHEMBL622875,Intermediate,10116.0,,N,,A,9669,,,Rattus norvegicus,1,,,
,10363,1,BAO_0000218,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,50597,,,CHEMBL622876,Intermediate,10116.0,,N,,A,9670,,,Rattus norvegicus,1,,,
,4796,1,BAO_0000218,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,50597,,,CHEMBL622877,Intermediate,10116.0,,N,,A,9671,,,Rattus norvegicus,1,,,
,4910,1,BAO_0000218,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,50597,,,CHEMBL622878,Intermediate,10116.0,,N,,A,9672,,,Rattus norvegicus,1,,,
,4910,1,BAO_0000218,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,50597,,Plasma,CHEMBL622879,Intermediate,10116.0,,N,,A,9673,,,Rattus norvegicus,1,,1969.0,
,4839,1,BAO_0000218,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,50597,,,CHEMBL877602,Intermediate,10116.0,,N,,A,9674,,,Rattus norvegicus,1,,,
,15078,1,BAO_0000218,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",50597,,,CHEMBL622880,Intermediate,10116.0,,N,,A,9675,,,Rattus norvegicus,1,,,
,15078,1,BAO_0000218,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",50597,,,CHEMBL622881,Intermediate,10116.0,,N,,A,9676,,,Rattus norvegicus,1,,,
,15078,1,BAO_0000218,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",50597,,,CHEMBL622882,Intermediate,10116.0,,N,,A,9677,,,Rattus norvegicus,1,,,
,15078,1,BAO_0000218,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",50597,,,CHEMBL622883,Intermediate,10116.0,,N,,A,9678,,,Rattus norvegicus,1,,,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",50597,,Thyroid gland,CHEMBL622884,Intermediate,10116.0,,N,,A,9679,,,Rattus norvegicus,1,,2046.0,
,11450,1,BAO_0000218,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",50597,,Thyroid gland,CHEMBL622885,Intermediate,10116.0,,N,,A,9680,,,Rattus norvegicus,1,,2046.0,
,8151,1,BAO_0000218,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,50597,,,CHEMBL622886,Intermediate,10116.0,,N,,A,9681,,,Rattus norvegicus,1,,,
,8151,1,BAO_0000218,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,50597,,,CHEMBL622887,Intermediate,10116.0,,N,,A,9682,,,Rattus norvegicus,1,,,
,8151,1,BAO_0000218,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,50597,,Urine,CHEMBL622888,Intermediate,10116.0,,N,,A,9683,,,Rattus norvegicus,1,,1088.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,In vivo,Blood,CHEMBL622889,Intermediate,10116.0,,N,,A,9684,,,Rattus norvegicus,1,,178.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,In vivo,Blood,CHEMBL622890,Intermediate,10116.0,,N,,A,9685,,,Rattus norvegicus,1,,178.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,In vivo,Blood,CHEMBL622891,Intermediate,10116.0,,N,,A,9686,,,Rattus norvegicus,1,,178.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,In vivo,Blood,CHEMBL877603,Intermediate,10116.0,,N,,A,9687,,,Rattus norvegicus,1,,178.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,In vivo,Brain,CHEMBL622892,Intermediate,10116.0,,N,,A,9688,,,Rattus norvegicus,1,,955.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,In vivo,Brain,CHEMBL622893,Intermediate,10116.0,,N,,A,9689,,,Rattus norvegicus,1,,955.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,In vivo,Brain,CHEMBL622894,Intermediate,10116.0,,N,,A,9690,,,Rattus norvegicus,1,,955.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,In vivo,Brain,CHEMBL622895,Intermediate,10116.0,,N,,A,9691,,,Rattus norvegicus,1,,955.0,
,8677,1,BAO_0000218,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,50597,In vivo,Brain,CHEMBL622896,Intermediate,10116.0,,N,,A,9692,,,Rattus norvegicus,1,,955.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,In vivo,Heart,CHEMBL622897,Intermediate,10116.0,,N,,A,9693,,,Rattus norvegicus,1,,948.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,In vivo,Heart,CHEMBL622898,Intermediate,10116.0,,N,,A,9694,,,Rattus norvegicus,1,,948.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,In vivo,Heart,CHEMBL622899,Intermediate,10116.0,,N,,A,9695,,,Rattus norvegicus,1,,948.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,In vivo,Kidney,CHEMBL622900,Intermediate,10116.0,,N,,A,9696,,,Rattus norvegicus,1,,2113.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,In vivo,Kidney,CHEMBL624114,Intermediate,10116.0,,N,,A,9697,,,Rattus norvegicus,1,,2113.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,In vivo,Kidney,CHEMBL624115,Intermediate,10116.0,,N,,A,9698,,,Rattus norvegicus,1,,2113.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,In vivo,Kidney,CHEMBL624116,Intermediate,10116.0,,N,,A,9699,,,Rattus norvegicus,1,,2113.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,In vivo,Liver,CHEMBL624117,Intermediate,10116.0,,N,,A,9700,,,Rattus norvegicus,1,,2107.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,In vivo,Liver,CHEMBL624118,Intermediate,10116.0,,N,,A,9701,,,Rattus norvegicus,1,,2107.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,In vivo,Liver,CHEMBL624119,Intermediate,10116.0,,N,,A,9702,,,Rattus norvegicus,1,,2107.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,In vivo,Liver,CHEMBL624120,Intermediate,10116.0,,N,,A,9703,,,Rattus norvegicus,1,,2107.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,In vivo,Lung,CHEMBL624121,Intermediate,10116.0,,N,,A,9704,,,Rattus norvegicus,1,,2048.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,In vivo,Lung,CHEMBL624122,Intermediate,10116.0,,N,,A,9705,,,Rattus norvegicus,1,,2048.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,In vivo,Lung,CHEMBL624123,Intermediate,10116.0,,N,,A,9706,,,Rattus norvegicus,1,,2048.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,In vivo,Lung,CHEMBL624124,Intermediate,10116.0,,N,,A,9707,,,Rattus norvegicus,1,,2048.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,In vivo,Muscle tissue,CHEMBL624125,Intermediate,10116.0,,N,,A,9708,,,Rattus norvegicus,1,,2385.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,In vivo,Muscle tissue,CHEMBL624126,Intermediate,10116.0,,N,,A,9709,,,Rattus norvegicus,1,,2385.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,In vivo,Muscle tissue,CHEMBL624127,Intermediate,10116.0,,N,,A,9710,,,Rattus norvegicus,1,,2385.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,In vivo,Muscle tissue,CHEMBL624128,Intermediate,10116.0,,N,,A,9711,,,Rattus norvegicus,1,,2385.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,In vivo,Zone of skin,CHEMBL624129,Intermediate,10116.0,,N,,A,9712,,,Rattus norvegicus,1,,14.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,In vivo,Zone of skin,CHEMBL624130,Intermediate,10116.0,,N,,A,9713,,,Rattus norvegicus,1,,14.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,In vivo,Zone of skin,CHEMBL622340,Intermediate,10116.0,,N,,A,9714,,,Rattus norvegicus,1,,14.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,In vivo,Zone of skin,CHEMBL622341,Intermediate,10116.0,,N,,A,9715,,,Rattus norvegicus,1,,14.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,In vivo,Intestine,CHEMBL622342,Intermediate,10116.0,,N,,A,9716,,,Rattus norvegicus,1,,160.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,In vivo,Intestine,CHEMBL622343,Intermediate,10116.0,,N,,A,9717,,,Rattus norvegicus,1,,160.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,In vivo,Intestine,CHEMBL622344,Intermediate,10116.0,,N,,A,9718,,,Rattus norvegicus,1,,160.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,In vivo,Intestine,CHEMBL622345,Intermediate,10116.0,,N,,A,9719,,,Rattus norvegicus,1,,160.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,In vivo,Spleen,CHEMBL622346,Intermediate,10116.0,,N,,A,9720,,,Rattus norvegicus,1,,2106.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,In vivo,Spleen,CHEMBL622347,Intermediate,10116.0,,N,,A,9721,,,Rattus norvegicus,1,,2106.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,In vivo,Spleen,CHEMBL622348,Intermediate,10116.0,,N,,A,9722,,,Rattus norvegicus,1,,2106.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,In vivo,Spleen,CHEMBL622349,Intermediate,10116.0,,N,,A,9723,,,Rattus norvegicus,1,,2106.0,
,16434,1,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,,,CHEMBL622350,Intermediate,10116.0,,N,,A,9724,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,,,CHEMBL622351,Intermediate,10116.0,,N,,A,9725,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,,,CHEMBL622352,Intermediate,10116.0,,N,,A,9726,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,,,CHEMBL622353,Intermediate,10116.0,,N,,A,9727,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,,,CHEMBL622354,Intermediate,10116.0,,N,,A,9728,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,,,CHEMBL622355,Intermediate,10116.0,,N,,A,9729,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,,,CHEMBL622356,Intermediate,10116.0,,N,,A,9730,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,,,CHEMBL622357,Intermediate,10116.0,,N,,A,9731,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,,,CHEMBL622358,Intermediate,10116.0,,N,,A,9732,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,,,CHEMBL622359,Intermediate,10116.0,,N,,A,9733,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,,,CHEMBL874393,Intermediate,10116.0,,N,,A,9734,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,,,CHEMBL622872,Intermediate,10116.0,,N,,A,9735,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,,,CHEMBL622873,Intermediate,10116.0,,N,,A,9736,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,,,CHEMBL623047,Intermediate,10116.0,,N,,A,9737,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,,,CHEMBL623048,Intermediate,10116.0,,N,,A,9738,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,,,CHEMBL623049,Intermediate,10116.0,,N,,A,9739,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,,,CHEMBL623050,Intermediate,10116.0,,N,,A,9740,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,,,CHEMBL623051,Intermediate,10116.0,,N,,A,9741,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,,,CHEMBL623052,Intermediate,10116.0,,N,,A,9742,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,,,CHEMBL626343,Intermediate,10116.0,,N,,A,9743,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,,,CHEMBL626344,Intermediate,10116.0,,N,,A,9744,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,,,CHEMBL626345,Intermediate,10116.0,,N,,A,9745,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,,,CHEMBL626346,Intermediate,10116.0,,N,,A,9746,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,,,CHEMBL626347,Intermediate,10116.0,,N,,A,9747,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,,,CHEMBL626348,Intermediate,10116.0,,N,,A,9748,,,Rattus norvegicus,1,,,
,16434,1,BAO_0000218,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,,,CHEMBL626349,Intermediate,10116.0,,N,,A,9749,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,,,CHEMBL626350,Intermediate,10116.0,,N,,F,9750,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,,,CHEMBL626351,Intermediate,10116.0,,N,,A,9751,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,,,CHEMBL627650,Intermediate,10116.0,,N,,A,9752,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,,,CHEMBL627651,Intermediate,10116.0,,N,,F,9753,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,,,CHEMBL627652,Intermediate,10116.0,,N,,A,9754,,,Rattus norvegicus,1,,,
,16435,1,BAO_0000218,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,,,CHEMBL627653,Intermediate,10116.0,,N,,A,9755,,,Rattus norvegicus,1,,,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,50597,,,CHEMBL627654,Intermediate,10116.0,,N,,A,9756,,,Rattus norvegicus,1,,,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,50597,,,CHEMBL627835,Intermediate,10116.0,,N,,A,9757,,,Rattus norvegicus,1,,,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,50597,,,CHEMBL627836,Intermediate,10116.0,,N,,A,9758,,,Rattus norvegicus,1,,,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,50597,,,CHEMBL627837,Intermediate,10116.0,,N,,A,9759,,,Rattus norvegicus,1,,,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,50597,,,CHEMBL627838,Intermediate,10116.0,,N,,A,9760,,,Rattus norvegicus,1,,,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,50597,,,CHEMBL875338,Intermediate,10116.0,,N,,A,9761,,,Rattus norvegicus,1,,,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,50597,,,CHEMBL627839,Intermediate,10116.0,,N,,A,9762,,,Rattus norvegicus,1,,,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,50597,,,CHEMBL627840,Intermediate,10116.0,,N,,A,9763,,,Rattus norvegicus,1,,,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,50597,,,CHEMBL627841,Intermediate,10116.0,,N,,A,9764,,,Rattus norvegicus,1,,,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,50597,,,CHEMBL627842,Intermediate,10116.0,,N,,A,9765,,,Rattus norvegicus,1,,,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,50597,,,CHEMBL627843,Intermediate,10116.0,,N,,A,9766,,,Rattus norvegicus,1,,,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,50597,,,CHEMBL627844,Intermediate,10116.0,,N,,A,9767,,,Rattus norvegicus,1,,,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,50597,,,CHEMBL627845,Intermediate,10116.0,,N,,A,9768,,,Rattus norvegicus,1,,,
,5874,1,BAO_0000218,Half life period in rat by iv administration at a dose of 3 mg/kg,50597,In vivo,,CHEMBL627846,Intermediate,10116.0,,N,,A,9769,,,Rattus norvegicus,1,,,
,1515,1,BAO_0000218,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),50597,,Plasma,CHEMBL627847,Intermediate,10116.0,,N,,A,9770,,,Rattus norvegicus,1,,1969.0,
,1515,1,BAO_0000218,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),50597,,Plasma,CHEMBL873821,Intermediate,10116.0,,N,,A,9771,,,Rattus norvegicus,1,,1969.0,
,1515,1,BAO_0000218,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,50597,,Plasma,CHEMBL626079,Intermediate,10116.0,,N,,A,9772,,,Rattus norvegicus,1,,1969.0,
,1515,1,BAO_0000218,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,50597,,Plasma,CHEMBL626080,Intermediate,10116.0,,N,,A,9773,,,Rattus norvegicus,1,,1969.0,
,5491,1,BAO_0000218,Half life period was evaluated in rat plasma,50597,,Plasma,CHEMBL626081,Intermediate,10116.0,,N,,A,9774,,,Rattus norvegicus,1,,1969.0,
,5491,1,BAO_0000218,Half life period was evaluated in rat plasma; Not tested,50597,,Plasma,CHEMBL875344,Intermediate,10116.0,,N,,A,9775,,,Rattus norvegicus,1,,1969.0,
,1918,1,BAO_0000218,Half life period was evaluated in rats,50597,,,CHEMBL626082,Intermediate,10116.0,,N,,A,9776,,,Rattus norvegicus,1,,,
,1918,1,BAO_0000218,"Half life period was evaluated in rats, iv",50597,In vivo,,CHEMBL626250,Intermediate,10116.0,,N,,A,9777,,,Rattus norvegicus,1,,,
,6113,1,BAO_0000218,Half life period after intravenous administration at 5 mg/kg in rat,50597,In vivo,,CHEMBL626251,Intermediate,10116.0,,N,,A,9778,,,Rattus norvegicus,1,,,
,5546,1,BAO_0000218,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,50597,In vivo,,CHEMBL626252,Intermediate,10116.0,,N,,A,9779,,,Rattus norvegicus,1,,,
,5553,1,BAO_0000218,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,50597,In vivo,,CHEMBL626253,Intermediate,10116.0,,N,,A,9780,,,Rattus norvegicus,1,,,
,4188,1,BAO_0000218,Half life stability of compound was evaluated in rat plasma,50597,,Plasma,CHEMBL626254,Intermediate,10116.0,,N,,A,9781,,,Rattus norvegicus,1,,1969.0,
,6215,1,BAO_0000218,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,50597,In vivo,,CHEMBL626255,Intermediate,10116.0,,N,,A,9782,,,Rattus norvegicus,1,,,
,6141,1,BAO_0000218,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,50597,In vivo,,CHEMBL626256,Intermediate,10116.0,,N,,A,9783,,,Rattus norvegicus,1,,,
,5182,1,BAO_0000218,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,50597,In vivo,,CHEMBL626257,Intermediate,10116.0,,N,,A,9784,,,Rattus norvegicus,1,,,
,5182,1,BAO_0000218,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,50597,In vivo,,CHEMBL626258,Intermediate,10116.0,,N,,A,9785,,,Rattus norvegicus,1,,,
,5710,1,BAO_0000218,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,50597,In vivo,,CHEMBL626259,Intermediate,10116.0,,N,,A,9786,,,Rattus norvegicus,1,,,
,5789,1,BAO_0000218,Half in rat i.v.,50597,In vivo,,CHEMBL626260,Intermediate,10116.0,,N,,A,9787,,,Rattus norvegicus,1,,,
,6011,1,BAO_0000218,Half period in rat after intravenous administration,50597,In vivo,,CHEMBL875345,Intermediate,10116.0,,N,,A,9788,,,Rattus norvegicus,1,,,
,17594,1,BAO_0000218,Half-life after repeated oral dose of compound at 1 mg/kg in rats,50597,In vivo,,CHEMBL626261,Intermediate,10116.0,,N,,A,9789,,,Rattus norvegicus,1,,,
,12357,1,BAO_0000218,Half-life measured in in vitro Cathepsin B assay in rat liver,50597,In vitro,Liver,CHEMBL626262,Intermediate,10116.0,,N,,A,9790,,,Rattus norvegicus,1,,2107.0,
,5210,1,BAO_0000218,Half-life of compound was determined in rats,50597,,,CHEMBL626263,Intermediate,10116.0,,N,,A,9791,,,Rattus norvegicus,1,,,
,17596,1,BAO_0000218,Half-life at 10 mg/kg in rat upon intravenous administration,50597,In vivo,,CHEMBL625270,Intermediate,10116.0,,N,,A,9792,,,Rattus norvegicus,1,,,
,6672,1,BAO_0000218,Half-life determined in rat,50597,,,CHEMBL625271,Intermediate,10116.0,,N,,A,9793,,,Rattus norvegicus,1,,,
,6673,1,BAO_0000218,Half-life determined in rat,50597,,,CHEMBL625272,Intermediate,10116.0,,N,,A,9794,,,Rattus norvegicus,1,,,
,4910,1,BAO_0000218,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,50597,In vivo,Brain,CHEMBL625273,Intermediate,10116.0,,N,,A,9795,,,Rattus norvegicus,1,,955.0,
,3741,1,BAO_0000218,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",50597,,Plasma,CHEMBL625274,Intermediate,10116.0,,N,,A,9796,,,Rattus norvegicus,1,,1969.0,
,17671,1,BAO_0000218,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,50597,In vivo,,CHEMBL625275,Intermediate,10116.0,,N,,A,9797,,,Rattus norvegicus,1,,,
,4910,1,BAO_0000218,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,50597,In vivo,Plasma,CHEMBL625276,Intermediate,10116.0,,N,,A,9798,,,Rattus norvegicus,1,,1969.0,
,17537,1,BAO_0000218,Half-life in rat plasma,50597,,Plasma,CHEMBL625277,Intermediate,10116.0,,N,,A,9799,,,Rattus norvegicus,1,,1969.0,
,4965,1,BAO_0000218,Half-life in rat plasma was determined,50597,,Plasma,CHEMBL625278,Intermediate,10116.0,,N,,A,9800,,,Rattus norvegicus,1,,1969.0,
,17537,1,BAO_0000218,Half-life in rat plasma; Not tested,50597,,Plasma,CHEMBL625279,Intermediate,10116.0,,N,,A,9801,,,Rattus norvegicus,1,,1969.0,
,6124,1,BAO_0000218,Half-life in rat serum,50597,,Serum,CHEMBL625280,Intermediate,10116.0,,N,,A,9802,,,Rattus norvegicus,1,,1977.0,
,6124,1,BAO_0000218,Half-life in rat serum; na is not available,50597,,Serum,CHEMBL876797,Intermediate,10116.0,,N,,A,9803,,,Rattus norvegicus,1,,1977.0,
,6078,1,BAO_0000218,Half-life was calculated in rat,50597,,,CHEMBL625281,Intermediate,10116.0,,N,,A,9804,,,Rattus norvegicus,1,,,
,17668,1,BAO_0000218,Half-life was calculated in rat plasma,50597,,Plasma,CHEMBL873827,Intermediate,10116.0,,N,,A,9805,,,Rattus norvegicus,1,,1969.0,
,3185,1,BAO_0000218,Half-life was determined,50597,,,CHEMBL625282,Intermediate,10116.0,,N,,A,9806,,,Rattus norvegicus,1,,,
,4883,1,BAO_0000218,Half-life was determined,50597,,,CHEMBL625283,Intermediate,10116.0,,N,,A,9807,,,Rattus norvegicus,1,,,
,2959,1,BAO_0000218,Half-life after administration of 20 mg/Kg oral dose in rat,50597,In vivo,,CHEMBL625284,Intermediate,10116.0,,N,,A,9808,,,Rattus norvegicus,1,,,
,4029,1,BAO_0000218,Half-life after administration of 3.2 mg/kg intravenously in male rat,50597,In vivo,,CHEMBL625285,Intermediate,10116.0,,N,,A,9809,,,Rattus norvegicus,1,,,
,4029,1,BAO_0000218,Half-life after intravenous administration in female rat,50597,In vivo,,CHEMBL625286,Intermediate,10116.0,,N,,A,9810,,,Rattus norvegicus,1,,,
,4029,1,BAO_0000218,Half-life after intravenous administration in male rat,50597,In vivo,,CHEMBL625287,Intermediate,10116.0,,N,,A,9811,,,Rattus norvegicus,1,,,
,6180,1,BAO_0000218,Half-life after intravenous dose in rat,50597,In vivo,,CHEMBL625288,Intermediate,10116.0,,N,,A,9812,,,Rattus norvegicus,1,,,
,1557,1,BAO_0000218,Half-life in a rat liver homogenate preparation,50597,,Liver,CHEMBL625289,Intermediate,10116.0,,N,,A,9813,,,Rattus norvegicus,1,,2107.0,
,12500,1,BAO_0000218,Half-life in plasma of rat,50597,,Plasma,CHEMBL625290,Intermediate,10116.0,,N,,A,9814,,,Rattus norvegicus,1,,1969.0,
,12500,1,BAO_0000218,Half-life in plasma of rat at dose of 3-10 mgkg,50597,,Plasma,CHEMBL876798,Intermediate,10116.0,,N,,A,9815,,,Rattus norvegicus,1,,1969.0,
,5064,1,BAO_0000218,Half-life in rat,50597,,,CHEMBL625291,Intermediate,10116.0,,N,,A,9816,,,Rattus norvegicus,1,,,
,5145,1,BAO_0000218,Half-life in rat,50597,,,CHEMBL625292,Intermediate,10116.0,,N,,A,9817,,,Rattus norvegicus,1,,,
,5147,1,BAO_0000218,Half-life in rat,50597,,,CHEMBL625293,Intermediate,10116.0,,N,,A,9818,,,Rattus norvegicus,1,,,
,5833,1,BAO_0000218,Half-life in rat,50597,,,CHEMBL622832,Intermediate,10116.0,,N,,A,9819,,,Rattus norvegicus,1,,,
,6596,1,BAO_0000218,Half-life in rat,50597,,,CHEMBL622833,Intermediate,10116.0,,N,,A,9820,,,Rattus norvegicus,1,,,
,17655,1,BAO_0000218,Half-life in rat,50597,,,CHEMBL622834,Intermediate,10116.0,,N,,A,9821,,,Rattus norvegicus,1,,,
,6495,1,BAO_0000218,Half-life in rat after oral administration at 10 mg/kg,50597,In vivo,,CHEMBL622835,Intermediate,10116.0,,N,,A,9822,,,Rattus norvegicus,1,,,
,17538,1,BAO_0000218,Half-life in rat after po administration at a dose of 10 mg/kg,50597,In vivo,,CHEMBL622836,Intermediate,10116.0,,N,,A,9823,,,Rattus norvegicus,1,,,
,17538,1,BAO_0000218,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,50597,In vivo,,CHEMBL622837,Intermediate,10116.0,,N,,A,9824,,,Rattus norvegicus,1,,,
,10,1,BAO_0000218,Half-life in rat at 3 mg/kg dose administered intravenously,50597,In vivo,,CHEMBL622838,Intermediate,10116.0,,N,,A,9825,,,Rattus norvegicus,1,,,
,17669,1,BAO_0000218,Half-life in rat brain homogenate,50597,,Brain,CHEMBL622839,Intermediate,10116.0,,N,,A,9826,,,Rattus norvegicus,1,,955.0,
,17065,1,BAO_0000218,Half-life in rat plasma,50597,,Plasma,CHEMBL622840,Intermediate,10116.0,,N,,A,9827,,,Rattus norvegicus,1,,1969.0,
,4333,1,BAO_0000218,Half-life in rats,50597,,,CHEMBL622841,Intermediate,10116.0,,N,,A,9828,,,Rattus norvegicus,1,,,
,6827,1,BAO_0000218,Half-life in Dawley rats,50597,,,CHEMBL622842,Intermediate,10116.0,,N,,A,9829,,,Rattus norvegicus,1,,,
,889,1,BAO_0000218,Half-life in vitro in rat plasma,50597,In vitro,Plasma,CHEMBL622843,Intermediate,10116.0,,N,,A,9830,,,Rattus norvegicus,1,,1969.0,
,889,1,BAO_0000218,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,50597,In vitro,Plasma,CHEMBL622844,Intermediate,10116.0,,N,,A,9831,,,Rattus norvegicus,1,,1969.0,
,3747,1,BAO_0000218,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",50597,,,CHEMBL622845,Intermediate,10116.0,,N,,A,9832,,,Rattus norvegicus,1,,,
,15022,1,BAO_0000218,The area under the curve of compound was measured at the dose of 100 umol/kg,50597,,,CHEMBL622846,Intermediate,10116.0,,N,,A,9833,,,Rattus norvegicus,1,,,
,15022,1,BAO_0000218,The area under the curve of compound was measured at the dose of 300 umol/kg,50597,,,CHEMBL622847,Intermediate,10116.0,,N,,A,9834,,,Rattus norvegicus,1,,,
,15022,1,BAO_0000218,The area under the curve of compound was measured at the dose of 30 umol/kg,50597,,,CHEMBL622848,Intermediate,10116.0,,N,,A,9835,,,Rattus norvegicus,1,,,
,3360,1,BAO_0000218,Bioavailability as oral AUC in rats,50597,In vivo,,CHEMBL622849,Intermediate,10116.0,,N,,A,9836,,,Rattus norvegicus,1,,,
,5334,1,BAO_0000218,The plasma concentration versus time curve (AUC) was determined,50597,,Plasma,CHEMBL622850,Intermediate,10116.0,,N,,A,9837,,,Rattus norvegicus,1,,1969.0,
,17411,1,BAO_0000218,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,,,CHEMBL876807,Intermediate,10116.0,,N,,A,9838,,,Rattus norvegicus,1,,,
,17411,1,BAO_0000218,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,,,CHEMBL622851,Intermediate,10116.0,,N,,A,9839,,,Rattus norvegicus,1,,,
,17411,1,BAO_0000218,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,,,CHEMBL622852,Intermediate,10116.0,,N,,A,9840,,,Rattus norvegicus,1,,,
,6570,1,BAO_0000218,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,50597,,,CHEMBL622853,Intermediate,10116.0,,N,,A,9841,,,Rattus norvegicus,1,,,
,6570,1,BAO_0000218,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,50597,,,CHEMBL622854,Intermediate,10116.0,,N,,A,9842,,,Rattus norvegicus,1,,,
,17411,1,BAO_0000218,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,,,CHEMBL622855,Intermediate,10116.0,,N,,A,9843,,,Rattus norvegicus,1,,,
,14941,1,BAO_0000218,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",50597,,Plasma,CHEMBL622856,Intermediate,10116.0,,N,,A,9844,,,Rattus norvegicus,1,,1969.0,
,14941,1,BAO_0000218,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",50597,,Plasma,CHEMBL622857,Intermediate,10116.0,,N,,A,9845,,,Rattus norvegicus,1,,1969.0,
,17538,1,BAO_0000218,AUC in rat after po administration at a dose of 10 mg/kg,50597,,Plasma,CHEMBL622858,Intermediate,10116.0,,N,,A,9846,,,Rattus norvegicus,1,,1969.0,
,17752,1,BAO_0000218,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,50597,,Plasma,CHEMBL622859,Intermediate,10116.0,,N,,A,9847,,,Rattus norvegicus,1,,1969.0,
,17509,1,BAO_0000218,Area under curve value 24 hr after 10 mg/kg iv administration in rats,50597,,,CHEMBL622860,Intermediate,10116.0,,N,,A,9848,,,Rattus norvegicus,1,,,
,17509,1,BAO_0000218,Area under curve value 24 hr after 10 mg/kg oral administration in rats,50597,,,CHEMBL622861,Intermediate,10116.0,,N,,A,9849,,,Rattus norvegicus,1,,,
,17509,1,BAO_0000218,Area under curve value 24 hr after 2 mg/kg iv administration in rats,50597,,,CHEMBL622862,Intermediate,10116.0,,N,,A,9850,,,Rattus norvegicus,1,,,
,17509,1,BAO_0000218,Area under curve value 24 hr after 2 mg/kg oral administration in rats,50597,,,CHEMBL622863,Intermediate,10116.0,,N,,A,9851,,,Rattus norvegicus,1,,,
,17509,1,BAO_0000218,Area under curve value 6 hr after po administration in rat,50597,,,CHEMBL623817,Intermediate,10116.0,,N,,A,9852,,,Rattus norvegicus,1,,,
,17717,1,BAO_0000218,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,,,CHEMBL623818,Intermediate,10116.0,,N,,A,9853,,,Rattus norvegicus,1,,,
,17717,1,BAO_0000218,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",50597,,,CHEMBL623819,Intermediate,10116.0,,N,,A,9854,,,Rattus norvegicus,1,,,
,17717,1,BAO_0000218,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,,,CHEMBL623820,Intermediate,10116.0,,N,,A,9855,,,Rattus norvegicus,1,,,
,17717,1,BAO_0000218,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,50597,,,CHEMBL623821,Intermediate,10116.0,,N,,A,9856,,,Rattus norvegicus,1,,,
,6642,1,BAO_0000218,AUC normalized for dose (AUCN) in rat,50597,,Plasma,CHEMBL623822,Intermediate,10116.0,,N,,A,9857,,,Rattus norvegicus,1,,1969.0,
,6640,1,BAO_0000218,Area under curve in rat after p.o. administration,50597,,,CHEMBL623823,Intermediate,10116.0,,N,,A,9858,,,Rattus norvegicus,1,,,
,6641,1,BAO_0000218,Area under curve in rat after p.o. administration,50597,,,CHEMBL623824,Intermediate,10116.0,,N,,A,9859,,,Rattus norvegicus,1,,,
,6641,1,BAO_0000218,Area under curve in rat after p.o. administration; Not determined,50597,,,CHEMBL623825,Intermediate,10116.0,,N,,A,9860,,,Rattus norvegicus,1,,,
,6641,1,BAO_0000218,Area under curve in rat after peroral administration,50597,,,CHEMBL622070,Intermediate,10116.0,,N,,A,9861,,,Rattus norvegicus,1,,,
,3603,1,BAO_0000218,Area under curve (carotid artery) value of the compound,50597,,,CHEMBL622071,Intermediate,10116.0,,N,,A,9862,,,Rattus norvegicus,1,,,
,3550,1,BAO_0000218,Bioavailability expressed as the area under curve of rat carotid artery,50597,,,CHEMBL622072,Intermediate,10116.0,,N,,A,9863,,,Rattus norvegicus,1,,,
,15662,1,BAO_0000218,Area under curve in male SD rats was observed after intravenous administration in rat,50597,,,CHEMBL622073,Intermediate,10116.0,,N,,A,9864,,,Rattus norvegicus,1,,,
,17720,1,BAO_0000218,Area under curve of the compound was determined,50597,,,CHEMBL622074,Intermediate,10116.0,,N,,A,9865,,,Rattus norvegicus,1,,,
,5407,1,BAO_0000218,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,50597,,,CHEMBL622075,Intermediate,10116.0,,N,,A,9866,,,Rattus norvegicus,1,,,
,17752,1,BAO_0000218,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,50597,,Plasma,CHEMBL622076,Intermediate,10116.0,,N,,A,9867,,,Rattus norvegicus,1,,1969.0,
,17752,1,BAO_0000218,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,50597,,Plasma,CHEMBL622077,Intermediate,10116.0,,N,,A,9868,,,Rattus norvegicus,1,,1969.0,
,3603,1,BAO_0000218,Area under curve (portal vein) value of the compound,50597,,,CHEMBL622078,Intermediate,10116.0,,N,,A,9869,,,Rattus norvegicus,1,,,
,3550,1,BAO_0000218,Bioavailability expressed as the area under curve of rat portal vein,50597,,,CHEMBL622079,Intermediate,10116.0,,N,,A,9870,,,Rattus norvegicus,1,,,
,17655,1,BAO_0000218,Area Under plasma concentration time curve in rat upon peroral administration,50597,,Plasma,CHEMBL622080,Intermediate,10116.0,,N,,A,9871,,,Rattus norvegicus,1,,1969.0,
,17582,1,BAO_0000218,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,50597,,,CHEMBL877612,Intermediate,10116.0,,N,,A,9872,,,Rattus norvegicus,1,,,
,17582,1,BAO_0000218,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,50597,,,CHEMBL622081,Intermediate,10116.0,,N,,A,9873,,,Rattus norvegicus,1,,,
,17791,1,BAO_0000218,Compound was evaluated for oral bioavailability in rats,50597,,,CHEMBL622082,Intermediate,10116.0,,N,,A,9874,,,Rattus norvegicus,1,,,
,17791,1,BAO_0000218,Compound was evaluated for oral bioavailability in rats after iv administration,50597,,,CHEMBL622083,Intermediate,10116.0,,N,,A,9875,,,Rattus norvegicus,1,,,
,17791,1,BAO_0000218,Compound was evaluated for oral bioavailability in rats; 30-80,50597,,,CHEMBL622084,Intermediate,10116.0,,N,,A,9876,,,Rattus norvegicus,1,,,
,17791,1,BAO_0000218,Compound was evaluated for oral bioavailability in rats; 50-60,50597,,,CHEMBL622085,Intermediate,10116.0,,N,,A,9877,,,Rattus norvegicus,1,,,
,17791,1,BAO_0000218,Compound was evaluated for oral bioavailability in rats; no data,50597,,,CHEMBL622086,Intermediate,10116.0,,N,,A,9878,,,Rattus norvegicus,1,,,
,17791,1,BAO_0000218,Compound was evaluated for oral bioavailability in rats; peptide,50597,,,CHEMBL622087,Intermediate,10116.0,,N,,A,9879,,,Rattus norvegicus,1,,,
,7768,1,BAO_0000218,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",50597,,Blood,CHEMBL622088,Intermediate,10116.0,,N,,A,9880,,,Rattus norvegicus,1,,178.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",50597,,Blood,CHEMBL622089,Intermediate,10116.0,,N,,A,9881,,,Rattus norvegicus,1,,178.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",50597,,Blood,CHEMBL623685,Intermediate,10116.0,,N,,A,9882,,,Rattus norvegicus,1,,178.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",50597,,Blood,CHEMBL623686,Intermediate,10116.0,,N,,A,9883,,,Rattus norvegicus,1,,178.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,In vivo,Stomach,CHEMBL623687,Intermediate,10116.0,,N,,A,9884,,,Rattus norvegicus,1,,945.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,In vivo,Stomach,CHEMBL623688,Intermediate,10116.0,,N,,A,9885,,,Rattus norvegicus,1,,945.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,In vivo,Stomach,CHEMBL623689,Intermediate,10116.0,,N,,A,9886,,,Rattus norvegicus,1,,945.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,In vivo,Stomach,CHEMBL622485,Intermediate,10116.0,,N,,A,9887,,,Rattus norvegicus,1,,945.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,In vivo,Thyroid gland,CHEMBL622486,Intermediate,10116.0,,N,,A,9888,,,Rattus norvegicus,1,,2046.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,In vivo,Thyroid gland,CHEMBL877613,Intermediate,10116.0,,N,,A,9889,,,Rattus norvegicus,1,,2046.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,In vivo,Thyroid gland,CHEMBL622487,Intermediate,10116.0,,N,,A,9890,,,Rattus norvegicus,1,,2046.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,In vivo,Thyroid gland,CHEMBL622488,Intermediate,10116.0,,N,,A,9891,,,Rattus norvegicus,1,,2046.0,
,8677,1,BAO_0000218,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,In vivo,Heart,CHEMBL622489,Intermediate,10116.0,,N,,A,9892,,,Rattus norvegicus,1,,948.0,
,6899,1,BAO_0000218,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,50597,,Urine,CHEMBL622490,Intermediate,10116.0,,N,,A,9893,,,Rattus norvegicus,1,,1088.0,
,6899,1,BAO_0000218,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,50597,,Urine,CHEMBL622491,Intermediate,10116.0,,N,,A,9894,,,Rattus norvegicus,1,,1088.0,
,6899,1,BAO_0000218,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,50597,,Liver,CHEMBL622492,Intermediate,10116.0,,N,,A,9895,,,Rattus norvegicus,1,,2107.0,
,6899,1,BAO_0000218,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,50597,,Urine,CHEMBL622493,Intermediate,10116.0,,N,,A,9896,,,Rattus norvegicus,1,,1088.0,
,6899,1,BAO_0000218,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,50597,,Urine,CHEMBL622494,Intermediate,10116.0,,N,,A,9897,,,Rattus norvegicus,1,,1088.0,
,8677,1,BAO_0000218,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,,Muscle tissue,CHEMBL622495,Intermediate,10116.0,,N,,A,9898,,,Rattus norvegicus,1,,2385.0,
,6899,1,BAO_0000218,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,50597,,,CHEMBL622496,Intermediate,10116.0,,N,,A,9899,,,Rattus norvegicus,1,,,
,6899,1,BAO_0000218,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,50597,,Urine,CHEMBL622497,Intermediate,10116.0,,N,,A,9900,,,Rattus norvegicus,1,,1088.0,
,2189,1,BAO_0000218,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,50597,,,CHEMBL622498,Intermediate,10116.0,,N,,A,9901,,,Rattus norvegicus,1,,,
,2189,1,BAO_0000218,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,50597,,Urine,CHEMBL624918,Intermediate,10116.0,,N,,A,9902,,,Rattus norvegicus,1,,1088.0,
,2189,1,BAO_0000218,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,50597,,Urine,CHEMBL624919,Intermediate,10116.0,,N,,A,9903,,,Rattus norvegicus,1,,1088.0,
,10839,1,BAO_0000218,Biodistribution of compound in rat blood after 5 min of administration,50597,In vivo,Blood,CHEMBL624920,Intermediate,10116.0,,N,,A,9904,,,Rattus norvegicus,1,,178.0,
,10839,1,BAO_0000218,Biodistribution of compound in rat blood after 5 min of administration.,50597,In vivo,Blood,CHEMBL624921,Intermediate,10116.0,,N,,A,9905,,,Rattus norvegicus,1,,178.0,
,10839,1,BAO_0000218,Biodistribution of compound in rat brain after 5 min of administration,50597,In vivo,Brain,CHEMBL624922,Intermediate,10116.0,,N,,A,9906,,,Rattus norvegicus,1,,955.0,
,10839,1,BAO_0000218,Biodistribution of compound in rat heart after 5 min of administration,50597,In vivo,Heart,CHEMBL624923,Intermediate,10116.0,,N,,A,9907,,,Rattus norvegicus,1,,948.0,
,10839,1,BAO_0000218,Biodistribution of compound in rat heart after 5 min of administration.,50597,In vivo,Heart,CHEMBL624924,Intermediate,10116.0,,N,,A,9908,,,Rattus norvegicus,1,,948.0,
,10839,1,BAO_0000218,Biodistribution of compound in rat kidney after 5 min of administration,50597,In vivo,Kidney,CHEMBL624925,Intermediate,10116.0,,N,,A,9909,,,Rattus norvegicus,1,,2113.0,
,10839,1,BAO_0000218,Biodistribution of compound in rat kidney after 5 min of administration.,50597,In vivo,Kidney,CHEMBL624926,Intermediate,10116.0,,N,,A,9910,,,Rattus norvegicus,1,,2113.0,
,10839,1,BAO_0000218,Biodistribution of compound in rat liver after 5 min of administration,50597,In vivo,Liver,CHEMBL624927,Intermediate,10116.0,,N,,A,9911,,,Rattus norvegicus,1,,2107.0,
,10839,1,BAO_0000218,Biodistribution of compound in rat liver after 5 min of administration.,50597,In vivo,Liver,CHEMBL874402,Intermediate,10116.0,,N,,A,9912,,,Rattus norvegicus,1,,2107.0,
,10839,1,BAO_0000218,Biodistribution of compound in rat lung after 5 min of administration,50597,In vivo,Lung,CHEMBL624928,Intermediate,10116.0,,N,,A,9913,,,Rattus norvegicus,1,,2048.0,
,10839,1,BAO_0000218,Biodistribution of compound in rat lung after 5 min of administration.,50597,In vivo,Lung,CHEMBL624929,Intermediate,10116.0,,N,,A,9914,,,Rattus norvegicus,1,,2048.0,
,10839,1,BAO_0000218,Biodistribution of compound in rat muscle after 5 min of administration,50597,In vivo,Muscle tissue,CHEMBL624930,Intermediate,10116.0,,N,,A,9915,,,Rattus norvegicus,1,,2385.0,
,10839,1,BAO_0000218,Biodistribution of compound in rat muscle after 5 min of administration.,50597,In vivo,Muscle tissue,CHEMBL624931,Intermediate,10116.0,,N,,A,9916,,,Rattus norvegicus,1,,2385.0,
,4043,1,BAO_0000218,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,,Heart,CHEMBL624932,Intermediate,10116.0,,N,,A,9917,,,Rattus norvegicus,1,,948.0,
,4043,1,BAO_0000218,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,,Heart,CHEMBL624933,Intermediate,10116.0,,N,,A,9918,,,Rattus norvegicus,1,,948.0,
,4043,1,BAO_0000218,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,,Liver,CHEMBL624934,Intermediate,10116.0,,N,,A,9919,,,Rattus norvegicus,1,,2107.0,
,4043,1,BAO_0000218,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,,Liver,CHEMBL624935,Intermediate,10116.0,,N,,A,9920,,,Rattus norvegicus,1,,2107.0,
,4043,1,BAO_0000218,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,,,CHEMBL624936,Intermediate,10116.0,,N,,A,9921,,,Rattus norvegicus,1,,,
,4043,1,BAO_0000218,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,,,CHEMBL624937,Intermediate,10116.0,,N,,A,9922,,,Rattus norvegicus,1,,,
,4043,1,BAO_0000218,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,,Spleen,CHEMBL624938,Intermediate,10116.0,,N,,A,9923,,,Rattus norvegicus,1,,2106.0,
,4043,1,BAO_0000218,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,,Spleen,CHEMBL624939,Intermediate,10116.0,,N,,A,9924,,,Rattus norvegicus,1,,2106.0,
,4043,1,BAO_0000218,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,,,CHEMBL624940,Intermediate,10116.0,,N,,A,9925,,,Rattus norvegicus,1,,,
,4043,1,BAO_0000218,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,,,CHEMBL874403,Intermediate,10116.0,,N,,A,9926,,,Rattus norvegicus,1,,,
,1446,1,BAO_0000218,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,50597,,,CHEMBL624941,Intermediate,10116.0,,N,,A,9927,,,Rattus norvegicus,1,,,
,9971,1,BAO_0000218,Dose required to lower urine osmolality to 300 mOsm/kg in rat,50597,,Urine,CHEMBL624942,Intermediate,10116.0,,N,,A,9928,,,Rattus norvegicus,1,,1088.0,
,9971,1,BAO_0000218,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,50597,,Urine,CHEMBL624943,Intermediate,10116.0,,N,,A,9929,,,Rattus norvegicus,1,,1088.0,
,5765,1,BAO_0000218,% Bioavailability after 1 day of the drug administration in rats,50597,In vivo,,CHEMBL624944,Intermediate,10116.0,,N,,A,9930,,,Rattus norvegicus,1,,,
,5765,1,BAO_0000218,% Bioavailability after 4 day of the drug administration in rats,50597,In vivo,,CHEMBL624945,Intermediate,10116.0,,N,,A,9931,,,Rattus norvegicus,1,,,
,4257,1,BAO_0000218,Absolute bioavailability was evaluated in rat,50597,In vivo,,CHEMBL624946,Intermediate,10116.0,,N,,A,9932,,,Rattus norvegicus,1,,,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,50597,,,CHEMBL624947,Intermediate,10116.0,,N,,A,9933,,,Rattus norvegicus,1,,,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,50597,,,CHEMBL624948,Intermediate,10116.0,,N,,A,9934,,,Rattus norvegicus,1,,,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,50597,,,CHEMBL624949,Intermediate,10116.0,,N,,A,9935,,,Rattus norvegicus,1,,,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,50597,,Kidney,CHEMBL622025,Intermediate,10116.0,,N,,A,9936,,,Rattus norvegicus,1,,2113.0,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,50597,,Kidney,CHEMBL622026,Intermediate,10116.0,,N,,A,9937,,,Rattus norvegicus,1,,2113.0,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,50597,,Kidney,CHEMBL622027,Intermediate,10116.0,,N,,A,9938,,,Rattus norvegicus,1,,2113.0,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,50597,,Kidney,CHEMBL622028,Intermediate,10116.0,,N,,A,9939,,,Rattus norvegicus,1,,2113.0,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,50597,,Liver,CHEMBL622029,Intermediate,10116.0,,N,,A,9940,,,Rattus norvegicus,1,,2107.0,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,50597,,Liver,CHEMBL622208,Intermediate,10116.0,,N,,A,9941,,,Rattus norvegicus,1,,2107.0,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,50597,,Liver,CHEMBL622209,Intermediate,10116.0,,N,,A,9942,,,Rattus norvegicus,1,,2107.0,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,50597,,Liver,CHEMBL622210,Intermediate,10116.0,,N,,A,9943,,,Rattus norvegicus,1,,2107.0,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,50597,,,CHEMBL622211,Intermediate,10116.0,,N,,A,9944,,,Rattus norvegicus,1,,,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,50597,,,CHEMBL622212,Intermediate,10116.0,,N,,A,9945,,,Rattus norvegicus,1,,,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,50597,,,CHEMBL622213,Intermediate,10116.0,,N,,A,9946,,,Rattus norvegicus,1,,,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,50597,,,CHEMBL874404,Intermediate,10116.0,,N,,A,9947,,,Rattus norvegicus,1,,,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,50597,,Muscle tissue,CHEMBL620452,Intermediate,10116.0,,N,,A,9948,,,Rattus norvegicus,1,,2385.0,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,50597,,Muscle tissue,CHEMBL620453,Intermediate,10116.0,,N,,A,9949,,,Rattus norvegicus,1,,2385.0,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,50597,,Muscle tissue,CHEMBL620454,Intermediate,10116.0,,N,,A,9950,,,Rattus norvegicus,1,,2385.0,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,50597,,Muscle tissue,CHEMBL624067,Intermediate,10116.0,,N,,A,9951,,,Rattus norvegicus,1,,2385.0,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,50597,,,CHEMBL624068,Intermediate,10116.0,,N,,A,9952,,,Rattus norvegicus,1,,,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,50597,,Female gonad,CHEMBL624069,Intermediate,10116.0,,N,,A,9953,,,Rattus norvegicus,1,,992.0,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,50597,,Female gonad,CHEMBL624070,Intermediate,10116.0,,N,,A,9954,,,Rattus norvegicus,1,,992.0,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,50597,,Female gonad,CHEMBL624071,Intermediate,10116.0,,N,,A,9955,,,Rattus norvegicus,1,,992.0,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,50597,,Uterus,CHEMBL624072,Intermediate,10116.0,,N,,A,9956,,,Rattus norvegicus,1,,995.0,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,50597,,Uterus,CHEMBL624073,Intermediate,10116.0,,N,,A,9957,,,Rattus norvegicus,1,,995.0,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,50597,,Uterus,CHEMBL624788,Intermediate,10116.0,,N,,A,9958,,,Rattus norvegicus,1,,995.0,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,50597,,Uterus,CHEMBL624789,Intermediate,10116.0,,N,,A,9959,,,Rattus norvegicus,1,,995.0,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,50597,,,CHEMBL624790,Intermediate,10116.0,,N,,A,9960,,,Rattus norvegicus,1,,,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,50597,,,CHEMBL624791,Intermediate,10116.0,,N,,A,9961,,,Rattus norvegicus,1,,,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,50597,,,CHEMBL624792,Intermediate,10116.0,,N,,A,9962,,,Rattus norvegicus,1,,,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,50597,,,CHEMBL624793,Intermediate,10116.0,,N,,A,9963,,,Rattus norvegicus,1,,,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,50597,,Muscle tissue,CHEMBL877491,Intermediate,10116.0,,N,,A,9964,,,Rattus norvegicus,1,,2385.0,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,50597,,Muscle tissue,CHEMBL624957,Intermediate,10116.0,,N,,A,9965,,,Rattus norvegicus,1,,2385.0,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,50597,,Muscle tissue,CHEMBL624958,Intermediate,10116.0,,N,,A,9966,,,Rattus norvegicus,1,,2385.0,
,13091,1,BAO_0000218,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,50597,,Muscle tissue,CHEMBL624959,Intermediate,10116.0,,N,,A,9967,,,Rattus norvegicus,1,,2385.0,
,11977,1,BAO_0000218,Dissociation constant was determined,50597,,,CHEMBL624960,Intermediate,10116.0,,N,,A,9968,,,Rattus norvegicus,1,,,
,14941,1,BAO_0000218,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",50597,,,CHEMBL624961,Intermediate,10116.0,,N,,A,9969,,,Rattus norvegicus,1,,,
,15078,1,BAO_0000218,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",50597,,,CHEMBL624962,Intermediate,10116.0,,N,,A,9970,,,Rattus norvegicus,1,,,
,15078,1,BAO_0000218,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",50597,,,CHEMBL624963,Intermediate,10116.0,,N,,A,9971,,,Rattus norvegicus,1,,,
,4755,1,BAO_0000218,Observed rate constant in 80% rat plasma at 37 degree Centigrade,50597,,,CHEMBL624964,Intermediate,10116.0,,N,,A,9972,,,Rattus norvegicus,1,,,
,589,1,BAO_0000218,LogP value was evaluated in the in situ rat gut perfusion assay,50597,,,CHEMBL624965,Intermediate,10116.0,,N,,A,9973,,,Rattus norvegicus,1,,,
,17582,1,BAO_0000218,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,50597,In vivo,,CHEMBL624966,Intermediate,10116.0,,N,,A,9974,,,Rattus norvegicus,1,,,
,5031,1,BAO_0000218,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,50597,In vivo,,CHEMBL624967,Intermediate,10116.0,,N,,A,9975,,,Rattus norvegicus,1,,,
,17764,1,BAO_0000218,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,50597,In vivo,,CHEMBL624968,Intermediate,10116.0,,N,,A,9976,,,Rattus norvegicus,1,,,
,17720,1,BAO_0000218,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,,,CHEMBL624969,Intermediate,10116.0,,N,,A,9977,,,Rattus norvegicus,1,,,
,2862,1,BAO_0000218,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,50597,,,CHEMBL624970,Expert,10116.0,,N,,F,9978,,,Rattus norvegicus,1,,,
,16423,1,BAO_0000218,Half-life was evaluated after 10 uM/kg of intra arterial administration,50597,,,CHEMBL624971,Intermediate,10116.0,,N,,A,9979,,,Rattus norvegicus,1,,,
,16423,1,BAO_0000218,Half-life was evaluated after 20 uM/kg of peroral administration,50597,In vivo,,CHEMBL624972,Intermediate,10116.0,,N,,A,9980,,,Rattus norvegicus,1,,,
,6005,1,BAO_0000218,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,50597,In vivo,,CHEMBL624973,Intermediate,10116.0,,N,,A,9981,,,Rattus norvegicus,1,,,
,2938,1,BAO_0000218,Half-life was evaluated in plasma of rat,50597,,Plasma,CHEMBL624974,Intermediate,10116.0,,N,,A,9982,,,Rattus norvegicus,1,,1969.0,
,6410,1,BAO_0000218,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,50597,In vivo,,CHEMBL624975,Intermediate,10116.0,,N,,A,9983,,,Rattus norvegicus,1,,,
,6410,1,BAO_0000218,Half-life was evaluated in rats at an oral dose of 30 mg/kg,50597,In vivo,,CHEMBL877492,Intermediate,10116.0,,N,,A,9984,,,Rattus norvegicus,1,,,
,6062,1,BAO_0000218,Half-life was measured in rat after an iv dose of 1 mg/kg,50597,In vivo,,CHEMBL624976,Intermediate,10116.0,,N,,A,9985,,,Rattus norvegicus,1,,,
,6571,1,BAO_0000218,Half-life period of compound in rats after peroral administration,50597,In vivo,,CHEMBL624977,Intermediate,10116.0,,N,,A,9986,,,Rattus norvegicus,1,,,
,3136,1,BAO_0000218,Half-life period of compound was measured in rat plasma.,50597,,Plasma,CHEMBL626848,Intermediate,10116.0,,N,,A,9987,,,Rattus norvegicus,1,,1969.0,
,3136,1,BAO_0000218,Half-life period of compound was measured in rat plasma; ND is not determined,50597,,Plasma,CHEMBL626849,Intermediate,10116.0,,N,,A,9988,,,Rattus norvegicus,1,,1969.0,
,3136,1,BAO_0000218,Half-life period of compound was measured in rat plasma; not determined,50597,,Plasma,CHEMBL626850,Intermediate,10116.0,,N,,A,9989,,,Rattus norvegicus,1,,1969.0,
,4521,1,BAO_0000218,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,50597,In vivo,,CHEMBL626851,Intermediate,10116.0,,N,,A,9990,,,Rattus norvegicus,1,,,
,5871,1,BAO_0000218,Half-life period in rat by iv administration,50597,In vivo,,CHEMBL626852,Intermediate,10116.0,,N,,A,9991,,,Rattus norvegicus,1,,,
,6077,1,BAO_0000218,Half-life period in rats following intravenous administration at 2 mg/kg,50597,In vivo,,CHEMBL626853,Intermediate,10116.0,,N,,A,9992,,,Rattus norvegicus,1,,,
,6679,1,BAO_0000218,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50597,In vivo,,CHEMBL626854,Intermediate,10116.0,,N,,A,9993,,,Rattus norvegicus,1,,,
,5144,1,BAO_0000218,Half-life period was determined for the compound in rat,50597,,,CHEMBL627486,Intermediate,10116.0,,N,,A,9994,,,Rattus norvegicus,1,,,
,4498,1,BAO_0000218,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",50597,In vivo,,CHEMBL627487,Intermediate,10116.0,,N,,A,9995,,,Rattus norvegicus,1,,,
,4498,1,BAO_0000218,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",50597,In vivo,,CHEMBL627488,Intermediate,10116.0,,N,,A,9996,,,Rattus norvegicus,1,,,
,1908,1,BAO_0000218,Half-life value after IV dose at a dose of 5 mg/kg in rats.,50597,In vivo,,CHEMBL627489,Intermediate,10116.0,,N,,A,9997,,,Rattus norvegicus,1,,,
,6211,1,BAO_0000218,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,50597,In vivo,,CHEMBL627490,Intermediate,10116.0,,N,,A,9998,,,Rattus norvegicus,1,,,
,5529,1,BAO_0000218,Half-life was determined in rat after intravenous administration (0.5 mg/kg),50597,In vivo,,CHEMBL873829,Intermediate,10116.0,,N,,A,9999,,,Rattus norvegicus,1,,,
,6444,1,BAO_0000218,Half-life was determined in rat at a dose of 1 mpk i.v.,50597,In vivo,,CHEMBL627655,Intermediate,10116.0,,N,,A,10000,,,Rattus norvegicus,1,,,
,6444,1,BAO_0000218,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,50597,In vivo,,CHEMBL625994,Intermediate,10116.0,,N,,A,10001,,,Rattus norvegicus,1,,,
,6444,1,BAO_0000218,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,50597,In vivo,,CHEMBL625995,Intermediate,10116.0,,N,,A,10002,,,Rattus norvegicus,1,,,
,5207,1,BAO_0000218,Half-life in rat,50597,,,CHEMBL625996,Intermediate,10116.0,,N,,A,10003,,,Rattus norvegicus,1,,,
,530,1,BAO_0000218,In vitro half life in rat plasma,50597,In vitro,Plasma,CHEMBL625850,Intermediate,10116.0,,N,,A,10004,,,Rattus norvegicus,1,,1969.0,
,1116,1,BAO_0000218,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",50597,In vitro,Plasma,CHEMBL625851,Intermediate,10116.0,,N,,A,10005,,,Rattus norvegicus,1,,1969.0,
,3219,1,BAO_0000218,In vitro half life in rat,50597,In vitro,,CHEMBL625852,Intermediate,10116.0,,N,,A,10006,,,Rattus norvegicus,1,,,
,6109,1,BAO_0000218,In vivo half life period after intravenous administration in rat,50597,In vivo,,CHEMBL625853,Intermediate,10116.0,,N,,A,10007,,,Rattus norvegicus,1,,,
,17582,1,BAO_0000218,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,50597,In vivo,,CHEMBL625854,Intermediate,10116.0,,N,,A,10008,,,Rattus norvegicus,1,,,
,17582,1,BAO_0000218,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,50597,In vivo,,CHEMBL874450,Intermediate,10116.0,,N,,A,10009,,,Rattus norvegicus,1,,,
,5974,1,BAO_0000218,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,In vivo,,CHEMBL625855,Intermediate,10116.0,,N,,A,10010,,,Rattus norvegicus,1,,,
,5974,1,BAO_0000218,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,In vivo,,CHEMBL625856,Intermediate,10116.0,,N,,A,10011,,,Rattus norvegicus,1,,,
,5974,1,BAO_0000218,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,50597,In vivo,,CHEMBL625857,Intermediate,10116.0,,N,,A,10012,,,Rattus norvegicus,1,,,
,5974,1,BAO_0000218,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,In vivo,,CHEMBL873831,Intermediate,10116.0,,N,,A,10013,,,Rattus norvegicus,1,,,
,17853,1,BAO_0000218,Longer half-life in rat (i.v.) at 0.5 mpk,50597,In vivo,,CHEMBL625858,Intermediate,10116.0,,N,,A,10014,,,Rattus norvegicus,1,,,
,17853,1,BAO_0000218,Longer half-life in rat (p.o.) at 2.0 mpk,50597,In vivo,,CHEMBL625859,Intermediate,10116.0,,N,,A,10015,,,Rattus norvegicus,1,,,
,3457,1,BAO_0000218,Pharmacokinetic property (half life) in rat,50597,,,CHEMBL625860,Intermediate,10116.0,,N,,A,10016,,,Rattus norvegicus,1,,,
,2792,1,BAO_0000218,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,50597,In vivo,,CHEMBL625861,Intermediate,10116.0,,N,,A,10017,,,Rattus norvegicus,1,,,
,2792,1,BAO_0000218,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,50597,In vivo,,CHEMBL625862,Intermediate,10116.0,,N,,A,10018,,,Rattus norvegicus,1,,,
,2792,1,BAO_0000218,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,50597,In vivo,,CHEMBL625863,Intermediate,10116.0,,N,,A,10019,,,Rattus norvegicus,1,,,
,2792,1,BAO_0000218,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,50597,In vivo,,CHEMBL625864,Intermediate,10116.0,,N,,A,10020,,,Rattus norvegicus,1,,,
,5739,1,BAO_0000218,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,50597,In vivo,,CHEMBL625865,Intermediate,10116.0,,N,,A,10021,,,Rattus norvegicus,1,,,
,15765,1,BAO_0000218,Pharmacokinetic half time was determined intravenously in rats.,50597,In vivo,,CHEMBL625866,Intermediate,10116.0,,N,,A,10022,,,Rattus norvegicus,1,,,
,6567,1,BAO_0000218,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,50597,In vivo,Plasma,CHEMBL625867,Intermediate,10116.0,,N,,A,10023,,,Rattus norvegicus,1,,1969.0,
,2448,1,BAO_0000218,Plasma half life of hydrolysis of the compound,50597,,Plasma,CHEMBL625868,Intermediate,10116.0,,N,,A,10024,,,Rattus norvegicus,1,,1969.0,
,5423,1,BAO_0000218,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,50597,In vivo,Plasma,CHEMBL625869,Intermediate,10116.0,,N,,A,10025,,,Rattus norvegicus,1,,1969.0,
,4853,1,BAO_0000218,Plasma half life period was calculated in rat,50597,,Plasma,CHEMBL874451,Intermediate,10116.0,,N,,A,10026,,,Rattus norvegicus,1,,1969.0,
,4514,1,BAO_0000218,Plasma half-life in Sprague-Dawley rats,50597,,Plasma,CHEMBL625870,Intermediate,10116.0,,N,,A,10027,,,Rattus norvegicus,1,,1969.0,
,4514,1,BAO_0000218,Plasma half-life in Sprague-Dawley rats; Not determined,50597,,Plasma,CHEMBL625871,Intermediate,10116.0,,N,,A,10028,,,Rattus norvegicus,1,,1969.0,
,1500,1,BAO_0000218,Plasma half-life in rats,50597,,Plasma,CHEMBL625872,Intermediate,10116.0,,N,,A,10029,,,Rattus norvegicus,1,,1969.0,
,1500,1,BAO_0000218,Plasma half-life in rats; <MQL,50597,,Plasma,CHEMBL625873,Intermediate,10116.0,,N,,A,10030,,,Rattus norvegicus,1,,1969.0,
,5334,1,BAO_0000218,Plasma half-life period (0-8 h) was determined,50597,,Plasma,CHEMBL625874,Intermediate,10116.0,,N,,A,10031,,,Rattus norvegicus,1,,1969.0,
,5334,1,BAO_0000218,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,50597,,Plasma,CHEMBL625875,Intermediate,10116.0,,N,,A,10032,,,Rattus norvegicus,1,,1969.0,
,5334,1,BAO_0000218,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,50597,In vivo,Plasma,CHEMBL625876,Intermediate,10116.0,,N,,A,10033,,,Rattus norvegicus,1,,1969.0,
,5334,1,BAO_0000218,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,50597,In vivo,Plasma,CHEMBL631258,Intermediate,10116.0,,N,,A,10034,,,Rattus norvegicus,1,,1969.0,
,4956,1,BAO_0000218,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,50597,,Plasma,CHEMBL631259,Intermediate,10116.0,,N,,A,10035,,,Rattus norvegicus,1,,1969.0,
,4956,1,BAO_0000218,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,50597,,Plasma,CHEMBL631260,Intermediate,10116.0,,N,,A,10036,,,Rattus norvegicus,1,,1969.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",50597,,Blood,CHEMBL631261,Intermediate,10116.0,,N,,A,10037,,,Rattus norvegicus,1,,178.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",50597,,Blood,CHEMBL631262,Intermediate,10116.0,,N,,A,10038,,,Rattus norvegicus,1,,178.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",50597,,Blood,CHEMBL631263,Intermediate,10116.0,,N,,A,10039,,,Rattus norvegicus,1,,178.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",50597,,,CHEMBL631264,Intermediate,10116.0,,N,,A,10040,,,Rattus norvegicus,1,,,
,7768,1,BAO_0000218,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",50597,,,CHEMBL631265,Intermediate,10116.0,,N,,A,10041,,,Rattus norvegicus,1,,,
,7768,1,BAO_0000218,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",50597,,,CHEMBL631266,Intermediate,10116.0,,N,,A,10042,,,Rattus norvegicus,1,,,
,7768,1,BAO_0000218,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",50597,,,CHEMBL631267,Intermediate,10116.0,,N,,A,10043,,,Rattus norvegicus,1,,,
,7768,1,BAO_0000218,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",50597,,,CHEMBL631268,Intermediate,10116.0,,N,,A,10044,,,Rattus norvegicus,1,,,
,7768,1,BAO_0000218,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",50597,,,CHEMBL631269,Intermediate,10116.0,,N,,A,10045,,,Rattus norvegicus,1,,,
,7768,1,BAO_0000218,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",50597,,,CHEMBL631270,Intermediate,10116.0,,N,,A,10046,,,Rattus norvegicus,1,,,
,7768,1,BAO_0000218,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",50597,,Heart,CHEMBL631271,Intermediate,10116.0,,N,,A,10047,,,Rattus norvegicus,1,,948.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",50597,,Heart,CHEMBL631272,Intermediate,10116.0,,N,,A,10048,,,Rattus norvegicus,1,,948.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",50597,,Heart,CHEMBL631273,Intermediate,10116.0,,N,,A,10049,,,Rattus norvegicus,1,,948.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",50597,,Heart,CHEMBL631274,Intermediate,10116.0,,N,,A,10050,,,Rattus norvegicus,1,,948.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",50597,,Heart,CHEMBL631275,Intermediate,10116.0,,N,,A,10051,,,Rattus norvegicus,1,,948.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",50597,,Heart,CHEMBL626984,Intermediate,10116.0,,N,,A,10052,,,Rattus norvegicus,1,,948.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",50597,,Heart,CHEMBL626985,Intermediate,10116.0,,N,,A,10053,,,Rattus norvegicus,1,,948.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",50597,,Liver,CHEMBL626986,Intermediate,10116.0,,N,,A,10054,,,Rattus norvegicus,1,,2107.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",50597,,Liver,CHEMBL626987,Intermediate,10116.0,,N,,A,10055,,,Rattus norvegicus,1,,2107.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",50597,,Liver,CHEMBL626988,Intermediate,10116.0,,N,,A,10056,,,Rattus norvegicus,1,,2107.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",50597,,Liver,CHEMBL626989,Intermediate,10116.0,,N,,A,10057,,,Rattus norvegicus,1,,2107.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",50597,,Liver,CHEMBL626990,Intermediate,10116.0,,N,,A,10058,,,Rattus norvegicus,1,,2107.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",50597,,Liver,CHEMBL626991,Intermediate,10116.0,,N,,A,10059,,,Rattus norvegicus,1,,2107.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",50597,,Liver,CHEMBL626992,Intermediate,10116.0,,N,,A,10060,,,Rattus norvegicus,1,,2107.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",50597,,Lung,CHEMBL626993,Intermediate,10116.0,,N,,A,10061,,,Rattus norvegicus,1,,2048.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",50597,,Lung,CHEMBL874593,Intermediate,10116.0,,N,,A,10062,,,Rattus norvegicus,1,,2048.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",50597,,Lung,CHEMBL626994,Intermediate,10116.0,,N,,A,10063,,,Rattus norvegicus,1,,2048.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",50597,,Lung,CHEMBL626995,Intermediate,10116.0,,N,,A,10064,,,Rattus norvegicus,1,,2048.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",50597,,Lung,CHEMBL626190,Intermediate,10116.0,,N,,A,10065,,,Rattus norvegicus,1,,2048.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",50597,,Lung,CHEMBL626191,Intermediate,10116.0,,N,,A,10066,,,Rattus norvegicus,1,,2048.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",50597,,Lung,CHEMBL626364,Intermediate,10116.0,,N,,A,10067,,,Rattus norvegicus,1,,2048.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",50597,,Thyroid gland,CHEMBL626365,Intermediate,10116.0,,N,,A,10068,,,Rattus norvegicus,1,,2046.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",50597,,Thyroid gland,CHEMBL626366,Intermediate,10116.0,,N,,A,10069,,,Rattus norvegicus,1,,2046.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",50597,,Thyroid gland,CHEMBL626367,Intermediate,10116.0,,N,,A,10070,,,Rattus norvegicus,1,,2046.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",50597,,Thyroid gland,CHEMBL626368,Intermediate,10116.0,,N,,A,10071,,,Rattus norvegicus,1,,2046.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",50597,,Thyroid gland,CHEMBL626369,Intermediate,10116.0,,N,,A,10072,,,Rattus norvegicus,1,,2046.0,
,7768,1,BAO_0000218,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",50597,,Thyroid gland,CHEMBL626370,Intermediate,10116.0,,N,,A,10073,,,Rattus norvegicus,1,,2046.0,
,4498,1,BAO_0000218,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",50597,In vivo,,CHEMBL626371,Intermediate,10116.0,,N,,A,10074,,,Rattus norvegicus,1,,,
,4498,1,BAO_0000218,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",50597,In vivo,,CHEMBL626372,Intermediate,10116.0,,N,,A,10075,,,Rattus norvegicus,1,,,
,3603,1,BAO_0000218,Bioavailability after a dose of 10 mg/kg p.o.,50597,In vivo,,CHEMBL626373,Intermediate,10116.0,,N,,A,10076,,,Rattus norvegicus,1,,,
,6215,1,BAO_0000218,Bioavailability after peroral administration (10 mg/kg) was determined in rat,50597,In vivo,,CHEMBL626374,Intermediate,10116.0,,N,,A,10077,,,Rattus norvegicus,1,,,
,5710,1,BAO_0000218,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,50597,In vivo,,CHEMBL626375,Intermediate,10116.0,,N,,A,10078,,,Rattus norvegicus,1,,,
,5710,1,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),50597,In vivo,,CHEMBL626376,Intermediate,10116.0,,N,,A,10079,,,Rattus norvegicus,1,,,
,5676,1,BAO_0000218,Bioavailability in rat po was determined,50597,In vivo,,CHEMBL626377,Intermediate,10116.0,,N,,A,10080,,,Rattus norvegicus,1,,,
,17667,1,BAO_0000218,Bioavailability of compound at 10 mg/kg in rat after oral administration,50597,In vivo,,CHEMBL626378,Intermediate,10116.0,,N,,A,10081,,,Rattus norvegicus,1,,,
,17667,1,BAO_0000218,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,50597,In vivo,,CHEMBL626379,Intermediate,10116.0,,N,,A,10082,,,Rattus norvegicus,1,,,
,6848,1,BAO_0000218,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),50597,In vivo,,CHEMBL626380,Intermediate,10116.0,,N,,A,10083,,,Rattus norvegicus,1,,,
,6848,1,BAO_0000218,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),50597,In vivo,,CHEMBL626381,Intermediate,10116.0,,N,,A,10084,,,Rattus norvegicus,1,,,
,17267,1,BAO_0000218,Bioavailability in rat,50597,In vivo,,CHEMBL626382,Intermediate,10116.0,,N,,A,10085,,,Rattus norvegicus,1,,,
,6362,1,BAO_0000218,Bioavailability in rat (Sprague-Dawley) (female),50597,In vivo,,CHEMBL626383,Intermediate,10116.0,,N,,A,10086,,,Rattus norvegicus,1,,,
,17671,1,BAO_0000218,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,50597,In vivo,,CHEMBL874652,Intermediate,10116.0,,N,,A,10087,,,Rattus norvegicus,1,,,
,17671,1,BAO_0000218,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),50597,In vivo,,CHEMBL626384,Intermediate,10116.0,,N,,A,10088,,,Rattus norvegicus,1,,,
,4333,1,BAO_0000218,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,50597,In vivo,,CHEMBL626385,Intermediate,10116.0,,N,,A,10089,,,Rattus norvegicus,1,,,
,6077,1,BAO_0000218,Bioavailability in rat at an oral dose of 2 mg/kg,50597,In vivo,,CHEMBL626386,Intermediate,10116.0,,N,,A,10090,,,Rattus norvegicus,1,,,
,3278,1,BAO_0000218,Bioavailability in rat,50597,In vivo,,CHEMBL626387,Intermediate,10116.0,,N,,A,10091,,,Rattus norvegicus,1,,,
,5964,1,BAO_0000218,Bioavailability in rat,50597,In vivo,,CHEMBL626388,Intermediate,10116.0,,N,,A,10092,,,Rattus norvegicus,1,,,
,4884,1,BAO_0000218,Bioavailability in rat,50597,In vivo,,CHEMBL626389,Intermediate,10116.0,,N,,A,10093,,,Rattus norvegicus,1,,,
,4905,1,BAO_0000218,Bioavailability in rat,50597,In vivo,,CHEMBL626390,Intermediate,10116.0,,N,,A,10094,,,Rattus norvegicus,1,,,
,4884,1,BAO_0000218,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,50597,In vivo,,CHEMBL626391,Intermediate,10116.0,,N,,A,10095,,,Rattus norvegicus,1,,,
,6850,1,BAO_0000218,Bioavailability in rat,50597,In vivo,,CHEMBL626392,Intermediate,10116.0,,N,,A,10096,,,Rattus norvegicus,1,,,
,2864,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL626393,Intermediate,10116.0,,N,,A,10097,,,Rattus norvegicus,1,,,
,5780,1,BAO_0000218,Bioavailability was determined in rat,50597,In vivo,,CHEMBL623026,Intermediate,10116.0,,N,,A,10098,,,Rattus norvegicus,1,,,
,1465,1,BAO_0000218,Bioavailability,50597,In vivo,,CHEMBL623027,Intermediate,10116.0,,N,,A,10099,,,Rattus norvegicus,1,,,
,5199,1,BAO_0000218,Bioavailability,50597,In vivo,,CHEMBL623028,Intermediate,10116.0,,N,,A,10100,,,Rattus norvegicus,1,,,
,5765,1,BAO_0000218,Bioavailability in rat after 1 day dosing,50597,In vivo,,CHEMBL623029,Intermediate,10116.0,,N,,A,10101,,,Rattus norvegicus,1,,,
,5765,1,BAO_0000218,Bioavailability in rat after 4 day dosing,50597,In vivo,,CHEMBL623030,Intermediate,10116.0,,N,,A,10102,,,Rattus norvegicus,1,,,
,6518,1,BAO_0000218,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,50597,In vivo,,CHEMBL623031,Intermediate,10116.0,,N,,A,10103,,,Rattus norvegicus,1,,,
,6518,1,BAO_0000218,Bioavailability after IV dosing at 1 mg/kg in rat; no data,50597,In vivo,,CHEMBL623032,Intermediate,10116.0,,N,,A,10104,,,Rattus norvegicus,1,,,
,6518,1,BAO_0000218,Bioavailability after oral administration at a dose of 2 mg/kg in rat,50597,In vivo,,CHEMBL623033,Intermediate,10116.0,,N,,A,10105,,,Rattus norvegicus,1,,,
,6518,1,BAO_0000218,Bioavailability after oral administration at a dose of 4 mg/kg in rat,50597,In vivo,,CHEMBL623034,Intermediate,10116.0,,N,,A,10106,,,Rattus norvegicus,1,,,
,2083,1,BAO_0000218,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,50597,In vivo,,CHEMBL623035,Intermediate,10116.0,,N,,A,10107,,,Rattus norvegicus,1,,,
,17260,1,BAO_0000218,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,50597,In vivo,,CHEMBL623036,Intermediate,10116.0,,N,,A,10108,,,Rattus norvegicus,1,,,
,4956,1,BAO_0000218,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),50597,In vivo,,CHEMBL623037,Intermediate,10116.0,,N,,A,10109,,,Rattus norvegicus,1,,,
,4368,1,BAO_0000218,Bioavailability by intravenous administration of 3.4 mg/kg in rat,50597,In vivo,,CHEMBL623038,Intermediate,10116.0,,N,,A,10110,,,Rattus norvegicus,1,,,
,17752,1,BAO_0000218,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,50597,In vivo,Plasma,CHEMBL874385,Intermediate,10116.0,,N,,A,10111,,,Rattus norvegicus,1,,1969.0,
,1446,1,BAO_0000218,Bioavailability in rat (Fisher) (fasted),50597,In vivo,,CHEMBL623039,Intermediate,10116.0,,N,,A,10112,,,Rattus norvegicus,1,,,
,2891,0,BAO_0000218,Bioavailability in monkey after po administration of 10 mg/kg dose,22224,In vivo,,CHEMBL623040,Intermediate,9443.0,,U,,A,10113,,,Primates,1,,,
,2891,0,BAO_0000218,Oral bioavailability in monkey (dose 10 mg/kg),22224,In vivo,,CHEMBL623041,Intermediate,9443.0,,U,,A,10114,,,Primates,1,,,
,6672,1,BAO_0000218,Bioavailability in rat,50597,In vivo,,CHEMBL623741,Intermediate,10116.0,,N,,A,10115,,,Rattus norvegicus,1,,,
,6673,1,BAO_0000218,Bioavailability in rat,50597,In vivo,,CHEMBL623742,Intermediate,10116.0,,N,,A,10116,,,Rattus norvegicus,1,,,
,17655,1,BAO_0000218,Bioavailability in rat,50597,In vivo,,CHEMBL623743,Intermediate,10116.0,,N,,A,10117,,,Rattus norvegicus,1,,,
,17796,1,BAO_0000218,Bioavailability in rat,50597,In vivo,,CHEMBL623744,Intermediate,10116.0,,N,,A,10118,,,Rattus norvegicus,1,,,
,17853,1,BAO_0000218,Bioavailability in rat (dose 2.0 mg/kg p.o.),50597,In vivo,,CHEMBL623745,Intermediate,10116.0,,N,,A,10119,,,Rattus norvegicus,1,,,
,4521,1,BAO_0000218,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),50597,In vivo,,CHEMBL623746,Intermediate,10116.0,,N,,A,10120,,,Rattus norvegicus,1,,,
,4940,1,BAO_0000218,Oral bioavailability in rat (dose 5 mg/kg p.o.),50597,In vivo,,CHEMBL623747,Intermediate,10116.0,,N,,A,10121,,,Rattus norvegicus,1,,,
,2891,0,BAO_0000218,Bioavailability in rat after po administration of 30 mg/kg dose,22224,In vivo,,CHEMBL623748,Intermediate,10116.0,,U,,A,10122,,,Rattus norvegicus,1,,,
,2891,0,BAO_0000218,Bioavailability in rat after po administration of 30 mg/kg dose,22224,In vivo,,CHEMBL623916,Intermediate,10116.0,,U,,A,10123,,,Rattus norvegicus,1,,,
,4521,1,BAO_0000218,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,50597,In vivo,,CHEMBL623917,Intermediate,10116.0,,N,,A,10124,,,Rattus norvegicus,1,,,
,17686,1,BAO_0000218,Bioavailability in rat (dose 2 mg/kg i.v.),50597,In vivo,,CHEMBL623918,Intermediate,10116.0,,N,,A,10125,,,Rattus norvegicus,1,,,
,17796,1,BAO_0000218,Bioavailability in rat,50597,In vivo,,CHEMBL874386,Intermediate,10116.0,,N,,A,10126,,,Rattus norvegicus,1,,,
,17796,1,BAO_0000218,Bioavailability in rat; Only traces detected in rat plasma,50597,In vivo,Plasma,CHEMBL623919,Intermediate,10116.0,,N,,A,10127,,,Rattus norvegicus,1,,1969.0,
,5064,1,BAO_0000218,Bioavailability in rat,50597,In vivo,,CHEMBL623920,Intermediate,10116.0,,N,,A,10128,,,Rattus norvegicus,1,,,
,5147,1,BAO_0000218,Bioavailability upon oral administration of compound,50597,In vivo,,CHEMBL623148,Intermediate,10116.0,,N,,A,10129,,,Rattus norvegicus,1,,,
,1916,1,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),50597,In vivo,,CHEMBL623149,Intermediate,10116.0,,N,,A,10130,,,Rattus norvegicus,1,,,
,6049,1,BAO_0000218,Bioavailability in rat,50597,In vivo,,CHEMBL623150,Intermediate,10116.0,,N,,A,10131,,,Rattus norvegicus,1,,,
,1445,1,BAO_0000218,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",50597,In vivo,,CHEMBL623151,Intermediate,10116.0,,N,,A,10132,,,Rattus norvegicus,1,,,
,1445,1,BAO_0000218,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",50597,In vivo,,CHEMBL623152,Intermediate,10116.0,,N,,A,10133,,,Rattus norvegicus,1,,,
,2862,1,BAO_0000218,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,50597,,,CHEMBL623153,Expert,10116.0,,N,,F,10134,,,Rattus norvegicus,1,,,
,2862,1,BAO_0000218,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,50597,,,CHEMBL623154,Expert,10116.0,,N,,F,10135,,,Rattus norvegicus,1,,,
,4194,1,BAO_0000218,In vitro and metabolic stability was determined,50597,,,CHEMBL623155,Intermediate,10116.0,,N,,A,10136,,,Rattus norvegicus,1,,,
,4194,1,BAO_0000218,In vitro metabolic stability in rat hepatocytes,50597,,,CHEMBL623156,Intermediate,10116.0,,N,,A,10137,,,Rattus norvegicus,1,,,
,5486,1,BAO_0000218,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,50597,,,CHEMBL623157,Intermediate,10116.0,,N,,A,10138,,,Rattus norvegicus,1,,,
,17582,1,BAO_0000218,Metabolic rate for compound was observed in rat hepatocytes,50597,In vitro,Liver,CHEMBL623158,Intermediate,10116.0,,N,,A,10139,,401.0,Rattus norvegicus,1,,2107.0,Hepatocyte
,5600,1,BAO_0000218,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,50597,,,CHEMBL623159,Intermediate,10116.0,,N,,A,10140,,,Rattus norvegicus,1,,,
,14294,1,BAO_0000218,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),50597,,,CHEMBL874390,Intermediate,10116.0,,N,,A,10141,,,Rattus norvegicus,1,,,
,14294,1,BAO_0000218,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),50597,,,CHEMBL623160,Intermediate,10116.0,,N,,A,10142,,,Rattus norvegicus,1,,,
,14294,1,BAO_0000218,Metabolism of compound in rat S9 microsomes; Trace,50597,,,CHEMBL623161,Intermediate,10116.0,,N,,A,10143,,,Rattus norvegicus,1,,,
,17847,1,BAO_0000218,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,50597,,,CHEMBL623162,Intermediate,10116.0,,N,,A,10144,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,50597,,,CHEMBL623163,Intermediate,10116.0,,N,,A,10145,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,50597,,,CHEMBL623164,Intermediate,10116.0,,N,,A,10146,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,50597,,,CHEMBL623165,Intermediate,10116.0,,N,,A,10147,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,50597,,,CHEMBL623166,Intermediate,10116.0,,N,,A,10148,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,50597,,,CHEMBL624983,Intermediate,10116.0,,N,,A,10149,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,50597,,,CHEMBL624984,Intermediate,10116.0,,N,,A,10150,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,50597,,,CHEMBL624985,Intermediate,10116.0,,N,,A,10151,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,50597,,,CHEMBL622970,Intermediate,10116.0,,N,,A,10152,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,50597,,,CHEMBL622971,Intermediate,10116.0,,N,,A,10153,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,50597,,,CHEMBL622972,Intermediate,10116.0,,N,,A,10154,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,50597,,,CHEMBL622973,Intermediate,10116.0,,N,,A,10155,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,50597,,,CHEMBL622974,Intermediate,10116.0,,N,,A,10156,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,50597,,,CHEMBL622975,Intermediate,10116.0,,N,,A,10157,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,50597,,,CHEMBL622976,Intermediate,10116.0,,N,,A,10158,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,50597,,,CHEMBL622977,Intermediate,10116.0,,N,,A,10159,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,50597,,,CHEMBL624351,Intermediate,10116.0,,N,,A,10160,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,50597,,,CHEMBL624352,Intermediate,10116.0,,N,,A,10161,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,50597,,,CHEMBL624353,Intermediate,10116.0,,N,,A,10162,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,50597,,,CHEMBL622397,Intermediate,10116.0,,N,,A,10163,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,50597,,,CHEMBL622398,Intermediate,10116.0,,N,,A,10164,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,50597,,,CHEMBL622399,Intermediate,10116.0,,N,,A,10165,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,50597,,,CHEMBL622400,Intermediate,10116.0,,N,,A,10166,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,50597,,,CHEMBL628428,Intermediate,10116.0,,N,,A,10167,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,50597,,,CHEMBL628590,Intermediate,10116.0,,N,,A,10168,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,50597,,,CHEMBL628591,Intermediate,10116.0,,N,,A,10169,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,50597,,,CHEMBL628592,Intermediate,10116.0,,N,,A,10170,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,50597,,,CHEMBL628593,Intermediate,10116.0,,N,,A,10171,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,50597,,,CHEMBL875333,Intermediate,10116.0,,N,,A,10172,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,50597,,,CHEMBL628594,Intermediate,10116.0,,N,,A,10173,,,Rattus norvegicus,1,,,
,4969,1,BAO_0000218,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,50597,,Plasma,CHEMBL628595,Intermediate,10116.0,,N,,A,10174,,,Rattus norvegicus,1,,1969.0,
,6737,1,BAO_0000218,Stability in rat plasma was determined,50597,,Plasma,CHEMBL628596,Intermediate,10116.0,,N,,A,10175,,,Rattus norvegicus,1,,1969.0,
,6737,1,BAO_0000218,Stability in rat plasma was determined; ND= no data,50597,,Plasma,CHEMBL628597,Intermediate,10116.0,,N,,A,10176,,,Rattus norvegicus,1,,1969.0,
,5089,1,BAO_0000218,Tested for plasma half life period in rat (0-8 hr),50597,,Plasma,CHEMBL628598,Intermediate,10116.0,,N,,A,10177,,,Rattus norvegicus,1,,1969.0,
,5089,1,BAO_0000218,Tested for plasma half life period in rat (0-8 hr); Not determined,50597,,Plasma,CHEMBL628599,Intermediate,10116.0,,N,,A,10178,,,Rattus norvegicus,1,,1969.0,
,1466,1,BAO_0000218,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,50597,In vivo,,CHEMBL628600,Intermediate,10116.0,,N,,A,10179,,,Rattus norvegicus,1,,,
,1466,1,BAO_0000218,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,50597,In vivo,,CHEMBL628601,Intermediate,10116.0,,N,,A,10180,,,Rattus norvegicus,1,,,
,4950,1,BAO_0000218,Tested for the half life in rat,50597,,,CHEMBL628602,Intermediate,10116.0,,N,,A,10181,,,Rattus norvegicus,1,,,
,2412,1,BAO_0000218,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,50597,In vitro,,CHEMBL628603,Intermediate,10116.0,,N,,A,10182,,,Rattus norvegicus,1,,,
,2412,1,BAO_0000218,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,50597,In vitro,,CHEMBL628604,Intermediate,10116.0,,N,,A,10183,,,Rattus norvegicus,1,,,
,2412,1,BAO_0000218,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,50597,In vitro,,CHEMBL628605,Intermediate,10116.0,,N,,A,10184,,,Rattus norvegicus,1,,,
,2412,1,BAO_0000218,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,50597,In vitro,,CHEMBL628606,Intermediate,10116.0,,N,,A,10185,,,Rattus norvegicus,1,,,
,2412,1,BAO_0000218,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,50597,In vitro,,CHEMBL628607,Intermediate,10116.0,,N,,A,10186,,,Rattus norvegicus,1,,,
,15022,1,BAO_0000218,The biological half life the compound was measured at the dose of 100 umol/kg,50597,,,CHEMBL628608,Intermediate,10116.0,,N,,A,10187,,,Rattus norvegicus,1,,,
,15022,1,BAO_0000218,The biological half life the compound was measured at the dose of 30 umol/kg,50597,,,CHEMBL628609,Intermediate,10116.0,,N,,A,10188,,,Rattus norvegicus,1,,,
,406,1,BAO_0000218,The compound was evaluated for plasma half life period in rat,50597,,Plasma,CHEMBL628610,Intermediate,10116.0,,N,,A,10189,,,Rattus norvegicus,1,,1969.0,
,15078,1,BAO_0000218,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",50597,In vivo,,CHEMBL873819,Intermediate,10116.0,,N,,A,10190,,,Rattus norvegicus,1,,,
,15078,1,BAO_0000218,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",50597,In vivo,,CHEMBL628611,Intermediate,10116.0,,N,,A,10191,,,Rattus norvegicus,1,,,
,5247,1,BAO_0000218,The pharmacokinetic parameter half-life period in vivo in rats,50597,In vivo,,CHEMBL628612,Intermediate,10116.0,,N,,A,10192,,,Rattus norvegicus,1,,,
,5041,1,BAO_0000218,"The pharmacokinetic property, Half-life was determined",50597,In vivo,,CHEMBL628613,Intermediate,10116.0,,N,,A,10193,,,Rattus norvegicus,1,,,
,5041,1,BAO_0000218,"The pharmacokinetic property, Half-life in rat in vivo",50597,In vivo,,CHEMBL628614,Intermediate,10116.0,,N,,A,10194,,,Rattus norvegicus,1,,,
,5041,1,BAO_0000218,"The pharmacokinetic property, Half-life was determined; ND denotes no data",50597,In vivo,,CHEMBL628615,Intermediate,10116.0,,N,,A,10195,,,Rattus norvegicus,1,,,
,5041,1,BAO_0000218,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",50597,In vivo,,CHEMBL628616,Intermediate,10116.0,,N,,A,10196,,,Rattus norvegicus,1,,,
,3918,1,BAO_0000218,The plasma half life period in rats,50597,,Plasma,CHEMBL627924,Intermediate,10116.0,,N,,A,10197,,,Rattus norvegicus,1,,1969.0,
,2906,1,BAO_0000218,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,50597,,Liver,CHEMBL627925,Intermediate,10116.0,,N,,A,10198,,,Rattus norvegicus,1,,2107.0,
,6467,1,BAO_0000218,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,50597,In vivo,,CHEMBL627926,Intermediate,10116.0,,N,,A,10199,,,Rattus norvegicus,1,,,
,5510,1,BAO_0000218,t1/2 (apparent elimination)of the compound was determined,50597,,,CHEMBL627927,Intermediate,10116.0,,N,,A,10200,,,Rattus norvegicus,1,,,
,3788,1,BAO_0000218,t1/2 value in rat,50597,,,CHEMBL627928,Intermediate,10116.0,,N,,A,10201,,,Rattus norvegicus,1,,,
,17796,1,BAO_0000218,Half life in rat,50597,,,CHEMBL627539,Intermediate,10116.0,,N,,A,10202,,,Rattus norvegicus,1,,,
,12873,1,BAO_0000218,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",50597,In vivo,Plasma,CHEMBL876790,Intermediate,10116.0,,N,,A,10203,,,Rattus norvegicus,1,,1969.0,
,5983,1,BAO_0000218,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,50597,In vivo,,CHEMBL858186,Intermediate,10116.0,,N,,A,10204,,,Rattus norvegicus,1,,,
,15765,1,BAO_0000218,Half-life period in fasted rats,50597,,,CHEMBL627540,Intermediate,10116.0,,N,,A,10205,,,Rattus norvegicus,1,,,
,2661,1,BAO_0000218,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,50597,In vivo,,CHEMBL627541,Intermediate,10116.0,,N,,A,10206,,,Rattus norvegicus,1,,,
,2661,1,BAO_0000218,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,50597,In vivo,,CHEMBL627715,Intermediate,10116.0,,N,,A,10207,,,Rattus norvegicus,1,,,
,429,1,BAO_0000218,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,50597,In vivo,,CHEMBL627716,Intermediate,10116.0,,N,,A,10208,,,Rattus norvegicus,1,,,
,17655,1,BAO_0000218,Maximum time required to achieve Cmax was determined in rat,50597,,,CHEMBL627717,Intermediate,10116.0,,N,,A,10209,,,Rattus norvegicus,1,,,
,17717,1,BAO_0000218,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,In vivo,,CHEMBL627718,Intermediate,10116.0,,N,,A,10210,,,Rattus norvegicus,1,,,
,17717,1,BAO_0000218,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,In vivo,,CHEMBL627719,Intermediate,10116.0,,N,,A,10211,,,Rattus norvegicus,1,,,
,17717,1,BAO_0000218,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,50597,In vivo,,CHEMBL627720,Intermediate,10116.0,,N,,A,10212,,,Rattus norvegicus,1,,,
,6570,1,BAO_0000218,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,50597,In vivo,,CHEMBL627721,Intermediate,10116.0,,N,,A,10213,,,Rattus norvegicus,1,,,
,6570,1,BAO_0000218,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,50597,In vivo,,CHEMBL627722,Intermediate,10116.0,,N,,A,10214,,,Rattus norvegicus,1,,,
,5978,1,BAO_0000218,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,In vivo,,CHEMBL627723,Intermediate,10116.0,,N,,A,10215,,,Rattus norvegicus,1,,,
,5978,1,BAO_0000218,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,In vivo,,CHEMBL626058,Intermediate,10116.0,,N,,A,10216,,,Rattus norvegicus,1,,,
,5978,1,BAO_0000218,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,In vivo,,CHEMBL626059,Intermediate,10116.0,,N,,A,10217,,,Rattus norvegicus,1,,,
,5978,1,BAO_0000218,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,In vivo,,CHEMBL626060,Intermediate,10116.0,,N,,A,10218,,,Rattus norvegicus,1,,,
,17720,1,BAO_0000218,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,In vivo,Plasma,CHEMBL626061,Intermediate,10116.0,,N,,A,10219,,,Rattus norvegicus,1,,1969.0,
,4723,1,BAO_0000218,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,In vivo,,CHEMBL876791,Intermediate,10116.0,,N,,A,10220,,,Rattus norvegicus,1,,,
,4723,1,BAO_0000218,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,In vivo,,CHEMBL626062,Intermediate,10116.0,,N,,A,10221,,,Rattus norvegicus,1,,,
,4756,1,BAO_0000218,Tmax at the dose of 2 mg/Kg administered perorally in rats,50597,In vivo,,CHEMBL626063,Intermediate,10116.0,,N,,A,10222,,,Rattus norvegicus,1,,,
,4756,1,BAO_0000218,Tmax at the dose of 5 mg/Kg administered perorally in rats,50597,In vivo,,CHEMBL626064,Intermediate,10116.0,,N,,A,10223,,,Rattus norvegicus,1,,,
,17720,1,BAO_0000218,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,50597,In vivo,Plasma,CHEMBL626065,Intermediate,10116.0,,N,,A,10224,,,Rattus norvegicus,1,,1969.0,
,17720,1,BAO_0000218,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,50597,In vivo,Plasma,CHEMBL626066,Intermediate,10116.0,,N,,A,10225,,,Rattus norvegicus,1,,1969.0,
,1466,1,BAO_0000218,tmax upon peroral administration of 10.0 mg/Kg dose in rat,50597,In vivo,,CHEMBL626067,Intermediate,10116.0,,N,,A,10226,,,Rattus norvegicus,1,,,
,7449,1,BAO_0000218,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,50597,,,CHEMBL626068,Intermediate,10116.0,,N,,F,10227,,,Rattus norvegicus,1,,,
,7449,1,BAO_0000218,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,50597,,,CHEMBL626069,Intermediate,10116.0,,N,,F,10228,,,Rattus norvegicus,1,,,
,7449,1,BAO_0000218,Percent total excretion of 3-methoxyacetaminophen glucuronide,50597,,,CHEMBL626070,Intermediate,10116.0,,N,,F,10229,,,Rattus norvegicus,1,,,
,7449,1,BAO_0000218,Percent total excretion of N-methoxyacetaminophen glucuronide,50597,,,CHEMBL626071,Intermediate,10116.0,,N,,F,10230,,,Rattus norvegicus,1,,,
,7449,1,BAO_0000218,Percent total excretion of N-methoxyacetaminophen sulfate,50597,,,CHEMBL626072,Intermediate,10116.0,,N,,F,10231,,,Rattus norvegicus,1,,,
,7449,1,BAO_0000218,Percent total excretion of acetaminophen,50597,,,CHEMBL626073,Intermediate,10116.0,,N,,F,10232,,,Rattus norvegicus,1,,,
,7768,1,BAO_0000218,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",50597,,Thyroid gland,CHEMBL626741,Intermediate,10116.0,,N,,A,10233,,,Rattus norvegicus,1,,2046.0,
,17655,1,BAO_0000218,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",50597,,,CHEMBL626742,Intermediate,10116.0,,N,,A,10234,,,Rattus norvegicus,1,,,
,17735,1,BAO_0000218,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,50597,,,CHEMBL626743,Intermediate,10116.0,,N,,A,10235,,,Rattus norvegicus,1,,,
,5960,1,BAO_0000218,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,50597,,,CHEMBL876792,Intermediate,10116.0,,N,,A,10236,,,Rattus norvegicus,1,,,
,17735,1,BAO_0000218,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,50597,,,CHEMBL626744,Intermediate,10116.0,,N,,A,10237,,,Rattus norvegicus,1,,,
,7116,1,BAO_0000218,Compound was tested for antidiuretic activity in rats,50597,,,CHEMBL626745,Intermediate,10116.0,,N,,A,10238,,,Rattus norvegicus,1,,,
,4878,1,BAO_0000218,AUC in rat after 3mg/kg oral dose,50597,In vivo,Plasma,CHEMBL626746,Intermediate,10116.0,,N,,A,10239,,,Rattus norvegicus,1,,1969.0,
,5939,1,BAO_0000218,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,50597,,,CHEMBL626747,Intermediate,10116.0,,N,,A,10240,,,Rattus norvegicus,1,,,
,5939,1,BAO_0000218,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,50597,,,CHEMBL626748,Intermediate,10116.0,,N,,A,10241,,,Rattus norvegicus,1,,,
,16367,1,BAO_0000218,Bioavailability administered orally at a dose of 10 mg/kg to rats,50597,,,CHEMBL626749,Intermediate,10116.0,,N,,A,10242,,,Rattus norvegicus,1,,,
,16366,1,BAO_0000218,Oral Bioavailability was determined,50597,,,CHEMBL626750,Intermediate,10116.0,,N,,A,10243,,,Rattus norvegicus,1,,,
,4426,1,BAO_0000218,Oral bioavailability in rat,50597,,,CHEMBL626751,Intermediate,10116.0,,N,,A,10244,,,Rattus norvegicus,1,,,
,4426,1,BAO_0000218,Oral bioavailability in rat; Not performed.,50597,,,CHEMBL626913,Intermediate,10116.0,,N,,A,10245,,,Rattus norvegicus,1,,,
,5041,1,BAO_0000218,Bioavailability,50597,,,CHEMBL626914,Intermediate,10116.0,,N,,A,10246,,,Rattus norvegicus,1,,,
,5041,1,BAO_0000218,Bioavailability was determined; ND denotes no data,50597,,,CHEMBL626915,Intermediate,10116.0,,N,,A,10247,,,Rattus norvegicus,1,,,
,1500,1,BAO_0000218,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,50597,,,CHEMBL626916,Intermediate,10116.0,,N,,A,10248,,,Rattus norvegicus,1,,,
,1500,1,BAO_0000218,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,50597,,,CHEMBL626917,Intermediate,10116.0,,N,,A,10249,,,Rattus norvegicus,1,,,
,17409,1,BAO_0000218,Binding towards rat plasma protein at 10 uM,50597,,,CHEMBL626918,Intermediate,10116.0,,N,,A,10250,,,Rattus norvegicus,1,,,
,17409,1,BAO_0000218,Binding towards rat plasma protein at 100 uM,50597,,,CHEMBL626919,Intermediate,10116.0,,N,,A,10251,,,Rattus norvegicus,1,,,
,2959,1,BAO_0000218,Bioavailability in rat (dose 20 mg/kg p.o.),50597,In vivo,,CHEMBL626920,Intermediate,10116.0,,N,,A,10252,,,Rattus norvegicus,1,,,
,13501,1,BAO_0000218,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,50597,In vivo,,CHEMBL621976,Intermediate,10116.0,,N,,A,10253,,,Rattus norvegicus,1,,,
,6567,1,BAO_0000218,Bioavailability in rat after 5 mg/kg oral gavage,50597,In vivo,,CHEMBL877599,Intermediate,10116.0,,N,,A,10254,,,Rattus norvegicus,1,,,
,6571,1,BAO_0000218,Bioavailability in rat,50597,In vivo,,CHEMBL621977,Intermediate,10116.0,,N,,A,10255,,,Rattus norvegicus,1,,,
,6715,1,BAO_0000218,Bioavailability in rat (dose 1 mg/kg i.v.),50597,In vivo,,CHEMBL621978,Intermediate,10116.0,,N,,A,10256,,,Rattus norvegicus,1,,,
,6715,1,BAO_0000218,Bioavailability in rat (dose 3 mg/kg p.o.),50597,In vivo,,CHEMBL621979,Intermediate,10116.0,,N,,A,10257,,,Rattus norvegicus,1,,,
,2932,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL621980,Intermediate,10116.0,,N,,A,10258,,,Rattus norvegicus,1,,,
,4171,1,BAO_0000218,Bioavailability of the compound in rats after administration of 30 mg/kg,50597,In vivo,,CHEMBL621981,Intermediate,10116.0,,N,,A,10259,,,Rattus norvegicus,1,,,
,17509,1,BAO_0000218,Bioavailability after administration of 10 mg/kg in rats,50597,In vivo,,CHEMBL621982,Intermediate,10116.0,,N,,A,10260,,,Rattus norvegicus,1,,,
,17509,1,BAO_0000218,Bioavailability after administration of 2 mg/kg in rats,50597,In vivo,,CHEMBL882953,Intermediate,10116.0,,N,,A,10261,,,Rattus norvegicus,1,,,
,4527,1,BAO_0000218,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,50597,In vivo,,CHEMBL621983,Intermediate,10116.0,,N,,A,10262,,,Rattus norvegicus,1,,,
,4026,1,BAO_0000218,Bioavailability in dogs was determined; high,50597,In vivo,,CHEMBL621984,Intermediate,10116.0,,N,,A,10263,,,Rattus norvegicus,1,,,
,6659,1,BAO_0000218,Bioavailability in monkey after intravenous administration at 1 mpk,50597,In vivo,,CHEMBL621985,Intermediate,10116.0,,N,,A,10264,,,Rattus norvegicus,1,,,
,6659,1,BAO_0000218,Bioavailability in monkey after peroral administration at 10 mpk,50597,In vivo,,CHEMBL621986,Intermediate,10116.0,,N,,A,10265,,,Rattus norvegicus,1,,,
,6659,1,BAO_0000218,Bioavailability in rat after intravenous administration at 1 mpk,50597,In vivo,,CHEMBL621987,Intermediate,10116.0,,N,,A,10266,,,Rattus norvegicus,1,,,
,6659,1,BAO_0000218,Bioavailability in rat after intravenous administration at 2 mpk,50597,In vivo,,CHEMBL877600,Intermediate,10116.0,,N,,F,10267,,,Rattus norvegicus,1,,,
,6659,1,BAO_0000218,Bioavailability in rat after peroral administration at 30 mpk,50597,In vivo,,CHEMBL621988,Intermediate,10116.0,,N,,A,10268,,,Rattus norvegicus,1,,,
,6659,1,BAO_0000218,Bioavailability in rat after peroral administration at at 100 mpk,50597,In vivo,,CHEMBL621989,Intermediate,10116.0,,N,,F,10269,,,Rattus norvegicus,1,,,
,6597,1,BAO_0000218,Bioavailability in rats was evaluated,50597,In vivo,,CHEMBL621990,Intermediate,10116.0,,N,,A,10270,,,Rattus norvegicus,1,,,
,1202,1,BAO_0000218,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,50597,In vivo,,CHEMBL621991,Intermediate,10116.0,,N,,A,10271,,,Rattus norvegicus,1,,,
,1202,1,BAO_0000218,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,50597,In vivo,,CHEMBL621992,Intermediate,10116.0,,N,,A,10272,,,Rattus norvegicus,1,,,
,1202,1,BAO_0000218,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,50597,In vivo,,CHEMBL621993,Intermediate,10116.0,,N,,A,10273,,,Rattus norvegicus,1,,,
,1202,1,BAO_0000218,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,50597,In vivo,,CHEMBL621994,Intermediate,10116.0,,N,,A,10274,,,Rattus norvegicus,1,,,
,5207,1,BAO_0000218,Bioavailability in rat,50597,In vivo,,CHEMBL621995,Intermediate,10116.0,,N,,A,10275,,,Rattus norvegicus,1,,,
,5970,1,BAO_0000218,Bioavailability in rat,50597,In vivo,,CHEMBL621996,Intermediate,10116.0,,N,,A,10276,,,Rattus norvegicus,1,,,
,17538,1,BAO_0000218,Oral bioavailability in rat (dose 10 mg/kg),50597,In vivo,,CHEMBL621997,Intermediate,10116.0,,N,,A,10277,,,Rattus norvegicus,1,,,
,17538,1,BAO_0000218,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,50597,In vivo,,CHEMBL621998,Intermediate,10116.0,,N,,A,10278,,,Rattus norvegicus,1,,,
,1466,1,BAO_0000218,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,50597,In vivo,,CHEMBL621999,Intermediate,10116.0,,N,,A,10279,,,Rattus norvegicus,1,,,
,2879,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL622000,Intermediate,10116.0,,N,,A,10280,,,Rattus norvegicus,1,,,
,2879,1,BAO_0000218,Bioavailability was measured in rat after oral administration; 2-4,50597,In vivo,,CHEMBL622001,Intermediate,10116.0,,N,,A,10281,,,Rattus norvegicus,1,,,
,2879,1,BAO_0000218,Bioavailability was measured in rat after oral administration; 3-7,50597,In vivo,,CHEMBL622002,Intermediate,10116.0,,N,,A,10282,,,Rattus norvegicus,1,,,
,3777,1,BAO_0000218,Bioavailability in rat (intraduodenal administration),50597,In vivo,,CHEMBL622003,Intermediate,10116.0,,N,,A,10283,,,Rattus norvegicus,1,,,
,3777,1,BAO_0000218,Bioavailability in rat (intraduodenal administration),50597,In vivo,,CHEMBL877601,Intermediate,10116.0,,N,,A,10284,,,Rattus norvegicus,1,,,
,3777,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL624871,Intermediate,10116.0,,N,,A,10285,,,Rattus norvegicus,1,,,
,3777,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL622004,Intermediate,10116.0,,N,,A,10286,,,Rattus norvegicus,1,,,
,5423,1,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),50597,In vivo,,CHEMBL882954,Intermediate,10116.0,,N,,A,10287,,,Rattus norvegicus,1,,,
,16365,1,BAO_0000218,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,50597,In vivo,,CHEMBL622005,Intermediate,10116.0,,N,,A,10288,,,Rattus norvegicus,1,,,
,16365,1,BAO_0000218,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,50597,In vivo,,CHEMBL622006,Intermediate,10116.0,,N,,A,10289,,,Rattus norvegicus,1,,,
,4239,1,BAO_0000218,Bioavailability was measured in rat,50597,In vivo,,CHEMBL622007,Intermediate,10116.0,,N,,A,10290,,,Rattus norvegicus,1,,,
,5438,1,BAO_0000218,Bioavailability was reported,50597,In vivo,,CHEMBL622008,Intermediate,10116.0,,N,,A,10291,,,Rattus norvegicus,1,,,
,5334,1,BAO_0000218,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),50597,In vivo,,CHEMBL622009,Intermediate,10116.0,,N,,A,10292,,,Rattus norvegicus,1,,,
,5334,1,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),50597,In vivo,,CHEMBL622010,Intermediate,10116.0,,N,,A,10293,,,Rattus norvegicus,1,,,
,4199,1,BAO_0000218,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,50597,In vivo,,CHEMBL622011,Intermediate,10116.0,,N,,A,10294,,,Rattus norvegicus,1,,,
,4199,1,BAO_0000218,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),50597,In vivo,,CHEMBL622012,Intermediate,10116.0,,N,,A,10295,,,Rattus norvegicus,1,,,
,4199,1,BAO_0000218,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),50597,In vivo,,CHEMBL622013,Intermediate,10116.0,,N,,A,10296,,,Rattus norvegicus,1,,,
,4890,1,BAO_0000218,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,50597,In vivo,,CHEMBL622014,Intermediate,10116.0,,N,,A,10297,,,Rattus norvegicus,1,,,
,2792,1,BAO_0000218,Bioavailability was determined at 3 mg/kg po dose in rats,50597,In vivo,,CHEMBL624749,Intermediate,10116.0,,N,,A,10298,,,Rattus norvegicus,1,,,
,5529,1,BAO_0000218,Oral bioavailability in rat (dose 2 mg/kg),50597,In vivo,,CHEMBL624750,Intermediate,10116.0,,N,,A,10299,,,Rattus norvegicus,1,,,
,6685,1,BAO_0000218,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",50597,In vivo,,CHEMBL624751,Intermediate,10116.0,,N,,A,10300,,,Rattus norvegicus,1,,,
,6685,1,BAO_0000218,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",50597,In vivo,,CHEMBL624752,Intermediate,10116.0,,N,,A,10301,,,Rattus norvegicus,1,,,
,6685,1,BAO_0000218,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",50597,In vivo,,CHEMBL624753,Intermediate,10116.0,,N,,A,10302,,,Rattus norvegicus,1,,,
,6005,1,BAO_0000218,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,50597,In vivo,,CHEMBL624754,Intermediate,10116.0,,N,,A,10303,,,Rattus norvegicus,1,,,
,6410,1,BAO_0000218,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,50597,In vivo,,CHEMBL624755,Intermediate,10116.0,,N,,A,10304,,,Rattus norvegicus,1,,,
,6410,1,BAO_0000218,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,50597,In vivo,,CHEMBL624756,Intermediate,10116.0,,N,,A,10305,,,Rattus norvegicus,1,,,
,6103,1,BAO_0000218,Bioavailability in rat,50597,In vivo,,CHEMBL624757,Intermediate,10116.0,,N,,A,10306,,,Rattus norvegicus,1,,,
,6410,1,BAO_0000218,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,50597,In vivo,,CHEMBL624758,Intermediate,10116.0,,N,,A,10307,,,Rattus norvegicus,1,,,
,6410,1,BAO_0000218,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,50597,In vivo,,CHEMBL622270,Intermediate,10116.0,,N,,A,10308,,,Rattus norvegicus,1,,,
,5353,1,BAO_0000218,Bioavailability in rat (Sprague-Dawley),50597,In vivo,,CHEMBL622271,Intermediate,10116.0,,N,,A,10309,,,Rattus norvegicus,1,,,
,4727,1,BAO_0000218,Bioavailability in rat at the dose of 2 mg/kg,50597,In vivo,,CHEMBL622272,Intermediate,10116.0,,N,,A,10310,,,Rattus norvegicus,1,,,
,17804,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL622273,Intermediate,10116.0,,N,,A,10311,,,Rattus norvegicus,1,,,
,5809,1,BAO_0000218,Bioavailability in rat (cannulated) (dose 2 mg/kg),50597,In vivo,,CHEMBL622274,Intermediate,10116.0,,N,,A,10312,,,Rattus norvegicus,1,,,
,17804,1,BAO_0000218,Bioavailability value of compound in rats was determined after peroral administration,50597,In vivo,,CHEMBL622275,Intermediate,10116.0,,N,,A,10313,,,Rattus norvegicus,1,,,
,3634,1,BAO_0000218,Oral bioavailability in rat (dose 20 mg/kg),50597,In vivo,,CHEMBL622276,Intermediate,10116.0,,N,,A,10314,,,Rattus norvegicus,1,,,
,3341,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL622277,Intermediate,10116.0,,N,,A,10315,,,Rattus norvegicus,1,,,
,2690,1,BAO_0000218,Oral bioavailability in rat (dose 5 mg/kg),50597,In vivo,,CHEMBL622278,Intermediate,10116.0,,N,,A,10316,,,Rattus norvegicus,1,,,
,3184,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL622279,Intermediate,10116.0,,N,,A,10317,,,Rattus norvegicus,1,,,
,740,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL622280,Intermediate,10116.0,,N,,A,10318,,,Rattus norvegicus,1,,,
,1806,1,BAO_0000218,Compound was evaluated for oral bioavailability in rats; 15-27 %,50597,In vivo,,CHEMBL624083,Intermediate,10116.0,,N,,A,10319,,,Rattus norvegicus,1,,,
,4891,1,BAO_0000218,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,50597,In vivo,,CHEMBL624084,Intermediate,10116.0,,N,,A,10320,,,Rattus norvegicus,1,,,
,3634,1,BAO_0000218,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),50597,In vivo,,CHEMBL624085,Intermediate,10116.0,,N,,A,10321,,,Rattus norvegicus,1,,,
,64,1,BAO_0000218,Compound was tested for bioavailability in rats,50597,In vivo,,CHEMBL624086,Intermediate,10116.0,,N,,A,10322,,,Rattus norvegicus,1,,,
,4839,1,BAO_0000218,Bioavailability in rat,50597,In vivo,,CHEMBL624087,Intermediate,10116.0,,N,,A,10323,,,Rattus norvegicus,1,,,
,1094,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL624088,Intermediate,10116.0,,N,,A,10324,,,Rattus norvegicus,1,,,
,5005,0,BAO_0000218,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,22224,In vivo,,CHEMBL624089,Intermediate,9544.0,,U,,A,10325,,,Macaca mulatta,1,,,
,5005,0,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),22224,In vivo,,CHEMBL624090,Intermediate,10116.0,,U,,A,10326,,,Rattus norvegicus,1,,,
,4687,1,BAO_0000218,Evaluated for the bioavailability in rat (in vivo),50597,In vivo,,CHEMBL624091,Intermediate,10116.0,,N,,A,10327,,,Rattus norvegicus,1,,,
,17804,1,BAO_0000218,F value of compound in rats was determined after peroral administration,50597,In vivo,,CHEMBL624092,Intermediate,10116.0,,N,,A,10328,,,Rattus norvegicus,1,,,
,5974,1,BAO_0000218,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,In vivo,,CHEMBL624093,Intermediate,10116.0,,N,,A,10329,,,Rattus norvegicus,1,,,
,5974,1,BAO_0000218,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,In vivo,,CHEMBL624094,Intermediate,10116.0,,N,,A,10330,,,Rattus norvegicus,1,,,
,5974,1,BAO_0000218,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,50597,In vivo,,CHEMBL624095,Intermediate,10116.0,,N,,A,10331,,,Rattus norvegicus,1,,,
,5974,1,BAO_0000218,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,In vivo,,CHEMBL624096,Intermediate,10116.0,,N,,A,10332,,,Rattus norvegicus,1,,,
,1088,1,BAO_0000218,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",50597,In vivo,,CHEMBL624097,Intermediate,10116.0,,N,,A,10333,,,Rattus norvegicus,1,,,
,1742,1,BAO_0000218,Maximum fall in carotid flow in rat,50597,In vivo,,CHEMBL624098,Intermediate,10116.0,,N,,A,10334,,,Rattus norvegicus,1,,,
,4689,1,BAO_0000218,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,50597,In vivo,,CHEMBL874392,Intermediate,10116.0,,N,,A,10335,,,Rattus norvegicus,1,,,
,2463,1,BAO_0000218,Oral bioavailability in rat (dose 5 mg/kg),50597,In vivo,,CHEMBL624099,Intermediate,10116.0,,N,,A,10336,,,Rattus norvegicus,1,,,
,5654,1,BAO_0000218,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,50597,In vivo,,CHEMBL624100,Intermediate,10116.0,,N,,A,10337,,,Rattus norvegicus,1,,,
,5654,1,BAO_0000218,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,50597,In vivo,,CHEMBL624101,Intermediate,10116.0,,N,,A,10338,,,Rattus norvegicus,1,,,
,6874,1,BAO_0000218,Oral bioavailability in rat (male Wistar),50597,In vivo,,CHEMBL624102,Intermediate,10116.0,,N,,A,10339,,,Rattus norvegicus,1,,,
,5633,1,BAO_0000218,Oral bioavailability after administration (30 mg/kg) in rat; good,50597,In vivo,,CHEMBL624103,Intermediate,10116.0,,N,,A,10340,,,Rattus norvegicus,1,,,
,5496,1,BAO_0000218,Oral bioavailability at the dose of 2 mg/kg in rat,50597,In vivo,,CHEMBL624104,Intermediate,10116.0,,N,,A,10341,,,Rattus norvegicus,1,,,
,2358,1,BAO_0000218,Oral bioavailability determined in rats,50597,In vivo,,CHEMBL624105,Intermediate,10116.0,,N,,A,10342,,,Rattus norvegicus,1,,,
,16456,1,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),50597,In vivo,,CHEMBL624106,Intermediate,10116.0,,N,,A,10343,,,Rattus norvegicus,1,,,
,5302,1,BAO_0000218,Oral bioavailability in rat (dose single 10 mg/kg),50597,In vivo,,CHEMBL624107,Intermediate,10116.0,,N,,A,10344,,,Rattus norvegicus,1,,,
,5302,1,BAO_0000218,Oral bioavailability in rat (dose single 10 mg/kg),50597,In vivo,,CHEMBL623943,Intermediate,10116.0,,N,,A,10345,,,Rattus norvegicus,1,,,
,5302,1,BAO_0000218,Oral bioavailability in rat (dose 5 mg/kg,50597,In vivo,,CHEMBL623944,Intermediate,10116.0,,N,,A,10346,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,50597,,,CHEMBL623945,Intermediate,10116.0,,N,,A,10347,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,50597,,,CHEMBL623946,Intermediate,10116.0,,N,,A,10348,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,50597,,,CHEMBL623947,Intermediate,10116.0,,N,,A,10349,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,50597,,,CHEMBL623948,Intermediate,10116.0,,N,,A,10350,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,50597,,,CHEMBL623949,Intermediate,10116.0,,N,,A,10351,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,50597,,,CHEMBL623950,Intermediate,10116.0,,N,,A,10352,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,50597,,,CHEMBL874398,Intermediate,10116.0,,N,,A,10353,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,50597,,,CHEMBL623951,Intermediate,10116.0,,N,,A,10354,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,50597,,,CHEMBL623952,Intermediate,10116.0,,N,,A,10355,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,50597,,,CHEMBL623953,Intermediate,10116.0,,N,,A,10356,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,50597,,,CHEMBL623954,Intermediate,10116.0,,N,,A,10357,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,50597,,,CHEMBL623955,Intermediate,10116.0,,N,,A,10358,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,50597,,,CHEMBL623956,Intermediate,10116.0,,N,,A,10359,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,50597,,,CHEMBL627807,Intermediate,10116.0,,N,,A,10360,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,50597,,,CHEMBL627808,Intermediate,10116.0,,N,,A,10361,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,50597,,,CHEMBL627809,Intermediate,10116.0,,N,,A,10362,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,50597,,,CHEMBL627810,Intermediate,10116.0,,N,,A,10363,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",50597,,,CHEMBL627811,Intermediate,10116.0,,N,,A,10364,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",50597,,,CHEMBL627812,Intermediate,10116.0,,N,,A,10365,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",50597,,,CHEMBL627813,Intermediate,10116.0,,N,,A,10366,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",50597,,,CHEMBL627814,Intermediate,10116.0,,N,,A,10367,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",50597,,,CHEMBL875336,Intermediate,10116.0,,N,,A,10368,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",50597,,,CHEMBL627815,Intermediate,10116.0,,N,,A,10369,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",50597,,,CHEMBL627816,Intermediate,10116.0,,N,,A,10370,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",50597,,,CHEMBL627817,Intermediate,10116.0,,N,,A,10371,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",50597,,,CHEMBL627818,Intermediate,10116.0,,N,,A,10372,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",50597,,,CHEMBL627819,Intermediate,10116.0,,N,,A,10373,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",50597,,,CHEMBL627820,Intermediate,10116.0,,N,,A,10374,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",50597,,,CHEMBL627821,Intermediate,10116.0,,N,,A,10375,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,50597,,,CHEMBL628464,Intermediate,10116.0,,N,,A,10376,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,50597,,,CHEMBL626239,Intermediate,10116.0,,N,,A,10377,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,50597,,,CHEMBL626240,Intermediate,10116.0,,N,,A,10378,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,50597,,,CHEMBL626241,Intermediate,10116.0,,N,,A,10379,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,50597,,,CHEMBL626242,Intermediate,10116.0,,N,,A,10380,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,50597,,,CHEMBL626243,Intermediate,10116.0,,N,,A,10381,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,50597,,,CHEMBL626244,Intermediate,10116.0,,N,,A,10382,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,50597,,,CHEMBL626907,Intermediate,10116.0,,N,,A,10383,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,50597,,,CHEMBL626908,Intermediate,10116.0,,N,,A,10384,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,50597,,,CHEMBL626909,Intermediate,10116.0,,N,,A,10385,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,50597,,,CHEMBL626910,Intermediate,10116.0,,N,,A,10386,,,Rattus norvegicus,1,,,
,7449,1,BAO_0000218,Percent total excretion of acetaminophen cysteine conjugate,50597,,,CHEMBL875342,Intermediate,10116.0,,N,,F,10387,,,Rattus norvegicus,1,,,
,7449,1,BAO_0000218,Percent total excretion of acetaminophen glucuronide,50597,,,CHEMBL626911,Intermediate,10116.0,,N,,F,10388,,,Rattus norvegicus,1,,,
,7449,1,BAO_0000218,Percent total excretion of acetaminophen sulfate,50597,,,CHEMBL626912,Intermediate,10116.0,,N,,F,10389,,,Rattus norvegicus,1,,,
,7449,1,BAO_0000218,Percent total excretion of acetaminophen-mercapturic acid,50597,,,CHEMBL627065,Intermediate,10116.0,,N,,F,10390,,,Rattus norvegicus,1,,,
,3172,1,BAO_0000218,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,50597,,Urine,CHEMBL627066,Intermediate,10116.0,,N,,A,10391,,,Rattus norvegicus,1,,1088.0,
,16456,1,BAO_0000218,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,50597,In vivo,,CHEMBL627067,Intermediate,10116.0,,N,,A,10392,,,Rattus norvegicus,1,,,
,10839,0,BAO_0000218,Biodistribution of compound in rat muscle after 5 min of administration,22224,In vivo,Muscle tissue,CHEMBL627068,Autocuration,8656.0,,U,,A,10393,,,ratrat,1,,2385.0,
,10839,0,BAO_0000218,Biodistribution of compound in rat muscle after 5 min of administration.,22224,In vivo,Muscle tissue,CHEMBL627069,Autocuration,8656.0,,U,,A,10394,,,ratrat,1,,2385.0,
,5334,0,BAO_0000218,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),22224,In vivo,,CHEMBL627070,Autocuration,9940.0,,U,,A,10395,,,Ovis aries,1,,,
,5334,0,BAO_0000218,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),22224,In vivo,,CHEMBL627071,Autocuration,9940.0,,U,,A,10396,,,Ovis aries,1,,,
,5334,0,BAO_0000218,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),22224,In vivo,,CHEMBL627072,Autocuration,9940.0,,U,,A,10397,,,Ovis aries,1,,,
,5334,0,BAO_0000218,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),22224,In vivo,,CHEMBL627073,Autocuration,9940.0,,U,,A,10398,,,Ovis aries,1,,,
,5334,0,BAO_0000218,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),22224,In vivo,,CHEMBL625387,Autocuration,9940.0,,U,,A,10399,,,Ovis aries,1,,,
,5334,0,BAO_0000218,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),22224,In vivo,,CHEMBL625388,Autocuration,9940.0,,U,,A,10400,,,Ovis aries,1,,,
,5334,0,BAO_0000218,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),22224,In vivo,Plasma,CHEMBL625389,Autocuration,9940.0,,U,,A,10401,,,Ovis aries,1,,1969.0,
,5334,0,BAO_0000218,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),22224,In vivo,Plasma,CHEMBL875343,Autocuration,9940.0,,U,,A,10402,,,Ovis aries,1,,1969.0,
,1735,1,BAO_0000218,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),50497,,,CHEMBL876795,Intermediate,8570.0,,N,,A,10403,,,Serpentes,1,,,
,1469,1,BAO_0000218,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,50497,,,CHEMBL626552,Intermediate,8570.0,,N,,A,10404,,,Serpentes,1,,,
,1336,1,BAO_0000218,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,50497,,,CHEMBL626553,Intermediate,8570.0,,N,,A,10405,,,Serpentes,1,,,
,12403,0,BAO_0000366,The human biological plasma half life of the compound,22224,,Plasma,CHEMBL626554,Autocuration,9606.0,,U,,A,10406,,,Homo sapiens,1,,1969.0,
,8151,1,BAO_0000218,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,50597,,Urine,CHEMBL626555,Intermediate,10116.0,,N,,A,10407,,,Rattus norvegicus,1,,1088.0,
,8004,1,BAO_0000218,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,50597,,,CHEMBL626556,Intermediate,10116.0,,N,,A,10408,,,Rattus norvegicus,1,,,
,8004,1,BAO_0000218,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,50597,,,CHEMBL626557,Intermediate,10116.0,,N,,A,10409,,,Rattus norvegicus,1,,,
,8004,1,BAO_0000218,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,50597,,,CHEMBL626558,Intermediate,10116.0,,N,,A,10410,,,Rattus norvegicus,1,,,
,8004,1,BAO_0000218,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,50597,,,CHEMBL626559,Intermediate,10116.0,,N,,A,10411,,,Rattus norvegicus,1,,,
,8004,1,BAO_0000218,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,50597,,,CHEMBL626560,Intermediate,10116.0,,N,,A,10412,,,Rattus norvegicus,1,,,
,8004,1,BAO_0000218,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,50597,,,CHEMBL876803,Intermediate,10116.0,,N,,A,10413,,,Rattus norvegicus,1,,,
,8004,1,BAO_0000218,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,50597,,,CHEMBL627964,Intermediate,10116.0,,N,,A,10414,,,Rattus norvegicus,1,,,
,8004,1,BAO_0000218,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,50597,,,CHEMBL627965,Intermediate,10116.0,,N,,A,10415,,,Rattus norvegicus,1,,,
,8004,1,BAO_0000218,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,50597,,,CHEMBL627966,Intermediate,10116.0,,N,,A,10416,,,Rattus norvegicus,1,,,
,8004,1,BAO_0000218,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,50597,,,CHEMBL627967,Intermediate,10116.0,,N,,A,10417,,,Rattus norvegicus,1,,,
,8004,1,BAO_0000218,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,50597,,,CHEMBL627968,Intermediate,10116.0,,N,,A,10418,,,Rattus norvegicus,1,,,
,8004,1,BAO_0000218,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,50597,,,CHEMBL627969,Intermediate,10116.0,,N,,A,10419,,,Rattus norvegicus,1,,,
,8004,1,BAO_0000218,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,50597,,,CHEMBL627970,Intermediate,10116.0,,N,,A,10420,,,Rattus norvegicus,1,,,
,8004,1,BAO_0000218,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,50597,,Blood,CHEMBL627971,Intermediate,10116.0,,N,,A,10421,,,Rattus norvegicus,1,,178.0,
,8004,1,BAO_0000218,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,50597,,Blood,CHEMBL627972,Intermediate,10116.0,,N,,A,10422,,,Rattus norvegicus,1,,178.0,
,15917,9,BAO_0000357,Dissociation constant against binding to human cyclophilin A,180,,,CHEMBL856029,Expert,9606.0,,D,,B,10423,,,Homo sapiens,1,,,
,12396,8,BAO_0000019,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,11591,,,CHEMBL627973,Expert,9913.0,,H,,B,10424,,,Bos taurus,1,,,
,7065,0,BAO_0000019,-Log C was determined by performing the electroshock minimum test,22224,,,CHEMBL627974,Autocuration,,,U,,A,10425,,,,1,,,
,7065,0,BAO_0000019,-Log C was determined by performing the foot shock test,22224,,,CHEMBL627975,Autocuration,,,U,,A,10426,,,,1,,,
,7065,0,BAO_0000019,-Log C was determined by performing the incl screen test,22224,,,CHEMBL627976,Autocuration,,,U,,A,10427,,,,1,,,
,7065,0,BAO_0000019,-Log C was determined by performing the maximum electroshock test,22224,,,CHEMBL627977,Autocuration,,,U,,A,10428,,,,1,,,
,7065,0,BAO_0000019,-Log C was determined by performing the pentylenetetrazole test,22224,,,CHEMBL627978,Autocuration,,,U,,A,10429,,,,1,,,
,12415,0,BAO_0000019,Tested for experimental arotinoid inhibitory dose,22224,,,CHEMBL627979,Autocuration,,,U,,A,10430,,,,1,,,
,10256,0,BAO_0000019,Negative log transformed activity,22224,,,CHEMBL876804,Autocuration,,,U,,A,10431,,,,1,,,
,7991,0,BAO_0000019,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",22224,,,CHEMBL627980,Autocuration,,,U,,A,10432,,,,1,,,
,14342,1,BAO_0000218,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,50512,,,CHEMBL627981,Intermediate,10141.0,,N,,A,10433,,,Cavia porcellus,1,,,
,14342,1,BAO_0000218,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,50512,,,CHEMBL627982,Intermediate,10141.0,,N,,A,10434,,,Cavia porcellus,1,,,
,14342,1,BAO_0000218,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,50512,,,CHEMBL627983,Intermediate,10141.0,,N,,A,10435,,,Cavia porcellus,1,,,
,14342,1,BAO_0000218,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,50512,,Ileum,CHEMBL627984,Intermediate,10141.0,,N,,A,10436,,,Cavia porcellus,1,,2116.0,
,6047,0,BAO_0000100,Solubility in water was determined; values expressed as -log,22229,,,CHEMBL627985,Autocuration,,,U,,P,10437,,,,1,,,
,17269,0,BAO_0000019,Ratio of Kcat to that of Km was determined,22224,,,CHEMBL627986,Autocuration,,,U,,A,10438,,,,1,,,
,10026,0,BAO_0000019,Observed first order rate constant,22224,,,CHEMBL627987,Autocuration,,,U,,A,10439,,,,1,,,
,14583,0,BAO_0000019,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,22224,,,CHEMBL627988,Autocuration,,,U,,A,10440,,,,1,,,
,2661,1,BAO_0000218,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,50597,In vivo,,CHEMBL627989,Intermediate,10116.0,,N,,A,10441,,,Rattus norvegicus,1,,,
,2661,1,BAO_0000218,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,50597,In vivo,,CHEMBL627990,Intermediate,10116.0,,N,,A,10442,,,Rattus norvegicus,1,,,
,4029,1,BAO_0000218,Oral Bioavailability after administration of 10 mg/kg in male rat,50597,In vivo,,CHEMBL876805,Intermediate,10116.0,,N,,A,10443,,,Rattus norvegicus,1,,,
,17735,1,BAO_0000218,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),50597,In vivo,,CHEMBL627991,Intermediate,10116.0,,N,,A,10444,,,Rattus norvegicus,1,,,
,4576,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL627992,Intermediate,10116.0,,N,,A,10445,,,Rattus norvegicus,1,,,
,17582,1,BAO_0000218,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,50597,In vivo,,CHEMBL627993,Intermediate,10116.0,,N,,A,10446,,,Rattus norvegicus,1,,,
,17651,1,BAO_0000218,Oral bioavailability at 1 mg/kg was determined in rat,50597,In vivo,,CHEMBL622817,Intermediate,10116.0,,N,,A,10447,,,Rattus norvegicus,1,,,
,17651,1,BAO_0000218,Oral bioavailability at 10 mg/kg was determined in rat,50597,In vivo,,CHEMBL622818,Intermediate,10116.0,,N,,A,10448,,,Rattus norvegicus,1,,,
,17670,1,BAO_0000218,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",50597,In vivo,,CHEMBL622819,Intermediate,10116.0,,N,,A,10449,,,Rattus norvegicus,1,,,
,5045,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL872267,Intermediate,10116.0,,N,,A,10450,,,Rattus norvegicus,1,,,
,1696,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL622820,Intermediate,10116.0,,N,,A,10451,,,Rattus norvegicus,1,,,
,17764,1,BAO_0000218,Oral bioavailability after intravenous administration in rats at 24 uM/kg,50597,In vivo,,CHEMBL622821,Intermediate,10116.0,,N,,A,10452,,,Rattus norvegicus,1,,,
,6448,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL622822,Intermediate,10116.0,,N,,A,10453,,,Rattus norvegicus,1,,,
,6596,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL622823,Intermediate,10116.0,,N,,A,10454,,,Rattus norvegicus,1,,,
,17547,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL622824,Intermediate,10116.0,,N,,A,10455,,,Rattus norvegicus,1,,,
,17771,1,BAO_0000218,Oral bioavailability in rat at a dose of 3 mg/kg,50597,In vivo,,CHEMBL622825,Intermediate,10116.0,,N,,A,10456,,,Rattus norvegicus,1,,,
,6495,1,BAO_0000218,Oral bioavailability in rat after oral administration at 10 mg/kg,50597,In vivo,,CHEMBL622901,Intermediate,10116.0,,N,,A,10457,,,Rattus norvegicus,1,,,
,4558,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL622902,Intermediate,10116.0,,N,,A,10458,,,Rattus norvegicus,1,,,
,17596,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL621844,Intermediate,10116.0,,N,,A,10459,,,Rattus norvegicus,1,,,
,6827,1,BAO_0000218,Oral bioavailability in Dawley rats,50597,In vivo,,CHEMBL621845,Intermediate,10116.0,,N,,A,10460,,,Rattus norvegicus,1,,,
,4026,1,BAO_0000218,Oral bioavailability,50597,In vivo,,CHEMBL621846,Intermediate,10116.0,,N,,A,10461,,,Rattus norvegicus,1,,,
,10,1,BAO_0000218,Oral bioavailability in rat (dose 30 mg/kg),50597,In vivo,,CHEMBL621847,Intermediate,10116.0,,N,,A,10462,,,Rattus norvegicus,1,,,
,17717,1,BAO_0000218,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,50597,In vivo,,CHEMBL877609,Intermediate,10116.0,,N,,A,10463,,,Rattus norvegicus,1,,,
,17717,1,BAO_0000218,Bioavailability in rat (dose 3 mg/kg i.v.),50597,In vivo,,CHEMBL621848,Intermediate,10116.0,,N,,A,10464,,,Rattus norvegicus,1,,,
,17717,1,BAO_0000218,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,50597,In vivo,,CHEMBL621849,Intermediate,10116.0,,N,,A,10465,,,Rattus norvegicus,1,,,
,17717,1,BAO_0000218,Oral bioavailability in rat (dose 60 mg/kg p.o.),50597,In vivo,,CHEMBL622030,Intermediate,10116.0,,N,,A,10466,,,Rattus norvegicus,1,,,
,4796,1,BAO_0000218,Percent oral bioavailability determined in rats,50597,In vivo,,CHEMBL622031,Intermediate,10116.0,,N,,A,10467,,,Rattus norvegicus,1,,,
,4883,1,BAO_0000218,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,50597,In vivo,,CHEMBL622032,Intermediate,10116.0,,N,,A,10468,,,Rattus norvegicus,1,,,
,2137,1,BAO_0000218,The compound was evaluated for bioavailability in rats; 32-51,50597,In vivo,,CHEMBL622033,Intermediate,10116.0,,N,,A,10469,,,Rattus norvegicus,1,,,
,2959,1,BAO_0000218,Bioavailability in rat (dose 20 mg/kg p.o.),50597,In vivo,,CHEMBL622034,Intermediate,10116.0,,N,,A,10470,,,Rattus norvegicus,1,,,
,1361,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL622035,Intermediate,10116.0,,N,,A,10471,,,Rattus norvegicus,1,,,
,4727,1,BAO_0000218,Bioavailability percent in rat at the dose of 2 mg/kg,50597,In vivo,,CHEMBL882966,Intermediate,10116.0,,N,,A,10472,,,Rattus norvegicus,1,,,
,16423,1,BAO_0000218,Bioavailability was evaluated after 20 uM/kg of peroral administration,50597,In vivo,,CHEMBL622036,Intermediate,10116.0,,N,,A,10473,,,Rattus norvegicus,1,,,
,5206,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL622037,Intermediate,10116.0,,N,,A,10474,,,Rattus norvegicus,1,,,
,6448,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL622038,Intermediate,10116.0,,N,,A,10475,,,Rattus norvegicus,1,,,
,17723,1,BAO_0000218,Bioavailability in rats,50597,In vivo,,CHEMBL622039,Intermediate,10116.0,,N,,A,10476,,,Rattus norvegicus,1,,,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,50597,In vivo,Blood,CHEMBL622040,Intermediate,10116.0,,N,,A,10477,,,Rattus norvegicus,1,,178.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,50597,In vivo,Blood,CHEMBL622041,Intermediate,10116.0,,N,,A,10478,,,Rattus norvegicus,1,,178.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,50597,In vivo,Blood,CHEMBL622042,Intermediate,10116.0,,N,,A,10479,,,Rattus norvegicus,1,,178.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,50597,In vivo,Blood,CHEMBL622043,Intermediate,10116.0,,N,,A,10480,,,Rattus norvegicus,1,,178.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,50597,In vivo,Blood,CHEMBL622044,Intermediate,10116.0,,N,,A,10481,,,Rattus norvegicus,1,,178.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,50597,In vivo,Bone,CHEMBL622045,Intermediate,10116.0,,N,,A,10482,,,Rattus norvegicus,1,,10000001.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,50597,In vivo,Bone,CHEMBL622046,Intermediate,10116.0,,N,,A,10483,,,Rattus norvegicus,1,,10000001.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,50597,In vivo,Bone,CHEMBL622047,Intermediate,10116.0,,N,,A,10484,,,Rattus norvegicus,1,,10000001.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,50597,In vivo,Bone,CHEMBL877610,Intermediate,10116.0,,N,,A,10485,,,Rattus norvegicus,1,,10000001.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,50597,In vivo,Brain,CHEMBL622048,Intermediate,10116.0,,N,,A,10486,,,Rattus norvegicus,1,,955.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,50597,In vivo,Brain,CHEMBL622049,Intermediate,10116.0,,N,,A,10487,,,Rattus norvegicus,1,,955.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,50597,In vivo,Brain,CHEMBL622050,Intermediate,10116.0,,N,,A,10488,,,Rattus norvegicus,1,,955.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,50597,In vivo,Brain,CHEMBL622051,Intermediate,10116.0,,N,,A,10489,,,Rattus norvegicus,1,,955.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,50597,In vivo,,CHEMBL622052,Intermediate,10116.0,,N,,A,10490,,,Rattus norvegicus,1,,,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,50597,In vivo,,CHEMBL622053,Intermediate,10116.0,,N,,A,10491,,,Rattus norvegicus,1,,,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,50597,In vivo,,CHEMBL622054,Intermediate,10116.0,,N,,A,10492,,,Rattus norvegicus,1,,,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,50597,In vivo,,CHEMBL622055,Intermediate,10116.0,,N,,A,10493,,,Rattus norvegicus,1,,,
,5237,1,BAO_0000218,Oral bioavailability in rats was determined; High,50597,In vivo,,CHEMBL622056,Intermediate,10116.0,,N,,A,10494,,,Rattus norvegicus,1,,,
,5503,1,BAO_0000218,Oral bioavailability in the rat was determined,50597,In vivo,,CHEMBL622057,Intermediate,10116.0,,N,,A,10495,,,Rattus norvegicus,1,,,
,15765,1,BAO_0000218,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,50597,In vivo,,CHEMBL628008,Intermediate,10116.0,,N,,A,10496,,,Rattus norvegicus,1,,,
,15660,1,BAO_0000218,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),50597,In vivo,,CHEMBL622058,Intermediate,10116.0,,N,,A,10497,,,Rattus norvegicus,1,,,
,5978,1,BAO_0000218,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,In vivo,,CHEMBL622059,Intermediate,10116.0,,N,,A,10498,,,Rattus norvegicus,1,,,
,5978,1,BAO_0000218,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,In vivo,,CHEMBL622060,Intermediate,10116.0,,N,,A,10499,,,Rattus norvegicus,1,,,
,5978,1,BAO_0000218,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,In vivo,,CHEMBL622061,Intermediate,10116.0,,N,,A,10500,,,Rattus norvegicus,1,,,
,5978,1,BAO_0000218,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,In vivo,,CHEMBL622062,Intermediate,10116.0,,N,,A,10501,,,Rattus norvegicus,1,,,
,5656,1,BAO_0000218,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,50597,In vivo,,CHEMBL622063,Intermediate,10116.0,,N,,A,10502,,,Rattus norvegicus,1,,,
,3598,1,BAO_0000218,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,In vivo,,CHEMBL877611,Expert,10116.0,,N,,A,10503,,,Rattus norvegicus,1,,,
,4216,1,BAO_0000218,Oral bioavailability of compound in Sprague Dawley rats,50597,In vivo,,CHEMBL622064,Intermediate,10116.0,,N,,A,10504,,,Rattus norvegicus,1,,,
,17839,1,BAO_0000218,Oral bioavailability of compound in rat,50597,In vivo,,CHEMBL622065,Intermediate,10116.0,,N,,A,10505,,,Rattus norvegicus,1,,,
,6570,1,BAO_0000218,Oral bioavailability in rat (dose 2 mg/kg),50597,In vivo,,CHEMBL622066,Intermediate,10116.0,,N,,A,10506,,,Rattus norvegicus,1,,,
,5334,1,BAO_0000218,Oral bioavailability of compound in rat was determined,50597,In vivo,,CHEMBL622067,Intermediate,10116.0,,N,,A,10507,,,Rattus norvegicus,1,,,
,6886,1,BAO_0000218,Oral bioavailability of compound in rats,50597,In vivo,,CHEMBL622068,Intermediate,10116.0,,N,,A,10508,,,Rattus norvegicus,1,,,
,5210,1,BAO_0000218,Oral bioavailability of compound was determined in rats,50597,In vivo,,CHEMBL622069,Intermediate,10116.0,,N,,A,10509,,,Rattus norvegicus,1,,,
,4170,1,BAO_0000218,Oral bioavailability at a dose of 30 mg/kg in rats,50597,In vivo,,CHEMBL624796,Intermediate,10116.0,,N,,A,10510,,,Rattus norvegicus,1,,,
,6028,1,BAO_0000218,Oral bioavailability in rat (dose 10 mg/kg),50597,In vivo,,CHEMBL624797,Intermediate,10116.0,,N,,A,10511,,,Rattus norvegicus,1,,,
,6028,1,BAO_0000218,Oral bioavailability in rat (dose 10 mg/kg),50597,In vivo,,CHEMBL623053,Intermediate,10116.0,,N,,A,10512,,,Rattus norvegicus,1,,,
,6078,1,BAO_0000218,Oral bioavailability evaluated in rat,50597,In vivo,,CHEMBL623054,Intermediate,10116.0,,N,,A,10513,,,Rattus norvegicus,1,,,
,6168,1,BAO_0000218,Oral bioavailability in fasted rat,50597,In vivo,,CHEMBL623055,Intermediate,10116.0,,N,,A,10514,,,Rattus norvegicus,1,,,
,6168,1,BAO_0000218,Oral bioavailability in fed rat,50597,In vivo,,CHEMBL623056,Intermediate,10116.0,,N,,A,10515,,,Rattus norvegicus,1,,,
,5160,1,BAO_0000218,Oral bioavailability in rat (mature male) (dose 30 mg/kg),50597,In vivo,,CHEMBL623057,Intermediate,10116.0,,N,,A,10516,,,Rattus norvegicus,1,,,
,6057,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL623058,Intermediate,10116.0,,N,,A,10517,,,Rattus norvegicus,1,,,
,6535,1,BAO_0000218,Oral bioavailability in rat (dose 10 mg/kg p.o.),50597,In vivo,,CHEMBL623059,Intermediate,10116.0,,N,,A,10518,,,Rattus norvegicus,1,,,
,6535,1,BAO_0000218,Oral bioavailability in rat after administration of 10 mg/kg po,50597,In vivo,,CHEMBL623060,Intermediate,10116.0,,N,,A,10519,,,Rattus norvegicus,1,,,
,4194,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL623061,Intermediate,10116.0,,N,,A,10520,,,Rattus norvegicus,1,,,
,6230,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL623062,Intermediate,10116.0,,N,,A,10521,,,Rattus norvegicus,1,,,
,6619,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL623063,Intermediate,10116.0,,N,,A,10522,,,Rattus norvegicus,1,,,
,17607,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL623064,Intermediate,10116.0,,N,,A,10523,,,Rattus norvegicus,1,,,
,4942,1,BAO_0000218,Oral bioavailability in ratrs,50597,In vivo,,CHEMBL623065,Intermediate,10116.0,,N,,A,10524,,,Rattus norvegicus,1,,,
,4942,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL623066,Intermediate,10116.0,,N,,A,10525,,,Rattus norvegicus,1,,,
,6646,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL623067,Intermediate,10116.0,,N,,A,10526,,,Rattus norvegicus,1,,,
,5237,1,BAO_0000218,Oral bioavailability in rats was determined; High,50597,In vivo,,CHEMBL623068,Intermediate,10116.0,,N,,A,10527,,,Rattus norvegicus,1,,,
,6646,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL623069,Intermediate,10116.0,,N,,A,10528,,,Rattus norvegicus,1,,,
,4449,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL623070,Intermediate,10116.0,,N,,A,10529,,,Rattus norvegicus,1,,,
,6057,1,BAO_0000218,Oral bioavailability was calculated in rat,50597,In vivo,,CHEMBL623071,Intermediate,10116.0,,N,,A,10530,,,Rattus norvegicus,1,,,
,2552,1,BAO_0000218,Oral bioavailability,50597,In vivo,,CHEMBL623072,Intermediate,10116.0,,N,,A,10531,,,Rattus norvegicus,1,,,
,5496,1,BAO_0000218,Oral bioavailability,50597,In vivo,,CHEMBL623073,Intermediate,10116.0,,N,,A,10532,,,Rattus norvegicus,1,,,
,6484,1,BAO_0000218,Oral bioavailability,50597,In vivo,,CHEMBL623074,Intermediate,10116.0,,N,,A,10533,,,Rattus norvegicus,1,,,
,6485,1,BAO_0000218,Oral bioavailability,50597,In vivo,,CHEMBL623075,Intermediate,10116.0,,N,,A,10534,,,Rattus norvegicus,1,,,
,6616,1,BAO_0000218,Oral bioavailability after i.v. administration,50597,In vivo,,CHEMBL623076,Intermediate,10116.0,,N,,A,10535,,,Rattus norvegicus,1,,,
,4969,1,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),50597,In vivo,,CHEMBL623077,Intermediate,10116.0,,N,,A,10536,,,Rattus norvegicus,1,,,
,5862,1,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley),50597,In vivo,,CHEMBL623078,Intermediate,10116.0,,N,,A,10537,,,Rattus norvegicus,1,,,
,4514,1,BAO_0000218,Oral bioavailability in Sprague-Dawley rats,50597,In vivo,,CHEMBL623079,Intermediate,10116.0,,N,,A,10538,,,Rattus norvegicus,1,,,
,4514,1,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),50597,In vivo,,CHEMBL623080,Intermediate,10116.0,,N,,A,10539,,,Rattus norvegicus,1,,,
,4514,1,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),50597,In vivo,,CHEMBL623081,Intermediate,10116.0,,N,,A,10540,,,Rattus norvegicus,1,,,
,5546,1,BAO_0000218,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,50597,In vivo,,CHEMBL623082,Intermediate,10116.0,,N,,A,10541,,,Rattus norvegicus,1,,,
,6168,1,BAO_0000218,Oral bioavailability in fasted rat,50597,In vivo,,CHEMBL874400,Intermediate,10116.0,,N,,A,10542,,,Rattus norvegicus,1,,,
,6168,1,BAO_0000218,Oral bioavailability in fed rat,50597,In vivo,,CHEMBL623083,Intermediate,10116.0,,N,,A,10543,,,Rattus norvegicus,1,,,
,3624,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL623084,Intermediate,10116.0,,N,,A,10544,,,Rattus norvegicus,1,,,
,5213,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL623085,Intermediate,10116.0,,N,,A,10545,,,Rattus norvegicus,1,,,
,5496,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL623086,Intermediate,10116.0,,N,,A,10546,,,Rattus norvegicus,1,,,
,5553,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL623087,Intermediate,10116.0,,N,,A,10547,,,Rattus norvegicus,1,,,
,5833,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL623088,Intermediate,10116.0,,N,,A,10548,,,Rattus norvegicus,1,,,
,5836,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL623089,Intermediate,10116.0,,N,,A,10549,,,Rattus norvegicus,1,,,
,5865,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL623090,Intermediate,10116.0,,N,,A,10550,,,Rattus norvegicus,1,,,
,5960,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL623091,Intermediate,10116.0,,N,,A,10551,,,Rattus norvegicus,1,,,
,6249,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL623092,Intermediate,10116.0,,N,,A,10552,,,Rattus norvegicus,1,,,
,6448,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL623093,Intermediate,10116.0,,N,,A,10553,,,Rattus norvegicus,1,,,
,6453,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL874401,Intermediate,10116.0,,N,,A,10554,,,Rattus norvegicus,1,,,
,6640,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL623094,Intermediate,10116.0,,N,,A,10555,,,Rattus norvegicus,1,,,
,17607,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL623095,Intermediate,10116.0,,N,,A,10556,,,Rattus norvegicus,1,,,
,5939,1,BAO_0000218,Oral bioavailability in rat after peroral administration at 10 mg/kg,50597,In vivo,,CHEMBL623096,Intermediate,10116.0,,N,,A,10557,,,Rattus norvegicus,1,,,
,5939,1,BAO_0000218,Oral bioavailability in rat after peroral administration at 5 mg/kg,50597,In vivo,,CHEMBL624913,Intermediate,10116.0,,N,,A,10558,,,Rattus norvegicus,1,,,
,6281,1,BAO_0000218,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),50597,In vivo,,CHEMBL624914,Intermediate,10116.0,,N,,A,10559,,,Rattus norvegicus,1,,,
,5874,1,BAO_0000218,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,50597,In vivo,,CHEMBL624915,Intermediate,10116.0,,N,,A,10560,,,Rattus norvegicus,1,,,
,5213,1,BAO_0000218,Oral bioavailability in rat; Not measured,50597,In vivo,,CHEMBL624916,Intermediate,10116.0,,N,,A,10561,,,Rattus norvegicus,1,,,
,4964,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL624917,Intermediate,10116.0,,N,,A,10562,,,Rattus norvegicus,1,,,
,11020,1,BAO_0000218,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,50597,,,CHEMBL625157,Intermediate,10116.0,,N,,A,10563,,,Rattus norvegicus,1,,,
,6251,1,BAO_0000218,In vitro metabolic potential in rat liver microsomes,50597,,Liver,CHEMBL625158,Intermediate,10116.0,,N,,A,10564,,,Rattus norvegicus,1,,2107.0,
,1568,1,BAO_0000218,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",50597,In vivo,,CHEMBL625159,Intermediate,10116.0,,N,,A,10565,,,Rattus norvegicus,1,,,
,3032,1,BAO_0000218,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",50597,In vivo,,CHEMBL625160,Intermediate,10116.0,,N,,A,10566,,,Rattus norvegicus,1,,,
,3748,1,BAO_0000218,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,50597,In vivo,,CHEMBL625161,Intermediate,10116.0,,N,,A,10567,,,Rattus norvegicus,1,,,
,401,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL625162,Intermediate,10116.0,,N,,A,10568,,,Rattus norvegicus,1,,,
,6512,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL625163,Intermediate,10116.0,,N,,A,10569,,,Rattus norvegicus,1,,,
,17617,1,BAO_0000218,Oral bioavailability in rats at 10 mg/kg,50597,In vivo,,CHEMBL625164,Intermediate,10116.0,,N,,A,10570,,,Rattus norvegicus,1,,,
,6679,1,BAO_0000218,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50597,In vivo,,CHEMBL625165,Intermediate,10116.0,,N,,A,10571,,,Rattus norvegicus,1,,,
,6742,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL625166,Intermediate,10116.0,,N,,A,10572,,,Rattus norvegicus,1,,,
,589,1,BAO_0000218,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,50597,,,CHEMBL625167,Intermediate,10116.0,,N,,A,10573,,,Rattus norvegicus,1,,,
,589,1,BAO_0000218,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,50597,,,CHEMBL625168,Intermediate,10116.0,,N,,A,10574,,,Rattus norvegicus,1,,,
,3185,1,BAO_0000218,Plasma clearance of the compound,50597,In vivo,,CHEMBL625169,Intermediate,10116.0,,N,,A,10575,,,Rattus norvegicus,1,,,
,17596,1,BAO_0000218,Plasma clearance at 10 mg/kg in rat upon intravenous administration,50597,In vivo,,CHEMBL626264,Intermediate,10116.0,,N,,A,10576,,,Rattus norvegicus,1,,,
,2713,1,BAO_0000218,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,50597,In vivo,,CHEMBL626265,Intermediate,10116.0,,N,,A,10577,,,Rattus norvegicus,1,,,
,12500,1,BAO_0000218,The compound was tested for plasma clearance in rat,50597,In vivo,Plasma,CHEMBL626266,Intermediate,10116.0,,N,,A,10578,,,Rattus norvegicus,1,,1969.0,
,12500,1,BAO_0000218,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,50597,In vivo,Plasma,CHEMBL626267,Intermediate,10116.0,,N,,A,10579,,,Rattus norvegicus,1,,1969.0,
,2713,1,BAO_0000218,Plasma concentration upon oral administration of 1 mg/Kg in rats,50597,,,CHEMBL626268,Intermediate,10116.0,,N,,A,10580,,,Rattus norvegicus,1,,,
,1446,1,BAO_0000218,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,50597,,,CHEMBL626269,Intermediate,10116.0,,N,,A,10581,,,Rattus norvegicus,1,,,
,6227,1,BAO_0000218,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,50597,,,CHEMBL626270,Intermediate,10116.0,,N,,A,10582,,,Rattus norvegicus,1,,,
,4709,1,BAO_0000218,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,50597,,,CHEMBL626271,Intermediate,10116.0,,N,,A,10583,,,Rattus norvegicus,1,,,
,5510,1,BAO_0000218,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",50597,,,CHEMBL626272,Intermediate,10116.0,,N,,A,10584,,,Rattus norvegicus,1,,,
,5510,1,BAO_0000218,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",50597,,,CHEMBL626273,Intermediate,10116.0,,N,,A,10585,,,Rattus norvegicus,1,,,
,5510,1,BAO_0000218,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",50597,,,CHEMBL875346,Intermediate,10116.0,,N,,A,10586,,,Rattus norvegicus,1,,,
,5510,1,BAO_0000218,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",50597,,,CHEMBL626274,Intermediate,10116.0,,N,,A,10587,,,Rattus norvegicus,1,,,
,4514,1,BAO_0000218,Compound was tested for protein binding in rat plasma,50597,,,CHEMBL626275,Intermediate,10116.0,,N,,A,10588,,,Rattus norvegicus,1,,,
,2713,1,BAO_0000218,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,50597,,,CHEMBL624646,Intermediate,10116.0,,N,,A,10589,,,Rattus norvegicus,1,,,
,2713,1,BAO_0000218,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,50597,,,CHEMBL624647,Intermediate,10116.0,,N,,A,10590,,,Rattus norvegicus,1,,,
,5340,1,BAO_0000218,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,50597,,Liver,CHEMBL624648,Intermediate,10116.0,,N,,A,10591,,,Rattus norvegicus,1,,2107.0,
,12058,1,BAO_0000218,Area under curve ratio was determined (po/iv) in rat,50597,,,CHEMBL624649,Intermediate,10116.0,,N,,A,10592,,,Rattus norvegicus,1,,,
,11195,1,BAO_0000218,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,50597,,,CHEMBL624650,Intermediate,10116.0,,N,,A,10593,,,Rattus norvegicus,1,,,
,11195,1,BAO_0000218,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,50597,,,CHEMBL624651,Intermediate,10116.0,,N,,A,10594,,,Rattus norvegicus,1,,,
,11195,1,BAO_0000218,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,50597,,,CHEMBL624652,Intermediate,10116.0,,N,,A,10595,,,Rattus norvegicus,1,,,
,6495,1,BAO_0000218,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,50597,,,CHEMBL624653,Intermediate,10116.0,,N,,A,10596,,,Rattus norvegicus,1,,,
,6078,1,BAO_0000218,Ratio of AUCbrain to AUCplasma,50597,,,CHEMBL624654,Intermediate,10116.0,,N,,A,10597,,,Rattus norvegicus,1,,,
,5656,1,BAO_0000218,Ratio of brain to plasma,50597,,,CHEMBL624655,Intermediate,10116.0,,N,,A,10598,,,Rattus norvegicus,1,,,
,4910,1,BAO_0000218,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,50597,,,CHEMBL624656,Intermediate,10116.0,,N,,A,10599,,,Rattus norvegicus,1,,,
,4910,1,BAO_0000218,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,50597,,,CHEMBL624657,Intermediate,10116.0,,N,,A,10600,,,Rattus norvegicus,1,,,
,4910,1,BAO_0000218,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,50597,,,CHEMBL624658,Intermediate,10116.0,,N,,A,10601,,,Rattus norvegicus,1,,,
,10130,1,BAO_0000218,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,50597,,,CHEMBL624659,Intermediate,10116.0,,N,,A,10602,,,Rattus norvegicus,1,,,
,10130,1,BAO_0000218,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,50597,,,CHEMBL624660,Intermediate,10116.0,,N,,A,10603,,,Rattus norvegicus,1,,,
,10130,1,BAO_0000218,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,50597,,,CHEMBL624661,Intermediate,10116.0,,N,,A,10604,,,Rattus norvegicus,1,,,
,5213,1,BAO_0000218,Steady state brain :blood ratio was determined,50597,,,CHEMBL624662,Intermediate,10116.0,,N,,A,10605,,,Rattus norvegicus,1,,,
,4910,1,BAO_0000218,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,50597,,,CHEMBL625199,Intermediate,10116.0,,N,,A,10606,,,Rattus norvegicus,1,,,
,4910,1,BAO_0000218,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,50597,,,CHEMBL625200,Intermediate,10116.0,,N,,A,10607,,,Rattus norvegicus,1,,,
,4910,1,BAO_0000218,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,50597,,,CHEMBL625201,Intermediate,10116.0,,N,,A,10608,,,Rattus norvegicus,1,,,
,4910,1,BAO_0000218,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,50597,,,CHEMBL625202,Intermediate,10116.0,,N,,A,10609,,,Rattus norvegicus,1,,,
,2083,1,BAO_0000218,Percentage recovery after 3h incubation with rat hapatocytes was determined,50597,,,CHEMBL625203,Intermediate,10116.0,,N,,A,10610,,,Rattus norvegicus,1,,,
,2082,1,BAO_0000218,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,50597,,,CHEMBL625204,Intermediate,10116.0,,N,,A,10611,,,Rattus norvegicus,1,,,
,2082,1,BAO_0000218,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,50597,,,CHEMBL625205,Intermediate,10116.0,,N,,A,10612,,,Rattus norvegicus,1,,,
,6351,1,BAO_0000218,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,50597,,,CHEMBL625206,Intermediate,10116.0,,N,,A,10613,,,Rattus norvegicus,1,,,
,14583,0,BAO_0000019,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",22224,,,CHEMBL625207,Autocuration,,,U,,A,10614,,,,1,,,
,14583,0,BAO_0000019,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,22224,,,CHEMBL625208,Autocuration,,,U,,A,10615,,,,1,,,
,4608,1,BAO_0000218,In vivo absorption in Caco-2 cell line monolayers was determined,50587,,,CHEMBL625209,Intermediate,9606.0,,N,,A,10616,,495.0,Homo sapiens,1,,,Caco-2
,13668,0,BAO_0000100,Calculated partition coefficient (clogP),22229,,,CHEMBL625210,Autocuration,,,U,,P,10617,,,,1,,,
,5669,1,BAO_0000218,Area under curve was determine after peroral administration at 10 mpk in Rat,50597,,,CHEMBL625211,Intermediate,10116.0,,N,,A,10618,,,Rattus norvegicus,1,,,
,5669,1,BAO_0000218,Area under curve was determine after peroral administration at 10 mpk in Rhesus,50797,,,CHEMBL625212,Intermediate,9544.0,,N,,A,10619,,,Macaca mulatta,1,,,
,5669,1,BAO_0000218,Area under curve was determine after peroral administration at 160 mpk in Rat,50597,,,CHEMBL625213,Intermediate,10116.0,,N,,A,10620,,,Rattus norvegicus,1,,,
,5669,1,BAO_0000218,Area under curve was determine after peroral administration at 20 mpk in Rat,50597,,,CHEMBL625214,Intermediate,10116.0,,N,,A,10621,,,Rattus norvegicus,1,,,
,5669,1,BAO_0000218,Area under curve was determine after peroral administration at 50 mpk in Rat,50597,,,CHEMBL874542,Intermediate,10116.0,,N,,A,10622,,,Rattus norvegicus,1,,,
,6472,0,BAO_0000100,Calculated partition coefficient (clogP) (AlogP),22229,,,CHEMBL625215,Autocuration,,,U,,P,10623,,,,1,,,
,15106,0,BAO_0000019,Activated partial thromboplastin time measured,22224,,,CHEMBL625216,Autocuration,,,U,,A,10624,,,,1,,,
,15207,0,BAO_0000100,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),22224,,,CHEMBL625217,Autocuration,,,U,,P,10625,,,,1,,,
,15207,0,BAO_0000100,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),22224,,,CHEMBL625218,Autocuration,,,U,,P,10626,,,,1,,,
,13941,1,BAO_0000218,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,50588,,Plasma,CHEMBL622864,Intermediate,9615.0,,N,,A,10627,,,Canis lupus familiaris,1,,1969.0,
,13941,1,BAO_0000218,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,50597,,Plasma,CHEMBL622865,Intermediate,10116.0,,N,,A,10628,,,Rattus norvegicus,1,,1969.0,
,13941,1,BAO_0000218,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,50597,,Plasma,CHEMBL622866,Intermediate,10116.0,,N,,A,10629,,,Rattus norvegicus,1,,1969.0,
,13941,1,BAO_0000218,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,50588,,Plasma,CHEMBL622867,Intermediate,9615.0,,N,,A,10630,,,Canis lupus familiaris,1,,1969.0,
,15240,1,BAO_0000218,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,50512,,Plasma,CHEMBL876808,Intermediate,10141.0,,N,,A,10631,,,Cavia porcellus,1,,1969.0,
,10655,0,BAO_0000019,AUC in brain,22224,,Brain,CHEMBL627725,Autocuration,,,U,,A,10632,,,,1,,955.0,
,10655,0,BAO_0000019,AUC in serum,22224,,Serum,CHEMBL627726,Autocuration,,,U,,A,10633,,,,1,,1977.0,
,6504,0,BAO_0000019,AUC was determined,22224,,Plasma,CHEMBL627727,Autocuration,,,U,,A,10634,,,,1,,1969.0,
,10615,0,BAO_0000019,AUC of the compound.,22224,,Plasma,CHEMBL627728,Autocuration,,,U,,A,10635,,,,1,,1969.0,
,10353,0,BAO_0000019,AUC value (0-4 hr),22224,,Plasma,CHEMBL627729,Autocuration,,,U,,A,10636,,,,1,,1969.0,
,14907,0,BAO_0000019,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",22224,,Plasma,CHEMBL627730,Autocuration,,,U,,A,10637,,,,1,,1969.0,
,14907,0,BAO_0000019,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,22224,,Plasma,CHEMBL627731,Autocuration,,,U,,A,10638,,,,1,,1969.0,
,14907,0,BAO_0000019,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",22224,,Plasma,CHEMBL627732,Autocuration,,,U,,A,10639,,,,1,,1969.0,
,14907,0,BAO_0000019,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",22224,,Plasma,CHEMBL627733,Autocuration,,,U,,A,10640,,,,1,,1969.0,
,16359,1,BAO_0000218,AUC(area under curve) was determined after intravenous administration in rats,50597,,Plasma,CHEMBL627734,Intermediate,10116.0,,N,,A,10641,,,Rattus norvegicus,1,,1969.0,
,16359,1,BAO_0000218,AUC(area under curve) was determined after oral administration in rats,50597,,Plasma,CHEMBL627735,Intermediate,10116.0,,N,,A,10642,,,Rattus norvegicus,1,,1969.0,
,15240,1,BAO_0000218,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,50512,,Plasma,CHEMBL627736,Intermediate,10141.0,,N,,A,10643,,,Cavia porcellus,1,,1969.0,
,15240,1,BAO_0000218,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,50597,,Plasma,CHEMBL876809,Intermediate,10116.0,,N,,A,10644,,,Rattus norvegicus,1,,1969.0,
,15469,0,BAO_0000019,Area Under Curve after oral dosing of 100 uM/Kg,22224,,,CHEMBL627737,Autocuration,,,U,,A,10645,,,,1,,,
,15469,0,BAO_0000019,Area Under Curve after oral dosing of 30 uM/Kg,22224,,,CHEMBL627738,Autocuration,,,U,,A,10646,,,,1,,,
,13520,0,BAO_0000019,Area Under Curve was measured by ploting the graph between concentration verses time,22224,,,CHEMBL627739,Autocuration,,,U,,A,10647,,,,1,,,
,17025,1,BAO_0000218,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,50588,,,CHEMBL626143,Intermediate,9615.0,,N,,A,10648,,,Canis lupus familiaris,1,,,
,17025,0,BAO_0000218,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,22224,,,CHEMBL626144,Autocuration,314293.0,,U,,A,10649,,,Simiiformes,1,,,
,17025,1,BAO_0000218,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,50592,,,CHEMBL626145,Intermediate,9986.0,,N,,A,10650,,,Oryctolagus cuniculus,1,,,
,17025,1,BAO_0000218,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,50597,,,CHEMBL626146,Intermediate,10116.0,,N,,A,10651,,,Rattus norvegicus,1,,,
,12032,1,BAO_0000218,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,50597,,Blood,CHEMBL626147,Intermediate,10116.0,,N,,A,10652,,,Rattus norvegicus,1,,178.0,
,10291,0,BAO_0000019,Area under curve (AUC) was determined,22224,,,CHEMBL626148,Autocuration,,,U,,A,10653,,,,1,,,
,5767,0,BAO_0000218,Area under curve (AUC) following ip administration at 1 mg/kg,22224,,,CHEMBL626149,Autocuration,,,U,,A,10654,,,,1,,,
,1434,0,BAO_0000019,Area under curve (AUC) was determined; ND is Not determined,22224,,,CHEMBL626150,Autocuration,,,U,,A,10655,,,,1,,,
,14925,1,BAO_0000218,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,50588,,,CHEMBL626151,Intermediate,9615.0,,N,,A,10656,,,Canis lupus familiaris,1,,,
,14925,1,BAO_0000218,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,50588,,,CHEMBL626152,Intermediate,9615.0,,N,,A,10657,,,Canis lupus familiaris,1,,,
,14925,1,BAO_0000218,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,50588,,,CHEMBL626153,Intermediate,9615.0,,N,,A,10658,,,Canis lupus familiaris,1,,,
,1434,0,BAO_0000019,Area under curve (AUR) was determined,22224,,,CHEMBL626154,Autocuration,,,U,,A,10659,,,,1,,,
,11883,0,BAO_0000019,Area under curve at 1 uM/dg administered intravenously,22224,,,CHEMBL626155,Autocuration,,,U,,A,10660,,,,1,,,
,11883,0,BAO_0000019,Area under curve at 10 uM/dg administered perorally,22224,,,CHEMBL626156,Autocuration,,,U,,A,10661,,,,1,,,
,11883,0,BAO_0000019,Area under curve at 2 uM/dg administered intravenously,22224,,,CHEMBL626157,Autocuration,,,U,,A,10662,,,,1,,,
,11883,0,BAO_0000019,Area under curve at 20 uM/dg administered perorally,22224,,,CHEMBL626158,Autocuration,,,U,,A,10663,,,,1,,,
,15233,1,BAO_0000218,Area under curve at a peroral dose of 3 mg/kg in dog,50588,,,CHEMBL626159,Intermediate,9615.0,,N,,A,10664,,,Canis lupus familiaris,1,,,
,15233,1,BAO_0000218,Area under curve at a peroral dose of 3 mg/kg in rat,50597,,,CHEMBL626160,Intermediate,10116.0,,N,,A,10665,,,Rattus norvegicus,1,,,
,15233,1,BAO_0000218,Area under curve at an iv dose of 1 mg/kg in dog,50588,,,CHEMBL626161,Intermediate,9615.0,,N,,A,10666,,,Canis lupus familiaris,1,,,
,15233,1,BAO_0000218,Area under curve at an iv dose of 1 mg/kg in rat,50597,,,CHEMBL626162,Intermediate,10116.0,,N,,A,10667,,,Rattus norvegicus,1,,,
,12978,0,BAO_0000019,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,22224,,,CHEMBL626163,Autocuration,,,U,,A,10668,,,,1,,,
,12978,0,BAO_0000019,Area under curve gives the effective duration for the angiotensin II antagonist effect.,22224,,,CHEMBL626164,Autocuration,,,U,,A,10669,,,,1,,,
,11355,1,BAO_0000218,Area under curve measured as conc vs time after intravenous administration to mice.,50594,,,CHEMBL626165,Intermediate,10090.0,,N,,A,10670,,,Mus musculus,1,,,
,11355,1,BAO_0000218,Area under curve measured as conc vs time after peroral administration to mice.,50594,,,CHEMBL626166,Intermediate,10090.0,,N,,A,10671,,,Mus musculus,1,,,
,12923,1,BAO_0000218,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,50588,,,CHEMBL626167,Intermediate,9615.0,,N,,A,10672,,,Canis lupus familiaris,1,,,
,12923,1,BAO_0000218,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,50588,,,CHEMBL626168,Intermediate,9615.0,,N,,A,10673,,,Canis lupus familiaris,1,,,
,12923,1,BAO_0000218,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,50588,,,CHEMBL877463,Intermediate,9615.0,,N,,A,10674,,,Canis lupus familiaris,1,,,
,12923,1,BAO_0000218,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,50588,,,CHEMBL626169,Intermediate,9615.0,,N,,A,10675,,,Canis lupus familiaris,1,,,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,50597,In vivo,Heart,CHEMBL626170,Intermediate,10116.0,,N,,A,10676,,,Rattus norvegicus,1,,948.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,50597,In vivo,Heart,CHEMBL626171,Intermediate,10116.0,,N,,A,10677,,,Rattus norvegicus,1,,948.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,50597,In vivo,Heart,CHEMBL626172,Intermediate,10116.0,,N,,A,10678,,,Rattus norvegicus,1,,948.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,50597,In vivo,Heart,CHEMBL626173,Intermediate,10116.0,,N,,A,10679,,,Rattus norvegicus,1,,948.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,50597,In vivo,Kidney,CHEMBL626174,Intermediate,10116.0,,N,,A,10680,,,Rattus norvegicus,1,,2113.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,50597,In vivo,Kidney,CHEMBL626175,Intermediate,10116.0,,N,,A,10681,,,Rattus norvegicus,1,,2113.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,50597,In vivo,Kidney,CHEMBL626176,Intermediate,10116.0,,N,,A,10682,,,Rattus norvegicus,1,,2113.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,50597,In vivo,Kidney,CHEMBL626177,Intermediate,10116.0,,N,,A,10683,,,Rattus norvegicus,1,,2113.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,50597,In vivo,Kidney,CHEMBL622499,Intermediate,10116.0,,N,,A,10684,,,Rattus norvegicus,1,,2113.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,50597,In vivo,Liver,CHEMBL622500,Intermediate,10116.0,,N,,A,10685,,,Rattus norvegicus,1,,2107.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,50597,In vivo,Liver,CHEMBL622501,Intermediate,10116.0,,N,,A,10686,,,Rattus norvegicus,1,,2107.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,50597,In vivo,Liver,CHEMBL622502,Intermediate,10116.0,,N,,A,10687,,,Rattus norvegicus,1,,2107.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,50597,In vivo,Liver,CHEMBL622503,Intermediate,10116.0,,N,,A,10688,,,Rattus norvegicus,1,,2107.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,50597,In vivo,Liver,CHEMBL877614,Intermediate,10116.0,,N,,A,10689,,,Rattus norvegicus,1,,2107.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,50597,In vivo,Lung,CHEMBL624839,Intermediate,10116.0,,N,,A,10690,,,Rattus norvegicus,1,,2048.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,50597,In vivo,Lung,CHEMBL624840,Intermediate,10116.0,,N,,A,10691,,,Rattus norvegicus,1,,2048.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,50597,In vivo,Lung,CHEMBL624841,Intermediate,10116.0,,N,,A,10692,,,Rattus norvegicus,1,,2048.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,50597,In vivo,Lung,CHEMBL624842,Intermediate,10116.0,,N,,A,10693,,,Rattus norvegicus,1,,2048.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,50597,In vivo,Muscle tissue,CHEMBL624843,Intermediate,10116.0,,N,,A,10694,,,Rattus norvegicus,1,,2385.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,50597,In vivo,Muscle tissue,CHEMBL624844,Intermediate,10116.0,,N,,A,10695,,,Rattus norvegicus,1,,2385.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,50597,In vivo,Muscle tissue,CHEMBL624845,Intermediate,10116.0,,N,,A,10696,,,Rattus norvegicus,1,,2385.0,
,17738,1,BAO_0000218,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,50597,In vivo,Muscle tissue,CHEMBL621904,Intermediate,10116.0,,N,,A,10697,,,Rattus norvegicus,1,,2385.0,
,11195,1,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,50597,In vivo,Blood,CHEMBL621905,Intermediate,10116.0,,N,,A,10698,,,Rattus norvegicus,1,,178.0,
,11195,1,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,50597,In vivo,Blood,CHEMBL874382,Intermediate,10116.0,,N,,A,10699,,,Rattus norvegicus,1,,178.0,
,11195,1,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,50597,In vivo,Blood,CHEMBL621906,Intermediate,10116.0,,N,,A,10700,,,Rattus norvegicus,1,,178.0,
,11195,1,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,50597,In vivo,Brain,CHEMBL621907,Intermediate,10116.0,,N,,A,10701,,,Rattus norvegicus,1,,955.0,
,11195,1,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,50597,In vivo,Brain,CHEMBL622096,Intermediate,10116.0,,N,,A,10702,,,Rattus norvegicus,1,,955.0,
,11195,1,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,50597,In vivo,Brain,CHEMBL622097,Intermediate,10116.0,,N,,A,10703,,,Rattus norvegicus,1,,955.0,
,11195,1,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,50597,In vivo,Heart,CHEMBL622098,Intermediate,10116.0,,N,,A,10704,,,Rattus norvegicus,1,,948.0,
,11195,1,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,50597,In vivo,Heart,CHEMBL622099,Intermediate,10116.0,,N,,A,10705,,,Rattus norvegicus,1,,948.0,
,11195,1,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,50597,In vivo,Heart,CHEMBL622100,Intermediate,10116.0,,N,,A,10706,,,Rattus norvegicus,1,,948.0,
,11195,1,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,50597,In vivo,Kidney,CHEMBL622101,Intermediate,10116.0,,N,,A,10707,,,Rattus norvegicus,1,,2113.0,
,11195,1,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,50597,In vivo,Kidney,CHEMBL622102,Intermediate,10116.0,,N,,A,10708,,,Rattus norvegicus,1,,2113.0,
,11195,1,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,50597,In vivo,Kidney,CHEMBL622103,Intermediate,10116.0,,N,,A,10709,,,Rattus norvegicus,1,,2113.0,
,11195,1,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,50597,In vivo,Liver,CHEMBL622104,Intermediate,10116.0,,N,,A,10710,,,Rattus norvegicus,1,,2107.0,
,11195,1,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,50597,In vivo,Liver,CHEMBL622105,Intermediate,10116.0,,N,,A,10711,,,Rattus norvegicus,1,,2107.0,
,11195,1,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,50597,In vivo,Liver,CHEMBL622106,Intermediate,10116.0,,N,,A,10712,,,Rattus norvegicus,1,,2107.0,
,11195,1,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,50597,In vivo,Lung,CHEMBL622107,Intermediate,10116.0,,N,,A,10713,,,Rattus norvegicus,1,,2048.0,
,11195,1,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,50597,In vivo,Lung,CHEMBL622108,Intermediate,10116.0,,N,,A,10714,,,Rattus norvegicus,1,,2048.0,
,11195,1,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,50597,In vivo,Lung,CHEMBL622109,Intermediate,10116.0,,N,,A,10715,,,Rattus norvegicus,1,,2048.0,
,11195,1,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,50597,In vivo,Muscle tissue,CHEMBL622110,Intermediate,10116.0,,N,,A,10716,,,Rattus norvegicus,1,,2385.0,
,11195,1,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,50597,In vivo,Muscle tissue,CHEMBL622111,Intermediate,10116.0,,N,,A,10717,,,Rattus norvegicus,1,,2385.0,
,11195,1,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,50597,In vivo,Muscle tissue,CHEMBL874383,Intermediate,10116.0,,N,,A,10718,,,Rattus norvegicus,1,,2385.0,
,11195,1,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,50597,In vivo,Zone of skin,CHEMBL622112,Intermediate,10116.0,,N,,A,10719,,,Rattus norvegicus,1,,14.0,
,11195,1,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,50597,In vivo,Zone of skin,CHEMBL622113,Intermediate,10116.0,,N,,A,10720,,,Rattus norvegicus,1,,14.0,
,11195,1,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,50597,In vivo,Zone of skin,CHEMBL622114,Intermediate,10116.0,,N,,A,10721,,,Rattus norvegicus,1,,14.0,
,11195,1,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,50597,In vivo,Spleen,CHEMBL622115,Intermediate,10116.0,,N,,A,10722,,,Rattus norvegicus,1,,2106.0,
,11195,1,BAO_0000218,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,50597,In vivo,Spleen,CHEMBL622116,Intermediate,10116.0,,N,,A,10723,,,Rattus norvegicus,1,,2106.0,
,6193,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL622117,Intermediate,10116.0,,N,,A,10724,,,Rattus norvegicus,1,,,
,6803,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL622118,Intermediate,10116.0,,N,,A,10725,,,Rattus norvegicus,1,,,
,6647,1,BAO_0000218,Oral bioavailability in rats at 6 mg/kg,50597,In vivo,,CHEMBL622119,Intermediate,10116.0,,N,,A,10726,,,Rattus norvegicus,1,,,
,6647,1,BAO_0000218,Oral bioavailability in rat (dose 6 mg/kg),50597,In vivo,,CHEMBL622120,Intermediate,10116.0,,N,,A,10727,,,Rattus norvegicus,1,,,
,6647,1,BAO_0000218,Oral bioavailability in rats at 6 mg/kg dose; Not tested,50597,In vivo,,CHEMBL622121,Intermediate,10116.0,,N,,A,10728,,,Rattus norvegicus,1,,,
,6640,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL622122,Intermediate,10116.0,,N,,A,10729,,,Rattus norvegicus,1,,,
,6641,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL622123,Intermediate,10116.0,,N,,A,10730,,,Rattus norvegicus,1,,,
,6641,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL622124,Intermediate,10116.0,,N,,A,10731,,,Rattus norvegicus,1,,,
,6642,1,BAO_0000218,Bioavailability in rat,50597,In vivo,,CHEMBL622125,Intermediate,10116.0,,N,,A,10732,,,Rattus norvegicus,1,,,
,5472,1,BAO_0000218,Oral bioavailability,50597,In vivo,,CHEMBL622126,Intermediate,10116.0,,N,,A,10733,,,Rattus norvegicus,1,,,
,6141,1,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),50597,In vivo,,CHEMBL620455,Intermediate,10116.0,,N,,A,10734,,,Rattus norvegicus,1,,,
,4390,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL620456,Intermediate,10116.0,,N,,A,10735,,,Rattus norvegicus,1,,,
,5472,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL620457,Intermediate,10116.0,,N,,A,10736,,,Rattus norvegicus,1,,,
,5472,1,BAO_0000218,Oral bioavailability was evaluated; Not tested,50597,In vivo,,CHEMBL620458,Intermediate,10116.0,,N,,A,10737,,,Rattus norvegicus,1,,,
,5438,1,BAO_0000218,Oral bioavailability,50597,In vivo,,CHEMBL620459,Intermediate,10116.0,,N,,A,10738,,,Rattus norvegicus,1,,,
,4883,1,BAO_0000218,Oral bioavailability in rat by oral dosing,50597,In vivo,,CHEMBL620460,Intermediate,10116.0,,N,,A,10739,,,Rattus norvegicus,1,,,
,1908,1,BAO_0000218,Oral bioavailability in rat (dose 10 mg/kg p.o.),50597,In vivo,,CHEMBL620461,Intermediate,10116.0,,N,,A,10740,,,Rattus norvegicus,1,,,
,4853,1,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley),50597,In vivo,,CHEMBL620462,Intermediate,10116.0,,N,,A,10741,,,Rattus norvegicus,1,,,
,4853,1,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),50597,In vivo,,CHEMBL620463,Intermediate,10116.0,,N,,A,10742,,,Rattus norvegicus,1,,,
,4853,1,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),50597,In vivo,,CHEMBL620464,Intermediate,10116.0,,N,,A,10743,,,Rattus norvegicus,1,,,
,4853,1,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),50597,In vivo,,CHEMBL620465,Intermediate,10116.0,,N,,A,10744,,,Rattus norvegicus,1,,,
,4853,1,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),50597,In vivo,,CHEMBL620466,Intermediate,10116.0,,N,,A,10745,,,Rattus norvegicus,1,,,
,4853,1,BAO_0000218,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,50597,In vivo,,CHEMBL620467,Intermediate,10116.0,,N,,A,10746,,,Rattus norvegicus,1,,,
,4853,1,BAO_0000218,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,50597,In vivo,,CHEMBL620468,Intermediate,10116.0,,N,,A,10747,,,Rattus norvegicus,1,,,
,12873,1,BAO_0000218,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,50597,In vivo,,CHEMBL620469,Intermediate,10116.0,,N,,A,10748,,,Rattus norvegicus,1,,,
,12873,1,BAO_0000218,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,50597,In vivo,,CHEMBL620470,Intermediate,10116.0,,N,,A,10749,,,Rattus norvegicus,1,,,
,3169,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL620471,Intermediate,10116.0,,N,,A,10750,,,Rattus norvegicus,1,,,
,6305,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL620472,Intermediate,10116.0,,N,,A,10751,,,Rattus norvegicus,1,,,
,4762,1,BAO_0000218,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,50597,In vivo,,CHEMBL620473,Intermediate,10116.0,,N,,A,10752,,,Rattus norvegicus,1,,,
,17847,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL620474,Intermediate,10116.0,,N,,A,10753,,,Rattus norvegicus,1,,,
,6211,1,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),50597,In vivo,,CHEMBL620475,Intermediate,10116.0,,N,,A,10754,,,Rattus norvegicus,1,,,
,6011,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL620476,Intermediate,10116.0,,N,,A,10755,,,Rattus norvegicus,1,,,
,6317,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL620477,Intermediate,10116.0,,N,,A,10756,,,Rattus norvegicus,1,,,
,6644,1,BAO_0000218,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,50597,In vivo,,CHEMBL620478,Intermediate,10116.0,,N,,A,10757,,,Rattus norvegicus,1,,,
,6644,1,BAO_0000218,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,50597,In vivo,,CHEMBL618768,Intermediate,10116.0,,N,,A,10758,,,Rattus norvegicus,1,,,
,6644,1,BAO_0000218,Oral bioavailability in rat after oral administration at 13 mg/kg dose,50597,In vivo,,CHEMBL618769,Intermediate,10116.0,,N,,A,10759,,,Rattus norvegicus,1,,,
,6644,1,BAO_0000218,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,50597,In vivo,,CHEMBL618770,Intermediate,10116.0,,N,,A,10760,,,Rattus norvegicus,1,,,
,6113,1,BAO_0000218,Oral bioavailability (dose 20 mg/kg p.o.),50597,In vivo,,CHEMBL618771,Intermediate,10116.0,,N,,A,10761,,,Rattus norvegicus,1,,,
,5937,1,BAO_0000218,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,50597,In vivo,,CHEMBL618772,Intermediate,10116.0,,N,,A,10762,,,Rattus norvegicus,1,,,
,5711,1,BAO_0000218,Oral bioavailability in rat at 10 mg/kg of the compound,50597,In vivo,,CHEMBL618773,Intermediate,10116.0,,N,,A,10763,,,Rattus norvegicus,1,,,
,17717,1,BAO_0000218,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,50597,In vivo,,CHEMBL875842,Intermediate,10116.0,,N,,A,10764,,,Rattus norvegicus,1,,,
,17717,1,BAO_0000218,Bioavailability in rat (dose 3 mg/kg i.v.),50597,In vivo,,CHEMBL618774,Intermediate,10116.0,,N,,A,10765,,,Rattus norvegicus,1,,,
,17717,1,BAO_0000218,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,50597,In vivo,,CHEMBL618775,Intermediate,10116.0,,N,,A,10766,,,Rattus norvegicus,1,,,
,17717,1,BAO_0000218,Oral bioavailability in rat (dose 60 mg/kg p.o.),50597,In vivo,,CHEMBL618776,Intermediate,10116.0,,N,,A,10767,,,Rattus norvegicus,1,,,
,4722,1,BAO_0000218,Percent bioavailability (F) in rats after iv administration,50597,In vivo,,CHEMBL618777,Intermediate,10116.0,,N,,A,10768,,,Rattus norvegicus,1,,,
,4722,1,BAO_0000218,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,50597,In vivo,,CHEMBL618778,Intermediate,10116.0,,N,,A,10769,,,Rattus norvegicus,1,,,
,4353,1,BAO_0000218,Bioavailability in rat (dose 5 uM/kg p.o.),50597,In vivo,,CHEMBL618779,Intermediate,10116.0,,N,,A,10770,,,Rattus norvegicus,1,,,
,15662,1,BAO_0000218,Oral bioavailability,50597,In vivo,,CHEMBL618780,Intermediate,10116.0,,N,,A,10771,,,Rattus norvegicus,1,,,
,4756,1,BAO_0000218,Bioavailability in rat (dose 2 mg/kg p.o.),50597,In vivo,,CHEMBL618781,Intermediate,10116.0,,N,,A,10772,,,Rattus norvegicus,1,,,
,4756,1,BAO_0000218,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,50597,In vivo,,CHEMBL618782,Intermediate,10116.0,,N,,A,10773,,,Rattus norvegicus,1,,,
,3436,1,BAO_0000218,Oral bioavailability in rat (dose 20 mg/kg),50597,In vivo,,CHEMBL618783,Intermediate,10116.0,,N,,A,10774,,,Rattus norvegicus,1,,,
,17800,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL618784,Intermediate,10116.0,,N,,A,10775,,,Rattus norvegicus,1,,,
,15762,1,BAO_0000218,Percent oral bioavailability evaluated in rat,50597,In vivo,,CHEMBL618785,Intermediate,10116.0,,N,,A,10776,,,Rattus norvegicus,1,,,
,5089,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL618786,Intermediate,10116.0,,N,,A,10777,,,Rattus norvegicus,1,,,
,5089,1,BAO_0000218,Percent oral bioavailability in rat; Not determined,50597,In vivo,,CHEMBL618787,Intermediate,10116.0,,N,,A,10778,,,Rattus norvegicus,1,,,
,3185,1,BAO_0000218,Oral bioavailability in rat,50597,In vivo,,CHEMBL618788,Intermediate,10116.0,,N,,A,10779,,,Rattus norvegicus,1,,,
,5145,1,BAO_0000218,Bioavailability in rat,50597,In vivo,,CHEMBL618789,Intermediate,10116.0,,N,,A,10780,,,Rattus norvegicus,1,,,
,3457,1,BAO_0000218,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),50597,In vivo,,CHEMBL618790,Intermediate,10116.0,,N,,A,10781,,,Rattus norvegicus,1,,,
,3457,1,BAO_0000218,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),50597,In vivo,,CHEMBL618791,Intermediate,10116.0,,N,,A,10782,,,Rattus norvegicus,1,,,
,5983,1,BAO_0000218,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,50597,In vivo,,CHEMBL875843,Intermediate,10116.0,,N,,A,10783,,,Rattus norvegicus,1,,,
,5739,1,BAO_0000218,Oral bioavailability in rat (dose 20 mg/kg p.o.),50597,In vivo,,CHEMBL618792,Intermediate,10116.0,,N,,A,10784,,,Rattus norvegicus,1,,,
,3579,1,BAO_0000218,Cmax at a dose of 30 mg/kg in rat,50597,In vivo,,CHEMBL623395,Intermediate,10116.0,,N,,A,10785,,,Rattus norvegicus,1,,,
,17788,0,BAO_0000218,Cmax in monkeys at a dose of 1 mg/kg,22224,In vivo,,CHEMBL623396,Autocuration,314293.0,,U,,A,10786,,,Simiiformes,1,,,
,14956,1,BAO_0000218,Cmax in rat,50597,In vivo,,CHEMBL623397,Intermediate,10116.0,,N,,A,10787,,,Rattus norvegicus,1,,,
,17788,1,BAO_0000218,Cmax in rats at a dose of 1 mg/kg,50597,In vivo,,CHEMBL623398,Intermediate,10116.0,,N,,A,10788,,,Rattus norvegicus,1,,,
,9750,1,BAO_0000218,Cmax was measured in mice after an oral dose of 50 mg/kg.,50594,In vivo,,CHEMBL623399,Intermediate,10090.0,,N,,A,10789,,,Mus musculus,1,,,
,12767,0,BAO_0000218,"Cmax value at a dose of 12.7 uM/kg, po",22224,In vivo,,CHEMBL623400,Autocuration,,,U,,A,10790,,,,1,,,
,12767,0,BAO_0000218,"Cmax value at a dose of 6.3 uM/kg, iv",22224,In vivo,,CHEMBL623401,Autocuration,,,U,,A,10791,,,,1,,,
,12767,0,BAO_0000218,"Cmax value at a dose of 7.1 uM/kg, iv",22224,In vivo,,CHEMBL623402,Autocuration,,,U,,A,10792,,,,1,,,
,12703,0,BAO_0000218,Cmax value of compound was determined after 1 hr,22224,In vivo,,CHEMBL623403,Autocuration,,,U,,A,10793,,,,1,,,
,15778,0,BAO_0000218,Cmax value of the compound,22224,In vivo,,CHEMBL623404,Autocuration,,,U,,A,10794,,,,1,,,
,12818,1,BAO_0000218,Cmax value administered intraintestinal in rats.,50597,In vivo,,CHEMBL625997,Intermediate,10116.0,,N,,A,10795,,,Rattus norvegicus,1,,,
,14964,1,BAO_0000218,Cmax value administered perorally was determined in rat; Not determined,50597,In vivo,,CHEMBL625998,Intermediate,10116.0,,N,,A,10796,,,Rattus norvegicus,1,,,
,15808,0,BAO_0000218,Cmax value at the dose of 2.3 mg/kg,22224,In vivo,,CHEMBL625999,Autocuration,,,U,,A,10797,,,,1,,,
,15808,0,BAO_0000218,Cmax value at the dose of 5 mg/kg,22224,In vivo,,CHEMBL626000,Autocuration,,,U,,A,10798,,,,1,,,
,15778,0,BAO_0000218,Cmax value in the period of 8 hr after dosing. ,22224,In vivo,,CHEMBL626001,Autocuration,,,U,,A,10799,,,,1,,,
,3715,0,BAO_0000218,Cmax value at a oral dose of 20 mg/kg; Not tested,22224,In vivo,,CHEMBL626002,Autocuration,,,U,,A,10800,,,,1,,,
,3715,0,BAO_0000218,Cmax value at a oral dose of 20 mg/kg,22224,In vivo,,CHEMBL626003,Autocuration,,,U,,A,10801,,,,1,,,
,1446,1,BAO_0000218,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,50597,In vivo,,CHEMBL626004,Intermediate,10116.0,,N,,A,10802,,,Rattus norvegicus,1,,,
,15240,1,BAO_0000218,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,50512,In vivo,,CHEMBL626005,Intermediate,10141.0,,N,,A,10803,,,Cavia porcellus,1,,,
,15240,1,BAO_0000218,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,50597,In vivo,,CHEMBL626006,Intermediate,10116.0,,N,,A,10804,,,Rattus norvegicus,1,,,
,14810,1,BAO_0000218,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,50597,In vivo,Plasma,CHEMBL626007,Intermediate,10116.0,,N,,A,10805,,,Rattus norvegicus,1,,1969.0,
,14239,1,BAO_0000218,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,50594,In vivo,Plasma,CHEMBL626008,Intermediate,10090.0,,N,,A,10806,,,Mus musculus,1,,1969.0,
,12555,1,BAO_0000218,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,50588,In vivo,Liver,CHEMBL626009,Intermediate,9615.0,,N,,A,10807,,,Canis lupus familiaris,1,,2107.0,
,10754,1,BAO_0000218,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,50588,In vivo,,CHEMBL626010,Intermediate,9615.0,,N,,A,10808,,,Canis lupus familiaris,1,,,
,10754,1,BAO_0000218,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,50594,In vivo,Blood,CHEMBL626011,Intermediate,10090.0,,N,,A,10809,,,Mus musculus,1,,178.0,
,10754,1,BAO_0000218,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,50594,In vivo,Blood,CHEMBL626012,Intermediate,10090.0,,N,,A,10810,,,Mus musculus,1,,178.0,
,10754,1,BAO_0000218,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,50594,In vivo,Blood,CHEMBL626013,Intermediate,10090.0,,N,,A,10811,,,Mus musculus,1,,178.0,
,10754,1,BAO_0000218,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,50594,In vivo,Blood,CHEMBL626014,Intermediate,10090.0,,N,,A,10812,,,Mus musculus,1,,178.0,
,10754,1,BAO_0000218,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,50594,In vivo,Blood,CHEMBL877496,Intermediate,10090.0,,N,,A,10813,,,Mus musculus,1,,178.0,
,14600,1,BAO_0000218,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,50588,In vivo,,CHEMBL626015,Intermediate,9615.0,,N,,F,10814,,,Canis lupus familiaris,1,,,
,14600,1,BAO_0000218,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,50588,In vivo,,CHEMBL626016,Intermediate,9615.0,,N,,F,10815,,,Canis lupus familiaris,1,,,
,14600,1,BAO_0000218,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,50588,In vivo,,CHEMBL626017,Intermediate,9615.0,,N,,F,10816,,,Canis lupus familiaris,1,,,
,13543,1,BAO_0000218,Bioavailability as maximal plasma concentration in dogs,50588,In vivo,Plasma,CHEMBL626018,Intermediate,9615.0,,N,,A,10817,,,Canis lupus familiaris,1,,1969.0,
,13543,1,BAO_0000218,Bioavailability as maximal plasma concentration in dogs,50588,In vivo,Plasma,CHEMBL626692,Intermediate,9615.0,,N,,A,10818,,,Canis lupus familiaris,1,,1969.0,
,13543,1,BAO_0000218,Bioavailability as maximal plasma concentration in rats,50597,In vivo,Plasma,CHEMBL626693,Intermediate,10116.0,,N,,A,10819,,,Rattus norvegicus,1,,1969.0,
,13543,0,BAO_0000218,Bioavailability as maximal plasma concentration in rats,22224,In vivo,Plasma,CHEMBL626694,Autocuration,10116.0,,U,,A,10820,,,Rattus norvegicus,1,,1969.0,
,14600,1,BAO_0000218,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,50588,In vivo,Blood,CHEMBL626695,Intermediate,9615.0,,N,,A,10821,,,Canis lupus familiaris,1,,178.0,
,14600,1,BAO_0000218,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,50588,In vivo,Blood,CHEMBL626696,Intermediate,9615.0,,N,,A,10822,,,Canis lupus familiaris,1,,178.0,
,14600,1,BAO_0000218,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,50588,In vivo,Blood,CHEMBL626697,Intermediate,9615.0,,N,,A,10823,,,Canis lupus familiaris,1,,178.0,
,14600,1,BAO_0000218,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,50588,In vivo,Blood,CHEMBL626859,Intermediate,9615.0,,N,,A,10824,,,Canis lupus familiaris,1,,178.0,
,14600,1,BAO_0000218,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,50588,In vivo,Blood,CHEMBL626860,Intermediate,9615.0,,N,,A,10825,,,Canis lupus familiaris,1,,178.0,
,14600,1,BAO_0000218,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,50588,In vivo,Blood,CHEMBL626861,Intermediate,9615.0,,N,,A,10826,,,Canis lupus familiaris,1,,178.0,
,14681,1,BAO_0000218,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,50597,In vivo,,CHEMBL626296,Intermediate,10116.0,,N,,A,10827,,,Rattus norvegicus,1,,,
,15905,0,BAO_0000218,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,22224,In vivo,,CHEMBL626297,Autocuration,,,U,,A,10828,,,,1,,,
,15905,0,BAO_0000218,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,22224,In vivo,Plasma,CHEMBL626298,Autocuration,,,U,,A,10829,,,,1,,1969.0,
,13304,1,BAO_0000218,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",50597,In vivo,Plasma,CHEMBL626299,Intermediate,10116.0,,N,,A,10830,,,Rattus norvegicus,1,,1969.0,
,15137,1,BAO_0000218,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,50597,In vivo,Plasma,CHEMBL626300,Intermediate,10116.0,,N,,A,10831,,,Rattus norvegicus,1,,1969.0,
,15137,1,BAO_0000218,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,50597,In vivo,Plasma,CHEMBL626301,Intermediate,10116.0,,N,,A,10832,,,Rattus norvegicus,1,,1969.0,
,15137,1,BAO_0000218,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,50597,In vivo,Plasma,CHEMBL626962,Intermediate,10116.0,,N,,A,10833,,,Rattus norvegicus,1,,1969.0,
,15137,1,BAO_0000218,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,50597,In vivo,Plasma,CHEMBL626963,Intermediate,10116.0,,N,,A,10834,,,Rattus norvegicus,1,,1969.0,
,15137,1,BAO_0000218,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,50597,In vivo,Plasma,CHEMBL626964,Intermediate,10116.0,,N,,A,10835,,,Rattus norvegicus,1,,1969.0,
,14839,1,BAO_0000218,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,100710,In vivo,Plasma,CHEMBL626965,Intermediate,9541.0,,N,,A,10836,,,Macaca fascicularis,1,,1969.0,
,14839,1,BAO_0000218,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,In vivo,Plasma,CHEMBL626966,Intermediate,10090.0,,N,,A,10837,,,Mus musculus,1,,1969.0,
,14839,1,BAO_0000218,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,In vivo,Plasma,CHEMBL626967,Intermediate,10090.0,,N,,A,10838,,,Mus musculus,1,,1969.0,
,14839,1,BAO_0000218,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,100710,In vivo,Plasma,CHEMBL626968,Intermediate,9541.0,,N,,A,10839,,,Macaca fascicularis,1,,1969.0,
,8418,1,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,50597,,Heart,CHEMBL626969,Intermediate,10116.0,,N,,A,10840,,,Rattus norvegicus,1,,948.0,
,8418,1,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,50597,,Heart,CHEMBL627126,Intermediate,10116.0,,N,,A,10841,,,Rattus norvegicus,1,,948.0,
,8418,1,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,50597,,Heart,CHEMBL631276,Intermediate,10116.0,,N,,A,10842,,,Rattus norvegicus,1,,948.0,
,8418,1,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,50597,,Heart,CHEMBL631277,Intermediate,10116.0,,N,,A,10843,,,Rattus norvegicus,1,,948.0,
,8418,1,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,50597,,Heart,CHEMBL631278,Intermediate,10116.0,,N,,A,10844,,,Rattus norvegicus,1,,948.0,
,8418,1,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,50597,,Heart,CHEMBL874457,Intermediate,10116.0,,N,,A,10845,,,Rattus norvegicus,1,,948.0,
,8418,1,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,50597,,Heart,CHEMBL631279,Intermediate,10116.0,,N,,A,10846,,,Rattus norvegicus,1,,948.0,
,8418,1,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,50597,,Heart,CHEMBL631280,Intermediate,10116.0,,N,,A,10847,,,Rattus norvegicus,1,,948.0,
,8418,1,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,50597,,Heart,CHEMBL631281,Intermediate,10116.0,,N,,A,10848,,,Rattus norvegicus,1,,948.0,
,8418,1,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,50597,,Heart,CHEMBL631968,Intermediate,10116.0,,N,,A,10849,,,Rattus norvegicus,1,,948.0,
,8418,1,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,50597,,Heart,CHEMBL631969,Intermediate,10116.0,,N,,A,10850,,,Rattus norvegicus,1,,948.0,
,8418,1,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,50597,,Heart,CHEMBL631970,Intermediate,10116.0,,N,,A,10851,,,Rattus norvegicus,1,,948.0,
,8418,1,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,50597,,Heart,CHEMBL631971,Intermediate,10116.0,,N,,A,10852,,,Rattus norvegicus,1,,948.0,
,8418,1,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,50597,,Heart,CHEMBL631972,Intermediate,10116.0,,N,,A,10853,,,Rattus norvegicus,1,,948.0,
,8418,1,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,50597,,Heart,CHEMBL630435,Intermediate,10116.0,,N,,A,10854,,,Rattus norvegicus,1,,948.0,
,8418,1,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,50597,,Heart,CHEMBL630436,Intermediate,10116.0,,N,,A,10855,,,Rattus norvegicus,1,,948.0,
,8418,1,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,50597,,Heart,CHEMBL630437,Intermediate,10116.0,,N,,A,10856,,,Rattus norvegicus,1,,948.0,
,8418,1,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,50597,,Heart,CHEMBL630438,Intermediate,10116.0,,N,,A,10857,,,Rattus norvegicus,1,,948.0,
,8418,1,BAO_0000218,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,50597,,Heart,CHEMBL630439,Intermediate,10116.0,,N,,A,10858,,,Rattus norvegicus,1,,948.0,
,8418,1,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,50597,,Kidney,CHEMBL630440,Intermediate,10116.0,,N,,A,10859,,,Rattus norvegicus,1,,2113.0,
,8418,1,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,50597,,Kidney,CHEMBL630441,Intermediate,10116.0,,N,,A,10860,,,Rattus norvegicus,1,,2113.0,
,8418,1,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,50597,,Kidney,CHEMBL630442,Intermediate,10116.0,,N,,A,10861,,,Rattus norvegicus,1,,2113.0,
,8418,1,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,50597,,Kidney,CHEMBL625234,Intermediate,10116.0,,N,,A,10862,,,Rattus norvegicus,1,,2113.0,
,8418,1,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,50597,,Kidney,CHEMBL625235,Intermediate,10116.0,,N,,A,10863,,,Rattus norvegicus,1,,2113.0,
,8418,1,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,50597,,Kidney,CHEMBL625236,Intermediate,10116.0,,N,,A,10864,,,Rattus norvegicus,1,,2113.0,
,8418,1,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,50597,,Kidney,CHEMBL625237,Intermediate,10116.0,,N,,A,10865,,,Rattus norvegicus,1,,2113.0,
,8418,1,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,50597,,Kidney,CHEMBL626125,Intermediate,10116.0,,N,,A,10866,,,Rattus norvegicus,1,,2113.0,
,8418,1,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,50597,,Kidney,CHEMBL626126,Intermediate,10116.0,,N,,A,10867,,,Rattus norvegicus,1,,2113.0,
,8418,1,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,50597,,Kidney,CHEMBL626127,Intermediate,10116.0,,N,,A,10868,,,Rattus norvegicus,1,,2113.0,
,8418,1,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,50597,,Kidney,CHEMBL626128,Intermediate,10116.0,,N,,A,10869,,,Rattus norvegicus,1,,2113.0,
,8418,1,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,50597,,Kidney,CHEMBL626129,Intermediate,10116.0,,N,,A,10870,,,Rattus norvegicus,1,,2113.0,
,8418,1,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,50597,,Kidney,CHEMBL626130,Intermediate,10116.0,,N,,A,10871,,,Rattus norvegicus,1,,2113.0,
,8418,1,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,50597,,Kidney,CHEMBL626131,Intermediate,10116.0,,N,,A,10872,,,Rattus norvegicus,1,,2113.0,
,8418,1,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,50597,,Kidney,CHEMBL626132,Intermediate,10116.0,,N,,A,10873,,,Rattus norvegicus,1,,2113.0,
,8418,1,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,50597,,Kidney,CHEMBL626752,Intermediate,10116.0,,N,,A,10874,,,Rattus norvegicus,1,,2113.0,
,8418,1,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,50597,,Kidney,CHEMBL626753,Intermediate,10116.0,,N,,A,10875,,,Rattus norvegicus,1,,2113.0,
,8418,1,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,50597,,Kidney,CHEMBL626754,Intermediate,10116.0,,N,,A,10876,,,Rattus norvegicus,1,,2113.0,
,8418,1,BAO_0000218,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,50597,,Kidney,CHEMBL626755,Intermediate,10116.0,,N,,A,10877,,,Rattus norvegicus,1,,2113.0,
,8418,1,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,50597,,Liver,CHEMBL626756,Intermediate,10116.0,,N,,A,10878,,,Rattus norvegicus,1,,2107.0,
,8418,1,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,50597,,Liver,CHEMBL626757,Intermediate,10116.0,,N,,A,10879,,,Rattus norvegicus,1,,2107.0,
,8418,1,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,50597,,Liver,CHEMBL626758,Intermediate,10116.0,,N,,A,10880,,,Rattus norvegicus,1,,2107.0,
,8418,1,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,50597,,Liver,CHEMBL626759,Intermediate,10116.0,,N,,A,10881,,,Rattus norvegicus,1,,2107.0,
,8418,1,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,50597,,Liver,CHEMBL626760,Intermediate,10116.0,,N,,A,10882,,,Rattus norvegicus,1,,2107.0,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),50588,,,CHEMBL626394,Intermediate,9615.0,,N,,A,10883,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,50588,,,CHEMBL626395,Intermediate,9615.0,,N,,A,10884,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),50588,,,CHEMBL626396,Intermediate,9615.0,,N,,A,10885,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),50588,,,CHEMBL626397,Intermediate,9615.0,,N,,A,10886,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),50588,,,CHEMBL626398,Intermediate,9615.0,,N,,A,10887,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),50588,,,CHEMBL626399,Intermediate,9615.0,,N,,A,10888,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,50597,,,CHEMBL874653,Intermediate,10116.0,,N,,A,10889,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),50597,,,CHEMBL626400,Intermediate,10116.0,,N,,A,10890,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),50597,,,CHEMBL626401,Intermediate,10116.0,,N,,A,10891,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),50597,,,CHEMBL626402,Intermediate,10116.0,,N,,A,10892,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),50597,,,CHEMBL626403,Intermediate,10116.0,,N,,A,10893,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),50597,,,CHEMBL626404,Intermediate,10116.0,,N,,A,10894,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,50597,,,CHEMBL626405,Intermediate,10116.0,,N,,A,10895,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),50597,,,CHEMBL625529,Intermediate,10116.0,,N,,A,10896,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),50597,,,CHEMBL625530,Intermediate,10116.0,,N,,A,10897,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),50597,,,CHEMBL625531,Intermediate,10116.0,,N,,A,10898,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),50597,,,CHEMBL625532,Intermediate,10116.0,,N,,A,10899,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),50597,,,CHEMBL625533,Intermediate,10116.0,,N,,A,10900,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,50597,,,CHEMBL875474,Intermediate,10116.0,,N,,A,10901,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),50597,,,CHEMBL625534,Intermediate,10116.0,,N,,A,10902,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),50597,,,CHEMBL625535,Intermediate,10116.0,,N,,A,10903,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),50597,,,CHEMBL625536,Intermediate,10116.0,,N,,A,10904,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),50597,,,CHEMBL625537,Intermediate,10116.0,,N,,A,10905,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),50597,,,CHEMBL625538,Intermediate,10116.0,,N,,A,10906,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,50597,,,CHEMBL625539,Intermediate,10116.0,,N,,A,10907,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),50597,,,CHEMBL625540,Intermediate,10116.0,,N,,A,10908,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),50597,,,CHEMBL625541,Intermediate,10116.0,,N,,A,10909,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),50597,,,CHEMBL625542,Intermediate,10116.0,,N,,A,10910,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),50597,,,CHEMBL625543,Intermediate,10116.0,,N,,A,10911,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),50597,,,CHEMBL625544,Intermediate,10116.0,,N,,A,10912,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,50588,,,CHEMBL625545,Intermediate,9615.0,,N,,A,10913,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),50588,,,CHEMBL625546,Intermediate,9615.0,,N,,A,10914,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,50588,,,CHEMBL625547,Intermediate,9615.0,,N,,A,10915,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),50588,,,CHEMBL625548,Intermediate,9615.0,,N,,A,10916,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),50588,,,CHEMBL625549,Intermediate,9615.0,,N,,A,10917,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),50588,,,CHEMBL625550,Intermediate,9615.0,,N,,A,10918,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),50588,,,CHEMBL625551,Intermediate,9615.0,,N,,A,10919,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),50588,,,CHEMBL875475,Intermediate,9615.0,,N,,A,10920,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),50588,,,CHEMBL625552,Intermediate,9615.0,,N,,A,10921,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),50588,,,CHEMBL625553,Intermediate,9615.0,,N,,A,10922,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),50588,,,CHEMBL625554,Intermediate,9615.0,,N,,A,10923,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),50588,,,CHEMBL625555,Intermediate,9615.0,,N,,A,10924,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),50588,,,CHEMBL625556,Intermediate,9615.0,,N,,A,10925,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,50588,,,CHEMBL624986,Intermediate,9615.0,,N,,A,10926,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),50588,,,CHEMBL624987,Intermediate,9615.0,,N,,A,10927,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),50588,,,CHEMBL624988,Intermediate,9615.0,,N,,A,10928,,,Canis lupus familiaris,1,,,
,9025,1,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,50588,In vivo,Artery,CHEMBL624989,Intermediate,9615.0,,N,,A,10929,,,Canis lupus familiaris,1,,1637.0,
,9025,1,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,50588,In vivo,Artery,CHEMBL624990,Intermediate,9615.0,,N,,A,10930,,,Canis lupus familiaris,1,,1637.0,
,9025,1,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,50588,In vivo,Artery,CHEMBL874391,Intermediate,9615.0,,N,,A,10931,,,Canis lupus familiaris,1,,1637.0,
,9025,1,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,50588,In vivo,Artery,CHEMBL624991,Intermediate,9615.0,,N,,A,10932,,,Canis lupus familiaris,1,,1637.0,
,9025,1,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,50588,In vivo,Artery,CHEMBL624992,Intermediate,9615.0,,N,,A,10933,,,Canis lupus familiaris,1,,1637.0,
,9025,1,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,50588,In vivo,Artery,CHEMBL624993,Intermediate,9615.0,,N,,A,10934,,,Canis lupus familiaris,1,,1637.0,
,9025,1,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,50588,In vivo,Artery,CHEMBL624994,Intermediate,9615.0,,N,,A,10935,,,Canis lupus familiaris,1,,1637.0,
,9025,1,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,50588,In vivo,Artery,CHEMBL624995,Intermediate,9615.0,,N,,A,10936,,,Canis lupus familiaris,1,,1637.0,
,9025,1,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,50588,In vivo,Artery,CHEMBL624996,Intermediate,9615.0,,N,,A,10937,,,Canis lupus familiaris,1,,1637.0,
,9025,1,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,50588,In vivo,Artery,CHEMBL624997,Intermediate,9615.0,,N,,A,10938,,,Canis lupus familiaris,1,,1637.0,
,9025,1,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,50588,In vivo,Artery,CHEMBL624998,Intermediate,9615.0,,N,,A,10939,,,Canis lupus familiaris,1,,1637.0,
,9025,1,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,50588,In vivo,Artery,CHEMBL624999,Intermediate,9615.0,,N,,A,10940,,,Canis lupus familiaris,1,,1637.0,
,9025,1,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,50588,In vivo,Artery,CHEMBL882955,Intermediate,9615.0,,N,,A,10941,,,Canis lupus familiaris,1,,1637.0,
,9025,1,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,50588,In vivo,Artery,CHEMBL625000,Intermediate,9615.0,,N,,A,10942,,,Canis lupus familiaris,1,,1637.0,
,9025,1,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,50588,In vivo,Artery,CHEMBL625001,Intermediate,9615.0,,N,,A,10943,,,Canis lupus familiaris,1,,1637.0,
,9025,1,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,50588,In vivo,Artery,CHEMBL625089,Intermediate,9615.0,,N,,A,10944,,,Canis lupus familiaris,1,,1637.0,
,9025,1,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,50588,In vivo,Artery,CHEMBL625090,Intermediate,9615.0,,N,,A,10945,,,Canis lupus familiaris,1,,1637.0,
,9025,1,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,50588,In vivo,Artery,CHEMBL625091,Intermediate,9615.0,,N,,A,10946,,,Canis lupus familiaris,1,,1637.0,
,9025,1,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,50588,In vivo,Artery,CHEMBL625092,Intermediate,9615.0,,N,,A,10947,,,Canis lupus familiaris,1,,1637.0,
,9025,1,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,50588,In vivo,Artery,CHEMBL625093,Intermediate,9615.0,,N,,A,10948,,,Canis lupus familiaris,1,,1637.0,
,9025,1,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,50588,In vivo,Artery,CHEMBL625094,Intermediate,9615.0,,N,,A,10949,,,Canis lupus familiaris,1,,1637.0,
,9025,1,BAO_0000218,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,50588,In vivo,Artery,CHEMBL625095,Intermediate,9615.0,,N,,A,10950,,,Canis lupus familiaris,1,,1637.0,
,2249,1,BAO_0000218,Compound was evaluated for its bioavailability in the dogs,50588,In vivo,,CHEMBL625096,Intermediate,9615.0,,N,,A,10951,,,Canis lupus familiaris,1,,,
,2249,1,BAO_0000218,Compound was evaluated for its bioavailability in the rats,50597,In vivo,,CHEMBL625097,Intermediate,10116.0,,N,,A,10952,,,Rattus norvegicus,1,,,
,17515,0,BAO_0000218,Compound was evaluated for oral bioavailability,22224,In vivo,,CHEMBL882956,Autocuration,,,U,,A,10953,,,,1,,,
,14541,1,BAO_0000218,Compound was evaluated for percentage of Oral bioavailability in rats,50597,In vivo,,CHEMBL625098,Intermediate,10116.0,,N,,A,10954,,,Rattus norvegicus,1,,,
,12797,0,BAO_0000218,Bioavailability in guinea pig,22224,In vivo,,CHEMBL625099,Autocuration,10141.0,,U,,A,10955,,,Cavia porcellus,1,,,
,12797,1,BAO_0000218,Compound was evaluated for the oral bioavailability in rat,50597,In vivo,,CHEMBL625100,Intermediate,10116.0,,N,,A,10956,,,Rattus norvegicus,1,,,
,12797,1,BAO_0000218,Compound was evaluated for the oral bioavailability in dog,50588,In vivo,,CHEMBL625101,Intermediate,9615.0,,N,,A,10957,,,Canis lupus familiaris,1,,,
,12797,1,BAO_0000218,Compound was evaluated for the oral bioavailability in rat,50597,In vivo,,CHEMBL874396,Intermediate,10116.0,,N,,A,10958,,,Rattus norvegicus,1,,,
,11727,0,BAO_0000218,Bioavailability in dog (dosed i.v.),22224,In vivo,,CHEMBL625102,Autocuration,9615.0,,U,,F,10959,,,Canis lupus familiaris,1,,,
,13249,1,BAO_0000218,Compound was tested for in vivo bioavailability in dog,50588,In vivo,,CHEMBL625103,Intermediate,9615.0,,N,,A,10960,,,Canis lupus familiaris,1,,,
,13249,1,BAO_0000218,Compound was tested for in vivo bioavailability in hamsters,100712,In vivo,,CHEMBL625104,Intermediate,10026.0,,N,,A,10961,,,Cricetinae,1,,,
,13249,0,BAO_0000218,Compound was tested for in vivo bioavailability in monkey,22224,In vivo,,CHEMBL625105,Autocuration,314293.0,,U,,A,10962,,,Simiiformes,1,,,
,13249,1,BAO_0000218,Compound was tested for in vivo bioavailability in rat,50597,In vivo,,CHEMBL625106,Intermediate,10116.0,,N,,A,10963,,,Rattus norvegicus,1,,,
,9552,0,BAO_0000218,Oral bioavailability in mouse,22224,In vivo,,CHEMBL625107,Autocuration,10090.0,,U,,A,10964,,,Mus musculus,1,,,
,9552,1,BAO_0000218,Compound was tested for percent of oral bioavailability in mice; 56-74,50594,In vivo,,CHEMBL625108,Intermediate,10090.0,,N,,A,10965,,,Mus musculus,1,,,
,14839,0,BAO_0000218,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),22224,In vivo,,CHEMBL625109,Autocuration,10090.0,,U,,A,10966,,,Mus musculus,1,,,
,14839,0,BAO_0000218,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),22224,In vivo,,CHEMBL625110,Autocuration,9541.0,,U,,A,10967,,,Macaca fascicularis,1,,,
,14839,0,BAO_0000218,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),22224,In vivo,,CHEMBL625111,Autocuration,9541.0,,U,,A,10968,,,Macaca fascicularis,1,,,
,14839,1,BAO_0000218,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),50594,In vivo,,CHEMBL625112,Intermediate,10090.0,,N,,A,10969,,,Mus musculus,1,,,
,14839,1,BAO_0000218,Oral bioavailability in nude mice,50594,In vivo,,CHEMBL875334,Intermediate,10090.0,,N,,A,10970,,,Mus musculus,1,,,
,11219,0,BAO_0000218,Bioavailability in monkey (i.d. dosing),22224,In vivo,,CHEMBL628617,Autocuration,9443.0,,U,,A,10971,,,Primates,1,,,
,9552,0,BAO_0000218,Bioavailability in rat,22224,In vivo,,CHEMBL628618,Autocuration,10116.0,,U,,A,10972,,,Rattus norvegicus,1,,,
,11732,0,BAO_0000218,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,22224,In vivo,,CHEMBL628619,Autocuration,,,U,,A,10973,,,,1,,,
,11732,0,BAO_0000218,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,22224,In vivo,,CHEMBL628620,Autocuration,,,U,,A,10974,,,,1,,,
,14839,1,BAO_0000218,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",100710,In vivo,,CHEMBL628621,Intermediate,9541.0,,N,,A,10975,,,Macaca fascicularis,1,,,
,14839,1,BAO_0000218,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",100710,In vivo,,CHEMBL628622,Intermediate,9541.0,,N,,A,10976,,,Macaca fascicularis,1,,,
,14839,1,BAO_0000218,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",100710,In vivo,,CHEMBL628623,Intermediate,9541.0,,N,,A,10977,,,Macaca fascicularis,1,,,
,14839,1,BAO_0000218,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,100710,In vivo,Plasma,CHEMBL628624,Intermediate,9541.0,,N,,A,10978,,,Macaca fascicularis,1,,1969.0,
,14839,1,BAO_0000218,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,In vivo,Plasma,CHEMBL628625,Intermediate,10090.0,,N,,A,10979,,,Mus musculus,1,,1969.0,
,14839,1,BAO_0000218,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,100710,In vivo,Plasma,CHEMBL628626,Intermediate,9541.0,,N,,A,10980,,,Macaca fascicularis,1,,1969.0,
,14839,1,BAO_0000218,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,In vivo,Plasma,CHEMBL627041,Intermediate,10090.0,,N,,A,10981,,,Mus musculus,1,,1969.0,
,14839,1,BAO_0000218,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,In vivo,Plasma,CHEMBL627042,Intermediate,10090.0,,N,,A,10982,,,Mus musculus,1,,1969.0,
,14839,1,BAO_0000218,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,In vivo,Plasma,CHEMBL627043,Intermediate,10090.0,,N,,A,10983,,,Mus musculus,1,,1969.0,
,13932,0,BAO_0000218,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,22224,In vivo,Plasma,CHEMBL627044,Autocuration,,,U,,A,10984,,,,1,,1969.0,
,11637,1,BAO_0000218,Cmax in mouse plasma,50594,In vivo,Plasma,CHEMBL627045,Intermediate,10090.0,,N,,A,10985,,,Mus musculus,1,,1969.0,
,11637,0,BAO_0000218,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,22224,In vivo,Plasma,CHEMBL627046,Autocuration,,,U,,A,10986,,,,1,,1969.0,
,13960,1,BAO_0000218,Maximal plasma concentration in rat,50597,In vivo,Plasma,CHEMBL627047,Intermediate,10116.0,,N,,A,10987,,,Rattus norvegicus,1,,1969.0,
,15905,1,BAO_0000218,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,50597,In vivo,Plasma,CHEMBL627048,Intermediate,10116.0,,N,,A,10988,,,Rattus norvegicus,1,,1969.0,
,14062,1,BAO_0000218,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,50597,In vivo,,CHEMBL627049,Intermediate,10116.0,,N,,A,10989,,,Rattus norvegicus,1,,,
,14062,1,BAO_0000218,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,50597,In vivo,,CHEMBL627050,Intermediate,10116.0,,N,,A,10990,,,Rattus norvegicus,1,,,
,14062,1,BAO_0000218,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,50597,In vivo,,CHEMBL627051,Intermediate,10116.0,,N,,A,10991,,,Rattus norvegicus,1,,,
,14062,1,BAO_0000218,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,50597,In vivo,,CHEMBL627052,Intermediate,10116.0,,N,,A,10992,,,Rattus norvegicus,1,,,
,14062,1,BAO_0000218,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,50597,In vivo,,CHEMBL627053,Intermediate,10116.0,,N,,A,10993,,,Rattus norvegicus,1,,,
,14062,1,BAO_0000218,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,50597,In vivo,,CHEMBL627054,Intermediate,10116.0,,N,,A,10994,,,Rattus norvegicus,1,,,
,15011,1,BAO_0000218,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,50594,In vivo,,CHEMBL627055,Intermediate,10090.0,,N,,A,10995,,,Mus musculus,1,,,
,15011,1,BAO_0000218,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,50594,In vivo,,CHEMBL627056,Intermediate,10090.0,,N,,A,10996,,,Mus musculus,1,,,
,15011,1,BAO_0000218,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),50594,In vivo,,CHEMBL627057,Intermediate,10090.0,,N,,A,10997,,,Mus musculus,1,,,
,15011,1,BAO_0000218,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,50594,In vivo,,CHEMBL627058,Intermediate,10090.0,,N,,A,10998,,,Mus musculus,1,,,
,15011,1,BAO_0000218,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,50594,In vivo,,CHEMBL626211,Intermediate,10090.0,,N,,A,10999,,,Mus musculus,1,,,
,10291,0,BAO_0000218,Maximum Concentration of the compound.,22224,In vivo,,CHEMBL626212,Autocuration,,,U,,A,11000,,,,1,,,
,14599,1,BAO_0000218,Maximum Concentration was measured after iv administration into Beagle dog,50588,In vivo,,CHEMBL626213,Intermediate,9615.0,,N,,A,11001,,,Canis lupus familiaris,1,,,
,14599,1,BAO_0000218,Maximum Concentration was measured after iv administration into Beagle dog.,50588,In vivo,,CHEMBL626214,Intermediate,9615.0,,N,,A,11002,,,Canis lupus familiaris,1,,,
,14599,1,BAO_0000218,Maximum Concentration was measured after po administration into Beagle dog,50588,In vivo,,CHEMBL626215,Intermediate,9615.0,,N,,A,11003,,,Canis lupus familiaris,1,,,
,14599,1,BAO_0000218,Maximum Concentration was measured after po administration into Beagle dog.,50588,In vivo,,CHEMBL626216,Intermediate,9615.0,,N,,A,11004,,,Canis lupus familiaris,1,,,
,12767,0,BAO_0000218,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,22224,In vivo,Blood,CHEMBL626217,Autocuration,,,U,,A,11005,,,,1,,178.0,
,12767,0,BAO_0000218,Maximum blood level reached after an iv dose of 12.2 uM/kg,22224,In vivo,Blood,CHEMBL626218,Autocuration,,,U,,A,11006,,,,1,,178.0,
,12767,0,BAO_0000218,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,22224,In vivo,Blood,CHEMBL626219,Autocuration,,,U,,A,11007,,,,1,,178.0,
,12767,0,BAO_0000218,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,22224,In vivo,Blood,CHEMBL626220,Autocuration,,,U,,A,11008,,,,1,,178.0,
,12767,0,BAO_0000218,Maximum blood level reached after an oral dose of 5.0 mg/kg,22224,In vivo,Blood,CHEMBL626221,Autocuration,,,U,,A,11009,,,,1,,178.0,
,12767,0,BAO_0000218,Maximum blood level reached at dose of 10.6 uM/kg orally,22224,In vivo,Blood,CHEMBL626222,Autocuration,,,U,,A,11010,,,,1,,178.0,
,14706,1,BAO_0000218,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,50512,In vivo,,CHEMBL626223,Intermediate,10141.0,,N,,A,11011,,,Cavia porcellus,1,,,
,14706,1,BAO_0000218,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,50512,In vivo,,CHEMBL626224,Intermediate,10141.0,,N,,A,11012,,,Cavia porcellus,1,,,
,14793,1,BAO_0000218,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,50597,In vivo,Brain,CHEMBL626225,Intermediate,10116.0,,N,,A,11013,,,Rattus norvegicus,1,,955.0,
,14793,1,BAO_0000218,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,50597,In vivo,Brain,CHEMBL626226,Intermediate,10116.0,,N,,A,11014,,,Rattus norvegicus,1,,955.0,
,14793,1,BAO_0000218,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,50597,In vivo,Brain,CHEMBL626227,Intermediate,10116.0,,N,,A,11015,,,Rattus norvegicus,1,,955.0,
,14793,1,BAO_0000218,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,50597,In vivo,Brain,CHEMBL626228,Intermediate,10116.0,,N,,A,11016,,,Rattus norvegicus,1,,955.0,
,14793,1,BAO_0000218,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,50597,In vivo,,CHEMBL626229,Intermediate,10116.0,,N,,A,11017,,,Rattus norvegicus,1,,,
,14793,1,BAO_0000218,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,50597,In vivo,,CHEMBL626921,Intermediate,10116.0,,N,,A,11018,,,Rattus norvegicus,1,,,
,14793,1,BAO_0000218,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,50597,In vivo,,CHEMBL876793,Intermediate,10116.0,,N,,A,11019,,,Rattus norvegicus,1,,,
,14793,1,BAO_0000218,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,50597,In vivo,,CHEMBL625309,Intermediate,10116.0,,N,,A,11020,,,Rattus norvegicus,1,,,
,10524,1,BAO_0000218,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),50278,In vivo,,CHEMBL625310,Intermediate,1423.0,,N,,A,11021,,,Bacillus subtilis,1,,,
,11871,0,BAO_0000218,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,22224,In vivo,,CHEMBL625311,Autocuration,314293.0,,U,,A,11022,,,Simiiformes,1,,,
,11871,1,BAO_0000218,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,50597,In vivo,,CHEMBL625312,Intermediate,10116.0,,N,,A,11023,,,Rattus norvegicus,1,,,
,3437,0,BAO_0000218,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,22224,In vivo,,CHEMBL625313,Autocuration,,,U,,A,11024,,,,1,,,
,12038,1,BAO_0000218,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,50594,In vivo,,CHEMBL625314,Intermediate,10090.0,,N,,A,11025,,,Mus musculus,1,,,
,12038,1,BAO_0000218,Maximum concentration in male rats after iv administration of 20 mg/kg,50597,In vivo,,CHEMBL625315,Intermediate,10116.0,,N,,A,11026,,,Rattus norvegicus,1,,,
,8418,1,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,50597,,Liver,CHEMBL625316,Intermediate,10116.0,,N,,A,11027,,,Rattus norvegicus,1,,2107.0,
,8418,1,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,50597,,Liver,CHEMBL625317,Intermediate,10116.0,,N,,A,11028,,,Rattus norvegicus,1,,2107.0,
,8418,1,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,50597,,Liver,CHEMBL625318,Intermediate,10116.0,,N,,A,11029,,,Rattus norvegicus,1,,2107.0,
,8418,1,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,50597,,Liver,CHEMBL625319,Intermediate,10116.0,,N,,A,11030,,,Rattus norvegicus,1,,2107.0,
,8418,1,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,50597,,Liver,CHEMBL625320,Intermediate,10116.0,,N,,A,11031,,,Rattus norvegicus,1,,2107.0,
,8418,1,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,50597,,Liver,CHEMBL625321,Intermediate,10116.0,,N,,A,11032,,,Rattus norvegicus,1,,2107.0,
,8418,1,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,50597,,Liver,CHEMBL625322,Intermediate,10116.0,,N,,A,11033,,,Rattus norvegicus,1,,2107.0,
,8418,1,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,50597,,Liver,CHEMBL876801,Intermediate,10116.0,,N,,A,11034,,,Rattus norvegicus,1,,2107.0,
,8418,1,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,50597,,Liver,CHEMBL625323,Intermediate,10116.0,,N,,A,11035,,,Rattus norvegicus,1,,2107.0,
,8418,1,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,50597,,Liver,CHEMBL625324,Intermediate,10116.0,,N,,A,11036,,,Rattus norvegicus,1,,2107.0,
,8418,1,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,50597,,Liver,CHEMBL625325,Intermediate,10116.0,,N,,A,11037,,,Rattus norvegicus,1,,2107.0,
,8418,1,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,50597,,Liver,CHEMBL625326,Intermediate,10116.0,,N,,A,11038,,,Rattus norvegicus,1,,2107.0,
,8418,1,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,50597,,Liver,CHEMBL625327,Intermediate,10116.0,,N,,A,11039,,,Rattus norvegicus,1,,2107.0,
,8418,1,BAO_0000218,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,50597,,Liver,CHEMBL625328,Intermediate,10116.0,,N,,A,11040,,,Rattus norvegicus,1,,2107.0,
,8418,1,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,50597,,Lung,CHEMBL625329,Intermediate,10116.0,,N,,A,11041,,,Rattus norvegicus,1,,2048.0,
,8418,1,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,50597,,Lung,CHEMBL625330,Intermediate,10116.0,,N,,A,11042,,,Rattus norvegicus,1,,2048.0,
,8418,1,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,50597,,Lung,CHEMBL627774,Intermediate,10116.0,,N,,A,11043,,,Rattus norvegicus,1,,2048.0,
,8418,1,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,50597,,Lung,CHEMBL627775,Intermediate,10116.0,,N,,A,11044,,,Rattus norvegicus,1,,2048.0,
,8418,1,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,50597,,Lung,CHEMBL627949,Intermediate,10116.0,,N,,A,11045,,,Rattus norvegicus,1,,2048.0,
,8418,1,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,50597,,Lung,CHEMBL627950,Intermediate,10116.0,,N,,A,11046,,,Rattus norvegicus,1,,2048.0,
,8418,1,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,50597,,Lung,CHEMBL627951,Intermediate,10116.0,,N,,A,11047,,,Rattus norvegicus,1,,2048.0,
,8418,1,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,50597,,Lung,CHEMBL627952,Intermediate,10116.0,,N,,A,11048,,,Rattus norvegicus,1,,2048.0,
,8418,1,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,50597,,Lung,CHEMBL627953,Intermediate,10116.0,,N,,A,11049,,,Rattus norvegicus,1,,2048.0,
,8418,1,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,50597,,Lung,CHEMBL627954,Intermediate,10116.0,,N,,A,11050,,,Rattus norvegicus,1,,2048.0,
,8418,1,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,50597,,Lung,CHEMBL627955,Intermediate,10116.0,,N,,A,11051,,,Rattus norvegicus,1,,2048.0,
,8418,1,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,50597,,Lung,CHEMBL627956,Intermediate,10116.0,,N,,A,11052,,,Rattus norvegicus,1,,2048.0,
,8418,1,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,50597,,Lung,CHEMBL876802,Intermediate,10116.0,,N,,A,11053,,,Rattus norvegicus,1,,2048.0,
,8418,1,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,50597,,Lung,CHEMBL627957,Intermediate,10116.0,,N,,A,11054,,,Rattus norvegicus,1,,2048.0,
,8418,1,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,50597,,Lung,CHEMBL627958,Intermediate,10116.0,,N,,A,11055,,,Rattus norvegicus,1,,2048.0,
,8418,1,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,50597,,Lung,CHEMBL627959,Intermediate,10116.0,,N,,A,11056,,,Rattus norvegicus,1,,2048.0,
,8418,1,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,50597,,Lung,CHEMBL627960,Intermediate,10116.0,,N,,A,11057,,,Rattus norvegicus,1,,2048.0,
,8418,1,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,50597,,Lung,CHEMBL627961,Intermediate,10116.0,,N,,A,11058,,,Rattus norvegicus,1,,2048.0,
,8418,1,BAO_0000218,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,50597,,Lung,CHEMBL627962,Intermediate,10116.0,,N,,A,11059,,,Rattus norvegicus,1,,2048.0,
,9796,1,BAO_0000218,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,50597,,,CHEMBL627963,Intermediate,10116.0,,N,,A,11060,,,Rattus norvegicus,1,,,
,9796,1,BAO_0000218,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,50597,,,CHEMBL624759,Intermediate,10116.0,,N,,A,11061,,,Rattus norvegicus,1,,,
,9796,1,BAO_0000218,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,50597,,,CHEMBL624760,Intermediate,10116.0,,N,,A,11062,,,Rattus norvegicus,1,,,
,9796,1,BAO_0000218,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,50597,,,CHEMBL624761,Intermediate,10116.0,,N,,A,11063,,,Rattus norvegicus,1,,,
,9796,1,BAO_0000218,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,50597,,,CHEMBL877607,Intermediate,10116.0,,N,,A,11064,,,Rattus norvegicus,1,,,
,9796,1,BAO_0000218,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,50597,,Liver,CHEMBL624762,Intermediate,10116.0,,N,,A,11065,,,Rattus norvegicus,1,,2107.0,
,9796,1,BAO_0000218,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,50597,,Liver,CHEMBL624763,Intermediate,10116.0,,N,,A,11066,,,Rattus norvegicus,1,,2107.0,
,9796,1,BAO_0000218,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,50597,,Liver,CHEMBL624764,Intermediate,10116.0,,N,,A,11067,,,Rattus norvegicus,1,,2107.0,
,9796,1,BAO_0000218,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,50597,,Liver,CHEMBL624765,Intermediate,10116.0,,N,,A,11068,,,Rattus norvegicus,1,,2107.0,
,9796,1,BAO_0000218,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,50597,,Liver,CHEMBL624766,Intermediate,10116.0,,N,,A,11069,,,Rattus norvegicus,1,,2107.0,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),50588,,,CHEMBL624767,Intermediate,9615.0,,N,,A,11070,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,50588,,,CHEMBL624768,Intermediate,9615.0,,N,,A,11071,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),50588,,,CHEMBL624769,Intermediate,9615.0,,N,,A,11072,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),50588,,,CHEMBL624770,Intermediate,9615.0,,N,,A,11073,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),50588,,,CHEMBL624771,Intermediate,9615.0,,N,,A,11074,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),50588,,,CHEMBL624772,Intermediate,9615.0,,N,,A,11075,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,50597,,,CHEMBL624773,Intermediate,10116.0,,N,,A,11076,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),50597,,,CHEMBL624774,Intermediate,10116.0,,N,,A,11077,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),50597,,,CHEMBL624775,Intermediate,10116.0,,N,,A,11078,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),50597,,,CHEMBL624776,Intermediate,10116.0,,N,,A,11079,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),50597,,,CHEMBL624777,Intermediate,10116.0,,N,,A,11080,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),50597,,,CHEMBL624778,Intermediate,10116.0,,N,,A,11081,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,50597,,,CHEMBL624779,Intermediate,10116.0,,N,,A,11082,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),50597,,,CHEMBL624780,Intermediate,10116.0,,N,,A,11083,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),50597,,,CHEMBL624781,Intermediate,10116.0,,N,,A,11084,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),50597,,,CHEMBL877608,Intermediate,10116.0,,N,,A,11085,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),50597,,,CHEMBL624782,Intermediate,10116.0,,N,,A,11086,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),50597,,,CHEMBL624783,Intermediate,10116.0,,N,,A,11087,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,50597,,,CHEMBL624784,Intermediate,10116.0,,N,,A,11088,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),50597,,,CHEMBL624785,Intermediate,10116.0,,N,,A,11089,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),50597,,,CHEMBL624786,Intermediate,10116.0,,N,,A,11090,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),50597,,,CHEMBL624787,Intermediate,10116.0,,N,,A,11091,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),50597,,,CHEMBL628676,Intermediate,10116.0,,N,,A,11092,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,50597,,,CHEMBL621842,Intermediate,10116.0,,N,,A,11093,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),50597,,,CHEMBL621843,Intermediate,10116.0,,N,,A,11094,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),50597,,,CHEMBL623873,Intermediate,10116.0,,N,,A,11095,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),50597,,,CHEMBL623874,Intermediate,10116.0,,N,,A,11096,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),50597,,,CHEMBL623875,Intermediate,10116.0,,N,,A,11097,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),50597,,,CHEMBL623876,Intermediate,10116.0,,N,,A,11098,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,50588,,,CHEMBL623877,Intermediate,9615.0,,N,,A,11099,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),50588,,,CHEMBL623878,Intermediate,9615.0,,N,,A,11100,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,50588,,,CHEMBL623879,Intermediate,9615.0,,N,,A,11101,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),50588,,,CHEMBL623880,Intermediate,9615.0,,N,,A,11102,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),50588,,,CHEMBL623881,Intermediate,9615.0,,N,,A,11103,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),50588,,,CHEMBL623957,Intermediate,9615.0,,N,,A,11104,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),50588,,,CHEMBL623958,Intermediate,9615.0,,N,,A,11105,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),50588,,,CHEMBL623959,Intermediate,9615.0,,N,,A,11106,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),50588,,,CHEMBL623960,Intermediate,9615.0,,N,,A,11107,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),50588,,,CHEMBL623961,Intermediate,9615.0,,N,,A,11108,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),50588,,,CHEMBL623962,Intermediate,9615.0,,N,,A,11109,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),50588,,,CHEMBL624676,Intermediate,9615.0,,N,,A,11110,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),50588,,,CHEMBL624677,Intermediate,9615.0,,N,,A,11111,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,50588,,,CHEMBL624678,Intermediate,9615.0,,N,,A,11112,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),50588,,,CHEMBL624679,Intermediate,9615.0,,N,,A,11113,,,Canis lupus familiaris,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),50588,,,CHEMBL624680,Intermediate,9615.0,,N,,A,11114,,,Canis lupus familiaris,1,,,
,11732,0,BAO_0000218,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,22224,In vivo,,CHEMBL624849,Autocuration,,,U,,A,11115,,,,1,,,
,11732,0,BAO_0000218,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,22224,In vivo,,CHEMBL624850,Autocuration,,,U,,A,11116,,,,1,,,
,11732,0,BAO_0000218,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,22224,In vivo,,CHEMBL874399,Autocuration,,,U,,A,11117,,,,1,,,
,11732,0,BAO_0000218,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,22224,In vivo,,CHEMBL624851,Autocuration,,,U,,A,11118,,,,1,,,
,11732,0,BAO_0000218,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,22224,In vivo,,CHEMBL624852,Autocuration,,,U,,A,11119,,,,1,,,
,13359,0,BAO_0000218,Oral bioavailability in rat (dose 10 mg/kg),22224,In vivo,,CHEMBL624853,Autocuration,10116.0,,U,,A,11120,,,Rattus norvegicus,1,,,
,16618,0,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley),22224,In vivo,,CHEMBL624854,Autocuration,10116.0,,U,,A,11121,,,Rattus norvegicus,1,,,
,13960,0,BAO_0000218,Oral bioavailability in rat,22224,In vivo,,CHEMBL624855,Autocuration,10116.0,,U,,A,11122,,,Rattus norvegicus,1,,,
,13917,0,BAO_0000218,Oral bioavailability in rats was determined in vivo,22224,In vivo,,CHEMBL624856,Autocuration,10116.0,,U,,A,11123,,,Rattus norvegicus,1,,,
,14266,0,BAO_0000218,Oral bioavailability in dog,22224,In vivo,,CHEMBL882957,Autocuration,9615.0,,U,,A,11124,,,Canis lupus familiaris,1,,,
,12359,0,BAO_0000218,Oral bioavailability of compound in monkey,22224,In vivo,,CHEMBL624857,Autocuration,314293.0,,U,,A,11125,,,Simiiformes,1,,,
,12359,1,BAO_0000218,Oral bioavailability of compound in rat,50597,In vivo,,CHEMBL622202,Intermediate,10116.0,,N,,A,11126,,,Rattus norvegicus,1,,,
,12359,0,BAO_0000218,Bioavailability in rat of PMEA prodrug,22224,In vivo,,CHEMBL622203,Autocuration,10116.0,,U,,A,11127,,,Rattus norvegicus,1,,,
,12359,1,BAO_0000218,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,50597,In vivo,,CHEMBL625522,Intermediate,10116.0,,N,,A,11128,,,Rattus norvegicus,1,,,
,10791,0,BAO_0000218,Serum conc at 3 hours following 25 mg/kg dose,22224,In vivo,,CHEMBL622868,Autocuration,9544.0,,U,,A,11129,,,Macaca mulatta,1,,,
,10791,0,BAO_0000218,Urine conc 0-5 hours following 25 mg/kg dose,22224,In vivo,Urine,CHEMBL622869,Autocuration,9544.0,,U,,A,11130,,,Macaca mulatta,1,,1088.0,
,10791,0,BAO_0000218,Urine conc 0-24 hours following 25 mg/kg dose,22224,In vivo,Urine,CHEMBL622870,Autocuration,9544.0,,U,,A,11131,,,Macaca mulatta,1,,1088.0,
,138,0,BAO_0000218,Oral bioavailability in African green monkeys; 20-25,22224,In vivo,,CHEMBL622871,Autocuration,9534.0,,U,,A,11132,,,Chlorocebus aethiops,1,,,
,14521,1,BAO_0000218,Oral bioavailability in cynomolgus monkey.,100710,In vivo,,CHEMBL620560,Intermediate,9541.0,,N,,A,11133,,,Macaca fascicularis,1,,,
,13953,0,BAO_0000218,Oral bioavailability in dog,22224,In vivo,,CHEMBL620561,Autocuration,9615.0,,U,,A,11134,,,Canis lupus familiaris,1,,,
,12836,1,BAO_0000218,Oral bioavailability in dog at 10 mg/kg oral dose,50588,In vivo,,CHEMBL620562,Intermediate,9615.0,,N,,A,11135,,,Canis lupus familiaris,1,,,
,12836,1,BAO_0000218,Oral bioavailability in hamster at 10 mg/kg oral dose,100712,In vivo,,CHEMBL620563,Intermediate,10026.0,,N,,A,11136,,,Cricetinae,1,,,
,12836,1,BAO_0000218,Oral bioavailability in rat at 10 mg/kg oral dose,50597,In vivo,,CHEMBL620564,Intermediate,10116.0,,N,,A,11137,,,Rattus norvegicus,1,,,
,14521,0,BAO_0000218,Oral bioavailability in rat,22224,In vivo,,CHEMBL872265,Autocuration,10116.0,,U,,A,11138,,,Rattus norvegicus,1,,,
,13953,0,BAO_0000218,Oral bioavailability in rat,22224,In vivo,,CHEMBL620565,Autocuration,10116.0,,U,,A,11139,,,Rattus norvegicus,1,,,
,6799,0,BAO_0000218,Oral bioavailability,22224,In vivo,,CHEMBL620566,Autocuration,9347.0,,U,,A,11140,,,Eutheria,1,,,
,11311,0,BAO_0000218,Oral bioavailability was determined; range 49-102%,22224,In vivo,,CHEMBL620567,Autocuration,,,U,,A,11141,,,,1,,,
,4013,1,BAO_0000218,Oral bioavailability was determined in dogs,50588,In vivo,,CHEMBL620568,Intermediate,9615.0,,N,,A,11142,,,Canis lupus familiaris,1,,,
,4013,0,BAO_0000218,Oral bioavailability in rat,22224,In vivo,,CHEMBL620569,Autocuration,10116.0,,U,,A,11143,,,Rattus norvegicus,1,,,
,17591,0,BAO_0000218,Oral bioavailability,22224,In vivo,,CHEMBL620570,Autocuration,9347.0,,U,,A,11144,,,Eutheria,1,,,
,17591,0,BAO_0000218,Oral bioavailability was determined; Not orally available,22224,In vivo,,CHEMBL620571,Autocuration,,,U,,A,11145,,,,1,,,
,15011,1,BAO_0000218,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),50594,In vivo,,CHEMBL620572,Intermediate,10090.0,,N,,A,11146,,,Mus musculus,1,,,
,15011,0,BAO_0000218,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),22224,In vivo,,CHEMBL620573,Autocuration,10090.0,,U,,A,11147,,,Mus musculus,1,,,
,15011,0,BAO_0000218,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,22224,In vivo,,CHEMBL620574,Autocuration,10090.0,,U,,A,11148,,,Mus musculus,1,,,
,9552,0,BAO_0000218,Oral bioavailability in Rhesus monkey,22224,In vivo,,CHEMBL620575,Autocuration,9544.0,,U,,A,11149,,,Macaca mulatta,1,,,
,9552,0,BAO_0000218,Oral bioavailability in dog (female mongrel),22224,In vivo,,CHEMBL620576,Autocuration,9615.0,,U,,A,11150,,,Canis lupus familiaris,1,,,
,3639,0,BAO_0000218,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,22224,In vivo,,CHEMBL875846,Autocuration,,,U,,A,11151,,,,1,,,
,13397,0,BAO_0000218,Oral bioavailability in dog,22224,In vivo,,CHEMBL620577,Autocuration,9615.0,,U,,A,11152,,,Canis lupus familiaris,1,,,
,3031,0,BAO_0000218,Percentage Bioavailability was evaluated.,22224,In vivo,,CHEMBL620578,Autocuration,,,U,,A,11153,,,,1,,,
,12818,0,BAO_0000218,Bioavailability in rat administered i.d.,22224,In vivo,,CHEMBL620579,Autocuration,10116.0,,U,,A,11154,,,Rattus norvegicus,1,,,
,4847,0,BAO_0000218,Bioavailability,22224,In vivo,,CHEMBL621248,Autocuration,9347.0,,U,,A,11155,,,Eutheria,1,,,
,12421,0,BAO_0000218,Bioavailability in dog (male Beagle) i.v. administration,22224,In vivo,,CHEMBL625390,Autocuration,9615.0,,U,,A,11156,,,Canis lupus familiaris,1,,,
,11966,0,BAO_0000218,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",22224,In vivo,,CHEMBL625391,Autocuration,10116.0,,U,,A,11157,,,Rattus norvegicus,1,,,
,11218,0,BAO_0000218,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),22224,In vivo,,CHEMBL872266,Autocuration,9443.0,,U,,A,11158,,,Primates,1,,,
,13129,0,BAO_0000218,Oral bioavailability in rat (Sprague-Dawley) (male),22224,In vivo,,CHEMBL625392,Autocuration,10116.0,,U,,A,11159,,,Rattus norvegicus,1,,,
,12350,1,BAO_0000218,The oral bioavailability was measured on rats after oral administration,50597,In vivo,,CHEMBL625393,Intermediate,10116.0,,N,,A,11160,,,Rattus norvegicus,1,,,
,2231,1,BAO_0000218,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,50597,In vivo,,CHEMBL625394,Intermediate,10116.0,,N,,A,11161,,,Rattus norvegicus,1,,,
,2231,1,BAO_0000218,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,50797,In vivo,,CHEMBL625395,Intermediate,9544.0,,N,,A,11162,,,Macaca mulatta,1,,,
,12187,0,BAO_0000218,Bioavailability in rat (dose 10 mg/kg i.d.),22224,In vivo,,CHEMBL625396,Autocuration,10116.0,,U,,A,11163,,,Rattus norvegicus,1,,,
,12421,0,BAO_0000218,Bioavailability in dog (male Beagle) i.v. administration,22224,In vivo,,CHEMBL625397,Autocuration,9615.0,,U,,A,11164,,,Canis lupus familiaris,1,,,
,13256,1,BAO_0000218,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,In vivo,,CHEMBL625398,Intermediate,10090.0,,N,,A,11165,,,Mus musculus,1,,,
,13256,1,BAO_0000218,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,In vivo,Blood,CHEMBL625399,Intermediate,10090.0,,N,,A,11166,,,Mus musculus,1,,178.0,
,13256,1,BAO_0000218,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,In vivo,Cerebellum,CHEMBL626074,Intermediate,10090.0,,N,,A,11167,,,Mus musculus,1,,2037.0,
,13256,1,BAO_0000218,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,In vivo,,CHEMBL626075,Intermediate,10090.0,,N,,A,11168,,,Mus musculus,1,,,
,2231,1,BAO_0000218,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,50597,In vivo,Plasma,CHEMBL626076,Intermediate,10116.0,,N,,A,11169,,,Rattus norvegicus,1,,1969.0,
,2231,1,BAO_0000218,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,50797,In vivo,Plasma,CHEMBL626077,Intermediate,9544.0,,N,,A,11170,,,Macaca mulatta,1,,1969.0,
,12178,1,BAO_0000218,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),50597,In vivo,Blood,CHEMBL626078,Intermediate,10116.0,,N,,A,11171,,,Rattus norvegicus,1,,178.0,
,12178,0,BAO_0000218,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),22224,In vivo,Blood,CHEMBL625846,Autocuration,,,U,,A,11172,,,,1,,178.0,
,12178,0,BAO_0000218,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),22224,In vivo,Blood,CHEMBL625847,Autocuration,,,U,,A,11173,,,,1,,178.0,
,15633,1,BAO_0000218,Maximum concentration observed in rats at an oral dose of 50 mg/kg,50597,In vivo,,CHEMBL625848,Expert,10116.0,,N,,A,11174,,,Rattus norvegicus,1,,,
,14258,1,BAO_0000218,Maximum concentration of compound in plasma administered orally to rats,50597,In vivo,Plasma,CHEMBL625849,Intermediate,10116.0,,N,,A,11175,,,Rattus norvegicus,1,,1969.0,
,14224,1,BAO_0000218,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",50588,In vivo,Plasma,CHEMBL626023,Intermediate,9615.0,,N,,A,11176,,,Canis lupus familiaris,1,,1969.0,
,14224,1,BAO_0000218,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",50588,In vivo,Plasma,CHEMBL626024,Intermediate,9615.0,,N,,A,11177,,,Canis lupus familiaris,1,,1969.0,
,14224,1,BAO_0000218,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",50588,In vivo,Plasma,CHEMBL626025,Intermediate,9615.0,,N,,A,11178,,,Canis lupus familiaris,1,,1969.0,
,5566,0,BAO_0000218,Maximum concentration after 10 mg/kg by oral administration,22224,In vivo,,CHEMBL626026,Autocuration,,,U,,A,11179,,,,1,,,
,16935,0,BAO_0000218,Maximum concentration at a dose of 1.5 mg/kg,22224,In vivo,,CHEMBL626027,Autocuration,,,U,,A,11180,,,,1,,,
,16935,0,BAO_0000218,Maximum concentration at a dose of 2.0 mg/kg,22224,In vivo,,CHEMBL626028,Autocuration,,,U,,A,11181,,,,1,,,
,14224,1,BAO_0000218,Maximum concentration in dog plasma,50588,In vivo,Plasma,CHEMBL626029,Intermediate,9615.0,,N,,A,11182,,,Canis lupus familiaris,1,,1969.0,
,12536,0,BAO_0000218,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,22224,In vivo,Plasma,CHEMBL626030,Autocuration,,,U,,A,11183,,,,1,,1969.0,
,12536,0,BAO_0000218,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,22224,In vivo,Plasma,CHEMBL626031,Autocuration,,,U,,A,11184,,,,1,,1969.0,
,12536,0,BAO_0000218,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,22224,In vivo,Plasma,CHEMBL626032,Autocuration,,,U,,A,11185,,,,1,,1969.0,
,12536,0,BAO_0000218,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,22224,In vivo,Plasma,CHEMBL626033,Autocuration,,,U,,A,11186,,,,1,,1969.0,
,12536,0,BAO_0000218,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,22224,In vivo,Plasma,CHEMBL626034,Autocuration,,,U,,A,11187,,,,1,,1969.0,
,9994,1,BAO_0000218,Maximum concentration in plasma after oral administration in dog (25 mg/kg),50588,In vivo,Plasma,CHEMBL626035,Intermediate,9615.0,,N,,A,11188,,,Canis lupus familiaris,1,,1969.0,
,1434,0,BAO_0000218,Maximum concentration in plasma at Tmax,22224,In vivo,Plasma,CHEMBL626036,Autocuration,,,U,,A,11189,,,,1,,1969.0,
,12836,1,BAO_0000218,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,50588,In vivo,Plasma,CHEMBL626037,Expert,9615.0,,N,,A,11190,,,Canis lupus familiaris,1,,1969.0,
,12836,1,BAO_0000218,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,100712,In vivo,Plasma,CHEMBL626038,Intermediate,10026.0,,N,,A,11191,,,Cricetinae,1,,1969.0,
,12836,1,BAO_0000218,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,50597,In vivo,Plasma,CHEMBL626039,Intermediate,10116.0,,N,,A,11192,,,Rattus norvegicus,1,,1969.0,
,12545,1,BAO_0000218,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,50597,In vivo,Plasma,CHEMBL626040,Intermediate,10116.0,,N,,A,11193,,,Rattus norvegicus,1,,1969.0,
,13856,1,BAO_0000218,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,50592,In vivo,Plasma,CHEMBL626041,Intermediate,9986.0,,N,,A,11194,,,Oryctolagus cuniculus,1,,1969.0,
,3550,0,BAO_0000218,Maximum concentration was calculated,22224,In vivo,,CHEMBL626042,Autocuration,,,U,,A,11195,,,,1,,,
,2632,0,BAO_0000218,Maximum concentration was calculated.,22224,In vivo,,CHEMBL626043,Autocuration,,,U,,A,11196,,,,1,,,
,5566,0,BAO_0000218,Maximum concentration at a peroral dose of 10 mg/kg,22224,In vivo,,CHEMBL626044,Autocuration,,,U,,A,11197,,,,1,,,
,11883,0,BAO_0000218,Maximum concentration of the drug at 10 uM/dg administered perorally,22224,In vivo,,CHEMBL626045,Autocuration,,,U,,A,11198,,,,1,,,
,11883,0,BAO_0000218,Maximum concentration of the drug at 2 uM/dg administered intravenously,22224,In vivo,,CHEMBL626046,Autocuration,,,U,,A,11199,,,,1,,,
,14122,1,BAO_0000218,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",50588,In vivo,Plasma,CHEMBL626047,Intermediate,9615.0,,N,,A,11200,,,Canis lupus familiaris,1,,1969.0,
,14122,1,BAO_0000218,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",100712,In vivo,Plasma,CHEMBL626048,Intermediate,10026.0,,N,,A,11201,,,Cricetinae,1,,1969.0,
,14122,1,BAO_0000218,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",50597,In vivo,Plasma,CHEMBL626049,Intermediate,10116.0,,N,,A,11202,,,Rattus norvegicus,1,,1969.0,
,12542,1,BAO_0000218,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,50597,In vivo,Plasma,CHEMBL626050,Intermediate,10116.0,,N,,A,11203,,,Rattus norvegicus,1,,1969.0,
,12542,1,BAO_0000218,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,50588,In vivo,Plasma,CHEMBL874541,Intermediate,9615.0,,N,,A,11204,,,Canis lupus familiaris,1,,1969.0,
,12542,1,BAO_0000218,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,100712,In vivo,Plasma,CHEMBL622826,Intermediate,10026.0,,N,,A,11205,,,Cricetinae,1,,1969.0,
,12542,1,BAO_0000218,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,100712,In vivo,Plasma,CHEMBL622827,Intermediate,10026.0,,N,,A,11206,,,Cricetinae,1,,1969.0,
,12542,1,BAO_0000218,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,50597,In vivo,Plasma,CHEMBL622828,Intermediate,10116.0,,N,,A,11207,,,Rattus norvegicus,1,,1969.0,
,14080,1,BAO_0000218,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,50597,In vivo,Plasma,CHEMBL622829,Intermediate,10116.0,,N,,A,11208,,,Rattus norvegicus,1,,1969.0,
,11911,1,BAO_0000218,Maximum concentration reached following intravenous administration in male rat,50597,In vivo,,CHEMBL876806,Intermediate,10116.0,,N,,A,11209,,,Rattus norvegicus,1,,,
,13204,1,BAO_0000218,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,50588,In vivo,,CHEMBL622830,Intermediate,9615.0,,N,,A,11210,,,Canis lupus familiaris,1,,,
,13204,1,BAO_0000218,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,50597,In vivo,,CHEMBL622831,Intermediate,10116.0,,N,,A,11211,,,Rattus norvegicus,1,,,
,14346,1,BAO_0000218,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,50588,In vivo,,CHEMBL626794,Intermediate,9615.0,,N,,A,11212,,,Canis lupus familiaris,1,,,
,14346,1,BAO_0000218,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,50597,In vivo,,CHEMBL626795,Intermediate,10116.0,,N,,A,11213,,,Rattus norvegicus,1,,,
,14346,1,BAO_0000218,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,50597,In vivo,,CHEMBL626796,Intermediate,10116.0,,N,,A,11214,,,Rattus norvegicus,1,,,
,14346,1,BAO_0000218,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,50597,In vivo,,CHEMBL626797,Intermediate,10116.0,,N,,A,11215,,,Rattus norvegicus,1,,,
,14127,1,BAO_0000218,Maximum drug concentration is determined after oral dosing in rats.,50597,In vivo,,CHEMBL626798,Intermediate,10116.0,,N,,A,11216,,,Rattus norvegicus,1,,,
,14339,1,BAO_0000218,Maximum observed concentration in oral (5 mg/kg) fasted dogs,50588,In vivo,,CHEMBL626799,Intermediate,9615.0,,N,,A,11217,,,Canis lupus familiaris,1,,,
,14339,1,BAO_0000218,Maximum observed concentration in oral (5 mg/kg) fed dogs,50588,In vivo,,CHEMBL626800,Intermediate,9615.0,,N,,A,11218,,,Canis lupus familiaris,1,,,
,13494,0,BAO_0000218,Maximum plasma concentration,22224,In vivo,Plasma,CHEMBL626801,Autocuration,,,U,,A,11219,,,,1,,1969.0,
,14925,1,BAO_0000218,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,50597,In vivo,Plasma,CHEMBL876816,Intermediate,10116.0,,N,,A,11220,,,Rattus norvegicus,1,,1969.0,
,14474,1,BAO_0000218,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,50597,In vivo,Plasma,CHEMBL626802,Intermediate,10116.0,,N,,A,11221,,,Rattus norvegicus,1,,1969.0,
,14474,1,BAO_0000218,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,50588,In vivo,Plasma,CHEMBL626803,Intermediate,9615.0,,N,,A,11222,,,Canis lupus familiaris,1,,1969.0,
,13917,0,BAO_0000218,Maximum plasma concentration following oral administration of 30 umol/kg,22224,In vivo,Plasma,CHEMBL626804,Autocuration,,,U,,A,11223,,,,1,,1969.0,
,9796,1,BAO_0000218,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,50597,,Plasma,CHEMBL626805,Intermediate,10116.0,,N,,A,11224,,,Rattus norvegicus,1,,1969.0,
,9796,1,BAO_0000218,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,50597,,Plasma,CHEMBL626309,Intermediate,10116.0,,N,,A,11225,,,Rattus norvegicus,1,,1969.0,
,9796,1,BAO_0000218,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,50597,,Plasma,CHEMBL626310,Intermediate,10116.0,,N,,A,11226,,,Rattus norvegicus,1,,1969.0,
,9796,1,BAO_0000218,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,50597,,Plasma,CHEMBL626311,Intermediate,10116.0,,N,,A,11227,,,Rattus norvegicus,1,,1969.0,
,9796,1,BAO_0000218,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,50597,,Plasma,CHEMBL626312,Intermediate,10116.0,,N,,A,11228,,,Rattus norvegicus,1,,1969.0,
,9796,1,BAO_0000218,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,50597,,Uterus,CHEMBL626313,Intermediate,10116.0,,N,,A,11229,,,Rattus norvegicus,1,,995.0,
,9796,1,BAO_0000218,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,50597,,Uterus,CHEMBL626314,Intermediate,10116.0,,N,,A,11230,,,Rattus norvegicus,1,,995.0,
,9796,1,BAO_0000218,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,50597,,Uterus,CHEMBL626315,Intermediate,10116.0,,N,,A,11231,,,Rattus norvegicus,1,,995.0,
,9796,1,BAO_0000218,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,50597,,Uterus,CHEMBL626316,Intermediate,10116.0,,N,,A,11232,,,Rattus norvegicus,1,,995.0,
,9796,1,BAO_0000218,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,50597,,Uterus,CHEMBL626317,Intermediate,10116.0,,N,,A,11233,,,Rattus norvegicus,1,,995.0,
,8363,1,BAO_0000218,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),50597,,,CHEMBL626318,Intermediate,10116.0,,N,,A,11234,,,Rattus norvegicus,1,,,
,8363,1,BAO_0000218,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),50597,,,CHEMBL626319,Intermediate,10116.0,,N,,A,11235,,,Rattus norvegicus,1,,,
,8363,1,BAO_0000218,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),50597,,,CHEMBL626320,Intermediate,10116.0,,N,,A,11236,,,Rattus norvegicus,1,,,
,8363,1,BAO_0000218,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),50597,,,CHEMBL875053,Intermediate,10116.0,,N,,A,11237,,,Rattus norvegicus,1,,,
,8363,1,BAO_0000218,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),50597,,,CHEMBL626321,Intermediate,10116.0,,N,,A,11238,,,Rattus norvegicus,1,,,
,8363,1,BAO_0000218,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),50597,,,CHEMBL626322,Intermediate,10116.0,,N,,A,11239,,,Rattus norvegicus,1,,,
,8363,1,BAO_0000218,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),50597,,,CHEMBL626323,Intermediate,10116.0,,N,,A,11240,,,Rattus norvegicus,1,,,
,8363,1,BAO_0000218,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),50597,,,CHEMBL626324,Intermediate,10116.0,,N,,A,11241,,,Rattus norvegicus,1,,,
,8363,1,BAO_0000218,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),50597,,,CHEMBL626325,Intermediate,10116.0,,N,,A,11242,,,Rattus norvegicus,1,,,
,8363,1,BAO_0000218,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),50597,,,CHEMBL626326,Intermediate,10116.0,,N,,A,11243,,,Rattus norvegicus,1,,,
,8363,1,BAO_0000218,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),50597,,,CHEMBL626327,Intermediate,10116.0,,N,,A,11244,,,Rattus norvegicus,1,,,
,8363,1,BAO_0000218,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),50597,,,CHEMBL626328,Intermediate,10116.0,,N,,A,11245,,,Rattus norvegicus,1,,,
,8684,1,BAO_0000218,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",50597,,Blood,CHEMBL626329,Intermediate,10116.0,,N,,A,11246,,,Rattus norvegicus,1,,178.0,
,8684,1,BAO_0000218,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",50597,,Blood,CHEMBL626330,Intermediate,10116.0,,N,,A,11247,,,Rattus norvegicus,1,,178.0,
,8684,1,BAO_0000218,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",50597,,Blood,CHEMBL626331,Intermediate,10116.0,,N,,A,11248,,,Rattus norvegicus,1,,178.0,
,8684,1,BAO_0000218,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",50597,,Blood,CHEMBL626332,Intermediate,10116.0,,N,,A,11249,,,Rattus norvegicus,1,,178.0,
,8684,1,BAO_0000218,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",50597,,Blood,CHEMBL626333,Intermediate,10116.0,,N,,A,11250,,,Rattus norvegicus,1,,178.0,
,8684,1,BAO_0000218,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",50597,,Blood,CHEMBL626334,Intermediate,10116.0,,N,,A,11251,,,Rattus norvegicus,1,,178.0,
,8684,1,BAO_0000218,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",50597,,Blood,CHEMBL626335,Intermediate,10116.0,,N,,A,11252,,,Rattus norvegicus,1,,178.0,
,8684,1,BAO_0000218,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",50597,,Blood,CHEMBL624798,Intermediate,10116.0,,N,,A,11253,,,Rattus norvegicus,1,,178.0,
,8684,1,BAO_0000218,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",50597,,Brain,CHEMBL624799,Intermediate,10116.0,,N,,A,11254,,,Rattus norvegicus,1,,955.0,
,8684,1,BAO_0000218,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",50597,,Brain,CHEMBL624800,Intermediate,10116.0,,N,,A,11255,,,Rattus norvegicus,1,,955.0,
,8684,1,BAO_0000218,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",50597,,Brain,CHEMBL624801,Intermediate,10116.0,,N,,A,11256,,,Rattus norvegicus,1,,955.0,
,8684,1,BAO_0000218,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",50597,,Brain,CHEMBL624802,Intermediate,10116.0,,N,,A,11257,,,Rattus norvegicus,1,,955.0,
,8684,1,BAO_0000218,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",50597,,Brain,CHEMBL624803,Intermediate,10116.0,,N,,A,11258,,,Rattus norvegicus,1,,955.0,
,8684,1,BAO_0000218,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",50597,,Brain,CHEMBL624804,Intermediate,10116.0,,N,,A,11259,,,Rattus norvegicus,1,,955.0,
,8684,1,BAO_0000218,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",50597,,Brain,CHEMBL624805,Intermediate,10116.0,,N,,A,11260,,,Rattus norvegicus,1,,955.0,
,8684,1,BAO_0000218,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",50597,,Brain,CHEMBL624806,Intermediate,10116.0,,N,,A,11261,,,Rattus norvegicus,1,,955.0,
,8684,1,BAO_0000218,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",50597,,,CHEMBL624807,Intermediate,10116.0,,N,,A,11262,,,Rattus norvegicus,1,,,
,8684,1,BAO_0000218,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",50597,,,CHEMBL624808,Intermediate,10116.0,,N,,A,11263,,,Rattus norvegicus,1,,,
,8684,1,BAO_0000218,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",50597,,,CHEMBL624809,Intermediate,10116.0,,N,,A,11264,,,Rattus norvegicus,1,,,
,8684,1,BAO_0000218,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",50597,,,CHEMBL624810,Intermediate,10116.0,,N,,A,11265,,,Rattus norvegicus,1,,,
,8684,1,BAO_0000218,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",50597,,,CHEMBL877618,Intermediate,10116.0,,N,,A,11266,,,Rattus norvegicus,1,,,
,8684,1,BAO_0000218,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",50597,,,CHEMBL624811,Intermediate,10116.0,,N,,A,11267,,,Rattus norvegicus,1,,,
,8684,1,BAO_0000218,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",50597,,,CHEMBL624812,Intermediate,10116.0,,N,,A,11268,,,Rattus norvegicus,1,,,
,8684,1,BAO_0000218,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",50597,,,CHEMBL624813,Intermediate,10116.0,,N,,A,11269,,,Rattus norvegicus,1,,,
,8684,1,BAO_0000218,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",50597,,,CHEMBL624814,Intermediate,10116.0,,N,,A,11270,,,Rattus norvegicus,1,,,
,8684,1,BAO_0000218,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",50597,,,CHEMBL624815,Intermediate,10116.0,,N,,A,11271,,,Rattus norvegicus,1,,,
,8684,1,BAO_0000218,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",50597,,,CHEMBL624816,Intermediate,10116.0,,N,,A,11272,,,Rattus norvegicus,1,,,
,8684,1,BAO_0000218,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",50597,,,CHEMBL624817,Intermediate,10116.0,,N,,A,11273,,,Rattus norvegicus,1,,,
,6996,1,BAO_0000218,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),50588,,,CHEMBL624818,Intermediate,9615.0,,N,,A,11274,,,Canis lupus familiaris,1,,,
